PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Horuk, R; Clayberger, C; Krensky, AM; Wang, ZH; Grone, HJ; Weber, C; Weber, KSC; Nelson, PJ; May, K; Rosser, M; Dunning, L; Liang, M; Buckmann, B; Ghannam, A; Ng, HP; Islam, I; Bauman, JG; Wei, GP; Monahan, S; Xu, W; Snider, RM; Morrissey, MM; Hesselgesser, J; Perez, HD				Horuk, R; Clayberger, C; Krensky, AM; Wang, ZH; Grone, HJ; Weber, C; Weber, KSC; Nelson, PJ; May, K; Rosser, M; Dunning, L; Liang, M; Buckmann, B; Ghannam, A; Ng, HP; Islam, I; Bauman, JG; Wei, GP; Monahan, S; Xu, W; Snider, RM; Morrissey, MM; Hesselgesser, J; Perez, HD			A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-TRANSPLANTATION; MONOCYTE ARREST; CYCLOSPORINE-A; EXPRESSION; RANTES; MECHANISM; KIDNEY; LIGAND; BETA	Chemokines like RANTES appear to play a role in organ transplant rejection. Because RANTES is a potent agonist for the chemokine receptor CCR1, we examined whether the CCR1 receptor antagonist BX471 is efficacious in a rat heterotopic heart transplant rejection model. Treatment of animals with BX471 and a subtherapeutic dose of cyclosporin (2.5 mg/kg), which is by itself ineffective in prolonging transplant rejection, is much more efficacious in prolonging transplantation rejection than animals treated with either cyclosporin or BX471 alone. We have examined the mechanism of action of the CCR1 antagonist in in vitro flow assays over microvascular endothelium and have discovered that the antagonist blocks the firm adhesion of monocytes triggered by RANTES on inflamed endothelium. Together, these data demonstrate a significant role for CCR1 in allograft rejection.	Berlex Biosci, Dept Immunol, Richmond, CA 94806 USA; Berlex Biosci, Dept Discovery Res, Richmond, CA 94806 USA; Stanford Univ, Dept Cardiothorac Surg, Stanford, CA 94305 USA; Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; German Canc Res Ctr, Dept Expt Pathol, D-69111 Heidelberg, Germany; Univ Munich, Inst Prophylaxe Kreislaufkrankheiten, D-80336 Munich, Germany; Univ Munich, Med Poliklin, D-80336 Munich, Germany	Stanford University; Stanford University; Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; University of Munich	Horuk, R (corresponding author), Berlex Biosci, Dept Immunol, 15049 San Pablo Ave, Richmond, CA 94806 USA.		Krensky, Alan/F-7956-2011; Weber, Christian/AAW-2153-2020	Weber, Christian/0000-0003-4610-8714				Bennett WM, 1996, TRANSPL P, V28, P2100; BILLINGHAM ME, 1990, CARDIAC TRANSPLANTAT; Cecka M, 1998, SURG CLIN N AM, V78, P133, DOI 10.1016/S0039-6109(05)70639-3; Conklyn MJ, 1996, CYTOKINE, V8, P762, DOI 10.1006/cyto.1996.0101; Gao W, 2000, J CLIN INVEST, V105, P35, DOI 10.1172/JCI8126; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; LI B, 1991, J EXP MED, V174, P1259, DOI 10.1084/jem.174.5.1259; Liang M, 2000, J BIOL CHEM, V275, P19000, DOI 10.1074/jbc.M001222200; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NISCO S, 1994, J IMMUNOL, V152, P3786; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; PATTISON J, 1994, LANCET, V343, P209, DOI 10.1016/S0140-6736(94)90992-X; Pattison JM, 1996, J HEART LUNG TRANSPL, V15, P1194; PEREZ HD, 1994, J BIOL CHEM, V269, P22485; SCHALL TJ, 1994, CYTOKINE HDB, P419; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; VADDI K, 1994, J IMMUNOL, V153, P4721; Weber KSC, 1999, EUR J IMMUNOL, V29, P700, DOI 10.1002/(SICI)1521-4141(199902)29:02<700::AID-IMMU700>3.0.CO;2-1	22	106	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4199	4204		10.1074/jbc.M007457200	http://dx.doi.org/10.1074/jbc.M007457200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11054419	hybrid			2022-12-25	WOS:000166921200063
J	Lutters, BCH; Meijers, JCM; Derksen, RHWM; Arnout, J; de Groot, PG				Lutters, BCH; Meijers, JCM; Derksen, RHWM; Arnout, J; de Groot, PG			Dimers of beta(2)-glycoprotein I mimic the in vitro effects of beta(2)-glycoprotein I-anti-beta(2)-glycoprotein I antibody complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-C; SYSTEMIC LUPUS-ERYTHEMATOSUS; BETA-2-GLYCOPROTEIN-I APOLIPOPROTEIN-H; AUTOIMMUNE ANTIPHOSPHOLIPID ANTIBODIES; AMINO-ACID-SEQUENCE; ANTICARDIOLIPIN ANTIBODIES; PHOSPHOLIPID-BINDING; ANTICOAGULANT ACTIVITY; ANTI-BETA(2)-GLYCOPROTEIN-I ANTIBODY; PROTHROMBINASE ACTIVITY	Anti-beta (2)-glycoprotein I antibodies are thought to cause lupus anticoagulant activity by forming bivalent complexes with beta (2)-glycoprotein I (beta (2)GPI). To test this hypothesis, chimeric fusion proteins were constructed of the dimerization domain (apple 4) of factor XI and beta (2)GPI. Both a covalent (apple 4-beta (2)GPI) and a noncovalent (apple 4-C321S-beta (2)GPI) chimer were constructed. As controls, apple 2-beta (2)GPI and apple 4-C321S-beta (2)GPI-W316S, in which beta (2)GPI-W316S is not able to bind to phospholipids, were made. In a phospholipid binding assay, apple 4-beta (2)GPI and apple 4-C321S-beta (2)GPI were able to bind to phospholipids with an affinity 35 times higher than that of plasma-derived beta (2)GPI and apple 2-beta (2)GPI. Apple 4-C321S-beta (2)GPI-W316S did not bind at all. Only apple 4-beta (2)GPI and apple 4-C321S-beta (2)GPI were able to bind to adhered platelets as shown by immunofluorescence. Using the prothrombin time, which was the most responsive coagulation assay, the clotting time was approximately doubled when 200 mug/ml apple 4-beta (2)GPI or apple 4-C321S-beta (2)GPI was added. Addition of 200 mug/ml plasma-derived beta (2)GPI, apple 2-beta (2)GPI, or apple 4-C321S-beta (2)GPI-W316S did not affect clotting time. Clotting time could be corrected with the addition of extra phospholipids, which is indicative for lupus anticoagulant activity. An additional increase in clotting times for apple 4-beta (2)GPI or apple 4-C321S-beta (2)GPI was achieved by the addition of monoclonal antibodies against beta (2)GPI. In conclusion, dimerization of beta (2)GPI explains the in vitro observed effects of beta (2)GPI-anti-beta (2)GPI antibody complexes.	Univ Utrecht, Med Ctr, Thrombosis & Haemostasis Lab, Dept Haematol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3508 TB Utrecht, Netherlands; Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands; Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	Utrecht University; Utrecht University; Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; KU Leuven	Lutters, BCH (corresponding author), Univ Utrecht, Med Ctr, Thrombosis & Haemostasis Lab, Dept Haematol, G03-647,POB 85-500, NL-3508 GA Utrecht, Netherlands.		Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780				Arnout J, 1998, THROMB HAEMOSTASIS, V79, P79; Balasubramanian K, 1997, J BIOL CHEM, V272, P31113, DOI 10.1074/jbc.272.49.31113; BENDIXEN E, 1992, BIOCHEMISTRY-US, V31, P3611, DOI 10.1021/bi00129a009; BEVERS EM, 1991, THROMB HAEMOSTASIS, V66, P629; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; BRANDT JT, 1993, THROMB HAEMOSTASIS, V70, P598; BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185; BRUNNER J, 1976, BIOCHIM BIOPHYS ACTA, V455, P322, DOI 10.1016/0005-2736(76)90308-4; Chamley LW, 1999, CLIN EXP IMMUNOL, V115, P571; CHONN A, 1995, J BIOL CHEM, V270, P25845, DOI 10.1074/jbc.270.43.25845; DAHLBACK B, 1983, BLOOD, V62, P218; DEGROOT PG, 1993, BAILLIERE CLIN HAEM, V6, P691, DOI 10.1016/S0950-3536(05)80194-5; EXNER T, 1991, THROMB HAEMOSTASIS, V65, P320; Forastiero R, 1998, THROMB HAEMOSTASIS, V79, P42, DOI 10.1055/s-0037-1614216; Galazka M, 1999, APPL BIOCHEM BIOTECH, V76, P1, DOI 10.1385/ABAB:76:1:1; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1988, ANNU REV MED, V39, P261, DOI 10.1146/annurev.med.39.1.261; Hasunuma Y, 1997, CLIN EXP IMMUNOL, V107, P569, DOI 10.1046/j.1365-2249.1997.d01-948.x; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Horbach DA, 1998, THROMB HAEMOSTASIS, V80, P791; Horbach DA, 1996, THROMB HAEMOSTASIS, V76, P916; HUNT J, 1994, J IMMUNOL, V152, P653; HUNT JE, 1993, P NATL ACAD SCI USA, V90, P2141, DOI 10.1073/pnas.90.6.2141; ICHIKAWA K, 1994, ARTHRITIS RHEUM, V37, P1453, DOI 10.1002/art.1780371008; Ieko M, 1998, SEMIN THROMB HEMOST, V24, P211, DOI 10.1055/s-2007-995844; KATO H, 1991, BIOCHEMISTRY-US, V30, P11687, DOI 10.1021/bi00114a012; KEELING DM, 1993, J CLIN PATHOL, V46, P908, DOI 10.1136/jcp.46.10.908; KRISTENSEN T, 1991, FEBS LETT, V289, P183, DOI 10.1016/0014-5793(91)81065-G; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; MATSUDA J, 1995, AM J HEMATOL, V49, P89, DOI 10.1002/ajh.2830490116; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; Mehdi H, 2000, EUR J BIOCHEM, V267, P1770, DOI 10.1046/j.1432-1327.2000.01174.x; MEIJERS JC, 1992, BIOCHEMISTRY-US, V31, P4684; MEIJERS JCM, 1992, BLOOD, V79, P1435; Mori T, 1996, THROMB HAEMOSTASIS, V75, P49; NIMPF J, 1985, THROMB HAEMOSTASIS, V54, P397; NIMPF J, 1986, BIOCHIM BIOPHYS ACTA, V884, P142, DOI 10.1016/0304-4165(86)90237-0; OOSTING JD, 1992, THROMB HAEMOSTASIS, V67, P499; PENGO V, 1995, THROMB HAEMOSTASIS, V73, P29; PERMPIKUL P, 1994, BLOOD, V83, P2878, DOI 10.1182/blood.V83.10.2878.2878; ROUBEY RAS, 1994, BLOOD, V84, P2854; ROUBEY RAS, 1992, J CLIN INVEST, V90, P1100, DOI 10.1172/JCI115926; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHOUSBOE I, 1995, THROMB HAEMOSTASIS, V73, P798; SCHOUSBOE I, 1980, THROMB RES, V19, P225, DOI 10.1016/0049-3848(80)90421-1; SCHOUSBOE I, 1985, BLOOD, V66, P1086; Sheng YH, 1996, J IMMUNOL, V157, P3744; Sheng YH, 1998, J IMMUNOL, V161, P2038; SHI W, 1993, THROMB HAEMOSTASIS, V70, P342; SMIRNOV MD, 1995, J CLIN INVEST, V95, P309, DOI 10.1172/JCI117657; STEINKASSERER A, 1992, FEBS LETT, V313, P193, DOI 10.1016/0014-5793(92)81442-O; Takeya H, 1997, J CLIN INVEST, V99, P2260, DOI 10.1172/JCI119401; vanWijnen M, 1996, THROMB HAEMOSTASIS, V76, P397; vanZanten GH, 1996, BLOOD, V88, P3862, DOI 10.1182/blood.V88.10.3862.bloodjournal88103862; WAGENKNECHT DR, 1993, THROMB HAEMOSTASIS, V69, P361; Wang SX, 2000, BIOCHEM J, V348, P103, DOI 10.1042/0264-6021:3480103; Willems GM, 1996, BIOCHEMISTRY-US, V35, P13833, DOI 10.1021/bi960657q; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X	62	73	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3060	3067		10.1074/jbc.M008224200	http://dx.doi.org/10.1074/jbc.M008224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11053420	hybrid			2022-12-25	WOS:000166784900014
J	Savouret, JF; Antenos, M; Quesne, M; Xu, J; Milgrom, E; Casper, RF				Savouret, JF; Antenos, M; Quesne, M; Xu, J; Milgrom, E; Casper, RF			7-ketocholesterol is an endogenous modulator for the arylhydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL OXIDATION-PRODUCTS; HUMAN MONOCYTE-MACROPHAGES; AH RECEPTOR; 7-ALPHA-HYDROXYCHOLESTEROL DEHYDROGENASE; ACTIVATION; OXYSTEROLS; TOXICITY; DIOXIN	We have identified 7-ketocholesterol (7-KC) as an endogenous modulator that inhibits transactivation by the arylhydrocarbon receptor (AhR) through competitive binding against xenobiotic ligands. 7-KC binds AhR and displaces labeled dioxin (2,3,7,8-tetrachlorodibenzo(p)dioxin (TCDD)). IC50 is 5 x 10(-7) M in vivo and 7 x 10(-6) M in vitro. These figures are consistent with its concentration in human blood plasma and tissues. Association with 7-KC prevents AhR binding to DNA. 7-KC blocks the TCDD-mediated transactivation of stably expressed reporter gene constructs in T47-D cells as well as the expression of the endogenous CYP 1A1 gene in HepG2 cells and in primary porcine aortic endothelial cells. Injection of 7-KC to rats blocks the induction of CYP 1A1 messenger RNA and protein in endothelial cells from myocardial blood vessels. The differential sensitivity of mammalian species to toxic effects of AhR ligands, especially dioxin (TCDD), correlates with the expression of 7-hydroxycholesterol dehydrogenase, which synthesizes 7-KC from 7-hydroxycholesterol. The documented involvement of AhR ligands in cardiovascular diseases through lipid peroxidation and endothelium dysfunction can now be examined in the context of displacement of this protective modulator.	CHU Niveau 3, INSERM, U135, Hop Bicetre, F-94270 Le Kremlin Bicetre, France; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Zool, Toronto, ON M5G 1A1, Canada	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Savouret, JF (corresponding author), CHU Niveau 3, INSERM, U135, Hop Bicetre, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France.		Casper, Robert F./E-3775-2013; Antenos, Monica/J-8985-2017	Casper, Robert F./0000-0002-6249-462X; Antenos, Monica/0000-0001-6350-2911				ADDIS PB, 1989, FREE RADICAL BIO MED, V7, P179, DOI 10.1016/0891-5849(89)90011-7; Alexander DL, 1998, J CELL SCI, V111, P3311; Bertazzi PA, 1998, ENVIRON HEALTH PERSP, V106, P625, DOI 10.2307/3433813; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brodie AE, 1997, TOXICOL LETT, V90, P91, DOI 10.1016/S0378-4274(96)03833-7; Casper RF, 1999, MOL PHARMACOL, V56, P784; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; CLARE K, 1995, ATHEROSCLEROSIS, V118, P67, DOI 10.1016/0021-9150(95)05594-M; Colles SM, 1996, J LIPID RES, V37, P2018; Crawford RB, 1997, MOL PHARMACOL, V52, P921, DOI 10.1124/mol.52.6.921; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; EBERHART DC, 1991, MOL PHARMACOL, V40, P859; Edwards PA, 1998, CURR OPIN LIPIDOL, V9, P433, DOI 10.1097/00041433-199810000-00007; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FLESCHJANYS D, 1995, AM J EPIDEMIOL, V142, P1165, DOI 10.1093/oxfordjournals.aje.a117575; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; Hardwick SJ, 1996, J PATHOL, V179, P294; Heath-Pagliuso S, 1998, BIOCHEMISTRY-US, V37, P11508, DOI 10.1021/bi980087p; Hengstler JG, 1999, DRUG METAB REV, V31, P917, DOI 10.1081/DMR-100101946; KANDUTSCH AA, 1975, J CELL PHYSIOL, V85, P415, DOI 10.1002/jcp.1040850408; KUCUK O, 1994, LIPIDS, V29, P657, DOI 10.1007/BF02536101; KUCUK O, 1992, CELL IMMUNOL, V139, P541, DOI 10.1016/0008-8749(92)90091-3; KURL RN, 1985, PHARMACOLOGY, V30, P241, DOI 10.1159/000138073; Lyons MA, 1999, INT J BIOCHEM CELL B, V31, P369, DOI 10.1016/S1357-2725(98)00123-X; MOOG C, 1989, INT J IMMUNOPHARMACO, V11, P559, DOI 10.1016/0192-0561(89)90186-0; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Phelan D, 1998, ARCH BIOCHEM BIOPHYS, V357, P155, DOI 10.1006/abbi.1998.0814; Schaldach CM, 1999, BIOCHEMISTRY-US, V38, P7594, DOI 10.1021/bi982861e; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Smith LL, 1996, LIPIDS, V31, P453, DOI 10.1007/BF02522641; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; Song W, 1996, ARCH BIOCHEM BIOPHYS, V328, P272, DOI 10.1006/abbi.1996.0173; SONG W, 1991, BIOCHEM PHARMACOL, V41, P1439, DOI 10.1016/0006-2952(91)90559-N; Song W, 1998, J BIOL CHEM, V273, P16223, DOI 10.1074/jbc.273.26.16223; Toborek M, 1995, J Biochem Toxicol, V10, P219, DOI 10.1002/jbt.2570100406; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Vena J, 1998, ENVIRON HEALTH PERSP, V106, P645, DOI 10.2307/3433815; WILHELMSSON A, 1994, J BIOL CHEM, V269, P19028	39	100	102	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3054	3059		10.1074/jbc.M005988200	http://dx.doi.org/10.1074/jbc.M005988200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042205	hybrid			2022-12-25	WOS:000166784900013
J	Matson, SW; Sampson, JK; Byrd, DRN				Matson, SW; Sampson, JK; Byrd, DRN			F plasmid conjugative DNA transfer - The TraI helicase activity is essential for DNA strand transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; CLEAVING-JOINING REACTION; ESCHERICHIA-COLI; SEX-FACTOR; BACTERIAL CONJUGATION; GENE-PRODUCT; I CATALYZES; NICKING REACTION; SEQUENCE MOTIFS; RELAXASE TRAI	The product of the Escherichia coli F plasmid traI gene is required for DNA transfer via bacterial conjugation. This bifunctional protein catalyzes the unwinding of duplex DNA and is a sequence-specific DNA transesterase. The latter activity provides the site- and strand-specific nick required to initiate DNA transfer. To address the role of the TraI helicase activity in conjugative DNA transfer traI mutants were constructed and their function in DNA transfer was evaluated using genetic and biochemical methods. A traI deletion/insertion mutant was transfer-defective as expected. A traI C-terminal deletion that removed the helicase-associated motifs was also transfer-defective despite the fact that the region of traI encoding the transesterase activity was intact. Biochemical studies demonstrated that the N-terminal domain was sufficient to catalyze oriT-dependent transesterase activity. Thus, a functional transesterase was not sufficient to support DNA transfer. Finally, a point mutant, TraI-K998M, that lacked detectable helicase activity was characterized. This protein catalyzed oriT-dependent transesterase activity in vitro and in vivo but failed to complement a traI deletion strain in conjugative DNA transfer assays. Thus, both the transesterase and helicase activities of TraI are essential for DNA strand transfer.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Matson, SW (corresponding author), Univ N Carolina, Dept Biol, CB 3280,Coker Hall, Chapel Hill, NC 27599 USA.	smatson@bio.unc.edu			NIGMS NIH HHS [GM33476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; [Anonymous], 1996, ESCHERICHIA COLI SAL; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Byrd DR, 1997, MOL MICROBIOL, V25, P1011, DOI 10.1046/j.1365-2958.1997.5241885.x; DASH PK, 1992, MOL MICROBIOL, V6, P1163, DOI 10.1111/j.1365-2958.1992.tb01555.x; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; GAMAS P, 1987, MOL GEN GENET, V207, P302, DOI 10.1007/BF00331593; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; Hall MC, 1998, J MOL BIOL, V277, P257, DOI 10.1006/jmbi.1997.1614; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HANAI R, 1993, J BIOL CHEM, V268, P23830; HOWARD MT, 1995, J BIOL CHEM, V270, P28381; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; IPPENIHLER KA, 1986, ANNU REV GENET, V20, P593, DOI 10.1146/annurev.ge.20.120186.003113; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; KOONIN EV, 1993, BIOSYSTEMS, V30, P241, DOI 10.1016/0303-2647(93)90074-M; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; LAHUE EE, 1990, J BACTERIOL, V172, P1385, DOI 10.1128/jb.172.3.1385-1391.1990; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; LLOSA M, 1994, J MOL BIOL, V235, P448, DOI 10.1006/jmbi.1994.1005; MANNING PA, 1982, J BACTERIOL, V150, P76, DOI 10.1128/JB.150.1.76-88.1982; MATSON SW, 1991, J BIOL CHEM, V266, P16232; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; Moscoso M, 1997, J MOL BIOL, V268, P840, DOI 10.1006/jmbi.1997.1012; NELSON WC, 1995, J BIOL CHEM, V270, P28374; OHKI M, 1968, COLD SPRING HARB SYM, V33, P651, DOI 10.1101/SQB.1968.033.01.074; PANICKER M, 1985, THESIS CARNEGIE MELL; PANSEGRAU W, 1994, J BIOL CHEM, V269, P2782; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; PANSEGRAU W, 1991, NUCLEIC ACIDS RES, V19, P3455, DOI 10.1093/nar/19.12.3455; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; RUPP WD, 1968, COLD SPRING HARB SYM, V33, P647, DOI 10.1101/SQB.1968.033.01.073; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; SCHERZINGER E, 1993, EUR J BIOCHEM, V217, P929, DOI 10.1111/j.1432-1033.1993.tb18323.x; SHERMAN JA, 1994, J BIOL CHEM, V269, P26220; THOMPSON TL, 1989, J MOL BIOL, V207, P505, DOI 10.1016/0022-2836(89)90460-9; TRAXLER BA, 1987, J BACTERIOL, V169, P3251, DOI 10.1128/jb.169.7.3251-3259.1987; TRAXLER BA, 1988, J MOL BIOL, V204, P205, DOI 10.1016/0022-2836(88)90609-2; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; WILLETTS N, 1979, MOL GEN GENET, V169, P325, DOI 10.1007/BF00382278	47	42	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2372	2379		10.1074/jbc.M008728200	http://dx.doi.org/10.1074/jbc.M008728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11054423	hybrid			2022-12-25	WOS:000166784800012
J	Postow, L; Ullsperger, C; Keller, RW; Bustamante, C; Vologodskii, AV; Cozzarelli, NR				Postow, L; Ullsperger, C; Keller, RW; Bustamante, C; Vologodskii, AV; Cozzarelli, NR			Positive torsional strain causes the formation of a four-way junction at replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; SUPERCOILED DNA; TOPOISOMERASE-I; CRUCIFORM FORMATION; BRANCH MIGRATION; MOLECULES; KINETICS; GYRASE; TRANSCRIPTION; CHROMOSOME	The advance of a DNA replication fork requires an unwinding of the parental double helix. This in turn creates a positive superhelical stress, a (+)-Delta Lk, that must be relaxed by topoisomerases for replication to proceed. Surprisingly, partially replicated plasmids with a (+)-Delta Lk were not supercoiled nor were the replicated arms interwound in precatenanes. The electrophoretic mobility of these molecules indicated that they have no net writhe. Instead, the (+)-Delta Lk is absorbed by a regression of the replication fork. As the parental DNA strands re-anneal, the resultant displaced daughter strands base pair to each other to form a four-way junction at the replication fork, which is locally identical to a Holliday junction in recombination. We showed by restriction endonuclease digestion that the junction can form at either the terminus or the origin of replication and we visualized the structure with scanning force microscopy. We discuss possible physiological implications of the junction for stalled replication in vivo.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; NYU, Dept Chem, New York, NY 10003 USA	University of California System; University of California Berkeley; New York University	Cozzarelli, NR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Vologodskii, Alexander V/I-6201-2013; Vologodskii, Alexander V/A-6994-2009	Bustamante, Carlos/0000-0002-2970-0073				CHAMPOUX JJ, 1980, MECH STUDIES DNA REP, V19, P809; COUREY AJ, 1983, CELL, V33, P817, DOI 10.1016/0092-8674(83)90024-7; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; GELLERT M, 1983, P NATL ACAD SCI-BIOL, V80, P5545, DOI 10.1073/pnas.80.18.5545; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1994, J BIOL CHEM, V269, P32655; HIASA H, 1994, J BIOL CHEM, V269, P2093; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HORIUCHI T, 1987, MOL GEN GENET, V210, P394, DOI 10.1007/BF00327188; HORIUCHI T, 1995, J BACTERIOL, V177, P783, DOI 10.1128/jb.177.3.783-791.1995; INMAN RB, 1984, BIOCHIM BIOPHYS ACTA, V783, P205, DOI 10.1016/0167-4781(84)90030-7; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LOUARN JM, 1991, J BACTERIOL, V173, P5097, DOI 10.1128/jb.173.16.5097-5104.1991; MARIANS KJ, 1977, P NATL ACAD SCI USA, V74, P1965, DOI 10.1073/pnas.74.5.1965; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Mulrooney SB, 1996, J BIOL CHEM, V271, P9648, DOI 10.1074/jbc.271.16.9648; NILSEN T, 1979, J MOL BIOL, V133, P319, DOI 10.1016/0022-2836(79)90396-6; PANYUTIN I, 1984, J BIOMOL STRUCT DYN, V1, P1311, DOI 10.1080/07391102.1984.10507522; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; Peter BJ, 1998, CELL, V94, P819, DOI 10.1016/S0092-8674(00)81740-7; Postow L, 1999, BIOESSAYS, V21, P805, DOI 10.1002/(SICI)1521-1878(199910)21:10<805::AID-BIES1>3.0.CO;2-7; Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Sogo JM, 1999, J MOL BIOL, V286, P637, DOI 10.1006/jmbi.1998.2510; Viguera E, 2000, NUCLEIC ACIDS RES, V28, P498, DOI 10.1093/nar/28.2.498; Vologodskaia MY, 1999, J MOL BIOL, V289, P851, DOI 10.1006/jmbi.1999.2811; WANG JC, 1974, J MOL BIOL, V89, P783, DOI 10.1016/0022-2836(74)90053-9; WANG JC, 1986, CYCLIC POLYM, P225; WANKA F, 1977, NUCLEIC ACIDS RES, V4, P2083, DOI 10.1093/nar/4.6.2083; WARING MJ, 1965, J MOL BIOL, V13, P269, DOI 10.1016/S0022-2836(65)80096-1	41	182	186	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2790	2796		10.1074/jbc.M006736200	http://dx.doi.org/10.1074/jbc.M006736200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11056156	hybrid			2022-12-25	WOS:000166784800068
J	Gosslau, A; Ruoff, P; Mohsenzadeh, S; Hobohm, U; Rensing, L				Gosslau, A; Ruoff, P; Mohsenzadeh, S; Hobohm, U; Rensing, L			Heat shock and oxidative stress-induced exposure of hydrophobic protein domains as common signal in the induction of hsp68	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; IMMUNOSUPPRESSANT DEOXYSPERGUALIN; FACTOR-I; ACTIVATION; HSP70; EXPRESSION; INVOLVEMENT; CELLS; ACID	The hypothesis of a common signal for heat shock (HS) and oxidative stress (OS) was analyzed in C6 cells with regard to the induction of heat shock proteins (Hsps). The synthesis rate and level of the strictly inducible Hsp68 was significantly higher after HS (44 degreesC) compared with OS (2 mM H2O2). This difference corresponded to higher and lower activation of the heat shock factor (HSF) by HS and OS, respectively. OS, on the other hand, showed stronger cytotoxicity compared with HS as indicated by drastic lipid peroxidation and inhibition of protein synthesis as well as of mitochondrial and endocytotic activity. Lactic dehydrogenase also revealed stronger inhibition of enzyme activity by OS than by HS as shown in cells and in vitro experiments. Conformational analysis of lactic dehydrogenase by the fluorophore 1-anilinonaphtalene-8-sulfonic acid, however, showed stronger exposure of hydrophobic domains after HS than after OS which correlates positively with the Hsp68 response. Treatment of cells with deoxyspergualin, which exhibits high affinity to Hsps, the putative inhibitors of HSF, strongly increased only OS-induced hsp68 expression. In conclusion, the results suggest that exposure of hydrophobic domains of cytosolic proteins represents the common first signal in the multistep activation pathway of HSF.	Univ Bremen, Inst Cell Biol Biochem & Biotechnol, D-28334 Bremen, Germany; Stavanger Univ Coll, Sch Sci & Technol, N-4091 Stavanger, Norway	University of Bremen; Equinor; Universitetet i Stavanger	Rensing, L (corresponding author), Univ Bremen, Inst Cell Biol Biochem & Biotechnol, POB 33 04 40, D-28334 Bremen, Germany.	rensing@uni-bremen.de		Ruoff, Peter/0000-0003-4430-0382				ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; BABICH H, 1987, TOXICOL IN VITRO, V1, P3, DOI 10.1016/0887-2333(87)90031-2; Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BERG K, 1990, APMIS, V98, P156, DOI 10.1111/j.1699-0463.1990.tb01016.x; BERNHEIM F, 1948, J BIOL CHEM, V174, P257; BRUCE JL, 1993, CANCER RES, V53, P12; Burdon R H, 1987, Free Radic Res Commun, V3, P129, DOI 10.3109/10715768709069778; Chen HW, 1999, SHOCK, V12, P63, DOI 10.1097/00024382-199907000-00009; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; DAS DK, 1995, J MOL CELL CARDIOL, V27, P181, DOI 10.1016/S0022-2828(08)80017-X; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; Ding XZ, 1998, FASEB J, V12, P451, DOI 10.1096/fasebj.12.6.451; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; Freeman ML, 1999, FREE RADICAL BIO MED, V26, P737, DOI 10.1016/S0891-5849(98)00258-5; GOODSON ML, 1995, BIOCHEM BIOPH RES CO, V211, P943, DOI 10.1006/bbrc.1995.1903; Gosslau A, 2000, BRAIN RES, V864, P114, DOI 10.1016/S0006-8993(00)02195-8; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hatayama T, 1999, BIOCHEM BIOPH RES CO, V265, P763, DOI 10.1006/bbrc.1999.1751; Huang J, 1996, BRAIN RES, V711, P184, DOI 10.1016/0006-8993(95)01376-8; HUANG LE, 1994, J BIOL CHEM, V269, P30718; Hung JJ, 1998, J CELL BIOCHEM, V71, P21; JacquierSarlin MR, 1996, BIOCHEM J, V318, P187, DOI 10.1042/bj3180187; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; JORNOT L, 1991, AM J RESP CELL MOL, V5, P265, DOI 10.1165/ajrcmb/5.3.265; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KEYSE SM, 1987, J BIOL CHEM, V262, P14821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; Liu HD, 1996, GENE DEV, V10, P592; Liu JK, 1997, ANAL BIOCHEM, V245, P161, DOI 10.1006/abio.1996.9990; Liu PCC, 1999, J BIOL CHEM, V274, P17219, DOI 10.1074/jbc.274.24.17219; LIU RY, 1995, MOL CELL BIOCHEM, V144, P27, DOI 10.1007/BF00926737; McDuffee AT, 1997, J CELL PHYSIOL, V171, P143, DOI 10.1002/(SICI)1097-4652(199705)171:2<143::AID-JCP4>3.0.CO;2-O; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MUNRO S, 1985, NATURE, V317, P477, DOI 10.1038/317477a0; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; NEUHOFF V, 1979, H-S Z PHYSIOL CHEM, V360, P1657, DOI 10.1515/bchm2.1979.360.2.1657; Ohnishi K, 1999, MOL CELL BIOCHEM, V197, P129, DOI 10.1023/A:1006937513154; Ovelgonne JH, 1996, J MOL CELL CARDIOL, V28, P1617, DOI 10.1006/jmcc.1996.0152; PTISYN OB, 1990, FEBS LETT, V262, P20; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; RICHARME G, 1993, J BIOL CHEM, V268, P24074; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Senisterra GA, 1997, BIOCHEMISTRY-US, V36, P11002, DOI 10.1021/bi9711590; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stephanou A, 1999, GENE EXPRESSION, V7, P311; Stuhlmeier KM, 2000, EUR J BIOCHEM, V267, P1161, DOI 10.1046/j.1432-1327.2000.01112.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; WEINER L, 1994, BIOCHEM BIOPH RES CO, V198, P915, DOI 10.1006/bbrc.1994.1130; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zhong M, 1999, J BIOL CHEM, V274, P3135, DOI 10.1074/jbc.274.5.3135; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	70	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1814	1821		10.1074/jbc.M008280200	http://dx.doi.org/10.1074/jbc.M008280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042186	hybrid			2022-12-25	WOS:000166528000024
J	Anfosso, F; Bardin, N; Vivier, E; Sabatier, F; Sampol, J; Dignat-George, F				Anfosso, F; Bardin, N; Vivier, E; Sabatier, F; Sampol, J; Dignat-George, F			Outside-in signaling pathway linked to CD146 engagement in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CAPACITATIVE CALCIUM-ENTRY; SMOOTH-MUSCLE CELLS; TYROSINE KINASE; PHOSPHOLIPASE-C; ACTIVATION; PHOSPHORYLATION; P130(CAS); SRC; PROTEIN	CD146 (S-Endo 1 Ag or MUC18) is a transmembrane glycoprotein expressed on endothelial cells on the whole vascular tree. CD146 is located at the intercellular junction where it plays a role in the cohesion of the endothelial monolayer, CD146 engagement initiates an outside-in signaling pathway involving the protein tyrosine kinases FYN and FAK as well as paxillin, Here we report that CD146 engagement by its specific monoclonal antibody in human umbilical vein endothelial cells induces a Ca2+ influx that is sensitive to thapsigargin and EGTA treatment, indicating that CD146 engagement initiates a store-operated calcium mobilization, In addition, biochemical and pharmacological analysis revealed that CD146 engagement initiates the tyrosine phosphorylation of phospholipase C-gamma, Pyk2, and p130(Cas). Pharmacological inhibition of Ca2+ flux with 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acetoxymethyl ester and EGTA indicated that an increase in Ca2+ is required for Pyk2 and p130(Cas) tyrosine phosphorylation. Moreover, a complex association was observed between Pyk2, p130(Cas), and paxillin. These results indicate that CD146 is coupled to a FYN-dependent pathway that triggers Ca2+ flux via phospholipase C-gamma activation leading subsequently to the tyrosine phosphorylation of downstream targets such as Pyk2, p130(Cas), FAK, and paxillin. In addition to its role in cell-cell adhesion, CD146 is a signaling molecule involved in the dynamics of actin cytoskeleton rearrangement.	Univ Mediterranee, EMI 0019, Lab Hematol Immunol, UFR Pharm, F-13385 Marseille 5, France; CNRS, INSERM, Ctr Immunol, Marseille, France; Inst Univ France, F-13276 Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Universitaire de France	Anfosso, F (corresponding author), Univ Mediterranee, EMI 0019, Lab Hematol Immunol, UFR Pharm, 27 Bd Jean Moulin, F-13385 Marseille 5, France.	anfosso@pharmacie.univ-mrs.fr	DIGNAT-GEORGE, Françoise/R-1129-2016; Vivier, Eric/F-8939-2010; Bardin, Nathalie/AAL-3663-2020	DIGNAT-GEORGE, Françoise/0000-0001-7006-4462; Vivier, Eric/0000-0001-7022-8287; Bardin, Nathalie/0000-0003-3680-082X				Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bardin N, 1996, BIOCHEM BIOPH RES CO, V218, P210, DOI 10.1006/bbrc.1996.0037; Bardin N, 1996, TISSUE ANTIGENS, V48, P531, DOI 10.1111/j.1399-0039.1996.tb02666.x; BENNETT J, 1986, BRIT MED BULL, V42, P385, DOI 10.1093/oxfordjournals.bmb.a072156; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DeLisser HM, 1997, TRENDS CARDIOVAS MED, V7, P203, DOI 10.1016/S1050-1738(97)00049-2; DHAR A, 1994, J BIOL CHEM, V269, P9123; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DONNADIEU E, 1994, J BIOL CHEM, V269, P32828; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gurubhagavatula I, 1998, J CLIN INVEST, V101, P212, DOI 10.1172/JCI269; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; HUANG AJ, 1993, J CELL BIOL, V120, P1371, DOI 10.1083/jcb.120.6.1371; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Johnson JP, 1997, INT J CANCER, V73, P769; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; LEHMANN JM, 1987, CANCER RES, V47, P841; LEHMANN JM, 1989, P NATL ACAD SCI USA, V96, P9691; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PATCH LA, 1995, J CELL SCI, V108, P1371; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PFAU S, 1995, J CELL BIOL, V128, P969, DOI 10.1083/jcb.128.5.969; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shih IM, 1998, J CELL SCI, V111, P2655; Shih IM, 1997, CANCER RES, V57, P3835; SHIH LE, 1999, J PATHOL, V189, P4; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Sun J, 2000, J CELL SCI, V113, P1459; Taira E, 1999, EXP CELL RES, V253, P697, DOI 10.1006/excr.1999.4713; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	62	113	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1564	1569		10.1074/jbc.M007065200	http://dx.doi.org/10.1074/jbc.M007065200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11036077	hybrid			2022-12-25	WOS:000166430900094
J	Gurvitz, A; Hamilton, B; Ruis, H; Hartig, A				Gurvitz, A; Hamilton, B; Ruis, H; Hartig, A			Peroxisomal degradation of trans-unsaturated fatty acids in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS PIP2P; BETA-OXIDATION; DOUBLE-BONDS; OLEIC-ACID; 2,4-DIENOYL-COA REDUCTASE; DEPENDENT PATHWAY; COENZYME-A; GENE SPS19; PROLIFERATION; METABOLISM	Degradation of trans-unsaturated fatty acids was studied in the yeast Saccharomyces cerevisiae, Propagation of yeast cells on trans-9 elaidic acid medium resulted in transcriptional up-regulation of the SPS19 gene, whose promoter contains an oleate response element. This up-regulation depended on the Pip2p-Oaf1p transcription factor and was accompanied by induction of import-competent peroxisomes. Utilization of trans fatty acids as a single carbon and energy source was evaluated by monitoring the formation of clear zones around cell growth on turbid media containing fatty acids dispersed with Tween 80. For metabolizing odd-numbered trans double bonds, cells required the beta -oxidation auxiliary enzyme Delta (3)-Delta (2)-enoyl-CoA isomerase Eci1p, Metabolism of the corresponding even-numbered double bonds proceeded in the absence of Sps19p (2,4-dienoyl-CoA reductase) and Dci1p (Delta (3,5)-Delta (2,4)-dienoyl-CoA isomerase). trans-2,trans-4-Dienoyl-CoAs could enter beta -oxidation directly via Fox2p (2-enoyl-CoA hydratase 2 and D-specific 3-hydroxyacyl-CoA dehydrogenase) without the involvement of Sps19p, whereas trans-2,cis-4-dienoyl-CoAs could not. This reductase-independent metabolism of trans-2,trans-4-dienoyl-CoAs resembled the situation postulated for mammalian mitochondria in which oleic acid is degraded through a di-isomerase-dependent pathway. In this hypothetical process, trans-2,trans-4-dienoyl-CoA metabolites are generated by Delta (3)-Delta (2)-enoyl-CoA isomerase and Delta (3,5)-Delta (2,4)-dienoyl-CoA isomerase and are degraded by 8-enoyl-CoA hydratase 1 in the absence of 2,4-dienoyl-CoA reductase. Growth of a yeast fox2sps19 Delta mutant in which Fox2p was exchanged with rat peroxisomal multifunctional enzyme type 1 on trans-9,trans-12 linolelaidic acid medium gave credence to this theory. We propose an amendment to the current scheme of the carbon flux through beta -oxidation taking into account the dispensability of beta -oxidation auxiliary enzymes for metabolizing trans double bonds at even-numbered positions.	Vienna Bioctr, Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria; Univ Vienna, Inst Biochem & Mol Zellbiol, A-1030 Vienna, Austria	Ludwig Boltzmann Institute; Vienna Biocenter (VBC); University of Vienna	Gurvitz, A (corresponding author), Vienna Bioctr, Inst Biochem & Mol Zellbiol, Dr Bohrgasse 9, A-1030 Vienna, Austria.			Hartig, Andreas/0000-0003-3334-2763				CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; FILPPULA SA, 1995, J BIOL CHEM, V270, P27453, DOI 10.1074/jbc.270.46.27453; Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184; Geisbrecht BV, 1999, BIOCHEM BIOPH RES CO, V260, P28, DOI 10.1006/bbrc.1999.0860; Gurvitz A, 1997, MOL MICROBIOL, V26, P675, DOI 10.1046/j.1365-2958.1997.5931969.x; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; Gurvitz A, 1999, J BIOL CHEM, V274, P24514, DOI 10.1074/jbc.274.35.24514; Gurvitz A, 1998, J BIOL CHEM, V273, P31366, DOI 10.1074/jbc.273.47.31366; Gurvitz A, 1999, BIOCHEM J, V344, P903, DOI 10.1042/0264-6021:3440903; Gurvitz A, 1999, MOL GEN GENET, V262, P481; Guzman M, 1999, LIPIDS, V34, P381, DOI 10.1007/s11745-999-0376-6; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; Hiltunen JK, 1996, ANN NY ACAD SCI, V804, P116, DOI 10.1111/j.1749-6632.1996.tb18612.x; IGUAL JC, 1991, YEAST, V7, P379, DOI 10.1002/yea.320070408; JONES EW, 1977, GENETICS, V85, P23; Karpichev IV, 2000, J CELL SCI, V113, P533; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Liang XQ, 1999, J BIOL CHEM, V274, P13830, DOI 10.1074/jbc.274.20.13830; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; MENSINK RP, 1992, J LIPID RES, V33, P1493; Qin YM, 1999, J BIOL CHEM, V274, P28619, DOI 10.1074/jbc.274.40.28619; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Sambrook J., 2002, MOL CLONING LAB MANU; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; SINCLAIR HM, 1990, BIOCHEM SOC T, V18, P756, DOI 10.1042/bst0180756; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VOORNBROUWER T, 1993, BIOCHIM BIOPHYS ACTA, V1216, P325, DOI 10.1016/0167-4781(93)90166-B	36	18	18	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					895	903		10.1074/jbc.M003305200	http://dx.doi.org/10.1074/jbc.M003305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032827	hybrid			2022-12-25	WOS:000166430900006
J	Chen, XS; Funk, CD				Chen, XS; Funk, CD			The N-terminal "beta-barrel" domain of 5-lipoxygenase is essential for nuclear membrane translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLATELET 12-LIPOXYGENASE; CYTOSOLIC PHOSPHOLIPASE A(2); GENE CHROMOSOMAL ASSIGNMENT; CA2+-DEPENDENT TRANSLOCATION; LEUKOTRIENE PRODUCTION; FUNCTIONAL EXPRESSION; ALVEOLAR MACROPHAGES; MOLECULAR-CLONING; HUMAN-LEUKOCYTES; CDNA CLONING	5-Lipoxygenase is the key enzyme in the formation of leukotrienes, which are potent lipid mediators of asthma pathophysiology, This enzyme translocates to the nuclear envelope in a calcium-dependent manner for leukotriene biosynthesis, Eight green fluorescent protein (GFP)-lipoxygenase constructs, representing the major human and mouse enzymes within this family, were constructed and their cDNAs transfected into human embryonic kidney 293 cells. Of these eight lipoxygenases, only the B-lipoxygenase was clearly nuclear localized and translocated to the nuclear envelope upon stimulation with the calcium ionophore A23187. The N-terminal "beta -barrel" domain of 5-lipoxgenase, but not the catalytic domain, was necessary and sufficient for nuclear envelope translocation, The GFP-N-terminal 5-lipoxygenase domain translocated faster than GFP-5-lipoxygenase. beta -Barrel/catalytic domain chimeras with 12- and 15-lipoxygenase indicated that only the N-terminal domain of 5-lipoxygenase could carry out this translocation function. Mutations of iron atom binding ligands (His550 or deletion of C-terminal isoleucine) that disrupt nuclear localization do not alter translocation capacity indicating distinct determinants of nuclear localization and translocation. Moreover, data show that GFP-5-lipoxygenase beta -barrel containing constructs can translocate to the nuclear membrane whether cytoplasmic or nuclear localized. Thus, the predicted beta barrel domain of 5-lipoxygenase may function like the C2 domain within protein kinase C and cytosolic phospholipase A(2) with unique determinants that direct its localization to the nuclear envelope.	Univ Penn, Dept Pharmacol, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania	Funk, CD (corresponding author), Univ Penn, Dept Pharmacol, Ctr Expt Therapeut, 421 Curie Blvd,Rm 814, Philadelphia, PA 19104 USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058464] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58464] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABA A, 1989, J BIOL CHEM, V264, P15790; Battey, 1986, BASIC METHODS MOL BI; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Borngraber S, 1996, J MOL BIOL, V264, P1145, DOI 10.1006/jmbi.1996.0702; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Christmas P, 1999, J BIOL CHEM, V274, P25594, DOI 10.1074/jbc.274.36.25594; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COFFEY M, 1992, J BIOL CHEM, V267, P570; Funk CD, 1996, J BIOL CHEM, V271, P23338, DOI 10.1074/jbc.271.38.23338; FUNK CD, 1991, ADV PROSTAG THROMB L, V21, P33; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; HAGMANN W, 1995, PROSTAGLANDINS, V49, P49, DOI 10.1016/0090-6980(94)00005-H; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Healy AM, 1999, J BIOL CHEM, V274, P29812, DOI 10.1074/jbc.274.42.29812; HOGABOOM GK, 1986, MOL PHARMACOL, V30, P510; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; Kinzig A, 1999, GENOMICS, V58, P158, DOI 10.1006/geno.1999.5816; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; May C, 2000, EUR J BIOCHEM, V267, P1100, DOI 10.1046/j.1432-1327.2000.01105.x; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Reddy KV, 2000, BIOCHEMISTRY-US, V39, P1840, DOI 10.1021/bi9919246; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P7505, DOI 10.1073/pnas.82.22.7505; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; Skorey KI, 1998, BIOCHEMISTRY-US, V37, P8027, DOI 10.1021/bi980371g; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; Sun DX, 1998, J BIOL CHEM, V273, P33540, DOI 10.1074/jbc.273.50.33540; UEDA N, 1986, J BIOL CHEM, V261, P7982; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; WONG A, 1992, BIOCHEMISTRY-US, V31, P4046, DOI 10.1021/bi00131a021; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; Zhang YY, 2000, BIOCHEM J, V351, P697, DOI 10.1042/0264-6021:3510697	55	111	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					811	818		10.1074/jbc.M008203200	http://dx.doi.org/10.1074/jbc.M008203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11042185	hybrid			2022-12-25	WOS:000166280700109
J	Hajek, P; Villani, G; Attardi, G				Hajek, P; Villani, G; Attardi, G			Rate-limiting step preceding cytochrome c release in cells primed for Fas-mediated apoptosis revealed by analysis of cellular mosaicism of respiratory changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE ACTIVATION; JURKAT CELLS; IN-VIVO; MITOCHONDRIA; BCL-2; PHOSPHATIDYLSERINE; MEMBRANE; HOMEOSTASIS; OXIDASE; DEATH	In the present work, Jurkat cells undergoing anti-Pas antibody (anti-Fas)-triggered apoptosis exhibited in increasing proportion a massive release of cytochrome c from mitochondria, as revealed by double-labeling confocal immunofluorescence microscopy. The cytochrome c release was followed by a progressive reduction in the respiratory activity of the last respiratory enzyme, cytochrome c oxidase (COX), and with a little delay, by a decrease in overall endogenous respiration rate, as measured in vivo in the whole cell population. Furthermore, in vivo titration experiments showed that an similar to 30% excess of COX capacity over that required to support endogenous respiration, found in naive cells, was maintained in anti-Pas-treated cells having lost similar to 40% of their COX respiratory activity. This observation strongly suggested that only a subpopulation of anti-Pas-treated cells, which maintained the excess of COX capacity, respired. Fractionation of cells on annexin V-coated paramagnetic beads did indeed separate a subpopulation of annexin V-binding apoptotic cells with fully released cytochrome c and completely lacking respiration, and a nonbound cell subpopulation exhibiting nearly intact respiration and in their great majority preserving the mitochondrial cytochrome c localization. The above findings showed a cellular mosaicism in cytochrome c release and respiration loss, and revealed the occurrence of a rate-limiting step preceding cytochrome c release in the apoptotic cascade. Furthermore, the striking observation that controlled digitonin treatment caused a massive and very rapid release of cytochrome c and complete loss of respiration in the still respiring anti-Fas-treated cells, but not in naive cells, indicated that the cells responding to digitonin had already been primed for apoptosis, and that this treatment bypassed or accelerated the rate-limiting step most probably at the level of the mitochondrial outer membrane.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Bari, Dept Med Biochem & Biol, I-70124 Bari, Italy	California Institute of Technology; Universita degli Studi di Bari Aldo Moro	Attardi, G (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.				NIGMS NIH HHS [GM11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FADOK VA, 1992, J IMMUNOL, V148, P2207; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; JONES DP, 1979, BIOCHIM BIOPHYS ACTA, V576, P17, DOI 10.1016/0005-2795(79)90480-X; KENNEDY FG, 1986, AM J PHYSIOL, V250, pC374, DOI 10.1152/ajpcell.1986.250.3.C374; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linsinger G, 1999, MOL CELL BIOL, V19, P3299; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mannella CA, 1998, BIOFACTORS, V8, P225, DOI 10.1002/biof.5520080309; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	37	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					606	615		10.1074/jbc.M007871200	http://dx.doi.org/10.1074/jbc.M007871200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027691	hybrid, Green Accepted			2022-12-25	WOS:000166280700082
J	Yu, AX; Malek, TR				Yu, AX; Malek, TR			The proteasome regulates receptor-mediated endocytosis of interleukin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; DOWN-REGULATION; GAMMA-CHAIN; BETA-CHAIN; UBIQUITIN; LIGAND; DEGRADATION; INTERNALIZATION; PROTEIN; SUBUNIT	Recent studies have increasingly implicated the proteasome in the regulation of cell surface receptors. In the present study, we investigated the role of the proteasome for ligand-dependent endocytosis and degradation of the interleukin-2 (IL-S)-interleukin-2 receptor (IL-BR) complex. Proteasome inhibitors impaired internalization of IL-2IL-2R and prevented the lysosomal degradation of this cytokine. Based on time-course studies, proteasome activity is primarily required after initial endocytosis of the IL-2 IL-2R. Proteasome function was also necessary for the lysosomal degradation of IL-2 internalized by IL-BR that were comprised of cytoplasmic tailless beta- or alpha -subunits, suggesting that the target protein for the proteasome is independent of either the cytoplasmic tail of the IL-BR beta- or gammac-subunits and their associated signaling components. Therefore, a functional proteasome is required for optimal endocytosis of the IL-SR/ligand complex and is essential for the subsequent lysosomal degradation of IL-2, possibly by regulating trafficking to the lysosome.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA	University of Miami	Malek, TR (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, 1600 NW 10th Ave, Miami, FL 33136 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040114, R56AI040114] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40114] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DUPREZ V, 1992, J BIOL CHEM, V267, P18639; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FURSE RK, 1993, EUR J IMMUNOL, V23, P3181, DOI 10.1002/eji.1830231221; He YW, 1998, CRIT REV IMMUNOL, V18, P503, DOI 10.1615/CritRevImmunol.v18.i6.20; HE YW, 1995, J IMMUNOL, V154, P1596; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Malek TR, 2000, J IMMUNOL, V164, P2905, DOI 10.4049/jimmunol.164.6.2905; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; Strous GJ, 1999, J CELL SCI, V112, P1417; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; SUBTIL A, 1994, J CELL SCI, V107, P3461; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; WEISSMAN AM, 1986, P NATL ACAD SCI USA, V83, P1463, DOI 10.1073/pnas.83.5.1463; YEE NS, 1994, J BIOL CHEM, V269, P31991; Yu AX, 2000, J IMMUNOL, V165, P2556, DOI 10.4049/jimmunol.165.5.2556; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017	29	86	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					381	385		10.1074/jbc.M007991200	http://dx.doi.org/10.1074/jbc.M007991200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11032838	hybrid			2022-12-25	WOS:000166280700052
J	Brown, K; Djinovic-Carugo, K; Haltia, T; Cabrito, I; Saraste, M; Moura, JJG; Moura, I; Tegoni, M; Cambillau, C				Brown, K; Djinovic-Carugo, K; Haltia, T; Cabrito, I; Saraste, M; Moura, JJG; Moura, I; Tegoni, M; Cambillau, C			Revisiting the catalytic CuZ cluster of nitrous oxide (N2O) reductase - Evidence of a bridging inorganic sulfur	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-STUTZERI; COPPER SITES	Nitrous-oxide reductases (N2OR) catalyze the two-electron reduction of N2O to N-2. The crystal structure of N(2)ORs from Pseudomonas nautica (Pn) and Paracoccus denitrificans (Pd) were solved at resolutions of 2.4 and 1.6 Angstrom respectively. The Pn N2OR structure revealed that the catalytic CuZ center belongs to a new type of metal cluster in which four copper ions are liganded by seven histidine residues. A bridging oxygen moiety and two other hydroxide ligands were proposed to complete the ligation scheme (Brown, K., Tegoni, RI., Prudencio, M., Pereira, A. S., Besson, S., Moura, J. J. G., Moura, I., and Cambillau, C, (2000) Nat. Struct Biol. 7, 191-195). However, in the CuZ cluster, inorganic sulfur chemical determination and the high resolution structure of Pd N2OR identified a bridging inorganic sulfur instead of an oxygen, This result reconciles the novel CuZ cluster with the hitherto puzzling spectroscopic data.	Architecture & Fonct Macromol Biol, UMR 6098, F-13402 Marseille 20, France; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, CQFB, P-2825114 Monte De Caparica, Portugal; Sincrotrone Trieste, Struct Biol Lab, I-34012 Bassovizza, TS, Italy; European Mol Biol Lab, D-69012 Heidelberg, Germany; Univ Helsinki, Helsinki Bioenerget Grp, Dept Med Chem, Inst Biomed Sci, FIN-00014 Helsinki, Finland	UDICE-French Research Universities; Aix-Marseille Universite; Universidade Nova de Lisboa; Elettra Sincrotrone Trieste; European Molecular Biology Laboratory (EMBL); University of Helsinki	Cambillau, C (corresponding author), Architecture & Fonct Macromol Biol, UMR 6098, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	cambillau@afmb.cnrs-mrs.fr	Moura, José J G/D-6426-2013; Djinovic-Carugo, Kristina/AAW-1167-2021; Moura, Isabel/D-6339-2013	Moura, José J G/0000-0002-4726-2388; Djinovic-Carugo, Kristina/0000-0003-0252-2972; Moura, Isabel/0000-0003-0971-4977				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Brown K, 2000, NAT STRUCT BIOL, V7, P191; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DOOLEY DM, 1987, J AM CHEM SOC, V109, P6730, DOI 10.1021/ja00256a029; DOOLEY DM, 1991, INORG CHEM, V30, P3006, DOI 10.1021/ic00015a013; Farrar JA, 1998, P NATL ACAD SCI USA, V95, P9891, DOI 10.1073/pnas.95.17.9891; FARRAR JA, 1991, FEBS LETT, V294, P11, DOI 10.1016/0014-5793(91)81331-2; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POILLON WN, 1963, BIOCHIM BIOPHYS ACTA, V77, P27, DOI 10.1016/0006-3002(63)90466-9; Prudencio M, 2000, BIOCHEMISTRY-US, V39, P3899, DOI 10.1021/bi9926328; Rasmussen T, 2000, BIOCHEMISTRY-US, V39, P12753, DOI 10.1021/bi001811i; RIESTER J, 1989, EUR J BIOCHEM, V178, P751, DOI 10.1111/j.1432-1033.1989.tb14506.x; Roussel A, 1991, SILICON GRAPHICS GEO, P81; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	19	160	161	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41133	41136		10.1074/jbc.M008617200	http://dx.doi.org/10.1074/jbc.M008617200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024061	hybrid			2022-12-25	WOS:000166114600064
J	Datta, SA; Rao, CM				Datta, SA; Rao, CM			Packing-induced conformational and functional changes in the subunits of alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK PROTEINS; NON-LENTICULAR TISSUES; HUMAN LENS CRYSTALLINS; B-CRYSTALLIN; A-CRYSTALLIN; QUATERNARY STRUCTURE; CELL-DIFFERENTIATION; MOLECULAR CHAPERONE; CIRCULAR-DICHROISM	The heteroaggregate alpha -crystallin and homoaggregates of its subunits, alphaA- and alphaB-crystallins, function like molecular chaperones and prevent the aggregation of several proteins. Although modulation of the chaperone-like activity of alpha -crystallin by both temperature and chaotropic agents has been demonstrated in vitro, the mechanism(s) of its regulation in vivo have not been elucidated. The subunits of alpha -crystallin exchange freely, resulting in its dynamic and variable quaternary structure. Mixed aggregates of the zeta -crystallins and other mammalian small heat shock proteins (sHSPs) have also been observed in vivo. We have investigated the time-dependent structural and functional changes during the course of heteroaggregate formation by the exchange of subunits between homoaggregates of alphaA- and alphaB-crystallins. Native isoelectric focusing was used to follow the time course of subunit exchange. Circular dichroism revealed large tertiary structural alterations in the subunits upon subunit exchange and packing into heteroaggregates, indicating specific homologous and heterologous interactions between the subunits. Subunit exchange also resulted in quaternary structural changes as demonstrated by gel filtration chromatography. Interestingly, we found time-dependent changes in chaperone-like activity against the dithiothreitol-induced aggregation of insulin, which correlated with subunit exchange and the resulting tertiary and quaternary structural changes. Heteroaggregates of varying subunit composition, as observed during eye lens epithelial cell differentiation, generated by subunit exchange displayed differential chaperone-like activity. It was possible to alter chaperone-like activity of preexisting oligomeric sHSPs by alteration of subunit composition by subunit exchange. Our results demonstrate that subunit exchange and the resulting structural and functional changes observed could constitute a mechanism of regulation of chaperone-like activity of alpha -crystallin (and possibly other mammalian sHSPs) in vivo.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.			Datta, Siddhartha/0000-0002-4098-7490				AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V102, P775; BINDELS JG, 1979, OPHTHALMIC RES, V11, P411; BLOEMENDAL B, 1981, MOL CELLULAR BIOL EY, P1; BLOEMENDAL H, 1962, EXP EYE RES, V1, P300, DOI 10.1016/S0014-4835(62)80015-3; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BRAHMA SK, 1987, CURR EYE RES, V6, P1291, DOI 10.3109/02713688708997554; CHIESA R, 1989, CURR EYE RES, V8, P151, DOI 10.3109/02713688908995186; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; CLAUWAERT J, 1989, CURR EYE RES, V8, P397, DOI 10.3109/02713688908996387; CLAYTON RM, 1974, EYE, V5, P399; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; DEBLOCK J, 1986, LENS RES, V3, P119; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1982, Z SAUGETIERKD, V47, P257; DELCOUR J, 1974, BIOCHEM BIOPH RES CO, V57, P134, DOI 10.1016/S0006-291X(74)80367-0; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Haley DA, 1999, EXP EYE RES, V68, P133, DOI 10.1006/exer.1998.0610; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JEDZINIAK JA, 1972, INVEST OPHTH VISUAL, V11, P905; KATO K, 1993, BIOCHIM BIOPHYS ACTA, V1175, P257, DOI 10.1016/0167-4889(93)90214-A; Kato K, 1997, CELL STRESS CHAPERON, V2, P199, DOI 10.1379/1466-1268(1997)002<0199:MOTAIE>2.3.CO;2; KATO K, 1992, J BIOL CHEM, V267, P7718; KELLEY MJ, 1993, J BIOL CHEM, V268, P18844; KLEMENZ R, 1994, VERH DEUT G, V78, P34; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KLEMENZ R, 1993, J CELL BIOL, V120, P103; LI LK, 1972, EXP EYE RES, V13, P110, DOI 10.1016/0014-4835(72)90023-1; LI LK, 1973, EXP EYE RES, V15, P179, DOI 10.1016/0014-4835(73)90117-6; LI LK, 1974, EXP EYE RES, V19, P49, DOI 10.1016/0014-4835(74)90071-2; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MCFALLNGAI MJ, 1985, EXP EYE RES, V41, P745, DOI 10.1016/0014-4835(85)90183-6; MITTEN KP, 1997, BIOCHEM BIOPH RES CO, V253, P69; NENE V, 1986, MOL BIOCHEM PARASIT, V21, P179, DOI 10.1016/0166-6851(86)90021-6; PURI N, 1983, EUR J BIOCHEM, V134, P321, DOI 10.1111/j.1432-1033.1983.tb07569.x; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; Rao CM, 1998, INT J BIOL MACROMOL, V22, P271; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; SIEZEN RJ, 1982, EXP EYE RES, V34, P969, DOI 10.1016/0014-4835(82)90077-X; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P387, DOI 10.1111/j.1432-1033.1978.tb12691.x; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SIEZEN RJ, 1979, EXP EYE RES, V28, P551, DOI 10.1016/0014-4835(79)90043-5; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V749, P227, DOI 10.1016/0167-4838(83)90229-7; SPECTOR A, 1974, INVEST OPHTH VISUAL, V13, P795; SPECTOR A, 1971, INVEST OPHTH VISUAL, V10, P677; SPECTOR A, 1973, EXP EYE RES, V16, P115, DOI 10.1016/0014-4835(73)90306-0; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Sun TX, 1998, FEBS LETT, V430, P401, DOI 10.1016/S0014-5793(98)00707-8; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1985, EXP EYE RES, V40, P393, DOI 10.1016/0014-4835(85)90152-6; THOMSON JA, 1989, BIOCHIM BIOPHYS ACTA, V994, P246, DOI 10.1016/0167-4838(89)90300-2; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; VANDENOETELAAR PJM, 1987, J CHROMATOGR, V398, P323, DOI 10.1016/S0021-9673(01)96520-3; VANDEROU.FJ, 1974, EUR J BIOCHEM, V49, P157; Vanhoudt J, 1998, INT J BIOL MACROMOL, V22, P229, DOI 10.1016/S0141-8130(98)00020-8; VANKAMP GJ, 1974, BIOCHIM BIOPHYS ACTA, V342, P89, DOI 10.1016/0005-2795(74)90109-3; VERETOUT F, 1989, J MOL BIOL, V205, P713, DOI 10.1016/0022-2836(89)90316-1; VERMORKEN AJM, 1978, NATURE, V271, P779, DOI 10.1038/271779a0; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZANTEMA A, 1989, J VIROL, V63, P3368, DOI 10.1128/JVI.63.8.3368-3375.1989	82	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41004	41010		10.1074/jbc.M007686200	http://dx.doi.org/10.1074/jbc.M007686200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024058	hybrid			2022-12-25	WOS:000166114600048
J	Zhang, H; Thomsen, JS; Johansson, L; Gustafsson, JA; Treuter, E				Zhang, H; Thomsen, JS; Johansson, L; Gustafsson, JA; Treuter, E			DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; LIGAND-BINDING; MOLECULAR-BASIS; N-COR; EXPRESSION; GENE; COACTIVATOR; ALPHA; BETA; DOMAIN	We have discovered that the orphan receptor DAX-1 (NROB1) interacts with the estrogen receptors ER alpha and ER beta. Interaction occurs with ligand-activated ERs in solution and on DNA and is mediated by the unique DAX-1 N-terminal repeat domain. Each of the three repeats contains a leucine-rich receptor-binding motif, known as the LXXLL motif, which is usually found in nuclear receptor coactivators. We have demonstrated that DAX-1 functions as an inhibitor of ER activation in mammalian cells and suggest a mechanism involving two sequential events, occupation of the ligand-induced coactivator-binding surface and subsequent recruitment of corepressors. Accordingly, we propose that DAX-1 itself acts as a corepressor for ERs. Because DAX-1 is coexpressed with ERs in reproductive tissues, these interactions could play significant roles by influencing estrogen signaling pathways. Our results point at functional similarities between DAX-1 and the orphan receptor SHP (NROB2) in that they have acquired features of transcriptional coregulators that are unique for members of the nuclear receptor family.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Treuter, E (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.	eckardt.treuter@cbt.ki.se		thomsen, jane/0000-0002-9336-5695; Treuter, Eckardt/0000-0002-4147-8989				Abe S, 1999, AM J MED GENET, V84, P87, DOI 10.1002/(SICI)1096-8628(19990521)84:2<87::AID-AJMG1>3.0.CO;2-7; Albrecht ED, 1999, ENDOCRINOLOGY, V140, P5953, DOI 10.1210/en.140.12.5953; Altincicek B, 2000, J BIOL CHEM, V275, P7662, DOI 10.1074/jbc.275.11.7662; Bae DS, 1996, ENDOCRINOLOGY, V137, P3921, DOI 10.1210/en.137.9.3921; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Glass CK, 2000, GENE DEV, V14, P121; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kawabe K, 1999, MOL ENDOCRINOL, V13, P1267, DOI 10.1210/me.13.8.1267; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; Lalli E, 1998, ENDOCRINOLOGY, V139, P4237, DOI 10.1210/en.139.10.4237; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Lemmen JG, 1999, MECH DEVELOP, V81, P163, DOI 10.1016/S0925-4773(98)00223-8; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Saunders PTK, 1997, J ENDOCRINOL, V154, pR13, DOI 10.1677/joe.0.154R013; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CA, 2000, J MOL ENDOCRINOL, V24, P23, DOI 10.1677/jme.0.0240023; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; Taylor AH, 2000, J MOL ENDOCRINOL, V24, P145, DOI 10.1677/jme.0.0240145; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; VANDERPELT AMM, 1999, ENDOCRINOLOGY, V140, P478; Yu RN, 1998, TRENDS ENDOCRIN MET, V9, P169, DOI 10.1016/S1043-2760(98)00048-4; Yu RN, 1998, NAT GENET, V20, P353, DOI 10.1038/3822; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899	50	147	153	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39855	39859		10.1074/jbc.C000567200	http://dx.doi.org/10.1074/jbc.C000567200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11053406	hybrid			2022-12-25	WOS:000166039500011
J	MacKeigan, JP; Collins, TS; Ting, JPY				MacKeigan, JP; Collins, TS; Ting, JPY			MEK inhibition enhances paclitaxel-induced tumor apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; INDUCED CELL-DEATH; C-JUN; SIGNAL-TRANSDUCTION; IN-VIVO; TAXOL; PATHWAY; PHOSPHORYLATION; BCL-2	The anti-cancer drug paclitaxel (Taxol) alters microtubule assembly and activates pro-apoptotic signaling pathways. Previously, we and others found that paclitaxel activates endogenous JNK in tumor cells, and the activation of JNK contributes to tumor cell apoptosis. Here we find that paclitaxel activates the prosurvival MEK/ERK pathway, which conversely may compromise the efficacy of paclitaxel. Hence, a combination treatment of paclitaxel and MER inhibitors was pursued to determine whether this treatment could lead to enhanced apoptosis. The inhibition of MEK/ERK with a pharmacologic inhibitor, U0126, together with paclitaxel resulted in a dramatic enhancement of apoptosis that is four times more than the additive value of the two drugs alone. Enhanced apoptosis was verified by the terminal transferase-mediated dUTP nick end labeling assay, by an enzyme-linked immunosorbent assay for histone-associated DNA fragments, and by flow cytometric analysis for DNA content. Specificity of the pharmacologic inhibitor was confirmed by the use of (a) a second MEK/ERK inhibitor and (b) a transdominant-negative MEK. Enhanced apoptosis was verified in breast, ovarian, and lung tumor cell lines, suggesting this effect is not cell type-specific. This is the first report of enhanced apoptosis detected in the presence of paclitaxel and MEK inhibition and suggests a new anticancer strategy.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Campus BOx 7295, Chapel Hill, NC 27599 USA.			MacKeigan, Jeffrey/0000-0002-0198-5679	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045580] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45580, AI 41751] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amato SF, 1998, CANCER RES, V58, P241; Baselga J, 1998, CANCER RES, V58, P2825; BHALLA K, 1993, LEUKEMIA, V7, P563; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ETTINGER DS, 1993, J NATL CANC I MONOGR, V15, P177; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1997, CANCER RES, V57, P229; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SETH A, 1992, J BIOL CHEM, V267, P24796; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Torres K, 1998, CANCER RES, V58, P3620; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	34	206	216	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38953	38956		10.1074/jbc.C000684200	http://dx.doi.org/10.1074/jbc.C000684200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11038347	Green Published, hybrid			2022-12-25	WOS:000165953100002
J	Ganglberger, E; Grunberger, K; Sponer, B; Radauer, C; Breiteneder, H; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E				Ganglberger, E; Grunberger, K; Sponer, B; Radauer, C; Breiteneder, H; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E			Allergen mimotopes for 3-dimensional epitope search and induction of antibodies inhibiting human IgE	FASEB JOURNAL			English	Article						Bet v 1; IgE epitope; mimotope; phage; biopanning; blocking IgG	BIRCH POLLEN ALLERGEN; BET-V-I; PHAGE-DISPLAYED PEPTIDES; T-CELL CLONES; MONOCLONAL-ANTIBODIES; DISCONTINUOUS EPITOPES; AFFINITY PURIFICATION; OVERLAPPING PEPTIDES; FILAMENTOUS PHAGE; POTENTIAL USE	There is no definite information available on the structural characteristics of IgE binding epitopes on allergenic molecules, although it is widely accepted that most of them are conformational. In the current study we aimed to characterize the IgE epitope of Bet v 1, the major birch pollen allergen, by the application of phage display peptide libraries. We purified IgE specific for Bet v 1 from allergic patients' sera to select mimotopes representing artificial IgE epitopes by biopanning of phage libraries. By linear alignment, it was not possible to attribute mimotope sequences to the primary structure of Bet v 1. We developed a computer-aided, S-dimensional coarse-grained epitope search. The 3-dimensional. search, followed by statistical analysis, revealed an exposed area on the Bet v 1 molecule (located between residues 9-22 and 104-123) as the IgE binding structure. The IgE epitope was located at a 30 Angstrom distance from a previously described IgG epitope and the respective mimotope, designated Bet mim E. Such mimotopes could potentially be used for the induction of IgG capable of interfering with the IgE/allergen interaction. To test this hypothesis, we immunized BALB/c mice with the phage-displayed Bet mim E. Immunizations resulted in the induction of Bet v 1-specific IgG, which was able to block the IgE binding to Bet v 1 in vitro. Based on these observations, we propose that immunotherapy with IgE mimotopes generated by biopannings result in formation of blocking IgG. We conclude that mimotope immunotherapy may represent a new and promising concept for treatment of type I allergic disease.	Univ Vienna, Sch Med, AKH, Dept Pathophysiol, A-1090 Vienna, Austria	University of Vienna	Jensen-Jarolim, E (corresponding author), Univ Vienna, Sch Med, AKH, Dept Pathophysiol, EBO-3Q,Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Jensen-Jarolim, Erika/C-5120-2018; Radauer, Christian/AAN-6260-2021	Jensen-Jarolim, Erika/0000-0003-4019-5765; Radauer, Christian/0000-0001-9920-4449				BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Delmastro P, 1997, VACCINE, V15, P1276, DOI 10.1016/S0264-410X(97)00072-8; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Friedl-Hajek R, 1999, MOL IMMUNOL, V36, P639, DOI 10.1016/S0161-5890(99)00078-4; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; JAROLIM E, 1990, J ALLERGY CLIN IMMUN, V85, P996, DOI 10.1016/0091-6749(90)90043-4; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Jensen-Jarolim E, 1999, INT ARCH ALLERGY IMM, V118, P224, DOI 10.1159/000024078; Jensen-Jarolim E, 1998, FASEB J, V12, P1635, DOI 10.1096/fasebj.12.15.1635; JENSENJAROLIM E, 1992, J ALLERGY CLIN IMMUN, V89, P31, DOI 10.1016/S0091-6749(05)80038-7; KREMSER M, 1989, WIEN MED WSCHR, V6, P135; Lebecque S, 1997, J ALLERGY CLIN IMMUN, V99, P374, DOI 10.1016/S0091-6749(97)70056-3; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MEOLA A, 1995, J IMMUNOL, V154, P3162; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; Schafer T, 1997, ALLERGY, V52, P14, DOI 10.1111/j.1398-9995.1997.tb04864.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Visco V, 1996, J IMMUNOL, V157, P956; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836; ZURCHER AW, 1995, IMMUNOL LETT, V46, P49, DOI 10.1016/0165-2478(95)00014-V	33	55	66	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2177	2184		10.1096/fj.99-1000com	http://dx.doi.org/10.1096/fj.99-1000com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053238				2022-12-25	WOS:000165190800010
J	Ron, D; Vagts, AJ; Dohrman, DP; Yaka, R; Jiang, Z; Yao, L; Crabbe, J; Grisel, JE; Diamond, I				Ron, D; Vagts, AJ; Dohrman, DP; Yaka, R; Jiang, Z; Yao, L; Crabbe, J; Grisel, JE; Diamond, I			Uncoupling of beta IIPKC from its targeting protein RACK1 in response to ethanol in cultured cells and mouse brain	FASEB JOURNAL			English	Article						PKC; activated C kinase receptor; cAMP; signal transduction; ethanol; targeting protein	ACTIVATED C-KINASE; A RECEPTORS; RAT-BRAIN; ANCHORING PROTEINS; CALCIUM CHANNELS; PHORBOL ESTERS; UP-REGULATION; MICE LACKING; SUBUNIT; LOCALIZATION	Protein kinase C (PKC) is involved in many neuroadaptive responses to ethanol in the nervous system, PKC activation results in translocation of the enzyme from one intracellular site to another. Compartmentalization of PKC isozymes is regulated by targeting proteins such as receptors for activated C kinase (RACKs), It is possible, therefore, that ethanol-induced changes in the function and compartmentalization of PKC isozymes could be due to changes in PKC targeting proteins. Here we study the response of the targeting protein RACK1 and its corresponding kinase beta IIPKC to ethanol, and propose a novel mechanism to explain how ethanol modulates signaling cascades. In cultured cells, ethanol induces movement of RACK1 to the nucleus without affecting the compartmentalization of beta IIPKC. Ethanol also inhibits beta IIPKC translocation in response to activation, These results suggest that ethanol inhibition of beta IIPKC translocation is due to miscompartmentalization of the targeting protein RACK1. Similar events occurred in mouse brain. In vive exposure to ethanol caused RACK1 to localize to nuclei in specific brain regions, but did not affect the compartmentalization of beta IIPKC, Thus, some of the cellular and neuroadaptive responses to ethanol may be related to ethanol-induced movement of RACK1 to the nucleus, thereby preventing the translocation and corresponding function of beta IIPKC.-Ron, D., Vagts, A. J., Dohrman, D. P., Yaka, R., Jiang, Z., Yao, L., Crabbe, J., Grisel, J. E., Diamond, I, Uncoupling of beta IIPKC from its targeting protein RACK1 in response to ethanol in cultured cells and mouse brain.	Univ Calif San Francisco, Ernest Gallo Res Ctr, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Res Ctr, Dept Cellular & Mol Pharmacol Pediat, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Res Ctr, Grad Program Neurosci, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Res Ctr, Ctr Neurobiol & Addict, San Francisco, CA 94110 USA; Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Portland, OR 97201 USA; Vet Affairs Med Ctr, Portland, OR 97201 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ron, D (corresponding author), Ernest Gallo Res Ctr, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.		Grisel, Judith G./I-6152-2013	Grisel, Judith G./0000-0001-9719-2739	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER; NIAAA NIH HHS [P60 AA010760] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BATTAINI F, 1989, ALCOHOL, V6, P169, DOI 10.1016/0741-8329(89)90043-8; Battaini F, 1999, EXP NEUROL, V159, P559, DOI 10.1006/exnr.1999.7151; Battaini F, 1997, TRENDS NEUROSCI, V20, P410, DOI 10.1016/S0166-2236(97)01084-9; Brandon NJ, 1999, J NEUROSCI, V19, P9228; Chandler LJ, 1998, TRENDS PHARMACOL SCI, V19, P491, DOI 10.1016/S0165-6147(98)01268-1; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Corsini E, 1999, J IMMUNOL, V163, P3468; CRABBLE JC, 1986, J PHARMACOL EXP THER, V239, P3237; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DILDYMAYFIELD JE, 1995, J NEUROSCI, V15, P3162; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; Escriba PV, 1999, BRIT J PHARMACOL, V127, P343, DOI 10.1038/sj.bjp.0702555; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Gerstin EH, 1998, J BIOL CHEM, V273, P16409, DOI 10.1074/jbc.273.26.16409; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; Hodge CW, 1999, NAT NEUROSCI, V2, P997, DOI 10.1038/14795; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KRUGER H, 1993, NEUROCHEM INT, V22, P575, DOI 10.1016/0197-0186(93)90032-Z; LARSSON C, 1995, BIOCHEM PHARMACOL, V50, P647, DOI 10.1016/0006-2952(95)00179-4; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MACDONALD RL, 1995, P NATL ACAD SCI USA, V92, P3633, DOI 10.1073/pnas.92.9.3633; Mascia MP, 1998, BRIT J PHARMACOL, V125, P263; MESSING RO, 1990, J NEUROCHEM, V55, P1383, DOI 10.1111/j.1471-4159.1990.tb03150.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NAGY LE, 1990, J BIOL CHEM, V265, P1946; Padanilam BJ, 1997, AM J PHYSIOL-RENAL, V272, pF160, DOI 10.1152/ajprenal.1997.272.2.F160; Pascale A, 1996, J NEUROCHEM, V67, P2471; RABIN RA, 1992, J PHARMACOL EXP THER, V262, P257; ROIVAINEN R, 1993, BRAIN RES, V624, P85, DOI 10.1016/0006-8993(93)90063-S; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, J BIOL CHEM, V269, P21395; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SAITO T, 1985, J NEUROCHEM, V44, P1037, DOI 10.1111/j.1471-4159.1985.tb08722.x; STEINER J, 1997, ALCOHOL, V14, P219; Stubbs CD, 1999, ALCOHOL CLIN EXP RES, V23, P1552; TANAKA C, 1992, NEUROCHEM INT, V21, P499, DOI 10.1016/0197-0186(92)90081-2; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; WEINER JL, 1994, J PHARMACOL EXP THER, V268, P1388; Weiner JL, 1997, J NEUROCHEM, V68, P1949; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zheng X, 1997, J NEUROSCI, V17, P8676	52	47	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2303	2314		10.1096/fj.00-0143com	http://dx.doi.org/10.1096/fj.00-0143com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053252				2022-12-25	WOS:000165190800024
J	Bondzi, C; Grant, S; Krystal, GW				Bondzi, C; Grant, S; Krystal, GW			A novel assay for the measurement of Raf-1 kinase activity	ONCOGENE			English	Article						Raf-1; activation-specific antibody; kinase assay	ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; MAP KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BIOLOGICAL-ACTIVITY; V-RAF; TAXOL; RESIDUES; GROWTH	Raf-1 is a serine-threonine protein kinase that functions as a central component of the mitogen-activated protein kinase signal transduction pathway, Raf-1 activity is currently assayed in vitro by either measuring P-32 incorporation into MEK, Raf-1's only characterized substrate, or by using the phosphorylated MEK to initiate a coupled assay culminating in the phosphorylation of myelin basic protein by MAP kinase, These assays are plagued by a potential lack of specificity in the case of the former, and the time consuming and error-prone nature of the later indirect assay, In this report, we demonstrate a novel single step assay for Raf-1 kinase activity based on phosphorylation of recombinant MEK-1, detected using an activation-specific MEK antibody that recognizes MEK only when specifically phosphorylated by Raf-1 on Ser 217 and Ser 221, The assay readily detected stem cell factor-mediated Raf-1 activation, MEK phosphorylation by immunoprecipitated Raf-1 plateaued at 10 min following initiation of the kinase reaction and was completely dependent on the inclusion of Raf-1 There was a linear correlation between the degree of MEK phosphorylation and the amount of Raf-1 protein immunoprecipitated, In addition to detecting growth factor-mediated activation, the assay was also able to detect paclitaxel-mediated Raf-1 activation, This assay is rapid, sensitive, and specific and therefore is a marked improvement over currently utilized techniques.	McGuire VA Med Ctr, Richmond, VA 23249 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol Immunol, Richmond, VA 23249 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23249 USA	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University; Virginia Commonwealth University	Krystal, GW (corresponding author), McGuire VA Med Ctr, 111K,1201 Broad Rock Blvd, Richmond, VA 23249 USA.				NATIONAL CANCER INSTITUTE [R01CA083705, R01CA063753] Funding Source: NIH RePORTER; NCI NIH HHS [CA83705, CA63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BHALLA K, 1993, LEUKEMIA, V7, P563; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Krystal GW, 1998, CANCER RES, V58, P4660; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LOU Z, 1997, MOL CELL BIOL, V17, P46; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MARIAS R, 1995, EMBO J, V14, P3136; OKUDA K, 1992, BLOOD, V79, P2880; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROWINSKY EK, 1988, CANCER RES, V48, P4093; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; Torres K, 1998, CANCER RES, V58, P3620; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	29	22	22	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5030	5033		10.1038/sj.onc.1203862	http://dx.doi.org/10.1038/sj.onc.1203862			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042690				2022-12-25	WOS:000089834300010
J	Sheng, ZJ; Sun, WP; Smith, E; Cohen, C; Sheng, Z; Xu, XX				Sheng, ZJ; Sun, WP; Smith, E; Cohen, C; Sheng, Z; Xu, XX			Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells	ONCOGENE			English	Article						disabled-2; cell positioning; extracellular matrix; basement membrane; Ras pathway	CYTOPLASMIC DOMAIN; APOPTOSIS; INTEGRIN; RECEPTOR; BRAIN; GENE; ORGANIZATION; SUPPRESSION; DOWNSTREAM; DISRUPTION	The physical interaction of epithelial cells with the basement membrane ensures correct positioning and acts as a survival factor for epithelial cells. Cells that detach from the basement membrane often undergo apoptosis; however, in carcinomas, this positional control is absent, permitting disorganized cell proliferation. In the majority of breast and ovarian carcinomas (85-90%), the expression of a candidate tumor suppressor, Disabled-2 (Dab2), is frequently lost. The Dab2-negative tumor cells are no longer in contact with an intact basement membrane, as indicated by the absence of collagen IV (in about 90% of cases), However, in the subset (10-15%) of ovarian tumors in which Dab2, expression is positive, the presence of a basement membrane-like structure around tumor cells was observed. Recombinant adenovirus-mediated expression of Dab2 was used in Dab2-negative ovarian and breast cancer cells, and re-expression of Dab2 was found to lead to cell death or growth arrest. Dab2 expression suppressed MAPK activation and c-fos expression, Plating the infected cells on a basement membrane matrigel rescued the cells from death and growth arrest. Thus, Dab2 exhibits a negative activity for cell growth and survival, which can be countered by attachment of the cells to basement membrane matrix. We conclude that Dab2 functions in cell positioning control and mediates the exigency for basement membrane attachment of epithelial cells, Loss of Dab2 may contribute to the basement membrane-independent, disorganized proliferation of tumor cells in ovarian and breast carcinomas.	Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, Philadelphia, PA 19111 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Fox Chase Cancer Center; Emory University; Emory University; Emory University; Amgen	Xu, XX (corresponding author), Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		sheng, zejuan/H-3034-2013		NATIONAL CANCER INSTITUTE [R01CA079716, R01CA075389] Funding Source: NIH RePORTER; NCI NIH HHS [CA 79716, CA 75389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Goffinet AM, 1997, NATURE, V389, P668, DOI 10.1038/39453; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Hagios C, 1998, PHILOS T R SOC B, V353, P857, DOI 10.1098/rstb.1998.0250; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Rice DS, 1998, DEVELOPMENT, V125, P3719; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STENBACK F, 1985, EUR J OBSTET GYN R B, V20, P357, DOI 10.1016/0028-2243(85)90059-0; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; THOMSON M, 1991, CAN J PUBLIC HEALTH, V82, P203; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vignoud L, 1997, J CELL SCI, V110, P1421; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WONG KK, 1993, INT J ONCOL, V3, P13; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; XU XX, 1995, J BIOL CHEM, V270, P14181	36	67	67	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4847	4854		10.1038/sj.onc.1203853	http://dx.doi.org/10.1038/sj.onc.1203853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039902				2022-12-25	WOS:000089757800007
J	Robert, V; Massimino, ML; Tosello, V; Marsault, R; Cantini, M; Sorrentino, V; Pozzan, T				Robert, V; Massimino, ML; Tosello, V; Marsault, R; Cantini, M; Sorrentino, V; Pozzan, T			Alteration in calcium handling at the subcellular level in mdx myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; ENDOPLASMIC-RETICULUM; DYSTROPHIC MDX; APOPTOSIS; HOMEOSTASIS; CHANNELS	In this study, we have tested the hypothesis that augmented [Ca2+] in subcellular regions or organelles, which are known to play a key role in cell survival, is the missing link between Ca2+ homeostasis alterations and muscular degeneration associated with muscular dystrophy. To this end, different targeted chimeras of the Ca2+-sensitive photoprotein aequorin have been transiently expressed in subcellular compartments of skeletal. myotubes of mdx: mice, the animal model of Duchenne muscular dystrophy. Direct measurements of the [Ca2+] in the sarcoplasmic reticulum, [Ca2+](sr), show a higher steady state level at rest and a larger drop after KCl-induced depolarization in mdx compared with control myotubes. The peaks in [Ca2+] occurring in the mitochondrial matrix of mdx myotubes are significantly larger than in controls upon KCl-induced depolarization or caffeine application. The augmented response of mitochondria precedes the alterations in the Ca2+ responses of the cytosol and of the cytoplasmic region beneath the membrane, which become significant only at a later stage of myotube differentiation. Taking into account the key role played by mitochondria Ca2+ handling in the control of cell death, our data suggest that mitochondria are potential targets of impaired Ca2+ homeostasis in muscular dystrophy.	Univ Padua, Dept Biomed Sci, CNR, Ctr Biomembranes, I-35121 Padua, Italy; Ist Sci San Raffaele, DIBIT, I-20132 Milan, Italy; Univ Siena, Dept Neurosci, Sect Mol Med, I-53100 Siena, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; Vita-Salute San Raffaele University; University of Siena	Robert, V (corresponding author), Univ Padua, Dept Biomed Sci, CNR, Ctr Biomembranes, Via G Colombo 3, I-35121 Padua, Italy.	pozzan@civ.bio.unipd.it	Sorrentino, Vincenzo/A-4793-2014; Massimino, Maria Lina/AAX-8773-2020; Tosello, Valeria/N-1010-2016	Sorrentino, Vincenzo/0000-0002-8573-8631; Tosello, Valeria/0000-0001-9560-340X; massimino, maria lina/0000-0002-1839-1404	Telethon [1226] Funding Source: Medline	Telethon(Fondazione Telethon)		BAKKER AJ, 1993, J PHYSIOL-LONDON, V460, P1; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 1997, MOL BIOL CELL, V8, P129, DOI 10.1091/mbc.8.1.129; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GAILLY P, 1993, CELL CALCIUM, V14, P473, DOI 10.1016/0143-4160(93)90006-R; HEAD SI, 1993, J PHYSIOL-LONDON, V469, P11, DOI 10.1113/jphysiol.1993.sp019801; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOLF FW, 1996, AM J PHYSIOL, V271, pC1325; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuznetsov AV, 1998, MOL CELL BIOCHEM, V183, P87, DOI 10.1023/A:1006868130002; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; PRESSMAR J, 1994, PFLUEGERS ARCH, V6, P499; RIVETBASTIDE M, 1993, CELL CALCIUM, V14, P563, DOI 10.1016/0143-4160(93)90077-J; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Robert V, 1998, J BIOL CHEM, V273, P30372, DOI 10.1074/jbc.273.46.30372; Sandri M, 1998, LAB INVEST, V78, P1005; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; TIDBALL JG, 1995, J CELL SCI, V108, P2197; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0	25	121	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4647	4651		10.1074/jbc.M006337200	http://dx.doi.org/10.1074/jbc.M006337200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11029464	hybrid			2022-12-25	WOS:000168484300018
J	Challet, C; Maechler, P; Wollheim, CB; Ruegg, UT				Challet, C; Maechler, P; Wollheim, CB; Ruegg, UT			Mitochondrial calcium oscillations in C2C12 myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CA2+ OSCILLATIONS; SKELETAL-MUSCLE MYOTUBES; MDX MOUSE; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; BETA-CELL; AEQUORIN; HOMEOSTASIS; RESPONSES; CHANNELS	Mitochondrial Ca2+ concentration ([Ca2+],) was monitored in C2C12 skeletal muscle cells stably expressing the Ca2+-sensitive photoprotein aequorin targeted to mitochondria. In myotubes, KCI-induced depolarization caused a peak of 3.03 +/- 0.14 muM [Ca2+], followed by an oscillatory second phase (5.1 +/- 0.1 per min). Chelation of extracellular Ca2+ or blockade of the voltage-operated Ca2+ channel attenuated both phases of the KCl response. The inhibitor of the sarcoplasmic reticulum Ca2+-ATPase, cyclopiazonic acid, reduced the amplitude of the KCl-induced [Ca2+](m) peak and prevented the oscillations, suggesting that these were generated intracellularly, No such [Ca2+](m) oscillations occurred with the nicotinic agonist carbachol, cyclopiazonic acid alone, or the purinergic agonist ATP. In contrast, caffeine produced an oscillatory behavior, indicating a role of ryanodine receptors as mediators of the oscillations. The [Ca2+](m) response was desensitized when cells were exposed to two consecutive challenges with KCl separated by a 5-min wash, whereas a second pulse of carbachol potentiated [Ca2+](m) indicating differences in intracellular Ca2+ redistribution. Cross-desensitization between KCl and carbachol and cross-potentiation between carbachol and KCl were observed. These results suggest that close contacts between mitochondria and sarcoplasmic reticulum exist permitting Ca2+ ex changes during KCl depolarization. These newly demonstrated dynamic changes in [Ca2+](m) in stimulated skeletal muscle cells might contribute to the understanding of physiological and pathological processes in muscular disorders.	Univ Lausanne, Pharmacol Grp, Sch Pharm, BEP, CH-1015 Lausanne, Switzerland; Univ Geneva, Med Ctr, Div Clin Biochem, Dept Internal Med, CH-1211 Geneva 4, Switzerland	University of Lausanne; University of Geneva	Ruegg, UT (corresponding author), Univ Lausanne, Pharmacol Grp, Sch Pharm, BEP, CH-1015 Lausanne, Switzerland.			Maechler, Pierre/0000-0002-2005-1433; RUEGG, Urs/0000-0001-6078-8280				Alderton JM, 2000, J BIOL CHEM, V275, P9452, DOI 10.1074/jbc.275.13.9452; ALLEN DG, 1978, NATURE, V273, P509, DOI 10.1038/273509a0; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 1997, MOL BIOL CELL, V8, P129, DOI 10.1091/mbc.8.1.129; Brini M, 2000, CELL MOL LIFE SCI, V57, P354, DOI 10.1007/PL00000698; COBBOLD PH, 1983, J CELL SCI, V61, P123; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Engel AG, 1994, MYOLOGY BASIC CLIN, V2, P1133; GAILLY P, 1993, CELL CALCIUM, V14, P473, DOI 10.1016/0143-4160(93)90006-R; Gillis JM, 1999, J MUSCLE RES CELL M, V20, P605, DOI 10.1023/A:1005545325254; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAROOTUNIAN AT, 1991, CELL CALCIUM, V12, P153, DOI 10.1016/0143-4160(91)90017-9; Henning RH, 1996, BRIT J PHARMACOL, V117, P1785, DOI 10.1111/j.1476-5381.1996.tb15355.x; Hopf FW, 1996, AM J PHYSIOL-CELL PH, V271, pC1325, DOI 10.1152/ajpcell.1996.271.4.C1325; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; Jouaville LS, 1998, MOL CELL BIOCHEM, V184, P371, DOI 10.1023/A:1006850121769; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Leijendekker WJ, 1996, BRIT J PHARMACOL, V118, P611, DOI 10.1111/j.1476-5381.1996.tb15445.x; LUCASHERON B, 1994, NEUROSCI LETT, V169, P97, DOI 10.1016/0304-3940(94)90365-4; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; MCCORMACK JG, 1994, NEWS PHYSIOL SCI, V9, P71; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nakazaki M, 1998, DIABETOLOGIA, V41, P279, DOI 10.1007/s001250050904; Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046; Ogata T, 1997, ANAT REC, V248, P214; Pulido SM, 1998, FEBS LETT, V439, P357, DOI 10.1016/S0014-5793(98)01399-4; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robert V, 1998, J BIOL CHEM, V273, P30372, DOI 10.1074/jbc.273.46.30372; Ruegg Urs T., 1999, Trends in Pharmacological Sciences, V20, P351, DOI 10.1016/S0165-6147(99)01377-2; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Ward CW, 2000, J PHYSIOL-LONDON, V525, P91, DOI 10.1111/j.1469-7793.2000.t01-2-00091.x; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345	42	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3791	3797		10.1074/jbc.M006209200	http://dx.doi.org/10.1074/jbc.M006209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11036072	hybrid			2022-12-25	WOS:000166921200011
J	Salomons, FA; Faber, KN; Veenhuis, M; van der Klei, IJ				Salomons, FA; Faber, KN; Veenhuis, M; van der Klei, IJ			Peroxisomal remnant structures in Hansenula polymorpha pex5 cells can develop into normal peroxisomes upon induction of the PTS2 protein amine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN; SACCHAROMYCES-CEREVISIAE; METHANOL METABOLISM; TARGETING SIGNAL; PICHIA-PASTORIS; GENE ENCODES; BIOGENESIS; IMPORT; MUTANT; COMPLEMENTATION	have analyzed the properties of peroxisomal remnants in Hantsenula polymorpha pex5 cells. In such cells PTS1 matrix protein import is fully impaired. In H. polymorpha pex5 cells, grown on ethanol/ammonium sulfate, conditions that repressed the PTS2 protein amine oxidase (AMO), peroxisomal structures were below the limit of detection. In methanol/ammonium sulfate-grown cells, normal peroxisomes are absent, but a few small membranous structures were observed that apparently represented peroxisomal ghosts since they contained Pex14p. These structures were the target of a Pex10p.myc fusion protein that was produced in pex5 cells under the control of the homologous alcohol oxidase promoter (strain pex5::P-AOX.PEX10.MYC). Glycerol/methanol/ammonium sulfate-grown cells of this transformant were placed in fresh glucose/methylamine media, conditions that fully repress the synthesis of the Pex10p.myc fusion protein but induce the synthesis of AMO. Two hours after the shift Pex10p.myc-containing structures were detectable that had accumulated newly synthesized AMO protein and which during further cultivation developed in normal peroxisomes. Concurrently, the remaining portion of these structures was rapidly degraded. These findings indicate that peroxisomal remnants in pex5 cells can develop into peroxisomes. Also, as for normal peroxisomes in H. polymorpha, apparently a minor portion of these structures actually take part in the development of these organelles.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	University of Groningen	van der Klei, IJ (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.		van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679				Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; BRODSKY JL, 1998, PROTEIN TARGETING TR, P169; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; FABER KN, 1994, P NATL ACAD SCI USA, V91, P12985, DOI 10.1073/pnas.91.26.12985; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Gotte K, 1998, MOL CELL BIOL, V18, P616; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; HOVIUS R, 1998, PROTEIN TARGETING TR, P231; Kiel JAKW, 1999, YEAST, V15, P1059, DOI 10.1002/(SICI)1097-0061(199908)15:11<1059::AID-YEA434>3.0.CO;2-I; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Kragler F, 1998, P NATL ACAD SCI USA, V95, P13336, DOI 10.1073/pnas.95.22.13336; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; NUTTLEY WM, 1995, GENE, V160, P33, DOI 10.1016/0378-1119(95)00230-4; ROGGENKAMP R, 1989, MOL CELL BIOL, V9, P988, DOI 10.1128/MCB.9.3.988; ROGGENKAMP R, 1986, MOL GEN GENET, V202, P302, DOI 10.1007/BF00331655; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; van der Klei IJ, 1998, CURR GENET, V34, P1, DOI 10.1007/s002940050360; van der Klei IJ, 1998, EMBO J, V17, P3608, DOI 10.1093/emboj/17.13.3608; vanderKlei IJ, 1996, ANN NY ACAD SCI, V804, P47; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERKLEI IJ, 1991, ARCH MICROBIOL, V156, P15, DOI 10.1007/BF00418181; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; VEENHUIS M, 1981, ARCH MICROBIOL, V129, P35, DOI 10.1007/BF00417176; Veenhuis M, 1996, FEBS LETT, V383, P114, DOI 10.1016/0014-5793(96)00220-7; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; VEENHUIS M, 1989, ARCH MICROBIOL, V151, P105, DOI 10.1007/BF00414422; VEENHUIS M, 1987, PEROXISOMES BIOL MED, P436; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963; WATERHAM HR, 1993, EMBO J, V12, P4785, DOI 10.1002/j.1460-2075.1993.tb06167.x; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Yamasaki M, 1999, J BIOL CHEM, V274, P35293, DOI 10.1074/jbc.274.50.35293	48	7	7	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4190	4198		10.1074/jbc.M008476200	http://dx.doi.org/10.1074/jbc.M008476200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050097	hybrid, Green Published			2022-12-25	WOS:000166921200062
J	Dulhunty, A; Gage, P; Curtis, S; Chelvanayagam, G; Board, P				Dulhunty, A; Gage, P; Curtis, S; Chelvanayagam, G; Board, P			The glutathione transferase structural family includes a nuclear chloride channel and a ryanodine receptor calcium release channel modulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PROTEIN; LYMPHOCYTES; EXPRESSION; MUSCLE; ZETA; GENE; ADP	The ubiquitous glutathione transferases (GSTs) catalyze glutathione conjugation to many compounds and have other diverse functions that continue to, be discovered. We noticed sequence similarities between Omega class GSTs and a nuclear chloride channel, NCC27 (CLIC1), and show here that NCC27 belongs to the GST structural family. The structural homology prompted us to investigate whether the human Omega class glutathione transferase GSTO1-1 forms or modulates ion channels. We find that GSTO1-1 modulates ryanodine receptors (RyR), which are calcium channels in the endoplasmic reticulum of various cells. Cardiac RyR2 activity was inhibited by GSTO1-1, whereas skeletal muscle RyR1 activity was potentiated. An enzymatically active conformation of GSTO1-1 was required for inhibition of RyR2, and mutation of the active site cysteine (Cys-32 --> Ala) abolished the inhibitory activity. We propose a novel role for GSTO1-1 in protecting cells containing RyR2 from apoptosis induced by Ca2+ mobilization from intracellular stores.	Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research	Board, P (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, POB 334, Canberra, ACT 2601, Australia.		Dulhunty, Angela/AAO-5421-2020	Dulhunty, Angela/0000-0001-9493-4944				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; Fernandez-Canon JM, 1998, J BIOL CHEM, V273, P329, DOI 10.1074/jbc.273.1.329; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; Kermode H, 1998, BIOPHYS J, V74, P1296, DOI 10.1016/S0006-3495(98)77843-9; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; Laver DR, 1997, BIOPHYS J, V73, P1913, DOI 10.1016/S0006-3495(97)78222-5; LAVER DR, 1995, J MEMBRANE BIOL, V147, P7; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; Mariot P, 2000, PROSTATE, V43, P205; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MINIUM EW, 1993, STAT REASONING REASO; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Sei Y, 1999, J BIOL CHEM, V274, P5995, DOI 10.1074/jbc.274.9.5995; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tong Z, 1998, CHEM RES TOXICOL, V11, P1332, DOI 10.1021/tx980144f; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Villafania A, 2000, ANN CLIN LAB SCI, V30, P57; Whittington AT, 1999, BIOCHEM J, V337, P141, DOI 10.1042/0264-6021:3370141; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; Xu L, 1998, ANN NY ACAD SCI, V853, P130	28	222	231	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3319	3323		10.1074/jbc.M007874200	http://dx.doi.org/10.1074/jbc.M007874200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035031	hybrid			2022-12-25	WOS:000166784900045
J	Eisen, A; Utley, RT; Nourani, A; Allard, S; Schmidt, P; Lane, WS; Lucchesi, JC; Cote, J				Eisen, A; Utley, RT; Nourani, A; Allard, S; Schmidt, P; Lane, WS; Lucchesi, JC; Cote, J			The yeast NuA4 and Drosophila MSL complexes contain homologous subunits important for transcription regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE COMPLEXES; DOSAGE COMPENSATION; X-CHROMOSOME; SACCHAROMYCES-CEREVISIAE; ACTIVATION DOMAIN; PROTEIN DATABASE; MALELESS PROTEIN; IN-VIVO; CHROMATIN; GENE	In Drosophila, the MSL complex is required for the dosage compensation of X-linked genes in males and contains a histone acetyltransferase, MOF. A point mutation in the MOF acetyl-CoA-binding site results in male-specific lethality. Yeast Esa1p, a MOF homolog, is essential for cell cycle progression and is the catalytic subunit of the NuA4 acetyltransferase complex. Here we report that NuA4 purified from yeast with a point mutation in the acetyl-CoA-binding domain of Esa1p exhibits a strong decrease in histone acetyltransferase activity, yet has no effect on growth. We demonstrate that Eaf3p (Esa1p-associated factor-3 protein), a yeast protein homologous to the Drosophila dosage compensation protein MSL3, is also a stable component of the NuA4 complex. Unlike other subunits of the complex, it is not essential, and the deletion mutant has no growth phenotype. NuA4 purified from the mutant strain has a decreased apparent molecular mass, but retains wildtype levels of histone H4 acetyltransferase activity. The EAF3 deletion and the ESA1 mutation lead to a decrease in PHO5 gene expression; the EAF3 deletion also significantly reduces HIS4 and TRP4 expressions. These results, together with those previously obtained with both the MSL and NuA4 complexes, underscore the importance of targeted histone H4 acetylation for the gene-specific activation of transcription.	Univ Laval, Canc Res Ctr, Hotel Dieu Quebec, Ctr Hosp Univ Quebec, Quebec City, PQ G1R 2J6, Canada; Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Laval University; Emory University; Harvard University	Cote, J (corresponding author), Univ Laval, Canc Res Ctr, Hotel Dieu Quebec, Ctr Hosp Univ Quebec, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.		Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X				Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Ehrenstein D, 1998, SCIENCE, V279, P177, DOI 10.1126/science.279.5348.177; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Franke A, 1999, MOL CELL, V4, P117, DOI 10.1016/S1097-2765(00)80193-8; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Gu WG, 1998, DEV GENET, V22, P56, DOI 10.1002/(SICI)1520-6408(1998)22:1<56::AID-DVG6>3.0.CO;2-6; Harlow E., 1988, ANTIBODIES LAB MANUA; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jiang YW, 1996, GENE DEV, V10, P604, DOI 10.1101/gad.10.5.604; John S, 2000, GENE DEV, V14, P1196; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1997, EMBO J, V16, P2671, DOI 10.1093/emboj/16.10.2671; Lennon JC, 1998, MOL CELL BIOL, V18, P5771, DOI 10.1128/MCB.18.10.5771; Lucchesi JC, 1996, BIOESSAYS, V18, P541, DOI 10.1002/bies.950180705; Lucchesi JC, 1998, CURR OPIN GENET DEV, V8, P179, DOI 10.1016/S0959-437X(98)80139-1; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Radcliffe P, 1998, MOL BIOL CELL, V9, P1757, DOI 10.1091/mbc.9.7.1757; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Scott MJ, 2000, EMBO J, V19, P144, DOI 10.1093/emboj/19.1.144; Sinclair DAR, 1998, GENETICS, V148, P211; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Stankunas K, 1998, DEVELOPMENT, V125, P4055; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	60	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3484	3491		10.1074/jbc.M008159200	http://dx.doi.org/10.1074/jbc.M008159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11036083	hybrid			2022-12-25	WOS:000166784900065
J	Wu, XL; Webster, SR; Chen, JJ				Wu, XL; Webster, SR; Chen, JJ			Characterization of turner-associated Chk2 mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; FHA DOMAIN; KINASE; ATM; DOWNSTREAM; PROTEIN	The integrity of the DNA damage response pathway is essential for prevention of neoplastic transformation. Several proteins involved in this pathway including p53, BRCA1, and ATM are frequently mutated in human cancer. Checkpoint kinase 2 (Chk2) is a DNA damage-activated protein kinase that lies downstream of ATM in this pathway. Recently, heterozygous germline mutations in Chk2 have been identified in a subset of patients with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype, suggesting that Chk2 is a tumor suppressor gene. In this study, we have reported the biochemical characterization of the four tumor-associated Chk2 mutants. Two of the reported Chk2 mutations identified in Li-Fraumeni syndrome result in loss of Chk2 kinase activity, Whereas one mutation within the Chk2 forkhead homology-associated (FHA) domain, R145W, retains some basal kinase activity, this mutant cannot be phosphorylated at an ATM-dependent phosphorylation site (Thr-68) and cannot be activated following gamma radiation. Wild-type Chk2 exists mainly in a protein complex of M-r similar to 200,000 whereas the R145W mutant forms a larger, presumably inactive complex in the cell. The other FHA domain mutant, I157T, behaves as wild-type Chk2 in all the assays used here. Because the FHA domain is involved in protein-protein interactions, this mutation may affect associations of Chk2 with other proteins. Additionally, we have shown that Chk2 can also be inactivated by down-regulation of its expression in cancer cells. Thus, Chk2 may be inactivated by multiple mechanisms in the cell.	Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA	Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin & Mayo Fdn, Div Oncol Res, 200 1st St SW,Guggenheim 1342, Rochester, MN 55905 USA.							Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Busby EC, 2000, CANCER RES, V60, P2108; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Shieh SY, 2000, GENE DEV, V14, P289; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	15	129	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2971	2974		10.1074/jbc.M009727200	http://dx.doi.org/10.1074/jbc.M009727200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053450	hybrid			2022-12-25	WOS:000166784800090
J	Baldursson, O; Ostedgaard, LS; Rokhlina, T; Cotten, JF; Welsh, MJ				Baldursson, O; Ostedgaard, LS; Rokhlina, T; Cotten, JF; Welsh, MJ			Cystic fibrosis transmembrane conductance regulator Cl- channels with R domain deletions and translocations show phosphorylation-dependent and -independent activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; CFTR; PROTEIN	Phosphorylation of the R domain regulates cystic fibrosis transmembrane conductance regulator Cl- channel activity. Earlier studies suggested that the R domain controls activity via more than one mechanism; a phosphorylated R domain may stimulate activity, and an unphosphorylated R domain may prevent constitutive activity, i.e, opening with ATP alone. However, the mechanisms responsible for these two regulatory properties are not understood. In this study we asked whether the two effects are dependent on its position in the protein and whether smaller regions from the R domain mediate the effects. We found that several portions of the R domain conferred phosphorylation-stimulated activity. This was true whether the R domain sequences were present in their normal location or were translocated to the C terminus. We also found that some parts of the R domain could be deleted without inducing constitutive activity. However, when residues 760-783 were deleted, channels opened without phosphorylation, Translocation of the R domain to the C terminus did not prevent constitutive activity, These results suggest that different parts of the phosphorylated R domain can stimulate activity and that their location within the protein is not critical. In contrast, prevention of constitutive activity required a short specific sequence that could not be moved to the C terminus. These results are consistent with a recent model of an R domain composed primarily of random coil in which more than one phosphorylation site is capable of stimulating channel activity, and net activity reflects interactions between multiple sites in the R domain and the rest of the channel.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, 500 EMRB, Iowa City, IA 52242 USA.			Ostedgaard, Lynda/0000-0001-7717-3442; Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL061234, R01HL058340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61234, HL58340] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldursson O, 2000, AM J PHYSIOL-LUNG C, V279, pL835, DOI 10.1152/ajplung.2000.279.5.L835; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DULHANTY AM, 1994, FEBS LETT, V343, P109, DOI 10.1016/0014-5793(94)80300-5; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Luo JX, 1998, AM J PHYSIOL-CELL PH, V274, pC1397, DOI 10.1152/ajpcell.1998.274.5.C1397; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; Ma JJ, 1997, J BIOL CHEM, V272, P28133, DOI 10.1074/jbc.272.44.28133; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Ostedgaard LS, 2000, P NATL ACAD SCI USA, V97, P5657, DOI 10.1073/pnas.100588797; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RICH DP, 1993, J BIOL CHEM, V268, P20259; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Travis SM, 1997, P NATL ACAD SCI USA, V94, P11055, DOI 10.1073/pnas.94.20.11055; Vankeerberghen A, 1999, BIOCHEMISTRY-US, V38, P14988, DOI 10.1021/bi991520d; Wilkinson DJ, 1997, AM J PHYSIOL-LUNG C, V273, pL127, DOI 10.1152/ajplung.1997.273.1.L127; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; Xie JX, 2000, BIOPHYS J, V78, P1293, DOI 10.1016/S0006-3495(00)76685-9	25	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1904	1910		10.1074/jbc.M006934200	http://dx.doi.org/10.1074/jbc.M006934200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038358	hybrid			2022-12-25	WOS:000166528000036
J	DiGregorio, PJ; Ubersax, JA; O'Farrell, PH				DiGregorio, PJ; Ubersax, JA; O'Farrell, PH			Hypoxia and nitric oxide induce a rapid, reversible cell cycle arrest of the drosophila syncytial divisions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYOS; OXYGEN	Cells can respond to reductions in oxygen (hypoxia) by metabolic adaptations, quiescence or cell death (1), The nuclear division cycles of syncytial stage Drosophila melanogaster embryos reversibly arrest upon hypoxia, We examined this rapid arrest in real time using a fusion of green fluorescent protein and histone 2A In addition to an interphase arrest, mitosis was specifically blocked in metaphase, much like a checkpoint arrest. Nitric oxide, recently proposed as a hypoxia signal in Drosophila, induced a reversible arrest of the nuclear divisions comparable with that induced by hypoxia. Syncytial stage embryos die during prolonged hypoxia, whereas post-gastrulation embryos (cellularized) survive (2, 3). We examined ATP levels and morphology of syncytial and cellularized embryos arrested by hypoxia, nitric oxide, or cyanide. Upon oxygen deprivation, the ATP levels declined only slightly in cellularized embryos and more substantially in syncytial embryos. Reversal of hypoxia restored ATP levels and relieved the cell cycle and developmental arrests. However, morphological abnormalities suggested that syncytial embryos suffered irreversible disruption of developmental programs. Our results suggest that nitric oxide plays a role in the response of the syncytial embryo to hypoxia but that it is not the sole mediator of these responses.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	O'Farrell, PH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, POB 0448, San Francisco, CA 94143 USA.			O'Farrell, Patrick/0000-0003-0011-2734	NIGMS NIH HHS [R01 GM060988, R01 GM060988-02, GM 37193, R01 GM037193-14, GM 60988, R01 GM060988-01, R01 GM037193, R37 GM037193] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060988, R01GM037193, R37GM037193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M, 1989, DROSOPHILA LAB MANUA, P434; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Clarkson M, 1999, DNA CELL BIOL, V18, P457, DOI 10.1089/104454999315178; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; Green SL, 1998, CANCER J SCI AM, V4, P218; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; Truman JW, 1996, DEVELOPMENT, V122, P3949; WILSON JD, 1991, HARRISONS PRINCIPLES, P2568; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	15	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1930	1937		10.1074/jbc.M003911200	http://dx.doi.org/10.1074/jbc.M003911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11054409	Green Accepted, hybrid			2022-12-25	WOS:000166528000040
J	Hayes, CS; Alarcon-Hernandez, E; Setlow, P				Hayes, CS; Alarcon-Hernandez, E; Setlow, P			N-terminal amino acid residues mediate protein-protein interactions between DNA-bound alpha/ss-type small, acid-soluble spore proteins from Bacillus species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS SPORES; IN-VITRO; BINDING; EXPRESSION; GENE; IDENTIFICATION; SPORULATION; RESISTANCE; CLONING	The binding of alpha/beta -type small, acid-soluble spore proteins (SASP) to DNA of spores of Bacillus species is the major determinant of DNA resistance to a variety of damaging treatments. The primary sequence of alpha/beta -type SASP is highly conserved; however, the N-terminal third of these proteins is less well conserved than the C-terminal two-thirds. To determine the functional importance of residues in the N-terminal region of alpha/beta -type SASP, variants of SspC (a minor alpha/beta -type SASP from Bacillus subtilis) with modified N termini were generated and their structural and DNA binding properties studied in vitro and in vivo. SspC variants with deletions of up to 14 residues (similar to 20% of SspC residues) were able to bind DNA in vitro and adopted similar conformations when bound to DNA, as determined by circular dichroism spectroscopy and protein-protein cross-linking. Progressive deletion of up to 11 N-terminal residues resulted in proteins with progressively lower DNA binding affinity. However, SspC(Delta 14) (in which 14 N-terminal residues have been deleted) showed significantly higher affinity for DNA than the larger proteins, SspC(Delta 10) and SspC(Delta 11). The affinity of these proteins for DNA was shown to be largely dependent upon the charge of the first few N-terminal residues. These results are interpreted in the context of a model for DNA-dependent alpha/beta -type SASP protein-protein interaction involving the N-terminal regions of these proteins.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Connecticut	Setlow, P (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA.	setlow@sun.uchc.edu	Hayes, Christopher/A-5505-2009		NIGMS NIH HHS [GM19698] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019698, R01GM019698] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; CONNORS MJ, 1985, J BACTERIOL, V161, P333, DOI 10.1128/JB.161.1.333-339.1985; DIXON HBF, 1964, BIOCHEM J, V92, P661, DOI 10.1042/bj0920661; Driks A, 2000, PROKARYOTIC DEVELOPMENT, P191; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; GOLDRICK S, 1983, J BACTERIOL, V155, P1459, DOI 10.1128/JB.155.3.1459-1462.1983; GRIFFITH J, 1994, P NATL ACAD SCI USA, V91, P8224, DOI 10.1073/pnas.91.17.8224; Hayes CS, 1998, J BIOL CHEM, V273, P17326, DOI 10.1074/jbc.273.28.17326; Hayes CS, 1997, J BACTERIOL, V179, P6020, DOI 10.1128/jb.179.19.6020-6027.1997; Hayes DS, 2000, J BIOL CHEM, V275, P35040, DOI 10.1074/jbc.M005669200; ILLADESAGUIAR B, 1994, J BACTERIOL, V176, P2788, DOI 10.1128/JB.176.10.2788-2795.1994; MASON JM, 1986, J BACTERIOL, V167, P174, DOI 10.1128/jb.167.1.174-178.1986; MASON JM, 1988, J BACTERIOL, V170, P239, DOI 10.1128/jb.170.1.239-244.1988; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MOHR SC, 1991, P NATL ACAD SCI USA, V88, P77, DOI 10.1073/pnas.88.1.77; NICHOLSON WL, 1990, J BACTERIOL, V172, P6900, DOI 10.1128/jb.172.12.6900-6906.1990; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; POPHAM DL, 1995, APPL ENVIRON MICROB, V61, P3633, DOI 10.1128/AEM.61.10.3633-3638.1995; RAO H, 1992, FEBS LETT, V305, P115, DOI 10.1016/0014-5793(92)80876-I; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; SETLOW B, 1995, J BACTERIOL, V177, P4149, DOI 10.1128/jb.177.14.4149-4151.1995; SETLOW B, 1992, J BACTERIOL, V174, P2312, DOI 10.1128/JB.174.7.2312-2322.1992; SETLOW P, 1992, J BACTERIOL, V174, P2737, DOI 10.1128/JB.174.9.2737-2741.1992; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; TOVARROJO F, 1991, J BACTERIOL, V173, P4827, DOI 10.1128/jb.173.15.4827-4835.1991; VANHEYNINGEN S, 1967, BIOCH J, V104; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	33	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2267	2275		10.1074/jbc.M007858200	http://dx.doi.org/10.1074/jbc.M007858200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11044450	hybrid			2022-12-25	WOS:000166528000083
J	Kojima, K; Kitada, S; Ogishima, T; Ito, A				Kojima, K; Kitada, S; Ogishima, T; Ito, A			A proposed common structure of substrates bound to mitochondrial processing peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; PROTEIN IMPORT; ALPHA-SUBUNIT; BETA-SUBUNIT; ALDEHYDE DEHYDROGENASE; SYNTHETIC PEPTIDE; AMINO-ACIDS; RECOGNITION; CLEAVAGE; BINDING	Mitochondrial processing peptidase (MPP), a metalloendopeptidase consisting of alpha- and beta -subunits, specifically cleaves off the N-terminal presequence of the mitochondrial protein precursor. Structural information of the substrate bound to MPP was obtained using fluorescence resonance energy transfer (FRET) measurement. A series of the peptide substrates, which have distal arginine residues required for effective cleavage at positions -7, - 10, - 14, and -17 from the cleavage site, were synthesized and covalently labeled with 7-diethyl aminocoumarin-3-carboxylic acid at the N termini and N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa- 1,3-diazol-4-yl)ethylenediamine (IANBD) at position +4, as fluorescent donor and acceptor, respectively. When the peptides were bound to MPP, substantially the same distances were obtained between the two probes, irrespective of the length of the intervening sequence between the two probes. When 7-diethylamino-3-(4'-maleimidyl phenyl)-4-methyl coumarin was introduced into a single cysteine residue in beta -MPP as a donor and IANBD was coupled either at the N terminus or the +4 position of the peptide substrate as an acceptor, intermolecular FRET measurements also demonstrated that distances of the donor-acceptor pair were essentially the same among the peptides with different lengths of intervening sequences, The results indicate that the N-terminal portion and the portion around the cleavage site of the presequence interact with specific sites in the MPP molecule, irrespective of the length of the intervening sequence between the two portions, suggesting the structure of the intervening sequence is flexible when bound to the MPP.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan	Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.							Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Ito A, 1999, BIOCHEM BIOPH RES CO, V265, P611, DOI 10.1006/bbrc.1999.1703; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; Kitada S, 1998, J BIOL CHEM, V273, P32547, DOI 10.1074/jbc.273.49.32547; Kojima K, 1998, J BIOL CHEM, V273, P32542, DOI 10.1074/jbc.273.49.32542; Makarova KS, 1999, PROTEIN SCI, V8, P2537; Moriwaki K, 1999, J BIOCHEM, V126, P874, DOI 10.1093/oxfordjournals.jbchem.a022529; Nagao Y, 2000, J BIOL CHEM, V275, P34552, DOI 10.1074/jbc.M003110200; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; Roise D, 1997, J BIOENERG BIOMEMBR, V29, P19, DOI 10.1023/A:1022403604273; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; Shimokata K, 1998, J BIOL CHEM, V273, P25158, DOI 10.1074/jbc.273.39.25158; Shimokata K, 1997, J BIOCHEM-TOKYO, V122, P1019; Song MC, 1996, J BIOCHEM-TOKYO, V120, P1163; Song MC, 1998, J BIOCHEM, V124, P1045, DOI 10.1093/oxfordjournals.jbchem.a022198; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	29	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2115	2121		10.1074/jbc.M003111200	http://dx.doi.org/10.1074/jbc.M003111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11031253	hybrid			2022-12-25	WOS:000166528000064
J	Toyofuku, T; Akamatsu, Y; Zhang, H; Kuzuya, T; Tada, M; Hori, M				Toyofuku, T; Akamatsu, Y; Zhang, H; Kuzuya, T; Tada, M; Hori, M			c-Src regulates the interaction between connexin-43 and ZO-1 in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION CHANNELS; ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; PDZ-DOMAIN; CELL COMMUNICATION; EPITHELIAL-CELLS; MOLECULAR-BASIS; EXPRESSION; HEART; PERMEABILITY	Connexin-43 is known to interact directly with ZO-1 in cardiac myocytes, but little is known about the role of ZO-1 in connexin 43 function. In cardiac myocytes, constitutively active c-Src inhibited endogenous interaction between connexin-43 and ZO-1 by binding to connexin-43, In HEK293 cells, by contrast, a connexin-43 mutant lacking the Src phosphorylation site (Tyr(265)) interacted with ZO-1 despite cotransfection of a constitutively active c-Src. Moreover, in vitro binding assays using recombinant proteins synthesized from regions of connexin-43 and ZO-1 showed that the tyrosine-phosphorylated C terminus of connexin-43 interacts with the c-Src SH2 domain in parallel with the loss of its interaction with ZO 1. Cell surface biotinylation revealed that, by phosphorylating Tyr(265), constitutively active c-Src reduces total and cell surface connexin-43 down to the levels seen in cells expressing a mutant connexin-43 lacking the ZO-1 binding domain. Finally, electrophysiological analysis showed that both the tyrosine phosphorylation site and the ZO-1-binding domain of connexin-43 were involved in the regulation of gap junctional function. We therefore conclude that c-Src regulates the interaction between connexin 43 and ZO-1 through tyrosine phosphorylation and through the binding of its SH2 domain to connexin-43.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Pathol & Pathophysiol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Toyofuku, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; Bennett M V, 1992, Semin Cell Biol, V3, P29; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DUNHAM B, 1992, CIRC RES, V70, P1233, DOI 10.1161/01.RES.70.6.1233; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FISHMAN GI, 1991, P NATL ACAD SCI USA, V88, P3525, DOI 10.1073/pnas.88.9.3525; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GUERRIER A, 1995, J CELL SCI, V108, P2609; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KWAK BR, 1995, EXP CELL RES, V220, P456, DOI 10.1006/excr.1995.1337; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; LAMPE PD, 1994, J CELL BIOL, V127, P1895, DOI 10.1083/jcb.127.6.1895; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; LUQUE EA, 1994, J MORPHOL, V222, P203, DOI 10.1002/jmor.1052220207; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MORENO AP, 1994, CIRC RES, V74, P1050, DOI 10.1161/01.RES.74.6.1050; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; OH SY, 1991, BIOCHIM BIOPHYS ACTA, V1094, P243, DOI 10.1016/0167-4889(91)90016-Q; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; Potts W M, 1988, Oncogene Res, V3, P343; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPRAY DC, 1994, BIOPHYS J, V67, P491, DOI 10.1016/S0006-3495(94)80510-7; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Toyofuku T, 1999, CIRC RES, V85, P672, DOI 10.1161/01.RES.85.8.672; Toyofuku T, 1998, J BIOL CHEM, V273, P1519, DOI 10.1074/jbc.273.3.1519; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	48	173	178	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1780	1788		10.1074/jbc.M005826200	http://dx.doi.org/10.1074/jbc.M005826200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035005	hybrid			2022-12-25	WOS:000166528000019
J	Tsivkovskii, R; MacArthurs, BC; Lutsenko, S				Tsivkovskii, R; MacArthurs, BC; Lutsenko, S			The Lys(1010)-Lys(1325) fragment of the Wilson's disease protein binds nucleotides and interacts with the N-terminal domain of this protein in a copper-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; ESCHERICHIA-COLI; MENKES-DISEASE; FUNCTIONAL EXPRESSION; TRANSPORTING ATPASE; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC LOOP; CANDIDATE GENE; ATP7B; IDENTIFICATION	Wilson's disease, an autosomal disorder associated with vast accumulation of copper in tissues, is caused by mutations in a gene encoding a copper-transporting ATPase (Wilson's disease protein, WNDP), Numerous mutations have been identified throughout the WNDP sequence, particularly in the Lys(1010)-Lys(1325) segment; however, the biochemical properties and molecular mechanism of WNDP remain poorly characterized. Here, the Lys(1010)-Lys(1325) fragment of WNDP was overexpressed, purified, and shown to form an independently folded ATP-binding domain (ATP-BD). ATP-BD binds the fluorescent ATP analogue trinitrophenyl-ATP with high affinity, and ATP competes with trinitrophenyl-ATP for the binding site; ADP and AMP appear to bind to ATP-BD at the site separate from ATP. Purified ATP-BD hydrolyzes ATP and interacts specifically with the N-terminal copper-binding domain of WNDP (N-WNDP). Strikingly, copper binding to N-WNDP diminishes these interactions, suggesting that the copper-dependent change in domain-domain contact may represent the mechanism of WNDP regulation. In agreement with this hypothesis, N-WNDP induces conformational changes in ATP-BD as evidenced by the altered nucleotide binding properties of ATP-BD in the presence of N-WNDP, Significantly, the effects of copper-free and copper-bound N-WNDP on ATP-BD are not identical. The implications of these results for the WNDP function are discussed.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	lutsenko@ohsu.edu		MacArthur, Brian/0000-0003-1048-5243				Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Harrison MD, 1999, BBA-MOL BASIS DIS, V1453, P254, DOI 10.1016/S0925-4439(98)00110-0; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Moncalian G, 1999, J BIOL CHEM, V274, P36117, DOI 10.1074/jbc.274.51.36117; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; Noll M, 1998, J BIOL CHEM, V273, P21393, DOI 10.1074/jbc.273.33.21393; Ogawa H, 2000, FEBS LETT, V471, P99, DOI 10.1016/S0014-5793(00)01374-0; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; Ralle M, 1998, J AM CHEM SOC, V120, P13525, DOI 10.1021/ja982990i; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Scheinberg IH, 1984, WILSONS DIS MAJOR PR, V23; Shah AB, 1997, AM J HUM GENET, V61, P317, DOI 10.1086/514864; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TSAI KJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P267, DOI 10.1006/abbi.1993.1421; VERGA V, 1991, AM J HUM GENET, V48, P1133; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; WylerDuda P, 1996, FEBS LETT, V399, P143, DOI 10.1016/S0014-5793(96)01306-3; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471	41	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2234	2242		10.1074/jbc.M003238200	http://dx.doi.org/10.1074/jbc.M003238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053407	hybrid			2022-12-25	WOS:000166528000078
J	Long, KE; Asou, H; Snider, MD; Lemmon, V				Long, KE; Asou, H; Snider, MD; Lemmon, V			The role of endocytosis in regulating L1-mediated adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; COATED VESICLE FORMATION; II PHOSPHORYLATION SITE; MOLECULE L1; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; CRASH SYNDROME	L1 is a neural cell adhesion molecule critical for neural development. Full-length L1 (L1(FL)) contains an alternatively spliced cytoplasmic sequence, RSLE, which is absent in L1 expressed in nonneuronal cells. The RSLE sequence follows a tyrosine, creating an endocytic motif that allows rapid internalization via clathrin-mediated endocytosis. We hypothesized that L1(FL) would internalize more rapidly than L1 lacking the RSLE sequence (L1(Delta RSLE)) and that internalization might regulate L1-mediated adhesion. L1 internalization was measured by immunofluorescence microscopy and by uptake of I-125-anti-rat-L1 antibody, demonstrating that L1(FL) is internalized 2-3 times faster than L1(Delta RSLE). Inhibition of clathrin-mediated endocytosis slowed internalization of L1(FL) but did not affect initial uptake of L1(Delta RSLE) To test whether L1 endocytosis regulates L1 adhesion, cell aggregation rates were tested. L1 Delta (RSLE) cells aggregated two times faster than L1(FL), cells. Inhibition of clathrin-mediated endocytosis increases the aggregation rate of the L1(Delta RSLE) cells. Our results demonstrate that rapid internalization of L1 dramatically affects L1 adhesion.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Tokyo Metropolitan Inst Gerontol, Dept Neurobiol, Itabashi Ku, Tokyo 1730015, Japan	Case Western Reserve University; Case Western Reserve University; Tokyo Metropolitan Institute of Gerontology	Lemmon, V (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Rm E661,2109 Adelbert Rd, Cleveland, OH 44106 USA.		Lemmon, Vance/A-7410-2010; Lemmon, Vance/A-2565-2008	Lemmon, Vance/0000-0003-3550-7576; 	NATIONAL EYE INSTITUTE [P30EY011373, R01EY005285] Funding Source: NIH RePORTER; NEI NIH HHS [P30EY11373, R01 EY005285-23, EY-05285, P30 EY011373, R01 EY005285] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BARAMI K, 1994, NEURON, V13, P567, DOI 10.1016/0896-6273(94)90026-4; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Bradshaw JD, 1997, BIOCHEMISTRY-US, V36, P15975, DOI 10.1021/bi971762i; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; BRITTIS PA, 1995, MOL CELL NEUROSCI, V6, P433, DOI 10.1006/mcne.1995.1032; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; Burden-Gulley Susan M., 1995, Seminars in Developmental Biology, V6, P79, DOI 10.1016/S1044-5781(06)80017-4; CARPENTIER JL, 1989, J CELL PHYSIOL, V138, P519, DOI 10.1002/jcp.1041380311; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; CROWE DT, 1994, J BIOL CHEM, V269, P14411; DahlinHuppe K, 1997, MOL CELL NEUROSCI, V9, P144, DOI 10.1006/mcne.1997.0608; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DAVIS RJ, 1987, J BIOL CHEM, V262, P13126; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; FRANSEN E, 1995, EUR J HUM GENET, V3, P273; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; Holbrook MR, 1999, BIOCHEMISTRY-US, V38, P9348, DOI 10.1021/bi990195r; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kamiguchi H, 1998, J NEUROSCI, V18, P3749, DOI 10.1523/jneurosci.18-10-03749.1998; KAMIGUCHI H, 2000, J ENUROSCI, V15, P3676; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MIURA M, 1992, J BIOL CHEM, V267, P10752; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHAEFER A, 1998, CELL ADHES COMMUN S, V6, P75; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; SCHMIDT CE, 1995, J NEUROSCI, V15, P3400; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; Takeda Y, 1996, J NEUROCHEM, V66, P2338; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wong EV, 1996, J NEUROCHEM, V66, P779; Wong EV, 1995, NEUROSCI LETT, V200, P155, DOI 10.1016/0304-3940(95)12100-I; Wong EV, 1996, J BIOL CHEM, V271, P18217, DOI 10.1074/jbc.271.30.18217; Yamasaki M, 1997, NEUROPEDIATRICS, V28, P175, DOI 10.1055/s-2007-973696	60	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1285	1290		10.1074/jbc.M006658200	http://dx.doi.org/10.1074/jbc.M006658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035015	hybrid, Green Accepted			2022-12-25	WOS:000166430900058
J	Nguyen, DT; Alarco, AM; Raymond, M				Nguyen, DT; Alarco, AM; Raymond, M			Multiple Yap1p-binding sites mediate induction of the yeast major facilitator FLR1 gene in response to drugs, oxidants, and alkylating agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; YAP-1 TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; NUCLEAR EXPORT; ESCHERICHIA-COLI; TARGET GENE; GLUTATHIONE; TRANSPORTER; RESISTANCE; EXPRESSION	The bZip transcription factor Yap1p plays an important role in oxidative stress response and multidrug resistance in Saccharomyces cerevisiae, We have previously demonstrated that the FLR1 gene, encoding a multidrug transporter of the major facilitator superfamily, is a transcriptional target of Yap1p. The FLR1 promoter contains three potential Yap1p response elements (YREs) at positions -148 (YRE1), -167 (YRE2), and -364 (YRE3). To address the function of these YREs, the three sites have been individually mutated and tested in transactivation assays. Our results show that (i) each of the three YREs is functional and important for the optimal transactivation of FLR1 by Yap1p and that (ii) the three YREs are not functionally equivalent, mutation of YRE3 being the most deleterious, followed by YRE2 and YRE1, Simultaneous mutation of the three YREs abolished transactivation of the promoter by Yap1p, demonstrating that the three sites are essential for the regulation of FLR1 by Yap1p. Gel retardation assays confirmed that Yap1p differentially binds to the three YREs (YRE3 > YRE2 > YRE1). We show that the transcription of FLR1 is induced upon cell treatment with the oxidizing agents diamide, diethylmaleate, hydrogen peroxide, and tert-butyl hydroperoxide, the antimitotic drug benomyl, and the alkylating agent methylmethane sulfonate and that this induction is mediated by Yap1p through the three YREs, Finally, we show that FLR1 overexpression confers resistance to diamide, diethylmaleate, and menadione but hypersensitivity to H2O2, demonstrating that the Flr1p transporter participates in Yap1p mediated oxidative stress response in S. cerevisiae.	Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Raymond, M (corresponding author), Clin Res Inst Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	raymonm@ircm.qc.ca						Alarco AM, 1997, J BIOL CHEM, V272, P19304, DOI 10.1074/jbc.272.31.19304; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broco N, 1999, YEAST, V15, P1595; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Coleman ST, 1997, J BIOL CHEM, V272, P23224, DOI 10.1074/jbc.272.37.23224; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dumond H, 2000, MOL MICROBIOL, V36, P830, DOI 10.1046/j.1365-2958.2000.01845.x; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Jungwirth H, 2000, EUR J BIOCHEM, V267, P4809, DOI 10.1046/j.1432-1327.2000.01537.x; Kolaczkowska A, 1999, DRUG RESIST UPDATE, V2, P403, DOI 10.1054/drup.1999.0113; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Oskouian B, 1999, MOL GEN GENET, V261, P346, DOI 10.1007/s004380050975; SantoniRugiu E, 1997, CARCINOGENESIS, V18, P2255, DOI 10.1093/carcin/18.11.2255; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stephen DWS, 1997, MOL MICROBIOL, V23, P203, DOI 10.1046/j.1365-2958.1997.2081572.x; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Sugiyama K, 2000, J BIOL CHEM, V275, P15535, DOI 10.1074/jbc.275.20.15535; Toone WM, 1999, CURR OPIN GENET DEV, V9, P55, DOI 10.1016/S0959-437X(99)80008-2; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; Wemmie JA, 1997, MOL MICROBIOL, V25, P683, DOI 10.1046/j.1365-2958.1997.5061868.x; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zadzinski R, 1998, BIOCHEM MOL BIOL INT, V44, P747	51	82	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1138	1145		10.1074/jbc.M008377200	http://dx.doi.org/10.1074/jbc.M008377200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11056165	hybrid			2022-12-25	WOS:000166430900040
J	Trotti, D; Aoki, M; Pasinelli, P; Berger, UV; Danbolt, NC; Brown, RH; Hediger, MA				Trotti, D; Aoki, M; Pasinelli, P; Berger, UV; Danbolt, NC; Brown, RH; Hediger, MA			Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; RAT-BRAIN; REENTRANT LOOP; SPINAL-CORD; EXPRESSION; GLT-1; EAAT2; GENE; SUBSTRATE; GLYCOSYLATION	We have investigated the functional impact of a naturally occurring mutation of the human glutamate transporter GLT1 (EAAT2), which had been detected in a patient with sporadic amyotrophic lateral sclerosis, The mutation involves a substitution of the putative N-linked glycosylation site asparagine 206 by a serine residue (N206S) and results in reduced glycosylation of the transporter and decreased uptake activity. Electrophysiological analysis of N206S revealed a pronounced reduction in transport rate compared with wild-type, but there was no alteration in the apparent affinities for glutamate and sodium. In addition, no change in the sensitivity for the specific transport inhibitor dihydrokainate was observed, However, the decreased rate of transport was associated with a reduction of the N206S transporter in the plasma membrane. Under ionic conditions, which favor the reverse operation mode of the transporter, N206S exhibited an increased reverse transport capacity. Furthermore, if coexpressed in the same cell, N206S manifested a dominant negative effect on the wild-type GLT1 activity, whereas it did not affect wild-type EAAC1, These findings provide evidence for a role of the N-linked glycosylation in both cellular trafficking and transport function. The resulting alteration in glutamate clearance capacity likely contributes to excitotoxicity that participates in motor neuron degeneration in amyotrophic lateral sclerosis.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cecil B Day Lab Neuromuscular Res, Charlestown, MA 02129 USA; Univ Oslo, Inst Basic Med Sci, Dept Physiol, N-0337 Oslo, Norway	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Oslo	Hediger, MA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Membrane Biol Program, Harvard Inst Med Bldg,Rm 570,77 Ave Louis Pasteur, Boston, MA 02115 USA.	mhediger@rics.bwh.harvard.edu	Danbolt, Niels Christian/A-1907-2014	Danbolt, Niels Christian/0000-0003-4227-4520; Hediger, Matthias/0000-0003-1946-027X; Pasinelli, Piera/0000-0002-3385-2707; Trotti, Davide/0000-0001-6338-6404	NATIONAL INSTITUTE ON AGING [P01AG012992] Funding Source: NIH RePORTER; Fondazione Telethon Funding Source: Custom; AHRQ HHS [5F32HS10064] Funding Source: Medline; NIA NIH HHS [1PO1AG12992-04] Funding Source: Medline; Telethon [342/B] Funding Source: Medline; ONDIEH CDC HHS [1PO1ND31248-05] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Fondazione Telethon(Fondazione Telethon); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Telethon(Fondazione Telethon); ONDIEH CDC HHS		Aoki M, 1998, ANN NEUROL, V43, P645, DOI 10.1002/ana.410430514; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bergles DE, 1997, NEURON, V19, P1297, DOI 10.1016/S0896-6273(00)80420-1; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; CONRADT M, 1995, EUR J BIOCHEM, V229, P682, DOI 10.1111/j.1432-1033.1995.tb20514.x; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; Dehnes Y, 1998, J NEUROSCI, V18, P3606; Diamond JS, 1997, J NEUROSCI, V17, P4672; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Gaal L, 1998, J NEUROPHYSIOL, V79, P190, DOI 10.1152/jn.1998.79.1.190; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; HAYES G, 1994, J BIOL CHEM, V269, P24143; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kugler P, 1999, GLIA, V27, P129, DOI 10.1002/(SICI)1098-1136(199908)27:2<129::AID-GLIA3>3.0.CO;2-Y; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; Mennerick S, 1999, J NEUROSCI, V19, P9242; Meyer T, 1998, J NEUROL NEUROSUR PS, V65, P954, DOI 10.1136/jnnp.65.6.954; Meyer T, 1997, NEUROREPORT, V8, P775, DOI 10.1097/00001756-199702100-00039; Meyer T, 1996, ANN NEUROL, V40, P456, DOI 10.1002/ana.410400317; MEYER T, 1995, ANN NEUROL, V37, P817, DOI 10.1002/ana.410370618; Meyer T, 1998, NEUROSCI LETT, V241, P68, DOI 10.1016/S0304-3940(97)00973-7; Nagai M, 1998, NEUROSCI LETT, V244, P165, DOI 10.1016/S0304-3940(98)00158-X; Nguyen TT, 1996, J NEUROCHEM, V67, P645; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Rothstein JD, 1996, CLIN NEUROSCI, V3, P348; Roux MJ, 2000, NEURON, V25, P373, DOI 10.1016/S0896-6273(00)80901-0; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Trotti D, 1996, J BIOL CHEM, V271, P5976, DOI 10.1074/jbc.271.11.5976; Trotti D, 1999, NAT NEUROSCI, V2, P427, DOI 10.1038/8091; Trotti D, 1998, TRENDS PHARMACOL SCI, V19, P328, DOI 10.1016/S0165-6147(98)01230-9; Trotti D, 1997, EUR J NEUROSCI, V9, P2207, DOI 10.1111/j.1460-9568.1997.tb01388.x; Trotti D, 1997, EUR J NEUROSCI, V9, P1236, DOI 10.1111/j.1460-9568.1997.tb01478.x; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	53	140	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					576	582		10.1074/jbc.M003779200	http://dx.doi.org/10.1074/jbc.M003779200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031254	hybrid			2022-12-25	WOS:000166280700078
J	Siskind, LJ; Colombini, M				Siskind, LJ; Colombini, M			The lipids C-2- and C-16-ceramide form large stable channels - Implications for apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; MEMBRANE-FUSION; CYTOCHROME-C; CERAMIDE; MITOCHONDRIAL; GENERATION; ACTIVATION; STABILITY; RELEASE	We report that physiological concentrations of both short- and long-chain ceramides, despite being lipids, form large stable pores in membranes. Some of these pores should be large enough to allow cytochrome c to permeate. Dihydroceramide differs from ceramide by the reduction of one double bond, and yet both its apoptogenic and channel-forming activities are greatly reduced. A structural model provides insight into how ceramides might form pores. According to a mathematical model, both the individual conductance of the channels and the overall membrane conductance are directly related to the overall concentration of ceramide in the membrane. Slight changes in concentration have dramatic effects on the size of the channels formed, providing an easy way for rapidly altering membrane permeability by changing the activity of local synthetic and catabolic enzymes. A possible role for these channels in apoptosis is discussed.	Univ Maryland, Dept Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Colombini, M (corresponding author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA.	mc34@umail.umd.edu	Colombini, Marco/A-1540-2014	Siskind, Leah/0000-0001-5026-5187	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS042467] Funding Source: NIH RePORTER; NINDS NIH HHS [F31 NS042467, F31 NS042467-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ariga T, 1998, J LIPID RES, V39, P1; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Castedo M, 1996, J IMMUNOL, V157, P512; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Huang HW, 1998, EUR BIOPHYS J BIOPHY, V27, P361, DOI 10.1007/s002490050143; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; PASCHER I, 1976, BIOCHIM BIOPHYS ACTA, V455, P433, DOI 10.1016/0005-2736(76)90316-3; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	33	231	237	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38640	38644		10.1074/jbc.C000587200	http://dx.doi.org/10.1074/jbc.C000587200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11027675	hybrid, Green Accepted			2022-12-25	WOS:000165739800068
J	Sansal, I; Dupont, E; Toru, D; Evrard, C; Rouget, P				Sansal, I; Dupont, E; Toru, D; Evrard, C; Rouget, P			NPDC-1, a regulator of neural cell proliferation and differentiation, interacts with E2F-1, reduces its binding to DNA and modulates its transcriptional activity	ONCOGENE			English	Article						cell proliferation; regulatory genes; regulatory proteins; neural differentiation	TERMINAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; SKELETAL-MUSCLE; DUAL MECHANISMS; CYCLE ARREST; EXPRESSION; KINASE; PHOSPHORYLATION; INHIBITION; REPRESSION	We have previously identified NPDC-1, a neural factor involved in the control of proliferation and differentiation, and we have shown that the stable introduction of NPDC-1 into transformed cells down-regulates cell proliferation both by increasing the generation time and by suppressing transformed properties. The data presented here indicate that, in vitro, NPDC-1 is able to interact with the transcription factor E2F-1 and some cell cycle proteins, such as D-cyclins and cdk2, In addition, two-hybrid experiments in mammalian cells show that the interaction between NPDC-1 and E2F-1 can also occur in vivo. This interaction reduces the binding of E2F-1 to DNA and its transcriptional activity. Taken together, the data suggest that NPDC-1 could influence cell cycle progression and neural differentiation through its association with E2F-1.	Inst Gustave Roussy, CNRS, UMR 1599, Unite Genet Oncol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Rouget, P (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, Unite Genet Oncol, PR-1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.							BIOU V, 1988, PROTEIN ENG, V2, P185, DOI 10.1093/protein/2.3.185; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Dupont E, 1998, J NEUROSCI RES, V51, P257, DOI 10.1002/(SICI)1097-4547(19980115)51:2<257::AID-JNR14>3.0.CO;2-5; GALIANA E, 1995, P NATL ACAD SCI USA, V92, P1560, DOI 10.1073/pnas.92.5.1560; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Harlow E., 1988, ANTIBODIES LAB MANUA; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; KITAGAWA M, 1995, ONCOGENE, V10, P229; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEMESLEVARLOOT L, 1993, COMPUT APPL BIOSCI, V9, P37; Magae J, 1997, ONCOGENE, V15, P759, DOI 10.1038/sj.onc.1201251; Muller H, 1997, MOL CELL BIOL, V17, P5508; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; UNGER R, 1989, PROTEINS, V5, P355, DOI 10.1002/prot.340050410; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x	35	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2000	19	43					5000	5009		10.1038/sj.onc.1203843	http://dx.doi.org/10.1038/sj.onc.1203843			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042687				2022-12-25	WOS:000089834300007
J	Yuasa, M; Masutani, C; Eki, T; Hanaoka, F				Yuasa, M; Masutani, C; Eki, T; Hanaoka, F			Genomic structure, chromosomal localization and identification of mutations in the xeroderma pigmentosum variant (XPV) gene	ONCOGENE			English	Article						xeroderma pigmentosum variant (XPV); DNA polymerase eta; genomic structure; chromosome 6; mutation analysis; TATA-less promoter; translesion synthesis	DNA-POLYMERASE-ZETA; THYMINE DIMER; ULTRAVIOLET-LIGHT; MAMMALIAN-CELLS; MOUSE HOMOLOGS; REPLICATION; TRANSCRIPTION; EXTRACTS; BYPASS; HYPERMUTABILITY	The xeroderma pigmentosum variant (XP-V) is one of the most common forms of this cancer-prone syndrome. XP groups A through G are characterized by defective nucleotide excision repair, whereas the XP-V phenotype is proficient in this pathway. The XPV gene encodes DNA polymerase eta, which catalyzes an accurate translesion synthesis, indicating that the XPV gene contributes tumor suppression in normal individuals. Here me describe the genomic structure and chromosomal localization of the XPV gene, which includes 11 exons covering the entire coding sequence, lacks a TATA sequence in the upstream region of the transcription-initiation, and is located at the chromosome band 6p21.1-6p12, Analyses of patient-derived XP-V cell lines strongly suggested that three of four cell lines carried homozygous mutations in the XPV gene, The fourth cell line, XP1RO, carried heterozygous point mutations in the XPV gene, one of which was located at the splice acceptor site of exon 2, resulting in the omission of exon 2 from the mature mRNA, These findings provide a basis for diagnosis and therapy of XP-V patients.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Osaka University; Japan Science & Technology Agency (JST); RIKEN	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.		Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227				BrayWard P, 1996, GENOMICS, V32, P1, DOI 10.1006/geno.1996.0070; Carty MP, 1996, J BIOL CHEM, V271, P9637, DOI 10.1074/jbc.271.16.9637; CLEAVER JE, 1972, J INVEST DERMATOL, V58, P124, DOI 10.1111/1523-1747.ep12538913; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Ensch-Simon I, 1998, BIOCHEMISTRY-US, V37, P8218, DOI 10.1021/bi972460j; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; LIM SK, 1992, EMBO J, V11, P3271, DOI 10.1002/j.1460-2075.1992.tb05405.x; Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; MISRA RR, 1993, MOL CELL BIOL, V13, P1002, DOI 10.1128/MCB.13.2.1002; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; OKUMURA K, 1995, GENOMICS, V25, P274, DOI 10.1016/0888-7543(95)80135-9; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Svoboda DL, 1998, CANCER RES, V58, P2445; TAKAHASHI E, 1990, HUM GENET, V86, P14; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Xiao W, 1998, CARCINOGENESIS, V19, P945, DOI 10.1093/carcin/19.5.945; Yamada A, 2000, NUCLEIC ACIDS RES, V28, P2473, DOI 10.1093/nar/28.13.2473; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	40	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4721	4728		10.1038/sj.onc.1203842	http://dx.doi.org/10.1038/sj.onc.1203842			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032022				2022-12-25	WOS:000089528800006
J	O'Malley, KM; Cooperman, BS				O'Malley, KM; Cooperman, BS			Formation of the covalent chymotrypsin center dot antichymotrypsin complex involves no large-scale movement of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERPIN-PROTEINASE COMPLEX; REACTIVE CENTER LOOP; ALPHA-CHYMOTRYPSIN; CONFORMATIONAL-CHANGES; INHIBITION-MECHANISM; PROTEASE COMPLEXES; STRUCTURAL BASIS; ENERGY-TRANSFER; ACTIVE-SITE; BINDING	alpha (1)-Antichymotrypsin is a member of the serine proteinase inhibitor, or serpin, family that typically forms very long-lived, enzymatically inactive 1:1 complexes (denoted E*I*) with its target proteinases. Serpins share a conserved tertiary structure, in which an exposed region of amino acid residues (called the reactive center loop or RCL acts as bait for a target proteinase. Within E*'I*, the two proteins are linked covalently as a result of nucleophilic attack by Ser(195) of the serine proteinase on the P1 residue within the RCL of the serpin. This species is formally similar to the acyl enzyme species normally seen as an intermediate in serpin proteinase catalysis. However, its subsequent hydrolysis is extremely slow as a result of structural changes within the enzyme leading to distortion of the active site. There is at present an ongoing debate concerning the structure of the E*I* complex; in particular, as to whether the enzyme, bound to P1, maintains its original position at the top of the serpin molecule or instead translocates across the entire length of the serpin, with concomitant insertion of RCL residues P1-P14 within beta -sheet A and a large separation of the enzyme and RCL residue P1'. We report time-resolved fluorescence energy transfer and rapid mixing/quench studies that support the former model. Our results indicate that the distance between residue P1' in alpha (1)-antichymotrypsin and the amino terminus of chymotrypsin actually decreases on conversion of the encounter complex E.I to E*I*. These results led us to formulate a comprehensive mechanism that accounted both for our results and for those of others supporting the two different E*I* structures. In this mechanism, partial insertion of the RCL, with no large perturbation of the P1' enzyme distance, is followed by covalent acyl enzyme formation. Full insertion can subsequently take place, in a reversible fashion, with the position of equilibrium between the partially and fully inserted complexes depending on the particular serpin-proteinase pair under consideration.	Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	University of Pennsylvania	Cooperman, BS (corresponding author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.	cooprman@pobox.upenn.edu			NIA NIH HHS [AG 10599] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; BLEVINS RA, 1985, J BIOL CHEM, V260, P4264; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CONRAD RH, 1968, BIOCHEMISTRY-US, V7, P777, DOI 10.1021/bi00842a036; CORRIE JET, 1994, J CHEM SOC PERK T 1, P2975, DOI 10.1039/p19940002975; DIXON GH, 1957, J BIOL CHEM, V225, P1049; ENGH R, 1989, PROTEIN ENG, V2, P407, DOI 10.1093/protein/2.6.407; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; FINK AL, 1979, P NATL ACAD SCI USA, V76, P1566, DOI 10.1073/pnas.76.4.1566; FINK AL, 1976, BIOCHEMISTRY-US, V15, P1580, DOI 10.1021/bi00652a031; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; GROSSMAN SH, 1983, BIOCHEMISTRY-US, V22, P5369, DOI 10.1021/bi00292a018; HIRS CHW, 1956, J BIOL CHEM, V219, P611; HOANG DV, 1962, ARCH BIOCHEM BIOPH S, V1, P232; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KATZ DS, 1993, PROTEIN ENG, V6, P701, DOI 10.1093/protein/6.7.701; KELLA NKD, 1984, J BIOL CHEM, V259, P4777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; Luo Y, 1999, J BIOL CHEM, V274, P17733, DOI 10.1074/jbc.274.25.17733; MEEDOM B, 1956, ACTA CHEM SCAND, V10, P881, DOI 10.3891/acta.chem.scand.10-0881; Mellet P, 2000, J BIOL CHEM, V275, P10788, DOI 10.1074/jbc.275.15.10788; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Nash P, 2000, FEBS LETT, V475, P1, DOI 10.1016/S0014-5793(00)01620-3; OHLSSON K, 1976, CLIN SCI MOL MED, V51, P87, DOI 10.1042/cs0510087; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; Picard V, 1999, J BIOL CHEM, V274, P4586, DOI 10.1074/jbc.274.8.4586; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RICHMOND V, 1966, BIOCHIM BIOPHYS ACTA, V127, P499, DOI 10.1016/0304-4165(66)90403-X; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHILLER PW, 1975, BIOCH FLUORESCENCE C, P285; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; Shrikumar A, 1998, J BIOL CHEM, V273, P17459, DOI 10.1074/jbc.273.28.17459; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stone SR, 1997, ADV EXP MED BIOL, V425, P5; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; WACHSSTOCK DH, 1994, BIOPHYS J, V67, P1260, DOI 10.1016/S0006-3495(94)80598-3; Wells MJ, 1999, THROMB HAEMOSTASIS, V81, P325, DOI 10.1055/s-0037-1614472; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	53	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6631	6639		10.1074/jbc.M008478200	http://dx.doi.org/10.1074/jbc.M008478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11027695	hybrid			2022-12-25	WOS:000167261000074
J	Bell, AW; Ward, MA; Blackstock, WP; Freeman, HNM; Choudhary, JS; Lewis, AP; Chotai, D; Fazel, A; Gushue, JN; Paiement, J; Palcy, S; Chevet, E; Lafreniere-Roula, M; Solari, R; Thomas, DY; Rowley, A; Bergeron, JJM				Bell, AW; Ward, MA; Blackstock, WP; Freeman, HNM; Choudhary, JS; Lewis, AP; Chotai, D; Fazel, A; Gushue, JN; Paiement, J; Palcy, S; Chevet, E; Lafreniere-Roula, M; Solari, R; Thomas, DY; Rowley, A; Bergeron, JJM			Proteomics characterization of abundant Golgi membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE PROTEIN; ENDOPLASMIC-RETICULUM; BREFELDIN-A; VESICULAR TRANSPORT; VESICLE TRANSPORT; MASS-SPECTROMETRY; PLASMA-MEMBRANE; MEDIAL GOLGI; SEQUENCE; BINDING	A mass spectrometric analysis of proteins partitioning into Triton X-114 from purified hepatic Golgi apparatus (84% purity by morphometry, 122-fold enrichment over the homogenate for the Golgi marker galactosyl transferase) led to the unambiguous identification of 81 proteins including a novel Golgi-associated protein of 34 kDa (GPP34), The membrane protein complement was resolved by SDS-polyacrylamide gel electrophoresis and subjected to a hierarchical approach using delayed extraction matrix-assisted laser desorption ionization mass spectrometry characterization by peptide mass fingerprinting, tandem mass spectrometry to generate sequence tags, and Edman sequencing of proteins. Major membrane proteins corresponded to known Golgi residents, a Golgi lectin, anterograde cargo, and an abundance of trafficking proteins including KDEL receptors, p24 family members, SNAREs, Rabs, a single ARF-guanine nucleotide exchange factor, and two SCAMPs. Analytical fractionation and gold immunolabeling of proteins in the purified Golgi fraction were used to assess the intra-Golgi and total cellular distribution of GPP34, two SNAREs, SCAMPs, and the trafficking proteins GBF1, BAP31, and alpha (2)P24 identified by the proteomics approach as well as the endoplasmic reticulum contaminant calnexin, Although GPP34 has never previously been identified as a protein, the localization of GPP34 to the Golgi complex, the conservation of GPP34 from yeast to humans, and the cytosolically exposed location of GPP34 predict a role for a novel coat protein in Golgi trafficking.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England; Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3T 1J4, Canada	McGill University; GlaxoSmithKline; Universite de Montreal	Bergeron, JJM (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.	bergeron@med.mcgill.ca	Bergeron, John/AAW-1893-2021; chevet, eric/E-4992-2016; Lafreniere-Roula, Myriam/A-5443-2011; Choudhary, Jyoti/S-1232-2017; Thomas, David/M-7661-2017	chevet, eric/0000-0001-5855-4522; Choudhary, Jyoti/0000-0003-0881-5477; Thomas, David/0000-0002-8854-762X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amshoff C, 1999, BIOL CHEM, V380, P669, DOI 10.1515/BC.1999.083; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; ANTONY C, 1992, J CELL SCI, V103, P785; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; Baranes D, 1996, P NATL ACAD SCI USA, V93, P4706, DOI 10.1073/pnas.93.10.4706; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; BAUDHUIN P, 1967, J CELL BIOL, V35, P631, DOI 10.1083/jcb.35.3.631; BEAUFAY H, 1964, BIOCHEM J, V92, P184, DOI 10.1042/bj0920184; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BONNER R, 1995, RAPID COMMUN MASS SP, V9, P1067, DOI 10.1002/rcm.1290091119; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Dominguez M, 1999, J CELL BIOL, V145, P673, DOI 10.1083/jcb.145.4.673; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DUVE CD, 1971, J CELL BIOL, V50, pD20, DOI 10.1083/jcb.50.1.20d; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, J CELL SCI, V109, P271; GOLGI C, 1898, ARCH ITAL BIOL, V30, P60; Gonatas JO, 1998, J CELL SCI, V111, P249; Harlow E., 1988, ANTIBODIES LAB MANUA; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jensen ON, 1997, ANAL CHEM, V69, P4741, DOI 10.1021/ac970896z; Kelner MJ, 2000, J BIOL CHEM, V275, P13000, DOI 10.1074/jbc.275.17.13000; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Lavoie C, 1999, J CELL BIOL, V146, P285, DOI 10.1083/jcb.146.2.285; Lin CC, 1999, J CELL BIOL, V147, P1457, DOI 10.1083/jcb.147.7.1457; Lippincott-Schwartz J, 1998, HISTOCHEM CELL BIOL, V109, P449, DOI 10.1007/s004180050247; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Mansour SJ, 1998, GENOMICS, V54, P323, DOI 10.1006/geno.1998.5563; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; Schimmoller F, 1998, GENE, V216, P311, DOI 10.1016/S0378-1119(98)00349-7; SHEER DG, 1991, BIOTECHNIQUES, V11, P526; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; SINGERKRUGER B, 1993, J BIOL CHEM, V268, P14376; Singleton DR, 1997, J CELL SCI, V110, P2099; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Southern MR, 1998, BIOINFORMATICS, V14, P821, DOI 10.1093/bioinformatics/14.9.821; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; THORPE GHG, 1985, CLIN CHEM, V31, P1335; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEIBEL ER, 1979, STEREOLOGICAL METHOD, V1, P101; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435	79	190	208	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5152	5165		10.1074/jbc.M006143200	http://dx.doi.org/10.1074/jbc.M006143200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11042173	hybrid			2022-12-25	WOS:000168484300085
J	Alberts, AS				Alberts, AS			Identification of a carboxyl-terminal diaphanous-related formin homology protein autoregulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CYTOSKELETON; SACCHAROMYCES-CEREVISIAE; RHO-FAMILY; FISSION YEAST; CELL-DIVISION; SRC KINASE; REORGANIZATION; CYTOKINESIS; ACTIVATION; DROSOPHILA	Mammalian and fungal Diaphanous-related formin homology (DRF) proteins contain several regions of conserved sequence homology. These include an amino-terminal GTPase binding domain (GBD) that interacts with activated Rho family members and formin homology domains that mediate targeting or interactions with signaling kinases and actin-binding proteins. DRFs also contain a conserved Dia-autoregulatory domain (DAD) in their carboxyl termini that binds the GBD. The GBD is a bifunctional autoinhibitory domain that is regulated by activated Rho. Expression of the isolated DAD in cells causes actin fiber formation and stimulates serum response factor-regulated gene expression. Inhibitor experiments show that the effects of exogenous DAD expression are dependent upon cellular Dia proteins. Alanine substitution of DAD consensus residues that disrupt GBD binding also eliminate DAD biological activity. Thus, DAD expression activates nuclear signaling and actin remodeling by mimicking activated Rho and unlatching the autoinhibited state of the cellular complement of Dia proteins.	Van Andel Res Inst, Lab Cell Struct & Signal Integrat, Grand Rapids, MI 49503 USA	Van Andel Institute	Alberts, AS (corresponding author), 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.							Afshar K, 2000, DEVELOPMENT, V127, P1887; Akada R, 1997, MOL GEN GENET, V254, P267, DOI 10.1007/s004380050415; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; FRAZIER JA, 1997, CURR BIOL, V7, P414; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harris SD, 1997, EMBO J, V16, P3474, DOI 10.1093/emboj/16.12.3474; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Kikyo M, 1999, ONCOGENE, V18, P7046, DOI 10.1038/sj.onc.1203184; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Suetsugu S, 1999, FEBS LETT, V457, P470, DOI 10.1016/S0014-5793(99)01086-8; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Uetz P, 1996, J BIOL CHEM, V271, P33525, DOI 10.1074/jbc.271.52.33525; Umikawa M, 1998, ONCOGENE, V16, P2011, DOI 10.1038/sj.onc.1201724; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Zahner JE, 1996, MOL CELL BIOL, V16, P1857; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	42	263	271	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2824	2830		10.1074/jbc.M006205200	http://dx.doi.org/10.1074/jbc.M006205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035012	hybrid			2022-12-25	WOS:000166784800073
J	Bjorkman, AM; Dunten, P; Sandgren, MOJ; Dwarakanath, VN; Mowbray, SL				Bjorkman, AM; Dunten, P; Sandgren, MOJ; Dwarakanath, VN; Mowbray, SL			Mutations that affect ligand binding to the Escherichia coli aspartate receptor - Implications for transmembrane signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; SALMONELLA-TYPHIMURIUM; TAR CHEMORECEPTOR; SENSORY RECEPTOR; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL-CHANGES; MALTOSE CHEMOTAXIS; PROTEIN STRUCTURES; CROSS-LINKING; DOMAIN	Three arginine residues of the binding site of the Escherchia coli aspartate receptor contribute to its high affinity for aspartate (K-d similar to3 mum). Site-directed mutations at residue 64 had the greatest effect on aspartate binding. No residue could substitute for the native arginine; all changes resulted in an apparent K-d of similar to 35 mM. These mutations had little impact on maltose responses. At residue Arg-69, a lysine substitution was least disruptive, conferring an apparent K-d of 0.3 mM for aspartate, Results obtained for an alanine mutant were similar to those with cysteine and histidine mutants (K-d similar to5 mM) indicating that side chain size was not an important factor here. Proline and aspartate caused more severe defects, presumably for reasons related to conformation and charge. The impact of residue 69 mutations on the maltose response was small. Mutations at Arg-73 had similar effects on aspartate binding (K-d 0.3-7 mm) but more severe consequences for maltose responses. Larger side chains resulted in the best aspartate binding, implying steric considerations are important here. Signaling in the mutant proteins was surprisingly robust. Given aspartate binding, signaling occurred with essentially wild-type efficiency. These results were evaluated in the context of available structural data.	Swedish Univ Agr Sci, Dept Biol Mol, Ctr Biomed, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Swedish University of Agricultural Sciences; Uppsala University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mowbray, SL (corresponding author), Swedish Univ Agr Sci, Dept Biol Mol, Ctr Biomed, Box 590, S-75124 Uppsala, Sweden.		Mowbray, Sherry L/D-2141-2013	Sandgren, Mats/0000-0002-2358-4534				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BOGONEZ E, 1985, P NATL ACAD SCI USA, V82, P4891, DOI 10.1073/pnas.82.15.4891; Bornhorst JA, 2000, BIOCHEMISTRY-US, V39, P9486, DOI 10.1021/bi0002737; BOWIE JU, 1995, ACTA CRYSTALLOGR D, V51, P145, DOI 10.1107/S0907444994010498; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Chi YI, 1997, FEBS LETT, V414, P327, DOI 10.1016/S0014-5793(97)01027-2; CLARKE S, 1979, J BIOL CHEM, V254, P9695; Djordjevic S, 1998, J STRUCT BIOL, V124, P189, DOI 10.1006/jsbi.1998.4034; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; Gardina PJ, 1998, MOL MICROBIOL, V29, P1147, DOI 10.1046/j.1365-2958.1998.00964.x; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HILL AV, 1910, J PHYSIOL-LONDON, V90, pR4; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KERMODE JC, 1989, BIOCHEM PHARMACOL, V38, P2053, DOI 10.1016/0006-2952(89)90057-9; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kolodziej AF, 1996, BIOCHEMISTRY-US, V35, P14782, DOI 10.1021/bi961481v; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MANSON MD, 1985, J BIOL CHEM, V260, P9727; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1993, J BIOL CHEM, V268, P19991; MIZUNO T, 1986, J BACTERIOL, V165, P890, DOI 10.1128/jb.165.3.890-895.1986; MOWBRAY SL, 1990, J BIOL CHEM, V265, P15638; Mowbray SL, 1998, J STRUCT BIOL, V124, P257, DOI 10.1006/jsbi.1998.4043; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; SCOTT WG, 1994, STRUCTURE, V2, P877, DOI 10.1016/S0969-2126(94)00088-3; SHAKKED Z, 1994, NATURE, V368, P469, DOI 10.1038/368469a0; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; TERWILLIGER TC, 1983, J BIOL CHEM, V258, P9608; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; WOLFF C, 1983, THESIS U KONSTANZ GE; YEH JI, 1993, J BIOL CHEM, V268, P9787; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507; Zhang YH, 1999, P NATL ACAD SCI USA, V96, P939, DOI 10.1073/pnas.96.3.939; ZHANG YH, 1992, J BIOL CHEM, V267, P22813	53	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2808	2815		10.1074/jbc.M009593200	http://dx.doi.org/10.1074/jbc.M009593200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042221	hybrid			2022-12-25	WOS:000166784800071
J	Daub, H; Gevaert, K; Vandekerckhove, J; Sobel, A; Hall, A				Daub, H; Gevaert, K; Vandekerckhove, J; Sobel, A; Hall, A			Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC TARGET; ONCOPROTEIN 18; CELL MOTILITY; INTACT-CELLS; RHO GTPASES; IN-VITRO; KINASE; DYNAMICS; CDC42; IDENTIFICATION	We have identified a rapid protein phosphorylation event at residue serine 16 of stathmin using two-dimensional gel electrophoresis coupled to matrix-assisted laser desorption/ionization mass spectrometry in combination with post-source decay analysis, which is induced by the epidermal growth factor receptor. Phosphorylation is specifically mediated by the small GTPases Rac and Cdc42 and their common downstream target, the serine/threonine kinase p65PAK. Both GTPases have previously been shown to regulate the dynamics of actin polymerization. Because stathmin destabilizes microtubules, and this process is inhibited by phosphorylation at residue 16, Rac and Cdc42 can potentially regulate both F-actin and microtubule dynamics.	UCL, MRC, Mol Cell Biol Lab, Canc Res Campaign,Oncogene & Signal Transduct Grp, London WC1E 6BT, England; UCL, Dept Biochem, London WC1E 6BT, England; State Univ Ghent VIB, Dept Biochem & Med Prot Res, B-900 Ghent, Belgium; INSERM, IFM, U440, F-75005 Paris, France	University of London; University College London; University of London; University College London; Flanders Institute for Biotechnology (VIB); Ghent University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Hall, A (corresponding author), UCL, MRC, Mol Cell Biol Lab, Canc Res Campaign,Oncogene & Signal Transduct Grp, Gower St, London WC1E 6BT, England.	alan.hall@ucl.ac.uk	Gevaert, Kris/H-3637-2013; Gevaert, Kris/D-6489-2017; Gevaert, Kris/AAE-4212-2019	Gevaert, Kris/0000-0002-4237-0283; Gevaert, Kris/0000-0002-4237-0283; Gevaert, Kris/0000-0002-4237-0283				Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Gavet O, 1998, J CELL SCI, V111, P3333; Gevaert K, 1998, ELECTROPHORESIS, V19, P909, DOI 10.1002/elps.1150190606; Gevaert K, 1997, ELECTROPHORESIS, V18, P2950, DOI 10.1002/elps.1150181537; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; Griffin PR, 1995, RAPID COMMUN MASS SP, V9, P1546, DOI 10.1002/rcm.1290091515; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; le Gouvello S, 1998, J IMMUNOL, V161, P1113; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Lin MZ, 2000, CELL, V101, P239, DOI 10.1016/S0092-8674(00)80833-8; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Wadsworth P, 1999, CELL MOTIL CYTOSKEL, V42, P48, DOI 10.1002/(SICI)1097-0169(1999)42:1<48::AID-CM5>3.3.CO;2-#; WagenknechtWiesner A, 1997, FEMS MICROBIOL LETT, V152, P109, DOI 10.1016/S0378-1097(97)00189-4; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	25	221	234	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1677	1680		10.1074/jbc.C000635200	http://dx.doi.org/10.1074/jbc.C000635200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11058583	hybrid			2022-12-25	WOS:000166528000004
J	Kobayashi, H; Suzuki, M; Tanaka, Y; Hirashima, Y; Terao, T				Kobayashi, H; Suzuki, M; Tanaka, Y; Hirashima, Y; Terao, T			Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL INVASION; LEWIS-LUNG-CARCINOMA; BREAST-CANCER CELLS; PLASMINOGEN-ACTIVATOR; GENE-EXPRESSION; DISTINCT FORMS; LINK PROTEIN; DOMAIN-II; METASTASIS; BINDING	Urinary trypsin inhibitor (UTI), a Kunitz-type protease inhibitor, interacts with cells as a negative modulator of the invasive cells, Human ovarian cancer cell line, HRA,was treated with phorbol ester (PMA) to evaluate the effect on expression of urokinase-type plasminogen activator (uPA), since the action of uPA has been implicated in matrix degradation and cell motility. Preincubation of the cells with UTI reduced the ability of PMA to trigger the uPA expression at the gene level and at the protein level. UTI-induced down-regulation of PMA-stimulated uPA expression is irreversible and is independent of a cytotoxic effect. Down-regulation of uPA by UTI is mediated by its binding to the cells. me next asked whether the mechanism of inhibition of uPA expression by UTI was due to interference with the protein kinase C second messenger system. An assay for PKC activity demonstrated that UTI does not directly inhibit the catalytic activity of PKC and that PIMA translocation of PKC from cytosol to membrane was inhibited by UTI, indicating that UTI inhibits the activation cascade of PKC. PMA could also activate a signaling pathway involving MEK1/ERK2/c-Jun-dependent uPA expression. When cells were preincubated with UTI, we could detect suppression of phosphorylation of these proteins. Like several types of PHC inhibitor, UTI inhibited PMA-stimulated invasiveness. We conclude that UTI markedly suppresses the cell motility possibly through negative regulation of PKC and MEK/ERK/c-Jun-dependent mechanisms, and that these changes in behavior are correlated with a coordinated down-regulation of uPA which is likely to contribute to the cell invasion processes.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Hamamatsu, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handacho 3600, Hamamatsu, Shizuoka 4313192, Japan.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DUBOIS P, 1988, BIOCHEM PHARMACOL, V37, P2139, DOI 10.1016/0006-2952(88)90572-2; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FRIEDRICH B, 1988, IMMUNOBIOLOGY, V176, P465, DOI 10.1016/S0171-2985(88)80027-5; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; JOHNSON MD, 1993, CANCER RES, V53, P873; KIKUCHI Y, 1987, CANCER RES, V47, P592; Kobayashi H, 1999, ENDOCRINOLOGY, V140, P3835, DOI 10.1210/en.140.8.3835; Kobayashi H, 1996, EUR J CELL BIOL, V71, P380; KOBAYASHI H, 1995, CANCER RES, V55, P1847; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; KOBAYASHI H, 1995, BRIT J CANCER, V72, P1131, DOI 10.1038/bjc.1995.476; KOBAYASHI H, 1995, INT J CANCER, V63, P455, DOI 10.1002/ijc.2910630326; Kobayashi H, 1998, EUR J BIOCHEM, V253, P817, DOI 10.1046/j.1432-1327.1998.2530817.x; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOBAYASHI H, 1994, CANCER RES, V54, P844; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; Kobayashi H, 1998, BBA-PROTEIN STRUCT M, V1383, P253, DOI 10.1016/S0167-4838(97)00215-X; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MIZUNO K, 1995, FEBS LETT, V359, P259, DOI 10.1016/0014-5793(95)00042-8; NAGAMINE Y, 1995, FIBRINOLYSIS; NIIYA K, 1994, THROMB HAEMOSTASIS, V72, P92; Reuning U, 1998, INT J ONCOL, V13, P893; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; SAKSELA O, 1981, ANAL BIOCHEM, V111, P276, DOI 10.1016/0003-2697(81)90564-9; SEKIGUCHI K, 1987, BIOCHEM BIOPH RES CO, V145, P797, DOI 10.1016/0006-291X(87)91035-7; Sun GW, 1999, J HISTOCHEM CYTOCHEM, V47, P1433, DOI 10.1177/002215549904701109; WALTON GM, 1987, ANAL BIOCHEM, V161, P425, DOI 10.1016/0003-2697(87)90471-4; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Young SW, 1996, FEBS LETT, V384, P181, DOI 10.1016/0014-5793(96)00287-6	36	63	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2015	2022		10.1074/jbc.M007650200	http://dx.doi.org/10.1074/jbc.M007650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050091	hybrid			2022-12-25	WOS:000166528000051
J	Lien, E; Chow, JC; Hawkins, LD; McGuinness, PD; Miyake, K; Espevik, T; Gusovsky, F; Golenbock, DT				Lien, E; Chow, JC; Hawkins, LD; McGuinness, PD; Miyake, K; Espevik, T; Gusovsky, F; Golenbock, DT			A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE DIFFERENTIATION ANTIGEN; TUMOR-NECROSIS-FACTOR; CUTTING EDGE; SOLUBLE CD14; ENDOTOXIN; LPS; RECOGNITION; EXPRESSION; PROTEIN; RESPONSIVENESS	ER-112022 is a novel acyclic synthetic lipid A analog that contains six symmetrically organized fatty acids on a noncarbohydrate backbone. Chinese hamster ovary (CHO)-K1 fibroblasts and U373 human astrocytoma cells do not respond to lipopolysaccharide (LPS) in the absence of CD14. In contrast, exposure to ER-112022 effectively induced activation of CHO and U373 cells under serum-free conditions. Expression of CD14 was not necessary for cells to respond to ER-112022, although the presence of soluble CD14 enhanced the sensitivity of the response. Several lines of evidence suggested that ER-112022 stimulates cells via the LPS signal transduction pathway. First, the diglucosamine based LPS antagonists E5564 and E5531 blocked ER-112022-induced stimulation of CHO-RI, U373, and RAW264.7 cells. Second, ER-112022 was unable to activate C3H/HeJ mouse peritoneal macrophages, containing a mutation in Toll-like receptor (TLR) 4, as well as HEK293 cells, an epithelial cell line that does not express TLR4, Third, ER-112022 activated NF-KB in HEK293 cells transfected with TLR4/ MD-2. Finally, tumor necrosis factor release from primary human monocytes exposed to ER-112022 was blocked by TLR4 antibodies but not by TLR2 antibodies. Our results suggest that ER-112022 and the family of lipid A-like LPS antagonists can functionally associate with TLR4 in the absence of CD14. Synthetic molecules like ER-112022 may prove to be valuable tools to characterize elements in the LPS receptor complex, as well as to activate or inhibit the TLR4 signaling pathway for therapeutic purposes.	Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, Univ Med Ctr, N-7489 Trondheim, Norway; Boston Med Ctr, Evans Biomed Res Ctr, Boston, MA 02118 USA; Eisai Res Inst, Andover, MA 01810 USA; Saga Med Sch, Saga 8498501, Japan	Norwegian University of Science & Technology (NTNU); Boston Medical Center; Eisai Co Ltd; Saga University	Lien, E (corresponding author), Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, Univ Med Ctr, N-7489 Trondheim, Norway.	egil.lien@medisin.ntnu.no			NIAID NIH HHS [AI38515] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054060, R01GM054060] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; Delude RL, 1998, J IMMUNOL, V161, P3001; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; HAZIOT A, 1988, J IMMUNOL, V141, P547; Heine H, 1999, J IMMUNOL, V162, P6971; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoshino K, 1999, J IMMUNOL, V162, P3749; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Ingalls RR, 1997, J IMMUNOL, V159, P433; Ingalls RR, 1998, J IMMUNOL, V161, P5413; Ingalls RR, 1999, J BIOL CHEM, V274, P13993, DOI 10.1074/jbc.274.20.13993; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; Lien E, 1998, BLOOD, V92, P2084, DOI 10.1182/blood.V92.6.2084.418k26_2084_2092; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; LYNN WA, 1991, J IMMUNOL, V147, P3072; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MANTHEY CL, 1994, J IMMUNOL, V153, P2653; Means TK, 1999, J IMMUNOL, V163, P3920; Means TK, 1999, J IMMUNOL, V163, P6748; Ogata H, 2000, J EXP MED, V192, P23, DOI 10.1084/jem.192.1.23; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Rossignol DP, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P699; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SIMMONS DL, 1989, BLOOD, V73, P284; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J EXP MED, V186, P2051, DOI 10.1084/jem.186.12.2051; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4	52	70	103	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1873	1880		10.1074/jbc.M009040200	http://dx.doi.org/10.1074/jbc.M009040200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11032843	hybrid			2022-12-25	WOS:000166528000032
J	Sung, JS; Bennett, SE; Mosbaugh, DW				Sung, JS; Bennett, SE; Mosbaugh, DW			Fidelity of uracil-initiated base excision DNA repair in Escherichia coli cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASES; 5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; GLYCOSYLASE; PROTEIN; RESIDUES; SITE; NUCLEOTIDE; SUBSTRATE; DEOXYRIBOPHOSPHODIESTERASE; 3,N-4-ETHENOCYTOSINE	The error frequency and mutational specificity associated with Escherichia coli uracil-initiated base excision repair were measured using an M13mp2 lacZ alpha DNA-based reversion assay. Repair was detected in cell-free extracts utilizing a form I DNA substrate containing a site-specific uracil residue. The rate and extent of complete uracil-DNA repair were measured using uracil-DNA glycosylase (Ung)- or double-strand uracil-DNA glycosylase (Dug)-proficient and -deficient isogenic E. coli cells. In reactions utilizing E. coli NR8051 (ung(+) dug(+)), similar to 80% of the uracil-DNA was repaired, whereas about 20% repair was observed using NR8052 (ung(-) dug(+)) cells, The Ung-deficient reaction was insensitive to inhibition by the PBS2 uracil-DNA glycosylase inhibitor protein, implying the involvement of Dug activity. Under both conditions, repaired form I DNA accumulated in conjunction with limited DNA synthesis associated with a repair patch size of 1-20 nucleotides. Reactions conducted with E. coli BH156 (ung(-) dug(+)), BH157 (ung(+) dug(-)), and BH158 (ung(-) dug(-)) cells provided direct evidence for the involvement of Dug in uracil-DNA repair. The rate of repair was B-fold greater in the Ung-proficient than in the Ung-deficient reactions, while repair was not detected in reactions deficient in both Ung and Dug. The base substitution reversion frequency associated with uracil-DNA repair was determined to be similar to5.5 x 10(-4) with transversion mutations dominating the mutational spectrum. In the presence of Dug, inactivation of Ung resulted in up to a 7.3-fold increase in mutation frequency without a dramatic change in mutational specificity.	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Ctr Environm Hlth Sci, Corvallis, OR 97331 USA	Oregon State University; Oregon State University; Oregon State University	Mosbaugh, DW (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.	mosbaugd@ucs.orst.edu			NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; GISH G, 1988, SCIENCE, V240, P1520, DOI 10.1126/science.2453926; GOSSARD F, 1978, EUR J BIOCHEM, V82, P321, DOI 10.1111/j.1432-1033.1978.tb12026.x; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; Lutsenko E, 1999, J BIOL CHEM, V274, P31034, DOI 10.1074/jbc.274.43.31034; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; Roy S, 1998, PROTEIN EXPRES PURIF, V13, P155, DOI 10.1006/prep.1998.0878; Sanderson RJ, 1996, J BIOL CHEM, V271, P29170, DOI 10.1074/jbc.271.46.29170; Sanderson RJ, 1998, J BIOL CHEM, V273, P24822, DOI 10.1074/jbc.273.38.24822; SANDERSON RJ, 2000, IN PRESS PROG NUCL A, V68; SANDERSON RJ, 1998, THESIS OREGON STATE; SANDIGURSKY M, 1992, NUCLEIC ACIDS RES, V20, P4699, DOI 10.1093/nar/20.18.4699; Sandigursky M, 1998, NUCLEIC ACIDS RES, V26, P1282, DOI 10.1093/nar/26.5.1282; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; TYE BK, 1978, P NATL ACAD SCI USA, V75, P233, DOI 10.1073/pnas.75.1.233; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776	41	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2276	2285		10.1074/jbc.M008147200	http://dx.doi.org/10.1074/jbc.M008147200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035036	hybrid			2022-12-25	WOS:000166528000084
J	Kliger, Y; Gallo, SA; Peisajovich, SG; Munoz-Barroso, I; Avkin, S; Blumenthal, R; Shai, Y				Kliger, Y; Gallo, SA; Peisajovich, SG; Munoz-Barroso, I; Avkin, S; Blumenthal, R; Shai, Y			Mode of action of an antiviral peptide from HIV-1 - Inhibition at a post-lipid mixing stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 ENVELOPE GLYCOPROTEIN; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; CRYSTAL-STRUCTURE; COILED-COIL; SIV GP41; PHOSPHOLIPID-MEMBRANES; TRANSMEMBRANE PROTEIN; CHEMOKINE RECEPTORS; CYTOPLASMIC TAIL	DP178, a synthetic peptide corresponding to a segment of the transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus, type 1 (HIV-l), is a potent inhibitor of viral infection and virus-mediated cell-cell fusion, Nevertheless, DP178 does not contain gp41 coiled-coil cavity binding residues postulated to be essential for inhibiting HIV-1 entry. We find that DP178 inhibits phospholipid redistribution mediated by the HIV-1 envelope glycoprotein at a concentration 8 times greater than that of solute redistribution (the IC,, values are 43 and 335 nM, respectively), In contrast, C34, a synthetic peptide which overlaps with DP178 but contains the cavity binding residues, did not show this phenomenon (11 and 25 nM, respectively). The ability of DP178 to inhibit membrane fusion at a post-lipid mixing stage correlates with its ability to bind and oligomerize on the surface of membranes. Furthermore, our results are consistent with a model in which DP178 inhibits the formation of gp41 viral hairpin structure at low affinity, whereas C34 inhibits its formation at high affinity: the failure to form the viral hairpin prevents both lipid and solute from redistributing between cells, However, our data also suggest an additional membrane-bound inhibitory site for DP178 in the ectodomain of gp41 within a region immediately adjacent to the membrane-spanning domain. By binding to this higher affinity site, DP178 inhibits the recruitment of several. gp41-membrane complexes, thus inhibiting fusion pore formation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; NCI, Lab Expt & Computat Biol, NIH, Frederick, MD 21702 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il	Peisajovich, Sergio/C-6641-2011	Gallo, Stephen/0000-0001-6043-2153				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; AROETI B, 1991, J BIOL CHEM, V266, P15845; Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 1999, PROTEIN SCI, V8, P1904, DOI 10.1110/ps.8.9.1904; Carr CM, 2000, NATURE, V404, P347, DOI 10.1038/35006200; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; CHERNOMORDIK L, 1994, J VIROL, V68, P7115, DOI 10.1128/JVI.68.11.7115-7123.1994; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; De Clercq E, 1999, Drugs R D, V2, P321, DOI 10.2165/00126839-199902050-00010; Delahunty MD, 1996, VIROLOGY, V218, P94, DOI 10.1006/viro.1996.0169; Doranz BJ, 1999, J VIROL, V73, P10346, DOI 10.1128/JVI.73.12.10346-10358.1999; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EISENBERG D, 1990, BIOPOLYMERS, V29, P171, DOI 10.1002/bip.360290122; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Fass D, 1995, CURR BIOL, V5, P1377, DOI 10.1016/S0960-9822(95)00275-2; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; FREY S, 1995, J VIROL, V69, P1462, DOI 10.1128/JVI.69.3.1462-1472.1995; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; FUJII G, 1992, PROTEIN SCI, V1, P1454, DOI 10.1002/pro.5560011107; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; GAWRISCH K, 1993, BIOCHEMISTRY-US, V32, P3112, DOI 10.1021/bi00063a024; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; HAFFAR OK, 1988, J CELL BIOL, V107, P1677, DOI 10.1083/jcb.107.5.1677; HAFFAR OK, 1991, VIROLOGY, V180, P439, DOI 10.1016/0042-6822(91)90054-F; JONAK ZL, 1993, AIDS RES HUM RETROV, V9, P23, DOI 10.1089/aid.1993.9.23; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Kliger Y, 1997, BIOCHEMISTRY-US, V36, P5157, DOI 10.1021/bi962935r; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Matsuzaki K, 1997, BIOPHYS J, V73, P831, DOI 10.1016/S0006-3495(97)78115-3; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MILLER MA, 1993, VIROLOGY, V196, P89, DOI 10.1006/viro.1993.1457; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Munoz-Barroso I, 1999, J VIROL, V73, P6089; Murphy PM, 2000, PHARMACOL REV, V52, P145; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Pilcher CD, 1999, AIDS, V13, P2171, DOI 10.1097/00002030-199910220-00024; RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390, DOI 10.1021/bi00041a016; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Rizo J, 1998, NAT STRUCT BIOL, V5, P839, DOI 10.1038/2280; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; SATTENTAU QJ, 1995, VIROLOGY, V206, P713, DOI 10.1016/S0042-6822(95)80094-8; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; Stephenson J, 1999, JAMA-J AM MED ASSOC, V282, P1994, DOI 10.1001/jama.282.21.1994; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; YANG CL, 1995, P NATL ACAD SCI USA, V92, P9871, DOI 10.1073/pnas.92.21.9871; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116	88	140	146	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1391	1397		10.1074/jbc.M004113200	http://dx.doi.org/10.1074/jbc.M004113200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11027678	hybrid			2022-12-25	WOS:000166430900072
J	Nilius, B; Vennekens, R; Prenen, J; Hoenderop, JGJ; Droogmans, G; Bindels, RJM				Nilius, B; Vennekens, R; Prenen, J; Hoenderop, JGJ; Droogmans, G; Bindels, RJM			The single pore residue Asp(542) determines Ca2+ permeation and Mg2+ block of the epithelial Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-IDENTIFICATION; CAPSAICIN-RECEPTOR; REABSORPTION; EXPRESSION; CALCIUM; CELLS; HEAT	The epithelial Ca2+ channel (ECaC), which was recently cloned from rabbit kidney, exhibits distinctive properties that support a facilitating role in transcellular Ca2+ (re)absorption, ECaC is structurally related to the family of six transmembrane-spanning ion channels with a pore-forming region between 55 and S6, Using point mutants of the conserved negatively charged amino acids present in the putative pore, we have identified a single aspartate residue that determines Ca2+ permeation of ECaC and modulation by extracellular Mg2+. Mutation of the aspartate residue, D542A, abolishes Ca2+ permeation and Ca2+ dependent current decay as well as block by extracellular Mg2+, whereas monovalent cations still permeate the mutant channel. Variation of the side chain length in mutations D542N, D542E, and D542M attenuated Ca2+ permeability and Ca2+-dependent current decay, Block of monovalent currents through ECaC by Mg2+ was decreased. Exchanging the aspartate residue for a positively charged amino acid, D542K, resulted in a nonfunctional channel, Mutations of two neighboring negatively charged residues, i,e. Glu(535) and Asp(550), had only minor effects on Ca2+ permeation properties.	Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium; Univ Nijmegen, Inst Cellular Signaling, Dept Cell Physiol, NL-6525 GA Nijmegen, Netherlands	KU Leuven; Radboud University Nijmegen	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Bindels, René JM/B-9824-2013; Hoenderop, Joost G.J./H-8047-2014; Vennekens, Rudi/AAQ-1664-2020	Bindels, René JM/0000-0003-1167-1339; Hoenderop, Joost G.J./0000-0002-1816-8544; Vennekens, Rudi/0000-0002-2564-5150				Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Hoenderop JGJ, 2000, AM J PHYSIOL-RENAL, V278, pF352, DOI 10.1152/ajprenal.2000.278.3.F352; Hoenderop JGJ, 1999, P NATL ACAD SCI USA, V96, P6084, DOI 10.1073/pnas.96.11.6084; Hoenderop JGJ, 1999, KIDNEY INT, V55, P225, DOI 10.1046/j.1523-1755.1999.00228.x; Hoenderop JGJ, 1999, BIOCHEM BIOPH RES CO, V261, P488, DOI 10.1006/bbrc.1999.1059; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Hoenderop JGJ, 2000, CURR OPIN NEPHROL HY, V9, P335, DOI 10.1097/00041552-200007000-00003; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; UGATE G, 1998, BIOL RES, V31, P17; Vennekens R, 1999, J PHYSIOL-LONDON, V515, P75, DOI 10.1111/j.1469-7793.1999.075ad.x; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211	17	138	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1020	1025		10.1074/jbc.M006184200	http://dx.doi.org/10.1074/jbc.M006184200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035011	Green Published, hybrid			2022-12-25	WOS:000166430900023
J	Hengst, U; Albrecht, H; Hess, D; Monard, D				Hengst, U; Albrecht, H; Hess, D; Monard, D			The phosphatidylethanolamine-binding protein is the prototype of a novel family of serine protease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN CYTOSOL; AMINO-ACID-SEQUENCE; NEURITE OUTGROWTH; CRYSTAL-STRUCTURE; 21-KDA PROTEIN; MESSENGER-RNA; RAF KINASE; THROMBIN; PURIFICATION; HOMOLOGY	Serine proteases are involved in many processes in the nervous system and specific inhibitors tightly control their proteolytic activity. Thrombin is thought to play a role in tissue development and homeostasis. To date, protease nexin-l is the only known endogenous protease inhibitor that specifically interferes with thrombotic activity and is expressed in the brain. In this study, we report the detection of a novel thrombin inhibitory activity in the brain of protease nexin-1((-/-)) mice. Purification and subsequent analysis by tandem mass spectrometry identified this protein as the phosphatidylethanolamine-binding protein (PEBP), We demonstrate that PEEP exerts inhibitory activity against several serine proteases including thrombin, neuropsin, and chymotrypsin, whereas trypsin, tissue type plasminogen activator, and elastase are not affected. Since PEEP does not share significant homology with other serine protease inhibitors, our results define it as the prototype of a novel class of serine protease inhibitors. PEEP immunoreactivity is found on the surface of Rat-1 fibroblast cells and although its sequence contains no secretion signal, PEBP-H(6) can be purified from the conditioned medium upon recombinant expression.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Monard, D (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	monard@fmi.ch	Hengst, Ulrich/L-1413-2014; Albrecht, Hugo/F-9569-2011	Hengst, Ulrich/0000-0002-8061-2861; Albrecht, Hugo/0000-0002-3951-1866				Apostolidis A, 1997, CELL SIGNAL, V9, P439, DOI 10.1016/S0898-6568(97)00034-X; ARAKI Y, 1992, BIOL REPROD, V47, P832, DOI 10.1095/biolreprod47.5.832; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BERNIER I, 1986, BIOCHIM BIOPHYS ACTA, V871, P19, DOI 10.1016/0167-4838(86)90128-7; BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8; BOLLENGIER F, 1988, J NEUROCHEM, V50, P1210, DOI 10.1111/j.1471-4159.1988.tb10594.x; BOLLENGIER F, 1980, NEUROPEPTIDES, V1, P119, DOI 10.1016/0143-4179(80)90015-3; Bradley D, 1996, NATURE, V379, P791, DOI 10.1038/379791a0; Bruun AW, 1998, BIOCHEMISTRY-US, V37, P3351, DOI 10.1021/bi971286w; BUCQUOY S, 1994, EUR J BIOCHEM, V225, P1203, DOI 10.1111/j.1432-1033.1994.1203b.x; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; Davies BJ, 1998, J BIOL CHEM, V273, P23004, DOI 10.1074/jbc.273.36.23004; DAWES J, 1984, THROMB RES, V36, P397, DOI 10.1016/0049-3848(84)90296-2; Frayne J, 1999, CELL TISSUE RES, V298, P415, DOI 10.1007/s004419900113; GEMS D, 1995, J BIOL CHEM, V270, P18517, DOI 10.1074/jbc.270.31.18517; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; LOBOS E, 1990, MOL BIOCHEM PARASIT, V39, P135, DOI 10.1016/0166-6851(90)90016-F; Luthi A, 1997, J NEUROSCI, V17, P4688; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MONARD D, 1983, PROG BRAIN RES, V58, P359, DOI 10.1016/S0079-6123(08)60037-0; MORTENSEN UH, 1998, HDB PROTEOLYTIC ENZY, P389; Ohshima S, 1997, MOL GEN GENET, V254, P186, DOI 10.1007/s004380050407; Ojika K, 2000, PROG NEUROBIOL, V60, P37, DOI 10.1016/S0301-0082(99)00021-0; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; PERRY ACF, 1994, BIOCHEM J, V301, P235, DOI 10.1042/bj3010235; PIKIELNY CW, 1994, NEURON, V12, P35, DOI 10.1016/0896-6273(94)90150-3; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; SCHOENTGEN F, 1995, FEBS LETT, V369, P22, DOI 10.1016/0014-5793(95)00376-K; SEDDIQI N, 1994, J MOL EVOL, V39, P655, DOI 10.1007/BF00160411; Seeds NW, 1999, P NATL ACAD SCI USA, V96, P14118, DOI 10.1073/pnas.96.24.14118; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TROTTEIN F, 1995, MOL BIOCHEM PARASIT, V70, P235, DOI 10.1016/0166-6851(95)00031-U; Tsirka SE, 1997, J NEUROSCI, V17, P543; Turgeon VL, 1997, BRAIN RES REV, V25, P85, DOI 10.1016/S0165-0173(97)00015-5; VANNOSTRAND WE, 1988, BIOCHEMISTRY-US, V27, P2176, DOI 10.1021/bi00406a054; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686	49	153	168	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					535	540		10.1074/jbc.M002524200	http://dx.doi.org/10.1074/jbc.M002524200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11034991	hybrid			2022-12-25	WOS:000166280700072
J	Lozano, J; Menendez, S; Morales, A; Ehleiter, D; Liao, WC; Wagman, R; Haimovitz-Friedman, A; Fuks, Z; Kolesnick, R				Lozano, J; Menendez, S; Morales, A; Ehleiter, D; Liao, WC; Wagman, R; Haimovitz-Friedman, A; Fuks, Z; Kolesnick, R			Cell autonomous apoptosis defects in acid sphingomyelinase knockout fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; EPSTEIN-BARR-VIRUS; STRESS-INDUCED APOPTOSIS; NIEMANN-PICK DISEASE; IONIZING-RADIATION; CERAMIDE FORMATION; DEFICIENT MICE; ACTIVATION; PROTEIN	A body of evidence suggests that stress-induced sphingomyelin hydrolysis to the second messenger ceramide initiates apoptosis in some cells. Although studies using lymphoblasts from Niemann-Pick disease patients or acid sphingomyelinase (ASMase)-deficient mice have provided genetic support for this hypothesis, these models have not been universally accepted as definitive. Here, we show that mouse embryonic fibroblasts (MEFs) prepared from osmose mice manifest cell autonomous defects in apoptosis in response to several stresses. In particular, asmase(-/-) MEFs failed to generate ceramide and were totally resistant to radiation-induced apoptosis but remained sensitive to staurosporine, which did not induce ceramide, asmase(-/-) MEFs were also partially resistant to tumor necrosis factor alpha/ actinomycin D and serum withdrawal. Thus, resistance to apoptosis in asmase(-/-) MEFs was not global but rather stress type specific. Most importantly, the sensitivity to stress could be restored in the asmase(-/-) MEFs by administration of natural ceramide, Overcoming apoptosis resistance by natural ceramide is evidence that it is the lack of ceramide, not ASMase, that determines apoptosis sensitivity. The ability to rescue the apoptotic phenotype without reversing the genotype by the product of the enzymatic deficiency provides proof that ceramide is obligate for apoptosis induction in response to some stresses.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.		Morales, Albert/E-2988-2013; Lozano, José/C-2760-2014	Morales, Albert/0000-0001-8702-2269; Lozano, José/0000-0002-8187-2833	NATIONAL CANCER INSTITUTE [R01CA085714] Funding Source: NIH RePORTER; NCI NIH HHS [CA85714, CA52462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bieberich E, 1999, J NEUROCHEM, V72, P1040, DOI 10.1046/j.1471-4159.1999.0721040.x; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bose R, 1998, J BIOL CHEM, V273, P28852, DOI 10.1074/jbc.273.44.28852; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Chmura SJ, 1997, CANCER RES, V57, P4340; Chmura SJ, 1997, CANCER RES, V57, P1270; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Khanna KK, 1997, J BIOL CHEM, V272, P9489; KIM MY, 1991, J BIOL CHEM, V266, P484; Kimura K, 1999, CANCER RES, V59, P1606; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Laethem RM, 1998, BLOOD, V91, P4350, DOI 10.1182/blood.V91.11.4350.411k27_4350_4360; LEIST M, 1994, J IMMUNOL, V153, P1778; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; Lin XH, 1998, J BIOL CHEM, V273, P14374, DOI 10.1074/jbc.273.23.14374; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LOZANO J, 2000, IN PRESS CELL DEATH; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Michael JM, 1997, CANCER RES, V57, P3600; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Moley KH, 1998, NAT MED, V4, P1421, DOI 10.1038/4013; Nix M, 2000, CELL DEATH DIFFER, V7, P413, DOI 10.1038/sj.cdd.4400666; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OMURA S, 1995, J ANTIBIOT, V48, P535, DOI 10.7164/antibiotics.48.535; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; Payne SG, 1999, J CELL PHYSIOL, V180, P263, DOI 10.1002/(SICI)1097-4652(199908)180:2<263::AID-JCP14>3.0.CO;2-H; Pena LA, 2000, CANCER RES, V60, P321; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shao RG, 1997, CANCER RES, V57, P4029; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Xing HR, 2000, J BIOL CHEM, V275, P17276, DOI 10.1074/jbc.C900989199; Xu Y, 1998, GASTROENTEROLOGY, V115, P1229, DOI 10.1016/S0016-5085(98)70095-2; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	58	77	78	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					442	448		10.1074/jbc.M006353200	http://dx.doi.org/10.1074/jbc.M006353200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031259	hybrid			2022-12-25	WOS:000166280700060
J	Hiasa, H; Shea, ME				Hiasa, H; Shea, ME			DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-IV; ESCHERICHIA-COLI; PBR322 DNA; IN-VITRO; LEADING-STRAND; MECHANISM; ORIGIN; UNLINKING; CLEAVAGE; PRIMASE	The ability of DNA gyrase (Gyr) to wrap the DNA strand around itself allows Gyr to introduce negative supercoils into DNA molecules, It has been demonstrated that the deletion of the C-terminal DNA-binding domain of the GyrA subunit abolishes the ability of Gyr to wrap the DNA strand and catalyze the supercoiling reaction (Kampranis, S. C., and Maxwell, A (1996) Proc. Natl, Acad Sci, U.S. A. 93, 14416-14421), By using this mutant Gyr, Gyr (A59), we have studied effects of Gyr-mediated wrapping of the DNA strand on its replicative function and its interaction with the quinolone antibacterial drugs. We find that Gyr (A59) can support oriC DNA replication in vitro, However, Gyr (A59)-catalyzed decatenation activity is not efficient enough to complete the decatenation of replicating daughter DNA molecules, As is the case with topoisomerase TV, the active cleavage and reunion activity of Gyr is required for the formation of the ternary complex that can arrest replication fork progression in vitro. Although the quinolone drugs stimulate the covalent Gyr (A59)-DNA complex formation, the Gyr (A59)-quinolone-DNA ternary complexes do not arrest the progression of replication forks. Thus, the quinolone-induced covalent topoisomerase DNA complex formation is necessary but not sufficient to cause the inhibition of DNA replication, We also assess the stability of ternary complexes formed with Gyr (A59), the wild type Gyr, or topoisomerase IV. The ternary complexes formed with Gyr (A59) are more sensitive to salt than those formed with either the wild type Gyr or topoisomerase IV. Furthermore, a competition experiment demonstrates that the ternary complexes formed with Gyr (A59) readily disassociate from the DNA, whereas the ternary complexes formed with either the wild type Gyr or topoisomerase IV remain stably bound. Thus, Gyr-mediated wrapping of the DNA strand is required for the formation of the stable Gyr-quinolone-DNA ternary complex that can arrest replication fork progression.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Hiasa, H (corresponding author), 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NIGMS NIH HHS [GM59465] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059465] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1994, J BIOL CHEM, V269, P16371; Hiasa H, 1999, J BIOL CHEM, V274, P27244, DOI 10.1074/jbc.274.38.27244; HIASA H, 1994, J BIOL CHEM, V269, P2093; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; Levine C, 1998, J BACTERIOL, V180, P1232, DOI 10.1128/JB.180.5.1232-1240.1998; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P191; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; Shea ME, 2000, J BIOL CHEM, V275, P14649, DOI 10.1074/jbc.275.19.14649; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WU CA, 1992, J BIOL CHEM, V267, P4030; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	24	45	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34780	34786		10.1074/jbc.M001608200	http://dx.doi.org/10.1074/jbc.M001608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	11053451	hybrid			2022-12-25	WOS:000165095300104
J	English, D; Welch, Z; Kovala, AT; Harvey, K; Volpert, OV; Brindley, DN; Garcia, JGN				English, D; Welch, Z; Kovala, AT; Harvey, K; Volpert, OV; Brindley, DN; Garcia, JGN			Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis	FASEB JOURNAL			English	Article						lipid mediators; vascular endothelium; angiogenesis; endothelial cell migration; hemostasis; SIP	FIBROBLAST GROWTH-FACTOR; COUPLED RECEPTOR EDG-1; LYSOPHOSPHATIDIC ACID; TUMOR ANGIOGENESIS; SPHINGOSINE-1-PHOSPHATE; INHIBITION; MEMBRANE; INVIVO	Recent studies have identified factors responsible for angiogenesis within developing tumors, but mediators of vessel formation at sites of trauma, injury, and wound healing are not clearly established. Here we show that sphingosine l-phosphate (S1P) released by platelets during blood clotting is a potent, specific, and selective endothelial cell chemoattractant that accounts for most of the strong endothelial cell chemotactic activity of blood serum, an activity that is markedly diminished in plasma. Preincubation, of endothelial cells with pertussis toxin inhibited this effect of S1P, demonstrating the involvement of a G(alphai)-coupled receptor, After S1P-induced migration, endothelial cells proliferated avidly and differentiated forming multicellular structures suggestive of early blood vessel formation. SIP was strikingly effective in enhancing the ability of fibroblast growth factor to induce angiogenesis in the avascular mouse cornea, Our results show that blood coagulation initiates endothelial cell angiogenic responses through the release of SIP, a potent endothelial cell chemoattractant that exerts its effects by activating a receptor-dependent process,-English, D., Welch, Z., Kovala, A, T., Harvey, K., Volpert, O. V,, Brindley, D. N., Garcia, J. G. N. Sphingosine l-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis.	Methodist Res Inst, Expt Cell Res Program, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, RH Lurie Canc Ctr, Chicago, IL 60611 USA; Univ Alberta, Dept Biochem, Lipid & Lipoprot Res Grp, Edmonton, AB T6H 5M3, Canada; Johns Hopkins Univ, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA	Indiana University System; Indiana University System; Indiana University-Purdue University Indianapolis; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Alberta; Johns Hopkins University	English, D (corresponding author), Methodist Res Inst, Expt Cell Res Program, 1701 N Senate Ave, Indianapolis, IN 46202 USA.	dkenglish@msn.com	Garcia, Joe GN/E-8862-2010	Kovala, A. Thomas/0000-0002-2908-5613; Volpert, Olga/0000-0003-1381-5543	NHLBI NIH HHS [R01 HL 61751, P0 1 HL 58064] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064, R01HL061751] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GROSS JL, 1993, J NATL CANCER I, V85, P121, DOI 10.1093/jnci/85.2.121; HLA T, 1990, J BIOL CHEM, V265, P9308; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Moore BB, 1998, J LAB CLIN MED, V132, P97, DOI 10.1016/S0022-2143(98)90004-X; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; Nissen NN, 1998, AM J PATHOL, V152, P1445; PASSANITI A, 1992, LAB INVEST, V67, P519; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; Siddiqui RA, 1997, BBA-LIPID LIPID MET, V1349, P81, DOI 10.1016/S0005-2760(97)00085-4; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; TIGYI G, 1992, J BIOL CHEM, V267, P21360; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	31	243	257	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2255	2265		10.1096/fj.00-0134com	http://dx.doi.org/10.1096/fj.00-0134com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053247				2022-12-25	WOS:000165190800019
J	de los Santos, C; Zaliznyak, T; Johnson, F				de los Santos, C; Zaliznyak, T; Johnson, F			NMR characterization of a DNA duplex containing the major acrolein-derived deoxyguanosine adduct gamma-OH-1,N-2-propano-2 '-deoxyguanosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM HISD3052; OPPOSITE DEOXYADENOSINE; 1,N-2-PROPANODEOXYGUANOSINE ADDUCTS; 1,N2-PROPANODEOXYGUANOSINE ADDUCTS; ESCHERICHIA-COLI; PROPANODEOXYGUANOSINE; MUTAGENESIS; PH; MUTAGENICITY; INDUCTION	The environmental and endogenous mutagen acrolein reacts with cellular DNA to produce several isomeric 1,N-2-propanodeoxyguanosine adducts. High resolution NMR spectroscopy was used to establish the structural features of the major acrolein-derived adduct, gamma -OH-1,N-2-propano-2'-deoxyguanosine. In aqueous solution, this adduct was shown to assume a ring-closed form. In contrast, when gamma -OH-1,N-2-propano-2'-deoxyguanosine pairs with dC at the center of an 11-mer oligodeoxynucleotide duplex, the exocyclic ring opens, enabling the modified base to participate in a standard Watson-Crick base pairing alignment. Analysis of the duplex spectra reveals a regular right-handed helical structure with all residues adopting an anti orientation around the glycosidic torsion angle and Watson-Crick alignments for all base pairs. We conclude from this study that formation of duplex DNA triggers the hydrolytic conversion of gamma -OH-1,N-2-propano-2'-deoxyguanosine to an open chain form, a structure that facilitates pairing with dC during DNA replication and accounts for the surprising lack of mutagenicity associated with this DNA adduct.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	de los Santos, C (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Basic Sci tower,7th Fl Rm 147, Stony Brook, NY 11794 USA.	cds@pharm.sunysb.edu			NCI NIH HHS [CA77094, CA47995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALARCON RA, 1976, CANCER TREAT REP, V60, P327; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; Boerth DW, 1998, CHEM RES TOXICOL, V11, P284, DOI 10.1021/tx970152g; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; Chung FL, 1999, MUTAT RES-FUND MOL M, V424, P71, DOI 10.1016/S0027-5107(99)00009-3; Chung FL, 1999, IARC SCI PUBL, P45; CHUNG FL, 1984, CANCER RES, V44, P990; CURREN RD, 1988, MUTAT RES, V209, P17, DOI 10.1016/0165-7992(88)90104-2; de los Santos, 1999, COMPREHENSIVE NATURA, P55; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; GALLIANI G, 1983, TETRAHEDRON LETT, V24, P4491, DOI 10.1016/S0040-4039(00)85935-3; Hashim MF, 1996, J BIOL CHEM, V271, P9160, DOI 10.1074/jbc.271.15.9160; Hashim MF, 1997, J BIOL CHEM, V272, P20205, DOI 10.1074/jbc.272.32.20205; HUANG P, 1993, BIOCHEMISTRY-US, V32, P3852, DOI 10.1021/bi00066a004; HUANG P, 1992, BIOCHEMISTRY-US, V31, P6518, DOI 10.1021/bi00143a023; KAWANISHI M, 1998, MUTAT RES, V417, P63; Khullar S, 1999, J MED CHEM, V42, P947, DOI 10.1021/jm980605u; KOUCHAKDJIAN M, 1990, BIOCHEMISTRY-US, V29, P4456, DOI 10.1021/bi00470a028; KOUCHAKDJIAN M, 1989, BIOCHEMISTRY-US, V28, P5647, DOI 10.1021/bi00439a047; Lee Y, 1998, J BIOL CHEM, V273, P19490, DOI 10.1074/jbc.273.31.19490; Mao H, 1999, P NATL ACAD SCI USA, V96, P6615, DOI 10.1073/pnas.96.12.6615; MARNETT LJ, 1985, MUTAT RES, V148, P25; MCDIARMID MA, 1991, MUTAT RES, V248, P93, DOI 10.1016/0027-5107(91)90091-2; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nath RG, 1996, CANCER RES, V56, P452; Nechev LV, 2000, CHEM RES TOXICOL, V13, P421, DOI 10.1021/tx990167+; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PLUM GE, 1992, BIOCHEMISTRY-US, V31, P12096, DOI 10.1021/bi00163a019; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SINGH US, 1993, CHEM RES TOXICOL, V6, P825, DOI 10.1021/tx00036a012; SMITH RA, 1990, CARCINOGENESIS, V11, P497, DOI 10.1093/carcin/11.3.497; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; VanderVeen LA, 2001, J BIOL CHEM, V276, P9066, DOI 10.1074/jbc.M008900200; VANDEVEN FJM, 1988, EUR J BIOCHEM, V178, P1; *WHO PUBL, 1992, WHO ENV HLTH CRIT SE, V127; WU HY, 1995, ANAL CHEM, V67, P1603, DOI 10.1021/ac00105a020; Yang IY, 2001, J BIOL CHEM, V276, P9071, DOI 10.1074/jbc.M008918200	40	102	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9077	9082		10.1074/jbc.M009028200	http://dx.doi.org/10.1074/jbc.M009028200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11054428	hybrid			2022-12-25	WOS:000167607700063
J	Huai, JS; Drescher, U				Huai, JS; Drescher, U			An ephrin-A-dependent signaling pathway controls integrin function and is linked to the tyrosine phosphorylation of a 120-kDa protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; RECEPTOR; FAMILY; LIGANDS; KINASE; CAVEOLAE; REQUIRES; CELLS; ACTIVATION; DOMAINS	The Eph family of receptor tyrosine kinases and their ligands, the ephrins, have been implicated in the development of the retinotectal projection. Here, glycosylphosphatidylinositol-anchored A-ephrins are not only expressed in the tectum but also on retinal axons, raising the possibility that they function in this context as receptors. We now show that activation of ephrin-A2 or ephrin-A5 by one of their receptors, ephA3, results in a beta1-integrin-dependent increased adhesion of ephrin-A-expressing cells to laminin. In the search for an ephrin-A-dependent signaling pathway controlling integrin activation, we identified a 120-kDa raft membrane protein that is tyrosine-phosphorylated specifically after ephrin-A activation. Tyrosine phosphorylation of this protein is not seen after stimulating ephrin-A2-expressing cells with basic fibroblast growth factor, epidermal growth factor, insulin growth factor, or fetal calf serum containing a large set of different growth factors. The role of p120 as a mediator of an ephrin-A-integrin coupling is supported by the finding that inhibiting tyrosine phosphorylation of p120 correlates with an abolishment of the beta1-dependent cell adhesion.	Max Planck Dev Biol, Dept Phys Biol, D-72076 Tubingen, Germany	Max Planck Society	Drescher, U (corresponding author), Kings Coll London, MRC, Ctr Dev Neurobiol, 4th Floor,New Hunts House,Guys Campus, London SE1 1UL, England.	uwe.drescher@kcl.ac.uk	Drescher, Uwe/C-5438-2009	Drescher, Uwe/0000-0001-9725-7643				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; Ciossek T, 1998, EUR J NEUROSCI, V10, P1574, DOI 10.1046/j.1460-9568.1998.00180.x; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Davy A, 2000, J NEUROCHEM, V74, P676, DOI 10.1046/j.1471-4159.2000.740676.x; DOHERTY P, 1993, J CELL BIOL, V122, P181, DOI 10.1083/jcb.122.1.181; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; Dutting D, 1999, DEV BIOL, V216, P297, DOI 10.1006/dbio.1999.9489; ECONOMIDES AN, 1995, SCIENCE, V270, P1351, DOI 10.1126/science.270.5240.1351; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Massague J, 1996, NATURE, V382, P29, DOI 10.1038/382029a0; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; O'Leary DDM, 1999, CELL, V96, P255, DOI 10.1016/S0092-8674(00)80565-6; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	45	125	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6689	6694		10.1074/jbc.M008127200	http://dx.doi.org/10.1074/jbc.M008127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11053419	hybrid			2022-12-25	WOS:000167261000080
J	Farley, RA; Schreiber, S; Wang, SG; Scheiner-Bobis, G				Farley, RA; Schreiber, S; Wang, SG; Scheiner-Bobis, G			A hybrid between Na+,K+-ATPase and H+,K+-ATPase is sensitive to palytoxin, ouabain, and SCH 28080	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NA,K-ATPASE ALPHA-SUBUNIT; NA+/K+-ATPASE COMPLEXES; MAMMALIAN SODIUM-PUMP; GASTRIC H+/K+-ATPASE; BETA-SUBUNIT; MEMBRANE TOPOLOGY; ACID-SECRETION; ION CHANNELS; CARDIAC-GLYCOSIDES	Na+,K+-ATPase is inhibited by cardiac glycosides such as ouabain, and palytoxin, which do not inhibit gastric H+,K+-ATPase. Gastric H+,K+-ATPase is inhibited by SCH28080, which has no effect on Na+,K(+-)ATPase, The goal of the current study was to identify amino acid sequences of the gastric proton-potassium pump that are involved in recognition of the pump-specific inhibitor SCH 28080, A chimeric polypeptide consisting of the rat sodium pump alpha3 subunit with the peptide Gln(905)-Val(930) of the gastric proton pump alpha subunit substituted in place of the original Asn(886)-Ala(911) sequence was expressed together with the gastric beta subunit in the yeast Saccharomyces cerevisiae. Yeast cells that express this subunit combination are sensitive to palytoxin, which interacts specifically with the sodium pump, and lose intracellular K+ ions. The palytoxin-induced K+ efflux is inhibited by the sodium pump-specific inhibitor ouabain and also by the gastric proton pump-specific inhibitor SCH 28080, The IC50 for SCH 28080 inhibition of palytoxin-induced K+ efflux is 14.3 a 2.4 muM, which is similar to the K-i for SCH 28080 inhibition of ATP hydrolysis by the gastric H+,K+-ATPase. In contrast, palytoxin-induced K+ efflux from cells expressing either the native alpha3 and pi subunits of the sodium pump or the alpha3 subunit of the sodium pump together with the beta subunit of the gastric proton pump is inhibited by ouabain but not by SCH 28080. The acquisition of SCH 28080 sensitivity by the chimera indicates that the Gln(905)-Val(930) peptide of the gastric proton pump is likely to be involved in the interactions of the gastric proton-potassium pump with SCH 28080.	Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90033 USA; Univ Giessen, Fachbereich Vet Med, Inst Biochem & Endokrinol, D-35392 Giessen, Germany	University of Southern California; Justus Liebig University Giessen	Farley, RA (corresponding author), Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, 1333 San Pablo St,MMR 250, Los Angeles, CA 90033 USA.	rfarley@hsc.usc.edu			NIGMS NIH HHS [GM28673] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028673] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Asano S, 1999, J BIOL CHEM, V274, P6848, DOI 10.1074/jbc.274.11.6848; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; BEIL W, 1986, BRIT J PHARMACOL, V88, P19, DOI 10.1111/j.1476-5381.1986.tb09466.x; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; Croyle ML, 1997, EUR J BIOCHEM, V248, P488, DOI 10.1111/j.1432-1033.1997.00488.x; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; FAMBROUGH DM, 1988, TRENDS NEUROSCI, V11, P325, DOI 10.1016/0166-2236(88)90096-3; Fiedler B, 1996, J BIOL CHEM, V271, P29312, DOI 10.1074/jbc.271.46.29312; HABERMANN E, 1989, TOXICON, V27, P1171, DOI 10.1016/0041-0101(89)90026-3; HANSEN O, 1984, PHARMACOL REV, V36, P143; Harlow E., 1988, ANTIBODIES LAB MANUA; HERSEY SJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P49, DOI 10.1016/0167-4838(88)90296-8; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; IKEDA M, 1988, N-S ARCH PHARMACOL, V337, P591; ISHIDA Y, 1983, J BIOL CHEM, V258, P7900; KIM SY, 1995, N-S ARCH PHARMACOL, V351, P542; Lambrecht N, 1998, J BIOL CHEM, V273, P13719, DOI 10.1074/jbc.273.22.13719; Lambrecht N, 2000, J BIOL CHEM, V275, P4041, DOI 10.1074/jbc.275.6.4041; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEVENSON R, 1994, REV PHYSIOL BIOCH P, V123, P1, DOI 10.1007/BFb0030902; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lyu RM, 1997, AM J PHYSIOL-CELL PH, V272, pC1717, DOI 10.1152/ajpcell.1997.272.5.C1717; MCDONOUGH AA, 1995, J MOL CELL CARDIOL, V27, P1001, DOI 10.1016/0022-2828(95)90069-1; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRINZ C, 1992, YALE J BIOL MED, V65, P577; Redondo J, 1996, MOL PHARMACOL, V49, P49; Repke K R, 1993, Prog Med Chem, V30, P135, DOI 10.1016/S0079-6468(08)70377-1; SACHS G, 1994, YALE J BIOL MED, V67, P81; SACHS G, 1991, Current Opinion in Cell Biology, V3, P685, DOI 10.1016/0955-0674(91)90042-W; SACHS G, 1990, DIGEST DIS SCI, V35, P1537, DOI 10.1007/BF01540572; Scheiner-Bobis G, 1999, BIOCHEMISTRY-US, V38, P9198, DOI 10.1021/bi983010+; Scheiner-Bobis G, 1998, N-S ARCH PHARMACOL, V357, P477, DOI 10.1007/PL00005196; SCHEINERBOBIS G, 1994, MOL PHARMACOL, V45, P1132; Schneider H, 1997, J BIOL CHEM, V272, P16158, DOI 10.1074/jbc.272.26.16158; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCOTT DR, 1992, BIOCHIM BIOPHYS ACTA, V1112, P246, DOI 10.1016/0005-2736(92)90398-6; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; VITARELLI A, 1995, CARDIOLOGY, V86, P94, DOI 10.1159/000176847; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; Wang SG, 1997, AM J PHYSIOL-CELL PH, V272, pC923, DOI 10.1152/ajpcell.1997.272.3.C923; YOON KL, 1994, J BIOL CHEM, V269, P28249	52	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2608	2615		10.1074/jbc.M008784200	http://dx.doi.org/10.1074/jbc.M008784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11054424	hybrid			2022-12-25	WOS:000166784800044
J	Hartford, OM; Wann, ER; Hook, M; Foster, TJ				Hartford, OM; Wann, ER; Hook, M; Foster, TJ			Identification of residues in the Staphylococcus aureus fibrinogen-binding MSCRAMM clumping factor A (ClfA) that are important for ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PROTEINS; NUCLEOTIDE-SEQUENCE; GAMMA-CHAIN; CELL-WALL; RECEPTOR; DOMAIN; FIBRONECTIN; PEPTIDES; ADHERENCE; CLEAVAGE	Clumping factor A (ClfA) is a cell surface-associated protein of Staphylococcus aureus that promotes binding of this pathogen to both soluble and immobilized fibrinogen (Fg), Previous studies have localized the Fg-binding activity of ClfA to residues 221-559 within the A region of this protein. In addition, the C-terminal part of the A region (residues 484-550) has been implicated as being important for Fg binding, In this study, we further investigate the involvement of this part of ClfA in the interaction of this protein with Fg, Polyclonal antibodies generated against a recombinant protein encompassing residues 500-559 of the A region inhibited the interaction of both S, aureus and recombinant ClfA with immobilized Fg in a dose-dependent manner. Using site-directed mutagenesis, two adjacent residues, Glu(526) and Val(527), were identified as being important for the activity of ClfA S. aureus expressing ClfA containing either the E526A or V5275 substitution exhibited a reduced ability to bind to soluble Fg and to adhere to immobilized Fg, Furthermore, bacteria expressing ClfA containing both substitutions were almost completely defective in Fg binding. The E526A and V527S substitutions were also introduced into recombinant ClfA (rClfA-(221-559)) expressed in Escherichia coli, The single mutant rClfA-(221-559) proteins showed a significant reduction in affinity for both immobilized Fg and a synthetic fluorescein-labeled C-terminal gamma -chain peptide compared with the wild-type protein, whereas the double mutant rClfA-(221-559) protein was almost completely defective in binding to either species. Substitution of Glu(526) and/or Val(527) did not appear to alter the secondary structure of rClfA-(221-559) as determined by far-UV circular dichroism spectroscopy. These data suggest that the C terminus of the A region may contain at least part of the Fg-binding site of ClfA and that Glu(526) and Val(527) may be involved in ligand recognition.	Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland; Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Dept Biochem & Biophys, Houston, TX 77030 USA	Trinity College Dublin; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Foster, TJ (corresponding author), Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland.	tfoster@tcd.ie			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGUSTIN J, 1990, FEMS MICROBIOL LETT, V66, P203, DOI 10.1016/0378-1097(90)90283-V; Deivanayagam CCS, 1999, ACTA CRYSTALLOGR D, V55, P554, DOI 10.1107/S0907444998012426; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Fa W., 1995, PRINCIPLES PRACTICES, V4, P1754; Foster TJ, 1998, METHOD MICROBIOL, V27, P433; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GULINO D, 1992, J BIOL CHEM, V267, P1001; Hartford O, 1999, MICROBIOL-SGM, V145, P2497, DOI 10.1099/00221287-145-9-2497; Hartford O, 1997, MOL MICROBIOL, V25, P1065, DOI 10.1046/j.1365-2958.1997.5291896.x; HAWIGER J, 1982, BIOCHEMISTRY-US, V21, P1407, DOI 10.1021/bi00535a047; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; JONSSON K, 1991, EUR J BIOCHEM, V202, P1041, DOI 10.1111/j.1432-1033.1991.tb16468.x; Josefsson E, 1998, MICROBIOL-UK, V144, P3387, DOI 10.1099/00221287-144-12-3387; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; McCrea KW, 2000, MICROBIOL-SGM, V146, P1535, DOI 10.1099/00221287-146-7-1535; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; OSKOUIAN B, 1990, J BACTERIOL, V172, P3804, DOI 10.1128/jb.172.7.3804-3812.1990; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SMITH JW, 1994, J BIOL CHEM, V269, P960; Spraggon G, 1998, P NATL ACAD SCI USA, V95, P9099, DOI 10.1073/pnas.95.16.9099; STRONG DD, 1982, BIOCHEMISTRY-US, V21, P1414, DOI 10.1021/bi00535a048; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; Tung HS, 2000, BIOCHEM J, V345, P611, DOI 10.1042/0264-6021:3450611; VAUDAUX P, 1993, J INFECT DIS, V167, P633, DOI 10.1093/infdis/167.3.633; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863	39	56	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2466	2473		10.1074/jbc.M007979200	http://dx.doi.org/10.1074/jbc.M007979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11044451	Green Published, hybrid			2022-12-25	WOS:000166784800024
J	Lamb, TM; Xu, WJ; Diamond, A; Mitchell, AP				Lamb, TM; Xu, WJ; Diamond, A; Mitchell, AP			Alkaline response genes of Saccharomyces cerevisiae and their relationship to the RIM101 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER TRANSCRIPTION FACTOR; MEMBRANE H+-ATPASE; PH-REGULATED GENE; CANDIDA-ALBICANS; PLASMA-MEMBRANE; AMBIENT PH; PHOSPHATASE CALCINEURIN; BINDING-SITES; ENA1 GENE; YEAST	Environmental pH exerts broad control over growth and differentiation, but the molecular responses to external pH changes are poorly understood. Here we have used open reading frame macroarray hybridization to identify alkaline response genes in Saccharomyces cer evisiae. Northern or lacZ fusion assays confirmed the alkaline induction of two ion pump genes (ENA1 and VMA4), several ion limitation genes (CTR3, FRE1, PHO11/12, and PHO84), a siderophore-iron transporter gene (ARN4/ENB1), two transcription factor genes (NRG2 and TIS11), and two predicted membrane protein genes (YAR068W/YHR214W and YOL154W). Unlike ENA1 and SHC1, these new alkaline response genes are not induced by high salinity. The known pH-responsive genes in other fungi depend on the conserved PacC/Rim101p transcription factor, but induction of several of these new genes relied upon Rim101p-independent pH signaling mechanisms. Rim101p-dependent genes were also dependent on Rim13p, a protease required for Rim101p processing. The Rim101p-dependent gene VMA4 is required for growth in alkaline conditions, illustrating how Rim101p may control adaptation. Because Rim101p activates ion pump genes, we tested the role of RIM101 in ion homeostasis and found that RIM101 promotes resistance to elevated cation concentrations. Thus, gene expression surveys can reveal new functions for characterized transcription factors in addition to uncovering physiological responses to environmental conditions.	Columbia Univ, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Canc Res Inst, New York, NY 10032 USA; Columbia Univ, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Mitchell, AP (corresponding author), Columbia Univ, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.	apm4@columbia.edu	Xu, Wenjie/F-5453-2010	Mitchell, Aaron/0000-0002-0868-4000	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039531] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39531] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; Bearson S, 1997, FEMS MICROBIOL LETT, V147, P173, DOI 10.1016/S0378-1097(96)00503-4; Brink SJ, 1999, ACTA PAEDIATR, V88, P14, DOI 10.1111/j.1651-2227.1999.tb14335.x; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Davis D, 2000, MOL CELL BIOL, V20, P971, DOI 10.1128/MCB.20.3.971-978.2000; Davis D, 2000, INFECT IMMUN, V68, P5953, DOI 10.1128/IAI.68.10.5953-5959.2000; De Bernardis F, 1998, INFECT IMMUN, V66, P3317, DOI 10.1128/IAI.66.7.3317-3325.1998; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DESTEENSMA HY, 1989, CURR GENET, V16, P131, DOI 10.1007/BF00391468; El Barkani A, 2000, MOL CELL BIOL, V20, P4635, DOI 10.1128/MCB.20.13.4635-4647.2000; Espeso EA, 1996, J BIOL CHEM, V271, P28825, DOI 10.1074/jbc.271.46.28825; Falk GW, 1999, ENDOSCOPY, V31, P9, DOI 10.1055/s-1999-13643; FOURY F, 1990, J BIOL CHEM, V265, P18554; Futai E, 1999, MOL GEN GENET, V260, P559, DOI 10.1007/s004380050929; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gragnani A, 1998, THEOR POPUL BIOL, V54, P257, DOI 10.1006/tpbi.1997.1377; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; HO MN, 1993, J BIOL CHEM, V268, P221; Hong SK, 1999, BIOCHEM BIOPH RES CO, V255, P116, DOI 10.1006/bbrc.1999.0158; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaiser C., 1994, METHODS YEAST GENETI; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; Lambert M, 1997, MOL CELL BIOL, V17, P3966, DOI 10.1128/MCB.17.7.3966; LI W, 1996, THESIS COLUMBIA U; Li WS, 1997, GENETICS, V145, P63; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Louden JD, 1999, KIDNEY INT, V56, pS85, DOI 10.1046/j.1523-1755.1999.07319.x; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Montecucco C, 1999, FEBS LETT, V452, P16, DOI 10.1016/S0014-5793(99)00652-3; Muhlschlegel FA, 1997, MOL CELL BIOL, V17, P5960; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Ogawa N, 1995, MOL GEN GENET, V249, P406, DOI 10.1007/BF00287102; OGAWA N, 1995, MOL CELL BIOL, V15, P997; OREJAS M, 1995, GENE DEV, V9, P1622, DOI 10.1101/gad.9.13.1622; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Porta A, 1999, J BACTERIOL, V181, P7516, DOI 10.1128/JB.181.24.7516-7523.1999; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Proft M, 1999, MOL CELL BIOL, V19, P537; Ramon AM, 1999, J BACTERIOL, V181, P7524, DOI 10.1128/JB.181.24.7524-7530.1999; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; Segurado M, 1999, INFECT IMMUN, V67, P2377, DOI 10.1128/IAI.67.5.2377-2382.1999; Sentandreu M, 1998, J BACTERIOL, V180, P282, DOI 10.1128/JB.180.2.282-289.1998; SMITH HE, 1989, MOL CELL BIOL, V9, P2142, DOI 10.1128/MCB.9.5.2142; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Suarez T, 1996, MOL MICROBIOL, V20, P529, DOI 10.1046/j.1365-2958.1996.5421065.x; Tenney KA, 1999, MOL CELL BIOCHEM, V191, P161, DOI 10.1023/A:1006893824947; TILBURN J, 1995, EMBO J, V14, P779, DOI 10.1002/j.1460-2075.1995.tb07056.x; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Treton B, 2000, MOL GEN GENET, V263, P505, DOI 10.1007/s004380051195; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; Withee JL, 1998, GENETICS, V149, P865	59	196	204	2	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1850	1856		10.1074/jbc.M008381200	http://dx.doi.org/10.1074/jbc.M008381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050096	hybrid			2022-12-25	WOS:000166528000029
J	Silberg, JJ; Hoff, KG; Tapley, TL; Vickery, LE				Silberg, JJ; Hoff, KG; Tapley, TL; Vickery, LE			The Fe/S assembly protein IscU behaves as a substrate for the molecular chaperone Hsc66 from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; PEPTIDE BINDING; ATP HYDROLYSIS; DNAK; HSP70; SYSTEM; SPECIFICITY; KINETICS	IscU, a NifU-like Fe/S-escort protein, binds to and stimulates the ATPase activity of Hsc66, a hsp70-type molecular chaperone, We present evidence that stimulation arises from interactions of IscU with the substrate-binding site of Hsc66, IscU inhibited the ability of Hsc66 to suppress the aggregation of the denatured model substrate proteins rhodanese and citrate synthase, and calorimetric and surface plasmon resonance measurements showed that ATP destabilizes HscBB IscU complexes in a manner expected for hsp70-substrate complexes. Studies on the interaction of IscU with Hsc66 truncation mutants further showed that IscU does not bind the isolated ATPase domain of Hsc66 but does bind and stimulate a mutant containing the ATPase domain and substrate binding beta -sandwich subdomain, These results support a role for IscU as a substrate for Hsc66 and suggest a specialized function for Hsc66 in the assembly, stabilization, or transfer of Fe/S clusters formed on IscU.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	lvickery@uci.edu	Silberg, Jonathan J/A-3817-2010		NIGMS NIH HHS [GM07311, GM54264] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KAWULA TH, 1994, J BACTERIOL, V176, P610, DOI 10.1128/jb.176.3.610-619.1994; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; WANG TF, 1993, J BIOL CHEM, V268, P26409; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	29	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1696	1700		10.1074/jbc.M009542200	http://dx.doi.org/10.1074/jbc.M009542200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053447	hybrid			2022-12-25	WOS:000166528000007
J	Brennan, P; Floettmann, JE; Mehl, A; Jones, M; Rowe, M				Brennan, P; Floettmann, JE; Mehl, A; Jones, M; Rowe, M			Mechanism of action of a novel latent membrane protein-1 dominant negative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; NF-KAPPA-B; C-TERMINUS; SIGNAL-TRANSDUCTION; DOWN-REGULATION; KINASE PATHWAY; STAT PROTEINS; BINDING-SITE; LMP1; ACTIVATION	Latent membrane protein-1 (LMP1) is a signaling molecule expressed by Epstein-Barr virus during latency. LMP1 is essential for B-cell immortalization by Epstein-Barr virus and transforms rodent fibroblasts. It activates many distinct signaling pathways including the transcription factors NF kappaB and AP1. We have generated a mutant of LMP1 with four point mutations; amino acids 204, 206, and 208 were mutated to alanine, and amino acid 384 was mutated to glycine. This mutant, termed LMP1(AAAG), is not only unable to activate nuclear signaling pathways, but also inhibits signaling from wild type LMP1, We have demonstrated the effectiveness, selectivity, and mechanism of this inhibitory molecule. It inhibits LMP1-stimulated NF kappaB, STAT, and Jun transcriptional activity. It is selective, as it does not inhibit TNF or interleukin-2 signaling. We have demonstrated that it does not sequester the downstream signaling molecule, TRAF2, but instead binds LMP1 and interferes with its ability to bind TRAF2. This demonstrates the importance of the interplay between the signaling domains of LMP1 and the oligomeric structure of LMP1 for effective signaling. It identifies a tool that will be useful to probe LMP1 function in disease.	Univ Wales Coll Cardiff, Coll Med, Dept Med, Cardiff CF14 4XX, S Glam, Wales	Cardiff University	Brennan, P (corresponding author), Univ Wales Coll Cardiff, Coll Med, Dept Med, Tenovus Bldg,Heath Pk, Cardiff CF14 4XX, S Glam, Wales.	brennanp@cardiff.ac.uk	Brennan, Paul/B-9210-2009; Brennan, Paul/ABB-9196-2021; Rowe, Martin/B-2880-2009	Brennan, Paul/0000-0001-8792-0499; Brennan, Paul/0000-0001-8792-0499; Rowe, Martin/0000-0003-4139-7326				ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Erickson KD, 2000, J VIROL, V74, P1057, DOI 10.1128/JVI.74.2.1057-1060.2000; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JL, 1998, ONCOGENE, V17, P2383, DOI 10.1038/sj.onc.1202144; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HORI T, 1987, BLOOD, V70, P1069; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1999, J VIROL, V73, P9908, DOI 10.1128/JVI.73.12.9908-9916.1999; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kim SH, 2000, BLOOD, V95, P294; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 2001, METHODS MOL BIOL EPS; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang S, 1996, CANCER RES, V56, P4610; WeberNordt RM, 1996, BLOOD, V88, P809	46	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1195	1203		10.1074/jbc.M005461200	http://dx.doi.org/10.1074/jbc.M005461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11031256	hybrid			2022-12-25	WOS:000166430900047
J	Hagopian, JC; Kirtley, MP; Stevenson, LM; Gergis, RM; Russo, AA; Pavletich, NP; Parsons, SM; Lew, J				Hagopian, JC; Kirtley, MP; Stevenson, LM; Gergis, RM; Russo, AA; Pavletich, NP; Parsons, SM; Lew, J			Kinetic basis for activation of CDK2/clyclin A by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRUCTURAL BASIS; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; MECHANISM; YEAST; CAK	The activation of most protein kinases requires phosphorylation at a conserved site within a structurally defined segment termed the activation loop. A classic example is the regulation of the cell cycle central enzyme, CDK2/cyclin A, in which catalytic activation depends on phosphorylation at Thr(160) in CDK2, The structural consequences of phosphorylation have been revealed by x-ray crystallographic studies on CDE2-cyclin A and include changes in conformation, mainly of the activation loop. Here, we describe the kinetic basis for activation by phosphorylation in CDK2/cyclin A. Phosphorylation results in a 100,000-fold increase in catalytic efficiency and an approximate 1,000-fold increase in the overall turnover rate. The effects of phosphorylation on the individual steps in the catalytic reaction pathway were determined using solvent viscosometric techniques. It was found that the increase in catalytic power arises mainly from a 3,000-fold increase in the rate of the phosphoryl group transfer step with a more moderate increase in substrate binding affinity. In contrast, the rate of phosphoryl group transfer in the ATPase pathway was unaffected by phosphorylation, demonstrating that phosphorylation at Thr(160) does not serve to stabilize ATP in the ATPase reaction. Thus, we hypothesize that the role of phosphorylation in the kinase reaction may be to specifically stabilize the peptide phosphoacceptor group.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Interdept Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Calif Santa Barbara, Interdept Grad Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; University of California System; University of California Santa Barbara	Lew, J (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.			Parsons, Stanley/0000-0001-7097-8221				ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P683; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Cauthron RD, 1998, MOL CELL BIOL, V18, P1416, DOI 10.1128/MCB.18.3.1416; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; HACKNEY DD, 1990, ENZYMES, V19, P1; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Russo AA, 1997, METHOD ENZYMOL, V283, P3; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Saylor P, 1998, BIOCHEMISTRY-US, V37, P17875, DOI 10.1021/bi981775b	24	55	57	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					275	280		10.1074/jbc.M007337200	http://dx.doi.org/10.1074/jbc.M007337200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029468	hybrid			2022-12-25	WOS:000166280700038
J	Nakamura, T; Ohta, M; Sugiura, M; Sugita, M				Nakamura, T; Ohta, M; Sugiura, M; Sugita, M			Chloroplast ribonucleoproteins function as a stabilizing factor of ribosome-free mRNAs in the stroma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3 INVERTED REPEATS; BINDING PROTEINS; GENE-EXPRESSION; IMPORTANT DETERMINANTS; TOBACCO CHLOROPLASTS; PSBA; DEGRADATION; PHOSPHORYLATION; IDENTIFICATION; SEQUENCE	Post-transcriptional RNA processing is an important step in the regulation of chloroplast gene expression, and a number of chloroplast ribonucleoproteins (cpRNPs) are likely to be involved in this process, The major tobacco cpRNPs are composed of five species: cp28, cp29A, cp29B, cp31, and cp33 and these are divided into three groups (I, II, and III). By immunoprecipitation, gel filtration, and Western blot analysis, we demonstrated that these cpRNPs are abundant stromal proteins that exist as complexes with ribosome-free mRNAs. Many ribosome-free psbA mRNAs coprecipitate with cpRNPs, indicating that the majority of stromal psbA mRNAs are associated with cpRNPs, In addition, an In vitro mRNA degradation assay indicated that exogenous psbA mRNA is more rapidly degraded in cpRNP-depleted extracts than in nondepleted extracts. When the depleted extract was reconstituted with recombinant cpRNPs, the psbA mRNA in the extract was protected from degradation to a similar extent as the psbA mRNA in the nondepleted extract. Moreover, restoration of the stabilizing activity varied following addition of individual group-specific cpRNPs alone or in combination, When the five cpRNPs were supplemented in the depleted extract, full activity was restored. We propose that these cpRNPs act as stabilizing factors for nonribosome-bound mRNAs in the stroma.	Nagoya Univ, Ctr Gene Res, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Human Informat, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Sugita, M (corresponding author), Nagoya Univ, Ctr Gene Res, Nagoya, Aichi 4648601, Japan.	sugita@info.human.nagoya-u.ac.jp						ADAMS CC, 1990, NUCLEIC ACIDS RES, V18, P6003, DOI 10.1093/nar/18.20.6003; Alexander C, 1998, NUCLEIC ACIDS RES, V26, P2265, DOI 10.1093/nar/26.10.2265; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; CHEN HC, 1991, MOL CELL BIOL, V11, P4380, DOI 10.1128/MCB.11.9.4380; CHEN QY, 1995, MOL CELL BIOL, V15, P2010; Churin Y, 1999, CURR GENET, V36, P173, DOI 10.1007/s002940050488; COOK WB, 1992, NUCLEIC ACIDS RES, V20, P359, DOI 10.1093/nar/20.2.359; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DEAN C, 1982, PLANT PHYSIOL, V69, P904, DOI 10.1104/pp.69.4.904; Drager RG, 1998, PLANT J, V13, P85, DOI 10.1046/j.1365-313X.1998.00016.x; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GRUISSEM W, 1988, TRENDS GENET, V4, P258, DOI 10.1016/0168-9525(88)90033-9; Hayes R, 1999, TRENDS BIOCHEM SCI, V24, P199, DOI 10.1016/S0968-0004(99)01388-2; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; HESS WR, 1994, PLANT CELL, V6, P1455, DOI 10.1105/tpc.6.10.1455; Hubschmann T, 1996, PLANT MOL BIOL, V30, P109, DOI 10.1007/BF00017806; Jenkins BD, 1997, PLANT CELL, V9, P283, DOI 10.1105/tpc.9.3.283; KIM J, 1994, PLANT MOL BIOL, V25, P459, DOI 10.1007/BF00043874; KIM MY, 1993, PLANT MOL BIOL, V22, P447, DOI 10.1007/BF00015975; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; Klaff P, 1995, NUCLEIC ACIDS RES, V23, P4885, DOI 10.1093/nar/23.23.4885; LI YQ, 1990, EMBO J, V9, P3059, DOI 10.1002/j.1460-2075.1990.tb07502.x; LI YQ, 1991, NUCLEIC ACIDS RES, V19, P2893, DOI 10.1093/nar/19.11.2893; Liere K, 1997, NUCLEIC ACIDS RES, V25, P2403, DOI 10.1093/nar/25.12.2403; LISITSKY I, 1995, NUCLEIC ACIDS RES, V23, P2506, DOI 10.1093/nar/23.13.2506; LISITSKY I, 1995, PLANT PHYSIOL, V107, P933, DOI 10.1104/pp.107.3.933; Memon AR, 1996, PLANT MOL BIOL, V30, P1195, DOI 10.1007/BF00019552; Meurer J, 1996, PLANT CELL, V8, P1193, DOI 10.1105/tpc.8.7.1193; MULLET JE, 1987, EMBO J, V6, P1571, DOI 10.1002/j.1460-2075.1987.tb02402.x; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; Nakamura T, 1999, FEBS LETT, V460, P437, DOI 10.1016/S0014-5793(99)01390-3; Nakamura T, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P2957; Nakano T, 1997, PLANT CELL, V9, P1673, DOI 10.1105/tpc.9.9.1673; NICKELSEN J, 1993, PLANT J, V3, P537, DOI 10.1046/j.1365-313X.1993.03040537.x; NICKELSEN J, 1994, EMBO J, V13, P3182, DOI 10.1002/j.1460-2075.1994.tb06617.x; Nickelsen J, 1999, PLANT CELL, V11, P957, DOI 10.1105/tpc.11.5.957; OHTA M, 1995, PLANT MOL BIOL, V27, P529, DOI 10.1007/BF00019319; RAPP JC, 1992, J BIOL CHEM, V267, P21404; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; Rochaix JD, 1995, ANNU REV GENET, V29, P209, DOI 10.1146/annurev.ge.29.120195.001233; Rott R, 1998, PLANT MOL BIOL, V36, P307, DOI 10.1023/A:1005943701253; Sakai A, 1998, PLANT CELL PHYSIOL, V39, P928, DOI 10.1093/oxfordjournals.pcp.a029456; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; STERN DB, 1989, J BIOL CHEM, V264, P18742; STERN DB, 1987, CELL, V51, P1145, DOI 10.1016/0092-8674(87)90600-3; STERN DB, 1991, PLANT CELL, V3, P285; Sugita M, 1996, PLANT MOL BIOL, V32, P315, DOI 10.1007/BF00039388; VERA A, 1994, EMBO J, V13, P2211, DOI 10.1002/j.1460-2075.1994.tb06498.x; Yang JJ, 1996, PLANT CELL, V8, P1409, DOI 10.1105/tpc.8.8.1409; YE LZ, 1991, NUCLEIC ACIDS RES, V19, P6485, DOI 10.1093/nar/19.23.6485; YE LZ, 1992, NUCLEIC ACIDS RES, V20, P6275, DOI 10.1093/nar/20.23.6275	54	65	67	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					147	152		10.1074/jbc.M008817200	http://dx.doi.org/10.1074/jbc.M008817200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11038367	hybrid			2022-12-25	WOS:000166280700021
J	Blazquez, C; Galve-Roperh, I; Guzman, M				Blazquez, C; Galve-Roperh, I; Guzman, M			De novo-synthesized ceramide signals apoptosis in astrocytes via extracellular signal-regulated kinase	FASEB JOURNAL			English	Article						cell death; sphingolipids; mitogen-activated protein kinases; neural cells	CARNITINE PALMITOYLTRANSFERASE-I; ACTIVATED PROTEIN-KINASE; DAUNORUBICIN-INDUCED APOPTOSIS; FREE FATTY-ACIDS; CELL-DEATH; SPHINGOMYELIN HYDROLYSIS; RAF-1; INHIBITION; BRAIN; TRANSDUCTION	Recent observations support the importance of ceramide synthesis de novo in the induction of apoptosis. However, the downstream targets of de novo-synthesized ceramide are unknown, Here we show that palmitate incorporated into ceramide and induced apoptotic DNA fragmentation in astrocytes, These effects of palmitate were exacerbated when fatty acid breakdown was uncoupled and were not evident in neurons, which show a very low capacity to take up and metabolize palmitate, Palmitate-induced apoptosis of astrocytes was prevented by L-cycloserine and fumonisin B1, two inhibitors of ceramide synthesis de novo, and by PD098059, an inhibitor of the extracellular signal-regulated kinase (ERK) cascade. Accordingly, palmitate activated ERK by a process that was dependent on ceramide synthesis de novo and Raf-1, but independent of kinase suppressor of Ras, Other potential targets of ceramide in the control of cell fate, namely, c-Jun amino-terminal kinase, p38 mitogen-activated protein kinase, and protein kinase B, were not significantly affected in astrocytes exposed to palmitate. Results show that the Raf-1/ERK cascade is the selective downstream target of de novo-synthesized ceramide in the induction of apoptosis in astrocytes and also highlight the importance of ceramide synthesis de novo in apoptosis of astrocytes, which might have pathophysiological relevance.-Blazquez, C., Galve-Roperh, I., Guzman, M. De novo-synthesized ceramide signals apoptosis in astrocytes via extracellular signal-regulated kinase.	Univ Complutense Madrid, Sch Biol, Dept Biochem & Biol 1, Madrid 28040, Spain	Complutense University of Madrid	Guzman, M (corresponding author), Univ Complutense Madrid, Sch Biol, Dept Biochem & Biol 1, Madrid 28040, Spain.		Galve-Roperh, Ismael/AAG-2369-2020	Guzman, Manuel/0000-0001-7475-118X				Andrieu-Abadie N, 1999, FASEB J, V13, P1501, DOI 10.1096/fasebj.13.12.1501; Ariga T, 1998, J LIPID RES, V39, P1; AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; BAZAN NG, 1971, J NEUROCHEM, V18, P1379, DOI 10.1111/j.1471-4159.1971.tb00002.x; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; Blazquez C, 1998, J NEUROCHEM, V71, P1597; Blazquez C, 1999, J NEUROCHEM, V72, P1759, DOI 10.1046/j.1471-4159.1999.721759.x; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; del Pulgar T, 2000, BIOCHEM J, V347, P369, DOI 10.1042/bj3470369; EDMOND J, 1992, CAN J PHYSIOL PHARM, V70, P118; Futerman AH, 1999, BIOCHEM SOC T, V27, P432, DOI 10.1042/bst0270432; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Guzman M, 2000, TRENDS ENDOCRIN MET, V11, P49, DOI 10.1016/S1043-2760(99)00223-4; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Lehtonen JYA, 1999, J BIOL CHEM, V274, P16901, DOI 10.1074/jbc.274.24.16901; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Marshall CJ, 1998, NATURE, V392, P553, DOI 10.1038/33293; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Paumen MB, 1997, BIOCHEM BIOPH RES CO, V231, P523, DOI 10.1006/bbrc.1997.6089; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Price DL, 1999, NATURE, V399, pA3, DOI 10.1038/399a003; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Riboni L, 1999, BIOCHEM J, V338, P147, DOI 10.1042/0264-6021:3380147; Sanchez C, 1998, MOL PHARMACOL, V54, P834, DOI 10.1124/mol.54.5.834; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Velasco G, 1998, J BIOL CHEM, V273, P21497, DOI 10.1074/jbc.273.34.21497; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	41	131	135	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2315	2322		10.1096/fj.00-0122com	http://dx.doi.org/10.1096/fj.00-0122com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053253				2022-12-25	WOS:000165190800025
J	Provot, S; Pouponnot, C; Lecoq, O; Calothy, G; Felder-Schmittbuhl, MP				Provot, S; Pouponnot, C; Lecoq, O; Calothy, G; Felder-Schmittbuhl, MP			Characterization of a novel quiescence responsive element downregulated by v-Src in the promoter of the neuroretina specific QR1 gene	ONCOGENE			English	Article						growth arrest; differentiation; neuroretina; gene expression; oncogene; Maf	ROUS-SARCOMA VIRUS; EXTRACELLULAR-MATRIX PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; TRANSCRIPTION FACTOR NRL; ARREST-SPECIFIC GENE; RETINA-SPECIFIC QR1; GROWTH-ARREST; CELL-PROLIFERATION; MAMMALIAN-CELLS; DOWN-REGULATION	The neuroretina is a functional unit of the central nervous system which arises through successive steps of division, growth arrest and differentiation of neuroectodermal precursors. Postmitotic quail neuroretina (QNR) cells are conditionally induced to divide upon infection with temperature sensitive mutants of Rous sarcoma virus (RSV), since QNR cell division can be arrested by either inactivating p60v-Src at the nonpermissive temperature (41 degrees C) or by serum deprivation at 37 degrees C. We are studying the transcriptional control of QR1, a neuroretina specific gene, whose expression is down-regulated in proliferating cells at 37 degrees C and is fully restored when these cells are made quiescent. We previously showed that this quiescence specific upregulation implicates a promoter region named A box, which binds Maf transcription factors. We report the identification of the C box, a second promoter sequence that activates QR1 transcription in non dividing cells. This sequence is able to form two DNA-protein complexes, one of which (C4) is predominantly detected in growth arrested NR cells. We identified the DNA binding site for C4 and described mutations that abolish both C4 binding and promoter activity in quiescent cells. Moreover, we show that a multimerized C box is able to stimulate a heterologous promoter in non dividing cells and constitutes, therefore, a novel quiescence responsive enhancer. Finally, me report that QR1 transcriptional response to cell quiescence requires cooperation between the C box and A box.	CNRS, UMR 146, Inst Curie, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Felder-Schmittbuhl, MP (corresponding author), CNRS, UMR 146, Inst Curie, Batiment 110 Ctr Univ, F-91405 Orsay, France.			PROVOT, SYLVAIN/0000-0003-4087-4450				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; Bendik I, 1998, CANCER RES, V58, P626; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; Casado FJ, 1996, MECH DEVELOP, V54, P237, DOI 10.1016/0925-4773(95)00482-3; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; FABBRETTI E, 1995, GENE DEV, V9, P1846, DOI 10.1101/gad.9.15.1846; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Goruppi S, 1996, ONCOGENE, V12, P471; Grossi M, 1998, ONCOGENE, V17, P1629, DOI 10.1038/sj.onc.1202090; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kim S, 1999, MOL CELL BIOL, V19, P5718; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; MAO PL, 1993, J BIOL CHEM, V268, P8131; McKinnon PJ, 1996, GENOME RES, V6, P1077, DOI 10.1101/gr.6.11.1077; Nelson PS, 1998, CANCER RES, V58, P232; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PEYSSONNAUX C, 2000, IN PRESS MOL CELL BI; PIERANI A, 1993, MOL CELL BIOL, V13, P3401, DOI 10.1128/MCB.13.6.3401; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Ring BZ, 2000, DEVELOPMENT, V127, P307; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SIMONNEAU L, 1986, MOL CELL BIOL, V6, P3704, DOI 10.1128/MCB.6.11.3704; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VARDIMON L, 1991, MOL CELL BIOL, V11, P5275, DOI 10.1128/MCB.11.10.5275; Zavitz KH, 1997, CURR OPIN CELL BIOL, V9, P773, DOI 10.1016/S0955-0674(97)80077-4; Zhang PM, 1999, CURR OPIN CELL BIOL, V11, P655, DOI 10.1016/S0955-0674(99)00032-0	58	4	4	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4736	4745		10.1038/sj.onc.1203837	http://dx.doi.org/10.1038/sj.onc.1203837			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032024				2022-12-25	WOS:000089528800008
J	Radic, Z; Taylor, P				Radic, Z; Taylor, P			Interaction kinetics of reversible inhibitors and substrates with acetylcholinesterase and its fasciculin 2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL SITE; CRYSTAL-STRUCTURE; ANIONIC SITE; ACTIVE-SITE; BINDING; LIGANDS; SPECIFICITY; CATALYSIS; ENZYME; CHOLINESTERASES	Fasciculin 2 (Fas2), a three-fingered peptide of 61 amino acids, binds tightly to the peripheral site of acetylcholinesterases (AChE; EC 3.1.1.7), occluding the entry portal into the active center gorge of the enzyme and inhibiting its catalytic activity. We investigated the mechanism of Fas2 inhibition by studying hydrolysis of cationic and neutral substrates and by determining the kinetics of interaction for fast equilibrating cationic and neutral reversible inhibitors with the AChE.Fas2 complex and free AChE. Catalytic parameters, derived by eliminating residual Fas2-resistant activity, reveal that Fas2 reduces k(cat)/K-m up to 10(6)-fold for cationic substrates and less than 10(3)-fold for neutral substrates. Rate constants for association of reversible inhibitors with the active center of the AChE.Fas2 complex were reduced about 10(4)-fold for both cationic and neutral inhibitors, while dissociation rate constants were reduced 10(2)-to 10(3)-fold, compared with AChE alone, Rates of ligand association with both AChE and AChE.Fas2 complex were dependent on the protonation state of ionizable ligands but were also markedly reduced by protonation of enzyme residue(s) with pK(a) of 6.1-6.2. Linear free energy relationships between the equilibrium constant and the kinetic constants show that Fas2, presumably through an allosteric influence, markedly alters the position of the transition state in the reaction pathway, Since Fas2 complexation introduces an energetic barrier for hydrolysis of substrates that exceeds that found for association of reversible ligands, Fas2 influences catalytic parameters by a more complex mechanism than simple restriction of diffusional entry and exit from the active center. Conformational flexibility appears critical for facilitating ligand passage in the narrow active center gorge for both AChE and the AChE Fas2 complex.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu			NIGMS NIH HHS [GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRIDGE WN, 1972, FRONTIERS BIOL; ASHANI Y, 1994, MOL PHARMACOL, V45, P555; ASHANI Y, 1992, BIOCHEM BIOPH RES CO, V184, P719, DOI 10.1016/0006-291X(92)90649-6; BERMAN HA, 1991, CHOLINESTERASES STRU, P229; BOLGER MB, 1979, BIOCHEMISTRY-US, V18, P3622, DOI 10.1021/bi00583a029; Botti SA, 1999, BIOPHYS J, V77, P2430, DOI 10.1016/S0006-3495(99)77080-3; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Camps P, 2000, MOL PHARMACOL, V57, P409; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HODGE AS, 1992, MOL PHARMACOL, V41, P937; HOSEA NA, 1995, BIOCHEMISTRY-US, V34, P11528, DOI 10.1021/bi00036a028; Kryger G, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P323; Leffler J.E., 1963, RATES EQUILIBRIUM OR; Mallender WD, 1999, J BIOL CHEM, V274, P8491, DOI 10.1074/jbc.274.13.8491; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; Radic Z, 1997, J BIOL CHEM, V272, P23265, DOI 10.1074/jbc.272.37.23265; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Ravelli RBG, 1998, ACTA CRYSTALLOGR D, V54, P1359, DOI 10.1107/S0907444998005277; REINER E, 1967, BIOCHEM J, V105, P171, DOI 10.1042/bj1050171; Reiner E., 2000, CHOLINESTERASES CHOL, V3rd, P103; ROSENBERRY TL, 1971, BIOCHEMISTRY-US, V10, P4114, DOI 10.1021/bi00798a016; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3870, DOI 10.1021/bi00636a024; Rosenberry TL, 1996, BIOCHEMISTRY-US, V35, P685, DOI 10.1021/bi952431d; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14232, DOI 10.1021/bi961119g; SELWOOD T, 1993, J AM CHEM SOC, V115, P10477, DOI 10.1021/ja00076a002; Simeon-Rudolf V, 1999, CHEM-BIOL INTERACT, V119, P119, DOI 10.1016/S0009-2797(99)00020-4; Stojan J, 1998, FEBS LETT, V440, P85, DOI 10.1016/S0014-5793(98)01434-3; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; Zhou HX, 1998, P NATL ACAD SCI USA, V95, P9280, DOI 10.1073/pnas.95.16.9280	43	69	71	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4622	4633		10.1074/jbc.M006855200	http://dx.doi.org/10.1074/jbc.M006855200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11036076	hybrid			2022-12-25	WOS:000168484300015
J	Dode, L; Van Baelen, K; Wuytack, F; Dean, WL				Dode, L; Van Baelen, K; Wuytack, F; Dean, WL			Low temperature molecular adaptation of the skeletal muscle sarco(endo)plasmic reticulum Ca2+-ATPase 1 (SERCA 1) in the wood frog (Rana sylvatica)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM; ADENOSINE-TRIPHOSPHATASE; PLATELET MEMBRANES; MESSENGER-RNA; RABBIT; ATPASE; GENE; TRANSPORT; MECHANISM	We have compared the primary sequence and enzymatic properties of the sarcoplasmic reticulum Ca2+-ATPases from a cold-tolerant frog Rana sylvatica with those of a closely related cold-intolerant frog, Rana clamitans, Sarcoplasmic reticulum isolated from leg muscles of both species contains a major protein (similar to 100 kDa) that reacts with a monoclonal antibody against sarco(endo)plasmic reticulum Ca2+-ATPase type 1 (SERCA1). The apparent molecular mass of R. sylvatica SERCA1 is 115 kDa, whereas that of R. clamitans is 105 kDa. However, the deduced amino acid sequences obtained from cDNAs do not indicate a difference in molecular weight, thus suggesting post-translational protein modification of R. sylvatica SERCA1, Comparison of the temperature dependence of both ATP hydrolysis and Ca2+ transport indicates that R. sylvatica SERCA1 exhibits significantly lower activation energy below 20 degreesC and an similar to2-fold greater Ca2+-ATPase activity near 0 degreesC. Furthermore, R. sylvatica SERCA1 exhibits simple Michaelis-Menten kinetics with ATP and Ca2+ as opposed to the two-site ATP kinetics and positive cooperativity with Ca2+ observed for R. clamitans and mammalian SERCA1s. Cooperativity has been linked to protein-protein interaction in SERCA1, and this property may be altered in R. sylvatica SERCA1. Primary sequence comparison shows that R. sylvatica SERCA1 exhibits seven unique amino acid substitutions, three of which are in the ATP binding domain. We also report for the first time the presence of alternative splicing in the frog, resulting in isoforms SERCA1a and SERCA1b, Thus, it appears that the low temperature muscle contractility of R. sylvatica can be explained partially by significant functional and structural differences in SERCA1.	Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA	University of Louisville; KU Leuven; University of Louisville	Dean, WL (corresponding author), Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.	bill.dean@louisville.edu						BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CHINI EN, 1993, BIOCHEM J, V293, P469, DOI 10.1042/bj2930469; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONSTANZO JP, 1993, AM J PHYSIOL, V265, pR721; DALO NL, 1995, J EXP BIOL, V198, P1765; DEAMER DW, 1973, J BIOL CHEM, V248, P5477; DEAN WL, 1980, J BIOL CHEM, V255, P7514; DEAN WL, 1978, BIOCHEMISTRY-US, V17, P1683, DOI 10.1021/bi00602a016; DEAN WL, 1995, CELL CALCIUM, V17, P65, DOI 10.1016/0143-4160(95)90103-5; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V290, P178, DOI 10.1016/0005-2736(72)90062-4; ESCALANTE R, 1994, J BIOL CHEM, V269, P13005; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Hemmings SJ, 1996, CELL BIOCHEM FUNCT, V14, P139, DOI 10.1002/cbf.661; HEMMINGS SJ, 1996, CAN J PHYSL PHARM, V72, P1552; HESKETH TR, 1976, BIOCHEMISTRY-US, V15, P4145, DOI 10.1021/bi00664a002; INESI G, 1973, J MOL BIOL, V81, P483, DOI 10.1016/0022-2836(73)90518-4; Johnson JD, 1997, AM J PHYSIOL-CELL PH, V272, pC1437, DOI 10.1152/ajpcell.1997.272.5.C1437; KALABOKIS V, 1988, J BIOL CHEM, V263, P15184; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; KOSSLER F, 1987, BIOMED BIOCHIM ACTA, V46, P815; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AG, 1974, BIOCHEMISTRY-US, V13, P3699, DOI 10.1021/bi00715a013; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAGYAR A, 1995, BIOCHEM J, V310, P757, DOI 10.1042/bj3100757; Martonosi AN, 1996, BBA-BIOENERGETICS, V1275, P111, DOI 10.1016/0005-2728(96)00059-X; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOMMSEN TP, 1992, GEN COMP ENDOCR, V87, P44, DOI 10.1016/0016-6480(92)90148-D; NEET KE, 1977, ARCH BIOCHEM BIOPHYS, V178, P588, DOI 10.1016/0003-9861(77)90230-2; OGAWA Y, 1970, J BIOCHEM-TOKYO, V67, P667, DOI 10.1093/oxfordjournals.jbchem.a129295; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; STOREY KB, 1988, PHYSIOL REV, V68, P27, DOI 10.1152/physrev.1988.68.1.27; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VERJOVSKIALMEIDA S, 1981, J BIOL CHEM, V256, P2940; VILSEN B, 1992, FEBS LETT, V306, P213, DOI 10.1016/0014-5793(92)81003-5; VRBJAR N, 1990, BIOCHIM BIOPHYS ACTA, V1030, P94, DOI 10.1016/0005-2736(90)90243-H	43	17	17	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3911	3919		10.1074/jbc.M007719200	http://dx.doi.org/10.1074/jbc.M007719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11044449	hybrid			2022-12-25	WOS:000166921200027
J	Maurer, U; Jehan, F; Englert, C; Hubinger, G; Weidmann, E; DeLuca, HF; Bergmann, L				Maurer, U; Jehan, F; Englert, C; Hubinger, G; Weidmann, E; DeLuca, HF; Bergmann, L			The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D-3 by induction of the vitamin D receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR WT1; CD34(+) PROGENITORS; GROWTH-INHIBITION; MESSENGER-RNA; DIFFERENTIATION; EXPRESSION; APOPTOSIS; PROTEINS; PROMOTER; CELLS	The Wilms' tumor gene (wt1) encodes a transcription factor involved in urogenital development, in particular in renal differentiation, and in hematopoietic differentiation. Differentiation of a number of solid tumor and leukemic cells lines can be mediated by 1,25-dihydroxyvitamin D-3. This is predominantly mediated by the nuclear receptor for 1,25-dihydroxyvitamin D-3, the vitamin D receptor (VDR). In initial experiments addressing a possible link between WT1 and VDR, we observed a correlated expression of WT1 and VDR mRNA in samples from renal tissues. HT29 colon carcinoma cells, stably transfected to express WT1, exhibited elevated endogenous VDR levels compared with control cells transfected with a control construct. Elevated VDR expression was found in wt1-transfected human embryonic kidney 293 cells, as well. In transient cotransfection experiments, we observed an activation of a vdr promoter reporter by WT1 through a WT1 recognition element, indicating transcriptional regulation of the vdr gene expression by WT1. The responsive sequence element was specifically bound by wild-type, but not by mutated WT1, in electrophoretic mobility shift assays. HT29 colon carcinoma cells, which respond to 1,25-dihydroxyvitamin D, with slow induction of growth arrest, were investigated for the influence of WT1 on 1,25-dihydroxyvitamin D-3-mediated growth suppression. Although HT29 cells transfected with a control construct responded moderately to 1,25-dihydroxyvitamin Dar the response of HT29 cells expressing WT1 was strikingly enhanced, Stimulation with dihydroxyvitamin D, caused an up to 3-fold reduction in the growth rate of different HT29 clones expressing WT1 as compared with control cells lacking WT1 expression. Thus, induction of VDR by WT1 leads to an enhanced response to 1,25-dihydroxyvitamin D-3. We conclude that the vitamin D receptor gene is a target for transcriptional activation by WT1, suggesting a possible physiological role of this regulatory pathway.	Univ Ulm, Dept Internal Med 3, D-89081 Ulm, Germany; Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Univ Frankfurt, Dept Internal Med 3, D-60590 Frankfurt, Germany	Ulm University; University of Wisconsin System; University of Wisconsin Madison; Helmholtz Association; Karlsruhe Institute of Technology; Goethe University Frankfurt	Maurer, U (corresponding author), Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Jehan, Frederic/P-1568-2014	Jehan, Frederic/0000-0003-1271-6594; Englert, Christoph/0000-0002-5931-3189				Bergmann L, 1997, BLOOD, V90, P1217, DOI 10.1182/blood.V90.3.1217.1217_1217_1225; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Christakos S, 1996, BIOCHEM J, V316, P361, DOI 10.1042/bj3160361; Diaz GD, 2000, CANCER RES, V60, P2304; Elser B, 1997, J BIOL CHEM, V272, P27908, DOI 10.1074/jbc.272.44.27908; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Guan LS, 1998, J BIOL CHEM, V273, P27047, DOI 10.1074/jbc.273.42.27047; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583; Jehan F, 2000, ARCH BIOCHEM BIOPHYS, V377, P273, DOI 10.1006/abbi.2000.1788; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maurer U, 1997, BLOOD, V90, P4230, DOI 10.1182/blood.V90.10.4230; Maurer U, 1997, EXP HEMATOL, V25, P945; Maurer U., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P736; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; SHABAHANG M, 1994, CANCER RES, V54, P4057; Svedberg H, 1998, ONCOGENE, V16, P925, DOI 10.1038/sj.onc.1201613; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; WERNER H, 1995, MOL CELL BIOL, V15, P3516	29	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3727	3732		10.1074/jbc.M005292200	http://dx.doi.org/10.1074/jbc.M005292200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050081	hybrid			2022-12-25	WOS:000166921200003
J	Tarui, T; Mazar, AP; Cines, DB; Takada, Y				Tarui, T; Mazar, AP; Cines, DB; Takada, Y			Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SIGNAL-TRANSDUCTION; HUMAN CARCINOMA; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY; POINT MUTATION; GROWTH-FACTORS; BINDING; ADHESION; TUMOR	Binding of urokinase-type plasminogen activator (uPA) to its receptor (uPAR/CD87) regulates cellular adhesion, migration, and tumor cell invasion, However, it is unclear how glycosyl phosphatidylinositol-anchored uPAR, which lacks a transmembrane structure, mediates signal transduction. It has been proposed that uPAR forms cis-interactions with integrins as an associated protein and thereby transduces proliferative or migratory signals to cells upon binding of uPk We provide evidence that soluble uPAR (suPAR) specifically binds to integrins alpha4 beta1, alpha6 beta1, alpha9 beta1, and alphav beta3 on Chinese hamster ovary cells in a cation-dependent manner. Anti-integrin and anti-uPAR antibodies effectively block binding of suPAR to these integrins, Binding of suPAR to alpha4 beta1 and alphav beta3 is blocked by known soluble ligands and by the integrin mutations that inhibit ligand binding. These results suggest that uPAR is an integrin Ligand rather than, or in addition to, an integrin-associated protein. In addition, we demonstrate that glycosyl phosphatidylinositol-anchored uPAR on the cell surface specifically binds to integrins on the apposing cells, suggesting that uPAR-integrin interaction may mediate cell-cell interaction (trans-interaction). These previously unrecognized uPAR-integrin interactions may allow uPAR to transduce signals through the engaged integrin without a hypothetical transmembrane adapter and may provide a potential therapeutic target for control of inflammation and cancer.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Attenuon LLC, San Diego, CA 92121 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Scripps Research Institute; University of Pennsylvania	Takada, Y (corresponding author), Scripps Res Inst, Dept Vasc Biol, CAL-10,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	takada@scripps.edu	Tarui, Takehiko/L-4778-2019	Tarui, Takehiko/0000-0002-2519-7052; takada, yoshikazu/0000-0001-5481-9589	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047175] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60169] Funding Source: Medline; NIGMS NIH HHS [GM47175, GM49899] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJT ML, 1994, J BIOL CHEM, V269, P20913; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; FALCIONI R, 1988, CANCER RES, V48, P816; Fowler B, 1998, THROMB HAEMOSTASIS, V80, P148, DOI 10.1055/s-0037-1615154; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gum R, 1998, ONCOGENE, V17, P213, DOI 10.1038/sj.onc.1201917; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Higazi AAR, 1997, J BIOL CHEM, V272, P5348, DOI 10.1074/jbc.272.8.5348; Holst-Hansen C, 1999, BRIT J CANCER, V81, P203, DOI 10.1038/sj.bjc.6690678; HUANG XZ, 1995, AM J RESP CELL MOL, V13, P245, DOI 10.1165/ajrcmb.13.2.7626292; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Johnston B, 2000, J IMMUNOL, V164, P3337, DOI 10.4049/jimmunol.164.6.3337; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Matsuura N, 1996, AM J PATHOL, V148, P55; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; MIN HY, 1992, J IMMUNOL, V148, P3636; Min HY, 1996, CANCER RES, V56, P2428; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Mustjoki S, 1999, THROMB HAEMOSTASIS, V81, P705; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; PEDERSEN N, 1993, J CLIN INVEST, V92, P2160, DOI 10.1172/JCI116817; Piguet PF, 1999, CIRCULATION, V99, P3315, DOI 10.1161/01.CIR.99.25.3315; Ploug M, 1998, J BIOL CHEM, V273, P13933, DOI 10.1074/jbc.273.22.13933; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Sier CFM, 1998, CANCER RES, V58, P1843; Slot O, 1999, ANN RHEUM DIS, V58, P488, DOI 10.1136/ard.58.8.488; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; Takada Y, 1997, MATRIX BIOL, V16, P143, DOI 10.1016/S0945-053X(97)90002-0; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Xue W, 1997, CANCER RES, V57, P1682; XUE W, 1994, J IMMUNOL, V152, P4630; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	61	153	163	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3983	3990		10.1074/jbc.M008220200	http://dx.doi.org/10.1074/jbc.M008220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053440	hybrid			2022-12-25	WOS:000166921200037
J	Vandorpe, DH; Chernova, MN; Jiang, LW; Sellin, LK; Wilhelm, S; Stuart-Tilley, AK; Walz, G; Alper, SL				Vandorpe, DH; Chernova, MN; Jiang, LW; Sellin, LK; Wilhelm, S; Stuart-Tilley, AK; Walz, G; Alper, SL			The cytoplasmic C-terminal fragment of polycystin-1 regulates a Ca2+-permeable cation channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKD1 GENE-PRODUCT; KIDNEY-DISEASE; XENOPUS OOCYTES; IN-VITRO; PROTEIN; IDENTIFICATION; MEMBRANE; HOMOLOG; DOMAIN; PHOSPHORYLATION	The cytoplasmic C-terminal portion of the polycystin-1 polypeptide (PKD1(1-226)) regulates several important cell signaling pathways, and its deletion suffices to cause autosomal dominant polycystic kidney disease, However, a functional link between PKD1 and the ion transport processes required to drive renal cyst enlargement has remained elusive, We report here that expression at the Xenopus oocyte surface of a transmembrane fusion protein encoding the C-terminal portion of the PKD1 cytoplasmic tail, PKD1(115-226), but not the N-terminal portion, induced a large, Ca2+-permeable cation current, which shifted oocyte reversal potential (E-rev) by +33 mV, Whole cell currents were sensitive to inhibition by La3+, Gd3+, and Zn2+, and partially inhibited by SKF96365 and amiloride, Currents were not activated by bath hypertonicity, but were inhibited by acid pH, Outside-out patches pulled from PKD1(115-226)-expressing oocytes exhibited a 5.1-fold increased NP, of endogenous 20-picosiemens cation channels of linear conductance. PKD1(115-226)-injected oocytes also exhibited elevated NPo of unitary calcium currents in outside-out and cell-attached patches, and elevated calcium permeability documented by fluorescence ratio and Ca-45(2+) flux experiments. Both Ca2+ conductance and influx were inhibited by La3+, Mutation of candidate phosphorylation sites within PKD1(115-226) abolished the cation current. We conclude that the C-terminal cytoplasmic tail of PKD1 up-regulates inward current that includes a major contribution from Ca2+-permeable nonspecific cation channels. Dysregulation of these or similar channels in autosomal dominant polycystic kidney disease may contribute to cyst formation or expansion.	Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med & Cell Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Alper, SL (corresponding author), Beth Israel Deaconess Med Ctr, Mol Med Unit, 330 Brookline Ave, Boston, MA 02215 USA.				NHLBI NIH HHS [HL15157] Funding Source: Medline; NIDDK NIH HHS [DK34854, DK51059, DK52897] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052897, R01DK051059, P30DK034854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Benzing T, 2000, J BIOL CHEM, V275, P28167; Bielfeld-Ackermann A, 1998, PFLUG ARCH EUR J PHY, V436, P329, DOI 10.1007/PL00008085; Bobanovic LK, 1999, BIOCHEM J, V340, P593, DOI 10.1042/0264-6021:3400593; Burckhardt BC, 1997, PFLUG ARCH EUR J PHY, V434, P306, DOI 10.1007/s004240050401; Busch AE, 1996, J PHYSIOL-LONDON, V491, P735, DOI 10.1113/jphysiol.1996.sp021253; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; Ebihara L, 1996, BIOPHYS J, V71, P742, DOI 10.1016/S0006-3495(96)79273-1; Harris PC, 1999, HUM MOL GENET, V8, P1861, DOI 10.1093/hmg/8.10.1861; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; HUMPHREYS BD, 1995, AM J PHYSIOL-CELL PH, V268, pC201, DOI 10.1152/ajpcell.1995.268.1.C201; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Koch JP, 1999, J MEMBRANE BIOL, V168, P131, DOI 10.1007/s002329900503; Li HP, 1999, BIOCHEM BIOPH RES CO, V259, P356, DOI 10.1006/bbrc.1999.0780; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Neophytou P, 1996, HUM GENET, V98, P437, DOI 10.1007/s004390050235; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Parnell SC, 1999, BIOCHEM BIOPH RES CO, V259, P539, DOI 10.1006/bbrc.1999.0810; Peral B, 1996, AM J HUM GENET, V58, P86; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROSETTI S, 1996, AM J MED GENET, V65, P155; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; TSOKIAS L, 1997, P NATL ACAD SCI U S, V94, P6965; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; Wang XY, 1997, FEBS LETT, V409, P391, DOI 10.1016/S0014-5793(97)00559-0; Weber WM, 1999, J MEMBRANE BIOL, V170, P1, DOI 10.1007/s002329900532; Wilkinson NC, 1998, J MEMBRANE BIOL, V165, P161, DOI 10.1007/s002329900430; Wilson PD, 1999, LAB INVEST, V79, P1311; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703	47	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4093	4101		10.1074/jbc.M006252200	http://dx.doi.org/10.1074/jbc.M006252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11044446	hybrid			2022-12-25	WOS:000166921200050
J	Shiraishi, N; Natsume, A; Togayachi, A; Endo, T; Akashima, T; Yamada, Y; Imai, N; Nakagawa, S; Koizumi, S; Sekine, S; Narimatsu, H; Sasaki, K				Shiraishi, N; Natsume, A; Togayachi, A; Endo, T; Akashima, T; Yamada, Y; Imai, N; Nakagawa, S; Koizumi, S; Sekine, S; Narimatsu, H; Sasaki, K			Identification and characterization of three novel beta 1,3-N-acetylglucosaminyltransferases structurally related to the beta 1,3-galactosyltransferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; ALPHA-D-GALACTOSAMINE; HUMAN COLONIC ADENOCARCINOMA; SIALYL-LEWIS-X; BLOOD-GROUP-I; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; DEVELOPMENTALLY-REGULATED MEMBER; ELAM-1-DEPENDENT CELL-ADHESION; TUMOR-ASSOCIATED ANTIGEN; MOLECULAR-CLONING	We have isolated three types of cDNAs encoding novel beta1,3-N-acetylglucosaminyltransferases (designated beta 3Gn-T2, -T3, and -T4) from human gastric mucosa and the neuroblastoma cell Line SK-N-MC, These enzymes are predicted to be type 2 transmembrane proteins of 397, 372, and 378 amino acids, respectively, They share motifs conserved among members of the beta1,3-galactosyltransferase family and a beta1,3-N-acetylglucosaminyltransferase (designated beta 3Gn-T1), but show no structural similarity to another type of pl,3-N-acetylglucosaminyltransferase (iGnT). Each of the enzymes expressed by insect cells as a secreted protein fused to the FLAG peptide showed beta1,3N-acetylglucosaminyltransferase activity for type 2 oligosaccharides but not pl,3-galactosyltransferase activity. These enzymes exhibited different substrate specificity. Transfection of Namalwa KJM-1 cells with beta 3Gn-T2, -T3, or -T4 cDNA led to an increase in poly-N-acetyllactosamines recognized by an anti-i-antigen antibody or specific lectins, The expression profiles of these beta 3Gn-Ts were different among 35 human tissues, beta 3Gn-T2 was ubiquitously expressed, whereas expression of beta 3Gn-T3 and -T4 was relatively restricted. beta 3Gn-T3 was expressed in colon, jejunum, stomach, esophagus, placenta, and trachea beta 3Gn-T4 was mainly expressed in brain. These results have revealed that several beta1,3-N-acetylglucosaminyltransferases form a family with structural similarity to the pl,3-galactosyltransferase family. Considering the differences in substrate specificity and distribution, each pl,3-N-acetylglucosaminyltransferase may play different roles,	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 1948533, Japan; Soka Univ, Inst Life Sci, Div Cell Biol, Hachioji, Tokyo 1928577, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, Tokyo 113, Japan; Tokyo Univ Agr, Fac Bioind, Lab Anim Resources, Abashiri, Hokkaido 0992422, Japan	Kyowa Kirin Ltd; Soka University; University of Tokyo; Tokyo University of Agriculture	Sasaki, K (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahi Machi, Machida, Tokyo 1948533, Japan.		Natsume, Atsushi/I-7364-2014	Natsume, Atsushi/0000-0002-9113-0470				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; BASU M, 1991, CARBOHYD RES, V209, P261, DOI 10.1016/0008-6215(91)80162-G; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; Fukumoto S, 1999, J BIOL CHEM, V274, P9271, DOI 10.1074/jbc.274.14.9271; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GU J, 1992, J BIOL CHEM, V267, P2994; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P14, DOI 10.1016/0003-9861(89)90410-4; HOLMES EH, 1988, ARCH BIOCHEM BIOPHYS, V260, P461, DOI 10.1016/0003-9861(88)90470-5; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; Ishii A, 1998, J BIOL CHEM, V273, P31652, DOI 10.1074/jbc.273.48.31652; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; KAWASHIMA H, 1990, GLYCOCONJUGATE J, V7, P323, DOI 10.1007/BF01073376; Kim YJ, 1996, BIOCHEM BIOPH RES CO, V228, P324, DOI 10.1006/bbrc.1996.1660; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; Kono M, 1996, J BIOL CHEM, V271, P29366, DOI 10.1074/jbc.271.46.29366; Kono M, 1998, BIOCHEM BIOPH RES CO, V253, P170, DOI 10.1006/bbrc.1998.9768; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; Kudo T, 1998, LAB INVEST, V78, P797; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE N, 1990, J BIOL CHEM, V265, P20476; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; LEE YC, 1994, J BIOL CHEM, V269, P10028; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LOWE BJ, 1994, MOL GLYCOBIOLOGY, P163; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAKAMORI S, 1993, CANCER RES, V53, P3632; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Okajima T, 2000, J BIOL CHEM, V275, P6717, DOI 10.1074/jbc.275.10.6717; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Okajima T, 1999, J BIOL CHEM, V274, P30557, DOI 10.1074/jbc.274.43.30557; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PILLER F, 1983, J BIOL CHEM, V258, P2293; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SASAKI K, 1994, Patent No. 0618759; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; Shinkai A, 1997, PROTEIN EXPRES PURIF, V10, P379, DOI 10.1006/prep.1997.0751; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; STROUD MR, 1991, J BIOL CHEM, V266, P8439; STULTS CLM, 1993, ARCH BIOCHEM BIOPHYS, V303, P125, DOI 10.1006/abbi.1993.1263; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Tsuji Y, 1996, BBA-GEN SUBJECTS, V1289, P115, DOI 10.1016/0304-4165(95)00130-1; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P16717, DOI 10.1074/jbc.274.24.16717; Ujita M, 1999, J BIOL CHEM, V274, P9296, DOI 10.1074/jbc.274.14.9296; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; WALTZ G, 1990, SCIENCE, V250, P1132; WEN DX, 1992, J BIOL CHEM, V267, P21011; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	105	103	115	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3498	3507		10.1074/jbc.M004800200	http://dx.doi.org/10.1074/jbc.M004800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042166	hybrid			2022-12-25	WOS:000166784900067
J	Guiral, M; Bess, K; Goodwin, G; Jayaraman, PS				Guiral, M; Bess, K; Goodwin, G; Jayaraman, PS			PRH represses transcription in hematopoietic cells by at least two independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; EVEN-SKIPPED PROTEIN; HOMEOBOX GENE; HOMEODOMAIN PROTEINS; PROMOTER ACTIVITY; GLOBAL REPRESSOR; TARGET GENES; DNA; HEX; INTERACTS	PRH (proline-rich homeodomain protein) is strongly expressed in the hematopoietic compartment, Here we show that PRH is a repressor of transcription in hematopoietic cells. A fragment of PRH that includes the homeodomain can bind to TATA box sequences in vitro and can also bind to the TATA box-binding protein. PRH represses transcription from TATA box-containing promoters in intact cells but does not repress transcription from a promoter lacking a TATA box. A mutation in the PRH homeodomain that blocks binding to DNA but that has little or no effect on binding to the TATA box-binding protein significantly reduces the ability of the protein to repress transcription and provides the first clear demonstration that a homeodomain can bring about transcriptional repression in vivo by binding to a TATA box. However, we also show that mutation of the PRH homeodomain does not block the ability of PRH to repress transcription when this protein is tethered upstream of the TATA box via a heterologous DNA-binding domain. PRH also contains an N-terminal proline-rich repression domain that is separate from the homeodomain, Deletion mapping suggests that this repression domain contains at least two regions that both independently contribute to transcriptional repression.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Inst Canc Res, Sutton SM2 5NG, Surrey, England	University of Bristol; University of London; Institute of Cancer Research - UK	Jayaraman, PS (corresponding author), Univ Bristol, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.			/0000-0002-6500-9095				Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Briata P, 1997, FEBS LETT, V402, P131, DOI 10.1016/S0014-5793(96)01512-8; CATRON KM, 1995, MOL CELL BIOL, V15, P861; Cole EG, 1997, NUCLEIC ACIDS RES, V25, P3705, DOI 10.1093/nar/25.18.3705; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Ford Kevin G., 1994, V30, P185; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Jayaraman PS, 2000, LEUKEMIA RES, V24, P1023, DOI 10.1016/S0145-2126(00)00072-2; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Jones CM, 1999, CURR BIOL, V9, P946, DOI 10.1016/S0960-9822(99)80421-7; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Keng VW, 1998, FEBS LETT, V426, P183, DOI 10.1016/S0014-5793(98)00342-1; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Li XL, 1999, EMBO J, V18, P198, DOI 10.1093/emboj/18.1.198; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; MADDEN SL, 1993, ONCOGENE, V8, P1713; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Patterson KD, 1998, CURR TOP DEV BIOL, V40, P1, DOI 10.1016/S0070-2153(08)60363-4; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; Tanaka T, 1999, BIOCHEM J, V339, P111, DOI 10.1042/0264-6021:3390111; TENHARMSEL A, 1993, MOL CELL BIOL, V13, P2742, DOI 10.1128/MCB.13.5.2742; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Topcu Z, 1999, ONCOGENE, V18, P7091, DOI 10.1038/sj.onc.1203201; UM M, 1995, MOL CELL BIOL, V15, P5007; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764	52	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2961	2970		10.1074/jbc.M004948200	http://dx.doi.org/10.1074/jbc.M004948200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11054411	hybrid			2022-12-25	WOS:000166784800089
J	Leonard, JL; Visser, TJ; Leonard, DM				Leonard, JL; Visser, TJ; Leonard, DM			Characterization of the subunit structure of the catalytically active type I iodothyronine deiodinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; RAT-LIVER; 5'-DEIODINASE ACTIVITY; THYROID-HORMONE; THYROXINE 5'-DEIODINASE; PLASMA-MEMBRANE; KIDNEY; IDENTIFICATION; SELENOCYSTEINE; PROPYLTHIOURACIL	Type I iodothyronine deiodinase is a similar to 50-kDa, integral membrane protein that catalyzes the outer ring deiodination of thyroxine, Despite the identification and cloning of a 27-kDa selenoprotein with the catalytic properties of the type I enzyme, the composition and the physical nature of the active deiodinase are unknown. In this report, we use a molecular approach to determine holoenzyme composition, the role of the membrane anchor on enzyme assembly, and the contribution of individual 27-kDa subunits to catalysis. Overexpression of an immunologically unique rat 27-kDa protein in LLC-PK1 cells that contain abundant catalytically active 27-kDa selenoprotein decreased deiodination by similar to 50%, and >95% of the LLC-PK1 derived 27-kDa selenoprotein was specifically immune precipitated by the anti-rat enzyme antibody. The hybrid enzyme had a molecular mass of 54 kDa and an s(20,w) of similar to3.5 S indicating that every native 27-kDa selenoprotein partnered with an inert rat 27-kDa subunit in a homodimer, Enzyme assembly did not depend on the presence of the N-terminal membrane anchor of the 27-kDa subunit, Direct visualization of the deiodinase dimer showed that the holoenzyme was sorted to the basolateral plasma membrane of the renal epithelial cell.	Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA; Erasmus Univ, Sch Med, NL-3015 GD Rotterdam, Netherlands	University of Massachusetts System; University of Massachusetts Worcester; Erasmus University Rotterdam	Leonard, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.		Visser, Theo J/C-8059-2013	Visser, Theo J/0000-0002-6997-284X				BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1992, J BIOL CHEM, V267, P18055; Croteau W, 1998, J BIOL CHEM, V273, P25230, DOI 10.1074/jbc.273.39.25230; FEKKES D, 1982, FEBS LETT, V137, P40, DOI 10.1016/0014-5793(82)80310-4; FEKKES D, 1983, BIOCHIM BIOPHYS ACTA, V742, P324, DOI 10.1016/0167-4838(83)90318-7; FEKKES D, 1980, BIOCHIM BIOPHYS ACTA, V613, P41, DOI 10.1016/0005-2744(80)90190-4; GOSWAMI A, 1990, BIOCHEM BIOPH RES CO, V173, P6, DOI 10.1016/S0006-291X(05)81013-7; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; KOHRLE J, 1987, HORM RES, V26, P58, DOI 10.1159/000180686; KOHRLE J, 1990, J BIOL CHEM, V265, P6146; Larsen PR, 1997, BIOCHEM SOC T, V25, P588, DOI 10.1042/bst0250588; LARSEN PR, 1994, THYROID, V4, P357, DOI 10.1089/thy.1994.4.357; LEONARD JL, 1991, J BIOL CHEM, V266, P11262; LEONARD JL, 1981, BIOCHIM BIOPHYS ACTA, V659, P205, DOI 10.1016/0005-2744(81)90285-0; LEONARD JL, 1980, ENDOCRINOLOGY, V107, P1376, DOI 10.1210/endo-107-5-1376; LEONARD JL, 1984, BIOCHIM BIOPHYS ACTA, V787, P122, DOI 10.1016/0167-4838(84)90070-0; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P274, DOI 10.1210/endo-103-1-274; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P2137, DOI 10.1210/endo-103-6-2137; Leonard JL, 1986, THYROID HORMONE META, P189; MOL JA, 1984, BIOCHEM BIOPH RES CO, V120, P28, DOI 10.1016/0006-291X(84)91409-8; MOL JA, 1984, BIOCHEM BIOPH RES CO, V124, P475, DOI 10.1016/0006-291X(84)91578-X; Prabakaran D, 1999, J CELL SCI, V112, P1247; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SAFRAN M, 1990, ENDOCRINOLOGY, V126, P826, DOI 10.1210/endo-126-2-826; Sanders JP, 1997, ENDOCRINOLOGY, V138, P5153, DOI 10.1210/en.138.12.5153; SCHONMAKERS CHH, 1992, BIOCHIM BIOPHYS ACTA, V1121, P160, DOI 10.1016/0167-4838(92)90349-I; Sun BC, 1997, ENDOCRINOLOGY, V138, P5452, DOI 10.1210/en.138.12.5452; TOYODA N, 1995, J BIOL CHEM, V270, P12310, DOI 10.1074/jbc.270.20.12310; TOYODA N, 1994, J BIOL CHEM, V269, P20329; Toyoda N, 1997, ENDOCRINOLOGY, V138, P213, DOI 10.1210/en.138.1.213; VISSER TJ, 1992, BIOCHEM BIOPH RES CO, V189, P1362, DOI 10.1016/0006-291X(92)90224-9; VISSER TJ, 1980, BIOCHIM BIOPHYS ACTA, V611, P371, DOI 10.1016/0005-2744(80)90074-1; Visser TJ, 1996, ACTA MED AUST, V23, P10	36	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2600	2607		10.1074/jbc.M006973200	http://dx.doi.org/10.1074/jbc.M006973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11044448	hybrid, Green Published			2022-12-25	WOS:000166784800043
J	Muller, JJ; Lapko, A; Bourenkov, G; Ruckpaul, K; Heinemann, U				Muller, JJ; Lapko, A; Bourenkov, G; Ruckpaul, K; Heinemann, U			Adrenodoxin reductase-adrenodoxin complex structure suggests electron transfer path in steroid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTATIONS; CROSS-LINKED COMPLEX; FERREDOXIN REDUCTASE; BOVINE ADRENODOXIN; CRYSTAL-STRUCTURE; CYTOCHROME-P-450SCC; IDENTIFICATION; ENZYMES; SYSTEMS; MODEL	The steroid hydroxylating system of adrenal cortex mitochondria consists of the membrane-attached NADPH-dependent adrenodoxin reductase (AR), the soluble one-electron transport protein adrenodoxin (Adx), and a membrane-integrated cytochrome P450 of the CYP11 family. In the 2.3-Angstrom resolution crystal structure of the Adx AR complex, 580 Angstrom (2) of partly polar surface are buried. Main interaction sites are centered around Asp(79), Asp(76), Asp(72), and Asp(39) Of Adx and around Arg(211), Arg(240), Arg(244) and Lys(27) Of AR, respectively. In particular, the region around Asp(39) defines a new protein interaction site for Adn, similar to those found in plant and bacterial ferredoxins. Additional contacts involve the electron transfer region between the redox centers of AR and Adx and C-terminal residues of Adx, The Adx residues Asp(113) to Arg(15) adopt 3(10)-helical conformation and engage in loose intermolecular contacts within a deep cleft of AR. Complex formation is accompanied by a slight domain rearrangement in AR. The [2Fe-2S] cluster of Adx and the isoalloxazine rings of FAD of AR are 10 Angstrom apart suggesting a possible electron transfer route between these redox centers. The AR . Adx complex represents the first structure of a biologically relevant complex between a ferredoxin and its reductase.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; DESY, MPG ASMB, D-22603 Hamburg, Germany; Free Univ Berlin, Inst Chem Kristallog, D-14195 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Free University of Berlin	Muller, JJ (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.		Heinemann, Udo/AAH-4766-2019; Bourenkov, Gleb P/C-7794-2017; Heinemann, Udo/S-3379-2016	Heinemann, Udo/0000-0002-8191-3850; Bourenkov, Gleb P/0000-0002-2617-5920; Heinemann, Udo/0000-0002-8191-3850				BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; Bernhardt R, 1996, REV PHYSIOL BIOCH P, V127, P137, DOI 10.1007/BFb0048267; BRANDT ME, 1993, J BIOL CHEM, V268, P17126; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1992, J BIOL CHEM, V267, P8932; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Grinberg AV, 2000, PROTEINS, V40, P590, DOI 10.1002/1097-0134(20000901)40:4<590::AID-PROT50>3.0.CO;2-P; HANUKOGLU I, 1992, J STEROID BIOCHEM, V43, P779, DOI 10.1016/0960-0760(92)90307-5; HARA T, 1989, J BIOCHEM-TOKYO, V105, P594, DOI 10.1093/oxfordjournals.jbchem.a122710; HARA T, 1994, CYTOCHROME P450, P417; HARA T, 1991, J BIOCHEM-TOKYO, V110, P261, DOI 10.1093/oxfordjournals.jbchem.a123568; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; Ishimura K, 1997, MICROSC RES TECHNIQ, V36, P445, DOI 10.1002/(SICI)1097-0029(19970315)36:6<445::AID-JEMT2>3.0.CO;2-H; KIDO T, 1979, J BIOL CHEM, V254, P1806; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; Lapko A, 1997, PROTEINS, V28, P289; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Muller A, 1998, STRUCTURE, V6, P269, DOI 10.1016/S0969-2126(98)00031-8; Muller JJ, 1999, J MOL BIOL, V294, P501, DOI 10.1006/jmbi.1999.3253; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Pikuleva IA, 2000, ARCH BIOCHEM BIOPHYS, V373, P44, DOI 10.1006/abbi.1999.1536; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; Ziegler GA, 1999, J MOL BIOL, V289, P981, DOI 10.1006/jmbi.1999.2807	31	133	137	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2786	2789		10.1074/jbc.M008501200	http://dx.doi.org/10.1074/jbc.M008501200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053423	hybrid			2022-12-25	WOS:000166784800067
J	Guillard, C; Chretien, S; Jockers, R; Fichelson, S; Mayeux, P; Duprez, V				Guillard, C; Chretien, S; Jockers, R; Fichelson, S; Mayeux, P; Duprez, V			Coupling of heterotrimeric G(i) proteins to the erythropoietin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NUCLEOTIDE-BINDING-PROTEINS; GROWTH-FACTOR RECEPTOR; SENSITIVE G-PROTEINS; DEPENDENT CELL-LINE; FACTOR-II RECEPTOR; TYROSINE PHOSPHORYLATION; PERTUSSIS-TOXIN; ADENYLATE-CYCLASE; RESPONSIVE CELLS	To identify new proteins involved in erythropoietin (Epo) signal transduction, we purified the entire set of proteins reactive with anti-phosphotyrosine antibodies from Epo-stimulated UT7 cells. Antisera generated against these proteins mere used to screen a lambda EXlox expression library. One of the isolated cDNAs encodes G beta (2), the beta (2) subunit of heterotrimeric GTP-binding proteins. G beta and G alpha (i) coprecipitated with the Epo receptor (EpoR) in extracts from human and murine cell Lines and from normal human erythroid progenitor cells. In addition, in vitro G beta associated with a fusion protein containing the intracellular domain of the EpoR. Using EpoR mutants, we found that the distal part of the EpoR (between amino acids 459-479) was required for G(i) binding. Epo activation of these cells induced the release of the G(i) protein from the EpoR. Moreover in isolated cell membranes, Epo treatment inhibited ADP-ribosylation of G(i) and increased the binding of GTP. Our results show that heterotrimeric G(i) proteins associate with the C-terminal end of the EpoR. Receptor activation leads to the activation and dissociation of G(i) from the receptor, suggesting a functional role of G(i) protein in Epo signal transduction.	INSERM, U363, F-75014 Paris, France; Inst Cochin Genet Mol, CNRS UPR 0415, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Duprez, V (corresponding author), Hop Cochin, INSERM U363, ICGM, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Chretien, Stany/M-5166-2018; Jockers, Ralf/P-2272-2017; Jockers, Ralf/Q-2100-2019	Jockers, Ralf/0000-0002-4354-1750; Jockers, Ralf/0000-0002-4354-1750				AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; BILLAT C, 1991, BIOL NEONATE, V60, P371; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BONANOUTZEDAKI SA, 1986, EUR J BIOCHEM, V155, P363, DOI 10.1111/j.1432-1033.1986.tb09499.x; CENCIARELLI C, 1992, J BIOL CHEM, V267, P14527; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; Chretien S, 1997, ONCOGENE, V15, P1995, DOI 10.1038/sj.onc.1201364; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; Damen JE, 1996, EXP HEMATOL, V24, P1455; DAMEN JE, 1993, BLOOD, V82, P2296; Duprez V, 1998, J BIOL CHEM, V273, P33985, DOI 10.1074/jbc.273.51.33985; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Freyssinier JM, 1999, BRIT J HAEMATOL, V106, P912; Ghose S, 1999, J BIOL CHEM, V274, P12848, DOI 10.1074/jbc.274.18.12848; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; HANAZONO Y, 1993, BLOOD, V81, P3193; HE YX, 1988, BLOOD, V71, P1187; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; IMBODEN JB, 1986, P NATL ACAD SCI USA, V83, P5673, DOI 10.1073/pnas.83.15.5673; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; KITAMURA T, 1989, BLOOD, V73, P375; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; KOMATSU N, 1991, CANCER RES, V51, P341; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LIANG M, 1991, J BIOL CHEM, V266, P13342; Lippert E, 1997, FEBS LETT, V417, P292, DOI 10.1016/S0014-5793(97)01308-2; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MCCOLL SR, 1989, BLOOD, V73, P588; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; Miller BA, 1996, J CLIN INVEST, V98, P1728, DOI 10.1172/JCI118971; MILLER BA, 1991, BLOOD, V77, P486; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; REN HY, 1994, J BIOL CHEM, V269, P19633; Roka F, 1999, MOL PHARMACOL, V56, P1014, DOI 10.1124/mol.56.5.1014; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TSAI SC, 1984, J BIOL CHEM, V259, P5320; TSUDA H, 1989, EXP HEMATOL, V17, P211; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; WILLIAMS AG, 1990, BLOOD, V76, P721; WINKELMANN JC, 1995, BLOOD, V85, P179, DOI 10.1182/blood.V85.1.179.bloodjournal851179; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZUMBIHL R, 1995, J IMMUNOL, V155, P181	70	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2007	2014		10.1074/jbc.M003527200	http://dx.doi.org/10.1074/jbc.M003527200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053408	hybrid			2022-12-25	WOS:000166528000050
J	Leimkuhler, S; Rajagopalan, KV				Leimkuhler, S; Rajagopalan, KV			In vitro incorporation of nascent molybdenum cofactor into human sulfite oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STRUCTURAL-CHARACTERIZATION; NITRATE REDUCTASE; BIOSYNTHESIS; MOLYBDOPTERIN; IDENTIFICATION; MOLYBDATE; PURIFICATION; INVOLVEMENT; COMPONENT	We were able to reconstitute molybdopterin (MPT)free sulfite oxidase in vitro with the molybdenum cofactor (Moco) synthesized de novo from precursor Z and molybdate. MPT-free human sulfite oxidase apoprotein was obtained by heterologous expression in an Escherichia coli mutant with a defect in the early steps of MPT biosynthesis. In vitro reconstitution of the purified apoprotein was achieved using an incubation mixture containing purified precursor Z, purified MPT synthase, and sodium molybdate. In vitro synthesized MPT generated from precursor Z by MPT synthase remains bound to the synthase. Surprisingly, MPT synthase was found capable of donating bound MPT to MPT- free sulfite oxidase. MPT was not released from MPT synthase when either bovine serum albumin or Moco-containing sulfite oxidase was used in place of aposulfite oxidase. After the inclusion of sodium molybdate in the reconstitution mixture, active sulfite oxidase was obtained, revealing that in vitro MPT synthase and aposulfite oxidase are sufficient for the insertion of MPT into sulfite oxidase and the conversion of MPT into Moco in the presence of high concentrations of molybdate. The conversion of MPT into Moco by molybdate chelation apparently occurs concomitantly with the insertion of RIFT into sulfite oxidase.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu		Leimkuhler, Silke/0000-0003-3238-2122	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044283] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44283] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COHEN HJ, 1971, J BIOL CHEM, V246, P359; Grunden AM, 1997, ARCH MICROBIOL, V168, P345, DOI 10.1007/s002030050508; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1997, INT PEDIAT, V12, P23; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JONES HP, 1977, J BIOL CHEM, V252, P4988; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Kozmin SG, 2000, J BACTERIOL, V182, P3361, DOI 10.1128/JB.182.12.3361-3367.2000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; Rajagopalan K.V., 1980, MOLYBDENUM MOLYBDENU, P241; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; RUDOLPH MJ, 2001, IN PRESS NAT STRUCT; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493	22	51	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1837	1844		10.1074/jbc.M007304200	http://dx.doi.org/10.1074/jbc.M007304200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042213	hybrid			2022-12-25	WOS:000166528000027
J	Li, GF; Bishop, KJ; Hall, TC				Li, GF; Bishop, KJ; Hall, TC			De novo activation of the beta-phaseolin promoter by phosphatase or protein synthesis inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; MESSENGER-RNAS; C-FOS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; OKADAIC ACID; HISTONE H3; CYCLOHEXIMIDE; KINASE; PHOSPHORYLATION	The promoter for the phaseolin (phas) bean seed protein gene adopts an inactive chromatin structure in leaves of transgenic tobacco. This repressive architecture, which confers stringent spatial regulation, is disrupted upon transcriptional activation during embryogenesis in a process that requires the presence of both a transcription factor (PvALF) and abscisic acid (ABA). Toward determining the need for de novo synthesis of proteins other than PvALF in transcriptional activation we explored the effect of several eukaryotic protein synthesis inhibitors. Surprisingly, cycloheximide (CHX), emetine, and verrucarin A were able to induce transcription from the phas promoter in tobacco and bean leaf tissue in the absence of either PVALF or ABA. This induction was decreased by the replication inhibitors hydroxyurea and aphidicolin but not by genistein or mimosine. Since protein phosphatases and kinases are essential components of the ABA signal transduction pathway, it is conceivable that CHX is also capable of inducing phosphorylation of proteins usually involved in ABA-mediated activation. Interestingly, okadaic acid, an inhibitor of serine/threonine phosphatase, also strongly activated transcription from the phas promoter. In contrast, the protein synthesis inhibitors anisomycin and puromycin did not activate transcription from the phas promoter, nor did the tyrosine phosphatase inhibitors phenylarsine oxide and sodium orthovanadate, These discrete but different results on transcriptional activation may reflect specific modes of action of the inhibitors, or they may reflect differential interactions of the inhibitors or of downstream events resulting from inhibitor activity with presently unknown components of the transcriptional activation system.	Texas A&M Univ, Inst Dev & Mol Biol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Hall, TC (corresponding author), Texas A&M Univ, Inst Dev & Mol Biol, College Stn, TX 77843 USA.	tim@idmb.tamu.edu						ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; ANTHONY JL, 1991, PLANT PHYSIOL, V97, P839, DOI 10.1104/pp.97.2.839; Berberich T, 1997, MOL GEN GENET, V254, P275, DOI 10.1007/s004380050416; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTOS MM, 1989, PLANT CELL, V1, P839, DOI 10.1105/tpc.1.9.839; Cesari M, 1998, BIOCHEM J, V336, P619, DOI 10.1042/bj3360619; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EDWARDS Y, 1980, NATURE, V284, P511, DOI 10.1038/284511a0; Feldbrugge M, 1996, MOL GEN GENET, V251, P619, DOI 10.1007/s004380050210; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GUBLER F, 1995, PLANT CELL, V7, P1879, DOI 10.1105/tpc.7.11.1879; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; Kawagoe Y, 1996, PLANT SCI, V116, P47, DOI 10.1016/0168-9452(96)04366-X; KLIMCZAK LJ, 1992, PLANT CELL, V4, P87, DOI 10.1105/tpc.4.1.87; Knetsch MLW, 1996, PLANT CELL, V8, P1061, DOI 10.1105/tpc.8.6.1061; KOSHIBA T, 1995, J MOL BIOL, V253, P396, DOI 10.1006/jmbi.1995.0562; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; Li GF, 1998, P NATL ACAD SCI USA, V95, P4772, DOI 10.1073/pnas.95.8.4772; Li GF, 1999, P NATL ACAD SCI USA, V96, P7104, DOI 10.1073/pnas.96.12.7104; Li GF, 1999, PLANT J, V18, P633, DOI 10.1046/j.1365-313x.1999.00490.x; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MartinezGarcia M, 1996, MOL GEN GENET, V252, P587, DOI 10.1007/s004380050266; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; NUNBERG AN, 1994, PLANT CELL, V6, P473, DOI 10.1105/tpc.6.4.473; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEFFENS WS, 1990, DEV GENET, V11, P65, DOI 10.1002/dvg.1020110108; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; SHEN QX, 1993, J BIOL CHEM, V268, P23652; SLIGHTOM JL, 1983, P NATL ACAD SCI-BIOL, V80, P1897, DOI 10.1073/pnas.80.7.1897; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; VANDERGEEST AHM, 1995, PLANT PHYSIOL, V109, P1151, DOI 10.1104/pp.109.4.1151; Wang P, 1998, GENE, V210, P79, DOI 10.1016/S0378-1119(98)00035-3; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Yakisich JS, 1999, EXP NEUROL, V159, P164, DOI 10.1006/exnr.1999.7121	43	11	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2062	2068		10.1074/jbc.M007504200	http://dx.doi.org/10.1074/jbc.M007504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11031270	hybrid			2022-12-25	WOS:000166528000057
J	Stewart, RS; Harris, DA				Stewart, RS; Harris, DA			Most pathogenic mutations do not alter the membrane topology of the prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; ENDOPLASMIC-RETICULUM; BIOCHEMICAL-PROPERTIES; TERMINAL DOMAIN; PHOSPHOLIPASE-C; PRP 27-30; BIOGENESIS; DISEASES; MUTANT; FORM	The prion protein (PrP), a glycolipid-anchored membrane glycoprotein, contains a conserved hydrophobic sequence that can span the lipid bilayer in either direction, resulting in two transmembrane forms designated (PrP)-Pr-Ntm and (PrP)-Pr-Ctm. Previous studies have shown that the proportion of (PrP)-Pr-Ctm is increased by mutations in the membrane-spanning segment, and it has been hypothesized that (PrP)-Pr-Ctm represents a key intermediate in the pathway of prion-induced neurodegeneration, To further test this idea, we have surveyed a number of mutations associated with familial prion diseases to determine whether they alter the proportions of (PrP)-Pr-Ntm and (PrP)-Pr-Ctm produced in vitro, in transfected cells, and in transgenic mice. For the in vitro experiments, PrP mRNA was translated in the presence of murine thymoma microsomes which, in contrast to the canine pancreatic microsomes used in previous studies, are capable of efficient glycolipidation, We confirmed that mutations within or near the transmembrane domain enhance the formation of (PrP)-Pr-Ctm, and we demonstrate for the first time that this species contains a C-terminal glycolipid anchor, thus exhibiting an unusual, dual mode of membrane attachment. However, we find that pathogenic mutations in other regions of the molecule have no effect on the amounts of (PrP)-Pr-Ctm and (PrP)-Pr-Ntm, arguing against the proposition that transmembrane PrP plays an obligate role in the pathogenesis of prion diseases.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Harris, David/0000-0002-6985-5790	NINDS NIH HHS [T32 NS07129, R01 NS35496] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496, T32NS007129] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chiesa R, 2000, J NEUROCHEM, V75, P72, DOI 10.1046/j.1471-4159.2000.0750072.x; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; FASEL N, 1989, P NATL ACAD SCI USA, V86, P6858, DOI 10.1073/pnas.86.18.6858; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hegde RS, 1999, TRENDS CELL BIOL, V9, P132, DOI 10.1016/S0962-8924(99)01504-4; HITT AL, 1994, J CELL BIOL, V126, P1421, DOI 10.1083/jcb.126.6.1421; HOWELL S, 1994, J BIOL CHEM, V269, P16993; KOSTER B, 1994, ARCH BIOCHEM BIOPHYS, V310, P108, DOI 10.1006/abbi.1994.1146; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MASTRIANNI JA, 1995, NEUROLOGY, V45, P2042, DOI 10.1212/WNL.45.11.2042; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Priola SA, 1998, J BIOL CHEM, V273, P11980, DOI 10.1074/jbc.273.19.11980; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; PRUSINER SB, 1999, PRION BIOL DIS; ROSENBERRY TL, 1991, CELL BIOL INT REP, V15, P1133, DOI 10.1016/0309-1651(91)90060-V; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; Tateishi J, 1996, NEUROLOGY, V46, P532, DOI 10.1212/WNL.46.2.532; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TRANCHANT C, 1992, J NEUROL NEUROSUR PS, V55, P185, DOI 10.1136/jnnp.55.3.185; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Young Katherine, 1999, P139	47	56	59	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2212	2220		10.1074/jbc.M006763200	http://dx.doi.org/10.1074/jbc.M006763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053411	hybrid			2022-12-25	WOS:000166528000075
J	Braun, FJ; Broad, LM; Armstrong, DL; Putney, JW				Braun, FJ; Broad, LM; Armstrong, DL; Putney, JW			Stable activation of single Ca2+ release-activated Ca2+ channels in divalent cation-free solutions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; JURKAT T-LYMPHOCYTES; STORE DEPLETION; MAST-CELLS; ANTIGEN	The regulation of store-operated, calcium-selective channels in the plasma membrane of rat basophilic leukemia cells (RBL-2H3 m1), an immortalized mucosal mast cell line, was studied at the single-channel level with the patch clamp technique by removing divalent cations from both sides of the membrane. The activity of the single channels in excised patches could be modulated by Ca2+, Mg2+, and pH. The maximal activation of these channels by divalent cation-free conditions occurred independently of depletion of intracellular Ca2+ stores, whether in excised patches or in whole cell mode. Yet, a number of points of evidence establish these single-channel openings as amplified store-operated channel events. Specifically, (i) the single channels are exquisitely sensitive to inhibition by intracellular Ca2+, and (ii) both the store-operated current and the single-channel openings are completely blocked by the capacitative calcium entry blocker, 2-aminoethoxydiphenyl borane, In addition, in Jurkat T cells single-channel openings with lower open probability have been observed in the whole cell mode with intracellular Mg2+ present (Kerschbaum, H. H., and Cahalan, M. D. (1999) Science 283, 836-839), and in RBL-2H3 m1 cells a current with similar properties is activated by store depletion.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Braun, FJ (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, ZIAES080043, Z01ES080043, Z01ES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; CHOI OH, 1993, J IMMUNOL, V151, P5586; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Krause E, 1999, J BIOL CHEM, V274, P36957, DOI 10.1074/jbc.274.52.36957; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Zubov AI, 1999, J BIOL CHEM, V274, P25983, DOI 10.1074/jbc.274.37.25983; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	26	99	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1063	1070		10.1074/jbc.M008348200	http://dx.doi.org/10.1074/jbc.M008348200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042187	hybrid			2022-12-25	WOS:000166430900029
J	Fewell, SW; Day, BW; Brodsky, JL				Fewell, SW; Day, BW; Brodsky, JL			Identification of an inhibitor of hsc70-mediated protein translocation and ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN-VIRUS-40 LARGE T; MOLECULAR CHAPERONE; J-DOMAIN; IMMUNOSUPPRESSANT DEOXYSPERGUALIN; POLYPEPTIDE TRANSLOCATION; QUALITY-CONTROL; HSP70; DNAJ; HSC70; 15-DEOXYSPERGUALIN	Members of the hsc70 family of molecular chaperones are critical players in the folding and quality control of cellular proteins, Because several human diseases arise from defects in protein folding, the activity of hsc70 chaperones is a potential therapeutic target for these disorders, By using a known hsc70 modulator, 15-deoxyspergualin, as a seed, we identified a novel inhibitor of hsc70 activity. This compound, R/1, inhibits the endogenous and DnaJ-stimulated ATPase activity of hsc70 by 48 and 51%, respectively, and blocks the hsc70-mediated translocation of a preprotein into yeast endoplasmic reticulum-derived microsomal vesicles. Biochemical studies demonstrate that WI most likely exerts these effects by altering the oligomeric state of hsc70.	Univ Pittsburgh, Dept Sci Biol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Brodsky, JL (corresponding author), Univ Pittsburgh, Dept Sci Biol, Pittsburgh, PA 15260 USA.	jbrodsky@pitt.edu		Day, Billy/0000-0001-6208-9950	NATIONAL CANCER INSTITUTE [P01CA078039, F32CA083270] Funding Source: NIH RePORTER; NCI NIH HHS [1 F32 CA83270-01, CA78039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; Becker J, 1996, MOL CELL BIOL, V16, P4378; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Brodsky JL, 1999, BIOCHEM PHARMACOL, V57, P877, DOI 10.1016/S0006-2952(98)00376-1; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; Davis JE, 1999, P NATL ACAD SCI USA, V96, P9269, DOI 10.1073/pnas.96.16.9269; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DURCHSCHLAG H, 1981, EUR J BIOCHEM, V114, P255, DOI 10.1111/j.1432-1033.1981.tb05144.x; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hughes SE, 1996, J CLIN PHARMACOL, V36, P1081, DOI 10.1002/j.1552-4604.1996.tb04160.x; JIANG C, 1998, AM J PHYSIOL, V275, P171; King C, 1999, BIOCHEMISTRY-US, V38, P12452, DOI 10.1021/bi9902788; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; Lebreton L, 1999, J MED CHEM, V42, P4749, DOI 10.1021/jm991043x; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McClellan AJ, 1998, MOL BIOL CELL, V9, P3533, DOI 10.1091/mbc.9.12.3533; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MUKAI H, 1997, GUIDEBOOK MOL CHAPER, P76; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; NADLER SG, 1995, THER DRUG MONIT, V17, P700, DOI 10.1097/00007691-199512000-00026; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	42	58	62	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					910	914		10.1074/jbc.M008535200	http://dx.doi.org/10.1074/jbc.M008535200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11036084	hybrid			2022-12-25	WOS:000166430900008
J	Bruno, S; Schiaretti, F; Burkhard, P; Kraus, JP; Janosik, M; Mozzarelli, A				Bruno, S; Schiaretti, F; Burkhard, P; Kraus, JP; Janosik, M; Mozzarelli, A			Functional properties of the active core of human cystathionine beta-synthase crystals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-ACETYLSERINE SULFHYDRYLASE; TRYPTOPHAN SYNTHASE; ALPHA(2)BETA(2) COMPLEX; SALMONELLA-TYPHIMURIUM; HEME PROTEIN; 3-DIMENSIONAL STRUCTURE; PYRIDOXAL 5'-PHOSPHATE; ENZYME; MICROSPECTROPHOTOMETRY; BINDING	Human cystathionine beta -synthase is a pyridoxal 5'-phosphate enzyme containing a heme binding domain and an S-adenosyl-L-methionine regulatory site. We have investigated by single crystal microspectrophotometry the functional properties of a mutant lacking the S-adenosyhmethionine binding domain. Polarized absorption spectra indicate that oxidized and reduced hemes are reversibly formed. Exposure of the reduced form of enzyme crystals to carbon monoxide led to the complete release of the heme moiety. This process, which takes place reversibly and without apparent crystal damage, facilitates the preparation of a heme-free human enzyme. The heme-free enzyme crystals exhibited polarized absorption spectra typical of a pyridoxal 5'-phosphate-dependent protein. The exposure of these crystals to increasing concentrations of the natural substrate L-serine readily led to the formation of the key catalytic intermediate alpha -aminoacrylate. The dissociation constant of L-serine was found to be 6 mM, close to that determined in solution. The amount of the alpha -aminoacrylate Schiff base formed in the presence of L-serine was pH independent between 6 and 9, However, the rate of the disappearance of the alpha -aminoacrylate, likely forming pyruvate and ammonia, was found to increase at pH values higher than 8, Finally, in the presence of homocysteine the alpha -aminoacrylate-enzyme absorption band readily disappears with the concomitant formation of the absorption band of the internal aldimine, indicating that cystathionine beta -synthase crystals catalyze both beta -elimination and beta -replacement reactions. Taken together, these findings demonstrate that the heme moiety is not directly involved in the condensation reaction catalyzed by cystathionine beta -synthase.	Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy; Univ Basel, Biozentrum, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland; Univ Colorado, Sch Med, Dept Pediat, Denver, CO 80262 USA	University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma; University of Basel; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Mozzarelli, A (corresponding author), Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy.	biochim@unipr.it	Mozzarelli, Andrea/C-3615-2014; Bruno, Stefano/A-4582-2011	Mozzarelli, Andrea/0000-0003-3762-0062; Bruno, Stefano/0000-0002-7890-2472				ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; DOUZOU P, 1984, ADV PROTEIN CHEM, V36, P245, DOI 10.1016/S0065-3233(08)60299-5; DRUMMOND JT, 1995, ANAL BIOCHEM, V228, P323, DOI 10.1006/abio.1995.1358; Eaton W A, 1981, Methods Enzymol, V76, P175; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JANOSIK M, 2000, IN PRESS ACTA CRYSTA; Jhee KH, 2000, J BIOL CHEM, V275, P11541, DOI 10.1074/jbc.C000056200; Jhee KH, 2000, BIOCHEMISTRY-US, V39, P10548, DOI 10.1021/bi001020g; Kery V, 1999, BIOCHEMISTRY-US, V38, P2716, DOI 10.1021/bi981808n; Kery V, 1998, ARCH BIOCHEM BIOPHYS, V355, P222, DOI 10.1006/abbi.1998.0723; KERY V, 1994, J BIOL CHEM, V269, P25283; MCPHERSON A, 1982, PREPARATION ANAL PRO, P94; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MOFFAT K, 1989, ANNU REV BIOPHYS BIO, V18, P309, DOI 10.1146/annurev.biophys.18.1.309; Mozzarelli A, 1998, J MOL BIOL, V283, P135, DOI 10.1006/jmbi.1998.2038; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; Mozzarelli A, 2000, J BIOL CHEM, V275, P6956, DOI 10.1074/jbc.275.10.6956; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; ROSSI GL, 1970, J MOL BIOL, V49, P85, DOI 10.1016/0022-2836(70)90377-3; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Taoka S, 1999, BIOCHEMISTRY-US, V38, P2738, DOI 10.1021/bi9826052; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t	35	44	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					16	19		10.1074/jbc.C000588200	http://dx.doi.org/10.1074/jbc.C000588200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11042162	hybrid			2022-12-25	WOS:000166280700003
J	DeGregorio-Rocasolano, N; Gasull, T; Trullas, R				DeGregorio-Rocasolano, N; Gasull, T; Trullas, R			Overexpression of neuronal pentraxin 1 is involved in neuronal death evoked by low K+ in cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; DIFFERENTIAL DISPLAY; GROWTH-FACTOR; APOPTOSIS; SURVIVAL; EXCITOTOXICITY; DEPOLARIZATION; EXPRESSION; POTASSIUM	Mature cerebellar granule cells in culture die by a process that requires new RNA and protein synthesis when deprived of depolarizing concentrations of potassium. We investigated gene expression during the early phase of the cell death program evoked by potassium deprivation, Using a differential gene display technique, we isolated a cDNA that was increased by potassium deprivation. This cDNA was homologous to the 3' mRNA end of neuronal pentraxin 1 (NP1), a gene encoding a secreted glycoprotein whose expression is restricted to the nervous system. Reverse-Northern and Northern blot analyses confirmed that treatment with low potassium induces overexpression of NP1 mRNA, with a subsequent increase in NP1 protein levels. Time-course studies indicated that overexpression of NP1 protein reaches a maximum after 4 h of exposure to potassium deprivation and 4 h before significant cell death. Incubation of cerebellar granule cells with an antisense oligodeoxyribonucleotide directed against NP1 mRNA reduced low potassium-evoked NP1 protein levels by 60% and attenuated neuronal death by 50%, whereas incubation with the corresponding sense oligodeoxyribonucleotide was ineffective. Furthermore, acute treatment with lithium significantly inhibited both overexpression of NP1 and cell death evoked by low potassium. These results indicate that NP1 is part of the gene expression program of apoptotic cell death activated by nondepolarizing culture conditions in cerebellar granule cells.	CSIC, Inst Invest Biomed Barcelona, Neurobiol Unit, Inst Invest Biomed August Pi I Sunyer, Barcelona 08036, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Trullas, R (corresponding author), CSIC, Inst Invest Biomed Barcelona, Neurobiol Unit, Inst Invest Biomed August Pi I Sunyer, Rossello 161, Barcelona 08036, Spain.		Trullas, Ramon/D-2197-2016; De Gregorio - Rocasolano, Nuria/M-1523-2014	Trullas, Ramon/0000-0001-7951-9881; GASULL, TERESA/0000-0002-9321-1741; De Gregorio - Rocasolano, Nuria/0000-0001-5248-7525				Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Burek MJ, 1996, BRAIN PATHOL, V6, P427, DOI 10.1111/j.1750-3639.1996.tb00874.x; Catania MV, 1999, NEUROSCIENCE, V91, P1529, DOI 10.1016/S0306-4522(98)00544-2; Chang JY, 1997, NEUROCHEM RES, V22, P43, DOI 10.1023/A:1027373220133; Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; D'Mello SR, 1997, J NEUROSCI, V17, P1548; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eldadah BA, 1997, J NEUROSCI, V17, P6105; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6; Ishitani R, 1997, MOL PHARMACOL, V51, P542, DOI 10.1124/mol.51.4.542; Kirkpatrick LL, 2000, J BIOL CHEM, V275, P17786, DOI 10.1074/jbc.M002254200; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Manji HK, 2000, J CLIN PSYCHIAT, V61, P82; Miller TM, 1996, J NEUROSCI, V16, P7487; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Nardi N, 1997, J NEUROCHEM, V68, P750; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; Omeis IA, 1996, GENOMICS, V36, P543, DOI 10.1006/geno.1996.0503; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Rudolph JG, 1997, NEUROSCI LETT, V221, P149, DOI 10.1016/S0304-3940(96)13313-9; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; SUNAGA K, 1995, NEUROSCI LETT, V200, P133, DOI 10.1016/0304-3940(95)12098-O; Tsui CC, 1996, J NEUROSCI, V16, P2463; Viu E, 1998, J PHARMACOL EXP THER, V285, P527; Watson A, 1998, J NEUROSCI, V18, P751; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; Zhang H, 1996, NUCLEIC ACIDS RES, V24, P2454, DOI 10.1093/nar/24.12.2454	40	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					796	803		10.1074/jbc.M007967200	http://dx.doi.org/10.1074/jbc.M007967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031272	hybrid			2022-12-25	WOS:000166280700107
J	Hammamieh, R; Yang, DCH				Hammamieh, R; Yang, DCH			Magnesium ion-mediated binding to tRNA by an amino-terminal peptide of a class II tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; PROTEIN-PROTEIN INTERACTIONS; ELONGATION-FACTOR 1-ALPHA; METHIONYL-TRANSFER-RNA; HIGH-MR COMPLEX; ESCHERICHIA-COLI; MULTISYNTHETASE COMPLEX; FUNCTIONAL-ANALYSIS; AMPHIPHILIC HELIX; RAT-LIVER	Aspartyl-tRNA synthetase is a class II tRNA synthetase and occurs in a multisynthetase complex in mammalian cells. Human Asp-tRNA synthetase contains a short 32-residue amino-terminal extension that can control the release of charged tRNA and its direct transfer to elongation factor 1 alpha; however, whether the extension binds to tRNA directly or interacts with the synthetase active site is not known. Full-length human AspRS, but not amino-terminal 32 residue-deleted, fully active As-pRS, was found to bind to noncognate tRNA(fMet) in the presence of Mg2+. Synthetic amino-terminal peptides bound similarly to tRNA(fMet), whereas little or no binding of polynucleotides, poly(dA-dT), or polyphosphate to the peptides was found. The apparent binding constants to tRNA by the peptide increased with increasing concentrations of Mg2+, suggesting Mg2+ mediates the binding as a new mode of RNA peptide interactions. The binding of tRNA(fMet), amino-terminal peptides was also observed using fluorescence-labeled tRNAs and circular dichroism. These results suggest that a small peptide can bind to tRNA selectively and that evolution of class II tRNA synthetases may involve structural changes of amino-terminal extensions for enhanced selective binding of tRNA.	Georgetown Univ, Dept Chem, Washington, DC 20057 USA	Georgetown University	Yang, DCH (corresponding author), Georgetown Univ, Dept Chem, Washington, DC 20057 USA.	yangdc@georgetown.edu	Yang, David/A-7294-2009	Hammamieh, Rasha/0000-0001-8643-6232				AGOU F, 1995, BIOCHEMISTRY-US, V34, P569, DOI 10.1021/bi00002a023; Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; BEC G, 1989, J BIOL CHEM, V264, P21138; BITTMAN R, 1969, J MOL BIOL, V46, P251, DOI 10.1016/0022-2836(69)90420-3; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CIRAKOGLU B, 1985, EUR J BIOCHEM, V151, P101, DOI 10.1111/j.1432-1033.1985.tb09074.x; de Pouplana LR, 1998, EMBO J, V17, P5449, DOI 10.1093/emboj/17.18.5449; ESCALANTE C, 1994, MOL CELL BIOCHEM, V140, P55, DOI 10.1007/BF00928366; ESCALANTE C, 1993, J BIOL CHEM, V268, P6014; FERGUSON BQ, 1986, BIOCHEMISTRY-US, V25, P2743, DOI 10.1021/bi00358a001; FERGUSON BQ, 1986, BIOCHEMISTRY-US, V25, P5298, DOI 10.1021/bi00366a046; FETT R, 1991, J BIOL CHEM, V266, P1448; Frugier M, 2000, EMBO J, V19, P2371, DOI 10.1093/emboj/19.10.2371; Glasfeld E, 1997, BIOCHEMISTRY-US, V36, P6739, DOI 10.1021/bi970151n; GODAR DE, 1988, BIOCHEMISTRY-US, V27, P6921, DOI 10.1021/bi00418a038; Grosshans H, 2000, J STRUCT BIOL, V129, P288, DOI 10.1006/jsbi.2000.4226; Hammamich R, 1997, FASEB J, V11, pA1024; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; Job P, 1928, ANN CHIM FRANCE, V9, P113; JOHNSON DL, 1980, J BIOL CHEM, V255, P4362; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; MIRANDE M, 1992, EUR J BIOCHEM, V203, P459, DOI 10.1111/j.1432-1033.1992.tb16570.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1989, J BIOL CHEM, V264, P842; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; REED VS, 1994, J BIOL CHEM, V269, P32932; REED VS, 1994, J BIOL CHEM, V269, P32937; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Sauter C, 2000, J MOL BIOL, V299, P1313, DOI 10.1006/jmbi.2000.3791; SELLAMI M, 1985, GENE, V40, P349, DOI 10.1016/0378-1119(85)90060-5; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; STEIN A, 1976, BIOCHEMISTRY-US, V15, P157, DOI 10.1021/bi00646a024; TAO T, 1970, BIOCHEMISTRY-US, V9, P3514, DOI 10.1021/bi00820a004; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wang CC, 2000, J BIOL CHEM, V275, P17180, DOI 10.1074/jbc.M001057200; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	46	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					428	433		10.1074/jbc.M007570200	http://dx.doi.org/10.1074/jbc.M007570200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035022	hybrid			2022-12-25	WOS:000166280700058
J	Kobayashi, A; Miyake, T; Ohyama, Y; Kawaichi, M; Kokubo, T				Kobayashi, A; Miyake, T; Ohyama, Y; Kawaichi, M; Kokubo, T			Mutations in the TATA-binding protein, affecting transcriptional activation, show synthetic lethality with the TAF145 gene lacking the TAF N-terminal domain in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IN-VIVO; BOX-BINDING; EUKARYOTIC TRANSCRIPTION; TBP BINDING; DNA-BINDING; PREINITIATION COMPLEX; BASAL TRANSCRIPTION; YEAST; PROMOTER	The general transcription factor TFIID, which is composed of the TATA box-binding protein (TBP) and a set of TBP-associated factors (TAFs), is crucial for both basal and regulated transcription by RNA polymerase II. The N-terminal small segment of yeast TAF145 (yTAF145) binds to TBP and thereby inhibits TBP function. To understand the physiological role of this inhibitory domain, which is designated as TAND (TAF N-terminal domain), we screened mutations, synthetically lethal with the TAF145 gene lacking TAND (taf145 Delta TAND), in Saccharomyces cerevisiae by exploiting a red/white colony-sectoring assay. Our screen yielded several recessive nsl (Delta TAND synthetic lethal) mutations, two of which, nsl1-1 and nsl1-2, define the same complementation group. The NSL1 gene was found to be identical to the SPT15 gene encoding TBP, Interestingly, both temperature-sensitive nsl1/spt15 alleles, which harbor the single amino acid substitutions, S118L and P65S, respectively, were defective in transcriptional activation in vivo. Several other previously characterized activation-deficient spt15 alleles arise displayed synthetic lethal interactions with taf145 Delta TAND, indicating that TAND and TBP carry an overlapping but as yet unidentified function that is specifically required for transcriptional regulation.	Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 6300101, Japan	Nara Institute of Science & Technology	Kokubo, T (corresponding author), Nara Inst Sci & Technol, Div Gene Funct Anim, 8916-5 Takayama, Nara 6300101, Japan.	kokubo@bs.aist-nara.ac.jp						Adams A, 1997, METHODS YEAST GENETI; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bagby S, 2000, FEBS LETT, V468, P149, DOI 10.1016/S0014-5793(00)01213-8; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Baker RE, 1998, GENETICS, V149, P73; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burley SK, 1998, CELL, V94, P551, DOI 10.1016/S0092-8674(00)81596-2; Cang Y, 1999, EMBO J, V18, P6662, DOI 10.1093/emboj/18.23.6662; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; Chen CY, 1998, GENETICS, V150, P577; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; Dorris DR, 2000, MOL CELL BIOL, V20, P4350, DOI 10.1128/MCB.20.12.4350-4358.2000; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; Knutson A, 2000, J BIOL CHEM, V275, P14190, DOI 10.1074/jbc.275.19.14190; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Kressler D, 1999, MOL CELL BIOL, V19, P8633; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; LEE M, 1995, MOL CELL BIOL, V15, P5461; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; LIEBERMAN P, 1994, MOL CELL BIOL, V14, P8365, DOI 10.1128/MCB.14.12.8365; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; LUNDBLACK V, 1998, CURRENT PROTOCOLS MO; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; Muldrow TA, 1999, MOL CELL BIOL, V19, P2835; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Stargell LA, 1996, MOL CELL BIOL, V16, P4456; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; Stargell LA, 2000, J BIOL CHEM, V275, P12374, DOI 10.1074/jbc.275.17.12374; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Tsukihashi Y, 2000, MOL CELL BIOL, V20, P2385, DOI 10.1128/MCB.20.7.2385-2399.2000; vanderKnaap JA, 1997, P NATL ACAD SCI USA, V94, P11827, DOI 10.1073/pnas.94.22.11827; XIAO H, 1995, MOL CELL BIOL, V15, P5757; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; Zaman Z, 1998, COLD SPRING HARB SYM, V63, P167, DOI 10.1101/sqb.1998.63.167	85	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					395	405		10.1074/jbc.M008208200	http://dx.doi.org/10.1074/jbc.M008208200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035037	hybrid			2022-12-25	WOS:000166280700054
J	Servant, MJ; ten Oever, B; LePage, C; Conti, L; Gessani, S; Julkunen, I; Lin, RT; Hiscott, J				Servant, MJ; ten Oever, B; LePage, C; Conti, L; Gessani, S; Julkunen, I; Lin, RT; Hiscott, J			Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CASCADES; KAPPA-B ACTIVATION; IKK-BETA SUBUNIT; GENE-EXPRESSION; VIRUS-INFECTION; GROWTH-FACTOR; IN-VITRO; TRANSCRIPTION; CELLS; INHIBITOR	Infection of host cells by viruses leads to the activation of multiple signaling pathways, resulting in the expression of host genes involved in the establishment of the antiviral state. Among the transcription factors mediating the immediate response to virus is interferon regulatory factor-3 (IRF-3) which is post-translationally modified as a result of virus infection. Phosphorylation of latent cytoplasmic IRF-3 on serine and threonine residues in the C-terminal region leads to dimerization, cytoplasmic to nuclear translocation, association with the p300/CBP coactivator, and stimulation of DNA binding and transcriptional activities. We now demonstrate that IRF-3 is a phosphoprotein that is uniquely activated via virus-dependent C-terminal phosphorylation. Paramyxoviridae including measles virus and rhabdoviridae, vesicular stomatitis virus, are potent inducers of a unique virus-activated kinase activity. In contrast, stress inducers, growth factors, DNA-damaging agents, and cytokines do not induce C-terminal IRF-3 phosphorylation, translocation or transactivation, but rather activate a MAPKKK-related signaling pathway that results in N-terminal IRF-3 phosphorylation, The failure of numerous well characterized pharmacological inhibitors to abrogate virus-induced IRF-3 phosphorylation suggests the involvement of a novel kinase activity in IRF-3 regulation by viruses.	McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Natl Publ Hlth Inst, Dept Virol, FIN-00300 Helsinki, Finland; Ist Super Sanita, I-00161 Rome, Italy	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; Finland National Institute for Health & Welfare; Istituto Superiore di Sanita (ISS)	Hiscott, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mijh@musica.mcgill.ca	Lin, Rongtuan/A-1442-2008; Conti, Lucia/C-3159-2009; Le Page, Cecile/B-3215-2010; Conti, Lucia/K-2723-2016; Gessani, Sandra/K-5151-2016	Lin, Rongtuan/0000-0002-2238-3503; Le Page, Cecile/0000-0002-8020-1544; Conti, Lucia/0000-0001-9439-081X; Gessani, Sandra/0000-0002-8451-0758				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Azimi N, 2000, J VIROL, V74, P7338, DOI 10.1128/JVI.74.16.7338-7348.2000; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DeLuca C, 1998, VIROLOGY, V244, P27, DOI 10.1006/viro.1998.9085; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Genin P, 1995, NUCLEIC ACIDS RES, V23, P5055; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; Kim T, 2000, J BIOL CHEM, V275, P16910, DOI 10.1074/jbc.M000524200; Kim TK, 2000, CANCER RES, V60, P1153; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATTERSON JL, 1990, REV INFECT DIS, V12, P1139; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; YANO H, 1993, J BIOL CHEM, V268, P25846; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	47	177	183	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					355	363		10.1074/jbc.M007790200	http://dx.doi.org/10.1074/jbc.M007790200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035028	hybrid			2022-12-25	WOS:000166280700049
J	Cooper, CB; Arnot, MI; Feng, ZP; Jarvis, SE; Hamid, J; Zamponi, GW				Cooper, CB; Arnot, MI; Feng, ZP; Jarvis, SE; Hamid, J; Zamponi, GW			Cross-talk between G-protein and protein kinase C modulation of N-type calcium channels is dependent on the G-protein beta subunit isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; GAMMA-SUBUNITS; INHIBITION; FACILITATION; DETERMINANTS; CURRENTS; BINDING; NEURONS	The modulation of N-type calcium current by protein kinases and G-proteins is a factor in the fine tuning of neurotransmitter release. We have previously shown that phosphorylation of threonine 422 in the alpha (1B) calcium channel domain I-II linker region resulted in a dramatic reduction in somatostatin receptor-mediated G-protein inhibition of the channels and that the I-II linker consequently serves as an integration center for cross-talk between protein kinase C (PKC) and G-proteins (Hamid, J,, Nelson, D,, Spaetgens, R,, Dubel, S, J,, Snutch, T. P,, and Zamponi, G, W, (1999) J, Biol, Chem, 274, 6195-6202), Here we show that opioid receptor-mediated inhibition of N-type channels is affected to a lesser extent compared with that seen with somatostatin receptors, hinting at the possibility that PKC/G-protein cross-talk might be dependent on the G-protein subtype. To address this issue, we have examined the effects of four different types of G-protein beta subunits on both wild type and mutant alpha (1B) calcium channels in which residue 422 has been replaced by glutamate to mimic PKC-dependent phosphorylation and on channels that have been directly phosphorylated by protein kinase C, Our data show that phosphorylation or mutation of residue 422 antagonizes the effect of G beta (1) on channel activity, whereas G beta (2) G beta (3), and G beta (4) are not affected. Our data therefore suggest that the observed cross-talk between G-proteins and protein kinase C modulation of N-type channels is a selective feature of the G beta (1) subunit.	Univ Calgary, Dept Physiol & Biophys, Neurosci & Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Neurosci & Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; NeuroMed Technol Inc, Vancouver, BC, Canada	University of Calgary; University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Neurosci & Smooth Muscle Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Zamponi, Gerald W./0000-0002-0644-9066				Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; Barrett CF, 2000, J GEN PHYSIOL, V115, P277, DOI 10.1085/jgp.115.3.277; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bertram R, 1999, J COMPUT NEUROSCI, V7, P197, DOI 10.1023/A:1008976129832; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Brody DL, 2000, J NEUROSCI, V20, P889, DOI 10.1523/JNEUROSCI.20-03-00889.2000; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; Currie KPM, 1997, J NEUROSCI, V17, P4570; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; Garcia DE, 1998, J NEUROSCI, V18, P9163; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; STEFANI A, 1994, BRAIN RES, V642, P339, DOI 10.1016/0006-8993(94)90940-7; STUART GJ, 1991, NEUROSCI LETT, V126, P179, DOI 10.1016/0304-3940(91)90548-8; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	30	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40777	40781		10.1074/jbc.C000673200	http://dx.doi.org/10.1074/jbc.C000673200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11053424	hybrid			2022-12-25	WOS:000166114600017
J	Weyand, M; Schlichting, I				Weyand, M; Schlichting, I			Structural basis for the impaired channeling and allosteric inter-subunit communication in the beta A169L/beta C170W mutant of tryptophan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; ALPHA(2)BETA(2) COMPLEX; 3-DIMENSIONAL STRUCTURE; SALMONELLA-TYPHIMURIUM; CATALYTIC ACTIVITY; BIENZYME COMPLEX; PROTEIN MODELS; SPECIFICITY; REFINEMENT; MECHANISM	We determined the 2.25 Angstrom resolution crystal structure of the beta A169L/beta C170W mutant form of the tryptophan synthase alpha (2)beta (2), complex from Salmonella typhimurium complexed:with the alpha -active site substrate analogue 5-fluoro-indole-propanol-phosphate to identify the structural basis for the changed kinetic properties of the mutant (Anderson, K. S., Kim, A. Y., Quillen, J. M., Sayers, E, Yang, X. J., and Miles, E. W. (1995) J. Biol. Chem, 270, 29936-29944), Comparison with the wild-type enzyme showed that the beta Trp(170) Side chain occludes the tunnel connecting the (alpha- and beta -active sites, explaining the accumulation of the intermediate indole during a single enzyme turnover. To prevent a steric clash between beta Leu(169) and beta Gly(135), located in the beta -sheet of the COMM (communication) domain (beta Gly(102)-beta Gly(189)), the latter reorganizes, The changed COMM domain conformation results in a loss of the hydrogen bonding networks between the alpha- and beta -active sites, explaining the poor activation of the alpha -reaction upon formation of the aminoacrylate complex at the beta -active site. The 100-fold reduced affinity for serine seems to result from a movement of beta Asp(305) away from the beta -active site so that it cannot interact with the hydroxyl group of a pyridoxal phosphate-bound serine, The proposed structural dissection:of the effects of each single mutation in the beta A169L/beta C170W mutant would explain the very different kinetics of this mutant and beta C170F.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany	Max Planck Society	Schlichting, I (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, Otto Hahn Str 11, D-44227 Dortmund, Germany.	ilme.schlichting@mpi-dortmund.mpg.de	Schlichting, Ilme/I-1339-2013					AHMED SA, 1991, J BIOL CHEM, V266, P21548; ANDERSON KS, 1995, J BIOL CHEM, V270, P29936; Anderson KS, 1999, METHOD ENZYMOL, V308, P111; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miles E W, 1995, Subcell Biochem, V24, P207; MILES EW, 1989, J BIOL CHEM, V264, P6280; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; RUVINOV SB, 1995, J BIOL CHEM, V270, P6357, DOI 10.1074/jbc.270.11.6357; SCHLICHTING I, 1994, J BIOL CHEM, V269, P26591; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Weyand M, 1999, BIOCHEMISTRY-US, V38, P16469, DOI 10.1021/bi9920533	27	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41058	41063		10.1074/jbc.C000479200	http://dx.doi.org/10.1074/jbc.C000479200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11034989	hybrid			2022-12-25	WOS:000166114600054
J	Wang, GS; Peterkofsky, A; Clore, GM				Wang, GS; Peterkofsky, A; Clore, GM			A novel membrane anchor function for the N-terminal amphipathic sequence of the signal-transducing protein IIA(Glucose) of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; SALMONELLA-TYPHIMURIUM; SECONDARY STRUCTURE; NMR-SPECTROSCOPY; SUGAR-TRANSPORT; IIIGLC; DOMAIN; IIA(GLC); PERMEASE; HELIX	Enzyme IIA(Glucose) (IIA(Glc)) is a signal-transducing protein in the phosphotransferase system of Escherichia coli. Structural studies of free IIA(Glc) and the HPr-IIA(Glc) complex have shown that IIA(Glc) comprises a globular P-sheet sandwich core (residues 19-168) and a disordered N-terminal tail (residues 1-18). Although the presence of the N-terminal tail is not required for IIA(Glc) to accept a phosphorus from the histidine phosphocarrier protein HPr, its presence is essential for effective phosphotransfer from IIA(Glc) to the membrane-bound IIBCGlc. The sequence of the N-terminal tail suggests that it has the potential to form an amphipathic helix. Using CD, we demonstrate that a peptide, corresponding to the N-terminal 18 residues of IIA(Glc), adopts a helical conformation in the presence of either the anionic lipid phosphatidylglycerol or a mixture of anionic E. coli lipids phosphatidylglycerol (25%) and phosphatidylethanolamine (75%), The peptide, however, is in a random coil state in the presence of the zwitterionic lipid phosphatidylcholine, indicating that electrostatic interactions play a role in the binding of the lipid to the peptide. In addition, we show that intact IIA(Glc) also interacts with anionic lipids, resulting in an increase in helicity, which can be directly attributed to the N-terminal segment. From these data we propose that IIA(Glc) comprises two functional domains: a folded domain containing the active site and capable of weakly interacting with the peripheral IIB domain of the membrane protein IIBCGlc; and the N-terminal tail, which interacts with the negatively charged E, coli membrane, thereby stabilizing the complex of IIA(Glc) with IIBCGlc. This stabilization is essential for the final step of the phosphoryl transfer cascade in the glucose transport pathway.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B1-30I, Bethesda, MD 20892 USA.		Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000151] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Feese MD, 1997, BIOCHEMISTRY-US, V36, P16087, DOI 10.1021/bi971999e; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; Huang K, 1998, STRUCTURE, V6, P697, DOI 10.1016/S0969-2126(98)00072-0; JACKSON RL, 1973, J BIOL CHEM, V248, P5218; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P9509, DOI 10.1021/bi980340l; Kadner R. J., 1996, ESCHERICHIA COLI SAL, P58; MCLACHLAN AD, 1977, NATURE, V267, P465, DOI 10.1038/267465a0; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1986, J BIOL CHEM, V261, P3504; NOVOTNY MJ, 1985, J BACTERIOL, V162, P810, DOI 10.1128/JB.162.2.810-816.1985; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; ROTTEM S, 1980, BIOCHIM BIOPHYS ACTA, V604, P65, DOI 10.1016/0005-2736(80)90585-4; SCHNETZ K, 1990, J BIOL CHEM, V265, P13464; SEGREST JP, 1992, J LIPID RES, V33, P141; Wang GS, 1996, BIOCHEMISTRY-US, V35, P10358, DOI 10.1021/bi960934t; Wang GS, 2000, J BIOL CHEM, V275, P16401, DOI 10.1074/jbc.C000167200; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; Wang GS, 1996, BBA-LIPID LIPID MET, V1301, P174, DOI 10.1016/0005-2760(96)00037-9; Wang GS, 1997, BIOCHEMISTRY-US, V36, P13657, DOI 10.1021/bi971151q; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	26	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39811	39814		10.1074/jbc.C000709200	http://dx.doi.org/10.1074/jbc.C000709200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11044440	hybrid			2022-12-25	WOS:000166039500003
J	Reshkin, SJ; Bellizzi, A; Caldeira, S; Albarani, V; Malanchi, I; Poignee, M; Alunni-Fabbroni, M; Casavola, V; Tommasino, M				Reshkin, SJ; Bellizzi, A; Caldeira, S; Albarani, V; Malanchi, I; Poignee, M; Alunni-Fabbroni, M; Casavola, V; Tommasino, M			Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes	FASEB JOURNAL			English	Article						cytoplasmic alkalinization; NHE-1; HPV16 E7 oncoprotein	HPV16 E7 PROTEIN; DNA-SYNTHESIS; TUMOR-CELLS; IN-VITRO; PH; FIBROBLASTS; BINDING; REQUIREMENT; INHIBITION; METABOLISM	In this study we investigate the mechanism of intracellular pH change and its role in malignant transformation using the E7 oncogene of human papillomavirus type 16 (HPV16). Infecting NIH3T3 cells with recombinant retroviruses expressing the HPV16 E7 or a transformation deficient mutant we show that alkalinization is transformation specific. In NIH3T3 cells in which transformation can be turned on and followed by induction of the HPV16 E7 oncogene expression, we demonstrate that cytoplasmic alkalinization is an early event and was driven by stimulation of Na+/H+ exchanger activity via an increase in the affinity of the intracellular NHE-1 proton regulatory site. Annulment of the E7-induced cytoplasmic alkalinization by specific inhibition of the NHE-1, acidification of culture medium, or clamping the pHi to nontransformed levels prevented the development of later transformed phenotypes such as increased growth rate, serum-independent growth, anchorage-independent growth, and glycolytic metabolism. These findings were verified in human keratinocytes (HPKIA), the natural host of HPV. Results from both NIH3T3 and HPKIA cells show that alkalinization acts on pathways that are independent of the E2F-mediated transcriptional activation of cell cycle regulator genes. Moreover, we show that the transformation-dependent increase in proliferation is independent of the concomitant stimulation of glycolysis. Finally, treatment of nude mice with the specific inhibitor of NHE-1, DMA, delayed the development of HPV16-keratinocyte tumors. Our data confirm that activation of the NHE-1 and resulting cellular alkalinization is a key mechanism in oncogenic transformation and is necessary for the development and maintenance of the transformed phenotype.	Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany; Univ Bari, Dept Gen & Environm Physiol, Bari, Italy	Helmholtz Association; German Cancer Research Center (DKFZ); Universita degli Studi di Bari Aldo Moro	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.		Caldeira, Sandra/Y-3652-2019; Reshkin, Stephan/AAI-6680-2020; paradiso, angelo V/J-9457-2018	Caldeira, Sandra/0000-0002-6057-5979; Reshkin, Stephan/0000-0001-9757-5908; CASAVOLA, Valeria/0000-0003-4471-4948				BANKS L, 1990, ONCOGENE, V5, P1383; BARRY MA, 1993, CANCER RES, V53, P2349; BELT JA, 1979, BIOCHEMISTRY-US, V18, P3506, DOI 10.1021/bi00583a011; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRANDT RB, 1982, METHOD ENZYMOL, V89, P35; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Durst M, 1995, CANCER GENET CYTOGEN, V85, P105, DOI 10.1016/0165-4608(95)00155-7; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; HARGUINDEY S, 1995, CRIT REV ONCOGENESIS, V6, P1; HU TH, 1995, INT J ONCOL, V6, P167; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; MAIDORN RP, 1993, BRIT J CANCER, V67, P297, DOI 10.1038/bjc.1993.56; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MONTROSE MH, 1987, J MEMBRANE BIOL, V97, P63, DOI 10.1007/BF01869615; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RESHKIN SJ, 1995, INT J ONCOL, V7, P371; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROTIN D, 1989, CANCER RES, V49, P205; ROZHIN J, 1994, CANCER RES, V54, P6517; Shrode LD, 1997, J BIOENERG BIOMEMBR, V29, P393, DOI 10.1023/A:1022407116339; SICZKOWSKI M, 1994, AM J PHYSIOL, V267, pC745, DOI 10.1152/ajpcell.1994.267.3.C745; Tedone T, 1996, EUR J CANCER, V32A, P849, DOI 10.1016/0959-8049(95)00660-5; TOMMASINO M, 1993, ONCOGENE, V8, P195; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WATSON AJM, 1994, BBA-BIOMEMBRANES, V1193, P316, DOI 10.1016/0005-2736(94)90168-6; Webb SD, 1999, J THEOR BIOL, V196, P237, DOI 10.1006/jtbi.1998.0836; Yamagata M, 1996, BRIT J CANCER, V73, P1328, DOI 10.1038/bjc.1996.254	42	297	311	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2185	2197		10.1096/fj.00-0029com	http://dx.doi.org/10.1096/fj.00-0029com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053239				2022-12-25	WOS:000165190800011
J	Schildmeyer, LA; Braun, R; Taffet, G; Debiasi, M; Burns, AE; Bradley, A; Schwartz, RJ				Schildmeyer, LA; Braun, R; Taffet, G; Debiasi, M; Burns, AE; Bradley, A; Schwartz, RJ			Impaired vascular contractility and blood pressure homeostasis in the smooth muscle alpha-actin null mouse	FASEB JOURNAL			English	Article						SM alpha-actin gene; homologous recombination; vascular tone	PHENOL-CHLOROFORM EXTRACTION; AMINO-ACID SEQUENCE; SINGLE-STEP METHOD; SKELETAL-MUSCLE; MESSENGER-RNA; GAMMA-ACTIN; SARCOMERIC ACTIN; TRANSGENIC MICE; STROMAL CELLS; CARDIAC ACTIN	The smooth muscle (SM) alpha -actin gene activated during the early stages of embryonic cardiovascular development is switched off in late stage heart tissue and replaced by cardiac and skeletal alpha -actins. SM alpha -actin also appears during vascular development, but becomes the single most abundant protein in adult vascular smooth muscle cells. Tissue-specific expression of SM alpha -actin is thought to be required for the principal force-generating capacity of the vascular smooth muscle cell. We wanted to determine whether SM alpha -actin gene expression actually relates to an actin isoform's function. Analysis of SM alpha -actin null mice indicated that SM alpha -actin is not required for the formation of the cardiovascular system. Also, SM alpha -actin null mice appeared to have no difficulty feeding or reproducing. Survival in the absence of SM alpha -actin may result from other actin isoforms partially substituting for this isoform. In fact, skeletal alpha -actin gene, an actin isoform not usually expressed in vascular smooth muscle, was activated in the aortas of these SM alpha -actin null mice. However, even with a modest increase in skeletal alpha -actin activity, highly compromised vascular contractility, tone, and blood flow were detected in SM alpha -actin-defective mice. This study supports the concept that SM alpha -actin has a central role in regulating vascular contractility and blood pressure homeostasis, but is not required for the formation of the cardiovascular system.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Cardiovasc Sci Sect, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	schwartz@bcm.tmc.edu	De Biasi, Mariella/M-7646-2017	De Biasi, Mariella/0000-0002-0687-8872				BABAI F, 1990, DIFFERENTIATION, V44, P132, DOI 10.1111/j.1432-0436.1990.tb00546.x; BARJA F, 1986, LAB INVEST, V55, P226; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CHANG KS, 1984, MOL CELL BIOL, V4, P2498, DOI 10.1128/MCB.4.11.2498; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CINTORINO M, 1991, INT J CANCER, V47, P843, DOI 10.1002/ijc.2910470609; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; DIAMOND JR, 1995, AM J PATHOL, V146, P121; EINAT P, 1990, DIFFERENTIATION, V44, P36, DOI 10.1111/j.1432-0436.1990.tb00534.x; GABBIANI G, 1994, PATHOL RES PRACT, V190, P851; Gunning P, 1997, CELL STRUCT FUNCT, V22, P173, DOI 10.1247/csf.22.173; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; KREGEL KC, 1988, J APPL PHYSIOL, V64, P2582, DOI 10.1152/jappl.1988.64.6.2582; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; LLOYD C, 1992, J CELL BIOL, V117, P787, DOI 10.1083/jcb.117.4.787; Makino H, 1996, DIABETES, V45, P488, DOI 10.2337/diabetes.45.4.488; MCHUGH KM, 1988, MOL CELL BIOL, V8, P5224, DOI 10.1128/MCB.8.12.5224; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIN BH, 1990, J BIOL CHEM, V265, P16667; OWENS GK, 1986, J BIOL CHEM, V261, P3373; OWENS GK, 1995, PHYSIOL REV, V75, P487; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RubbiaBrandt L, 1997, TRANSPLANT P, V29, P2390, DOI 10.1016/S0041-1345(97)00415-6; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512; SCHEVZOV G, 1992, J CELL BIOL, V117, P775, DOI 10.1083/jcb.117.4.775; SCHLAGER G, 1994, CLIN EXP HYPERTENS, V16, P809, DOI 10.3109/10641969409078027; SKALLI O, 1988, AM J PATHOL, V130, P515; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGI Y, 1992, DEV DYNAM, V193, P116, DOI 10.1002/aja.1001930203; Sun Y, 1996, J LAB CLIN MED, V127, P94, DOI 10.1016/S0022-2143(96)90170-5; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; VANDEKERCKHOVE J, 1978, P NATL ACAD SCI USA, V75, P1106, DOI 10.1073/pnas.75.3.1106; VANDEKERCKHOVE J, 1981, EUR J BIOCHEM, V113, P595, DOI 10.1111/j.1432-1033.1981.tb05104.x; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V14, P123, DOI 10.1111/j.1432-0436.1979.tb01021.x; WOODCOCKMITCHELL J, 1988, DIFFERENTIATION, V39, P161, DOI 10.1111/j.1432-0436.1988.tb00091.x	39	151	155	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2213	2220		10.1096/fj.99-0927com	http://dx.doi.org/10.1096/fj.99-0927com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053242				2022-12-25	WOS:000165190800014
J	Shiels, A; MacKay, D; Bassnett, S; Al-Ghoul, K; Kuszak, J				Shiels, A; MacKay, D; Bassnett, S; Al-Ghoul, K; Kuszak, J			Disruption of lens fiber cell architecture in mice expressing a chimeric AQP0-LTR protein	FASEB JOURNAL			English	Article						lens; major intrinsic protein; water channel; cataract; mouse	NEPHROGENIC DIABETES-INSIPIDUS; MAJOR INTRINSIC PROTEIN; AQUAPORIN-1 NULL MICE; WATER CHANNELS; CONGENITAL CATARACT; GENE; MOUSE; INSERTION; MUTATIONS; MUTANT	Aquaporin-0 (AQP0) is the major intrinsic protein of lens fiber cells and the founder member of the water channel gene family. Here we show that disruption of the AQP0 gene by an early transposon (ETn) element results in expression of a chimeric protein, comprised of similar to 75% AQP0 and similar to 25% ETn long terminal repeat (LTR) sequence, in the cataract Eraser (Cat(Fr)) mouse lens, Immunoblot analysis showed that mutant AQP0-LTR was similar in mass to wild-type AQP0, However, immunofluorescence microscopy revealed that AQP0-LTR was localized to intracellular membranes rather than to plasma membranes of lens fiber cells. Heterozygous Cat(Fr) lenses were similar in size to wild-type but displayed abnormal regions of translucence and light scattering, Scanning electron microscopy further revealed that mature fiber cells within the core of the heterozygous Cat(Fr) lens failed to stratify into uniform, concentric growth shells, suggesting that the AQP0 water channel facilitates the development of the unique cellular architecture of the crystalline lens.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Rush Presbyterian St Lukes Med Ctr, Dept Pathol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Ophthalmol, Chicago, IL 60612 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Rush University; Rush University	Shiels, A (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Box 8096,660 S Euclid Ave, St Louis, MO 63110 USA.			Mackay, Donna/0000-0002-2499-1203; Bassnett, Steven/0000-0002-8337-2760	NEI NIH HHS [EY11411, EY09852, P30 EY002687, EY06642] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009852, R01EY011411, P30EY002687] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Berry V, 2000, NAT GENET, V25, P15, DOI 10.1038/75538; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; FRASER FC, 1962, GENET RES, V3, P383, DOI 10.1017/S0016672300003220; Froger A, 1998, PROTEIN SCI, V7, P1458, DOI 10.1002/pro.5560070623; HAMAI Y, 1975, INVEST OPHTH VISUAL, V14, P517; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; Kuszak J R, 1989, Lens Eye Toxic Res, V6, P639; KUSZAK JR, 1994, EXP EYE RES, V59, P521, DOI 10.1006/exer.1994.1138; LYON MF, 1981, GENET RES, V38, P337, DOI 10.1017/S0016672300020668; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Moon BC, 1997, GENOMICS, V42, P152, DOI 10.1006/geno.1997.4701; MUGGLETONHARRIS AL, 1987, GENET RES, V49, P235, DOI 10.1017/S0016672300027129; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; SAKURAGAWA M, 1975, EXP EYE RES, V21, P381, DOI 10.1016/0014-4835(75)90048-2; Schey KL, 1997, INVEST OPHTH VIS SCI, V38, P2508; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; SHELL BE, 1990, GENE, V86, P269, DOI 10.1016/0378-1119(90)90289-4; SHIELS A, 1991, BIOCHIM BIOPHYS ACTA, V1097, P318, DOI 10.1016/0925-4439(91)90087-P; SHIELS A, 1993, CURR EYE RES, V12, P913, DOI 10.3109/02713689309020398; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Varadaraj K, 1999, J MEMBRANE BIOL, V170, P191, DOI 10.1007/s002329900549; VERRUSIO AC, 1966, GENET RES, V8, P377, DOI 10.1017/S0016672300010223; ZWAAN J, 1968, J EXP ZOOL, V169, P407, DOI 10.1002/jez.1401690404; ZWAAN J, 1969, EXP EYE RES, V8, P161, DOI 10.1016/S0014-4835(69)80027-8	32	55	56	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2207	2212		10.1096/fj.99-1071com	http://dx.doi.org/10.1096/fj.99-1071com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053241				2022-12-25	WOS:000165190800013
J	Oertli, B; Han, J; Marte, BM; Sethi, T; Downward, J; Ginsberg, M; Hughes, PE				Oertli, B; Han, J; Marte, BM; Sethi, T; Downward, J; Ginsberg, M; Hughes, PE			The effector loop and prenylation site of R-Ras are involved in the regulation of integrin function	ONCOGENE			English	Article						R-Ras; integrin activation; effector binding	NUCLEOTIDE DISSOCIATION STIMULATOR; PHOSPHOINOSITIDE 3-KINASE; CELLULAR-TRANSFORMATION; CYTOPLASMIC DOMAINS; SIGNAL-TRANSDUCTION; PUTATIVE EFFECTOR; EPITHELIAL-CELLS; PROTEIN; ACTIVATION; IDENTIFICATION	The closely related small GTP-binding proteins H-Ras and R-Ras have opposing effects on the regulation of integrin cell adhesion receptors, To gain insight into the properties of R-Ras with respect to the regulation of integrin function and interactions with downstream effecters we performed an analysis of R-Ras variants containing mutations in the effector binding domain and C-terminal prenylation site. We found that the activation of the downstream effector PI 3-kinase was sensitive to mutations in the effector binding domain, as was the binding to the effecters, Ral-GDS, Raf-1 and the novel effector Norel, Furthermore, specific mutations in the effector binding loop and C-terminal prenylation motif impaired the ability of R-Ras to regulate integrin function in CHO cells. However, the ability of the R-Ras effector loop mutants to bind, and activate known effecters did not correlate with their ability to regulate integrin function. Thus, the known R-Ras effecters are not critical for regulating integrin activation, at least in CHO cells, Consequently, these studies provide insight into the structural basis of the interactions between R-Ras and its candidate effecters and suggest the existence of novel mechanisms through which this GTPase could regulate cell adhesion.	Scripps Res Inst, Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England; Univ Edinburgh, Sch Med, Dept Resp Med, Edinburgh EH8 9AG, Midlothian, Scotland	Scripps Research Institute; Cancer Research UK; University of Edinburgh	Hughes, PE (corresponding author), Scripps Res Inst, Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729	NHLBI NIH HHS [HL57900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; COX AD, 1994, ONCOGENE, V9, P3281; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KINASHI T, 2000, IN PRESS J BIOL CHEM; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Osada M, 1999, MOL CELL BIOL, V19, P6333; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Park SH, 1995, ONCOGENE, V11, P2349; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; REY I, 1994, ONCOGENE, V9, P685; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; Takayama S, 1997, Methods Mol Biol, V69, P171; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	38	42	43	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4961	4969		10.1038/sj.onc.1203876	http://dx.doi.org/10.1038/sj.onc.1203876			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042683				2022-12-25	WOS:000089834300003
J	Nikiforov, MA; Kotenko, I; Petrenko, O; Beavis, A; Valenick, L; Lemischka, I; Cole, MD				Nikiforov, MA; Kotenko, I; Petrenko, O; Beavis, A; Valenick, L; Lemischka, I; Cole, MD			Complementation of Myc-dependent cell proliferation by cDNA expression library screening	ONCOGENE			English	Article						c-myc; N-myc; myc-null fibroblasts; proliferation; cDNA library	C-MYC; GROWTH; COOPERATION; MECHANISM; ONCOGENES; TARGET	The targeted knockout of the c-myc gene from rat fibroblasts leads to a stable defect in cell proliferation. We used complex cDNA libraries expressed from retroviral vectors and an efficient sorting procedure to rapidly select for cDNAs that can restore the growth rate of c-myc deficient cells, All of the biologically active cDNAs contained either c-myc or N-myc, suggesting that no other cellular genes can effectively bypass the requirement for c-myc in fibroblast proliferation. This approach provides a powerful screening method for cell cycle changes in genetically defined systems.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							ADAMS JM, 1992, CANCER SURV, V15, P119; CORVI R, 1995, CANCER RES, V55, P3471; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; WESTON SA, 1990, J IMMUNOL METHODS, V133, P87, DOI 10.1016/0022-1759(90)90322-M; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	18	25	27	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4828	4831		10.1038/sj.onc.1203880	http://dx.doi.org/10.1038/sj.onc.1203880			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039899				2022-12-25	WOS:000089757800004
J	Benoit, V; Hellin, AC; Huygen, S; Gielen, J; Bours, V; Merville, MP				Benoit, V; Hellin, AC; Huygen, S; Gielen, J; Bours, V; Merville, MP			Additive effect between NF-kappa B subunits and p53 protein for transcriptional activation of human p53 promoter	ONCOGENE			English	Article						p53; autoregulation; NF-kappa B; transcription factors	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; NUCLEAR-FACTOR; BINDING PROTEIN; DNA-BINDING; GENE-EXPRESSION; OWN TRANSCRIPTION; IN-VITRO; CANCER; CELL	The tumor suppressor p53 plays a pivotal role in the cellular response to DNA damage as it controls DNA repair, cell cycle arrest and apoptosis, We studied the autoregulation of human p53 gene transcription in colon cancer cell lines. Wild-type p53 has been show positively or negatively and probably in a cell-type-specific manner. Indeed, a p53 binding site has been described in the human and murine p53 promoters, but a direct binding of wild-type p53 protein to this site has never been reported. In this study, we demonstrated a transactivation of human p53 pn to autoregulate its own transcription either promoter by wild-type p53 in human colon cancer cells. We identified in the human p53 promoter a novel potential p53-responsive element that binds wildtype p53. Moreover, wild-type p53 protein transactivated a reporter plasmid containing a luciferase gene driven by a minimal promoter harboring this p53 binding site. Finally, as the p53 promoter contains an NF-kappa B binding site, we demonstrated an additive effect when NF-kappa B subunits and p53 protein combined to transactivate the human p53 promoter.	Univ Liege, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium	University of Liege	Merville, MP (corresponding author), Univ Liege, Lab Med Chem & Med Oncol, Pathol B23, B-4000 Liege, Belgium.			BENOIT, Valerie/0000-0002-1098-9452				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baichwal V. R., 1997, CURR BIOL, V7, P94; Balint E, 1996, CANCER RES, V56, P1648; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAINAUT P, 1993, CANCER RES, V53, P4469; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ravi R, 1998, CANCER RES, V58, P4531; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; SUN XG, 1995, MOL CELL BIOL, V15, P4489; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; VAN AD, 1996, SCIENCE, V274, P787; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768	49	41	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4787	4794		10.1038/sj.onc.1203831	http://dx.doi.org/10.1038/sj.onc.1203831			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032029				2022-12-25	WOS:000089528800013
J	Steensma, E; Gordon, E; Oster, LM; Ferguson, SJ; Hajdu, J				Steensma, E; Gordon, E; Oster, LM; Ferguson, SJ; Hajdu, J			Heme ligation and conformational plasticity in the isolated c domain of cytochrome cd(1) nitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-PANTOTROPHUS; LIGAND-EXCHANGE; YEAST ISO-1-CYTOCHROME-C; MAGNETIC-RESONANCE; CHEMICAL-SHIFTS; ACTIVE-SITES; SPECTROSCOPY; IDENTIFICATION; PROTEINS; COOA	The heme ligation in the isolated c domain of Paracoccus pantotrophus cytochrome ed, nitrite reductase has been characterized in both oxidation states in solution by NMR spectroscopy. In the reduced form, the heme ligands are His(69)-Met(106), and the tertiary structure around the c heme is similar to that found in reduced crystals of intact cytochrome ed, nitrite reductase. In the oxidized state, however, the structure of the isolated c domain is different from the structure seen in oxidized crystals of intact cytochrome ed,, where the c heme Ligands are His(69)-His(17). An equilibrium mixture of heme Ligands is present in isolated oxidized c domain. Two-dimensional exchange NMR spectroscopy shows that the dominant species has His69-Met106 ligation, similar to reduced c domains. This form is in equilibrium with a high-spin form in which Met(106) has Left the heme iron. Melting studies show that the midpoint of unfolding of the isolated c domain is 320.9 +/- 1.2 K in the oxidized and 357.7 +/- 0.6 K in the reduced form. The thermally denatured forms are high-spin in both oxidation states. The results reveal how redox changes modulate conformational plasticity around the c heme and show the first key steps in the mechanism that lead to ligand switching in the holoenzyme. This process is not solely a function of the properties of the c domain. The role of the d(1) heme in guiding His(17) to the c heme in the oxidized holoenzyme is discussed.	Uppsala Univ, Dept Biochem, S-75123 Uppsala, Sweden; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	Uppsala University; University of Oxford	Steensma, E (corresponding author), Uppsala Univ, Dept Biochem, Box 576, S-75123 Uppsala, Sweden.	elles@xray.bmc.uu.se						Adams P. A., 1996, CYTOCHROME C MULTIDI, P635; ANGSTROM J, 1982, BIOCHIM BIOPHYS ACTA, V703, P87, DOI 10.1016/0167-4838(82)90014-0; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BECKER ED, 1969, J AM CHEM SOC, V91, P7784, DOI 10.1021/ja50001a068; BERTINI I, 1989, METHOD ENZYMOL, V177, P246; BOYD J, 1984, J MAGN RESON, V58, P511, DOI 10.1016/0022-2364(84)90159-8; Colon W, 1997, BIOCHEMISTRY-US, V36, P12535, DOI 10.1021/bi971697c; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Feinberg BA, 1998, BIOCHEMISTRY-US, V37, P13091, DOI 10.1021/bi981037n; Fetrow JS, 1999, BIOCHEMISTRY-US, V38, P4480, DOI 10.1021/bi9827417; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; Giles PM, 1999, PURE APPL CHEM, V71, P587, DOI 10.1351/pac199971040587; Goldbeck RA, 1999, P NATL ACAD SCI USA, V96, P2782, DOI 10.1073/pnas.96.6.2782; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hammack B, 1998, J MOL BIOL, V275, P719, DOI 10.1006/jmbi.1997.1493; Jafferji A, 2000, J BIOL CHEM, V275, P25089, DOI 10.1074/jbc.M001377200; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kolczak U, 1997, J AM CHEM SOC, V119, P12643, DOI 10.1021/ja9722133; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; KOPPENHOFER A, 1998, THESIS U OXFORD OXFO; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Markley JL, 1998, J MOL BIOL, V280, P933, DOI 10.1006/jmbi.1998.1852; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moore GR, 1990, SPRINGER SERIES MOL; MOURA I, 1988, EUR J BIOCHEM, V177, P673, DOI 10.1111/j.1432-1033.1988.tb14422.x; Nakajima H, 1999, CHEM LETT, P1233, DOI 10.1246/cl.1999.1233; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nurizzo D, 1999, J BIOL CHEM, V274, P14997, DOI 10.1074/jbc.274.21.14997; Nurizzo D, 1997, STRUCTURE, V5, P1157, DOI 10.1016/S0969-2126(97)00267-0; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PAGE MD, 1989, MOL MICROBIOL, V3, P653, DOI 10.1111/j.1365-2958.1989.tb00213.x; PETTIGREW GW, 1987, SPRINGER SERIES MOL; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Rainey FA, 1999, INT J SYST BACTERIOL, V49, P645, DOI 10.1099/00207713-49-2-645; Ranghino G, 2000, BIOCHEMISTRY-US, V39, P10958, DOI 10.1021/bi000178y; Schejter A, 1996, J AM CHEM SOC, V118, P477, DOI 10.1021/ja9529448; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; Telford JR, 1999, BIOCHEMISTRY-US, V38, P1944, DOI 10.1021/bi981933z; Tezcan FA, 1998, J AM CHEM SOC, V120, P13383, DOI 10.1021/ja982536e; TIMKOVICH R, 1985, ARCH BIOCHEM BIOPHYS, V240, P689, DOI 10.1016/0003-9861(85)90077-3; TURNER DL, 1993, EUR J BIOCHEM, V211, P563, DOI 10.1111/j.1432-1033.1993.tb17583.x; UBBINK M, 1993, BIOCHEMISTRY-US, V32, P13893, DOI 10.1021/bi00213a019; Van Mierlo CPM, 1998, PROTEIN SCI, V7, P2331, DOI 10.1002/pro.5560071110; Wang L, 1998, PROTEINS, V30, P435, DOI 10.1002/(SICI)1097-0134(19980301)30:4<435::AID-PROT10>3.0.CO;2-J; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Winkler JR, 1997, P NATL ACAD SCI USA, V94, P4246, DOI 10.1073/pnas.94.9.4246; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xu YJ, 1998, NAT STRUCT BIOL, V5, P774, DOI 10.1038/1810; YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P379; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51; Yeh SR, 1999, J BIOL CHEM, V274, P17853, DOI 10.1074/jbc.274.25.17853; Yeh SR, 1998, NAT STRUCT BIOL, V5, P222, DOI 10.1038/nsb0398-222	61	14	14	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5846	5855		10.1074/jbc.M007345200	http://dx.doi.org/10.1074/jbc.M007345200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11035020	hybrid			2022-12-25	WOS:000167115100061
J	Gotoh, I; Adachi, M; Nishida, E				Gotoh, I; Adachi, M; Nishida, E			Identification and characterization of a novel MAP kinase kinase kinase, MLTK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEAR EXPORT SIGNAL; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR; ACTIN CYTOSKELETON; CELL MORPHOLOGY; GENE-EXPRESSION; TRANSDUCTION; CASCADES; PATHWAY	The MAPK cascades regulate a wide variety of cellular functions, including cell proliferation, differentiation, and stress responses. Here we have identified a novel MAP kinase kinase kinase (MAPKKK), termed MLTK (for MLK-like mitogen-activated protein triple kinase), whose expression is increased by activation of the ERK/MAPK pathway. There are two alternatively spliced forms of MLTK, MLTK alpha and MLT beta. When overexpressed in cells, both MLTK alpha and MLTK beta are able to activate the ERK, JNK/SAPK p38, and ERK5 pathways. Moreover, both MTLK alpha and MLTK beta are activated in response to osmotic shock with hyperosmolar media through autophosphorylation. Remarkably, expression of MLTK alpha; but not MLTK beta, in Swiss 3T3 cells results in the disruption of actin stress fibers and dramatic morphological changes. A kinase-dead form of MLTK alpha does not cause these phenomena. Inhibition of the p38 pathway significantly blocks MTLK alpha -induced stress fiber disruption and morphological changes. These results suggest that MLTK is a stress-activated MAPKKK that may be involved in the regulation of actin organization.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.							Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; GOTOH Y, 1994, ONCOGENE, V9, P1891; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hout J, 1998, J CELL BIOL, V143, P1361; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VAN AL, 1997, GENE DEV, V11, P2295; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	44	88	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4276	4286		10.1074/jbc.M008595200	http://dx.doi.org/10.1074/jbc.M008595200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042189	hybrid			2022-12-25	WOS:000166921200073
J	Khan, AH; Thurmond, DC; Yang, CM; Ceresa, BP; Sigmund, CD; Pessin, JE				Khan, AH; Thurmond, DC; Yang, CM; Ceresa, BP; Sigmund, CD; Pessin, JE			Munc18c regulates insulin-stimulated GLUT4 translocation to the transverse tubules in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASES GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSGENIC MICE; SNAP RECEPTORS; DNA-SYNTHESIS; CELL-SURFACE; RAT; CONTRACTION; MEMBRANE	To examine the intracellular trafficking and translocation of GLUT4 in skeletal muscle, we have generated transgenic mouse lines that specifically express a GLUT4-EGFP (enhanced green fluorescent protein) fusion protein under the control of the human skeletal muscle actin promoter. These transgenic mice displayed EGFP fluorescence restricted to skeletal muscle and increased glucose tolerance characteristic of enhanced insulin sensitivity. The GLUT4-EGFP protein localized to the same intracellular compartment as the endogenous GLUT4 protein and underwent insulin- and exercise-stimulated translocation to both the sarcolemma and transverse-tubule membranes. Consistent with previous studies in adipocytes, overexpression of the syntaxin 4-binding Munc18c isoform, but not the related Munc18b isoform, in vivo specifically inhibited insulin-stimulated GLUT4 EGFP translocation, Surprisingly, however, Munc18c inhibited GLUT4 translocation to the transverse-tubule membrane without affecting translocation to the sarcolemma membrane. The ability of Munc18c to block GLUT4-EGFP translocation to the transverse-tubule membrane but not the sarcolemma membrane was consistent with substantially reduced levels of syntaxin 4 in the transverse-tubule membrane. Together, these data demonstrate that Munc18c specifically functions in the compartmentalized translocation of GLUT4 to the transverse-tubules in skeletal muscle, In addition, these results underscore the utility of this transgenic model to directly visualize GLUT4 translocation in skeletal muscle.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.		Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NIDDK NIH HHS [R01 DK033823, DK25295, DK09813, DK33823, R37 DK033823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009813, R01DK033823, R37DK033823, P30DK025295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUM MJ, 1995, CURR OPIN ENDOCRINOL, V2, P383; Brozinick JT, 1996, BIOCHEM J, V313, P133, DOI 10.1042/bj3130133; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Elmendorf JS, 1999, J BIOL CHEM, V274, P37357, DOI 10.1074/jbc.274.52.37357; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Hayashi T, 1997, AM J PHYSIOL-ENDOC M, V273, pE1039, DOI 10.1152/ajpendo.1997.273.6.E1039; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Katz EB, 1996, J MOL MED, V74, P639, DOI 10.1007/s001090050068; Lund S, 1998, FEBS LETT, V425, P472, DOI 10.1016/S0014-5793(98)00293-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MARETTE A, 1992, DIABETES, V41, P1562, DOI 10.2337/diabetes.41.12.1562; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUNOZ P, 1995, BIOCHEM J, V312, P393, DOI 10.1042/bj3120393; OKADA T, 1994, J BIOL CHEM, V269, P3568; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Sherwood DJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE870, DOI 10.1152/ajpendo.1999.276.5.E870; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Thurmond DC, 2000, MOL CELL BIOL, V20, P379, DOI 10.1128/MCB.20.1.379-388.2000; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Timmers KI, 1996, BIOCHEM J, V320, P429, DOI 10.1042/bj3200429; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Zhou M, 1998, AM J PHYSIOL-ENDOC M, V275, pE187, DOI 10.1152/ajpendo.1998.275.2.E187	52	64	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4063	4069		10.1074/jbc.M007419200	http://dx.doi.org/10.1074/jbc.M007419200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11054418	hybrid, Green Accepted			2022-12-25	WOS:000166921200046
J	van Kerkhof, P; Sachse, M; Klumperman, J; Strous, GJ				van Kerkhof, P; Sachse, M; Klumperman, J; Strous, GJ			Growth hormone receptor ubiquitination coincides with recruitment to clathrin-coated membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; MEDIATED INTERNALIZATION; POTASSIUM-DEPLETION; ENDOCYTOSIS; PROTEIN; SYSTEM; SIGNAL; MOTIF; IDENTIFICATION; ACIDIFICATION	Endocytosis of the growth hormone receptor (GHR) depends on a functional ubiquitin conjugation system, A 10-amino acid residue motif within the GHR cytosolic tail (the ubiquitin-dependent endocytosis motif) is involved in both GHR ubiquitination and endocytosis. As shown previously, ubiquitination of the receptor itself is not required. In this paper ubiquitination of the GHR was used as a tool to address the question of at which stage the ubiquitin conjugation system acts in the process of GHR endocytosis. If potassium depletion was used to interfere with early stages of coated pit formation, both GHR endocytosis and ubiquitination were inhibited. Treatment of cells with methyl-beta -cyclodextrin inhibited endocytosis at the stage of coated vesicle formation. Growth hormone addition to methyl-beta -cyclodextrin-treated cells resulted in an accumulation of ubiquitinated GHR at the cell surface. Using immunoelectron microscopy, the GHR was localized in flattened clathrin-coated membranes. In addition, when clathrin-mediated endocytosis was inhibited in HeLa cells expressing a temperature-sensitive dynamin mutant, ubiquitinated GHR accumulated at the cell surface. Together, these data show that the GHR is ubiquitinated at the plasma membrane, before endocytosis occurs, and indicate that the resident time of the GHR at the cell surface is regulated by the ubiquitin conjugation system together with the endocytic machinery.	Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University	Strous, GJ (corresponding author), Univ Utrecht, Med Ctr, Dept Cell Biol, Heidelberglaan 100,AZU-G02-525, NL-3584 CX Utrecht, Netherlands.	strous@med.uu.nl	Sachse, Martin/W-7403-2019	van Kerkhof, Peter/0000-0002-8954-2230; Sachse, Martin/0000-0001-5981-9166				ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Benmerah A, 1999, J CELL SCI, V112, P1303; BENTHAM J, 1994, J HISTOCHEM CYTOCHEM, V42, P103, DOI 10.1177/42.1.8263321; Brown CM, 1999, BIOCHEM CELL BIOL, V77, P439; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; ILONDO MM, 1986, P NATL ACAD SCI USA, V83, P6460, DOI 10.1073/pnas.83.17.6460; ILONDO MM, 1991, ENDOCRINOLOGY, V128, P1597, DOI 10.1210/endo-128-3-1597; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strous GJ, 1999, J CELL SCI, V112, P1417; Strous GJ, 1997, J BIOL CHEM, V272, P40; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; Vleurick L, 1999, MOL ENDOCRINOL, V13, P1823, DOI 10.1210/me.13.11.1823	43	56	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3778	3784		10.1074/jbc.M007326200	http://dx.doi.org/10.1074/jbc.M007326200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042179	hybrid			2022-12-25	WOS:000166921200009
J	Hisamoto, K; Ohmichi, M; Kurachi, H; Hayakawa, J; Kanda, Y; Nishio, Y; Adachi, K; Tasaka, K; Miyoshi, E; Fujiwara, N; Taniguchi, N; Murata, Y				Hisamoto, K; Ohmichi, M; Kurachi, H; Hayakawa, J; Kanda, Y; Nishio, Y; Adachi, K; Tasaka, K; Miyoshi, E; Fujiwara, N; Taniguchi, N; Murata, Y			Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY HEART-DISEASE; PROTEIN-KINASE B/AKT; PHOSPHATIDYLINOSITOL 3-KINASE; POSTMENOPAUSAL WOMEN; GROWTH-FACTOR; BAD PHOSPHORYLATION; SIGNALING PATHWAY; RECEPTOR CDNA; RISK-FACTORS; FOLLOW-UP	Although estrogen is known to activate endothelial nitric oxide synthase (eNOS) in the vascular endothelium, the molecular mechanism responsible for this effect remains to be elucidated. In studies of both human umbilical vein endothelial cells (HUVECs) and simian virus 40-transformed rat lung vascular endothelial cells (TRLECs), 17 beta -estradiol (E2), but not 17 alpha -E2, caused acute activation of eNOS that was unaffected by actino-mycin D and was specifically blocked by the pure estrogen receptor antagonist ICI-182,780, Treatment of both TRLECs and HUVECs with 17 beta -E2 stimulated the activation of Akt, and the PI3K inhibitor wortmannin blocked the 17 beta -E2-induced activation of Akt, 17 beta -E2-induced Akt activation was also inhibited by ICI-182,780, but not by actinomycin D, Either treatment with wortmannin or exogenous expression of a dominant negative Akt in TRLECs decreased the 17 beta -E2-induced eNOS activation. Moreover, 17 beta -E2-induced Akt activation actually enhances the phosphorylation of eNOS, 17 beta -E2-induced Akt activation was dependent on both extracellular and intracellular Ca2+. We further examined the 17 beta -E2-induced Akt activity in Chinese hamster ovary (CHO) cells transiently transfected with cDNAs for estrogen receptor cw (ER alpha) or estrogen receptor beta (ER beta), 17 beta -E2 stimulated the activation of Akt in CHO cells expressing ERa but not in CHO cells expressing ERP, Our findings suggest that 17P-E2 induced eNOS activation through an Akt-dependent mechanism, which is mediated by ER alpha via a nongenomic mechanism.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Yamagata Univ, Sch Med, Dept Obstet & Gynecol, Yamagata 9909585, Japan	Osaka University; Osaka University; Yamagata University	Ohmichi, M (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				ADAMS MR, 1987, ARTERIOSCLEROSIS, V7, P378, DOI 10.1161/01.ATV.7.4.378; ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1050; Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; BarrettConnor E, 1997, CIRCULATION, V95, P252, DOI 10.1161/01.CIR.95.1.252; Binko J, 1998, AM J PHYSIOL-HEART C, V274, pH853, DOI 10.1152/ajpheart.1998.274.3.H853; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CaulinGlaser T, 1997, CIRC RES, V81, P885; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; Chen SJ, 1996, CIRCULATION, V93, P577, DOI 10.1161/01.CIR.93.3.577; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiDomenico M, 1996, CANCER RES, V56, P4516; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; Guetta V, 1997, CIRCULATION, V96, P2795, DOI 10.1161/01.CIR.96.9.2795; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hayakawa J, 2000, CANCER RES, V60, P5988; Homma H, 2000, J BIOL CHEM, V275, P11404, DOI 10.1074/jbc.275.15.11404; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; JACOBSSON J, 1992, J HEART LUNG TRANSPL, V11, P1188; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jiang BB, 1998, J CARDIOVASC PHARM, V31, pS142, DOI 10.1097/00005344-199800001-00042; Karas RH, 1999, P NATL ACAD SCI USA, V96, P15133, DOI 10.1073/pnas.96.26.15133; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kimura A, 2000, J BIOL CHEM, V275, P3667, DOI 10.1074/jbc.275.5.3667; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kubohara Y, 1999, BIOCHEM BIOPH RES CO, V263, P790, DOI 10.1006/bbrc.1999.1468; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; LANTINHERMOSO RL, 1997, AM J PHYSIOL, V273, P119; Levy H, 1936, J AMER MED ASSOC, V107, P97; Lindner V, 1998, CIRC RES, V83, P224, DOI 10.1161/01.RES.83.2.224; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; Naka M, 2000, BIOCHEM BIOPH RES CO, V270, P663, DOI 10.1006/bbrc.2000.2474; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PIETRAS RJ, 1979, J STEROID BIOCHEM, V11, P1471, DOI 10.1016/0022-4731(79)90124-9; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; REIS SE, 1994, CIRCULATION, V89, P52, DOI 10.1161/01.CIR.89.1.52; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SEO HG, 1994, J BIOCHEM-TOKYO, V115, P602, DOI 10.1093/oxfordjournals.jbchem.a124382; SEO HG, 1995, BIOCHEM BIOPH RES CO, V208, P10, DOI 10.1006/bbrc.1995.1298; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Taniguchi H, 1999, N-S ARCH PHARMACOL, V360, P69, DOI 10.1007/s002109900033; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yokoi T, 2000, J BIOL CHEM, V275, P21639, DOI 10.1074/jbc.M910252199; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539	81	308	315	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3459	3467		10.1074/jbc.M005036200	http://dx.doi.org/10.1074/jbc.M005036200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11044445	hybrid			2022-12-25	WOS:000166784900062
J	Hoegy, SE; Oh, HR; Corcoran, ML; Stetler-Stevenson, WG				Hoegy, SE; Oh, HR; Corcoran, ML; Stetler-Stevenson, WG			Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; FACTOR RECEPTOR; CELL-SURFACE; IN-VITRO; PROMOTING ACTIVITY; GELATINASE-A; MATRIX; INVASION; BINDING; PROLIFERATION	The tissue inhibitors of metalloproteinases (TIMPs) block matrix metalloproteinase (MMP)-mediated increases in cell proliferation, migration, and invasion that are associated with extracellular matrix (ECM) turnover. Here we demonstrate a direct role for TIMP-2 in regulating tyrosine kinase-type growth factor receptor activation. We show that TIMP-2 suppresses the mitogenic response to tyrosine kinase-type receptor growth factors in a fashion that is independent of MMP inhibition. The TIMP-2 suppression of mitogenesis is reversed by the adenylate cyclase inhibitor SQ22536, and implicates cAMP as the second messenger in these effects. TIMP-2 neither altered the release of transforming growth factor alpha from the cell surface, nor epidermal growth factor (EGF) binding to the cognate receptor, EGFR, TIMP-2 binds to the surface of AS49 cells in a specific and saturable fashion (K-d = 147 pM), that is not competed by the synthetic MMP inhibitor BB-94 and is independent of MT-1-MMP. TIMP-2 induces a decrease in phosphorylation of EGFR and a concomitant reduction in Grb-2 association. TIMP-2 prevents SH2-protein-tyrosine phosphatase-l (SHP-1) dissociation from immunoprecipitable EGFR complex and a selective increase in total SHP-1 activity. These studies represent a new functional paradigm for TIMP-2 in which TIMP suppresses EGF-mediated mitogenic signaling by short-circuiting EGFR activation.	NCI, Pathol Lab, Extracellular Matrix Pathol Sect, Div Clin Sci,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stetler-Stevenson, WG (corresponding author), NCI, Pathol Lab, Extracellular Matrix Pathol Sect, Div Clin Sci,NIH, Bldg 10,Room 2A33,MSC 1500, Bethesda, MD 20892 USA.		Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; BISSELL MJ, 1999, CANCER RES, V59, P1757; Blavier L, 1997, MOL BIOL CELL, V8, P1513, DOI 10.1091/mbc.8.8.1513; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; CARAGLIA M, 1993, CANCER IMMUNOL IMMUN, V37, P150, DOI 10.1007/BF01525428; Catalan RE, 1997, FEBS LETT, V400, P280, DOI 10.1016/S0014-5793(96)01405-6; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Codony-Servat J, 1999, CANCER RES, V59, P1196; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; DECLERCK YA, 1992, CANCER RES, V52, P701; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; Fabbri E, 1991, J Enzyme Inhib, V5, P87, DOI 10.3109/14756369109069062; Fedi P., 1997, CANC MED, P41; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Imren S, 1996, CANCER RES, V56, P2891; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Li GY, 1999, CANCER RES, V59, P6267; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Martin DC, 1999, LAB INVEST, V79, P225; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NEMETH JA, 1993, EXP CELL RES, V207, P376, DOI 10.1006/excr.1993.1204; Nemeth JA, 1996, EXP CELL RES, V224, P110, DOI 10.1006/excr.1996.0117; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Sherr CJ, 2000, CANCER RES, V60, P3689; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WELGUS HG, 1982, J BIOL CHEM, V257, P1534; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Yamashita K, 1996, FEBS LETT, V396, P103, DOI 10.1016/0014-5793(96)01066-6; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	67	93	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3203	3214		10.1074/jbc.M008157200	http://dx.doi.org/10.1074/jbc.M008157200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042184	hybrid			2022-12-25	WOS:000166784900031
J	Pilot, G; Lacombe, B; Gaymard, F; Cherel, I; Boucherez, J; Thibaud, JB; Sentenac, H				Pilot, G; Lacombe, B; Gaymard, F; Cherel, I; Boucherez, J; Thibaud, JB; Sentenac, H			Guard cell inward K+ channel activity in Arabidopsis involves expression of the twin channel subunits KAT1 and KAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; PLANT POTASSIUM CHANNEL; XENOPUS-OOCYTES; TRANSLATIONAL REGULATION; ALPHA-SUBUNITS; ION CHANNELS; ATPASE GENE; THALIANA; DOMAIN; VOLTAGE	Stomatal opening, which controls gas exchanges between plants and the atmosphere, results from an increase in turgor of the two guard cells that surround the pore of the stoma, KAT1 was the only inward K+ channel shown to be expressed in Arabidopsis guard cells, where it was proposed to mediate a K+ influx that enables stomatal opening, We report that another Arabidopsis K+ channel, KAT2, is expressed in guard cells. More than KAT1, KAT2 displays functional features resembling those of native inward K+ channels in guard cells. Coexpression in Xenopus oocytes and two-hybrid experiments indicated that KAT1 and KAT2 can form heteromultimeric channels. The data indicate that KAT2 plays a crucial role in the stomatal opening machinery.	Univ Montpellier 2, INRA, CNRS, UMR 5004, F-34060 Montpellier 1, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier	Sentenac, H (corresponding author), Univ Montpellier 2, INRA, CNRS, UMR 5004, Pl Viala, F-34060 Montpellier 1, France.		Lacombe, Benoit/B-1202-2013	THIBAUD, Jean-Baptiste/0000-0002-0824-6465; Pilot, Guillaume/0000-0001-7520-1059; Sentenac, Herve/0000-0003-3641-4822; Lacombe, Benoit/0000-0001-9924-3093; Cherel, Isabelle/0000-0001-8007-7099				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Baizabal-Aguirre VM, 1999, J MEMBRANE BIOL, V167, P119, DOI 10.1007/s002329900476; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Bruggemann L, 1999, P NATL ACAD SCI USA, V96, P3298, DOI 10.1073/pnas.96.6.3298; Bruggemann L, 1999, PLANTA, V207, P370, DOI 10.1007/s004250050494; Butt AD, 1997, J PLANT PHYSIOL, V150, P652, DOI 10.1016/S0176-1617(97)80279-9; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DAMIANI RD, 1993, P NATL ACAD SCI USA, V90, P8244, DOI 10.1073/pnas.90.17.8244; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; Devic M, 1997, PLANT PHYSIOL BIOCH, V35, P331; Dreyer I, 1999, J EXP BOT, V50, P1073, DOI 10.1093/jexbot/50.suppl_1.1073; Dreyer I, 1997, BIOPHYS J, V72, P2143, DOI 10.1016/S0006-3495(97)78857-X; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; Ehrhardt T, 1997, FEBS LETT, V409, P166, DOI 10.1016/S0014-5793(97)00502-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HEDRICH R, 1995, EUR BIOPHYS J, V24, P107, DOI 10.1007/BF00211406; HILLE B, 1992, IONIC CHANNELS EXCIT, P272; HOFGEN R, 1988, NUCLEIC ACIDS RES, V16, P9877, DOI 10.1093/nar/16.20.9877; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; Hoth S, 1999, J BIOL CHEM, V274, P11599, DOI 10.1074/jbc.274.17.11599; Ichida AM, 1997, PLANT CELL, V9, P1843, DOI 10.1105/tpc.9.10.1843; Ichida AM, 1996, J MEMBRANE BIOL, V151, P53, DOI 10.1007/s002329900057; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lacombe B, 1998, J MEMBRANE BIOL, V166, P91, DOI 10.1007/s002329900451; Lacombe B, 2000, FEBS LETT, V466, P351, DOI 10.1016/S0014-5793(00)01093-0; Lacombe B, 2000, PLANT CELL, V12, P837, DOI 10.1105/tpc.12.6.837; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; LANG A, 1983, PLANT CELL ENVIRON, V6, P683, DOI 10.1111/1365-3040.ep11589312; Li JX, 1998, PLANT PHYSIOL, V116, P785, DOI 10.1104/pp.116.2.785; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; Lukaszewicz M, 1998, PLANT J, V14, P413, DOI 10.1046/j.1365-313X.1998.00139.x; MacRobbie EAC, 1998, PHILOS T ROY SOC B, V353, P1475, DOI 10.1098/rstb.1998.0303; Marten I, 1999, P NATL ACAD SCI USA, V96, P7581, DOI 10.1073/pnas.96.13.7581; MENGEL K, 1977, PLANT PHYSIOL, V59, P282, DOI 10.1104/pp.59.2.282; MICHELET B, 1994, PLANT CELL, V6, P1375, DOI 10.1105/tpc.6.10.1375; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; Roelfsema MRG, 1998, PLANTA, V205, P100, DOI 10.1007/s004250050301; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; Tang HX, 1996, PLANT CELL, V8, P1545, DOI 10.1105/tpc.8.9.1545; VERY AA, 1994, PFLUG ARCH EUR J PHY, V428, P422, DOI 10.1007/BF00724528; VERY AA, 1995, PLANT J, V7, P321, DOI 10.1046/j.1365-313X.1995.7020321.x; Wang XQ, 1998, PLANT PHYSIOL, V118, P1421, DOI 10.1104/pp.118.4.1421; Zimmermann S, 1999, CURR OPIN PLANT BIOL, V2, P477, DOI 10.1016/S1369-5266(99)00020-5	52	171	197	3	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3215	3221		10.1074/jbc.M007303200	http://dx.doi.org/10.1074/jbc.M007303200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042178	Green Published, hybrid			2022-12-25	WOS:000166784900032
J	Otera, H; Nishimura, M; Setoguchi, K; Mori, T; Fujiki, Y				Otera, H; Nishimura, M; Setoguchi, K; Mori, T; Fujiki, Y			Biogenesis of nonspecific lipid transfer protein and sterol carrier protein x - Studies using peroxisome assembly-defective pex cell mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ACYL-COENZYME-A; RAT-LIVER; 3-KETOACYL-COA THIOLASE; TARGETING SIGNAL; FUNCTIONAL COMPLEMENTATION; ZELLWEGER-SYNDROME; NUCLEOTIDE-SEQUENCE; PTS1 RECEPTOR; CDNA CLONING	Nonspecific lipid transfer protein (nsLTP; also called sterol carrier protein 2) with a molecular mass of 13 kDa is synthesized as a larger 15-kDa precursor (pre-nsLTP) with an N-terminal IO-amino acid extension presequence, as well as with the peroxisome targeting signal type 1 (PTS1), Ala-Lys-Leu, at the C terminus. The precursor pre-nsLTP is processed to mature nsLTP by proteolytic removal of the presequence, most likely after being imported into peroxisomes. Sterol carrier protein x (SCPx), a 59-kDa branched-chain fatty acid thiolase of peroxisomes, contains the entire pre-nsLTP moiety at the C-terminal part and is converted to the 46-kDa form and nsLTP after the transport to peroxisomes. We investigated which of these two potential topogenic sequences functions in biogenesis of nsLTP and SCPx. Morphological and biochemical analyses, making use of Chinese hamster ovary cell per mutants such as the PTS1 receptor-impaired pex5 and PTS2 import-defective pex7, as well as green fluorescent protein chimeras, revealed that both pre-nsLTP and SCPx are imported into peroxisomes by the Pex5p-mediated PTS1 pathway. Nearly half of the pre-nsLTP remains in the cytosol, as assessed by subcellular fractionation of the wild-type Chinese hamster ovary cells. In an in vitro binding assay, only mature nsLTP, but not pre-nsLTP, from the cell lysates interacted with the Pex5p. It is likely, therefore, that modulation of the C-terminal PTS1 by the presequence gives rise to cytoplasmic localization of pre-nsLTP.	Kyushu Univ, Grad Sch, Fac Sci,Dept Biol, Higashi Ku, Fukuoka 8128581, Japan; Meiji Milk Prod Co, Odawara, Kanagawa 2500862, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1700013, Japan	Kyushu University; Meiji Holdings Co., Ltd.; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch, Fac Sci,Dept Biol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.			Miyata, Kiyoko/0000-0001-5303-6240				Antonenkov VD, 1997, J BIOL CHEM, V272, P26023, DOI 10.1074/jbc.272.41.26023; BunYa M, 1997, EUR J BIOCHEM, V245, P252, DOI 10.1111/j.1432-1033.1997.t01-1-00252.x; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Ferdinandusse S, 2000, J LIPID RES, V41, P336; FUJIKI Y, 1989, J BIOCHEM, V106, P1126, DOI 10.1093/oxfordjournals.jbchem.a122977; Ghaedi K, 1999, EXP CELL RES, V248, P489, DOI 10.1006/excr.1999.4413; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; KAWAJIRI K, 1977, J BIOCHEM, V82, P1403, DOI 10.1093/oxfordjournals.jbchem.a131828; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; Matsumura T, 2000, J BIOL CHEM, V275, P21715, DOI 10.1074/jbc.M000721200; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MONCECCHI D, 1991, J BIOL CHEM, V266, P9885; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; OHBA T, 1995, BIOCHEMISTRY-US, V34, P10660, DOI 10.1021/bi00033a042; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; OSSENDORP BC, 1991, EUR J BIOCHEM, V201, P233, DOI 10.1111/j.1432-1033.1991.tb16279.x; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; SEEDORF U, 1991, J BIOL CHEM, V266, P630; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; TRZECIAK WH, 1987, J BIOL CHEM, V262, P3713; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510; VANHEUSDEN GPH, 1990, J BIOL CHEM, V265, P4105; Wanders RJA, 1997, BIOCHEM BIOPH RES CO, V236, P565, DOI 10.1006/bbrc.1997.7007; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	41	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2858	2864		10.1074/jbc.M007730200	http://dx.doi.org/10.1074/jbc.M007730200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042217	hybrid			2022-12-25	WOS:000166784800077
J	Sai, KP; Jagannadham, MV; Vairamani, M; Raju, NP; Devi, AS; Nagaraj, R; Sitaram, N				Sai, KP; Jagannadham, MV; Vairamani, M; Raju, NP; Devi, AS; Nagaraj, R; Sitaram, N			Tigerinins: Novel antimicrobial peptides from the Indian frog Rana tigerina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPHIBIAN SKIN; ESCHERICHIA-COLI; OUTER-MEMBRANE; ANTIBIOTICS; MECHANISM; SEQUENCE; ANTIBACTERIAL; INDOLICIDIN; DEFENSINS; CELLS	Four broad-spectrum, 11 and 12 residue, novel antimicrobial peptides have been isolated from the adrenaline-stimulated skin secretions of the Indian frog Rana tigerina, Sequences of these peptides have been determined by automated Edman degradation, by mass spectral analysis and confirmed by chemical synthesis. These peptides, which we have named as tigerinins, are characterized by an intramolecular disulfide bridge between two cysteine residues forming a nonapeptide ring. This feature is not found in other amphibian peptides, Conformational analysis indicate that the peptides tend to form p-turn structures, The peptides are cationic and exert their activity by permeabilizing bacterial membranes. Tigerinins represent the smallest, nonhelical, cationic antimicrobial peptides from amphibians.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Indian Inst Chem Technol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT)	Sitaram, N (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.		Korrapati, Purna sai/ABC-6918-2020; Sitaram, Narasimhaiah/F-2211-2010; Jagannadham, Medicharla V. V./AAW-6773-2021; Sitaram, Narasimaiah/M-6309-2019; Korrapati, Purna sai/AAB-6375-2021	Sitaram, Narasimaiah/0000-0003-4179-1972; Vairamani, Mariappanadar/0000-0002-8356-6258				ALLEN G, 1981, LAB TECHNIQUES BIOCH, P17; Atherton E., 1990, SOLID PHASE PEPTIDE; BARRA D, 1995, TRENDS BIOTECHNOL, V13, P205, DOI 10.1016/S0167-7799(00)88947-7; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; CLARK DP, 1994, J BIOL CHEM, V269, P10849; Clarke BT, 1997, BIOL REV, V72, P365, DOI 10.1017/S0006323197005045; CSORDAS A, 1969, TOXICON, V7, P103, DOI 10.1016/0041-0101(69)90072-5; Dutta SK, 1997, AMPHIBIANS INDIA SRI; Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Ganz T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2; Goraya J, 1999, PEPTIDES, V20, P159, DOI 10.1016/S0196-9781(98)00174-0; Goraya J, 2000, EUR J BIOCHEM, V267, P894, DOI 10.1046/j.1432-1327.2000.01074.x; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HAYASHI R, 1973, J BIOL CHEM, V218, P2236; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; Kim S, 1999, J BIOCHEM MOL BIOL, V32, P12; Kwon MY, 1998, BBA-PROTEIN STRUCT M, V1387, P239, DOI 10.1016/S0167-4838(98)00123-X; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; LONGKUMAR Y, 1992, INT C IUCN SSC ISRAG; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; Miller J.H., 1972, EXPT MOL GENETICS; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PARK JM, 1994, BIOCHEM BIOPH RES CO, V205, P948, DOI 10.1006/bbrc.1994.2757; PERCZEL A, 1991, J AM CHEM SOC, V113, P9772, DOI 10.1021/ja00026a010; Ponti D, 1999, EUR J BIOCHEM, V263, P921, DOI 10.1046/j.1432-1327.1999.00597.x; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SABERWAL G, 1994, BBA-REV BIOMEMBRANES, V1197, P109, DOI 10.1016/0304-4157(94)90002-7; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; Simmaco M, 1998, BIOPOLYMERS, V47, P435, DOI 10.1002/(SICI)1097-0282(1998)47:6<435::AID-BIP3>3.3.CO;2-#; SIMMACO M, 1994, J BIOL CHEM, V269, P11951; SITARAM N, 1990, J BIOL CHEM, V265, P10438; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; Subbalakshmi C, 1998, FEMS MICROBIOL LETT, V160, P91, DOI 10.1016/S0378-1097(98)00008-1; Subbalakshmi C, 1996, FEBS LETT, V395, P48, DOI 10.1016/0014-5793(96)00996-9; Suh JY, 1996, FEBS LETT, V392, P309, DOI 10.1016/0014-5793(96)00840-X; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; VEBER DF, 1972, J AM CHEM SOC, V94, P5456, DOI 10.1021/ja00770a600; Wu MH, 1999, J BIOL CHEM, V274, P29, DOI 10.1074/jbc.274.1.29; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	50	93	103	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2701	2707		10.1074/jbc.M006615200	http://dx.doi.org/10.1074/jbc.M006615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11031261	hybrid			2022-12-25	WOS:000166784800056
J	Territo, PR; French, SA; Dunleavy, MC; Evans, FJ; Balaban, RS				Territo, PR; French, SA; Dunleavy, MC; Evans, FJ; Balaban, RS			Calcium activation of heart mitochondrial oxidative phosphorylation - Rapid kinetics of m(V) over dot (O2), NADH, and light scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; RABBIT CARDIAC MYOCYTES; NUCLEAR-MAGNETIC-RESONANCE; PHOSPHATE ENERGY SHUTTLE; FREE CA2+ CONCENTRATION; ATP-ADP TRANSLOCASE; CREATINE-KINASE; MUSCLE-CELLS; INTRACELLULAR CALCIUM; INNER MEMBRANE	Parallel activation of heart mitochondria NADH and ATP production by Ca2+ has been shown to involve the Ca2+-sensitive dehydrogenases and the F0F1-ATPase, In the current study we hypothesize that the response time of Ca2+-activated ATP production is rapid enough to support step changes in myocardial workload (similar to 100 ms). To test this hypothesis, the rapid kinetics of Ca2+ activation of m(V)over dot (O2) [NADH], and light scattering were evaluated in isolated porcine heart mitochondria at 37 degreesC using a variety of optical techniques. The addition of Ca2+ was associated with an initial response time (IRT) of m(V)over dot (O2), that was dose-dependent with a minimum IRT of 0.27 +/- 0.02 a (n = 41) at 535 mM Ca2+. The IRTs for NADH fluorescence and light scattering in response to Ca2+ additions were similar to m(V)over dot (O2). The Ca2+ IRT for m(V)over dot(O2) was significantly shorter than 1.6 mM ADP (2.36 +/- 0.47 a; p less than or equal to 0.001, n = 13), 2.2 mM P-i (2.32 +/- 0.29,p less than or equal to 0.001, n = 13), or 10 mM creatine (15.6. +/- 1.18 s,p less than or equal to 0.001, n = 18) under similar experimental conditions. Calcium effects were inhibited with 8 muM ruthenium red (2.4 +/- 0.31 s;p less than or equal to 0.001, n = 16) and reversed with EG;TA (1.6 +/- 0.44;p less than or equal to 0.01, n = 6), Estimates of Ca2+ uptake into mitochondria using optical Ca2+ indicators trapped in the matrix revealed a sufficiently rapid uptake to cause the metabolic effects observed. These data are consistent with the notion that extramitochondrial Ca2+ can modify ATP production, via an increase in matrix Ca2+ content, rapidly enough to support cardiac work transitions in vivo.	NHLBI, Cardiac Energet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Territo, PR (corresponding author), NHLBI, Cardiac Energet Lab, NIH, Bldg 10,Rm B1D-400, Bethesda, MD 20892 USA.	territop@zeus.nhlbi.nih.gov	Balaban, Robert S/A-7459-2009	Balaban, Robert S/0000-0003-4086-0948	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004601, Z01HL004601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnold S, 1999, FEBS LETT, V443, P105, DOI 10.1016/S0014-5793(98)01694-9; Arnold S, 1997, EUR J BIOCHEM, V249, P350, DOI 10.1111/j.1432-1033.1997.t01-1-00350.x; AZZI A, 1966, BIOCHIM BIOPHYS ACTA, V120, P466, DOI 10.1016/0926-6585(66)90316-5; AZZI A, 1965, BIOCHIM BIOPHYS ACTA, V105, P265, DOI 10.1016/S0926-6593(65)80151-5; AZZI A, 1967, BIOCHIM BIOPHYS ACTA, V131, P468, DOI 10.1016/0005-2728(67)90006-0; AZZONE GF, 1965, P NATL ACAD SCI USA, V53, P1084, DOI 10.1073/pnas.53.5.1084; Balaban RS, 1996, ANAL BIOCHEM, V237, P274, DOI 10.1006/abio.1996.0239; BALABAN RS, 1981, AM J PHYSIOL, V240, pF337, DOI 10.1152/ajprenal.1981.240.4.F337; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BESSMAN SP, 1966, BIOCHEM BIOPH RES CO, V22, P597, DOI 10.1016/0006-291X(66)90317-2; BESSMAN SP, 1987, ANAL BIOCHEM, V161, P519, DOI 10.1016/0003-2697(87)90483-0; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BISHOP PD, 1984, ARCH BIOCHEM BIOPHYS, V230, P335, DOI 10.1016/0003-9861(84)90116-4; BROWN GC, 1992, BIOCHEM J, V284, P1; BUNGER R, 1984, AM J PHYSIOL, V247, pC45, DOI 10.1152/ajpcell.1984.247.1.C45; CARAFOLI E, 1988, METHOD ENZYMOL, V157, P3; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; Chacon E, 1996, FEBS LETT, V382, P31, DOI 10.1016/0014-5793(96)00138-X; CHACON E, 1994, BIOPHYS J, V66, P942, DOI 10.1016/S0006-3495(94)80904-X; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHAPPELL JB, 1968, BRIT MED BULL, V24, P150, DOI 10.1093/oxfordjournals.bmb.a070618; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CORNISHBOWEN A, 1976, PRINCIPLES ENZYME KI; DAS AM, 1990, BIOCHEM SOC T, V18, P554, DOI 10.1042/bst0180554; DOELLER JE, 1990, AM J PHYSIOL, V259, pH1851, DOI 10.1152/ajpheart.1990.259.6.H1851; EISENHARDT RH, 1968, BIOCHEMISTRY-US, V7, P1327, DOI 10.1021/bi00844a012; ERICKSONVIITANEN S, 1982, J BIOL CHEM, V257, P4395; ERICKSONVIITANEN S, 1982, ADV EXP MED BIOL, V151, P115; ERICKSONVIITANEN S, 1982, J BIOL CHEM, V257, P4405; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLAHERTY JT, 1982, CIRCULATION, V65, P561, DOI 10.1161/01.CIR.65.3.561; FONT B, 1983, ARCH BIOCHEM BIOPHYS, V220, P541, DOI 10.1016/0003-9861(83)90445-9; French SA, 1998, AM J PHYSIOL-CELL PH, V275, pC900, DOI 10.1152/ajpcell.1998.275.3.C900; GARLID KD, 1985, J BIOL CHEM, V260, P3434; Gunter TE, 1998, BBA-BIOENERGETICS, V1366, P5, DOI 10.1016/S0005-2728(98)00117-0; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HALESTRAP AP, 1986, BIOCHEM J, V236, P779, DOI 10.1042/bj2360779; HALESTRAP AP, 1987, BIOCHEM J, V244, P159, DOI 10.1042/bj2440159; HANSFORD RG, 1989, ANN NY ACAD SCI, V573, P240, DOI 10.1111/j.1749-6632.1989.tb15001.x; HANSFORD RG, 1972, BIOCHEM J, V127, P271, DOI 10.1042/bj1270271; HANSFORD RG, 1982, J BIOENERG BIOMEMBR, V14, P361, DOI 10.1007/BF00743064; HANSFORD RG, 1975, BIOCHEM J, V146, P537, DOI 10.1042/bj1460537; Hansford RG, 1998, MOL CELL BIOCHEM, V184, P359, DOI 10.1023/A:1006893903113; HARRIS DA, 1991, BIOCHEM J, V280, P561, DOI 10.1042/bj2800561; Hasselbach W, 1998, ANN NY ACAD SCI, V853, P1, DOI 10.1111/j.1749-6632.1998.tb08251.x; HEINEMAN FW, 1990, J CLIN INVEST, V85, P843, DOI 10.1172/JCI114511; HELDT HW, 1967, EUR J BIOCHEM, V1, P199, DOI 10.1111/j.1432-1033.1967.tb00064.x; ISENBERG G, 1993, CARDIOVASC RES, V27, P1800, DOI 10.1093/cvr/27.10.1800; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; JACOBUS WE, 1986, J BIOL CHEM, V261, P6579; Jeneson JAL, 1996, J BIOL CHEM, V271, P27995, DOI 10.1074/jbc.271.45.27995; Jou MJ, 1996, J PHYSIOL-LONDON, V497, P299, DOI 10.1113/jphysiol.1996.sp021769; KAPLAN LJ, 1995, BIOCHIMIE, V77, P245, DOI 10.1016/0300-9084(96)88131-4; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; Kavanagh NI, 2000, BBA-BIOENERGETICS, V1457, P57, DOI 10.1016/S0005-2728(00)00054-2; KLINGENBERG M, 1966, REGULATION METABOLIC, P180; KORETSKY AP, 1987, BIOCHIM BIOPHYS ACTA, V893, P398, DOI 10.1016/0005-2728(87)90092-2; KUZNETSOV AV, 1989, ARCH BIOCHEM BIOPHYS, V268, P176, DOI 10.1016/0003-9861(89)90578-X; KUZNETSOV AV, 1986, BIOCHEM BIOPH RES CO, V134, P359, DOI 10.1016/0006-291X(86)90571-1; LEE HC, 1987, P NATL ACAD SCI USA, V84, P7793, DOI 10.1073/pnas.84.21.7793; LEISEY JR, 1993, AM J PHYSIOL, V265, pH1203; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCMURCHIE EJ, 1979, BIOCHIM BIOPHYS ACTA, V554, P364, DOI 10.1016/0005-2736(79)90377-8; MINKOV IB, 1979, BIOCHEM BIOPH RES CO, V89, P1300, DOI 10.1016/0006-291X(79)92150-8; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Mootha VK, 1997, AM J PHYSIOL-HEART C, V272, pH769, DOI 10.1152/ajpheart.1997.272.2.H769; MOREADITH RW, 1982, J BIOL CHEM, V257, P899; Napiwotzki J, 1998, BIOL CHEM, V379, P335, DOI 10.1515/bchm.1998.379.3.335; Ohata H, 1998, J BIOENERG BIOMEMBR, V30, P207, DOI 10.1023/A:1020588618496; POOL PE, 1966, CIRC RES, V19, P221, DOI 10.1161/01.RES.19.2.221; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Sahlin K, 1997, AM J PHYSIOL-CELL PH, V273, pC172, DOI 10.1152/ajpcell.1997.273.1.C172; SAKS VA, 1985, J BIOL CHEM, V260, P7757; SAKS VA, 1987, BIOCHIM BIOPHYS ACTA, V891, P138, DOI 10.1016/0005-2728(87)90005-3; SAKS VA, 1995, J MOL CELL CARDIOL, V27, P625, DOI 10.1016/S0022-2828(08)80056-9; SAKS VA, 1991, AM J PHYSIOL, V261, P30, DOI 10.1152/ajplung.1991.261.4.L30; SAKS VA, 1984, BIOCHIM BIOPHYS ACTA, V803, P254, DOI 10.1016/0167-4889(84)90115-0; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SAKS VA, 1980, J BIOL CHEM, V255, P755; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; SAKS VA, 1986, BIOCHEM BIOPH RES CO, V139, P1262, DOI 10.1016/S0006-291X(86)80314-X; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; STARNES JW, 1985, AM J PHYSIOL, V249, pH799, DOI 10.1152/ajpheart.1985.249.4.H799; SYROESHKIN AV, 1995, FEBS LETT, V366, P29, DOI 10.1016/0014-5793(95)00487-T; Territo PR, 2000, AM J PHYSIOL-CELL PH, V278, pC423, DOI 10.1152/ajpcell.2000.278.2.C423; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; Trollinger DR, 2000, BIOPHYS J, V79, P39, DOI 10.1016/S0006-3495(00)76272-2; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VIGNAIS P, 1976, CELL BIOL HDB, P159; Vinogradov AD, 2000, J EXP BIOL, V203, P41; Wier WG, 1999, CIRC RES, V85, P770, DOI 10.1161/01.RES.85.9.770; WIER WG, 1995, CIBA F SYMP, V188, P146; WILSON DF, 1988, J BIOL CHEM, V263, P2712; YOSHIKANE H, 1986, J SUBMICR CYTOL PATH, V18, P629; YUAN GX, 1992, BIOCHIM BIOPHYS ACTA, V1140, P78, DOI 10.1016/0005-2728(92)90022-T	100	120	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2586	2599		10.1074/jbc.M002923200	http://dx.doi.org/10.1074/jbc.M002923200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11029457	hybrid			2022-12-25	WOS:000166784800042
J	Torigoe, H; Hari, Y; Sekiguchi, M; Obika, S; Imanishi, T				Torigoe, H; Hari, Y; Sekiguchi, M; Obika, S; Imanishi, T			2 '-O,4 '-C-methylene bridged nucleic acid modification promotes pyrimidine motif tripler DNA formation at physiological pH - Thermodynamic and kinetic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX FORMATION; NUCLEOSIDE ANALOGS; OPTICAL BIOSENSOR; NEUTRAL PH; BASE-PAIRS; OLIGODEOXYNUCLEOTIDES; OLIGONUCLEOTIDES; RECOGNITION; STABILITY; BINDING	Extreme instability of pyrimidine motif tripler DNA at physiological pH severely limits its use in an artificial control of gene expression in vivo, Stabilization of the pyrimidine motif tripler at physiological pH is, therefore, crucial in improving its therapeutic potential. To this end, we have investigated the thermodynamic and kinetic effects of our previously reported chemical modification, 2'-O,4'-C-methylene bridged nucleic acid (2',4'-BNA) modification of tripler-forming oligonucleotide (TFO), on pyrimidine motif tripler formation at physiological pH, The thermodynamic analyses indicated that the 2',4'-BNA modification of TFO increased the binding constant of the pyrimidine motif tripler formation at neutral pH by similar to 20 times. The number and position of the 2',4'-BNA modification introduced into the TFO did not significantly affect the magnitude of the increase in the binding constant. The consideration of the observed thermodynamic parameters suggested that the increased rigidity itself of the 2',4'-BNA-modified TFO in the free state relative to the unmodified TFO may enable the significant increase in the binding constant at neutral pH, Kinetic data demonstrated that the observed increase in the binding constant at neutral pH by the 2',4'-BNA modification of TFO resulted from the considerable decrease in the dissociation rate constant. Our results certainly support the idea that the 2',4'-BNA modification of TFO could be a key chemical modification and may eventually lead to progress in therapeutic applications of the antigene strategy in vivo.	RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan	RIKEN; Osaka University	Torigoe, H (corresponding author), RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	torigoe@rtc.riken.go.jp		Hari, Yoshiyuki/0000-0002-3903-7340				BATES PJ, 1995, NUCLEIC ACIDS RES, V23, P3627, DOI 10.1093/nar/23.18.3627; Biltonen R L, 1979, Methods Enzymol, V61, P287; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; CHENG YK, 1992, PROG BIOPHYS MOL BIO, V58, P225, DOI 10.1016/0079-6107(92)90007-S; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; Edelhoch H, 1976, Adv Protein Chem, V30, P183, DOI 10.1016/S0065-3233(08)60480-5; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRANKKAMENETSKII MD, 1992, METHOD ENZYMOL, V211, P180; HAMPEL KJ, 1991, BIOCHEMISTRY-US, V30, P4455, DOI 10.1021/bi00232a012; Imanishi T, 1999, J SYN ORG CHEM JPN, V57, P969, DOI 10.5059/yukigoseikyokaishi.57.969; JETTER MC, 1993, BIOCHEMISTRY-US, V32, P3249, DOI 10.1021/bi00064a006; JOHNSON KH, 1991, NUCLEIC ACIDS RES, V19, P2275, DOI 10.1093/nar/19.9.2275; Kamiya M, 1996, J AM CHEM SOC, V118, P4532, DOI 10.1021/ja952287j; KOH JS, 1992, J AM CHEM SOC, V114, P1470, DOI 10.1021/ja00030a050; Koshkin AA, 1998, TETRAHEDRON, V54, P3607, DOI 10.1016/S0040-4020(98)00094-5; KRAWCZYK SH, 1992, P NATL ACAD SCI USA, V89, P3761, DOI 10.1073/pnas.89.9.3761; Langerman N, 1979, Methods Enzymol, V61, P261; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MANZINI G, 1990, J MOL BIOL, V213, P833, DOI 10.1016/S0022-2836(05)80267-0; MILLIGAN JF, 1993, NUCLEIC ACIDS RES, V21, P327, DOI 10.1093/nar/21.2.327; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MOUSCADET JF, 1994, BIOCHEMISTRY-US, V33, P4187, DOI 10.1021/bi00180a011; Obika S, 1999, CHEM COMMUN, P2423, DOI 10.1039/a907218g; Obika S, 1999, BIOORG MED CHEM LETT, V9, P515, DOI 10.1016/S0960-894X(99)00028-1; Obika S, 1999, TETRAHEDRON LETT, V40, P6465, DOI 10.1016/S0040-4039(99)01324-6; Obika S, 1998, TETRAHEDRON LETT, V39, P5401, DOI 10.1016/S0040-4039(98)01084-3; Obika S, 1997, TETRAHEDRON LETT, V38, P8735, DOI 10.1016/S0040-4039(97)10322-7; Obika S, 2000, TETRAHEDRON LETT, V41, P221, DOI 10.1016/S0040-4039(99)02052-3; Obika S, 2000, TETRAHEDRON LETT, V41, P215, DOI 10.1016/S0040-4039(99)01998-X; ONO A, 1991, J AM CHEM SOC, V113, P4032, DOI 10.1021/ja00010a077; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; Shafer RH, 1998, PROG NUCLEIC ACID RE, V59, P55; SHINDO H, 1993, BIOCHEMISTRY-US, V32, P8963, DOI 10.1021/bi00085a030; Singh SK, 1998, CHEM COMMUN, P455, DOI 10.1039/a708608c; SINGLETON SF, 1992, BIOCHEMISTRY-US, V31, P10995, DOI 10.1021/bi00160a008; Soyfer V.N., 1996, TRIPLE HELICAL NUCL; SUN JS, 1991, P NATL ACAD SCI USA, V88, P6023, DOI 10.1073/pnas.88.14.6023; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; Sun JS, 1996, CURR OPIN STRUC BIOL, V6, P327, DOI 10.1016/S0959-440X(96)80051-0; Torigoe H, 1999, BIOCHEMISTRY-US, V38, P14653, DOI 10.1021/bi990832d; Torigoe H, 1999, J BIOL CHEM, V274, P6161, DOI 10.1074/jbc.274.10.6161; Torigoe H, 1999, NUCLEOS NUCLEOT, V18, P1655, DOI 10.1080/07328319908044812; Ueno Y, 1998, BIOCONJUGATE CHEM, V9, P33, DOI 10.1021/bc9701508; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625	47	124	125	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2354	2360		10.1074/jbc.M007783200	http://dx.doi.org/10.1074/jbc.M007783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035027	hybrid			2022-12-25	WOS:000166784800010
J	Weinreich, F; Jentsch, TJ				Weinreich, F; Jentsch, TJ			Pores formed by single subunits in mixed dimers of different CLC chloride channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO ELECTROPLAX; VOLTAGE; DEPENDENCE; RECONSTITUTION; STOICHIOMETRY; EXPRESSION; MUTATIONS; DOMINANT; MYOTONIA; REGIONS	CLC chloride channels comprise a gene family with nine mammalian members. Probably all CLC channels form homodimers, and some CLC proteins may also associate to heterodimers, ClC-0 and ClC-1, the only CLC channels investigated at the single-channel level, display two conductances of equal size which are thought to result from two separate pores, formed individually by the two monomers. We generated concatemeric channels containing one subunit of ClC-0 together with one subunit of ClC-1 or ClC-2, They should display two different conductances if one monomer were sufficient to form one pore. Indeed, we found a 8-picosiemens (pS) conductance (corresponding to ClC-0) that was associated with either a 1.8-pS (ClC-1) or a 2.8-pS (ClC-2) conductance, These conductances retained their typical gating, but the slow gating of ClC-0 that affects both pores simultaneously was lost. ClC-2 and ClC-0 current components were modified by point mutations in the corresponding subunit, The ClC-2 single pore of the mixed dimer was compared with the pores in the ClC-2 homodimer and found to be unaltered. We conclude that each monomer individually forms a gated pore. CLC dimers in general must be imagined as having two pores, as shown previously for ClC-0.	Univ Hamburg, ZMNH, Zentrum Mok Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Hamburg	Jentsch, TJ (corresponding author), Univ Hamburg, ZMNH, Zentrum Mok Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	jentsch@plexus.uke.uni-hamburg.de		Jentsch, Thomas/0000-0002-3509-2553				Akabas MH, 1997, J BIOENERG BIOMEMBR, V29, P453, DOI 10.1023/A:1022482923122; Astill DS, 1996, BBA-BIOMEMBRANES, V1280, P178, DOI 10.1016/0005-2736(95)00281-2; BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HANKE W, 1983, J GEN PHYSIOL, V82, P25, DOI 10.1085/jgp.82.1.25; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Lin YW, 1999, J GEN PHYSIOL, V114, P1, DOI 10.1085/jgp.114.1.1; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Ludewig U, 1997, J GEN PHYSIOL, V110, P165, DOI 10.1085/jgp.110.2.165; Ludewig U, 1997, BIOPHYS J, V73, P789, DOI 10.1016/S0006-3495(97)78111-6; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Maduke M, 1999, J GEN PHYSIOL, V114, P713, DOI 10.1085/jgp.114.5.713; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; Purdy MD, 2000, FEBS LETT, V466, P26, DOI 10.1016/S0014-5793(99)01740-8; Pusch M, 1997, J GEN PHYSIOL, V109, P105, DOI 10.1085/jgp.109.1.105; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Pusch M, 1995, NEURON, V15, P1455, DOI 10.1016/0896-6273(95)90023-3; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; Sheppard David N., 1999, Physiological Reviews, V79, pS23; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0	29	121	123	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2347	2353		10.1074/jbc.M005733200	http://dx.doi.org/10.1074/jbc.M005733200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035003	hybrid			2022-12-25	WOS:000166784800009
J	Cornea, A; Janovick, DA; Maya-Nunez, G; Conn, PM				Cornea, A; Janovick, DA; Maya-Nunez, G; Conn, PM			Gonadotropin-releasing hormone receptor microaggregation - Rate monitored by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELLS; DIMERIZATION; AGONIST; INTERNALIZATION; DESENSITIZATION; VISUALIZATION; ACTIVATION; LIGAND; DOMAIN	Gonadotropin-releasing hormone (GmRH) regulates pituitary gonadotropin release and is a therapeutic target for human and animal reproductive diseases, In the present study we have utilized the technique of fluorescence resonance energy transfer to monitor the rate of GnRH receptor-receptor interactions. This technique relies on the observation that the degree of physical intimacy of molecules can be assessed by the tendency of proximal fluorophores to exchange energy. Our data indicate that GnRH agonist, but not antagonist, occupancy of the GnRH receptor promotes physical intimacy (microaggregation) between receptors. The time course indicates that this occurs promptly (<1 min) after occupancy and persists for at least 80 min and within the physiologically relevant range of the releasing hormone. The process measured is not inhibited by 0.1 mM vinblastin, 2 <mu>M cytochalasin D, or 3 mM EGTA, an observation that distinguishes it from macroaggregation (patching, capping, and internalization). These observations, along with reports from other laboratories, are consonant with a growing body of evidence that indicates that microaggregation is an early event following agonist occupancy of the receptor and part of the mechanism by which effector regulation occurs.	Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA; Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University	Conn, PM (corresponding author), 505 NW 185th Ave, Beaverton, OR 97006 USA.				NCRR NIH HHS [RR00163] Funding Source: Medline; NICHD NIH HHS [HD18185, HD19899] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019899, R37HD019899] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Blakely BT, 2000, NAT BIOTECHNOL, V18, P218, DOI 10.1038/72686; BLUM JJ, 1982, P NATL ACAD SCI-BIOL, V79, P7307, DOI 10.1073/pnas.79.23.7307; BLUM JJ, 2000, AM J PHYSIOL, V2, pE263; CONN PM, 1984, MOL PHARMACOL, V25, P51; CONN PM, 1982, NATURE, V296, P653, DOI 10.1038/296653a0; CONN PM, 1982, ENDOCRINOLOGY, V111, P335, DOI 10.1210/endo-111-1-335; CONN PM, 1985, J CELL BIOCHEM, V7, P13; Cornea A, 1999, ENDOCRINOLOGY, V140, P4272, DOI 10.1210/en.140.9.4272; DOSREMEDIOS CG, 1995, J STRUCT BIOL, V115, P175, DOI 10.1006/jsbi.1995.1042; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GREGORY H, 1982, NATURE, V300, P269, DOI 10.1038/300269a0; GUO CM, 1995, J BIOL CHEM, V270, P27562, DOI 10.1074/jbc.270.46.27562; HARMATZ D, 1985, BIOCHEM BIOPH RES CO, V127, P687, DOI 10.1016/S0006-291X(85)80216-3; HAZUM E, 1980, P NATL ACAD SCI-BIOL, V77, P6692, DOI 10.1073/pnas.77.11.6692; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUCKLE WR, 1987, METHOD ENZYMOL, V141, P149; Janovick JA, 1996, ENDOCRINOLOGY, V137, P3602, DOI 10.1210/en.137.8.3602; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lin XW, 1998, MOL CELL ENDOCRINOL, V146, P27, DOI 10.1016/S0303-7207(98)00204-4; MITRA BD, 1995, PROGR POL ALT I MOL, P13; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Pinter J H, 1999, Pituitary, V2, P181, DOI 10.1023/A:1009946807430; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; SMITH WA, 1984, ENDOCRINOLOGY, V114, P553, DOI 10.1210/endo-114-2-553; SMITH WA, 1983, ENDOCRINOLOGY, V112, P408, DOI 10.1210/endo-112-1-408; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818	30	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2153	2158		10.1074/jbc.M007850200	http://dx.doi.org/10.1074/jbc.M007850200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035030	hybrid			2022-12-25	WOS:000166528000068
J	Salero, E; Perez-Sen, R; Aruga, J; Gimenez, C; Zafra, F				Salero, E; Perez-Sen, R; Aruga, J; Gimenez, C; Zafra, F			Transcription factors Zic1 and Zic2 bind and transactivate the apolipoprotein E gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E MESSENGER-RNA; ALZHEIMERS-DISEASE; CHOLESTEROL TRANSPORT; REGULATORY REGION; DEFICIENT MICE; TYPE-4 ALLELE; CELL LINEAGE; APOE GENE; EPSILON 4; EXPRESSION	We have used the yeast one-hybrid system to identify transcription factors that bind to specific sequences in proximal regions of the apolipoprotein E gene promoter. The sequence between -163 and -124, that has been previously defined as a functional promoter element, was used as a bait to screen a human brain cDNA library. Ten cDNA clones that encoded portions of the human Zic1 (five clones) and Zic2 (five clones) transcription factors were isolated. Electrophoretic mobility shift assays confirmed the presence of a binding site for Zic1 and Zic2 in the -136/-125 region. Displacement of binding with oligonucleotides derived from adjacent sequences within the APOE promoter revealed the existence of two additional Zic-binding sequences in this promoter. These sequences were identified by electrophoretic mobility shift assays and mutational analysis in regions -65/-54 and -185/-174. Cotransfection of Zic1 and Zic2 expression vector and different APOE promoter-luciferase reporter constructs in U87 glioblastoma cell line showed that the three binding sites partially contributed to the trans-stimulation of the luciferase reporter. Ectopic expression of Zic1 and Zic2 in U87 cells also trans-stimulated the expression of the endogenous gene, increasing the amount of apolipopro tein E produced by glial cells. These data indicate that Zic proteins might contribute to the transcriptional activity of the apolipoprotein E gene and suggest that apolipoprotein E could mediate some of the developmental processes in which Zic proteins are involved.	Univ Autonoma Madrid, CSIC, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); RIKEN	Zafra, F (corresponding author), Univ Autonoma Madrid, CSIC, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	fzafra@cbm.uam.es	Aruga, Jun/H-5837-2011; Perez-Sen, Raquel/L-6975-2014; Gimenez, Cecilio/K-8027-2014; Zafra, Francisco/A-6121-2008	Aruga, Jun/0000-0001-7936-1375; Perez-Sen, Raquel/0000-0001-6213-3376; Gimenez, Cecilio/0000-0001-6726-8405; Zafra, Francisco/0000-0003-3801-3109				Allan CM, 1997, J BIOL CHEM, V272, P29113, DOI 10.1074/jbc.272.46.29113; Arendt T, 1997, J NEUROSCI, V17, P516; Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Aruga J, 1998, J NEUROSCI, V18, P284; ARUGA J, 1994, J NEUROCHEM, V63, P1880; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Bachner D, 1999, BIOFACTORS, V9, P11; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BERG DT, 1995, J BIOL CHEM, V270, P15447, DOI 10.1074/jbc.270.26.15447; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; Buttini M, 1999, J NEUROSCI, V19, P4867; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Garcia MA, 1996, J NEUROSCI, V16, P7550; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; JO DW, 1995, J BIOCHEM-TOKYO, V117, P915, DOI 10.1093/oxfordjournals.jbchem.a124796; KAYDEN HJ, 1985, ARCH BIOCHEM BIOPHYS, V239, P388, DOI 10.1016/0003-9861(85)90704-0; Kelley RI, 1996, AM J MED GENET, V66, P478, DOI 10.1002/(SICI)1096-8628(19961230)66:4<478::AID-AJMG22>3.0.CO;2-Q; KolfClauw M, 1996, TERATOLOGY, V54, P115, DOI 10.1002/(SICI)1096-9926(199609)54:3<115::AID-TERA1>3.0.CO;2-2; KOO C, 1985, J BIOL CHEM, V260, P1934; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Lanoue L, 1997, AM J MED GENET, V73, P24; LIAW GJ, 1994, BIOTECHNIQUES, V17, P668; LINLEE YC, 1981, BIOCHEMISTRY-US, V20, P6474, DOI 10.1021/bi00525a028; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Masliah E, 1997, BRAIN RES, V751, P307, DOI 10.1016/S0006-8993(96)01420-5; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; Nagai T, 2000, P NATL ACAD SCI USA, V97, P1618, DOI 10.1073/pnas.97.4.1618; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nicoll JAR, 1996, ANN NEUROL, V39, P682, DOI 10.1002/ana.410390521; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAIK YK, 1988, J BIOL CHEM, V263, P13340; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; REUE KL, 1984, J BIOL CHEM, V259, P2100; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Shih SJ, 2000, J BIOL CHEM, V275, P31567, DOI 10.1074/jbc.M005468200; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SMITH JD, 1988, J BIOL CHEM, V263, P8300; SNIPS GJ, 1986, P NATL ACAD SCI USA, V83, P1130, DOI 10.1073/pnas.83.4.1130; Srivastava RAK, 1996, BIOCHEM MOL BIOL INT, V38, P91; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; Stone DJ, 1998, J NEUROSCI, V18, P3180; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Xu PT, 1998, NEUROSCI LETT, V246, P65, DOI 10.1016/S0304-3940(98)00247-X; Yokota N, 1996, CANCER RES, V56, P377	66	48	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1881	1888		10.1074/jbc.M007008200	http://dx.doi.org/10.1074/jbc.M007008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038359	hybrid			2022-12-25	WOS:000166528000033
J	Kim, YS; Cape, SP; Chi, E; Raffen, R; Wilkins-Stevens, P; Stevens, FJ; Manning, MC; Randolph, TW; Solomon, A; Carpenter, JF				Kim, YS; Cape, SP; Chi, E; Raffen, R; Wilkins-Stevens, P; Stevens, FJ; Manning, MC; Randolph, TW; Solomon, A; Carpenter, JF			Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREFERENTIAL HYDRATION; CHEMICAL CHAPERONES; PROTEIN-STRUCTURE; IN-VITRO; AGGREGATION; DISEASE; SCRAPIE; FIBRILLOGENESIS; TRANSTHYRETIN; CONSEQUENCES	In primary (light chain-associated) amyloidosis, immunoglobulin light chains deposit as amyloid fibrils in vital organs, especially the kidney. Because the kidney contains high concentrations of urea that can destabilize light chains as well as solutes such as betaine and sorbitol that serve as protein stabilizers, we investigated the effects of these solutes on in vitro amyloid fibril formation and thermodynamic stability of light chains, Two recombinant light chain proteins, one amyloidogenic and the other nonamyloidogenic, were used as models, For both light chains, urea enhanced fibril formation by reducing the nucleation lag time and diminished protein thermodynamic stability. Conversely, betaine or sorbitol increased thermodynamic stability of the proteins and partially inhibited fibril formation. These solutes also counteracted urea-induced reduction in protein thermodynamic stability and accelerated fibril formation. Betaine was more effective than sorbitol. A model is presented to explain how the thermodynamic effects of the solutes on protein state equilibria can alter nucleation lag time and, hence, fibril formation kinetics. Our results provide evidence that renal solutes control thermodynamic and kinetic stability of light chains and thus may modulate amyloid fibril formation in the kidney.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Dept Chem Engn, Boulder, CO 80309 USA; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA; Univ Tennessee, Human Immunol & Canc Program, Grad Sch Med, Knoxville, TN 37920 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder; United States Department of Energy (DOE); Argonne National Laboratory; University of Tennessee System; University of Tennessee Health Science Center	Carpenter, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA.	John.Carpenter@uchsc.edu		Kim, Yong-Sung/0000-0003-2673-1509	NCI NIH HHS [CA10050] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKAWA T, 1983, ARCH BIOCHEM BIOPHYS, V224, P169, DOI 10.1016/0003-9861(83)90201-1; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Burg MB, 1998, AM J PHYSIOL-RENAL, V274, pF762, DOI 10.1152/ajprenal.1998.274.4.F762; Burg MB, 1996, KIDNEY INT, V50, pS100; Carpenter JF, 1999, METHOD ENZYMOL, V309, P236; COELHOSAMPAIO T, 1994, EUR J BIOCHEM, V221, P1103, DOI 10.1111/j.1432-1033.1994.tb18830.x; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Davis DP, 2000, IMMUNITY, V13, P433, DOI 10.1016/S1074-7613(00)00043-1; Dhodapkar MV, 1997, HEMATOL ONCOL CLIN N, V11, P89, DOI 10.1016/S0889-8588(05)70417-2; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; Dong AC, 2000, J BIOL CHEM, V275, P27689; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P39, DOI 10.1093/oxfordjournals.jbchem.a133468; GLENNER GG, 1971, SCIENCE, V174, P712, DOI 10.1126/science.174.4010.712; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kim YS, 2000, J BIOL CHEM, V275, P1570, DOI 10.1074/jbc.275.3.1570; KYLE RA, 1995, SEMIN HEMATOL, V32, P45; KYLE RA, 1994, ANNU REV MED, V45, P71; MARSH DJ, 1992, RENAL PHYSL, P1317; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MYATT EA, 1994, P NATL ACAD SCI USA, V91, P3034, DOI 10.1073/pnas.91.8.3034; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Pace C N, 1986, Methods Enzymol, V131, P266; Raffen R, 1999, PROTEIN SCI, V8, P509; RONCO PM, 1997, DIS KIDNEY, V3, P2129; SANTORA MM, 1988, BIOCHEMISTRY-US, V27, P8603; SLUZKY V, 1991, P NATL ACAD SCI USA, V88, P9377, DOI 10.1073/pnas.88.21.9377; Solomon A, 1998, P NATL ACAD SCI USA, V95, P9547, DOI 10.1073/pnas.95.16.9547; STEVENS FJ, 1995, BIOCHEMISTRY-US, V34, P10697, DOI 10.1021/bi00034a001; STEVENS FJ, 1989, IMMUNOL TODAY, V20, P453; STEVENS PW, 1995, PROTEIN SCI, V4, P421; STRIKER LJM, 1994, RENAL PATHOLOGY, V2, P1442; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; Wall J, 1999, BIOCHEMISTRY-US, V38, P14101, DOI 10.1021/bi991131j; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; WELTZEL R, 1997, ADV PROTEIN CHEM, V50, P183; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Xie GF, 1997, PROTEIN SCI, V6, P211; YANCEY PH, 1979, BIOCHEM J, V183, P317, DOI 10.1042/bj1830317; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970	47	79	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1626	1633		10.1074/jbc.M007766200	http://dx.doi.org/10.1074/jbc.M007766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050093	hybrid			2022-12-25	WOS:000166430900102
J	Song, ES; Mukherjee, A; Juliano, MA; St Pyrek, J; Goodman, JP; Juliano, L; Hersh, LB				Song, ES; Mukherjee, A; Juliano, MA; St Pyrek, J; Goodman, JP; Juliano, L; Hersh, LB			Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; DEGRADATION; IDENTIFICATION; PROTEIN	Recombinant rat insulysin was shown to cleave the internally quenched fluorogenic peptide 2-aminobenzyl-GGFLRKVGQ-ethylenediamine-2,4-dinitrophenol at the R-K bond, exhibiting a K-m of 13 muM and a V-max of 2.6 mu mol min(-1) mg(-1). Derivatives of this peptide in which the P-2 leucine or the P-2' valine were replaced with other residues were used to probe the subsite specificity of the enzyme. Varying the P-2 residue produced a l-fold range in K-m and a 7-fold range in k(cat). The nature of the P-2 residue had a significant effect on the site of cleavage. Leucine, isoleucine, valine, and aspartate produced cleavage at the R-K bond, Asparagine produced 36% cleavage at the N-R bond and 64% cleavage at the RK bond, whereas with alanine or serine the A-R and S-R bonds were the major cleavage sites. With tyrosine, phenylalanine, methionine, or histidine representing the varied residue X, cleavages at F-X, X-R, and RK were seen, whereas with tryptophan equal cleavage occurred at the F-W and W-R bonds. Variable P-2' residues produce less of a change in both K-m and k(cat) and have little influence on the cleavage site. Exceptions are phenylalanine, tyrosine, leucine, and isoleucine, which in addition to producing cleavage at the RK bond, produce significant cleavage at the GR bond. Alanine and tyrosine were unique in producing cleavage at the F-L bond. Taken together, these data suggest that insulysin specificity is directed toward the amino side of hydrophobic and basic residues and that the enzyme has an extended substrate binding site.	Univ Kentucky, Albert B Chandler Med Ctr, Coll Med, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Mass Spectrometry Facil, Lexington, KY 40506 USA; Escola Paulista Med, Dept Biophys, BR-04034 Sao Paulo, Brazil	University of Kentucky; University of Kentucky; Universidade Federal de Sao Paulo (UNIFESP)	Hersh, LB (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Coll Med, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.	lhersh@pop.uky.edu	Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822	NIDA NIH HHS [DA 07062, DA02243] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Authier F, 1996, CLIN INVEST MED, V19, P149; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; CHAGAS JR, 1991, ANAL BIOCHEM, V192, P419, DOI 10.1016/0003-2697(91)90558-B; Cleland W W, 1979, Methods Enzymol, V63, P103; Csuhai E, 1999, ANAL BIOCHEM, V269, P149, DOI 10.1006/abio.1999.4033; DUCKWORTH WC, 1994, J BIOL CHEM, V269, P24575; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; GARCIA JV, 1989, J CELL BIOL, V109, P1301, DOI 10.1083/jcb.109.3.1301; GEHM BD, 1993, J BIOL CHEM, V268, P7943; Gershkovich A, 1996, J BIOCHEM BIOPH METH, V33, P135, DOI 10.1016/S0165-022X(96)00023-1; KUPFER SR, 1994, J BIOL CHEM, V269, P20622; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; MIRSKY A, 1949, ARCH BIOCHEM, V20, P1; Mukherjee A, 2000, J NEUROSCI, V20, P8745; MULLER D, 1992, BIOCHEMISTRY-US, V31, P11138; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROTH RA, 1984, ENDOCR RES, V10, P101, DOI 10.3109/07435808409035411; Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEMPLE JW, 1989, J IMMUNOL, V142, P4184; Seta KA, 1997, BIOCHEM BIOPH RES CO, V231, P167, DOI 10.1006/bbrc.1997.6066; Vekrellis K, 2000, J NEUROSCI, V20, P1657	26	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1152	1155		10.1074/jbc.M008702200	http://dx.doi.org/10.1074/jbc.M008702200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042190	hybrid			2022-12-25	WOS:000166430900042
J	Takahashi, M; Takahashi, K; Hiratsuka, Y; Uchida, K; Yamagishi, A; Uyeda, TQP; Yazawa, M				Takahashi, M; Takahashi, K; Hiratsuka, Y; Uchida, K; Yamagishi, A; Uyeda, TQP; Yazawa, M			Functional characterization of vertebrate nonmuscle myosin IIB isoforms using Dictyostelium chimeric myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; HEAVY CHAIN-B; ACTIN-BINDING LOOP; MOTOR DOMAIN; ATPASE ACTIVITY; ADENOSINE-TRIPHOSPHATASE; MOLECULAR MOTOR; MESSENGER-RNAS; SURFACE LOOPS; SUBFRAGMENT-1	The alternatively spliced isoform of nonmuscle myosin II heavy chain B (MHC-IIB) with an insert of 21 amino acids in the actin-binding surface loop (loop 2), MHC-IIB(BE), is expressed specifically in the central nervous system of vertebrates. To examine the role of the B2 insert in the motor activity of the myosin II molecule, we expressed chimeric myosin heavy chain molecules using the Dictyostelium myosin II heavy chain as the backbone. We replaced the Dictyostelium native loop 2 with either the noninserted form of loop 2 from human MHC-IIB or the BE-inserted form of loop 2 from human MHC-IIB(BE), The transformant Dictyostelium cells expressing only the B2-inserted chimeric myosin formed unusual fruiting bodies. We then assessed the function of chimeric proteins, using an in vitro motility assay and by measuring ATPase activities and binding to F-actin, We demonstrate that the insertion of the B2 sequence reduces the motor activity of Dictyostelium myosin II, with reduction of the maximal actin-activated ATPase activity and a decrease in the affinity for actin, In addition, we demonstrate that the native loop 2 sequence of Dictyostelium myosin II is required for the regulation of the actin-activated ATPase activity by phosphorylation of the regulatory light chain.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan; Natl Inst Adv Interdisciplinary Res, Biomol Res Grp, Tsukuba, Ibaraki 3058562, Japan	Hokkaido University; Hokkaido University; National Institute of Advanced Industrial Science & Technology (AIST)	Takahashi, M (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan.	takahash@sci.hokudai.ac.jp	Takahashi, Masayuki/D-8079-2012	Takahashi, Masayuki/0000-0002-5923-2813; Hiratsuka, Yuichi/0000-0002-0237-081X				BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; Bernstein SI, 1997, J MOL BIOL, V271, P1, DOI 10.1006/jmbi.1997.1160; Bobkov AA, 1996, P NATL ACAD SCI USA, V93, P2285, DOI 10.1073/pnas.93.6.2285; BOTTS J, 1982, BIOCHEMISTRY-US, V21, P6903, DOI 10.1021/bi00269a043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUSSEPIED P, 1988, P NATL ACAD SCI USA, V85, P7471, DOI 10.1073/pnas.85.20.7471; COOK RK, 1993, J BIOL CHEM, V268, P2410; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EGELHOFF TT, 1990, DEV BIOL, V137, P359, DOI 10.1016/0012-1606(90)90260-P; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Giese KC, 1997, BIOCHEMISTRY-US, V36, P8465, DOI 10.1021/bi963141f; GONZALEZROMO P, 1992, ANAL BIOCHEM, V200, P235, DOI 10.1016/0003-2697(92)90458-J; Goodson HV, 1999, J MOL BIOL, V287, P173, DOI 10.1006/jmbi.1999.2565; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kawamoto S, 1996, J BIOL CHEM, V271, P17613; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Knetsch MLW, 1999, J BIOL CHEM, V274, P20133, DOI 10.1074/jbc.274.29.20133; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mendelson R, 1997, P NATL ACAD SCI USA, V94, P8533, DOI 10.1073/pnas.94.16.8533; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Miyazaki T, 2000, NEUROSCI RES, V37, P299, DOI 10.1016/S0168-0102(00)00130-9; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; MURAKAMI N, 1993, DEV BIOL, V157, P19, DOI 10.1006/dbio.1993.1108; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; NYITRAY L, 1994, P NATL ACAD SCI USA, V91, P12686, DOI 10.1073/pnas.91.26.12686; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Rovner AS, 1998, J BIOL CHEM, V273, P27939, DOI 10.1074/jbc.273.43.27939; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Smith JL, 1996, EMBO J, V15, P6075, DOI 10.1002/j.1460-2075.1996.tb00996.x; Spudich JA, 1995, COLD SPRING HARB SYM, V60, P783, DOI 10.1101/SQB.1995.060.01.084; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Takahashi M, 1999, BIOCHEM BIOPH RES CO, V259, P29, DOI 10.1006/bbrc.1999.0717; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; YAMAMOTO K, 1979, J BIOCHEM-TOKYO, V86, P1869, DOI 10.1093/oxfordjournals.jbchem.a132710; YAMAMOTO K, 1979, J BIOCHEM, V86, P1855, DOI 10.1093/oxfordjournals.jbchem.a132708; YAMAMOTO K, 1991, J MOL BIOL, V217, P229, DOI 10.1016/0022-2836(91)90535-E; YOUNT RG, 1995, BIOPHYS J S, V68, P44	62	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1034	1040		10.1074/jbc.M005370200	http://dx.doi.org/10.1074/jbc.M005370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042201	Green Submitted, hybrid			2022-12-25	WOS:000166430900025
J	Baeckstrom, D; Lu, PJ; Taylor-Papadimitriou, J				Baeckstrom, D; Lu, PJ; Taylor-Papadimitriou, J			Activation of the alpha(2)beta(1) integrin prevents c-erbB2-induced scattering and apoptosis of human mammary epithelial cells in collagen	ONCOGENE			English	Article						epithelial-mesenchymal conversion; E-cadherin; heregulin; morphogenesis; anchorage-independent growth	PHOSPHOINOSITIDE 3-OH KINASE; EPIDERMAL GROWTH-FACTOR; EXTRACELLULAR-MATRIX; TYROSINE KINASE; CARCINOMA-CELLS; ERBB RECEPTORS; BREAST-CANCER; TUMOR-CELLS; EXPRESSION; ADHESION	Constitutive overexpression of C-erbB2 in the mammary epithelial cell line MTSV1-7 has been shown to result in epithelial-mesenchymal conversion, anchorage-independent growth and loss of organized morphogenesis in collagen. To elucidate the events leading to this drastic change, MTSV1-7 cells and its subclone HB2 (which shows a more strictly epithelial phenotype) were transfected with the hybrid trk-neu receptor consisting of the extracellular domain of the trkA nerve growth factor (NGF) receptor and the transmembrane and cytoplasmic domains of c-erbB2 (neu), In cells expressing this construct, c-erbB2 homodimerization can be mimicked by addition of NGF, In trk-neu transfectants of HB2 cells, modest expression led to increased cell proliferation upon NGF treatment. When clones with higher expression levels were grown in collagen, NGF instead induced cell scattering, diminished viability and dramatically increased apoptosis, Interestingly, both the dissociation of colonies and loss of cell viability could be completely reversed by treatment of the cells with antibodies that activate the adhesive capacity of the alpha(2)beta(1) integrin, Long-term NGF treatment of high-expressing transfectants generated fibroblastic clones displaying a reduced expression of integrin alpha(2) and E-cadherin, and extensive apoptosis in collagen. These results, which indicate that strong c-erbB2 signalling may lead to downregulation and/or inactivation of the alpha(2)beta(1) integrin, promoting apoptosis in collagen, provide one possible explanation to the increased apoptosis frequently seen in early tumour development.	Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden; Guys Hosp, Imperial Canc Res Fund, Breast Canc Biol Lab, London SE1 9RT, England	University of Gothenburg; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust	Baeckstrom, D (corresponding author), Univ Gothenburg, Dept Biochem Med, Box 440, SE-40530 Gothenburg, Sweden.							Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Alford D, 1998, J CELL SCI, V111, P521; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Baasner S, 1996, ONCOGENE, V13, P901; Baeckstrom D, 2000, INT J ONCOL, V16, P1081; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Berdichevsky Feodor, 1994, Molecular and Cellular Differentiation, V2, P255; DEPOTTER CR, 1995, VIRCHOWS ARCH, V426, P107, DOI 10.1007/BF00192631; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DSOUZA B, 1993, ONCOGENE, V8, P1797; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Genersch E, 1996, J MOL MED-JMM, V74, P609, DOI 10.1007/s001090050064; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Krensel K, 1999, INT J CANCER, V80, P546, DOI 10.1002/(SICI)1097-0215(19990209)80:4<546::AID-IJC11>3.0.CO;2-9; LAUEROVA L, 1988, HYBRIDOMA, V7, P495, DOI 10.1089/hyb.1988.7.495; Lo SS, 1999, MOL CARCINOGEN, V25, P150; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nowak F, 1997, EXP CELL RES, V231, P251, DOI 10.1006/excr.1996.3468; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Sambrook J., MOL CLONING LAB MANU; Shak S, 1999, SEMIN ONCOL, V26, P71; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Soini Y, 1998, AM J PATHOL, V153, P1041, DOI 10.1016/S0002-9440(10)65649-0; Tagliabue E, 1996, BRIT J CANCER, V74, P1427, DOI 10.1038/bjc.1996.560; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; Ye JP, 1996, MOL CELL BIOL, V16, P6178; ZUTTER MM, 1993, AM J PATHOL, V142, P1439	33	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4592	4603		10.1038/sj.onc.1203792	http://dx.doi.org/10.1038/sj.onc.1203792			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030148				2022-12-25	WOS:000089438200005
J	Periyasamy, S; Ammanamanchi, S; Tillekeratne, MPM; Brattain, M				Periyasamy, S; Ammanamanchi, S; Tillekeratne, MPM; Brattain, M			Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency	ONCOGENE			English	Article						azacytidine; transforming growth factor-beta; transforming growth factor-beta receptor type I (RI)	COLON-CARCINOMA CELLS; TGF-BETA; O-GLYCOSYLATION; CANCER CELLS; MICROSATELLITE INSTABILITY; TRANSCRIPTION FACTOR; PROTEIN-KINASE; ACTIVATION; MECHANISM; GENE	In this report, we describe the mechanism of TGF-beta receptor type I (RI) repression in the CEO human colon carcinoma cells. Treatment of GEO cells with the DNA methyltransferase inhibitor, 5 azacytidine induced RI expression and restored TGF-beta response. A stably transfected RI promoter-reporter construct (RI-Luc) expressed higher activity in the 5 aza C treated GEO cells, suggesting the activation of a transactivator for RI transcription. Gel shift analysis indicated enhanced binding of proteins from the 5 aza C treated nuclear extracts to radiolabeled Sp1 oligonucleotides specifically contained in the RT promoter, Protein stability studies after cyclohexamide treatment suggested an increase in the Spl protein stability from the 5 aza C treated GEO cells. Further, transfection of Sp1 cDNA into untreated GEO control cells increased RI promoter activity and thus induced RI expression. 5 aza C mediated Spl expression in Sp1 deficient CEO colon and MCF-7 breast cancer cells also enhanced the activity of several other Sp1 dependent promoters such as TGF-beta receptor type II (RII), Cyclin A and p21/waf1/cip1. These results indicate that restoration of Sp1 in several different types of Sp1 deficient cells leads to enhanced activation of a wide range of Sp1 dependent promoters.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA	University of Texas System; University of Texas Health San Antonio	Brattain, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL CANCER INSTITUTE [R37CA038173, R01CA072001, R01CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38173, CA 72001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones PA, 1996, CANCER RES, V56, P2463; Kim DH, 1997, J BIOL CHEM, V272, P688; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Periyasamy S, 1996, J CELL PHYSIOL, V168, P711, DOI 10.1002/(SICI)1097-4652(199609)168:3<711::AID-JCP24>3.0.CO;2-#; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; SHEN WJ, 1995, J BIOL CHEM, V270, P20525, DOI 10.1074/jbc.270.35.20525; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Yoshizumi M, 1997, J BIOL CHEM, V272, P22259, DOI 10.1074/jbc.272.35.22259	31	30	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4660	4667		10.1038/sj.onc.1203822	http://dx.doi.org/10.1038/sj.onc.1203822			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030155				2022-12-25	WOS:000089438200012
J	Yamaguchi, A; Tamatani, M; Matsuzaki, H; Namikawa, K; Kiyama, H; Vitek, MP; Mitsuda, N; Tohyama, M				Yamaguchi, A; Tamatani, M; Matsuzaki, H; Namikawa, K; Kiyama, H; Vitek, MP; Mitsuda, N; Tohyama, M			Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; BAX EXPRESSION; CELL-DEATH; KINASE B; SURVIVAL; BCL-2; TARGET; GENE	Survival factors suppress apoptosis by activating the serine/threonine kinase Akt. To investigate the molecular mechanism underlying activated Akt's ability to protect neurons from hypoxia or nitric oxide (NO) toxicity, we focused on the apoptosis-related functions of p53 and caspases, We eliminated p53 by employing p53-deficient neurons and increased p53 by infection with recombinant adenovirus capable of transducing p53 expression, and we now show that p53 is implicated in the apoptosis induced by hypoxia or NO treatments of primary cultured hippocampal neurons. Although hypoxia and NO induced p53, treatment with insulin-like growth factor-1 significantly inhibited caspase-3-like activation, neuronal death and transcriptional activity of p53. These insulin-like growth factor-1 effects are prevented by wortmannin, a phosphatidylinositol 3-kinase inhibitor, Adenovirus-mediated expression of activated-Akt kinase suppressed p53-dependent transcriptional activation of responsive genes such as Bax, suppressed caspase-3-like protease activity and suppressed neuronal cell death with no effect on the cellular accumulation and nuclear translocation of p53. In contrast, overexpression of kinase-defective Akt failed to suppress these same activities. These results suggest a mechanism where Akt kinase activation reduces p53's transcriptional activity that ultimately rescues neurons from hypoxia- or NO-mediated cell death.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Asahikawa Med Coll, Dept Anat, Asahikawa, Hokkaido 0788510, Japan; Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; Japan Sci & Technol, CREST, Kawaguchi, Saitama 3320012, Japan	Osaka University; Asahikawa Medical College; Duke University; Japan Science & Technology Agency (JST)	Tamatani, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tama@anat2.med.osaka-u.ac.jp	Kiyama, Hiroshi/M-8867-2014; MATSUZAKI, HIDEO/AAE-5246-2020	Kiyama, Hiroshi/0000-0001-5963-046X; MATSUZAKI, HIDEO/0000-0002-6869-1261; Vitek, Michael/0000-0001-8140-8048				Ahmad F, 2000, J IMMUNOL, V164, P4678, DOI 10.4049/jimmunol.164.9.4678; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cregan SP, 1999, J NEUROSCI, V19, P7860; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Guan J, 2000, J CEREBR BLOOD F MET, V20, P513, DOI 10.1097/00004647-200003000-00010; Halterman MW, 1999, EXP NEUROL, V159, P65, DOI 10.1006/exnr.1999.7160; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; MIYASHITA T, 1995, CELL, V80, P293; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; Ozes ON, 1999, NATURE, V401, P82; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Tamatani M, 2000, J NEUROCHEM, V75, P683, DOI 10.1046/j.1471-4159.2000.0750683.x; Tamatani M, 1998, CELL DEATH DIFFER, V5, P911, DOI 10.1038/sj.cdd.4400439; Tamatani M, 1998, J NEUROCHEM, V71, P1588; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TSUKADA T, 1993, ONCOGENE, V8, P3313; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xiang H, 1998, J NEUROSCI, V18, P1363; ZHANG WW, 1994, CANCER GENE THER, V1, P5	41	192	198	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5256	5264		10.1074/jbc.M008552200	http://dx.doi.org/10.1074/jbc.M008552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11054421	hybrid			2022-12-25	WOS:000168484300097
J	Polyak, SW; Chapman-Smith, A; Mulhern, TD; Cronan, JE; Wallace, JC				Polyak, SW; Chapman-Smith, A; Mulhern, TD; Cronan, JE; Wallace, JC			Mutational analysis of protein substrate presentation in the post-translational attachment of biotin to biotin domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; DEHYDROGENASE MULTIENZYME COMPLEX; YEAST PYRUVATE-CARBOXYLASE; ESCHERICHIA-COLI; LIPOYL DOMAIN; PHAGE-DISPLAY; PROPIONIBACTERIUM-SHERMANII; EXCEPTIONAL SPECIFICITY; 3-DIMENSIONAL STRUCTURE; AZOTOBACTER-VINELANDII	Biotinylation in vivo is an extremely selective posttranslational event where the enzyme biotin protein ligase (BPL) catalyzes the covalent attachment of biotin to one specific and conserved lysine residue of biotin-dependent enzymes. The biotin-accepting lysine, present in a conserved Met-Lys-Met motif, resides in a structured domain that functions as the BPL substrate. We have employed phage display coupled with a genetic selection to identify determinants of the biotin domain (yPC-104) of yeast pyruvate carboxylase 1 (residues 1075-1178) required for interaction with BPL. Mutants isolated using this strategy were analyzed by in vivo biotinylation assays performed at both 30 degreesC and 37 degreesC, The temperature-sensitive substrates were reasoned to have structural mutations, leading to compromised conformations at the higher temperature. This interpretation was supplemented by molecular modeling of yPC-104, since these mutants mapped to residues involved in defining the structure of the biotin domain. In contrast, substitution of the Met residue N-terminal to the target lysine with either Val or Thr produced mutations that were temperature-insensitive in the in vivo assay. Furthermore, these two mutant proteins and wild-type yPC-104 showed identical susceptibility to trypsin, consistent with these substitutions having no structural effect. Kinetic analysis of enzymatic biotinylation using purified Met --> Thr/Val mutant proteins with both yeast and Escherichia coli BPLs revealed that these substitutions had a strong effect upon K-m values but not k(cat). The Met --> Thr mutant was a poor substrate for both BPLs, whereas the Met --> Val substitution was a poor substrate for bacterial BPL but had only at S-fold lower affinity for yeast BPL than the wild-type peptide. Our data suggest that substitution of Thr or Val for the Met N-terminal of the biotinyl-lys results in mutants specifically compromised in their interaction with BPL.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Adelaide; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Wallace, JC (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	john.wallace@adelaide.edu.au	Polyak, Steven W/A-7488-2019; Mulhern, Terrence/A-1206-2007; Cronan, John/V-6626-2019; Polyak, Steven W./G-3185-2011; , John/AAP-5150-2020	Polyak, Steven W/0000-0002-8458-5194; Polyak, Steven W./0000-0002-8458-5194; Mulhern, Terrence/0000-0002-1609-7498				Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; Berg A, 1997, EUR J BIOCHEM, V244, P352, DOI 10.1111/j.1432-1033.1997.00352.x; Berg A, 1996, J MOL BIOL, V261, P432, DOI 10.1006/jmbi.1996.0474; BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; Chapman-Smith A, 1999, J NUTR, V129, p477S, DOI 10.1093/jn/129.2.477S; Chapman-Smith A, 1999, J BIOL CHEM, V274, P1449, DOI 10.1074/jbc.274.3.1449; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; Demartis S, 1999, J MOL BIOL, V286, P617, DOI 10.1006/jmbi.1998.2476; DOWNER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127; Fischer D, 1996, PROTEIN SCI, V5, P947; GU HD, 1995, PROTEIN SCI, V4, P1108, DOI 10.1002/pro.5560040609; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Hudson PJ, 1998, CURR OPIN BIOTECH, V9, P395, DOI 10.1016/S0958-1669(98)80014-1; Jitrapakdee S, 1999, BIOCHEM J, V340, P1, DOI 10.1042/bj3400001; Katz BA, 1997, ANNU REV BIOPH BIOM, V26, P27, DOI 10.1146/annurev.biophys.26.1.27; KONDO H, 1984, INT J PEPT PROT RES, V23, P559; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LI SJ, 1992, J BIOL CHEM, V267, P855; LIM F, 1988, J BIOL CHEM, V263, P11493; Lucic MR, 1998, J BIOTECHNOL, V61, P95, DOI 10.1016/S0168-1656(98)00012-1; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Polyak SW, 1997, PROTEIN ENG, V10, P615, DOI 10.1093/protein/10.6.615; Polyak SW, 1999, J BIOL CHEM, V274, P32847, DOI 10.1074/jbc.274.46.32847; Reche P, 1998, BIOCHEM J, V329, P589, DOI 10.1042/bj3290589; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; Reddy DV, 1997, BIOCHEMISTRY-US, V36, P14676, DOI 10.1021/bi971674y; Reddy DV, 1998, PROTEIN SCI, V7, P2156, DOI 10.1002/pro.5560071013; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sharma RC, 1996, BIOTECHNIQUES, V20, P42; SHENOY BC, 1988, FASEB J, V2, P2396, DOI 10.1096/fasebj.2.8.3360240; SHENOY BC, 1992, J BIOL CHEM, V267, P18407; Stolz J, 1998, FEBS LETT, V440, P213, DOI 10.1016/S0014-5793(98)01454-9; Val DL, 1995, BIOCHEM J, V312, P817, DOI 10.1042/bj3120817; Wallis NG, 1996, J MOL BIOL, V263, P463, DOI 10.1006/jmbi.1996.0589; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; Xu Y, 1997, METHOD ENZYMOL, V279, P405; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f	48	34	37	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3037	3045		10.1074/jbc.M003968200	http://dx.doi.org/10.1074/jbc.M003968200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042165	hybrid			2022-12-25	WOS:000166784900011
J	Raspe, E; Duez, H; Gervois, P; Fievet, C; Fruchart, JC; Besnard, S; Mariani, J; Tedgui, A; Staels, B				Raspe, E; Duez, H; Gervois, P; Fievet, C; Fruchart, JC; Besnard, S; Mariani, J; Tedgui, A; Staels, B			Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor ROR alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; APO-CIII; A-I; APOCIII PROMOTER; DNA-BINDING; TRANSGENIC MICE; ACTIVATION; HORMONE; MODULATION; HYPERTRIGLYCERIDEMIA	Triglyceride-rich remnant lipoproteins are considered as major risk factors contributing to the pathogenesis of atherosclerosis. Because apolipoprotein (apo) C-III is a major determinant of plasma triglyceride and remnant lipoprotein metabolism, it is important to understand how the expression of this gene is regulated. In the present study, we identified the orphan nuclear receptor ROR alpha1 as a regulator of human and mouse apo C-III gene expression. Plasma triglyceride and apo C-III protein concentrations in staggerer (sg/sg) mice, homozygous for a deletion in the ROR alpha gene, were significantly lower than in wild type littermates. The lowered plasma apo C-III levels were associated with reduced apo C-III mRNA levels in liver and intestine of sg/sg mice. Transient transfection experiments in human hepatoma HepG2, human colonic CaCO2, and rabbit kidney RK13 cells demonstrated that overexpression of the human ROR alpha1 isoform specifically increases human apo C-III promoter activity, indicating that ROR alpha1 enhances human apo C-III gene transcription. ROR alpha1 response elements were mapped by promoter deletion analysis and gel shift experiments to two AGGTCA halfsites located at positions -83/-78 (within the C3P site) and -23/-18 (downstream of the TATA box) in the human apo C-III promoter, with the -23/-18 site exhibiting the highest binding affinity. Transfection of site-directed mutated constructs in HepG2 cells indicated that the ROR alpha1 effect is predominantly mediated by the -23/-18 site. This site is conserved in the mouse apo C-III gene promoter. Moreover, ROR alpha binds to the equivalent mouse site and activates constructs containing three copies of the mouse site cloned in front of an heterologous promoter. Taken together, our data identify ROR alpha as a transcriptional regulator of apo C-III gene expression, providing a novel, physiological role for ROR alpha1 in the regulation of genes controlling triglyceride metabolism.	Inst Pasteur, INSERM, U325, F-59019 Lille, France; INSERM, U141, F-75745 Paris 10, France; Univ Paris 06, CNRS, UMR 7624, F-75005 Paris, France; Ctr Rech & Dev, Grp Merck Lipha, F-69003 Lyon, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite de Lille - ISITE; Universite de Lille	Staels, B (corresponding author), Inst Pasteur, INSERM, U325, 1 Rue Calmette, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Duez, Helene/M-7609-2017; Duez, Helene/AAC-3217-2019; Staels, Bart/N-9497-2016	Duez, Helene/0000-0002-4130-7987; Staels, Bart/0000-0002-3784-1503; Mariani, Jean/0000-0002-2701-1581				AaltoSetala K, 1996, J LIPID RES, V37, P1802; AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Assmann G, 1998, EUR HEART J, V19, pA2; Austin S, 1998, CELL GROWTH DIFFER, V9, P267; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CHEN M, 1994, J LIPID RES, V35, P1918; CLAVEY V, 1995, ARTERIOSCL THROM VAS, V15, P963, DOI 10.1161/01.ATV.15.7.963; Davignon J, 1996, ATHEROSCLEROSIS, V124, pS57, DOI 10.1016/0021-9150(96)05858-3; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1; Ebara T, 1997, J CLIN INVEST, V99, P2672, DOI 10.1172/JCI119456; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Fraser JD, 1998, NUCLEIC ACIDS RES, V26, P2702, DOI 10.1093/nar/26.11.2702; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; Gotto AM, 1998, CIRCULATION, V97, P1027, DOI 10.1161/01.CIR.97.11.1027; Greiner EF, 1996, P NATL ACAD SCI USA, V93, P10105, DOI 10.1073/pnas.93.19.10105; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Harding HP, 1997, MOL ENDOCRINOL, V11, P1737, DOI 10.1210/me.11.11.1737; Haubenwallner S, 1995, J LIPID RES, V36, P2541; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; Hodis HN, 1999, CIRCULATION, V99, P2852, DOI 10.1161/01.CIR.99.22.2852; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JANUZZI JL, 1992, GENOMICS, V14, P1081, DOI 10.1016/S0888-7543(05)80133-8; Jong MC, 1999, ARTERIOSCL THROM VAS, V19, P472, DOI 10.1161/01.ATV.19.3.472; KINNUNEN PKJ, 1976, FEBS LETT, V65, P354, DOI 10.1016/0014-5793(76)80145-7; Krauss RM, 1998, AM J CARDIOL, V81, p13B, DOI 10.1016/S0002-9149(98)00032-0; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; Lacorte JM, 1997, FEBS LETT, V415, P217, DOI 10.1016/S0014-5793(97)01127-7; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; LE NA, 1988, J LIPID RES, V29, P669; LEFF T, 1989, J BIOL CHEM, V264, P16132; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; LINLEE YC, 1993, J LIPID RES, V34, P249; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MALMENDIER CL, 1989, ATHEROSCLEROSIS, V77, P139, DOI 10.1016/0021-9150(89)90075-0; Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Matsui T, 1996, BIOCHEM BIOPH RES CO, V220, P405, DOI 10.1006/bbrc.1996.0418; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; OGAMI K, 1990, J BIOL CHEM, V265, P9808; QUARFORDT SH, 1982, J BIOL CHEM, V257, P4642; Raspe E, 1999, J LIPID RES, V40, P2099; Schaeren-Wiemers N, 1997, EUR J NEUROSCI, V9, P2687, DOI 10.1111/j.1460-9568.1997.tb01698.x; SCHONFELD G, 1979, METABOLISM, V28, P1001, DOI 10.1016/0026-0495(79)90004-0; Schoonjans K, 1999, FEBS LETT, V452, P160, DOI 10.1016/S0014-5793(99)00632-8; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; STOCKS J, 1979, LANCET, V2, P667; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; Talmud PJ, 1997, CURR OPIN LIPIDOL, V8, P154, DOI 10.1097/00041433-199706000-00005; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; Vu-Dac N, 1998, J CLIN INVEST, V102, P625, DOI 10.1172/JCI1581; VuDac N, 1997, J BIOL CHEM, V272, P22401, DOI 10.1074/jbc.272.36.22401; VUDAC N, 1994, J BIOL CHEM, V269, P31012; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WINDLER E, 1980, J BIOL CHEM, V255, P8303	69	106	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2865	2871		10.1074/jbc.M004982200	http://dx.doi.org/10.1074/jbc.M004982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053433	hybrid			2022-12-25	WOS:000166784800078
J	Krasel, C; Dammeier, S; Winstel, R; Brockmann, J; Mischak, H; Lohse, MJ				Krasel, C; Dammeier, S; Winstel, R; Brockmann, J; Mischak, H; Lohse, MJ			Phosphorylation of GRK2 by protein kinase C abolishes its inhibition by calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; LOCALIZATION; SUBSTRATE; RHODOPSIN; ISOZYMES; BINDING; DOMAIN; CELLS; RAF-1	G-protein-coupled receptor kinases (GRKs) are important regulators of G-protein-coupled receptor function. Two members of this family L, GRK2 and GRK5 L, have been shown to be substrates for protein kinase C (PKC). Whereas PRC-mediated phosphorylation results in inhibition of GRK5, it increases the activity of GRK2 toward its substrates probably through increased affinity for receptor-containing membranes. We show here that this increase in activity may be caused by relieving a tonic inhibition of GRK2 by calmodulin. In vitro, GRK2 was preferentially phosphorylated by PKC isoforms alpha, gamma, and delta, Two-dimensional peptide mapping of PHC alpha -phosphorylated GRK2 showed a single site of phosphorylation, which was identified as serine 29 by HPLC-MS. A S29A mutant of GRK2 was not phosphorylated by PKC in vitro and showed no phorbol ester-stimulated phosphorylation when transfected into human embryonic kidney (HEK)293 cells. Serine 29 is located in the calmodulinbinding region of GRK2, and binding of calmodulin to GRK2 results in inhibition of kinase activity. This inhibition was almost completely abolished in vitro when GRK2 was phosphorylated by PHC. These data suggest that calmodulin may be an inhibitor of GRK2 whose effects can be abolished with PKC-mediated phosphorylation of GRK2.	Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany; GSF, Forschungzentrum Umwelt & Gesundheit, Inst Klin Molkularbiol & Tumorgenet, D-81377 Munich, Germany; Med Hsch Hannover, Nephrol Abt, D-30526 Hannover, Germany	University of Wurzburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Hannover Medical School	Krasel, C (corresponding author), Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Mischak, Harald/E-8685-2011; Krasel, Cornelius/AAH-7074-2019; Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510; Mischak, Harald/0000-0003-0323-0306; Krasel, Cornelius/0000-0001-8309-8696				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; CULLEN B, 1987, METHOD ENZYMOL, V152, P687; Gan XQ, 2000, J BIOL CHEM, V275, P8469, DOI 10.1074/jbc.275.12.8469; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIM CM, 1993, RECEPTOR, V3, P39; KRASEL C, 1999, N-S ARCH PHARMACOL, V359, pR19; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Levay K, 1998, BIOCHEMISTRY-US, V37, P13650, DOI 10.1021/bi980998z; Lohse MJ, 1996, KIDNEY INT, V49, P1047, DOI 10.1038/ki.1996.153; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Mischak H, 1996, MOL CELL BIOL, V16, P5409; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; SOHLEMANN P, 1993, FEBS LETT, V324, P59, DOI 10.1016/0014-5793(93)81532-5; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; WINSTEL R, 1997, N-S ARCH PHARMACOL S, V355, pR50; Yu QM, 1999, J NEUROCHEM, V73, P1222, DOI 10.1046/j.1471-4159.1999.0731222.x	28	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1911	1915		10.1074/jbc.M008773200	http://dx.doi.org/10.1074/jbc.M008773200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042191	hybrid			2022-12-25	WOS:000166528000037
J	Pinnix, I; Musunuru, U; Tun, H; Sridharan, A; Golde, T; Eckman, C; Ziani-Cherif, C; Onstead, L; Sambamurti, K				Pinnix, I; Musunuru, U; Tun, H; Sridharan, A; Golde, T; Eckman, C; Ziani-Cherif, C; Onstead, L; Sambamurti, K			A novel gamma-secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; IN-VIVO; CARBOXYL-TERMINUS; ANCHORED PROTEINS; CLEAVAGE SITE; PRESENILIN-1; PEPTIDE; CELLS; GENERATION; PATHOGENESIS	Alzheimer's disease is characterized by the deposits of the 4-kDa amyloid beta peptide (A beta). The A beta protein precursor (APP) is cleaved by beta -secretase to, generate a C-terminal fragment, CTF beta, which in turn is cleaved by gamma -secretase to generate A beta. Alternative cleavage of the APP by alpha -secretase at A beta 16/17 generates the C-terminal fragment, CTF alpha. In addition to AP, endoproteolytic cleavage of CTF alpha and CTF beta by gamma -secretase should yield a C-terminal fragment of 57-59 residues (CTF gamma), However, CTF gamma has not yet been reported in either brain or cell lysates, presumably due to its instability in vivo. We detected the in vitro generation of A beta as well as an similar to6-kDa fragment from guinea pig brain membranes. We have provided biochemical and pharmacological evidence that this 6-kDa fragment is the elusive CTF gamma, and we describe an in vitro assay for gamma -secretase activity. The fragment migrates with a synthetic peptide corresponding to the 57-residue CTF gamma fragment. Three cornpounds previously identified as gamma -secretase inhibitors, pepstatin-Al MG132, and a substrate-based dlifluoroketone (t-butoxycarbonyl-Val-Ile-(S)-4-amino-3-difluoropentanoyl-Val-Ile-OMe), reduced the yield of CTF gamma, providing additional evidence that the fragment arises from gamma -secretase cleavage. Consistent with reports that presenilins are the elusive gamma -secretases, subcellular fractionation studies showed that presenilin-1, CTF alpha, and CTF beta are enriched in the CTF gamma -generating fractions. The in vitro gamma -secretase assay described here will be useful for the detailed characterization of the enzyme and to screen for gamma -secretase inhibitors.	Mayo Clin, Jacksonville, FL 32224 USA	Mayo Clinic	Sambamurti, K (corresponding author), Mayo Clin, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	samba@mayo.edu	ziani-cherif, chewki/P-1556-2016; Sambamurti, Kumar/A-1620-2012	ziani-cherif, chewki/0000-0001-5759-8275; Sambamurti, Kumar/0000-0001-9507-9214				ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BARRET A, 1998, HDB PROTEOLYTIC ENZY, P405; Berger-Sweeney J, 1999, MOL BRAIN RES, V66, P150, DOI 10.1016/S0169-328X(99)00014-5; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BROWN D, 1994, BRAZ J MED BIOL RES, V27, P309; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHECLER F, 1995, J NEUROCHEM, V65, P1431; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; DICE JF, 1992, ANN NY ACAD SCI, V674, P58, DOI 10.1111/j.1749-6632.1992.tb27477.x; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; GANDY S, 1994, NEUROBIOL AGING, V15, P253, DOI 10.1016/0197-4580(94)90125-2; GERVAIS FG, 1999, NEUROREPORT, V10, P1035; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Koike H, 1999, J BIOCHEM-TOKYO, V126, P235, DOI 10.1093/oxfordjournals.jbchem.a022428; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Parkin ET, 1999, BIOCHEM J, V344, P23, DOI 10.1042/0264-6021:3440023; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tjernberg LO, 1997, J BIOL CHEM, V272, P1870, DOI 10.1074/jbc.272.3.1870; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verdile G, 2000, J BIOL CHEM, V275, P20794, DOI 10.1074/jbc.C000208200; Waragai M, 1997, BIOCHEM BIOPH RES CO, V239, P480, DOI 10.1006/bbrc.1997.7488; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Younkin SG, 2000, J NEUROCHEM, V74, pS42; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	67	127	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					481	487		10.1074/jbc.M005968200	http://dx.doi.org/10.1074/jbc.M005968200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035007	hybrid			2022-12-25	WOS:000166280700065
J	Pomorski, T; Meyer, TF; Naumann, M				Pomorski, T; Meyer, TF; Naumann, M			Helicobacter pylori-induced prostaglandin E-2 synthesis involves activation of cytosolic phospholipase A(2) in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PROTEIN-KINASE-C; HUMAN NEUTROPHILS; BINDING PROTEIN; HUMAN PLATELETS; ALPHA-SUBUNIT; HELA-CELLS; KAPPA-B; INHIBITION; PHOSPHORYLATION	Helicobacter pylori initiates an inflammatory response and gastric diseases, which are more common in patients infected with H. pylori strains carrying the pathogenicity island, by colonizing the gastric epithelium, In the present study we investigated the mechanism of prostaglandin E-2 (PGE(2)) synthesis in response to H, pylori infection. We demonstrate that H. pylori induces the synthesis of PGE(2) via release of arachidonic acid predominately from phosphatidylinositol. In contrast to H. pylori wild type, an isogenic H. pylori strain with a mutation in the pathogenicity island exerts only weak arachidonic acid and PGE(2) synthesis. The H. pylori-induced arachidonic acid release was abolished by phospholipase A(2) (PLA(2)) inhibitors and by pertussis toxin (affects the activity of G alpha (i)/G alpha (o)), The role of phospholipase C, diacylglycerol lipase, or phospholipase D was excluded by using specific inhibitors. An inhibitor of the stress-activated p38 kinase (SB202190), but neither inhibitors of protein kinase C nor an inhibitor of the extracellular-regulated kinase pathway (PD98059), decreased the H. pylori-induced arachidonic acid release. H. pylori-induced phosphorylation of p38 kinase and cytosolic PLA(2) was blocked by SB202190, These results indicate that H. pylori induces the release of PGE(2) from epithelial cells by cytosolic PLA(2) activation via G alpha (i)/G alpha (o) proteins and the p38 kinase pathway.	Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany	Max Planck Society	Naumann, M (corresponding author), Max Planck Inst Infekt Biol, Mol Biol Abt, Schumannstr 21-22, D-10117 Berlin, Germany.		Pomorski, Thomas Günther/G-4804-2014; Meyer, Thomas F. F/J-2485-2013; Naumann, Michael/B-5285-2011	Pomorski, Thomas Günther/0000-0002-4889-0829; Meyer, Thomas F. F/0000-0002-6120-8679; Naumann, Michael/0000-0002-8060-2313				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BALSINDE J, 1991, J BIOL CHEM, V266, P15638; BLASER MJ, 1987, GASTROENTEROLOGY, V93, P371, DOI 10.1016/0016-5085(87)91028-6; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodger K, 1998, BRIT MED BULL, V54, P139; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; Burke JR, 1997, BBA-PROTEIN STRUCT M, V1341, P223, DOI 10.1016/S0167-4838(97)00085-X; Buschbeck M, 1999, BIOCHEM J, V344, P359, DOI 10.1042/0264-6021:3440359; Chan EC, 1999, INT J MOL MED, V3, P421; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; Eckmann L, 1997, J CLIN INVEST, V100, P296, DOI 10.1172/JCI119535; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; HII CST, 1989, FEBS LETT, V257, P35, DOI 10.1016/0014-5793(89)81779-X; HONG SL, 1981, J BIOL CHEM, V256, P5215; HUANG CF, 1990, J BIOL CHEM, V265, P14858; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Keates S, 1999, J IMMUNOL, V163, P5552; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; KOBAYASHI K., 1995, J CLIN GASTROENTE S1, V21, P12; LANGTON SR, 1992, J CLIN PATHOL, V45, P221, DOI 10.1136/jcp.45.3.221; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lin YL, 1998, FEBS LETT, V423, P249, DOI 10.1016/S0014-5793(98)00087-8; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; MURRAYWHELAN R, 1995, EUR J BIOCHEM, V230, P164, DOI 10.1111/j.1432-1033.1995.tb20547.x; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Nishio E, 1996, BIOCHEM BIOPH RES CO, V219, P277, DOI 10.1006/bbrc.1996.0223; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; OTTLECZ A, 1993, DIGEST DIS SCI, V38, P2071, DOI 10.1007/BF01297087; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PUCCIARELLI MG, 1995, FEMS MICROBIOL LETT, V129, P293, DOI 10.1016/0378-1097(95)00174-4; Romano M, 1998, J BIOL CHEM, V273, P28560, DOI 10.1074/jbc.273.44.28560; SAKURAI J, 1994, INFECT IMMUN, V62, P717, DOI 10.1128/IAI.62.2.717-721.1994; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Syrbu SI, 1999, J IMMUNOL, V162, P2334; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; VISHWANATH BS, 1988, INFLAMMATION, V12, P549, DOI 10.1007/BF00914317; Wakabayashi H, 1998, J GASTROEN HEPATOL, V13, P566, DOI 10.1111/j.1440-1746.1998.tb00691.x; WALLACE JL, 1995, ALIMENT PHARM THERAP, V9, P227; WEITKAMP JH, 1993, ZBL BAKT-INT J MED M, V280, P11; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; WINITZ S, 1994, J BIOL CHEM, V269, P1889; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	62	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					804	810		10.1074/jbc.M003819200	http://dx.doi.org/10.1074/jbc.M003819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11034994	hybrid, Green Published			2022-12-25	WOS:000166280700108
J	Saurin, AT; Martin, JL; Heads, RJ; Foley, C; Mockridge, JW; Wright, MJ; Wang, YB; Marber, MS				Saurin, AT; Martin, JL; Heads, RJ; Foley, C; Mockridge, JW; Wright, MJ; Wang, YB; Marber, MS			The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes	FASEB JOURNAL			English	Article						myocardial ischemia; cardioprotection; ischemic preconditioning; cytoprotection	N-TERMINAL KINASES; ISOLATED RABBIT CARDIOMYOCYTES; IN-VITRO MODEL; P38 MAP KINASE; CARDIAC MYOCYTES; ISCHEMIC MYOCARDIUM; SIMULATED ISCHEMIA; STRESS PROTEINS; A(3) RECEPTOR; RAT-HEART	Activation of protein kinase C (PKC) and more recently mitogen-activated protein kinases (MAPKs) have been associated with the cardioprotective effect of ischemic preconditioning. We examined the interplay between these kinases in a characterized model of ischemic preconditioning in cultured rat neonatal ventricular cardiocytes where ectopic expression of active PKC-delta results in protection. Two members of the MAPK family, p38 and p42/44, were activated transiently during preconditioning by brief simulated ischemia/reoxygenation. Overexpression of active PKC-delta, rather than augmenting, completely abolished this activation. We therefore determined whether a similar process occurred during lethal prolonged simulated ischemia. In contrast to ischemia, brief, lethal-simulated ischemia activated only p38 (2.8+/-0.45 vs, basal, P<0.01), which was attenuated by expression of active PKC-<delta> or by preconditioning (0.48+/-0.1 vs. ischemia, P<0.01). To determine whether reduced p38 activation was the cause or an effect of protection, we used SB203580, a p38 inhibitor. SB203580 reduced ischemic injury (CK release 38.0+/-3.1%, LDH release 77.3+/-4.0%, and MTT bioreduction 127.1+/-4.8% of control, n=20, P<0.05). To determine whether p38 activation was isoform selective, myocytes were infected with adenoviruses encoding wild-type p38 alpha or p38 beta. Transfected p38 alpha and beta show differential activation (P<0.001) during sustained simulated ischemia, with p38<alpha> remaining activated (1.48+/-0.36 vs, basal) but p38 beta deactivated (0.36+/-0.1 vs, basal, P<0.01). Prior preconditioning prevented the activation of p38<alpha> (0.65+/-0.11 vs. ischemia, P<0.05). Moreover, cells expressing a dominant negative p38<alpha>, which prevented ischemic p38 activation, were resistant to lethal. simulated ischemia (CK release 82.9+/-3.9% and MTT bioreduction 130.2+/-6.5% of control, n=8, P<0.05). Thus, inhibition of p38<alpha> activation during ischemia reduces injury and may contribute to preconditioning-induced cardioprotection in this model.	St Thomas Hosp, Rayne Inst, Dept Cardiol, KCL, London SE1 7EH, England; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University System of Maryland; University of Maryland Baltimore	Marber, MS (corresponding author), St Thomas Hosp, Rayne Inst, Dept Cardiol, KCL, London SE1 7EH, England.		marber, michael/AAW-7916-2021	Saurin, Adrian/0000-0001-9317-2255; Marber, Michael/0000-0002-3463-7128; Wright, Matthew/0000-0002-0541-7556; Wang, Yibin/0000-0003-0852-0767				ARMSTRONG S, 1994, CARDIOVASC RES, V28, P1049, DOI 10.1093/cvr/28.7.1049; ARMSTRONG S, 1994, CARDIOVASC RES, V28, P72, DOI 10.1093/cvr/28.1.72; Armstrong SC, 1999, J MOL CELL CARDIOL, V31, P555, DOI 10.1006/jmcc.1998.0891; Arstall MA, 1998, J MOL CELL CARDIOL, V30, P1019, DOI 10.1006/jmcc.1998.0666; Barancik M, 2000, J CARDIOVASC PHARM, V35, P474, DOI 10.1097/00005344-200003000-00019; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; COHEN MV, 1994, CIRC RES, V74, P998, DOI 10.1161/01.RES.74.5.998; Cumming DVE, 1996, J MOL CELL CARDIOL, V28, P2343, DOI 10.1006/jmcc.1996.0227; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GOTO M, 1995, CIRC RES, V77, P611, DOI 10.1161/01.RES.77.3.611; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Hart SL, 1998, HUM GENE THER, V9, P575, DOI 10.1089/hum.1998.9.4-575; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; IKONOMIDIS JS, 1994, CARDIOVASC RES, V28, P1285, DOI 10.1093/cvr/28.8.1285; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kitakaze M, 1996, CIRCULATION, V93, P781, DOI 10.1161/01.CIR.93.4.781; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lasley RD, 1997, J MOL CELL CARDIOL, V29, P3345, DOI 10.1006/jmcc.1997.0559; Liang BT, 1999, CIRC RES, V84, P1396; Liu Y, 1996, BASIC RES CARDIOL, V91, P450, DOI 10.1007/BF00788726; LIU YG, 1995, J MOL CELL CARDIOL, V27, P883, DOI 10.1016/0022-2828(95)90038-1; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Marber MS, 2000, CIRC RES, V86, P926, DOI 10.1161/01.RES.86.9.926; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; Maulik N, 1998, AM J PHYSIOL-HEART C, V275, pH1857, DOI 10.1152/ajpheart.1998.275.5.H1857; MITCHELL MB, 1995, CIRC RES, V76, P73, DOI 10.1161/01.RES.76.1.73; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nagarkatti DS, 1998, J MOL CELL CARDIOL, V30, P1651, DOI 10.1006/jmcc.1998.0733; Nakano A, 2000, CIRC RES, V86, P144, DOI 10.1161/01.RES.86.2.144; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ovelgonne JH, 1996, J MOL CELL CARDIOL, V28, P1617, DOI 10.1006/jmcc.1996.0152; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; SCHULTZ JEJ, 1995, AM J PHYSIOL-HEART C, V268, pH2157, DOI 10.1152/ajpheart.1995.268.5.H2157; Shirai T, 1998, J THORAC CARDIOV SUR, V115, P210, DOI 10.1016/S0022-5223(98)70459-3; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; TSUCHIDA A, 1994, CIRC RES, V75, P576, DOI 10.1161/01.RES.75.3.576; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VANWINKLE DM, 1999, CORONARY HEART DIS, V2, P613; WALSH RS, 1994, CARDIOVASC RES, V28, P1337, DOI 10.1093/cvr/28.9.1337; Wang PP, 1996, J MOL CELL CARDIOL, V28, P579, DOI 10.1006/jmcc.1996.0054; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WEBSTER KA, 1995, J MOL CELL CARDIOL, V27, P453, DOI 10.1016/S0022-2828(08)80041-7; Weinbrenner C, 1997, J MOL CELL CARDIOL, V29, P2383, DOI 10.1006/jmcc.1997.0473; Wu S, 1999, CIRC RES, V84, P1388; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; Zhao J, 1998, J BIOL CHEM, V273, P23072, DOI 10.1074/jbc.273.36.23072	58	135	137	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2237	2246		10.1096/fj.99-0671com	http://dx.doi.org/10.1096/fj.99-0671com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053245				2022-12-25	WOS:000165190800017
J	Vannucchi, S; Percario, ZA; Chiantore, MV; Matarrese, P; Chelbi-Alix, MK; Fagioli, M; Pelicci, PG; Malorni, W; Fiorucci, G; Romeo, G; Affabris, E				Vannucchi, S; Percario, ZA; Chiantore, MV; Matarrese, P; Chelbi-Alix, MK; Fagioli, M; Pelicci, PG; Malorni, W; Fiorucci, G; Romeo, G; Affabris, E			Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells	ONCOGENE			English	Article						interferon; all-trans retinoic acid; PML; cell cycle; squamous carcinoma cells	PROMYELOCYTIC LEUKEMIA PROTEIN; PRIMARY BILIARY-CIRRHOSIS; CREB BINDING-PROTEIN; LARGE T-ANTIGEN; RETINOIC ACID; NUCLEAR-BODIES; GROWTH-SUPPRESSOR; CDK-INHIBITOR; APL CELLS; TRANSCRIPTIONAL ACTIVATION	Type I Interferon (IFN) and all-trans retinoic acid (RA) inhibit cell proliferation of squamous carcinoma cell Lines (SCC), Examinations of growth-affected cell populations show that SCC lines ME-180 and SiHa treated with IFN-beta undergo a specific slower progression through the S phase that seems to trigger cellular death. In combination treatment RA potentiates IFN-beta effect in SCC ME-180 but not in SiHa cell line, partially resistant to RA antiproliferative action. RA added as single agent affects cell proliferation differently by inducing a slight GI accumulation. The IFN-beta-induced S phase lengthening parallels the increased expression of PML, a nuclear phosphoprotein specifically up-regulated at transcriptional level by IFN, whose overexpression induces cell growth inhibition and tumor suppression. We report that PML up-regulation may account for the alteration of cell cycle progression induced by IFN-beta in SCC by infecting cells with PML-PINCO recombinant retrovirus carrying the PML3 cDNA under the control of the 5' LTR. In fact PML overexpression reproduces the IFN-beta-induced S phase lengthening, These findings provide important insight into the mechanism of tumor suppressing function of PML and could allow PML to be included in the pathways responsible for IFN-induced cell growth suppression.	Univ Roma 3, Dept Biol, I-00146 Rome, Italy; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Ist Super Sanita, Lab Ultrastruct, I-00161 Rome, Italy; Hop St Louis, CNRS, UPR 9051, F-75010 Paris, France; Univ Perugia, Monteluce Policlin, I-06100 Perugia, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; CNR, Ist Tecnol Biomed, Rome, Italy	Roma Tre University; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of Perugia; IRCCS European Institute of Oncology (IEO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Affabris, E (corresponding author), Univ Roma 3, Dept Biol, Viale G Marconi 446, I-00146 Rome, Italy.		Malorni, Walter/G-5874-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Fiorucci, Gianna/B-3064-2013; Matarrese, Paola/A-4369-2014; CHIANTORE, MARIA VINCENZA/C-2948-2016; Romeo, Giovanna/AAB-2613-2019; romeo, giovanna/P-8348-2015	CHIANTORE, MARIA VINCENZA/0000-0001-5163-2698; romeo, giovanna/0000-0002-7638-1001; AFFABRIS, Elisabetta/0000-0001-5142-8144; malorni, walter/0000-0002-1223-7000; matarrese, paola/0000-0001-5477-3752				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; DANIEL MT, 1993, BLOOD, V82, P1858; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dyson N, 1999, CURR OPIN GENET DEV, V9, P11, DOI 10.1016/S0959-437X(99)80002-1; Everett RD, 1999, J CELL SCI, V112, P4581; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Giandomenico V, 1998, EUR CYTOKINE NETW, V9, P619; Giandomenico V, 1997, CELL GROWTH DIFFER, V8, P91; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Grignani F, 1998, CANCER RES, V58, P14; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hara E, 1996, MOL CELL BIOL, V16, P859; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Kalemkerian G. P., 1996, APOPTOSIS, V1, P11; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LANCILLOTTI F, 1995, CANCER RES, V55, P3158; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lippman SM, 1997, INT J CANCER, V70, P481, DOI 10.1002/(SICI)1097-0215(19970207)70:4<481::AID-IJC20>3.0.CO;2-H; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; Matarrese P, 1998, INT J CANCER, V76, P531, DOI 10.1002/(SICI)1097-0215(19980518)76:4<531::AID-IJC15>3.0.CO;2-A; Matsuoka M, 1998, ONCOGENE, V16, P2075, DOI 10.1038/sj.onc.1201745; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Qin XQ, 1997, J INTERF CYTOK RES, V17, P355, DOI 10.1089/jir.1997.17.355; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; ROMEO G, 1996, RETINOIDS TODAY TOMO, V45, P32; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Subramaniam PS, 1998, ONCOGENE, V16, P1885, DOI 10.1038/sj.onc.1201712; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1	64	25	27	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5041	5053		10.1038/sj.onc.1203883	http://dx.doi.org/10.1038/sj.onc.1203883			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042692	Green Published			2022-12-25	WOS:000089930100001
J	Hannan, KM; Hannan, RD; Smith, SD; Jefferson, LS; Lun, MY; Rothblum, LI				Hannan, KM; Hannan, RD; Smith, SD; Jefferson, LS; Lun, MY; Rothblum, LI			Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1	ONCOGENE			English	Article						retinoblastoma protein; ribosomal RNA; transcription; UBF; DNA-binding	RIBOSOMAL DNA-TRANSCRIPTION; RETINOBLASTOMA SUSCEPTIBILITY GENE; TATA-BINDING PROTEIN; III TRANSCRIPTION; CELL-CYCLE; MOLECULAR-CLONING; NEONATAL CARDIOMYOCYTES; LUNG-CANCER; MOUSE P130; P107	We have previously demonstrated that the protein encoded by the retinoblastoma susceptibility gene (Rb) functions as a regulator of transcription by RNA polymerase I (rDNA transcription) by inhibiting UBF-mediated transcription. In the present study, we have examined the mechanism by which Rb represses UBF-dependent rDNA transcription and determined if other Rb-like proteins have similar effects. We demonstrate that authentic or recombinant UBF and Rb interact directly and this requires a functional A/B pocket. DNase footprinting and band-shift assays demonstrated that the interaction between Rb and UBF does not inhibit the binding of UBF to DNA, However, the formation of an UBF/Rb complex does block the interaction of UBF with SL-1, as indicated by using the 48 kDa subunit as a marker for SL-1, Additional evidence is presented that another pocket protein, p130 but not p107, can be found in a complex with UBF, Interestingly, the cellular content of p130 inversely correlated with the rate of rDNA transcription in two physiological systems, and overexpression of p130 inhibited rDNA transcription. These results suggest that p130 may regulate rDNA transcription in a similar manner to Rb.	Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Rothblum, LI (corresponding author), Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.			Hannan, Ross/0000-0002-2166-4493; Hannan, Katherine/0000-0003-4186-8167	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15658] Funding Source: Medline; NIGMS NIH HHS [GM48991] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BIGNON YJ, 1990, CELL GROWTH DIFFER, V1, P647; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; Chen G, 1996, J BIOL CHEM, V271, P9567, DOI 10.1074/jbc.271.16.9567; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; Farshid M, 1994, J Viral Hepat, V1, P45, DOI 10.1111/j.1365-2893.1994.tb00061.x; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 1998, AM J PHYSIOL-CELL PH, V275, pC130, DOI 10.1152/ajpcell.1998.275.1.C130; Hannan R, 1999, NUCLEIC ACIDS RES, V27, P1205, DOI 10.1093/nar/27.4.1205; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; Hannan RD, 1996, P NATL ACAD SCI USA, V93, P8750, DOI 10.1073/pnas.93.16.8750; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Hempel WM, 1996, MOL CELL BIOL, V16, P557; HENSEL CH, 1990, CANCER RES, V50, P3067; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P4631, DOI 10.1093/nar/19.17.4631; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LeCouter JE, 1996, ONCOGENE, V12, P1433; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LIU Y, 1994, INT J CANCER, V58, P663, DOI 10.1002/ijc.2910580508; MCSTAY B, 1991, GENE DEV, V5, P1957, DOI 10.1101/gad.5.11.1957; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; PIKAARD CS, 1990, MOL CELL BIOL, V10, P3810, DOI 10.1128/MCB.10.7.3810; PUTNAM CD, 1992, MOL CELL BIOL, V12, P4970, DOI 10.1128/MCB.12.11.4970; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; XIE WQ, 1992, NUCLEIC ACIDS RES, V20, P1587, DOI 10.1093/nar/20.7.1587	64	105	106	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4988	4999		10.1038/sj.onc.1203875	http://dx.doi.org/10.1038/sj.onc.1203875			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042686				2022-12-25	WOS:000089834300006
J	Ball, SG; Baldock, C; Kielty, CM; Shuttleworth, CA				Ball, SG; Baldock, C; Kielty, CM; Shuttleworth, CA			The role of the C1 and C2 A-domains in type VI collagen assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; ALPHA-2(VI) CHAINS; CRYSTAL-STRUCTURE; GLOBULAR DOMAINS; PROTEIN VARIANTS; MESSENGER-RNA; PROCOLLAGEN; EXPRESSION; SEQUENCE; ALPHA-1(VI)	Constructs of each of the three chains of type VI collagen were generated and examined in an in vitro transcription/translation assay supplemented with semipermeabilized cells. Each of the constructs when used in the in vitro system was shown to be glycosylated and to undergo intracellular assembly, the extent of which was determined by the nature of the C-terminal globular domains. All three chains containing the C1 domain formed monomers; however, the C2 domain was required for dimer and tetramer formation. In the case of the full-length alpha2(VI) chain, monomers, dimers, and tetramers formed in a time-dependent manner. Although the splice variant alpha2(VI)C2a could form monomers, it was unable-to form dimers and tetramers. Similar results to the alpha2(VI) chain were found for the full-length alpha1(VI) chain, although assembly was at a slower rate. In the case: of the alpha3(VI) chain containing both C1 and C2 domains only monomers were observed. Addition of the C3, C4, and C5 did not change this pattern. Homology modeling suggested that a 10-amino acid insertion in the C2 domain of the alpha3(VI) chain may interfere with dimer formation. A near full-length construct of the alpha3(VI) chain only formed monomers but was shown to facilitate tetramer formation in cotranslation experiments.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Shuttleworth, CA (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford,Oxford Rd, Manchester M13 9PT, Lancs, England.	ashuttle@fs1.scg.man.ac.uk		Baldock, Clair/0000-0003-3497-1959				AYAD S, 1989, BIOCHEM J, V262, P753, DOI 10.1042/bj2620753; BIENKOWSKI RS, 1995, P SOC EXP BIOL MED, V209, P118; BONALDO P, 1990, MATRIX, V10, P139, DOI 10.1016/S0934-8832(11)80162-9; Bulleid NJ, 1996, SEMIN CELL DEV BIOL, V7, P667, DOI 10.1006/scdb.1996.0081; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; CARTER WG, 1984, J CELL BIOL, V99, P105, DOI 10.1083/jcb.99.1.105; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COLOMBATTI A, 1992, EUR J BIOCHEM, V209, P785, DOI 10.1111/j.1432-1033.1992.tb17349.x; COLOMBATTI A, 1995, J BIOL CHEM, V270, P13105, DOI 10.1074/jbc.270.22.13105; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CRAWFORD SW, 1985, BIOCHEM J, V227, P491, DOI 10.1042/bj2270491; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Illidge C, 1998, J BIOL CHEM, V273, P22091, DOI 10.1074/jbc.273.34.22091; JANDER R, 1983, EUR J BIOCHEM, V133, P39, DOI 10.1111/j.1432-1033.1983.tb07427.x; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; KUO WW, 1979, J BIOL CHEM, V254, P2234; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamande SR, 1998, J BIOL CHEM, V273, P7423, DOI 10.1074/jbc.273.13.7423; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Rost B, 1996, METHOD ENZYMOL, V266, P525; SAITTA B, 1990, J BIOL CHEM, V265, P6473; STOKES DG, 1991, J BIOL CHEM, V266, P8626; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; TRUEB B, 1987, EUR J BIOCHEM, V166, P699, DOI 10.1111/j.1432-1033.1987.tb13568.x; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; ZANUSSI S, 1992, J BIOL CHEM, V267, P24082	32	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7422	7430		10.1074/jbc.M002816200	http://dx.doi.org/10.1074/jbc.M002816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11036066	hybrid			2022-12-25	WOS:000167442900078
J	Fridman, JS; Parsels, J; Rehemtulla, A; Maybaum, J				Fridman, JS; Parsels, J; Rehemtulla, A; Maybaum, J			Cytochrome c depletion upon expression of Bcl-XS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED-PROXIMITY MODEL; FAS-MEDIATED APOPTOSIS; PROGRAMMED CELL-DEATH; ISOLATED-MITOCHONDRIA; CASPASE ACTIVATION; BAX; BCL-X(L); PROTEINS; RELEASE; CHEMILUMINESCENCE	We have shown previously that Bcl-XS causes acute cell death in 3T3 cells without activating caspases (Fridman, J. S,, Benedict, M. k, and Maybaum, J. (1999) Cancer Res. 59, 5999-6004). In this study, we determined that the explanation for lack of caspase activation is the cellular depletion of cytochrome c. Electron microscopy revealed gross structural changes in the mitochondria of Bcl-XS-expressing cells; however, cytochrome c was not detected in cytosolic fractions from these cells. Surprisingly, it was determined that cellular cytochrome c levels decreased as Bcl-XS expression levels increased. Experiments performed to eliminate other possible explanations for the lack of caspase activation showed that these 3T3 cells have a functional cytoplasmic apoptosome, a complex of proteins that form a functional trigger capable of activating the proximal caspase in an apoptotic pathway Chinnaiyan, k M. (1999) Neoplasia 1, 5-15, as cytosolic extracts from these cells were capable of cleaving pro-caspase-9. These cells were also able to release cytochrome c from their mitochondria after appropriate stimulation, other than Bcl-XS expression (i.e. withdrawal from serum for 24 h), and initiate a cell death that is inhibited by a dominant negative caspase-9. We conclude that lack of caspase activation is due to a Bcl-XS-induced depletion of active cytochrome c, a phenomenon that represents an alternative cell death effector pathway and/or a novel mechanism for regulating caspase activation.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Maybaum, J (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.	maybaum@umich.edu			NATIONAL CANCER INSTITUTE [R01CA056663] Funding Source: NIH RePORTER; NCI NIH HHS [CA56663] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; BOYD JM, 1995, ONCOGENE, V11, P1921; Chinnaiyan Arul M., 1999, Neoplasia (New York), V1, P5; DORWARD DW, 1993, ANAL BIOCHEM, V209, P219, DOI 10.1006/abio.1993.1110; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fridman JS, 1999, CANCER RES, V59, P5999; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Munn EA, 1974, STRUCTURE MITOCHONDR; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SeminoMora C, 1997, LAB INVEST, V76, P487; SHEWACH DS, 1994, CANCER RES, V54, P3218; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	30	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4205	4210		10.1074/jbc.M008171200	http://dx.doi.org/10.1074/jbc.M008171200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11044452	hybrid			2022-12-25	WOS:000166921200064
J	Tchougounova, E; Forsberg, F; Angelborg, G; Kjellen, L; Pejler, G				Tchougounova, E; Forsberg, F; Angelborg, G; Kjellen, L; Pejler, G			Altered processing of fibronectin in mice lacking heparin - A role for heparin-dependent mast cell chymase in fibronectin degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULE PROTEASES; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; SERINE PROTEASES; CATHEPSIN-G; IN-VIVO; MOUSE; RAT; PROTEOGLYCAN	We have previously generated a mouse strain with a defect in its heparin biosynthesis by targeting the gene for N-deacetylase/N-sulfotransferase-2 (NDST-2). The NDST-2(-/-) mice show reduced levels of various mast cell mediators such as histamine and various heparin-binding mast cell proteases, including chymases, tryptases, and carboxypeptidase A In this work we have addressed the possible functional consequences of the lack of sulfated heparin. Peritoneal cells were harvested from normal and NDST-2(-/-) mice. After culturing the cells, conditioned media were collected and were subjected to SDS-polyacrylamide gel electrophoresis under reducing conditions. Several differences in the protein patterns were observed, including the presence of large amounts of a similar to 250-kDa protein in medium from NDST-2(-/-) mice that was absent in normal controls. Peptide microsequencing revealed identity of this protein with fibronectin. Western blot analysis showed the presence of fibronectin degradation products in cell cultures from normal mice, which were absent in cultures from NDST-2(-/-) animals. Further experiments showed that the degradation of fibronectin observed in cell cultures hom NDST-2(+/+) mice was catalyzed by mast cell chymase in a strongly heparin-dependent manner. This report thus indicates a biological function for chymase/heparin proteoglycan complexes in fibronectin turnover.	Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, S-75123 Uppsala, Sweden; Uppsala Univ, Dept Med Biochem & Microbiol, S-75124 Uppsala, Sweden	Swedish University of Agricultural Sciences; Uppsala University	Pejler, G (corresponding author), Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, Box 575, S-75123 Uppsala, Sweden.		Kjellen, Lena/F-1362-2011					ALITALO K, 1980, J EXP MED, V151, P602, DOI 10.1084/jem.151.3.602; BANOVAC K, 1993, P SOC EXP BIOL MED, V203, P221; Compton SJ, 1999, INT ARCH ALLERGY IMM, V118, P204, DOI 10.1159/000024068; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GERVASONI JE, 1986, J IMMUNOL, V136, P285; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; He SH, 1997, J IMMUNOL, V159, P6216; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; He SH, 1998, EUR J PHARMACOL, V352, P91, DOI 10.1016/S0014-2999(98)00343-4; Homandberg Gene A., 1999, Frontiers in Bioscience, V4, pd713, DOI 10.2741/Homandberg; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Hynes RO, 1990, FIBRONECTINS SPRINGE; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; Kofford MW, 1997, J BIOL CHEM, V272, P7127, DOI 10.1074/jbc.272.11.7127; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Lindstedt L, 1996, J CLIN INVEST, V97, P2174, DOI 10.1172/JCI118658; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MAIER M, 1983, J IMMUNOL, V130, P2352; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; Molinari JF, 1995, J APPL PHYSIOL, V79, P1966, DOI 10.1152/jappl.1995.79.6.1966; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nakano A, 1997, J IMMUNOL, V159, P1987; PEJIER G, 1994, J BIOL CHEM, V269, P14451; Pejler G, 1999, BIOCHEMISTRY-US, V38, P12187, DOI 10.1021/bi991046b; PEJLER G, 1995, EUR J BIOCHEM, V233, P192, DOI 10.1111/j.1432-1033.1995.192_1.x; PEJLER G, 1993, J BIOL CHEM, V268, P11817; PEJLER G, 1994, BIOCHEM J, V299, P507, DOI 10.1042/bj2990507; Pejler G, 1996, FEBS LETT, V383, P170, DOI 10.1016/0014-5793(96)00239-6; REILLY CF, 1985, BIOCHEM BIOPH RES CO, V127, P443, DOI 10.1016/S0006-291X(85)80180-7; REILLY CF, 1982, J BIOL CHEM, V257, P8619; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; STERK AR, 1982, J IMMUNOL, V128, P838; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; SUZUKI K, 1995, BIOCHEM J, V305, P301, DOI 10.1042/bj3050301; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; VARTIO T, 1981, J BIOL CHEM, V256, P471; WACHTFOGEL YT, 1988, J CLIN INVEST, V81, P1310, DOI 10.1172/JCI113456; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; XIE DL, 1993, BLOOD, V81, P186	52	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3772	3777		10.1074/jbc.M008434200	http://dx.doi.org/10.1074/jbc.M008434200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11035040	hybrid			2022-12-25	WOS:000166921200008
J	Murayama, T; Ogawa, Y				Murayama, T; Ogawa, Y			Selectively suppressed Ca2+-induced Ca2+ release activity of alpha-ryanodine receptor (alpha-RyR) in frog skeletal muscle sarcoplasmic reticulum - Potential distinct modes in Ca2+ release between alpha- and beta-RyR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN ISOFORMS; CALCIUM-RELEASE; CHANNELS; PURIFICATION; CONTRACTION; RABBIT; RECONSTITUTION; ACID	We reported earlier that the two ryanodine receptor (RyR) isoforms (alpha- and beta -RyR) purified from frog skeletal muscle were equipotent in the Ca2+-induced Ca2+ release (CICR) activity (Murayama, T., Kurebayashi, N., and Ogawa, Y. (2000) Biophys. J. 78, 1810-1824), Whether this is also the case with the native Ca2+ release channel in the sarcoplasmic reticulum (SR), however, remains to be determined. Taking advantage of the facts that [SH]ryanodine binds only to the open form of the channels and that it is practically irreversible at 4 degreesC, we devised a method to separate the total binding to contributions of alpha- and beta -RyR, using immunoprecipitation with an alpha -RyR-specific monoclonal antibody. Surprisingly, the binding of alpha -RyR was strongly suppressed to as low as similar to4% that of beta -RyR in the SR vesicles. The two isoforms, however, showed no difference in sensitivity to Ca2+, adenine nucleotides, or caffeine. This reduced binding of alpha -RyR was ascribed to the low affinity for [3H]ryanodine, with no change in the maximal binding sites. Solubilization of SR with 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonic acid partly remedied this nonequivalence, whereas 1 M NaCl was ineffective. 12-kDa FK506-binding protein (FKBP12), however, could not be responsible for it, because FK506 treatment did not eliminate the suppression, in contrast to marked removal of 12-kDa FK506-binding protein from alpha -RyR. These results suggest that alpha -RyR in the SR may serve Ca2+ release in a mode other than CICR, being selectively suppressed in CICR.	Juntendo Univ, Sch Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Ogawa, Y (corresponding author), Juntendo Univ, Sch Med, Dept Pharmacol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ysogawa@med.juntendo.ac.jp						AIREY JA, 1993, DEV DYNAM, V197, P169, DOI 10.1002/aja.1001970303; Barg S, 1997, AM J PHYSIOL-CELL PH, V272, pC1726, DOI 10.1152/ajpcell.1997.272.5.C1726; Bertocchini F, 1997, EMBO J, V16, P6956, DOI 10.1093/emboj/16.23.6956; BULL R, 1993, FEBS LETT, V331, P223, DOI 10.1016/0014-5793(93)80341-Q; Conklin MW, 1999, BIOPHYS J, V77, P1394, DOI 10.1016/S0006-3495(99)76988-2; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; Copello JA, 1999, BIOPHYS J, V76, pA469; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; KISHIRO Y, 1995, CELL STRUCT FUNCT, V20, P151, DOI 10.1247/csf.20.151; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Murayama T, 1997, J BIOL CHEM, V272, P24030, DOI 10.1074/jbc.272.38.24030; Murayama T, 1996, FEBS LETT, V380, P267, DOI 10.1016/0014-5793(96)00053-1; Murayama T, 2000, BIOPHYS J, V78, P1810, DOI 10.1016/S0006-3495(00)76731-2; Murayama T, 1996, J BIOL CHEM, V271, P5079; MURAYAMA T, 1993, BIOMED RES-TOKYO, V14, P71; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; Oba T, 1997, AM J PHYSIOL-CELL PH, V273, pC1588, DOI 10.1152/ajpcell.1997.273.5.C1588; Ogawa Y, 1999, MOL CELL BIOCHEM, V190, P191, DOI 10.1023/A:1006903401123; OGAWA Y, 1990, J BIOCHEM-TOKYO, V107, P887, DOI 10.1093/oxfordjournals.jbchem.a123143; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065-227X(99)80004-5; OGAWA Y, 1990, J BIOCHEM-TOKYO, V107, P894, DOI 10.1093/oxfordjournals.jbchem.a123144; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; Shirokova N, 1999, J PHYSIOL-LONDON, V521, P483, DOI 10.1111/j.1469-7793.1999.00483.x; Shirokova N, 1998, J PHYSIOL-LONDON, V512, P377, DOI 10.1111/j.1469-7793.1998.377be.x; SUDA N, 1995, J PHYSIOL-LONDON, V486, P105, DOI 10.1113/jphysiol.1995.sp020794; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; Wagenknecht T, 1997, CURR OPIN STRUC BIOL, V7, P258, DOI 10.1016/S0959-440X(97)80034-6; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3	42	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2953	2960		10.1074/jbc.M005809200	http://dx.doi.org/10.1074/jbc.M005809200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11054412	hybrid			2022-12-25	WOS:000166784800088
J	Trigueros, S; Roca, J				Trigueros, S; Roca, J			Circular minichromosomes become highly recombinogenic in topoisomerase-deficient yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; S-CEREVISIAE; CAMPTOTHECIN; SEGREGATION; REPLICATION; CHROMOSOMES; MUTATION; SEQUENCE	In topoisomerase-deficient yeast cells, we have found that circular minichromosomes are present as broad distributions of multimeric forms, which consist of tandemly repeated copies of their monomeric sequences. This phenomenon selectively occurs in Delta top1 cells, and is highly magnified in double mutant Delta top1 top2-4 cells, No multimers are observed in single mutant top2-4 or Delta top3 cells, or in Delta top1 cells that express a plasmid-borne TOPI gene. Interconversion among multimeric forms takes place rapidly in double mutant Delta top1 top2-4 cells, and the multimeric distributions are readily reverted to the monomeric form when a plasmid-borne TOPI gene is expressed from an inducible promoter. These observations are a new example of the interplay between DNA topology and genome stability, and suggest that the cell capacity to modulate DNA supercoiling is limited when DNA is organized in small topological domains. Yeast minichromosome multimerization provides an appropriate system in which to study mechanistic aspects of DNA recombination.	CSIC, IBMB, Barcelona 08034, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Roca, J (corresponding author), CSIC, IBMB, Jordi Girona 18-26, Barcelona 08034, Spain.	jrbbmc@cid.csic.es	Roca, Joaquim/AAP-1077-2020; Trigueros, Sonia/O-7358-2014	Roca, Joaquim/0000-0003-1462-954X; Trigueros, Sonia/0000-0001-5621-7303				BENEDETTI P, 1993, CANCER RES, V53, P4343; BJORNSTI MA, 1989, CANCER RES, V49, P6318; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; FISHEL RA, 1981, NATURE, V294, P184, DOI 10.1038/294184a0; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; GIAEVER G, 1986, J BIOL CHEM, V261, P2448; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; HARASHIMA S, 1989, MOL GEN GENET, V219, P495, DOI 10.1007/BF00259627; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAMES AA, 1982, J MOL BIOL, V160, P411, DOI 10.1016/0022-2836(82)90305-9; KIM RA, 1995, P NATL ACAD SCI USA, V92, P2667, DOI 10.1073/pnas.92.7.2667; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; KIM RA, 1992, J BIOL CHEM, V267, P17178; KOLODNER R, 1980, P NATL ACAD SCI-BIOL, V77, P4847, DOI 10.1073/pnas.77.8.4847; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1981, NUCLEIC ACIDS RES, V9, P3979, DOI 10.1093/nar/9.16.3979; OTTER H, 1977, P NATL ACAD SCI USA, V74, P4168; ROCA J, 1992, NUCLEIC ACIDS RES, V20, P4671, DOI 10.1093/nar/20.17.4671; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAAVEDRA RA, 1986, CELL, V45, P65, DOI 10.1016/0092-8674(86)90538-6; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherman F., 1983, METHODS YEAST GENETI; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	34	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2243	2248		10.1074/jbc.M008930200	http://dx.doi.org/10.1074/jbc.M008930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11054426	Green Submitted, hybrid			2022-12-25	WOS:000166528000079
J	Koh, SS; Chen, DG; Lee, YH; Stallcup, MR				Koh, SS; Chen, DG; Lee, YH; Stallcup, MR			Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE N-METHYLTRANSFERASE; STEROID-HORMONE RECEPTORS; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; ANDROGEN RECEPTOR; TERMINAL DOMAIN; BINDING; MULTIPLE; TRANSACTIVATION	Nuclear receptors (NRs) activate gene transcription by binding to specific enhancer elements and recruiting coactivators of the p160 family to promoters of target genes. The p160 coactivators in turn enhance transcription by recruiting secondary coactivators, including histone acetyltransferases such as CREB-binding protein (CBP) and p300/CBP-associated factor (p/CAF), as well as the recently identified protein methyltransferase, coactivator-associated arginine methyltransferase 1 (CARM1), In the current study, protein arginine methyltransferase 1 (PRMT1), another arginine-specific protein methyltransferase that shares a region of high homology with CARM1, was also found to act as a coactivator for NRs, PRMT1, like CARM1, bound to the C-terminal AD2 activation domain of p160 coactivators and thereby enhanced the activity of NRs in transient transfection assays. The shape of the graphs of reporter gene activity versus the amounts of CARM1 or PRMT1 expression vector indicated a cooperative relationship between coactivator concentration and activity. Moreover, CARM1 and PRMT1 acted in a synergistic manner to enhance reporter gene activation by both hormone-dependent and orphan NRs, The synergy was most evident at low levels of transfected NR expression vectors, where activation of reporter genes was almost completely dependent on the presence of NR and all three exogenously supplied coactivators, i.e. GRIP1, CARM1, and PRMT1, In contrast, with the higher levels of NR expression vectors typically used in transient transfection assays, NR activity was much less dependent on the combination of coactivators, suggesting that target gene activation occurs by different mechanisms at high versus low cellular concentrations of NR, Because multiple coactivators are presumably required to mediate transcriptional activation of native genes in vivo, the low-NR conditions may provide a more physiologically relevant assay for coactivator function.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		zhang, shijun/K-3688-2013; Lee, Young-Ho/G-2361-2014	Lee, Young-Ho/0000-0001-6415-4912	NIA NIH HHS [AG00093] Funding Source: Medline; NIDDK NIH HHS [DK55274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; ING NH, 1992, J BIOL CHEM, V267, P17617; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Ma H, 1999, MOL CELL BIOL, V19, P6164; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Westin S, 2000, ADV PHARMACOL, V47, P89; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	53	287	296	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1089	1098		10.1074/jbc.M004228200	http://dx.doi.org/10.1074/jbc.M004228200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050077	hybrid			2022-12-25	WOS:000166430900033
J	Torres, J; Pulido, R				Torres, J; Pulido, R			The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus - Implications for PTEN stability to proteasome-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; CASEIN KINASE-2; PHOSPHATASE; EXPRESSION; CELLS; GENE; ASSOCIATION; PTEN/MMAC1; SUBUNITS; PATHWAY	The tumor suppressor phosphatase PTEN regulates cell migration, growth, and survival by dephosphorylating phosphatidylinositol second messengers and signaling phosphoproteins, PTEN possesses a C-terminal noncatalytic regulatory domain that contains multiple putative phosphorylation sites, which could play an important role in the control of its biological activity. The protein kinase CK2 phosphorylated, in a constitutive manner, a cluster of Ser/Thr residues located at the PTEN C terminus, PTEN-phosphorylated defective mutants showed decreased stability in comparison with wild type PTEN and were more rapidly degraded by the proteasome, Inhibition of PTEN phosphorylation by the CK2 inhibitor 5,6-dichloro-1-beta -D-ribofuranosyl-benzimidazole also diminished the PTEN protein content. Our results support the notion that proper phosphorylation of PTEN by CK2 is important for PTEN protein stability to proteasome-mediated degradation.	Inst Invest Citol, Valencia 46010, Spain		Pulido, R (corresponding author), Inst Invest Citol, C Amadeo Saboya 4, Valencia 46010, Spain.		Torres, Josema/F-7070-2013	Torres, Josema/0000-0001-6906-7164; Pulido, Rafael/0000-0001-9100-248X				Adey NB, 2000, CANCER RES, V60, P35; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li DM, 1997, CANCER RES, V57, P2124; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LORENZ P, 1993, J BIOL CHEM, V268, P2733; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Torres J, 2001, EUR J CANCER, V37, P114, DOI 10.1016/S0959-8049(00)00366-X; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Zhang P, 2000, CANCER RES, V60, P1457	49	505	524	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					993	998		10.1074/jbc.M009134200	http://dx.doi.org/10.1074/jbc.M009134200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035045	hybrid, Green Published			2022-12-25	WOS:000166430900019
J	Wang, XQ; Rothnagel, JA				Wang, XQ; Rothnagel, JA			Post-transcriptional regulation of the GLI1 oncogene by the expression of alternative 5 ' untranslated regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMAS; PRE-MESSENGER-RNA; SONIC-HEDGEHOG; HUMAN HOMOLOG; TRANSCRIPTION FACTOR; GENE-EXPRESSION; KRUPPEL FAMILY; TRANSLATION; MUTATIONS; SEQUENCES	The oncogene GLI1 is involved in the formation of basal cell carcinoma and other tumor types as a result of the aberrant signaling of the Sonic hedgehog-Patched pathway. In this study, we have identified alternative GLI1 transcripts that differ in their 5' untranslated regions (UTRs) and are generated by exon skipping. These are denoted (alpha -UTR, beta -UTR, and gamma -UTR according to the number of noncoding exons possessed (three, two, and one, respectively). The alpha- and beta -UTR forms represent the major Gli1 transcripts expressed in mouse tissues, whereas the gamma -UTR is present at relatively low levels but is markedly induced in mouse skin treated with 12-O-tetradecanoylphorbol 13-acetate, Transcripts corresponding to the murine beta and gamma forms were identified in human tissues, but significantly, only the gamma -UTR form was present in basal cell carcinomas and in proliferating cultures of a keratinocyte cell line. Flow cytometry analysis determined that the gamma -UTR variant expresses a heterologous reporter gene 14-23-fold higher than the alpha -UTR and 5-13-fold higher than the beta -UTR in a variety of cell types. Because expression of the gamma -UTR variant correlates with proliferation, consistent with a role for GLI1 in growth promotion, up-regulation of GLI1 expression through skipping of 5' noncoding exons may be an important tumorigenic mechanism.	Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Rothnagel, JA (corresponding author), Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia.	josephr@biosci.uq.edu.au	Rothnagel, Joe/A-4874-2010; Wang, Xue-Qing/F-1758-2010	Rothnagel, Joe/0000-0002-6710-3165; 				Altaba ARI, 1999, NAT CELL BIOL, V1, pE147, DOI 10.1038/14099; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Darville MI, 1997, NUCLEIC ACIDS RES, V25, P2759, DOI 10.1093/nar/25.14.2759; Du KY, 1998, J BIOL CHEM, V273, P35208, DOI 10.1074/jbc.273.52.35208; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; FERRARI M, 1962, VIROLOGY, V16, P147; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Graves LE, 1999, NATURE, V399, P802, DOI 10.1038/21682; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HEYDEN A, 1994, DIFFERENTIATION, V57, P187, DOI 10.1046/j.1432-0436.1994.5730187.x; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jan E, 1997, EMBO J, V16, P6301, DOI 10.1093/emboj/16.20.6301; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lee J, 1997, DEVELOPMENT, V124, P2537; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Liu CZ, 1998, GENE, V209, P1, DOI 10.1016/S0378-1119(97)00668-9; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park HL, 2000, DEVELOPMENT, V127, P1593; Reifenberger J, 1998, CANCER RES, V58, P1798; ROBERTS WM, 1989, CANCER RES, V49, P5407; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Stein U, 1999, CANCER RES, V59, P1890; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	51	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1311	1316		10.1074/jbc.M005191200	http://dx.doi.org/10.1074/jbc.M005191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032829	hybrid			2022-12-25	WOS:000166430900062
J	Zhao, RB; Gao, F; Wang, YH; Diaz, GA; Gelb, BD; Goldman, ID				Zhao, RB; Gao, F; Wang, YH; Diaz, GA; Gelb, BD; Goldman, ID			Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHOTREXATE TRANSPORT-SYSTEM; MEGALOBLASTIC-ANEMIA SYNDROME; MEMBRANE-TRANSPORT; RESPONSIVE ANEMIA; PHOSPHATE-ESTERS; SMALL-INTESTINE; RAT; MONOPHOSPHATE; MUTATIONS; L1210-CELLS	The thiamin transporter encoded by SLC19A2 and the reduced folate carrier (RFC1) share 40% homology at the protein level, but the thiamin transporter does not mediate transport of folates, By using murine leukemia cell lines that express no, normal, or high levels of RFC1, we demonstrate that RFC1 does not mediate thiamin influx. However, high level RFC1 expression substantially reduced accumulation of the active thiamin coenzyme, thiamin pyrophosphate (TPP), This decreased level of TPP, synthesized intracellularly from imported thiamin, resulted from RFC1-mediated efflux of TPP, This conclusion was supported by the following observations. (i) Efflux of intracellular TPP was increased in cells with high expression of RFC1. (ii) Methotrexate inhibits TPP influx. (iii) TPP competitively inhibits methotrexate influx. (iv) Loading cells, which overexpress RFC1 to high levels of methotrexate to inhibit competitively RFC1-mediated TPP efflux, augment TPP accumulation. (v) There was an inverse correlation between thiamin accumulation and RFC1 activity in cells grown at a physiological concentration of thiamin. The modulation of thiamin accumulation by RFC1 in murine leukemia cells suggests that this carrier may play a role in thiamin homeostasis and could serve as a modifying factor in thiamin nutritional deficiency as well as when the high affinity thiamin transporter is mutated.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; CUNY Mt Sinai Sch Med, Dept Human Genet & Pediat, New York, NY 10029 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Goldman, ID (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Res Ctr, 1300 Morris Pk Ave,Chanin 2, Bronx, NY 10461 USA.	igoldman@aecom.yu.edu	Diaz, George/AAF-6199-2021		NCI NIH HHS [CA-39807, CA-82621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082621, R35CA039807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barile M, 1998, FEBS LETT, V435, P6, DOI 10.1016/S0014-5793(98)01007-2; BETTENDORFF L, 1995, NEUROCHEM INT, V26, P295, DOI 10.1016/0197-0186(94)00123-C; BOWEN D, 1979, J BIOL CHEM, V254, P5333; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Chiao JH, 1997, J BIOL CHEM, V272, P11165, DOI 10.1074/jbc.272.17.11165; CYBULSKI RL, 1982, BIOCHIM BIOPHYS ACTA, V714, P435, DOI 10.1016/0304-4165(82)90151-9; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; DIXON KH, 1994, J BIOL CHEM, V269, P17; Dutta B, 1999, J BIOL CHEM, V274, P31925, DOI 10.1074/jbc.274.45.31925; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; FRY DW, 1982, J BIOL CHEM, V257, P1890; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HENDERSON GB, 1985, J MEMBRANE BIOL, V85, P263, DOI 10.1007/BF01871521; Kril JJ, 1996, METAB BRAIN DIS, V11, P9, DOI 10.1007/BF02080928; Kumar CK, 1998, AM J PHYSIOL-CELL PH, V274, pC289, DOI 10.1152/ajpcell.1998.274.1.C289; Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372; MANDEL H, 1984, NEW ENGL J MED, V311, P836, DOI 10.1056/NEJM198409273111307; MATSUDA T, 1981, ANAL BIOCHEM, V117, P203, DOI 10.1016/0003-2697(81)90711-9; MATSUDA T, 1978, J NUTR SCI VITAMINOL, V24, P123; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PATRINI C, 1988, J NEUROCHEM, V50, P90; Rindi G, 1997, METHOD ENZYMOL, V279, P118; RINDI G, 1995, ARCH PHYSIOL BIOCHEM, V103, P33, DOI 10.3109/13813459509007560; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SHANE B, 1989, VITAM HORM, V45, P263; Sierra EE, 1999, SEMIN ONCOL, V26, P11; Stagg AR, 1999, J CLIN INVEST, V103, P723, DOI 10.1172/JCI3895; Tallaksen CME, 1997, METHOD ENZYMOL, V279, P67; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067; Zhao R, 2000, CLIN CANCER RES, V6, P3304; Zhao RB, 2000, J BIOL CHEM, V275, P26599, DOI 10.1074/jbc.M002580200; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207	35	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1114	1118		10.1074/jbc.M007919200	http://dx.doi.org/10.1074/jbc.M007919200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038362	hybrid			2022-12-25	WOS:000166430900036
J	Kitada, T; Miyoshi, E; Noda, K; Higashiyama, S; Ihara, H; Matsuura, N; Hayashi, N; Kawata, S; Matsuzawa, Y; Taniguchi, N				Kitada, T; Miyoshi, E; Noda, K; Higashiyama, S; Ihara, H; Matsuura, N; Hayashi, N; Kawata, S; Matsuzawa, Y; Taniguchi, N			The addition of bisecting N-acetylglucosamine residues to E-cadherin down-regulates the tyrosine phosphorylation of beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; III GENE TRANSFECTION; CELL-CELL-ADHESION; HUMAN CANCER; ABERRANT GLYCOSYLATION; CYTOPLASMIC DOMAIN; EXPRESSION; OLIGOSACCHARIDES; BINDING; INVASIVENESS	The enzyme GnT-III (beta1,4-N-acetylglucosaminyltransferase III) catalyzes the addition of a bisecting N-acetylglucosamine (GlcNAc) residue on glycoproteins. Our previous study described that the transfection of GnT-lll into mouse melanoma cells results in the enhanced expression of E-cadherin, which in turn leads to, the suppression of lung metastasis. It has recently been proposed that the phosphorylation of a tyrosine residue of beta -catenin is associated with cell migration. The present study reports on the importance of bisecting GlcNAc residues by GnT-III on tyrosine phosphorylation of beta -catenin using three types of cancer cell lines. An addition of bisecting GlcNAc residues to E-cadherin leads to an alteration in cell morphology and the localization of beta -catenin after epidermal growth factor stimulation. These changes are the result of a down-regulation in the tyrosine phosphorylation of beta -catenin, In addition, tyrosine phosphorylation of beta -catenin by transfection of constitutively active c-src was suppressed in GnT-III transfectants as well as in the case of epidermal growth factor stimulation. Treatment with tunicamycin abolished any differences in beta -catenin phosphorylation for the mock vis a vis the GnT-III transfectants. Thus, the addition of a specific N-glycan structure, the bisecting GlcNAc to E-cadherin-beta -catenin complex, down-regulates the intracellular signaling pathway, suggesting its implication in cell motility and the suppression of cancer metastasis.	Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Mol Therapeut, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Med, Sch Allied Hlth Sci, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Med, Sch Allied Hlth Sci, Dept Pathol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University	Taniguchi, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Ihara, Hideyuki/0000-0003-0490-6355				BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Biscardi JS, 1999, ADV CANCER RES, V76, P61; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DORUDI S, 1993, AM J PATHOL, V142, P981; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; MAYER B, 1993, CANCER RES, V53, P1690; MIYOSHI E, 1993, CANCER RES, V53, P3899; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SOMMERS CL, 1994, CANCER RES, V54, P3544; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Taniguchi N, 1996, GLYCOBIOLOGY, V6, P691, DOI 10.1093/glycob/6.7.691; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; UMBAS R, 1992, CANCER RES, V52, P5104; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	35	82	87	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					475	480		10.1074/jbc.M006689200	http://dx.doi.org/10.1074/jbc.M006689200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024053	hybrid			2022-12-25	WOS:000166280700064
J	Mack, CP; Somlyo, AV; Hautmann, M; Somlyo, AP; Owens, GK				Mack, CP; Somlyo, AV; Hautmann, M; Somlyo, AP; Owens, GK			Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; TINMAN HOMOLOG NKX-2.5; HEAVY-CHAIN GENE; TRANSCRIPTIONAL ACTIVATION; FAMILY GTPASES; GROWTH-FACTOR; BINDING TARGETS; CALDESMON GENE; PROTEIN-KINASE; CELLS	complex array of local environmental cues, but the intracellular signaling pathways and the transcription mechanisms that regulate this process are largely unknown. We and others have shown that serum response factor (SRF) contributes to SMC-specific gene transcription, and because the small GTPase RhoA has been shown to regulate SRF, the goal of the present study was to test the hypothesis that RhoA signaling is a critical mechanism for regulating SMC differentiation. Coexpression of constitutively active RhoA in rat aortic SMC cultures significantly increased the activity of the SMC-specific promoters, SM22 and SM alpha -actin, whereas coexpression of C3 transferase abolished the activity of these promoters. Inhibition of either stress fiber formation with the Rho kinase inhibitor Y-27632 (10 muM) or actin polymerization with latrunculin B (0.5 muM) significantly decreased the activity of SM22 and SM alpha -actin promoters. In contrast, increasing actin polymerization with jasplakinolide (0.5 muM) increased SM22 and SM alpha -actin promoter activity by 22-fold and 13-fold, respectively. The above interventions had little or no effect on the transcription of an SRF-dependent c-fos promoter or on a minimal thymidine kinase promoter that is not SRF-dependent. Taken together, the results of these studies indicate that in SMC, RhoA-dependent regulation of the actin cytoskeleton selectively regulates SMC differentiation marker gene expression by modulating SRF-dependent transcription. The results also suggest that RhoA signaling may serve as a convergence point for the multiple signaling pathways that regulate SMC differentiation.	Univ Virginia, Ctr Hlth Sci, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany	University of Virginia	Owens, GK (corresponding author), Univ Virginia, Ctr Hlth Sci, Sch Med, Dept Mol Physiol & Biol Phys, Box 449, Charlottesville, VA 22908 USA.	gko@virginia.edu			NHLBI NIH HHS [R01 HL 19242, R01 HL 38854] Funding Source: Medline; PHS HHS [P01 19242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; BLANK RS, 1990, J CELL PHYSIOL, V142, P635, DOI 10.1002/jcp.1041420325; BLANK RS, 1992, J BIOL CHEM, V267, P984; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Carson JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1624, DOI 10.1152/ajpcell.1996.270.6.C1624; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Groisman R, 1996, J BIOL CHEM, V271, P5258; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Kemp PR, 2000, BIOCHEM J, V345, P445, DOI 10.1042/0264-6021:3450445; Kim JH, 1997, BIOCHEM BIOPH RES CO, V232, P223, DOI 10.1006/bbrc.1997.6261; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; KOCHER O, 1991, LAB INVEST, V65, P459; KOCHER O, 1986, HUM PATHOL, V17, P875, DOI 10.1016/S0046-8177(86)80637-2; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mack CP, 1999, CIRC RES, V84, P852; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; Miano JM, 2000, J BIOL CHEM, V275, P9814, DOI 10.1074/jbc.275.13.9814; Momiyama T, 1998, BIOCHEM BIOPH RES CO, V242, P429, DOI 10.1006/bbrc.1997.7959; Numaguchi K, 1999, CIRC RES, V85, P5; Owens GK, 1997, AGENT ACTION SUPPL, V48, P3; OWENS GK, 1995, PHYSIOL REV, V75, P487; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUNGGER D, 1979, NATURE, V282, P320, DOI 10.1038/282320a0; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Yamakawa T, 2000, HYPERTENSION, V35, P313, DOI 10.1161/01.HYP.35.1.313; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	62	325	340	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					341	347		10.1074/jbc.M005505200	http://dx.doi.org/10.1074/jbc.M005505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035001	hybrid			2022-12-25	WOS:000166280700047
J	Colussi, C; Albertini, MC; Coppola, S; Rovidati, S; Galli, F; Ghibelli, L				Colussi, C; Albertini, MC; Coppola, S; Rovidati, S; Galli, F; Ghibelli, L			H2O2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis	FASEB JOURNAL			English	Article						NAD; oxidative stress; hydrogen peroxide; 3-aminobenzamide	NICOTINAMIDE ADENINE-DINUCLEOTIDE; ISLET-ACTIVATING PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HYDROGEN-PEROXIDE; NITRIC-OXIDE; COVALENT MODIFICATION; MAMMALIAN-CELLS; S-NITROSYLATION; INDUCED INJURY; GSH EXTRUSION	H2O2 treatment on U937 cells leads to the block of glycolytic flux and the inactivation of glyceraldehyde-3-phosphate-dehydrogenase by a posttranslational modification (possibly ADP-ribosylation), Glycolysis spontaneously reactivates after 2 h of recovery from oxidative stress; thereafter cells begin to undergo apoptosis, The specific ADP-ribosylation inhibitor 3-aminobenzamide inhibits the stress-induced inactivation of glyceraldehyde-3-phosphate-dehydrogenase and the block of glycolysis; concomitantly, it anticipates and increases apoptosis, Exogenous block of glycolysis (i.e., by culture in glucose-free medium or with glucose analogs or after NAD depletion), turns the transient block into a stable one: this results in protection from apoptosis, even when downstream cell metabolism is kept active by the addition of pyruvate, All this evidence indicates that the stress-induced block of glycolysis is not the result of a passive oxidative damage, but rather an active cell reaction programmed via ADP-ribosylation for cell self-defense.-Colussi, C., Albertini, M. C., Coppola, S., Rovidati, S., Galli, F., Ghibelli, L. H2O2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ Urbino, Ist Biochim G Fornaini, Rome, Italy	University of Rome Tor Vergata; University of Urbino	Ghibelli, L (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci, I-00133 Rome, Italy.		Coppola, Simona/A-6638-2015; Galli, Francesco/K-5048-2016; Colussi, Claudia/H-8609-2019; Albertini, Maria Cristina/AAG-6980-2019	Coppola, Simona/0000-0001-7851-9409; Galli, Francesco/0000-0003-3626-051X; Albertini, Maria Cristina/0000-0003-4549-1475; Colussi, Claudia/0000-0002-7727-8911				ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; ARGILES JM, 1990, MED HYPOTHESES, V32, P151, DOI 10.1016/0306-9877(90)90039-H; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BERVOFSKI C, 1973, ANAL BIOCHEM, V53, P452; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BOUCHERIE H, 1995, FEMS MICROBIOL LETT, V125, P127; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CLANCY RM, 1993, BIOCHEM BIOPH RES CO, V191, P847, DOI 10.1006/bbrc.1993.1294; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; COPPOLA S, 1995, EXP CELL RES, V221, P462, DOI 10.1006/excr.1995.1397; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HINSHAW DB, 1988, AM J PATHOL, V132, P479; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; HYSLOP PA, 1986, J CELL PHYSIOL, V129, P356, DOI 10.1002/jcp.1041290314; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; KATADA T, 1982, J BIOL CHEM, V257, P7210; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; Mohr S, 1996, J BIOL CHEM, V271, P4209; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; MOSS J, 1977, J BIOL CHEM, V252, P2455; NATH KA, 1994, KIDNEY INT, V45, P166, DOI 10.1038/ki.1994.20; NATH KA, 1995, AM J PHYSIOL-CELL PH, V268, pC227, DOI 10.1152/ajpcell.1995.268.1.C227; Neermann J, 1996, J CELL PHYSIOL, V166, P152; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; OMANN GM, 1994, ARCH BIOCHEM BIOPHYS, V308, P407, DOI 10.1006/abbi.1994.1057; Petronini PG, 1996, J CELL PHYSIOL, V169, P175, DOI 10.1002/(SICI)1097-4652(199610)169:1<175::AID-JCP18>3.0.CO;2-C; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; RUBIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P450, DOI 10.1016/0003-9861(84)90010-9; SCHLAFER M, 1994, J NEUROCHEM, V63, P1924; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHRAUFSTATTER IU, 1985, J CLIN INVEST, V76, P1131, DOI 10.1172/JCI112068; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; SHALL S, 1995, BIOCHIMIE, V77, P313, DOI 10.1016/0300-9084(96)88140-5; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Soukri A, 1996, BBA-PROTEIN STRUCT M, V1292, P177, DOI 10.1016/0167-4838(95)00200-6; SPRAGG RG, 1985, J CLIN INVEST, V76, P1471, DOI 10.1172/JCI112126; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Vertessy BG, 1996, FEBS LETT, V379, P191, DOI 10.1016/0014-5793(95)01510-8; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	55	125	129	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2266	2276		10.1096/fj.00-0074com	http://dx.doi.org/10.1096/fj.00-0074com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053248				2022-12-25	WOS:000165190800020
J	Chang, YC; Nakajima, H; Illenye, S; Lee, YS; Honjo, N; Makiyama, T; Fujiwara, I; Mizuta, N; Sawai, K; Saida, K; Mitsui, Y; Heintz, NH; Magae, J				Chang, YC; Nakajima, H; Illenye, S; Lee, YS; Honjo, N; Makiyama, T; Fujiwara, I; Mizuta, N; Sawai, K; Saida, K; Mitsui, Y; Heintz, NH; Magae, J			Caspase-dependent apoptosis by ectopic expression of E2F-4	ONCOGENE			English	Article						E2F; apoptosis; cell cycle	S-PHASE ENTRY; DIHYDROFOLATE-REDUCTASE GENE; CELL-CYCLE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; TUMOR-SUPPRESSOR; SUBCELLULAR-LOCALIZATION; FAMILY PROTEINS; DNA-SYNTHESIS	E2F is a family of transcription factors which regulates cell cycle and apoptosis of mammalian cells. E2F-1-3 localize in the nucleus, and preferentially bind pRb, while E2F-4 and 5 have no nuclear localization signal and preferentially bind p107/p130. E2F-6 suppresses the transcriptional activity of other E2F proteins. DP-1 and 2 are heterodimeric partners of each E2F protein. Using tetracycline-responsive promoters, here we compared the effects of ectopic expression of E2F-1, DP-I and E2F-4 on cell cycle progression and apoptosis in Chinese hamster cell lines, We found that E2F-4, as well as DP-I and E2F-1, induced growth arrest and caspase-dependent apoptosis, E2F-4 did not have a marked effect on cell cycle progression, while E2P-1 induced DNA synthesis of resting cells and DP-1 arrested cells in G1, Ectopic expression of E2F-4 did not activate E2F-dependent transcription. Our results suggest that expression of E2F-4 at elevated levels induces growth arrest and apoptosis of mammalian cells through a mechanism distinct from E2F-1 and DP-1.	Inst Res & Innovat, Kashiwa, Chiba 2770861, Japan; Univ Vermont, Coll Med, Dept Pathol, S Burlington, VT 05403 USA; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Kyoto Prefectural Univ Med, Dept Surg 2, Kamikyo Ku, Kyoto 602, Japan	University of Vermont; National Institute of Advanced Industrial Science & Technology (AIST); Kyoto Prefectural University of Medicine	Magae, J (corresponding author), Inst Res & Innovat, 1201 Takada, Kashiwa, Chiba 2770861, Japan.				NIGMS NIH HHS [GM54726] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054726] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BARGOU RC, 1996, J EXP MED, V183, P3; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; delaLuna S, 1996, J CELL SCI, V109, P2443; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; He S, 2000, MOL CELL BIOL, V20, P363, DOI 10.1128/MCB.20.1.363-371.2000; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Huang DY, 1996, J BIOL CHEM, V271, P1218, DOI 10.1074/jbc.271.2.1218; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Magae J, 1996, J CELL SCI, V109, P1717; Magae J, 1997, ONCOGENE, V15, P759, DOI 10.1038/sj.onc.1201251; Magae J, 1999, ONCOGENE, V18, P593, DOI 10.1038/sj.onc.1202345; MILBRANDT JD, 1981, P NATL ACAD SCI USA, V78, P6042; Muller H, 1997, MOL CELL BIOL, V17, P5508; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHULL S, 1991, J BIOL CHEM, V266, P24398; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wells J, 1996, MOL CELL BIOL, V16, P634; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	49	13	13	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4713	4720		10.1038/sj.onc.1203833	http://dx.doi.org/10.1038/sj.onc.1203833			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032021				2022-12-25	WOS:000089528800005
J	Varma, H; Conrad, SE				Varma, H; Conrad, SE			Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain	ONCOGENE			English	Article						antiestrogen; breast cancer; cell cycle; pRb; T antigen	LARGE T-ANTIGEN; HUMAN-BREAST-CANCER; SV40 LARGE-T; CARCINOMA-CELLS; SV40-TRANSFORMED CELLS; TRANSCRIPTION FACTOR; SUSCEPTIBILITY GENE; ESTROGEN-RECEPTOR; E-CDK2 ACTIVATION; QUIESCENT CELLS	Proliferation of MCF-7 cells is estrogen dependent and antiestrogen sensitive. In the absence of estrogens or presence of antiestrogens MCF-7 cells arrest in the G(1) phase of the cell cycle, and this arrest is associated with an accumulation of the active, hypophosphorylated form of the retinoblastoma protein (pRb), Because active pRb negatively regulates passage from G(1) to S phase, this suggests that pRb is a crucial target of estrogen action, and that its inactivation might lead to antiestrogen resistance. We tested this hypothesis by expressing viral tumor antigens (T antigens), which bind and inactivate pRb, in MCF-7 cells, and determining the effects on cell proliferation in the presence of antiestrogens. The results of these experiments demonstrate that T antigen expression confers antiestrogen resistance to MCF-7 cells, Using a panel of mutant T antigens, we further demonstrate that the pRb-binding, but not the p53 binding domain is required to confer antiestrogen resistance. Thus, pRb is an important target of estrogen action, and its inactivation can contribute to the development of antiestrogen resistance.	Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Grad Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Conrad, SE (corresponding author), Michigan State Univ, Dept Microbiol, Giltner Hall, E Lansing, MI 48824 USA.				NCI NIH HHS [CA76647] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076647] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson JJ, 1996, J PATHOL, V180, P65, DOI 10.1002/(SICI)1096-9896(199609)180:1<65::AID-PATH607>3.0.CO;2-C; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; BRUNNER N, 1993, CANCER RES, V53, P3229; Brunner N, 1997, CANCER RES, V57, P3486; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; Cole Charles N., 1996, P917; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Gao QS, 1996, CANCER RES, V56, P3129; GLUZMAN Y, 1979, COLD SPRING HARB SYM, V44, P293; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Howes SH, 1996, J VIROL, V70, P3581, DOI 10.1128/JVI.70.6.3581-3588.1996; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Johnston SD, 1996, J VIROL, V70, P1191, DOI 10.1128/JVI.70.2.1191-1202.1996; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KATO J, 1993, GENE DEV, V7, P331; KELLER JM, 1984, CELL, V36, P381, DOI 10.1016/0092-8674(84)90231-9; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAROSE A, 1990, VIROLOGY, V176, P98, DOI 10.1016/0042-6822(90)90234-I; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIPPMAN M, 1976, CANCER RES, V36, P4595; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MELORA DB, 1998, PRINCIPLES MOL MED; Nemethova M, 1999, J VIROL, V73, P1734, DOI 10.1128/JVI.73.2.1734-1739.1999; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; OSBORNE CK, 1985, CANCER RES, V45, P584; Pacilio C, 1998, CANCER RES, V58, P871; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P615, DOI 10.1016/0277-5379(83)90177-3; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WAKELING AE, 1991, CANCER RES, V51, P3867; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	56	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4746	4753		10.1038/sj.onc.1203827	http://dx.doi.org/10.1038/sj.onc.1203827			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032025				2022-12-25	WOS:000089528800009
J	Ruttimann-Johnson, C; Rangaraj, P; Shah, VK; Ludden, PW				Ruttimann-Johnson, C; Rangaraj, P; Shah, VK; Ludden, PW			Requirement of homocitrate for the transfer of a V-49-labeled precursor of the iron-vanadium cofactor from VnfX to nif-apodinitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII; MOLYBDENUM COFACTOR; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; INVITRO SYNTHESIS; STRUCTURAL GENES; NITROGENASE; DINITROGENASE; PROTEIN; PURIFICATION	A vanadium- and iron-containing cluster has been shown previously to accumulate on VnfX in the Azotobacter vinelandii mutant strain CA11.1 (Delta nifHDKvnfDGK::spc). In the present study, we show the homocitrate-dependent transfer of V-49 label from VnfX to nif-apodinitrogenase in vitro. This transfer of radiolabel correlates with acquisition of acetylene reduction activity. Acetylene is reduced both to ethylene and ethane by the hybrid holodinitrogenase so formed, a feature characteristic of alternative nitrogenases. Structural analogues of homocitrate prevent the acetylene reduction ability of the resulting dinitrogenase. Addition of NifB cofactor (-co) or a source of vanadium (Na3VO4 or VCl3) does not increase nitrogenase activity. Our results suggest that there is in vitro incorporation of homocitrate into the V-Fe-S cluster associated with VnfX and that the completed cluster can be inserted into nif-apodinitrogenase. The homocitrate incorporation react-ion and the insertion of the cluster into nif-apodinitrogenase (alpha (2)beta (2)gamma (2)) do not require MgATP. Attempts to achieve FeV-co synthesis using extracts of other FeV-co-negative mutants were unsuccessful, showing that earlier steps in FeV-co synthesis, such as the steps requiring VnfNE or VnfH do not occur in vitro.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; Bishop PE, 1992, BIOL NITROGEN FIXATI, P736; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; Chatterjee R, 1996, J BIOL CHEM, V271, P6819, DOI 10.1074/jbc.271.12.6819; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; DILWORTH MJ, 1988, BIOCHEM J, V249, P745, DOI 10.1042/bj2490745; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KENNEDY C, 1992, MOL GEN GENET, V231, P494, DOI 10.1007/BF00292722; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LUQUE F, 1991, MOL GEN GENET, V227, P481, DOI 10.1007/BF00273941; Premakumar R, 1996, J BACTERIOL, V178, P691, DOI 10.1128/jb.178.3.691-696.1996; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; Ruttimann-Johnson C, 1999, J BIOL CHEM, V274, P18087, DOI 10.1074/jbc.274.25.18087; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1985, J BIOL CHEM, V260, P3891; SMITH BE, 1988, BIOCHEM J, V250, P299, DOI 10.1042/bj2500299; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; WOLFINGER ED, 1991, J BACTERIOL, V173, P7565, DOI 10.1128/jb.173.23.7565-7572.1991; Zheng LM, 1997, J BACTERIOL, V179, P5963, DOI 10.1128/jb.179.18.5963-5966.1997	33	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4522	4526		10.1074/jbc.M007288200	http://dx.doi.org/10.1074/jbc.M007288200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053414	hybrid			2022-12-25	WOS:000166921200104
J	Samuel, D; Kumar, TKS; Balamurugan, K; Lin, WY; Chin, DH; Yu, C				Samuel, D; Kumar, TKS; Balamurugan, K; Lin, WY; Chin, DH; Yu, C			Structural events during the refolding of an all beta-sheet protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DIHYDROFOLATE-REDUCTASE; EARLY FOLDING INTERMEDIATE; FIBROBLAST-GROWTH-FACTOR; MUSCLE ACYLPHOSPHATASE; TRANSITION-STATE; KINETICS; STABILITY; MECHANISM; LYSOZYME; EXCHANGE	The refolding kinetics of the 140-residue, all beta -sheet, human fibroblast growth factor (hFGF-1) is studied using a variety of biophysical techniques such as stopped-flow fluorescence, stopped-flow circular dichroism, and quenched-flow hydrogen exchange in conjunction with multidimensional NMR spectroscopy. Urea-induced unfolding of hFGF-1 under equilibrium conditions reveals that the protein folds via a two-state (native <----> unfolded) mechanism without the accumulation of stable intermediates. However, measurement of the unfolding and refolding rates in various concentrations of urea shows that the refolding of hFGF-1 proceeds through accumulation of kinetic intermediates. Results of the quenched-flow hydrogen exchange experiments reveal that the hydrogen bonds linking the N- and C-terminal ends are the first to form during the refolding of hFGF-1. The basic beta -trefoil framework is provided by the simultaneous formation of beta -strands I, IV, IX, and X. The other beta -strands comprising the beta -barrel structure of hFGF-1 are formed relatively slowly with time constants ranging from 4 to 13 s.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 300, Taiwan; Natl Changhua Univ Educ, Dept Chem, Changhua 500, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 10764, Taiwan	National Tsing Hua University; National Changhua University of Education; National Taiwan University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 300, Taiwan.	cyu@mx.nthu.edu.tw	KUMAR, P. SURESH/AAT-8951-2020; Kumar, Dr Suresh/HHZ-2615-2022; Kumar, Suresh Thallapuranam/R-5606-2016	KUMAR, P. SURESH/0000-0003-3222-2604; Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; Balamurugan, Prof. Dr. Krishnaswamy/0000-0001-9316-8141				BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURKE CJ, 1993, BIOCHEMISTRY-US, V32, P6419, DOI 10.1021/bi00076a015; Chiti F, 1998, BIOCHEMISTRY-US, V37, P1447, DOI 10.1021/bi971692f; Clementi C, 2000, P NATL ACAD SCI USA, V97, P5871, DOI 10.1073/pnas.100547897; Cota E, 2000, PROTEIN SCI, V9, P112; ENGELHARD M, 1995, PROTEIN SCI, V4, P1553, DOI 10.1002/pro.5560040813; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Finke JM, 2000, BIOCHEMISTRY-US, V39, P575, DOI 10.1021/bi991518m; Grantcharova VP, 1997, BIOCHEMISTRY-US, V36, P15685, DOI 10.1021/bi971786p; HAMMOND GS, 1955, J AM CHEM SOC, V77, P334, DOI 10.1021/ja01607a027; Heidary DK, 1997, NAT STRUCT BIOL, V4, P725, DOI 10.1038/nsb0997-725; Heidary DK, 2000, P NATL ACAD SCI USA, V97, P5866, DOI 10.1073/pnas.100547697; HOGAN SJ, 2000, J MOL BIOL, V297, P781; Ionescu RM, 2000, BIOCHEMISTRY-US, V39, P9540, DOI 10.1021/bi000511y; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; JACKSON SE, 1994, BIOCHEMISTRY-US, V30, P10436; JONES BE, 1994, BIOCHEMISTRY-US, V33, P15250, DOI 10.1021/bi00255a005; Jonsson T, 1996, BIOCHEMISTRY-US, V35, P4795, DOI 10.1021/bi953056s; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSZEWSKI J, 1994, PROTEIN SCI, V3, P1945, DOI 10.1002/pro.5560031106; Lozano RM, 2000, BIOCHEMISTRY-US, V39, P4982, DOI 10.1021/bi992544n; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; Main ERG, 1999, J MOL BIOL, V291, P429, DOI 10.1006/jmbi.1999.2941; MANN CJ, 1993, BIOCHEMISTRY-US, V32, P5282, DOI 10.1021/bi00071a002; Matagne A, 2000, J MOL BIOL, V297, P193, DOI 10.1006/jmbi.2000.3540; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; Mirny LA, 1998, P NATL ACAD SCI USA, V95, P4976, DOI 10.1073/pnas.95.9.4976; Ogura K, 1999, J BIOMOL NMR, V13, P11, DOI 10.1023/A:1008330622467; Oliveberg M, 1998, J MOL BIOL, V277, P933, DOI 10.1006/jmbi.1997.1612; Otzen DE, 1999, BIOCHEMISTRY-US, V38, P6499, DOI 10.1021/bi982819j; Parker MJ, 1999, J MOL BIOL, V293, P1195, DOI 10.1006/jmbi.1999.3204; Plaxco KW, 1998, BIOCHEMISTRY-US, V37, P2529, DOI 10.1021/bi972075u; Ptitsyn Oleg B., 1992, P243; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; Ropson IJ, 1997, BIOCHEMISTRY-US, V36, P8594, DOI 10.1021/bi962983b; Schonbrunner N, 1997, J MOL BIOL, V268, P526, DOI 10.1006/jmbi.1997.0960; Shakhnovich E, 1996, NATURE, V379, P96, DOI 10.1038/379096a0; SHASTRY MCR, 1995, J MOL BIOL, V247, P1013, DOI 10.1006/jmbi.1994.0196; Silow M, 1999, BIOCHEMISTRY-US, V38, P13006, DOI 10.1021/bi9909997; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Sivaraman T, 1998, J BIOL CHEM, V273, P10181, DOI 10.1074/jbc.273.17.10181; Socci ND, 1998, PROTEINS, V32, P136, DOI 10.1002/(SICI)1097-0134(19980801)32:2<136::AID-PROT2>3.3.CO;2-5; Staniforth RA, 2000, P NATL ACAD SCI USA, V97, P5790, DOI 10.1073/pnas.97.11.5790; van Nuland NAJ, 1998, J MOL BIOL, V283, P883, DOI 10.1006/jmbi.1998.2009; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P2142, DOI 10.1021/bi00174a022; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	50	43	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4134	4141		10.1074/jbc.M005921200	http://dx.doi.org/10.1074/jbc.M005921200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11038349	hybrid, Green Published			2022-12-25	WOS:000166921200055
J	Yang, ZY; Li, H; Chai, ZL; Fullerton, MJ; Cao, Y; Toh, BH; Funder, JW; Liu, JP				Yang, ZY; Li, H; Chai, ZL; Fullerton, MJ; Cao, Y; Toh, BH; Funder, JW; Liu, JP			Dynamin II regulates hormone secretion in neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; SYNAPTIC VESICLE ENDOCYTOSIS; DISTINCT FUNCTIONS; MAMMALIAN-CELLS; PROTEIN; KINASE; DOMAIN; ALPHA; REDUNDANT; ISOFORMS	The dynamin family of GTP-binding proteins has been implicated as playing an important role in endocytosis. In Drosophila shibire, mutations of the single dynamin gene cause blockade of endocytosis and neurotransmitter release, manifest as temperature-sensitive neuromuscular paralysis. Mammals express three dynamin genes: the neural specific dynamin I, ubiquitous dynamin II, and predominantly testicular dynamin III. Mutations of dynamin I result in a blockade of synaptic vesicle recycling and receptor-mediated endocytosis. Here, we show that dynamin II plays a key role in controlling constitutive and regulated hormone secretion from mouse pituitary corticotrope (AtT20) cells. Dynamin II is preferentially localized to the Golgi apparatus where it interacts with G-protein py subunit and regulates secretory vesicle release. The presence of dynamin II at the Golgi apparatus and its interaction with the py subunit are mediated by the pleckstrin homology domain of the GTPase, Overexpression of the pleckstrin homology domain, or a dynamin II mutant lacking the C-terminal SH3-binding domain, induces translocation of endogenous dynamin II. from the Golgi apparatus to the plasma membrane and transformation of dynamin II from activity in the secretory pathway to receptor-mediated endocytosis. Thus, dynamin II regulates secretory vesicle formation from the Golgi apparatus and hormone release from mammalian neuroendocrine cells.	Monash Univ, Sch Med, Baker Med Res Inst, Prahran, Vic 3181, Australia; Monash Univ, Sch Med, Dept Pathol & Immunol, Prahran, Vic 3181, Australia	Baker Heart and Diabetes Institute; Monash University; Monash University	Liu, JP (corresponding author), Baker Med Res Inst, Mol Signalling Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.		CHAI, ZHONGLIN/X-1342-2019; Chai, Zhonglin/E-7482-2010	CHAI, ZHONGLIN/0000-0001-8182-8579; Liu, Jun-Ping/0000-0001-7442-2116				ALI SA, 1995, BIOTECHNIQUES, V18, P746; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Gleeson PA, 1996, J CELL SCI, V109, P2811; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kasai K, 1999, J BIOCHEM, V125, P780, DOI 10.1093/oxfordjournals.jbchem.a022349; Kelly RB, 1999, NAT CELL BIOL, V1, pE8, DOI 10.1038/8957; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li H, 1998, INT J BIOCHEM CELL B, V30, P1389, DOI 10.1016/S1357-2725(98)00093-4; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; LIU JP, 1990, J BIOL CHEM, V265, P14136; Liu JP, 1997, MOL CELL ENDOCRINOL, V132, P61, DOI 10.1016/S0303-7207(97)00120-2; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Shields D, 1999, CURR OPIN CELL BIOL, V11, P489, DOI 10.1016/S0955-0674(99)80070-2; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107	36	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4251	4260		10.1074/jbc.M006371200	http://dx.doi.org/10.1074/jbc.M006371200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11032832	hybrid			2022-12-25	WOS:000166921200070
J	Dash, C; Rao, M				Dash, C; Rao, M			Interactions of a novel inhibitor from an extremophilic Bacillus sp with HIV-1 protease - Implications for the mechanism of inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 PROTEASE; RETROVIRAL PROTEINASES; ASPARTIC PROTEINASES; CRYSTAL-STRUCTURE; RESISTANCE; RESOLUTION; DESIGN; AIDS; BINDING; MUTANTS	The active site cleft of the HIV-1 protease (PR) is bound by two identical conformationally mobile loops known as flaps, which are important for substrate binding and catalysis, The present article reports, for the first time, an HIV-1 PR inhibitor, ATBI, from an extremophilic Bacillus sp. The inhibitor is found to be a hydrophilic peptide with Mr of 1147, and an amino acid sequence of Ala-Gly-Lys-Lys-Asp-Asp-Asp-Asp-Pro-Pro-Glu, Sequence homology exhibited no similarity with the reported peptidic inhibitors of HIV-1 PR. Investigation of the kinetics of the enzyme-inhibitor interactions revealed that ATBI is a noncompetitive and tight binding inhibitor with the IC50 and K-i values 18.0 and 17.8 nM, respectively. The binding of the inhibitor with the enzyme and the subsequent induction of the localized conformational changes in the flap region of the HIV-1 PR were monitored by exploiting the intrinsic fluorescence of the surface exposed Trp-42 residues, which are present at the proximity of the flaps. We have demonstrated by fluorescence and circular dichroism studies that ATBI binds in the active site of the HIV-1 PR and thereby leads to the inactivation of the enzyme. Based on our results, we propose that the inactivation is due to the reorganization of the flaps impairing its flexibility leading toward inaccessibility of the substrate to the active site of the enzyme.	Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL)	Rao, M (corresponding author), Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India.	malarao@dalton.ncl.res.in		Dash, Chandravanu/0000-0003-4466-8355				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; Bardi JS, 1997, BIOCHEMISTRY-US, V36, P6588, DOI 10.1021/bi9701742; *BIOS MOL SIM, 1995, INS 2; BLUNDELL T, 1989, NATURE, V337, P596, DOI 10.1038/337596a0; CHA S, 1976, BIOCHEM PHARMACOL, V25, P2695, DOI 10.1016/0006-2952(76)90259-8; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; DASH C, 1998, Patent No. 983560; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; Ermolieff J, 1997, BIOCHEMISTRY-US, V36, P12364, DOI 10.1021/bi971072e; GIGLI I, 1970, J IMMUNOL, V104, P574; GRIFFITHS JT, 1994, J BIOL CHEM, V269, P4787; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; LANG M, 1993, ARCH PHARM, V326, P921, DOI 10.1002/ardp.19933261202; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; Nair AC, 1998, BIOCHEM BIOPH RES CO, V242, P545, DOI 10.1006/bbrc.1997.8008; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PAWAR HS, 1988, J BIOSCIENCE, V3, P43; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; Pettit Steve C., 1993, Perspectives in Drug Discovery and Design, V1, P69, DOI 10.1007/BF02171656; PHYLIP LH, 1990, BIOCHEM BIOPH RES CO, V171, P439, DOI 10.1016/0006-291X(90)91412-L; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; RODRIGUEZ EJ, 1993, BIOCHEMISTRY-US, V32, P3557, DOI 10.1021/bi00065a006; RUTENBER E, 1993, J BIOL CHEM, V268, P15343; SARUBBI E, 1993, FEBS LETT, V319, P253, DOI 10.1016/0014-5793(93)80557-B; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TANG J, 1978, NATURE, V271, P618, DOI 10.1038/271618a0; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	43	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2487	2493		10.1074/jbc.M005662200	http://dx.doi.org/10.1074/jbc.M005662200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042202	hybrid, Green Submitted			2022-12-25	WOS:000166784800027
J	He, XY; Futterer, J; Hohn, T				He, XY; Futterer, J; Hohn, T			Sequence-specific and methylation-dependent and -independent binding of rice nuclear proteins to a rice tungro bacilliform virus vascular bundle expression element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BZIP TRANSCRIPTIONAL ACTIVATOR; IN-VITRO BINDING; DNA METHYLATION; CPG METHYLATION; CHROMOSOMAL-PROTEIN; BETA-GLUCURONIDASE; INHIBITS BINDING; GENE FUSION; PROMOTER; REPRESSION	Nuclear proteins from rice (Oryza sativa) were identified that bind specifically to a rice tungro bacilliform virus promoter region containing a vascular bundle expression element (VBE). One set of proteins of 29, 33, and 37 kDa, present in shoot and cell suspension extracts but hardly detectable in root extracts, bound to a site containing the sequence AGAAGGACCAGA within the VEE, which also contains two CpG and one CpNpG potential methylation motifs, Binding by these proteins was determined to be cytosine methylation-independent. However, a novel protein present in all analyzed extracts bound specifically to the methylated VEE. A region of at least 49 nucleotides overlapping the VEE and complete cytosine methylation of the three Cp(Np)G motifs was required for efficient binding of this methylated VBE-binding protein (MVBP).	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland	Friedrich Miescher Institute for Biomedical Research; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hohn, T (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	thomas.hohn@fmi.ch						Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; CHEN G, 1994, VIROLOGY, V204, P91, DOI 10.1006/viro.1994.1513; Chen G, 1996, J VIROL, V70, P8411, DOI 10.1128/JVI.70.12.8411-8421.1996; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; DATTA SK, 1990, BIO-TECHNOL, V8, P736, DOI 10.1038/nbt0890-736; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; Finnegan EJ, 2000, CURR OPIN GENET DEV, V10, P217, DOI 10.1016/S0959-437X(00)00061-7; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; Guilfoyle T. J., 1997, Genetic engineering: principles and methods. Volume 19., P15; HATTON D, 1995, PLANT J, V7, P859, DOI 10.1046/j.1365-313X.1995.07060859.x; HAUFFE KD, 1993, PLANT J, V4, P235, DOI 10.1046/j.1365-313X.1993.04020235.x; HE X, 2000, THESIS U BASE; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; INAMDAR NM, 1991, PLANT MOL BIOL, V17, P111, DOI 10.1007/BF00036811; Jackson S. P., 1993, Gene transcription: a practical approach., P189; JEFFERSON RA, 1987, EMBO J, V6, P3901; JOST JP, 1991, NUCLEIC ACIDS RES, V19, P5771, DOI 10.1093/nar/19.20.5771; Jost JP, 1997, PROG NUCLEIC ACID RE, V57, P217, DOI 10.1016/S0079-6603(08)60282-2; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KELLER B, 1989, EMBO J, V8, P1309, DOI 10.1002/j.1460-2075.1989.tb03510.x; Kloti A, 1999, PLANT MOL BIOL, V40, P249, DOI 10.1023/A:1006119517262; Kooter JM, 1999, TRENDS PLANT SCI, V4, P340, DOI 10.1016/S1360-1385(99)01467-3; KUNZE R, 1989, EMBO J, V8, P3177, DOI 10.1002/j.1460-2075.1989.tb08476.x; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Meisel L, 1997, Genet Eng (N Y), V19, P183; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Neustaedter DA, 1999, PLANT J, V18, P77, DOI 10.1046/j.1365-313X.1999.00430.x; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; PAUL AL, 1994, PLANT J, V5, P523, DOI 10.1046/j.1365-313X.1994.5040523.x; Radtke F, 1996, BIOL CHEM H-S, V377, P47, DOI 10.1515/bchm3.1996.377.1.47; Rossi V, 1997, J BIOL CHEM, V272, P13758, DOI 10.1074/jbc.272.21.13758; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; SHILLITO RD, 1985, BIO-TECHNOL, V3, P1099, DOI 10.1038/nbt1285-1099; STAIGER D, 1989, P NATL ACAD SCI USA, V86, P6930, DOI 10.1073/pnas.86.18.6930; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Thain A, 1996, J VIROL, V70, P7233, DOI 10.1128/JVI.70.10.7233-7235.1996; TorresSchumann S, 1996, PLANT J, V9, P283, DOI 10.1046/j.1365-313X.1996.09030283.x; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; WANG RYH, 1986, NUCLEIC ACIDS RES, V14, P1599, DOI 10.1093/nar/14.4.1599; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Yin YH, 1997, EMBO J, V16, P5247, DOI 10.1093/emboj/16.17.5247; Yin YH, 1997, PLANT J, V12, P1179, DOI 10.1046/j.1365-313X.1997.12051179.x; YIN YH, 1995, PLANT J, V7, P969, DOI 10.1046/j.1365-313X.1995.07060969.x; ZHANG DL, 1989, MOL CELL BIOL, V9, P1351, DOI 10.1128/MCB.9.3.1351; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387	53	8	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2644	2651		10.1074/jbc.M006653200	http://dx.doi.org/10.1074/jbc.M006653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11036074	hybrid			2022-12-25	WOS:000166784800049
J	Phylip, LH; Lees, WE; Brownsey, BG; Bur, D; Dunn, BM; Winther, JR; Gustchina, A; Li, M; Copeland, T; Wlodawer, A; Kay, J				Phylip, LH; Lees, WE; Brownsey, BG; Bur, D; Dunn, BM; Winther, JR; Gustchina, A; Li, M; Copeland, T; Wlodawer, A; Kay, J			The potency and specificity of the interaction between the IA(3) inhibitor and its target aspartic proteinase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-D; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURES; PORCINE PEPSIN; YEAST; PURIFICATION; RESOLUTION; EXPRESSION; CLONING; ENZYME	The yeast IA, polypeptide consists of only 68 residues, and the free inhibitor has little intrinsic secondary structure. IA, showed subnanomolar potency toward its target, proteinase A from Saccharomyces cerevisiae, and did not inhibit any of a large number of aspartic proteinases with similar sequences/structures from a wide variety of other species. Systematic truncation and mutagenesis of the IA, polypeptide revealed that the inhibitory activity is located in the N-terminal half of the sequence. Crystal structures of different forms of Lc, complexed with proteinase A showed that residues in the N-terminal half of the IA, sequence became ordered and formed an almost perfect cr-helix in the active site of the enzyme. This potent, specific interaction was directed primarily by hydrophobic interactions made by three key features in the inhibitory sequence. Whereas IA,was cut as a substrate by the nontarget aspartic proteinases, it mas not cleaved by proteinase A. The random coil IA, polypeptide escapes cleavage by being stabilized in a helical conformation upon interaction with the active site of proteinase A. This results, paradoxically, in potent selective inhibition of the target enzyme.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Wales, Coll Med, Dept Med, Cardiff CF14 4XN, S Glam, Wales; Hoffmann La Roche Ag, CH-4070 Basel, Switzerland; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Carlsberg Lab, Dept Yeast Genet, DK-2500 Copenhagen Valby, Denmark; NCI, Prot Struct Sect, Macromol Crystallog Lab, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, Frederick, MD 21702 USA; NCI, Program Core, DBS, Frederick, MD 21702 USA	Cardiff University; Cardiff University; Roche Holding; State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kay, J (corresponding author), Cardiff Univ, Sch Biosci, POB 911, Cardiff CF10 3US, S Glam, Wales.		Winther, Jakob R./K-4451-2014	Winther, Jakob R./0000-0001-6995-9154				Aguilar CF, 1997, J MOL BIOL, V267, P899, DOI 10.1006/jmbi.1996.0880; Arnold D, 1997, EUR J BIOCHEM, V249, P171, DOI 10.1111/j.1432-1033.1997.t01-1-00171.x; AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; BIEDERMANN K, 1980, CARLSBERG RES COMMUN, V45, P225, DOI 10.1007/BF02906176; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christeller JT, 1998, EUR J BIOCHEM, V254, P160, DOI 10.1046/j.1432-1327.1998.2540160.x; DREYER T, 1985, BIOCHEM J, V231, P777, DOI 10.1042/bj2310777; DREYER T, 1986, CARLSBERG RES COMMUN, V51, P27, DOI 10.1007/BF02907993; HILL J, 1994, FEBS LETT, V352, P155, DOI 10.1016/0014-5793(94)00940-6; Houston ME, 1998, J PEPT RES, V52, P81; Kageyama T, 1998, EUR J BIOCHEM, V253, P804, DOI 10.1046/j.1432-1327.1998.2530804.x; KAY J, 1983, PROTEINASE INHIBITOR, P201; Khan AR, 1998, PROTEIN SCI, V7, P815; Kreft S, 1997, PHYTOCHEMISTRY, V44, P1001, DOI 10.1016/S0031-9422(96)00668-1; Lenarcic B, 1999, J BIOL CHEM, V274, P563, DOI 10.1074/jbc.274.2.563; Li M, 2000, NAT STRUCT BIOL, V7, P113, DOI 10.1038/72378; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SAHEKI T, 1974, EUR J BIOCHEM, V47, P325, DOI 10.1111/j.1432-1033.1974.tb03697.x; SCHU P, 1991, FEBS LETT, V283, P78, DOI 10.1016/0014-5793(91)80558-K; Shintani T, 1997, J BIOL CHEM, V272, P18855, DOI 10.1074/jbc.272.30.18855; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; Takahashi S, 1999, J BIOCHEM-TOKYO, V125, P348, DOI 10.1093/oxfordjournals.jbchem.a022293; Tigue NJ, 1998, J BIOL CHEM, V273, P26441, DOI 10.1074/jbc.273.41.26441; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; White PC, 1999, J BIOL CHEM, V274, P16685, DOI 10.1074/jbc.274.24.16685	27	33	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2023	2030		10.1074/jbc.M008520200	http://dx.doi.org/10.1074/jbc.M008520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042188	hybrid			2022-12-25	WOS:000166528000052
J	Schwer, B; Lehman, K; Saha, N; Shuman, S				Schwer, B; Lehman, K; Saha, N; Shuman, S			Characterization of the mRNA capping apparatus of Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; CAP METHYLTRANSFERASE; MUTATIONAL ANALYSIS; POLYMERASE-II; GUANYLYLTRANSFERASE COMPONENT; SCHIZOSACCHAROMYCES-POMBE; ENZYME BINDS; YEAST; TRIPHOSPHATASE; PHOSPHORYLATION	The mRNA capping apparatus of the pathogenic fungus Candida albicans consists of three components: a 520-amino acid RNA triphosphatase (CaCet1p), a 449-amino acid RNA guanylyltransferase (Cgt1p), and a 474-amino acid RNA (guanine-N7-)-methyltransferase (Ccm1p). The fungal guanylyltransferase and methyltransferase are structurally similar to their mammalian counterparts, whereas the fungal triphosphatase is mechanistically and structurally unrelated to the triphosphatase of mammals. Hence, the triphosphatase is an attractive antifungal target. Here we identify a biologically active C-terminal do main of CaCet1p from residues 202 to 520. We find that CaCet1p function in vivo requires the segment from residues 202 to 256 immediately flanking the catalytic domain from 257 to 520. Genetic suppression data implicate the essential flanking segment in the binding of CaCet1p to the fungal guanylyltransferase, Deletion analysis of the Candida guanylyltransferase demarcates an N-terminal domain, Cgt1(1-387)p, that suffices for catalytic activity in vitro and for cell growth, An even smaller domain, Cgt1(1-367)p, suffices for binding to the guanylyltransferase docking site on yeast RNA triphosphatase. Deletion analysis of the cap methyltransferase identifies a C-terminal domain, Ccm1(137-474)p, as being sufficient for cap methyltransferase function in vivo and in vitro. Ccm1(137-474)p binds in, vitro to synthetic peptides comprising the phosphorylated C-terminal domain of the largest subunit of RNA polymerase II, Binding is enhanced when the C-terminal domain is phosphorylated on both Ser-2 and Ser-5 of the YSPTSPS heptad repeat. We show that the entire three-component Saccharomyces cerevisiae capping apparatus can be replaced by C, albicans enzymes, Isogenic yeast cells expressing "all-Candida" versus "all-mammalian" capping components can be used to screen for cytotoxic agents that specifically target the fungal capping enzymes.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Janbon G, 1997, YEAST, V13, P985, DOI 10.1002/(SICI)1097-0061(199708)13:10<985::AID-YEA153>3.0.CO;2-T; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Mao XD, 1996, MOL CELL BIOL, V16, P475; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Schwer B, 2000, GENETICS, V155, P1561; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V251, P27, DOI 10.1006/bbrc.1998.9402; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yamada-Okabe T, 1999, MICROBIOL-UK, V145, P3023, DOI 10.1099/00221287-145-11-3023; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; YamadaOkabe T, 1996, MICROBIOL-UK, V142, P2515, DOI 10.1099/00221287-142-9-2515; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	36	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1857	1864		10.1074/jbc.M006072200	http://dx.doi.org/10.1074/jbc.M006072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035009	hybrid			2022-12-25	WOS:000166528000030
J	Escobar-Henriques, M; Daignan-Fornier, B				Escobar-Henriques, M; Daignan-Fornier, B			Transcriptional regulation of the yeast GMP synthesis pathway by its end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMP DEHYDROGENASE; INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE; HUMAN NORMAL LYMPHOCYTES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MYCOPHENOLATE MOFETIL; INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE; GENE-EXPRESSION; BETA-SUBUNIT; CELL LINES	AMP and GMP are synthesized from IMP by specific conserved pathways. In yeast, whereas IMP and AMP synthesis are coregulated, we found that the GMP synthesis pathway is specifically regulated. Transcription of the IMD genes, encoding the yeast homologs of IMP dehydrogenase, was repressed by extracellular guanine. Only this first step of GDP synthesis pathway is regulated, since the latter steps, encoded by the GUA1 and GUK1 genes, are guanine-insensitive. Use of mutants affecting GDP metabolism revealed that guanine had to be transformed into GDP to allow repression of the IMD genes. IMD gene transcription was also strongly activated by mycophenolic acid (MPA), a specific inhibitor of IMP dehydrogenase activity. Serial deletions of the IMD2 gene promoter revealed the presence of a negative cis-element, required for guanine regulation. Point mutations in this guanine response element strongly enhanced IMD2 expression, also making it insensitive to guanine and MPA. From these data, we propose that the guanine response element sequence mediates a repression process, which is enhanced by guanine addition, through GDP or a GDP derivative, and abolished in the presence of MPA.	CNRS UMR 5095, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Daignan-Fornier, B (corresponding author), CNRS UMR 5095, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	Daignan-Fornier@ibgc.u-bordeaux2.fr		Escobar-Henriques, Mafalda/0000-0002-0879-3119				ALLISON AC, 1975, LANCET, V2, P1179; ALLISON AC, 1994, TRANSPLANT P, V26, P3205; Barton AB, 1997, YEAST, V13, P1251; COLLART FR, 1990, BLOOD, V75, P570; COLLART FR, 1992, CANCER RES, V52, P5826; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; DUJARDIN G, 1994, GENE, V139, P127, DOI 10.1016/0378-1119(94)90535-5; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; ELFORD HL, 1968, BIOCHEM BIOPH RES CO, V33, P129, DOI 10.1016/0006-291X(68)90266-0; FUKUCHI T, 1993, GENE, V129, P141; GILBERT HJ, 1979, BIOCHEM J, V183, P481, DOI 10.1042/bj1830481; GLESNE DA, 1991, MOL CELL BIOL, V11, P5417, DOI 10.1128/MCB.11.11.5417; Guetsova ML, 1997, GENETICS, V147, P383; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; IKEGAMI T, 1987, LIFE SCI, V40, P2277, DOI 10.1016/0024-3205(87)90064-6; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; Jain A, 1999, SURG CLIN N AM, V79, P59, DOI 10.1016/S0039-6109(05)70007-4; KANZAKI N, 1990, NUCLEIC ACIDS RES, V18, P6710, DOI 10.1093/nar/18.22.6710; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; KONNO Y, 1991, J BIOL CHEM, V266, P506; KONRAD M, 1992, J BIOL CHEM, V267, P25652; Lecoq K, 2000, GENETICS, V156, P953; Liu YA, 1998, MOL BIOL CELL, V9, P15, DOI 10.1091/mbc.9.1.15; MENG LM, 1990, MOL MICROBIOL, V4, P2187, DOI 10.1111/j.1365-2958.1990.tb00580.x; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MUKAI Y, 1991, MOL CELL BIOL, V11, P3773, DOI 10.1128/MCB.11.7.3773; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NAKAMURA H, 1992, LEUKEMIA RES, V16, P561, DOI 10.1016/0145-2126(92)90002-O; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NELSON PH, 1990, J MED CHEM, V33, P833, DOI 10.1021/jm00164a057; OKADA M, 1983, J BIOCHEM-TOKYO, V94, P1605; SHAW LM, 1995, THER DRUG MONIT, V17, P690, DOI 10.1097/00007691-199512000-00025; SIFRI CD, 1994, BBA-GENE STRUCT EXPR, V1217, P103; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; SOLLINGER HW, 1995, KIDNEY INT, V48, pS14; TIEDEMAN AA, 1991, GENE, V97, P289, DOI 10.1016/0378-1119(91)90065-J; TRICOT GJ, 1989, CANCER RES, V49, P3696; VITOLS E, 1970, BIOCHEM BIOPH RES CO, V41, P71, DOI 10.1016/0006-291X(70)90470-5; WENG ML, 1995, P NATL ACAD SCI USA, V92, P7455, DOI 10.1073/pnas.92.16.7455; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; WOODS RA, 1983, MOL GEN GENET, V191, P407, DOI 10.1007/BF00425755; ZHANG M, 1991, GENE, V97, P153, DOI 10.1016/0378-1119(91)90047-F; Zimmermann AG, 1998, PROG NUCLEIC ACID RE, V61, P181, DOI 10.1016/S0079-6603(08)60827-2	48	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1523	1530		10.1074/jbc.M007926200	http://dx.doi.org/10.1074/jbc.M007926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035032	hybrid			2022-12-25	WOS:000166430900089
J	Suzuki-Inoue, K; Ozaki, Y; Kainoh, M; Shin, YC; Wu, Y; Yatomi, Y; Ohmori, T; Tanaka, T; Satoh, K; Morita, T				Suzuki-Inoue, K; Ozaki, Y; Kainoh, M; Shin, YC; Wu, Y; Yatomi, Y; Ohmori, T; Tanaka, T; Satoh, K; Morita, T			Rhodocytin induces platelet aggregation by interacting with glycoprotein Ia/IIa (GPIa/IIa, integrin alpha(2)beta(1)) - Involvement of GPIa/IIa-associated Src and protein tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; RECEPTOR-GAMMA-CHAIN; COLLAGEN-STIMULATED ACTIVATION; SIGNAL-TRANSDUCTION PATHWAYS; MEDIATED CELL-ADHESION; VON-WILLEBRAND-FACTOR; C-TYPE LECTIN; PHOSPHOLIPASE C-GAMMA-2; SUBSTRATE P130(CAS); DEPENDENT ADHESION	Although glycoprotein Ia/IIa (GPIa/IIa, integrin alpha (2)beta (1)) has established its role as a collagen receptor, it remains unclear whether GPIa/IIa mediates activation signals. In this study, we show that rhodocytin, purified from the Calloselasma rhodostoma venom, induces platelet aggregation, which can be blocked by anti-GPIa monoclonal antibodies. Studies with rhodocytin-coupled beads and liposomes loaded with recombinant GPIa/IIa demonstrated that rhodocytin directly binds to GPIa/IIa independently of divalent cations, In vitro kinase assays and Western blotting of GPIa immunoprecipitates revealed that Src and Lyn constitutively associate with GPIa/IIa and that Src activity increases transiently after rhodocytin stimulation. Src specifically associates with p130 Crk-associated substrate (Cas) in a manner dependent upon Cas phosphorylation, suggesting that Src is responsible for Cas tyrosine phosphorylation. While all these phenomena occur early after rhodocytin stimulation in a cAMP-resistant manner, tyrosine phosphorylation of Syk and phospholipase C gamma2, intracellular Ca2+ mobilization, and platelet aggregation occur later in a cAMP-sensitive manner. Cytochalasin D, which interferes with actin polymerization and blocks receptor clustering, inhibits all the rhodocytin-mediated signals we examined in this study. We suggest that rhodocytin, by clustering GPIalIIa, activates GPIa/IIa-associated Src, which then mediates downstream activation signals.	Yamanashi Med Univ, Dept Clin Lab & Med, Yamanashi 4093898, Japan; Toray Ind Inc, Pharmaceut Res Labs, Kanagawa 2488555, Japan; Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	University of Yamanashi; Toray Industries, Inc.; Meiji Pharmaceutical University	Ozaki, Y (corresponding author), Yamanashi Med Univ, Dept Clin Lab & Med, Shimokato 1110, Yamanashi 4093898, Japan.			Yatomi, Yutaka/0000-0003-1719-4297				ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Asazuma N, 1996, THROMB HAEMOSTASIS, V75, P648; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; FUJII C, 1994, EUR J BIOCHEM, V226, P243, DOI 10.1111/j.1432-1033.1994.tb20047.x; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; HANDA M, 1995, THROMB HAEMOSTASIS, V73, P521; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HUANG TF, 1995, BIOCHEM J, V309, P1021, DOI 10.1042/bj3091021; Ichinohe T, 1997, J BIOL CHEM, V272, P63; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; Inoue K, 1999, BIOCHEM BIOPH RES CO, V256, P114, DOI 10.1006/bbrc.1999.0295; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kamiguti AS, 1997, J BIOL CHEM, V272, P32599, DOI 10.1074/jbc.272.51.32599; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Kehrel B, 1998, BLOOD, V91, P491; KEHREL B, 1988, BLOOD, V71, P1074; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Manie SN, 1997, J BIOL CHEM, V272, P15636, DOI 10.1074/jbc.272.25.15636; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; NAKANO T, 1989, J BIOL CHEM, V264, P5400; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ohmori T, 2000, BIOCHEMISTRY-US, V39, P5797, DOI 10.1021/bi991849z; Ohmori T, 1999, THROMB RES, V93, P291, DOI 10.1016/S0049-3848(98)00188-1; PEERSCHKE EI, 1980, THROMB HAEMOSTASIS, V43, P58; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Shin Y, 1998, BIOCHEM BIOPH RES CO, V245, P741, DOI 10.1006/bbrc.1998.8516; SMITH JB, 1993, BIOCHEM BIOPH RES CO, V191, P695, DOI 10.1006/bbrc.1993.1273; SMITH JB, 1992, BIOCHEM J, V283, P889, DOI 10.1042/bj2830889; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Ueki K, 1998, FEBS LETT, V432, P197, DOI 10.1016/S0014-5793(98)00862-X; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Verkleij MW, 1998, BLOOD, V91, P3808; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang RH, 1999, BIOCHEMISTRY-US, V38, P7584, DOI 10.1021/bi982132z; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3	62	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1643	1652		10.1074/jbc.M006191200	http://dx.doi.org/10.1074/jbc.M006191200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038351	hybrid			2022-12-25	WOS:000166430900104
J	Fitzgerald, J; Morgelin, M; Selan, C; Wiberg, C; Keene, DR; Lamande, SR; Bateman, JF				Fitzgerald, J; Morgelin, M; Selan, C; Wiberg, C; Keene, DR; Lamande, SR; Bateman, JF			The N-terminal N5 subdomain of the alpha 3(VI) chain is important for collagen VI microfibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETHLEM MYOPATHY; VONWILLEBRAND-FACTOR; FILAMENTOUS NETWORK; MATRIX DEPOSITION; GLOBULAR DOMAINS; MESSENGER-RNA; HUMAN-SKIN; A-DOMAINS; PROTEIN; SECRETION	Collagen VI assembly is unique within the collagen superfamily in that the alpha1(VI), alpha2(VI), and alpha3(VI) chains associate intracellularly to form triple hlelical monomers, and then dimers and tetramers, which are secreted from the cell. Secreted tetramers associate end-to-end to form the distinctive extracellular microfibrils that are found in virtually all connective tissues. Although the precise protein interactions involved in this process are unknown, the N-terminal globular regions, which are composed of multiple copies elf von Willebrand factor type A-like domains, are likely to play a critical role in microfibril formation, because they are exposed at both ends of the tetramers. To explore the role of these subdomains in collagen VI intracellular and extracellular assembly, alpha3(VI) cDNA expression constructs with sequential N-terminal deletions were stably transfected into SaOS-2 cells, producing cell lines that express alpha3(VI) chains with N-terminal globular domains containing modules N9-N1, N6-N1, N5-N1, M4-N1, N3-N1, or N1, as well as the complete triple helix and C-terminal globular domain (C1-C5). All of these transfected alpha3(VI) chains were able to associate with endogenous (alpha1(VI) and alpha2(VI) to form collagen VI monomers, dimers, and tetramers, which were secreted. Importantly, cells that expressed alpha3(VI) chains containing the N5 subdomain, alpha3(VI) N9-C5, N6-C5, and N5-C5, formed microfibrils and deposited a collagen VI matrix. In contrast, cells that expressed the shorter alpha3(Vl) chains, N4-C5, N3-C5, and N1-C5, were severely compromised in their ability to form end-to-end tetramer assemblies and failed to deposit a collagen VI matrix. These data demonstrate that the alpha3(VI) N5 module is critical for microfibril formation, thus identifying a functional role for a specific type A subdomain in collagen VI assembly.	Univ Melbourne, Dept Paediat, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, S-22100 Lund, Sweden; Shriners Hosp Res Facil, Portland, OR 97201 USA	University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Lund University	Lamande, SR (corresponding author), Univ Melbourne, Dept Paediat, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia.			Lamande, Shireen/0000-0003-2938-2711; Bateman, John/0000-0001-8542-0730				BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BOHME K, 1995, DEV DYNAM, V204, P432; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; Chen Q, 1999, MOL BIOL CELL, V10, P2149, DOI 10.1091/mbc.10.7.2149; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COLOMBATTI A, 1991, BLOOD, V77, P2305; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; Keene DR, 1997, MICROSC RES TECHNIQ, V38, P394, DOI 10.1002/(SICI)1097-0029(19970815)38:4<394::AID-JEMT7>3.0.CO;2-J; KUO HJ, 1989, BIOCHEMISTRY-US, V28, P3757, DOI 10.1021/bi00435a020; Lamande SR, 1998, J BIOL CHEM, V273, P7423, DOI 10.1074/jbc.273.13.7423; Lamande SR, 1999, J BIOL CHEM, V274, P21817, DOI 10.1074/jbc.274.31.21817; Lamande SR, 1998, HUM MOL GENET, V7, P981, DOI 10.1093/hmg/7.6.981; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Mazzucato M, 1999, J BIOL CHEM, V274, P3033, DOI 10.1074/jbc.274.5.3033; Pan TC, 1998, HUM MOL GENET, V7, P807, DOI 10.1093/hmg/7.5.807; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P43; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; STOKES DG, 1991, J BIOL CHEM, V266, P8626; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; ZANUSSI S, 1992, J BIOL CHEM, V267, P24082	32	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					187	193		10.1074/jbc.M008173200	http://dx.doi.org/10.1074/jbc.M008173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027693	hybrid			2022-12-25	WOS:000166280700027
J	Peri, R; Wible, BA; Brown, AM				Peri, R; Wible, BA; Brown, AM			Mutations in the Kv beta 2 binding site for NADPH and their effects on Kv1.4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL BETA-SUBUNIT; FUNCTIONAL EXPRESSION; K+ CHANNELS; INACTIVATION; CLONING	Kv beta2 enhances the rate of inactivation and level of expression of Kv1.4 currents. The crystal structure of Kv beta2 binds NADP(+), and it has been suggested that Kv beta2 is an oxidoreductase enzyme (1). To investigate how this function might relate to channel modulation, we made point mutations in Kv beta2 in either the NADPH docking or putative catalytic sites. Using the yeast two-hybrid system, we found that these mutations did not disrupt the interaction of Kv beta2 with Kv alpha1 channels. To characterize the Kv beta2 mutants functionally, we coinjected wild-type or mutant Kv beta2 cRNAs and Kv1.4 cRNA in Xenopus laevis oocytes. Kv beta2 increased both the amplitude and rate of inactivation of Kv1.4 currents. The cellular content of Kv1.4 protein was unchanged on Western blot, but the amount in the plasmalemma was increased. Mutations in either the orientation or putative catalytic sites for NADPH abolished the expression-enhancing effect on Kv1.4 current. Western blots showed that both types of mutation reduced Kv1.4 protein. Like the wild-type Kv beta2, both types of mutation increased the rate of inactivation of Kv1.4, confirming the physical association of mutant Kv beta2 subunits with Kv1.4, Thus, mutations that should interfere with NADPH function uncouple the expression-enhancing ef. feet of Kv beta2 on Kv1.4 currents from its effect on the rate of inactivation. These results suggest that the binding of NADPH and the putative oxidoreductase activity of Kv beta2 may play a role in the processing of Kv1.4.	Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Physiol & Biochem, Cleveland, OH 44109 USA	MetroHealth System; Case Western Reserve University	Peri, R (corresponding author), Rammelkamp Ctr Educ & Res, R301,MetroHlth Dr, Cleveland, OH 44109 USA.				NHLBI NIH HHS [HL60759, HL36930, HL55404] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930, R01HL055404, R01HL060759] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accili EA, 1998, J PHYSIOL-LONDON, V512, P325, DOI 10.1111/j.1469-7793.1998.325be.x; Accili EA, 1997, J BIOL CHEM, V272, P25824, DOI 10.1074/jbc.272.41.25824; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; Wang ZG, 1996, J BIOL CHEM, V271, P28311, DOI 10.1074/jbc.271.45.28311; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745	14	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					738	741		10.1074/jbc.M008445200	http://dx.doi.org/10.1074/jbc.M008445200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024060	hybrid			2022-12-25	WOS:000166280700099
J	Yang, Z; Champoux, JJ				Yang, Z; Champoux, JJ			The role of histidine 632 in catalysis by human topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SIMIAN VIRUS-40 DNA; EUKARYOTIC TOPOISOMERASE; VACCINIA TOPOISOMERASE; WHEAT-GERM; SV40 DNA; CAMPTOTHECIN; CLEAVAGE; SEQUENCE; IDENTIFICATION	Based on the crystal structure of human topoisomerase I, we hypothesized that hydrogen bonding between the side chain of the highly conserved His(632) and one of the nonbridging oxygens of the scissile phosphate contributes to catalysis by stabilizing the transition state. This hypothesis has been tested by examining the effects of changing His(632) to glutamine, asparagine, alanine, and tryptophan, The change to glutamine reduced both the relaxation activity and single-turnover cleavage activity by approximately 100-fold, whereas the same change at three other conserved histidines (positions 222, 387, and 406) had no significant effect on the relaxation activity. The properties of the mutant protein containing asparagine instead of histidine at position 632 were similar to those of the glutamine mutant, whereas mutations to alanine or tryptophan reduced the activity by approximately 4 orders of magnitude. The reduction in activity for the mutants was not due to alterations in substrate binding affinities or changes in the cleavage specificities of the proteins. The above results for the glutamine mutation in conjunction with the similar effects of pH on the wild type and the H632Q mutant enzyme rule out the possibility that His(632) acts as a general acid to protonate the leaving 5'-oxygen during the cleavage reaction, Taken together, these data strongly support the hypothesis that the only role for His632 is to stabilize the pentavalent transition state through hydrogen bonding to one of the nonbridging oxygens.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Champoux JJ, 1998, PROG NUCLEIC ACID RE, V60, P111, DOI 10.1016/S0079-6603(08)60891-0; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; CHENG C, 1997, J BIOL CHEM, V22, P8263; CHRISTIANSEN K, 1987, J MOL BIOL, V193, P517, DOI 10.1016/0022-2836(87)90264-6; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; FERST A, 1999, STRUCTURE MECH PROTE, P170; GOTO T, 1984, J BIOL CHEM, V259, P422; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Ireton GC, 2000, J BIOL CHEM, V275, P25820, DOI 10.1074/jbc.M002144200; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; KIKUCHI A, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P121; KIM RA, 1992, J BIOL CHEM, V267, P17178; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2000, BIOCHEMISTRY-US, V39, P6422, DOI 10.1021/bi000184u; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; MADDEN KR, 1992, CANCER RES, V52, P525; PARKER LH, 1993, J MOL BIOL, V231, P6, DOI 10.1006/jmbi.1993.1252; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; PORTER SE, 1989, MOL CELL BIOL, V9, P541, DOI 10.1128/MCB.9.2.541; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Redinbo Matthew R., 1999, Current Opinion in Structural Biology, V9, P29, DOI 10.1016/S0959-440X(99)80005-0; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	44	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					677	685		10.1074/jbc.M007593200	http://dx.doi.org/10.1074/jbc.M007593200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024057	hybrid			2022-12-25	WOS:000166280700091
J	Basso, J; Briggs, J; Findlay, C; Bos, T				Basso, J; Briggs, J; Findlay, C; Bos, T			Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts	ONCOGENE			English	Article						v-Jun; chicken; binding mutants	MOUSE C-JUN; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; TRANSCRIPTION FACTORS; CELL-TRANSFORMATION; NUCLEAR-PROTEIN; LEUCINE ZIPPER; BZIP PROTEINS; TARGET GENE; FOS	Overexpression of v-Jun in chicken embryo fibroblasts (CEF) leads to oncogenic transformation phenotypically characterized by anchorage independent growth and release from contact inhibition (focus formation). The mechanisms involved in this oncogenic conversion however, are not yet clear. Because Jun is a transcription factor, it has been assumed that oncogenic transformation results directly from deregulated AP-1 target gene expression. However, a number of experimental observations in avian cell culture models fail to correlate oncogenesis with AP-I activity suggesting that transformation induced by v-Jun may occur through an indirect mechanism, To test this possibility, we introduced point mutations into the basic DNA binding domain of v-Jun and created mutants that exhibit altered binding specificity, When expressed in CEF, these mutants fail to deregulate three known v-Jun target genes (JTAP-1, apolipoprotein Al,: c-Jun) thus demonstrating in vivo specificity changes, Each of the binding specificity mutants was also tested for its ability to induce oncogenic transformation. Interestingly, expression of these mutants in CEF results in a phenotype indistinguishable from the vector control with respect to growth rate, focus formation and the ability to form colonies in soft agar, These results are consistent with a model requiring direct AP-1 target deregulation as a prerequisite of v-Jun induced cell transformation. With this in mind, we generated a series of additional mutants that retain the ability to bind AP-1 sequence elements, but vary in their oncogenic potential. We demonstrate the use of these mutants to screen v-Jun induced gene targets for a functional role in cell transformation.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA	Eastern Virginia Medical School	Bos, T (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, POB 1980, Norfolk, VA 23501 USA.				NCI NIH HHS [R01 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN PH, 1993, ONCOGENE, V8, P877; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HADMAN M, 1993, ONCOGENE, V8, P1895; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; Hadman M, 1996, ONCOGENE, V12, P135; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; METIVIER C, 1993, ONCOGENE, V8, P2311; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; TOURAY M, 1991, ONCOGENE, V6, P1227; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; VOGT PK, 1990, CANCER BIOL, V1, P27; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206	50	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2000	19	42					4876	4885		10.1038/sj.onc.1203863	http://dx.doi.org/10.1038/sj.onc.1203863			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039905				2022-12-25	WOS:000089757800010
J	Elliott, K; Ge, K; Du, W; Prendergast, GC				Elliott, K; Ge, K; Du, W; Prendergast, GC			The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program	ONCOGENE			English	Article						transformation; apoptosis; cancer; amphiphysin-like protein/amph1	TUMOR-SUPPRESSOR BIN1; ABL TYROSINE KINASE; INDUCED APOPTOSIS; GENE-EXPRESSION; SCHIZOSACCHAROMYCES-POMBE; MEDIATED ENDOCYTOSIS; AMPHIPHYSIN ISOFORM; EMBRYO FIBROBLASTS; PROSTATE-CANCER; SPLICE VARIANTS	Cell death processes are progressively inactivated during malignant development, in part by loss of tumor suppressors that can promote cell death. The Bin1 gene encodes a nucleocytosolic adaptor protein with tumor suppressor properties, initially identified through its ability to interact with and inhibit malignant transformation by c-Myc and other oncogenes, Bin1 is frequently missing or functionally inactivated in breast and prostate cancers and in melanoma, In this study, we show that Bin1 engages a caspase-independent cell death process similar to type II apoptosis, characterized by cell shrinkage, substratum detachment, vacuolated cytoplasm, and DNA degradation. Cell death induction was relieved by mutation of the BAR domain, a putative effector domain, or by a missplicing event that occurs in melanoma and inactivates suppressor activity. Cells in all phases of the cell cycle were susceptible to death and p53 and Rb were dispensable. Notably, Bin1 did not activate caspases and the broad spectrum caspase inhibitor ZVAD,fmk did not block cell death. Consistent with the lack of caspase involvement, dying cells lacked nucleosomal DNA cleavage and nuclear lamina degradation. Moreover, neither Bcl-2 or dominant inhibition of the Pas pathway had any effect. In previous work, we showed that Bin1 could not suppress cell transformation by SV40 large T antigen. Consistent with this finding, we observed that T antigen suppressed the death program engaged by Bin1, This observation was interesting in light of emerging evidence that T antigen has roles in cell immortalization and human cell transformation beyond Rb and p53 inactivation. In support of a link to c-Myc-induced death processes, AEBSF, a serine protease inhibitor that inhibits apoptosis by c-Myc, potently suppressed DNA degradation by Bin1, Our findings suggest that the tumor suppressor activity of Bin1 reflects engagement of a unique cell death program, We propose that loss of Bin1 may promote malignancy by blunting death penalties associated with oncogene activation.	Dupont Merck Pharmaceut Co, Glenolden Lab, Glenolden, PA 19036 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	DuPont; The Wistar Institute	Prendergast, GC (corresponding author), Dupont Merck Pharmaceut Co, Glenolden Lab, Glenolden, PA 19036 USA.		Ge, Kai/H-2810-2019	Ge, Kai/0000-0002-7442-5138				ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barbieri MA, 1998, J BIOL CHEM, V273, P19367, DOI 10.1074/jbc.273.31.19367; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bowen C, 1998, CANCER RES, V58, P3275; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Conzen SD, 1995, ONCOGENE, V11, P2295; Crouch DH, 1996, ONCOGENE, V12, P2689; Dang CV, 1999, MOL CELL BIOL, V19, P1; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Davis RA, 1996, ECONOMET THEOR, V12, P1, DOI 10.1017/S0266466600006423; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harlow E, 1998, ANTIBODIES LAB MANUA; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Jenkins RB, 1997, CANCER RES, V57, P524; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KYPRIANOU N, 1990, CANCER RES, V50, P3748; KYPRIANOU N, 1991, CANCER RES, V51, P162; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LEMAITRE JM, 1995, MOL CELL BIOL, V15, P5054; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mao NC, 1999, GENOMICS, V56, P51, DOI 10.1006/geno.1998.5709; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Powell AJ, 1999, ONCOGENE, V18, P7343, DOI 10.1038/sj.onc.1203154; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; Tsuneoka M, 2000, ONCOGENE, V19, P115, DOI 10.1038/sj.onc.1203232; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang P, 2000, INT J CANCER, V85, P599, DOI 10.1002/(SICI)1097-0215(20000301)85:5<599::AID-IJC1>3.0.CO;2-#	97	84	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4669	4684		10.1038/sj.onc.1203681	http://dx.doi.org/10.1038/sj.onc.1203681			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032017				2022-12-25	WOS:000089528800001
J	Jackson, JG; Kreisberg, JI; Koterba, AP; Yee, D; Brattain, M				Jackson, JG; Kreisberg, JI; Koterba, AP; Yee, D; Brattain, M			Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells	ONCOGENE			English	Article						forkhead; FKHR; EGF; breast cancer	PROTEIN-KINASE-B; CAENORHABDITIS-ELEGANS; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; FACTOR RECEPTORS; BINDING-SITE; INSULIN; AKT; TRANSLOCATION; LONGEVITY	Akt, when activated by IGF/insulin, can phosphorylate forkhead transcription factors. We undertook this study to determine whether epidermal growth factor (EGF) treatment could produce a signaling cascade resulting in phosphorylation of the forkhead transcription factor FKHR in a breast cancer cell line, MDA-MB-231, After establishing ErbB1, cbl, PI3 kinase and Akt were activated in EGF treated MDA-MB-231, we determined by immunoblot with FKHR antiserum that the electrophoretic mobility of FKHR was retarded after EGF treatment. This mobility retardation was reversible by treatment with alkaline phosphatase, and immunoblot with phospho-Ser(256) FKHR antibody further confirmed phosphorylation on an Akt consensus site after EGF treatment. EGF stimulated FKHR phosphorylation was blocked by the PI3 kinase inhibitor LY294002, and the ErbB1 inhibitor AG1478, FKHR immunoblotting after purification of nuclear and cytoplasmic proteins showed that EGF induced a simultaneous increase of FKHR in the cytoplasm and decrease in the nucleus. This finding was confirmed by immunofluorescence staining. Treatment of cells with pharmacological inhibitors of PI3 kinase or ErbB1 blocked this effect. Thus, these results demonstrate the phosphorylation and nuclear exclusion of FKHR after EGF treatment by a PI3 kinase dependent mechanism, and represent the first report of growth factor regulation of endogenous FKHR localization.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Audie L Murphy Mem Vet Hosp, Div Res & Dev, San Antonio, TX 78229 USA; Univ Minnesota, Ctr Canc, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Minnesota System; University of Minnesota Twin Cities	Brattain, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Yee, Douglas/0000-0002-3387-4009; Jackson, James Griffith/0000-0002-2640-6442	NATIONAL CANCER INSTITUTE [R01CA054807, R01CA034432, R01CA074285] Funding Source: NIH RePORTER; NCI NIH HHS [CA74285, CA54807, CA34432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLASS WF, 1993, J CELL PHYSIOL, V157, P296; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lewis GD, 1996, CANCER RES, V56, P1457; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; Vijapurkar U, 1998, J BIOL CHEM, V273, P20996, DOI 10.1074/jbc.273.33.20996; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	39	73	73	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4574	4581		10.1038/sj.onc.1203825	http://dx.doi.org/10.1038/sj.onc.1203825			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030146				2022-12-25	WOS:000089438200003
J	Llera, AS; Viedma, F; Sanchez-Madrid, F; Tormo, J				Llera, AS; Viedma, F; Sanchez-Madrid, F; Tormo, J			Crystal structure of the C-type lectin-like domain from the human hematopoietic cell receptor CD69	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION INDUCER MOLECULE; MHC CLASS-I; CARBOHYDRATE-RECOGNITION; GENE-COMPLEX; INHIBITORY RECEPTOR; ESCHERICHIA-COLI; HLA-E; EXPRESSION; PROTEIN; ANTIGEN	CD69,: one of the earliest specific antigens acquired during lymphoid activation, acts as a signal-transducing receptor,involved in cellular activation events, including proliferation and induction of specific genes. CD69 belongs:to a family of receptors that modulate the immune response and whose genes are clustered in the natural killer (NK) gene complex. The extracellular portion of these receptors represent a subfamily of C-type lectin-like domains (CTLDs), which are divergent from true C-type lectins and are referred to as NK-cell domains (NKDs). We have determined the three-dimensional:Structure of human CD69 NKD in two different crystal forms. CD69 NKD adopts the canonical CTLD fold but lacks:the features involved in Ca2+ and carbohydrate binding by C-type lectins. CD69 NKD dimerizes noncovalently, both in solution and in crystalline state. The dimer interface consists of a hydrophobic, loosely packed core,:surrounded by polar interactions, including an interdomain beta sheet. The intersubunit core shows certain structural plasticity that may facilitate conformational: rearrangements for binding to ligands. The surface equivalent to the binding site of other members of the CTLD superfamily reveals a hydrophobic patch surrounded by conserved charged residues that probably constitutes:the CD69 ligand-binding site.	Univ Autonoma Madrid, Natl Biotechnol Ctr, Dept Macromol Struct, E-28049 Madrid, Spain; Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Estudios Inmunidad Humoral, RA-1113 Buenos Aires, DF, Argentina; Univ Autonoma Madrid, Hosp Princesa, Serv Immunol, Madrid 28006, Spain	Autonomous University of Madrid; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Autonomous University of Madrid; Hospital de La Princesa	Tormo, J (corresponding author), Univ Autonoma Madrid, Natl Biotechnol Ctr, Dept Macromol Struct, E-28049 Madrid, Spain.	jtormo@cnb.uam.es	Sanchez-Madrid, Francisco/M-7889-2016; Llera, Andrea S/AAW-8116-2021	Sanchez-Madrid, Francisco/0000-0001-5303-0762; Llera, Andrea/0000-0002-0089-0061				BAJORATH J, 1994, J BIOL CHEM, V269, P32457; Bates EEM, 1999, J IMMUNOL, V163, P1973; Blery M, 2000, HUM IMMUNOL, V61, P51, DOI 10.1016/S0198-8859(99)00157-3; Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brown MG, 1997, IMMUNOL REV, V155, P53, DOI 10.1111/j.1600-065X.1997.tb00939.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CEBRIAN M, 1988, J EXP MED, V168, P1621, DOI 10.1084/jem.168.5.1621; Childs RA, 1999, BIOCHEM BIOPH RES CO, V266, P19, DOI 10.1006/bbrc.1999.1762; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HAMANN J, 1993, J IMMUNOL, V150, P4920; Hubbard S. J., 1993, NACCESS; Hubbard SJ, 1996, J MOL BIOL, V261, P289, DOI 10.1006/jmbi.1996.0460; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauzurica P, 2000, BLOOD, V95, P2312, DOI 10.1182/blood.V95.7.2312.007k16_2312_2320; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Lopez-Botet M, 2000, SEMIN IMMUNOL, V12, P109, DOI 10.1006/smim.2000.0213; Lopez-Botet M, 1999, CURR OPIN IMMUNOL, V11, P301, DOI 10.1016/S0952-7915(99)80048-X; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; Marzio R, 1999, IMMUNOPHARM IMMUNOT, V21, P565, DOI 10.3109/08923979909007126; Masumoto M, 1999, J IMMUNOL, V163, P5039; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKAMURA S, 1989, J EXP MED, V169, P677, DOI 10.1084/jem.169.3.677; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SANCHEZMATEOS P, 1991, EUR J IMMUNOL, V21, P2317, DOI 10.1002/eji.1830211005; SANCHEZMATEOS P, 1989, IMMUNOLOGY, V68, P72; SANTIS AG, 1992, EUR J IMMUNOL, V22, P1253, DOI 10.1002/eji.1830220521; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suzuki N, 1996, J IMMUNOL, V156, P128; TESTI R, 1988, J IMMUNOL, V141, P2557; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; TESTI R, 1989, J IMMUNOL, V143, P1123; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; Ugolini S, 2000, CURR OPIN IMMUNOL, V12, P295, DOI 10.1016/S0952-7915(00)00090-X; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; ZIEGLER SF, 1994, J IMMUNOL, V152, P1228; Zingoni A, 2000, EUR J IMMUNOL, V30, P644, DOI 10.1002/1521-4141(200002)30:2<644::AID-IMMU644>3.0.CO;2-H	60	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7312	7319		10.1074/jbc.M008573200	http://dx.doi.org/10.1074/jbc.M008573200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11036086	Green Published, hybrid			2022-12-25	WOS:000167442900063
J	Kavurma, MM; Santiago, FS; Bonfoco, E; Khachigian, LM				Kavurma, MM; Santiago, FS; Bonfoco, E; Khachigian, LM			Sp1 phosphorylation regulates apoptosis via extracellular FsasL-Fas engagement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; HUMAN ATHEROSCLEROTIC LESIONS; T-CELLS; TRANSCRIPTIONAL REGULATION; GLUCOSE-TRANSPORT; LIGAND EXPRESSION; OKADAIC ACID; HIV-1 TAT; ACTIVATION	Apoptosis of smooth muscle cells (SMC) in atherosclerotic vessels can destabilize the atheromatus plaque and result in rupture, thrombosis, and sudden death. In efforts to understand the molecular processes regulating apoptosis in this cell type, we have defined a novel mechanism involving the ubiquitously expressed transcription factor Sp1. Subtypes of SMC expressing abundant levels of Spl produce the death agonist, Fas ligand (FasL) and undergo greater spontaneous apoptosis, Sp1 activates the FasL promoter via a distinct nucleotide recognition element whose integrity is crucial for inducible expression. Inducible FasL promoter activation is also inhibited by a dominant-negative form of Sp1, Increased SMC apoptosis is preceded by Sp1 phosphorylation, increased FasL transcription, and the autocrine/ paracrine engagement of FasL with its cell-surface receptor, Fas, Inducible FasL transcription and apoptosis are blocked by dominant-negative protein kinase C-zeta, whose wild-type counterpart phosphorylates Sp1. Thus, Sp1 phosphorylation is a proapoptotic transcriptional event in vascular SMC and, given the wide distribution of this housekeeping transcription factor, may be a common regulatory theme in apoptotic signal transduction.	Univ New S Wales, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Scripps Res Inst, La Jolla, CA 92037 USA	University of New South Wales Sydney; Scripps Research Institute	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323; Kavurma, Mary/0000-0001-7353-0932				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bennett MR, 1997, CIRC RES, V81, P591, DOI 10.1161/01.RES.81.4.591; Bjorkerud S, 1996, AM J PATHOL, V149, P367; Cai WJ, 1997, ATHEROSCLEROSIS, V131, P177, DOI 10.1016/S0021-9150(97)06099-1; CHENG GC, 1993, CIRCULATION, V87, P1179, DOI 10.1161/01.CIR.87.4.1179; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAVIES MJ, 1993, BRIT HEART J, V69, P377; DAVIS MA, 1994, TOXICOL PATHOL, V22, P595, DOI 10.1177/019262339402200604; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Flynn PD, 1997, BLOOD, V89, P4378, DOI 10.1182/blood.V89.12.4378; Geng YJ, 1998, CIRCULATION, V98, P48; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones MM, 1997, TOXICOLOGY, V116, P169, DOI 10.1016/S0300-483X(96)03541-X; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Kockx MM, 1998, EUR HEART J, V19, pG23; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Kockx MM, 1998, ARTERIOSCL THROM VAS, V18, P1519, DOI 10.1161/01.ATV.18.10.1519; Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LEMIRE JM, 1994, AM J PATHOL, V144, P1068; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LI YC, 1994, J BIOL CHEM, V269, P30616; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; Luo ZY, 1999, CIRCULATION, V99, P1776, DOI 10.1161/01.CIR.99.14.1776; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Newby AC, 1997, CORONARY ARTERY DIS, V8, P213, DOI 10.1097/00019501-199703000-00013; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pantazis P, 1995, LEUKEMIA RES, V19, P775, DOI 10.1016/0145-2126(95)00048-8; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758; RICHARDSON PD, 1989, LANCET, V2, P941; Sandoval M, 1997, FREE RADICAL BIO MED, V22, P489, DOI 10.1016/S0891-5849(96)00374-7; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Schneider DB, 2000, ARTERIOSCL THROM VAS, V20, P298, DOI 10.1161/01.ATV.20.2.298; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Thompson RW, 1997, CORONARY ARTERY DIS, V8, P623, DOI 10.1097/00019501-199710000-00005; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; YO FM, 2000, CIRCULATION, V101, P2618; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	56	73	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4964	4971		10.1074/jbc.M009251200	http://dx.doi.org/10.1074/jbc.M009251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11053446	hybrid			2022-12-25	WOS:000168484300060
J	Ohmori, T; Yatomi, Y; Okamoto, H; Miura, Y; Rile, G; Satoh, K; Ozaki, Y				Ohmori, T; Yatomi, Y; Okamoto, H; Miura, Y; Rile, G; Satoh, K; Ozaki, Y			G(i)-mediated Cas tyrosine phosphorylation in vascular endothelial cells stimulated with sphingosine 1-phosphate - Possible involvement in cell motility enhancement in cooperation with Rho-mediated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MULTIPLE SIGNALING PATHWAYS; G-PROTEIN; C-SRC; LYSOPHOSPHATIDIC ACID; MONOCLONAL-ANTIBODY; SURFACE-RECEPTOR; HUMAN PLATELETS; V-SRC; P130(CAS)	Since blood platelets release sphingosine 1-phosphate (Sph-1-P) upon activation, it is important to examine the effects of this bioactive lipid on vascular endothelial cell functions from the viewpoint of platelet-endothelial cell interactions. In the present study, we examined Sph-1-P-stimulated signaling pathways related to human umbilical vein endothelial cell (HUVEC) motility, with a special emphasis on the cytoskeletal docking protein Crk-associated substrate (Cas). Sph-1-P stimulated tyrosine phosphorylation of Gas, which was inhibited by the G(i) inactivator pertussis toxin but not by the Rho inactivator C3 exoenzyme or the Rho kinase inhibitor Y-27632. Fyn constitutively associated with and phosphorylated Gas, suggesting that Gas tyrosine phosphorylation may be catalyzed by Fyn. Furthermore, upon HUVEC stimulation with Sph-1-P, Crk, through its SH2 domain, interacted with tyrosine-phosphorylated Gas, and the Cas-Crk complex translocated to the cell periphery (membrane ruffles), through mediation of G(i) (Fyn) but not Rho. In contrast, tyrosine phosphorylation of focal adhesion kinase, and formation of stress fibers and focal adhesion were mediated by Rho but not G(i) (Fyn). Finally, Sph-1-P-enhanced HUVEC motility, assessed by a phagokinetic assay using gold sol-coated plates and a Boyden's chamber assay, was markedly inhibited not only by pertussis toxin (or the Fyn kinase inhibitor PP2) but also by C3 exoenzyme (or Y-27632). In HUVECs stimulated with Sph-1-P, these data suggest the following: (i) cytoskeletal signalings may be separable into G(i)-mediated signaling pathways (involving Gas) and Rho-mediated ones (involving FAK), and (ii) coordinated signalings from both pathways are required for Sph-1-P-enhanced HUVEC motility. Since HUVECs reportedly express the Sph-1-P receptors EDG-1 (coupled with G(i)) and EDG-3 (coupled with G(13) and G(q)) and the EDG-3 antagonist suramin was found to block specifically Rho-mediated responses, it is likely that Gas-related responses following G(i) activation originate from EDG-1, whereas Rho-related responses originate from EDG-3.	Yamanashi Med Univ, Dept Lab Med, Yamanashi 4093898, Japan	University of Yamanashi	Yatomi, Y (corresponding author), Yamanashi Med Univ, Dept Lab Med, Yamanashi 4093898, Japan.	yatomiy@res.yamanashi-med.ac.jp		Yatomi, Yutaka/0000-0003-1719-4297				ALBRECHTBUEHLER G, 1977, CELL, V12, P333, DOI 10.1016/0092-8674(77)90109-X; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; ILLC D, 1995, NATURE, V377, P539; Kaibuchi K, 1999, Prog Mol Subcell Biol, V22, P23; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; MCCARTHY JB, 1983, J CELL BIOL, V97, P772, DOI 10.1083/jcb.97.3.772; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; MORII N, 1995, METHOD ENZYMOL, V256, P196; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OZAKI Y, 1995, J BIOL CHEM, V270, P15119, DOI 10.1074/jbc.270.25.15119; Rozengurt E, 1998, AM J PHYSIOL-GASTR L, V275, pG177, DOI 10.1152/ajpgi.1998.275.2.G177; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; TAKAISHI K, 1995, METHOD ENZYMOL, V256, P336; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Wu Y, 2000, BBA-MOL CELL RES, V1497, P27, DOI 10.1016/S0167-4889(00)00043-4; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	52	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5274	5280		10.1074/jbc.M005405200	http://dx.doi.org/10.1074/jbc.M005405200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11056155	hybrid			2022-12-25	WOS:000168484300099
J	Kutty, RK; Kutty, G; Samuel, W; Duncan, T; Bridges, CC; El-Sherbeeny, A; Nagineni, CN; Smith, SB; Wigger, B				Kutty, RK; Kutty, G; Samuel, W; Duncan, T; Bridges, CC; El-Sherbeeny, A; Nagineni, CN; Smith, SB; Wigger, B			Molecular characterization and developmental expression of NORPEG, a novel gene induced by retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; MESSENGER-RNA; ALTERNATIVE POLYADENYLATION; BINDING PROTEIN; MOUSE; RECEPTOR; COMPLEX; LINE; DIFFERENTIATION; TRANSCRIPTS	We have characterized NORPEG, a novel gene from human retinal pigment epithelial cells (ARPE-19), in which its expression is induced by all-trans-retinoic acid. Two transcripts (similar to3 and similar to5 kilobases in size) have been detected for this gene, which is localized to chromosome band 5p13.2-13.3. Placenta and testis showed the highest level of expression among various human tissues tested. Six ankyrin repeats and a long coiled-coil domain are present in the predicted sequence of the NORPEG protein, which contains 980 amino acid residues. This similar to 110-kDa protein was transiently expressed in COS-7 cells as a FLAG fusion protein and immunolocalized to the cytoplasm, Confocal microscopic analysis of the NORPEG protein in ARPE-19 cells showed threadlike projections in the cytoplasm reminiscent of the cytoskeleton, Consistent with this localization, the expressed NORPEG protein showed resistance to solubilization by Triton X-100 and KCl. An ortholog of NORPEG characterized from mouse encoded a protein that showed 91% sequence similarity to the human NORPEG protein. The expression of Norpeg mRNA was detected in mouse embryo at embryonic day 9.5 by in situ hybridization, and the expression appears to be developmentally regulated. In adult mouse, the highest level of expression was detected in the seminiferous tubules of testis.	NEI, LRCMB, NIH, Biochem Sect, Bethesda, MD 20892 USA; NEI, Immunol Lab, NIH, Immunol & Virol Sect, Bethesda, MD 20892 USA; Med Coll Georgia, Dept Cellular Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Kutty, RK (corresponding author), NEI, LRCMB, NIH, Biochem Sect, 6 Ctr Dr,Rm 338, Bethesda, MD 20892 USA.	krishnan@helix.nih.gov	El-Sherbeeny, Ahmed/ABC-7879-2020	Bridges, Christy/0000-0003-1603-1445	NEI NIH HHS [EY 13089] Funding Source: Medline; NATIONAL EYE INSTITUTE [R21EY013089] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; BOK D, 1993, J CELL SCI, P189; Chancy CD, 2000, J BIOL CHEM, V275, P20676, DOI 10.1074/jbc.M002328200; Chen F, 1999, P NATL ACAD SCI USA, V96, P15149, DOI 10.1073/pnas.96.26.15149; CONLON RA, 1995, TRENDS GENET, V11, P314, DOI 10.1016/S0168-9525(00)89089-7; Crouch RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P613, DOI 10.1111/j.1751-1097.1996.tb03114.x; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Faber J.J., 1983, PLACENTAL PHYSL; Fawcett DW, 1975, HDB PHYSIOLOGY     7, VV, P21; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; FRANKE WW, 1981, J MOL BIOL, V153, P933, DOI 10.1016/0022-2836(81)90460-5; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Janssen JJM, 2000, NEUROREPORT, V11, P1571, DOI 10.1097/00001756-200005150-00040; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Komada M, 2000, GENE DEV, V14, P1332; Krebber H, 1996, GENE, V180, P7, DOI 10.1016/S0378-1119(96)00389-7; LU Y, 1994, GENE, V145, P261; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]; McCaffery P, 2000, CYTOKINE GROWTH F R, V11, P233, DOI 10.1016/S1359-6101(00)00002-2; McCaffery P, 1996, P NATL ACAD SCI USA, V93, P12570, DOI 10.1073/pnas.93.22.12570; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MISHIMA K, 1992, J BIOL CHEM, V267, P24109; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Rao NA, 2000, PROG RETIN EYE RES, V19, P41, DOI 10.1016/S1350-9462(99)00003-8; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Sapin V, 1997, DEV DYNAM, V208, P199, DOI 10.1002/(SICI)1097-0177(199702)208:2<199::AID-AJA7>3.0.CO;2-D; SCHMITT MC, 1993, BIOL REPROD, V49, P972, DOI 10.1095/biolreprod49.5.972; Sibley CP, 1998, FETAL NEONATAL PHYSL, P77; Sporn M.B., 1994, RETINOIDS BIOL CHEM; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANPELT AMM, 1991, ENDOCRINOLOGY, V128, P697, DOI 10.1210/endo-128-2-697; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; YAMAUCHITAKIHARA K, 1989, P NATL ACAD SCI USA, V86, P3504, DOI 10.1073/pnas.86.10.3504; YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1145/1165387.275645	52	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2831	2840		10.1074/jbc.M007421200	http://dx.doi.org/10.1074/jbc.M007421200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042181	hybrid			2022-12-25	WOS:000166784800074
J	Murakami, E; Deppenmeier, U; Ragsdale, SW				Murakami, E; Deppenmeier, U; Ragsdale, SW			Characterization of the intramolecular electron transfer pathway from 2-hydroxyphenazine to the heterodisulfide reductase from Methanosarcina thermophilo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; MAZEI GO1; OXIDOREDUCTASE SYSTEM; THIOREDOXIN REDUCTASE; F420H2 DEHYDROGENASE; METHANOGENIC ARCHAEA; ENERGY-CONSERVATION; SPINACH FERREDOXIN; PURIFICATION; COMPLEX	Heterodisulfide reductase (HDR) is a component of the energy-conserving electron transfer system in methanogens, HDR catalyzes the two-electron reduction of coenzyme B-S-S-coenzyme M (CoB-S-S-CoM), the heterodisulfide product of the methyl-CoM reductase reaction, to free thiols, HS-CoB and HS-CoM, HDR from Methanosarcina thermophila contains two b-hemes and two [Fe4S4] clusters. The physiological electron donor for HDR appears to be methanophenazine (MPhen), a membrane-bound cofactor, which can be replaced by a water-soluble analog, 2-hydroxyphenazine (HPhen), This report describes the electron transfer pathway from reduced HPhen (HPhenH(2)) to CoB-S-S-CoM. Steady-state kinetic studies indicate a ping-pong mechanism for heterodisulfide reduction by HPhenH(2) with the following values: k(cat) = 74 s(-1) at 25 degreesC, K-m (HPhenH(2)) = 92 muM, K-m (CoB-S-S-CoM) = 144 muM Rapid freeze-quench EPR and stopped-flow kinetic studies and inhibition experiments using CO and diphenylene iodonium indicate that only the low spin heme and the high potential FeS cluster are involved in CoB-S-S-CoM reduction by HPhenH(2). Fe-S cluster disruption by mersalyl acid inhibits heme reduction by HPhenH(2), suggesting that a 4Fe cluster is the initial electron acceptor from HPhenH(2). We propose the following electron transfer pathway: HPhenH(2) to the high potential 4Fe cluster, to the low potential heme, and finally, to CoB-S-S-CoM.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA; Univ Gottingen, Inst Mikrobiol, D-37077 Gottingen, Germany	University of Nebraska System; University of Nebraska Lincoln; University of Gottingen	Ragsdale, SW (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA.							Abken HJ, 1997, FEMS MICROBIOL LETT, V154, P231, DOI 10.1111/j.1574-6968.1997.tb12649.x; Abken HJ, 1998, J BACTERIOL, V180, P2027, DOI 10.1128/JB.180.8.2027-2032.1998; Baumer S, 1998, FEBS LETT, V428, P295, DOI 10.1016/S0014-5793(98)00555-9; BAUMER S, 2000, J BIOL CHEM; Becker DF, 1998, BIOCHEMISTRY-US, V37, P2639, DOI 10.1021/bi972145x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brodersen J, 1999, EUR J BIOCHEM, V259, P218, DOI 10.1046/j.1432-1327.1999.00017.x; Deppenmeier U, 1999, FEBS LETT, V457, P291, DOI 10.1016/S0014-5793(99)01026-1; DEPPENMEIER U, 1990, P NATL ACAD SCI USA, V87, P9449, DOI 10.1073/pnas.87.23.9449; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; ELLERMANN J, 1988, EUR J BIOCHEM, V172, P669, DOI 10.1111/j.1432-1033.1988.tb13941.x; ELLIOTT JI, 1982, J BACTERIOL, V151, P328, DOI 10.1128/JB.151.1.328-333.1982; GATLEY SJ, 1976, BIOCHEM J, V158, P307, DOI 10.1042/bj1580307; HAASE P, 1992, EUR J BIOCHEM, V203, P527, DOI 10.1111/j.1432-1033.1992.tb16579.x; Ide T, 1999, J BACTERIOL, V181, P4076, DOI 10.1128/JB.181.13.4076-4080.1999; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; KUHN W, 1983, EUR J BIOCHEM, V135, P89, DOI 10.1111/j.1432-1033.1983.tb07621.x; Kunkel A, 1997, EUR J BIOCHEM, V244, P226, DOI 10.1111/j.1432-1033.1997.00226.x; KUNOW J, 1994, EUR J BIOCHEM, V223, P503, DOI 10.1111/j.1432-1033.1994.tb19019.x; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; Meuer J, 1999, EUR J BIOCHEM, V265, P325, DOI 10.1046/j.1432-1327.1999.00738.x; Muller V, 1999, J BIOENERG BIOMEMBR, V31, P15, DOI 10.1023/A:1005451311009; PEER CW, 1994, J BACTERIOL, V176, P6974, DOI 10.1128/JB.176.22.6974-6979.1994; RAGAN CI, 1977, BIOCHEM J, V163, P605, DOI 10.1042/bj1630605; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; Simianu M, 1998, BIOCHEMISTRY-US, V37, P10027, DOI 10.1021/bi9726483; SOWERS KR, 1984, CURR MICROBIOL, V11, P227, DOI 10.1007/BF01567165; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Staples CR, 1998, BIOCHEMISTRY-US, V37, P4612, DOI 10.1021/bi9729763; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H	30	24	28	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2432	2439		10.1074/jbc.M004809200	http://dx.doi.org/10.1074/jbc.M004809200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11034998	hybrid			2022-12-25	WOS:000166784800020
J	Shompole, S; Jasmer, DP				Shompole, S; Jasmer, DP			Cathepsin B-like cysteine proteases confer intestinal cysteine protease activity in Haemonchus contortus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; PROTECTIVE IMMUNITY; MOLECULAR-CLONING; ADULT WORMS; GUT; INHIBITORS; ANTIGENS; GENES; IMMUNIZATION; DEGRADATION	Cathepsin B-like cysteine protease genes (cbls) constitute large multigene families in parasitic and nonparasitic nematodes. Although expressed in the intestine of some nematodes, the biological and biochemical functions of the CBL proteins remain unresolved. Di- and tetra-oligopeptides were used as fluorogenic substrates and irreversible/competitive inhibitors to establish CBL functions in the intestine of the parasitic nematode Haemonchus contortus. Cysteine protease activity was detected against diverse substrates including the cathepsin Bn substrate FR, the caspase 1 substrate YVAD, the cathepsin B substrate RR, but not the CED-3 (caspase 3) substrate DEVD. The pH at which maximum activity was detected varied according to substrate and ranged from pH 5.0 to 7.0. Individual CBLs were affinity isolated using FA and YVAD substrates. pH influenced CBL affinity isolation in a substrate-specific manner that paralleled pH effects on individual substrates. N-terminal sequencing identified two isolated CBLs as H. contortus GCP-7 (33 kDa) and AC-4 (37 kDa). N termini of each began at a position consistent with proregion cleavage and protease activation. Isolation of the GCP-7 band by each peptide was preferentially inhibited when competed with a diazomethane-conjugated inhibitor, Z-FA-CHN2, demonstrating one functional difference among CBLs and among inhibitors. Substrate-based histological analysis placed CBLs on the intestinal microvilli. Data indicate that CBLs are responsible for cysteine protease activity described from H. contortus intestine. Results also support a role of CBLs in nutrient digestion.	Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA	Washington State University	Shompole, S (corresponding author), Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA.							Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Brindley PJ, 1997, MOL BIOCHEM PARASIT, V89, P1, DOI 10.1016/S0166-6851(97)00098-4; COX GN, 1990, MOL BIOCHEM PARASIT, V41, P25, DOI 10.1016/0166-6851(90)90093-2; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GILMOR SA, 1997, PROTEIN SCI, V6, P1603; HARROP SA, 1995, TROP MED PARASITOL, V46, P119; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; HASNAIN S, 1993, J BIOL CHEM, V268, P235; HUGHES AL, 1994, MOL PHYLOGENET EVOL, V3, P310, DOI 10.1006/mpev.1994.1038; Jasmer DP, 2000, MOL BIOCHEM PARASIT, V105, P81, DOI 10.1016/S0166-6851(99)00169-3; JASMER DP, 1991, INFECT IMMUN, V59, P4412, DOI 10.1128/IAI.59.12.4412-4417.1991; JASMER DP, 1993, J IMMUNOL, V151, P5450; KARANU FN, 1993, EXP PARASITOL, V77, P362, DOI 10.1006/expr.1993.1093; Knox DP, 1999, PARASITE IMMUNOL, V21, P201, DOI 10.1046/j.1365-3024.1999.00220.x; Larminie CGC, 1996, DNA CELL BIOL, V15, P75, DOI 10.1089/dna.1996.15.75; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; PRATT D, 1992, MOL BIOCHEM PARASIT, V51, P209, DOI 10.1016/0166-6851(92)90071-Q; Rehman A, 1998, MOL BIOCHEM PARASIT, V97, P55, DOI 10.1016/S0166-6851(98)00132-7; Rehman A, 1999, MOL BIOCHEM PARASIT, V102, P297, DOI 10.1016/S0166-6851(99)00086-9; RHOADS ML, 1995, J PARASITOL, V81, P505, DOI 10.2307/3283844; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; SHAW E, 1986, BIOMED BIOCHIM ACTA, V45, P1397; Skuce PJ, 1999, PARASITOLOGY, V119, P405, DOI 10.1017/S0031182099004813; Smith SK, 1999, PARASITE IMMUNOL, V21, P187, DOI 10.1046/j.1365-3024.1999.00217.x; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; Vaux DL, 1997, MOL CELL BIOL, V17, P6502, DOI 10.1128/MCB.17.11.6502; Wasilewski MM, 1996, MOL BIOCHEM PARASIT, V81, P179, DOI 10.1016/0166-6851(96)02703-X; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	29	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2928	2934		10.1074/jbc.M007321200	http://dx.doi.org/10.1074/jbc.M007321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11032834	hybrid			2022-12-25	WOS:000166784800085
J	Petro, JB; Khan, WN				Petro, JB; Khan, WN			Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappa B signaling pathway in B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN-RECEPTOR; X-LINKED AGAMMAGLOBULINEMIA; SURFACE-IMMUNOGLOBULIN; C-REL; ACTIVATION; EXPRESSION; APOPTOSIS; MICE; PROLIFERATION; COMPLEX	Mutations in the gene encoding Bruton's tyrosine kinase (BTK) interfere with B cell proliferation and lead to an X-Linked immunodeficiency in mice characterized by reduced B cell numbers. Recent studies have established that BTK transmits signals from the B cell antigen receptor (BCR) to transcription factor NF-kappaB, which in turn reprograms a set of genes required for normal B cell growth. We now demonstrate that induction of NF-kappaB via this pathway requires the intermediate action of the -gamma2 isoform of phospholipase C (PLC-gamma2), a potential phosphorylation substrate of BTK. Specifically, pharmacologic agents that block the action of either PLC-gamma2 or its second messengers prevent BCR-induced activation of I kappaB kinase. Moreover, activation of NF-kappaB in response to BCR signaling is completely abolished in B cells deficient for PLC-gamma2. Taken together, these findings strongly suggest that PLC-gamma2 functions as an integral component of the BTK/NF-kappaB axis following BCR ligation. Interference with this NF-kappaB cascade may account for some of the B cell defects reported for plc-gamma2(-/-) mice, which develop an X-linked immunodeficiency-like phenotype.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Khan, WN (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.							Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bendall HH, 1999, MOL IMMUNOL, V36, P187, DOI 10.1016/S0161-5890(99)00031-0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Chen CL, 1999, BIOCHEM BIOPH RES CO, V257, P798, DOI 10.1006/bbrc.1999.0548; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Ozes ON, 1999, NATURE, V401, P82; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Solvason N, 1998, J EXP MED, V187, P1081, DOI 10.1084/jem.187.7.1081; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VENKATARAMAN L, 1995, J EXP MED, V181, P1091, DOI 10.1084/jem.181.3.1091; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; Zandi E, 1999, MOL CELL BIOL, V19, P4547	33	116	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1715	1719		10.1074/jbc.M009137200	http://dx.doi.org/10.1074/jbc.M009137200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042193	hybrid			2022-12-25	WOS:000166528000010
J	Weber, JT; Rzigalinski, BA; Ellis, EF				Weber, JT; Rzigalinski, BA; Ellis, EF			Traumatic injury of cortical neurons causes changes in intracellular calcium stores and capacitative calcium influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; OPERATED HTRP3 CHANNELS; STRETCH-INDUCED INJURY; CENTRAL-NERVOUS-SYSTEM; BRAIN INJURY; DELAYED DEPOLARIZATION; ENDOPLASMIC-RETICULUM; GLUTAMATE RECEPTORS; TRANSMITTER RELEASE; ARACHIDONIC-ACID	Using an in vitro traumatic injury model, we examined the effects of mechanical (stretch) injury on intracellular Ca2+ store-mediated signaling in cultured cortical neurons using fura-2. We previously found that elevation of [Ca2+](i) by the endoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin, was abolished 15 min post-injury. In the current studies, pre-injury inhibition of phospholipase C with neomycin sulfate maintained Ca2+-replete stores 15 min post-injury, suggesting that the initial injury-induced store depletion may be due to increased inositol trisphosphate production. Thapsigargin-stimulated elevation of [Ca2+], returned with time after injury and was potentiated at 3 h. Stimulation with thapsigargin in Ca2+-free media revealed that the size of the Ca2+ stores was normal at 3 h post-injury, However, Ca2+ influx triggered by depletion of intracellular Ca2+ stores (capacitative Ca2+ influx) was enhanced 3 h after injury. Enhancement was blocked by inhibitors of cytosolic phospholipase A, and cytochrome P450 epoxygenase. Since intracellular Ca2+ store-mediated signaling plays an important role in neuronal function, the observed changes may contribute to dysfunction produced by traumatic brain injury. Additionally, our results suggest that capacitative Ca2+ influx may be mediated by both conformational coupling and a diffusible messenger synthesized by the combined action of cytosolic PLA, and P450.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University	Rzigalinski, BA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Box 980613, Richmond, VA 23298 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57869] Funding Source: Medline; NINDS NIH HHS [NS-27214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AbdulGhani MA, 1996, J NEUROPHYSIOL, V76, P2691, DOI 10.1152/jn.1996.76.4.2691; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BRORSON JR, 1991, J NEUROSCI, V11, P4024; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Budd SL, 1996, J NEUROCHEM, V67, P2282; Choi S, 1996, J NEUROSCI, V16, P36; DELAHUNTY TM, 1992, BRAIN RES, V594, P507; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Doutheil J, 1997, BRAIN RES, V775, P43, DOI 10.1016/S0006-8993(97)00899-8; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Fomina AF, 1999, J NEUROSCI, V19, P3711; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; Garaschuk O, 1997, J PHYSIOL-LONDON, V502, P13, DOI 10.1111/j.1469-7793.1997.013bl.x; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Jonas S, 1997, ANN NY ACAD SCI, V825, P389, DOI 10.1111/j.1749-6632.1997.tb48449.x; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kohn EC, 1996, CANCER RES, V56, P569; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Ma L, 1998, J NEUROPHYSIOL, V79, P1183, DOI 10.1152/jn.1998.79.3.1183; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; McIntosh TK, 1996, LAB INVEST, V74, P315; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Picard L, 1998, CELL CALCIUM, V23, P339, DOI 10.1016/S0143-4160(98)90029-X; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sakaki Y, 1997, J NEUROBIOL, V32, P62, DOI 10.1002/(SICI)1097-4695(199701)32:1<62::AID-NEU6>3.0.CO;2-C; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCHLAEPFER WW, 1985, PROG BRAIN RES, V63, P185; Scholz WK, 1998, J NEUROCHEM, V71, P580; SCHREIBER D, 1995, P 1995 INT RES C BIO; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; White RJ, 1996, J NEUROSCI, V16, P5688; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	70	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1800	1807		10.1074/jbc.M009209200	http://dx.doi.org/10.1074/jbc.M009209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050103	hybrid			2022-12-25	WOS:000166528000022
J	Bernard, ML; Peterson, YK; Chung, P; Jourdan, J; Lanier, SM				Bernard, ML; Peterson, YK; Chung, P; Jourdan, J; Lanier, SM			Selective interaction of AGS3 with G-proteins and the influence of AGS3 on the activation state of G-proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; RECEPTOR; IDENTIFICATION; DIVISIONS; SITES	AGS3 (activator of G-protein Signaling 3) was isolated in a yeast-based functional screen for receptor-independent activators of heterotrimeric G-proteins, As an initial approach to define the role of AGS3 in mammalian signal processing, we defined the AGS3 subdomains involved in G-protein interaction, its selectivity for G-proteins, and its influence on the activation state of G-protein, Immunoblot analysis with AGS3 antisera indicated expression in rat brain, the neuronal-like cell lines PC12 and NG108-15, as well as the smooth muscle cell line DDT1-MF2, Immunofluorescence studies and confocal imaging indicated that AGS3 was predominantly cytoplasmic and enriched in microdomains of the cell. AGS3 coimmunoprecipitated with G alpha (i3) from cell and tissue lysates, indicating that a subpopulation of AGS3 and G alpha (1) exist as a complex in the cell. The coimmunoprecipitation of AGS3 and G alpha (i) was dependent upon the conformation of G alpha (i3) (GDP much greater than GTP gammaS (guanosine 5'-3-O-(thio)triphosphate)). The regions of AGS3 that bound G alpha (i) were localized to four amino acid repeats (G-protein regulatory motif (GPR)) in the carboxyl terminus (Pro(465)-Ser(650)), each of which were capable of binding G alpha (i). AGS3-GPR domains selectively interacted with G alpha (i) in tissue and cell lysates and with purified G alphai/G(alphat). Subsequent experiments with purified G alpha (i2) and G alpha (i3) indicated that the carboxyl-terminal region containing the four GPR motifs actually bound more than one G alpha (i) subunit at the same time. The AGS3GPR domains effectively competed with GP gamma for binding to G alpha (t(GDP)) and blocked GTP gammaS binding to G alpha (i). AGS3 and related proteins provide unexpected mechanisms for coordination of G-protein signaling pathways.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29403 USA	Medical University of South Carolina	Lanier, SM (corresponding author), Med Univ S Carolina, Dept Pharmacol, 173 Ashley Ave, Charleston, SC 29403 USA.	laniersm@musc.edu	Bernard, Michael/AAW-3944-2021	Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM08716] Funding Source: Medline; NIMH NIH HHS [MH5993] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; DUZIC E, 1992, J BIOL CHEM, V267, P24045; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Makhlouf M, 1996, BBA-MOL CELL RES, V1312, P163, DOI 10.1016/0167-4889(96)00019-5; MIXON MB, 1996, SCIENCE, V270, P964; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; Rodbell M, 1996, MT SINAI J MED, V63, P381; ROSS EM, 1994, METHOD ENZYMOL, V237, P26; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	27	120	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1585	1593		10.1074/jbc.M005291200	http://dx.doi.org/10.1074/jbc.M005291200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042168	hybrid			2022-12-25	WOS:000166430900097
J	Masson, P; Andersson, O; Petersens, UM; Young, P				Masson, P; Andersson, O; Petersens, UM; Young, P			Identification and characterization of a Drosophila nuclear proteasome regulator - A homolog of human 11 S REG gamma (PA28 gamma)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PA28; MULTICATALYTIC PROTEASE; RECEPTOR FAMILY; 20S PROTEASOME; ALPHA-SUBUNIT; BETA-SUBUNIT; CELL-CYCLE; KI ANTIGEN; LOCALIZATION; EXPRESSION	We report the cloning and characterization of a Drosophila proteasome 11 S REG gamma (PA28) homolog. The 28-kDa protein shows 47% identity to the human REG gamma and strongly enhances the trypsin-like activities of both Drosophila and mammalian 20 S proteasomes. Surprisingly, the Drosophila REG was found to inhibit the proteasome's chymotrypsin-like activity against the fluorogenic peptide succinyl-LLVY-7-amino-4-methylcoumarin. Immunocytological analysis reveals that the Drosophila REG is localized to the nucleus but is distributed throughout the cell when nuclear envelope breakdown occurs during mitosis, Through site-directed mutagenesis studies, we have identified a functional nuclear localization signal present in the homolog-specific insert region. The Drosophila PA28 NLS is similar to the oncogene c-Myc nuclear localization motif. Comparison between uninduced and innate immune induced Drosophila cells suggests that the REG gamma proteasome activator has a role independent of the invertebrate immune system. Our results support the idea that gamma class proteasome activators have an ancient conserved function within metazoans and were present prior to the emergence of the (alpha and beta REG classes.	Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden	Stockholm University	Young, P (corresponding author), Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden.	patrick.young@molbio.su.se	Masson, Patrick/AAA-7213-2019	Masson, Patrick/0000-0002-7837-3662; Masson, Patrick/0000-0001-7646-0052				Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Covi JA, 1999, ARCH BIOCHEM BIOPHYS, V368, P85, DOI 10.1006/abbi.1999.1294; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; Fahmy O. G., 1958, DROS INFORM SERV, V32, P67; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Kandil E, 1997, IMMUNOGENETICS, V46, P337, DOI 10.1007/s002510050281; Kloetzel PM, 1999, BIOL CHEM, V380, P293, DOI 10.1515/BC.1999.040; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; Kohda K, 1998, J IMMUNOL, V160, P4923; Li J, 2000, J MOL BIOL, V299, P641, DOI 10.1006/jmbi.2000.3800; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MA CP, 1992, J BIOL CHEM, V267, P10515; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Murata S, 1999, J BIOL CHEM, V274, P38211, DOI 10.1074/jbc.274.53.38211; Murray BW, 2000, SCAND J IMMUNOL, V51, P571; NIKAIDO T, 1990, CLIN EXP IMMUNOL, V79, P209; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Paesen GC, 1996, BBA-GENE STRUCT EXPR, V1309, P9, DOI 10.1016/S0167-4781(96)00116-9; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; Soza A, 1997, FEBS LETT, V413, P27, DOI 10.1016/S0014-5793(97)00864-8; Stohwasser R, 2000, MOL IMMUNOL, V37, P13, DOI 10.1016/S0161-5890(00)00017-1; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; Tanaka K, 1998, IMMUNOL REV, V163, P161; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tojo T, 1981, Ryumachi, V21 Suppl, P129; Wojcik C, 1998, EUR J CELL BIOL, V77, P151, DOI 10.1016/S0171-9335(98)80083-6; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; Zhang ZG, 1998, J BIOL CHEM, V273, P9501, DOI 10.1074/jbc.273.16.9501; Zhang ZG, 1998, P NATL ACAD SCI USA, V95, P2807, DOI 10.1073/pnas.95.6.2807	50	39	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1383	1390		10.1074/jbc.M007379200	http://dx.doi.org/10.1074/jbc.M007379200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11027688	hybrid			2022-12-25	WOS:000166430900071
J	Nantes, IL; Zucchi, MR; Nascimento, OR; Faljoni-Alario, A				Nantes, IL; Zucchi, MR; Nascimento, OR; Faljoni-Alario, A			Effect of heme iron valence state on the conformation of cytochrome c and its association witt membrane interfaces - A CD and EPR investigation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM; CASPASE ACTIVATION; INDUCED APOPTOSIS; RELEASE; PEROXIDATION; CARDIOLIPIN; MECHANISM; OXIDATION	Recently cytochrome c has been mentioned as an important mediator in the events of cellular oxidative stress and apoptosis, To investigate the influence of charged interfaces on the conformation of cytochrome c, the CD and magnetic circular dichroic behavior of ferric and ferrous cytochrome c in homogeneous medium and in phosphatidylcholine/phosphatidylethanolamine/cardiolipin and dicetylphosphate liposomes was studied in the 300-600 and 200-320 nm wavelength region. EPR spectra demonstrate that the association of cytochrome c with membranes promotes alterations of the crystal field symmetry and spin state of the heme Fe3+. The studies also include the effect of P-i, NaCl, and CaCl2. Magnetic circular dichroism and CD results show that the interaction of both ferrous and ferric cytochrome c with charged interfaces promotes conformational changes in the cy-helix content, tertiary structure, and heme iron spin state. Moreover, the association of cytochrome c with different liposomes is sensitive to the heme iron valence state. The more effective association with membranes occurs with ferrous cytochrome c. Dicetylphosphate liposomes, as a negatively charged membrane model, promoted a more pronounced conformational modification in the cytochrome c structure. A decrease in the lipid/protein association is detected in the presence of increasing amounts of CaCl2, NaCl, and P-i, in response to the increase of the ionic strength.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil; UMC, Diretoria Pesquisa & Posgrad, CIIB, BR-08780911 Sao Paulo, Brazil; Univ Sao Paulo, Inst Fis Sao Carlos, Grp Biofis, BR-13560970 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Mogi das Cruzes; Universidade de Sao Paulo	Faljoni-Alario, A (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, CP 26077, BR-05513970 Sao Paulo, Brazil.		Nantes, Iseli Lourenço/B-9517-2012; DO ROSARIO ZUCCHI, MARIA/AAG-7660-2021	Nantes, Iseli Lourenço/0000-0003-1434-3154; 				Almeida AM, 1999, FREE RADICAL BIO MED, V27, P744, DOI 10.1016/S0891-5849(99)00136-7; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CILENTO G, 1995, FREE RADICAL BIO MED, V19, P103, DOI 10.1016/0891-5849(95)00002-F; Eaton W A, 1981, Methods Enzymol, V76, P175; GALLARDO H, 1984, BIOCHIM BIOPHYS ACTA, V789, P57, DOI 10.1016/0167-4838(84)90060-8; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Iwase H, 1996, BIOCHEM BIOPH RES CO, V222, P83, DOI 10.1006/bbrc.1996.0701; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; MORTARA RA, 1978, BIOCHEM BIOPH RES CO, V81, P1080, DOI 10.1016/0006-291X(78)91246-9; Nantes IL, 1998, FREE RADICAL BIO MED, V25, P546, DOI 10.1016/S0891-5849(98)00082-3; NANTES IL, 1995, PHOTOCHEM PHOTOBIOL, V62, P522, DOI 10.1111/j.1751-1097.1995.tb02378.x; Nantes IL, 2000, FREE RADICAL BIO MED, V28, P786, DOI 10.1016/S0891-5849(00)00170-2; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PINHEIRO TJT, 1994, BIOCHIMIE, V76, P489, DOI 10.1016/0300-9084(94)90173-2; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STOREY BT, 1973, BIOCHIM BIOPHYS ACTA, V292, P554, DOI 10.1016/0005-2728(73)90004-2; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; VINCENT JS, 1987, BIOCHEMISTRY-US, V26, P2312, DOI 10.1021/bi00382a036; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	28	85	88	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					153	158		10.1074/jbc.M006338200	http://dx.doi.org/10.1074/jbc.M006338200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027687	hybrid			2022-12-25	WOS:000166280700022
J	Shao, J; Grammatikakis, N; Scroggins, BT; Uma, S; Huang, WJ; Chen, JJ; Hartson, SD; Matts, RL				Shao, J; Grammatikakis, N; Scroggins, BT; Uma, S; Huang, WJ; Chen, JJ; Hartson, SD; Matts, RL			Hsp90 regulates p50(cdc27) function during the biogenesis of the active conformation of the heme-regulated eIF2 alpha kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTE LYSATE; CYCLE CONTROL PROTEIN; HEAT-SHOCK PROTEIN; EIF-2-ALPHA KINASE; SIGNAL-TRANSDUCTION; MOLECULAR CHAPERONE; TERMINAL DOMAIN; BINDING-SITE; CDC37; COMPLEX	Recent studies indicate that p50(cdc37) facilitates Hsp90-mediated biogenesis of certain protein kinases. In this report, we examined whether p50(cdc37) is required for the biogenesis of the heme-regulated eIF2 alpha kinase (HRI) in reticulocyte lysate. p50cdc37 interacted with nascent HRI co-translationally and this interaction persisted during the maturation and activation of HRI, p50(cdc37) stimulated HRI's activation in response to heme deficiency, but did not activate HRI per se. p50cdc37 function was specific to immature and inactive forms of the kinase, Analysis of mutant Cdc37 gene products indicated that the N-terminal portion of p50(cdc37) interacted with immature HRI, but not with Hsp90, while the C-terminal portion of p50(cdc37) interacted with HspSO. The Hsp90-specific inhibitor geldanamycin disrupted the ability of both HspSO and p50(cdc37) to bind HRI and promote its activation, but did not disrupt the native association of p50(cdc37) With HsP90. A C-terminal truncated mutant of p50(cdc37) inhibited HRI's activation, prevented the interaction of HspSO with HRI, and bound to HRI irrespective of geldanamycin treatment. Additionally, native complexes of HRI with p50(cdc37) were detected in cultured K562 erythroleukemia cells. These results suggest that p50(cdc37) provides an activity essential to HRI biogenesis via a process regulated by nucleotide-mediated conformational switching of its partner HspSO.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Oklahoma State University System; Oklahoma State University - Stillwater; Jefferson University; Harvard University; Massachusetts Institute of Technology (MIT)	Matts, RL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, 246 NRC, Stillwater, OK 74078 USA.	rmatts@biochem.okstate.edu			NIDDK NIH HHS [DK-53223, R01 DK016272] Funding Source: Medline; NIEHS NIH HHS [ES04299] Funding Source: Medline; NIGMS NIH HHS [GM15608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004299, R29ES004299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM015608] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1993, TRANSLATIONAL REGULA, V2, P349; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Dey B, 1996, MOL BIOL CELL, V7, P1405, DOI 10.1091/mbc.7.9.1405; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hartson SD, 1999, BIOCHEMISTRY-US, V38, P3837, DOI 10.1021/bi983027s; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; Hartson SD, 1998, J BIOL CHEM, V273, P8475, DOI 10.1074/jbc.273.14.8475; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Matsuda S, 1999, J BIOL CHEM, V274, P34515, DOI 10.1074/jbc.274.49.34515; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; O'Keeffe B, 2000, J BIOL CHEM, V275, P279, DOI 10.1074/jbc.275.1.279; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Thulasiraman V, 1998, EUR J BIOCHEM, V255, P552, DOI 10.1046/j.1432-1327.1998.2550552.x; Uma S, 1999, MOL CELL BIOL, V19, P5861; Uma S, 1997, J BIOL CHEM, V272, P11648; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu ZY, 1997, EUR J BIOCHEM, V246, P461, DOI 10.1111/j.1432-1033.1997.t01-1-00461.x	37	75	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					206	214		10.1074/jbc.M007583200	http://dx.doi.org/10.1074/jbc.M007583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11036079	hybrid			2022-12-25	WOS:000166280700030
J	Shi, XM; Bai, ST; Li, LN; Cao, X				Shi, XM; Bai, ST; Li, LN; Cao, X			Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; OSTEOGENIC PROTEIN-1; TUMOR-SUPPRESSOR; ACTS DOWNSTREAM; BONE-FORMATION; SMAD PROTEINS; TGF; BINDING; IDENTIFICATION; OSTEOCLASTS	Smad2 and Smad3 are downstream transforming growth factor-beta (TGF-beta) signaling molecules. Upon phosphorylation by its type I receptor, Smad2 or Smad3 forms a complex with Smad4 and translocates to the nucleus where the complex activates target gene transcription. In the present study, we report that Smad3 binds directly to the osteopontin (OPN) promoter and that Smad4 interacts with the Hox protein and displaces it from its cognate DNA binding site in response to TGF-beta stimulation. In gel shift assays, the glutathione S-transferase-Smad3 fusion protein was found to bind to a 50-base pair DNA element (-179 to -229) from the OPN promoter. Also, we found that both Hoxc-8 and Hoxa-9 bound to a Hox binding site adjacent to Smad3 binding sequence. Interestingly, Smad4, the common partner for both bone morphogenic protein and TGF-beta signaling pathways, inhibited the binding of Hox protein to DNA. FLAG-tagged Smad4 coimmunoprecipitated with HA-tagged Hoxa-9 from cotransfected COS-1 cells, demonstrating an interaction between Smad4 and Hoxa-9. Transfection studies showed that Hoxa-9 is a strong transcriptional repressor; it suppresses the transcription of the luciferase reporter gene driven by a 124-base pair OPN promoter fragment containing both Smad3 and Hox binding sites. Taken together, these data demonstrate a unique TGF-beta -induced transcription mechanism. Smad3 and Smad4 exhibit different functions in activation of OPN transcription. Smad4 binds directly to the OPN promoter as a sequence-specific activator, and Smad4 displaces the transcription repressor, Hoxa-9, by formation of Smad4/Hox complex as part of the transcription mechanism in response to TGF-beta stimulation.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Cao, X (corresponding author), Univ Alabama Birmingham, Dept Pathol, 1670 Univ Blvd,Volker Hall G002, Birmingham, AL 35294 USA.	cao@path.uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053757] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53757] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Candia AF, 1997, DEVELOPMENT, V124, P4467; CENTRELLA M, 1991, J BONE JOINT SURG AM, V73A, P1418, DOI 10.2106/00004623-199173090-00022; Cheifetz S, 1996, CONNECT TISSUE RES, V35, P71, DOI 10.3109/03008209609029176; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MERRY K, 1993, J CELL SCI, V104, P1013; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama T, 1998, DEVELOPMENT, V125, P857; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; NODA M, 1989, CONNECT TISSUE RES, V21, P401, DOI 10.3109/03008208909049997; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	43	66	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					850	855		10.1074/jbc.M005955200	http://dx.doi.org/10.1074/jbc.M005955200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11042172	hybrid			2022-12-25	WOS:000166280700114
J	Belanger, H; Fleysh, N; Cox, S; Bartman, G; Deka, D; Trudel, M; Koprowski, H; Yusibov, V				Belanger, H; Fleysh, N; Cox, S; Bartman, G; Deka, D; Trudel, M; Koprowski, H; Yusibov, V			Human respiratory syncytial virus vaccine antigen produced in plants	FASEB JOURNAL			English	Article						G-protein; alfalfa mosaic virus; respiratory tract; RSV	MOSAIC-VIRUS; MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDE; G-GLYCOPROTEIN; F-PROTEIN; SEROPOSITIVE CHILDREN; FUSION GLYCOPROTEIN; FOREIGN PEPTIDES; INFECTION; MICE	Human respiratory syncytial virus (RSV) is the primary cause of respiratory infection in infants worldwide. Currently there is no available vaccine, although studies in animal models have demonstrated protective immunity induced by an epitope of the RSV G-protein representing amino acids 174-187. Two peptides containing amino acids 174-187 of the G-protein of the human RSV A2 strain (NF1-RSV/172-187 and NF2-RSV/170-191) were separately engineered as translational fusions with the alfalfa mosaic virus coat protein and individually expressed in Nicotiana tabacum cv. Samsun NN plants through virus infection. RSV G-protein peptides were expressed in infected plant tissues at significant levels within 2 wk of inoculation and purified as part of recombinant alfalfa mosaic virions. BALB/c mice immunized intraperitoneally with three doses of the purified recombinant viruses showed high levels of serum antibody specific for RSV G-protein and were protected against infection with RSV Long strain.-Belanger, H., Fleysh, N., Cox, S., Bartman, G., Deka, D., Trudel, M., Koprowski, H., Yusibov, V. Human respiratory syncytial virus vaccine antigen produced in plants.	Thomas Jefferson Univ, Biotechnol Fdn Labs, Philadelphia, PA 19107 USA; Univ Quebec, Inst Armand Frappier, INRS, Ctr Rech Santehumaine, Laval, PQ, Canada	Jefferson University; University of Quebec; Institut national de la recherche scientifique (INRS)	Yusibov, V (corresponding author), Thomas Jefferson Univ, Biotechnol Fdn Labs, 1020 Locust St,Room 346 JAH, Philadelphia, PA 19107 USA.		Yusibov, Vidadi/AAA-7408-2019					AKERLINDSTOPNER B, 1995, J MED VIROL, V47, P120, DOI 10.1002/jmv.1890470203; AKERLINDSTOPNER B, 1990, J VIROL, V64, P5143, DOI 10.1128/JVI.64.10.5143-5148.1990; ANDERSON LJ, 1995, J INFECT DIS, V171, P1, DOI 10.1093/infdis/171.1.1; ARBIZA J, 1992, J GEN VIROL, V73, P2225, DOI 10.1099/0022-1317-73-9-2225; Bastien N, 1999, VACCINE, V17, P832, DOI 10.1016/S0264-410X(98)00267-9; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; Buraphacheep W, 1997, J CLIN MICROBIOL, V35, P354, DOI 10.1128/JCM.35.2.354-357.1997; CHANOCK RM, 1965, PEDIATRICS, V36, P21; CONNORS M, 1991, J VIROL, V65, P1634, DOI 10.1128/JVI.65.3.1634-1637.1991; DEDIEU JF, 1992, J VIROL, V66, P3161, DOI 10.1128/JVI.66.5.3161-3167.1992; ELANGO N, 1986, P NATL ACAD SCI USA, V83, P1906, DOI 10.1073/pnas.83.6.1906; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; Groothuis JR, 1998, J INFECT DIS, V177, P467, DOI 10.1086/517377; HAMAMOTO H, 1993, BIO-TECHNOL, V11, P930, DOI 10.1038/nbt0893-930; Joelson T, 1997, J GEN VIROL, V78, P1213, DOI 10.1099/0022-1317-78-6-1213; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Modelska A, 1998, P NATL ACAD SCI USA, V95, P2481, DOI 10.1073/pnas.95.5.2481; MUFSON MA, 1991, J CLIN MICROBIOL, V29, P162, DOI 10.1128/JCM.29.1.162-165.1991; PORTA C, 1994, VIROLOGY, V202, P949, DOI 10.1006/viro.1994.1417; Sambrook S, 1989, MOL CLONING LAB MANU; SCOPES GE, 1990, J GEN VIROL, V71, P53, DOI 10.1099/0022-1317-71-1-53; Simard C, 1997, VACCINE, V15, P423, DOI 10.1016/S0264-410X(97)00189-8; STOTT EJ, 1986, J VIROL, V60, P607, DOI 10.1128/JVI.60.2.607-613.1986; Sullender WM, 1996, J GEN VIROL, V77, P641, DOI 10.1099/0022-1317-77-4-641; SULLENDER WM, 1990, VIROLOGY, V178, P195, DOI 10.1016/0042-6822(90)90394-7; TASCHNER PEM, 1991, VIROLOGY, V181, P445, DOI 10.1016/0042-6822(91)90876-D; TAYLOR G, 1992, J GEN VIROL, V73, P2217, DOI 10.1099/0022-1317-73-9-2217; TAYLOR G, 1984, IMMUNOLOGY, V52, P137; TRISTRAM DA, 1993, J INFECT DIS, V167, P191, DOI 10.1093/infdis/167.1.191; TRUDEL M, 1987, J GEN VIROL, V68, P2273, DOI 10.1099/0022-1317-68-9-2273; TRUDEL M, 1991, ARCH VIROL, V117, P59, DOI 10.1007/BF01310492; TRUDEL M, 1991, VIROLOGY, V185, P749, DOI 10.1016/0042-6822(91)90546-N; USHA R, 1993, VIROLOGY, V197, P366, DOI 10.1006/viro.1993.1598; Verch T, 1998, J IMMUNOL METHODS, V220, P69, DOI 10.1016/S0022-1759(98)00149-5; WERTZ GW, 1987, J VIROL, V61, P293, DOI 10.1128/JVI.61.2.293-301.1987; Yusibov V, 1997, P NATL ACAD SCI USA, V94, P5784, DOI 10.1073/pnas.94.11.5784; YUSIBOV VM, 1995, VIROLOGY, V208, P405, DOI 10.1006/viro.1995.1168	38	37	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2323	2328		10.1096/fj.00-0144com	http://dx.doi.org/10.1096/fj.00-0144com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053254				2022-12-25	WOS:000165190800026
J	Matesic, LE; Niemitz, EL; De Maio, A; Reeves, RH				Matesic, LE; Niemitz, EL; De Maio, A; Reeves, RH			Quantitative trait loci modulate neutrophil infiltration in the liver during LPS-induced inflammation	FASEB JOURNAL			English	Article						mapping; quantitative trait loci; inbred strains (A/J and C57BL/6J); sepsis; multiple organ dysfunction syndrome	NECROSIS-FACTOR-ALPHA; INTERCELLULAR-ADHESION MOLECULE-1; DROSOPHILA TOLL; ORGAN FAILURE; SEVERE SEPSIS; MICE; ENDOTOXIN; LIPOPOLYSACCHARIDE; POLYMORPHISM; IMMUNE	A crucial aspect of the inflammatory response is the recruitment of activated neutrophils (PMN) to the site of damage. Lytic enzymes and oxygen radicals released by PMN are important in clearing an infection or cellular debris, but can also produce host tissue damage. Failure to properly regulate the inflammatory response contributes to a variety of human diseases like sepsis and multiple organ dysfunction syndrome, the leading cause of morbidity and mortality in surgical intensive care units. Many aspects of human disease pathology, including hepatic PMN infiltration, can be recapitulated in mice using an endotoxic shock model. Six quantitative trait loci that predispose to high infiltration of PMN in hepatic sinusoids after high-dose endotoxin administration were provisionally identified. Two of these loci, Hpi1 and Hpi2 on mouse chromosomes 5 and 13, were mapped to the significant and highly significant level using a lo cv-resolution genome scan on 122 intercross animals. These loci interact epistatically to produce a high degree of PMN infiltration. Intercross and recombinant inbred strain mice with a specific genotype at these loci always had a high infiltration response, indicating that genotype analysis at just these two loci can accurately predict a high PMN infiltration response. Genetic predisposition to the degree of PMN infiltration in the inflammatory response in mice suggests that analogous genetic mechanisms occur in human beings that could be used for diagnostic purposes.-Matesic, L. E., Niemitz, E. L., De Maio, A., Reeves, R. H. Quantitative trait loci modulate neutrophil infiltration in the liver during LPS-induced inflammation.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Pediat Surg, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Reeves, RH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St,Biophys 203, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM57317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCKLIN SE, 1993, INFECT IMMUN, V61, P3184, DOI 10.1128/IAI.61.8.3184-3189.1993; CERRA FB, 1987, SURGERY, V101, P1; CHURCHILL GA, 1994, GENETICS, V138, P963; Cox A, 1996, J PEDIATR ENDOCR MET, V9, P129; De Maio A, 1998, SHOCK, V10, P319; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; Eakes AT, 1997, AM J PHYSIOL-GASTR L, V272, pG605, DOI 10.1152/ajpgi.1997.272.3.G605; ESSANI NA, 1995, HEPATOLOGY, V21, P1632, DOI 10.1002/hep.1840210623; Fang XM, 1999, CRIT CARE MED, V27, P1330, DOI 10.1097/00003246-199907000-00024; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; HEWETT JA, 1992, LAB INVEST, V66, P347; Hierholzer C, 1998, AM J PHYSIOL-LUNG C, V275, pL611, DOI 10.1152/ajplung.1998.275.3.L611; HOEKZEMA R, 1992, INVEST OPHTH VIS SCI, V33, P532; JACOB CO, 1991, CYTOKINE, V3, P551, DOI 10.1016/1043-4666(91)90481-R; Jaeschke H, 1996, SHOCK, V6, P351, DOI 10.1097/00024382-199611000-00009; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Livingston D H, 1995, New Horiz, V3, P257; MAEMURA K, 1994, BIOCHEM BIOPH RES CO, V201, P538, DOI 10.1006/bbrc.1994.1735; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; Matesic LE, 1999, GENOMICS, V62, P34, DOI 10.1006/geno.1999.5986; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mochida S, 1996, HEPATOLOGY, V23, P320; Nussler AK, 1999, LANGENBECK ARCH SURG, V384, P222, DOI 10.1007/s004230050196; O'Malley J, 1998, J HERED, V89, P525, DOI 10.1093/jhered/89.6.525; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROSENBLOOM AJ, 1995, JAMA-J AM MED ASSOC, V274, P58, DOI 10.1001/jama.274.1.58; Sampson SB, 1998, MAMM GENOME, V9, P688, DOI 10.1007/s003359900849; SHANLEY TP, 1995, MOL MED TODAY, V1, P40, DOI 10.1016/1357-4310(95)80019-0; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; Stuber F, 1996, CRIT CARE MED, V24, P381, DOI 10.1097/00003246-199603000-00004; THOMAS KR, 1992, MOL CELL BIOL, V12, P2919, DOI 10.1128/MCB.12.7.2919; VINCEK V, 1993, CANCER RES, V53, P728; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; Zivot J B, 1995, New Horiz, V3, P267	37	26	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2247	2254		10.1096/fj.99-1051com	http://dx.doi.org/10.1096/fj.99-1051com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053246				2022-12-25	WOS:000165190800018
J	van Adelsberg, J; Sehgal, S; Kukes, A; Brady, C; Barasch, J; Yang, J; Huan, YH				van Adelsberg, J; Sehgal, S; Kukes, A; Brady, C; Barasch, J; Yang, J; Huan, YH			Activation of hepatocyte growth factor (HGF) by endogenous HGF activator is required for metanephric kidney morphogenesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITOR; FACTOR SCATTER FACTOR; MET TYROSINE KINASE; PLASMINOGEN ACTIVATORS; FACTOR/SCATTER FACTOR; MOLECULAR-CLONING; GENE-EXPRESSION; RECEPTOR; BINDING; PROTHROMBIN	The interaction of hepatocyte growth factor (HGF) with c-Met has been implicated in morphogenesis of the kidney, lung, mammary gland, liver, placenta, and limb bud. HGF is secreted as an inactive zymogen and must be cleaved by a serine protease to initiate Met signaling. We show here that a serine protease specific for HGF, HGF activator (HGFA), is expressed and activated by the ureteric bud of the developing kidney in vivo and in vitro. Inhibition of HGFA activity with serine protease inhibitors reduced ureteric bud branching and inhibited glomerulogenesis and nephrogenesis. Activated HGF rescued developing kidneys from the effects of inhibitors. HGFA was localized around the tips of the ureteric bud in developing kidneys, while HGF was expressed diffusely throughout the mesenchyme. These data show that expression of HGF is not sufficient for development, but that its activation is also required. The localization of HCFA to the ureteric bud and the mesenchyme immediately adjacent to it suggests that HGFA creates a gradient of HGF activity in the developing kidney. The creation and shape of gradients of activated HGF by the localized secretion of HGF activators could play an important role in pattern formation by HGF responsive tissues.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	van Adelsberg, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barasch J, 1996, AM J PHYSIOL-RENAL, V271, pF50, DOI 10.1152/ajprenal.1996.271.1.F50; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; Grover PK, 2000, EUR J BIOCHEM, V267, P61, DOI 10.1046/j.1432-1327.2000.00954.x; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; LIJNEN HR, 1986, J BIOL CHEM, V261, P1253; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MARS WM, 1993, AM J PATHOL, V143, P949; Matsubara Y, 1998, BIOCHEM BIOPH RES CO, V253, P477, DOI 10.1006/bbrc.1998.9808; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; Ohmichi H, 1998, DEVELOPMENT, V125, P1315; Piepenhagen PA, 1995, AM J PHYSIOL-CELL PH, V269, pC1417, DOI 10.1152/ajpcell.1995.269.6.C1417; Sakata H, 1997, J BIOL CHEM, V272, P9457; Sakurai H, 1997, P NATL ACAD SCI USA, V94, P6279, DOI 10.1073/pnas.94.12.6279; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; Scaal M, 1999, DEVELOPMENT, V126, P4885; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Stapleton AMF, 1998, BRIT J UROL, V81, P666; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Sumiya J, 1997, J BIOCHEM-TOKYO, V122, P983; Suzuki K, 1999, J AM SOC NEPHROL, V10, pS408; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171	39	43	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15099	15106		10.1074/jbc.M006634200	http://dx.doi.org/10.1074/jbc.M006634200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11032833	hybrid			2022-12-25	WOS:000168528800077
J	Billas, IML; Moulinier, L; Rochel, N; Moras, D				Billas, IML; Moulinier, L; Rochel, N; Moras, D			Crystal structure of the ligand-binding domain of the ultraspiracle protein USP, the ortholog of retinoid X receptors in insects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; ECDYSONE RECEPTOR; DROSOPHILA METAMORPHOSIS; ESTROGEN-RECEPTOR; ACID RECEPTOR; RXR-ALPHA; RAR-GAMMA; ANTAGONISM; HORMONES; COMPLEX	The major postembryonic developmental events happening in insect life, including molting and metamorphosis, are regulated and coordinated temporally by pulses of ecdysone. The biological activity of this steroid hormone is mediated by two nuclear receptors: the ecdysone receptor (EcR) and the Ultraspiracle protein (USP). The crystal structure of the ligand-binding domain from the lepidopteran Heliothis virescens USP reported here shows that the loop connecting helices H1 and H3 precludes the canonical agonist conformation. The key residues that stabilize this unique loop conformation are strictly conserved within the lepidopteran USP family. The presence of an unexpected bound ligand that drives an unusual antagonist conformation confirms the induced-fit mechanism accompanying the ligand binding The ligand-binding pocket exhibits a retinoid X receptor-like anchoring part near a conserved arginine, which could interact with a USP ligand functional group. The structure of this receptor provides the template for designing inhibitors, which could be utilized as a novel type of environmentally safe insecticides.	Univ Strasbourg 1, Genom & Struct Biol Lab, UPR 9004, Inst Genet & Biol Mol & Cellulaire,CNRS,INSERM, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), Univ Strasbourg 1, Genom & Struct Biol Lab, UPR 9004, Inst Genet & Biol Mol & Cellulaire,CNRS,INSERM, 1 Rue Laurent Fries,Cite Univ Strasbourg, F-67404 Illkirch, France.		Rochel, Natacha/A-5718-2016; Billas, Isabelle M.L./I-2790-2016	Rochel, Natacha/0000-0002-3573-5889; Billas, Isabelle M.L./0000-0003-2323-4208				Auwerx J, 1999, CELL, V97, P161; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Blondel A, 1999, J MOL BIOL, V291, P101, DOI 10.1006/jmbi.1999.2879; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Buszczak M, 1998, CURR BIOL, V8, pR879, DOI 10.1016/S0960-9822(07)00550-7; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Egea PF, 2000, FEBS LETT, V476, P62, DOI 10.1016/S0014-5793(00)01672-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Hall BL, 1999, AM ZOOL, V39, P714; Hall BL, 1998, DEVELOPMENT, V125, P4709; Jones G, 1997, P NATL ACAD SCI USA, V94, P13499, DOI 10.1073/pnas.94.25.13499; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klaholz BP, 1998, NAT STRUCT BIOL, V5, P199, DOI 10.1038/nsb0398-199; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lezzi M, 1999, ARCH INSECT BIOCHEM, V41, P99, DOI 10.1002/(SICI)1520-6327(1999)41:2&lt;99::AID-ARCH6&gt;3.0.CO;2-W; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nijhout H.F., 1994, INSECT HORMONES; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Riddiford LM, 1999, AM ZOOL, V39, P736; RIDDIFORD LM, 1993, RECEPTOR, V3, P203; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Thummel CS, 1996, TRENDS GENET, V12, P306, DOI 10.1016/0168-9525(96)10032-9; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697; VOET D, 1995, BIOCHEMISTRY-US, P290; Wang SF, 1998, J BIOL CHEM, V273, P27531, DOI 10.1074/jbc.273.42.27531; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0	40	133	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7465	7474		10.1074/jbc.M008926200	http://dx.doi.org/10.1074/jbc.M008926200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11053444	hybrid			2022-12-25	WOS:000167442900084
J	Lomonte, P; Sullivan, KF; Everett, RD				Lomonte, P; Sullivan, KF; Everett, RD			Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-DEPENDENT DEGRADATION; IMMEDIATE-EARLY GENE-1; NUCLEAR-BODIES; PML; CHROMATIN; VMW110; DNA; INFECTION; DOMAIN; ND10	Cells infected by herpes simplex virus type 1 in the G(2) phase of the cell cycle become stalled at an unusual stage of mitosis defined as pseudoprometaphase, This block correlates with the viral immediate-early protein ICP0-induced degradation of the centromere protein CENP-C. However, the observed pseudoprometaphase phenotype of infected mitotic cells suggests that the stability of other centromere proteins may also be affected. Here, we demonstrate that ICP0 also induces the proteasome-dependent degradation of the centromere protein CENP-A. By a series of Western blot and immunofluorescence experiments we show that the endogenous 17-kDa CENP-A and an exogenous tagged version of CENP A are lost from centromeres and degraded in infected and transfected cells as a result of ICP0 expression. CENP-A is a histone H3-like protein associated with nucleosome structures in the inner plate of the kinetochore. Unlike fully transcribed lytic viral DNA, the transcriptionally repressed latent herpes simplex virus type 1 genome has been reported to have a nucleosomal structure similar to that of cellular chromatin, Because ICP0 plays an essential part in controlling the balance between the lytic and latent outcomes of infection, the ICP0-induced degradation of CENP-A is an intriguing feature connecting different aspects of viral and/or cellular genome regulation.	MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Lomonte, P (corresponding author), Univ Lyon 1, CNRS, CGMC, Ctr Genet Mol & Cellulaire,UMR 5534, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	lomonte@maccgmc.univ-lyon1.fr		Sullivan, Kevin/0000-0002-5374-8245; LOMONTE, PATRICK/0000-0001-9248-648X	NIGMS NIH HHS [GM39068] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039068, R29GM039068] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; Boddy MN, 1996, ONCOGENE, V13, P971; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Choo KHA, 2000, TRENDS CELL BIOL, V10, P182, DOI 10.1016/S0962-8924(00)01739-6; CLEMENTS GB, 1989, J GEN VIROL, V70, P2501, DOI 10.1099/0022-1317-70-9-2501; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; DESHMANE SL, 1989, J VIROL, V63, P943, DOI 10.1128/JVI.63.2.943-947.1989; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EISSENBERG JC, 1992, GENETICS, V131, P345; Everett RD, 2000, J VIROL, V74, P9994, DOI 10.1128/JVI.74.21.9994-10005.2000; Everett RD, 1999, J CELL SCI, V112, P3443; EVERETT RD, 1993, VIROLOGY, V197, P751, DOI 10.1006/viro.1993.1651; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; EVERETT RD, 1989, J GEN VIROL, V70, P1185, DOI 10.1099/0022-1317-70-5-1185; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; EVERETT RD, 1991, CONTROL HERPES SIMPL, P50; FIELDS BN, 1996, VIROLOGY, V2; HARRIS RA, 1989, J VIROL, V63, P3513, DOI 10.1128/JVI.63.8.3513-3515.1989; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; ISHOV AM, 1999, J CELL BIOL, V147, P221, DOI [10.1083/jcb.147.2.221, DOI 10.1083/JCB.147.2.221]; Kapoor M, 1998, CHROMOSOMA, V107, P570, DOI 10.1007/s004120050343; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; LEIB DA, 1989, J VIROL, V63, P759, DOI 10.1128/JVI.63.2.759-768.1989; Lomonte P, 1999, J VIROL, V73, P9456, DOI 10.1128/JVI.73.11.9456-9467.1999; MATSUMOTO H, 1989, EXP CELL RES, V181, P181; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MUGGERIDGE MI, 1986, J VIROL, V59, P764, DOI 10.1128/JVI.59.3.764-767.1986; Muller S, 1999, J VIROL, V73, P5137; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; Parkinson J, 2000, J VIROL, V74, P10006, DOI 10.1128/JVI.74.21.10006-10017.2000; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; Pluta AF, 1998, J CELL SCI, V111, P2029; POST LE, 1981, CELL, V25, P227, DOI 10.1016/0092-8674(81)90247-6; Preston CM, 1997, J VIROL, V71, P7807, DOI 10.1128/JVI.71.10.7807-7813.1997; PRESTON CM, 1979, J VIROL, V29, P275, DOI 10.1128/JVI.29.1.275-284.1979; SACKS WR, 1985, J VIROL, V55, P796, DOI 10.1128/JVI.55.3.796-805.1985; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Samaniego LA, 1998, J VIROL, V72, P3307, DOI 10.1128/JVI.72.4.3307-3320.1998; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; SHOWALTER SD, 1981, INFECT IMMUN, V34, P684, DOI 10.1128/IAI.34.3.684-692.1981; STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Vafa O, 1997, CURR BIOL, V7, P897, DOI 10.1016/S0960-9822(06)00381-2; Valdivia MM, 1998, FEBS LETT, V422, P5, DOI 10.1016/S0014-5793(97)01583-4; Wagner EK, 1997, CLIN MICROBIOL REV, V10, P419, DOI 10.1128/CMR.10.3.419; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; ZHU XX, 1990, J VIROL, V64, P4489, DOI 10.1128/JVI.64.9.4489-4498.1990	58	129	134	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5829	5835		10.1074/jbc.M008547200	http://dx.doi.org/10.1074/jbc.M008547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11053442	hybrid			2022-12-25	WOS:000167115100058
J	Dallongeville, J; Bauge, E; Tailleux, A; Peters, JM; Gonzalez, FJ; Fruchart, JC; Staels, B				Dallongeville, J; Bauge, E; Tailleux, A; Peters, JM; Gonzalez, FJ; Fruchart, JC; Staels, B			Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; POLYUNSATURATED FATTY-ACIDS; HIGH-DENSITY-LIPOPROTEINS; MESSENGER-RNA ABUNDANCE; ELEMENT-BINDING PROTEIN; S14 GENE-TRANSCRIPTION; EICOSAPENTAENOIC ACID; ACYL-COENZYME; DIETARY-FAT; C-III	Similar to fibrate hypolipidemic drugs, long chain polyunsaturated fatty acids contained in fish oil are activators of peroxisome proliferator-activated receptor alpha (PPAR alpha), The goal of this study was to assess the contribution of PPAR alpha in mediating the effect of fish oil on plasma lipid, lipoprotein, and apolipoprotein levels. To this end, PPAR alpha -deficient mice and wild-type littermates were fed isocaloric fish oil or coconut oil diets, the content of which varied reciprocally between 0, 3, 7, and 10% for 1 week. In both wild-type and PPAR alpha -deficient mice, fish oil feeding was associated with a dose-dependent decrease in triglycerides, cholesterol, and phospholipids associated with lower levels of very low density lipoprotein (VLDL) triglycerides and high density lipoprotein (HDL) cholesterol, The lowering of triglycerides and VLDL triglycerides was associated with a significant decrease of plasma apoC-III in both genotypes, Fish oil treatment did not influence hepatic apoC-III mRNA levels in either genotype indicating that apoC-III is not under transcriptional control by fish oil. The lowering of HDL cholesterol observed in both genotypes was associated with reduced plasma apoA-II without changes in liver apoA-II mRNA levels. In contrast, plasma apoA-I and liver apoA-I mRNA levels were decreased in wild-type but not in PPAR alpha -deficient mice after fish oil feeding indicating that PPAR alpha contributes to the effect of fish oil on apoA-I gene expression. In conclusion, PPAR alpha is not rate-limiting for fish oil to exert its triglyceride- and HDL-lowering action. Furthermore, PPAR alpha mediates, at least partly, the decrease of apoA-I after fish oil treatment, whereas apoC-III and apoA-II levels are affected in a PPAR alpha -independent manner. Altogether, these results show major molecular differences in action between fibrates and fish oil providing a molecular rationale for combination treatment with these compounds.	Inst Pasteur, Dept Atherosclerose, F-59019 Lille, France; Inst Pasteur, INSERM, U508, F-59019 Lille, France; Inst Pasteur, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59000 Lille, France; Penn State Univ, Ctr Mol Toxicol, University Pk, PA 16802 USA; NCI, Mol Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dallongeville, J (corresponding author), Inst Pasteur, Dept Atherosclerose, 1 Rue Professeur Calmette, F-59019 Lille, France.		TAILLEUX, Anne/R-5530-2018; Staels, Bart/N-9497-2016; Peters, Jeffrey/D-8847-2011; Bauge, Eric/R-6522-2018	TAILLEUX, Anne/0000-0003-1430-2627; Staels, Bart/0000-0002-3784-1503; Peters, Jeffrey/0000-0003-2782-2998; Bauge, Eric/0000-0001-9994-8667				AHN YS, 1994, J NUTR, V124, P2147, DOI 10.1093/jn/124.11.2147; Andersson Y, 1999, ARTERIOSCL THROM VAS, V19, P115, DOI 10.1161/01.ATV.19.1.115; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BERTHOU L, 1995, EUR J BIOCHEM, V232, P179, DOI 10.1111/j.1432-1033.1995.tb20797.x; BOCOS C, 1995, J STEROID BIOCHEM, V53, P467, DOI 10.1016/0960-0760(95)00093-F; BROUSSEAU ME, 1995, J NUTR, V125, P425; BROUSSEAU ME, 1995, ATHEROSCLEROSIS, V115, P107, DOI 10.1016/0021-9150(94)05505-D; BURGAYA F, 1989, BIOCHEM J, V259, P159, DOI 10.1042/bj2590159; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECRAEMER D, 1994, J LIPID RES, V35, P1241; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GRONN M, 1992, BIOCHIM BIOPHYS ACTA, V1125, P35, DOI 10.1016/0005-2760(92)90152-L; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HALMINSKI MA, 1991, J NUTR, V121, P1554, DOI 10.1093/jn/121.10.1554; Harris WS, 1997, AM J CLIN NUTR, V65, P1611; Harris WS, 1997, AM J CLIN NUTR, V65, P1645, DOI 10.1093/ajcn/65.5.1645S; HARRIS WS, 1989, J LIPID RES, V30, P785; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KUSHWAHA RS, 1991, J LIPID RES, V32, P1929; LEACH AB, 1984, LIPIDS, V19, P25, DOI 10.1007/BF02534604; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; NOSSEN JO, 1986, BIOCHIM BIOPHYS ACTA, V879, P56, DOI 10.1016/0005-2760(86)90266-3; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Power GW, 1997, J NUTR, V127, P2142, DOI 10.1093/jn/127.11.2142; QUARFORDT SH, 1982, J BIOL CHEM, V257, P4642; RAMIREZ I, 1985, BIOCHEM J, V232, P229, DOI 10.1042/bj2320229; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; RUSTAN AC, 1988, J LIPID RES, V29, P1417; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schoonjans K, 1996, J LIPID RES, V37, P907; SHEPHERD J, 1978, J CLIN INVEST, V61, P1582, DOI 10.1172/JCI109078; SORCITHOMAS M, 1992, J LIPID RES, V33, P1147; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; STAELS B, 1989, J LIPID RES, V30, P1137; STUCCHI AF, 1991, ARTERIOSCLER THROMB, V11, P1719, DOI 10.1161/01.ATV.11.6.1719; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WILLUMSEN N, 1993, LIPIDS, V28, P683, DOI 10.1007/BF02535987; WINDLER E, 1980, J BIOL CHEM, V255, P8303; WONG S, 1985, METABOLISM, V34, P900, DOI 10.1016/0026-0495(85)90135-0; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577	57	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4634	4639		10.1074/jbc.M008809200	http://dx.doi.org/10.1074/jbc.M008809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11050100	hybrid			2022-12-25	WOS:000168484300016
J	Joel, PB; Trybus, KM; Sweeney, HL				Joel, PB; Trybus, KM; Sweeney, HL			Two conserved lysines at the 50/20-kDa junction of myosin are necessary for triggering actin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; ACTOMYOSIN INTERACTIONS; ATPASE ACTIVITY; MOTOR DOMAIN; CHIMERIC SUBSTITUTIONS; CHARGED RESIDUES; BINDING SITES; HEAVY-CHAIN; N-TERMINUS; SUBFRAGMENT-1	Actin stimulates myosin's activity by inducing structural alterations that correlate with the transition from a weakly to a strongly bound state, during which time inorganic phosphate (P-i) is released from myosin's active site. The surface loop at the 50/20-kDa junction of myosin (loop 2) is part of the actin interface. Here we demonstrate that elimination of two highly conserved lysines at the C-terminal end of loop 2 specifically blocks the ability of heavy meromyosin to undergo a weak to strong binding transition with actin in the presence of ATP, Removal of these lysines has no effect on strong binding in the absence of nucleotide, on the rate of ADP binding or release, or on the basal ATPase activity. We further show that the 16 amino acids of loop 2 preceding the lysine-rich region are not essential for actin activation, although they do modulate myosin's affinity for actin in the presence of ATP. We conclude that interaction of the conserved lysines with acidic residues in subdomain I of actin either triggers a structural change or stabilizes a conformation that is necessary for actin-activated release of P-i and completion of the ATPase cycle.	Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Vermont; University of Pennsylvania	Trybus, KM (corresponding author), Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Given Bldg E205, Burlington, VT 05405 USA.	trybus@salus.med.uvm.edu	Sweeney, H Lee/F-1862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035661] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54568] Funding Source: Medline; NIAMS NIH HHS [AR35661] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHAUSSEPIED P, 1983, FEBS LETT, V161, P84, DOI 10.1016/0014-5793(83)80735-2; CHAUSSEPIED P, 1988, P NATL ACAD SCI USA, V85, P7471, DOI 10.1073/pnas.85.20.7471; CHEUNG P, 1992, BIOCHEM BIOPH RES CO, V189, P1143, DOI 10.1016/0006-291X(92)92323-P; COOK RK, 1993, J BIOL CHEM, V268, P2410; DASGUPTA G, 1992, BIOCHEMISTRY-US, V31, P1836, DOI 10.1021/bi00121a036; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEEVES MA, 1991, BIOCHEM J, V274, P1; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; Knetsch MLW, 1999, J BIOL CHEM, V274, P20133, DOI 10.1074/jbc.274.29.20133; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER CJ, 1995, BIOCHEMISTRY-US, V34, P2694, DOI 10.1021/bi00008a037; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rovner AS, 1998, J BIOL CHEM, V273, P27939, DOI 10.1074/jbc.273.43.27939; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; Wong WNW, 1999, BIOCHEMISTRY-US, V38, P1365, DOI 10.1021/bi982467g; YAMAMOTO K, 1990, BIOCHEMISTRY-US, V29, P844, DOI 10.1021/bi00455a035; YAMAMOTO K, 1991, J MOL BIOL, V217, P229, DOI 10.1016/0022-2836(91)90535-E	36	63	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					2998	3003		10.1074/jbc.M006930200	http://dx.doi.org/10.1074/jbc.M006930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042210	hybrid			2022-12-25	WOS:000166784900005
J	Rumenapp, U; Asmus, M; Schablowski, H; Woznicki, M; Han, L; Jakobs, KH; Fahimi-Vahid, M; Michalek, C; Wieland, T; Schmidt, M				Rumenapp, U; Asmus, M; Schablowski, H; Woznicki, M; Han, L; Jakobs, KH; Fahimi-Vahid, M; Michalek, C; Wieland, T; Schmidt, M			The M-3 muscarinic acetylcholine receptor expressed in HEK-293 cells signals to phospholipase D via G(12) but not G(q)-type G proteins - Regulators of G proteins as tools to dissect pertussis toxin-resistant G proteins in receptor-effector coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; ADP-RIBOSYLATION-FACTOR; SERUM RESPONSE FACTOR; SMOOTH-MUSCLE CELLS; ALPHA-SUBUNITS; RGS PROTEINS; DEPENDENT ACTIVATION; TRANSITION-STATE; ANGIOTENSIN-II	The M-3 muscarinic acetylcholine receptor (mAChR) expressed in HEK-293 cells couples to G(q) and G(12) proteins and stimulates phospholipase C (PLC) and phospholipase D (PLD) in a pertussis toxin-insensitive manner. To determine the type of G protein mediating M-3 mAChR-PLD coupling in comparison to M-3 mAChR-PLC coupling, we expressed various G alpha proteins and regulators of the G protein signaling (RGS), which act as GTPase-activating proteins for G(q)- or G(12)-type G proteins. PLD stimulation by the M-3 mAChR was enhanced by the overexpression of G alpha (12), and G alpha (13), whereas the overexpression of G alpha (q) strongly increased PLC activity without affecting PLD activity. Expression of the RGS homology domain of Lsc, which acts specifically on G alpha (12) and G alpha (13), blunted the M-3 mAChR-induced PLD stimulation without affecting PLC stimulation. On the other hand, overexpression of RGS4, which acts on G alpha (q)- but not G alpha (12)-type G proteins, suppressed the M-3 mAChR-induced PLC stimulation without altering PLD stimulation. We conclude that the M-3 mAChR in HEK-293 cells apparently signals to PLD via G alpha (q)- but not G alpha (12)-type G proteins and that G protein subtype-selective RGS proteins can be used as powerful tools to dissect the pertussis toxin-resistant G proteins and their role in receptor-effector coupling.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany; Univ Hamburg, Krankenhaus Eppendorf, Inst Expt & Klin Pharmakol & Toxicol, D-20246 Hamburg, Germany	University of Duisburg Essen; University of Hamburg	Rumenapp, U (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.		Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012; Schmidt, Martina/C-5339-2018	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261; Schmidt, Martina/0000-0003-3075-0630				Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gsell S, 2000, FASEB J, V14, P17, DOI 10.1096/fasebj.14.1.17; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rumenapp U, 1997, EUR J BIOCHEM, V248, P407, DOI 10.1111/j.1432-1033.1997.00407.x; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; Schurmann A, 1999, J BIOL CHEM, V274, P9744, DOI 10.1074/jbc.274.14.9744; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Ushio-Fukai M, 1999, MOL PHARMACOL, V55, P142, DOI 10.1124/mol.55.1.142; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; WIELAND T, 1993, J BIOL CHEM, V268, P18111; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924	45	73	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2474	2479		10.1074/jbc.M004957200	http://dx.doi.org/10.1074/jbc.M004957200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11036069	hybrid			2022-12-25	WOS:000166784800025
J	Songyang, Z; Yamanashi, Y; Liu, D; Baltimore, D				Songyang, Z; Yamanashi, Y; Liu, D; Baltimore, D			Domain-dependent function of the rasGAP-binding protein p62Dok in cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEIN; V-SRC; TYROSINE PHOSPHORYLATION; DOCKING PROTEIN; PTB DOMAIN; C-SRC; DOK-R; RECEPTOR; FAMILY	p62Dok, the rasGAP-binding protein, is a common target of protein-tyrosine kinases. It is one of the major tyrosine-phosphorylated molecules in v-Src-transformed cells. Dok consists of an amino-terminal Pleckstrin homology domain, a putative phosphotyrosine binding domain, and a carboxyl-terminal tail containing multiple tyrosine phosphorylation sites. The importance and function of these sequences in Dok signaling remain largely unknown. We have demonstrated here that the expression of Dok can inhibit cellular transformation by the Src tyrosine kinase, Both the phosphotyrosine binding domain and the carboxyl-terminal tail of Dok tin particular residues 336-363) are necessary for such activity. Using a combinatorial peptide library approach, we have shown that the Dok phosphotyrosine binding domain binds phosphopeptides with the consensus motif of Y/MXXNXL-phosphotyrosine. Furthermore, Dok can homodimerize through its phosphotyrosine binding domain and Tyr(146) at the amino-terminal region. Mutations of this domain or Tyr(146) that block homodimerization significantly reduce the ability of Dok to inhibit Src transformation. Our results suggest that Dok oligomerization through its multiple domains plays a critical role in Dok signaling in response to tyrosine kinase activation.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 108, Japan; CALTECH, Pasadena, CA 91125 USA	Baylor College of Medicine; University of Tokyo; California Institute of Technology	Songyang, Z (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	songyang@cbcm.tmc.edu						Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; Cong F, 1999, MOL CELL BIOL, V19, P8314; DARBY C, 1994, J IMMUNOL, V152, P5429; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dunant NM, 2000, CELL SIGNAL, V12, P317, DOI 10.1016/S0898-6568(00)00073-5; ELLIS C, 1991, ONCOGENE, V6, P895; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAWLEY RG, 1994, GENE THER, V1, P136; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Jones N, 1999, CURR BIOL, V9, P1057, DOI 10.1016/S0960-9822(99)80458-8; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; NEET K, 1995, MOL CELL BIOL, V15, P4908; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Shoelson SE, 1997, CURR OPIN CHEM BIOL, V1, P227, DOI 10.1016/S1367-5931(97)80014-2; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhou SY, 1999, PROG BIOPHYS MOL BIO, V71, P359, DOI 10.1016/S0079-6107(98)00045-5	36	64	64	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2459	2465		10.1074/jbc.M005504200	http://dx.doi.org/10.1074/jbc.M005504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042170	Green Accepted, hybrid			2022-12-25	WOS:000166784800023
J	Waidner, LA; Flynn, EK; Wu, M; Li, X; Karpel, RL				Waidner, LA; Flynn, EK; Wu, M; Li, X; Karpel, RL			Domain effects on the DNA-interactive properties of bacteriophage T4 gene 32 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BINDING-SITE; NUCLEIC-ACID; T4-GENE 32-PROTEIN; COOPERATIVITY DOMAIN; MELTING PROTEINS; REPLICATION; PURIFICATION; RECOMBINATION; FLUORESCENCE; ASSOCIATION	Bacteriophage T4 gene 32 protein, a model for single-strand specific nucleic acid-binding proteins, consists of three structurally and functionally distinct domains. We have studied the effects of the N and C domains on the protein structure and its nucleic acid-interactive properties. Although the presence of the C domain decreases the proteolytic susceptibility of the core (central) domain, quenching of the core tryptophan fluorescence by iodide is unaltered by the presence of the terminal domains. These results suggest that the overall conformation of the core domain remains largely independent of the flanking domains. Removal of the N or the C terminus does not abolish the DNA renaturation activity of the protein. However, intact protein and its three truncated forms differ in DNA helix-destabilizing activity. The C domain alone is responsible for the kinetic barrier to natural DNA helix destabilization seen with intact protein. Intact protein and core domain potentiate the DNA helix-destabilizing activity of truncated protein lacking only the C domain (*I), enhancing the observed hyperchromicity while increasing the melting temperature. Proteolysis experiments suggest that the affinity of core domain for single-stranded DNA is increased in the presence of *I. We propose that *I can "mingle" with intact protein or core domain while bound to single-stranded DNA.	Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21250 USA	University System of Maryland; University of Maryland Baltimore County	Karpel, RL (corresponding author), Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21250 USA.		Waidner, Lisa/F-8573-2010; Li, Xing/D-3852-2009; Waidner, Lisa/L-8921-2019	Waidner, Lisa/0000-0003-0117-665X	NIGMS NIH HHS [1R01GM52530] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BITTNER M, 1979, J BIOL CHEM, V254, P9565; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; CASASFINET JR, 1993, J MOL BIOL, V229, P873, DOI 10.1006/jmbi.1993.1093; CASASFINET JR, 1993, BIOCHEMISTRY-US, V32, P9735, DOI 10.1021/bi00088a028; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; HOSODA J, 1978, J BIOL CHEM, V253, P7547; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KARPEL RL, 1987, J BIOL CHEM, V262, P9359; KELLY RC, 1976, J BIOL CHEM, V251, P7229; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; VILLEMAIN JL, 1993, BIOCHEMISTRY-US, V32, P11235, DOI 10.1021/bi00092a038; Villemain JL, 1996, J BIOL CHEM, V271, P27623, DOI 10.1074/jbc.271.44.27623; Wheeler LJ, 1996, J BIOL CHEM, V271, P11156, DOI 10.1074/jbc.271.19.11156; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; Wu M, 1999, J MOL BIOL, V286, P1107, DOI 10.1006/jmbi.1999.2541	25	23	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2509	2516		10.1074/jbc.M007778200	http://dx.doi.org/10.1074/jbc.M007778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053417	hybrid			2022-12-25	WOS:000166784800030
J	Medstrand, P; Landry, JR; Mager, DL				Medstrand, P; Landry, JR; Mager, DL			Long terminal repeats are used as alternative promoters for the endothelin B receptor and apolipoprotein C-I genes in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS RETROVIRUS; TRANSPOSABLE ELEMENTS; CYTOSINE METHYLATION; EXPRESSION; GROWTH; FAMILY; HYBRIDIZATION; PLEIOTROPHIN; TRANSCRIPTS; EVOLUTION	To examine the potential regulatory involvement of retroelements in the human genome, we screened the transcribed sequences of GenBank(TM) and expressed sequence tag data bases with long terminal repeat (LTR) elements derived from different human endogenous retroviruses. These screenings detected human transcripts containing LTRs belonging to the human endogenous retrovirus-E family fused to the apolipoprotein CI (apoC-I) and the endothelin B receptor (EBR) genes. However, both genes are known to have non-LTR (native) promoters. Initial reverse transcription-polymerase chain reaction experiments confirmed and authenticated the presence of transcripts from both the native and LTR promoters. Using a 5'-rapid amplification of cDNA ends protocol, we showed that the alternative transcripts of apoC-I and EBR are initiated and promoted by the LTRs, The LTR-apoC-I fusion and native apoC-I transcripts are present in many of the tissues tested. As expected, we found apoC-I preferentially expressed in liver, where about 15% of the transcripts are derived from the LTR promoter, Transient transfections suggest that the expression is not dependent on the LTR itself, but the presence of the LTR increases activity of the apoC-I promoter from both humans and baboons, The native EBR-driven transcripts were also detected in many tissues, whereas the LTR-driven transcripts appear limited to placenta. In contrast to the LTR of apoC-I, the EBR LTR promotes a significant proportion of the total EBR transcripts, and transient transfection results indicate that the LTR acts as a strong promoter and enhancer in a placental cell line. This investigation reports two examples where LTR sequences contribute to increased transcription of human genes and illustrates the impact of mobile elements on gene and genome evolution.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; University of British Columbia	Mager, DL (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	dixie@interchange.ubc.ca		Mager, Dixie/0000-0002-5955-2550				ARAI H, 1993, J BIOL CHEM, V268, P3463; Bi S, 1997, J BIOL CHEM, V272, P30583, DOI 10.1074/jbc.272.48.30583; Boeke J. D., 1997, P343; Britten RJ, 1997, GENE, V205, P177, DOI 10.1016/S0378-1119(97)00399-5; Brosius J, 1999, GENE, V238, P115, DOI 10.1016/S0378-1119(99)00227-9; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; FANT ME, 1992, J CLIN ENDOCR METAB, V74, P1158, DOI 10.1210/jc.74.5.1158; Freitas EM, 2000, J MOL EVOL, V50, P391, DOI 10.1007/s002399910042; Germain AM, 1997, MOL CELL ENDOCRINOL, V132, P161, DOI 10.1016/S0303-7207(97)00130-5; GOODCHILD NL, 1993, VIROLOGY, V196, P778, DOI 10.1006/viro.1993.1535; HANDWERGER S, 1995, J LAB CLIN MED, V125, P679; Jong MC, 1999, ARTERIOSCL THROM VAS, V19, P472, DOI 10.1161/01.ATV.19.3.472; Kapitonov VV, 1999, J MOL EVOL, V48, P248, DOI 10.1007/PL00013153; Kidwell MG, 1997, P NATL ACAD SCI USA, V94, P7704, DOI 10.1073/pnas.94.15.7704; LARSSON E, 1989, CURR TOP MICROBIOL, V148, P115; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LI WH, 1988, J LIPID RES, V29, P245; LI WH, 1987, NATURE, V326, P93, DOI 10.1038/326093a0; MCMAHON LP, 1993, CLIN SCI, V85, P417, DOI 10.1042/cs0850417; MEDSTRAND P, 1992, J GEN VIROL, V73, P2463, DOI 10.1099/0022-1317-73-9-2463; Medstrand P, 1998, J VIROL, V72, P9782, DOI 10.1128/JVI.72.12.9782-9787.1998; NAKAMUTA M, 1991, BIOCHEM BIOPH RES CO, V177, P34, DOI 10.1016/0006-291X(91)91944-8; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; PASTORCIC M, 1992, GENOMICS, V13, P368, DOI 10.1016/0888-7543(92)90255-Q; RABSON AB, 1985, J VIROL, V56, P176, DOI 10.1128/JVI.56.1.176-182.1985; REPASKE R, 1985, J VIROL, V54, P764, DOI 10.1128/JVI.54.3.764-772.1985; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Schulte AM, 1998, J VIROL, V72, P6065, DOI 10.1128/JVI.72.7.6065-6072.1998; Shigematsu K, 1996, ENDOCRINOLOGY, V137, P738, DOI 10.1210/en.137.2.738; SHIH A, 1991, VIROLOGY, V182, P495, DOI 10.1016/0042-6822(91)90590-8; SIBLEY CG, 1987, J MOL EVOL, V26, P99, DOI 10.1007/BF02111285; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; SMIT M, 1988, HUM GENET, V78, P90, DOI 10.1007/BF00291243; Sverdlov ED, 1998, FEBS LETT, V428, P1, DOI 10.1016/S0014-5793(98)00478-5; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; Tristem M, 2000, J VIROL, V74, P3715, DOI 10.1128/JVI.74.8.3715-3730.2000; Tsutsumi M, 1999, GENE, V228, P43, DOI 10.1016/S0378-1119(99)00014-1; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; WILKINSON DA, 1994, RETROVIRIDAE, V3, P465; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	41	168	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1896	1903		10.1074/jbc.M006557200	http://dx.doi.org/10.1074/jbc.M006557200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11054415	hybrid			2022-12-25	WOS:000166528000035
J	Watt, WC; Storm, DR				Watt, WC; Storm, DR			Odorants stimulate the ERK/mitogen-activated protein kinase pathway and activate cAMP-response element-mediated transcription in olfactory sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; NUCLEOTIDE-GATED CHANNELS; MAP KINASE; GENE-EXPRESSION; RECEPTOR-CELLS; PHOSPHORYLATION; INHIBITION; CREB; CASCADE; BINDING	Olfactory sensory neurons (OSNs) respond acutely to volatile molecules and exhibit adaptive responses including desensitization to odorant exposure. Although mechanisms for short term adaptation have been described, there is little evidence that odorants cause long lasting, transcription-dependent changes in OSNs. Here we report that odorants stimulate cAMP-response element (CRE)-mediated transcription in OSNs through Ca2+ activation of the ERK/MAPK/p90(rsh) pathway, Odorant stimulation of ERK phosphorylation was ablated by inhibition of calmodulin-dependent protein kinase II suggesting that odorant activation of ERK is mediated through this kinase. Moreover, a brief exposure in vivo to an odorant in vapor phase stimulated CRE-mediated gene transcription in discrete populations of OSNs. These data suggest that like central nervous system neurons, OSNs may undergo long term adaptive changes mediated through CRE-mediated transcription.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Storm, DR (corresponding author), Univ Washington, Dept Pharmacol, Mail Box 357280,Hlth Sci Bldg, Seattle, WA 98195 USA.	dstorm@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004156] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC04156] Funding Source: Medline; NIGMS NIH HHS [GM07270] Funding Source: Medline; NINDS NIH HHS [NS357056] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraham ST, 1997, CIRC RES, V81, P575, DOI 10.1161/01.RES.81.4.575; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Barth AL, 2000, J NEUROSCI, V20, P4206; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Blum S, 1999, J NEUROSCI, V19, P3535; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BORISY FF, 1992, J NEUROSCI, V12, P915; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; Dittman AH, 1997, NEURON, V19, P381, DOI 10.1016/S0896-6273(00)80947-2; Duchamp-Viret P, 1999, SCIENCE, V284, P2171, DOI 10.1126/science.284.5423.2171; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRINGS S, 1991, J GEN PHYSIOL, V97, P725, DOI 10.1085/jgp.97.4.725; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREVAL SS, 2000, J BIOL CHEM, V275, P3722; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hirotsu T, 2000, NATURE, V404, P289, DOI 10.1038/35005101; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; LeindersZufall T, 1997, J NEUROSCI, V17, P4136; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Lindstrom L, 1999, CLIN PHYSIOL, V19, P1, DOI 10.1046/j.1365-2281.1999.00137.x; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1989, P NATL ACAD SCI USA, V86, P5641, DOI 10.1073/pnas.86.14.5641; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Moon C, 1999, P NATL ACAD SCI USA, V96, P14605, DOI 10.1073/pnas.96.25.14605; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Obrietan K, 1999, J BIOL CHEM, V274, P17748, DOI 10.1074/jbc.274.25.17748; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; Pham TA, 1999, NEURON, V22, P63, DOI 10.1016/S0896-6273(00)80679-0; RONNETT GV, 1991, P NATL ACAD SCI USA, V88, P2366, DOI 10.1073/pnas.88.6.2366; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tully T, 1998, NAT NEUROSCI, V1, P543, DOI 10.1038/2780; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WANG HW, 1993, SCIENCE, V260, P998, DOI 10.1126/science.8493539; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Wei J, 1998, NEURON, V21, P495, DOI 10.1016/S0896-6273(00)80561-9; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZUFALL F, 1991, P ROY SOC B-BIOL SCI, V246, P225, DOI 10.1098/rspb.1991.0148; ZUFALL F, 1991, J NEUROSCI, V11, P3573	63	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2047	2052		10.1074/jbc.M006703200	http://dx.doi.org/10.1074/jbc.M006703200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042208	hybrid			2022-12-25	WOS:000166528000055
J	Hirsch, DS; Pirone, DM; Burbelo, PD				Hirsch, DS; Pirone, DM; Burbelo, PD			A new family of Cdc42 effector proteins, CEPs, function in fibroblast and epithelial cell shape changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-BINDING DOMAIN; P21-ACTIVATED KINASE; FILOPODIUM FORMATION; ACTIN-CYTOSKELETON; MDCK CELLS; N-WASP; RHO; RAC1; POLARIZATION; EXPRESSION	Cdc42, a Rho GTPase, regulates the organization of the actin cytoskeleton by its interaction with several distinct families of downstream effector proteins. Here, we report the identification of four new Cdc42-binding proteins that, along with MSE55, constitute a new family of effector proteins. These molecules, designated CEPs, contain three regions of homology, including a Cdc42 binding domain acid two unique domains called CI and CII. Experimentally, we have verified that CEP2 and CEP5 bind Cdc42. Expression of CEP2, CEP3, CEP4, and CEP5 in NIH-3T3 fibroblasts induced pseudopodia formation. Fibroblasts coexpressing dominant negative Cdc42 with CEP2 or expressing a Cdc42/Rac interactive binding domain mutant of CEP2 did not induce pseudopodia formation. In primary keratinocytes, CEP2-and CEP5-expressing cells showed reduced F-actin localization at the adherens junctions with an increase in thin stress fibers that extended the length of the cell body. Keratinocytes expressing CEPs also showed an altered vinculin distribution and a loss of E-cadherin from adherens junctions. Similar effects were observed in keratinocytes expressing constitutively active Cdc42, but were not seen with a Cdc42/Rac interactive binding domain mutant of CEP2. These results suggest that CEPs act downstream of Cdc42 to induce actin filament assembly leading to cell shape changes.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Burbelo, PD (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, Rm EG16,New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	burbelpd@gunet.georgetown.edu	Burbelo, Peter D./B-1027-2009		NATIONAL CANCER INSTITUTE [R29CA077459] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA77459-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; BAHOU WF, 1992, J BIOL CHEM, V267, P13986; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Burbelo PD, 1999, P NATL ACAD SCI USA, V96, P9083, DOI 10.1073/pnas.96.16.9083; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; Clayton L, 1999, DEV BIOL, V205, P322, DOI 10.1006/dbio.1998.9117; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Dutartre H, 1996, J CELL SCI, V109, P367; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Pirone DM, 2000, J BIOL CHEM, V275, P22650, DOI 10.1074/jbc.M002832200; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Stoffler HE, 1998, J CELL SCI, V111, P2779; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	48	73	81	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					875	883		10.1074/jbc.M007039200	http://dx.doi.org/10.1074/jbc.M007039200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035016	hybrid			2022-12-25	WOS:000166430900004
J	Ho, HH; Ganeshalingam, N; Rosenhouse-Dantsker, A; Osman, R; Gershengorn, MC				Ho, HH; Ganeshalingam, N; Rosenhouse-Dantsker, A; Osman, R; Gershengorn, MC			Charged residues at the intracellular boundary of transmembrane helices 2 and 3 independently affect constitutive activity of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; ALPHA(1B)-ADRENERGIC RECEPTOR; ACTIVATION; RHODOPSIN; ONCOGENE; MUTATION; LYMPHOMA; HELIX-6	Because charged residues at the intracellular ends of transmembrane helix (TMH) 2 and TMH3 of G protein-coupled receptors (GPCRs) affect signaling, we performed mutational analysis of these residues in the constitutively signaling Kaposi's sarcoma-associated herpesvirus GPCR (KSNV-GPCR), KSHV-GPCR contains the amino acid sequence Val-Arg-Tyr rather than the Asp/Glu-Arg-Tyr ((D/ E)RY) moth at the intracellular end of TMH3, Mutation of Arg-143 to Ala (R143A) or Gln (R143Q) abolished constitutive signaling whereas R143K exhibited 50% of the basal activity of RSHV-GPCR, R143A was not stimulated by agonist, whereas R143Q was stimulated by growth-related oncogene-cu, and R143K, similar to KSHV-GPCR, was stimulated further. These findings show that Arg-143 is critical for signal generation in KSHV-GPCR In other GPCRs, Arg in this position may act as a signaling switch by movement of its sidechain from a hydrophilic pocket in the TMH bundle to a position outside the bundle. In rhodopsin, the Arg of Glu-Arg-Tyr interacts with the adjacent Asp to constrain Arg outside the TMH bundle. V142D was 70% more active than KSHV-GPCR, suggesting that an Arg residue, which is constrained outside the bundle by interacting with Asp-142, leads to a receptor that signals more actively, Because the usually conserved Asp in the middle of TMH2 is not present in KSHV-GPCR, we tested whether Asp-83 at the intracellular end of TMH2 was involved in signaling. D83N and D83A were 110 and 190% more active than KSHV-GPCR, respectively. The double mutant D83A/V142D was 510% more active than KSHV-GPCR That is, cosubstitutions of Asp-83 by Ala and Val-142 by Asp act synergistically to increase basal signaling. A model of RSHV-GPCR predicts that Arg-143 interacts with residues in the TMH bundle and that the sidechain of Asp-83 does not interact with Arg-143, These data are consistent with the hypothesis that Arg-143 and Asp-83 independently affect the signaling activity of KSHV-GPCR.	Cornell Univ, Weill Med Coll, Dept Med, Div Mol Med, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Cornell University; Cornell University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Gershengorn, MC (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Mol Med, 1300 York Ave,Rm A328, New York, NY 10021 USA.							Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Arvanitakis L, 1998, TRENDS ENDOCRIN MET, V9, P27, DOI 10.1016/S1043-2760(98)00007-1; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Burger M, 1999, J IMMUNOL, V163, P2017; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Colson AO, 1998, MOL PHARMACOL, V54, P968, DOI 10.1124/mol.54.6.968; Donohue PJ, 1999, BIOCHEMISTRY-US, V38, P9366, DOI 10.1021/bi990544h; Fanelli F, 1999, MOL PHARMACOL, V56, P214, DOI 10.1124/mol.56.1.214; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; IMAI A, 1987, METHOD ENZYMOL, V141, P100; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Offermann MK, 1996, TRENDS MICROBIOL, V4, P419, DOI 10.1016/0966-842X(96)84953-5; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PERLMAN JH, 1995, MOL PHARMACOL, V47, P480; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; Porter JE, 1999, J BIOL CHEM, V274, P34535, DOI 10.1074/jbc.274.49.34535; Rhee MH, 2000, FEBS LETT, V466, P300, DOI 10.1016/S0014-5793(00)01094-2; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Scheer A, 2000, MOL PHARMACOL, V57, P219; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	35	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1376	1382		10.1074/jbc.M007885200	http://dx.doi.org/10.1074/jbc.M007885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11031271	hybrid			2022-12-25	WOS:000166430900070
J	Myohanen, S; Baylin, SB				Myohanen, S; Baylin, SB			Sequence-specific DNA binding activity of RNA helicase A to the p16(INK4a) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APRT GENE PROMOTER; CPG ISLAND; HISTONE DEACETYLASE; DOSAGE COMPENSATION; MALELESS PROTEIN; POLYMERASE-II; SP1; METHYLATION; P16; TRICHOSTATIN	p16(INK4a) is frequently altered in human cancer, often through epigenetically mediated transcriptional silencing. However, little is known about the transcriptional regulation of this gene. To learn more about such control, we initiated studies of proteins that bind to the promoter in cancer cells that do, and do not, express the gene. We identify RNA helicase A (RHA) as a protein that binds much better to the p16(INK4a) promoter in the expressing cells. RHA has not previously been characterized to manifest sequence-specific DNA interaction but does so to the sequence 5' CGG ACC GCG TGC GC 3' in the p16(INK4a) promoter. The Drosophila homologue to RHA, maleless (Mle), functions in the fly for a-fold activation of male X-chromosome genes. In our experimental setting, RHA induces a similar modest up-regulation of the p16(INK4a) promoter that is dependent upon its sequence-specific interaction. Mle colocalizes with hyperacetylated H4Ac16 on the X-chromosome and some autosomal loci. The decreased binding of RHA to p16(INK4a) in our cells, where the gene is transcriptionally inactive, is associated with decreased amounts of RHA that immunoprecipitate with acetylated lysine antibodies. Finally, we show RHA to be a cellular substrate for caspase-3, which decreases its sequence-specific binding to p16(INK4a) by cleavage of the N terminus. Thus, we have identified a new protein interaction with the p16(INK4a) promoter that involves an important protein for transcriptional modulation. This interaction is decreased in cancer cells, where this gene is aberrantly transcriptionally silent.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Baylin, SB (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu			NCI NIH HHS [R01 CA43318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bashaw GJ, 1996, CURR OPIN GENET DEV, V6, P496, DOI 10.1016/S0959-437X(96)80073-6; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Hara E, 1996, MOL CELL BIOL, V16, P859; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; LI Y, 1994, CANCER RES, V54, P6078; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Medina V, 1997, CANCER RES, V57, P3697; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Tang H, 1999, MOL CELL BIOL, V19, P3540; Wong DJ, 1999, MOL CELL BIOL, V19, P5642; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016; ZHANG SS, 1995, J BIOL CHEM, V270, P16422, DOI 10.1074/jbc.270.27.16422; Zhang SS, 1997, J BIOL CHEM, V272, P11487	33	64	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1634	1642		10.1074/jbc.M004481200	http://dx.doi.org/10.1074/jbc.M004481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038348	hybrid			2022-12-25	WOS:000166430900103
J	Parks, IK; Klug, CA; Li, KJ; Jerabek, L; Li, LH; Nanamori, M; Neubig, RR; Hood, L; Weissman, IL; Clarke, MF				Parks, IK; Klug, CA; Li, KJ; Jerabek, L; Li, LH; Nanamori, M; Neubig, RR; Hood, L; Weissman, IL; Clarke, MF			Molecular cloning and characterization of a novel regulator of G-protein signaling from mouse hematopoietic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RGS PROTEIN; MESSENGER-RNA; CORE DOMAIN; CHEMOATTRACTANT RECEPTORS; SACCHAROMYCES-CEREVISIAE; MEMBRANE ASSOCIATION; MEDIATED MODULATION; KINASE ACTIVATION; PHOSPHOLIPASE-C	A novel regulator of G-protein signaling (RGS) has been isolated from a highly purified population of mouse long-term hematopoietic stem cells, and designated RGS18. It has 234 amino acids consisting of a central RGS box and short divergent NH2 and COOH termini, The calculated molecular weight of RGS18 is 27,610 and the isoelectric point is 8.63. Mouse RGS18 is expressed from a single gene and shows tissue specific distribution. It is most highly expressed in bone marrow followed by fetal liver, spleen, and then lung. In bone marrow, RGS18 level is highest in long-term and short-term hematopoietic stem cells, and is decreased as they differentiate into more committed multiple progenitors. The human RGS18 ortholog has a tissue-specific expression pattern similar to that of mouse RGS18. Purified RGS18 interacts with the alpha subunit of both G(i) and G(q) subfamilies. The results of in vitro GTPase single-turnover assays using G alpha (i) indicated that RGS18 accelerates the intrinsic GTPase activity of G alpha (i). Transient overexpression of RGS18 attenuated inositol phosphates production via angiotensin receptor and transcriptional activation through cAMP-responsive element via M1 muscarinic receptor. This suggests RGS18 can act on G(q)-mediated signaling pathways in vivo.	Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Stanford University; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan	Clarke, MF (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol & Oncol, CCGC 4431,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.			Neubig, Richard/0000-0003-0501-0008	NIDDK NIH HHS [DK53074-04] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; Beadling C, 1999, J IMMUNOL, V162, P2677; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BLUM S, 1990, DNA CELL BIOL, V9, P589, DOI 10.1089/dna.1990.9.589; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; Denecke B, 1999, J BIOL CHEM, V274, P26860, DOI 10.1074/jbc.274.38.26860; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Granderath S, 1999, DEVELOPMENT, V126, P1781; Grant SL, 2000, MOL PHARMACOL, V57, P460, DOI 10.1124/mol.57.3.460; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, DNA CELL BIOL, V16, P589, DOI 10.1089/dna.1997.16.589; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HONG JX, 1993, J IMMUNOL, V150, P3895; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Maniatis T., 1989, MOL CLONING LAB MANU; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Moratz C, 2000, J IMMUNOL, V164, P1829, DOI 10.4049/jimmunol.164.4.1829; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; Natochin M, 1998, J BIOL CHEM, V273, P4300, DOI 10.1074/jbc.273.8.4300; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nomoto S, 1997, BIOCHEM BIOPH RES CO, V241, P281, DOI 10.1006/bbrc.1997.7802; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Thomas EA, 1998, J NEUROSCI RES, V52, P118, DOI 10.1002/(SICI)1097-4547(19980401)52:1<118::AID-JNR11>3.0.CO;2-6; Thompson JB, 1998, J PHARMACOL EXP THER, V285, P216; Versele M, 1999, EMBO J, V18, P5577, DOI 10.1093/emboj/18.20.5577; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WU HK, 1995, LEUKEMIA, V9, P1291; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851	67	45	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					915	923		10.1074/jbc.M005947200	http://dx.doi.org/10.1074/jbc.M005947200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042171	hybrid			2022-12-25	WOS:000166430900009
J	Schaenman, JM; Gilchrist, CA; Mann, BJ; Petri, WA				Schaenman, JM; Gilchrist, CA; Mann, BJ; Petri, WA			Identification of two Entamoeba histolytica sequence-specific URE4 enhancer-binding proteins with homology to the RNA-binding motif RRM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT MUTANT; LECTIN GENE; TRANSCRIPTIONAL ANALYSIS; CRYSTAL-STRUCTURE; ALPHA-AMANITIN; POLYMERASE-II; CODING GENES; EXPRESSION; PROMOTER; DOMAIN	To study transcriptional regulation in the lower branching eukaryote Entamoeba histolytica, we have identified two sequence-specific DNA-binding proteins that recognize the upstream regulatory element URE4, an enhancer that regulates expression of the Gal/GalNAc lectin heavy subunit gene hgl5, A chromatographic purification of E, histolytica nuclear extracts by gel filtration, cation exchange, and sequence-specific DNA affinity chromatography led to a 700-fold increase in URE4 binding activity and the appearance of two dominant protein species with molecular masses of 28 and 18 kDa, These proteins, termed E, histolytica enhancer-binding proteins 1 and 2 (EhEBP1 and EhEBP2), were sequenced by tandem mass spectroscopy and their corresponding cDNA clones identified. Recombinant EhEBP1 and EhEBPB were able to bind double-stranded oligonucleotides bearing the URE4 motif in a sequence-specific manner, and antibodies raised against EhEBP1 were able to interfere with the formation of URE4-protein complexes in crude nuclear extracts, Overexpression of EhEBP1 in E, histolytica trophozoites resulted in a 7-fold drop in promoter activity in transiently transfected reporter gene constructs when the URE4 motif was present, confirming its ability to specifically recognize the URE4 motif and suggesting that additional cofactors may be required for transcriptional activation by URE4, Further characterization and identification of binding partners for EhEBP1 and EhEBP2, the first proteins with demonstrated sequence-specific DNA binding activity to be identified in E, histolytica, should provide new insights into transcriptional regulation in this protozoan parasite.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Petri, WA (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, MR4 Bldg,Rm 2115,300 Pk Pl, Charlottesville, VA 22908 USA.		Petri, William A./D-3639-2019; Petri, William/AAL-3642-2020	Petri, William/0000-0002-7268-1218	NIAID NIH HHS [AI 37941] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037941] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P925, DOI 10.1089/dna.1993.12.925; BUSS H, 1995, MOL BIOCHEM PARASIT, V72, P1, DOI 10.1016/0166-6851(95)00060-E; DEANGELO DJ, 1995, MOL CELL BIOL, V15, P1254; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Gilchrist CA, 1995, MOL BIOCHEM PARASIT, V74, P1, DOI 10.1016/0166-6851(95)02474-3; Gilchrist CA, 1998, INFECT IMMUN, V66, P2383, DOI 10.1128/IAI.66.5.2383-2386.1998; Gomez C, 1998, J BIOL CHEM, V273, P7277, DOI 10.1074/jbc.273.13.7277; HOLBERTON DV, 1995, NUCLEIC ACIDS RES, V23, P2945, DOI 10.1093/nar/23.15.2945; Huang WB, 1997, J BIOL CHEM, V272, P3852, DOI 10.1074/jbc.272.6.3852; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LIOUTAS C, 1995, MOL BIOCHEM PARASIT, V73, P259, DOI 10.1016/0166-6851(95)00101-6; Liston DR, 1999, MOL CELL BIOL, V19, P2380; LIU F, 1992, GENE, V120, P143, DOI 10.1016/0378-1119(92)90087-6; Luna-Arias JP, 1999, MICROBIOL-SGM, V145, P33, DOI 10.1099/13500872-145-1-33; Maxson JM, 1996, PLANT MOL BIOL, V31, P751, DOI 10.1007/BF00019463; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; ORTNER S, 1995, MOL BIOCHEM PARASIT, V73, P189, DOI 10.1016/0166-6851(95)00115-H; Perez DG, 1998, J BIOL CHEM, V273, P7285, DOI 10.1074/jbc.273.13.7285; Purdy JE, 1996, MOL BIOCHEM PARASIT, V78, P91, DOI 10.1016/S0166-6851(96)02614-X; PURDY JE, 1994, P NATL ACAD SCI USA, V91, P7099, DOI 10.1073/pnas.91.15.7099; Quon DVK, 1996, J MOL EVOL, V43, P253, DOI 10.1007/PL00006084; Ramakrishnan G, 1997, MOL BIOCHEM PARASIT, V84, P93, DOI 10.1016/S0166-6851(96)02784-3; Schaenman JM, 1998, MOL BIOCHEM PARASIT, V94, P309, DOI 10.1016/S0166-6851(98)00081-4; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; Singh U, 1997, P NATL ACAD SCI USA, V94, P8812, DOI 10.1073/pnas.94.16.8812; Vines RR, 1998, MOL BIOL CELL, V9, P2069, DOI 10.1091/mbc.9.8.2069; VIONES RR, 1995, MOL BIOCHEM PARASIT, P265	30	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1602	1609		10.1074/jbc.M006866200	http://dx.doi.org/10.1074/jbc.M006866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038357	hybrid			2022-12-25	WOS:000166430900099
J	Andres, G; Alejo, A; Simon-Mateo, C; Salas, ML				Andres, G; Alejo, A; Simon-Mateo, C; Salas, ML			African swine fever virus protease, a new viral member of the SUMO-1-specific protease family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADENOVIRUS PROTEINASE; VACCINIA VIRUS; SEQUENCE; POLYPROTEIN; EXPRESSION; CLEAVAGE; GENE; MORPHOGENESIS; POLYMERASE; PEPTIDE	African swine fever virus (ASFV) is a complex DNA virus that employs polyprotein processing at Gly-Gly-Xaa sites as a strategy to produce several major core components of the viral particle. The virus gene S273R encodes a 31-kDa protein that contains a "core domain" with the conserved catalytic residues characteristic of SUMO-l-specific proteases and the adenovirus protease. Using a COS cell expression system, it was found that protein pS273R is capable of cleaving the viral polyproteins pp62 and pp220 in a specific way giving rise to the same intermediates and mature products as those produced in ASFV-infected cells. Furthermore, protein pS273R, like adenovirus protease and SUMO-1-specific enzymes, is a cysteine protease, because its activity is abolished by mutation of the predicted catalytic histidine and cysteine residues and is inhibited by sulfhydryl-blocking reagents. Protein pS273R is expressed late after infection and is localized in the cytoplasmic viral factories, where it is found associated with virus precursors and mature virions. In the virions, the protein is present in the core shell, a domain where the products of the viral polyproteins are also located. The identification of the ASFV protease will allow a better understanding of the role of polyprotein processing in virus assembly and may contribute to our knowledge of the emerging family of SUMO-1-specific proteases.	UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, ML (corresponding author), UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.		Alejo, Ali/AAF-1477-2020; Andres, German/E-2632-2016; Simon Mateo, Carmen/D-4878-2013	Alejo, Ali/0000-0002-1613-6063; Andres, German/0000-0003-0265-5409; Simon Mateo, Carmen/0000-0002-4251-0821				ALMAZAN F, 1992, J VIROL, V66, P6655; ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; Andres G, 1997, J VIROL, V71, P2331; Andres G, 1998, J VIROL, V72, P8988; CARRASCOSA AL, 1985, J VIROL, V54, P337, DOI 10.1128/JVI.54.2.337-344.1985; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COTTEN M, 1995, VIROLOGY, V213, P494, DOI 10.1006/viro.1995.0022; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; ENJUANES L, 1976, J GEN VIROL, V32, P471, DOI 10.1099/0022-1317-32-3-471; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARCIABEATO R, 1992, VIROLOGY, V188, P938, DOI 10.1016/0042-6822(92)90558-7; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gorbalenya AE, 1996, PERSPECT DRUG DISCOV, V6, P64, DOI 10.1007/BF02174046; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KANE EM, 1993, J VIROL, V67, P2689, DOI 10.1128/JVI.67.5.2689-2698.1993; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LEE PY, 1994, J BIOL CHEM, V269, P8616; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; Mangel WF, 1996, J BIOL CHEM, V271, P536, DOI 10.1074/jbc.271.1.536; MOSS B, 1973, J MOL BIOL, V81, P267, DOI 10.1016/0022-2836(73)90195-2; SALAS ML, 1986, VIROLOGY, V152, P228, DOI 10.1016/0042-6822(86)90387-9; Sambrook J., 2002, MOL CLONING LAB MANU; SANZ A, 1985, J VIROL, V54, P199, DOI 10.1128/JVI.54.1.199-206.1985; Simon-Mateo C, 1997, J VIROL, V71, P5799; SIMONMATEO C, 1993, EMBO J, V12, P2977, DOI 10.1002/j.1460-2075.1993.tb05960.x; Sircar S, 1998, ANTIVIR RES, V40, P45, DOI 10.1016/S0166-3542(98)00040-0; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; TIHANYI K, 1993, J BIOL CHEM, V268, P1780; VANSLYKE JK, 1991, VIROLOGY, V183, P467, DOI 10.1016/0042-6822(91)90976-I; VINUELA E, 1985, CURR TOP MICROBIOL, V116, P151; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; YANEZ RJ, 1993, J GEN VIROL, V74, P1633, DOI 10.1099/0022-1317-74-8-1633; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	42	79	88	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					780	787		10.1074/jbc.M006844200	http://dx.doi.org/10.1074/jbc.M006844200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031264	Green Published, hybrid			2022-12-25	WOS:000166280700105
J	Delgado, M; Ganea, D				Delgado, M; Ganea, D			Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; IN-VITRO; C-JUN; MEDIATED TRANSCRIPTION; SIGNAL-TRANSDUCTION; CYTOKINE PRODUCTION; MURINE MACROPHAGES; KINASE PATHWAYS	The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) suppress monocyte/macrophage production of proinflammatory agents. The transcription factor NF-KB regulates the transcription of most agents. VIP/ PACAP inhibit NF-KB transactivation in the lipopolysaccharide-stimulated human monocytic cell line THP-1 at multiple levels. First, VIP/PACAP inhibit p65 nuclear translocation and NF-KB DNA binding by stabilizing the inhibitor IKB alpha. Second, VIP/PACAP induce phosphorylation of the CRE-binding protein (CREB) and its binding to the CREB-binding protein (CBP). This results in a decrease in p65 CBP complexes, which further reduces NF-KB transactivation. Third, VIP and PACAP reduce the phosphorylation of the TATA box-binding protein (TBP), resulting in a reduction in TBP binding to both p65 and the TATA box. All these effects are mediated through the specific receptor VPAC1. The cAMP/cAMP-dependent protein kinase pathway mediates the effects on CBP and TBP, whereas a cAMP-independent pathway is the major transducer for the effects on p65 nuclear translocation. Since NF-KB represents a focal point for various stimuli and induces the expression of many proinflammatory genes, its targeting by VIP and PACAP positions them as important anti-inflammatory agents. The VIP/PACAP inhibition of NF-KB at various levels and through different transduction pathways could offer a significant advantage over other anti-inflammatory agents.	Rutgers State Univ, Dept Sci Biol, Newark, NJ 07102 USA; Univ Complutense Madrid, Dept Biol Celular, Fac Biol, Madrid 28040, Spain	Rutgers State University Newark; Rutgers State University New Brunswick; Complutense University of Madrid	Ganea, D (corresponding author), Rutgers State Univ, Dept Sci Biol, Newark, NJ 07102 USA.		Delgado, Mario/P-1524-2016	Delgado, Mario/0000-0003-1893-5982	NIAID NIH HHS [AI 041786-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041786, R21AI041786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; CHEDEVILLE A, 1993, FEBS LETT, V319, P171, DOI 10.1016/0014-5793(93)80061-X; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; Delgado M, 1999, J BIOL CHEM, V274, P31930, DOI 10.1074/jbc.274.45.31930; Delgado M, 1999, ANN NY ACAD SCI, V897, P401, DOI 10.1111/j.1749-6632.1999.tb07909.x; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; Delgado M, 1999, J IMMUNOL, V162, P4685; Delgado M, 1999, J IMMUNOL, V163, P4213; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 1999, J IMMUNOL, V162, P1707; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dewit D, 1998, IMMUNOL LETT, V60, P57, DOI 10.1016/S0165-2478(97)00129-6; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LALLI E, 1994, J BIOL CHEM, V269, P17359; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martinez C, 1998, J LEUKOCYTE BIOL, V63, P591, DOI 10.1002/jlb.63.5.591; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Parry GCN, 1997, J IMMUNOL, V159, P5450; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TREDE NS, 1995, J IMMUNOL, V155, P902; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang HY, 1999, REGUL PEPTIDES, V84, P55, DOI 10.1016/S0167-0115(99)00068-3; Xin ZC, 1998, J NEUROIMMUNOL, V89, P206, DOI 10.1016/S0165-5728(98)00140-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	53	92	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					369	380		10.1074/jbc.M006923200	http://dx.doi.org/10.1074/jbc.M006923200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029467	hybrid			2022-12-25	WOS:000166280700051
J	Pise-Masison, CA; Mahieux, R; Radonovich, M; Jiang, H; Brady, JN				Pise-Masison, CA; Mahieux, R; Radonovich, M; Jiang, H; Brady, JN			Human T-lymphotropic virus type I tax protein utilizes distinct pathways for p53 inhibition that are cell type-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; NF-KAPPA-B; TRANSFORMS RAT FIBROBLASTS; LEUKEMIA-VIRUS; HTLV-I; DNA-DAMAGE; TUMOR-SUPPRESSOR; BINDING-PROTEIN; LYMPHOCYTES; GENE	p53 plays a pivotal role in transmitting signals from many forms of genotoxic stress to genes and factors that control the cell cycle and apoptosis, We have previously shown that the human T-lymphotropic virus type I Tax protein can inhibit p53 function. Recently we reported that Tax inhibits p53 function in Jurkat cells and mouse embryo fibroblasts through a mechanism involving the nuclear factor kappaB pathway and correlates with phosphorylation on serines 15 and 392 of p53, However, several groups have also observed a mechanism that correlates with p300 binding of Tax. To address this controversy and to determine the mechanism by which Tax inhibits p53 function, we examined the activation functions of Tax required for p53 inhibition. In HeLa and H1299 cells the cAMP-response element-binding protein/activating transcription factor activation function is essential, as demonstrated by the Tax mutants M47 and K88k In addition, expression of exogenous p300 in H1299 cells allows full recovery of p53 transactivation in the presence of Tax. Consistent with p300 being a limiting factor in H1299, Saos-2, and HeLa cells, we found that the level of endogenous p300 is relatively low in these cells compared with Jurkat cells or the human T-lymphotropic virus type I-infected C81 and MT2 cells. Thus our data suggests that Tax utilizes distinct mechanisms to inhibit p53 function that are cell type-dependent.	NCI, Basic Res Lab, Virus Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brady, JN (corresponding author), NCI, Basic Res Lab, Virus Tumor Biol Sect, NIH, Bldg 41-B201, Bethesda, MD 20892 USA.			mahieux, renaud/0000-0002-5129-6804				Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Anderson CW, 1998, J PROTEIN CHEM, V17, P527; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GESSAIN A, 1985, LANCET, V2, P407; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; KASHANCHI F, 1999, PERSISTENT VIRAL INF, P47; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Liu L, 1999, MOL CELL BIOL, V19, P1202; Manteuffel-Cymborowska M, 1999, ACTA BIOCHIM POL, V46, P77, DOI 10.18388/abp.1999_4185; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OSAME M, 1986, LANCET, V1, P1031; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REID RL, 1993, ONCOGENE, V8, P3029; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tsai HL, 1996, J BIOL CHEM, V271, P3534; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	52	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					200	205		10.1074/jbc.M005601200	http://dx.doi.org/10.1074/jbc.M005601200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11036071	hybrid			2022-12-25	WOS:000166280700029
J	Woods, M; Bobanovic, F; Brown, D; Alexander, DR				Woods, M; Bobanovic, F; Brown, D; Alexander, DR			Lyn and Syk tyrosine kinases are not activated in B-lineage lymphoid cells exposed to low-energy electromagnetic fields	FASEB JOURNAL			English	Article						neoplasia; cancer; protein tyrosine phosphorylation	FREQUENCY MAGNETIC-FIELDS; CHILDHOOD-CANCER; SIGNAL-TRANSDUCTION; POWER-LINES; RECEPTOR; RISK; CHILDREN; STIMULATION; PATHWAYS	Exposure of B-lineage lymphoid cells to a 100 muT 60 Hz AC magnetic field has been reported to stimulate the rapid activation of Lyn and Syk tyrosine kinases and the induction of protein tyrosine phosphorylation. These findings are significant because of the critical role played by these B cell signaling events in the control of growth and differentiation, and therefore the potential of electromagnetic field (EMF) exposure to induce cancer. We report the first study carried out with the aim of reproducing the reported EMF effects on Lyn and Syk tyrosine kinases, The system used enabled EMF exposure conditions to be carefully controlled and also allowed experiments to be performed blind. The effects of a 100 mur 60 Hz AC magnetic field on protein tyrosine phosphorylation and on Lyn and Syk tyrosine kinase activities were investigated in Nalm-6 and DT40 B cells in the absence and presence of a 46 muT DC magnetic field. However, no significant effects of low-energy electromagnetic fields on tyrosine kinase activities or protein phosphorylation were observed.-Woods, M., Bobanovic, F., Brown, D., Alexander, D. R. Lyn and Syk tyrosine kinases are not activated in B-lineage lymphoid cells exposed to low-energy electromagnetic fields.	Babraham Inst, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England; Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Babraham Inst, Lab Computat Neurosci, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Alexander, DR (corresponding author), Babraham Inst, Lab Lymphocyte Signalling & Dev, Babraham Hall, Cambridge CB2 4AT, England.							Benschop RJ, 1999, CURR OPIN IMMUNOL, V11, P143, DOI 10.1016/S0952-7915(99)80025-9; Cheng KK, 1999, LANCET, V354, P1925, DOI 10.1016/S0140-6736(99)10074-6; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; Feychting M, 1995, EUR J CANCER, V31A, P2035, DOI 10.1016/0959-8049(95)00472-6; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; FEYCHTING M, 1992, 692 IMM SWED NAT I O; Kristupaitis D, 1998, J BIOL CHEM, V273, P12397, DOI 10.1074/jbc.273.20.12397; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lacy-Hulbert A, 1998, FASEB J, V12, P395, DOI 10.1096/fasebj.12.6.395; LACYHULBERT A, 1995, RADIAT RES, V144, P9, DOI 10.2307/3579230; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; Miller SC, 1998, J BIOL CHEM, V273, P32618, DOI 10.1074/jbc.273.49.32618; MYERS A, 1990, BRIT J CANCER, V62, P1008, DOI 10.1038/bjc.1990.428; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; UCKUN FM, 1995, J BIOL CHEM, V270, P27666, DOI 10.1074/jbc.270.46.27666; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VERKASALO PK, 1993, BRIT MED J, V307, P895, DOI 10.1136/bmj.307.6909.895	23	10	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2284	2290		10.1096/fj.00-0164com	http://dx.doi.org/10.1096/fj.00-0164com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053250				2022-12-25	WOS:000165190800022
J	Berns, K; Martins, C; Dannenberg, JH; Berns, A; Riele, HT; Bernards, R				Berns, K; Martins, C; Dannenberg, JH; Berns, A; Riele, HT; Bernards, R			p27(kip1)-independent cell cycle regulation by MYC	ONCOGENE			English	Article						CDK-inhibitors; cell cycle; retinoblastoma protein; c-Myc oncogene	C-MYC; RESPONSIVE GENES; KINASE-ACTIVITY; PROTEIN; TUMORIGENESIS; EXPRESSION; E2F; IDENTIFICATION; SEQUESTRATION; INDUCTION	MYC transcription factors are potent stimulators of cell proliferation. It has been suggested that the CDK-inhibitor p27(kip1) is a critical G1 phase cell cycle target of c-MYC. We show here that mouse embryo fibroblasts deficient for both p27(kip1) and the related p21(cip1) are still responsive to stimulation by c-MYC and can be arrested in G1 by a dominant negative mutant of c-MYC. This growth arrest can be overruled by ectopic expression of E2F or adenovirus E1A, but not by a mutant of E1A defective for binding to retinoblastoma family proteins. We show that fibroblasts with a genetic disruption of all three retinoblastoma family members (pRb, p107 and p130) are unresponsive to a dominant negative c-MYC mutant. These data indicate that p27(kip1) is not the only rate limiting cell cycle target of c-MYC and suggest that regulation of E2F is also essential for c-MYC's mitogenic activity.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423				BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; Berns K, 2000, ONCOGENE, V19, P3330, DOI 10.1038/sj.onc.1203639; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	27	25	25	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4822	4827		10.1038/sj.onc.1203879	http://dx.doi.org/10.1038/sj.onc.1203879			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039898	Green Published			2022-12-25	WOS:000089757800003
J	Wong, ESM; Lim, J; Low, BC; Chen, QP; Guy, GR				Wong, ESM; Lim, J; Low, BC; Chen, QP; Guy, GR			Evidence for direct interaction between sprouty and Cbl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; PROTOONCOGENE C-CBL; NEGATIVE REGULATOR; EGF-RECEPTOR; DROSOPHILA SPROUTY; SIGNALING PATHWAYS; UBIQUITIN LIGASE; RING FINGER; PROTEIN	Sprouty (SPRY) was first identified in a genetic screen in Drosophila as an antagonist of fibroblast and epidermal growth factor receptors and Sevenless signaling, seemingly by inhibiting the receptor tyrosine kinase (RTK)/Ras/MAPK pathway. To date, four mammalian Sprouty genes have been identified; the primary sequences of the gene products share a well conserved cysteine-rich C-terminal domain with their Drosophila counterpart. The N-terminal regions do not, however, exhibit a large degree of homology. This study was aimed at identifying proteins with which human SPRY2 (hSPRY2) interacts in an attempt to understand the mechanism by which Sprouty proteins exert their down-regulatory effects. Here, we demonstrate that hSPRY2 associates directly with c-Cbl, a known down-regulator of RTK signaling. A short sequence in the N terminus of hSPRY2 was found to bind directly to the Ring finger domain of c-Cbl. Parallel binding was apparent between the Drosophila homologs of Sprouty and Cbl, with cross-species associations occurring at least in vitro. Coexpression of hSPRY2 abrogated an increase in the rate of epidermal growth factor receptor internalization induced by c-Cb1, whereas a mutant hSPRY2 protein unable to bind c-Cbl showed no such effect. Our results suggest that one function of hSPRY2 in signaling processes downstream of RTKs may be to modulate c-Cbl physiological function such as that seen with receptor-mediated endocytosis.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Guy, GR (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.		Low, Boon Chuan/H-8049-2012; Lim, Jormay/A-7257-2011; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Lim, Jormay/0000-0001-7191-545X; Low, Boon Chuan/0000-0003-0756-096X				Barinaga M, 1999, SCIENCE, V286, P223, DOI 10.1126/science.286.5438.223; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; FUKAZAWA T, 1996, J BIOL CHEM, V271, P14454; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kramer S, 1999, DEVELOPMENT, V126, P2515; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lim YP, 1997, J BIOL CHEM, V272, P29892, DOI 10.1074/jbc.272.47.29892; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Minowada G, 1999, DEVELOPMENT, V126, P4465; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Reich A, 1999, DEVELOPMENT, V126, P4139; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	48	107	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5866	5875		10.1074/jbc.M006945200	http://dx.doi.org/10.1074/jbc.M006945200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11053437	hybrid			2022-12-25	WOS:000167115100063
J	Alvarez, C; Garcia-Mata, R; Hauri, HP; Sztul, E				Alvarez, C; Garcia-Mata, R; Hauri, HP; Sztul, E			The p115-interactive proteins GM130 and giantin participate in endoplasmic reticulum-Golgi traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; MEMBRANE-PROTEIN; INTERMEDIATE COMPARTMENT; REQUIRES USO1P; MATRIX PROTEIN; COPI VESICLES; HELA-CELLS; COMPLEX; FUSION; APPARATUS	The transport factor p115 is essential for endoplasmic reticulum (ER) to Golgi traffic. P115 interacts with two Golgi proteins, GM130 and giantin, suggesting that they might also participate in ER-Golgi traffic. Here, we show that peptides containing the GM130 or the giantin p115 binding domain and anti-GM130 and anti-giantin antibodies inhibit transport of vesicular stomatitis virus (VSV)-G protein to a mannosidase II-containing Golgi compartment, To determine whether p115, GM130, and giantin act together or sequentially during transport, we compared kinetics of traffic inhibition, Anti-p115, anti-GM130, and anti-giantin antibodies inhibited transport at temporally distinct steps, with the p115-requiring step before the GM130-requiring stage, and both preceding the giantin-requiring stage. Examination of the distribution of the arrested VSV-G protein showed that anti-p115 antibodies inhibited transport at the level of vesicular-tubular clusters, whereas anti-GM130 and anti-giantin antibodies inhibited after the VSV-G protein moved to the Golgi complex. Our results provide the first evidence that GM130 and giantin are required for the delivery of a cargo protein to the mannosidase II-containing Golgi compartment, These data are most consistent with a model where transport from the ER to the cis/medial-Golgi compartments requires the action of p115, GM130, and giantin in a sequential rather than coordinate mechanism.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Basel, Biozentrum, Dept Pharmacol, CH-4056 Basel, Switzerland	University of Alabama System; University of Alabama Birmingham; University of Basel	Sztul, E (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, McCallum Bldg,Rm 668,1530 3rd Ave S, Birmingham, AL 35294 USA.	esztul@uab.edu		Fujita, Hideaki/0000-0002-4105-4430; Garcia-Mata, Rafael/0000-0002-7116-4411	PHS HHS [99508358] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Alvarez C, 1999, J CELL BIOL, V147, P1205, DOI 10.1083/jcb.147.6.1205; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DAVIDSON HW, 1992, METHOD ENZYMOL, V219, P261; Dirac-Svejstrup AB, 2000, J CELL BIOL, V150, P475, DOI 10.1083/jcb.150.3.475; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Lesa GM, 2000, J BIOL CHEM, V275, P2831, DOI 10.1074/jbc.275.4.2831; Linstedt AD, 2000, J BIOL CHEM, V275, P10196, DOI 10.1074/jbc.275.14.10196; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SCHWANINGER R, 1992, METHOD ENZYMOL, V219, P110; SEELIG HP, 1994, MOL CELL BIOL, V14, P2564, DOI 10.1128/MCB.14.4.2564; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Shorter J, 1999, J CELL BIOL, V146, P57, DOI 10.1083/jcb.146.1.57; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157	49	103	106	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2693	2700		10.1074/jbc.M007957200	http://dx.doi.org/10.1074/jbc.M007957200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035033	hybrid			2022-12-25	WOS:000166784800055
J	Horie, S; Ishii, H; Matsumoto, F; Kusano, M; Kizaki, K; Matsuda, J; Kazama, M				Horie, S; Ishii, H; Matsumoto, F; Kusano, M; Kizaki, K; Matsuda, J; Kazama, M			Acceleration of thrombomodulin gene transcription by retinoic acid - Retinoic acid receptors and Sp1 regulate the promoter activity through interactions with two different sequences in the 5 '-flanking region of human gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; THROMBIN-CATALYZED ACTIVATION; DEPENDENT PROTEIN-KINASE; X-RECEPTOR; THYROID-HORMONE; TISSUE-FACTOR; NUCLEAR RECEPTORS; ANTICOAGULANT ACTIVITY; ESTROGEN-RECEPTOR	The interactions between retinoic acid- (RA)-dependent transcriptional regulatory sequences of the 5'-untranslated region of the thrombomodulin gene and nuclear RA-responsive proteins were studied using human pancreas BxPC-3 cells. Deletion mutants of pTM-CAT plasmid revealed the presence of distal and proximal RA-responsive regions containing direct repeat with 4 spaces (DR4) and three of four Spl sites, respectively. Cotransfection of a pTM-CAT plasmid with expression plasmids of RA receptors (RAR alpha, RAR beta, and RAR gamma) augmented the promoter activity under the condition of lower retinoid X receptor-alpha (RXR alpha) expression, whereas the activity was greatly diminished when RXR alpha was highly expressed. An electrophoretic mobility shift assay with cDNA containing the DR4 indicated that heterodimers of RAR and RXR alpha interacted with the DR4 site, although the interaction gradually disappeared with the increase in the ratio of RXR alpha /RAR. On the other hand, Spl protein interacted especially with the tandem Spl site corresponding to the first and second Spl sequences of the four Spl sites in the proximal RA-responsive region. The binding of Spl to Spl sites was independent of RAR-RXR heterodimer but increased with the increase in Spl concentration in the presence of unknown factor(s) of reticulocyte lysate, Upon treatment of the cells with RA, time-dependent increases in the ratio of RAR beta to RXR alpha and the phosphorylated form of Spl were observed. We concluded that two genomic DNA regions, the DR4 site (-1531 to -1516) and the first and second Spl-binding sites (-145 to -121), were involved in the RA-dependent augmentation of thrombomodulin gene expression through increased interactions of the two regions with heterodimer of RAR-RXR alpha and nuclear Spl, respectively.	Teikyo Univ, Fac Pharmaceut Sci, Dept Clin Biochem, Kanagawa 1990195, Japan; Showa Coll Pharmaceut Sci, Dept Publ Hlth, Tokyo 1948543, Japan	Teikyo University; Showa Pharmaceutical University	Horie, S (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Dept Clin Biochem, 1091-1 Suarashi, Kanagawa 1990195, Japan.							ARCHIPOFF G, 1991, BIOCHEM J, V273, P679, DOI 10.1042/bj2730679; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DITTMAN WA, 1990, BLOOD, V75, P329; DITTMAN WA, 1994, J BIOL CHEM, V269, P16925; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Duprez E, 1996, ONCOGENE, V12, P2443; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMADA H, 1995, BLOOD, V86, P225, DOI 10.1182/blood.V86.1.225.bloodjournal861225; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; HORIE S, 1994, BIOCHEM J, V301, P683, DOI 10.1042/bj3010683; HORIE S, 1992, BIOCHEM J, V281, P149, DOI 10.1042/bj2810149; Hu ZZ, 1998, J BIOL CHEM, V273, P26225, DOI 10.1074/jbc.273.40.26225; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Ishii H, 1996, J BIOL CHEM, V271, P8458, DOI 10.1074/jbc.271.14.8458; ISHII H, 1990, THROMB RES, V59, P841, DOI 10.1016/0049-3848(90)90397-U; ISHII H, 1992, BLOOD, V80, P2556; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kang SH, 1996, J BIOL CHEM, V271, P7330, DOI 10.1074/jbc.271.13.7330; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOOISTRA T, 1995, EUR J BIOCHEM, V232, P425, DOI 10.1111/j.1432-1033.1995.425zz.x; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Rusten LS, 1996, BLOOD, V87, P1728; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Shibakura M, 1997, BLOOD, V90, P1545, DOI 10.1182/blood.V90.4.1545.1545_1545_1551; SHIRAI T, 1988, J BIOCHEM-TOKYO, V103, P281, DOI 10.1093/oxfordjournals.jbchem.a122261; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TAZAWA R, 1993, J BIOCHEM-TOKYO, V113, P600, DOI 10.1093/oxfordjournals.jbchem.a124089; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; YU K, 1992, J BIOL CHEM, V267, P23237; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	73	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2440	2450		10.1074/jbc.M004942200	http://dx.doi.org/10.1074/jbc.M004942200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11036068	hybrid			2022-12-25	WOS:000166784800021
J	Han, SI; Oh, SY; Woo, SH; Kim, KH; Kim, JH; Kim, HD; Kang, HS				Han, SI; Oh, SY; Woo, SH; Kim, KH; Kim, JH; Kim, HD; Kang, HS			Implication of a small GTPase Rac1 in the activation of c-Jun N-terminal kinase and heat shock factor in response to heat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HSF1; STRESS-INDUCED APOPTOSIS; CELL-CYCLE PROGRESSION; PROTEIN-KINASE; BINDING PROTEIN; ACTIN POLYMERIZATION; MAMMALIAN-CELLS; CDC42 GTPASES; GROWTH-FACTOR; MAP KINASE	Heat shock induces c-Jun N-terminal kinase (JNK) activation as well as heat shock protein (HSP) expression through activation of the heat shock factor (HSP), but its signal pathway is not clearly understood. Since a small GTPase Rad has been suggested to participate in the cellular response to stresses, we examined whether Rad is involved in the heat shock response. Here we show that moderate heat shock (39-41 degreesC) induces membrane translocation of Rad and membrane ruffling in a Rad-dependent manner. In addition, Rac1N17, a dominant negative mutant of Rad, significantly inhibited JNK activation by heat shock. Since Rac1V12 was able to activate JNK, it is suggested that heat shock may activate JNK via Rad, Similar inhibition by Rac1N17 of HSP activation in response to heat shock was observed. However, inhibitory effects of Rac1N17 on heat shock-induced JNK and HSF activation were reduced as the heat shock temperature increased. Rac1N17 also inhibited HSF activation by L-azetidine-2-carboxylic acid, a proline analog, and heavy metals (CdCl2), suggesting that Rad may be linked to HSF activation by denaturation of polypeptides in response to various proteotoxic stresses. However, Rac1N17 did not prevent phosphorylation of HSF1 in response to these proteotoxic stresses. Interestingly, a constitutively active mutant Rac1V12 did not activate the HSF. Therefore, Rad activation may be necessary, but not sufficient, for heat shock-inducible HSF activation and HSP expression, or otherwise a signal pathway(s) involving Rad may be indirectly involved in the HSF activation. In sum, we suggest that Rad may play a critical role(s) in several aspects of the heat shock response.	Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 506712, South Korea	Pusan National University; Gwangju Institute of Science & Technology (GIST)	Kang, HS (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.	hspkang@hyowon.cc.pusan.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANDERSON RL, 1982, INT J RADIAT BIOL, V42, P57, DOI 10.1080/09553008214550911; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DEWEY WC, 1989, RADIAT RES, V120, P191, DOI 10.2307/3577707; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; Gorman AM, 1999, FEBS LETT, V445, P98, DOI 10.1016/S0014-5793(99)00094-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kim HR, 1999, IUBMB LIFE, V48, P429, DOI 10.1080/713803536; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Maroni P, 2000, CELL BIOL INT, V24, P145, DOI 10.1006/cbir.1999.0493; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MurakamiMurofushi K, 1997, J BIOL CHEM, V272, P486; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ozaki M, 2000, J BIOL CHEM, V275, P35377, DOI 10.1074/jbc.M005287200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VAN AL, 1997, GENE DEV, V11, P2295; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; WELCH WJ, 1991, CURR TOP MICROBIOL, V167, P31; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu QB, 2000, CIRC RES, V86, P1122; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	50	50	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1889	1895		10.1074/jbc.M006042200	http://dx.doi.org/10.1074/jbc.M006042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050083	hybrid			2022-12-25	WOS:000166528000034
J	Leung, IWL; Lassam, N				Leung, IWL; Lassam, N			The kinase activation loop is the key to mixed lineage kinase-3 activation via both autophosphorylation and hematopoetic progenitor kinase 1 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; PROTEIN-KINASE; MOLECULAR-CLONING; STRUCTURAL BASIS; SH3 DOMAIN; MAP KINASE; IDENTIFICATION; PATHWAY; FAMILY; MEMBER	We have demonstrated previously that Cdc42 induced MLK-3 homodimerization leads to both autophosphorylation and activation of MLK-3 and postulated that auto phosphorylation is an intermediate step of MLK-3 activation following its dimerization, In this report we sought to refine further the mechanism of MLK-3 activation and study the role of the putative kinase activation loop in MLK-3 activation. First we mutated the three potential phosphorylation sites in MLK-3 putative activation loop to alanine in an effort to abrogate MLK-3 autophosphorylation, Mutant T277A displayed almost no autophosphorylation activity and was nearly nonfunctional; mutant S281A, that displayed a low level of autophosphorylation, only slightly activated its downstream targets, whereas the T278A mutant, that exhibited autophosphorylation comparable to that of the wild type, was almost fully functional. Thus, these residues within the activation loop are critical for MLK-3 autophosphorylation and activation. In addition, when the Thr(277) and Ser(281) residues were mutated to negatively charged glutamic acid to mimic phosphorylated serine/threonine residues, the resulting mutants were fully functional, implying that these two residues may serve as the autophosphorylation sites. Interestingly, HPK1 also phosphorylated MLK-3 activation loop in vitro, and Ser281 was found to be the major phosphorylation site, indicating that HPK1 also activates MLK-3 via phosphorylation of the kinase activation loop.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Lab Med & Patholbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto	Leung, IWL (corresponding author), Univ Toronto, Dept Med Biophys, Rm 7360,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.							BOSSEMEYER D, 1995, FEBS LETT, V369, P57, DOI 10.1016/0014-5793(95)00580-3; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chiang GG, 2000, J BIOL CHEM, V275, P6055, DOI 10.1074/jbc.275.9.6055; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; EZOE K, 1994, ONCOGENE, V9, P935; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hehner SP, 2000, J IMMUNOL, V164, P3829, DOI 10.4049/jimmunol.164.7.3829; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; ING YL, 1994, ONCOGENE, V9, P1745; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; KATOH M, 1995, ONCOGENE, V10, P1447; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Matsui N, 1996, BIOCHEM BIOPH RES CO, V229, P571, DOI 10.1006/bbrc.1996.1845; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V205, P1494, DOI 10.1006/bbrc.1994.2834; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; SHOJI S, 1979, J BIOL CHEM, V254, P6211; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	38	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1961	1967		10.1074/jbc.M004092200	http://dx.doi.org/10.1074/jbc.M004092200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053428	hybrid			2022-12-25	WOS:000166528000044
J	Lin, L; Sohar, I; Lackland, H; Lobel, P				Lin, L; Sohar, I; Lackland, H; Lobel, P			The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; INSENSITIVE CARBOXYL PROTEINASE; TRIPEPTIDYL-PEPTIDASE; PARTIAL-PURIFICATION; IDENTIFICATION; AMINOPEPTIDASE; EXPRESSION; MECHANISM; DEFICIENT; RESIDUES	The CLN2 gene mutated in the fatal hereditary neurodegenerative disease late infantile neuronal ceroid lipofuscinosis encodes a lysosomal protease with tripeptidyl-peptidase I activity. To understand the enzymological properties of the protein, we purified and characterized C-terminal hexahistidine-tagged human CLN2p/tripeptidyl-peptidase I produced from insect cells transfected with a baculovirus vector. The N terminus of the secreted 66-kDa protein corresponds to residue 20 of the primary CLN2 gene translation product, indicating removal of a 19-pesidue signal peptide. The purified protein is enzymatically inactive; however, upon acidification, it is proteolytically processed and concomitantly acquires enzymatic activity. The N terminus of the final 46-kDa processed form (Leu(196)) corresponds to that of mature CLN2p/tripeptidyl-peptidase I purified from human brain. The activity of the mature enzyme is irreversibly inhibited by the serine esterase inhibitor diisopropyl fluorophosphate, which specifically and stoichiometrically reacts with CLN2p/tripeptidyl-peptidase I at Ser(475), demonstrating that this residue represents the active site nucleophile, Expression of wild type and mutant proteins in CHO cells indicate that Ser(475), Asp(360), Asp(517), but not His(236) are essential for activity. These data indicate that the CLN2 gene product is synthesized as an inactive proenzyme that is autocatalytically converted to an active serine protease.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Grad Program Cell & Dev Biol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lobel, P (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037918] Funding Source: NIH RePORTER; NCRR NIH HHS [RR13824] Funding Source: Medline; NIDDK NIH HHS [DK45992] Funding Source: Medline; NINDS NIH HHS [NS37918] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARRETT AJ, 1994, METHOD ENZYMOL, V244, P1; Cohen J.A., 1967, METHODS ENZYMOLOGY, P686; Ezaki J, 2000, BIOCHEM BIOPH RES CO, V268, P904, DOI 10.1006/bbrc.2000.2207; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FUHLBRIGGE RC, 1988, J IMMUNOL, V141, P2643; GOEBEL HH, 1999, NEURONAL CEROID LIPO, V33; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; Ito M, 1999, J BIOCHEM, V125, P210, DOI 10.1093/oxfordjournals.jbchem.a022261; Junaid MA, 2000, J NEUROCHEM, V74, P287, DOI 10.1046/j.1471-4159.2000.0740287.x; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONALD JK, 1985, BIOCHEM BIOPH RES CO, V126, P63, DOI 10.1016/0006-291X(85)90571-6; Oda K, 1996, J BIOCHEM, V120, P564; ODA K, 1994, J BIOL CHEM, V269, P26518; ODA K, 1987, BIOCHIM BIOPHYS ACTA, V923, P463, DOI 10.1016/0304-4165(87)90055-9; Oyama H, 1999, J BIOL CHEM, V274, P27815, DOI 10.1074/jbc.274.39.27815; PAGE AE, 1993, ARCH BIOCHEM BIOPHYS, V306, P354, DOI 10.1006/abbi.1993.1523; POWERS JC, 1986, PROTEINASE INHIBITOR, V12, P55; Rawlings ND, 1999, BBA-PROTEIN STRUCT M, V1429, P496, DOI 10.1016/S0167-4838(98)00238-6; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; Sohar I, 2000, CLIN CHEM, V46, P1005; Sohar I, 1999, J NEUROCHEM, V73, P700, DOI 10.1046/j.1471-4159.1999.0730700.x; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; Vines DJ, 1999, FEBS LETT, V443, P131, DOI 10.1016/S0014-5793(98)01683-4; WATANABE Y, 1992, BIOCHEM INT, V27, P869	29	105	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2249	2255		10.1074/jbc.M008562200	http://dx.doi.org/10.1074/jbc.M008562200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11054422	hybrid			2022-12-25	WOS:000166528000080
J	Mizugishi, K; Aruga, J; Nakata, K; Mikoshiba, K				Mizugishi, K; Aruga, J; Nakata, K; Mikoshiba, K			Molecular properties of Zic proteins as transcriptional regulators and their relationship to GLI proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE CUBITUS-INTERRUPTUS; NEURAL CREST DEVELOPMENT; ZINC-FINGER PROTEIN; SONIC HEDGEHOG; BINDING-PROPERTIES; CELL LINEAGE; MOUSE ZIC1; IN-VITRO; DROSOPHILA; EXPRESSION	Zic family genes encode zinc finger proteins, which play important roles in vertebrate development. The zinc finger domains are highly conserved between Zic proteins and show a notable homology to those of Gli family proteins. In this study, we investigated the functional properties of Zic proteins and their relationship to the GLI proteins. We first established an optimal binding sequence for Zic1, Zic2, and Zic3 proteins by electrophoretic mobility shift assay based target selection and mutational analysis. The selected sequence was almost identical to the GLI binding sequence. However, the binding affinity was lower than that of GLI. Consistent results were obtained in reporter assays, in which transcriptional activation by Zic proteins was less dependent on the GLI binding sequence than GLI1. Moreover, Zic proteins activated a wide range of promoters irrespective of the presence of a GLI binding sequence. When Zic and GLI proteins were cotransfected into cultured cells, Zic proteins enhanced or suppressed sequence-dependent, GLI-mediated transactivation depending on cell type. Taken together, these results suggest that Zic proteins may act as transcriptional coactivators and that their function may be modulated by the GLI proteins and possibly by other cell type-specific cofactors.	RIKEN, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan; Univ Tokyo, Sch Med, Dept Pediat, Tokyo 1130033, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Tokyo 1088639, Japan	RIKEN; University of Tokyo; University of Tokyo	Aruga, J (corresponding author), RIKEN, Dev Neurobiol Lab, Brain Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Mikoshiba, Katsuhiko/N-7943-2015; Aruga, Jun/H-5837-2011	Aruga, Jun/0000-0001-7936-1375				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Aruga J, 1999, MECH DEVELOP, V89, P141, DOI 10.1016/S0925-4773(99)00220-8; Aruga J, 1998, J NEUROSCI, V18, P284; ARUGA J, 1994, J NEUROCHEM, V63, P1880; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Aruga J, 2000, MOL BRAIN RES, V78, P15, DOI 10.1016/S0169-328X(00)00057-7; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; Brewster R, 1998, NATURE, V393, P579, DOI 10.1038/31242; BROWN S, 1995, AM J HUM GENET, V57, P859; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; CIMBORA DM, 1995, DEV BIOL, V169, P580, DOI 10.1006/dbio.1995.1171; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Feledy JA, 1999, NUCLEIC ACIDS RES, V27, P764, DOI 10.1093/nar/27.3.764; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Grinblat Y, 1998, DEVELOPMENT, V125, P4403; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Lee J, 1997, DEVELOPMENT, V124, P2537; Lin JC, 1998, J NEUROSCI, V18, P9342; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagai T, 2000, P NATL ACAD SCI USA, V97, P1618, DOI 10.1073/pnas.97.4.1618; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; Nakata K, 1998, MECH DEVELOP, V75, P43, DOI 10.1016/S0925-4773(98)00073-2; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Schubart DB, 1996, NUCLEIC ACIDS RES, V24, P1913, DOI 10.1093/nar/24.10.1913; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VORTKAMP A, 1995, DNA CELL BIOL, V14, P629, DOI 10.1089/dna.1995.14.629; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; WANANDI I, 1993, J BIOL CHEM, V268, P6629; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Yokota N, 1996, CANCER RES, V56, P377; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691	46	148	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2180	2188		10.1074/jbc.M004430200	http://dx.doi.org/10.1074/jbc.M004430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053430	hybrid			2022-12-25	WOS:000166528000072
J	Taylor, WR; Schonthal, AH; Galante, J; Stark, GR				Taylor, WR; Schonthal, AH; Galante, J; Stark, GR			p130/E2F4 binds to and represses the cdc2 promoter in response to p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; TOPOISOMERASE II-ALPHA; DNA-DAMAGE CHECKPOINT; CELL-CYCLE; TRANSCRIPTION FACTOR; S-PHASE; G(2) CHECKPOINT; NUCLEAR-LOCALIZATION; HISTONE DEACETYLASE; IONIZING-RADIATION	p53 represses the transcription of cdc2 and cyclin B1, causing loss of Cdc2 activity and Cf, arrest. Here we show that the region -22 to -2 of the cdc2 promoter called the R box is required for repression by p53 but not for basal promoter activity. The R box confers p53-dependent repression on heterologous promoters and binds to p130/E2F4 in response to overexpression of p53. R box-dependent repression requires p21/waf1, and overexpression of p21/waf1 also represses the cdc2 promoter. These observations suggest that p53 represses the cdc2 promoter by inducing p21/waf1, which inhibits cyclin dependent kinase activity, enhancing the binding of p130 and E2F4, which together bind to and repress the cdc2 promoter.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA; Univ So Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	Cleveland Clinic Foundation; University of Southern California; University of Southern California	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org	Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653	NIGMS NIH HHS [GM 49345] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen X, 1999, MOL CELL BIOL, V19, P4695; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hughes TA, 1996, EXP CELL RES, V222, P275, DOI 10.1006/excr.1996.0035; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; KASTAN MB, 1991, CANCER RES, V51, P6304; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Massimi P, 1996, ONCOGENE, V12, P2325; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Olgiate J, 1999, VIROLOGY, V258, P257, DOI 10.1006/viro.1999.9755; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Philips A, 1999, ONCOGENE, V18, P6222, DOI 10.1038/sj.onc.1203017; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Reed SI, 1997, CANCER SURV, V29, P7; Rey O, 2000, VIROLOGY, V268, P372, DOI 10.1006/viro.1999.0175; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; SAMBROOK J., 1989, MOL CLONING LAB MANU, pB23; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; STEWART N, 1995, ONCOGENE, V10, P109; Stiegler P, 1998, J CELL BIOCHEM, P30; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	88	92	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1998	2006		10.1074/jbc.M005101200	http://dx.doi.org/10.1074/jbc.M005101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11032828	hybrid			2022-12-25	WOS:000166528000049
J	Van Putten, V; Refaat, Z; Dessev, C; Blaine, S; Wick, M; Butterfield, L; Han, SY; Heasley, LE; Nemenoff, RA				Van Putten, V; Refaat, Z; Dessev, C; Blaine, S; Wick, M; Butterfield, L; Han, SY; Heasley, LE; Nemenoff, RA			Induction of cytosolic phospholipase A(2) by oncogenic Ras is mediated through the JNK and ERK pathways in rat epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; SYNTHASE-2 GENE-EXPRESSION; PROTEIN-KINASE PATHWAY; SMOOTH-MUSCLE CELLS; LUNG-CANCER CELLS; C-JUN; GROWTH-FACTOR; TRANSCRIPTION FACTOR; CYTOKINE GENES; ALPHA-ACTIN	Mutations in ras genes have been detected with high frequency in nonsmall cell lung cancer cells (NSCLC) and contribute to transformed growth of these cells. It has previously been shown that expression of oncogenic forms of Ras in these cells is associated with elevated expression of cytosolic phospholipase A(2) (cPLA(2)) and cyclooxygenase-2 (COX-2), resulting in high constitutive levels of prostaglandin production. To determine whether expression of constitutively active Res is sufficient to induce expression of these enzymes in nontransformed cells, normal lung epithelial cells were transfected with H-Ras, Stable expression of H-Ras increased expression of cPLA(2) and COX-2 protein. Transient transfection with II-Pas increased promoter activity for both enzymes. H-Ras expression also activated all three families of MAP kinase: ERKs, JNKs, and p38 MAP kinase, Expression of constitutively active Raf did not increase either cPLA(2) or COX-2 promoter activity, but inhibition of the ERK pathway with pharmacological agents or expression of dominant negative ERK partially blocked the H-Ras-mediated induction of cPLA(2) promoter activity. Expression of dominant negative JNK kinases decreased cPLA(2) promoter activity in NSCLC cell lines and inhibited H-Ras-mediated induction in normal epithelial cells, whereas expression of constructs encoding constitutively active JNKs increased promoter activity. Inhibition of p38 MAP kinase or NF-KB had no effect on cPLA(2) expression. Truncational analysis revealed that the region of the cPLA(2) promoter from -58 to +12 contained sufficient elements to mediate H-Ras induction. We conclude that expression of oncogenic forms of Res directly increases cPLA(2) expression in normal epithelial cells through activation of the JNK and ERR pathways.	Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nemenoff, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, 4200 E 9th Ave,Box C-281, Denver, CO 80262 USA.				NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928, R01DK039902] Funding Source: NIH RePORTER; NCI NIH HHS [CA-58187] Funding Source: Medline; NIDDK NIH HHS [DK-39902, DK-19928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEBRAVO MG, 1991, LIPIDS, V26, P866, DOI 10.1007/BF02535969; DEMETRI GD, 1990, J CLIN INVEST, V86, P1261, DOI 10.1172/JCI114833; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DeWitt DL, 1993, AM J MED S2A, V95, P40, DOI DOI 10.1016/0002-9343(93)90396-7; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Giaccone G, 1996, CHEST, V109, pS130, DOI 10.1378/chest.109.5_Supplement.130S; GOPPELTSTRUEBE M, 1992, BIOCHIM BIOPHYS ACTA, V1127, P163, DOI 10.1016/0005-2760(92)90273-X; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; Guthridge CJ, 1995, ANTICANCER RES, V15, P1957; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Hida T, 1998, ANTICANCER RES, V18, P775; Higashita R, 1997, J BIOL CHEM, V272, P25845, DOI 10.1074/jbc.272.41.25845; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HUANG M, 1995, CANCER RES, V55, P3847; HUBBARD WC, 1989, CANCER RES, V49, P826; HUBBARD WC, 1988, CANCER RES, V48, P4770; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; JAMES GL, 1994, J BIOL CHEM, V269, P27705; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li XM, 1997, BIOCHEM J, V327, P709, DOI 10.1042/bj3270709; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUNO K, 1994, JPN J CANCER RES, V85, P179, DOI 10.1111/j.1349-7006.1994.tb02080.x; ROBERTS PE, 1990, AM J PHYSIOL, V259, pL415, DOI 10.1152/ajplung.1990.259.6.L415; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; TAY A, 1994, BBA-GENE STRUCT EXPR, V1217, P345, DOI 10.1016/0167-4781(94)90299-2; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wang JY, 1996, J INTERF CYTOK RES, V16, P53, DOI 10.1089/jir.1996.16.53; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	54	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1226	1232		10.1074/jbc.M003581200	http://dx.doi.org/10.1074/jbc.M003581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042196	hybrid			2022-12-25	WOS:000166430900051
J	Honke, K; Tsuda, M; Koyota, S; Wada, Y; Iida-Tanaka, N; Ishizuka, I; Nakayama, J; Taniguchi, N				Honke, K; Tsuda, M; Koyota, S; Wada, Y; Iida-Tanaka, N; Ishizuka, I; Nakayama, J; Taniguchi, N			Molecular cloning and characterization of a human beta-gal-3 '-sulfotransferase that acts on both type 1 and type 2 (Gal beta 1-3/1-4GlcNAc-R) oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; O-GLYCAN BIOSYNTHESIS; SULFATED OLIGOSACCHARIDES; LEUKOCYTE ADHESION; COLON-CARCINOMA; L-SELECTIN; SULFOTRANSFERASE; EXPRESSION; CANCER; LIGANDS	A novel sulfotransferase gene (designated GP3ST) was identified on human chromosome 2q37.3 based on its similarity to the cerebroside 3'-sulfotransferase (CST) cDNA (Honke, K, Tsuda, M,, Hirahara, Y., Ishii, A., Makita, A., and Wade, Y, (1997) J. Biol. Chem, 272, 4864-4868), A full-length cDNA was obtained by reverse transcription-polymerase chain reaction and 5'- and 3'-rapid amplification of cDNA ends analyses of human colon mRNA, The isolated cDNA clone predicts that the protein is a type II transmembrane protein composed of 398 amino acid residues. The amino acid sequence indicates 33% identity to the human CST sequence. A recombinant protein that is expressed in COS-1 cells showed no CST activity, but did show sulfotransferase activities toward oligosaccharides containing nonreducing beta -galactosides such as N-acetyllactosamine, lactose, lacto-N-tetraose (Lc4), lacto-N-neotetraos (nLc4), and Gal beta1-3GalNAc alpha -benzyl (O-glycan core 1 oligosaccharide). To characterize the cloned sulfotransferase, at sulfotransferase assay method was developed that uses pyridylaminated (PA) Lc4 and nLc4 as enzyme substrates. The enzyme product using PA-Lc4 as an acceptor was identified as HSO3-3Gal beta1-3GlcNAc beta1-8Gal beta1-4Glc-PA by two-dimensional H-1 NMR, Kinetics studies suggested that GP3ST is able to act on both type 1 (Gal beta1-3Glc-NAc-R) and type 2 (Gal beta1-4GlcNAc-R) chains with a similar efficiency, In situ hybridization demonstrated that the GP3ST gene is expressed in epithelial cells lining the lower to middle layer of the crypts in colonic mucosa, hepatocytes surrounding the central vein of the liver, extravillous cytotrophoblasts in the basal plate and septum of the placenta, renal tubules of the kidney, and neuronal cells of the cerebral cortex. The results of this study indicate the existence of a never beta -Gal-3'-sulfotransferase gene family.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Mol Med, Izumi, Osaka 5941101, Japan; Teikyo Univ, Sch Med, Dept Biochem, Tokyo 1738605, Japan; Shinshu Univ, Grad Sch Med, Inst Organ Transplants REconstruct Med & Tissue E, Matsumoto, Nagano 3908621, Japan	Osaka University; Teikyo University; Shinshu University	Honke, K (corresponding author), Osaka Univ, Sch Med, Dept Biochem, Rm B1,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	khonke@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Brockhausen I, 1997, TRENDS GLYCOSCI GLYC, V9, P379, DOI 10.4052/tigg.9.379; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; Feizi T, 1999, TRENDS BIOCHEM SCI, V24, P369, DOI 10.1016/S0968-0004(99)01458-9; FILIPE MI, 1969, GUT, V10, P577, DOI 10.1136/gut.10.7.577; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HASE S, 1978, BIOCHEM BIOPH RES CO, V85, P257, DOI 10.1016/S0006-291X(78)80037-0; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HOKKE CH, 1994, EUR J BIOCHEM, V221, P491, DOI 10.1111/j.1432-1033.1994.tb18762.x; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Iida-Tanaka N, 2000, CARBOHYD RES, V324, P218, DOI 10.1016/S0008-6215(99)00291-8; IRIMURA T, 1991, CANCER RES, V51, P5728; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; KATO Y, 1989, J BIOL CHEM, V264, P3364; Kawakami M, 1997, CANCER RES, V57, P2321; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; MATSUBARA T, 1994, BBA-LIPID LIPID MET, V1214, P97, DOI 10.1016/0005-2760(94)90014-0; MAWHINNEY TP, 1987, J BIOL CHEM, V262, P2994; Murray J, 1999, GENOME RES, V9, P130; Namavar F, 1998, INFECT IMMUN, V66, P444, DOI 10.1128/IAI.66.2.444-447.1998; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; RAOUF AH, 1992, CLIN SCI, V83, P623, DOI 10.1042/cs0830623; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; STRECKER G, 1987, GLYCOCONJUGATE J, V4, P329, DOI 10.1007/BF01048366; Tadano-Aritomi K, 1998, GLYCOBIOLOGY, V8, P341, DOI 10.1093/glycob/8.4.341; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; VAVASSEUR F, 1994, EUR J BIOCHEM, V222, P415, DOI 10.1111/j.1432-1033.1994.tb18880.x; Yamamoto H, 1999, J BIOCHEM-TOKYO, V125, P923, DOI 10.1093/oxfordjournals.jbchem.a022370; YAMORI T, 1987, CANCER RES, V47, P2741; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; Zakrzewicz A, 1997, BLOOD, V89, P3228, DOI 10.1182/blood.V89.9.3228	48	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					267	274		10.1074/jbc.M005666200	http://dx.doi.org/10.1074/jbc.M005666200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029462	hybrid			2022-12-25	WOS:000166280700037
J	Xu, DL; Joglekar, AP; Williams, AL; Hay, JC				Xu, DL; Joglekar, AP; Williams, AL; Hay, JC			Subunit structure of a mammalian ER/Golgi SNARE complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; TRANSPORT VESICLES; GOLGI-APPARATUS; V-SNARES; T-SNARES; PROTEIN; BOS1P; ER	SNAP receptor (SNARE) complexes bridge opposing membranes to promote membrane fusion within the secretory and endosomal pathways. Because only the exocytic SNARE complexes have been characterized in detail, the structural features shared by SNARE complexes from different fusion steps are not known. We now describe the subunit structure, assembly, and regulation of a quaternary SNARE complex, which appears to mediate an early step in endoplasmic reticulum (ER) to Golgi transport. Purified recombinant syntaxin 5, membrin, and rbet1, three Q-SNAREs, assemble cooperatively to create a high affinity binding site for sec22b, an R-SNARE. The syntaxin 5 amino-terminal domain potently inhibits SNARE complex assembly. The ER/Golgi quaternary complex is remarkably similar to the synaptic complex, suggesting that a common pattern is followed at all transport steps, where three Q-helices assemble to form a high affinity binding site for a fourth R-helix on an opposing membrane. Interestingly, although sec22b binds to the combination of syntaxin 5, membrin, and rbet1, it can only bind if it is present while the others assemble; sec22b cannot bind to a pre-assembled ternary complex of syntaxin 5, membrin, and rbet1. Finally, we demonstrate that the quaternary complex containing sec22b is not an in vitro entity only, but is a bona fide species in living cells.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Biomed Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hay, JC (corresponding author), Univ Michigan, Dept Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.		Williams, Antionette/GQP-2255-2022		NIGMS NIH HHS [T32 GM007315, GM59378] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059378, T32GM007315] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Stone S, 1997, MOL BIOL CELL, V8, P1175, DOI 10.1091/mbc.8.7.1175; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435	37	93	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39631	39639		10.1074/jbc.M007684200	http://dx.doi.org/10.1074/jbc.M007684200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11035026	hybrid			2022-12-25	WOS:000165953100090
J	Gordon, J; Del Valle, L; Otte, J; Khalili, K				Gordon, J; Del Valle, L; Otte, J; Khalili, K			Pituitary neoplasia induced by expression of human neurotropic polyomavirus, JCV, early genome in transgenic mice	ONCOGENE			English	Article						JC virus; T-antigen pituitary neoplasia; transgenic animal model	EARLY PROTEIN; HUMAN BRAIN; TUMORS; VIRUS; GENE; P53; ADENOMAS; GROWTH; PATHOGENESIS; PAPOVAVIRUS	In recent years, there has been mounting evidence pointing to the association of polyomaviruses with a wide range of human cancers. The human neurotropic polyomavirus, JCV, infecting greater than 75% of the human population produces a regulators protein named T-antigen which is expressed at the early phase of viral lytic infection and plays a critical role in completion of the viral life cycle, Furthermore, this protein has the ability to transform neural cells in vivo and its expression has been detected in several human neural-origin tumors. To further investigate the oncogenic potential of the JCV early protein in vivo, transgenic mice expressing JCV T-antigen under the control of its own promoter were generated, Nearly 50% of the animals developed large, solid masses within the base of the skull by 1 year of age. Evaluation of the location as well as histological and immunohistochemical data suggest that the tumors arise from the pituitary gland. As T-antigen is known to interact with several cell cycle regulators, the neoplasms were analysed for the presence of the tumor suppressor protein, p53. Immunoprecipitation/Western blot analysis demonstrated overexpression of wild-type, but not mutant p53 within tumor tissue. In addition, co-immunoprecipitation established an interaction between p53 and T-antigen and overexpression of p53 downstream target protein, p21/WAF1, This report describes the analysis of inheritable pituitary adenomas induced by expression of the human polyomavirus. JCV T-antigen in transgenic mice where T-antigen disrupts the p53 pathway by binding to and sequestering mild-type p53, This animal model may serve as a useful tool to further evaluate mechanisms of tumorigenesis by JCV T-antigen.	Temple Univ, Coll Sci & Technol, Ctr Neurobiol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurobiol & Canc Biol, 1900 N 12th St,Room 203, Philadelphia, PA 19122 USA.		Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				ARBEIT JM, 1993, AM J PATHOL, V142, P1187; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BUCKLEY N, 1994, J CLIN ENDOCR METAB, V79, P1513, DOI 10.1210/jc.79.5.1513; Franks RR, 1996, ONCOGENE, V12, P2573; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gordon J, 1998, DEV BIOL STAND, V94, P93; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; HAAS S, 1994, VIROLOGY, V202, P89, DOI 10.1006/viro.1994.1325; HELSETH A, 1992, AM J PATHOL, V140, P1071; KOVACS K, 1983, ATLAS TUMOR PATHOLOG, V10; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; LEON SP, 1994, NEUROSURGERY, V34, P708, DOI 10.1227/00006123-199404000-00021; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY A, 1994, CLIN ENDOCRINOL, V41, P809, DOI 10.1111/j.1365-2265.1994.tb02797.x; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Marx S, 1998, ANN INTERN MED, V129, P484, DOI 10.7326/0003-4819-129-6-199809150-00011; Shimon I, 1997, J CLIN ENDOCR METAB, V82, P1675, DOI 10.1210/jc.82.6.1675; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SPADA A, 1994, EUR J ENDOCRINOL, V130, P43, DOI 10.1530/eje.0.1300043; Thapar K, 1996, NEUROSURGERY, V38, P765, DOI 10.1227/00006123-199604000-00027; Woloschak M, 1996, CANCER RES, V56, P2493; Zeng YX, 1996, ONCOGENE, V12, P1557; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	27	46	46	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4840	4846		10.1038/sj.onc.1203849	http://dx.doi.org/10.1038/sj.onc.1203849			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039901				2022-12-25	WOS:000089757800006
J	Newey, SE; Howman, EV; Ponting, CP; Benson, MA; Nawrotzki, R; Loh, NY; Davies, KE; Blake, DJ				Newey, SE; Howman, EV; Ponting, CP; Benson, MA; Nawrotzki, R; Loh, NY; Davies, KE; Blake, DJ			Syncoilin, a novel member of the intermediate filament superfamily that interacts with alpha-dystrobrevin in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; MUSCULAR-DYSTROPHY; GLYCOPROTEIN COMPLEX; CELL-LINES; EXPRESSION; UTROPHIN; GENE; TORPEDO; LOCALIZATION; SYNTROPHIN	Dystrophin coordinates the assembly of a complex of structural and signaling proteins that are required for normal muscle function. A key component of the dystrophin protein complex is alpha -dystrobrevin, a dystrophin-associated protein whose absence results in neuromuscular junction defects and muscular dystrophy. To gain further insights into the role of alpha -dystrobrevin in skeletal muscle, we used the yeast two-hybrid system to identify a novel alpha -dystrobrevin-binding partner called syncoilin. Syncoilin is a new member of the intermediate filament superfamily and is highly expressed in skeletal and cardiac muscle. In normal skeletal muscle, syn coilin is concentrated at the neuromuscular junction, where it colocalizes and coimmunoprecipitates with alpha -dystrobrevin-1. Expression studies in mammalian cells demonstrate that, while alpha -dystrobrevin and syncoilin associate directly, overexpression of syncoilin does not result in the self-assembly of intermediate filaments. Finally, unlike many components of the dystrophin protein complex, we show that syncoiIin expression is upregulated in dystrophin-deficient muscle. These data suggest that alpha -dystrobrevin provides a link between the dystrophin protein complex and the intermediate filament network at the neuromuscular junction, which may be important for the maintenance and maturation of the synapse.	Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, Oxford OX1 3QX, England	University of Oxford	Davies, KE (corresponding author), Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, S Parks Rd, Oxford OX1 3QX, England.	kay.davies@anat.ox.ac.uk	Ponting, Chris/AAV-2621-2021	Ponting, Chris/0000-0003-0202-7816; Benson, Matthew/0000-0003-4459-0439				AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ambrose HJ, 1997, GENOMICS, V39, P359, DOI 10.1006/geno.1996.4515; Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; ASKANAS V, 1990, NEUROLOGY, V40, P949, DOI 10.1212/WNL.40.6.949; Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; BILAK M, 1994, SYNAPSE, V16, P280, DOI 10.1002/syn.890160405; Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BLAKE DJ, 1997, PROTEIN DYSFUNCTION, P219; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; Bredt DS, 1999, NAT CELL BIOL, V1, pE89, DOI 10.1038/12085; BROWN SC, 1993, BIOESSAYS, V15, P413, DOI 10.1002/bies.950150608; Corman B, 1999, AM J HUM GENET, V64, P126, DOI 10.1086/302206; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; Ehlers MD, 1998, J NEUROSCI, V18, P720; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Flaherty L, 1998, MAMM GENOME, V9, P417, DOI 10.1007/s003359900788; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Loh NY, 2000, J CELL SCI, V113, P2715; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; Mitsui T, 2000, J CELL BIOCHEM, V77, P584, DOI 10.1002/(SICI)1097-4644(20000615)77:4<584::AID-JCB6>3.0.CO;2-U; MIZUNO Y, 1993, J NEUROL SCI, V119, P43, DOI 10.1016/0022-510X(93)90190-A; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Nawrotzki R, 1998, J CELL SCI, V111, P2595; Newey SE, 2000, CURR BIOL, V10, P1295, DOI 10.1016/S0960-9822(00)00760-0; Newey SE, 2001, MOL CELL NEUROSCI, V17, P127, DOI 10.1006/mcne.2000.0918; NGUYEN TM, 1992, BIOCHEM J, V288, P663, DOI 10.1042/bj2880663; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; Peters MF, 1998, J CELL BIOL, V142, P1269, DOI 10.1083/jcb.142.5.1269; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; SANTAVUORI P, 1989, BRAIN DEV-JPN, V11, P147, DOI 10.1016/S0387-7604(89)80088-9; SEALOCK R, 1989, SYNAPSE, V3, P315, DOI 10.1002/syn.890030404; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Tews DS, 1997, EXP NEUROL, V146, P125, DOI 10.1006/exnr.1997.6512; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Vaittinen S, 1999, AM J PATHOL, V154, P591, DOI 10.1016/S0002-9440(10)65304-7; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	61	103	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6645	6655		10.1074/jbc.M008305200	http://dx.doi.org/10.1074/jbc.M008305200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11053421	Green Accepted, hybrid			2022-12-25	WOS:000167261000076
J	Martin-Rivera, L; Blasco, MA				Martin-Rivera, L; Blasco, MA			Identification of functional domains and dominant negative mutations in vertebrate telomerase RNA using an in vivo reconstitution system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; TETRAHYMENA-TELOMERASE; REVERSE-TRANSCRIPTASE; SECONDARY STRUCTURE; MAMMALIAN TELOMERASE; LACKING TELOMERASE; IN-VITRO; PROTEIN; CELLS; RIBONUCLEOPROTEIN	The telomerase holoenzyme consists of two essential components, a reverse transcriptase, TERT (telomerase reverse transcriptase), and an RNA molecule, TR (telomerase RNA, also known as TERC), that contains the template for the synthesis of new telomeric repeats. Telomerase RNA has been isolated from 32 different vertebrates, and a common secondary structure has been proposed (Chen, J.-L., Blasco, M. A., and Greider, C. W, (2000) Cell 100, 503-514). me have generated 25 mutants in the four conserved structural domains of the mouse telomerase RNA molecule, mTR, and assayed their ability to reconstitute telomerase activity in mTR(-/-) cells in vivo. We found that the pseudoknot and the CR4/6R5 domains are required for telomerase activity but are not essential for mTR stability in the cell, whereas mutations in the]BoxH/ACA and the CR7 domains affect mTR accumulation in the cell. We have also identified mTR mutants that are able to inhibit wild type telomerase in vivo.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Blasco, MA (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BLACKBURN EH, 1991, NATURE, V350, P568; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gilley D, 1999, P NATL ACAD SCI USA, V96, P6621, DOI 10.1073/pnas.96.12.6621; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; MCCORMICKGRAHAM M, 1995, NUCLEIC ACIDS RES, V23, P1091, DOI 10.1093/nar/23.7.1091; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Roy J, 1998, GENE DEV, V12, P3286, DOI 10.1101/gad.12.20.3286; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SINGER MS, 1994, SCIENCE, V266, P387; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Tesmer VM, 1999, MOL CELL BIOL, V19, P6207; Tsao DA, 1998, GENE, V221, P51, DOI 10.1016/S0378-1119(98)00432-6; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	39	62	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5856	5865		10.1074/jbc.M008419200	http://dx.doi.org/10.1074/jbc.M008419200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11056167	hybrid			2022-12-25	WOS:000167115100062
J	Burritt, JB; DeLeo, FR; McDonald, CL; Prigge, JR; Dinauer, MC; Nakamura, M; Nauseef, WM; Jesaitis, AJ				Burritt, JB; DeLeo, FR; McDonald, CL; Prigge, JR; Dinauer, MC; Nakamura, M; Nauseef, WM; Jesaitis, AJ			Phage display epitope mapping of human neutrophil flavocytochrome b(558) - Identification of two juxtaposed extracellular domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PHAGOCYTE NADPH OXIDASE; SRC HOMOLOGY-3 DOMAINS; CYTOCHROME-B; MONOCLONAL-ANTIBODIES; BINDING-SITE; MATURATION; MEMBRANE; CARRIER; FEMALE	Despite extensive experimental and clinical evidence demonstrating the critical role of flavocytochrome b(558) (Cyt b) in the NADPH-dependent oxidase, there is paucity of direct structural data defining its topology in the phagocyte membrane. Unlike other Cyt b-specific monoclonal antibodies, 7D5 binds exclusively to an extracellular domain, and identification of its epitope should provide novel insight into the membrane topology of Cyt b. To that end, we examined biochemical features of 7D5-Cyt b binding and used the J404 phage display nonapeptide library to identify the bound epitope. 7D5 precipitated only heterodimeric gp91-p22(phox) and not individual or denatured Cyt b subunits from detergent extracts of human neutrophils and promyelocytic leukemia cells (gp91-PLB). Moreover, 7D5 precipitated precursor gp65-p22(phox) complexes from detergent extracts of the biosynthetically active gp91-PLB cells, demonstrating that complex carbohydrates were not required for epitope recognition. Epitope mimetics selected from the J404 phage display library by 7D5 demonstrated that (226)RIVRG(230) and (IKNP163)-I-160 regions of gp91(phox) were both bound by 7D5, These studies reveal specific information about Cyt b membrane topology and structure, namely that gp91(phox) residues (226)RIVRG(230) and (IKNP163)-I-160 closely juxtaposed on extracytoplasmic domains and that predicted helices containing residues Gly(165)-Ile(190) and Ser(200)-Glu(226) are adjacent to each other in the membrane.	Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA; Vet Affairs Med Ctr, Inflammat Program, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Iowa City, IA 52242 USA; Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Inst Trop Med, Nagasaki 8528523, Japan	Montana State University System; Montana State University Bozeman; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Jesaitis, AJ (corresponding author), Montana State Univ, Dept Microbiol, 109 Lewis Hall, Bozeman, MT 59717 USA.	umbaj@gemini.oscs.montana.edu		DeLeo, Frank/0000-0003-3150-2516; Jesaitis, Algirdas/0000-0001-9001-5617; Nauseef, William/0000-0003-4032-757X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635, R01HL053592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026711, R01AI034879] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53592, HL 45635] Funding Source: Medline; NIAID NIH HHS [R01 AI 34879, R01 AI 26711] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; BATOT G, 1995, EUR J BIOCHEM, V234, P208, DOI 10.1111/j.1432-1033.1995.208_c.x; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Burritt JB, 1998, J BIOL CHEM, V273, P24847, DOI 10.1074/jbc.273.38.24847; Burritt JB, 1996, ANAL BIOCHEM, V238, P1, DOI 10.1006/abio.1996.0241; Burritt JB, 2000, EUR J HAEMATOL, V65, P407, DOI 10.1034/j.1600-0609.2000.065006407.x; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DUSI S, 1990, ACTA HAEMATOL-BASEL, V84, P49; EMMENDORFFER A, 1994, CYTOMETRY, V18, P147, DOI 10.1002/cyto.990180306; Faizunnessa NN, 1997, HUM GENET, V99, P469, DOI 10.1007/PL00008702; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; GUILLET V, 1993, STRUCTURE, V1, P165, DOI 10.1016/0969-2126(93)90018-C; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; INGERSLEV J, 1989, CLIN GENET, V35, P41; JESAITIS AJ, 1995, J IMMUNOL, V155, P3286; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; KALADHAR RB, 1984, HUM GENET, V67, P460; KURIBAYASHI F, 1995, BIOCHEM BIOPH RES CO, V209, P146, DOI 10.1006/bbrc.1995.1482; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; MARCUS S, 1992, HUM GENET, V89, P395; MIZUNO Y, 1988, J PEDIATR-US, V113, P458, DOI 10.1016/S0022-3476(88)80628-0; MOSER H, 1974, CLIN GENET, V5, P271; NAKAMURA M, 1987, BLOOD, V69, P1404; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; PARK MY, 1994, BIOCHEM BIOPH RES CO, V204, P924, DOI 10.1006/bbrc.1994.2548; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1992, MOL BASIS OXIDATIVE; Roos D, 1996, BLOOD, V87, P1663; ROPERS HH, 1977, AM J HUM GENET, V29, P361; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TAYLOR SAM, 1991, P NATL ACAD SCI USA, V88, P39, DOI 10.1073/pnas.88.1.39; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	60	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2053	2061		10.1074/jbc.M006236200	http://dx.doi.org/10.1074/jbc.M006236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11027685	hybrid			2022-12-25	WOS:000166528000056
J	Frickel, EM; Jemth, P; Widersten, M; Mannervik, B				Frickel, EM; Jemth, P; Widersten, M; Mannervik, B			Yeast glyoxalase I is a monomeric enzyme with two active sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUCRASE-ISOMALTASE; GENE DUPLICATION; PROTEIN; METHYLGLYOXAL; MECHANISM; ISOMERASE; SEGMENTS; MEMBRANE; MAMMALS	The tertiary structure of the monomeric yeast glyoxalase I has been modeled based on the crystal structure of the dimeric human glyoxalase I and a sequence alignment of the two enzymes, The model suggests that yeast glyoxalase I has two active sites contained in a single polypeptide, To investigate this, a recombinant expression clone of yeast glyoxalase I was constructed for overproduction of the enzyme in Escherichia coli. Each putative active site was inactivated by site-directed mutagenesis. According to the alignment, glutamate 163 and glutamate 318 in yeast glyoxalase I correspond to glutamate 172 in human glyoxalase I, a Zn(II) ligand and proposed general base in the catalytic mechanism. The residues were each replaced by glutamine and a double mutant containing both mutations was also constructed. Steady-state kinetics and metal analyses of the recombinant enzymes corroborate that yeast glyoxalase I has two functional active sites. The activities of the catalytic sites seem to be somewhat different, The metal ions bound in the active sites are probably one Fe(II) and one Zn(II), but Mn(II) may replace Zn(II). Yeast glyoxalase I appears to be one of the few enzymes that are present as a single polypeptide with two active sites that catalyze the same reaction.	Uppsala Univ, Ctr Biomed, Dept Biochem, SE-75123 Uppsala, Sweden	Uppsala University	Mannervik, B (corresponding author), Uppsala Univ, Ctr Biomed, Dept Biochem, Box 576, SE-75123 Uppsala, Sweden.	Bengt.Mannervik@biokem.uu.se	Widersten, Mikael/O-2565-2015					ARONSSON AC, 1978, BIOCHEM BIOPH RES CO, V81, P1235, DOI 10.1016/0006-291X(78)91268-8; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BJORNESTEDT R, 1992, BIOCHEM J, V282, P505; Cameron AD, 1997, EMBO J, V16, P3386, DOI 10.1093/emboj/16.12.3386; Cameron AD, 1999, BIOCHEMISTRY-US, V38, P13480, DOI 10.1021/bi990696c; Clugston SL, 1997, GENE, V186, P103, DOI 10.1016/S0378-1119(96)00691-9; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; IYENGAR R, 1981, BIOCHEMISTRY-US, V20, P1229, DOI 10.1021/bi00508a027; JAGT DLV, 1973, BIOCHEMISTRY-US, V12, P5161, DOI 10.1021/bi00749a022; JONES TA, 1991, O MANUAL; KALAPOS MP, 1994, TOXICOL LETT, V73, P3, DOI 10.1016/0378-4274(94)90184-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LO TWC, 1994, J BIOL CHEM, V269, P32299; MARMSTAL E, 1979, BIOCHEM J, V183, P23, DOI 10.1042/bj1830023; MARMSTAL E, 1978, FEBS LETT, V85, P275, DOI 10.1016/0014-5793(78)80472-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitsuhashi S, 2000, J BIOL CHEM, V275, P5521, DOI 10.1074/jbc.275.8.5521; RACKER E, 1951, J BIOL CHEM, V190, P685; Ridderstrom M, 1998, J BIOL CHEM, V273, P21623, DOI 10.1074/jbc.273.34.21623; Ridderstrom M, 1996, BIOCHEM J, V316, P1005, DOI 10.1042/bj3161005; Ridderstrom M, 1997, BIOCHEM J, V328, P231, DOI 10.1042/bj3280231; SELLIN S, 1984, J BIOL CHEM, V259, P1426; SJOSTROM H, 1980, J BIOL CHEM, V255, P1332; VACA CE, 1994, CARCINOGENESIS, V15, P1887, DOI 10.1093/carcin/15.9.1887; VANDERJAGT DL, 1972, BIOCHEMISTRY-US, V11, P3735, DOI 10.1021/bi00770a011; VANDERJAGT DL, 1989, GLUTATHIONE CHEM B A, P597; WACKER H, 1984, J BIOL CHEM, V259, P4878	30	42	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1845	1849		10.1074/jbc.M005760200	http://dx.doi.org/10.1074/jbc.M005760200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050082	hybrid			2022-12-25	WOS:000166528000028
J	Van Lenten, BJ; Wagner, AC; Navab, M; Fogelman, AM				Van Lenten, BJ; Wagner, AC; Navab, M; Fogelman, AM			Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; LOW-DENSITY-LIPOPROTEIN; ACUTE-PHASE RESPONSE; MESSENGER-RNA LEVELS; APOLIPOPROTEIN-J; SERUM; CYTOKINES; ACTIVATION; EXPRESSION; CLUSTERIN	In this study, we tested if interleukin-6 (IL-6) plays a role in mediating the effects of oxidized phospholipids (OXPL). Treatment of HepG2 cells with oxidized 1-palmitoyl-2-arachidonyl-sn-gIycero-3-phosphoryl choline (OX-PAPC), or biologically active lipids present in mildly oxidized low density lipoprotein, increased apo lipoprotein J (apoJ), and decreased paraoxonase (PON) mRNA levels. Antibodies to IL-6 blocked these changes. IL-6 treatment in the absence of OXPL produced the same pattern of mRNA changes observed with OXPL treatment alone. In vivo, OX-PAPC injected into C57BL/6J mice resulted in a marked reduction in PON activity and an increase in apoJ levels in plasma after 16 h. Injection of OX-PAPC into IL-6-deficient C57BL/6J mice (IL-6 -/-) did not alter either PON activity or apoJ levels. We then tested if other mechanisms involved in fatty streak formation depended upon IL-6. Antibody to IL-6 had no effect on OX-PAPC-induced secretion of MCP-1 by endothelial cells nor on MCP-1 mRNA expression in HepG2 cells. C57BL/6J and IL-6 -/- mice fed an atherogenic diet both demonstrated markedly reduced plasma PON activities and the IL-6 -/- mice developed fatty streaks to a greater degree than wild-type mice. We conclude that IL-6 is critical to short term but not long term regulation of PON and that IL-6 is not required for OXPL regulation of MCP-1.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Van Lenten, BJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	bvalent@mednet.ucla.edu			NCRR NIH HHS [5M01RR00865-25] Funding Source: Medline; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT CA, 1995, ARTERIOSCL THROM VAS, V15, P1812, DOI 10.1161/01.ATV.15.11.1812; Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461; ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; Biasucci LM, 1996, CIRCULATION, V94, P874, DOI 10.1161/01.CIR.94.5.874; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; Dahmen H, 1998, BIOCHEM J, V331, P695, DOI 10.1042/bj3310695; EUGUI EM, 1994, INT IMMUNOL, V6, P409, DOI 10.1093/intimm/6.3.409; Feingold KR, 1998, ATHEROSCLEROSIS, V139, P307, DOI 10.1016/S0021-9150(98)00084-7; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Grayston JT, 1998, CIRCULATION, V97, P1669, DOI 10.1161/01.CIR.97.17.1669; HARDARDOTTIR I, 1994, J CLIN INVEST, V94, P1304, DOI 10.1172/JCI117449; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; Herbelin C, 1998, EUR CYTOKINE NETW, V9, P57; Huang JYH, 1999, J INTERF CYTOK RES, V19, P1403, DOI 10.1089/107999099312867; Huber SA, 1999, ARTERIOSCL THROM VAS, V19, P2364, DOI 10.1161/01.ATV.19.10.2364; KELSO GJ, 1994, BIOCHEMISTRY-US, V33, P832, DOI 10.1021/bi00169a026; Khovidhunkit W, 2000, J INFECT DIS, V181, pS462, DOI 10.1086/315611; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; Kumon Y, 1998, SCAND J IMMUNOL, V48, P419; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; MACKNESS MI, 1995, LANCET, V346, P856, DOI 10.1016/S0140-6736(95)92702-6; MCELVEEN J, 1986, CLIN CHEM, V32, P671; Meier CR, 1998, LANCET, V351, P1467, DOI 10.1016/S0140-6736(97)11084-4; Memon RA, 1998, ARTERIOSCL THROM VAS, V18, P1257, DOI 10.1161/01.ATV.18.8.1257; MULLEN PG, 1995, J SURG RES, V58, P124, DOI 10.1006/jsre.1995.1020; Navab M, 1997, J CLIN INVEST, V99, P2005, DOI 10.1172/JCI119369; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Orus J, 2000, J HEART LUNG TRANSPL, V19, P419, DOI 10.1016/S1053-2498(00)00083-8; Robak T, 1998, MEDIAT INFLAMM, V7, P347, DOI 10.1080/09629359890875; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Song H, 1998, CYTOKINE, V10, P275, DOI 10.1006/cyto.1997.0291; Sukovich DA, 1999, CIRCULATION, V100, P43; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; TSCHOPP J, 1997, CLIN EXP IMMUNOL S2, V2, P11; van Deuren M, 1998, CYTOKINE, V10, P897, DOI 10.1006/cyto.1998.0367; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359	43	107	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1923	1929		10.1074/jbc.M004074200	http://dx.doi.org/10.1074/jbc.M004074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11034996	hybrid			2022-12-25	WOS:000166528000039
J	Doostzadeh-Cizeron, J; Terry, NHA; Goodrich, DW				Doostzadeh-Cizeron, J; Terry, NHA; Goodrich, DW			The nuclear death domain protein p84N5 activates a G(2)/M cell cycle checkpoint prior to the onset of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; RETINOBLASTOMA PROTEIN; MAMMALIAN-CELLS; FAMILY-MEMBERS; P53; GENE; INHIBITION; INDUCTION; LIFE	In contrast to extracellular signals, the mechanisms utilized to transduce nuclear apoptotic signals are not well understood. Characterizing these mechanisms is important for predicting how tumors will respond to genotoxic radiation or chemotherapy. The retinoblastoma (Rb) tumor suppressor protein can regulate apoptosis triggered by DNA damage through an unknown mechanism. The nuclear death domain-containing protein p84N5 can induce apoptosis that is inhibited by association with Rb, The pattern of caspase and NF-kappaB activation during p84N5-induced apoptosis is similar to p53-independent cellular responses to DNA damage. One hallmark of this response is the activation of a G(2)/M cell cycle checkpoint. In this report, we characterize the effects of p84N5 on the cell cycle. Expression of p84N5 induces changes in cell cycle distribution and kinetics that are consistent with the activation of a G(2)/M cell cycle checkpoint. Like the radiation-induced checkpoint, caffeine blocks p84N5-induced G(2)/M arrest but not subsequent apoptotic cell death, The p84N5-induced checkpoint is functional in ataxia telangiectasia-mutated kinase-deficient cells. We conclude that p84N5 induces an ataxia telangiectasia-mutated kinase (ATM)independent, caffeine-sensitive G(2)/dM cell cycle arrest prior to the onset of apoptosis. This conclusion is consistent with the hypotheses that p84N5 functions in an Rb-regulated cellular response that is similar to that triggered by DNA damage.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Goodrich, DW (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.	goodrich@odin.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA070292, P01CA006294] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672, CA-06294, CA-70292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Bracey TS, 1997, CLIN CANCER RES, V3, P1371; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Darbon JM, 2000, J BIOL CHEM, V275, P15363, DOI 10.1074/jbc.275.20.15363; Doostzadeh-Cizeron J, 2000, J BIOL CHEM, V275, P25336, DOI 10.1074/jbc.M000793200; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812; HARRIS AL, 1985, CANCER SURV, V4, P601; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hong FD, 1999, CARCINOGENESIS, V20, P1161, DOI 10.1093/carcin/20.7.1161; HUYGHE BG, 1995, HUM GENE THER, V6, P1403, DOI 10.1089/hum.1995.6.11-1403; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Rotman G, 1997, CANCER SURV, V29, P285; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; TERRY NH, 1996, CLIN IMMUNOL NEWS, V16, P46; TERRY NHA, 1991, CYTOMETRY, V12, P234, DOI 10.1002/cyto.990120305; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WHITE RA, 1990, CYTOMETRY, V11, P314, DOI 10.1002/cyto.990110214; WHITE RA, 1990, CELL TISSUE KINET, V23, P561, DOI 10.1111/j.1365-2184.1990.tb01346.x; White RA, 2000, CYTOMETRY, V41, P1; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yin SM, 2000, CANCER GENE THER, V7, P985, DOI 10.1038/sj.cgt.7700194; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	37	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1127	1132		10.1074/jbc.M006944200	http://dx.doi.org/10.1074/jbc.M006944200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050087	hybrid			2022-12-25	WOS:000166430900038
J	Pellacani, A; Wiesel, P; Razavi, S; Vasilj, V; Feinberg, MW; Chin, MT; Reeves, R; Perrella, MA				Pellacani, A; Wiesel, P; Razavi, S; Vasilj, V; Feinberg, MW; Chin, MT; Reeves, R; Perrella, MA			Down-regulation of high mobility group-I(Y) protein contributes to the inhibition of nitric-oxide synthase 2 by transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; SMOOTH-MUSCLE-CELLS; E-SELECTIN; GENE-EXPRESSION; VIRUS INDUCTION; HMG-I; BINDING; ORGANIZATION; MACROPHAGES	The inducible isoform of nitric oxide synthase (NOS2) catalyzes the production of nitric oxide (NO), which participates in the pathophysiology of systemic inflammatory diseases such as sepsis. NOS2 is transcriptionally up-regulated by endotoxin and inflammatory cytokines, and down-regulated by transforming growth factor (TGF)-beta1, Recently we have shown that high mobility group (HMG)-I(Y) protein, an architectural transcription factor, contributes to NOS2 gene transactivation by inflammatory mediators. The aim of the present study was to determine whether regulation of HMG-ICY) by TGF-beta1 contributes to the TGF-beta1-mediated suppression of NOS2, By Northern blot analysis, we show that TGF-beta1 decreased cytokine-induced HMG-I(Y) mRNA levels in vascular smooth muscle cells and macrophages in vitro and in vivo. Western analysis confirmed the down-regulation of HMG-I(Y) protein by TGF-beta1, To determine whether the down-regulation of HMG-I(Y) contributed to a decrease in NOS2 gene transactivation by TGF-beta1, we performed cotransfection experiments. Overexpression of HMG-I(Y) was able to restore cytokine inducibility of the NOS2 promoter that was suppressed by TGF-beta1, The effect of TGF-beta1 on NOS2 gene transactivation was not related to a decrease in binding of HMG-I(Y) to the promoter of the NOS2 gene, but due to a decrease in endogenous HMG-ICY) protein. These data provide the first evidence that cytokine-induced HMG-I(Y) can be down-regulated by TGF-beta1, This downregulation of HMG-I(Y) contributes to the TGF-beta1-mediated decrease in NOS2 gene transactivation by proinflammatory stimuli.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Washington State University	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu		Feinberg, Mark/0000-0001-9523-3859	NHLBI NIH HHS [HL60788] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal BB, 1996, METHOD ENZYMOL, V269, P166; Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; COOK HT, 1994, CLIN SCI, V87, P179, DOI 10.1042/cs0870179; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; FORSTERMANN U, 1992, EUR J PHARM-MOLEC PH, V225, P161, DOI 10.1016/0922-4106(92)90096-E; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 2000, J IMMUNOL, V164, P3157, DOI 10.4049/jimmunol.164.6.3157; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kirkeboen KA, 1999, ACTA ANAESTH SCAND, V43, P275; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LUNDBERG K, 1989, BIOCHIM BIOPHYS ACTA, V1009, P277, DOI 10.1016/0167-4781(89)90113-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MONCADA S, 1992, J LAB CLIN MED, V120, P187; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; OGRAM SA, 1995, J BIOL CHEM, V270, P14235, DOI 10.1074/jbc.270.23.14235; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; Pellacani A, 1999, J BIOL CHEM, V274, P1525, DOI 10.1074/jbc.274.3.1525; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Perrella MA, 1996, P NATL ACAD SCI USA, V93, P2054, DOI 10.1073/pnas.93.5.2054; Perrella MA, 1998, MINER ELECTROL METAB, V24, P136, DOI 10.1159/000057361; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Sambrook J., 1989, MOL CLONING LAB MANU, V2; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Xiao DM, 2000, J NEUROCHEM, V74, P392, DOI 10.1046/j.1471-4159.2000.0740392.x; XIE OW, 1994, J BIOL CHEM, V269, P4706; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	51	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1653	1659		10.1074/jbc.M008170200	http://dx.doi.org/10.1074/jbc.M008170200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11056164	hybrid			2022-12-25	WOS:000166430900105
J	Shiose, A; Kuroda, J; Tsuruya, K; Hirai, M; Hirakata, H; Naito, S; Hattori, M; Sakaki, Y; Sumimoto, H				Shiose, A; Kuroda, J; Tsuruya, K; Hirai, M; Hirakata, H; Naito, S; Hattori, M; Sakaki, Y; Sumimoto, H			A novel superoxide-producing NAD(P)H oxidase in kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; SRC HOMOLOGY-3 DOMAINS; NADH/NADPH OXIDASE; ACTIVATION; BINDING; CYTOCHROME-B558; COMPONENT; SYSTEM; CELLS; GENE	During phagocytosis, gp91(phox), th, catalytic subunit of the phagocyte NADPH oxidase, becomes activated to produce superoxide, a precursor of microbicidal oxidants. Currently increasing evidence suggests that nonphagocytic cells contain similar superoxide-producing oxidases, which are proposed to play crucial roles in various events such as cell proliferation and oxygen sensing for erythropoiesis. Here we describe the cloning of human cDNA that encodes a novel NAD(P)H oxidase, designated NOX4. The NOX4 protein of 578 amino acids exhibits 39% identity to gp91(Phox) with special conservation in membrane-spanning regions and binding sites for heme, FAD, and NAD(P)H, indicative of its function as a superoxide-producing NAD(P)H oxidase. The membrane fraction of kidney derived human embryonic kidney (HEK) 293 cells, expressing NOX4, exhibits NADH-and NADPH-dependent superoxide-producing activities, both of which are inhibited by diphenylene iodonium, an agent known to block oxygen sensing, and decreased in cells expressing antisense NOX4 mRNA. The human NOX4 gene, comprising 18 exons, is located on chromosome 11q14.2-q21, and its expression is almost exclusively restricted to adult and fetal kidneys. in human renal cortex, high amounts of the NOX4 protein are present in distal tubular cells, which reside near erythropoietin-producing cells. In addition, overexpression of NOX4 in cultured cells leads to increased superoxide production and decreased rate of growth. The present findings thus suggest that the novel NAD(P)H oxidase NOX4 may serve as an oxygen sensor and/or a regulator of cell growth in kidney.	Kyushu Univ, Grad Sch Med Sci, Dept Mol & Struct Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Urol, Higashi Ku, Fukuoka 8128582, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Tokyo 1130033, Japan; RIKEN, Genom Sci Ctr, Sagamihara, Kanagawa 2288555, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1088639, Japan	Kyushu University; Kyushu University; Kyushu University; University of Tokyo; RIKEN; University of Tokyo	Sumimoto, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol & Struct Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Bunn HF, 1998, J EXP BIOL, V201, P1197; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Ebert BL, 1999, BLOOD, V94, P1864; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Griendling KK, 1997, TRENDS CARDIOVAS MED, V7, P301, DOI 10.1016/S1050-1738(97)00088-1; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MEYER JW, 1990, FEBS LETT, V472, P1; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAITO S, 1982, J UROLOGY, V128, P1117, DOI 10.1016/S0022-5347(17)53357-1; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; SMITH RM, 1991, BLOOD, V77, P673; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1989, BIOCHEM BIOPH RES CO, V165, P902, DOI 10.1016/S0006-291X(89)80051-8; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TAMAKI K, 1994, KIDNEY INT, V45, P525, DOI 10.1038/ki.1994.68; Ueda N, 2000, AM J MED, V108, P403, DOI 10.1016/S0002-9343(00)00311-9; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Vasserman NN, 1999, HUM HERED, V49, P129, DOI 10.1159/000022859; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	38	418	439	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1417	1423		10.1074/jbc.M007597200	http://dx.doi.org/10.1074/jbc.M007597200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032835	hybrid			2022-12-25	WOS:000166430900075
J	Johnson, C; Glover, G; Arias, J				Johnson, C; Glover, G; Arias, J			Regulation of DNA binding and trans-activation by a xenobiotic stress-activated plant transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; TISSUE-SPECIFIC EXPRESSION; SALICYLIC-ACID; INTRAMOLECULAR INHIBITION; GENE PROMOTER; FACTOR ASF-1; OCS-ELEMENT; AUXIN; INDUCTION; PROTEIN	As-1-type cis-elements augment transcription of both nuclear and pathogen genes in response to stress and defense cues in plants. Basic/leucine zipper proteins termed "TGA factors" that specifically bind as-1 elements are likely candidates for mediating these transcription activities. Our earlier work has shown that 2,4-dichlorophenoxyacetic acid-induced xenobiotic stress enhances trans-activation by a chimeric fusion protein of the yeast Gal4 binding domain and TGA1a, a TGA factor of tobacco. Here we demonstrate that xenobiotic stress also enhances the ability of native TGA1a to bind as-1 and activate transcription of a known target gene. In addition, the previously identified xenobiotic stress-responsive domain of TGA1a was found to inhibit this factor's trans-activation potential by a mechanism that appears to involve stimulus-reversible interactions with a nuclear repressor protein. Results from these and other studies can now be placed in the context of a working model to explain basal and xenobiotic stress-induced activities of TGA1a through its cognate cis-acting element.	Univ Maryland, Inst Biotechnol, Ctr Agr Biotechnol, College Pk, MD 20742 USA; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland Baltimore; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Arias, J (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Agr Biotechnol, 5115 Plant Sci Bldg, College Pk, MD 20742 USA.	arias@umbi.umd.edu						AN GH, 1990, PLANT CELL, V2, P225, DOI 10.1105/tpc.2.3.225; Angerer ND, 1999, J BIOL CHEM, V274, P4147, DOI 10.1074/jbc.274.7.4147; ARIAS JA, 1993, PLANT CELL, V5, P485, DOI 10.1105/tpc.5.4.485; BENFEY PN, 1990, EMBO J, V9, P1677, DOI 10.1002/j.1460-2075.1990.tb08291.x; BOUCHEZ D, 1989, EMBO J, V8, P4197, DOI 10.1002/j.1460-2075.1989.tb08605.x; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; Chen WQ, 1999, PLANT J, V19, P667, DOI 10.1046/j.1365-313x.1999.00560.x; Despres C, 2000, PLANT CELL, V12, P279, DOI 10.1105/tpc.12.2.279; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; Droog F, 1995, PLANT MOL BIOL, V29, P413, DOI 10.1007/BF00020974; Harlow E., 1988, ANTIBODIES LAB MANUA; KATAGIRI F, 1992, MOL CELL BIOL, V12, P4809, DOI 10.1128/MCB.12.11.4809; KIM YH, 1994, PLANT MOL BIOL, V24, P105, DOI 10.1007/BF00040578; Klinedinst S, 2000, PLANT MOL BIOL, V42, P679, DOI 10.1023/A:1006332708388; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Koehler SM, 1996, PLANT MOL BIOL, V31, P595, DOI 10.1007/BF00042232; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; LAWTON MA, 1987, MOL CELL BIOL, V7, P335, DOI 10.1128/MCB.7.1.335; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU XJ, 1994, J BIOL CHEM, V269, P668; MAUCH F, 1993, PLANT PHYSIOL, V102, P1193, DOI 10.1104/pp.102.4.1193; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; NEUHAUS G, 1994, PLANT CELL, V6, P827, DOI 10.1105/tpc.6.6.827; Niggeweg R, 2000, J BIOL CHEM, V275, P19897, DOI 10.1074/jbc.M909267199; Pascuzzi P, 1998, J BIOL CHEM, V273, P26631, DOI 10.1074/jbc.273.41.26631; Sano Y, 1998, J BIOL CHEM, V273, P29098, DOI 10.1074/jbc.273.44.29098; ULMASOV T, 1995, PLANT PHYSIOL, V108, P919, DOI 10.1104/pp.108.3.919; Xiang CB, 1998, PLANT CELL, V10, P1539, DOI 10.1105/tpc.10.9.1539; Xiang CB, 1996, PLANT MOL BIOL, V32, P415, DOI 10.1007/BF00019093; YAMAZAKI K, 1990, P NATL ACAD SCI USA, V87, P7035, DOI 10.1073/pnas.87.18.7035; Zhang B, 1995, PLANT CELL, V7, P2241, DOI 10.1105/tpc.7.12.2241; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523; Zhou JM, 2000, MOL PLANT MICROBE IN, V13, P191, DOI 10.1094/MPMI.2000.13.2.191	33	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					172	178		10.1074/jbc.M005143200	http://dx.doi.org/10.1074/jbc.M005143200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11034999	hybrid			2022-12-25	WOS:000166280700025
J	Zhang, YH; Heulsmann, A; Tondravi, MM; Mukherjee, A; Abu-Amer, Y				Zhang, YH; Heulsmann, A; Tondravi, MM; Mukherjee, A; Abu-Amer, Y			Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RHEUMATOID-ARTHRITIS; OSTEOPROTEGERIN LIGAND; THERAPEUTIC TARGET; KEY REGULATOR; ACTIVATION; BONE; CYTOKINE; KINASE; CELLS	Tumor necrosis factor-cw (TNF) and the ligand for receptor activator of NF-KB (RANKL) are abundant in sites of inflammatory bone erosion. Because these cytokines are potent osteoclastogenic factors and because their signaling pathways are considerably overlapping, we postulated that under pro-inflammatory conditions RANKL and TNF might synergistically orchestrate enhanced osteoclastogenesis via cooperative mechanisms. We found TNF, via TNF type 1 receptor (TNFr1), prompts robust osteoclastogenesis by osteoclast precursors pretreated with RANKL, and deletion of TNFrl abrogates this response. Enhanced osteoclastogenesis is associated with high expression of otherwise TNF and RANKL-induced mediators, including c-Src, TRAF2, TRAF6, and MEKK-1, levels of which were notably reduced in TNFrl knockouts. Recruitment of TRAFs and MEKK1 leads to activation of downstream pathways, primarily I kappaB/NF-kappaB, ERKs, and cJun/AP-1. Consistent with impaired osteoclastogenesis and reduced expression of TRAFs and MEKK1, we found that phosphorylation and activation of I kappaB, NF-kappaB, ERKs, and cJun/AP-1 are severely reduced in RANKL-treated TNFr1-null osteoclast precursors compared with wild type counterparts. Finally, we found that TNF and RANKL synergistically up-regulate RANK expression in wild type precursors, whereas basal and stimulated levels of RANK are significantly lower in TNFrl knockout cells. Our data suggest that exuberant TNF-induced osteoclastogensis is the result of coupling between RANK and TNFrl and is dependent upon signals transmitted by the latter receptor.	Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthopaed Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Pathol, St Louis, MO 63110 USA; Amer Red Cross, Dept Hematopoiesis, Rockville, MD 20855 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); American Red Cross	Abu-Amer, Y (corresponding author), Washington Univ, Sch Med, Dept Orthopaed Surg, 1 Barnes Hosp Plaza,11300 W Pavil,Campus Box 8233, St Louis, MO 63110 USA.	abuamery@msnotes.wustl.edu			NIDCR NIH HHS [DE 13754-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013754] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abu-Amer Y, 2000, J BIOL CHEM, V275, P27307; Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Allen JE, 1997, IMMUNOL TODAY, V18, P387, DOI 10.1016/S0167-5699(97)01102-X; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; CLOHISY DR, 1989, J BIOL CHEM, V264, P5370; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DROUET C, 1991, J IMMUNOL, V147, P1694; DUFF GW, 1994, SCAND J RHEUMATOL, P9; Feldmann M, 1995, ANN NY ACAD SCI, V766, P272, DOI 10.1111/j.1749-6632.1995.tb26675.x; Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HARRIS WH, 1995, CLIN ORTHOP RELAT R, P46; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Isomaki P, 1997, ANN MED, V29, P499, DOI 10.3109/07853899709007474; JIRANEK WA, 1993, J BONE JOINT SURG AM, V75A, P863, DOI 10.2106/00004623-199306000-00007; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li J, 1999, J BONE MINER RES, V14, pS149; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; MUNDY GR, 1993, J CELL BIOCHEM, V53, P296, DOI 10.1002/jcb.240530405; MUNDY GR, 1993, J BONE MINER RES, V8, pS505, DOI 10.1002/jbmr.5650081315; Schlaak JF, 1996, CLIN EXP RHEUMATOL, V14, P155; Takayanagi H, 2000, ARTHRITIS RHEUM-US, V43, P259, DOI 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W; Tetsuka T, 1996, BIOCHEM BIOPH RES CO, V218, P808, DOI 10.1006/bbrc.1996.0144; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; ULFGREN AK, 1995, ANN RHEUM DIS, V54, P654, DOI 10.1136/ard.54.8.654; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VILCEK J, 1991, J BIOL CHEM, V266, P7313; Wagner S, 1997, RHEUMATOL INT, V16, P191, DOI 10.1007/BF01330295; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355	43	384	420	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					563	568		10.1074/jbc.M008198200	http://dx.doi.org/10.1074/jbc.M008198200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11032840	hybrid			2022-12-25	WOS:000166280700076
J	Cai, L; Klein, JB; Kang, YJ				Cai, L; Klein, JB; Kang, YJ			Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; LIPID-PEROXIDATION; SUPEROXIDE; CELLS; ACTIVATION; OXIDATION; MEMBRANE; RADICALS; TOXICITY; HEART	Previous studies have demonstrated that metallothionein functions as an antioxidant that protects against oxidative DNA, protein, and lipid damage induced by superoxide anion, hydrogen peroxide, hydroxyl radical, and nitric oxide. The present study was undertaken to test the hypothesis that metallothionein also protects from DNA and lipoprotein damage induced by peroxynitrite, an important reactive nitrogen species that causes a diversity of pathological processes. A cell-free system was used. DNA damage was detected by the mobility of plasmid DNA in electrophoresis. Oxidation of low density lipoprotein was measured by a thiobarbituric acid-reactive substance, which was confirmed by lipid hydroperoxide assay. Plasmid DNA damage and low density lipoprotein oxidation were induced by 3-morpholinosydnomine, which produces peroxynitrite through the reaction between nitric oxide and superoxide anion or by synthesized peroxynitrite directly. DNA damage by 3-morpholinosydnomine was prevented by both metallothionein and superoxide dismutase, whereas the damage caused by peroxynitrite was prevented by metallothionein only. The oxidation of low density lipoprotein by 3-morpholinosydnomine and peroxynitrite was also significantly inhibited by metallothionein. This study thus demonstrates that metallothionein may react directly with peroxynitrite to prevent DNA and lipoprotein damage induced by this pathological reactive nitrogen species.	Univ Louisville, Sch Med, Dept Med, Louisville, KY 40202 USA; Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40292 USA; Jewish Hosp Heart & Lung Inst, Louisville, KY 40292 USA	University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Kang, YJ (corresponding author), Univ Louisville, Sch Med, Dept Med, 511 S Sloyd St,MDR 530, Louisville, KY 40202 USA.		Cai, Lu/A-6024-2008; Klein, Jon/B-9833-2013	Cai, Lu/0000-0003-3048-1135; 	NCI NIH HHS [CA68125] Funding Source: Medline; NHLBI NIH HHS [HL59225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068125] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059225] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Borutaite V, 1999, BBA-MOL BASIS DIS, V1453, P41, DOI 10.1016/S0925-4439(98)00082-9; Cai L, 1999, TOXICOLOGY, V132, P85, DOI 10.1016/S0300-483X(98)00150-4; CAI L, 1995, CHEM-BIOL INTERACT, V96, P143, DOI 10.1016/0009-2797(94)03585-V; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Gadelha FR, 1997, ARCH BIOCHEM BIOPHYS, V345, P243, DOI 10.1006/abbi.1997.0259; Grace SC, 1998, FEBS LETT, V426, P24, DOI 10.1016/S0014-5793(98)00298-1; Gutteridge JMC, 2000, ANN NY ACAD SCI, V899, P136, DOI 10.1111/j.1749-6632.2000.tb06182.x; Hermann M, 1999, FEBS LETT, V445, P212, DOI 10.1016/S0014-5793(99)00043-5; Jope RS, 2000, ARCH BIOCHEM BIOPHYS, V376, P365, DOI 10.1006/abbi.2000.1728; Kang YJ, 1999, P SOC EXP BIOL MED, V222, P263, DOI 10.1046/j.1525-1373.1999.d01-143.x; Kang YJ, 2000, J BIOL CHEM, V275, P13690, DOI 10.1074/jbc.275.18.13690; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Misra RR, 1996, CHEM RES TOXICOL, V9, P326, DOI 10.1021/tx950109y; Miura T, 1997, LIFE SCI, V60, P301; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Quesada AR, 1996, ARCH BIOCHEM BIOPHYS, V334, P241, DOI 10.1006/abbi.1996.0452; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; Spector A, 2000, J OCUL PHARMACOL TH, V16, P193, DOI 10.1089/jop.2000.16.193; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Wang GW, 1999, AM J PHYSIOL-HEART C, V276, pH167, DOI 10.1152/ajpheart.1999.276.1.H167; Weinstein DM, 2000, J PHARMACOL EXP THER, V294, P396	26	132	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38957	38960		10.1074/jbc.C000593200	http://dx.doi.org/10.1074/jbc.C000593200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11042194	hybrid			2022-12-25	WOS:000165953100003
J	Conner, EA; Lemmer, ER; Omori, M; Wirth, PJ; Factor, VM; Thorgeirsson, SS				Conner, EA; Lemmer, ER; Omori, M; Wirth, PJ; Factor, VM; Thorgeirsson, SS			Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis	ONCOGENE			English	Article						hepatocellular adenoma; hepatocellular carcinoma; c-myc; p53; mouse	CELL-CYCLE CONTROL; GROWTH-FACTOR-ALPHA; C-MYC; HEPATOCELLULAR-CARCINOMA; S-PHASE; MICE; CANCER; TRANSCRIPTION; EXPRESSION; APOPTOSIS	Deregulation of E2F transcriptional control has been implicated in oncogenic transformation. Consistent with this idea, we recently demonstrated that during hepatocarcinogenesis in c-myc/TGF alpha double transgenic mice, there is increased expression of E2F-1 and E2F-2, as well as induction of putative E2F target genes. Therefore, we generated transgenic mice expressing E2F-1 under the control of the albumin enhancer/promoter to test the hypothesis that E2F family members may contribute to liver tumor development. Overexpression of E2F-1 resulted in mild but persistent increases in cell proliferation and death during postnatal liver growth, and no increases in hepatic regenerative growth in response to partial hepatectomy. Nevertheless, from 2 months postnatally E2F-1 transgenic mice exhibited prominent hepatic histological abnormalities including preneoplastic foci adjacent to portal tracts and pericentral large cell dysplasia. From 6 to 8 months onward, there was an abrupt increase in the number of neoplastic nodules ('adenomas') with 100% incidence by 10 months. Some adenomas shelved evidence of malignant transformation, and two of six mice killed at IZ months showed trabecular hepatocellular carcinoma. Endogenous c-myc was up-regulated in the early stages of E2F-1 hepatocarcinogenesis, whereas p53 was overexpressed in the tumors, suggesting that both E2F-1-mediated proliferation and apoptosis are operative but at different stages of hepatocarcinogenesis. In conclusion, E2F-1 overexpression in the liver causes dysplasia and tumors and suggests a cooperation between E2F-1 and c-myc oncogenes during liver oncogenesis.	NCI, NIH, Expt Carcinogenesis Lab, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, NIH, Expt Carcinogenesis Lab, Div Basic Sci, 37 Convent Dr MSC4255,Bldg 37,Room 3C28, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC005750] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; COHEN C, 1986, CANCER, V57, P1535, DOI 10.1002/1097-0142(19860415)57:8<1535::AID-CNCR2820570816>3.0.CO;2-8; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DEPHINHO RA, 1991, ADV CANCER RES, V57, P1; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Factor VM, 1997, HEPATOLOGY, V26, P1434; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRITH CH, 1979, J ENVIRON PATHOL TOX, V3, P329; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Guy CT, 1996, MOL CELL BIOL, V16, P685; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Higgins GM, 1931, ARCH PATHOL, V12, P186; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; Macleod KF, 1999, J PATHOL, V187, P43, DOI 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO;2-P; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; MURAKAMI H, 1993, CANCER RES, V53, P1719; Nagy P, 1996, HEPATOLOGY, V23, P71, DOI 10.1053/jhep.1996.v23.pm0008550051; NEVINS JR, 1992, SCIENCE, V258, P424; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROUNBEHIER R, 2000, P AM ASSOC CANC RES, V41, P394; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SCHERR C, 1994, CELL, V79, P551; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1	40	122	126	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5054	5062		10.1038/sj.onc.1203885	http://dx.doi.org/10.1038/sj.onc.1203885			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042693				2022-12-25	WOS:000089930100002
J	Georgopoulos, NT; Proffitt, JL; Blair, GE				Georgopoulos, NT; Proffitt, JL; Blair, GE			Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins	ONCOGENE			English	Article						human papillomavirus; E7; MHC class I; TAP1; LMP2; transcriptional repression	CERVICAL CARCINOMAS; DOWN-REGULATION; CELL-LINE; EXPRESSION; TRANSACTIVATION; IDENTIFICATION; NEOPLASIA; ANTIGEN; CANCER; E1A	We have examined the possibility that the E7 proteins of the high-risk human papillomavirus (HPV) type 16 and 18 and the oncogenic adenovirus (Ad) type 12 E1A protein share the ability to down-regulate the expression of components of the antigen processing and presentation pathway, as a common strategy in the evasion of immune surveillance during the induction of cell transformation. Expression of the HPV 18 E7 oncoprotein, like Ad 12 E1A, resulted in repression of the major histocompatibility complex (MHC) class I heavy chain promoter, as well as repression of a bidirectional promoter that regulates expression of the genes encoding the transporter associated with antigen processing subunit 1 (TAP1) and a proteasome subunit, low molecular weight protein 2 (LMP2), HPV 16 E7 also caused a reduction in class I heavy chain promoter activity, however it did not have any significant effect on the activity of the bidirectional promoter. Interestingly, expression of the low-risk I-IPV 6b E7 protein resulted in an increase in MHC class I heavy chain promoter activity, while repressing the TAP1/LMP2 promoter, Interference with the class I pathway could also explain the ability of low-risk HPVs in inducing benign lesions.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Blair, GE (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.		Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795; Georgopoulos, Nik/0000-0002-6330-4947				ACKRILL AM, 1988, ONCOGENE, V3, P483; ARENDS MJ, 1993, HUM PATHOL, V24, P432, DOI 10.1016/0046-8177(93)90093-V; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BARBOSA MS, 1991, J VIROL, V65, P292, DOI 10.1128/JVI.65.1.292-298.1991; Bartholomew Jennifer, 1995, P233, DOI 10.1017/CBO9780511525339.010; Blair GE, 1998, SEMIN VIROL, V8, P387, DOI 10.1006/smvy.1997.0140; Burger RA, 1996, JNCI-J NATL CANCER I, V88, P1361, DOI 10.1093/jnci/88.19.1361; BYRD PJ, 1982, J GEN VIROL, V60, P279, DOI 10.1099/0022-1317-60-2-279; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; CONNOR ME, 1990, INT J CANCER, V46, P1029, DOI 10.1002/ijc.2910460614; COX JT, 1995, BAILLIERE CLIN OB GY, V9, P1, DOI 10.1016/S0950-3552(05)80357-8; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; CROMME FV, 1993, ONCOGENE, V8, P2969; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DERY CV, 1987, ONCOGENE, V2, P15; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HERRMANN CH, 1987, ONCOGENE, V2, P25; KEATING PJ, 1995, BRIT J CANCER, V72, P405, DOI 10.1038/bjc.1995.346; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; Rey O, 2000, J VIROL, V74, P4912, DOI 10.1128/JVI.74.10.4912-4918.2000; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Stern PL, 1996, ADV CANCER RES, V69, P175, DOI 10.1016/S0065-230X(08)60863-5; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; van Endert PM, 1999, CURR OPIN IMMUNOL, V11, P82, DOI 10.1016/S0952-7915(99)80015-6; WILCZYNSKI SP, 1993, HUM PATHOL, V24, P96, DOI 10.1016/0046-8177(93)90068-R; WILCZYNSKI SP, 1988, VIROLOGY, V166, P624, DOI 10.1016/0042-6822(88)90539-9; Williams DB, 1996, TRENDS CELL BIOL, V6, P267, DOI 10.1016/0962-8924(96)10020-9; Zwerschke W, 2000, ADV CANCER RES, V78, P1	40	110	112	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4930	4935		10.1038/sj.onc.1203860	http://dx.doi.org/10.1038/sj.onc.1203860			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039910				2022-12-25	WOS:000089757800015
J	Engels, IH; Stepczynska, A; Stroh, C; Lauber, K; Berg, C; Schwenzer, R; Wajant, H; Janicke, RUU; Porter, AG; Belka, C; Gregor, M; Schulze-Osthoff, K; Wesselborg, S				Engels, IH; Stepczynska, A; Stroh, C; Lauber, K; Berg, C; Schwenzer, R; Wajant, H; Janicke, RUU; Porter, AG; Belka, C; Gregor, M; Schulze-Osthoff, K; Wesselborg, S			Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis	ONCOGENE			English	Article						anticancer drugs; apoptosis; caspase-8; caspase-9; CD95	APO-1/FAS RECEPTOR/LIGAND SYSTEM; CYTOCHROME-C RELEASE; DEATH RECEPTORS; NEUROBLASTOMA-CELLS; MEDIATED APOPTOSIS; LEUKEMIA-CELLS; WILD-TYPE; ACTIVATION; BCL-2; MITOCHONDRIA	Caspase-8 plays an essential role in apoptosis triggered by death receptors, Through the cleavage of Bid, a proapoptotic Bcl-2 member, it further activates the mitochondrial cytochrome c/Apaf-1 pathway. Because caspase-8 can be processed also by anticancer drugs independently of death receptors, we investigated its exact role and order in the caspase cascade. We show that in Jurkat cells either deficient for caspase-8 or overexpressing its inhibitor c-FLIP apoptosis mediated by CD95, but not by anticancer drugs was inhibited. In the absence of active caspase-8, anticancer drugs still induced the processing of caspase-9, -3 and Bid, indicating that Bid cleavage does not require caspase-8, Overexpression of Bcl-x(L) prevented the processing of caspase-8 as well as caspase-9, -6 and Bid in response to drugs, but was less effective in CD95-induced apoptosis, Similar responses were observed by overexpression of a dominant-negative caspase-9 mutant, To further determine the order of caspase-8 activation, we employed MCF7 cells lacking caspase-3, In contrast to caspase-9 that was cleaved in these cells, anticancer drugs induced caspase-8 activation only in caspase-3 transfected MCF7 cells. Thus, our data indicate that, unlike its proximal role in receptor signaling, in the mitochondrial pathway caspase-8 rather functions as an amplifying executioner caspase.	Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Munster, Dept Immunol & Cell Biol, D-4400 Munster, Germany; Univ Stuttgart, Inst Cell Biol & Immunol, D-7000 Stuttgart, Germany; Univ Tubingen, Dept Radiat & Oncol, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen; University of Munster; University of Stuttgart; Eberhard Karls University of Tubingen	Wesselborg, S (corresponding author), Univ Tubingen, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Wajant, Harald/A-3020-2017; Schulze-Osthoff, Klaus/N-9025-2013	Wajant, Harald/0000-0002-2005-3949; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bantel H, 1999, CANCER RES, V59, P2083; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Day CL, 1999, CELL DEATH DIFFER, V6, P1125, DOI 10.1038/sj.cdd.4400584; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014-5793(97)01282-9; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kawahara A, 1998, ONCOGENE, V17, P2549, DOI 10.1038/sj.onc.1202192; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tolomeo M, 1998, CELL DEATH DIFFER, V5, P735, DOI 10.1038/sj.cdd.4400406; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Villunger A, 1997, CANCER RES, V57, P3331; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	58	229	234	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4563	4573		10.1038/sj.onc.1203824	http://dx.doi.org/10.1038/sj.onc.1203824			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030145				2022-12-25	WOS:000089438200002
J	Narvaez, CJ; Welsh, J				Narvaez, CJ; Welsh, J			Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; D ANALOG; BAX; DEATH; BCL-2; ACTIVATION; CLEAVAGE; EB1089	Vitamin D-3 compounds are currently in clinical trials for human breast cancer and offer an alternative approach to anti-hormonal therapies for this disease. 1 alpha ,25-Dihydroxyvitamin D-3 (1 alpha ,25(OH)(2)D-3), the active form of vitamin D-3, induces apoptosis in breast cancer cells and tumors, but the underlying mechanisms are poorly characterized. In these studies, we focused on the role of caspase activation and mitochondrial disruption in 1 alpha ,25(OH)(2)D-3-mediated apoptosis in breast cancer cells (MCF-7) in vitro. The effect of 1 alpha ,25(OH)(2)D-3 on MCF-7 cells was compared with that of tumor necrosis factor alpha, which induces apoptosis via a caspase-dependent pathway. Our major findings are that 1 alpha ,25(OH)(2)D-3 induces apoptosis in MCF-7 cells by disruption of mitochondrial function, which is associated with Bax translocation to mitochondria, cytochrome c release, and production of reactive oxygen species. Moreover, we show that Bax translocation and mitochondrial disruption do not occur after 1 alpha ,25(OH)(2)D-3 treatment of a MCF-7 cell clone selected for resistance to 1 alpha ,25(OH)(2)D-3-mediated apoptosis. These mitochondrial effects of 1 alpha ,25(OH)(2)D-3 do not require caspase activation, since they are not blocked by the cell-permeable caspase inhibitor z-Val-Ala-Asp-fluoromethylketone. Although caspase inhibition blocks 1 alpha ,25(OH)(2)D-3-mediated events downstream of mitochondria such as poly(ADP-ribose) polymerase cleavage, external display of phosphatidylserine, and DNA fragmentation, MCF-7 cells still execute apoptosis in the presence of z-Val-Ala-Asp-fluoromethylketone, indicating that the commitment to 1 alpha ,25(OH)(2)D-3-mediated cell death is caspase-independent.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	University of Notre Dame	Welsh, J (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.				NCI NIH HHS [CA69700] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069700] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fitch ME, 2000, CELL DEATH DIFFER, V7, P338, DOI 10.1038/sj.cdd.4400659; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gulliford T, 1998, BRIT J CANCER, V78, P6, DOI 10.1038/bjc.1998.434; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JAMES SY, 1995, J MOL ENDOCRINOL, V14, P391, DOI 10.1677/jme.0.0140391; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Mathiasen IS, 1999, CANCER RES, V59, P4848; Miyashita T, 1998, CELL DEATH DIFFER, V5, P1034, DOI 10.1038/sj.cdd.4400442; Narvaez CJ, 1996, ENDOCRINOLOGY, V137, P400, DOI 10.1210/en.137.2.400; Narvaez CJ, 1997, ENDOCRINOLOGY, V138, P4690, DOI 10.1210/en.138.11.4690; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; VanWeelden K, 1998, ENDOCRINOLOGY, V139, P2102, DOI 10.1210/en.139.4.2102; Welsh J, 1998, SUB CELL BIOCHEM, V30, P245; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	33	156	156	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9101	9107		10.1074/jbc.M006876200	http://dx.doi.org/10.1074/jbc.M006876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11053435	hybrid			2022-12-25	WOS:000167607700066
J	Li, Y; Baldauf, S; Lim, EK; Bowles, DJ				Li, Y; Baldauf, S; Lim, EK; Bowles, DJ			Phylogenetic analysis of the UDP-glycosyltransferase multigene family of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PROTEINS; ENDOPLASMIC-RETICULUM; PETUNIA-HYBRIDA; BIOCHEMICAL-CHARACTERIZATION; GLUCOSE GLUCOSYLTRANSFERASE; HETEROLOGOUS EXPRESSION; O-GLUCOSYLTRANSFERASE; AMINO-ACID; RAT-LIVER; ZEA-MAYS	A class of UDP-glycosyltransferases (UGTs) defined by the presence of a C-terminal consensus sequence is found throughout the plant and animal kingdoms. Whereas mammalian enzymes use UDP-glucuronic acid, the plant enzymes typically use UDP-glucose in the transfer reactions. A diverse array of aglycones can be glucosylated by these UGTs. In plants, the aglycones include plant hormones, secondary metabolites involved in stress and defense responses, and xenobiotics such as herbicides. Glycosylation is known to regulate many properties of the aglycones such as their bioactivity, their solubility, and their transport properties within the cell and throughout the plant. As a means of providing a framework to start to understand the substrate specificities and structure-function relationships of plant UGTs, we have now applied a molecular phylogenetic analysis to the multigene family of 99 UGT sequences in Arabidopsis. We have determined the overall organization and evolutionary relationships among individual members with a surprisingly high degree of confidence. Through constructing a composite phylogenetic tree that also includes all of the additional plant UGTs with known catalytic activities, we can start to predict both the evolutionary history and substrate specificities of new sequences as they are identified. The tree already suggests that while the activities of some subgroups of the UGT family are highly conserved among different plant species, others subgroups shift substrate specificity with relative ease.	Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK	Bowles, DJ (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5DD, N Yorkshire, England.			Baldauf, Sandra/0000-0003-4485-6671				Bak S, 1998, PLANT MOL BIOL, V38, P725, DOI 10.1023/A:1006064202774; BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; BRUGLIERA F, 1994, PLANT J, V5, P81, DOI 10.1046/j.1365-313X.1994.5010081.x; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; de Wildt SN, 1999, CLIN PHARMACOKINET, V36, P439, DOI 10.2165/00003088-199936060-00005; Edwards R, 2000, TRENDS PLANT SCI, V5, P193, DOI 10.1016/S1360-1385(00)01601-0; FEDOROFF NV, 1984, P NATL ACAD SCI USA, V81, P3829; Ford CM, 1998, J BIOL CHEM, V273, P9224, DOI 10.1074/jbc.273.15.9224; Fraissinet-Tachet L, 1998, FEBS LETT, V437, P319, DOI 10.1016/S0014-5793(98)01257-5; FURTEK D, 1988, PLANT MOL BIOL, V11, P473, DOI 10.1007/BF00039028; Halkier BA, 1999, NATURALLY OCCURRING GLYCOSIDES, P193; Hostel W., 1981, BIOCH PLANTS, V7, P725; HUGHES J, 1994, DNA SEQUENCE, V5, P41, DOI 10.3109/10425179409039703; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Jackson RG, 2001, J BIOL CHEM, V276, P4350, DOI 10.1074/jbc.M006185200; Jones PR, 1999, J BIOL CHEM, V274, P35483, DOI 10.1074/jbc.274.50.35483; KLECZKOWSKI K, 1995, CRIT REV PLANT SCI, V14, P283, DOI 10.1080/07352689509382361; Kranz HD, 1998, PLANT J, V16, P263, DOI 10.1046/j.1365-313x.1998.00278.x; KROON J, 1994, PLANT J, V5, P69, DOI 10.1046/j.1365-313X.1994.5010069.x; Lee H, 1999, J BIOL CHEM, V274, P36637, DOI 10.1074/jbc.274.51.36637; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; MACKENZIE PI, 1984, BIOCHEM BIOPH RES CO, V122, P1441, DOI 10.1016/0006-291X(84)91252-X; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MACKENZIE PI, 1990, FRONTIERS BIOTRANSFO, V2, P211; Martin RC, 1999, P NATL ACAD SCI USA, V96, P284, DOI 10.1073/pnas.96.1.284; Martin RC, 1999, PLANT PHYSIOL, V120, P553, DOI 10.1104/pp.120.2.553; Meech R, 1996, DNA CELL BIOL, V15, P489, DOI 10.1089/dna.1996.15.489; Miller KD, 1999, J BIOL CHEM, V274, P34011, DOI 10.1074/jbc.274.48.34011; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; Moehs CP, 1997, PLANT J, V11, P227, DOI 10.1046/j.1365-313X.1997.11020227.x; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; O'Donnell PJ, 1998, PLANT J, V14, P137, DOI 10.1046/j.1365-313X.1998.00110.x; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PATTHY L, 1991, BIOESSAYS, V13, P187, DOI 10.1002/bies.950130408; Radominska-Pandya A, 1999, DRUG METAB REV, V31, P817, DOI 10.1081/DMR-100101944; ROGERS JH, 1990, FEBS LETT, V268, P339, DOI 10.1016/0014-5793(90)81282-S; Sambrook J., 2002, MOL CLONING LAB MANU; SEMBDNER G, 1994, PLANT MOL BIOL, V26, P1459, DOI 10.1007/BF00016485; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; Tanaka Y, 1996, PLANT CELL PHYSIOL, V37, P711, DOI 10.1093/oxfordjournals.pcp.a029004; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Truesdale M. R., 1996, PLANT PHYSIOL, V112, P446; Vogt T, 1999, PLANT J, V19, P509, DOI 10.1046/j.1365-313X.1999.00540.x; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405; YOKOTA H, 1992, J BIOCHEM, V112, P192, DOI 10.1093/oxfordjournals.jbchem.a123876; 1997, Patent No. 9716559	49	311	483	17	112	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4338	4343		10.1074/jbc.M007447200	http://dx.doi.org/10.1074/jbc.M007447200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042215	hybrid			2022-12-25	WOS:000166921200081
J	Nechiporuk, T; Urness, LD; Keating, MT				Nechiporuk, T; Urness, LD; Keating, MT			ETL, a novel seven-transmembrane receptor that is Developmentally regulated in the heart - ETL is a member of the secretin family and belongs to the epidermal growth factor seven-transmembrane subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GENE-EXPRESSION; POSTNATAL-DEVELOPMENT; EXTRACELLULAR DOMAIN; VENTRICULAR MYOCYTES; LINKED RECEPTORS; DOWN-REGULATION; RAT; ACTIVATION; CALCIUM	Using differential display of rat fetal and postnatal cardiomyocytes, we have identified a novel seven-trans-membrane receptor, ETL. The cDNA-predicted amino acid sequence of ETL indicated that it encodes a 738-aa protein composed of a large extracellular domain with epidermal growth factor (EGF)-like repeats, a seven-transmembrane domain, and a short cytoplasmic tail. ETL belongs to the secretin family of G-protein-coupled peptide hormone receptors and the EGF-TM7 subfamily of receptors. The latter are characterized by a variable number of extracellular EGF and cell surface domains and conserved seven transmembrane-spanning regions. ETL mRNA expression is up-regulated in the adult rat and human heart. In situ hybridization analyses revealed expression in rat cardiomyocytes and abundant expression in vascular and bronchiolar smooth muscle cells. In COS-7 cells transfected with Myc-tagged rat ETL, rat ETL exists as a stable dimer and undergoes endoproteolytic cleavage of the extracellular domain. The proteolytic activity can be abolished by a specific mutation, T455A, in this domain. In transfected mammalian cells, ETL is associated with cell membranes and is also observed in cytoplasmic: vesicles. ETL is the first seven-transmembrane receptor containing EGF-like repeats that is developmentally regulated in the heart.	Univ Utah, Eccles Inst Human Genet, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Inst Human Genet, Dept Internal Med, Div Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Inst Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Keating, MT (corresponding author), Univ Utah, Eccles Inst Human Genet, Dept Human Genet, Salt Lake City, UT 84112 USA.	mkeating@genetics.med.harvard.edu						Abe J, 1999, J BIOL CHEM, V274, P19957, DOI 10.1074/jbc.274.28.19957; ANVERSA P, 1980, CIRC RES, V46, P495, DOI 10.1161/01.RES.46.4.495; Ayad S, 1998, EXTRACELLULAR MATRIX; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; BrayWard P, 1996, GENOMICS, V32, P1, DOI 10.1006/geno.1996.0070; CHENG W, 1995, LAB INVEST, V72, P646; Durocher D, 1998, RECENT PROG HORM RES, V53, P7; ENGELMANN GL, 1993, CARDIOVASC RES, V27, P1598, DOI 10.1093/cvr/27.9.1598; Engelmann GL, 1996, MOL CELL BIOCHEM, V164, P47, DOI 10.1007/BF00408640; Hadjantonakis AK, 1997, GENOMICS, V45, P97, DOI 10.1006/geno.1997.4892; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1998, EUR J IMMUNOL, V28, P1701, DOI 10.1002/(SICI)1521-4141(199805)28:05<1701::AID-IMMU1701>3.0.CO;2-2; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OZEKI Y, 1991, BIOCHEMISTRY-US, V30, P2391, DOI 10.1021/bi00223a014; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; RONDEAU E, 1995, NEPHROLOGIE, V16, P338; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; Sheikh F, 1997, MOL CELL BIOCHEM, V176, P89, DOI 10.1023/A:1006879029333; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; WATSON S, 1994, G PROTEIN LINKED REC, P1; ZAK R, 1984, GROWTH HEART HLTH DI, P140; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261; Zhu XL, 1996, DEV DYNAM, V207, P429, DOI 10.1002/(SICI)1097-0177(199612)207:4<429::AID-AJA7>3.0.CO;2-J	42	82	87	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4150	4157		10.1074/jbc.M004814200	http://dx.doi.org/10.1074/jbc.M004814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050079	hybrid			2022-12-25	WOS:000166921200057
J	Tang, MS; Nazimiec, M; Ye, XC; Iyer, GH; Eveleigh, J; Zheng, Y; Zhou, MJ; Tang, YY				Tang, MS; Nazimiec, M; Ye, XC; Iyer, GH; Eveleigh, J; Zheng, Y; Zhou, MJ; Tang, YY			Two forms of UvrC protein with different double-stranded DNA binding affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; (A)BC EXCINUCLEASE; EXCISION-REPAIR; UVRABC NUCLEASE; ACTIVE-SITE; 5' INCISION; ADDUCTS; GENE; PURIFICATION; REGION	Using phosphocellulose followed by single-stranded DNA-cellulose chromatography for purification of UvrC proteins ii om overproducing cells, we found that UvrC elutes at two peaks: 0.4 m KCl (UvrCI) and 0.6 m KCl (UvrCII). Both forms of UvrC have a major peptide band (>95%) of the same molecular weight and identical N-terminal amino acid sequences, which are consistent with the initiation codon being at the unusual GTG site. Both forms of UvrC are active in incising UV-irradiated, supercoiled phiX-174 replicative form I DNA in the presence of UvrA and UvrB proteins; however, the specific activity of UVrCII is one-fourth that of UvrCI, The molecular weight of UvrCII is four times that of UvrCI on the basis of results of size exclusion chromatography and glutaraldehyde cross-linking reactions, indicating that UvrCH is a tetramer of UvrCI, Functionally, these two forms of UvrC proteins can be distinguished under reaction conditions in which the protein/nucleotide molar ratio is >0.06 by using UV-irradiated, P-32-labeled DNA fragments as substrates; under these conditions UvrCII is inactive in incision, but UvrCI remains active. The activity of UvrCII in incising UV-irradiated, P-32-labeled DNA fragments can be restored by adding unirradiated competitive DNA, and the increased level of incision corresponds to a decreased level of UVrCII binding to the substrate DNA. The sites of incision at the 5' and 3' sides of a W-induced pyrimidine dimer are the same for UvrCI and UvrCII. Nitrocellulose filter binding and gel retardation assays show that UvrCII binds to both UV-irradiated and unirradiated double-stranded DNA with the same affinity (K-a, 9 x 10(8)/m) and in a concentration-dependent manner, whereas UvrCI does not, These two forms of UvrC were also produced by the endogenous uvrC operon, me propose that UvrCII-DNA binding may interfere with Uvr(A)(2)B-DNA damage complex formation. However, because of its low copy number and low binding affinity to DNA, UvrCII may not interfere with UVr(A)(2)B-DNA damage complex formation in vivo, but instead through double-stranded DNA binding UVrCII may become concentrated at genomic: areas and therefore may facilitate nucleotide excision repair.	NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA	New York University	Tang, MS (corresponding author), NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA.	tang@env.med.nyu.edu			NIEHS NIH HHS [ES08389, ES03124] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008389, R01ES003124] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; FORSTER JW, 1988, MOL GEN GENET, V211, P531, DOI 10.1007/BF00425712; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; KATO T, 1972, J BACTERIOL, V112, P1237, DOI 10.1128/JB.112.3.1237-1246.1972; Kowalski JC, 1999, NUCLEIC ACIDS RES, V27, P2115, DOI 10.1093/nar/27.10.2115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6824, DOI 10.1073/pnas.88.15.6824; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mattson DL, 1996, ANAL BIOCHEM, V240, P306, DOI 10.1006/abio.1996.0364; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; Moolenaar GF, 1998, NUCLEIC ACIDS RES, V26, P462, DOI 10.1093/nar/26.2.462; MOOLENAAR GF, 1987, NUCLEIC ACIDS RES, V15, P4273, DOI 10.1093/nar/15.10.4273; PIERCE JR, 1989, BIOCHEMISTRY-US, V28, P5821, DOI 10.1021/bi00440a018; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANCAR GB, 1984, NUCLEIC ACIDS RES, V12, P4593, DOI 10.1093/nar/12.11.4593; SEEBERG E, 1980, J BACTERIOL, V144, P97, DOI 10.1128/JB.144.1.97-104.1980; SELBY CP, 1988, BIOCHEMISTRY-US, V27, P7184, DOI 10.1021/bi00419a004; SHARMA S, 1986, NUCLEIC ACIDS RES, V14, P2301; SHARMA S, 1979, J BACTERIOL, V137, P397, DOI 10.1128/JB.137.1.397-408.1979; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; TANG MS, 1992, BIOCHEMISTRY-US, V31, P8429, DOI 10.1021/bi00151a006; TANG MS, 1982, NATURE, V299, P646, DOI 10.1038/299646a0; TANG MS, 1985, J BACTERIOL, V161, P933, DOI 10.1128/JB.161.3.933-938.1985; TANG MS, 1991, J MOL BIOL, V220, P855, DOI 10.1016/0022-2836(91)90358-D; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; Verhoeven EEA, 2000, J BIOL CHEM, V275, P5120, DOI 10.1074/jbc.275.7.5120; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	37	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3904	3910		10.1074/jbc.M008538200	http://dx.doi.org/10.1074/jbc.M008538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11056168	hybrid			2022-12-25	WOS:000166921200026
J	Traven, A; Wong, JMS; Xu, DM; Sopta, M; Ingles, CJ				Traven, A; Wong, JMS; Xu, DM; Sopta, M; Ingles, CJ			Interorganellar communication - Altered nuclear gene expression profiles in a yeast mitochondrial DNA mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENT STRE; HEAT-SHOCK RESPONSE; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; LARGE SUBUNIT; PROTEIN; TRANSCRIPTION; RIBOSOME; BINDING; COMPLEX	Communication between mitochondria and the nucleus is important for a variety of cellular processes such as carbohydrate and nitrogen metabolism, mating and sporulation, and cell growth and morphogenesis. It has long been known that the functional state of mitochondria can influence nuclear gene expression. For example, in yeast cells lacking the mitochondrial genome, the expression of several nuclear genes, such as CIT2 (citrate synthase), MRP13 (mitochondrial ribosomal protein), and DLD3 (D-lactate dehydrogenase) has been reported to be altered. Here we show by microarray analysis of the genome-wide transcription profile of Saccharomyces ces cerevisiae that yeast petite mutants lacking mitochondrial DNA induce genes coding for mitochondrial proteins, enzymes of the glycolytic pathway and of the citric acid cycle, cell wall components, membrane transporters, and genes normally induced by nutrient deprivation and a variety of stresses. Consistent with the observed induction of genes related to cell stress and those encoding membrane transporters, yeast petite cells showed increased resistance to severe heat shock and exhibited a pleiotropic drug resistance phenotype. The observed changes in nuclear gene expression in cells lacking mitochondrial DNA may have implications for the role of mitochondria in processes such as carcinogenesis and aging.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada; Rudjer Boskovic Inst, Dept Mol Genet, Zagreb, Croatia	University of Toronto; University of Toronto; Rudjer Boskovic Institute	Ingles, CJ (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	cj.ingles@utoronto.ca	Traven, Ana/H-8174-2017	Traven, Ana/0000-0001-6252-3104				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1994, J BIOL CHEM, V269, P2206; Boy-Marcotte E, 1999, MOL MICROBIOL, V33, P274, DOI 10.1046/j.1365-2958.1999.01467.x; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BROWN TA, 1995, J BACTERIOL, V177, P1380, DOI 10.1128/jb.177.5.1380-1382.1995; BUSSEREAU F, 1992, CURR GENET, V21, P325, DOI 10.1007/BF00351690; Cavalli LR, 1998, MUTAT RES-FUND MOL M, V398, P19, DOI 10.1016/S0027-5107(97)00223-6; Chelstowska A, 1999, YEAST, V15, P1377, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1377::AID-YEA473>3.0.CO;2-0; CODON AC, 1995, APPL ENVIRON MICROB, V61, P630; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; DUPONT CH, 1990, CURR GENET, V17, P465, DOI 10.1007/BF00313073; DUPONT CH, 1990, CURR GENET, V17, P507, DOI 10.1007/BF00313079; FARELL LE, 1990, STRUCTURE FUNCTION B, P131; FEARON K, 1988, MOL CELL BIOL, V8, P3636, DOI 10.1128/MCB.8.9.3636; FEARON K, 1992, J BIOL CHEM, V267, P5162; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Guarente L, 2000, GENE DEV, V14, P1021; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Herve M, 2000, EUR J BIOCHEM, V267, P3337, DOI 10.1046/j.1432-1327.2000.01365.x; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KANG W, 1991, J BACTERIOL, V173, P4013, DOI 10.1128/jb.173.13.4013-4020.1991; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kirchman PA, 1999, GENETICS, V152, P179; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; Lindquist S, 1996, P NATL ACAD SCI USA, V93, P5301, DOI 10.1073/pnas.93.11.5301; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; Liu HD, 1996, GENE DEV, V10, P592; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Martinus RD, 1996, EUR J BIOCHEM, V240, P98, DOI 10.1111/j.1432-1033.1996.0098h.x; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; MYERS AM, 1987, J BIOL CHEM, V262, P3388; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; Pan C, 1997, J BIOL CHEM, V272, P8165, DOI 10.1074/jbc.272.13.8165; PAN C, 1995, NUCLEIC ACIDS RES, V23, P3673, DOI 10.1093/nar/23.18.3673; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PARTALEDIS JA, 1988, MOL CELL BIOL, V8, P3647, DOI 10.1128/MCB.8.9.3647; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; Pillay V, 1998, J CELL BIOCHEM, V69, P463, DOI 10.1002/(SICI)1097-4644(19980615)69:4<463::AID-JCB7>3.0.CO;2-L; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; RICKWOOD D, 1988, YEAST PRACTICAL APPR, P185; Rothermel BA, 1997, J BIOL CHEM, V272, P19801, DOI 10.1074/jbc.272.32.19801; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; SHYJAN AW, 1993, CURR BIOL, V3, P398, DOI 10.1016/0960-9822(93)90212-7; Sinclair D, 1998, ANNU REV MICROBIOL, V52, P533, DOI 10.1146/annurev.micro.52.1.533; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; Tadi D, 1999, YEAST, V15, P1733, DOI 10.1002/(SICI)1097-0061(199912)15:16<1733::AID-YEA490>3.0.CO;2-L; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; Treger JM, 1998, J BIOL CHEM, V273, P26875, DOI 10.1074/jbc.273.41.26875; TREININ M, 1993, CURR GENET, V23, P223, DOI 10.1007/BF00351500; VANLOON APGM, 1982, GENE, V20, P323, DOI 10.1016/0378-1119(82)90201-3; WILKIE D, 1983, INT REV CYTOL, P157; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493	76	168	170	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4020	4027		10.1074/jbc.M006807200	http://dx.doi.org/10.1074/jbc.M006807200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11054416	hybrid			2022-12-25	WOS:000166921200041
J	Gille, H; Kowalski, J; Li, B; LeCouter, J; Moffat, B; Zioncheck, TF; Pelletier, N; Ferrara, N				Gille, H; Kowalski, J; Li, B; LeCouter, J; Moffat, B; Zioncheck, TF; Pelletier, N; Ferrara, N			Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) - A reassessment using novel receptor-specific vascular endothelial growth factor mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; NITRIC-OXIDE; TYROSINE KINASE; PHOSPHOINOSITIDE 3-KINASE; PERMEABILITY FACTOR; KDR/FLK-1 RECEPTOR; MAP KINASE; ORF VIRUS; IN-VIVO; BINDING	Endothelial cells express two related vascular endothelial growth factor (VEGF) receptor tyrosine kinases, KDR (kinase-insert domain containing receptor, or VEGFR-2) and Flt-1 (fms-like tyrosine kinase, or VEGFR-1). Although considerable experimental evidence links KDR activation to endothelial cell mitogenesis, there is still significant uncertainty concerning the role of individual VEGF receptors for other biological effects such as vascular permeability, VEGF mutants that bind to either KDR or Fit-1 with high selectivity were used to determine which of the two receptors serves to mediate different VEGF functions. In addition to mediating mitogenic signaling, selective KDR activation was sufficient for the activation of intracellular signaling pathways implicated in cell migration. KDR stimulation caused tyrosine phosphorylation of both phosphatidylinositol 3-kinase and phospholipase C gamma in primary endothelial cells and stimulated cell migration. KDR-selective VEGF was also able to induce angiogenesis in the rat cornea to an extent indistinguishable from wild type VEGF, We also demonstrate that KDR, but not Flt-1, stimulation is responsible for the induction of vascular permeability by VEGF.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Metab & Pharmacokinet, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Ferrara, N (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	nf@gene.com						Borgstrom P, 1996, CANCER RES, V56, P4032; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Fujii E, 1997, N-S ARCH PHARMACOL, V356, P475, DOI 10.1007/PL00005079; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARK JE, 1994, J BIOL CHEM, V269, P25646; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sadick MD, 1999, J PHARMACEUT BIOMED, V19, P883, DOI 10.1016/S0731-7085(98)00144-7; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	50	513	569	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3222	3230		10.1074/jbc.M002016200	http://dx.doi.org/10.1074/jbc.M002016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11058584	hybrid			2022-12-25	WOS:000166784900033
J	Wang, JY; Miller, SJ; Falls, DL				Wang, JY; Miller, SJ; Falls, DL			The N-terminal region of neuregulin isoforms determines the accumulation of cell surface and released neuregulin ectodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR-ALPHA; SCHWANN-CELLS; NEUROMUSCULAR-JUNCTIONS; NEURITE OUTGROWTH; CYTOPLASMIC TAIL; PROTGF-ALPHA; EXPRESSION; MEMBRANE; ARIA	Two neuregulin-1 isoforms highly expressed in the nervous system are the type III neuregulin III-beta 1a and the type I neuregulin I-beta 1a The sequence of these two isoforms differs only in the region that is N-terminal of the bioactive epidermal growth factor-like domain. While the biosynthetic processing of the I-beta 1a isoform has been well characterized, the processing of III-beta 1a has not been reported. In this study, we compared III-beta 1a and I-beta 1a processing. Both III-beta 1a and I-beta 1a were synthesized as transmembrane proproteins that were proteolytically cleaved to produce an N-terminal fragment containing the bioactive epidermal growth factor-like domain. For I-beta 1a, this product was released into the medium. However, for III-beta 1a, this product was a transmembrane protein. In cultures of cells expressing III-beta 1a, the amount of neuregulin at the cell surface was much greater, and the amount in the medium was much less than in cultures expressing I-beta 1a Phorbol eater treatment and truncation of the cytoplasmic tail had markedly different effects on III-beta 1a and I-beta 1a processing. These results demonstrate an important role for the N-terminal region in determining neuregulin biosynthetic processing and show that a major product of III-beta 1a processing is a tethered ligand that may act as a cell surface signaling molecule.	Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Emory University; University System of Ohio; University of Cincinnati	Falls, DL (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.				NIGMS NIH HHS [GM 56337] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM056337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Bermingham-McDonogh O, 1997, MOL CELL NEUROSCI, V10, P184, DOI 10.1006/mcne.1997.0654; BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; BURRY RW, 1993, J NEUROSCI RES, V36, P241, DOI 10.1002/jnr.490360302; Carroll SL, 1997, J NEUROSCI, V17, P1642; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; Han B, 1999, J BIOL CHEM, V274, P26407, DOI 10.1074/jbc.274.37.26407; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Liu XF, 1998, P NATL ACAD SCI USA, V95, P13024, DOI 10.1073/pnas.95.22.13024; Loeb JA, 1998, MOL CELL NEUROSCI, V11, P77, DOI 10.1006/mcne.1998.0676; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; Maurel P, 2000, J NEUROSCI, V20, P4635, DOI 10.1523/JNEUROSCI.20-12-04635.2000; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; Meyer D, 1997, DEVELOPMENT, V124, P3575; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Moore DD, 1995, GLOB MOB SURV; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; Osheroff PL, 1999, GROWTH FACTORS, V16, P241, DOI 10.3109/08977199909002133; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Rimer M, 1998, MOL CELL NEUROSCI, V12, P1, DOI 10.1006/mcne.1998.0695; Rosenbaum C, 1997, EXP NEUROL, V148, P604, DOI 10.1006/exnr.1997.6696; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; Sambrook J., 2002, MOL CLONING LAB MANU; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; Schroering A, 1998, J BIOL CHEM, V273, P30643, DOI 10.1074/jbc.273.46.30643; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Urena JM, 1999, J CELL SCI, V112, P773; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Wolpowitz D, 2000, NEURON, V25, P79, DOI 10.1016/S0896-6273(00)80873-9; WOOD PM, 1975, NATURE, V256, P662, DOI 10.1038/256662a0; Yang JF, 1999, MOL CELL NEUROSCI, V13, P415, DOI 10.1006/mcne.1999.0759; Yang X, 1998, NEURON, V20, P255, DOI 10.1016/S0896-6273(00)80454-7	55	103	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2841	2851		10.1074/jbc.M005700200	http://dx.doi.org/10.1074/jbc.M005700200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042203	hybrid			2022-12-25	WOS:000166784800075
J	Lochowska, A; Iwanicka-Nowicka, R; Plochocka, D; Hryniewicz, MM				Lochowska, A; Iwanicka-Nowicka, R; Plochocka, D; Hryniewicz, MM			Functional dissection of the LysR-type CysB transcriptional regulator - Regions important for DNA binding, inducer response, oligomerization, and positive control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO INTERACTIONS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; MUTATIONAL ANALYSIS; PROMOTER REGIONS; CYSJIH PROMOTER; PLASMID VECTORS; GENE-CLUSTER; PROTEIN; ACTIVATOR	CysB is a tetrameric LysR-type transcriptional regulator that acts as an activator of cys regulon genes and as an autorepressor. Positive control of cys genes requires the presence of the inducer N-acetylserine. Following random and site directed mutagenesis of the cysB gene, 20 CysB variants were isolated. Six single amino acid substitutions within the N terminus of CysB abolished the DNA-binding ability of the protein. Seven mutations in the central region of CysB affected its response to the inducer. Four of these CysB mutants retained repressing activity, but lost their activating function in vivo. Their DNA binding characteristics were consistent with an inability to respond to acetylserine by a qualitative change in the DNA-protein interaction. Three of the single residue substitutions resulted in constitutive activity of CysB. The electrophoretic mobility of the complex formed by one of the CysB(c) variants with the cysP promoter suggested a dimeric state of this protein. Characteristics of six truncated CysB variants lacking 5-30 C-terminal residues indicated the involvement of the C terminus in the DNA binding, oligomerization, and stability of CysB. The single substitution Y27G resulted in the CysB(Pc) variant, able to bind DNA and to respond to the inducer by a qualitative change in the DNA-protein complex, but defective in the positive control of the cysP promoter.	Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Hryniewicz, MM (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Pawinskiego 5A, PL-02106 Warsaw, Poland.	monikah@ibbrain.ibb.waw.pl	Iwanicka-Nowicka, Roksana/M-4910-2019					AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARTOWSKY E, 1991, MOL MICROBIOL, V5, P1715, DOI 10.1111/j.1365-2958.1991.tb01920.x; Cebolla A, 1997, J BIOL CHEM, V272, P3986, DOI 10.1074/jbc.272.7.3986; COLYER TE, 1994, MOL MICROBIOL, V13, P797, DOI 10.1111/j.1365-2958.1994.tb00472.x; Colyer TE, 1996, MOL MICROBIOL, V21, P247, DOI 10.1046/j.1365-2958.1996.6301347.x; FIJALKOWSKA IJ, 1995, J BACTERIOL, V177, P5979, DOI 10.1128/jb.177.20.5979-5986.1995; GIFFARD PM, 1988, MOL GEN GENET, V214, P148, DOI 10.1007/BF00340193; GOETHALS K, 1992, P NATL ACAD SCI USA, V89, P1646, DOI 10.1073/pnas.89.5.1646; Gosink KK, 1996, J BACTERIOL, V178, P5182, DOI 10.1128/jb.178.17.5182-5187.1996; Grob P, 1997, J BACTERIOL, V179, P5398, DOI 10.1128/jb.179.17.5398-5406.1997; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HRYNIEWICZ M, 1988, J GEN MICROBIOL, V134, P763; HRYNIEWICZ MM, 1991, J BACTERIOL, V173, P5876, DOI 10.1128/jb.173.18.5876-5886.1991; HRYNIEWICZ MM, 1994, J BACTERIOL, V176, P3673, DOI 10.1128/JB.176.12.3673-3682.1994; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; IWANICKANOWICKA R, 1995, GENE, V166, P11, DOI 10.1016/0378-1119(95)00606-8; JAGURA-BURDZY G, 1981, J BACTERIOL, V147, P744, DOI 10.1128/JB.147.3.744-751.1981; Jorgensen C, 1999, J BACTERIOL, V181, P4397; Jourdan AD, 1998, J BACTERIOL, V180, P4865, DOI 10.1128/JB.180.18.4865-4871.1998; KREDICH NM, 1992, MOL MICROBIOL, V6, P2747, DOI 10.1111/j.1365-2958.1992.tb01453.x; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P514; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MILLER BE, 1987, J BIOL CHEM, V262, P6006; MILLER JH, 1992, SHORT COURSE BACTERI, P268; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; MONROE RS, 1990, J BACTERIOL, V172, P6919, DOI 10.1128/jb.172.12.6919-6929.1990; Muse WB, 1999, J BACTERIOL, V181, P934, DOI 10.1128/JB.181.3.934-940.1999; OSTROWSKI J, 1990, J BACTERIOL, V172, P779, DOI 10.1128/jb.172.2.779-785.1990; OSTROWSKI J, 1987, J BIOL CHEM, V262, P5999; OSTROWSKI J, 1991, J BACTERIOL, V173, P2212, DOI 10.1128/JB.173.7.2212-2218.1991; PEREZRUEDA E, 2000, NUCLEIC ACIDS RES, V285, P1838; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SCHELL MA, 1990, J BIOL CHEM, V265, P3844; SHAMAH SM, 1995, METHOD ENZYMOL, V254, P565; SIKORSKI R S, 1991, P302; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Tyrrell R, 1997, STRUCTURE, V5, P1017, DOI 10.1016/S0969-2126(97)00254-2; van der Ploeg JR, 1999, J BIOL CHEM, V274, P29358, DOI 10.1074/jbc.274.41.29358; vanderPloeg JR, 1996, J BACTERIOL, V178, P5438, DOI 10.1128/jb.178.18.5438-5446.1996; vanderPloeg JR, 1997, J BACTERIOL, V179, P7671, DOI 10.1128/jb.179.24.7671-7678.1997; Whipple FW, 1997, J MOL BIOL, V265, P261, DOI 10.1006/jmbi.1996.0735	45	80	86	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2098	2107		10.1074/jbc.M007192200	http://dx.doi.org/10.1074/jbc.M007192200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038360	hybrid			2022-12-25	WOS:000166528000062
J	Kapur, R; Zhang, L				Kapur, R; Zhang, L			A novel mechanism of cooperation between c-Kit and erythropoietin receptor - Stem cell factor induces the expression of Stat5 and erythropoietin receptor, resulting in efficient proliferation and survival by erythropoietin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; ERYTHROID-DIFFERENTIATION; SEQUENCE SIMILARITY; HEMATOPOIETIC-CELLS; S-PHASE; GENE; TRANSCRIPTION; APOPTOSIS; GATA-1; DEATH	Optimal production of red cells in vivo requires collaboration between c-Kit, erythropoietin receptor (Epo-R), and GATA-1. However, the mechanism(s) of collaboration remain unclear. Utilizing an embryonic stem cell-derived erythroid progenitor cell line from mice deficient in GATA-1, we have examined the role of c-Kit and Epo-R in erythroid cell proliferation, survival, and differentiation. In the absence of GATA-1, we demonstrate an essential role for c-Kit in survival and proliferation of erythroid progenitors via the regulation of Bcl-2 expression. In addition, we demonstrate that Epo-R and Stat5 are regulated by a second, novel mechanism. We demonstrate that c-Kit stimulation by stem cell factor is essential for the maintenance of Epo-R and Stat5 protein expression, which results in significantly enhanced Bcl-x(L) induction and survival of erythroid progenitors in response to Epo stimulation Restoration of GATA-1 function results in terminal erythroid maturation and up-regulation of Epo-R and Bcl-K, expression, leading also to significantly enhanced survival of terminally differentiating erythroid progenitors in the presence of only Epo, These results demonstrate that c-Kit and Epo-R have unique role(s) during distinct phases of erythroid maturation, and both stem cell factor and Epo contribute to the regulation of the Epo-R-Stat5-Bcl-x(L) pathway to ensure optimal survival, proliferation, and differentiation of erythroid progenitors.	Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Dept Pediat,Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Kapur, R (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Inst Canc Res, 1044 W Walnut St,Rm 425, Indianapolis, IN 46202 USA.	rkapur@iupui.edu						Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; Kapur R, 1998, BLOOD, V91, P879, DOI 10.1182/blood.V91.3.879.879_879_889; Kapur R, 1999, BLOOD, V94, P1915; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KELLEY LL, 1993, BLOOD, V82, P2340; KOURY MJ, 1994, ANN NY ACAD SCI, V718, P259; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LANDSCHULZ KT, 1992, BLOOD, V79, P2749; LIN EY, 1993, J IMMUNOL, V151, P1979; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sato T, 1998, J BIOL CHEM, V273, P16921, DOI 10.1074/jbc.273.27.16921; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; SPIVAK JL, 1991, BLOOD, V77, P1228; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YU H, 1993, BLOOD, V81, P373; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	41	60	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1099	1106		10.1074/jbc.M007442200	http://dx.doi.org/10.1074/jbc.M007442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042182	hybrid			2022-12-25	WOS:000166430900034
J	Wei, HJ; Ashby, DG; Moreno, CS; Ogris, E; Yeong, FM; Corbett, AH; Pallas, DC				Wei, HJ; Ashby, DG; Moreno, CS; Ogris, E; Yeong, FM; Corbett, AH; Pallas, DC			Carboxymethylation of the PP2A catalytic subunit in Saccharomyces cerevisiae is required for efficient interaction with the B-type subunits CDC55p and RTS1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; SMALL-T ANTIGEN; REGULATORY SUBUNIT; TYROSINE PHOSPHORYLATION; OKADAIC ACID; BOVINE BRAIN; CELL-GROWTH; MIDDLE-T; YEAST; FORMS	Protein phosphatase 2A (PP2A) is an essential eukaryotic serine/threonine phosphatase known to play important roles in cell cycle regulation. Association of different B-type targeting subunits with the heterodimeric core (A/C) enzyme is known to be an important mechanism of regulating PP2A activity, substrate specificity, and localization. However, how the binding of these targeting subunits to the A/C heterodimer might be regulated is unknown. We have used the budding yeast Saccharomyces cerevisiae as a model system to investigate the hypothesis that covalent modification of the C subunit (Pph21p/Pph22p) carboxyl terminus modulates PP2A complex formation. Two approaches were taken. First, S, cerevisiae cells were generated whose survival depended on the expression of different carboxyl-terminal Pph21p mutants. Second, the major S, cerevisiae methyltransferase (Ppm1p) that catalyzes the methylation of the PH)2A C subunit carboxyl-terminal leucine was identified, and cells deleted for this methyltransferase were utilized for our studies. Our results demonstrate that binding of the yeast B subunit, Cdc55p, to Pph21p was disrupted by either acidic substitution of potential carboxyl-terminal phosphorylation sites on Pph21p or by deletion of the gene for Ppm1p, Loss of Cdc55p association was accompanied in each case by a large reduction in binding of the yeast A subunit, Tpd3p, to Pph21p, Moreover, decreased Cdc55p and Tpd3p binding invariably resulted in nocodazole sensitivity, a known phenotype of CDC55 or TPD3 deletion. Furthermore, loss of methylation also greatly reduced the association of another yeast B-type subunit, Rts1p, Thus, methylation of Pph21p is important for formation of PPSA trimeric and dimeric complexes, and consequently, for PP2A function. Taken together, our results indicate that methylation and phosphorylation may be mechanisms by which the cell dynamically regulates PP2A complex formation and function.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Univ Vienna, Inst Mol Biol, Vienna Bioctr, A-1030 Vienna, Austria	Emory University; Emory University; University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Pallas, DC (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.		yeong, foong m/J-7832-2012; Corbett, Anita/AAH-6106-2021; Moreno, Carlos S/B-3863-2009	yeong, foong m/0000-0002-5641-6588; Corbett, Anita/0000-0002-0461-6895; Moreno, Carlos S/0000-0002-5582-0028; Ogris, Egon/0000-0001-5950-9264	NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NCI NIH HHS [CA57327, R01 CA057327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams A, 1997, METHODS YEAST GENETI; Ayyavoo V, 1997, J LEUKOCYTE BIOL, V62, P93, DOI 10.1002/jlb.62.1.93; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CAYLA X, 1993, EUR J BIOCHEM, V214, P281, DOI 10.1111/j.1432-1033.1993.tb17922.x; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CLOTET J, 1995, EUR J BIOCHEM, V229, P207, DOI 10.1111/j.1432-1033.1995.tb20457.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; De Baere I, 1999, BIOCHEMISTRY-US, V38, P16539, DOI 10.1021/bi991646a; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HOPKIN K, 1995, J NIH RES, V7, P27; Hrimech M, 2000, EMBO J, V19, P3956, DOI 10.1093/emboj/19.15.3956; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kowluru A, 1996, ENDOCRINOLOGY, V137, P2315, DOI 10.1210/en.137.6.2315; LEE J, 1993, J BIOL CHEM, V268, P19192; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; LI M, 1994, BIOCHEM BIOPH RES CO, V202, P1023, DOI 10.1006/bbrc.1994.2031; Masuda M, 2000, J VIROL, V74, P2636, DOI 10.1128/JVI.74.6.2636-2646.2000; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SHU YM, 1995, MOL CELL BIOL, V15, P5618; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; SIKORSKI RS, 1989, GENETICS, V122, P19; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; USUI H, 1988, J BIOL CHEM, V263, P3752; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; WANG Y, 1997, MOL CELL BIOL, V17, P6220; XIE HY, 1994, J BIOL CHEM, V269, P1981; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	46	97	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1570	1577		10.1074/jbc.M008694200	http://dx.doi.org/10.1074/jbc.M008694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038366	Green Accepted, hybrid			2022-12-25	WOS:000166430900095
J	Zhang, YJ; Kornfeld, H; Cruikshank, WW; Kim, S; Reardon, CC; Center, DM				Zhang, YJ; Kornfeld, H; Cruikshank, WW; Kim, S; Reardon, CC; Center, DM			Nuclear Translocation of the N-terminal prodomain of interleukin-16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ-DOMAIN; PROTEIN-INTERACTION; IL-16; EXPRESSION; LOCALIZATION; LIM-KINASE-1; SEQUENCE; KINASES; FAMILY; CELLS	Interleukin-18 (IL-16) is a pleiotropic cytokine that functions as a chemoattractant factor, a modulator of T cell activation, and an inhibitor of human immunodeficiency virus (HIV) replication. These diverse functions are exclusively attributed to the secreted C-terminal peptide of 121 amino acids (mature IL 16), which is cleaved from the precursor protein (pro-IL-16) by caspase-3, Human pro-IL-16 is comprised of 631 amino acids with three PDZ domains, one of which is present in secreted mature IL-16, No cellular localization or biologic functions have been ascribed to the unusually large and highly conserved N-terminal prodomain formed as a result of proteolytic release of the third PDZ domain of pro-IL-16, Here we show that the N-terminal prodomain of pro-IL-16 translocates into the nucleus following cleavage of the C-terminal segment. The nuclear localization signal of pro-IL-16 consists of a classical bipartite nuclear targeting motif, We also show that the nuclear targeting of the IL-16 prodomain induces a G(0)/G(1) arrest in the cell cycle. Taken together, the high degree of conservation of the prodomain among species, the presence of two PDZ motifs, and the nuclear localization and subsequent inhibitory effect on cell cycle progression suggest that pro-IL-16 is cleaved into two functional proteins, a C-terminal-secreted cytokine and an N-terminal product, which affects the cell. cycle.	Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA	Boston University	Zhang, YJ (corresponding author), Boston Univ, Sch Med, Ctr Pulm, R-304,80 E Concord St, Boston, MA 02118 USA.		Kornfeld, Hardy/AAS-2903-2021	Center, David/0000-0002-5879-7978; Reardon, Christine/0000-0002-3709-8342	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032802] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32802] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baier M, 1997, P NATL ACAD SCI USA, V94, P5273, DOI 10.1073/pnas.94.10.5273; BALER M, 1995, NATURE, V378, P563; CENTER DM, 1982, J IMMUNOL, V128, P2562; CRUIKSHANK W, 1982, J IMMUNOL, V128, P2569; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P47; Keane J, 1998, J IMMUNOL, V160, P5945; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Maciaszek JW, 1997, J IMMUNOL, V158, P5; Osada H, 1996, BIOCHEM BIOPH RES CO, V229, P582, DOI 10.1006/bbrc.1996.1847; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Stevenson FT, 1997, P NATL ACAD SCI USA, V94, P508, DOI 10.1073/pnas.94.2.508; Theodore AC, 1996, J IMMUNOL, V157, P1958; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144; Zhou P, 1997, NAT MED, V3, P659, DOI 10.1038/nm0697-659	22	46	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1299	1303		10.1074/jbc.M008513200	http://dx.doi.org/10.1074/jbc.M008513200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032842	hybrid			2022-12-25	WOS:000166430900060
J	Zhang, YQ; Yin, LY; Hillgartner, FB				Zhang, YQ; Yin, LY; Hillgartner, FB			Thyroid hormone stimulates acetyl-CoA carboxylase-alpha transcription in hepatocytes by modulating the composition of nuclear receptor complexes bound to a thyroid hormone response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; CHICKEN MALIC ENZYME; GENE-EXPRESSION; MESSENGER-RNA; IN-VIVO; ACID; ACTIVATION; LXR; COACTIVATOR; PROMOTER	Triiodothyronine (T3) stimulates a 7-fold increase in transcription of the acetyl-CoA carboxylase-alpha (ACC alpha) gene in chick embryo hepatocytes, Here, we characterized an ACC alpha T3 response element (ACC alpha -T3RE) with unique functional and protein binding properties. ACCa-T3RE activated transcription both in the absence and presence of T3, with a greater activation observed in the presence of T3. In nuclear extracts from hepatocytes incubated in the absence of T3, ACC alpha -T3RE bound protein complexes (complexes 1 and 2) containing the liver X receptor (LXR) and the retinoid X receptor (RXR). In nuclear extracts from hepatocytes incubated in the presence of T3 for 24 h, ACC alpha -T3RE bound a different set of complexes. One complex contained LXR and RXR (complex 3) and another contained the nuclear T3 receptor (TR) and RXR (complex 4). Mutations of ACC alpha -T3RE that inhibited the binding of complexes 1 and 2 decreased transcriptional activation in the absence of T3, and mutations of ACC alpha -T3RE that inhibited the binding of complexes 3 and 4 decreased transcriptional activation in the presence of T3. The stimulation of ACC alpha transcription caused by T3 was closely associated with changes in the binding of complexes 1-4 to ACC alpha -T3RE, These data suggest that T3 regulates ACC alpha transcription by a novel mechanism involving changes in the composition of nuclear receptor complexes bound to ACC alpha -T3RE. We propose that complexes containing LXR/RXR ensure a basal level of ACC alpha expression for the synthesis of structural lipids in cell membranes and that complexes containing LXR/RXR and TR/RXR mediate the stimulation of ACC alpha expression caused by T3.	W Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA	West Virginia University	Hillgartner, FB (corresponding author), W Virginia Univ, Sch Med, Dept Biochem, POB 9142, Morgantown, WV 26506 USA.	fbhillgartner@hsc.wvu.edu						Anderson GW, 1998, J BIOL CHEM, V273, P16391, DOI 10.1074/jbc.273.26.16391; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; BAILLIE RA, 1993, J NUTR BIOCHEM, V4, P431, DOI 10.1016/0955-2863(93)90074-7; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Costet P, 2000, J BIOL CHEM, V275, P28240; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESVERGNE B, 1994, MOL CELL ENDOCRINOL, V100, P125, DOI 10.1016/0303-7207(94)90291-7; Desvergne B, 1997, NUCLEIC ACIDS RES, V25, P1774, DOI 10.1093/nar/25.9.1774; ElKhadirMounier C, 1996, BIOCHEM J, V314, P613; Fang XX, 2000, MOL CELL ENDOCRINOL, V164, P41, DOI 10.1016/S0303-7207(00)00238-0; FISCHER PWF, 1978, ARCH BIOCHEM BIOPHYS, V190, P332, DOI 10.1016/0003-9861(78)90283-7; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Glass CK, 2000, GENE DEV, V14, P121; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1924; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; Harbers M, 1996, NUCLEIC ACIDS RES, V24, P2252, DOI 10.1093/nar/24.12.2252; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HILLGARTNER FB, 1992, J BIOL CHEM, V267, P12299; Hillgartner FB, 1996, BIOCHEM J, V319, P263, DOI 10.1042/bj3190263; Hillgartner FB, 1997, ARCH BIOCHEM BIOPHYS, V337, P159, DOI 10.1006/abbi.1996.9776; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; Kim TS, 1996, J NUTR, V126, P611, DOI 10.1093/jn/126.3.611; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1994, J BIOL CHEM, V269, P31436; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; LOPEZCASILLAS F, 1992, METABOLISM, V41, P201, DOI 10.1016/0026-0495(92)90154-3; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Moore DD, 1995, GLOB MOB SURV; Olson DP, 1998, J BIOL CHEM, V273, P3375, DOI 10.1074/jbc.273.6.3375; ONATE SA, 1995, SCIENCE, V270, P1354; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Takeshita A, 1998, J BIOL CHEM, V273, P21554, DOI 10.1074/jbc.273.34.21554; Taylor AH, 1996, BIOCHEMISTRY-US, V35, P8281, DOI 10.1021/bi960269o; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Thurmond DC, 1998, J BIOL CHEM, V273, P1613, DOI 10.1074/jbc.273.3.1613; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	63	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					974	983		10.1074/jbc.M005894200	http://dx.doi.org/10.1074/jbc.M005894200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11027684	Green Published, hybrid			2022-12-25	WOS:000166430900017
J	Basar, T; Havlicek, V; Bezouskova, S; Hackett, M; Sebo, P				Basar, T; Havlicek, V; Bezouskova, S; Hackett, M; Sebo, P			Acylation of lysine 983 is sufficient for toxin activity of Bordetella pertussis adenylate cyclase - Substitutions of alanine 140 modulate acylation site selectivity of the toxin acyltransferase CyaC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL PROTEIN ACYLTRANSFERASE; ESCHERICHIA-COLI HEMOLYSIN; CELL-INVASIVE ACTIVITY; FATTY-ACYLATION; DIRECTED MUTAGENESIS; ENZYMATIC-ACTIVITY; IN-VIVO; CHEMICAL MODIFICATION; ACTIVATION; HLYC	The capacity of adenylate cyclase toxin (ACT) to penetrate into target cells depends on post-translational fatty-acylation by the acyltransferase CyaC, which can palmitoylate the conserved lysines 983 and 860 of ACT. Here, the in vivo acylating capacity of a set of mutated CyaC acyltransferases was characterized by two-dimensional gel electrophoresis and mass spectrometric analyses of the ACT product. Substitutions of the potentially catalytic serine 20 and histidine 33 residues ablated acylating activity of CyaC, Conservative replacements of alanine 140 by glycine (A140G) and valine (A140V) residues, however, affected selectivity of CyaC for the two acylation sites on ACT. Activation by the A140G variant of CyaC generated a mixture of bi- and monoacylated ACT molecules, modified either at both Lys-860 and Lys-983, or only at Lys-860, respectively. In contrast, the A140V CyaC produced a nearly 1:1 mixture of nonacylated pro-ACT with ACT monoacylated almost exclusively at Lys-983, The respective proportion of toxin molecules acylated at Lye-983 correlated well with the cell-invasive activity of both ACT mixtures, which was about half of that of ACT fully acylated on Lys-983 by intact CyaC, These results show that acylation of Lys-860 alone does not confer cell-invasive activity on ACT, whereas acylation of Lys-983 is necessary and sufficient.	CAS, Inst Microbiol, CZ-14220 Prague 4, Czech Republic; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Washington; University of Washington Seattle	Sebo, P (corresponding author), CAS, Inst Microbiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.		SEBO, Peter/F-7423-2011; SEBO, Peter/N-2043-2019; Havlicek, Vladimir/H-2626-2014; Basar, Tamer/V-6613-2019	SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; Havlicek, Vladimir/0000-0002-8614-7059; 	NCRR NIH HHS [S10 RR12939-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012939] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1995, INFECT IMMUN, V63, P3309, DOI 10.1128/IAI.63.9.3309-3315.1995; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; Dadaglio G, 2000, INFECT IMMUN, V68, P3867, DOI 10.1128/IAI.68.7.3867-3872.2000; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; Fayolle C, 1996, J IMMUNOL, V156, P4697; Fayolle C, 1999, J IMMUNOL, V162, P4157; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; Gueirard P, 1998, INFECT IMMUN, V66, P1718, DOI 10.1128/IAI.66.4.1718-1725.1998; GuzmanVerri C, 1997, J BACTERIOL, V179, P5959, DOI 10.1128/jb.179.18.5959-5962.1997; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HAVLICEK V, 2001, IN PRESS J MASS SPEC, V36; HEWLETT EL, 1984, ANN INTERN MED, V101, P5526; Hormozi K, 1999, Dev Biol Stand, V101, P147; Hormozi K, 1999, FEMS IMMUNOL MED MIC, V23, P273, DOI 10.1016/S0928-8244(98)00146-1; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; KHELEF N, 1992, MICROB PATHOGENESIS, V12, P227, DOI 10.1016/0882-4010(92)90057-U; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; LEPAGE G, 1986, J LIPID RES, V27, P114; Lim KB, 2000, J BIOL CHEM, V275, P36698, DOI 10.1074/jbc.C000544200; Ludwig A, 1996, J BACTERIOL, V178, P5422, DOI 10.1128/jb.178.18.5422-5430.1996; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; Saron MF, 1997, P NATL ACAD SCI USA, V94, P3314, DOI 10.1073/pnas.94.7.3314; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Stanley P, 1999, MOL MICROBIOL, V34, P887, DOI 10.1046/j.1365-2958.1999.01648.x; SZABO G, 1994, J BIOL CHEM, V269, P22496; Trent MS, 1999, BIOCHEMISTRY-US, V38, P9541, DOI 10.1021/bi9905617; Trent MS, 1999, BIOCHEMISTRY-US, V38, P3433, DOI 10.1021/bi982491u; Trent MS, 1998, BIOCHEMISTRY-US, V37, P4644, DOI 10.1021/bi971588y; Trent MS, 1999, BIOCHEMISTRY-US, V38, P8831, DOI 10.1021/bi990138y; Wang HL, 1997, ANAL BIOCHEM, V250, P162, DOI 10.1006/abio.1997.2214; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	46	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					348	354		10.1074/jbc.M006463200	http://dx.doi.org/10.1074/jbc.M006463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031260	hybrid			2022-12-25	WOS:000166280700048
J	Ellsworth, D; Finnen, RL; Flint, SJ				Ellsworth, D; Finnen, RL; Flint, SJ			Superimposed promoter sequences of the adenoviral E2 early RNA polymerase III and RNA polymerase II transcription units	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 FUNCTIONAL COMPONENTS; C-MYC GENE; CONTROL REGIONS; VAI RNA; ELEMENTS; CELLS; E1A; TRANSACTIVATION; REQUIREMENTS; TRANSLATION	The human adenovirus type 2 E2 early (E2E) transcriptional control region contains an efficient RNA polymerase III promoter, in addition to the well characterized promoter for RNA polymerase II. To determine whether this promoter includes intragenic sequences, we examined the effects of precise substitutions introduced between positions +2 and +62 on E2E transcription in an RNA polymerase III-specific, in vitro system. Two noncontiguous sequences within this region were necessary for efficient or accurate transcription by this enzyme. The sequence and properties of the functional element proximal to the sites of initiation identified it as an A box. Although a B box sequence could not be unambiguously located, substitutions between positions +42 and +62 that severely impaired transcription also inhibited binding of the human general initiation protein TFIIIC, Thus, this region of the RNA polymerase III E2E promoter contains a B box sequence. We also identified previously unrecognized intragenic sequences of the E2E RNA polymerase II promoter. In conjunction with our previous observations, these data establish that RNA polymerase II and RNA polymerase III promoter sequences are superimposed from approximately positions -30 to +20 of the complex E2E transcriptional control region. The alterations in transcription induced by certain mutations suggest that components of the RNA polymerase II and RNA polymerase III transcriptional machines compete for access to overlapping binding sites in the E2E template.	Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA	Princeton University	Flint, SJ (corresponding author), Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA.	sjflint@molbio.princeton.edu						BAKER CC, 1979, COLD SPRING HARB SYM, V44, P415, DOI 10.1101/SQB.1980.044.01.045; BENTLEY DL, 1989, GENE DEV, V3, P1179, DOI 10.1101/gad.3.8.1179; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BHAT RA, 1984, NUCLEIC ACIDS RES, V12, P7377, DOI 10.1093/nar/12.19.7377; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; CANNON RE, 1986, P NATL ACAD SCI USA, V83, P1285, DOI 10.1073/pnas.83.5.1285; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CHEN HJ, 1992, J BIOL CHEM, V267, P25457; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; FLINT SJ, 1986, ADV VIRUS RES, V31, P169, DOI 10.1016/S0065-3527(08)60264-X; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Gunnery S, 1999, J MOL BIOL, V286, P745, DOI 10.1006/jmbi.1998.2518; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; HOWE JG, 1988, J VIROL, V62, P2790, DOI 10.1128/JVI.62.8.2790-2798.1988; HOWE JG, 1993, MOL CELL BIOL, V13, P2655, DOI 10.1128/MCB.13.5.2655; HUANG WL, 1994, P NATL ACAD SCI USA, V91, P1265, DOI 10.1073/pnas.91.4.1265; HULL MW, 1994, MOL CELL BIOL, V14, P1266, DOI 10.1128/MCB.14.2.1266; KASAI Y, 1992, MOL CELL BIOL, V12, P2884, DOI 10.1128/MCB.12.6.2884; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; LEONG K, 1984, J BIOL CHEM, V259, P1527; MANOHAR CF, 1990, J VIROL, V64, P2457, DOI 10.1128/JVI.64.6.2457-2466.1990; MARTINEZ E, 1994, J BIOL CHEM, V269, P25692; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MATHEWS MB, 1996, TRANSLATIONAL CONTRO, P505; PRUZAN R, 1992, NUCLEIC ACIDS RES, V20, P5705, DOI 10.1093/nar/20.21.5705; RAILEY JF, 1988, MOL CELL BIOL, V8, P1147, DOI 10.1128/MCB.8.3.1147; Roeder R.G., 1976, RNA POLYMERASE, P285; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; Shenk T, 1981, Curr Top Microbiol Immunol, V93, P25; SHENK T, 1991, ADV CANCER RES, V57, P47; SHENK T, 1996, VIROLOGY, P2111; SODERLUND H, 1976, CELL, V7, P585, DOI 10.1016/0092-8674(76)90209-9; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; STEINBERG TH, 1992, J BIOL CHEM, V267, P20204; SUSSMAN DJ, 1991, NUCLEIC ACIDS RES, V19, P5045, DOI 10.1093/nar/19.18.5045; Swaminathan S, 1996, J MOL BIOL, V258, P736, DOI 10.1006/jmbi.1996.0283; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; TRIBOULEY C, 1994, J VIROL, V68, P4450, DOI 10.1128/JVI.68.7.4450-4457.1994; Wang ZX, 1996, MOL CELL BIOL, V16, P6841; Wang ZX, 1997, GENE DEV, V11, P2371, DOI 10.1101/gad.11.18.2371; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585	56	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					827	834		10.1074/jbc.M007036200	http://dx.doi.org/10.1074/jbc.M007036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031267	hybrid			2022-12-25	WOS:000166280700111
J	Datta, R; Yoshinaga, K; Kaneki, M; Pandey, P; Kufe, D				Datta, R; Yoshinaga, K; Kaneki, M; Pandey, P; Kufe, D			Phorbol ester-induced generation of reactive oxygen species is protein kinase C beta-dependent and required for SAPK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; HUMAN-IMMUNODEFICIENCY-VIRUS; LEUKEMIA-CELL-LINE; MONOCYTIC DIFFERENTIATION; MACROPHAGE DIFFERENTIATION; JUN KINASES; EXPRESSION; STRESS; TRANSCRIPTION; PROLIFERATION	Treatment of human U-937 myeloid leukemia cells with 12 O-tetradecanoylphorbol-13-acetate (TPA) is associated with protein kinase C (PKC) beta II-mediated activation of the stress-activated protein kinase (SAPK) pathway. The present studies demonstrate that the TPA response of U-937 cells includes the generation of reactive oxygen species (ROS), By contrast, the TPA-resistant U-937 cell variant (TUR), which is deficient in PKC beta II expression, failed to respond to TPA with the induction of ROS. Moreover, we show that TPA-induced ROS production is restored in TUR cells stably transfected to express PKC beta II, The results also demonstrate that TPA-induced ROS production is required for activation of the MEK kinase-1 (MEKI-1)--> SAPK pathway. In concert with this observation, treatment of U-937 with H2O2 as a source of ROS is associated with activation of the MEKK-1-->SAPK cascade. These findings indicate that PKC beta II is required for TPA-induced ROS production and that the MEKK-1-->SAPK pathway is activated by a ROS-mediated mechanism.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Datta, R (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.				NCI NIH HHS [CA42802] Funding Source: Medline; NIGMS NIH HHS [GM58200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLLINS SJ, 1987, BLOOD, V70, P1233; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Kaneki M, 1999, MOL CELL BIOL, V19, P461; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P221; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NISHIKAWA M, 1990, CANCER RES, V50, P621; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; Pongracz J, 1996, LEUKEMIA RES, V20, P319, DOI 10.1016/0145-2126(95)00074-7; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; YANG KD, 1994, BLOOD, V83, P490	31	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41000	41003		10.1074/jbc.M009322200	http://dx.doi.org/10.1074/jbc.M009322200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11042219	hybrid			2022-12-25	WOS:000166114600047
J	Pettersson, K; Delaunay, F; Gustafsson, JA				Pettersson, K; Delaunay, F; Gustafsson, JA			Estrogen receptor beta acts as a dominant regulator of estrogen signaling	ONCOGENE			English	Article						ER alpha; ER beta; heterodimerization; agonists; antagonists	NUCLEAR HORMONE RECEPTORS; MESSENGER-RNA EXPRESSION; BREAST-CANCER; PROMOTER-CONTEXT; ER-BETA; GLUCOCORTICOID RECEPTOR; CELL-TYPE; ALPHA; TRANSCRIPTION; HETERODIMERS	The physiological effects of estrogens are mediated by two intracellular transcription factors, the estrogen receptors (ERs), that regulate transcription of target genes through binding to specific DNA target sequences. Here we describe alterations in cellular responses to different ER agonists and to the anti-estrogenic compound tamoxifen resulting from co-expression of the two ERs in transient co-transfection experiments. Our results demonstrate that ER beta can act as a negative or positive dominant regulator of ER activity. This is manifested through reduced transcriptional activity at low concentrations of estradiol (E-2); increased antagonistic effects of tamoxifen on E-2 stimulated activity; and enhanced agonistic action of the phytoestrogenic compound genistein, Furthermore, using chimeric proteins lacking the N-terminal activation function 1 (AF-1), we show that the differential responses of ER alpha and ER beta to different agonists and antagonists are primarily dictated by inherent differences in the C-terminal ligand-binding domains of the receptors, whereas the magnitude of transcriptional activity is influenced by ER alpha AF-1, but not ER beta AF-1, The ER alpha AF-1 activity appears to be modulated upon co-expression of both ERs, The alterations in transcriptional activity resulting from co-expression of ER alpha and ER beta are probably due to the formation of alpha/beta heterodimeric complexes, This study demonstrates that co-localization and subsequent heterodimerization of ER alpha and ER beta may result in receptor activity distinct from that of ER homodimers.	Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet	Pettersson, K (corresponding author), Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden.			Delaunay, Franck/0000-0003-4927-1701				Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; Beato M, 1996, ANN NY ACAD SCI, V784, P93, DOI 10.1111/j.1749-6632.1996.tb16231.x; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Chen SY, 1997, J BIOL CHEM, V272, P14087, DOI 10.1074/jbc.272.22.14087; Ciocca DR, 1997, TRENDS ENDOCRIN MET, V8, P313, DOI 10.1016/S1043-2760(97)00122-7; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Dotzlaw H, 1999, CANCER RES, V59, P529; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; FORMAN BM, 1995, ANN NY ACAD SCI, V761, P29, DOI 10.1111/j.1749-6632.1995.tb31366.x; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; Grohe C, 1998, J ENDOCRINOL, V156, pR1, DOI 10.1677/joe.0.156R001; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352; HILLIER SG, 1989, J MOL ENDOCRINOL, V2, P39, DOI 10.1677/jme.0.0020039; Ingram D, 1997, LANCET, V350, P990, DOI 10.1016/S0140-6736(97)01339-1; Jordan VC, 1999, ENDOCR REV, V20, P253, DOI 10.1210/edrv.20.3.0368; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Leygue E, 1998, CANCER RES, V58, P3197; Li X, 1997, NEUROENDOCRINOLOGY, V66, P63, DOI 10.1159/000127221; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Sasano H, 1999, J CLIN ENDOCR METAB, V84, P781, DOI 10.1210/jc.84.2.781; Speirs V, 1999, CANCER RES, V59, P525; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Watanabe T, 1997, BIOCHEM BIOPH RES CO, V236, P140, DOI 10.1006/bbrc.1997.6915; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605	39	305	315	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2000	19	43					4970	4978		10.1038/sj.onc.1203828	http://dx.doi.org/10.1038/sj.onc.1203828			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042684				2022-12-25	WOS:000089834300004
J	Narayan, S; Wilson, SH				Narayan, S; Wilson, SH			Kinetic analysis of Sp1-mediated transcriptional activation of the human DNA polymerase beta promoter	ONCOGENE			English	Article						Sp1; beta-pol promoter; in vitro transcription; kinetic analysis	PROTEIN-PROTEIN INTERACTIONS; BOX-BINDING-PROTEINS; TATA-LESS PROMOTER; PREINITIATION COMPLEX; FUNCTIONAL-ANALYSIS; II TRANSCRIPTION; TFIID COMPLEX; SP1; INITIATOR; CLONING	In the present studies, we have examined the effect of Spl on the activation of the human DNA polymerase beta (beta-pol), a TATA-less promoter. A HeLa cell nuclear extract (NE) based in vitro runoff transcription system of core beta-pol promoter human DNA (p beta P8) three-step kinetic model of transcription initiation were used to describe the kinetic effect of Spl. The results showed that distal Spl-binding sites in the core beta-pol promoter are important for transcriptional activation of the p beta P8 promoter. A detailed kinetic analysis showed that Spl stimulates the activity of the p beta PS promoter through distal Spl-binding sites by increasing the amount of recruitment, instead of stimulating the apparent rate of RPc assembly (k(1)), There was no significant effect of Sp1 on the apparent rate of open complex (RP0) formation (k(2)) Or on the apparent rate of promoter clearance (k(3)) Of the p beta P8 promoter. These studies define the kinetic mechanisms by which Spl may regulate the rate of transcript formation of the p beta P8 promoter, and these results may have implications for Spl regulation of TATA-less promoters.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Narayan, S (corresponding author), Univ Florida, UF Shands Canc Ctr, POB 100232, Gainesville, FL 32610 USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NCI NIH HHS [CA77721] Funding Source: Medline; NIEHS NIH HHS [ES06492] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050159, R01ES006492, ZIAES050159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HE F, 1996, BIOCHEMISTRY-US, V35, P1776; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; Narayan S, 2000, BIOCHEMISTRY-US, V39, P818, DOI 10.1021/bi9912701; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; Yean D, 1996, NUCLEIC ACIDS RES, V24, P2723, DOI 10.1093/nar/24.14.2723; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	44	12	13	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4729	4735		10.1038/sj.onc.1203823	http://dx.doi.org/10.1038/sj.onc.1203823			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032023				2022-12-25	WOS:000089528800007
J	Cebo, C; Dambrouck, T; Maes, E; Laden, C; Strecker, G; Michalski, JC; Zanetta, JP				Cebo, C; Dambrouck, T; Maes, E; Laden, C; Strecker, G; Michalski, JC; Zanetta, JP			Recombinant human interleukins IL-1 alpha, IL-1 beta, IL-4, IL-6, and IL-7 show different and specific calcium-independent carbohydrate-binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; REDUCTIVE BETA-ELIMINATION; N-LINKED OLIGOSACCHARIDES; HEPTAFLUOROBUTYRATE DERIVATIVES; MONOCLONAL-ANTIBODIES; NITROCELLULOSE SHEETS; MASS-SPECTROMETRY; OVIDUCAL MUCINS; RAT-BRAIN; RECEPTOR	A method was developed for the determination of putative lectin activities of cytokines, It involved the immunoblotting measurement of the quantity of these cytokines unbound to a series of different immobilized glycoconjugates and displacement of the bound cytokines with oligosaccharides of known structures. This method allows demonstrating that the following interleukins specifically recognize different oligosaccharide structures in a calcium-independent mechanism: interleukin lcr binds to the biantennary disialylated N-glycan completed with two Neu5Ac alpha2-3 residues; interleukin-1 beta to a GM, sialylated glycolipid Neu5Ac alpha2-3Gal beta1-Cer having very long and unusual long-chain bases; interleukin-4 to the 1,7 intramolecular lactone of N-acetyl-neuraminic acid; interleukin-6 to compounds having N-linked and O-linked HNK-1-like epitopes; and interleukin-7 to the sialyl-Tn antigen. Because the glycan ligands are rare structures in human circulating cells, it is suggested that such activities could be essential for providing specific signaling systems to cells having both the receptors and the oligosaccharide ligands of the interleukin at their cell surface.	Univ Sci & Tech Lille Flandres Artois, Chim Biol Lab, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Zanetta, JP (corresponding author), Univ Sci & Tech Lille Flandres Artois, Chim Biol Lab, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France.							BABA H, 1986, J NEUROIMMUNOL, V13, P89, DOI 10.1016/0165-5728(86)90052-4; BADACHE A, 1992, DEV NEUROSCI-BASEL, V14, P342, DOI 10.1159/000111681; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; CLARKE D, 1995, CYTOKINE, V7, P325, DOI 10.1006/cyto.1995.0041; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; Florea D, 1997, CARBOHYD RES, V302, P179, DOI 10.1016/S0008-6215(97)00129-8; FU DT, 1994, CARBOHYD RES, V261, P173, DOI 10.1016/0008-6215(94)84015-6; Fukushima K, 1997, J BIOL CHEM, V272, P10579; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; GLASS WF, 1981, ANAL BIOCHEM, V115, P219, DOI 10.1016/0003-2697(81)90549-2; Guttman A, 1997, ELECTROPHORESIS, V18, P1136, DOI 10.1002/elps.1150180719; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; KAPLAN D, 1995, FASEB J, V9, P1096, DOI 10.1096/fasebj.9.11.7649410; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KITAMURA K, 1976, BIOCHIM BIOPHYS ACTA, V455, P606; KJELDSEN T, 1988, CANCER RES, V48, P2214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON G, 1986, ARCH BIOCHEM BIOPHYS, V246, P531, DOI 10.1016/0003-9861(86)90308-5; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; Licinio J, 1996, NAT MED, V2, P1314, DOI 10.1038/nm1296-1314; Maes E, 1999, ANAL BIOCHEM, V267, P300, DOI 10.1006/abio.1998.2967; MIRESLUIS A, 1995, BLOOD, V86, P2679; MONSIGNY M, 1988, ANAL BIOCHEM, V175, P525, DOI 10.1016/0003-2697(88)90578-7; Morelle W, 1997, GLYCOBIOLOGY, V7, P1129, DOI 10.1093/glycob/7.8.1129; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; OZAKI K, 1995, GLYCOCONJUGATE J, V12, P268, DOI 10.1007/BF00731329; OZAWA H, 1993, J BIOCHEM-TOKYO, V114, P5, DOI 10.1093/oxfordjournals.jbchem.a124138; Ozbek S, 1998, J BIOL CHEM, V273, P21374, DOI 10.1074/jbc.273.33.21374; PAGE TH, 1995, EUR J IMMUNOL, V25, P2956, DOI 10.1002/eji.1830251036; Pons A, 2000, ANAL BIOCHEM, V284, P201, DOI 10.1006/abio.2000.4686; QUARLES RH, 1983, BIOCHIM BIOPHYS ACTA, V757, P140, DOI 10.1016/0304-4165(83)90162-9; SCHAUER R, 1997, GLYCOPROTEINS 2 B, V29, P243; SHERBLOM AP, 1989, J IMMUNOL, V143, P939; SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; SPIK G, 1995, METHODS GLYCOCONJUGA, P41; STECK A, 1988, NEUROLOGY, V33, P19; STRECKER G, 1977, EUR J BIOCHEM, V75, P391, DOI 10.1111/j.1432-1033.1977.tb11540.x; Tandai-Hiruma M, 1999, J BIOL CHEM, V274, P4459, DOI 10.1074/jbc.274.7.4459; TETTAMANTI G, 1968, ARCH BIOCHEM BIOPHYS, V124, P41, DOI 10.1016/0003-9861(68)90301-9; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TOMOZAWA Y, 1995, NEUROSCI LETT, V195, P57, DOI 10.1016/0304-3940(95)11781-Q; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENKITARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168, DOI 10.1002/eji.1830240935; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; WATANABE K, 1981, J LIPID RES, V22, P1020; Zanetta JP, 1999, GLYCOBIOLOGY, V9, P255, DOI 10.1093/glycob/9.3.255; ZANETTA JP, 1980, LIPIDS, V15, P1055, DOI 10.1007/BF02534323; ZANETTA JP, 1975, BRAIN RES, V83, P337, DOI 10.1016/0006-8993(75)90940-3; Zanetta JP, 1998, GLYCOBIOLOGY, V8, P221, DOI 10.1093/glycob/8.3.221; Zanetta JP, 1996, BIOCHEM J, V318, P49, DOI 10.1042/bj3180049; ZANETTA JP, 1993, LECTINS GLYCOBIOLOGY, P182	54	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5685	5691		10.1074/jbc.M008662200	http://dx.doi.org/10.1074/jbc.M008662200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11050099	hybrid			2022-12-25	WOS:000167115100039
J	Dettenhofer, M; Yu, XF				Dettenhofer, M; Yu, XF			Characterization of the biosynthesis of human immunodeficiency virus type 1 Env from infected T-cells and the effects of glucose trimming of Env on virion infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; SEQUENTIAL INTERACTION; SYNCYTIUM FORMATION; APOLIPOPROTEIN-B; QUALITY-CONTROL; CALNEXIN; TRANSLOCATION; GLYCOPROTEINS; CHAPERONE	HIV (human immunodeficiency virus)-1 Env is displayed on the surface of infected cells and subsequently incorporated into virions, which is necessary for the initiation of a viral infection by recognition of the CD4 and the chemokine receptors (such as CCR5 or CXCR4) on the surface of new target cells. As a type 1 integral membrane glycoprotein, Env is cotranslationally translocated into the endoplasmic reticulum, In this report, we characterized the synthesis of Env, which did not occur at a constant rate but by translational/translocational pausing that has not previously been shown with a viral encoded glycoprotein, Overall translation was not impeded by the presence of the reducing agent dithiothreitol in vivo, although this did influence the cleavage of the precursor gp160 into its mature form, gp120. Env interacts transiently with resident components of the endoplasmic reticulum such as calnexin, which had maximal association at a 10-min post-translation. Addition of the glucosidase inhibitor, castanospermine, failed to significantly influence the association of Env with calnexin, consistent with the notion that calnexin recognizes components other than cu-terminal glucose. Moreover, castanospermine treatment failed to affect the infectivity of virions. Taken together, this report demonstrates the existence of translational/translocational pausing for a viral glycoprotein and suggests that trimming of glucose from HIV-1 Env is not essential for the initiation of virus infection.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	Johns Hopkins University	Yu, XF (corresponding author), 615 N Wolfe St, Baltimore, MD 21205 USA.	xfyu@jhsph.edu	Dettenhofer, Markus/ABB-9840-2021	Dettenhofer, Markus/0000-0003-1972-7026				BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FENNIE C, 1989, J VIROL, V63, P639, DOI 10.1128/JVI.63.2.639-646.1989; FISCHER P, 1995, J VIROL, V69, P5791, DOI 10.1128/JVI.69.9.5791-5797.1995; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; GRUTERS RA, 1987, NATURE, V330, P74, DOI 10.1038/330074a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KLIMPTON J, 1992, J VIROL, V66, P2232; LEE WR, 1992, J VIROL, V66, P1799, DOI 10.1128/JVI.66.3.1799-1803.1992; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALKER BD, 1987, P NATL ACAD SCI USA, V84, P8120, DOI 10.1073/pnas.84.22.8120; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WARRIER SV, 1994, J VIROL, V68, P4636, DOI 10.1128/JVI.68.7.4636-4642.1994; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	40	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5985	5991		10.1074/jbc.M008933200	http://dx.doi.org/10.1074/jbc.M008933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11054427	hybrid			2022-12-25	WOS:000167115100077
J	Alpy, F; Stoeckel, ME; Dierich, A; Escola, JM; Wendling, C; Chenard, MP; Vanier, MT; Gruenberg, J; Tomasetto, C; Rio, MC				Alpy, F; Stoeckel, ME; Dierich, A; Escola, JM; Wendling, C; Chenard, MP; Vanier, MT; Gruenberg, J; Tomasetto, C; Rio, MC			The steroidogenic acute regulatory protein homolog MLN64, a late endosomal cholesterol-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICK-C-DISEASE; BREAST-CANCER; STAR; TRANSPORT; ONCOGENE; PATHWAY; CELLS; IDENTIFICATION; CHROMOSOME-17; AMPLIFICATION	MLN64 is a transmembrane protein that shares homology with the cholesterol binding domain (START domain) of the steroidogenic acute regulatory protein. The steroidogenic acute regulatory protein is located in the inner membrane of mitochondria, where it facilitates cholesterol import into the mitochondria, Crystallographic analysis showed that the START domain of MLN64 is a cholesterol-binding domain, The present work was undertaken to determine which step of the intracellular cholesterol pathway ML64 participates in. Using immunocytofluorescence, MLN64 colocalizes with LBPA, a lipid found specifically in late endosomes. Electron microscopy indicates that MLN64 is restricted to the limiting membrane of late endosomes. Microinjection or endocytosis of specific antibodies shows that the START domain of MLN64 is cytoplasmic, Deletion and mutagenesis experiments demonstrate that the aminoterminal part of MLN64 is responsible for its addressing. Although this domain does not contain conventional dileucine- or tyrosine-based targeting signals, we show that a dileucine motif (Leu(66)-Leu(67)) and a tyrosine residue (Tyr(89)) are critical for the targeting or the proper folding of the molecule, Finally, MLN64 colocalizes with cholesterol and Niemann Pick CI protein in late endosomes. However, complementation assays show that MLN64 is not involved in the Niemann Pick C2 disease which, results in cholesterol lysosomal accumulation. Together, our results show that MLN64 plays a role at the surface of the late endosomes, where it might shuttle cholesterol from the limiting membrane to cytoplasmic acceptor(s).	Univ Strasbourg 1, INSERM, U184, CNRS,UPR 6520,IGBMC, F-67404 Illkirch, France; CU Strasbourg, Strasbourg, France; Univ Strasbourg 1, CNRS, URA 1446, Lab Physiol Gen, F-67084 Strasbourg, France; Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; CHU Hautepierre, Serv Anat Pathol Gen, F-67098 Strasbourg, France; Fac Med & Ctr Hosp Lyon Sud, Fdn Gillet Merieux, INSERM, U189, F-69921 Oullins, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Geneva; CHU Strasbourg; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Tomasetto, C (corresponding author), Univ Strasbourg 1, INSERM, U184, CNRS,UPR 6520,IGBMC, 1 Rue Laurent Fries,BP163, F-67404 Illkirch, France.		Chenard, Marie-Pierre/O-2373-2016; Tomasetto, Catherine Laure/J-2783-2014; Alpy, Fabien/ABD-5893-2020; Alpy, Fabien/H-8941-2016	Tomasetto, Catherine Laure/0000-0002-1811-5848; Alpy, Fabien/0000-0002-0526-0720; Alpy, Fabien/0000-0002-0526-0720				Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bieche I, 1996, CANCER RES, V56, P3886; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; DIERICH A, 1987, EMBO J, V6, P2305, DOI 10.1002/j.1460-2075.1987.tb02505.x; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Holtta-Vuori M, 2000, CURR BIOL, V10, P95, DOI 10.1016/S0960-9822(99)99991-8; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Laurent-Matha V, 1998, J CELL SCI, V111, P2539; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Rochefort H, 2000, CLIN CHIM ACTA, V291, P157, DOI 10.1016/S0009-8981(99)00226-0; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STEINBERG SJ, 1994, J MED GENET, V31, P317, DOI 10.1136/jmg.31.4.317; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Strauss JF, 1999, RECENT PROG HORM RES, V54, P369; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Vanier MT, 1996, AM J HUM GENET, V58, P118; Vanier MT, 1998, BRAIN PATHOL, V8, P163; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462	42	132	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4261	4269		10.1074/jbc.M006279200	http://dx.doi.org/10.1074/jbc.M006279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053434	Green Published, hybrid			2022-12-25	WOS:000166921200071
J	Lee, SH; Schloss, DJ; Jarvis, L; Krasnow, MA; Swain, JL				Lee, SH; Schloss, DJ; Jarvis, L; Krasnow, MA; Swain, JL			Inhibition of angiogenesis by a mouse sprouty protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; VASCULAR MORPHOGENESIS; DROSOPHILA-SPROUTY; CELL-MIGRATION; FGF; HOMOLOG; TRACHEAL; PATTERN; VASCULOGENESIS; CONSTRUCTION	Sprouty negatively modulates branching morphogenesis in the Drosophila tracheal system. To address the role of mammalian Sprouty homologues in angiogenesis, another form of branching morphogenesis, a recombinant adenovirus engineered to express murine Sprouty-4 selectively in endothelial cells, was injected into the sinus venosus of embryonic day 9.0 cultured mouse embryos. Sprouty-4 expression inhibited branching and sprouting of small vessels, resulting in abnormal embryonic development. In vitro, Sprouty-4 inhibited fibroblast growth factor and vascular endothelial cell growth factor-mediated cell proliferation and migration and prevented basic fibroblast growth factor and vascular endothelial cell growth factor-induced MAPK phosphorylation in endothelial cells, indicating inhibition of tyrosine kinase-mediated signaling pathways. The ability of constitutively activated mutant Ras(L61) to rescue Sprouty-4 inhibition of MAPK phosphorylation suggests that Sprouty inhibits receptor tyrosine kinase signaling upstream of Ras. Thus, Sprouty may regulate angiogenesis in normal and disease processes by modulating signaling by endothelial tyrosine kinases.	Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Swain, JL (corresponding author), Stanford Univ, Dept Med, Sch Med, S-102,300 Pasteur Dr, Stanford, CA 94305 USA.	jlswain@stanford.edu			NHLBI NIH HHS [HL 26831, T32 HL07708] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007708, R37HL026831, R01HL026831] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Baldwin HS, 1997, GENE THER, V4, P1142, DOI 10.1038/sj.gt.3300525; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; Kramer S, 1999, DEVELOPMENT, V126, P2515; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Leconte I, 1998, DEV DYNAM, V213, P421, DOI 10.1002/(SICI)1097-0177(199812)213:4<421::AID-AJA7>3.0.CO;2-B; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Minowada G, 1999, DEVELOPMENT, V126, P4465; Mizuguchi H, 1998, HUM GENE THER, V9, P2577, DOI 10.1089/hum.1998.9.17-2577; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Reich A, 1999, DEVELOPMENT, V126, P4139; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1	30	119	123	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4128	4133		10.1074/jbc.M006922200	http://dx.doi.org/10.1074/jbc.M006922200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053436	hybrid			2022-12-25	WOS:000166921200054
J	Mehta, VB; Hart, J; Wewers, MD				Mehta, VB; Hart, J; Wewers, MD			ATP-stimulated release of interleukin (IL)-1 beta and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; GAMMA-INDUCING FACTOR; IL-1-BETA-CONVERTING ENZYME; CONVERTING-ENZYME; IL-1-BETA RELEASE; MICROGLIAL CELLS; P-2Z RECEPTOR; IFN-GAMMA; EXPRESSION; ACTIVATION	Interleukin (IL)-1 beta and IL-18 are structurally similar proteins that require caspase-1 processing for activation. Both proteins are released hom the cytosol by unknown pathway(s). To better characterize the release pathway(s) for IL-1 beta and IL-18 we evaluated the role of lipopolysaccharide priming, of interleukin-1 beta -converting enzyme (ICE) inhibition, of human purinergic receptor (P2X(7) function, and of signaling pathways in human monocytes induced by ATP. Monocytes rapidly processed and released both IL-1 beta and IL-18 after exogenous ATP. Despite its constitutive cytosolic presence, IL-18 required lipopolysaccharide priming for the ATP-induced release. Neither IL-1 beta nor IL-18 release was prevented by ICE inhibition, and IL-18 release was not induced by ICE activation itself. Release of both cytokines was blocked completely by a P2X7 receptor antagonist, oxidized ATP, and partially by an antibody to P2X(7), receptor. In evaluating the signaling components involved in the ATP effect, we identified that the protein-tyrosine kinase inhibitor, AG126, produced a profound inhibition of both ICE activation as well as release of IG1 beta /IL-18 Taken together, these results suggest that, although synthesis of IL-1 beta and IL-18 differ, ATP-mediated release of both cytokines requires a priming step but not proteolytically functional caspase-1.	Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Div Pulm & Crit Care, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Wewers, MD (corresponding author), Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, 110L,473 W 12th, Columbus, OH 43210 USA.		Wewers, Mark/AAB-6202-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040871, R01HL040871] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40871] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA JM, 1994, J IMMUNOL, V153, P2592; Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Dinarello CA, 1998, ANN NY ACAD SCI, V856, P1, DOI 10.1111/j.1749-6632.1998.tb08307.x; DINARELLO CA, 1996, BLOOD, V87, P2147; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; GRIFFITHS RJ, 1995, J IMMUNOL, V154, P2821; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HERZYK DJ, 1992, J IMMUNOL, V149, P3052; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Laliberte RE, 1999, J BIOL CHEM, V274, P36944, DOI 10.1074/jbc.274.52.36944; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Marsh CB, 1999, J IMMUNOL, V162, P6217; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Munsch N, 1998, BIOMED PHARMACOTHER, V52, P180, DOI 10.1016/S0753-3322(98)80208-4; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Perregaux DG, 1998, J IMMUNOL, V160, P2469; Puren AJ, 1999, P NATL ACAD SCI USA, V96, P2256, DOI 10.1073/pnas.96.5.2256; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Sanz JM, 2000, J IMMUNOL, V164, P4893, DOI 10.4049/jimmunol.164.9.4893; SIDERS WM, 1995, J BIOL CHEM, V270, P16258, DOI 10.1074/jbc.270.27.16258; Spitzer JA, 1996, SHOCK, V6, P426, DOI 10.1097/00024382-199612000-00007; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Thomassen E, 1998, J INTERF CYTOK RES, V18, P1077, DOI 10.1089/jir.1998.18.1077; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Wewers MD, 1997, J IMMUNOL, V159, P5964; WEWERS MD, 1984, J CLIN INVEST, V74, P2208, DOI 10.1172/JCI111647; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; [No title captured]	42	203	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3820	3826		10.1074/jbc.M006814200	http://dx.doi.org/10.1074/jbc.M006814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11056157	hybrid			2022-12-25	WOS:000166921200015
J	Holtmann, H; Enninga, J; Kalble, S; Thiefes, A; Dorrie, A; Broemer, M; Winzen, R; Wilhelm, A; Ninomiya-Tsuji, J; Matsumoto, K; Resch, K; Kracht, M				Holtmann, H; Enninga, J; Kalble, S; Thiefes, A; Dorrie, A; Broemer, M; Winzen, R; Wilhelm, A; Ninomiya-Tsuji, J; Matsumoto, K; Resch, K; Kracht, M			The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; BETA SIGNAL-TRANSDUCTION; TERMINAL KINASE; TGF-BETA; (JNK)-BINDING PROTEIN; SCAFFOLD PROTEINS; RABBIT LIVER; MEK KINASE-1; JNK PATHWAY	Mechanisms of fulminant gene induction during an inflammatory response were investigated using expression of the chemoattractant cytokine interleukin-8 (IL-8) as a model. Recently we found that coordinate activation ofNF-kappaB and c-Jun N-terminal protein kinase (JNK) is required for strong IL-8 transcription, whereas the p38 MAP kinase (MAPK) pathway stabilizes the IL-8 mRNA It is unclear how these pathways are coupled to the receptor for IL-1, an important physiological inducer of IL-8. Expression of the MAP kinase kinase kinase (MAPKKK) TAK1 together with its coactivator TAB1 in HeLa cells activated all three pathways and was sufficient to induce IL-8 formation, NF-kappaB + JNK2-mediated transcription from a minimal IL-8 promoter, and p38 MAPK-mediated stabilization of a reporter mRNA containing IL-8-derived regulatory mRNA sequences. Expression of a kinase-inactive mutant of TAK1 largely blocked IL-1-induced transcription and mRNA stabilization, as well as formation of endogenous IL-8. Truncated TAB1, lacking the TAK1 binding domain, or a TAK1-derived peptide containing a TAK1 autoinhibitory domain were also efficient in inhibition. These data indicate that the previously described three-pathway model of IL-8 induction is operative in response to a physiological stimulus, IL-1, and that the MAPKKK TAK1 couples the IL-1 receptor to both transcriptional and RNA-targeted mechanisms mediated by the three pathways.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan	Hannover Medical School; Nagoya University	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kracht.Michael@MH-Hannover.de		Kracht, Michael/0000-0002-8501-043X; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito M, 1999, MOL CELL BIOL, V19, P7539; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Koyano S, 1999, FEBS LETT, V457, P385, DOI 10.1016/S0014-5793(99)01084-4; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	44	79	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3508	3516		10.1074/jbc.M004376200	http://dx.doi.org/10.1074/jbc.M004376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11050078	hybrid			2022-12-25	WOS:000166784900068
J	Zalevsky, J; Grigorova, I; Mullins, RD				Zalevsky, J; Grigorova, I; Mullins, RD			Activation of the Arp2/3 complex by the Listeria ActA protein - ActA binds two actin monomers and three subunits of the Arp2/3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; ACANTHAMOEBA-CASTELLANII; L-MONOCYTOGENES; N-WASP; PROFILIN; POLYMERIZATION; FILAMENTS; MOTILITY; NUCLEATION; FAMILY	ActA is a bacterially encoded protein that enables Listeria monocytogenes to hijack the host cell actin cytoskeleton. It promotes Arp2/3-dependent actin nucleation, but its interactions with cellular components of the nucleation machinery are not well understood. Here we show that two domains of ActA (residues 85-104 and 121-138) with sequence similarity to WASP homology 2 domains bind two actin monomers with submicromolar affinity. ActA binds Arp2/3 with a K-d of 0.6 muM and competes for binding with the WASP family proteins N-WASP and Scar1. By chemical cross-linking, ActA, N-WASP, and Scar1 contact the same three subunits of the Arp2/3 complex, p40, Arp2, and Arp3. Interestingly, profilin competes with ActA for binding of Arp2/3, but actophorin (cofilin) does not. The minimal Arp2/3-binding site of ActA (residues 144-170) is C-terminal to both actin-binding sites and shares sequence homology with Arp2/3-binding regions of WASP family proteins. The maximal activity at saturating concentrations of ActA is identical to the most active domains of the WASP family proteins. We propose that ActA and endogenous WASP family proteins promote Arp2/3-dependent nucleation by similar mechanisms and require simultaneous binding of Arp2 and Arp3.	Univ Calif San Francisco, Sch Med, Dept Mol & Cellular Pharmacol, San Francisco, CA 94129 USA	University of California System; University of California San Francisco	Mullins, RD (corresponding author), Univ Calif San Francisco, Sch Med, Dept Mol & Cellular Pharmacol, 513 Parnassus Ave, San Francisco, CA 94129 USA.		Grigorova, Irina/AAR-8795-2020	Grigorova, Irina/0000-0002-4963-7403	NIGMS NIH HHS [GM61010-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; Cicchetti G, 1999, J BIOL CHEM, V274, P33616, DOI 10.1074/jbc.274.47.33616; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; GIULIANO KA, 1988, BIOCHEMISTRY-US, V27, P8931, DOI 10.1021/bi00425a009; GORDON DJ, 1976, J BIOL CHEM, V251, P4778; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kaiser DA, 1999, J CELL SCI, V112, P3779; Kelleher JF, 1998, METHOD ENZYMOL, V298, P42, DOI 10.1016/S0076-6879(98)98007-7; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1996, TRENDS CELL BIOL, V6, P208, DOI 10.1016/0962-8924(96)20017-0; Mullins RD, 1999, CURR BIOL, V9, P405, DOI 10.1016/S0960-9822(99)80187-0; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Mullins RD, 1999, CURR OPIN STRUC BIOL, V9, P244; Otto IM, 2000, CURR BIOL, V10, P345, DOI 10.1016/S0960-9822(00)00388-2; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Skoble J, 2000, J CELL BIOL, V150, P527, DOI 10.1083/jcb.150.3.527; SMITH GA, 1995, MOL MICROBIOL, V17, P945, DOI 10.1111/j.1365-2958.1995.mmi_17050945.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	44	97	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3468	3475		10.1074/jbc.M006407200	http://dx.doi.org/10.1074/jbc.M006407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11029465	hybrid			2022-12-25	WOS:000166784900063
J	Bielli, P; Bellenchi, GC; Calabrese, L				Bielli, P; Bellenchi, GC; Calabrese, L			Site-directed mutagenesis of human ceruloplasmin - Production of a proteolytically stable protein and structure-activity relationships of type 1 sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER SITES; FET3 PROTEIN; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; OXIDASE; IRON; FERROXIDASE; YEAST; MODEL; GENE	A fully active recombinant human ceruloplasmin was obtained, and it was mutated to produce a ceruloplasmin stable to proteolysis. The stable ceruloplasmin was further mutated to perturb the environment of copper at the type 1 copper sites in two different domains. The wild type and the mutated ceruloplasmin were produced in the yeast Pichia pastoris and characterized. The mutations R481A, R701A, and K887A were at the proteolytic sites, did not alter the enzymatic activity, and were all necessary to protect ceruloplasmin from degradation. The mutation L329M was at the tricoordinate type 1 site of the domain 2 and was ineffective to induce modifications of the spectroscopic and catalytic properties of ceruloplasmin, supporting the hypothesis that this site is reduced and locked in a rigid frame. In contrast the mutation C1021S at the type 1 site of domain 6 substantially altered the molecular properties of the protein, leaving a small fraction endowed with oxidase activity. This result, while indicating the importance of this site in stabilizing the overall protein structure, suggests that another type 1 site is competent for dioxygen reduction. During the expression of ceruloplasmin, the yeast maintained a high level of Fet3 that was released from membranes of yeast not harboring the ceruloplasmin gene. This indicates that expression of ceruloplasmin induces a state of iron deficiency in yeast because the ferric iron produced in the medium by its ferroxidase activity is not available for the uptake.	Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy	Roma Tre University; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Bielli, P (corresponding author), Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, Dr Bohrgasse 9-4, A-1030 Vienna, Austria.	pamela@gem.univie.ac.at	Bielli, Pamela/K-1208-2018	Bielli, Pamela/0000-0003-3347-8345; BELLENCHI, GIANCARLO/0000-0002-9302-0021				AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Bianchini A, 1999, J BIOL CHEM, V274, P20265, DOI 10.1074/jbc.274.29.20265; Blackburn NJ, 2000, BIOCHEMISTRY-US, V39, P2316, DOI 10.1021/bi992334a; Bonomi F, 1996, J BIOL INORG CHEM, V1, P67, DOI 10.1007/s007750050024; Calabrese L., 1997, MULTICOPPER OXIDASES, P307; CANTERS GW, 1993, FEBS LETT, V325, P39, DOI 10.1016/0014-5793(93)81410-2; Cha MK, 1999, BIOCHEMISTRY-US, V38, P12104, DOI 10.1021/bi990444b; CHIDAMBARAM MV, 1983, FEBS LETT, V159, P137, DOI 10.1016/0014-5793(83)80432-3; deSilva D, 1997, J BIOL CHEM, V272, P14208, DOI 10.1074/jbc.272.22.14208; di Patti MCB, 1999, ARCH BIOCHEM BIOPHYS, V372, P295, DOI 10.1006/abbi.1999.1493; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Farver O, 1999, J BIOL CHEM, V274, P26135, DOI 10.1074/jbc.274.37.26135; FRIEDEN E, 1976, ADV ENZYMOL RAMB, V44, P187; Gitlin JD, 1998, PEDIATR RES, V44, P271, DOI 10.1203/00006450-199809000-00001; GUTTERIDGE JMC, 1983, FEBS LETT, V157, P37, DOI 10.1016/0014-5793(83)81111-9; Hall JF, 1999, BIOCHEMISTRY-US, V38, P12675, DOI 10.1021/bi990983g; Harris E D, 1993, Prog Clin Biol Res, V380, P163; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Libeu CAP, 1997, BIOCHEMISTRY-US, V36, P13160, DOI 10.1021/bi9704111; Lindley PF, 1997, J BIOL INORG CHEM, V2, P454, DOI 10.1007/s007750050156; Machonkin TE, 1998, BIOCHEMISTRY-US, V37, P9570, DOI 10.1021/bi980434v; MALMSTROM BG, 1982, ANNU REV BIOCHEM, V51, P21, DOI 10.1146/annurev.bi.51.070182.000321; Malmstrom BG, 1998, CURR OPIN CHEM BIOL, V2, P286, DOI 10.1016/S1367-5931(98)80071-9; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Miyajima H, 1996, FREE RADICAL BIO MED, V20, P757, DOI 10.1016/0891-5849(95)02178-7; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; MUSCI G, 1993, J BIOL CHEM, V268, P13388; MUSCI G, 1990, ARCH BIOCHEM BIOPHYS, V279, P8, DOI 10.1016/0003-9861(90)90455-8; Musci G, 1999, ADV EXP MED BIOL, V448, P175; MUSCI G, 1993, ARCH BIOCHEM BIOPHYS, V306, P111, DOI 10.1006/abbi.1993.1487; Musci G, 1999, J BIOL INORG CHEM, V4, P441, DOI 10.1007/s007750050330; MUSCI G, 1995, J PROTEIN CHEM, V14, P611, DOI 10.1007/BF01886887; Olsson MHM, 1999, J BIOL INORG CHEM, V4, P654, DOI 10.1007/s007750050389; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; OSAKI S, 1966, J BIOL CHEM, V241, P5053; OSAKI S, 1966, J BIOL CHEM, V241, P2746; Rafiq M, 1997, FEBS LETT, V407, P132, DOI 10.1016/S0014-5793(97)00325-6; ROMERO A, 1993, J MOL BIOL, V229, P1007, DOI 10.1006/jmbi.1993.1101; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SATO M, 1991, J BIOL CHEM, V266, P5128; Shimizu A, 1999, BIOCHEMISTRY-US, V38, P3034, DOI 10.1021/bi9819531; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; SWAIN J, 1995, FEBS LETT, V368, P513, DOI 10.1016/0014-5793(95)00726-P; Wittung-Stafshede P, 1998, J BIOL INORG CHEM, V3, P367, DOI 10.1007/s007750050246; Xu F, 1999, J BIOL CHEM, V274, P12372, DOI 10.1074/jbc.274.18.12372; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zaitsev VN, 1999, J BIOL INORG CHEM, V4, P579, DOI 10.1007/s007750050380; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	55	19	20	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2678	2685		10.1074/jbc.M007176200	http://dx.doi.org/10.1074/jbc.M007176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042176	hybrid			2022-12-25	WOS:000166784800053
J	Kumar, A; Eby, MT; Sinha, S; Jasmin, A; Chaudhary, PM				Kumar, A; Eby, MT; Sinha, S; Jasmin, A; Chaudhary, PM			The ectodermal dysplasia receptor activates the nuclear factor-kappa B, JNK, and cell death pathways and binds to ectodysplasin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE; EDA GENE; APOPTOSIS; DOMAIN; HOMOLOG; INDUCTION; MEMBRANE; ALPHA; BETA	The ectodermal dysplasia receptor (EDAR) is a recently isolated member of the tumor necrosis factor receptor family that has been shown to play a key role in the process of ectodermal differentiation. We present evidence that EDAR is capable of activating the nuclear factor-kappaB, JNK and caspase-independent cell death pathways and that these activities are impaired in mutants lacking its death domain or those associated with anhidrotic ectodermal dysplasia and the downless phenotype, Although EDAR possesses a death domain, it did not interact with the death domain-containing adaptor proteins TRADD and FADD, EDAR successfully interacted with various TRAP family members; however, a dominant-negative mutant of TRAF2 was incapable of blocking EDAR-induced nuclear factor-kappaB or JNK activation. Collectively, the above results suggest that EDAR utilizes a novel signal transduction pathway. Finally, ectodysplasin A can physically interact with the extracellular domain of EDAR and thus represents its biological ligand.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Chaudhary, Preet/E-1970-2018; Kumar, Arvind/B-6094-2009		NIAMS NIH HHS [P30 AR41940-09] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1996, ONCOGENE, V12, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Ezer S, 1997, HUM MOL GENET, V6, P1581, DOI 10.1093/hmg/6.9.1581; Ezer S, 1999, HUM MOL GENET, V8, P2079, DOI 10.1093/hmg/8.11.2079; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Ferguson BM, 1997, HUM MOL GENET, V6, P1589, DOI 10.1093/hmg/6.9.1589; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Frade JM, 1996, NATURE, V383, P166; Freire-Maia N, 1984, ECTODERMAL DYSPLASIA; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	47	136	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2668	2677		10.1074/jbc.M008356200	http://dx.doi.org/10.1074/jbc.M008356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035039	hybrid			2022-12-25	WOS:000166784800052
J	Reid, KJ; Hendy, SC; Saito, J; Sorensen, P; Nelson, CC				Reid, KJ; Hendy, SC; Saito, J; Sorensen, P; Nelson, CC			Two classes of androgen receptor elements mediate cooperativity through allosteric interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; DNA-BINDING SPECIFICITY; RESPONSE ELEMENT; ESTROGEN-RECEPTOR; AMINO-ACIDS; GLUCOCORTICOID-RECEPTOR; CHROMATIN-STRUCTURE; GENE ACTIVATION; CODING REGION	Genes uniquely regulated by the androgen receptor (AR) typically contain multiple androgen response elements (AREs) that in isolation are of low DNA binding affinity and transcriptional activity. However, specific combinations of AREs in their native promoter context result in highly cooperative DNA binding by AR and high levels of transcriptional activation. We demonstrate that the natural androgen-regulated promoters of prostate specific antigen and probasin contain two classes of AREs dictated by their primary nucleotide sequence that function to mediate cooperativity, Class I AR-binding sites display conventional guanine contacts. Class II AR-binding sites have distinctive atypical sequence features and, upon binding to AR, the DNA structure is dramatically altered through allosteric interactions with the receptor. Class II sites stabilize AR binding to adjacent class I sites and result in synergistic transcriptional activity and increased hormone sensitivity. We have determined that the specific nucleotide variation within the AR binding sites dictate differential functions to the receptor, We have identified the role of individual nucleotides within class II sites and predicted consensus sequences for class I and II sites. Our data suggest that this may be a universal mechanism by which AR achieved unique regulation of target genes through complex allosteric interactions dictated by primary binding sequences.	Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC, Canada	University of British Columbia	Nelson, CC (corresponding author), Vancouver Gen Hosp, Prostate Ctr, 2660 Oak St, Vancouver, BC, Canada.	ccnelson@interchange.ubc.ca		Reid, Kim/0000-0001-5484-7205				ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; CLAESSENS F, 1993, BIOCHEM BIOPH RES CO, V191, P688, DOI 10.1006/bbrc.1993.1272; Dai JL, 1996, MOL ENDOCRINOL, V10, P1582, DOI 10.1210/me.10.12.1582; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; ESPINAS ML, 1995, MOL CELL BIOL, V15, P5346; GEWIRTH DT, 1995, NAT STRUCT BIOL, V2, P386, DOI 10.1038/nsb0595-386; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Kasper S, 1999, J MOL ENDOCRINOL, V22, P313, DOI 10.1677/jme.0.0220313; KASPER S, 1994, J BIOL CHEM, V269, P31763; Kerppola TK, 1998, STRUCT FOLD DES, V6, P549, DOI 10.1016/S0969-2126(98)00057-4; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; List HJ, 1999, EXP CELL RES, V250, P414, DOI 10.1006/excr.1999.4517; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NELSON CC, 1995, J BIOL CHEM, V270, P16981, DOI 10.1074/jbc.270.28.16981; Nelson CC, 1996, J BIOL CHEM, V271, P19464, DOI 10.1074/jbc.271.32.19464; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; PHAM TA, 1991, J BIOL CHEM, V266, P18179; Ramesh V, 1996, J MOL BIOL, V260, P22, DOI 10.1006/jmbi.1996.0379; Rastinejad F, 2000, EMBO J, V19, P1045, DOI 10.1093/emboj/19.5.1045; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; Senear DF, 1998, METHODS, V16, P3, DOI 10.1006/meth.1998.0641; TAN JA, 1992, J BIOL CHEM, V267, P4456; Travers A, 1998, CURR BIOL, V8, pR616, DOI 10.1016/S0960-9822(98)70390-2; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2; ZILLIACUS J, 1994, P NATL ACAD SCI USA, V91, P4175, DOI 10.1073/pnas.91.10.4175; Zolfaghari A, 1996, PROSTATE, V28, P232	46	55	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2943	2952		10.1074/jbc.M009170200	http://dx.doi.org/10.1074/jbc.M009170200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11056175	hybrid, Green Published			2022-12-25	WOS:000166784800087
J	Vargo, MA; Colman, RF				Vargo, MA; Colman, RF			Affinity labeling of rat glutathione S-transferase isozyme 1-1 by 17 beta-iodoacetoxy-estradiol-3-sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; BINDING SITE; ACTIVE-SITE; COMPLEX; EVOLUTION; ACID; DRUG	Rat liver glutathione S-transferase, isozyme 1-1, catalyzes the glutathione dependent isomerization of Delta (5)-androstene-3,17-dione and also binds steroid sulfates at a nonsubstrate inhibitory steroid site. 17 beta -dodoacetoxyestradiol-3-sulfate, a reactive steroid analogue, produces a time-dependent inactivation of this glutathione S-transferase to a limit of 60% residual activity. The rate constant for inactivation (k(obs)) exhibits a nonlinear dependence on reagent concentration with K-I = 71 muM and k(max) = 0.0133 min(-1), Complete protection against inactivation is provided by 17 beta -estradiol-3,17-disulfate, whereas Delta (5)-androstene-3,17-dione and S-methylglutathhione have little effect on k(obs). These results indicate that 17 beta -iodoacetoxy-estradiol-3-sulfate reacts as an affinity label of the nonsubstrate steroid site rather than of the substrate sites occupied by Delta (5)-androstene-3,17-dione or glutathione. Loss of activity occurs concomitant with incorporation of about I mol C-14-labeled reagent/mol enzyme dimer when the enzyme is maximally inactivated, Isolation of the labeled peptide from the chymotryptic digest shows that Cys(17) is the only enzymic amino acid modified. Covalent modification of Cys(17) by 17 beta -iodoacetoxy-estradiol-3-sulfate on subunit A prevents reaction of the steroid analogue with subunit B, These results and examination of the crystal structure of the enzyme suggest that the interaction between the two subunits of glutathione S-transferase 1-1, and the electrostatic attraction between the 3-sulfate of the reagent and Arg(14) of subunit B, are important in binding steroid sulfates at the nonsubstrate steroid binding site and in determining the specificity of this affinity label.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	rfcolman@chem.udel.edu			NATIONAL CANCER INSTITUTE [R01CA066561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008550] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 66561] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08550] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Barycki JJ, 1997, ARCH BIOCHEM BIOPHYS, V345, P16, DOI 10.1006/abbi.1997.0244; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLMAN RF, 1997, PROTEIN FUNCTION, P155; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hu LQ, 1997, BIOCHEMISTRY-US, V36, P1635, DOI 10.1021/bi962119j; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; Ji XH, 1997, BIOCHEMISTRY-US, V36, P9690, DOI 10.1021/bi970805s; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; LISTOWSKY I, 1998, STRUCTURE FUNCTION G, P199; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; McHugh TE, 1996, J BIOL CHEM, V271, P27470, DOI 10.1074/jbc.271.44.27470; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; Oakley AJ, 1997, BIOCHEMISTRY-US, V36, P576, DOI 10.1021/bi962316i; Penefsky H S, 1979, Methods Enzymol, V56, P527; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PONS M, 1973, FEBS LETT, V36, P23, DOI 10.1016/0014-5793(73)80328-X; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SCHRAMM VL, 1984, J BIOL CHEM, V259, P714; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Vargo MA, 2000, BIOCHEMISTRY-US, V39, P1544; Wang JB, 1996, PROTEIN SCI, V5, P1032; Wang JB, 2000, J BIOL CHEM, V275, P5493, DOI 10.1074/jbc.275.8.5493; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; Wilchek M, 1977, Methods Enzymol, V46, P153	29	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2031	2036		10.1074/jbc.M008212200	http://dx.doi.org/10.1074/jbc.M008212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11031273	hybrid			2022-12-25	WOS:000166528000053
J	Areida, SK; Reinhardt, DP; Muller, PK; Fietzek, PP; Kowitz, J; Marinkovich, MP; Notbohm, H				Areida, SK; Reinhardt, DP; Muller, PK; Fietzek, PP; Kowitz, J; Marinkovich, MP; Notbohm, H			Properties of the collagen type XVII ectodomain - Evidence for N- to C-terminal triple helix folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS PEMPHIGOID ANTIGEN; MOLECULAR RECOGNITION; CYTOPLASMIC DOMAIN; BP180 ECTODOMAIN; TRIMER FORMATION; PROCOLLAGEN; HEMIDESMOSOMES; PROTEIN; CELLS; CLEAVAGE	Collagen XVII is a transmembrane component of hemidesmosomal cells with important functions in epithelial-basement membrane interactions. Here we report on properties of the extracellular ectodomain of collagen XVII, which harbors multiple collagenous stretches. We have recombinantly produced subdomains of the collagen XVII ectodomain in a mammalian expression system. rColXVII-A spans the entire ectodomain from delta NC16a to NC1, rColXVII-B is similar but lacks the NC1 domain, a small N-terminal polypeptide rColXVII-C encompasses domains delta NC16a to C15, and a small C-terminal polypeptide rColXVII-D comprises domains NC6 to NC1, Amino acid analysis of rColXVII-A and -C demonstrated prolyl and lysyl hydroxylation with ratios for hydroxyproline/proline of 0.4 and for hydroxylysine/lysine of 0,5, A small proportion of the hydroxylysyl residues in rColXVII-C (similar to3.3%) was glycosylated. Limited pepsin and trypsin degradation assays and analyses of circular dichroism spectra clearly demonstrated a triple-helical conformation for rColXVII-A, -B, and -C, whereas the C-terminal rColXVII-D did not adopt a triple-helical fold. These results were further substantiated by electron microscope analyses, which revealed extended molecules for rColXVII-A and -C, whereas rColXVII-D appeared globular, Thermal denaturation experiments revealed melting temperatures of 41 degreesC (rCol/XVII-A), 39 degreesC (rColXVII-B), and 35 degreesC (rColXVII-C), In summary, our data suggest that triple helix formation in the ectodomain of ColXVII occurs with an N- to C-terminal directionality.	Med Univ Lubeck, Inst Mol Sci Med, D-23538 Lubeck, Germany; Vet Affairs Palo Alto Hlth Care Syst, Dermatol Serv, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Univ Rostock, Orthopad Klin, D-18057 Rostock, Germany	University of Lubeck; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of Rostock	Notbohm, H (corresponding author), Med Univ Lubeck, Inst Mol Sci Med, Ratzeburger Allee 160, D-23538 Lubeck, Germany.		Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044012] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR 44012] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balding SD, 1997, BIOCHEMISTRY-US, V36, P8821, DOI 10.1021/bi970675n; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; Borradori L, 1997, J CELL BIOL, V136, P1333, DOI 10.1083/jcb.136.6.1333; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNERTUDERMA.L, 2000, CONNECTIVE TISSUE IT; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FIETZEK PP, 1972, EUR J BIOCHEM, V30, P163, DOI 10.1111/j.1432-1033.1972.tb02083.x; GIUDICE GJ, 1993, J IMMUNOL, V151, P5742; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Hirako Y, 1998, J BIOL CHEM, V273, P9711, DOI 10.1074/jbc.273.16.9711; Hirako Y, 1996, J BIOL CHEM, V271, P13739, DOI 10.1074/jbc.271.23.13739; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAZZORANA M, 1995, MATRIX BIOL, V14, P583, DOI 10.1016/S0945-053X(05)80007-1; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; OLSEN BR, 1976, ARCH BIOCHEM BIOPHYS, V175, P341, DOI 10.1016/0003-9861(76)90516-6; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Schumann H, 2000, AM J PATHOL, V156, P685, DOI 10.1016/S0002-9440(10)64772-4; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093	28	51	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1594	1601		10.1074/jbc.M008709200	http://dx.doi.org/10.1074/jbc.M008709200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042218	hybrid			2022-12-25	WOS:000166430900098
J	Bonicalzi, ME; Groulx, I; de Paulsen, N; Lee, S				Bonicalzi, ME; Groulx, I; de Paulsen, N; Lee, S			Role of exon 2-encoded beta-domain of the von Hippel-Lindau tumor suppressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27(KIP1); INDUCIBLE FACTOR 1-ALPHA; UBIQUITIN-LIKE PROTEIN; GENE-PRODUCT; NUCLEOCYTOPLASMIC TRANSPORT; RENAL-CARCINOMA; NUCLEAR EXPORT; MESSENGER-RNA; HUMAN TISSUES; GROWTH-FACTOR	Sporadic clear cell renal carcinomas frequently harbor inactivating mutations in exon 2 of the von Hippel-Lindau (VHL) tumor suppressor gene. Here, we examine the effect of the loss of exon 2-encoded beta -domain function on VHL biochemical properties. Exon 2-encoded residues are required for VHL-mediated NEDD8 conjugation on cullin-2 and assembly with hypoxia-inducible factor alpha (HIF alpha) and fibronectin. These residues are not essential for VHL ability to assemble with elongin BC/cullin-2, to display E3 ubiquitin ligase activity in vitro and to confer energy-dependent nuclear import properties to a reporter protein. Localization studies in)HIF-1 alpha -null embryonic cells suggest that exon 2-encoded beta -domain mediates transcription-dependent nuclear/cytoplasmic shuttling of VHL independently of assembly with HIF-1 alpha and oxygen concentration. Exon 2-encoded alpha -helical domain is required for VHL complex formation with BC/cullin-2 and E3 ubiquitin ligase activity, for binding to HIF alpha /fibronectin, but this domain is not essential for transcription-dependent nuclear/cytoplasmic trafficking. VHL-/- renal carcinoma cells expressing beta -domain mutants failed to produce an extracellular fibronectin matrix and to degrade HIF alpha which accumulated exclusively in the nucleus of normorric cells. These results demonstrate that exon 2-encoded residues are involved in two independent functions: substrate protein recognition and transcription-dependent nuclear/cytoplasmic trafficking. They also suggest that beta -domain mutations inactivate VHL function differently than alpha -domain mutations, potentially providing an explanation for the relationship between different mutations of the VHL gene and clinical outcome.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Kidney Res Ctr, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Lee, S (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	slee@uottawa.ca						Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chen LN, 1996, SOMAT CELL MOLEC GEN, V22, P477, DOI 10.1007/BF02369439; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Groulx I, 2000, J BIOL CHEM, V275, P8991, DOI 10.1074/jbc.275.12.8991; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; KISHIDA T, 1995, CANCER RES, V55, P4544; Knebelmann B, 1998, CANCER RES, V58, P226; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Los M, 1996, LAB INVEST, V75, P231; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Ryan HE, 2000, CANCER RES, V60, P4010; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Scheffner M, 1999, NATURE, V398, P103, DOI 10.1038/18105; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Siemeister G, 1996, CANCER RES, V56, P2299; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsuchiya H, 1996, CANCER RES, V56, P2881; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	52	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1407	1416		10.1074/jbc.M008295200	http://dx.doi.org/10.1074/jbc.M008295200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11024059	hybrid			2022-12-25	WOS:000166430900074
J	Tachiki, H; Kato, R; Kuramitsu, S				Tachiki, H; Kato, R; Kuramitsu, S			DNA binding and protein-protein interaction sites in MutS, a mismatched DNA recognition protein from Thermus thermophilus HB8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ATPASE ACTIVITY; ASPARTATE-AMINOTRANSFERASE; TRANSLOCATION MECHANISM; HETERODUPLEX DNA; REPAIR PROTEIN; HMUTS-ALPHA; BACTERIUM; HETERODIMER; CELLS	The mismatch repair system repairs mismatched base pairs, which are caused by either DNA replication errors, DNA damage, or genetic recombination. Mismatch repair begins with the recognition of mismatched base pairs in DNA by MutS. Protein denaturation and limited proteolysis experiments suggest that Thermus thermophilus MutS can be divided into three structural domains as follows: A (N-terminal domain), B (central domain), and C (C-terminal domain) (Tachiki, H., Kato, R., Masui, R., Hasegawa, K., Itakura, H., Fukuyama, K., and Kuramitsu, S, (1998) Nucleic Acids Res. 26, 4153-4159). To investigate the functions of each domain in detail, truncated genes corresponding to the domains were designed. The gene products were overproduced in Escherichia coli, purified, and assayed for various activities. The MutS-MutS protein interaction site was determined by size-exclusion chromatography to be located in the B domain. The B domain was also found to possess nonspecific double-stranded DNA-binding ability. The C domain, which contains a Walker's A-type nucleotide-binding motif, demonstrated ATPase activity and specific DNA recognition of mismatched base pairs. These ATPase and specific DNA binding activities were found to be dependent upon C domain dimerization.	Osaka Univ, Dept Biol, Grad Sch Sci, Toyonaka, Osaka 5600043, Japan	Osaka University	Kuramitsu, S (corresponding author), Osaka Univ, Dept Biol, Grad Sch Sci, 1-1 Machikaneyama Cho, Toyonaka, Osaka 5600043, Japan.	kuramitu@bio.sci.osaka-u.ac.jp		Kato, Ryuichi/0000-0003-2087-2896				Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; Biswas I, 1999, J BIOL CHEM, V274, P23673, DOI 10.1074/jbc.274.33.23673; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; CHI NW, 1994, J BIOL CHEM, V269, P29984; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Kaplan W, 1997, PROTEIN SCI, V6, P399; Kato R, 1999, EUR J BIOCHEM, V259, P592, DOI 10.1046/j.1432-1327.1999.00044.x; Kato R, 1997, J BACTERIOL, V179, P6499, DOI 10.1128/jb.179.20.6499-6503.1997; Kato R, 1996, J BIOL CHEM, V271, P9612, DOI 10.1074/jbc.271.16.9612; KEVIN MC, 1997, PLANT PHYSIOL, V115, P833; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Maniatis T., 1989, MOL CLONING LAB MAN; Mikawa T, 1998, NUCLEIC ACIDS RES, V26, P903, DOI 10.1093/nar/26.4.903; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Okamoto A, 1996, J BIOCHEM-TOKYO, V119, P135; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; ROVERT K, 1997, J IMMUNOL METHODS, V200, P121; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Tachiki H, 1998, NUCLEIC ACIDS RES, V26, P4153, DOI 10.1093/nar/26.18.4153; Takamatsu S, 1996, NUCLEIC ACIDS RES, V24, P640, DOI 10.1093/nar/24.4.640; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Whitehouse A, 1997, BIOCHEM BIOPH RES CO, V232, P10, DOI 10.1006/bbrc.1997.6211; Wu TH, 1999, J BIOL CHEM, V274, P5948, DOI 10.1074/jbc.274.9.5948; Yamamoto N, 1996, GENE, V171, P103, DOI 10.1016/0378-1119(96)00052-2	41	13	13	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40703	40709		10.1074/jbc.M007124200	http://dx.doi.org/10.1074/jbc.M007124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024056	hybrid			2022-12-25	WOS:000166114600008
J	Wijnhoven, SWP; Kool, HJM; Mullenders, LHF; van Zeeland, AA; Friedberg, EC; van der Horst, GTJ; van Steeg, H; Vrieling, H				Wijnhoven, SWP; Kool, HJM; Mullenders, LHF; van Zeeland, AA; Friedberg, EC; van der Horst, GTJ; van Steeg, H; Vrieling, H			Age-dependent spontaneous mutagenesis in Xpc mice defective in nucleotide excision repair	ONCOGENE			English	Article						nucleotide excision repair; Hprt; mutation; cancer; transgenic mice	DNA-REPAIR; INCREASED SUSCEPTIBILITY; PYRIMIDINE DIMERS; DHFR GENE; DAMAGE; ACCUMULATION; MUTATIONS; APOPTOSIS; INDUCTION; P53	DNA damages caused by cellular metabolites and environmental agents induce mutations, that may predispose to cancer. Nucleotide excision repair (NER) is a major cellular defence mechanism acting on a variety of DNA lesions. Here, we show that spontaneous mutant frequencies at the Hplt gene increased 30-fold in T-lymphocytes of 1 year old Xpc(-/-) mice, possessing only functional transcription-coupled repair (TCR), Hprt mutant frequencies in Xpa(-/-) and Csb(-/-) mice that both have a defect in this NER subpathway, remained low during ageing. In contrast to current models, the elevated mutation rate in Xpc(-/-) mice does not lead to an increased tumour incidence or premature ageing.	Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, MGC, NL-2333 AL Leiden, Netherlands; Erasmus Univ, Dept Cell Biol & Genet, MGC, NL-3000 DR Rotterdam, Netherlands; Interuniv Inst Radiopathol & Radiat Protect, JA Cohen Inst, Leiden, Netherlands; Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA; Natl Inst Publ Hlth & Environm, RIVM, Hlth Effects Res Lab, Dept Carcinogenesis Mutagenesis & Genet, NL-3720 BA Bilthoven, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Netherlands National Institute for Public Health & the Environment	Vrieling, H (corresponding author), Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, MGC, POB 9503, NL-2300 RA Leiden, Netherlands.		van der Horst, Gijsbertus TJ/E-3661-2015; Vrieling, Harry/ABC-8068-2020	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Vrieling, Harry/0000-0002-3034-2664				Ananthaswamy HN, 1999, ONCOGENE, V18, P7395, DOI 10.1038/sj.onc.1203147; BERG RJW, 2000, IN PRESS CANC RES; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Cheo DL, 2000, CANCER RES, V60, P1580; Cheo DL, 1997, MUTAT RES-FUND MOL M, V374, P1, DOI 10.1016/S0027-5107(97)00046-8; de Vries A, 1997, CARCINOGENESIS, V18, P2327, DOI 10.1093/carcin/18.12.2327; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; Friedberg EC, 2000, MUTAT RES-DNA REPAIR, V459, P99, DOI 10.1016/S0921-8777(99)00068-3; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KURAOKA I, 2000, IN PRESS P NATL ACAD; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Ljungman M, 1996, ONCOGENE, V13, P823; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Odagiri Y, 1998, NAT GENET, V19, P116, DOI 10.1038/468; Reis AM, 2000, CANCER RES, V60, P1571; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TATES AD, 1994, MUTAT RES-FUND MOL M, V309, P299, DOI 10.1016/0027-5107(94)90106-6; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VANOOSTEN M, 2000, IN PRESS P NATL ACAD; Wijnhoven SWP, 1998, P NATL ACAD SCI USA, V95, P13759, DOI 10.1073/pnas.95.23.13759; WIJNHOVEN SWP, 2000, IN PRESS CANC RES; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	28	52	53	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5034	5037		10.1038/sj.onc.1203844	http://dx.doi.org/10.1038/sj.onc.1203844			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042691				2022-12-25	WOS:000089834300011
J	Wu, HY; Lan, ZD; Li, WQ; Wu, SC; Weinstein, J; Sakamoto, KM; Dai, W				Wu, HY; Lan, ZD; Li, WQ; Wu, SC; Weinstein, J; Sakamoto, KM; Dai, W			p55CDC/hCDC20 is associated with BUBR1 and may be a downstream target of the spindle checkpoint kinase	ONCOGENE			English	Article						spindle checkpoint; cell cycle; protein kinase; mitosis	CYCLOSOME/ANAPHASE-PROMOTING COMPLEX; KINETOCHORE LOCALIZATION; PROTEIN-KINASE; BUDDING YEAST; CELLS; P55CDC; MITOSIS; CDC20; GENE; MAD2	Eukaryotic cells have evolved a mechanism that delays the progression of mitosis until condensed chromosomes are properly positioned on the mitotic spindle. We have been studying genes that regulated the spindle checkpoint in human cells. Enforced expression of human BUBR1, but not a BUBR1 mutant allele, enhances accumulation of mitotic cells. Yeast two-hybrid system and GST-pull-down analyses show that p55CDC/hCdc20, a protein known to link spindle checkpoint components such as MAD2 to anaphase promoting complex (APC), interacts with BUBR1, In addition, p55CDC is capable of pulling down BUBR1 in sf-9 cells infected with both p55CDC and His6-BUBR1 recombinant baculoviruses but not in the cells infected with p55CDC baculoviruses or with the baculoviral vector alone. Moreover, immunoprecipitation followed by Western blot analyses confirmed that native p55CDC is associated with BUBR1 in HeLa cells. Spindle checkpoint activation by nocodazole treatment enhances the association between p55CDC and His6-BUBR1, In nocodazole-arrested mitotic cells, both CDC16 and hyperphosphorylated CDC27, two APC components, preferentially associate with His6-BUBR1 resins, but not the control resins, Furthermore, BUBR1 phosphorylates p55CDC in vitro, and the phosphorylation of p55CDC by BUBR1 appears to be correlated with spindle checkpoint activation. Together, our studies strongly suggest that BUBR1 may target APC via p55CDC.	Amer Hlth Fdn, Valhalla, NY 10595 USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat & Pathol, Los Angeles, CA USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med, Los Angeles, CA 90024 USA; Univ Cincinnati, Div Hematol Oncol, Cincinnati, OH USA	American Health Foundation; Amgen; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University System of Ohio; University of Cincinnati	Dai, W (corresponding author), Amer Hlth Fdn, 1 Dana Rd, Valhalla, NY 10595 USA.			Sakamoto, Kathleen/0000-0003-0494-8838	NATIONAL CANCER INSTITUTE [R13CA074299] Funding Source: NIH RePORTER; NCI NIH HHS [CA74299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bin OY, 1998, CELL GROWTH DIFFER, V9, P877; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Donadelli R, 1998, BIOCHEM BIOPH RES CO, V246, P881, DOI 10.1006/bbrc.1998.8713; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kao CT, 1996, ONCOGENE, V13, P1221; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350	25	52	52	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4557	4562		10.1038/sj.onc.1203803	http://dx.doi.org/10.1038/sj.onc.1203803			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030144				2022-12-25	WOS:000089438200001
J	Lamberty, M; Zachary, D; Lanot, R; Bordereau, C; Robert, A; Hoffmann, JA; Bulet, P				Lamberty, M; Zachary, D; Lanot, R; Bordereau, C; Robert, A; Hoffmann, JA; Bulet, P			Insect immunity - Constitutive expression of a cysteine-rich antifungal and a linear antibacterial peptide in a termite insect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSESHOE-CRAB HEMOCYTES; ANTIMICROBIAL PEPTIDES; SEQUENCE HOMOLOGY; AEDES-AEGYPTI; CDNA CLONING; DROSOPHILA; DEFENSIN; INVERTEBRATES; DROSOMYCIN; CECROPIN	Two novel antimicrobial peptides, which we propose to name termicin and spinigerin, have been isolated from the fungus-growing termite Pseudacanthotermes spiniger (heterometabole insect, Isoptera). Termicin is a 36-amino acid residue antifungal peptide, with six cysteines arranged in a disulfide array similar to that of insect defensins. In contrast to most insect defensins, termicin is C-terminally amidated. Spinigerin consists of 25 amino acids and is devoid of cysteines. It is active against bacteria and fungi, Termicin and spinigerin show no obvious sequence similarities with other peptides. Termicin is constitutively present in hemocyte granules and in salivary glands. The presence of termicin and spinigerin in unchallenged termites contrasts with observations in evolutionary recent insects or insects undergoing complete metamorphosis, in which antimicrobial peptides are induced in the fat body and released into the hemolymph after septic injury.	CNRS, Inst Biol Mol & Cellulaire, Unite Propre Rech 9022, F-67084 Strasbourg, France; Univ Bourgogne, Zool Lab, CNRS, Unite Mixte Rech 5548, F-21000 Dijon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne	Bulet, P (corresponding author), CNRS, Inst Biol Mol & Cellulaire, Unite Propre Rech 9022, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	P.Bulet@ibmc.u-strasbg.fr	BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; Ekengren S, 1999, INSECT BIOCHEM MOLEC, V29, P965, DOI 10.1016/S0965-1748(99)00071-5; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; Ferrandon D, 1998, EMBO J, V17, P1217, DOI 10.1093/emboj/17.5.1217; HAN SH, 1992, SOCIOBIOLOGY, V20, P219; Hetru C, 1997, Methods Mol Biol, V78, P35; Hetru Charles, 1998, P40; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; Lowenberger C, 1999, J BIOL CHEM, V274, P20092, DOI 10.1074/jbc.274.29.20092; LOWENBERGER C, 1995, INSECT BIOCHEM MOLEC, V25, P867, DOI 10.1016/0965-1748(95)00043-U; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; Michaut L, 1996, FEBS LETT, V395, P6, DOI 10.1016/0014-5793(96)00992-1; Mitta G, 1999, J CELL SCI, V112, P4233; Mitta G, 1999, EUR J BIOCHEM, V265, P71, DOI 10.1046/j.1432-1327.1999.00654.x; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; Qiu P, 1998, DEVELOPMENT, V125, P1909; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SHIGENAGA T, 1990, J BIOL CHEM, V265, P21350; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; UttenweilerJoseph S, 1997, ANAL BIOCHEM, V247, P366, DOI 10.1006/abio.1997.2083; YAMADA K, 1993, BIOCHEM J, V291, P275, DOI 10.1042/bj2910275	32	204	252	4	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4085	4092		10.1074/jbc.M002998200	http://dx.doi.org/10.1074/jbc.M002998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053427	hybrid, Green Published			2022-12-25	WOS:000166921200049
J	Ohgami, N; Nagai, R; Ikemoto, M; Arai, H; Kuniyasu, A; Horiuchi, S; Nakayama, H				Ohgami, N; Nagai, R; Ikemoto, M; Arai, H; Kuniyasu, A; Horiuchi, S; Nakayama, H			CD36, a member of the class B scavenger receptor family, as a receptor for advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEMODIALYSIS-ASSOCIATED AMYLOIDOSIS; HUMAN ATHEROSCLEROTIC LESIONS; HUMAN MONOCYTE CHEMOTAXIS; GLUCOSE-MODIFIED PROTEINS; NECROSIS-FACTOR-ALPHA; GLYCOPROTEIN-IV CD36; INDUCED DIABETIC RAT; ADVANCED GLYCOSYLATION; IMMUNOCHEMICAL DETECTION	Interaction of advanced glycation end products (AGE) with AGE receptors induces several cellular phenomena potentially relating to diabetic complications. Five AGE receptors identified so far are RAGE (receptor for AGE), galectin-3, 80K-H, OST-48, and SRA (macrophage Scavenger receptor class A types I and II). Since SRA is known to belong to the class A scavenger receptor family, and the scavenger receptor collectively represents a family of multiligand lipoprotein receptors, it is possible that CD36, although belonging to the class B scavenger receptor family, can recognize AGE proteins as ligands. This was tested at the cellular level in this study using Chinese hamster ovary (CHO) cells overexpressing hu man CD36 (CD36-CHO cells). Cellular expression of CD36 was confirmed by immunoblotting and immunofluorescent microscopy using anti-CD36 antibody; Upon incubation at 37 degreesC, I-125-AGE-bovine serum albumin (AGE-BSA) and I-125-oxidized low density lipoprotein (LDL), an authentic ligand for CD36, were endocytosed in a dose-dependent fashion and underwent lysosomal degradation by CD36-CHO cells, but not wildtype CHO cells. In binding experiments at 4 degreesC, I-125-AGE-BSA exhibited specific and saturable binding to CD36-CHO cells (K-d = 5.6 mug/ml). The endocytic uptake of I-125-AGE-BSA by these cells was inhibited by 50% by oxidized LDL and by 60% by FA6-152, an anti-CD36 antibody inhibiting cellular binding of oxidized LDL. Our results indicate that CD36 expressed by these cells mediates the endocytic uptake and subsequent intracellular degradation of AGE proteins. Since CD36 is one of the major oxidized LDL receptors and is up-regulated in macrophage- and smooth muscle cell-derived foam cells in human atherosclerotic lesions, these results suggest that, like oxidized LDL, AGE proteins generated in situ are recognized by CD36, which might contribute to the pathogenesis of diabetic macrovascular complications.	Kumamoto Univ, Sch Med, Dept Biochem, Kumamoto 8600811, Japan; Kumamoto Univ, Fac Pharmaceut Sci, Dept Biofunct Chem, Kumamoto 8620973, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan	Kumamoto University; Kumamoto University; University of Tokyo; RIKEN	Horiuchi, S (corresponding author), Kumamoto Univ, Sch Med, Dept Biochem, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Ohgami, Nobutaka/I-4572-2014					Abumrad N, 1999, BBA-MOL CELL BIOL L, V1441, P4, DOI 10.1016/S1388-1981(99)00137-7; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; ARAKI N, 1992, J BIOL CHEM, V267, P10211; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Calvo D, 1998, J LIPID RES, V39, P777; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; DOI T, 1993, J BIOL CHEM, V268, P2126; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Finot P. A., 1982, Advances in Chemistry Series, V198, P91; Gotoda T, 1999, NAT GENET, V22, P226, DOI 10.1038/10285; GREENWALT DE, 1992, BLOOD, V80, P1105; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Huh HY, 1996, BLOOD, V87, P2020; Iwashima Y, 1999, BIOCHEM BIOPH RES CO, V264, P441, DOI 10.1006/bbrc.1999.1539; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KUME S, 1995, AM J PATHOL, V147, P654; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Lipsky RH, 1997, RECEPT SIGNAL TRANS, V7, P1; MAILLARD LC, 1992, C R ACAD SCI PARIS 3, V154, P66; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; Matsumoto K, 2000, ARTERIOSCL THROM VAS, V20, P1027, DOI 10.1161/01.ATV.20.4.1027; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MITSUHASHI T, 1993, DIABETES, V42, P826, DOI 10.2337/diabetes.42.6.826; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MIYATA T, 1994, J CLIN INVEST, V93, P521, DOI 10.1172/JCI117002; Nagai R, 2000, DIABETES, V49, P1714, DOI 10.2337/diabetes.49.10.1714; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAITO M, 1992, AM J PATHOL, V141, P591; NAKAMURA Y, 1993, AM J PATHOL, V143, P1649; Nakata A, 1999, ARTERIOSCL THROM VAS, V19, P1333, DOI 10.1161/01.ATV.19.5.1333; NAKAYAMA H, 1993, DIABETES, V42, P345, DOI 10.2337/diabetes.42.2.345; Navazo MDP, 1996, ARTERIOSCL THROM VAS, V16, P1033, DOI 10.1161/01.ATV.16.8.1033; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; SAKAI M, 1994, J BIOL CHEM, V269, P31430; Sakata N, 1999, ATHEROSCLEROSIS, V142, P67, DOI 10.1016/S0021-9150(98)00192-0; Sakata N, 1998, ATHEROSCLEROSIS, V141, P61, DOI 10.1016/S0021-9150(98)00149-X; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; Sfeir Z, 1999, MOL CELL BIOCHEM, V192, P3, DOI 10.1023/A:1006811300125; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SKOLNIK EY, 1991, J EXP MED, V174, P931, DOI 10.1084/jem.174.4.931; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TAKATA K, 1988, J BIOL CHEM, V263, P14819; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TEZUKA M, 1993, BIOCHEM BIOPH RES CO, V193, P674, DOI 10.1006/bbrc.1993.1677; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Uchida K, 1997, FEBS LETT, V410, P313, DOI 10.1016/S0014-5793(97)00610-8; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; VLASSARA H, 1994, LAB INVEST, V70, P138; YAMADA K, 1994, CLIN NEPHROL, V42, P354; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YUI S, 1994, J IMMUNOL, V152, P1943	73	189	200	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3195	3202		10.1074/jbc.M006545200	http://dx.doi.org/10.1074/jbc.M006545200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035013	hybrid			2022-12-25	WOS:000166784900030
J	Aurrand-Lions, M; Duncan, L; Ballestrem, C; Imhof, BA				Aurrand-Lions, M; Duncan, L; Ballestrem, C; Imhof, BA			JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRANDS; ADHESION MOLECULE; VASCULAR-PERMEABILITY; INTERCELLULAR-JUNCTIONS; ADHERENS JUNCTIONS; PROTEINS; OCCLUDIN; IDENTIFICATION; FAMILY; DISORGANIZATION	Cell-cell contacts are essential for morphogenesis and tissue function and play a vital role in mediating endothelial cohesion within the vascular system during vessel growth and organization. We identified a never junctional adhesion molecule, named JAM-2, by a selective RNA display method, which allowed identification of transcripts encoding immunoglobulin superfamily molecules regulated during coculture of endothelial cells with tumor cells. The JAM-2 transcript is highly expressed during embryogenesis and is detected in lymph node and Peyer's patches RNA of adult mice. Accordingly, antibodies specific for JAM-a stain high endothelial venules and lymphatic vessels in lymphoid organs, and vascular structures in the kidney. Using real time video microscopy, we show that JAM-2 is localized within minutes to the newly formed cell-cell contact, The role of the protein in the sealing of cell-cell contact is further suggested by the reduced paracellular permeability of cell monolayer transfected with JAM-2 cDNA, and by the localization of JAM-2 to tight junctional complexes of polarized cells. Taken together, our results suggest that JAM-2 is a novel vascular molecule, which participates in interendothelial junctional complexes.	Ctr Med Univ, Dept Pathol, CH-1211 Geneva, Switzerland	University of Geneva	Aurrand-Lions, M (corresponding author), Ctr Med Univ, Dept Pathol, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.		Aurrand-Lions, Michel/O-9953-2016	Aurrand-Lions, Michel/0000-0002-8361-3034; Ballestrem, Christoph/0000-0002-5375-7985				Allport JR, 1997, J EXP MED, V186, P517, DOI 10.1084/jem.186.4.517; Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; AurrandLions M, 1996, IMMUNITY, V5, P391, DOI 10.1016/S1074-7613(00)80496-3; AurrandLions M, 1997, CELL IMMUNOL, V176, P173, DOI 10.1006/cimm.1996.1073; Ballestrem C, 1998, J CELL SCI, V111, P1649; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Dejana E, 1996, J CLIN INVEST, V98, P1949, DOI 10.1172/JCI118997; Dejana E, 1996, HAEMOSTASIS, V26, P210; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Du Pasquier L, 1999, EUR J IMMUNOL, V29, P1729, DOI 10.1002/(SICI)1521-4141(199905)29:05<1729::AID-IMMU1729>3.0.CO;2-K; Ebnet K, 2000, J BIOL CHEM, V275, P27979; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARDER R, 1991, EXP CELL RES, V197, P259, DOI 10.1016/0014-4827(91)90431-S; Hirase T, 1997, J CELL SCI, V110, P1603; IMHOF BA, 1983, CELL, V35, P667, DOI 10.1016/0092-8674(83)90099-5; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; KRAMER RH, 1984, J CELL BIOL, V99, P692, DOI 10.1083/jcb.99.2.692; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MIKATA A, 1971, EXP MOL PATHOL, V14, P289, DOI 10.1016/0014-4800(71)90002-5; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; NAGY Z, 1991, ANN NY ACAD SCI, V633, P395; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PIALI L, 1995, J EXP MED, V181, P811, DOI 10.1084/jem.181.2.811; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; SIMIONESCU M, 1975, J CELL BIOL, V67, P863, DOI 10.1083/jcb.67.3.863; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Telo P, 1997, THERAPIE, V52, P395; VANDEURS B, 1975, LAB INVEST, V32, P201; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Wiedle G, 1999, CANCER RES, V59, P5255; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; WOLBURG H, 1994, J CELL SCI, V107, P1347	51	186	198	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2733	2741		10.1074/jbc.M005458200	http://dx.doi.org/10.1074/jbc.M005458200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053409	hybrid			2022-12-25	WOS:000166784800060
J	Levy, R; Wiedmann, M; Kreibich, G				Levy, R; Wiedmann, M; Kreibich, G			In vitro binding of ribosomes to the beta subunit of the Sec61p protein translocation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; MICROSOMAL-MEMBRANES; SECRETORY PROTEIN; ER MEMBRANE; BOUND RIBOSOMES; TRANSPORT; COMPONENTS; RECEPTOR; IDENTIFICATION	The Sec61p complex forms the core element of the protein translocation complex (translocon) in the rough endoplasmic reticulum trough ER) membrane. Translating or nontranslating ribosomes bind with high affinity to ER membranes that have been stripped of ribosomes or to liposomes containing purified Sec61p, Here we present evidence that the beta subunit of the complex (Sec61 beta) makes contact with nontranslating ribosomes, A fusion protein containing the Sec61 beta cytoplasmic domain (Sec61 beta (c)) prevents the binding of ribosomes to stripped ER-derived membranes and also binds to ribosomes directly with an affinity close to the affinity of ribosomes for stripped ER-derived membranes. The ribosome binding activity of Sec61 beta (c), like that of native ER membranes, is sensitive to high salt concentrations and is not based on an unspecific charge-dependent interaction of the relatively basic Sec61 beta (c) domain with ribosomal RNA. Like stripped ER membranes, the Sec61 beta (c) sequence binds to large ribosomal subunits in preference over small subunits, Previous studies have shown that Sec61 beta is inessential for ribosome binding and protein translocation, but translocation is impaired by the absence of Sec61 beta (c) and it has been proposed that Sec61 beta assists in the insertion of nascent proteins into the translocation pore. Our results suggest a physical interaction of the ribosome itself with Sec61 beta; this may normally occur alongside interactions between the ribosome and other elements of Sec61p, or it may represent one stage in a temporal sequence of binding.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	New York University; Memorial Sloan Kettering Cancer Center	Kreibich, G (corresponding author), NYU, Sch Med, Dept Cell Biol, 550 1St Ave, New York, NY 10016 USA.	kreibg01@-mcrcr.med.nyu.edu						ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; KISILEVSKY R, 1987, BIOCHIM BIOPHYS ACTA, V910, P282, DOI 10.1016/0167-4781(87)90121-7; KUHLBRANDT W, 1982, J MOL BIOL, V156, P431, DOI 10.1016/0022-2836(82)90259-5; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LEWIS JA, 1977, J BIOL CHEM, V252, P5547; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; Raden D, 2000, J CELL BIOL, V150, P53, DOI 10.1083/jcb.150.1.53; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Song WQ, 2000, CELL, V100, P333, DOI 10.1016/S0092-8674(00)80669-8; TASHIRO Y, 1965, J MOL BIOL, V11, P149, DOI 10.1016/S0022-2836(65)80047-X; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; UNWIN PNT, 1977, NATURE, V269, P118, DOI 10.1038/269118a0; UNWIN PNT, 1979, J MOL BIOL, V132, P69, DOI 10.1016/0022-2836(79)90496-0; UNWIN PNT, 1977, J MOL BIOL, V114, P491, DOI 10.1016/0022-2836(77)90174-7; Valcarcel R, 1999, J CELL SCI, V112, P4389; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; YOSHIDA H, 1987, BIOCHEM J, V245, P811, DOI 10.1042/bj2450811	48	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2340	2346		10.1074/jbc.M004867200	http://dx.doi.org/10.1074/jbc.M004867200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11036067	hybrid			2022-12-25	WOS:000166784800008
J	Tisdale, EJ				Tisdale, EJ			Glyceraldehyde-3-phosphate dehydrogenase is required for vesicular transport in the early secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BREFELDIN-A; TRANSMEMBRANE PROTEINS; MEMBRANE-TRANSPORT; ADP-RIBOSYLATION; GOLGI-APPARATUS; IDENTIFICATION; RAB2; ER; PHOSPHORYLATION	Protein transport in the early secretory pathway requires Rab2 GTPase, This protein promotes the recruitment of soluble components that participate in protein sorting and recycling from pre-Golgi intermediates (vesicular tubular clusters (VTCs)), We previously reported that a constitutively activated form of Rab2 (Q65L) as well as Rab2 wild type promoted vesicle formation from VTCs, These vesicles contained Rab2, P-COP, p53/gp58, and protein kinase C iota/lambda but lacked anterograde-directed cargo. To identify other candidate Rab2 effecters, the polypeptide composition of the vesicles was further analyzed. We found that vesicles released in response to Rab2 also contained the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), To study the relationship of this enzyme to Rab2 function, we performed a quantitative binding assay to measure recruitment of GAPDH to membrane when incubated with Rab2, Rab2-treated microsomes showed a 5-10-fold increase in the level of membrane-associated GAPDH. We generated an affinity-purified anti-GAPDH polyclonal to study the biochemical role of GAPDH in the early secretory pathway. The antibody arrests transport of a reporter molecule in an assay that reconstitutes ER to Golgi traffic. Furthermore, the affinity-purified antibody blocked the ability of Rab2 to recruit GAPDH to membrane. However, the antibody did not interfere with Rab2 stimulated vesicle release. These data suggest that GAPDH is required for ER to Golgi transport. We propose that membranes incubated with anti-GAPDH and Rab2 form "dead end" vesicles that are unable to transport and fuse with the acceptor compartment.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.	etisdale@med.wayne.edu						ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BECKERS CJ, 1989, CELL, V50, P523; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; Grigorieva JA, 1999, ARCH BIOCHEM BIOPHYS, V369, P252, DOI 10.1006/abbi.1999.1341; Han XL, 1998, BBA-BIOMEMBRANES, V1414, P95, DOI 10.1016/S0005-2736(98)00154-0; Harris J.I., 1976, ENZYMES, VXIII; Hessler RJ, 1998, J LEUKOCYTE BIOL, V63, P331, DOI 10.1002/jlb.63.3.331; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KUMAGAI H, 1983, J BIOCHEM-TOKYO, V93, P1259, DOI 10.1093/oxfordjournals.jbchem.a134260; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Reiss N, 1996, BIOCHEM MOL BIOL INT, V40, P1191; ROBBINS AR, 1995, J CELL BIOL, V130, P1093, DOI 10.1083/jcb.130.5.1093; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Tisdale EJ, 2000, TRAFFIC, V1, P702, DOI 10.1034/j.1600-0854.2000.010903.x; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; VINALS AEL, 1987, BIOCHEM BIOPH RES CO, V143, P403, DOI 10.1016/0006-291X(87)90680-2; VOLKER KW, 1995, COMP BIOCHEM PHYS B, V112, P503, DOI 10.1016/0305-0491(95)00096-8; Weigert R, 1997, J BIOL CHEM, V272, P14200, DOI 10.1074/jbc.272.22.14200	34	108	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2480	2486		10.1074/jbc.M007567200	http://dx.doi.org/10.1074/jbc.M007567200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035021	hybrid			2022-12-25	WOS:000166784800026
J	Carr, AC; Frei, B				Carr, AC; Frei, B			The nitric oxide congener nitrite inhibits myeloperoxidase/H2O2/Cl--mediated modification of low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; MYELOPEROXIDASE COMPOUND-I; HUMAN-BLOOD-PLASMA; HYPOCHLOROUS ACID; LIPID-PEROXIDATION; OXIDATIVE MODIFICATION; CATALYZED OXIDATION; TYROSINE NITRATION; HYDROGEN-PEROXIDE; PROTEIN NITRATION	Nitric oxide, a pivotal molecule in vascular homeostasis, is converted under aerobic conditions to nitrite. Recent studies have shown that myeloperoxidase (MPO), an abundant heme protein released by activated leuko- cytes, can oxidize nitrite (NO,) to a radical species, most likely nitrogen dioxide. Furthermore, hypochlorous acid (HOCl), the major strong oxidant generated by MPO in the presence of physiological concentrations of chloride ions, can also react with nitrite, forming the reactive intermediate nitryl chloride. Since MPO and MPO derived HOCl, as well as reactive nitrogen species, have been implicated in the pathogenesis of atherosclerosis through oxidative modification of low density lipoprotein (LDL), we investigated the effects of physio logical concentrations of nitrite (12.5-200 muM) on MPO-mediated modification of LDL in the absence and presence of physiological chloride concentrations. Interestingly, nitrite concentrations as low as 12.5 and 25 muM significantly decreased MPO/H2O2/Cl--induced modification of apoB lysine residues, formation of N-chloramines, and increases in the relative electrophoretic mobility of LDL. In contrast, none of these markers of LDL atherogenic modification were affected by the MPO/ H2O2/NO2- system. Furthermore, experiments using ascorbate (12.5-200 ECM) and the tyrosine analogue 4-hydroxyphenylacetic acid (12.5-200 muM), which are both substrates of MPO, indicated that nitrite inhibits MPO-mediated LDL modifications by trapping the enzyme in its inactive compound II form. These data offer a novel mechanism for a potential antiatherogenic effect of the nitric oxide congener nitrite.	Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA	Oregon State University	Carr, AC (corresponding author), Oregon State Univ, Linus Pauling Inst Sci & Med, 571 Weniger Hall, Corvallis, OR 97331 USA.			, Anitra/0000-0002-5890-2977	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056170] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56170] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P189, DOI 10.1016/0167-4838(84)90127-4; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; Buttery LDK, 1996, LAB INVEST, V75, P77; Byun J, 1999, FEBS LETT, V455, P243, DOI 10.1016/S0014-5793(99)00893-5; Carr AC, 2000, BIOCHEM J, V346, P491, DOI 10.1042/0264-6021:3460491; CHESNEY JA, 1991, ANAL BIOCHEM, V196, P262, DOI 10.1016/0003-2697(91)90463-4; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FOLKES LK, 1995, ARCH BIOCHEM BIOPHYS, V323, P120, DOI 10.1006/abbi.1995.0017; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; HABERLAND ME, 1982, P NATL ACAD SCI-BIOL, V79, P1712, DOI 10.1073/pnas.79.6.1712; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hogg N, 1998, FREE RADICAL RES, V28, P593, DOI 10.3109/10715769809065815; Hsuanyu Y, 1999, ARCH BIOCHEM BIOPHYS, V368, P413, DOI 10.1006/abbi.1999.1328; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; Kettle AJ, 1997, REDOX REP, V3, P257, DOI 10.1080/13510002.1997.11747120; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; Kono Y, 1995, BIOCHEM MOL BIOL INT, V36, P275; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; Kuhn H, 1997, CURR OPIN LIPIDOL, V8, P111; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V200, P951, DOI 10.1006/bbrc.1994.1542; Luoma JS, 1998, ARTERIOSCL THROM VAS, V18, P157, DOI 10.1161/01.ATV.18.2.157; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; Marcinkiewicz J, 2000, INFLAMM RES, V49, P280, DOI 10.1007/PL00000208; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Panasenko OM, 1997, ARCH BIOCHEM BIOPHYS, V343, P254, DOI 10.1006/abbi.1997.0171; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Reszka KJ, 1999, FREE RADICAL BIO MED, V26, P669, DOI 10.1016/S0891-5849(98)00244-5; RYU BH, 1995, BIOSCI BIOTECH BIOCH, V59, P1619, DOI 10.1271/bbb.59.1619; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SOMMER A, 1991, BIOCHEMISTRY-US, V30, P11245, DOI 10.1021/bi00111a008; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; TOYOOKA T, 1984, ANAL CHEM, V56, P2461, DOI 10.1021/ac00277a044; UEDA T, 1995, ELECTROPHORESIS, V16, P1002, DOI 10.1002/elps.11501601167; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; vanDalen CJ, 1997, BIOCHEM J, V327, P487; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Vodovotz Y, 1996, BIOTECHNIQUES, V20, P390; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; Ye YZ, 1996, METHOD ENZYMOL, V269, P201	68	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1822	1828		10.1074/jbc.M009082200	http://dx.doi.org/10.1074/jbc.M009082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11054430	hybrid			2022-12-25	WOS:000166528000025
J	Washington, MT; Johnson, RE; Prakash, S; Prakashs, L				Washington, MT; Johnson, RE; Prakash, S; Prakashs, L			Mismatch extension ability of yeast and human DNA polymerase eta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM; FIDELITY; BYPASS; FORM	DNA polymerase eta (Pol eta) functions in error-free replication of W-damaged DNA, and in vitro it efficiently bypasses a cis-syn T-T dimer by incorporating two adenines opposite the lesion. Steady state kinetic studies have shown that both yeast and human Pol eta are low-fidelity enzymes, and they misincorporate nucleotides with a frequency of 10(-2)-10(-3) on both undamaged and T-T dimer-containing DNA templates. To better understand the role of Pol eta in error-free translesion DNA synthesis, here we examine the ability of Pol eta to extend from base mismatches. We find that both yeast and human Pol eta extend from mismatched base pairs with a frequency of similar to 10(-3) relative to matched base pairs. In the absence of efficient extension of mismatched primer termini, the ensuing dissociation of Pol eta from DNA may favor the excision of mismatched nucleotides by a proofreading exonuclease. Thus, we expect DNA synthesis by Pol eta to be more accurate than that predicted from the fidelity of nucleotide incorporation alone.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakashs, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech Sts, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Washington, Todd/0000-0001-8680-2992; Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NIGMS NIH HHS [GM19261] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Creighton S, 1995, METHOD ENZYMOL, V262, P232; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835	12	43	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2263	2266		10.1074/jbc.M009049200	http://dx.doi.org/10.1074/jbc.M009049200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11054429	hybrid			2022-12-25	WOS:000166528000082
J	Kanipes, MI; Lin, SH; Cotter, RJ; Raetz, CRH				Kanipes, MI; Lin, SH; Cotter, RJ; Raetz, CRH			Ca2+-induced phosphoethanolamine transfer to the outer 3-deoxy-D-manno-octulosonic acid moiety of Escherichia coli lipopolysaccharide - A novel membrane enzyme dependent upon phosphatidylethanolamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; LIPID-A; VIRULENCE GENE; BIOSYNTHESIS; PURIFICATION; MUTANT; ENDOTOXINS; BACTERIAL	Certain strains of Escherichia coli and Salmonella contain lipopolysaccharide (LPS) modified with a phosphoethanolamine (pEtN) group at position 7 of the outer 3-deoxy-D-manno-octulosonic acid (Kdo) residue. Using the heptose-deficient E, coli mutant WBB06 (Brabetz, W,, Muller-Loennies, S., Hoist, O, and Brade, H. (1997) Eur. J. Biochem. 247, 716-724), we now demonstrate that the critical parameter determining the presence or absence of pEtN is the concentration of CaCl2 in the medium. As judged by mass spectrometry, half the LPS in WBB06, grown on nutrient broth with 5 mM CaCl2, is derivatized with a pEtN group, whereas LPS from WBB06 grown without supplemental CaCl2 is not. Membranes from E, coli WBB06 or wild-type W3110 grown on 5-50 mM CaCl2 contain a novel pEtN transferase that uses the precursor Kdo(2)-[4'-P-32]lipid IVA as an acceptor. Transferase is not present in membranes of E. coli grown with 5 mM MgCl2, BaCl2, or ZnCl2, Hydrolysis of the in vitro reaction product, pEtN-Kdo(2)-[4'-P-32]lipid IVA, at pH 4.5 shows that the pEtN substituent is located on the outer Kdo moiety, Membranes from an E, coli pss knockout mutant grown on 50 mM CaCl2, which lack phosphatidylethanolamine, do not contain measurable transferase activity unless exogenous phosphatidylethanolamine is added back to the assay system. The induction of the pEtN transferase by 5-50 mM CaCl2 suggests possible role(s) in establishing transformation competence or resisting environmental stress, and represents the first example of a regulated covalent modification of the inner core of E. coli LPS.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NIGMS NIH HHS [GM-54882, GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BERGMANS HEN, 1981, J BACTERIOL, V146, P564, DOI 10.1128/JB.146.2.564-570.1981; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brade H., 1999, ENDOTOXIN HLTH DIS; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Clementz T, 1997, J BIOL CHEM, V272, P10353; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Ferguson AD, 2000, STRUCTURE, V8, P585; Groisman EA, 1998, BIOESSAYS, V20, P96, DOI 10.1002/(SICI)1521-1878(199801)20:1<96::AID-BIES13>3.0.CO;2-3; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HASIN M, 1982, J BIOL CHEM, V257, P2475; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; Miller J.H., 1972, EXPT MOL GENETICS; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; QURESHI N, 1988, J BIOL CHEM, V263, P11971; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; STRAIN SM, 1983, J BIOL CHEM, V258, P3466; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; Yethon JA, 1998, J BIOL CHEM, V273, P26310, DOI 10.1074/jbc.273.41.26310; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	34	68	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1156	1163		10.1074/jbc.M009019200	http://dx.doi.org/10.1074/jbc.M009019200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042192	hybrid			2022-12-25	WOS:000166430900043
J	Liu, XQ; Wang, CC				Liu, XQ; Wang, CC			Disulfide-dependent folding and export of Escherichia coli DsbC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; BOND FORMATION; PERIPLASMIC PROTEIN; ISOMERASE; THIOREDOXIN; GENE; ELECTRONS; ENCODES; BINDING; FAMILY	DsbC, a member of the Dsb family in the periplasm of Gram-negative bacteria, is not only a disulfide isomerase but also a chaperone. Five DsbC mutants with Cys in the active site sequence of Cys(98)-Gly-Tyr-Cys(101) and the nonactive site disulfide Cys(141)-Cys(163) replaced by Ser have been studied. The results show that the active site Cys residues are necessary for enzyme activities but not required for chaperone activity, while the lack of the nonactive site disulfide results in a decreased chaperone activity in assisting the reactivation of denatured D-glyceraldehyde-3-phosphate dehydrogenase but has no effect on enzyme activities. Wild-type DsbC was overexpressed and correctly processed as a soluble periplasmic protein. Mutation in one of these Cys residues results in aggregation or extracellular/membrane locations, but does not affect the proper processing. DsbC mutated in either Cys residue of nonactive site disulfide shows higher sensitivity to unfolding by guanidine hydrochloride and slower refolding compared with wild-type DsbC and the active site Cys mutants. The above results provide experimental evidence for structural role of the nonactive site disulfide in folding and biological activities of DsbC.	Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, CC (corresponding author), Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.							AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; Betton JM, 1996, J BIOL CHEM, V271, P8046, DOI 10.1074/jbc.271.14.8046; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1994, J BIOL CHEM, V269, P24550; CARTER P, 1987, METHOD ENZYMOL, V154, P383; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; Chung J, 2000, MOL MICROBIOL, V35, P1099, DOI 10.1046/j.1365-2958.2000.01778.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frishman D, 1996, BIOCHEM BIOPH RES CO, V219, P686, DOI 10.1006/bbrc.1996.0295; GALISTEO EM, 1993, BIOCHIMIE, V75, P803; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Liu XQ, 1999, PROTEIN SCI, V8, P2085, DOI 10.1110/ps.8.10.2085; MCMARTHY AA, 2000, NAT STRUCT BIOL, V7, P196; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; OLIVE C, 1967, BIOCHEMISTRY-US, V6, P730, DOI 10.1021/bi00855a012; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; SAMUNI A, 1975, ANAL BIOCHEM, V63, P17, DOI 10.1016/0003-2697(75)90185-2; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; STADER JA, 1990, METHOD ENZYMOL, V185, P167; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; STRAATEN M, 1998, FEBS LETT, V428, P255; Thomas JG, 1997, APPL BIOCHEM BIOTECH, V66, P197, DOI 10.1007/BF02785589; Thorstenson YR, 1997, J BACTERIOL, V179, P5333, DOI 10.1128/jb.179.17.5333-5339.1997; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zheng WD, 1997, ARCH BIOCHEM BIOPHYS, V337, P326, DOI 10.1006/abbi.1996.9783	34	34	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1146	1151		10.1074/jbc.M004929200	http://dx.doi.org/10.1074/jbc.M004929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042167	hybrid			2022-12-25	WOS:000166430900041
J	Mehl, AM; Floettmann, JE; Jones, M; Brennan, P; Rowe, M				Mehl, AM; Floettmann, JE; Jones, M; Brennan, P; Rowe, M			Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor kappa B to activate transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA STABILIZATION; PHORBOL-MYRISTATE ACETATE; INTERFERON-GAMMA; GENE-EXPRESSION; C-TERMINUS; INFLAMMATORY CYTOKINES; SIGNAL-TRANSDUCTION; ESSENTIAL ROLES; LYMPHOCYTES-B	The latent membrane protein-1 (LMP1) of Epstein-Barr virus induces gene transcription, phenotypic changes, and oncogenic transformation. One cellular gene induced by LMP1 is that for intercellular adhesion molecule-1 (ICAM-1), which participates in a wide range of inflammatory and immune responses. ICAM-1 may enhance the immune recognition of cells transformed by Epstein-Barr virus, and thus combat development of malignancy. Despite growing understanding of the various signaling functions of LMP1, the molecular mechanisms by which LMP1 induces ICAM-1 are not understood. Here, we demonstrate that transcriptional activation by LMP1 is absolutely dependent upon a variant NF-kappaB motif within the tumor necrosis factor alpha (TNF alpha) response element of the ICAM-1 promoter. Although the TNF alpha response element is sufficient for TNF alpha induction of the ICAM-1 promoter, LMP1 also required the cooperation of additional upstream sequences for optimal induction, inhibitor studies of known LMP1-induced signaling pathways ruled out the involvement of c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase, and the Janus-activating tyrosine kinase 3 (JAK3), and confirmed NF-kappaB as a critical factor for induction of ICAM-1. However, although constitutive activation of NF-kappaB efficiently induced promoter activity, it was not sufficient to induce either ICAM-1 mRNA or ICAM-1 protein. Using signaling defective LMP1 mutants and deacetylation inhibitors, we showed that the C-terminal activator region 1 of LMP1 delivers a new cooperating signal to induce ICAM-1 mRNA.	Univ Wales, Coll Med, Dept Med, Cardiff CF14 4XX, S Glam, Wales	Cardiff University	Rowe, M (corresponding author), Univ Wales, Coll Med, Dept Med, Tenovus Bldg, Cardiff CF14 4XX, S Glam, Wales.		Rowe, Martin/B-2880-2009; Brennan, Paul/ABB-9196-2021; Brennan, Paul/B-9210-2009	Rowe, Martin/0000-0003-4139-7326; Brennan, Paul/0000-0001-8792-0499; Brennan, Paul/0000-0001-8792-0499				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; Chini BA, 1998, J VIROL, V72, P1623, DOI 10.1128/JVI.72.2.1623-1626.1998; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Dhanasekaran N, 1998, ONCOGENE, V17, P1329, DOI 10.1038/sj.onc.1202170; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Floettmann JL, 1998, ONCOGENE, V17, P2383, DOI 10.1038/sj.onc.1202144; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; JAHNKE A, 1995, EUR J BIOCHEM, V228, P439; JAHNKE A, 1995, IMMUNOBIOLOGY, V193, P305, DOI 10.1016/S0171-2985(11)80559-0; JONES M, 2001, METHODS MOL BIOL EPS, V174; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Koyama Y, 2000, BLOOD, V96, P1490, DOI 10.1182/blood.V96.4.1490.h8001490_1490_1495; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Liljeholm S, 1998, J GEN VIROL, V79, P2117, DOI 10.1099/0022-1317-79-9-2117; Magnaghi-Jaulin L, 2000, Prog Cell Cycle Res, V4, P41; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OHH M, 1994, J BIOL CHEM, V269, P30117; OHH M, 1994, BLOOD, V84, P2632; Papi A, 1999, J BIOL CHEM, V274, P30041, DOI 10.1074/jbc.274.42.30041; Paxton LLL, 1997, J BIOL CHEM, V272, P15928, DOI 10.1074/jbc.272.25.15928; Puls A, 1999, J CELL SCI, V112, P2983; RICKINSON A, 1996, FIELDS VIROLOGY, V2, P2397; Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wang S, 1996, CANCER RES, V56, P4610; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6	59	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					984	992		10.1074/jbc.M003758200	http://dx.doi.org/10.1074/jbc.M003758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11034993	hybrid			2022-12-25	WOS:000166430900018
J	Emanuelli, M; Carnevali, F; Saccucci, F; Pierella, F; Amici, A; Raffaelli, N; Magni, G				Emanuelli, M; Carnevali, F; Saccucci, F; Pierella, F; Amici, A; Raffaelli, N; Magni, G			Molecular cloning, chromosomal localization, tissue mRNA levels, bacterial expression, and enzymatic properties of human NMN adenylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE MONONUCLEOTIDE ADENYLYLTRANSFERASE; NAD BIOSYNTHESIS; CDNA SEQUENCE; PROTEIN; PURIFICATION; TIAZOFURIN; METABOLISM; BINDING; GENE	A 1329-base pair clone isolated from a human placenta cDNA library contains a full-length 837-base pair coding region for a 31.9-kDa protein whose deduced primary structure exhibits high homology to consensus sequences found in other NMN adenylyltransferases. Northern blotting detected a major 3.1-kilobase mRNA transcript as well as a minor 4.1-kilobase transcript in all human tissues examined. In several cancer cell lines, lower levels of mRNA expression were clearly evident. The gene encoding the human enzyme was mapped to chromosome band 1p32-35. High efficiency bacterial expression yielded 1.5 mg of recombinant enzyme/liter of culture medium. The molecular and kinetic properties of recombinant human NMR adenylyltransferase provide new directions for investigating metabolic pathways involving this enzyme.	Univ Ancona, Fac Med & Chirurg, Ist Biochim, I-60100 Ancona, Italy; Univ Ancona, Fac Med & Chirurg, Ist Biol & Genet, I-60100 Ancona, Italy	Marche Polytechnic University; Marche Polytechnic University	Magni, G (corresponding author), Univ Ancona, Fac Med & Chirurg, Ist Biochim, Via Ranieri, I-60100 Ancona, Italy.		Amici, Adolfo/C-5342-2012	Amici, Adolfo/0000-0002-1081-7749; Saccucci, Franca/0000-0002-8407-2516				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALDUCCI E, 1995, ANAL BIOCHEM, V228, P64, DOI 10.1006/abio.1995.1315; BALDUCCI E, 1995, BIOCHEM J, V310, P395, DOI 10.1042/bj3100395; BORK P, 1995, PROTEINS, V22, P259, DOI 10.1002/prot.340220306; Boulton S, 1997, BRIT J CANCER, V76, P845, DOI 10.1038/bjc.1997.473; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Emanuelli M, 1999, FEBS LETT, V455, P13, DOI 10.1016/S0014-5793(99)00852-2; EMANUELLI M, 1992, ARCH BIOCHEM BIOPHYS, V298, P29, DOI 10.1016/0003-9861(92)90089-F; EMANUELLI M, 1995, BIOCHEM PHARMACOL, V49, P575, DOI 10.1016/0006-2952(94)00478-5; FUNAKOSHI I, 1992, ARCH BIOCHEM BIOPHYS, V295, P180, DOI 10.1016/0003-9861(92)90504-P; GREENBAUM AL, 1968, BIOCHEM J, V107, P63, DOI 10.1042/bj1070063; HELMANN U, 1995, ANAL BIOCHEM, V224, P451; HOGEBOOM GH, 1952, J BIOL CHEM, V197, P611; HUGHES KT, 1983, J BACTERIOL, V155, P213, DOI 10.1128/JB.155.1.213-221.1983; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Jacobson EL, 1999, MOL CELL BIOCHEM, V193, P69, DOI 10.1023/A:1006960126369; JAYARAM HN, 1986, BIOCHEM PHARMACOL, V35, P587, DOI 10.1016/0006-2952(86)90352-7; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; MORTON RK, 1971, NATURE, V181, P540; NATALINI P, 1986, BIOCHEMISTRY-US, V25, P3725, DOI 10.1021/bi00360a037; Raffaelli N, 1997, J BACTERIOL, V179, P7718, DOI 10.1128/jb.179.24.7718-7723.1997; Raffaelli N, 1999, FEBS LETT, V444, P222, DOI 10.1016/S0014-5793(99)00068-X; Raffaelli N, 1999, J BACTERIOL, V181, P5509, DOI 10.1128/JB.181.17.5509-5511.1999; RAFFAELLI N, 2001, IN PRESS METHODS ENZ, V331; SOLAO PB, 1971, EXP CELL RES, V69, P295, DOI 10.1016/0014-4827(71)90227-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1986, J MOL BIOL, V189, P435; WILLIAMS SR, 1984, NUCLEIC ACIDS RES, V12, P5779, DOI 10.1093/nar/12.14.5779	33	116	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					406	412		10.1074/jbc.M008700200	http://dx.doi.org/10.1074/jbc.M008700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027696	hybrid			2022-12-25	WOS:000166280700055
J	Worm, J; Bartkova, J; Kirkin, AF; Straten, PT; Zeuthen, J; Bartek, J; Guldberg, P				Worm, J; Bartkova, J; Kirkin, AF; Straten, PT; Zeuthen, J; Bartek, J; Guldberg, P			Aberrant p27(Kip1) promoter methylation in malignant melanoma	ONCOGENE			English	Article						p27; Kip1; tumor suppressor; malignant melanoma; cell cycle; haploinsufficiency; methylation; cyclin-dependent kinase inhibitor	KINASE INHIBITOR P27; CELL LUNG-CANCER; CDK INHIBITORS; BREAST-CANCER; FREQUENT LOSS; GENE; CYCLE; HETEROZYGOSITY; EXPRESSION; MUTATION	p27(Kip1) is a regulator of the mammalian cell cycle and a putative tumor suppressor. Distinct altered patterns of p27(Kip1) protein expression are found in a variety of human carcinomas, and p27(Kip1) expression levels usually correlate directly with disease-free survival. The mechanism(s) by which p27(Kip1) expression is reduced or lost during tumorigenesis remains unclear, Specific alterations of the p27(Kip1) gene, including mutations and homozygous deletions, are exceedingly rare in human cancers. We have used methylation-specific PCR and bisulfite genomic sequencing to examine the methylation status of p27(Kip1) in 61 primary and metastatic tumors and 35 cell lines from patients with malignant melanoma, Dense methylation of a CpG island in the promoter region of p27(Kip1) was detected in four of 45 metastatic tumors (9%) and three of the cell lines (9%), including two cell lines established from two different metastases from the same patient. Examination of a naturally occurring, allele-specific sequence variant demonstrated that p27(Kip1) methylation is associated with transcriptional silencing in situ, Cell lines with p27(Kip1) methylation showed retention of the wild-type allele and detectable p27(Kip1) protein whose abundance was reduced compared with normal melanocytes, Collectively, our data suggest that DNA methylation may be a cause of monoallelic p27(Kip1) silencing in malignant melanoma, which would support a role for p27(Kip1) haploinsuffciency in human cancer.	Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	thor Straten, Per/0000-0002-4731-4969				Bartkova J, 1996, INT J CANCER, V66, P732, DOI 10.1002/(SICI)1097-0215(19960611)66:6<732::AID-IJC4>3.0.CO;2-0; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DECKER HJH, 1990, CANCER GENET CYTOGEN, V46, P135, DOI 10.1016/0165-4608(90)90021-2; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Guldberg P, 1997, CANCER RES, V57, P3660; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spirin KS, 1996, CANCER RES, V56, P2400; Takeuchi S, 1996, CANCER RES, V56, P738	26	55	64	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5111	5115		10.1038/sj.onc.1203891	http://dx.doi.org/10.1038/sj.onc.1203891			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042700				2022-12-25	WOS:000089930100009
J	Kubota, S; Kondo, S; Eguchi, T; Hattori, T; Nakanishi, T; Pomerantz, RJ; Takigawa, M				Kubota, S; Kondo, S; Eguchi, T; Hattori, T; Nakanishi, T; Pomerantz, RJ; Takigawa, M			Identification of an RNA element that confers post-transcriptional repression of connective tissue growth factor/hypertrophic chondrocyte specific 24 (ctgf/hcs24) gene: Similarities to retroviral RNA-protein interactions	ONCOGENE			English	Article						CTGF; angiogenesis; chondrocyte; HIV-1 Rev; 3 '-UTR	ANCHORAGE-INDEPENDENT GROWTH; VASCULAR ENDOTHELIAL-CELLS; ANGIOGENESIS IN-VIVO; CAP-BINDING-PROTEIN; MESSENGER-RNAS; FACTOR-BETA; NEGATIVE REGULATOR; NUCLEAR EXPORT; LINE HCS-2/8; REV PROTEIN	The repressive effect of the 3'-untranslated region (3'-UTR) in human connective tissue growth factor/hypertrophic chondrocyte specific 24 (ctgf/hcs24) mRNA on gene expression had been demonstrated in our previous study. Here, we identified a minimal RNA element in the 3'-UTR, which acts as a cis-acting element of structure-anchored repression (CAESAR). Deletion analyses of the 3'-UTR led us to minimize the element of 84 bases at the junction of the coding region and the 3'-UTR. The minimized RNA segment is predicted, and actually capable of forming a stable secondary structure in vitro. Mutational analyses disclosed a significant relationship between the predicted structure and repressive effect. The utility of CAESAR as a post-transcriptional regulatory element was represented by the fact that steady-state mRNA levels were not affected by CAESAR linked in cis, while protein levels from such a chimeric gene were markedly reduced. Of note, the CAESAR sequence exerted no effect, when it was placed upstream of the promoter. Finally, RNA gel electromobility-shift analyses demonstrated a nuclear factor that interacts with the folded CAESAR. Taken together, it was uncovered that CAESAR of ctgf is a novel post-transcriptional structured RNA regulatory element, probably acting through direct interactions with a nuclear factor as observed in retroviral RNA elements with certain proteins.	Okayama Univ, Sch Dent, Dept Biochem & Mol Dent, Okayama 7008525, Japan; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Ctr Human Virol,Div Infect Dis, Philadelphia, PA 19107 USA	Okayama University; Jefferson University	Takigawa, M (corresponding author), Okayama Univ, Sch Dent, Dept Biochem & Mol Dent, 2-5-1 Shikata Cho, Okayama 7008525, Japan.		Kondo, Seiji/I-4332-2017; Kondo, Seiji/ABD-3982-2020	Kondo, Seiji/0000-0001-9341-5069; Kondo, Seiji/0000-0001-9341-5069; Eguchi, Takanori/0000-0002-3297-6126	PHS HHS [A143876] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; Babic AM, 1999, MOL CELL BIOL, V19, P2958; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; ENOMOTO M, 1992, BIOL REGULATION CHON, P321; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GILMAN M, 1987, CURRENT PROTOCOLS MO; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hattori T, 1998, BIOCHEM BIOPH RES CO, V245, P679, DOI 10.1006/bbrc.1998.8505; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; KATAOKA N, 1995, NUCLEIC ACIDS RES, V23, P3638, DOI 10.1093/nar/23.18.3638; KIKUCHI K, 1995, J INVEST DERMATOL, V105, P128, DOI 10.1111/1523-1747.ep12313452; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kubo M, 1998, BRIT J DERMATOL, V139, P192; KUBOTA S, 1995, FEBS LETT, V375, P31, DOI 10.1016/0014-5793(95)01166-C; Kubota S, 1996, VIROLOGY, V220, P502, DOI 10.1006/viro.1996.0339; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; Kubota S, 1999, FEBS LETT, V450, P84, DOI 10.1016/S0014-5793(99)00480-9; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Nakanishi T, 1997, BIOCHEM BIOPH RES CO, V234, P206, DOI 10.1006/bbrc.1997.6528; Naveh-Many T, 1999, J BONE MINER RES, V14, pS167; Nishida T, 1998, BIOCHEM BIOPH RES CO, V247, P905, DOI 10.1006/bbrc.1998.8895; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Ogbourne S, 1998, BIOCHEM J, V331, P1; OHBA Y, 1995, BBA-GEN SUBJECTS, V1245, P1, DOI 10.1016/0304-4165(95)00065-J; OHNO M, 1990, NUCLEIC ACIDS RES, V18, P6989, DOI 10.1093/nar/18.23.6989; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Sterling K, 1996, MOL PHARMACOL, V49, P329; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TAKIGAWA M, 1989, CANCER RES, V49, P3996; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131; ZHU J, 1994, JPN J CANCER RES, V85, P364, DOI 10.1111/j.1349-7006.1994.tb02368.x	51	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4773	4786		10.1038/sj.onc.1203835	http://dx.doi.org/10.1038/sj.onc.1203835			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032028				2022-12-25	WOS:000089528800012
J	Vollmer, M; Thomsen, N; Wiek, S; Seeber, F				Vollmer, M; Thomsen, N; Wiek, S; Seeber, F			Apicomplexan parasites possess distinct nuclear-encoded, but apicoplast-localized, plant-type ferredoxin-NADP(+) reductase and ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; IRON-SULFUR PROTEINS; TOXOPLASMA-GONDII; PLASMODIUM-FALCIPARUM; ESCHERICHIA-COLI; ELECTRON-TRANSFER; RAPID ISOLATION; FATTY-ACIDS; CHLOROPLASTS; PURIFICATION	In searching for nuclear-encoded, apicoplast-localized proteins we have cloned ferredoxin-NADP(+) reductase from Toxoplasma gondii and a [2Fe-2S] ferredoxin from Plasmodium falciparum. This chloroplast-localized redox system has been extensively studied in photosynthetic organisms and is responsible for the electron transfer from photosystem I to NADP(+). Besides this light-dependent reaction in nonphotosynthetic plastids (e.g. from roots), electrons can also flow in the reverse direction, from NADPH to ferredoxin, which then serves as an important reductant for various plastid-localized enzymes. These plastids possess related, but distinct, ferredoxin-NADP(+) reductase and ferredoxin isoforms for this purpose. We provide phylogenetic evidence that the T. gondii reductase is similar to such nonphotosynthetic isoforms. Both the P. falciparum [2Fe-2S] ferredoxin and the T. gondii ferredoxin-NADP(+) reductase possess an N-terminal bipartite transit peptide domain typical for apicoplast-localized proteins. The recombinant proteins were obtained in active form, and antibodies raised against the reductase recognized two bands on Western blots of T. gondii tachyzoite lysates, indicative of the unprocessed and native form, respectively. We propose that the role of this redox system is to provide reduced ferredoxin, which might then be used for fatty acid desaturation or other biosynthetic processes yet to be defined. Thus, the interaction of these two proteins offers an attractive target for drug intervention.	Univ Marburg, Fachbereich Biol Parasitol, D-35032 Marburg, Germany	Philipps University Marburg	Seeber, F (corresponding author), Univ Marburg, Fachbereich Biol Parasitol, Karl von Frisch Str, D-35032 Marburg, Germany.			Seeber, Frank/0000-0002-2271-3699				Akashi T, 1999, J BIOL CHEM, V274, P29399, DOI 10.1074/jbc.274.41.29399; Aliverti A, 1999, FLAVINS FLAVOPROTEIN, P265; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BAKER RT, 1994, J BIOL CHEM, V269, P25381; Baker RT, 1996, CURR OPIN BIOTECH, V7, P541, DOI 10.1016/S0958-1669(96)80059-0; BENTING J, 1994, BIOCHEM J, V300, P821, DOI 10.1042/bj3000821; Bes MT, 1999, STRUCT FOLD DES, V7, P1201, DOI 10.1016/S0969-2126(00)80054-4; Blanchard JL, 1999, J EUKARYOT MICROBIOL, V46, P367, DOI 10.1111/j.1550-7408.1999.tb04615.x; BOOTHROYD JC, 1995, METH MOL G, V6, P3; CARRILLO N, 1987, LIGHT REACTIONS, P527; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; Corneille S, 1998, BBA-BIOENERGETICS, V1363, P59, DOI 10.1016/S0005-2728(97)00074-1; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Grinberg AV, 2000, PROTEINS, V40, P590, DOI 10.1002/1097-0134(20000901)40:4<590::AID-PROT50>3.0.CO;2-P; Gupta RS, 1998, MICROBIOL MOL BIOL R, V62, P1435, DOI 10.1128/MMBR.62.4.1435-1491.1998; Harlow E., 1988, ANTIBODIES LAB MANUA; JACQUOT JP, 1988, EUR J BIOCHEM, V174, P629, DOI 10.1111/j.1432-1033.1988.tb14144.x; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; KAGAWA N, 1995, ORTIZ MONTELLANO, P419; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; MAJUMDAR D, 1991, BIOTECHNIQUES, V11, P94; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; Martinez-Julvez M, 1998, BIOCHEMISTRY-US, V37, P13604, DOI 10.1021/bi9807411; Martinez-Julvez M, 1999, J BIOL INORG CHEM, V4, P568, DOI 10.1007/s007750050379; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Neuhaus HE, 2000, ANNU REV PLANT PHYS, V51, P111, DOI 10.1146/annurev.arplant.51.1.111; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Onda Y, 2000, PLANT PHYSIOL, V123, P1037, DOI 10.1104/pp.123.3.1037; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PIUBELLI L, 1995, PROTEIN EXPRES PURIF, V6, P298, DOI 10.1006/prep.1995.1039; Roos DS, 1999, CURR OPIN MICROBIOL, V2, P426, DOI 10.1016/S1369-5274(99)80075-7; SCHMIDT H, 1990, P NATL ACAD SCI USA, V87, P9477, DOI 10.1073/pnas.87.23.9477; Schmitz S, 1998, BBA-BIOENERGETICS, V1363, P85, DOI 10.1016/S0005-2728(97)00085-6; Seeber F, 1996, GENE, V169, P39, DOI 10.1016/0378-1119(95)00786-5; Seeber F, 1997, PARASITOL RES, V83, P309, DOI 10.1007/s004360050254; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sticht H, 1998, PROG BIOPHYS MOL BIO, V70, P95, DOI 10.1016/S0079-6107(98)00027-3; Striepen B, 2000, J CELL BIOL, V151, P1423, DOI 10.1083/jcb.151.7.1423; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Trigg P. I., 1998, MALARIA PARASITE BIO, P11; Vanoni MA, 1999, CELL MOL LIFE SCI, V55, P617, DOI 10.1007/s000180050319; WADA H, 1993, J BACTERIOL, V175, P544, DOI 10.1128/JB.175.2.544-547.1993; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 1997, MICROBIOL MOL BIOL R, V61, P1; WONG SY, 1993, AIDS, V7, P299, DOI 10.1097/00002030-199303000-00001	58	92	96	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5483	5490		10.1074/jbc.M009452200	http://dx.doi.org/10.1074/jbc.M009452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11056177	hybrid			2022-12-25	WOS:000167115100012
J	Soldevila, AI; Ghabrial, SA				Soldevila, AI; Ghabrial, SA			A novel alcohol oxidase/RNA-binding protein with affinity for mycovirus double-stranded RNA from the filamentous fungus Helminthosporium (Cochliobolus) victoriae - Molecular and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; 190S VIRUS; CAPSID PROTEIN; SACCHAROMYCES-CEREVISIAE; GMC OXIDOREDUCTASES; GLUCOSE-OXIDASE; SEQUENCE; YEAST; EXPRESSION; CLONING	We have cloned and sequenced a novel alcohol oxidase (Hv-p68) from the filamentous fungus Helminthosporium (Cochliobolus) victoriae that copurifies with mycoviral double-stranded RNAs, Sequence analysis revealed that Hv-p68 belongs to the large family of FAD-dependent glucose methanol choline oxidoreductases and that it shares significant sequence identity (>67%) with the alcohol oxidases of the methylotrophic yeasts. Unlike the intronless alcohol oxidases from methylotrophic yeasts, a genomic fragment of the Hv-p68 gene was found to contain four introns, Hv-p68, purified from fungal extracts, showed only limited methanol oxidizing activity, and its expression was not induced in cultures supplemented with methanol as the sole carbon source. Northern hybridization analysis indicated that overexpression of Hv-p68 is associated with virus infection, because significantly higher Hv-p68 mRNA levels (10- to 20-fold) were detected in virus-infected isolates compared with virus-free ones. We confirmed by Northwestern blot analysis that Hv-p68 exhibits RNA binding activity and demonstrated that the RNA-binding domain is localized within the N-terminal region that contains a typical ADP-binding beta-alpha-beta fold motif. The Hv-p68 gene, or closely similar genes, was present in all species of the genus Cochliobolus but absent in the filamentous fungus, Penicillium chrysogenum, as well as in two nonmethylotrophic yeasts examined. This study represents the first reported case that a member of the FAD-dependent glucose methanol choline oxidoreductase family, Hv-p68, may function as an RNA-binding protein.	Univ Kentucky, Dept Plant Pathol, Lexington, KY 40546 USA	University of Kentucky	Ghabrial, SA (corresponding author), Univ Kentucky, Dept Plant Pathol, S-305 Agr Sci Ctr N, Lexington, KY 40546 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALANCE DJ, 1986, YEAST, V2, P229; Berbee ML, 1999, MYCOLOGIA, V91, P964, DOI 10.2307/3761627; Boteva R, 1999, BIOCHEMISTRY-US, V38, P5034, DOI 10.1021/bi982266c; CAVENER DR, 1992, J MOL BIOL, V223, P811, DOI 10.1016/0022-2836(92)90992-S; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DISTEL B, 1987, EMBO J, V6, P3111, DOI 10.1002/j.1460-2075.1987.tb02620.x; DRYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289; EDELMANN SE, 1994, EXP MYCOL, V18, P70, DOI 10.1006/emyc.1994.1007; ELZINGA SDJ, 1993, NUCLEIC ACIDS RES, V21, P5328, DOI 10.1093/nar/21.23.5328; FREDERICK KR, 1990, J BIOL CHEM, V265, P3793; Ghabrial S. A., 1995, VIRUS TAXONOMY CLASS, P253; GHABRIAL SA, 1987, J GEN VIROL, V68, P1791, DOI 10.1099/0022-1317-68-7-1791; GHABRIAL SA, 1992, VIROLOGY, V188, P657, DOI 10.1016/0042-6822(92)90520-Y; GHABRIAL SA, 1989, J GEN VIROL, V70, P1025, DOI 10.1099/0022-1317-70-5-1025; Ghabrial SA, 1983, DOUBLE STRANDED RNA, P441; GHABRIAL SA, 1995, VIRUS TAXONOMY, P245; GHABRIAL SA, 1986, FUNGAL VIROLOGY, P163; GHABRIAL SA, 1999, ENCY VIROLOGY, V3, P1808; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; Huang SH, 1996, P NATL ACAD SCI USA, V93, P12541, DOI 10.1073/pnas.93.22.12541; Huang SH, 1997, VIROLOGY, V234, P130, DOI 10.1006/viro.1997.8631; Kiess M, 1998, EUR J BIOCHEM, V252, P90, DOI 10.1046/j.1432-1327.1998.2520090.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; SAKAI Y, 1992, GENE, V114, P67, DOI 10.1016/0378-1119(92)90708-W; SANDERLIN RS, 1978, VIROLOGY, V87, P142, DOI 10.1016/0042-6822(78)90166-6; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Soldevila AI, 2000, VIROLOGY, V272, P183, DOI 10.1006/viro.2000.0349; Soldevila AI, 1998, VIROLOGY, V251, P327, DOI 10.1006/viro.1998.9443; Soldevila AI, 2000, J VIROL, V74, P997, DOI 10.1128/JVI.74.2.997-1003.2000; Tanguay RL, 1996, J BIOL CHEM, V271, P14316, DOI 10.1074/jbc.271.24.14316; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDERKLEI IJ, 1990, METHOD ENZYMOL, V188, P420; Varela E, 1999, BIOCHEM J, V341, P113, DOI 10.1042/0264-6021:3410113; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Yoder OC, 1988, ADV PLANT PATHOL, P93, DOI 10.1016/B978-0-12-033706-4.50009-8	46	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4652	4661		10.1074/jbc.M007701200	http://dx.doi.org/10.1074/jbc.M007701200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11056160	hybrid			2022-12-25	WOS:000168484300019
J	Ding, XQ; Dolu, V; Hadac, EM; Holicky, EL; Pinon, DI; Lybrand, TP; Miller, LJ				Ding, XQ; Dolu, V; Hadac, EM; Holicky, EL; Pinon, DI; Lybrand, TP; Miller, LJ			Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminaI probe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BINDING-SITE; A RECEPTOR; DIRECT IDENTIFICATION; CCKA RECEPTOR; AFFINITY; GLYCOSYLATION; PEPTIDE; PANCREOZYMIN; INTERACT	Affinity labeling is a powerful tool to establish spatial approximations between photolabile residues within a ligand and its receptor. Here, we have utilized a cholecystokinin (CCK) analogue with a photolabile benzoylphenylalanine (Bpa) sited in position 24, adjacent to the pharmacophoric domain of this hormone (positions 27-33). This probe was a fully efficacious agonist that bound to the CCK receptor saturably and with high affinity (K-i = 8.9 +/- 1.1 nM). It covalently labeled the CCK receptor either within the amino terminus (between Asn(10) and Lys(37)) or within the third extracellular loop (Glu(345)), as demonstrated by proteolytic peptide mapping, deglycosylation, micropurification, and Edman degradation sequencing. Truncation of the receptor to eliminate residues 1-30 had no detrimental effect on CCK binding, stimulated signaling, or affinity labeling through a residue within the pharmacophore (Bpa(29)) but resulted in elimination of the covalent attachment of the Bpa(24) probe to the receptor, Thus, the distal amino terminus of the CCK: receptor resides above the docked ligand, compressing the portion of the peptide extending beyond its pharmacophore toward the receptor core. Exposure of wild type and truncated receptor constructs to extracellular trypsin damaged the truncated construct but not the wild type receptor, suggesting that this domain also may play a protective role. Use of these additional insights into molecular approximations provided key constraints for molecular modeling of the peptide-receptor complex, supporting the counterclockwise organization of the transmembrane helical domains.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37235 USA	Mayo Clinic; Vanderbilt University; Vanderbilt University	Miller, LJ (corresponding author), Mayo Clin, Ctr Basic Res Digest Dis, Guggenheim 17, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033290] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32878] Funding Source: Medline; NINDS NIH HHS [NS33290] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BODANSZKY M, 1980, INT J PEPT PROT RES, V16, P402; Dong MQ, 1999, J BIOL CHEM, V274, P4778, DOI 10.1074/jbc.274.8.4778; FOURNIEZALUSKI MC, 1986, BIOCHEMISTRY-US, V25, P3778, DOI 10.1021/bi00361a008; Gigoux V, 1999, PROTEIN SCI, V8, P2347; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; Gouldson P, 2000, EUR J PHARMACOL, V389, P115, DOI 10.1016/S0014-2999(99)00894-8; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Hadac EM, 1999, J MED CHEM, V42, P2105, DOI 10.1021/jm980732q; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Ho HH, 1999, BIOCHEMISTRY-US, V38, P1866, DOI 10.1021/bi981195e; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG SC, 1989, PEPTIDES, V10, P785, DOI 10.1016/0196-9781(89)90114-9; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; Keire DA, 1999, BIOCHEM BIOPH RES CO, V266, P400, DOI 10.1006/bbrc.1999.1825; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; KLUEPPELBERG UG, 1989, BIOCHEMISTRY-US, V28, P3463, DOI 10.1021/bi00434a047; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUTT V, 1980, COMPREHENSIVE ENDOCR, P169; ONDETTI MA, 1970, AM J DIG DIS, V15, P149, DOI 10.1007/BF02235646; Pang RTK, 1999, ENDOCRINOLOGY, V140, P5102, DOI 10.1210/en.140.11.5102; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PEARSON RK, 1987, BIOCHEM BIOPH RES CO, V147, P346, DOI 10.1016/S0006-291X(87)80128-6; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEARSON RK, 1987, J BIOL CHEM, V262, P869; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; POWERS SP, 1988, J BIOL CHEM, V263, P5295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Smeets RLL, 1997, EUR J PHARMACOL, V325, P93, DOI 10.1016/S0014-2999(97)00106-4; SWANSON E, 1995, PSSHOW 4D VERSION; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316	38	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4236	4244		10.1074/jbc.M003798200	http://dx.doi.org/10.1074/jbc.M003798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050076	hybrid			2022-12-25	WOS:000166921200068
J	Bond, CS; White, MF; Hunter, WN				Bond, CS; White, MF; Hunter, WN			High resolution structure of the phosphohistidine-activated form of Escherichia coli cofactor-dependent phosphoglycerate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN; MECHANISM; DATABASE; SUBUNIT; PROGRAM; COMPLEX; YEAST	The active conformation of the dimeric cofactor-dependent phosphoglycerate mutase (dPGM) from Escherichia coli has been elucidated by crystallographic methods to a resolution of 1.25 Angstrom (R-factor 0.121; R-free 0.168), The active site residue His(10), central in the catalytic mechanism of dPGM, is present as a phosphohistidine with occupancy of 0.28, The structural changes on histidine phosphorylation highlight various features that are significant in the catalytic mechanism, The C-terminal 10-residue tail, which is not observed in previous dPGM structures, is well ordered and interacts with residues implicated in substrate binding; the displacement of a loop adjacent to the active histidine brings previously overlooked residues into positions where they may directly influence catalysis. E. coli dPGM, like the mammalian dPGMs, is a dimer, whereas previous structural work has concentrated on monomeric and tetrameric yeast forms. We can now analyze the sequence differences that cause this variation of quaternary structure.	Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Hunter, WN (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	W.N.Hunter@dundee.ac.uk	Hunter, William/AAE-3947-2019; Bond, Charles S/B-4094-2011; White, Malcolm F/A-6055-2010; Bond, Charles/AAF-9608-2020	Bond, Charles S/0000-0002-9584-6783; White, Malcolm F/0000-0003-1543-9342; Bond, Charles/0000-0002-9584-6783				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BEARD LN, 1968, ACTA CRYSTALL B-STRU, VB 24, P1529, DOI 10.1107/S0567740868004590; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CAMPBELL JW, 1974, NATURE, V250, P301, DOI 10.1038/250301a0; Crowhurst GS, 1999, ACTA CRYSTALLOGR D, V55, P1822, DOI 10.1107/S0907444999009944; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; Fraser HI, 1999, FEBS LETT, V455, P344, DOI 10.1016/S0014-5793(99)00910-2; Fraser ME, 1999, J MOL BIOL, V285, P1633, DOI 10.1006/jmbi.1998.2324; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jedrzejas MJ, 2000, J BIOL CHEM, V275, P23146, DOI 10.1074/jbc.M002544200; Jedrzejas MJ, 2000, EMBO J, V19, P1419, DOI 10.1093/emboj/19.7.1419; Jones BE, 1997, PROTEIN SCI, V6, P2107; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McEvoy MM, 1997, CURR OPIN STRUC BIOL, V7, P793, DOI 10.1016/S0959-440X(97)80148-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAIRN J, 1995, FEBS LETT, V359, P192, DOI 10.1016/0014-5793(95)00044-A; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rigden DJ, 1999, J MOL BIOL, V289, P691, DOI 10.1006/jmbi.1999.2848; Rigden DJ, 1998, J MOL BIOL, V276, P449, DOI 10.1006/jmbi.1997.1554; Rigden DJ, 1999, J MOL BIOL, V286, P1507, DOI 10.1006/jmbi.1999.2566; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Uhrinova S, 1997, J BIOMOL NMR, V10, P309, DOI 10.1023/A:1018307210607; Walter RA, 1999, BIOCHEM J, V337, P89, DOI 10.1042/0264-6021:3370089; WHITE MF, 1993, BIOCHEM J, V295, P743, DOI 10.1042/bj2950743	37	65	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3247	3253		10.1074/jbc.M007318200	http://dx.doi.org/10.1074/jbc.M007318200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11038361	hybrid			2022-12-25	WOS:000166784900036
J	Murray, JM; Johnson, DI				Murray, JM; Johnson, DI			The Cdc42p GTPase and its regulators Nrf1p and Scd1p are involved in endocytic trafficking in the fission yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; TRANSPORT; FUSION; GROWTH; CELLS	Nrf1p was first identified in a screen for negative regulators of the Cdc42p GTPase. Overexpression of Nrf1p resulted in dose-dependent lethality, with cells exhibiting an ellipsoidal morphology and abnormal vacuolar phenotypes including an increase in vacuolar fusion. Green fluorescent protein (GFP)-Cdc42p and GFP-Nrf1p colocalized to vacuolar membranes and GFP-Nrf1p vacuolar localization depended on Scd1p, the Schizosaccharomyces pombe homolog of the Cdc24p guanine nucleotide exchange factor. In this study, site-directed mutagenesis was conducted on Nrf1p to determine its functional domains. Mutations in the three putative transmembrane domains resulted in mislocalization of GFP-Nrf1p and an inability to induce lethality, suggesting a loss of function. Mutations in the second extramembranous loop of Nrf1p also resulted in a loss of function and altered the ability of GFP-Nrf1p to localize to vacuolar membranes. Analysis of Delta nrf1 and Delta scd1 mutants revealed defects in endocytosis. In addition, overexpression of constitutively active Cdc42(GI2V)p re suited in an increase in endocytosis and an ability to rescue the endocytic defects in Delta nrf1 and Delta scd1 cells. These data are consistent with Nrf1p and Scd1p being necessary for efficient endocytosis, possibly through the regulation of Cdc42p.	Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Johnson, DI (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, 202B Stafford Hall, Burlington, VT 05405 USA.	dijohnso@zoo.uvm.edu						Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Bone N, 1998, CURR BIOL, V8, P135, DOI 10.1016/S0960-9822(98)00060-8; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Cohen A, 1999, J BIOL CHEM, V274, P26885, DOI 10.1074/jbc.274.38.26885; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Garrett WS, 2000, CELL, V102, P325, DOI 10.1016/S0092-8674(00)00038-6; GOODE NT, 1994, MOL BIOL CELL, V5, P907, DOI 10.1091/mbc.5.8.907; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murray JM, 2000, GENETICS, V154, P155; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sherman F., 1986, METHODS YEAST GENETI; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Toda T, 1996, MOL CELL BIOL, V16, P6752; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WHITNEY JA, 1995, CELL, V83, P703; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; ZIMAN M, 1994, YEAST, V10, P463, DOI 10.1002/yea.320100405	25	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3004	3009		10.1074/jbc.M007389200	http://dx.doi.org/10.1074/jbc.M007389200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042180	hybrid			2022-12-25	WOS:000166784900006
J	Ohkubo, N; Mitsuda, N; Tamatani, M; Yamaguchi, A; Lee, YD; Ogihara, T; Vitek, MP; Tohyama, M				Ohkubo, N; Mitsuda, N; Tamatani, M; Yamaguchi, A; Lee, YD; Ogihara, T; Vitek, MP; Tohyama, M			Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PRIMARY HIPPOCAMPAL-NEURONS; THROMBIN-CLEAVAGE FRAGMENT; SYNAPTIC PLASTICITY; TYPE-4 ALLELE; EXPRESSION; GENE; CREB; CALCIUM; PHOSPHORYLATION	Inheritance of the epsilon4 allele of the apolipoprotein E gene (APOE4) is a major risk factor for the development of Alzheimer's disease (AD). Although the association between APOE4 and AD is well documented, the mechanism by which apolipoprotein E exerts an isoform-specific effect on neurons in disease is unknown. In this report, we demonstrate that apoE4 stimulates the transcriptional activity of cAMP-response element-binding protein (CREB) by activating the extracellular signal-regulated kinase (ERK) cascade in rat primary hippocampal neurons. In contrast, apoE3 was unable to stimulate CREB transcriptional activity and unable to activate the ERK pathway. Elevation of intracellular Ca2+ levels are also involved because treatment with receptor-associated protein, nifedipine, MK801, removal of Ca2+ from the medium and dantrolene all served to inhibit calcium elevation and attenuate the activation of CREB, Treatment with an apoE peptide was also found to facilitate transcription of the CREB-dependent genes, c-fos and Bcl-2. In contrast to treatment with apoE3, our findings suggest apoE4 and apoE-peptide induce a novel signaling pathway.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Geriatr Med, Suita, Osaka 5650871, Japan; CREST Japan Sci & Technol, Yokohama, Kanagawa, Japan; Ajou Univ, Sch Med, Dept Anat, Suwon 442749, South Korea; Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA	Osaka University; Osaka University; Japan Science & Technology Agency (JST); Ajou University; Duke University	Mitsuda, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Vitek, Michael/0000-0001-8140-8048				Bortolotto ZA, 1999, NATURE, V402, P297, DOI 10.1038/46290; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLAY MA, 1995, BIOCHEMISTRY-US, V34, P11142, DOI 10.1021/bi00035a020; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Jordan J, 1998, J NEUROSCI, V18, P195; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Marques MA, 1996, NEUROREPORT, V7, P2529, DOI 10.1097/00001756-199611040-00025; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Moulder KL, 1999, J NEUROCHEM, V72, P1069, DOI 10.1046/j.1471-4159.1999.0721069.x; Poirier J, 1995, ANN MED, V27, P663, DOI 10.3109/07853899509019253; Rajadhyaksha A, 1999, J NEUROSCI, V19, P6348; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun YL, 1998, J NEUROSCI, V18, P3261; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tolar M, 1997, J NEUROSCI, V17, P5678; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Wang XS, 1997, J CELL PHYSIOL, V173, P73, DOI 10.1002/(SICI)1097-4652(199710)173:1<73::AID-JCP9>3.3.CO;2-B; Weisskopf MG, 1999, J NEUROSCI, V19, P10512	34	81	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3046	3053		10.1074/jbc.M005070200	http://dx.doi.org/10.1074/jbc.M005070200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042199	Green Published, hybrid			2022-12-25	WOS:000166784900012
J	Peters, MF; Ross, CA				Peters, MF; Ross, CA			Isolation of a 40-kDa Huntingtin-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE GENE-PRODUCT; NUCLEAR-LOCALIZATION; SUBCELLULAR-LOCALIZATION; EMBRYONIC LETHALITY; GLUTAMINE REPEATS; MUTANT HUNTINGTIN; INTERACTS; POLYGLUTAMINE; APOPTOSIS; INCLUSIONS	Huntington's disease is caused by an expanded CAG trinucleotide repeat coding for a polyglutamine stretch within the huntingtin protein. Currently, the function of normal huntingtin and the mechanism by which expanded huntingtin causes selective neurotoxicity remain unknown. Clues may come from the identification of huntingtin-associated proteins (HAPs). Here, we show that huntingtin copurifies with a single novel 40-kDa protein termed HAP40. HAP40 is encoded by the open reading frame factor VIII-associated gene A (F8A) located within intron 22 of the factor VIII gene. In transfected cell extracts, HAP40 coimmunoprecipitates with full-length huntingtin but not with an N-terminal huntingtin fragment. Recombinant HAP40 is cytoplasmic in the presence of huntingtin but is actively targeted to the nucleus in the absence of huntingtin. These data indicate that HAP40 is likely to contribute to the function of normal huntingtin and is a candidate for involvement in the aberrant nuclear localization of mutant huntingtin found in degenerating neurons in Huntington's disease.	Johns Hopkins Univ, Sch Med, Dept Psychiat, Mol Neurobiol Lab,Div Neurobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Program Cellular Mol Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Peters, MF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Mol Neurobiol Lab,Div Neurobiol, Ross 618,720 Rutland Ave, Baltimore, MD 21205 USA.	mfpeters@jhmi.edu; caross@jhu.edu	Ross, Christopher A/H-8395-2013		NINDS NIH HHS [NS38144, NS16375, NS34172] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034172, P50NS016375, R01NS038144, P01NS016375] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Bao J, 1996, P NATL ACAD SCI USA, V93, P5037, DOI 10.1073/pnas.93.10.5037; BESSERT DA, 1995, MOL BRAIN RES, V33, P165, DOI 10.1016/0169-328X(95)00124-B; Boutell JM, 1998, HUM MOL GENET, V7, P371, DOI 10.1093/hmg/7.3.371; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Gusella JF, 2000, NEUROSCIENCE NEWS, V3, P15; Harlow E., 1999, USING ANTIBODIES LAB; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Jones L., 2000, NEUROSCIENCE NEWS, V3, P55; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; LEVINSON B, 1992, GENOMICS, V13, P862, DOI 10.1016/0888-7543(92)90170-W; Li H, 2000, NAT GENET, V25, P385, DOI 10.1038/78054; Li H, 1999, HUM MOL GENET, V8, P1227, DOI 10.1093/hmg/8.7.1227; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; NAYLOR JA, 1995, HUM MOL GENET, V4, P1217, DOI 10.1093/hmg/4.7.1217; NUCIFORA FC, 2000, SOC NEUR ABSTR, V26, pS1030; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; PERUTZ MF, 1995, MOL MED, V1, P718, DOI 10.1007/BF03401886; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Singaraja RR, 1999, AM J HUM GENET, V65, pA112; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wells R.D., 1998, GENETIC INSTABILITIE; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; Wood JD, 1996, HUM MOL GENET, V5, P481, DOI 10.1093/hmg/5.4.481; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	49	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3188	3194		10.1074/jbc.M008099200	http://dx.doi.org/10.1074/jbc.M008099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035034	hybrid			2022-12-25	WOS:000166784900029
J	Taboy, CH; Vaughan, KG; Mietzner, TA; Aisen, P; Crumbliss, AL				Taboy, CH; Vaughan, KG; Mietzner, TA; Aisen, P; Crumbliss, AL			Fe3+ coordination and redox properties of a bacterial transferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-BINDING PROTEIN; SPECTROELECTROCHEMICAL METHOD; PATHOGENIC NEISSERIA; SERUM TRANSFERRIN; ACTIVE-SITE; C-LOBE; N-LOBE; HEMOGLOBINS; RESOLUTION; TRANSPORT	The Fe3+ binding site of recombinant nFbp, a ferric-binding protein found in the periplasmic space of pathogenic Neisseria, has been characterized by physicochemical techniques. An effective Fe3+ binding constant in the presence of 350 muM phosphate at pH 6.5 and 25 degreesC was determined as 2.4 x 10(18) M-1. EPR spectra for the recombinant Fe3+ nFbp gave g' = 4.3 and 9 signals characteristic of high spin Fe3+ in a strong ligand field of low (orthorhombic) symmetry. P-31 NMR experiments demonstrated the presence of bound phosphate in the hole form of nFbp and showed that phosphate can be dialyzed away in the absence of Fe3+ in apo-nFbp, Finally, an uncorrected Fe3+/2+ redox potential for Fe-nFbp was determined to be -290 mV (NHE) at pH 6.5, 20 degreesC, Whereas our findings show that nFbp and mammalian transferrin have similar Fe3+ binding constants and EPR spectra, they differ greatly in their redox potentials. This has implications for the mechanism of Fe transport across the periplasmic space of Gram-negative bacteria.	Duke Univ, Dept Chem, Durham, NC 27708 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yeshiva University; Albert Einstein College of Medicine	Crumbliss, AL (corresponding author), Duke Univ, Dept Chem, Durham, NC 27708 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015056] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL58248] Funding Source: Medline; NIAID NIH HHS [1 R29 AI32226] Funding Source: Medline; NIDDK NIH HHS [2 RO1 DK15056] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AASA R, 1963, BIOCHIM BIOPHYS ACTA, V75, P203, DOI 10.1016/0006-3002(63)90599-7; AASA R, 1967, J BIOL CHEM, V243, P2399; AISEN P, 1978, J BIOL CHEM, V253, P1930; AISEN P, 1994, IRON METABOLISM HLTH, P1; Albrecht-Gary AM, 1998, MET IONS BIOL SYST, V35, P239; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BERISH SA, 1990, J EXP MED, V171, P1535, DOI 10.1084/jem.171.5.1535; Braun V, 1997, BIOL CHEM, V378, P779; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; CRICHTON RR, 1991, INORGANIC BIOCH IRON, P29; FAULKNER KM, 1994, INORG CHIM ACTA, V226, P187, DOI 10.1016/0020-1693(94)04086-9; FAULKNER KM, 1995, J BIOL CHEM, V270, P13604, DOI 10.1074/jbc.270.23.13604; FERGUSON SJ, 1991, PROKARYOTIC STRUCTUR, P311; FILATOVA LN, 1966, ZH NEORG KHIM, V11, P1662; HARRIS DC, 1985, BIOCHIM BIOPHYS ACTA, V838, P295, DOI 10.1016/0304-4165(85)90226-0; HARRIS WR, 1986, J INORG BIOCHEM, V27, P41, DOI 10.1016/0162-0134(86)80107-6; KRAGTEN J, 1978, ATLAS METAL LIGAND E, P284; Kraiter DC, 1998, INORG CHEM, V37, P964, DOI 10.1021/ic970644g; KRETCHMAR SA, 1988, BIOCHIM BIOPHYS ACTA, V956, P85, DOI 10.1016/0167-4838(88)90301-9; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; MCREE DE, IN PRESS; MIETZNER TA, 1987, J EXP MED, V165, P1041, DOI 10.1084/jem.165.4.1041; Mietzner TA, 1998, CURR TOP MICROBIOL, V225, P113; MORSE S, 1988, REV INFECT DIS S, V10, P306; NOWALK AJ, 1994, BIOCHEMISTRY-US, V33, P12769, DOI 10.1021/bi00209a007; SCHWARZENBACH G, 1963, HELV CHIM ACTA, V46, P1390, DOI 10.1002/hlca.19630460434; Taboy CH, 1999, BIOELECTROCH BIOENER, V48, P79, DOI 10.1016/S0302-4598(98)00236-0; Wilkins R.G., 1991, KINETICS MECH REACTI, DOI 10.1002/bbpc.19920960429; Zak O, 1997, BIOCHEMISTRY-US, V36, P11036, DOI 10.1021/bi970628v; ZAK O, 1983, BIOCHIM BIOPHYS ACTA, V742, P490, DOI 10.1016/0167-4838(83)90266-2; ZAK O, 1985, BIOCHIM BIOPHYS ACTA, V829, P348, DOI 10.1016/0167-4838(85)90243-2; [No title captured]	35	63	64	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2719	2724		10.1074/jbc.M004763200	http://dx.doi.org/10.1074/jbc.M004763200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11029460	hybrid			2022-12-25	WOS:000166784800058
J	Xie, Y; Cohen, JB				Xie, Y; Cohen, JB			Contributions of Torpedo nicotinic acetylcholine receptor gamma Trp-55 and delta Trp-57 to agonist and competitive antagonist function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE DISULFIDE; DELTA-SUBUNIT; D-TUBOCURARINE; GAMMA-SUBUNIT; LIGAND-BINDING; ALPHA-SUBUNIT; CURARIFORM ANTAGONISTS; IDENTIFICATION; RESIDUES; AFFINITY	Results of affinity-labeling studies and mutational analyses provide evidence that the agonist binding sites of the nicotinic acetylcholine receptor (nAChR) are located at the alpha-gamma and alpha-delta subunit interfaces. For Torpedo nAChR, photoaffinity-labeling studies with the competitive antagonist d-[H-3]tubocurarine (dTC) identified two tryptophans, gamma Trp-55 and delta Trp-57, as the primary sites of photolabeling in the non-cu subunits, To characterize the importance of gamma Trp-55 and delta Trp-57 to the interactions of agonists and antagonists, Torpedo nAChRs were expressed in Xenopus oocytes, and equilibrium binding assays and electrophysiological recordings were used to examine the functional consequences when either or both tryptophans were mutated to leucine. Neither substitution altered the equilibrium binding of dTC. However, the delta W57L and gamma W55L mutations decreased acetylcholine (ACh) binding affinity by 20- and 7,000-fold respectively. For the wild-type, gamma W55L, and delta W57L nAChRs, the concentration dependence of channel activation was characterized by Hill coefficients of 1.8, 1.1, and 1.7, For the gamma W55L mutant, dTC binding at the alpha-gamma site acts not as a competitive antagonist but as a coactivator or partial agonist, These results establish that interactions with gamma Trp-55 of the Torpedo nAChR play a crucial role in agonist binding and in the agonist-induced conformational changes that lead to channel opening.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.				NINDS NIH HHS [NS 19522] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019522] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arias HR, 2000, NEUROCHEM INT, V36, P595, DOI 10.1016/S0197-0186(99)00154-0; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; Bren N, 1997, J BIOL CHEM, V272, P30793, DOI 10.1074/jbc.272.49.30793; Buhr A, 1997, J BIOL CHEM, V272, P11799, DOI 10.1074/jbc.272.18.11799; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; Chiara DC, 1998, FEBS LETT, V423, P223, DOI 10.1016/S0014-5793(98)00093-3; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Fletcher GH, 1996, MOL PHARMACOL, V49, P938; FU DX, 1994, J BIOL CHEM, V269, P26152; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KOPTA C, 1994, J NEUROSCI, V14, P3922; LORING RH, 1993, METHODS NEUROSCI, V12, P324; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; Martin MD, 1997, BIOCHEMISTRY-US, V36, P10742, DOI 10.1021/bi970896t; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; Osaka H, 1998, J BIOL CHEM, V273, P12758, DOI 10.1074/jbc.273.21.12758; Pedersen SE, 1995, J BIOL CHEM, V270, P31141, DOI 10.1074/jbc.270.52.31141; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Prince RJ, 1999, J BIOL CHEM, V274, P19623, DOI 10.1074/jbc.274.28.19623; Prince RJ, 1998, J BIOL CHEM, V273, P7843, DOI 10.1074/jbc.273.14.7843; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; PRINCE RJ, 1998, NICOTINIC ACETYLCHOL, P31; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1981, J BIOL CHEM, V256, P6692; STEINBACH JH, 1995, J NEUROSCI, V15, P230; Sullivan DA, 2000, J BIOL CHEM, V275, P12651, DOI 10.1074/jbc.275.17.12651; TAKEDA K, 1984, J PHYSIOL-LONDON, V349, P353, DOI 10.1113/jphysiol.1984.sp015160; Yan D, 1999, J BIOL CHEM, V274, P5537, DOI 10.1074/jbc.274.9.5537	40	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2417	2426		10.1074/jbc.M009085200	http://dx.doi.org/10.1074/jbc.M009085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11056174	hybrid			2022-12-25	WOS:000166784800018
J	Yang, BX; Gillespie, A; Carlson, EJ; Epstein, CJ; Verkman, AS				Yang, BX; Gillespie, A; Carlson, EJ; Epstein, CJ; Verkman, AS			Neonatal mortality in an aquaporin-2 knock-in mouse model of recessive nephrogenic diabetes insipidus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSENSITIVE WATER CHANNEL; COLLECTING DUCT; HEART-FAILURE; UP-REGULATION; RAT-KIDNEY; EXPRESSION; GENE; TRAFFICKING; MUTATIONS; MEMBRANE	Hereditary non-X-linked nephrogenic diabetes insipidus (NDI) is caused by mutations in the aquaporin-2 (AQP2) water channel. In transfected cells, the human disease-causing mutant AQP2-T126M is retained at the endoplasmic reticulum (ER) where it is functional and targetable to the plasma membrane with chemical chaperones. A mouse knock-in model of NDI was generated by targeted gene replacement using a Cre-loxP strategy. Along with T126M, mutations H122S, N124S, and A125T were introduced to preserve the consensus sequence for N-linked glycosylation found in human AQP2. Breeding of heterozygous mice yielded the expected Mendelian distribution with 26 homozygous mutant offspring of 99 live births. The mutant mice appeared normal at 2-3 days after birth but failed to thrive and generally died by day 6 if not given supplemental fluid. Urine/serum analysis showed a urinary concentrating defect with serum hyperosmolality and low urine osmolality that was not increased by a V2 vasopressin agonist, Northern blot analysis showed up-regulated AQP2-T126M transcripts of identical size to wild-type AQP2, Immunoblots showed complex glycosylation of wild-type AQP2 but mainly endoglycosidase H-sensitive core glycosylation of AQP2-T126M indicating ER-retention, Biochemical analysis revealed that the AQP2-T126M protein was resistant to detergent solubilization, Kidneys from mutant mice showed collecting duct dilatation, papillary atrophy, and unexpectedly, some plasma membrane AQP2 staining. The severe phenotype of the AQP2 mutant mice compared with that of mice lacking kidney water channels AQP1, AQP3, and AQP4 indicates a critical role for AQP2 in neonatal renal function in mice. Our results establish a mouse model of human autosomal NDI and provide the first in vivo biochemical data on a disease-causing AQP2 mutant.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL051854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51854, HL58198, HL60288] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bichet DG, 1998, AM J MED, V105, P431, DOI 10.1016/S0002-9343(98)00301-5; Brown D, 1998, AM J PHYSIOL-RENAL, V275, pF328, DOI 10.1152/ajprenal.1998.275.3.F328; Chou CL, 1998, AM J PHYSIOL-CELL PH, V274, pC549, DOI 10.1152/ajpcell.1998.274.2.C549; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Devuyst O, 1996, AM J PHYSIOL-RENAL, V271, pF169, DOI 10.1152/ajprenal.1996.271.1.F169; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; Hozawa S, 1996, AM J PHYSIOL-CELL PH, V270, pC1695, DOI 10.1152/ajpcell.1996.270.6.C1695; Lewandoski M, 1997, NAT GENET, V17, P223, DOI 10.1038/ng1097-223; MA T, 1998, AM J PHYSIOL, V273, P4296; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Marples D, 1998, P ASSOC AM PHYSICIAN, V110, P401; Marples D, 1999, AM J PHYSIOL-RENAL, V276, pF331, DOI 10.1152/ajprenal.1999.276.3.F331; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Nielsen S, 1997, P NATL ACAD SCI USA, V94, P5450, DOI 10.1073/pnas.94.10.5450; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Nielsen S, 1999, J AM SOC NEPHROL, V10, P647; Promeneur D, 2000, AM J PHYSIOL-RENAL, V279, pF370, DOI 10.1152/ajprenal.2000.279.2.F370; Saito T, 1999, AM J PHYSIOL-REG I, V277, pR427, DOI 10.1152/ajpregu.1999.277.2.R427; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Terris J, 1996, AM J PHYSIOL-RENAL, V271, pF414, DOI 10.1152/ajprenal.1996.271.2.F414; VANLIEBURG AF, 1994, AM J HUM GENET, V55, P648; Verkman AS, 2000, CURR OPIN NEPHROL HY, V9, P517, DOI 10.1097/00041552-200009000-00010; Ward DT, 1999, ANNU REV PHYSIOL, V61, P683, DOI 10.1146/annurev.physiol.61.1.683; Xu DL, 1997, J CLIN INVEST, V99, P1500, DOI 10.1172/JCI119312; YAMAMOTO T, 1995, EXP NEPHROL, V3, P193; Yamamoto T, 1998, KIDNEY INT, V54, P1041, DOI 10.1046/j.1523-1755.1998.00123.x; Yang Baoxue, 2000, Current Genomics, V1, P91, DOI 10.2174/1389202003351832; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200; Yang BX, 1999, GENOMICS, V57, P79, DOI 10.1006/geno.1999.5759; YUN J, 2000, J CLIN INVEST, V276, P624	35	115	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2775	2779		10.1074/jbc.M008216200	http://dx.doi.org/10.1074/jbc.M008216200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035038	hybrid			2022-12-25	WOS:000166784800065
J	Anflous, K; Armstrong, DD; Craigen, WJ				Anflous, K; Armstrong, DD; Craigen, WJ			Altered mitochondrial sensitivity for ADP and maintenance of creatine-stimulated respiration in oxidative striated muscles from VDAC1-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; ADENINE-NUCLEOTIDE TRANSLOCATOR; RAT-HEART MITOCHONDRIA; OUTER-MEMBRANE; SKELETAL-MUSCLE; IN-VIVO; ENERGY-TRANSPORT; KINASE; ISOFORMS; PORIN	Voltage-dependent anion channels (VDACs) form the main pathway for metabolites across the mitochondrial outer membrane. The mouse vdac1 gene has been disrupted by gene targeting, and the resulting mutant mice have been examined for defects in muscle physiology, To test the hypothesis that VDAC1 constitutes a pathway for ADP translocation into mitochondria, the apparent mitochondrial sensitivity for ADP (k(m(ADP))) and the calculated rate of respiration in the presence of the maximal ADP concentration (V-max) have been assessed using skinned fibers prepared from two oxidative muscles (ventricle and soleus) and a glycolytic muscle (gastrocnemius) in control and vdac1(-/-) mice. We observed a significant increase in the apparent K-m(ADP) in heart and gastrocnemius, whereas the V-max remained unchanged in both muscles. In contrast, a significant decrease in both the apparent K-m(ADP) and V-max was observed in soleus, To test whether VDAC1 is required for creatine stimulation of mitochondrial respiration in oxidative muscles, the apparent K-m(ADP) and V-max were determined in the presence of 25 mM creatine. The creatine effect on mitochondrial respiration was unchanged in both heart and soleus, These data, together with the significant increase in citrate synthase activity in heart, but not in soleus and gastrocnemius, suggest that distinct metabolic responses to altered mitochondrial outer membrane permeability occur in these different striated muscle types.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Craigen, WJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Rm S821,1 Baylor Plaza, Houston, TX 77030 USA.	wcraigen@bcm.tmc.edu			NIGMS NIH HHS [R01 GM055713-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055713] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anflous K, 1998, BBA-GENE STRUCT EXPR, V1399, P47, DOI 10.1016/S0167-4781(98)00088-8; Anflous K, 1997, BIOCHEM J, V322, P73, DOI 10.1042/bj3220073; BABEL D, 1991, BIOL CHEM H-S, V372, P1027, DOI 10.1515/bchm3.1991.372.2.1027; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BESSMAN SP, 1966, BIOCHEM BIOPH RES CO, V22, P597, DOI 10.1016/0006-291X(66)90317-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; BRDICZKA D, 1994, MOL CELL BIOCHEM, V133, P892; CLARK JF, 1994, BIOCHEM J, V300, P211, DOI 10.1042/bj3000211; COGSWELL AM, 1993, AM J PHYSIOL, V264, pC383, DOI 10.1152/ajpcell.1993.264.2.C383; CORNELIO F, 1985, J NEUROL, V232, P329, DOI 10.1007/BF00313831; Decker WK, 2000, MOL GENET METAB, V70, P69, DOI 10.1006/mgme.2000.2987; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DORING C, 1985, J MEMBRANE BIOL, V83, P81, DOI 10.1007/BF01868740; GELLERICH F, 1982, BIOCHEM BIOPH RES CO, V105, P1473, DOI 10.1016/0006-291X(82)90954-8; GELLERICH FN, 1983, BIOCHIM BIOPHYS ACTA, V722, P381, DOI 10.1016/0005-2728(83)90086-5; GOSALVEZ M, 1974, EUR J BIOCHEM, V46, P133, DOI 10.1111/j.1432-1033.1974.tb03605.x; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; Huizing M, 1996, PEDIATR RES, V39, P760, DOI 10.1203/00006450-199605000-00003; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; Kay L, 1997, BBA-BIOENERGETICS, V1322, P41, DOI 10.1016/S0005-2728(97)00071-6; Kuznetsov AV, 1996, EUR J BIOCHEM, V241, P909, DOI 10.1111/j.1432-1033.1996.00909.x; Lee AC, 1998, J MEMBRANE BIOL, V161, P173, DOI 10.1007/s002329900324; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; Ogata T, 1997, ANAT REC, V248, P214; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; PHILIPPI M, 1994, J EXP BIOL, V189, P1; Rahmani Z, 1998, EUR J HUM GENET, V6, P337, DOI 10.1038/sj.ejhg.5200198; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; SAKS V, 1995, BIOCHEM BIOPH RES CO, V208, P919, DOI 10.1006/bbrc.1995.1422; SAKS VA, 1995, J MOL CELL CARDIOL, V27, P625, DOI 10.1016/S0022-2828(08)80056-9; SAKS VA, 1975, EUR J BIOCHEM, V57, P273, DOI 10.1111/j.1432-1033.1975.tb02299.x; SAKS VA, 1980, J BIOL CHEM, V255, P755; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; Saks VA, 1996, MOL CELL BIOCHEM, V161, P195, DOI 10.1007/BF00240050; SAKS VA, 1991, BIOCHIM BIOPHYS ACTA, V1074, P302, DOI 10.1016/0304-4165(91)90168-G; Sampson MJ, 1996, GENOMICS, V36, P192, DOI 10.1006/geno.1996.0445; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Sampson MJ, 1996, GENOMICS, V33, P283, DOI 10.1006/geno.1996.0193; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SENGERS RCA, 1984, EUR J PEDIATR, V141, P192, DOI 10.1007/BF00572761; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; VEKSLER VI, 1987, BIOCHIM BIOPHYS ACTA, V892, P191, DOI 10.1016/0005-2728(87)90174-5; Wallimann T, 1998, BIOFACTORS, V8, P229, DOI 10.1002/biof.5520080310; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Xu X, 1999, J MEMBRANE BIOL, V170, P89, DOI 10.1007/s002329900540	51	105	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1954	1960		10.1074/jbc.M006587200	http://dx.doi.org/10.1074/jbc.M006587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11044447	hybrid			2022-12-25	WOS:000166528000043
J	Rodney, GG; Moore, CP; Williams, BY; Zhang, JZ; Krol, J; Pedersen, SE; Hamilton, SL				Rodney, GG; Moore, CP; Williams, BY; Zhang, JZ; Krol, J; Pedersen, SE; Hamilton, SL			Calcium binding to calmodulin leads to an N-terminal shift in its binding site on the ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; SKELETAL-MUSCLE; PROTEIN; APOCALMODULIN; COMPLEXES; DOMAINS; MUTANTS	The skeletal muscle calcium release channel, ryanodine receptor, is activated by calcium-free calmodulin and inhibited by calcium-bound calmodulin, Previous biochemical studies from our laboratory have shown that calcium-free calmodulin and calcium bound calmodulin protect sites at amino acids 3630 and 3637 from trypsin cleavage (Moore, C. P., Rodney, G,, Zhang, J. Z., Santacruz-Toloza, L,, Strasburg, G,, and Hamilton, S, L, (1999) Biochemistry 38, 8532-8537), We now demonstrate that both calcium-free calmodulin and calcium-bound calmodulin bind with nanomolar affinity to a synthetic peptide matching amino acids 3614-3643 of the ryanodine receptor, Deletion of the last nine amino acids (3635-3643) destroys the ability of the peptide to bind calcium-free calmodulin, but not calcium-bound calmodulin, We propose a novel mechanism for calmodulin's interaction with a target protein. Our data suggest that the binding sites for calcium-free calmodulin and calcium-bound calmodulin are overlapping and, when calcium binds to calmodulin, the calmodulin molecule shifts to a more N-terminal location on the ryanodine receptor converting it from an activator to an inhibitor of the channel, This region of the ryanodine receptor has previously been identified as a site of intersubunit contact, suggesting the possibility that calmodulin regulates ryanodine receptor activity by regulating subunit-subunit interactions.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.			Pedersen, Steen E./0000-0001-8755-8899; Hamilton, Susan/0000-0003-0241-9369	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802, R01AR044864] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41802, AR44864] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Gomes AV, 2000, ARCH BIOCHEM BIOPHYS, V379, P28, DOI 10.1006/abbi.2000.1827; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Moore CP, 1999, J BIOL CHEM, V274, P36831, DOI 10.1074/jbc.274.52.36831; Mukherjea P, 1996, PROTEIN SCI, V5, P468; MUKHERJEA P, 1993, BIOCHEM MOL BIOL INT, V29, P555; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; Weljie AM, 2000, PROTEIN ENG, V13, P59, DOI 10.1093/protein/13.1.59; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; Yuan T, 1998, BIOCHEMISTRY-US, V37, P3187, DOI 10.1021/bi9716579; Zhang JZ, 1999, AM J PHYSIOL-CELL PH, V276, pC46	23	110	110	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2069	2074		10.1074/jbc.M008891200	http://dx.doi.org/10.1074/jbc.M008891200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035044	hybrid			2022-12-25	WOS:000166528000058
J	Otero, DC; Omori, SA; Rickert, RC				Otero, DC; Omori, SA; Rickert, RC			CD19-dependent activation of Akt kinase in B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR COMPLEX; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; INOSITOL 5'-PHOSPHATASE; CA2+ MOBILIZATION; SYNTHASE KINASE-3; CD19 RECEPTOR; ASSOCIATION	CD19 is rapidly phosphorylated upon B-cell antigen receptor (BCR) cross-linking, leading to the recruitment of downstream signaling intermediates. A prominent feature of CD19 signaling is the binding and activation of phosphoinositide S-kinase (PI3K), which accounts for the majority of PI3K activity induced by BCR ligation. Recent findings have implicated activation of the serine/threonine kinase Akt as imparting survival signals in a PI3K-dependent fashion. Using CD19-deficient B-lymphhoma cells and mouse splenic B-cells, we show that CD19 is necessary for efficient activation of Akt following cross-linking of surface immunoglobulin or Ig beta, In the absence of CD19, Akt kinase activity is reduced and transient. In addition, coligation of CD19 with surface immunoglobulin leads to augmented Akt activity in a dose-dependent manner. Thus, CD19 is a key regulator of Akt activity in B-cells; as such it may contribute to pre-BCR or BCR-mediated cell survival in vivo.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Rickert, RC (corresponding author), 9500 Gilman Dr,0322, La Jolla, CA 92093 USA.	rrickert@ucsd.edu		Fitzpatrick, Sidne/0000-0002-5245-4624	NATIONAL CANCER INSTITUTE [T32CA009345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041649] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09345] Funding Source: Medline; NIAID NIH HHS [AI41649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Carter RH, 1997, J IMMUNOL, V158, P3062; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gold MR, 1999, J IMMUNOL, V163, P1894; Gupta N, 1999, J BIOL CHEM, V274, P7489, DOI 10.1074/jbc.274.11.7489; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Kitanaka A, 1997, J IMMUNOL, V159, P184; Li HL, 1999, P NATL ACAD SCI USA, V96, P6890, DOI 10.1073/pnas.96.12.6890; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; Xiao J, 1996, J BIOL CHEM, V271, P7659, DOI 10.1074/jbc.271.13.7659	24	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1474	1478		10.1074/jbc.M003918200	http://dx.doi.org/10.1074/jbc.M003918200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042164	hybrid			2022-12-25	WOS:000166430900082
J	Westmark, CJ; Malter, JS				Westmark, CJ; Malter, JS			Up-regulation of nucleolin mRNA and protein in peripheral blood mononuclear cells by extracellular-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-CLEAVING ACTIVITY; HEAT-SHOCK PROTEIN-70; RNA-BINDING-PROTEIN; PRE-RIBOSOMAL-RNA; MESSENGER-RNA; GLYCINE-RICH; 3'-UNTRANSLATED REGION; COMPLEX-FORMATION; PHOSPHORYLATION; IDENTIFICATION	The signal transduction pathways regulating nucleolin mRNA and protein production have yet to be elucidated. Peripheral blood mononuclear cells treated with phorbol 12-myristate 13-acetate showed steady state levels of nucleolin mRNA that were 2-2.5-fold greater than untreated control cells. The up-regulation of nucleolin mRNA was substantially repressed by U0126, a specific inhibitor that blocks phosphorylation of extracellular-regulated kinase (ERK), Calcium ionophores A23187 and ionomycin also activated ERK and substantially elevated nucleolin mRNA levels, demonstrating phorbol 12-myristate 13-acetate and calcium signaling converge on ERK, Drugs that affected protein kinase C, protein kinase A, and phospholipase C signal transduction pathways did not alter nucleolin mRNA levels significantly. The half-life of nucleolin mRNA increased from 1.8 h in resting cells to 3.2 h with phorbol ester activation, suggesting ERK-mediated posttranscriptional regulation. Concomitantly, full-length nucleolin protein was increased. The higher levels of nucleolin protein were accompanied by increased binding of a 70-kDa nucleolin fragment to the 29-base instability element in the 3'-untranslated region of amyloid precursor protein (APP) mRNA in gel mobility shift assays. Supplementation of rabbit reticulocyte lysate with nucleolin decreased APP mRNA stability and protein production. These data suggest ERK up-regulates nucleolin posttranscriptionally thereby controlling APP production.	Univ Wisconsin, Sch Med, Inst Aging, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Malter, JS (corresponding author), Univ Wisconsin Hosp & Clin, Rm K4-812,600 Highland Ave, Madison, WI 53792 USA.		Westmark, Cara J/L-4647-2019; Westmark, Cara/AAX-4408-2020		NATIONAL INSTITUTE ON AGING [R01AG010675] Funding Source: NIH RePORTER; NIA NIH HHS [AG00213, R01AG10675] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOURBON HM, 1983, MOL BIOL REP, V9, P39, DOI 10.1007/BF00777472; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; DERENZINI M, 1995, LAB INVEST, V73, P497; EGYHAZI E, 1988, EXP CELL RES, V178, P264, DOI 10.1016/0014-4827(88)90397-7; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; FUKUDA H, 1994, NEUROCHEM INT, V25, P567, DOI 10.1016/0197-0186(94)90155-4; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Herblot S, 1999, J IMMUNOL, V162, P3280; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; KONISHI T, 1995, J BIOCHEM-TOKYO, V117, P1170, DOI 10.1093/oxfordjournals.jbchem.a124840; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; Larrucea S, 1998, J BIOL CHEM, V273, P31718, DOI 10.1074/jbc.273.48.31718; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; LISCHWE MA, 1981, EXP CELL RES, V136, P101, DOI 10.1016/0014-4827(81)90041-0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MEHES G, 1995, CELL PROLIFERAT, V28, P329, DOI 10.1111/j.1365-2184.1995.tb00074.x; MEYUHAS O, 1990, BIOCHIM BIOPHYS ACTA, V1049, P38, DOI 10.1016/0167-4781(90)90082-D; MURAKAMI T, 1991, J BIOCHEM-TOKYO, V110, P146, DOI 10.1093/oxfordjournals.jbchem.a123533; OHMORI H, 1990, EXP CELL RES, V189, P227, DOI 10.1016/0014-4827(90)90240-B; OLSON MOJ, 1990, BIOCHEMISTRY-US, V29, P5682, DOI 10.1021/bi00476a006; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Rajagopalan LE, 1998, NUCLEIC ACIDS RES, V26, P3418, DOI 10.1093/nar/26.14.3418; Reddy PMS, 1996, AM J RESP CELL MOL, V15, P398, DOI 10.1165/ajrcmb.15.3.8810645; SCHNEIDER HR, 1989, BIOCHIM BIOPHYS ACTA, V1014, P98, DOI 10.1016/0167-4889(89)90246-2; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; Waggoner S, 1998, J VIROL, V72, P6699, DOI 10.1128/JVI.72.8.6699-6709.1998; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Yurkova MS, 1997, J BIOL CHEM, V272, P10870; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292	53	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1119	1126		10.1074/jbc.M009435200	http://dx.doi.org/10.1074/jbc.M009435200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042220	hybrid			2022-12-25	WOS:000166430900037
J	Cieslewicz, MJ; Kasper, DL; Wang, Y; Wessels, MR				Cieslewicz, MJ; Kasper, DL; Wang, Y; Wessels, MR			Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE; ESCHERICHIA-COLI; IMMUNOCHEMICAL CHARACTERIZATION; MOLECULAR CHARACTERIZATION; PNEUMONIAE SEROTYPE-14; OVERLAP EXTENSION; ACID CAPSULE; EXPRESSION; IDENTIFICATION; BIOSYNTHESIS	Several species of streptococci produce extracellular polysaccharides in the form of secreted exopolysaccharides or cell-associated capsules. Although the biological properties and repeating unit structures of these polysaccharides are diverse, sequence analysis of the genes required for their production has revealed a surprising degree of conservation among five genes found in the capsule gene cluster of each of several polysaccharide-producing streptococci. To determine the function of these conserved genes, we characterized a series of isogenic mutants derived from a wild-type strain of type Is group B Streptococcus by selectively inactivating each gene. Inactivation of cpsIaE resulted in an aeapsular phenotype, consistent with previous work that identified the cpsIaE product as the glycosyltransferase that initiates synthesis of the polysaccharide repeating unit. Mutants in cpsIaA, cpsIaB, cpsIaC, or cpsIaD produced type Is capsular polysaccharide, but in reduced amounts compared with the wild type. Analysis of the mutant polysaccharides and of capsule gene transcription in the mutant strains provided evidence that cpsIaA encodes a transcriptional activator that regulates expression of the capsule gene operon. Mutants in cpsIaC or cpsIaD produced polysaccharide of reduced molecular size but with an identical repeating unit structure as the wild-type strain. We conclude that CpsA to -D are not required for polysaccharide repeating unit biosynthesis but rather that they direct the coordinated polymerization and export of high molecular weight polysaccharide.	Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Wessels, MR (corresponding author), Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	mwessels@channing.harvard.edu			NIAID NIH HHS [AI42940, AI07061] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042940, R21AI042940] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberti S, 1998, MOL MICROBIOL, V28, P343, DOI 10.1046/j.1365-2958.1998.00800.x; BATCHELOR RA, 1991, J BACTERIOL, V173, P5699, DOI 10.1128/jb.173.18.5699-5704.1991; BECKER PT, 1995, RES NURS HEALTH, V18, P191, DOI 10.1002/nur.4770180302; DIFABIO JL, 1989, CAN J CHEM, V67, P877; GARCIA E, 1993, MOL GEN GENET, V239, P188; GUIDOLIN A, 1994, INFECT IMMUN, V62, P5384, DOI 10.1128/IAI.62.12.5384-5396.1994; Guttormsen HK, 1996, J INFECT DIS, V173, P142, DOI 10.1093/infdis/173.1.142; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JENNINGS HJ, 1990, CURR TOP MICROBIOL, V150, P97; JENNINGS HJ, 1983, BIOCHEMISTRY-US, V22, P1258, DOI 10.1021/bi00274a042; JENNINGS HJ, 1981, BIOCHEMISTRY-US, V20, P4511, DOI 10.1021/bi00519a001; KOGAN G, 1995, CARBOHYD RES, V277, P1, DOI 10.1016/0008-6215(95)00195-Y; Kogan G, 1996, J BIOL CHEM, V271, P8786, DOI 10.1074/jbc.271.15.8786; Kolkman MAB, 1998, J BIOCHEM, V123, P937; Kolkman MAB, 1997, J BIOL CHEM, V272, P19502, DOI 10.1074/jbc.272.31.19502; Kolkman MAB, 1996, J BACTERIOL, V178, P3736, DOI 10.1128/jb.178.13.3736-3741.1996; Koskiniemi S, 1998, FEMS IMMUNOL MED MIC, V21, P159, DOI 10.1111/j.1574-695X.1998.tb01162.x; LAZAREVIC V, 1992, J GEN MICROBIOL, V138, P1949, DOI 10.1099/00221287-138-9-1949; Morona JK, 2000, MOL MICROBIOL, V35, P1431, DOI 10.1046/j.1365-2958.2000.01808.x; OCONNOR SP, 1987, J INFECT DIS, V156, P495, DOI 10.1093/infdis/156.3.495; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; Paoletti LC, 1996, INFECT IMMUN, V64, P1220, DOI 10.1128/IAI.64.4.1220-1226.1996; PEREZCASAL J, 1993, MOL MICROBIOL, V8, P809, DOI 10.1111/j.1365-2958.1993.tb01628.x; RUBENS CE, 1987, P NATL ACAD SCI USA, V84, P7208, DOI 10.1073/pnas.84.20.7208; RUBENS CE, 1993, MOL MICROBIOL, V8, P843, DOI 10.1111/j.1365-2958.1993.tb01631.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sau S, 1997, MICROBIOL-UK, V143, P2395, DOI 10.1099/00221287-143-7-2395; Smith HE, 1999, INFECT IMMUN, V67, P1750; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; vanKranenburg R, 1997, MOL MICROBIOL, V24, P387, DOI 10.1046/j.1365-2958.1997.3521720.x; VIMR E, 1995, J IND MICROBIOL, V15, P352, DOI 10.1007/BF01569991; VONHUNOLSTEIN C, 1993, INFECT IMMUN, V61, P1272, DOI 10.1128/IAI.61.4.1272-1280.1993; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WESSELS MR, 1991, J BIOL CHEM, V266, P6714; WESSELS MR, 1993, INFECT IMMUN, V61, P4760, DOI 10.1128/IAI.61.11.4760-4766.1993; WESSELS MR, 1987, J BIOL CHEM, V262, P8262; Yamamoto S, 1999, J BACTERIOL, V181, P5176, DOI 10.1128/JB.181.17.5176-5184.1999; Yim HH, 1997, BIOTECHNIQUES, V23, P229, DOI 10.2144/97232bm11	39	128	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					139	146		10.1074/jbc.M005702200	http://dx.doi.org/10.1074/jbc.M005702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027683	hybrid			2022-12-25	WOS:000166280700020
J	Pohjanjoki, P; Fabrichniy, IP; Kasho, VN; Cooperman, BS; Goldman, A; Baykov, AA; Lahti, R				Pohjanjoki, P; Fabrichniy, IP; Kasho, VN; Cooperman, BS; Goldman, A; Baykov, AA; Lahti, R			Probing essential water in yeast pyrophosphatase by directed mutagenesis and fluoride inhibition measurements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; ESCHERICHIA-COLI; ACTIVE-SITE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ORTHO-PHOSPHATE; CATALYSIS; HYDROLYSIS; SUBSTITUTION	The pattern of yeast pyrophosphatase (Y-PPase) inhibition by fluoride suggests that it replaces active site Mg2+-bound nucleophilic water, for which two different locations were proposed previously. To localize the bound fluoride, we investigate here the effects of mutating Tyr(93) and five dicarboxylic amino acid residues forming two metal binding sites in Y-PPase on its inhibition by fluoride and its five catalytic functions (steady-state PPi hydrolysis and synthesis, formation of enzyme-bound PPi at equilibrium, phosphate-water oxygen exchange, and Mg2+ binding). D117E substitution had the largest effect on fluoride binding and made the P-O bond cleavage step rate-limiting in the catalytic cycle, consistent with the mechanism in which the nucleophile is coordinated by two metal ions and Asp(117). The effects of the mutations on PPi hydrolysis (as characterized by the catalytic constant and the net rate constant for P-O bond cleavage) were in general larger than on PPi synthesis (as characterized by the net rate constant for PPi release from active site). The effects of fluoride on the Y-PPase variants confirmed that PPase catalysis involves two enzyme PPi intermediates, which bind fluoride with greatly different rates (Baykov, A. A., Fabrichniy, I. P., Pobjanjoki, P., Zyryanov, A. B., and Lahti, R. (2000) Biochemistry 39, 11989-11947). A mechanism for the structural changes underlying the interconversion of the enzyme PPi intermediates is proposed.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, Sch Chem, Moscow 119899, Russia; Univ Turku, Dept Biochem, FIN-20014 Turku, Finland; Univ Calif Los Angeles, Dept Med, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	Lomonosov Moscow State University; Lomonosov Moscow State University; Finland National Institute for Health & Welfare; University of Turku; University of California System; University of California Los Angeles; University of Pennsylvania; University of Helsinki	Baykov, AA (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia.		Baykov, Alexander A/C-7981-2012; Baykov, Alexander/AAH-5301-2021	Baykov, Alexander/0000-0002-2495-8200				Avaeva S, 1996, FEBS LETT, V399, P99, DOI 10.1016/S0014-5793(96)01296-3; Avaeva SM, 1998, BIOCHEMISTRY-MOSCOW+, V63, P671; BAYKOV AA, 1973, EUR J BIOCHEM, V32, P136, DOI 10.1111/j.1432-1033.1973.tb02589.x; BAYKOV AA, 1992, EUR J BIOCHEM, V206, P463, DOI 10.1111/j.1432-1033.1992.tb16947.x; Baykov AA, 2000, BIOCHEMISTRY-US, V39, P11939, DOI 10.1021/bi000627u; BAYKOV AA, 1977, BIOCHIM BIOPHYS ACTA, V481, P184, DOI 10.1016/0005-2744(77)90150-4; BAYKOV AA, 1979, BIOCHIM BIOPHYS ACTA, V569, P228, DOI 10.1016/0005-2744(79)90058-5; Baykov AA, 1996, BIOCHEMISTRY-US, V35, P4655, DOI 10.1021/bi952635u; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; Belogurov GA, 2000, BIOCHEMISTRY-US, V39, P13931, DOI 10.1021/bi000895s; Chen GJ, 1997, BIOCHEMISTRY-US, V36, P4278, DOI 10.1021/bi9618676; DALEY LA, 1986, ANAL BIOCHEM, V157, P385, DOI 10.1016/0003-2697(86)90642-1; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; EMSLEY J, 1977, J CHEM SOC PERK T 2, P2079, DOI 10.1039/p29770002079; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; GONZALEZ MA, 1984, BIOCHEMISTRY-US, V23, P797, DOI 10.1021/bi00300a002; HACKNEY DD, 1980, J BIOL CHEM, V255, P5320; Harutyunyan EH, 1997, BIOCHEMISTRY-US, V36, P7754, DOI 10.1021/bi962637u; Harutyunyan EH, 1996, EUR J BIOCHEM, V239, P220, DOI 10.1111/j.1432-1033.1996.0220u.x; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Heikinheimo P, 1996, EUR J BIOCHEM, V239, P138, DOI 10.1111/j.1432-1033.1996.0138u.x; JANSON CA, 1979, J BIOL CHEM, V254, P3743; Kaminskaia NV, 2000, J AM CHEM SOC, V122, P6411, DOI 10.1021/ja993704l; KAPYLA J, 1995, BIOCHEMISTRY-US, V34, P792, DOI 10.1021/bi00003a012; KOLAKOWSKI LF, 1988, NUCLEIC ACIDS RES, V16, P10441, DOI 10.1093/nar/16.22.10441; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; LEBIODA L, 1993, PROTEINS, V16, P219, DOI 10.1002/prot.340160302; NYREN P, 1985, ANAL BIOCHEM, V151, P504, DOI 10.1016/0003-2697(85)90211-8; Pinkse MWH, 1999, BIOCHEMISTRY-US, V38, P9926, DOI 10.1021/bi990446w; Pohjanjoki P, 1998, BIOCHEMISTRY-US, V37, P1754, DOI 10.1021/bi971771r; SALMINEN T, 1995, BIOCHEMISTRY-US, V34, P782, DOI 10.1021/bi00003a011; SMIRNOVA I N, 1983, Biokhimiya, V48, P1643; SPRINGS B, 1981, BIOCHEMISTRY-US, V20, P6384, DOI 10.1021/bi00525a016; Todd MJ, 2000, BIOCHEMISTRY-US, V39, P5389, DOI 10.1021/bi992287m; Tuominen V, 1998, J MOL BIOL, V284, P1565, DOI 10.1006/jmbi.1998.2266; Volk SE, 1996, BIOCHEMISTRY-US, V35, P4662, DOI 10.1021/bi952636m; WEDEKIND JE, 1994, BIOCHEMISTRY-US, V33, P9333, DOI 10.1021/bi00197a038; WELSH KM, 1983, BIOCHEMISTRY-US, V22, P2243, DOI 10.1021/bi00278a029	38	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					434	441		10.1074/jbc.M007360200	http://dx.doi.org/10.1074/jbc.M007360200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031269	hybrid			2022-12-25	WOS:000166280700059
J	Schwarz, K; Walther, M; Anton, M; Gerth, C; Feussner, I; Kuhn, H				Schwarz, K; Walther, M; Anton, M; Gerth, C; Feussner, I; Kuhn, H			Structural basis for lipoxygenase specificity - Conversion of the human leukocyte 5-lipoxygenase to a 15-lipoxygenating enzyme species by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIONAL SPECIFICITY; PRIMARY DETERMINANT; GENE-EXPRESSION; 12/15-LIPOXYGENASE; INDUCTION; ASTHMA; ACID; INTERLEUKIN-13; INVOLVEMENT; SUBSTRATE	Mammalian lipoxygenases constitute a heterogeneous family of lipid-peroxidizing enzymes, and the various isoforms are categorized with respect to their positional specificity of arachidonic acid oxygenation into 5-, 8-, 12-, and 15-lipoxygenases, Structural modeling suggested that the substrate binding pocket of the human 5-lipoxygenase is 20% bigger than that of the reticulocyte-type 15-lipoxygenase; thus, reduction of the activesite volume was suggested to convert a 5-lipoxygenase to a 15-lipoxygenating enzyme species. To test this "spacebased" hypothesis of the positional specificity, the volume of the 5-lipoxygenase substrate binding pocket was reduced by introducing space-filling amino acids at critical positions, which have previously been identified as sequence determinants for the positional specificity of other lipoxygenase isoforms. We found that single point mutants of the recombinant human 5-lipoxygenase exhibited a similar specificity as the wild-type enzyme but double, triple, and quadruple mutations led to a gradual alteration of the positional specificity from 55- via 8S-toward 15S-lipoxygenation, The quadruple mutant F359W/A424I\N425M/A603I exhibited a major 15S-lipoxygenase activity (85-95%), with (8S,5Z,9E,11Z,14Z)-8-hydroperoxyeicosa-5,9,11,14-tetraenoic acid being a minor side product. These data indicate the principle possibility of interconverting 5- and 15-lipoxygenases by site-directed mutagenesis and appear to support the space-based hypothesis of positional specificity.	Humboldt Univ, Inst Biochem, Clin Charite, D-10115 Berlin, Germany; Inst Plant Biochem, D-06120 Halle, Germany	Humboldt University of Berlin; Leibniz Institut fur Pflanzenbiochemie	Kuhn, H (corresponding author), Humboldt Univ, Inst Biochem, Clin Charite, Hess Str 3-4, D-10115 Berlin, Germany.		Feussner, Ivo/H-9320-2013	Feussner, Ivo/0000-0002-9888-7003				Borngraber S, 1996, J MOL BIOL, V264, P1145, DOI 10.1006/jmbi.1996.0702; Borngraber S, 1999, J BIOL CHEM, V274, P37345, DOI 10.1074/jbc.274.52.37345; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Browner MF, 1998, NAT STRUCT BIOL, V5, P179, DOI 10.1038/nsb0398-179; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Funk CD, 1997, NAT STRUCT BIOL, V4, P966, DOI 10.1038/nsb1297-966; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; GEERTS A, 1994, PLANT PHYSIOL, V105, P269, DOI 10.1104/pp.105.1.269; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Heydeck D, 1998, BLOOD, V92, P2503, DOI 10.1182/blood.V92.7.2503.2503_2503_2510; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; OByrne PM, 1997, ANN INTERN MED, V127, P472, DOI 10.7326/0003-4819-127-6-199709150-00009; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Prigge ST, 1998, NAT STRUCT BIOL, V5, P178, DOI 10.1038/nsb0398-178; RAPOPORT SM, 1990, BLOOD CELL BIOCH, V1, P151; ROUZER CA, 1991, METHOD ENZYMOL, V187, P312; Roy B, 1998, J BIOL CHEM, V273, P32023, DOI 10.1074/jbc.273.48.32023; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; SUZUKI H, 1994, BBA-LIPID LIPID MET, V1210, P308, DOI 10.1016/0005-2760(94)90234-8; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Wenzel SE, 1996, ANN PHARMACOTHER, V30, P858, DOI 10.1177/106002809603000725; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	37	78	81	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					773	779		10.1074/jbc.M005114200	http://dx.doi.org/10.1074/jbc.M005114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027682	hybrid			2022-12-25	WOS:000166280700104
J	Liu, K; Li, LM; Nisson, PE; Gruber, C; Jessee, J; Cohen, SN				Liu, K; Li, LM; Nisson, PE; Gruber, C; Jessee, J; Cohen, SN			Neoplastic transformation and tumorigenesis associated with Sam68 protein deficiency in cultured murine fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; FAMILY TYROSINE KINASES; TUMOR-SUPPRESSOR GENES; RNA-BINDING PROTEIN; CANCER CELL-LINES; KH-DOMAIN; DEPENDENT DEGRADATION; SIGNAL-TRANSDUCTION; GSG DOMAIN; GERM-LINE	Sam68 is a multimeric 68-kDa RNA-binding nuclear protein of unknown function that interacts with, and is tyrosine-phosphorylated by, the oncogenic protein Src during mitosis. Random homozygous knock-out (RHKO) is a retroviral-based antisense RNA strategy that can identify chromosomal genes whose functional disablement leads to reversible tumorigenic capabilities. Here we report that RHKO-induced Sam68 deficiency results in neoplastic transformation of murine NIH3T3 fibroblasts. Whereas simple haploinsufficiency of Sam68 produced by insertion mutagenesis in a single chromosomal allele did not detectably affect cell growth, reduction of Sam68 protein to <25% of the wild type level was associated with anchorage-independent growth, defective contact inhibition, and the ability to form metastatic tumors in nude mice. These properties were reversed by cessation of RHKO inactivation. Our findings, which indicate that the Sam68 protein level can prominently affect cell proliferation, implicate Sam68 function in tumorigenesis. Consistent with these results is evidence that cells undergoing mitosis show a dramatic reduction in the level of Sam68 protein.	Stanford Univ, Sch Med, Med Ctr, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Sch Med, Dept Med, Stanford, CA 94305 USA; Life Technol Inc, Rockville, MD 20850 USA	Stanford University; Stanford University; Thermo Fisher Scientific	Cohen, SN (corresponding author), Stanford Univ, Sch Med, Med Ctr, Dept Genet, Rm M320, Stanford, CA 94305 USA.				NCI NIH HHS [CA09302] Funding Source: Medline; NHGRI NIH HHS [HG00044-04] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Frisch SM, 1996, MUTAT RES-FUND MOL M, V350, P261, DOI 10.1016/0027-5107(95)00103-4; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; Jabado N, 1998, J IMMUNOL, V161, P2798; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Karras JG, 2000, MOL PHARMACOL, V58, P380, DOI 10.1124/mol.58.2.380; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1989, INT S PRINCESS TAKAM, V20, P221; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Liu KY, 1999, MOL CELL BIOL, V19, P3696; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAA MC, 1994, MOL CELL BIOL, V14, P5466, DOI 10.1128/MCB.14.8.5466; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; NOWELL PC, 1986, CANCER RES, V46, P2203; Oka K, 1999, GENE CHROMOSOME CANC, V26, P47, DOI 10.1002/(SICI)1098-2264(199909)26:1<47::AID-GCC7>3.0.CO;2-8; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Sanchez-Margalet V, 1999, FEBS LETT, V455, P307, DOI 10.1016/S0014-5793(99)00887-X; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHALLOWAY D, 1992, CIBA F SYMP, V170, P248; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Sierakowska H, 1999, RNA, V5, P369, DOI 10.1017/S135583829998130X; Sierakowska H, 2000, METHOD ENZYMOL, V313, P506; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852	69	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40195	40201		10.1074/jbc.M006194200	http://dx.doi.org/10.1074/jbc.M006194200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11032831	hybrid			2022-12-25	WOS:000166039500056
J	Attoub, S; Noe, V; Pirola, L; Bruyneel, E; Chastre, E; Mareel, M; Wymann, MP; Gespach, C				Attoub, S; Noe, V; Pirola, L; Bruyneel, E; Chastre, E; Mareel, M; Wymann, MP; Gespach, C			Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, Rho-, and Rac-dependent signaling pathways	FASEB JOURNAL			English	Article						wortmannin; PI3 '-kinase; MDCK cells; leptin signaling; pertussis toxin	PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; COLORECTAL-CANCER; NEUROPEPTIDE-Y; 3-OH KINASE; OBESE GENE; RECEPTOR; INVASION; SRC	Leptin plays a key role regulating food intake, body weight and fat mass. These critical parameters are associated with an increased risk for digestive and mammary gland cancer in the Western population. Here we determined whether leptin contributes to the invasive phenotype of colonic and kidney epithelial cells at various stages of the neoplastic progression. First, leptin potently (EC50 10-30 ng/ml) induces invasion of collagen gels by premalignant familial adenomatous colonic cells PC/AA/C1 and nontumorigenic MDCK kidney epithelial cells, their src-transformed counterparts, and the human adenocarcinoma colonic cells LoVo and HCT-8/S11. Leptin and its Ob-Rb receptors were consistently identified by RT-PCR and immunoblotting in these cell, lines, as well as in human colonic epithelial crypts, polyps, colonic tumor resections, and adjacent mucosa. Leptin-induced invasion was effectively blocked by pharmacological inhibitors of several downstream signaling pathways involved in cell transformation, namely, JAK2 tyrosine kinase (AG490), phosphoinositide PI3'-kinase (wortmannin and LY294002), mTOR kinase (rapamycin), and protein kinases C (GF109203X, Go6976). Accordingly, leptin induces transient elevation of the PI3'-kinase Lipid products in JAK2 immunoprecipitates prepared from parental MDCK cells. The leptin effect on invasion was potentiated by the activated form of the small GTPase RhoA and was abrogated by dominant negative mutants of RhoA, Rad, and the p110 alpha of PI3'-K. Our data indicate that leptin may exert a local and beneficial effect on migration of normal colonic epithelial cells and reparation of the inflamed or wounded digestive mucosa. We also emphasize a new role for leptin, linking- the nutritional and body fat status to digestive cancer susceptibility by stimulating the invasive capacity of colonic epithelial cells at early stages of neoplasia. This finding has potential clinical implications for colon cancer progression and management of obesity.-Attoub, S., Noe, V., Pirola, L., Bruyneel, E., Chastre, E., Mareel, M., Wymann, M. P., Gespach, C. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, Rho-, and pac-dependent signaling pathways.	Hop St Antoine, INSERM Unit U482, F-75571 Paris 12, France; Hop St Antoine, IFR65, F-75571 Paris, France; State Univ Ghent, Expt Cancerol Lab, B-9000 Ghent, Belgium; Inst Biochem, CH-1700 Fribourg, Switzerland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Ghent University	Gespach, C (corresponding author), Hop St Antoine, INSERM Unit U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		Pirola, Luciano/I-5250-2018; Wymann, Matthias P/C-3227-2008; CHASTRE, Eric/L-8446-2018; Attoub, Samir/N-6852-2018	Wymann, Matthias P/0000-0003-3349-4281; CHASTRE, Eric/0000-0002-8993-1228; Pirola, Luciano/0000-0001-6539-5435				Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHIOU MM, 1996, CELL, V85, P573; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; LeMarchand L, 1997, CANCER RES, V57, P4787; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Martinez ME, 1999, J NATL CANCER I, V91, P950, DOI 10.1093/jnci/91.11.950; MAYAN N, 1996, NATURE, V379, P645; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Murakami Y, 1998, J CELL PHYSIOL, V175, P220, DOI 10.1002/(SICI)1097-4652(199805)175:2<220::AID-JCP12>3.0.CO;2-C; Noe V., 1996, Clinical and Experimental Metastasis, V14, P71; PRETZEL N, 1999, NATURE, V402, P884; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Schoen RE, 1999, JNCI-J NATL CANCER I, V91, P1147, DOI 10.1093/jnci/91.13.1147; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; Taouis M, 1998, GENE, V208, P239, DOI 10.1016/S0378-1119(97)00670-7; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; Wasan HS, 1997, P NATL ACAD SCI USA, V94, P3308, DOI 10.1073/pnas.94.7.3308; Xue LX, 1996, JNCI-J NATL CANCER I, V88, P1586, DOI 10.1093/jnci/88.21.1586; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	54	209	221	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2329	2338		10.1096/fj.00-0162	http://dx.doi.org/10.1096/fj.00-0162			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053255				2022-12-25	WOS:000165190800027
J	Farber, SA; Slack, BE; Blusztajn, JK				Farber, SA; Slack, BE; Blusztajn, JK			Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease	FASEB JOURNAL			English	Article						PC 12 cells; membrane turnover; phospholipase; CTP-phosphorylcholine cytidylyltransferase; glycerophosphorylcholine	AMYLOID PRECURSOR PROTEIN; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; DIFFERENTIATED PC12 CELLS; ENERGY-METABOLISM; OXIDATIVE-PHOSPHORYLATION; NEURODEGENERATIVE DISEASES; PHOSPHOLIPASE A(2); CYTOSOLIC CALCIUM; CHEMICAL HYPOXIA; GENE-EXPRESSION	Brain cells in Alzheimer's disease (AD) exhibit a membrane defect characterized by accelerated phospholipid turnover, The mechanism responsible for this defect remains unknown. Recent studies indicate that impairment of mitochondrial function is frequently observed in AD and may be responsible for certain aspects of its pathophysiology, We show that when PC12 cells are exposed to inhibitors of mitochondrial bioenergetics, the turnover of their major membrane phospholipid, phosphatidylcholine, is accelerated, producing a pattern of metabolic changes that mimics that observed in brains of AD patients, Abnormalities of mitochondrial function may therefore underlie the membrane defect in AD.	Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Boston University; Jefferson University	Blusztajn, JK (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, 85 E Newton St,Room M1009, Boston, MA 02118 USA.	jbluszta@bu.edu	Slack, Barbara/AAU-9917-2021; Farber, Steven A/G-5851-2012	Farber, Steven A/0000-0002-8037-7312; /0000-0001-8438-3122; Slack, Barbara/0000-0002-7619-410X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030791, F32NS010326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG09525] Funding Source: Medline; NINDS NIH HHS [F32 NS10326, R01 NS30791] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araki W, 1997, P NATL ACAD SCI USA, V94, P11946, DOI 10.1073/pnas.94.22.11946; BARANY M, 1985, LANCET, V1, P517; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BLASS JP, 1990, ARCH NEUROL-CHICAGO, V47, P864, DOI 10.1001/archneur.1990.00530080046009; BLUSZTAJN JK, 1990, BRAIN RES, V536, P240, DOI 10.1016/0006-8993(90)90030-F; Bonilla E, 1999, BBA-BIOENERGETICS, V1410, P171, DOI 10.1016/S0005-2728(98)00165-0; BUSH ML, 1995, P NATL ACAD SCI USA, V92, P1861, DOI 10.1073/pnas.92.6.1861; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CARROLL JM, 1992, J NEUROCHEM, V59, P1836, DOI 10.1111/j.1471-4159.1992.tb11017.x; CHAGNON P, 1995, NEUROREPORT, V6, P711, DOI 10.1097/00001756-199503270-00002; CHANDRASEKARAN K, 1994, MOL BRAIN RES, V24, P336, DOI 10.1016/0169-328X(94)90147-3; Chandrasekaran K, 1996, EXP NEUROL, V142, P80, DOI 10.1006/exnr.1996.0180; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; Davis JN, 1998, BIOCHEM BIOPH RES CO, V244, P877, DOI 10.1006/bbrc.1998.8353; ELLISON DW, 1987, BRAIN RES, V417, P389, DOI 10.1016/0006-8993(87)90471-9; Farber SA, 1996, BRAIN RES, V723, P90, DOI 10.1016/0006-8993(96)00221-1; Farooqui AA, 1997, J NEUROCHEM, V69, P889; FELDMAN DA, 1981, BIOCHIM BIOPHYS ACTA, V665, P53, DOI 10.1016/0005-2760(81)90231-9; FOLCH J, 1957, J BIOL CHEM, V226, P497; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GEDDES JW, 1985, SCIENCE, V230, P1179, DOI 10.1126/science.4071042; Gibson G, 1997, J NEUROCHEM, V69, P603; GIBSON GE, 1988, ARCH NEUROL-CHICAGO, V45, P836, DOI 10.1001/archneur.1988.00520320022009; Gibson GE, 1998, ANN NEUROL, V44, P676, DOI 10.1002/ana.410440414; GINSBERG L, 1993, MOL CHEM NEUROPATHOL, V19, P37, DOI 10.1007/BF03160167; GINSBERG L, 1995, BRAIN RES, V698, P223, DOI 10.1016/0006-8993(95)00931-F; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; HASHAM MI, 1994, CAN J PHYSIOL PHARM, V72, P728, DOI 10.1139/y94-104; Hoyer S, 1993, J Geriatr Psychiatry Neurol, V6, P3; HOYER S, 1992, MOL CHEM NEUROPATHOL, V16, P207, DOI 10.1007/BF03159971; JOHNSON JD, 1987, TOXICOL APPL PHARM, V88, P217, DOI 10.1016/0041-008X(87)90007-X; Jope RS, 1997, NEUROBIOL AGING, V18, P111, DOI 10.1016/S0197-4580(96)00205-9; JOPE RS, 1994, NEUROBIOL AGING, V15, P221, DOI 10.1016/0197-4580(94)90116-3; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KLEIN J, 1993, BRAIN RES, V630, P337, DOI 10.1016/0006-8993(93)90674-C; Klunk WE, 1996, NEUROBIOL AGING, V17, P349, DOI 10.1016/0197-4580(96)00035-8; Klunk WE, 1998, NEUROBIOL AGING, V19, P511, DOI 10.1016/S0197-4580(98)00105-5; LISCOVITCH M, 1985, ANAL BIOCHEM, V151, P182, DOI 10.1016/0003-2697(85)90069-7; LOPEZ G, 1992, J NEUROCHEM, V59, P338; Luo Y, 1997, P NATL ACAD SCI USA, V94, P9705, DOI 10.1073/pnas.94.18.9705; MADUH EU, 1991, J APPL TOXICOL, V11, P97, DOI 10.1002/jat.2550110205; MASON RP, 1995, NEUROBIOL AGING, V16, P531, DOI 10.1016/0197-4580(95)00057-L; MCCLURE RJ, 1994, ANN NY ACAD SCI, V747, P110; Mills EM, 1996, J NEUROCHEM, V67, P1039; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; PARKER WD, 1991, ANN NY ACAD SCI, V640, P59; Pedersen WA, 1997, J BIOL CHEM, V272, P22397, DOI 10.1074/jbc.272.36.22397; PELECH SL, 1983, J BIOL CHEM, V258, P6782; Pettegrew JW, 1997, ANN NY ACAD SCI, V826, P282, DOI 10.1111/j.1749-6632.1997.tb48480.x; Poirier J, 1999, J PSYCHIATR NEUROSCI, V24, P147; Purdon AD, 1998, BIOCHEM J, V335, P313, DOI 10.1042/bj3350313; RABIZADEH S, 1994, P NATL ACAD SCI USA, V91, P10703, DOI 10.1073/pnas.91.22.10703; Rapoport SI, 1996, NEURODEGENERATION, V5, P473, DOI 10.1006/neur.1996.0065; Redjems-Bennani N, 1998, GERONTOLOGY, V44, P300, DOI 10.1159/000022031; Ross BM, 1998, J NEUROCHEM, V70, P786; Satlin A, 1997, AM J PSYCHIAT, V154, P1459; SCHUBERT D, 1988, SCIENCE, V241, P223, DOI 10.1126/science.2968652; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SHEU KFR, 1985, ANN NEUROL, V17, P444; SIMS NR, 1987, ANN NEUROL, V21, P451, DOI 10.1002/ana.410210507; SIMS NR, 1983, J NEUROCHEM, V41, P1329, DOI 10.1111/j.1471-4159.1983.tb00829.x; SLACK BE, 1991, J BIOL CHEM, V266, P24503; SLACK BE, 1992, BRAIN RES, V585, P169, DOI 10.1016/0006-8993(92)91203-Q; SORBI S, 1995, ALZ DIS ASSOC DIS, V9, P73, DOI 10.1097/00002093-199509020-00003; STOKES CE, 1987, J NEUROCHEM, V48, P1018, DOI 10.1111/j.1471-4159.1987.tb05619.x; TOUCHSTONE JC, 1980, LIPIDS, V15, P61, DOI 10.1007/BF02534120; Webster MT, 1998, J NEURAL TRANSM, V105, P839, DOI 10.1007/s007020050098; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; Wells K, 1995, NEUROCHEM RES, V20, P1329, DOI 10.1007/BF00992508; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YANG XM, 1994, J RARE EARTH, V12, P124; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; ZUBENKO GS, 1992, NEUROPSYCHOPHARMACOL, V6, P77; Zubenko GS, 1999, AM J PSYCHIAT, V156, P50, DOI 10.1176/ajp.156.1.50	78	54	56	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2198	2206		10.1096/fj.99-0853	http://dx.doi.org/10.1096/fj.99-0853			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053240				2022-12-25	WOS:000165190800012
J	Benistant, C; Chapuis, H; Roche, S				Benistant, C; Chapuis, H; Roche, S			A specific function for phosphatidylinositol 3-kinase alpha (p85 alpha-p110 alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85 alpha-p110 beta) in de novo DNA synthesis of human colon carcinoma cells	ONCOGENE			English	Article						phosphatidylinositol 3-kinase; intracellular signalling; carcinoma; DNA synthesis; apoptosis	PHOSPHOINOSITIDE 3-OH KINASE; SIGNALING PATHWAY; LYSOPHOSPHATIDIC-ACID; CATALYTIC SUBUNIT; ACTIVATION; PROTEIN; GAMMA; RAS; TRANSFORMATION; CANCER	We have previously shown an important function of phosphatidylinositol 3-kinase (PI3K)alpha(p85 alpha-p110 alpha) and PI3K beta (p85-alpha-p110 beta) for DNA synthesis induced by various mitogens in non transformed fibroblasts and we now report a specific role of these enzymes in human colon cancer cell growth. Using antibodies specific to p110 alpha and to p110 beta catalytic subunits, increase in PI3K alpha and PI3K beta activities,vas detected in 15/19 human tumour biopsies relative to adjacent normal mucosa of human colon and bladder. Increase in such activities was also observed in adenocarcinoma cell lines CaCo2, CO115, HCT 116, LS 174T and WiDr relative to nontransformed fibroblasts. Maximal PI3K alpha activity was observed for LS 174T and PI3K beta activity for WiDr cells. This was partly correlated with an increase in p110 alpha and p110 beta protein levels both in some primary tumours and established cell lines, suggesting that PI3K overexpression is involved in enzymatic deregulation. Functional consequence of such activation was assessed by a microinjection approach. An injection of neutralizing antibody specific to p110 beta in WiDr, HCT116 and CO 115 cells inhibited de novo DNA synthesis, whereas antibodies specific to p110 gamma had no effect. Neutralizing antibodies specific to p110 alpha induced apoptosis, a response that was reverted by treating cells with the caspase inhibitor z-VAD-fmk. However anti-p110 beta and anti-p110 gamma antibodies did not affect cell survival, We concluded that PI3K alpha and PI3K beta play important roles in human colon cancer cell growth with a specific function for PI3K beta in de novo DNA synthesis and an involvement of PI3K alpha in cell survival.	CRBM, CNRS, UPR 1086, F-34293 Montpellier 05, France; Ctr Hosp Univ, Dept Anathomopathol, Nimes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; CHU de Nimes	Roche, S (corresponding author), CRBM, CNRS, UPR 1086, 1919 Route Mende, F-34293 Montpellier 05, France.		Benistant, Christine/M-5771-2018	roche, serge/0000-0003-3413-3859				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Gershtein ES, 1999, CLIN CHIM ACTA, V287, P59, DOI 10.1016/S0009-8981(99)00118-7; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Graves JD, 1995, ANN NY ACAD SCI, V766, P320, DOI 10.1111/j.1749-6632.1995.tb26684.x; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Moore SM, 1998, CANCER RES, V58, P5239; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	35	128	162	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5083	5090		10.1038/sj.onc.1203871	http://dx.doi.org/10.1038/sj.onc.1203871			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042696				2022-12-25	WOS:000089930100005
J	Ardini, E; Agresti, R; Tagliabue, E; Greco, M; Aiello, P; Yang, LT; Menard, S; Sap, J				Ardini, E; Agresti, R; Tagliabue, E; Greco, M; Aiello, P; Yang, LT; Menard, S; Sap, J			Expression of protein tyrosine phosphatase alpha (RPTP alpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo	ONCOGENE			English	Article						tyrosine phosphatase; c-Src; PTP; breast cancer; tumor marker	DOWN-REGULATION; MAMMARY-TUMORS; C-SRC; SIGNAL-TRANSDUCTION; PROGNOSTIC FACTOR; TRANSGENIC MICE; FACTOR RECEPTOR; NEU ONCOGENE; PTP-ALPHA; IN-VIVO	Tyrosine phosphorylation is controlled by a balance of tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), Whereas the contribution of PTKs to breast tumorigenesis is the subject of intense scrutiny, the potential role of PTPs is poorly known. RPTP alpha is implicated in the activation of Src family kinases, and regulation of integrin signaling, cell adhesion, and growth factor responsiveness. To explore its potential contribution to human neoplasia, we surveyed RPTPa protein levels in primary human breast cancer. We found RPTPa levels to vary widely among tumors, with 29% of cases manifesting significant overexpression, High RPTP alpha protein levels correlated significantly with low tumor grade and positive estrogen receptor status. Expression of RPTP alpha in breast carcinoma cells led to growth inhibition, associated with increased accumulation in G(0) and G(1), and delayed tumor growth and metastasis. To our knowledge, this is the first example of a study correlating expression level of a specific bona fide PTP with neoplastic disease status in humans.	Ist Nazl Tumori, Mol Targeting Unit, Div Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Gen Surg Breast Unit B, I-20133 Milan, Italy; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; New York University; New York University	Menard, S (corresponding author), Ist Nazl Tumori, Mol Targeting Unit, Div Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.		menard, sylvie mm/C-7940-2011; Agresti, Roberto/AAB-6062-2019; Tagliabue, Elda/B-9377-2017	Agresti, Roberto/0000-0003-4700-1951; Tagliabue, Elda/0000-0001-9877-2903	NCI NIH HHS [R29 CA68365, 5R21 CA66229-04, P30CA16087] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA066229, P30CA016087, R29CA068365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; BARKER KT, 1995, ONCOGENE, V10, P569; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Cong LN, 1999, BIOCHEM BIOPH RES CO, V255, P200, DOI 10.1006/bbrc.1999.0183; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; ELSON A, 1995, P NATL ACAD SCI USA, V92, P12335; ELSTON CW, 1984, AUST NZ J SURG, V54, P11, DOI 10.1111/j.1445-2197.1984.tb06677.x; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREISS G, 1994, MOL ENDOCRINOL, V8, P1389, DOI 10.1210/me.8.10.1389; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Keane MM, 1996, CANCER RES, V56, P4236; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lollini PL, 1998, INT J CANCER, V77, P937, DOI 10.1002/(SICI)1097-0215(19980911)77:6<937::AID-IJC24>3.0.CO;2-X; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; OTTENHOFFKALFF AE, 1995, BREAST CANCER RES TR, V33, P245, DOI 10.1007/BF00665949; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PEREIRA H, 1995, HISTOPATHOLOGY, V27, P219, DOI 10.1111/j.1365-2559.1995.tb00213.x; Petrone A, 2000, J CELL SCI, V113, P2345; PIZAO PE, 1992, BRIT J CANCER, V66, P660, DOI 10.1038/bjc.1992.333; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SILVESTRINI R, 1985, CANCER, V56, P1982, DOI 10.1002/1097-0142(19851015)56:8<1982::AID-CNCR2820560816>3.0.CO;2-I; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1996, J BIOL CHEM, V271, P28026; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; *UICC, 1997, ILL GUID TNM PTNM CL; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; ZHAI YF, 1993, CANCER RES, V53, P2272; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	63	69	72	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4979	4987		10.1038/sj.onc.1203869	http://dx.doi.org/10.1038/sj.onc.1203869			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042685				2022-12-25	WOS:000089834300005
J	Gabet, AS; Mortreux, F; Talarmin, A; Plumelle, Y; Leclercq, I; Leroy, A; Gessain, A; Clity, E; Joubert, M; Wattel, E				Gabet, AS; Mortreux, F; Talarmin, A; Plumelle, Y; Leclercq, I; Leroy, A; Gessain, A; Clity, E; Joubert, M; Wattel, E			High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis	ONCOGENE			English	Article						HTLV; leukemogenesis; adult T cell leukemia; genetic instability	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; FRENCH-WEST-INDIES; EPSTEIN-BARR-VIRUS; LEUKEMIA-LYMPHOMA; TAX PROTEIN; SEMIQUANTITATIVE ANALYSIS; POLYCLONAL INTEGRATION; STERCORALIS INFECTION; PERIPHERAL-BLOOD	Adult T cell leukemia (ATLL) develops in 3-5% of HTLV-1 carriers after a long period of latency during which a persistent polyclonal expansion of HTLV-1 infected lymphocytes is observed in all individuals. This incubation period is significantly shortened in HTLV-1 carrier with Strongyloides stercoralis (Ss) infection, suggesting that Ss could be a cofactor of ATLL, As an increased T cell proliferation at the asymptomatic stage of HTLV-1 infection could increase the risk of malignant transformation, the effect of Ss infection on infected T lymphocytes was assessed in vivo in HTLV-1 asymptomatic carriers. After real-time quantitative PCR, the mean circulating HTLV-1 proviral load was more than five times higher in HTLV-1 carriers with stongyloidiasis than in HTLV-1+ individuals without Ss infection (P < 0,009), This increased proviral load was found to result from the extensive proliferation of a restricted number of infected clones, i,e, from oligoclonal expansion, as evidenced by the semiquantitative amplification of HTLV-1 flanking sequences. The positive effect of Ss on clonal expansion was reversible under effective treatment of strongyloidiasis in one patient with parasitological cure whereas no significant modification of the HTLV-1 replication pattern was observed in an additional case with strongyloidiasis treatment failure. Therefore, Ss stimulates the oligoclonal proliferation of HTLV-1 infected cells in HTLV-1 asymptomatic carriers in vivo, This is thought to account for the shortened period of latency observed in ATLL patients with strongyloidiasis.	Univ Lyon 1, CNRS, UMR5537, Unit Oncogenese Virale,Ctr Leon Berard, F-69373 Lyon 08, France; Inst Rech Canc Lille, INSERM, Unite 524, Lille, France; Inst Pasteur Guyane, Cayenne, France; CHU Ft France, Serv Hematol Biol, Martinique, France; Ctr Oscar Lambret, Unite Oncogenese Virale, F-59020 Lille, France; Inst Pasteur, Unite Epidemiol Virus Oncogenes, Paris, France; Univ Mons, Serv Biol Mol, B-7000 Mons, Belgium	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Martinique; UNICANCER; Centre Oscar Lambret; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Mons	Wattel, E (corresponding author), Univ Lyon 1, CNRS, UMR5537, Unit Oncogenese Virale,Ctr Leon Berard, 28 Rue Laennec, F-69373 Lyon 08, France.		mortreux, franck/M-5944-2014; mortreux, franck/T-4564-2019	mortreux, franck/0000-0002-4840-021X; mortreux, franck/0000-0002-4840-021X				Agape P, 1999, J ACQ IMMUN DEF SYND, V20, P394, DOI 10.1097/00042560-199904010-00011; ALBERTINI RJ, 1990, ANNU REV GENET, V24, P305; ARAKAKI T, 1992, J TROP MED HYG, V95, P210; ARAKAKI T, 1992, TROP MED PARASITOL, V43, P199; Cavrois M, 1996, ONCOGENE, V12, P2419; CAVROIS M, 1995, RES VIROLOGY, V146, P179, DOI 10.1016/0923-2516(96)80578-4; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; Cavrois M, 1996, BLOOD, V88, P4646, DOI 10.1182/blood.V88.12.4646.bloodjournal88124646; CESARMAN E, 1992, BLOOD, V80, P3205; CHEN YX, 1995, INT J CANCER, V60, P798; CLEGHORN FR, 1995, JNCI-J NATL CANCER I, V87, P1009, DOI 10.1093/jnci/87.13.1009; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; de-The G, 1985, IARC Sci Publ, P165; DEOLIVEIRA MSP, 1995, INT J CANCER, V60, P823, DOI 10.1002/ijc.2910600617; deThe G, 1997, ANN MED INTERNE, V148, P357; DEVAULT GA, 1990, REV INFECT DIS, V12, P653; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769; FACER CA, 1989, ADV CANCER RES, V53, P33; FUJII M, 1991, ONCOGENE, V6, P1023; GELBER M, 1996, HAREFUAH, V130, P13; Gelber Moshe, 1996, Harefuah, V130, P90; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1985, LANCET, V2, P407; GORDON SM, 1994, J AM ACAD DERMATOL, V31, P255, DOI 10.1016/S0190-9622(94)70158-X; Goyal SB, 1998, SOUTHERN MED J, V91, P768, DOI 10.1097/00007611-199808000-00016; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Hayashi J, 1997, AM J TROP MED HYG, V56, P71, DOI 10.4269/ajtmh.1997.56.71; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; LAGRENADE L, 1990, LANCET, V336, P1345; Leclercq I, 1998, BRIT J HAEMATOL, V101, P500, DOI 10.1046/j.1365-2141.1998.00743.x; Leclercq I, 1999, BRIT J HAEMATOL, V105, P743, DOI 10.1046/j.1365-2141.1999.01389.x; MASSEY AC, 1990, VA MED Q, V117, P31; MATSUMOTO T, 1990, CLIN EXP IMMUNOL, V81, P207, DOI 10.1111/j.1365-2249.1990.tb03319.x; Mattos K, 1993, Arq Neuropsiquiatr, V51, P134; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MOCHIZUKI M, 1994, BRIT J OPHTHALMOL, V78, P149, DOI 10.1136/bjo.78.2.149; MOLBAK K, 1994, J INFECT DIS, V169, P581, DOI 10.1093/infdis/169.3.581; NAKANE S, 1988, J PHARM PHARMACOL, V40, P1, DOI 10.1111/j.2042-7158.1988.tb05139.x; NEWTON RC, 1992, AM J MED, V92, P202, DOI 10.1016/0002-9343(92)90113-P; Nonaka D, 1998, AM J TROP MED HYG, V59, P535, DOI 10.4269/ajtmh.1998.59.535; OHSHIMA K, 1991, CANCER RES, V51, P4639; OSAME M, 1986, LANCET, V1, P1031; Pagliuca A, 1999, BRIT J HAEMATOL, V105, P1, DOI 10.1111/j.1365-2141.1999.01401.x; PAGLIUCA A, 1988, BRIT MED J, V297, P1456, DOI 10.1136/bmj.297.6661.1456; PATEY O, 1992, AIDS, V6, P575, DOI 10.1097/00002030-199206000-00009; PHELPS KR, 1991, AM J MED SCI, V302, P224, DOI 10.1097/00000441-199110000-00006; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Plumelle Y, 1997, AM J CLIN PATHOL, V107, P81; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SATO K, 1991, ARTHRITIS RHEUM, V34, P714, DOI 10.1002/art.1780340612; SHERMAN MP, 1995, ARTHRITIS RHEUM, V38, P690, DOI 10.1002/art.1780380518; SHIMAMOTO Y, 1994, BLOOD, V84, P853; SHINZATO O, 1991, BLOOD, V78, P2082; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; Tsukasaki K, 1997, BLOOD, V89, P948, DOI 10.1182/blood.V89.3.948; WATTEL E, 1992, J ACQ IMMUN DEF SYND, V5, P943; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; YAMAGUCHI K, 1987, LANCET, V2, P94, DOI 10.1016/S0140-6736(87)92752-8; YAMAGUCHI K, 1988, BRIT J HAEMATOL, V68, P169, DOI 10.1111/j.1365-2141.1988.tb06185.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	67	103	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2000	19	43					4954	4960		10.1038/sj.onc.1203870	http://dx.doi.org/10.1038/sj.onc.1203870			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042682				2022-12-25	WOS:000089834300002
J	Wang, DZ; Yang, W; Du, JG; Devalaraja, MN; Liang, P; Matsumoto, K; Tsubakimoto, K; Endo, T; Richmond, A				Wang, DZ; Yang, W; Du, JG; Devalaraja, MN; Liang, P; Matsumoto, K; Tsubakimoto, K; Endo, T; Richmond, A			MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression	ONCOGENE			English	Article						chemokine; MGSA/GRO; Ras; AP-I; melanocytes; transformation	GROWTH-STIMULATORY ACTIVITY; PROTEIN-COUPLED RECEPTORS; SIGNALING PATHWAY; TISSUE DISTRIBUTION; CANCER-CELLS; SKIN TUMORS; KAPPA-B; C-FOS; ALPHA; BETA	The MGSA/GRO protein is endogenously expressed in almost 70% of the melanoma cell lines and tumors, but not in normal melanocytes. We have previously demonstrated that over-expression of human MGSA/GRO alpha, beta or gamma in immortalized murine melanocytes (melan-a cells) enables these cells to form tumors in SCID and nude mice. To examine the possibility that the MGSA/GRO effect on melanocyte transformation requires expression of other genes, differential display was performed. One of the mRNA's identified in the screen as overexpressed in MGSA/GRO transformed melan-a clones was the newly described M-Ras or R-Ras3 gene, a member of the Ras gene superfamily, Over-expression of MGSA/GRO upregulates M-Ras expression at both the mRNA and protein levels, and this induction requires an intact glutamine-leucine-arginine (ELR)-motif in the MGSA/ GRO protein. Western blot examination of Ras expression revealed that K- and N-Ras proteins are also elevated in MGSA/GRO-expressing melan-a clones, leading to an overall increase in the amount of activated Ras, MGSA/GRO-expressing melan-a clones exhibited enhanced AP-1 activity. The effects of MGSA/GRO on AP-I activation could be mimicked by over-expression of wild-type M-Ras or a constitutively activated M-Ras mutant in control melan-a cells as monitored by an API-luciferase reporter, while expression of a dominant negative M-Ras blocked AP-1-luciferase activity in MGSA/GRO-transformed melan-a clones. In the in vitro transformation assay, over-expression of M-Ras mimicked the effects of MGSA/GRO by inducing cellular transformation in control melan-a cells, while over-expression of dominant negative M-Ras in MGSA/ GRO alpha-expressing melan-a-6 cells blocked transformation. These data suggest that MGSA/GRO-mediated transformation requires Ras activation in melanocytes.	Vanderbilt Univ, Dept Cell Biol, Sch Med, Nashville, TN 37232 USA; VA Med Ctr, Nashville, TN 37232 USA; Chiba Univ, Dept Biol, Chiba, Japan	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Chiba University	Richmond, A (corresponding author), Vanderbilt Univ, Dept Cell Biol, Sch Med, Nashville, TN 37232 USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [R01 CA034590-19, CA56704, CA 68485, P30 CA068485, R01 CA034590, R01 CA034590-17, R01 CA056704-07, R01 CA034590-18, R01 CA056704-08] Funding Source: Medline; BLRD VA [IK6 BX005225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056704, P30CA068485, R01CA034590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arenberg DA, 1997, J LEUKOCYTE BIOL, V62, P554, DOI 10.1002/jlb.62.5.554; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; FUJIMOTO J, 1995, J STEROID BIOCHEM, V55, P25, DOI 10.1016/0960-0760(95)00145-P; GEISER T, 1993, J BIOL CHEM, V268, P15419; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUSAIN Z, 1990, ARCH DERMATOL, V126, P324, DOI 10.1001/archderm.126.3.324; IIDA N, 1990, MOL CELL BIOL, V10, P5596, DOI 10.1128/MCB.10.10.5596; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; KURDOWSKA A, 1994, CYTOKINE, V6, P124, DOI 10.1016/1043-4666(94)90033-7; Limatola C, 1999, J BIOL CHEM, V274, P36537, DOI 10.1074/jbc.274.51.36537; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; MANGUES R, 1992, ONCOGENE, V7, P2073; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MATTEI S, 1994, INT J CANCER, V56, P853, DOI 10.1002/ijc.2910560617; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rennekampff HO, 1997, ARCH DERMATOL RES, V289, P204, DOI 10.1007/s004030050181; RICHMOND A, 1988, J CELL BIOCHEM, V36, P185, DOI 10.1002/jcb.240360209; RICHMOND A, 1986, J CELL PHYSIOL, V129, P375, DOI 10.1002/jcp.1041290316; RODECK U, 1991, CANCER CELL-MON REV, V3, P308; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Rutberg SE, 1997, MOL CARCINOGEN, V20, P88, DOI 10.1002/(SICI)1098-2744(199709)20:1<88::AID-MC10>3.0.CO;2-5; Sadhu C, 1998, J IMMUNOL, V160, P5622; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; Shattuck-Brandt RL, 1997, DNA SEQUENCE, V7, P379, DOI 10.3109/10425179709034060; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shyamala V, 1998, BIOCHEMISTRY-US, V37, P15918, DOI 10.1021/bi9811415; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Zhang BX, 1997, P SOC EXP BIOL MED, V214, P359	56	61	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4647	4659		10.1038/sj.onc.1203820	http://dx.doi.org/10.1038/sj.onc.1203820			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030154	Green Accepted			2022-12-25	WOS:000089438200011
J	Feese, MD; Ingason, BP; Goranson-Siekierke, J; Holmes, RK; Hol, WGJ				Feese, MD; Ingason, BP; Goranson-Siekierke, J; Holmes, RK; Hol, WGJ			Crystal structure of the iron-dependent regulator from Mycobacterium tuberculosis at 2.0-angstrom resolution reveals the Src homology domain 3-like fold and metal binding function of the third domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN-REPRESSOR; CORYNEBACTERIUM-DIPHTHERIAE; ELEMENT DTXR; MACROMOLECULAR STRUCTURES; DNA-SEQUENCE; PROGRAM; GENE; COMPLEX; IDER; PROMOTER/OPERATORS	Iron-dependent regulators are primary transcriptional regulators of virulence factors and iron scavenging systems that are important for infection by several bacterial pathogens. Here we present the 2.0-Angstrom crystal structure of the wild type iron-dependent regulator from Mycobacterium tuberculosis in its fully active holorepressor conformation. Clear, unbiased electron density for the Src homology domain S-like third domain, which is often invisible in structures of iron-dependent regulators, was revealed by density modification and averaging. This domain is one of the rare examples of Src homology domain 3-like folds in bacterial proteins, and, in addition, displays a metal binding function by contributing two ligands, one Glu and one Gin, to the pentacoordinated cobalt atom at metal site 1, Both metal sites are fully occupied, and tightly bound water molecules at metal site 1 ("Water 1") and metal site 2 ("Water 2") are identified unambiguously. The main chain carbonyl of Leu(4) makes an indirect interaction with the cobalt atom at metal site 2 via Water 2, and the adjacent residue, Val(5), forms a rare gamma turn. Residues 1-3 are well ordered and make numerous interactions. These ordered solvent molecules and the conformation and interactions of the N-terminal pentapeptide thus might be important in metal-dependent activation.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hol, WGJ (corresponding author), Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA.				NCI NIH HHS [R01CA65656] Funding Source: Medline; NIAID NIH HHS [R01AI14107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYD J, 1990, P NATL ACAD SCI USA, V87, P5968, DOI 10.1073/pnas.87.15.5968; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Chen CSY, 2000, BIOCHEMISTRY-US, V39, P10397, DOI 10.1021/bi0009284; Ciubotaru M, 1999, J MOL BIOL, V294, P859, DOI 10.1006/jmbi.1999.3269; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Dickerson RE, 1998, STRUCTURE, MOTION, INTERACTION AND EXPRESSION OF BIOLOGICAL MACROMOLECULES, VOL 1, P17; Ding X, 1996, NAT STRUCT BIOL, V3, P382, DOI 10.1038/nsb0496-382; DOUKHAN L, 1995, GENE, V165, P67, DOI 10.1016/0378-1119(95)00427-8; Dussurget O, 1999, J BACTERIOL, V181, P3402, DOI 10.1128/JB.181.11.3402-3408.1999; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FEESE MD, 2001, IN PRESS HDB METALLO; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Goranson-Siekierke J, 1999, INFECT IMMUN, V67, P1806; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P734; Harding MM, 1999, ACTA CRYSTALLOGR D, V55, P1432, DOI 10.1107/S0907444999007374; Hilchey SP, 1997, J BIOL CHEM, V272, P1646, DOI 10.1074/jbc.272.3.1646; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JH, 1997, INFECT IMMUN, V65, P4273, DOI 10.1128/IAI.65.10.4273-4280.1997; Lee JH, 2000, J BACTERIOL, V182, P432, DOI 10.1128/JB.182.2.432-438.2000; LEE JH, 1999, 99 GEN M AM SOC MICR, P88; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; LIDE DR, 1999, CRC HDB CHEM PHYSICS; LITWIN CM, 1993, CLIN MICROBIOL REV, V6, P137, DOI 10.1128/CMR.6.2.137-149.1993; MACHAM LP, 1975, J GEN MICROBIOL, V89, P379, DOI 10.1099/00221287-89-2-379; Mackay K. M., 1989, INTRO MODERN INORGAN; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEMETHY G, 1972, MACROMOLECULES, V5, P755, DOI 10.1021/ma60030a017; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTTO BR, 1992, CRIT REV MICROBIOL, V18, P217, DOI 10.3109/10408419209114559; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; OVERALL CM, 1987, ANAL BIOCHEM, V165, P208, DOI 10.1016/0003-2697(87)90221-1; Pappenheimer AM, 1936, BRIT J EXP PATHOL, V17, P335; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Pohl E, 1998, J BIOL CHEM, V273, P22420, DOI 10.1074/jbc.273.35.22420; Pohl E, 1999, J MOL BIOL, V285, P1145, DOI 10.1006/jmbi.1998.2339; Pohl E, 1999, J MOL BIOL, V292, P653, DOI 10.1006/jmbi.1999.3073; POPOV EP, 1968, MOL BIOL, V2, P498; Qiu XY, 1996, BIOCHEMISTRY-US, V35, P12292, DOI 10.1021/bi960861d; QIU XY, 1995, STRUCTURE, V3, P87, DOI 10.1016/S0969-2126(01)00137-X; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHIERING N, 1995, P NATL ACAD SCI USA, V92, P9843, DOI 10.1073/pnas.92.21.9843; SCHMITT MP, 1993, MOL MICROBIOL, V9, P173, DOI 10.1111/j.1365-2958.1993.tb01679.x; SCHMITT MP, 1991, INFECT IMMUN, V59, P1899, DOI 10.1128/IAI.59.6.1899-1904.1991; Schmitt MP, 1997, INFECT IMMUN, V65, P4634, DOI 10.1128/IAI.65.11.4634-4641.1997; SCHMITT MP, 1995, INFECT IMMUN, V63, P4284, DOI 10.1128/IAI.63.11.4284-4289.1995; SCHMITT MP, 1994, J BACTERIOL, V176, P1141, DOI 10.1128/JB.176.4.1141-1149.1994; SCHMITT MP, 1992, P NATL ACAD SCI USA, V89, P7576, DOI 10.1073/pnas.89.16.7576; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TAI SPS, 1990, MICROB PATHOGENESIS, V9, P267, DOI 10.1016/0882-4010(90)90015-I; TAO X, 1993, P NATL ACAD SCI USA, V90, P8524, DOI 10.1073/pnas.90.18.8524; TAO X, 1992, P NATL ACAD SCI USA, V89, P5897, DOI 10.1073/pnas.89.13.5897; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; White A, 1998, NATURE, V394, P502, DOI 10.1038/28893; ZHANG XJ, 1995, J APPL CRYSTALLOGR, V28, P624, DOI 10.1107/S0021889895001063	59	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5959	5966		10.1074/jbc.M007531200	http://dx.doi.org/10.1074/jbc.M007531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11053439	hybrid			2022-12-25	WOS:000167115100074
J	Fingerhut, A; von Figura, K; Honing, S				Fingerhut, A; von Figura, K; Honing, S			Binding of AP2 to sorting signals is modulated by AP2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; LYSOSOMAL ACID-PHOSPHATASE; MEDIATED ENDOCYTOSIS; UNCOATING ATPASE; ARRESTIN/CLATHRIN INTERACTION; ASSEMBLY POLYPEPTIDES; CYTOPLASMIC DOMAIN; KINASE-ACTIVITIES; INVITRO BINDING; TERMINAL DOMAIN	The two clathrin-associated adaptor complexes API and AP2 are known to participate in the formation of clathrin-coated vesicles at the trans-Golgi network and at the plasma membrane. During this process adaptors are involved in the sequestration of vesicle cargo by binding to the sorting signals within the cytoplasmic domains of the cargo proteins and in the recruitment of the clathrin coat. After budding of the clathrin-coated vesicles, the clathrin and adaptors dissociate from the vesicles. Here we show that in vitro binding of AP2 to sorting signals, which is one of the initial steps in receptor-mediated endocytosis, is modulated by adaptor phosphorylation. AP2 was phosphorylated by incubating purified AP2 in the presence of ATP and dephosphorylated by incubation with alkaline phosphatase. Affinity for tyrosine-, leucine-based and noncanonical sorting motifs was 15-33 times higher for phosphorylated than for dephosphorylated AP2. Also the binding of AP2 to membranes was regulated by adaptor phosphorylation/dephosphorylation and was about 8-fold higher for phosphorylated than for dephosphorylated AP2. Moreover, AP2 isolated from cytosol is higher phosphorylated than membrane-extracted and exhibits a B-fold higher binding affinity than AP2 extracted from membranes. Taken together these data point to a cycle of phosphorylation/dephosphorylation as a mechanism for regulating the reversible association of AP2 with membranes and sorting signals during the process of recptor-mediated endocytosis.	Univ Gottingen, Inst Biochem 2, D-37073 Gottingen, Germany	University of Gottingen	Honing, S (corresponding author), Univ Gottingen, Inst Biochem 2, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.		Fingerhut, Abe/AAE-6424-2022	Fingerhut, Abe/0000-0003-4243-9196				BARZVI D, 1988, J BIOL CHEM, V263, P4408; BARZVI D, 1986, J BIOL CHEM, V261, P9614; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; Hannan LA, 1998, MOL BIOL CELL, V9, P2217, DOI 10.1091/mbc.9.8.2217; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HILL BL, 1988, J BIOL CHEM, V263, P5499; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; HONING S, 1994, J CELL SCI, V107, P1185; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; Iannolo G, 1997, CANCER RES, V57, P240; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lauritsen JPH, 2000, BBA-MOL CELL RES, V1497, P297, DOI 10.1016/S0167-4889(00)00065-3; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PAULOIN A, 1993, BIOCHEM J, V296, P409, DOI 10.1042/bj2960409; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHMID SL, 1984, NATURE, V311, P228, DOI 10.1038/311228a0; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SOSA MA, 1993, J BIOL CHEM, V268, P12537; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	44	61	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5476	5482		10.1074/jbc.M009516200	http://dx.doi.org/10.1074/jbc.M009516200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11044456	hybrid			2022-12-25	WOS:000167115100011
J	Small, KM; Brown, KM; Forbes, SL; Liggett, SB				Small, KM; Brown, KM; Forbes, SL; Liggett, SB			Polymorphic deletion of three intracellular acidic residues of the alpha(2B)-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-PROMOTED DESENSITIZATION; SUBTYPES; SITES; LOOP; IDENTIFICATION; INHIBITION; EXPRESSION	A polymorphic variant of the human alpha (2B)-adrenergic receptor (alpha (2B)AR), which consists of a deletion of three glutamic acids (residues 301-303) in the third intracellular loop was found to be common in Caucasians (31%) and to a lesser extent in African-Americans (12%), The consequences of this deletion were assessed by expressing wild-type and the Del301-303 receptors in Chinese hamster ovary and COS cells. Ligand binding was not affected, although a small decrease in coupling efficiency to the inhibition of adenylyl cyclase was observed with the mutant. The deletion occurs within a stretch of acidic residues that is thought to establish the milieu for agonist-promoted phosphorylation and desensitization of the receptor by G protein-coupled receptor kinases (GRKs). Agonist-promoted phosphorylation studies carried out in cells coexpressing the alpha (2B)ARs and GRK2 revealed that the Del301-303 receptor displayed similar to 56% of wild-type phosphorylation. Furthermore, the depressed phosphorylation imposed by the deletion was found to result in a complete loss of short term agonist-promoted receptor desensitization. Thus the major phenotype of the Del301-303 alpha (2B)AR is one of impaired phosphorylation and desensitization by GRKs, and thus the polymorphisms renders the receptor incapable of modulation by this key mechanism of dynamic regulation.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, 231 Albert Sabin Way,Rm G062, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL52318] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altman JD, 1999, MOL PHARMACOL, V56, P154, DOI 10.1124/mol.56.1.154; Baldwin CT, 1999, AM J HYPERTENS, V12, P853, DOI 10.1016/S0895-7061(99)00070-9; BARON BM, 1990, MOL PHARMACOL, V38, P348; EASON MG, 1993, MOL PHARMACOL, V44, P70; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; EASON MG, 1994, MOL PHARMACOL, V45, P696; EASON MG, 1992, J BIOL CHEM, V267, P25473; HANDY DE, 1993, HYPERTENSION, V21, P861, DOI 10.1161/01.HYP.21.6.861; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; Hein L, 1999, ANN NY ACAD SCI, V881, P265, DOI 10.1111/j.1749-6632.1999.tb09368.x; Heinonen P, 1999, J CLIN ENDOCR METAB, V84, P2429, DOI 10.1210/jc.84.7.2429; Jewell-Motz EA, 2000, J BIOL CHEM, V275, P28989, DOI 10.1074/jbc.M005381200; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; Makaritsis KP, 1999, HYPERTENSION, V33, P14, DOI 10.1161/01.HYP.33.1.14; Munroe PB, 2000, CURR OPIN GENET DEV, V10, P325, DOI 10.1016/S0959-437X(00)00081-2; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rohrer DK, 1998, PHYSIOL REV, V78, P35, DOI 10.1152/physrev.1998.78.1.35; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; Sallinen J, 1999, MOL PSYCHIATR, V4, P443, DOI 10.1038/sj.mp.4000543; Sallinen J, 1998, J NEUROSCI, V18, P3035; Small KM, 2000, J BIOL CHEM, V275, P23059, DOI 10.1074/jbc.M000796200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tavares A, 1996, HYPERTENSION, V27, P449, DOI 10.1161/01.HYP.27.3.449	30	129	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4917	4922		10.1074/jbc.M008118200	http://dx.doi.org/10.1074/jbc.M008118200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11056163	hybrid			2022-12-25	WOS:000168484300054
J	Barton, ES; Connolly, JL; Forrest, JC; Chappell, JD; Dermody, TS				Barton, ES; Connolly, JL; Forrest, JC; Chappell, JD; Dermody, TS			Utilization of sialic acid as a coreceptor enhances reovirus attachment by multistep adhesion strengthening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MURINE ERYTHROLEUKEMIA-CELLS; SIMPLEX VIRUS GD; TYPE-3 REOVIRUS; PROTEIN SIGMA-1; PERSISTENT INFECTIONS; MAMMALIAN REOVIRUSES; CHEMOKINE RECEPTORS; FUNCTIONAL DOMAINS; VIRAL ENTRY	Many serotype 3 reoviruses bind to two different host cell molecules, sialic acid and an unidentified protein, using discrete receptor-binding domains in viral attachment protein, sigma1. To determine mechanisms by which these receptor-binding events cooperate to mediate cell attachment, we generated isogenic reovirus strains that differ in the capacity to bind sialic acid. Strain SA+, but not SA-, bound specifically to sialic acid on a biosensor chip with nanomolar avidity. SA+ displayed 5-fold higher avidity for HeLa cells when compared with SA-, although both strains recognized the same proteinaceous receptor. Increased avidity of SA+ binding was mediated by increased k(on). Neuraminidase treatment to remove cell-surface sialic acid decreased the k(on) of SA+ to that of SA-. Increased k(on) of SA+ enhanced an infectious attachment process, since SA+ was 50-100 fold more efficient than SA- at infecting HeLa cells in a kinetic fluorescent focus assay. Sialic acid binding was operant early during SA+ attachment, since the capacity of soluble sialyllactose to inhibit infection decreased rapidly during the first 20 min of adsorption, These results indicate that reovirus binding to sialic acid enhances virus infection through adhesion of virus to the cell surface where access to a proteinaceous receptor is thermodynamically favored.	Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Dermody, TS (corresponding author), Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, D7235 MCN, Nashville, TN 37232 USA.			Barton, Erik/0000-0001-6942-6315	NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI038296, R01AI038296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09385, CA68485] Funding Source: Medline; NIAID NIH HHS [AI38296] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASSELDUBY R, 1986, J VIROL, V60, P64, DOI 10.1128/JVI.60.1.64-67.1986; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BURSTIN SJ, 1982, VIROLOGY, V117, P146, DOI 10.1016/0042-6822(82)90514-1; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; Clark AJ, 1927, J PHYSIOL-LONDON, V64, P123, DOI 10.1113/jphysiol.1927.sp002424; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; DEBIASI R, 1999, AM SOC VIR 18 ANN M; DERMODY TS, 1990, J VIROL, V64, P4842, DOI 10.1128/JVI.64.10.4842-4850.1990; DERMODY TS, 1990, J VIROL, V64, P5173, DOI 10.1128/JVI.64.10.5173-5176.1990; DICHTER MA, 1984, ANN NEUROL, V16, P603, DOI 10.1002/ana.410160512; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUNCAN R, 1991, VIROLOGY, V182, P810, DOI 10.1016/0042-6822(91)90622-I; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; GENTSCH JR, 1985, J VIROL, V56, P356, DOI 10.1128/JVI.56.2.356-364.1985; HAYWOOD AM, 1994, J VIROL, V68, P1; HRDY DB, 1979, J VIROL, V31, P104, DOI 10.1128/JVI.31.1.104-111.1979; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KAYE KM, 1986, J VIROL, V59, P90, DOI 10.1128/JVI.59.1.90-97.1986; Krummenacher C, 1999, J VIROL, V73, P8127, DOI 10.1128/JVI.73.10.8127-8137.1999; LAURENCE MB, 1991, CELL, V65, P859; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEONE G, 1992, CELL, V71, P479, DOI 10.1016/0092-8674(92)90516-F; LIMBIRD LE, 1996, CELL SURFACE RECEPTO, P61; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; NAGATA L, 1987, VIROLOGY, V160, P162, DOI 10.1016/0042-6822(87)90056-0; NIBERT ML, 1995, J VIROL, V69, P5057, DOI 10.1128/JVI.69.8.5057-5067.1995; NIBERT ML, 1996, FIELDS VIROLOGY, P1557; Oberhaus SM, 1997, J VIROL, V71, P2100, DOI 10.1128/JVI.71.3.2100-2106.1997; PACITTI AF, 1987, J VIROL, V61, P1407, DOI 10.1128/JVI.61.5.1407-1415.1987; PAUL RW, 1989, VIROLOGY, V172, P382, DOI 10.1016/0042-6822(89)90146-3; PAUL RW, 1987, VIROLOGY, V159, P94, DOI 10.1016/0042-6822(87)90351-5; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; *PHARM BIOS AB, BIAAPPL HDB; Pickles RJ, 2000, J VIROL, V74, P6050, DOI 10.1128/JVI.74.13.6050-6057.2000; Rajcani J, 1998, ACTA VIROL, V42, P103; RAMOSALVAREZ M, 1954, P SOC EXP BIOL MED, V87, P655, DOI 10.3181/00379727-87-21474; Rodgers SE, 1997, J VIROL, V71, P2540, DOI 10.1128/JVI.71.3.2540-2546.1997; Rott O, 1996, MED MICROBIOL IMMUN, V184, P185, DOI 10.1007/s004300050006; RUBIN DH, 1992, J CLIN INVEST, V90, P2536, DOI 10.1172/JCI116147; Sarrias MR, 1999, J VIROL, V73, P5681, DOI 10.1128/JVI.73.7.5681-5687.1999; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; Shukla D, 1999, J VIROL, V73, P4493, DOI 10.1128/JVI.73.5.4493-4497.1999; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; SPEAR PG, 1992, ADV EXP MED BIOL, V313, P341; SPRIGGS DR, 1983, SCIENCE, V220, P505, DOI 10.1126/science.6301010; TARDIEU M, 1983, ANN NEUROL, V13, P602, DOI 10.1002/ana.410130604; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TURNER DL, 1992, VIROLOGY, V186, P219, DOI 10.1016/0042-6822(92)90076-2; TYLER KL, 1986, SCIENCE, V233, P770, DOI 10.1126/science.3016895; TYLER KL, 1996, FIELDS VIROLOGY, P1597; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; VIRGIN HW, 1991, J VIROL, V65, P6772, DOI 10.1128/JVI.65.12.6772-6781.1991; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; WEINER HL, 1977, P NATL ACAD SCI USA, V74, P5744, DOI 10.1073/pnas.74.12.5744; WEINER HL, 1980, J INFECT DIS, V141, P609, DOI 10.1093/infdis/141.5.609; WEINER HL, 1980, J IMMUNOL, V124, P2143; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; Wetzel JD, 1997, J VIROL, V71, P1362, DOI 10.1128/JVI.71.2.1362-1369.1997; Wetzel JD, 1997, J VIROL, V71, P299, DOI 10.1128/JVI.71.1.299-306.1997; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0; Williams RK, 1997, J VIROL, V71, P1375, DOI 10.1128/JVI.71.2.1375-1380.1997; WILLIAMS WV, 1988, P NATL ACAD SCI USA, V85, P6488, DOI 10.1073/pnas.85.17.6488; Wilson GJ, 1996, J VIROL, V70, P6598, DOI 10.1128/JVI.70.10.6598-6606.1996; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YEUNG MC, 1989, VIROLOGY, V170, P62, DOI 10.1016/0042-6822(89)90352-8; Yeung SN, 1999, GENE THER, V6, P1536, DOI 10.1038/sj.gt.3300980	71	163	169	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2200	2211		10.1074/jbc.M004680200	http://dx.doi.org/10.1074/jbc.M004680200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11054410	hybrid			2022-12-25	WOS:000166528000074
J	Chan, JYH; Lee-Prudhoe, JE; Jorgensen, B; Ihrke, G; Doyonnas, R; Zannettino, ACW; Buckle, VJ; Ward, CJ; Simmons, PJ; Watt, SM				Chan, JYH; Lee-Prudhoe, JE; Jorgensen, B; Ihrke, G; Doyonnas, R; Zannettino, ACW; Buckle, VJ; Ward, CJ; Simmons, PJ; Watt, SM			Relationship between novel isoforms, functionally important domains, and subcellular distribution of CD164/endolyn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEMATOPOIETIC PROGENITORS; SINGLE-STEP METHOD; MESSENGER-RNA; CELL-ADHESION; CD164; SIALOMUCIN; CD34(+); TRANSCRIPTION; EXPRESSION; CLATHRIN	Functional analyses have indicated that the human CD164 sialomucin may play a key role in hematopoiesis by facilitating the adhesion of human CD34(+) cells to the stroma and by negatively regulating CD34(+)CD38(lo/-) cell proliferation. We have identified three novel human CD164 variants derived by alternative splicing of bona fide exons from a single genomic transcription unit. The predominant CD164(E1-6) isoform, encoded by six exons, is a type I transmembrane protein containing two extracellular mucin domains (I and II) interrupted by a cysteine-rich non-mucin domain, The 103B2/9E10 and 105A5 epitopes, which specify ligand binding characteristics, are located on the exon 1-encoded mucin domain I. Three human CD164(E1-6) mRNA species, exhibiting differential polyadenylation site usage, are differentially expressed in hematopoietic and non-hematopoietic tissues. This study provides additional evidence that human CD164(E1-6) represents the ortholog of murine MGC-24v and rat endolyn. Comparative analysis of murine MGC-24v/CD164(E1-6) with human CD164(E1-6) revealed two potential splice variants and a similar genomic structure. Whereas the human CD164 gene is located on chromosome 6q21, the mouse gene occurs in a syntenic region on chromosome 10B1-B2. By confocal microscopy, human CD164 in CD34(+)CD38(+) hematopoietic progenitor (KG1B) and epithelial cell lines appears to be localized primarily in endosomes and lysosomes, with low concentrations at the cell surface. However, in a minority of KG1B cells, CD164 is more prominently expressed at the plasma membrane and in the recycling endosomes, suggesting that its distribution is regulated in cells of hematopoietic origin.	Inst Mol Med, MRC, Mol Hematol Unit, Oxford OX3 9DS, England; Univ Cambridge, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge CB2 2XY, England; Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2XY, England; Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	University of Oxford; University of Cambridge; University of Cambridge; Institute Medical & Veterinary Science Australia; Peter Maccallum Cancer Center	Watt, SM (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC, Oxford OX3 9DS, England.	Swatt@molbiol.ox.ac.uk		Zannettino, Andrew/0000-0002-6646-6167; Doyonnas, Regis/0000-0002-3818-0807; Ihrke, Gudrun/0000-0003-4604-735X				Almeida-Porada G, 1999, BLOOD, V94, p462A; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Bazil V, 1996, BLOOD, V87, P1272, DOI 10.1182/blood.V87.4.1272.bloodjournal8741272; Bazil V, 1997, STEM CELLS, V15, P13, DOI 10.1002/stem.5530150804; BUCKLE VJ, 1993, HUMAN GENETIC DISEAS, V2, P59; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; Doyonnas R, 2000, J IMMUNOL, V165, P840, DOI 10.4049/jimmunol.165.2.840; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; FACKLER MJ, 1995, BLOOD, V85, P3040, DOI 10.1182/blood.V85.11.3040.bloodjournal85113040; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Hinds KA, 1999, BLOOD, V94, p44A; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HIRST MC, 1992, TRENDS GENET, V8, P6, DOI 10.1016/0168-9525(92)90005-O; Ihrke G, 2000, BIOCHEM J, V345, P287, DOI 10.1042/0264-6021:3450287; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kurosawa N, 1999, EUR J BIOCHEM, V265, P466, DOI 10.1046/j.1432-1327.1999.00777.x; Levesque JP, 1999, IMMUNITY, V11, P369, DOI 10.1016/S1074-7613(00)80112-0; MASUZAWA Y, 1992, J BIOCHEM-TOKYO, V112, P609, DOI 10.1093/oxfordjournals.jbchem.a123948; MILANESI L, 2001, IN PRESS BIOINFORMAT; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Miyamoto S, 1996, BIOCHEM J, V315, P791, DOI 10.1042/bj3150791; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TRIMAN KL, 1975, CYTOGENET CELL GENET, V15, P166, DOI 10.1159/000130515; Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609; Watt SM, 1998, BLOOD, V92, P849, DOI 10.1182/blood.V92.3.849.415k21_849_866; Watt SM, 2000, LEUKEMIA LYMPHOMA, V37, P1, DOI 10.3109/10428190009057625; Watt SM, 2000, BLOOD, V95, P3113; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Whetton AD, 1999, TRENDS CELL BIOL, V9, P233, DOI 10.1016/S0962-8924(99)01559-7; Zannettino ACW, 1998, BLOOD, V92, P2613, DOI 10.1182/blood.V92.8.2613.420k15_2613_2628	39	34	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2139	2152		10.1074/jbc.M007965200	http://dx.doi.org/10.1074/jbc.M007965200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11027692	Green Published, hybrid			2022-12-25	WOS:000166528000067
J	Fahlke, C; Desai, RR; Gillani, N; George, AL				Fahlke, C; Desai, RR; Gillani, N; George, AL			Residues lining the inner pore vestibule of human muscle chloride channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT MYOTONIA-CONGENITA; K+ CHANNEL; POTASSIUM CHANNELS; TETRAETHYLAMMONIUM ION; TORPEDO ELECTROPLAX; SELECTIVITY FILTER; PEPTIDE INHIBITOR; MOLECULAR-BASIS; ARCHITECTURE; PERMEATION	Chloride channels belonging to the ClC family are ubiquitous and participate in a wide variety of physiological and pathophysiological processes. To define sequence segments in ClC channels that contribute to the formation of their ion conduction pathway, we employed a combination of site-directed mutagenesis, heterologous expression, patch clamp recordings, and chemical modification of the human muscle ClC isoform, hClC-1. We demonstrate that a highly conserved 8-amino acid motif (P3) located in the linker between transmembrane domains D2 and D3 contributes to the formation of a wide pore vestibule facing the cell interior. Similar to a previously defined pore region (P1 region), this segment functionally interacts with the corresponding segment of the contralateral subunit. The use of cysteine-specific reagents of different size revealed marked differences in the diameter of pore-forming regions implying that ClC channels exhibit a pore architecture quite similar to that of certain cation channels, in which a narrow constriction containing major structural determinants of ion selectivity is neighbored by wide vestibules on both sides of the membrane.	Rhein Westfal TH Aachen, Inst Physiol, D-52057 Aachen, Germany; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Ctr Estudios Cient, Valdivia, Chile	RWTH Aachen University; Vanderbilt University; Vanderbilt University	Fahlke, C (corresponding author), Rhein Westfal TH Aachen, Inst Physiol, Pauwelsstr 30, D-52074 Aachen, Germany.	chfahlke@physiology.rwth-aachen.de	Fahlke, Christoph/G-3635-2013	Fahlke, Christoph/0000-0001-8602-9952	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044506] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44506] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANDERSEN OS, 1992, PHYSIOL REV, V72, P78; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; CECCHI X, 1987, BIOPHYS J, V52, P707, DOI 10.1016/S0006-3495(87)83265-4; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Dang TX, 1998, J GEN PHYSIOL, V111, P185, DOI 10.1085/jgp.111.2.185; EIGEN M, 1991, NEUROSCI RES PROGRAM, V9, P330; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; Fahlke C, 1997, J GEN PHYSIOL, V110, P551, DOI 10.1085/jgp.110.5.551; Fahlke C, 1996, BIOPHYS J, V71, P695, DOI 10.1016/S0006-3495(96)79269-X; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Fahlke C, 2000, KIDNEY INT, V57, P780, DOI 10.1046/j.1523-1755.2000.00915.x; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Holmgren M, 1997, J GEN PHYSIOL, V109, P527, DOI 10.1085/jgp.109.5.527; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Lu T, 1999, NEURON, V22, P571, DOI 10.1016/S0896-6273(00)80711-4; Ludewig U, 1997, J PHYSIOL-LONDON, V498, P691, DOI 10.1113/jphysiol.1997.sp021893; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; MILLER C, 1990, VOLTAGE DEPENDENT CH, P383; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rychkov GY, 1998, J GEN PHYSIOL, V111, P653, DOI 10.1085/jgp.111.5.653; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Vergara C, 1999, J GEN PHYSIOL, V114, P365, DOI 10.1085/jgp.114.3.365; Wollnik B, 1997, HUM MOL GENET, V6, P805, DOI 10.1093/hmg/6.5.805	42	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1759	1765		10.1074/jbc.M007649200	http://dx.doi.org/10.1074/jbc.M007649200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035024	hybrid			2022-12-25	WOS:000166528000016
J	Kataoka, K; Yoshitomo-Nakagawa, K; Shioda, S; Nishizawa, M				Kataoka, K; Yoshitomo-Nakagawa, K; Shioda, S; Nishizawa, M			A set of Hox proteins interact with the Maf oncoprotein to inhibit its DNA binding, transactivation, and transforming activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOGENOUS LEUKEMIA; A-CRYSTALLIN GENE; TRANSCRIPTION FACTOR; C-MAF; HOMEOBOX GENE; V-MAF; ALVEOLAR RHABDOMYOSARCOMA; HOMEODOMAIN PROTEINS; NUCLEAR ONCOPROTEIN; MYELOID-LEUKEMIA	Maf oncoprotein is a basic-leucine zipper (bZip) type of transcriptional activator, Since many transcription factors are known to form functional complexes, we searched for proteins that interact with the DNA-binding domain of Maf using the phage display method and identified two homeodomain-containing proteins, Hoxd12 and MHox/Prx1/Phox1/Pmx1. Studies with mutants of Hox and Maf proteins showed that they associate through their DNA-binding domains; the homeodomain of Hox and the bZip domain of Maf, respectively. Reflecting the high similarity of the bZip domain, all other Maf family members tested (c-/v-Maf, MafB, MafK, MafF, and MafG) also associated with the Hox proteins. Pax6, whose homeodomain is relatively similar to MHox, also could interact with Maf, However, two other bZip oncoproteins, Fos and Jun, failed to associate with the Hox proteins, while a distantly related Hox family member, Meis1, could not interact with Maf. Through interactions with the bZip domain, the Hox proteins inhibited the DNA binding activity of Maf, whereas the binding of Hox proteins to their recognition sequences was not abrogated by Maf. We further showed that coexpression of the Hox proteins repressed transcriptional activation and transforming activity of Maf. These results suggested that the interaction of a set of Hox proteins with Maf family members may interfere not only with their oncogenicity but also with their physiological roles.	Univ Tokyo, Inst Med Sci, Dept Virol, Minato Ku, Tokyo 1088639, Japan; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of Tokyo; Scripps Research Institute	Kataoka, K (corresponding author), Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	kkataoka@bio.titech.ac.jp						ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BENBROOK DM, 1990, ONCOGENE, V5, P295; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; CVEKL A, 1995, MOL CELL BIOL, V15, P653; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; DAVIS RJ, 1994, CANCER RES, V54, P2869; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HEDGE SP, 1999, BLOOD, V94, P1578; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 1996, ONCOGENE, V12, P53; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; Li MF, 1999, J VIROL, V73, P9178, DOI 10.1128/JVI.73.11.9178-9186.1999; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Moens CB, 1998, DEVELOPMENT, V125, P381; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Nakamura T, 1999, BLOOD, V94, P741, DOI 10.1182/blood.V94.2.741.414k04_741_747; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; NOHNO T, 1993, DEV BIOL, V158, P254, DOI 10.1006/dbio.1993.1184; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Sharon-Friling R, 1998, MOL CELL BIOL, V18, P2067, DOI 10.1128/MCB.18.4.2067; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	57	56	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					819	826		10.1074/jbc.M007643200	http://dx.doi.org/10.1074/jbc.M007643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11036080	hybrid			2022-12-25	WOS:000166280700110
J	Ko, JL; Loh, HH				Ko, JL; Loh, HH			Single-stranded DNA-binding complex involved in transcriptional regulation of mouse mu-opioid receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-K; MORPHINE-INDUCED ANALGESIA; PROTEIN PUR-ALPHA; MESSENGER-RNA; MOLECULAR-CLONING; TFIID COMPLEX; RAS PROMOTER; MICE LACKING; EXPRESSION; SEQUENCES	Previously, we reported the presence of dual (distal and proximal) promoters in mouse mu -opioid receptor (mor) gene, with mar transcription in mouse brain predominantly initiated by the proximal promoter. Sp factors, bound to double-stranded (ds) cis-regulatory elements, are critical for proximal promoter activity. Here, we further report that a single-stranded (ss) cis-regulatory element and trans-acting protein factor are also important for proximal promoter activity. A 26-bp mar polypyrimidine/polypurine region (PPy/u) can adopt ss DNA conformation, as demonstrated by S1 nuclease sensitivity. Using electrophoretic mobility shift analysis with nuclear extracts from mor-expressing SH-SY5Y cells, we demonstrate that the sense strand of PPy/u interacts with a major nuclear protein, termed mor polypyrimidine-binding protein (mPy), which is not related to Sp factors. Southwestern blot analysis indicated that mPy protein is similar to 25 kDa in size. Functional analysis suggests that mPy protein can trans-activate mar promoter as well as a heterologous promoter. Moreover, combinatorial activation of ss (mPy) and ds (Sps) DNA binding factors, interacting with an overlapping DNA (PPy/u) region, is necessary for proximal promoter activation. Thus our results suggest that transcription of mouse mar gene is regulated by an interplay of se and ds DNA binding factors.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Ko, JL (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	koxxx001@maroon.tc.umn.edu			NIDA NIH HHS [DA-00546, DA-05695, DA-01583] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA001583, R37DA001583, P01DA005695] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BACOLLA A, 1995, J BIOL CHEM, V270, P24556, DOI 10.1074/jbc.270.41.24556; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; Basbaum A.I., 1984, ANALGESICS NEUROCHEM, P97; BEHE MJ, 1987, BIOCHEMISTRY-US, V26, P7870, DOI 10.1021/bi00398a050; BIRNBOIM HC, 1978, J MOL BIOL, V121, P541, DOI 10.1016/0022-2836(78)90399-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CLARK SP, 1990, NUCLEIC ACIDS RES, V18, P5119, DOI 10.1093/nar/18.17.5119; DELFS JM, 1994, J NEUROCHEM, V63, P777; DELFS JM, 1994, J COMP NEUROL, V345, P46, DOI 10.1002/cne.903450104; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; Di Matteo G, 1998, J BIOL CHEM, V273, P495, DOI 10.1074/jbc.273.1.495; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Duncan R, 1996, MOL CELL BIOL, V16, P2274; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; Hyman SE, 1996, SCIENCE, V273, P611, DOI 10.1126/science.273.5275.611; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P190; Jurk M, 1996, NUCLEIC ACIDS RES, V24, P2799, DOI 10.1093/nar/24.14.2799; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Ko JL, 1998, J BIOL CHEM, V273, P27678, DOI 10.1074/jbc.273.42.27678; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; KOHWI Y, 1993, J MOL BIOL, V231, P1090, DOI 10.1006/jmbi.1993.1354; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; KRAUS J, 1995, BIOCHEM BIOPH RES CO, V215, P591, DOI 10.1006/bbrc.1995.2505; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; Liang YB, 1997, BRAIN RES, V769, P372, DOI 10.1016/S0006-8993(97)00854-8; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Menon RK, 1997, MOL ENDOCRINOL, V11, P1291, DOI 10.1210/me.11.9.1291; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; NESTLER EJ, 1994, BRAIN RES BULL, V35, P521, DOI 10.1016/0361-9230(94)90166-X; Pan YX, 1999, MOL PHARMACOL, V56, P396, DOI 10.1124/mol.56.2.396; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; Phillips BW, 1999, J BIOL CHEM, V274, P22197, DOI 10.1074/jbc.274.32.22197; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Solecki D, 1997, J BIOL CHEM, V272, P5579, DOI 10.1074/jbc.272.9.5579; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; Wendel B, 1998, J MOL MED-JMM, V76, P525, DOI 10.1007/s001090050246; Wood P. L., 1988, OPIATE RECEPTORS, P307; Xu G, 1996, J BIOL CHEM, V271, P16008, DOI 10.1074/jbc.271.27.16008	67	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					788	795		10.1074/jbc.M004279200	http://dx.doi.org/10.1074/jbc.M004279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027679	hybrid			2022-12-25	WOS:000166280700106
J	Schulte, V; Snell, D; Bergmeier, W; Zirngibl, H; Watson, SP; Nieswandt, B				Schulte, V; Snell, D; Bergmeier, W; Zirngibl, H; Watson, SP; Nieswandt, B			Evidence for two distinct epitopes within collagen for activation of murine platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; GLYCOPROTEIN-VI; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-2; INTEGRIN ALPHA(2)BETA(1); SYK; ASSOCIATION; AGGREGATION; CONVULXIN; ADHESION	It has recently been shown that the monoclonal antibody JAQ1 to murine glycoprotein VI (GPVI) can cause aggregation of mouse platelets upon antibody crosslinking and that collagen-induced platelet aggregation can be inhibited by preincubation of platelets with JAQ1 in the absence of cross-linking (Nieswandt, B,, Bergmeier, W,, Schulte, V,, Rackebrandt, K,, Gessner, J, E,, and Zirngibl, H, (2000) J. Biol, Chem, 275, 23998-24002), In the present study, we have shown that crosslinking of GPVI by JAQ1 results in tyrosine phosphorylation of the same profile of proteins as that induced by collagen, including the Fc receptor (FcR) gamma -chain, Syk, LAT, SLP-76, and phospholipase C gamma2. In contrast, platelet aggregation and tyrosine phosphorylation of these proteins were inhibited when mouse platelets were preincubated with JAQ1 in the absence of cross-linking and were subsequently stimulated with a collagen-related peptide (CRP) that is specific for GPVI and low concentrations of collagen. However, at higher concentrations of collagen, but not CRP, aggregation of platelets and tyrosine phosphorylation of the above proteins (except for the adapter LAT) is re-established despite the presence of JAQ1, These observations suggest that a second activatory binding site, which is distinct from the CRP binding site on GPVI on mouse platelets, is occupied in the presence of high concentrations of collagen. Although this could be a second site on GPVI that is activated by a novel motif within the collagen molecule, the absence of LAT phosphorylation in response to collagen in the presence of JAQ1 suggests that this is more likely to be caused by activation of a second receptor that is also coupled to the FcR gamma -chain. The possibility that this response is mediated by a receptor that is not coupled to FcR gamma -chain is excluded on the grounds that aggregation is absent in platelets from FcR gamma -chain-deficient mice.	Berg Univ Gesamthsch Wuppertal, Ferdinand SauerBruch Klinikum, Dept Mol Oncol, D-42117 Wuppertal, Germany; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Wuppertal; University of Oxford	Nieswandt, B (corresponding author), Berg Univ Gesamthsch Wuppertal, Ferdinand SauerBruch Klinikum, Dept Mol Oncol, ArrenbergerStr 20,Haus 10, D-42117 Wuppertal, Germany.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423				Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Gross BS, 1999, EUR J BIOCHEM, V263, P612, DOI 10.1046/j.1432-1327.1999.00560.x; Ichinohe T, 1997, J BIOL CHEM, V272, P63; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; SUGIYAMA T, 1987, BLOOD, V69, P1712; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528	20	34	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					364	368		10.1074/jbc.M007536200	http://dx.doi.org/10.1074/jbc.M007536200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11036078	hybrid			2022-12-25	WOS:000166280700050
J	Shimizu, T; Awai, N; Takeda, K				Shimizu, T; Awai, N; Takeda, K			Complex regulation of CDKs and G1 arrest during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells	ONCOGENE			English	Article						leukemia; differentiation; CDK; p27; p18	DEPENDENT KINASE INHIBITOR; RETINOIC ACID; CYCLE ARREST; MYELOID-LEUKEMIA; P21; P27(KIP1); INDUCTION; P18(INK4C); MEDIATOR; CLONING	We previously reported that all-trans retinoic acid (ATRA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) synergistically induced granulocytic differentiation in human myeloblastic leukemia ML-1 cells. The combination of these agents also suppressed DNA-synthesis. In the present study, we investigated the suppression of cyclin dependent kinase (CDK) activities resulting in G1 arrest in differentiated ML-1 cells. We show that treatment of ML-1 cells with ATRA plus GM-CSF results in G1 arrest and suppression of CDK activities, Protein levels of the G1 CDKs were essentially unchanged during this time, However, we observed an increase in CDK2-bound p27 and CDK4-bound pig, and a decrease in CDK6-bound cyclin D3, These results suggest that complex regulation of CDKs play a key role in Ct arrest of ML-l after treatment with ATRA and GM-CSF, We also showed that an increase in CDK2-bound p27 and CDK4-bound p18 are caused by treatment with ATRA and a decrease in CDK6-bound cyclin D3 is induced synergistically by treatment with both reagents. Furthermore, we propose that the changes in binding of p18 and cyclin D3 to CDKs are due to changes at the protein expression level and that the increase in p27 binding to CDK2 is due to a novel mechanism.	Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, Tokyo 1620826, Japan	Tokyo University of Science	Takeda, K (corresponding author), Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, 12 Ichigaya Funagawara Machi, Tokyo 1620826, Japan.							Asiedu C, 1997, BLOOD, V90, P3430, DOI 10.1182/blood.V90.9.3430; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oka Y, 1997, ANTICANCER RES, V17, P1951; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Saito Y, 1999, ANTICANCER RES, V19, P1069; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu T, 1999, LEUKEMIA RES, V23, P901, DOI 10.1016/S0145-2126(99)00106-X; Singh SP, 1998, CANCER RES, V58, P1730; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sueoka N, 1999, CANCER RES, V59, P3838; TAKEDA K, 1982, CANCER RES, V42, P5152; TAKEDA K, 1986, NATURE, V323, P338, DOI 10.1038/323338a0; TAKEI M, 1984, BIOCHEM BIOPH RES CO, V124, P100, DOI 10.1016/0006-291X(84)90922-7; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang QM, 1996, CANCER RES, V56, P264; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	47	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4640	4646		10.1038/sj.onc.1203821	http://dx.doi.org/10.1038/sj.onc.1203821			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030153				2022-12-25	WOS:000089438200010
J	Cook, TA; Ghomashchi, F; Gelb, MH; Florio, SK; Beavo, JA				Cook, TA; Ghomashchi, F; Gelb, MH; Florio, SK; Beavo, JA			The delta subunit of type 6 phosphodiesterase reduces light-induced cGMP hydrolysis in rod outer segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; RETINAL RODS; PHOTORECEPTOR PHOSPHODIESTERASE; DARK-ADAPTATION; VERTEBRATE PHOTORECEPTORS; GUANYLATE-CYCLASE; GTPASE ACTIVITY; PDE-DELTA; G-PROTEIN; BINDING	The delta subunit of the rod photoreceptor PDE has previously been shown to copurify with the soluble form of the enzyme and to solubilize the membrane-bound form (1), To determine the physiological effect of the delta subunit on the light response of bovine rod outer segments, we measured the real time accumulation of the products of cGMP hydrolysis in a preparation of permeablized rod outer segments. The addition of delta subunit GST fusion protein (delta -GST) to this preparation caused a reduction in the maximal rate of cGMP hydrolysis in response to light. The maximal reduction of the light response was about 80%, and the half-maximal effect occurred at 385 nM delta subunit, Several experiments suggest that this effect was not due to the effects of delta -GST on transducin or rhodopsin kinase. Immunoblots demonstrated that exogenous delta -GST solubilized the majority of the PDE in ROS but did not affect the solubility of transducin. Therefore, changes in the solubility of transducin cannot account for the effects of delta -GST in the pH assay. The reduction in cGMP hydrolysis was independent of ATP, which indicates that it was not due to effects of delta -GST on rhodopsin kinase. In addition to the effect on cGMP hydrolysis, the delta -GST fusion protein slowed the turn-off of the system. This is probably due, at least in part, to an observed reduction in the GTPase rate of transducin in the presence of delta -GST. These results demonstrate that delta -GST can modify the activity of the phototransduction cascade in preparations of broken rod outer segments, probably due to a functional uncoupling of the transducin to PDE step of the signal transduction cascade and suggest that the delta subunit may play a similar role in the intact outer segment.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Beavo, JA (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.			gelb, michael/0000-0001-7000-5219	NEI NIH HHS [EY01730, 2T32 EY07031-21, EY08197] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007031, R01EY008197, P30EY001730] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; BELLJE, 1988, PROTEINS ENZYMES, P317; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTY P, 1992, J BIOL CHEM, V267, P19489; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; CORNWALL MC, 1990, J GEN PHYSIOL, V96, P345, DOI 10.1085/jgp.96.2.345; Detwiler PB, 1996, CURR OPIN NEUROBIOL, V6, P440, DOI 10.1016/S0959-4388(96)80047-X; Fain GL, 1996, TRENDS NEUROSCI, V19, P502, DOI 10.1016/S0166-2236(96)10056-4; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GrayKeller MP, 1996, NEURON, V17, P323, DOI 10.1016/S0896-6273(00)80163-4; JONES GJ, 1995, J PHYSIOL-LONDON, V487, P441, DOI 10.1113/jphysiol.1995.sp020891; KAPLAN MW, 1993, METH NEUROSCI, V15, P205; KAWAMURA S, 1989, J GEN PHYSIOL, V94, P649, DOI 10.1085/jgp.94.4.649; KOCH KW, 1992, TRENDS BIOCHEM SCI, V17, P307, DOI 10.1016/0968-0004(92)90442-C; KONDO H, 1988, P NATL ACAD SCI USA, V85, P1322, DOI 10.1073/pnas.85.4.1322; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; LEIBROCK CS, 1994, VISION RES, V34, P2787, DOI 10.1016/0042-6989(94)90048-5; Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139; Li N, 1998, GENOMICS, V49, P76, DOI 10.1006/geno.1998.5210; Li N, 1998, FEBS LETT, V440, P454, DOI 10.1016/S0014-5793(98)01501-4; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315; Linari M, 1999, FEBS LETT, V458, P55, DOI 10.1016/S0014-5793(99)01117-5; LIU L, 1995, METHOD ENZYMOL, V250, P189; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Marzesco AM, 1998, J BIOL CHEM, V273, P22340, DOI 10.1074/jbc.273.35.22340; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; MIKI N, 1975, J BIOL CHEM, V250, P6320; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PEPPERBERG DR, 1994, VISUAL NEUROSCI, V11, P53, DOI 10.1017/S095252380001110X; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; QIN N, 1992, J BIOL CHEM, V267, P8458; QIN N, 1994, J BIOL CHEM, V269, P3265; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028	42	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5248	5255		10.1074/jbc.M004690200	http://dx.doi.org/10.1074/jbc.M004690200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11053432	hybrid			2022-12-25	WOS:000168484300096
J	Kasahara, H; Usheva, A; Ueyama, T; Aoki, H; Horikoshi, N; Izumo, S				Kasahara, H; Usheva, A; Ueyama, T; Aoki, H; Horikoshi, N; Izumo, S			Characterization of homo- and heterodimerization of cardiac Csx/Nkx2.5 homeoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL HEART-DISEASE; TINMAN-RELATED GENES; DNA-BINDING TARGETS; CASEIN KINASE-II; HOMEODOMAIN PROTEINS; VND/NK-2 HOMEODOMAIN; CRYSTAL-STRUCTURE; HOMEOBOX GENES; DROSOPHILA; TRANSCRIPTION	Csx/Nkx2.5 is an evolutionarily conserved homeodomain (HD)-containing transcription factor that is essential for early cardiac development. We found that the HD of Csx/Nkx2.5 binds as a monomer as well as a dimer to its DNA binding sites in the promoter of the atrial natriuretic factor (ANF) gene, an in vivo target gene of Csx/Nkx2.5. Csx/Nkx2.5 physically interacts with each other in vitro as well as in cells, and the HD is critical for homodimerization. Lys(193) and Arg(194), located at the COOH-terminal end of HD, are essential for dimerization. Lys193 is also required for a specific interaction with the zinc finger transcription factor GATA4. Csx/ Nkx2.5 can heterodimerize with other NK2 homeodomain proteins, Nkx2.3 and Nkx2.6/Tix, with different affinities. A single missense mutation, Ile(183) to Pro in the HD of Csx/Nkx2.5, preserved homodimerization function, but totally abolished DNA binding. Ile(183) --> Pro mutant acts in an inhibitory manner on wild type Csx/ Nkx2.5 transcriptional activity through the ANF promoter in 10T1/2 cells. However, Ile(183) --> Pro mutant does not inhibit wild type Csx/Nkx2.5 function on the ANF promoter in cultured neonatal cardiac myocytes, possibly due to failure of dimerization in the presence of the target DNA. These results suggest that complex protein-protein interactions of Csx/Nkx2.5 play a role in its transcriptional regulatory function.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA; Washington Univ, Sch Med, Radiat Oncol Ctr, Sect Canc Biol, St Louis, MO 63108 USA; Yamaguchi Univ, Sch Med, Dept Mol Cardiovasc Biol, Ube, Yamaguchi 7558505, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Washington University (WUSTL); Yamaguchi University	Kasahara, H (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Cardiovasc Div, 330 Brookline Ave,SL201, Boston, MA 02215 USA.		Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178	NHLBI NIH HHS [R01-HL61036, R01-HL51253] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051253, P50HL061036] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Biben C, 1998, MECH DEVELOP, V73, P125, DOI 10.1016/S0925-4773(98)00037-9; Biggin MD, 1997, DEVELOPMENT, V124, P4425; BODMER R, 1993, DEVELOPMENT, V118, P719; Brand T, 1997, MECH DEVELOP, V64, P53, DOI 10.1016/S0925-4773(97)00044-0; Buchberger A, 1996, MECH DEVELOP, V56, P151, DOI 10.1016/0925-4773(96)00521-7; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen JN, 1996, DEVELOPMENT, V122, P3809; Chin JW, 1999, CURR BIOL, V9, pR929, DOI 10.1016/S0960-9822(00)80107-4; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DUBOULE D, 1994, GUIDBOOK HOMEOBOX GE; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; EVANS SM, 1995, DEVELOPMENT, V121, P3889; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; GAY NJ, 1988, NUCLEIC ACIDS RES, V16, P6637, DOI 10.1093/nar/16.14.6637; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; Grow MW, 1998, DEV BIOL, V204, P187, DOI 10.1006/dbio.1998.9080; Gruschus JM, 1999, J MOL BIOL, V289, P529, DOI 10.1006/jmbi.1999.2774; Gruschus JM, 1997, BIOCHEMISTRY-US, V36, P5372, DOI 10.1021/bi9620060; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; Kasahara H, 1999, MOL CELL BIOL, V19, P526; Kasahara H, 2000, J CLIN INVEST, V106, P299, DOI 10.1172/JCI9860; Kasahara H, 1998, CIRC RES, V82, P936, DOI 10.1161/01.RES.82.9.936; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; Kohler JJ, 1999, P NATL ACAD SCI USA, V96, P11735, DOI 10.1073/pnas.96.21.11735; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Lee KH, 1996, DEV BIOL, V180, P722, DOI 10.1006/dbio.1996.0341; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; Mead PE, 1996, NATURE, V382, P357, DOI 10.1038/382357a0; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; Newman CS, 1998, DEV GENET, V22, P230; Pabst O, 1997, DEV DYNAM, V209, P29; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Tanaka M, 1999, DEVELOPMENT, V126, P1269; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; Weiss JB, 1998, GENE DEV, V12, P3591, DOI 10.1101/gad.12.22.3591; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WILSON DS, 1995, CURR BIOL, V5, P32, DOI 10.1016/S0960-9822(95)00010-8	63	78	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4570	4580		10.1074/jbc.M004995200	http://dx.doi.org/10.1074/jbc.M004995200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11042197	hybrid			2022-12-25	WOS:000168484300009
J	Jackson, RG; Lim, EK; Li, Y; Kowalczyk, M; Sandberg, G; Hoggett, J; Ashford, DA; Bowles, DJ				Jackson, RG; Lim, EK; Li, Y; Kowalczyk, M; Sandberg, G; Hoggett, J; Ashford, DA; Bowles, DJ			Identification and biochemical characterization of an Arabidopsis indole-3-acetic acid glucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-GLUCOSYL; ZEA-MAYS-L; ENZYMATIC-SYNTHESIS; ENZYMIC-SYNTHESIS; O-GLUCOSYLTRANSFERASE; LIQUID-CHROMATOGRAPHY; PHASEOLUS-LUNATUS; METABOLISM; GENE; INDOL-3-YLACETYL-MYO-INOSITOL	Biochemical characterization of recombinant gene products following a phylogenetic analysis of the UDP-glucosyltransferase (UGT) multigene family of Arabidopsis has identified one enzyme (UGT84B1) with high activity toward the plant hormone indole-3-acetic acid (IAA) and three related enzymes (UGT84B2, UGT75B1, and UGT75B2) with trace activities. The identity of the IAA conjugate has been confirmed to be 1-O-indole acetyl glucose ester. A sequence annotated as a UDP-glucose:IAA glucosyltransferase (IAA-UGT) in the Arabidopsis genome and expressed sequence tag data bases given its similarity to the maize iaglu gene sequence showed no activity toward IAA This study describes the first biochemical analysis of a recombinant IAA-UGT and provides the foundation for future genetic approaches to understand the role of 1-O-indole acetyl glucose ester in Arabidopsis.	Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England; Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, S-90183 Umea, Sweden	University of York - UK; Swedish University of Agricultural Sciences	Bowles, DJ (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5DD, N Yorkshire, England.		Kowalczyk, Mariusz/ABD-2910-2020	Kowalczyk, Mariusz/0000-0001-7454-4762				Bandurski Robert S., 1995, P39; Bartel Bonnie, 1997, Annu Rev Plant Physiol Plant Mol Biol, V48, P51, DOI 10.1146/annurev.arplant.48.1.51; BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; COHEN JD, 1982, ANNU REV PLANT PHYS, V33, P403, DOI 10.1146/annurev.pp.33.060182.002155; CORCUERA LJ, 1982, BIOCHEM J, V207, P283, DOI 10.1042/bj2070283; DIXON SC, 1989, PLANT PHYSIOL, V90, P1316, DOI 10.1104/pp.90.4.1316; EHMANN A, 1974, CARBOHYD RES, V34, P99, DOI 10.1016/S0008-6215(00)80374-2; ENTSCH B, 1979, BIOCHIM BIOPHYS ACTA, V570, P124, DOI 10.1016/0005-2744(79)90207-9; EPSTEIN E, 1980, PLANT PHYSIOL, V65, P415, DOI 10.1104/pp.65.3.415; EPSTEIN E, 1993, PHYSIOL PLANTARUM, V88, P382, DOI 10.1111/j.1399-3054.1993.tb05513.x; Graham Richard, 1997, Plant Physiology (Rockville), V113, P1004; Hostel W., 1981, BIOCH PLANTS, V7, P725; HUGHES J, 1994, DNA SEQUENCE, V5, P41, DOI 10.3109/10425179409039703; JAKAS A, 1993, J LABELLED COMPD RAD, V33, P933, DOI 10.1002/jlcr.2580331007; KLECZKOWSKI K, 1995, CRIT REV PLANT SCI, V14, P283, DOI 10.1080/07352689509382361; KOWALCZYK S, 1991, BIOCHEM J, V279, P509, DOI 10.1042/bj2790509; KOWALCZYK S, 1990, PLANT PHYSIOL, V94, P4, DOI 10.1104/pp.94.1.4; LETHAM DS, 1983, ANNU REV PLANT PHYS, V34, P163, DOI 10.1146/annurev.pp.34.060183.001115; LEZNICKI AJ, 1988, PLANT PHYSIOL, V88, P1481, DOI 10.1104/pp.88.4.1481; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 1998, J BIOL CHEM, V273, P34920, DOI 10.1074/jbc.273.52.34920; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; LUDWIGMULLER J, 1993, PLANT GROWTH REGUL, V13, P189, DOI 10.1007/BF00024261; Martin RC, 1999, P NATL ACAD SCI USA, V96, P284, DOI 10.1073/pnas.96.1.284; Martin RC, 1999, PLANT PHYSIOL, V120, P553, DOI 10.1104/pp.120.2.553; MICHALCZUK L, 1982, BIOCHEM J, V207, P273, DOI 10.1042/bj2070273; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; NOWACKI J, 1980, PLANT PHYSIOL, V65, P422, DOI 10.1104/pp.65.3.422; Ostin A, 1998, PLANT PHYSIOL, V118, P285, DOI 10.1104/pp.118.1.285; Pflugmacher S, 1998, PHYTOCHEMISTRY, V49, P507, DOI 10.1016/S0031-9422(98)00139-3; PIERS KL, 1993, GENE, V134, P7, DOI 10.1016/0378-1119(93)90168-3; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT R, 1985, PESTIC BIOCHEM PHYS, V24, P77, DOI 10.1016/0048-3575(85)90116-6; SCHMITT R, 1982, Z NATURFORSCH C, V37, P772; SCHNEIDER G, 1994, PLANT GROWTH REGUL, V15, P247, DOI 10.1007/BF00029898; SEMBDNER G, 1985, BIOL PLANTARUM, V27, P231, DOI 10.1007/BF02902167; SEMBDNER G, 1994, PLANT MOL BIOL, V26, P1459, DOI 10.1007/BF00016485; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; Tam YY, 2000, PLANT PHYSIOL, V123, P589, DOI 10.1104/pp.123.2.589; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362	41	206	223	4	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4350	4356		10.1074/jbc.M006185200	http://dx.doi.org/10.1074/jbc.M006185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042207	hybrid			2022-12-25	WOS:000166921200083
J	Gomez, A; Wellbrock, C; Gutbrod, H; Dimitrijevic, N; Schartl, M				Gomez, A; Wellbrock, C; Gutbrod, H; Dimitrijevic, N; Schartl, M			Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; XIPHOPHORUS MELANOMA-CELLS; TYROSINE KINASE-ACTIVITY; NEOPLASIA TYPE 2B; EGF-RECEPTOR; DISULFIDE BOND; POINT MUTATION; RET PROTOONCOGENE; GENE; BINDING	Overexpression of the oncogenic receptor tyrosine kinase ONC-Xmrk is the first step in the development of hereditary malignant melanoma in the fish Xiphophorus. However, overexpression of its proto-oncogene counterpart (INV-Xmrk) is not sufficient for the oncogenic function of the receptor. Compared with INV-Xmrk, the ONC-Xmrk receptor displays 14 amino acid changes, suggesting the presence of activating mutations. To identify such activating mutations, a series of chimeric and mutant receptors were studied. None of the mutations present in the intracellular domain was found to be involved in receptor activation. In the extracellular domain, we found two mutations responsible for activation of the receptor. One is the substitution of a conserved cysteine (C578S) involved in intramolecular disulfide bonding. The other is a glycine to arginine exchange (G359R) in subdomain III. Either mutation leads to constitutive dimer formation and thereby to activation of the ONC-Xmrk receptor. Besides, the presence of these mutations slows down the processing of the Xmrk receptor in the endoplasmic reticulum; which is apparent as an incomplete glycosylation.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany	University of Wurzburg	Schartl, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, Hubland, D-97074 Wurzburg, Germany.		Gómez, Ana/K-6998-2014	Gómez, Ana/0000-0003-4714-8064; Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bongarzone I, 1999, ONCOGENE, V18, P4833, DOI 10.1038/sj.onc.1202848; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CAO HN, 1992, J BIOL CHEM, V267, P20489; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Dimitrijevic N, 1998, ONCOGENE, V16, P1681, DOI 10.1038/sj.onc.1201693; FENDLY BM, 1990, CANCER RES, V50, P1550; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; Katz WS, 1996, MOL CELL BIOL, V16, P529; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; MALITSCHEK B, 1994, J BIOL CHEM, V269, P10423; Nanda I, 2000, CHROMOSOMA, V109, P173, DOI 10.1007/s004120050425; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P55, DOI 10.1073/pnas.90.1.55; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHARTL M, 1995, TRENDS GENET, V11, P185, DOI 10.1016/S0168-9525(00)89041-1; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Tessitore A, 1999, J CLIN ENDOCR METAB, V84, P3522, DOI 10.1210/jc.84.10.3522; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Weis S, 1998, GENETICS, V149, P1909; Wellbrock C, 1999, EUR J BIOCHEM, V260, P275, DOI 10.1046/j.1432-1327.1999.00180.x; Wellbrock C, 1998, ONCOGENE, V16, P3047, DOI 10.1038/sj.onc.1201844; Wellbrock C, 1998, INT J CANCER, V76, P437, DOI 10.1002/(SICI)1097-0215(19980504)76:3<437::AID-IJC24>3.0.CO;2-6; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0	55	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3333	3340		10.1074/jbc.M006574200	http://dx.doi.org/10.1074/jbc.M006574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11038352	hybrid			2022-12-25	WOS:000166784900047
J	Wells, KM; Rao, R				Wells, KM; Rao, R			The yeast Na+/H+ exchanger Nhx1 is an N-linked glycoprotein - Topological implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; GROWTH; ANTIPORTER; DOMAIN; PROTEINS; ATPASE	Nkx1, the endosomal Na+/H+ exchanger of Saccharomyces cerevisiae represents the founding member of a newly emerging subfamily of intracellular Na+/H+ exchangers. These proteins share significantly greater sequence homology to one another than to members of the mammalian Na+/H+ exchanger (NHE) family encoding plasma membrane Na+/H+ exchangers. Members of both subtypes are predicted to share a common organization, with an N-terminal transporter domain of transmembrane helices followed by a C-terminal hydrophilic tail. In the present study, we show that Nhx1 is an asparagine-linked glycoprotein and that the sites of glycosylation map to two residues within the C-terminal stretch of the polypeptide, This is the first evidence, to date, for glycosylation of the C-terminal region of any known NHE isoform, Importantly, the mapping of N-linked glycosylation to the C-terminal domain of Nhx1 is indicative of an unexpected membrane topology, particularly with regard to the orientation of the tail region. Although one recent study demonstrated that certain epitopes in the C-terminal domain of NHE3 were accessible from the exoplasmic side of the plasma membrane (Biemesderfer, D., DeGray, B,, and Aronson, P. S. (1998) J, Biol, Chem. 273, 12391-12396), numerous other studies implicate a cytosolic disposition for the hydrophilic C-terminal tail of plasma membrane NHE isoforms, Our analysis of the glycosylation of Nhx1 is strongly indicative of residence of at least some portion of the hydrophilic tail domain within the endosomal lumen, These findings imply that the organization of the tail domain may be more complex than previously assumed.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	rrao@jhmi.edu			NIDDK NIH HHS [DK54214] Funding Source: Medline; NIGMS NIH HHS [GM52414] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052414] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderie I, 1996, J MEMBRANE BIOL, V152, P195, DOI 10.1007/s002329900097; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; DUSKIN D, 1982, J BIOL CHEM, V257, P3105; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILDEN SA, 1990, AM J PHYSIOL, V258, pF1311; KEPES F, 1988, J BIOL CHEM, V263, P9155; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; Nass R, 1999, MICROBIOL-SGM, V145, P3221, DOI 10.1099/00221287-145-11-3221; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Quintero FJ, 2000, FEBS LETT, V471, P224, DOI 10.1016/S0014-5793(00)01412-5; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sorin A, 1997, J BIOL CHEM, V272, P9895; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TSE CM, 1994, BIOCHEMISTRY-US, V33, P12954, DOI 10.1021/bi00248a003; VANDYKE RW, 1995, AM J PHYSIOL-CELL PH, V269, pC943, DOI 10.1152/ajpcell.1995.269.4.C943; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51	34	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3401	3407		10.1074/jbc.M001688200	http://dx.doi.org/10.1074/jbc.M001688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11036065	hybrid			2022-12-25	WOS:000166784900055
J	Schramek, N; Bracher, A; Bacher, A				Schramek, N; Bracher, A; Bacher, A			Ring opening is not rate-limiting in the GTP cyclohydrolase I reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYDROBIOPTERIN; BIOSYNTHESIS; COFACTOR	GTP cyclohydrolase I catalyzes a mechanistically complex ring expansion affording dihydroneopterin triphosphate and formate from GTP, Single turnover quenched flow experiments were performed with the recombinant enzyme from Escherichia coli, The consumption of GTP and the formation of 5-formylamino-6-ribosylamino-2-amino-4(3H)-pyrimidinone triphosphate, formate, and dihydroneopterin triphosphate were determined by high pressure liquid chromatography analysis. A kinetic model comprising three consecutive unimolecular steps was used for interpretations where the first intermediate, 5-formylamino-6-ribosylamino-2-amino-4 (3H)-pyrimidinone 5'-triphosphate, was formed in a reversible reaction. The rate constant k(1) for the reversible opening of the imidazole ring of GTP was 0.9 s(-1), the rate constant k(3) for the release of formate from 5-formylamino-6-ribosylamino-2-amino-4(3N)-pyrimidinone triphosphate was 2.0 s(-1), and the rate constant k(1) for the formation of dihydroneopterin triphosphate was 0.03 s(-1). Thus, the hydrolytic opening of the imidazole ring of GTP is rapid by comparison with the overall reaction.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Bacher, A (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.							Auerbach G, 2000, P NATL ACAD SCI USA, V97, P13567, DOI 10.1073/pnas.240463497; Bracher A, 1998, J BIOL CHEM, V273, P28132, DOI 10.1074/jbc.273.43.28132; Bracher A, 1999, J BIOL CHEM, V274, P16727, DOI 10.1074/jbc.274.24.16727; Brown G. M., 1987, ESCHERICHIA COLI SAL, V1, P521; BURG AW, 1968, J BIOL CHEM, V243, P2349; DAWSON RCM, 1986, DATA BIOCH RES, P109; HOMMEL U, 1995, BIOCHEMISTRY-US, V34, P5429, DOI 10.1021/bi00016a014; KWON NS, 1989, J BIOL CHEM, V264, P20496; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PFLEIDERER W, 1985, FOLATES PTERINS, V2, P43; SHIOTA T, 1967, J BIOL CHEM, V242, P1961; TAYEH MA, 1989, J BIOL CHEM, V264, P19654	13	16	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2622	2626		10.1074/jbc.M004912200	http://dx.doi.org/10.1074/jbc.M004912200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11056154	hybrid			2022-12-25	WOS:000166784800046
J	Xia, ZF; Morales, JC; Dunphy, WG; Carpenter, PB				Xia, ZF; Morales, JC; Dunphy, WG; Carpenter, PB			Negative cell cycle regulation and DNA damage-inducible phosphorylation of the BRCT protein 53BP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; FISSION YEAST; CHECKPOINT PATHWAY; S-PHASE; TRANSCRIPTIONAL ACTIVATION; MIDBLASTULA TRANSITION; IONIZING-RADIATION; BUDDING YEAST	In a screen designed to discover suppressors of mitotic catastrophe, we identified the Xenopus ortholog of 53BP1 (X53BP1), a BRCT protein previously identified in humans through its ability to bind the p53 tumor suppressor. X53BP1 transcripts are highly expressed in ovaries, and the protein interacts with Xp53 throughout the cell cycle in embryonic extracts. However, no interaction between X53BP1 and Xp53 can be detected in somatic cells, suggesting that the association between the two proteins may be developmentally regulated. X53BP1 is modified via phosphorylation in a DNA damage-dependent manner that correlates with the dispersal of X53BP1 into multiple foci throughout the nucleus in somatic cells. Thus, X53BP1 can be classified as a novel participant in the DNA damage response pathway. We demonstrate that X53BP1 and its human ortholog can serve as good substrates in vitro as well as in vivo for the ATM kinase. Collectively, our results reveal that 53BP1 plays an important role in the checkpoint response to DNA damage, possibly in collaboration with ATM.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Program Canc Biol, Houston, TX 77030 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Carpenter, PB (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.			Morales, Julio/0000-0002-0854-7866				ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; Anderson JA, 1997, MOL BIOL CELL, V8, P1195, DOI 10.1091/mbc.8.7.1195; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carpenter PB, 1998, J BIOL CHEM, V273, P24891, DOI 10.1074/jbc.273.38.24891; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Clute P, 1997, DEV BIOL, V185, P1, DOI 10.1006/dbio.1997.8540; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COX LS, 1994, ONCOGENE, V9, P2951; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; HALAZONETIS TD, 1999, BIOCHIM BIOPHYS ACTA, V1424, P45; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOEVER M, 1994, ONCOGENE, V9, P109; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu QH, 2000, GENE DEV, V14, P1448; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shieh SY, 2000, GENE DEV, V14, P289; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; SMITH JC, 1991, METHOD CELL BIOL, V36, P636; SOUSSI T, 1987, ONCOGENE, V1, P71; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; Wang Y, 2000, GENE DEV, V14, P927; WANG Y, 1995, ONCOGENE, V10, P779; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang SS, 1997, J CELL BIOL, V136, P345, DOI 10.1083/jcb.136.2.345; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	81	80	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2708	2718		10.1074/jbc.M007665200	http://dx.doi.org/10.1074/jbc.M007665200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042216	Green Accepted, hybrid			2022-12-25	WOS:000166784800057
J	Burks, EA; Bezerra, PP; Le, H; Gallie, DR; Browning, KS				Burks, EA; Bezerra, PP; Le, H; Gallie, DR; Browning, KS			Plant initiation factor 3 subunit composition resembles mammalian initiation factor 3 and has a novel subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; FACTOR 3 EIF3; TEMPERATURE-SENSITIVE MUTANTS; MAMMARY-TUMOR VIRUS; FACTOR 4G EIF4G; TRANSLATION INITIATION; WHEAT-GERM; RNA-BINDING; FACTOR-III; CELL-PROLIFERATION	Eukaryotic initiation factor 3 (eIF3) is a multisubunit complex that is required for binding of mRNA to 40 S ribosomal subunits, stabilization of ternary complex binding to 40 S subunits, and dissociation of 40 and 60 S subunits. These functions and the complex nature of eIF3 suggest multiple interactions with many components of the translational machinery. Recently, the subunits of mammalian and Saccharomyces cerevisiae eIF3 were identified, and substantial differences in the subunit composition of mammalian and S. cerevisiae were observed. Mammalian eIF3 consists of 11 nonidentical subunits, whereas S. cerevisiae eIF3 consists of up to eight nonidentical subunits. Only five of the subunits of mammalian and S. cerevisiae are shared in common, and these five subunits comprise a "core" complex in S. cerevisiae. eIF3 from wheat consists of at least 10 subunits, but their relationship to either the mammalian or S. cerevisiae eIF3 subunits is unknown. Peptide sequences derived from purified wheat eIF3 subunits were used to correlate each subunit with mammalian and/or S. cerevisiae subunits. The peptide sequences were also used to identify Arabidopsis thaliana cDNAs for each of the eIF3 subunits. We report seven new cDNAs for A. thaliana eIF3 subunits. A. thaliana eIF3 was purified and characterized to confirm that the subunit composition and activity of wheat and A. thaliana eIF3 were similar. We report that plant eIF3 closely resembles the subunit composition of mammalian eIF3, having 10 out of 11 subunits in common. Further, we find a novel subunit in the plant eIF3 complex not present in either mammalian or S. cerevisiae eIF3. These results suggest that plant and mammalian eIF3 evolved similarly, whereas S. cerevisiae has diverged.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of California System; University of California Riverside	Browning, KS (corresponding author), Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA.	kbrowning@mail.utexas.edu						Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1985, PLANT PHYSIOL, V77, P370, DOI 10.1104/pp.77.2.370; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; CEGLARZ E, 1980, BIOCHIM BIOPHYS ACTA, V610, P181, DOI 10.1016/0005-2787(80)90068-4; CHANDHURI J, 1999, J BIOL CHEM, V274, P17975; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; CHECKLEY JW, 1981, J BIOL CHEM, V256, P1582; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DUMAS LB, 1982, MOL GEN GENET, V187, P42, DOI 10.1007/BF00384381; Fulop V, 1999, CURR OPIN STRUC BIOL, V9, P715, DOI 10.1016/S0959-440X(99)00035-4; Gallie DR, 1998, PLANT J, V14, P715, DOI 10.1046/j.1365-313x.1998.00175.x; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; Hanachi P, 1999, J BIOL CHEM, V274, P8546, DOI 10.1074/jbc.274.13.8546; HANICJOYCE PJ, 1987, EXP CELL RES, V172, P134, DOI 10.1016/0014-4827(87)90100-5; HANICJOYCE PJ, 1985, GENETICS, V110, P591; HARTWELL LH, 1968, J BACTERIOL, V96, P1664, DOI 10.1128/JB.96.5.1664-1671.1968; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; HEUFLER C, 1988, BIOCHIM BIOPHYS ACTA, V951, P182, DOI 10.1016/0167-4781(88)90039-5; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; Karniol B, 1998, FEBS LETT, V439, P173, DOI 10.1016/S0014-5793(98)01367-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAUER SJ, 1985, BIOCHEMISTRY-US, V24, P2928, DOI 10.1021/bi00333a017; LAUER SJ, 1985, BIOCHEMISTRY-US, V24, P2924, DOI 10.1021/bi00333a016; LAX SR, 1986, METHOD ENZYMOL, V118, P109; Linder P, 1999, YEAST, V15, P865; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Metz AM, 1999, BIOCHEM BIOPH RES CO, V266, P314, DOI 10.1006/bbrc.1999.1814; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; NYGARD O, 1982, BIOCHIM BIOPHYS ACTA, V697, P263, DOI 10.1016/0167-4781(82)90088-4; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEAL SN, 1983, J BIOL CHEM, V258, P866; Shen WH, 1999, PLANT SCI, V143, P45, DOI 10.1016/S0168-9452(99)00017-5; TAKADA Y, 1994, RAPID COMMUN MASS SP, V8, P695, DOI 10.1002/rcm.1290080906; van Buuren ML, 1999, MOL PLANT MICROBE IN, V12, P171, DOI 10.1094/MPMI.1999.12.3.171; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200	72	73	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2122	2131		10.1074/jbc.M007236200	http://dx.doi.org/10.1074/jbc.M007236200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042177	hybrid			2022-12-25	WOS:000166528000065
J	Piekielko, A; Drung, A; Rogalla, P; Schwanbeck, R; Heyduk, T; Gerharz, M; Bullerdiek, J; Wisniewski, JR				Piekielko, A; Drung, A; Rogalla, P; Schwanbeck, R; Heyduk, T; Gerharz, M; Bullerdiek, J; Wisniewski, JR			Distinct organization of DNA complexes of various HMGI/Y family proteins and their modulation upon mitotic phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; 4-WAY JUNCTION DNA; IFN-BETA GENE; PULMONARY CHONDROID HAMARTOMAS; GROUP CHROMOSOMAL-PROTEINS; MOBILITY GROUP PROTEINS; COLI RNA-POLYMERASE; NEOPLASTIC TRANSFORMATION; ARCHITECTURAL FACTOR; BINDING PROPERTIES	High mobility group (HMG) proteins HMGI, HMGY, HMGI-C, and Chironomus HMGI are DNA-binding proteins thought to modulate the assembly and the function of transcriptional complexes. Each of these proteins contains three DNA-binding domains (DBD), properties of which appear to be regulated by phosphorylation. High levels of these proteins are characteristic for rapidly dividing cells in embryonic tissues and tumors. On the basis of their occurrence, specific functions for each of these proteins have been postulated. In this study we demonstrate differences in the nature of contacts of these proteins with promoter region of the interferon-p gene. We show that HMGI and HMGY interact with this DNA via three DBDs, whereas HMGI-C and Chironomus HMGI bind to this DNA using only two domains. Phosphorylation of HMGY protein by Cdc2 kinase leads to impairing of contacts between the N-terminally located DBD and a single promoter element. The perturbations in the architecture of the protein DNA complexes involve changes in the degree of unbending of the intrinsically bent TFN beta promoter. Our results provide first insights into the molecular basis of functional specificity of proteins of the HMGI/Y family and their regulation by phosphorylation.	Univ Gottingen, Zool Inst Entwicklungsbiol 3, D-37073 Gottingen, Germany; Univ Bremen, Zentrum Humangenetik & Genet Beratung, ZHG, D-28359 Bremen, Germany; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	University of Gottingen; University of Bremen; Saint Louis University	Wisniewski, JR (corresponding author), Univ Gottingen, Zool Inst Entwicklungsbiol 3, D-37073 Gottingen, Germany.		Schwanbeck, Ralf/A-2648-2008; Piekielko-Witkowska, Agnieszka/V-1011-2019	Schwanbeck, Ralf/0000-0003-0925-929X; Piekielko-Witkowska, Agnieszka/0000-0002-5348-0760				ASHAR HR, 1995, CELL, V82, P57; Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; Blank C, 2000, CANCER GENET CYTOGEN, V121, P172, DOI 10.1016/S0165-4608(00)00249-1; Bol S, 1996, CANCER GENET CYTOGEN, V90, P88, DOI 10.1016/0165-4608(96)00062-3; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CARREY J, 1988, P NATL ACAD SCI USA, V85, P975; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CLAUS P, 1994, J BIOL CHEM, V269, P33042; Cmarik JL, 1998, ONCOGENE, V16, P3387, DOI 10.1038/sj.onc.1201888; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 1996, CANCER RES, V56, P1896; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Frank O, 1998, J BIOL CHEM, V273, P20015, DOI 10.1074/jbc.273.32.20015; Giannini G, 1999, CANCER RES, V59, P2484; Heyduk E, 1997, ANAL BIOCHEM, V248, P216, DOI 10.1006/abio.1997.2148; Heyduk E, 1999, J BIOL CHEM, V274, P3315, DOI 10.1074/jbc.274.6.3315; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; Heyduk E, 1998, P SOC PHOTO-OPT INS, V3256, P218, DOI 10.1117/12.307063; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KAZMIERCZAK B, 1995, CANCER RES, V55, P6038; Kazmierczak B, 1996, ONCOGENE, V12, P515; Kazmierczak B, 1996, J NATL CANCER I, V88, P1234, DOI 10.1093/jnci/88.17.1234; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Maxam A M, 1980, Methods Enzymol, V65, P499; MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; Rogalla P, 1997, MOL CARCINOGEN, V19, P153, DOI 10.1002/(SICI)1098-2744(199707)19:3<153::AID-MC2>3.0.CO;2-F; Rommel B, 1997, LEUKEMIA LYMPHOMA, V26, P603, DOI 10.3109/10428199709050896; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Schwanbeck R, 2000, J BIOL CHEM, V275, P1793, DOI 10.1074/jbc.275.3.1793; Schwanbeck R, 1997, J BIOL CHEM, V272, P27476, DOI 10.1074/jbc.272.43.27476; Schwanbeck R, 2000, BIOCHEMISTRY-US, V39, P14419, DOI 10.1021/bi0011274; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SELVIN PR, 1994, P NATL ACAD SCI USA, V91, P10024, DOI 10.1073/pnas.91.21.10024; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; SELVIN PR, 1996, IEEE J SEL TOP QUANT, V2, P1; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; Tamimi Y, 1996, BRIT J CANCER, V74, P573, DOI 10.1038/bjc.1996.403; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; Williams AJ, 1997, AM J PATHOL, V150, P911; Wisniewski JR, 1999, BBA-GENE STRUCT EXPR, V1447, P25, DOI 10.1016/S0167-4781(99)00123-2; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 2000, INT J MOL MED, V6, P409; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; Xiao DM, 2000, J NEUROCHEM, V74, P392, DOI 10.1046/j.1471-4159.2000.0740392.x; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	69	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1984	1992		10.1074/jbc.M004065200	http://dx.doi.org/10.1074/jbc.M004065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11034995	hybrid			2022-12-25	WOS:000166528000047
J	Barbera, MJ; Schluter, A; Pedraza, N; Iglesias, P; Villarroya, F; Giralt, M				Barbera, MJ; Schluter, A; Pedraza, N; Iglesias, P; Villarroya, F; Giralt, M			Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene - A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID TRANSPORT PROTEIN; PPAR-GAMMA ACTIVATORS; ADIPOSE-TISSUE; ADIPOCYTE DIFFERENTIATION; 5'-FLANKING REGION; NUCLEAR RECEPTOR; RETINOIC ACID; EXPRESSION; RAT; BETA	High expression of the peroxisome proliferator-activated receptor alpha (PPAR alpha) differentiates brown fat from white, and is related to its high capacity of lipid oxidation, We analyzed the effects of PPAR alpha activation on expression of the brown fat-specific uncoupling protein-1 (ucp-1) gene. Activators of PPAR alpha increased UCP-1 mRNA levels severalfold both in primary brown adipocytes and in brown fat in vivo. Transient transfection assays indicated that the (-4551)UCP1-CAT construct, containing the 5'-regulatory region of the rat ucp-1 gene, was activated by PPAR alpha co-transfection in a dose-dependent manner and this activation was potentiated by Wy 14,643 and retinoid X receptor alpha, The coactivators CBP and PPAR gamma -coactivator-1 (PGC-1), which is highly expressed in brown fat, also enhanced the PPAR alpha -dependent regulation of the ucp-1 gene. Deletion and point-mutation mapping analysis indicated that the PPAR alpha -responsive element was located in the upstream enhancer region of the ucp-1 gene. This -2485/-2458 element bound PPAR alpha and PPAR gamma from brown fat nuclei. Moreover, this element behaved as a promiscuous responsive site to either PPAR alpha or PPAR gamma activation, and we propose that it mediates ucp-1 gene up-regulation associated with adipogenic differentiation (via PPAR gamma) or in coordination with gene expression for the fatty acid oxidation machinery required for active thermogenesis (via PPAR alpha).	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain	University of Barcelona	Giralt, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Iglesias, Roser/C-5561-2017; Pedraza González, Neus/C-6390-2011; Schlüter, Agatha/N-4097-2014; Schluter, Agatha/AAA-9665-2021; Giralt, Marta/A-4756-2013; Villarroya, Francesc/K-4357-2014; Iglesias, P/AAU-1011-2020	Iglesias, Roser/0000-0002-7107-8097; Pedraza González, Neus/0000-0003-4749-5111; Schlüter, Agatha/0000-0001-6732-1528; Giralt, Marta/0000-0001-7968-4190; Iglesias, P/0000-0003-0126-1985; Villarroya, Francesc/0000-0003-1266-9142				ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; Alvarez R, 2000, BIOCHEM J, V345, P91, DOI 10.1042/0264-6021:3450091; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; BOUILLAUD F, 1985, P NATL ACAD SCI USA, V82, P445, DOI 10.1073/pnas.82.2.445; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CassardDoulcier AM, 1996, INT J OBESITY, V20, P278; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frohnert BI, 1999, J BIOL CHEM, V274, P3970, DOI 10.1074/jbc.274.7.3970; GIRALT M, 1990, BIOCHIM BIOPHYS ACTA, V1048, P270, DOI 10.1016/0167-4781(90)90066-B; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; Guardiola-Diaz HM, 1999, J BIOL CHEM, V274, P23368, DOI 10.1074/jbc.274.33.23368; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lindquist JM, 1998, J BIOL CHEM, V273, P30147, DOI 10.1074/jbc.273.46.30147; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; MARTIN I, 1989, BIOCHEM J, V263, P965, DOI 10.1042/bj2630965; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; NICHOLLS DG, 1986, BROWN ADIPOSE TISSUE, P52; Pedraza N, 2000, DIABETES, V49, P1224, DOI 10.2337/diabetes.49.7.1224; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Valmaseda A, 1999, MOL CELL ENDOCRINOL, V154, P101, DOI 10.1016/S0303-7207(99)00081-7; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yubero P, 1998, MOL ENDOCRINOL, V12, P1023, DOI 10.1210/me.12.7.1023; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	55	262	272	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1486	1493		10.1074/jbc.M006246200	http://dx.doi.org/10.1074/jbc.M006246200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050084	hybrid			2022-12-25	WOS:000166430900084
J	McLarrent, FW; Theriault, FM; Stifani, S				McLarrent, FW; Theriault, FM; Stifani, S			Association with the nuclear matrix and interaction with Groucho and RUNX proteins regulate the transcription repression activity of the basic helix loop helix factor Hes1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUCHO/TRANSDUCIN-LIKE ENHANCER; DROSOPHILA-ENHANCER; SENSORY NEURONS; TERMINAL DOMAIN; NERVOUS-SYSTEM; SPLIT COMPLEX; WRPW MOTIF; GENE; EXPRESSION; FAMILY	Hairy/Enhancer of split 1 (Hes1) is a mammalian transcriptional repressor that plays crucial roles in the regulation of several developmental processes, including neuronal differentiation. The aim of this study was to elucidate the molecular mechanisms that regulate the transcription repression activity of Hes1, It is shown here that Heel associates with the nuclear matrix, the ribonucleoprotein network of the nucleus that plays important roles in transcriptional regulation. Nuclear matrix binding is mediated by the same Hes1 C-terminal domain that is also required for transcriptional repression. This domain contains the WRPW motif that acts as a binding site for the transcriptional corepressor Groucho, which also localizes to the nuclear matrix. Both the nuclear matrix association and transcription repression activity of Heel are inhibited by deletion of the WRPW motif, indicating that Groucho acts as a transcriptional corepressor for Hes1. This corepressor role is not modulated by the Groucho-related gene product Grg5, In contrast, the Bunt-related protein RUNX2, which localizes to the nuclear matrix and interacts with Groucho and Hes1, can inhibit both the Groucho(.)Hes1 interaction and the transcription repression ability of Hes1, Together, these observations suggest that transcriptional repression by Hes1 requires interactions with Groucho at the nuclear matrix and that RUNX proteins act as negative regulators of the repressive activity of Groucho(.)Hes1 complexes.	McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada	McGill University	Stifani, S (corresponding author), McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	mdst@musica.mcgill.ca		Stifani, Stefano/0000-0002-2376-7701				Allen T, 1999, CELL MOL BIOL, V45, P687; Anderson DJ, 1999, CURR OPIN NEUROBIOL, V9, P517, DOI 10.1016/S0959-4388(99)00015-X; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; DEHNI G, 1995, MECH DEVELOP, V53, P269; DELIDAKIS C, 1991, GENETICS, V129, P803; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896-6273(00)80989-7; Grbavec D, 1999, BIOCHEM J, V337, P13, DOI 10.1042/0264-6021:3370013; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Heitzler P, 1996, DEVELOPMENT, V122, P161; HUSAIN J, 1996, BIOCHEM J, V317, P323; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Javed A, 2000, J CELL SCI, V113, P2221; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; KNUST E, 1992, GENETICS, V132, P505; Koop KE, 1996, MECH DEVELOP, V59, P73, DOI 10.1016/0925-4773(96)00582-5; Kramer SG, 1999, DEVELOPMENT, V126, P191; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; Matsue M, 1997, BONE, V20, P329, DOI 10.1016/S8756-3282(97)00005-7; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MIYASAKA H, 1993, EUR J BIOCHEM, V216, P343, DOI 10.1111/j.1432-1033.1993.tb18151.x; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Stein GS, 1999, CRIT REV EUKAR GENE, V9, P183, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.30; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Yao J, 1998, DEV GROWTH DIFFER, V40, P133; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746	53	73	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1578	1584		10.1074/jbc.M007629200	http://dx.doi.org/10.1074/jbc.M007629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035023	hybrid			2022-12-25	WOS:000166430900096
J	Sayama, K; Hanakawa, Y; Shirakata, Y; Yamasaki, K; Sawada, Y; Sun, L; Yamanishi, K; Ichijo, H; Hashimoto, K				Sayama, K; Hanakawa, Y; Shirakata, Y; Yamasaki, K; Sawada, Y; Sun, L; Yamanishi, K; Ichijo, H; Hashimoto, K			Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular inducer of keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; HUMAN INVOLUCRIN PROMOTER; TERMINAL DIFFERENTIATION; MOLECULAR-CLONING; MAP KINASE; CELLS; EXPRESSION; GROWTH; SKIN; TRANSGLUTAMINASE	Cells differentiate in response to various extracellular stimuli. This cellular response requires intracellular signaling pathways. The mitogen-activated protein (MAP) kinase cascade is a core signal transduction pathway that determines the fate of many kinds of cell. MAP kinase kinase kinase activates MAP kinase kinase, which in turn activates MAP kinase. Apoptosis signal-regulating kinase (ASK1) was Identified as a MAP kinase kinase kinase involved in the stress-induced apoptosis-signaling cascade that activates the SEK1-JNK and MKK3/MKK6-p38 MAP kinase cascades. Expression of the constitutively active form of ASK1 (ASK1-DeltaN) in keratinocytes induced significant morphological changes and differentiation markers, transglutaminase-1, loricrin, and involucrin, A transient increase in p21(Cip1/WAF1) reduced DNA synthesis, and cell cycle analysis verified the differentiation. p38 MAP kinase inhibitors, SB202190 and SB203580, abolished the induction of differentiation markers, transglutaminase-l, loricrin, and involucrin. In turn, the induction of differentiation with ceramide in keratinocytes caused an increase in ASK1 expression and activity. Furthermore, normal human skin expresses ASK1 protein in the upper epidermis, implicating ASK1 in in vivo keratinocyte differentiation. We propose that the ASK1-p38 MAP kinase cascade is a new intracellular regulator of keratinocyte differentiation.	Ehime Univ, Dept Dermatol, Sch Med, Shigenobucho, Ehime 7910295, Japan; Tokyo Med & Dent Univ, Grad Sch, Lab Cell Signalling, Tokyo 1138519, Japan; Dalian Med Univ, Affiliated Hosp 2, Dept Dermatol, Dalian, Peoples R China; Kyoto Prefectural Univ Med, Dept Dermatol, Kyoto 6020841, Japan	Ehime University; Tokyo Medical & Dental University (TMDU); Dalian Medical University; Kyoto Prefectural University of Medicine	Sayama, K (corresponding author), Ehime Univ, Dept Dermatol, Sch Med, Shigenobucho, Ehime 7910295, Japan.		Yamasaki, Kenshi/C-8905-2018; Yamanishi, Kiyofumi/R-2200-2019; Sawada, Yasuhiro/H-8044-2012	Yamasaki, Kenshi/0000-0002-5495-4956; Yamanishi, Kiyofumi/0000-0003-0484-2320; Sawada, Yasuhiro/0000-0003-0625-3335; Ichijo, Hidenori/0000-0002-5005-6438				CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DIUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; GHERZI R, 1992, BIOCHEM BIOPH RES CO, V184, P283, DOI 10.1016/0006-291X(92)91190-2; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUI MS, 1992, J INVEST DERMATOL, V99, P565, DOI 10.1111/1523-1747.ep12667411; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OKUMURA H, 1991, EXP CELL RES, V192, P647, DOI 10.1016/0014-4827(91)90089-D; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; PITTELKOW MR, 1986, J INVEST DERMATOL, V86, P410, DOI 10.1111/1523-1747.ep12285684; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 1999, J CELL PHYSIOL, V179, P40, DOI 10.1002/(SICI)1097-4652(199904)179:1<40::AID-JCP5>3.0.CO;2-Z; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; VANERP PEJ, 1989, AM J PATHOL, V135, P865; WAKITA H, 1994, ARCH DERMATOL RES, V286, P350, DOI 10.1007/BF00402228; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R; YUSPA SH, 1982, CANCER RES, V42, P2344	39	111	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					999	1004		10.1074/jbc.M003425200	http://dx.doi.org/10.1074/jbc.M003425200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11029458	hybrid			2022-12-25	WOS:000166430900020
J	Yan, ZF; Deng, XB; Friedman, E				Yan, ZF; Deng, XB; Friedman, E			Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; MEMBRANE PROTEOGLYCAN; DISEASE PROGRESSION; POTENTIAL MEDIATOR; EXPRESSION CLONING; TRANSGENIC MICE	Transforming growth factor-beta1 (TGF-beta1) can act as a tumor suppressor or a tumor promoter depending on the characteristics of the malignant cell. Each of three Ki-ras(G12V) transfectants of HD6-4 colon cancer cells had been shown to be more aggressive in vivo than controls in earlier studies (Yan, Z,, Chen, M,, Perucho, M., and Friedman, E. (1997) J, Biob. Chem. 272, 30928-30936). We now show that stable expression of oncogenic Ki-ras(G12V) converts the HD6-4 colon cancer cell line from insensitive to TGF-beta1 to growth-promoted by TGF-beta1, Each of three Ki-ras(G12V) transfectants responded to TGF-beta1 by an increase in proliferation and by decreasing the abundance of the Cdk inhibitor p21 and the tumor suppressor PTEN, whereas each of three wild-type Ki-ras transfectants remained unresponsive to TG-F-beta1. The wildtype Ki-ras transfectants lack functional TGF-beta receptors, whereas all three Ki-rasG12V transfectants expressed functional TGF-beta receptors that bound I-125-TGF-beta1. The previous studies showed that in cells with wild-type Ki-ras, TGF-beta receptors were not mutated, and receptor proteins were transported to the cell surface, but post-translational modification of TGF-beta receptor ill (T beta RIII) was incomplete. We now show that the betaglycan form of T beta RIII is highly modified following translation when transiently expressed in Ki-ras(G12V) cells, whereas no such post-translational modification of T beta RIII occurs in control cells. Antisense oligonucleotides directed to Ki-Ras decreased both T beta RIII posttranslational modification in Ki-ras(G12V) cells and TGF-beta1 down-regulation of p21, demonstrating the direct effect of mutant Res. Therefore, one mechanism by which mutant Ki-Ras confers a more aggressive tumor phenotype is by enhancing T beta RIII post-translational modification.	SUNY, Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College	Friedman, E (corresponding author), SUNY, Upstate Med Univ, Dept Pathol, Rm 2305,Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.				NATIONAL CANCER INSTITUTE [R01CA075708] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA75708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; Barrack ER, 1997, PROSTATE, V31, P61; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; CUI W, 1996, GROWTH FACTORS CYTOK; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; EASTON EW, 1991, J BIOL CHEM, V266, P21674; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; Factor VM, 1997, CANCER RES, V57, P2089; Farina AR, 1998, INT J CANCER, V75, P721; FILMUS J, 1992, ONCOGENE, V7, P521; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARPER JW, 1993, CELL, V75, P805; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOUCK KA, 1989, ONCOGENE, V4, P19; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; HUANG F, 1994, ONCOGENE, V9, P3701; HUANG F, 1995, CELL GROWTH DIFFER, V6, P1635; Kansra S, 2000, INT J CANCER, V87, P373, DOI 10.1002/1097-0215(20000801)87:3<373::AID-IJC10>3.0.CO;2-X; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Li DM, 1997, CANCER RES, V57, P2124; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; LONGSTREET M, 1992, ONCOGENE, V7, P1549; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Riggins GJ, 1997, CANCER RES, V57, P2578; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Robson H, 1996, BRIT J CANCER, V74, P753, DOI 10.1038/bjc.1996.432; SCHROY P, 1990, CANCER RES, V50, P261; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shim KS, 1999, CANCER-AM CANCER SOC, V85, P554, DOI 10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X; SIPES NJ, 1990, MOL CARCINOGEN, V3, P12, DOI 10.1002/mc.2940030106; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yan ZF, 1997, J BIOL CHEM, V272, P27902, DOI 10.1074/jbc.272.44.27902; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YAN ZF, 1992, ONCOGENE, V7, P801; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; ZHAO J, 1995, CANCER RES, V55, P6181	79	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1555	1563		10.1074/jbc.M004553200	http://dx.doi.org/10.1074/jbc.M004553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11029459	hybrid			2022-12-25	WOS:000166430900093
J	Jakubowiak, A; Pouponnot, C; Berguido, F; Frank, R; Mao, SF; Massague, J; Nimer, SD				Jakubowiak, A; Pouponnot, C; Berguido, F; Frank, R; Mao, SF; Massague, J; Nimer, SD			Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE CHROMOSOMAL TRANSLOCATIONS; TGF-BETA; FUNCTIONAL COOPERATION; TUMOR-SUPPRESSOR; SMAD PROTEINS; GENE; TRANSCRIPTION; PROMOTER; DNA; REPRESSION	The t(8;21) translocation, found in adult acute myelogenous leukemia, results in the formation of an AML1/ETO chimeric transcription factor. AML1/ETO expression leads to alterations in hematopoietic progenitor cell differentiation, although its role in leukemic transformation is not clear. The N-terminal portion of AML1, which is retained in AML1/ETO, contains a region of homology to the FAST proteins, which cooperate with Smads to regulate transforming growth factor beta1 (TGF-beta1) target genes. We have demonstrated the physical association of Smad proteins with AML1 and AML1/ETO by immunoprecipitation and have mapped the region of interaction to the rant homology domain in these AML1 proteins. Using confocal microscopy, we demonstrated that AML1, and ETO and/or AML1/ETO, colocalize with Smads in the nucleus of t(8;21)-positive Kasumi-1 cells, in the presence but not the absence of TGF-beta1. Using transient transfection assays and a reporter gene construct that contains both Smad and AML1 consensus binding sequences, we demonstrated that overexpression of AML1B cooperates with TGF-beta1 in stimulating reporter gene activity, whereas AML1/ETO represses basal promoter activity and blocks the response to TGF-beta1. Considering the critical role of TGF-beta1 in the growth and differentiation of hematopoietic cells, interference with TGF-beta1 signaling by AML1/ETO may contribute to leukemogenesis.	Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Div Hematol Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, 1275 York Ave,Box 575, New York, NY 10021 USA.	s-nimer@mskcc.org		Massague, Joan/0000-0001-9324-8408	NIDDK NIH HHS [DK43025] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Germain S, 2000, GENE DEV, V14, P435; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Im YH, 2000, CANCER RES, V60, P1536; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Nagarajan RP, 1999, J BIOL CHEM, V274, P31229, DOI 10.1074/jbc.274.44.31229; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shi MJ, 1998, J IMMUNOL, V161, P6751; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	48	74	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40282	40287		10.1074/jbc.C000485200	http://dx.doi.org/10.1074/jbc.C000485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11032826	hybrid			2022-12-25	WOS:000166039500067
J	Hou, YM; Azpiazu, I; Smrcka, A; Gautam, N				Hou, YM; Azpiazu, I; Smrcka, A; Gautam, N			Selective role of G protein gamma subunits in receptor interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MUSCARINIC RECEPTORS; COUPLED RECEPTORS; RECONSTITUTION; CELLS; PURIFICATION; MEMBRANES; GTPASE	Receptor stimulation of nucleotide exchange in a heterotrimeric G protein (alpha beta gamma) is the primary event-modulating signaling by G proteins, The molecular mechanisms at the basis of this event and the role of the G protein subunits, especially the py complex, in receptor activation are unclear. In a reconstituted system, a purified muscarinic receptor, M2, activates G protein heterotrimers alpha i2 beta1 gamma5 and alpha i2 beta1 gamma7 with equal efficacy. However, when the ct subunit type is substituted with alphao, alphao beta1 gamma7 shows a 100% increase in M2-stimulated GTP hydrolysis compared with alphao beta1 gamma5, Using a sensitive assay based on py complex stimulation of phospholipase C activity, we show that both beta1 gamma5 and beta1 gamma7 form heterotrimers equally well with alphao and alphai, These results indicate that the gamma subunit interaction with a receptor is critical for modulating nucleotide exchange and is influenced by the subunit-type composition of the heterotrimer.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	Washington University (WUSTL); Washington University (WUSTL); University of Rochester	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054, St Louis, MO 63110 USA.				NIGMS NIH HHS [R01 GM053536, GM46963, R01 GM046963, GM53536] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Hayashi MK, 1996, J BIOCHEM, V120, P1232; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Kostenis E, 1999, LIFE SCI, V64, P355, DOI 10.1016/S0024-3205(98)00574-8; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; Nathanson NM, 2000, P NATL ACAD SCI USA, V97, P6245, DOI 10.1073/pnas.97.12.6245; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PARKER EM, 1991, J BIOL CHEM, V266, P519; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; SHINOZAWA T, 1980, P NATL ACAD SCI-BIOL, V77, P1408, DOI 10.1073/pnas.77.3.1408; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588	22	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38961	38964		10.1074/jbc.C000604200	http://dx.doi.org/10.1074/jbc.C000604200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11042163	hybrid			2022-12-25	WOS:000165953100004
J	Gervais, V; Busso, D; Wasielewski, E; Poterszman, A; Egly, JM; Thierry, JC; Kieffer, B				Gervais, V; Busso, D; Wasielewski, E; Poterszman, A; Egly, JM; Thierry, JC; Kieffer, B			Solution structure of the N-terminal domain of the human TFIIH MAT1 subunit - New insights into the RING finger family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IIH; ACTIVATING KINASE CAK; NMR-SPECTROSCOPY; SUBSTRATE-SPECIFICITY; MAGNETIC-RESONANCE; PROTEIN STRUCTURES; DISTANCE GEOMETRY; CRYSTAL-STRUCTURE; CYCLIN-H; COMPLEXES	The human MAT1 protein belongs to the cyclin-dependent kinase-activating kinase complex, which is functionally associated to the transcription/DNA repair factor TFIIH. The N-terminal region of MAT1 consists of a C3HC4 RING finger, which contributes to optimal TFIIH transcriptional activities, We report here the solution structure of the human MAT1 RING finger domain (Met(1)-Asp(65)) as determined by H-1 NMR spectroscopy. The MAT1 RING finger domain presents the expected beta alpha beta beta topology with two interleaved zinc-binding sites conserved among the RING family. However, the presence of an additional helical segment in the N-terminal part of the domain and a conserved hydrophobic central beta strand are the defining features of this new structure and more generally of the MAT1 RING finger subfamily. Comparison of electrostatic surfaces of RING finger structures shows that the RING finger domain of MAT1 presents a remarkable positively charged surface. The functional implications of these MAT1 RING finger features are discussed.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, F-67400 Illkirch, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kieffer, B (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, F-67400 Illkirch, France.		Kieffer, Bruno/AAE-8999-2019; Wasielewski, Emeric/L-4424-2013	Wasielewski, Emeric/0000-0001-9656-4764; Gervais, Virginie/0000-0002-1144-6185; POTERSZMAN, Arnaud/0000-0002-6702-5777; Kieffer, Bruno/0000-0002-2033-4679				Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Andersen G, 1996, FEBS LETT, V397, P65, DOI 10.1016/S0014-5793(96)01143-X; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BAX A, 1985, J MAGN RESON, V61, P306, DOI 10.1016/0022-2364(85)90085-X; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Billeter M, 1995, J BIOMOL NMR, V5, P1; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BRUNGER AT, 1992, XPLOR 3 8 SOFTWARE M; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; DAIKUN GP, 1986, NATURE, V324, P688; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Riedl T, 2000, GENE EXPRESSION, V9, P3; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	37	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7457	7464		10.1074/jbc.M007963200	http://dx.doi.org/10.1074/jbc.M007963200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11056162	hybrid			2022-12-25	WOS:000167442900083
J	Mahalingam, S; Chaudhri, G; Tan, CL; John, A; Foster, PS; Karupiah, G				Mahalingam, S; Chaudhri, G; Tan, CL; John, A; Foster, PS; Karupiah, G			Transcription of the interferon gamma (IFN-gamma)-inducible chemokine Mig in IFN-gamma-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; BINDING PROTEIN GENE; RESPONSE ELEMENT; IN-VIVO; KAPPA-B; ACTIVATION; PROMOTER; EXPRESSION; INDUCTION; CYTOKINES	MuMig or Mig (murine monokine induced by interferon gamma) is a CXC chemokine whose induction is thought to be strictly dependent on interferon gamma (IFN-gamma). Here we have: studied the expression of this chemokine gene in various organs of mice infected with vaccinia virus. We have employed animals deficient in either IFN-gamma (IFN-/-), or receptors for IFN-alpha/beta, IFN-gamma, or both IFN-alpha/beta gamma and IFN-gamma (DR-/-) to dissect out the role of interferons in the: induction of Mig during the host response to virus infection. Our data show that Mig mRNA and protein are expressed in organs of vaccinia virus-infected IFN-gamma (-/-) mice,albeit at lower levels compared with infected, wild-type animals. In the DR-/- mice and in IFN-gamma (-/-) mice:treated:with a neutralizing antibody to IFN-alpha/beta, Mig mRNA transcripts were completely absent. Our data indicate that, in vaccinia virus-infected IFN-gamma (-/-) mice, Mg mRNA expression is mediated through the interaction between IFN-gamma responsive element 1 (gamma RE-1) and IFN-alpha/beta -induced STAT-1 complex referred to as IFN-y response factor 2 (gamma RF-2). Further, our findings support the view that gamma RF-2 is the IFN-alpha/beta induced STAT-1 complex,: IFN-alpha -activated factor. We have found that, in the absence of IFN-gamma, IFN-alpha/beta are able to induce Mig in response to a viral infection in vivo.	Univ Sydney, Dept Pathol, Host Def Grp, Div Fac Med, Sydney, NSW 2006, Australia; Australian Natl Univ, Sch Human & Biomed Sci, Div Sci & Design, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Cell Biol, Viral Engn & Cytokines Grp, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Med Mol Biol Grp, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Leukocyte Signalling & Regulat Grp, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia	University of Sydney; Australian National University; Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research	Karupiah, G (corresponding author), Univ Sydney, Dept Pathol, Host Def Grp, Div Fac Med, Blackburn Bldg,D06, Sydney, NSW 2006, Australia.		Foster, Paul/G-5057-2013; Chaudhri, Geeta/K-3290-2013; Karupiah, Gunasegaran/J-4707-2013	Chaudhri, Geeta/0000-0003-3388-2102; Karupiah, Gunasegaran/0000-0001-6306-4405				Amichay D, 1996, J IMMUNOL, V157, P4511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; COLONNO RJ, 1982, J BIOL CHEM, V257, P9234; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESPOSITO JJ, 1978, VIROLOGY, V89, P53, DOI 10.1016/0042-6822(78)90039-9; FARBER JM, 1993, BIOCHEM BIOPH RES CO, V192, P223, DOI 10.1006/bbrc.1993.1403; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GUYER NB, 1995, J IMMUNOL, V155, P3472; KARUPIAH G, 1993, J VIROL, V67, P4214, DOI 10.1128/JVI.67.7.4214-4226.1993; KARUPIAH G, 1990, J IMMUNOL, V144, P290; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIAO F, 1995, J EXP MED, V182, P1301, DOI 10.1084/jem.182.5.1301; Mahalingam S, 1999, J VIROL, V73, P1479, DOI 10.1128/JVI.73.2.1479-1491.1999; Mahalingam S, 1999, IMMUNOL CELL BIOL, V77, P469, DOI 10.1046/j.1440-1711.1999.00858.x; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SVETIC A, 1991, J IMMUNOL, V147, P2391; VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; WYNN TA, 1993, J IMMUNOL, V151, P1430	42	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7568	7574		10.1074/jbc.M005773200	http://dx.doi.org/10.1074/jbc.M005773200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11024052	hybrid			2022-12-25	WOS:000167442900096
J	van Horck, FPG; Ahmadian, MR; Haeusler, LC; Moolenaar, WH; Kranenburg, O				van Horck, FPG; Ahmadian, MR; Haeusler, LC; Moolenaar, WH; Kranenburg, O			Characterization of p190RhoGEF, a RhoA-specific guanine nucleotide exchange factor that interacts with microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; RAC SIGNALING PATHWAYS; STRESS FIBER FORMATION; DBL ONCOGENE PRODUCT; CELLULAR-TRANSFORMATION; LYSOPHOSPHATIDIC ACID; NEURITE RETRACTION; HOMOLOGY DOMAIN; P115 RHOGEF; ACTIVATION	Rho family GTPases control numerous cellular processes including cytoskeletal reorganization and transcriptional activation. Rho GTPases are activated by guanine nucleotide exchange factors (GEFs) which stimulate the exchange of bound GDP for GTP. We recently isolated a putative GEF, termed p190RhoGEF that binds to RhoA and, when overexpressed in neuronal cells, induces cell rounding and inhibits neurite outgrowth. Here we show that the isolated tandem Dbl homology/pleckstrin homology domain of p190RhoGEF activates RhoA in vitro, but not Rad or Cdc42, as determined by GDP release and protein binding assays, in contrast, full-length p190RhoGEF fails to activate RhoA in vitro. When overexpressed in intact cells, however, p190RhoGEF does activate RhoA with subsequent F-actin reorganization and serum response factor-mediated transcription. Immunofluorescence studies show that endogenous p190RhoGEF localizes to distinct RhoA-containing regions at the plasma membrane, to the cytosol and along microtubules. In vitro and in vivo binding experiments show that p190RhoGEF directly interacts with microtubules via its C-terminal region adjacent to the catalytic Dbl homology/pleckstrin homology domain. Our results indicate that p190RhoGEF is a specific activator of RhoA that requires as yet unknown binding partners to unmask its GDP/GTP exchange activity in vivo, and they suggest that p190RhoGEF may provide a link between microtubule dynamics and RhoA signaling.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Netherlands Cancer Institute; Max Planck Society	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Harhammer R, 1996, FEBS LETT, V399, P211, DOI 10.1016/S0014-5793(96)01327-0; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1997, J CELL SCI, V110, P2417; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; SELF AJ, 1995, SMALL GTPASES THEIR, P3; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	53	127	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4948	4956		10.1074/jbc.M003839200	http://dx.doi.org/10.1074/jbc.M003839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11058585	hybrid			2022-12-25	WOS:000168484300058
J	Zhang, W; Neer, EJ				Zhang, W; Neer, EJ			Reassembly of phospholipase C-beta(2) from separated domains - Analysis of basal and G protein-stimulated activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PLECKSTRIN HOMOLOGY DOMAINS; MEMBRANE-BINDING PROPERTIES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; C BETA-2; ACTIVATION; IDENTIFICATION; ASSOCIATION; INTERACTS; REGION	Phosphatidylinositol-specific phospholipase C-betas (PLC-betas) are the only PLC isoforms that are regulated by G; protein subunits, To further understand the regulation of PLC-beta (2) by G proteins and the functional roles of PLC-beta (2) structural domains, we tested whether the separately expressed amino and carboxyl halves of PLC-beta (2) could associate to form catalytically active enzymes as two polypeptides, and we explored how the complexes thus formed would be regulated by G protein py subunits (G beta gamma), We expressed cDNA constructs encoding PLC-beta (2), fragments of different lengths in COS-7 cells and demonstrated by coimmunoprecipitation that the coexpressed fragments could assemble and functionally reconstitute an active PLC-beta (2). The pleckstrin homology domain of PLC-beta (2) was required for its targeting to the membrane and for substrate hydrolysis, Reconstituted enzymes that contained the linker region that joins the two catalytic domains were as active or more active than the wild-type PLC-beta (2), When the linker region was removed, basal PLC-beta (2) enzymatic activity was increased further, suggesting that the linker region exerts an inhibitory effect on basal PLC-P, activity. The reconstituted enzymes, like wild-type PLC-beta (2), were activated by G beta gamma; when the C-terminal region was present in these constructs, they were also activated by G alpha (q). G beta gamma and G alpha (q) activated these PLC-beta (2) constructs equally in the presence or absence of the linker region. We conclude that the linker region is an inhibitory element in PLC-beta (2) and that G beta gamma and G alpha (q) do not stimulate PLC-beta (2) through easing the inhibition of enzymatic activity by the linker region.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Zhang, W (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.							Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Exton JH, 1997, ADV EXP MED BIOL, V400, P3; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HORTSMAN DA, 1996, P NATL ACAD SCI USA, V93, P7518; Irvine R, 1996, NATURE, V380, P581, DOI 10.1038/380581a0; Jenco JM, 1997, BIOCHEM J, V327, P431; JHON DY, 1993, J BIOL CHEM, V268, P6654; JIANG HP, 1994, J BIOL CHEM, V269, P7593; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE SB, 1993, J BIOL CHEM, V268, P25952; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; PARK DG, 1993, J BIOL CHEM, V268, P3710; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Schnabel P, 1998, BIOCHEM J, V330, P461, DOI 10.1042/bj3300461; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; WU DQ, 1993, J BIOL CHEM, V268, P3704	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2503	2508		10.1074/jbc.M003562200	http://dx.doi.org/10.1074/jbc.M003562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11044443	hybrid			2022-12-25	WOS:000166784800029
J	Mejillano, M; Yamamoto, M; Rozelle, AL; Sun, HQ; Wang, XD; Yin, HL				Mejillano, M; Yamamoto, M; Rozelle, AL; Sun, HQ; Wang, XD; Yin, HL			Regulation of apoptosis by phosphatidylinositol 4,5-bisphosphate inhibition of caspases, and caspase inactivation of phosphatidylinositol phosphate 5-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID KINASE FAMILY; CYTOCHROME-C; PHOSPHOLIPASE-C; IN-VIVO; GELSOLIN; BINDING; PHOSPHORYLATION; ACTIVATION; SPECIFICITY; PROTEASES	Phosphoinositides such as phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-bisphosphate promote cell survival and protect against apoptosis by activating Akt/PKB, which phosphorylates components of the apoptotic machinery. We now report that another phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2) is a direct inhibitor of initiator caspases 8 and 9, and their common effector caspase 3, PIP, inhibited procaspase 9 processing in cell extracts and in a reconstituted procaspase 9/Apaf1 apoptosome system. It inhibited purified caspase 3 and 8 activity, at physiologically attainable PIP, levels in mixed Lipid vesicles. Caspase 3 binding to PIP, was confirmed by cosedimentation with mixed lipid vesicles. Overexpression of phosphatidylinositol phosphate 5-kinase alpha (PIP5KI alpha), which synthesizes PIP2, suppressed apoptosis, whereas a kinase-deficient mutant did not. Protection by the wild-type PIP5KI alpha was accompanied by decreases in the generation of activated caspases and of caspase 3-cleaved PARP, Protection was not mediated through PIP3 or Akt activation. An anti-apoptotic role for PIP2 is further substantiated by our finding that PIP5KI alpha was cleaved by caspase 3 during apoptosis, and cleavage inactivated PIP5KI alpha in vitro. Mutation of the P-4 position (D279A) of the PIP5KI alpha caspase 3 cleavage consensus prevented cleavage in vitro, and during apoptosis in vivo. Significantly, the caspase 3-resistant PIP5KI alpha mutant was more effective in suppressing apoptosis than the wild-type kinase. These results show that PIP2 is a direct regulator of apical and effector caspases in the death receptor and mitochondrial pathways, and that PIP5KI alpha inactivation contributes to the progres sion of apoptosis, This novel feedforward amplification mechanism for maintaining the balance between life and death of a cell works through phosphoinositide regulation of caspases and caspase regulation of phosphoinositide synthesis.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yin, HL (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA.				NIAMS NIH HHS [AR41940] Funding Source: Medline; NIGMS NIH HHS [GM61203] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061203] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Ma L, 1998, J CELL BIOL, V140, P1125; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Yin HL, 1999, J BIOL CHEM, V274, P32529, DOI 10.1074/jbc.274.46.32529; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	69	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1865	1872		10.1074/jbc.M007271200	http://dx.doi.org/10.1074/jbc.M007271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042212	hybrid			2022-12-25	WOS:000166528000031
J	Orre, RS; Cotter, MA; Subramanian, C; Robertson, ES				Orre, RS; Cotter, MA; Subramanian, C; Robertson, ES			Prothymosin alpha functions as a cellular oncoprotein by inducing transformation of rodent fibroblasts in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F TRANSCRIPTION FACTOR; C-MYC; HL-60 CELLS; LIVER-REGENERATION; NUCLEAR-PROTEIN; LYMPHOCYTES-T; GENE-PRODUCT; HISTONE H1; IN-VITRO; EXPRESSION	Prothymosin alpha (ProT alpha), a cellular molecule known to be associated with cell proliferation, is transcriptionally up-regulated on expression of c-myc and interacts with histones in vitro and associates with histone H1 in cells. Previous studies have also shown that ProT alpha is involved in chromatin remodeling. Recent studies have shown that ProT alpha interacts with the acetyl transferase p300 and an essential Epstein-Barr virus protein, EBNA3C, involved in regulation of viral and cellular transcription. These studies suggest a potential involvement in regulation of histone acetylation through the association with these cellular and viral factors. In the current studies, we show that heterologous expression of ProTa! in the Rat-1 rodent fibroblast cell line results in increased proliferation, loss of contact inhibition, anchorage-independent growth, and decreased serum dependence, These phenotypic changes seen in transfected Rat-1 cells are similar to those observed with a known oncoprotein, Ras, expressed under the control of a heterologous promoter and are characteristic oncogenic growth properties. These results demonstrate that the ProTa gene may function as an oncogene when stably expressed in Rat-1 cells and may be an important downstream cellular target for inducers of cellular transformation, which may include Epstein-Barr virus and c-myc.	Univ Michigan, Dept Microbiol & Immunol, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Cellular & Mol Biol Grad Program, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Robertson, ES (corresponding author), Univ Michigan, Dept Microbiol & Immunol, Sch Med, 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA07215-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aster JC, 1997, J BIOL CHEM, V272, P11336; BARCIA MG, 1992, FEBS LETT, V312, P152, DOI 10.1016/0014-5793(92)80924-6; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; Castro JM, 1996, BIOCHEM BIOPH RES CO, V224, P140, DOI 10.1006/bbrc.1996.0997; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; DOMINGUEZ F, 1993, EUR J CANCER, V29A, P893, DOI 10.1016/S0959-8049(05)80433-2; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; Loidi L, 1997, CLIN CHEM, V43, P59; Lutz W, 1996, ONCOGENE, V13, P803; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MAKAROVA T, 1989, FEBS LETT, V257, P247, DOI 10.1016/0014-5793(89)81544-3; MANROW RE, 1991, J BIOL CHEM, V266, P3916; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; NEVINS JR, 1992, SCIENCE, V258, P424; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; Parker GA, 1996, ONCOGENE, V13, P2541; Rodriguez P, 1999, CELL DEATH DIFFER, V6, P3, DOI 10.1038/sj.cdd.4400450; Rodriguez P, 1998, BIOCHEM J, V331, P753, DOI 10.1042/bj3310753; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SCHMIDT G, 1991, BIOCHIM BIOPHYS ACTA, V1088, P442, DOI 10.1016/0167-4781(91)90141-8; SILVERMAN AL, 1994, ALCOHOL CLIN EXP RES, V18, P616, DOI 10.1111/j.1530-0277.1994.tb00919.x; SMITH MR, 1993, BLOOD, V82, P1127; SZABO P, 1992, BIOCHEM BIOPH RES CO, V185, P953, DOI 10.1016/0006-291X(92)91719-7; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TSITSILONI OE, 1993, P NATL ACAD SCI USA, V90, P9504, DOI 10.1073/pnas.90.20.9504; VARELI K, 1995, FEBS LETT, V371, P337, DOI 10.1016/0014-5793(95)00938-6; Vareli K, 1996, EUR J BIOCHEM, V238, P799, DOI 10.1111/j.1432-1033.1996.0799w.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6; Wu CG, 1997, BIOCHEM BIOPH RES CO, V232, P817, DOI 10.1006/bbrc.1997.6377; Wu CL, 1997, LIFE SCI, V61, P2091, DOI 10.1016/S0024-3205(97)00882-5	52	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1794	1799		10.1074/jbc.M008560200	http://dx.doi.org/10.1074/jbc.M008560200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11036085	hybrid			2022-12-25	WOS:000166528000021
J	Gaubert, F; Escaffit, F; Bertrand, C; Korc, M; Pradayrol, L; Clemente, F; Estival, A				Gaubert, F; Escaffit, F; Bertrand, C; Korc, M; Pradayrol, L; Clemente, F; Estival, A			Expression of the high molecular weight fibroblast growth factor-2 isoform of 210 amino acids is associated with modulation of protein kinases C delta and epsilon and ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; ENDOTHELIAL-CELLS; DIFFERENTIAL REGULATION; SELECTIVE INHIBITOR; MESSENGER-RNA; SIGNAL; BFGF; TRANSLATION; ISOZYMES; FORMS	The high molecular weight (HMW) fibroblast growth factor (FGF)-2 isoform of 210 amino acids initiated at a CUG start codon possesses a nuclear localization sequence and is not secreted, In contrast, the low molecular weight (LMW) isoform of 155 amino acids initiated at the AUG start codon can be secreted and activates the cell surface FGF receptors, The two isoforms possess different biological properties; however, little is known about the intracrine regulatory mechanisms involved in the biological effects of the HMW FGF-2 isoform, Using pancreatic cells stably transfected with cDNAs leading to the expression of either the HMW FGF-2 (A3 cells) or the LMW form (A5 cells), we provide evidence that the two FGF-2 isoforms differentially modulate PKC levels. The LMW FGF-2 up-regulated the PKC epsilon levels by 1.6-fold; by contrast the HMW isoform down-regulated the level of this PKC isotype by about 3-fold and increased the amount of PKC delta by 1.7-fold. PKC mRNAs were also modified, suggesting that PKC expression was regulated at a pretranslational level. Additionally, expression of different levels of the HMW FGF-2 with an inducible expression system confirmed the role of this isoform on PKC delta and epsilon expressions. Increased activation of ERK-1 and -2 was also observed in cells expressing the HMW FGF-2, By using different PKC inhibitors and a dominant negative PKC delta, it was found that ERK activation was PKC delta -dependent. These data indicate that expression of HMW FGF-2 can modify PKC levels by acting at the intracellular level and that the overexpression of PKC delta induces ERK-1/2 activation. The expression of a dominant negative FGFR1 did not reduce ERK-1/2 activation by the HMW FGF-2, suggesting that ERK activation does not require FGFR activity. The signaling cascade downstream of ERK might be involved in the known mitogenic effect exerted by this FGF-2 isoform.	CHU Rangueil, INSERM U531, ILB, F-31054 Toulouse, France; Univ Calif Irvine, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California Irvine	Clemente, F (corresponding author), CHU Rangueil, INSERM U531, ILB, Bat L3, F-31054 Toulouse, France.		ESCAFFIT, Fabrice/AAE-4832-2021					Arnaud E, 1999, MOL CELL BIOL, V19, P505; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BORNER C, 1992, J BIOL CHEM, V267, P12892; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Delrieu I, 1999, BIOCHEM J, V340, P201, DOI 10.1042/0264-6021:3400201; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; Escaffit F, 2000, INT J CANCER, V85, P555, DOI 10.1002/(SICI)1097-0215(20000215)85:4<555::AID-IJC18>3.0.CO;2-H; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; ESTIVAL A, 1993, CANCER RES, V53, P1182; Estival A, 1996, BIOCHEM J, V315, P619, DOI 10.1042/bj3150619; ESTIVAL A, 1992, GASTROENTEROLOGY, V103, P1851, DOI 10.1016/0016-5085(92)91444-9; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; Gualandris A, 1999, J CELL PHYSIOL, V181, P273, DOI 10.1002/(SICI)1097-4652(199911)181:2<273::AID-JCP9>3.0.CO;2-#; Hrzenjak M, 1997, RECEPT SIGNAL TRANS, V7, P207; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Klein S, 1996, J BIOL CHEM, V271, P22583, DOI 10.1074/jbc.271.37.22583; Lengye E, 1995, ONCOGENE, V11, P2639; Lim YP, 1999, J BIOL CHEM, V274, P19025, DOI 10.1074/jbc.274.27.19025; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Monzat V, 1996, EUR J CELL BIOL, V69, P316; Peters CA, 1999, J BIOL CHEM, V274, P37499, DOI 10.1074/jbc.274.52.37499; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Stachowiak MK, 1997, MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02740663; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Wagner M, 1998, GASTROENTEROLOGY, V114, P798, DOI 10.1016/S0016-5085(98)70594-3; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	51	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1545	1554		10.1074/jbc.M001184200	http://dx.doi.org/10.1074/jbc.M001184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11031252	hybrid			2022-12-25	WOS:000166430900092
J	Hawley, SB; Tamura, T; Miles, LA				Hawley, SB; Tamura, T; Miles, LA			Purification, cloning, and characterization of a profibrinolytic plasminogen-binding protein, TIP49a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUVB-LIKE PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; STRUCTURAL PROTEINS; DNA HELICASE; TUMOR-CELLS; EXPRESSION; ACTIVATION; RECEPTOR; SURFACE; UROKINASE	The plasminogen receptors responsible for enhancing cell surface-dependent plasminogen activation expose COOH-terminal lysines on the cell surface and are sensitive to proteolysis by carboxypeptidase B (CpB). We treated U937 cells with CpB, then subjected membrane fractions to two-dimensional gel electrophoresis followed by ligand blotting with I-125-plasminogen. A 54-kDa protein lost the ability to bind I-125-plasminogen after treatment of intact cells and was purified by two-dimensional gel electrophoresis and then sequenced by mass spectrometry. Two separate amino acid sequences were obtained and were identical to sequences contained within human and rat TIP49a. The cDNA for the 54-kDa protein matched the human TIP49a sequence, and encoded a COOH-terminal lysine, consistent with susceptibility to CpB. Antibodies against rat TIP49a recognized the plasminogen-binding protein on two-dimensional Western blots of U937 cell membranes. Human I-125-Glu-plasminogen bound specifically to TIP49a protein, and binding was inhibited by epsilon -aminocaproic acid. A single class of binding sites was detected, and a K-d of 0.57 +/- 0.14 muM was determined. TIP49a enhanced plasminogen activation 8-fold compared with the BSA control, and this was equivalent to the enhancement mediated by plasmin-treated fibrinogen. These results suggest that TIP49a is a previously unrecognized plasminogen-binding protein on the U937 cell surface.	Scripps Res Inst, Dept Vasc Biol CVN 26, La Jolla, CA 92037 USA; Chiba Univ, Chiba 2638522, Japan	Scripps Research Institute; Chiba University	Miles, LA (corresponding author), Scripps Res Inst, Dept Vasc Biol CVN 26, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038272, R29HL038272, R01HL045934, P01HL031950] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31950, HL45934, HL38272] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1995, NATURE, V377, P3; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; CAMACHO M, 1989, FEBS LETT, V245, P21, DOI 10.1016/0014-5793(89)80183-8; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Dudani AK, 1996, BRIT J HAEMATOL, V95, P168, DOI 10.1046/j.1365-2141.1996.7482367.x; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FELEZ J, 1993, THROMB HAEMOSTASIS, V69, P1232; Felez J, 1996, THROMB HAEMOSTASIS, V76, P577; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Gase K, 1996, EUR J BIOCHEM, V239, P42, DOI 10.1111/j.1432-1033.1996.0042u.x; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; HEYDORN WE, 1985, J NEUROCHEM, V44, P201, DOI 10.1111/j.1471-4159.1985.tb07131.x; Holzmann K, 1998, BIOCHEM BIOPH RES CO, V252, P39, DOI 10.1006/bbrc.1998.9604; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; Kanemaki M, 1997, BIOCHEM BIOPH RES CO, V235, P64, DOI 10.1006/bbrc.1997.6729; KATO K, 1983, CLIN CHIM ACTA, V127, P353, DOI 10.1016/0009-8981(83)90162-6; Kim SO, 1996, J BIOL CHEM, V271, P23761, DOI 10.1074/jbc.271.39.23761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBE RE, 1986, DIFFERENTIATION, V33, P69, DOI 10.1111/j.1432-0436.1986.tb00412.x; LIEPKALNS VA, 1990, J RECEPTOR RES, V10, P333, DOI 10.3109/10799899009064674; Makino Y, 1998, BIOCHEM BIOPH RES CO, V245, P819, DOI 10.1006/bbrc.1998.8504; Makino Y, 1999, J BIOL CHEM, V274, P15329, DOI 10.1074/jbc.274.22.15329; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MILES LA, 1988, J BIOL CHEM, V263, P11928; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NAMIRANIAN S, 1995, BIOCHEM J, V309, P977, DOI 10.1042/bj3090977; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; PLOW EF, 1990, CELL DIFFER DEV, V32, P293, DOI 10.1016/0922-3371(90)90042-U; Qiu XB, 1998, J BIOL CHEM, V273, P27786, DOI 10.1074/jbc.273.43.27786; REDLITZ A, 1995, EUR J BIOCHEM, V227, P407, DOI 10.1111/j.1432-1033.1995.tb20403.x; Salzer U, 1999, BBA-GENE STRUCT EXPR, V1446, P365, DOI 10.1016/S0167-4781(99)00104-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WALLEN P, 1970, BIOCHIM BIOPHYS ACTA, V221, P20, DOI 10.1016/0005-2795(70)90194-7; Winram SB, 1996, MICROBIOL-SGM, V142, P2311, DOI 10.1099/13500872-142-8-2311; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669	44	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					179	186		10.1074/jbc.M004919200	http://dx.doi.org/10.1074/jbc.M004919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027681	hybrid			2022-12-25	WOS:000166280700026
J	Kuboki, Y; Ito, M; Takamatsu, N; Yamamoto, K; Shiba, T; Yoshioka, K				Kuboki, Y; Ito, M; Takamatsu, N; Yamamoto, K; Shiba, T; Yoshioka, K			A scaffold protein in the c-Jun NH2-terminal kinase signaling pathways suppresses the extracellular signal-regulated kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; MITOGEN; ACTIVATION; TRANSDUCTION; INFLAMMATION; CASCADES; STRESS; YEAST; JNK	We previously reported that c-Jun NH2-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 (JSAP1) functions as a putative scaffold factor in the JNK mitogen-activated protein kinase (MAPK) cascades. In that study we also found MEK1 and Raf-1, which are involved in the extracellular signal-regulated kinase (ERK) MAPK cascades, bind to JSAP1. Here we have defined the regions of JSAP1 responsible for the interactions with MEK1 and Raf-1. Both of the binding regions were mapped to the COOH-terminal region (residues 1054-1305) of JSAP1. We next examined the effect of overexpressing JSAP1 on the activation of ERK by phorbol 12-myristate 13-acetate in transfected COS-7 cells and found that JSAP1 inhibits ERK's activation and that the COOH-terminal region of JSAP1 was required for the inhibition. Finally, we investigated the molecular mechanism of JSAP1's inhibitory function and showed that JSAP1 prevents MEK1 phosphorylation and activation by Raf-1, resulting in the suppression of the activation of ERK. Taken together, these results suggest that JSAP1 is involved both in the JNK cascades, as a scaffolding factor, and the ERK cascades, as a suppressor.	Kanazawa Univ, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan; Kitasato Univ, Sch Sci, Dept Biosci, Kanagawa 2288555, Japan	Kanazawa University; Kitasato University	Yoshioka, K (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Pathol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.							CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; HANCOCK JF, 1988, ONCOGENE, V3, P187; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Onishi I, 1997, FEBS LETT, V420, P201, DOI 10.1016/S0014-5793(97)01517-2; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000	19	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39815	39818		10.1074/jbc.C000403200	http://dx.doi.org/10.1074/jbc.C000403200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11044439	hybrid			2022-12-25	WOS:000166039500004
J	Murphy, KL; Dennis, AP; Rosen, JM				Murphy, KL; Dennis, AP; Rosen, JM			A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model	FASEB JOURNAL			English	Article						mutant p53; apoptosis; aneuploidy; centrosome abnormalities	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; SISTER-CHROMATID EXCHANGES; DNA-REPAIR; GENETIC INSTABILITY; TRANSGENIC MICE; MAMMALIAN-CELLS; BINDING PROTEIN; MUTATIONS; EXPRESSION; CANCER	Approximately 40% of human breast cancers contain alterations in the tumor suppressor p53, The p53 172R-H gain-of-function mutant (equivalent to the common 175R-H human breast cancer mutant) has been shown to promote aneuploidy and tumorigenesis in the mammary gland in transgenic mice and may affect genomic stability in part by causing centrosome abnormalities, The precise mechanism of action of these gain-of-function mutants is not well understood, and has been studied primarily in fibroblast cell lines. A novel p53-null mouse mammary epithelial cell line developed from p53-null mice has been used in adenovirus-mediated transient transfection experiments to study the properties of this p53 mutant, Marked centrosome amplification and an increased frequency of aberrant mitoses were observed within 72 h of introduction of p53 172R-H. However, few cells with aberrant centrosome numbers were observed in cells stably expressing the p53 172R-H mutant. Furthermore, stable expression of this p53 mutant reduced both basal and DNA damage-induced apoptosis, This result may be mediated in part through abrogation of p73 function. The p53 172R-H mutant, therefore, appears to influence tumorigenesis at the molecular level in two distinct ways: promoting the development of aneuploidy in cells while also altering their apoptotic response after DNA damage,-Murpby, K. L., Dennis, A. P., Rosen, J. M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Pl, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Agapova LS, 1996, MUTAT RES-FUND MOL M, V354, P129, DOI 10.1016/0027-5107(96)00062-0; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Brown JM, 1999, CANCER RES, V59, P1391; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1997, CANCER SURV, V29, P329; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gersten KM, 1997, NAT GENET, V17, P378, DOI 10.1038/ng1297-378; Gong JG, 1999, NATURE, V399, P806; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Honma M, 1997, MOL CELL BIOL, V17, P4774, DOI 10.1128/MCB.17.8.4774; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KITTRELL FS, 1992, CANCER RES, V52, P1924; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATT SA, 1981, MUTAT RES, V87, P17, DOI 10.1016/0165-1110(81)90003-8; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Li G, 1996, AM J PATHOL, V148, P1113; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; MCNALLY A, 1983, CYTOBIOS, V38, P159; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; Miyazaki M, 1999, CANCER RES, V59, P5283; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; OSBORNE RJ, 1991, CANCER RES, V51, P6194; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; RING D, 1982, J CELL BIOL, V94, P549, DOI 10.1083/jcb.94.3.549; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SMITH ML, 1995, ONCOGENE, V10, P1053; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; Wang CN, 1998, APPL ACOUST, V53, P35, DOI 10.1016/S0003-682X(97)00042-X; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	58	77	82	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2291	2302		10.1096/fj.00-0128com	http://dx.doi.org/10.1096/fj.00-0128com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053251				2022-12-25	WOS:000165190800023
J	Morgan, SE; Kim, R; Wang, PC; Bhat, UG; Kusumoto, H; Lu, TH; Beck, WT				Morgan, SE; Kim, R; Wang, PC; Bhat, UG; Kusumoto, H; Lu, TH; Beck, WT			Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells	ONCOGENE			English	Article						mutant p53; protein stability; teniposide resistance; ionizing radiation	DNA TOPOISOMERASE-II; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; IN-VIVO; GENE-EXPRESSION; UP-REGULATION; BAX GENE; MDM2; BINDING; BCL-2	We examined p53 protein stability and DNA damage-induced p53-dependent responses in a human leukemic CEM cell line and two teniposide-resistant sublines, CEM/VM-1 and CEM/VM-1-5 (similar to 40 and 400-fold resistant to teniposide, respectively). Although all cell lines contain the same p53 mutations at codons 175 (Arg-->His) and 248 (Arg-->Gln), the constitutive levels of p53 were progressively increased with the resistance of the cells to teniposide, By pulse-chase experiments, we found that the half-lives of mutant p53 protein were approximately 12, 17, and >30 h in CEM, CEM/VM-1, and CEM/VM-1-5 cells, respectively. The prolonged half-lives of p53 in these cells is consistent with the fact that the protein harbors the indicated mutations. Of note, however, is the fact that the increased p53 protein half-lives in the two drug-resistant cell lines corresponds to a proportional decrease in MDM2 protein levels but an increase in p53-MDM2 binding interactions. This suggests that MDM2-mediated p53 degradation may be altered in our leukemic cell lines. The DNA damage-induced p53 response is fully functional in the drug-sensitive CEM cells containing a mutant p53, but this pathway is attenuated in the drug-resistant cells. Specifically, while the mutant p53 was phosphorylated at serine-15 in response to ionizing radiation in all these cell lines, mutant p53 induction in response to teniposide or ionizing radiation and induction of the p53-target genes, p21 and GADD45 only occurred in the drug-sensitive CEM cells. As assessed by MTT cytotoxicity assay, CEM cells were also significantly more sensitive to ionizing radiation, compared to the drug-resistant cell lines, and this correlated with p53 induction. Collectively, these results suggest that changes in constitutive mutant p53 protein levels, p53-MDM2 binding interactions, and altered regulation of the DNA damage-inducible p53-dependent pathway may play a role in drug- and radiation-responsiveness in these cells.	Univ Illinois, Dept Mol Genet MC 669, Div Mol Pharmacol, Chicago, IL 60607 USA; Hiroshima Univ, Dept Surg Oncol, Minami Ku, Hiroshima 7348553, Japan; Fukuoka Dent Coll Hosp, Dept Gen Surg, Fukuoka 81401, Japan; St Jude Childrens Res Hosp, Dept Cell & Gene Therapy, Memphis, TN 38101 USA; Univ Illinois, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Hiroshima University; Fukuoka Dental College (FDC); St Jude Children's Research Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Beck, WT (corresponding author), Univ Illinois, Dept Mol Genet MC 669, Div Mol Pharmacol, 900 S Ashland Ave, Chicago, IL 60607 USA.				NATIONAL CANCER INSTITUTE [R01CA030103, R01CA040570] Funding Source: NIH RePORTER; NCI NIH HHS [CA30103, CA40570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon R, 1999, CANCER RES, V59, P6046; Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CHEN M, 1993, CANCER RES, V53, P5946; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DANKS MK, 1993, CANCER RES, V53, P1373; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; DANKS MK, 1987, CANCER RES, V47, P1297; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIM RS, 1994, CANCER RES, V54, P4958; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; KWOK TT, 1994, CANCER RES, V54, P2834; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARK DJ, 1994, ONCOGENE, V9, P1899; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TISHLER RB, 1993, CANCER RES, V53, P2212; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Wang QJ, 1998, CANCER RES, V58, P5762; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1993, ONCOGENE, V8, P2555	51	25	26	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5010	5019		10.1038/sj.onc.1203865	http://dx.doi.org/10.1038/sj.onc.1203865			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042688				2022-12-25	WOS:000089834300008
J	Vial, E; Perez, S; Castellazzi, M				Vial, E; Perez, S; Castellazzi, M			Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors	ONCOGENE			English	Article						v-Jun; Fra2; ATF2; Maf; AP1; SPARC promoter; chick embryo fibroblasts; cell transformation	RAT EMBRYO FIBROBLASTS; C-JUN; CELLULAR-TRANSFORMATION; NEOPLASTIC PROGRESSION; OSTEONECTIN PROMOTER; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; CYSTEINE SPARC; AP-1 FUNCTION; BONE-CELLS	Transformation of chick embryo fibroblasts by the v-Jun oncoprotein correlates with a down-regulation of the extracellular matrix protein SPARC and repression of the corresponding mRNA, Alteration in SPARC expression has been repeatedly reported in human cancers of various origin, and is thought to contribute to the remodeling of the extracellular matrix during neoplastic progression, Transcriptional control of SPARC is poorly understood, We show here that (i) v-Jun-mediated repression of the endogenous SPARC gene is enhanced by Fra2 but alleviated by ATF2, Fra2 and ATF2 being the two major partners of v-Jun in the transformed cells; (ii) high basal activity as well as repression by v-Jun and modulation by Fra2 and ATF2 is restricted to a small proximal fragment (-124/+16) of the chicken SPARC promoter; (iii) the activity of this minimal promoter is modulated by all the AP1 family members known in chickens (c-Jun and JunD; c-Fos and Fra2; ATF2; c-Maf, MafA, and MafB), Taken together these data demonstrate that, at least in avian primary cells, SPARC expression is under the control of the AP1 transcription factor. Further studies with the minimal (-124/+16) promoter fragment are needed to understand how this control takes place at the molecular level.	Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Castellazzi, M (corresponding author), Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, 46 Allee Italie, F-69364 Lyon 07, France.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENJAMIN T, 1990, VIROLOGY, V1, P317; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; Gao MH, 1996, CANCER RES, V56, P4229; Graham JD, 1997, EUR J CANCER, V33, P1654, DOI 10.1016/S0959-8049(97)00182-2; Hafner M, 1995, MATRIX BIOL, V14, P733, DOI 10.1016/S0945-053X(05)80016-2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JURDIC P, 1995, ONCOGENE, V11, P1699; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kilbey A, 1996, ONCOGENE, V12, P2409; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MCVEY JH, 1988, J BIOL CHEM, V263, P11111; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mok SC, 1996, ONCOGENE, V12, P1895; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NOMURA S, 1989, J BIOL CHEM, V264, P12201; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Reed MJ, 1996, CURR TOP MICROBIOL, V213, P81; SAGE H, 1984, J BIOL CHEM, V259, P3993; SONOBE MH, 1995, ONCOGENE, V10, P689; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TIMPL R, 1993, MOL CELLULAR ASPECTS, P211; Ungefroren H, 1998, J BIOL CHEM, V273, P29230, DOI 10.1074/jbc.273.44.29230; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; VOGT PK, 1994, FOS JUN FAMILIES TRA, P203; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; YOUNG MF, 1989, J BIOL CHEM, V264, P450	48	32	32	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5020	5029		10.1038/sj.onc.1203867	http://dx.doi.org/10.1038/sj.onc.1203867			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042689	Bronze			2022-12-25	WOS:000089834300009
J	Du Villard, J; Wicker, R; Crespo, P; Russo, D; Filetti, S; Gutkind, JS; Sarasin, A; Suarez, HG				Du Villard, J; Wicker, R; Crespo, P; Russo, D; Filetti, S; Gutkind, JS; Sarasin, A; Suarez, HG			Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation	ONCOGENE			English	Article						TSHR gene; mouse fibroblasts; transformation; pathways	HUMAN THYROTROPIN RECEPTOR; PROTEIN-COUPLED RECEPTORS; BETA-GAMMA-SUBUNITS; ALPHA-1B-ADRENERGIC RECEPTOR; MALIGNANT TRANSFORMATION; SIGNAL-TRANSDUCTION; GERMLINE MUTATIONS; THYROID CARCINOMAS; KINASE-A; RAS	Constitutive activating mutations of the TSHR gene, have been detected in about 30 per cent of hyperfunctioning human thyroid adenomas and in a minority of differentiated thyroid carcinomas. The mutations activating the TSHR gene(s) in the thyroid carcinomas, were located at the codon 623 changing an Ala to a Ser (GCC-->TCC) or in codon 632 changing a Thr to Ala or Ile (ACC-->GCC or ACC-->ATC). In order to study if the constitutively activated TSHR gene(s) has played a role in the determination of the malignant phenotype presented by these tumors, we investigated: (1) the transforming capacity after transfection of mouse 3T3 cells, of a TSHR cDNA activated by an Ala-->Ser mutation in codon 623 or an Thr-Ile mutation in codon 632 and (2) the pathway(s) eventually responsable(s) for the malignant phenotype of the cells transformed by these constitutively activated TSHR cDNAs, Our results show that (1) the TSHRM623 or(M632) cDNAs give rise to 3T3 clones presenting a fully neoplastic phenotype (growth in agar and nude mouse tumorigenesis); this phenotype was weaker in the cells transformed by the 632 cDNA; (2) suggest that the fully transformed phenotype of our 3T3 cells, may be the consequence of the additive effect of the activation of at least two different pathways: the cAMP pathway through G(alpha s) and the Ras dependent MAPK pathway through G(beta gamma) and PI3K and (3) show that the PI3K isoform playing a key role as an effector in the MAPK pathway activation in our 3T3-transformed cells is PI3K gamma. Signaling from PI3K gamma to MAPK appears to require in our murine cellular system a tyrosine kinase (still not characterized), Shc, Grb2, Sos, Ras and Raf. It is proposed that the constitutively activated TSHR genes detected in the thyroid carcinomas, may have played an oncogenic role, participating in their development through these two pathways.	Inst Rech Canc, CNRS IFR 89, Lab Instabil Genet & Canc, UPR 2169, F-94801 Villejuif, France; Univ Cantabria, Fac Med, Dept Mol Biol, Santander 39011, Spain; Univ Catanzaro, Dip Med Sperimentale & Clin, Cattedra Endocrinol, I-88100 Catanzaro, Italy; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA	Universidad de Cantabria; Magna Graecia University of Catanzaro; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Suarez, HG (corresponding author), Inst Rech Canc, CNRS IFR 89, Lab Instabil Genet & Canc, UPR 2169, 7 Rue Guy Moquet,BP 8, F-94801 Villejuif, France.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DUMONT JE, 1989, METABOLIC BASIS INHE, P555; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Fournes B, 1998, ONCOGENE, V16, P985, DOI 10.1038/sj.onc.1201626; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MICHELIN S, 1991, ONCOGENE, V196, P314; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; RUSSO D, 1995, ONCOGENE, V11, P1907; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; SHARIF M, 1994, MOL CELL ENDOCRINOL, V100, P115, DOI 10.1016/0303-7207(94)90289-5; Spambalg D, 1996, J CLIN ENDOCR METAB, V81, P3898, DOI 10.1210/jc.81.11.3898; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1988, ONCOGENE, V2, P403; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; VAN BT, 1995, NATURE, V376, P781	38	15	16	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4896	4905		10.1038/sj.onc.1203852	http://dx.doi.org/10.1038/sj.onc.1203852			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039907				2022-12-25	WOS:000089757800012
J	Bortner, CD; Gomez-Angelats, M; Cidlowski, JA				Bortner, CD; Gomez-Angelats, M; Cidlowski, JA			Plasma membrane depolarization without repolarization is an early molecular event in anti-Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTWARD POTASSIUM CURRENT; PROGRAMMED CELL-DEATH; HUMAN LYMPHOCYTE-T; GATED K+ CHANNELS; PERMEABILITY TRANSITION; NEURONAL APOPTOSIS; FLOW-CYTOMETRY; AMINO-ACIDS; ION-CHANNEL; X-RAY	The movement of intracellular monovalent cations has previously been shown to play a critical role in events leading to the characteristics associated with apoptosis. A loss of intracellular potassium and sodium occurs during apoptotic cell shrinkage establishing an intracellular environment favorable for nuclease activity and caspase activation. We have now investigated the potential movement of monovalent ions in Jurkat cells that occur prior to cell shrinkage following the induction of apoptosis. A rapid increase in intracellular sodium occurs early after apoptotic stimuli suggesting that the normal negative plasma membrane potential may change during cell death, We report here that diverse apoptotic stimuli caused a rapid cellular depolarization of Jurkat T-cells that occurs prior to and after cell shrinkage. In addition to the early increase in intracellular Na+, Rb-86(+) studies reveal a rapid inhibition of K+ uptake in response to anti-Fas. These effects on Na+ and K+ ions were accounted far by the inactivation of the Na+/K+-ATPase protein and its activity. Furthermore, ouabain, a cardiac glycoside inhibitor of the Na+/K+-ATPase, potentiated anti-Fas-induced apoptosis. Finally, activation of an anti-apoptotic signal, i.e. protein kinase C, prevented both cellular depolarization in response to anti-Pas and all downstream characteristics associated with apoptosis. Thus cellular depolarization is an important early event in anti-Pas-induced apoptosis, and the inability of cells to repolarize via inhibition of the Na+/K+-ATPase is a likely regulatory component of the death process.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				ADEBODUN F, 1993, J CELL PHYSIOL, V154, P199, DOI 10.1002/jcp.1041540123; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Bilney AJ, 1998, FEBS LETT, V424, P221, DOI 10.1016/S0014-5793(98)00172-0; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; Dallaporta B, 1998, J IMMUNOL, V160, P5605; DECKERS CLP, 1993, EXP CELL RES, V208, P362, DOI 10.1006/excr.1993.1257; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DUPRAT F, 1995, P NATL ACAD SCI USA, V92, P11796, DOI 10.1073/pnas.92.25.11796; Ferlini C, 1999, EXP CELL RES, V247, P160, DOI 10.1006/excr.1998.4343; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; Gilbert MS, 1996, J CELL PHYSIOL, V168, P114; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; HACKING C, 1981, BIOCHEM J, V194, P415, DOI 10.1042/bj1940415; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Inai Y, 1997, CELL STRUCT FUNCT, V22, P555, DOI 10.1247/csf.22.555; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JONAS D, 1994, INFECT IMMUN, V62, P1304, DOI 10.1128/IAI.62.4.1304-1312.1994; JONES GS, 1981, J CELL PHYSIOL, V106, P75, DOI 10.1002/jcp.1041060109; KALLEN RG, 1993, MOL NEUROBIOL, V7, P383, DOI 10.1007/BF02769184; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LONGO N, 1991, AM J PHYSIOL, V260, pC1341; Marakhova II, 1998, BBA-BIOMEMBRANES, V1368, P61, DOI 10.1016/S0005-2736(97)00164-8; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; PHILO RD, 1978, BIOCHEM J, V174, P801, DOI 10.1042/bj1740801; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SENN N, 1989, AM J PHYSIOL, V257, pC12, DOI 10.1152/ajpcell.1989.257.1.C12; Szabo I, 1997, PFLUG ARCH EUR J PHY, V433, P626, DOI 10.1007/s004240050323; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; WILLMAN CL, 1989, SEMIN DIAGN PATHOL, V6, P3; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Yu SP, 1998, NEUROBIOL DIS, V5, P81, DOI 10.1006/nbdi.1998.0186; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	48	141	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4304	4314		10.1074/jbc.M005171200	http://dx.doi.org/10.1074/jbc.M005171200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050080	hybrid			2022-12-25	WOS:000166921200077
J	Ammanamanchi, S; Brattain, MG				Ammanamanchi, S; Brattain, MG			Sp3 is a transcriptional repressor of transforming growth factor-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; HUMAN GASTRIC-CANCER; TGF-BETA; II RECEPTOR; MCF-7 CELLS; SP-FAMILY; EXPRESSION; ACTIVATION; RESISTANCE; PROMOTER	MCF-7E breast cancer cells express transforming growth factor-beta (TGF-beta) receptors RI and RII in comparison to MCF-7L cells. We present data showing that Sp3 acts as a transcriptional repressor of RI and RII in MCF-7L cells and GEO colon cancer cells. MCF-7L and GEO cells express high levels of Sp3 protein. Gel shift analysis indicated enhanced binding of Sp3 from MCF-7L cells to a consensus Spl oligonucleotide. Southwestern data indicated increased binding of Sp3 to RI and RII promoters in MCF-7L cells, suggesting a correlation between Sp3 binding and reduced expression of TGF-P receptors in MCF-7L cells. Cotransfection of CMV-Sp3 cDNA with RI and RII promoter-luciferase reporter constructs decreased RI and RII promoter activities by 70% in MCF-7E and GEO cells. Southwestern analysis detected the binding of transiently expressed Sp3 to RI and RII promoters in MCF-7E cells. Significantly, ectopic Sp3 expression led to repression of RI and RII transcripts in MCF-7E cells. This report demonstrates that inappropriate overexpression of Sp3 is a mechanism that contributes to repression of TGF-beta receptors.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Brattain, MG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL CANCER INSTITUTE [R37CA038173, R01CA072001, R01CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72001, CA 38173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kim DH, 1997, J BIOL CHEM, V272, P688; Ko Y, 1998, J CELL PHYSIOL, V176, P424, DOI 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.3.CO;2-N; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	29	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3348	3352		10.1074/jbc.M002462200	http://dx.doi.org/10.1074/jbc.M002462200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11027677	hybrid			2022-12-25	WOS:000166784900049
J	Wugeditsch, T; Paiment, A; Hocking, J; Drummelsmith, J; Forrester, C; Whitfield, C				Wugeditsch, T; Paiment, A; Hocking, J; Drummelsmith, J; Forrester, C; Whitfield, C			Phosphorylation of Wzc, a tyrosine autokinase, is essential for assembly of group 1 capsular polysaccharides in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-PROTEIN PHOSPHATASE; GRAM-NEGATIVE BACTERIA; LIPID A-CORE; CHAIN-LENGTH; MOLECULAR CHARACTERIZATION; GENE-CLUSTER; AUTOPHOSPHORYLATING PROTEIN; STREPTOCOCCUS-PNEUMONIAE; ACINETOBACTER-JOHNSONII; STAPHYLOCOCCUS-AUREUS	Wzc proteins are tyrosine autokinases, They are found in some important bacterial pathogens of humans and livestock as well as plant-associated bacteria, and are often encoded within gene clusters determining synthesis and assembly of capsular and extracellular polysaccharides, Autophosphorylation of Wzc(cps) is essential for assembly of the serotype K30 group 1 capsule in Escherichia coli O9a:K30, although a genetically unlinked Wzc(cps)-homologue (Etk) can also participate with low efficiency. While autophosphorylation of Wzc(cps) is required for assembly of high molecular weight K30 capsular polysaccharide, it is not essential for either the synthesis of the K30 repeat units or for activity of the K30 polymerase enzyme. Paradoxically, the cognate phosphotyrosine protein phosphatase for Wzc(cps), Wzb(cps), is also required for capsule expression. The tyrosine-rich domain at the C terminus of Wzc(cps) was identified as the site of phosphorylation and autophosphorylation of Wzc requires a functional Walker A motif, Intermolecular transphosphorylation of Wzc(cps) was detected in strains expressing a combination of mutant Wzc(cps) derivatives. The N- and C-terminal domains of Wzc(cps) were expressed independently to mimic the situation found naturally in Gram-positive bacteria. In this format, both domains were required for phosphorylation of the Wzc(cps) C terminus, and for capsule assembly. Regulation by a post-translational phosphorylation event represents a new dimension in the assembly of bacterial cell-surface polysaccharides.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	University of Guelph	Wugeditsch, T (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.							Amor PA, 1997, MOL MICROBIOL, V26, P145, DOI 10.1046/j.1365-2958.1997.5631930.x; Becker A, 1998, J BACTERIOL, V180, P395, DOI 10.1128/JB.180.2.395-399.1998; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P3172, DOI 10.1021/bi00010a006; Cieslewicz M, 1997, MOL MICROBIOL, V26, P237, DOI 10.1046/j.1365-2958.1997.5651942.x; Daniels C, 1999, MOL MICROBIOL, V34, P181, DOI 10.1046/j.1365-2958.1999.01591.x; Dodgson C, 1996, J BACTERIOL, V178, P1895, DOI 10.1128/jb.178.7.1895-1902.1996; Doublet P, 1999, FEBS LETT, V445, P137, DOI 10.1016/S0014-5793(99)00111-8; Drummelsmith J, 1999, MOL MICROBIOL, V31, P1321, DOI 10.1046/j.1365-2958.1999.01277.x; Drummelsmith J, 2000, EMBO J, V19, P57, DOI 10.1093/emboj/19.1.57; Duclos B, 1996, J MOL BIOL, V259, P891, DOI 10.1006/jmbi.1996.0366; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; Franco AV, 1998, J BACTERIOL, V180, P2670, DOI 10.1128/JB.180.10.2670-2675.1998; Gonzalez JE, 1998, P NATL ACAD SCI USA, V95, P13477, DOI 10.1073/pnas.95.23.13477; GOTTESMAN S, 1995, 2 COMPONENT SIGNAL T, P253; Grangeasse C, 1997, GENE, V204, P259, DOI 10.1016/S0378-1119(97)00554-4; Grangeasse C, 1998, J MOL BIOL, V278, P339, DOI 10.1006/jmbi.1998.1650; GUIDOLIN A, 1994, INFECT IMMUN, V62, P5384, DOI 10.1128/IAI.62.12.5384-5396.1994; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Ilan O, 1999, EMBO J, V18, P3241, DOI 10.1093/emboj/18.12.3241; Klee SR, 1997, J BACTERIOL, V179, P2421, DOI 10.1128/jb.179.7.2421-2425.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WS, 1994, J BACTERIOL, V176, P7005, DOI 10.1128/JB.176.22.7005-7016.1994; MACLACHLAN PR, 1993, J BACTERIOL, V175, P7515, DOI 10.1128/JB.175.23.7515-7522.1993; Morona JK, 1999, J BACTERIOL, V181, P3599, DOI 10.1128/JB.181.11.3599-3605.1999; Morona JK, 2000, MOL MICROBIOL, V35, P1431, DOI 10.1046/j.1365-2958.2000.01808.x; Morona R, 2000, MICROBIOL-UK, V146, P1, DOI 10.1099/00221287-146-1-1; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; Rahn A, 1999, J BACTERIOL, V181, P2307, DOI 10.1128/JB.181.7.2307-2313.1999; RUBENS CE, 1993, MOL MICROBIOL, V8, P843, DOI 10.1111/j.1365-2958.1993.tb01631.x; Sau S, 1997, MICROBIOL-UK, V143, P2395, DOI 10.1099/00221287-143-7-2395; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; vanKranenburg R, 1997, MOL MICROBIOL, V24, P387, DOI 10.1046/j.1365-2958.1997.3521720.x; Vincent C, 1999, J BACTERIOL, V181, P3472, DOI 10.1128/JB.181.11.3472-3477.1999; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WHITFIELD C, 1986, FEMS MICROBIOL LETT, V37, P351, DOI 10.1111/j.1574-6968.1986.tb01823.x; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; Yamamoto S, 1999, J BACTERIOL, V181, P5176, DOI 10.1128/JB.181.17.5176-5184.1999; Zhang ZY, 1997, BIOCHEMISTRY-US, V36, P1362, DOI 10.1021/bi9624043; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	46	151	158	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2361	2371		10.1074/jbc.M009092200	http://dx.doi.org/10.1074/jbc.M009092200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053445	hybrid			2022-12-25	WOS:000166784800011
J	Wolfe, MD; Parales, JV; Gibson, DT; Lipscomb, JD				Wolfe, MD; Parales, JV; Gibson, DT; Lipscomb, JD			Single turnover chemistry and regulation of O-2 activation by the oxygenase component of naphthalene 1,2-dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-METHOXYBENZOATE O-DEMETHYLASE; DIOXYGEN ACTIVATION; NITRIC-OXIDE; ACTIVE-SITE; METHANE MONOOXYGENASE; PROTOCATECHUATE 4,5-DIOXYGENASE; CATECHOL 2,3-DIOXYGENASE; PSEUDOMONAS-PUTIDA; SUBSTRATE-BINDING; AMINO-ACIDS	Naphthalene 1,2 dioxygenase (NDOS) is a three-component enzyme that catalyzes cis-(1R,2S)-dihydroxy-1,2-dihydronaphthalene formation from naphthalene, O-2, and NADH, We have determined the conditions for a single turnover of NDOS for the first time and studied the regulation of catalysis. As isolated, the alpha (3)beta (3) oxygenase component (NDO) has up to three catalytic pairs of metal centers tone mononuclear Fe2+ and one diferric Rieske iron-sulfur cluster). This form of NDO is unreactive with O-2. However, upon reduction of the Rieske cluster and exposure to naphthalene and O-2, similar to0.85 cis-diol product per occupied mononuclear iron site rapidly forms. Substrate binding is required for oxygen reactivity. Stopped-flow and chemical quench analyses indicate that the rate constant of the single turnover product-forming reaction significantly exceeds the NDOS turnover number. UV-visible and electron paramagnetic resonance spectroscopies show that during catalysis, one mononuclear iron and one Rieske cluster are oxidized per product formed, satisfying the two-electron reaction stoichiometry. The addition of oxidized or reduced NDOS ferredoxin component (NDF) increases both the product yield and rate of oxidation of formerly unreactive Rieske clusters. The results show that NDO alone catalyzes dioxygenase chemistry, whereas NDF appears to serve only an electron transport role, in this case redistributing electrons to competent active sites.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Met Biocatalysis, Minneapolis, MN 55455 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Ctr Biocatalysis & Bioproc, Iowa City, IA 52242 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Iowa; University of Iowa	Lipscomb, JD (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St, Minneapolis, MN 55455 USA.	lipsc001@tc.umn.edu		Lipscomb, John/0000-0002-8158-5594	NIGMS NIH HHS [GM29909, GM24689, R37 GM024689, GM08277, R01 GM024689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024689, R01GM024689, T32GM008277, R01GM029909] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1970, J CHEM PHYS, V52, P3919, DOI 10.1063/1.1673591; AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ARCIERO DM, 1983, J BIOL CHEM, V258, P4981; ARCIERO DM, 1985, J BIOL CHEM, V260, P4035; Ballou D, 1988, Prog Clin Biol Res, V274, P211; BATIE CJ, 1990, METHOD ENZYMOL, V188, P61; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; BERNHARD.FH, 1973, EUR J BIOCHEM, V35, P126, DOI 10.1111/j.1432-1033.1973.tb02818.x; BERNHARDT FH, 1975, BIOCHEM SOC T, V3, P878; BERNHARDT FH, 1980, BIOCHEM BIOPH RES CO, V93, P1247, DOI 10.1016/0006-291X(80)90623-3; BERNHARDT FH, 1981, EUR J BIOCHEM, V120, P547, DOI 10.1111/j.1432-1033.1981.tb05735.x; Bertini I, 1996, COORDIN CHEM REV, V151, P145, DOI 10.1016/S0010-8545(96)90203-9; BILL E, 1981, EUR J BIOCHEM, V121, P39, DOI 10.1111/j.1432-1033.1981.tb06426.x; Boyd DR, 1998, NAT PROD REP, V15, P309; Butler CS, 1997, ADV MICROB PHYSIOL, V38, P47; Carredano E, 2000, J MOL BIOL, V296, P701, DOI 10.1006/jmbi.1999.3462; Chen K, 1999, ANGEW CHEM INT EDIT, V38, P2227, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2227::AID-ANIE2227>3.0.CO;2-B; Chen K, 1999, CHEM COMMUN, P1375, DOI 10.1039/a901678c; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; ENSLEY BD, 1982, J BACTERIOL, V149, P948, DOI 10.1128/JB.149.3.948-954.1982; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; GASSNER GT, 1993, BIOCHEMISTRY-US, V32, P4820, DOI 10.1021/bi00069a017; Gibson DT, 2000, CURR OPIN BIOTECH, V11, P236, DOI 10.1016/S0958-1669(00)00090-2; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; HAIGLER BE, 1990, J BACTERIOL, V172, P465, DOI 10.1128/JB.172.1.465-468.1990; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; Ho RYN, 1999, CHEM COMMUN, P2161, DOI 10.1039/a905535e; Hudlicky T, 1999, ALDRICHIM ACTA, V32, P35; JEFFREY AM, 1975, BIOCHEMISTRY-US, V14, P575, DOI 10.1021/bi00674a018; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; Kim C, 1997, J AM CHEM SOC, V119, P5964, DOI 10.1021/ja9642572; Lau PCK, 1999, ENVIRON SCI TECHNOL, V33, p124A, DOI 10.1021/es9926865; Lee K, 1999, J BACTERIOL, V181, P2719, DOI 10.1128/JB.181.9.2719-2725.1999; Lee K, 1997, APPL ENVIRON MICROB, V63, P2067, DOI 10.1128/AEM.63.5.2067-2070.1997; LEE K, 1995, THESIS U IOWA; Lee KU, 1997, BIOCHEM BIOPH RES CO, V241, P553, DOI 10.1006/bbrc.1997.7863; LEE MH, 1994, BIOCHEMISTRY-US, V33, P3679, DOI 10.1021/bi00178a026; LEE SK, 1993, J BIOL CHEM, V268, P21569; LIPSCOMB JD, 1992, MET IONS BIOL SYST, V28, P243; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; LIU Y, 1995, J BIOL CHEM, V270, P24662, DOI 10.1074/jbc.270.42.24662; Parales RE, 2000, J BACTERIOL, V182, P1641, DOI 10.1128/JB.182.6.1641-1649.2000; Parales RE, 1999, J BACTERIOL, V181, P1831, DOI 10.1128/JB.181.6.1831-1837.1999; Pavel E G, 1994, Chem Biol, V1, P173, DOI 10.1016/1074-5521(94)90007-8; Que L, 2000, NAT STRUCT BIOL, V7, P182, DOI 10.1038/73270; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; Radi R, 1996, CHEM RES TOXICOL, V9, P828, DOI 10.1021/tx950176s; Resnick SM, 1996, J IND MICROBIOL BIOT, V17, P438, DOI 10.1007/BF01574775; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; SUEN WC, 1993, J BACTERIOL, V175, P5877, DOI 10.1128/JB.175.18.5877-5881.1993; SUEN WC, 1991, THESIS U IOWA; Timmis KN, 1999, TRENDS BIOTECHNOL, V17, P201, DOI 10.1016/S0167-7799(98)01295-5; TYSON CA, 1972, J BIOL CHEM, V247, P5777; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; WENDE P, 1989, EUR J BIOCHEM, V181, P189, DOI 10.1111/j.1432-1033.1989.tb14710.x; WHITTAKER JW, 1990, METHOD ENZYMOL, V188, P82; Wolfe MD, 1999, J INORG BIOCHEM, V74, P339; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3; Zang Y, 1997, J AM CHEM SOC, V119, P4197, DOI 10.1021/ja9638521	65	159	159	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1945	1953		10.1074/jbc.M007795200	http://dx.doi.org/10.1074/jbc.M007795200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11056161	hybrid			2022-12-25	WOS:000166528000042
J	Galanis, A; Yang, SH; Sharrocks, AD				Galanis, A; Yang, SH; Sharrocks, AD			Selective targeting of MAPKs to the ETS domain transcription factor SAP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; C-JUN; MAMMALIAN-CELLS; CELLULAR STRESSES; DOCKING SITES; SPECIFICITY; CYTOKINES; PATHWAYS; ELK-1; MKK6	MAPK pathways play important roles in regulating the key cellular processes of proliferation, differentiation, and apoptosis, There are multiple MAPK pathways, which are subject to different regulatory cues. It is important that these pathways maintain specificity in sig naling to elicit the activation of a specific program of gene expression. MAPK-docking domains in several transcription factors have been shown to play important roles in determining the specificity and efficiency of their phosphorylation by MAPKs. Here we investigate the mechanisms by which MAPKs are targeted to the ETS domain transcription factor SAP-I. We demonstrate that SAP-1 contains two different domains that are required for its efficient phosphorylation in vitro and activation in vivo by ERK2 and a subset of p38 MAPKs. The D-domain is closely related to other MAPK-docking domains, but exhibits a novel specificity and serves to promote selective targeting of ERK2, p38 alpha, and p38 beta (2) to SAP-1. A second important region, the FXF motif, also plays an important role in directing MAPKs to phosphorylate SAP-1. The FXF motif promotes targeting by ERK2 and, to a lesser extent, p38 alpha, but not p38 beta (2). Our data therefore demonstrate that a modular system of motifs is responsible for directing specific MAPK subtypes to SAP-1, but also point to important distinctions in the mechanism of action of the D-domain and FXF motif.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Newcastle Upon Tyne, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Manchester; Newcastle University - UK	Sharrocks, AD (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Blvd,Oxford Rd, Manchester M13 9PT, Lancs, England.		Galanis, Alex/ABF-4762-2020	Galanis, Alex/0000-0001-9991-3173				Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAI TN, 1995, ONCOGENE, V10, P849; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Pawson T, 2000, GENE DEV, V14, P1027; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SETH A, 1992, J BIOL CHEM, V267, P24796; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WHITMARSH AJ, 1998, SCIENCE, V17, P2360; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; YANG SH, 1999, GENE THER MOL BIOL, V3, P355	35	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					965	973		10.1074/jbc.M007697200	http://dx.doi.org/10.1074/jbc.M007697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11029469	hybrid			2022-12-25	WOS:000166430900016
J	Li, M; Shillinglaw, W; Henzel, WJ; Beg, AA				Li, M; Shillinglaw, W; Henzel, WJ; Beg, AA			The RelA(p65) subunit of NF-kappa B is essential for inhibiting double-stranded RNA-induced cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DEPENDENT PROTEIN-KINASE; INDUCED CELL-DEATH; INDUCED APOPTOSIS; EMBRYONIC LETHALITY; FACTOR RECEPTOR; CD95 FAS/APO-1; CASPASES; ACTIVATION; VIRUS	Double-stranded RNA (dsRNA) molecules generated during virus infection can initiate a host antiviral response to limit further infection. Such a response involves induction of antiviral gene expression by the dsRNA-activated protein kinase (PKR) and the NF-kappaB transcription factor. In addition, dsRNA can also induce apoptosis by an incompletely understood mechanism that may servo to further limit viral replication. Here we demonstrate a novel role for the RelA subunit of NF-KB in inhibiting dsRNA-induced cell death, dsRNA treatment resulted in caspase 3 activation and apoptotic morphological transformations in mouse embryonic fibroblasts (MEFs) derived from RelA-/- mice but not from RelA+/- mice. Such dsRNA-induced killing could be inhibited by expression of either a dominant-negative mutant of PKR or wild-type RelA Interestingly, caspase 3 activated following dsRNA treatment of RelA-/- MEFs was essential for apoptotic nuclear changes but dispensable for cytotoxicity. A broader specificity caspase inhibitor was also unable to inhibit dsRNA-induced cytotoxicity, suggesting that caspase activation is not essential for the induction of cell death by dsRNA in MEFs. However, combined inhibition of caspase 3 and reactive oxygen species production resulted in complete inhibition of dsRNA-induced cytotoxicity. These results demonstrate an essential role for NF-kappaB in protecting cells from dsRNA-induced apoptosis and suggest that NF-kappaB may inhibit both caspase-dependent and reactive oxygen species-dependent cytotoxic pathways.	Columbia Univ, Dept Biol Sci, Fairchild Ctr 1110, New York, NY 10027 USA; Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA	Columbia University; Roche Holding; Genentech	Beg, AA (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild Ctr 1110, 1212 Amsterdam Ave, New York, NY 10027 USA.			Henzel, William/0000-0003-2940-3797; li, ming/0000-0002-1383-0535	NCI NIH HHS [R01 CA074892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074892] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADERKA D, 1985, CELL IMMUNOL, V92, P218, DOI 10.1016/0008-8749(85)90003-6; Aranda M, 1998, VIROLOGY, V243, P261, DOI 10.1006/viro.1998.9032; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gil J, 1999, MOL CELL BIOL, V19, P4653; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li M, 2000, J VIROL, V74, P7470, DOI 10.1128/JVI.74.16.7470-7477.2000; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MIURA M, 1992, P NATL ACAD SCI USA, V92, P8218; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Schwarz EM, 1998, J VIROL, V72, P5654, DOI 10.1128/JVI.72.7.5654-5660.1998; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	61	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1185	1194		10.1074/jbc.M006647200	http://dx.doi.org/10.1074/jbc.M006647200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035014	hybrid			2022-12-25	WOS:000166430900046
J	Olin, AI; Morgelin, M; Sasaki, T; Timpl, R; Heinegard, D; Aspberg, A				Olin, AI; Morgelin, M; Sasaki, T; Timpl, R; Heinegard, D; Aspberg, A			The proteoglycans aggrecan and versican form networks with fibulin-2 through their lectin domain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX PROTEINS; ELECTRON-MICROSCOPY; CALCIUM-BINDING; CARTILAGE PROTEOGLYCANS; CELL-ADHESION; TENASCIN-R; EXPRESSION; BRAIN; MOUSE	Aggrecan, versican, neurocan, and brevican are important components of the extracellular matrix in various tissues. Their amino-terminal globular domains bind to hyaluronan, but the function of their carboxyl-terminal globular domains has long remained elusive. A picture is now emerging where the C-type lectin motif of this domain mediates binding to other extracellular matrix proteins. We here demonstrate that aggrecan, versican, and brevican lectin domains bind fibulin-2, whereas neurocan does not. As expected for a C-type lectin, the interactions are calcium-dependent, with K-D values in the nanomolar range as measured by surface plasmon resonance. Solid phase competition assays with previously identified ligands demonstrated that fibulin-2 and tenascin-a bind the same site on the proteoglycan lectin domains. Fibulin-1 has affinity for the common site on versican but may bind to a different site on the aggrecan lectin domain, By using deletion mutants, the interaction sites for aggrecan and versican lectin domains were mapped to epidermal growth factor-like repeats in domain II of fibulin-2. Affinity chromatography and solid phase assays confirmed that also native full-length aggrecan and versican bind the lectin domain ligands, Electron microscopy confirmed the mapping and demonstrated that hyaluronan-aggrecan complexes can be cross-linked by the fibulins.	Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, SE-22184 Lund, Sweden; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Lund University; Max Planck Society	Aspberg, A (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, BMC Plan C12, SE-22184 Lund, Sweden.			Aspberg, Anders/0000-0002-6588-6944				ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; DOEGE K, 1987, J BIOL CHEM, V262, P17757; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; FALTZ LL, 1979, J BIOL CHEM, V254, P1375; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; Henderson DJ, 1998, CIRC RES, V83, P523, DOI 10.1161/01.RES.83.5.523; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KLUGE M, 1990, EUR J BIOCHEM, V193, P651, DOI 10.1111/j.1432-1033.1990.tb19383.x; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Maroudas A, 1979, ADULT ARTICULAR CART, P215; Miosge N, 1998, CELL MOL LIFE SCI, V54, P606, DOI 10.1007/s000180050188; Miosge N, 1996, HISTOCHEM J, V28, P109, DOI 10.1007/BF02331415; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; RAUCH U, 1992, J BIOL CHEM, V267, P19536; Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905; RAUCH U, 1991, J BIOL CHEM, V266, P14785; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sasaki T, 1996, J CELL SCI, V109, P2895; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1997, EMBO J, V16, P3035, DOI 10.1093/emboj/16.11.3035; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 1996, PERSPECT DEV NEUROBI, V3, P307; Yamamura H, 1997, DEV BIOL, V186, P58, DOI 10.1006/dbio.1997.8559; Zhang HY, 1996, DEV DYNAM, V205, P348, DOI 10.1002/(SICI)1097-0177(199603)205:3<348::AID-AJA13>3.0.CO;2-0; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	48	166	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1253	1261		10.1074/jbc.M006783200	http://dx.doi.org/10.1074/jbc.M006783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038354	hybrid			2022-12-25	WOS:000166430900054
J	Santolini, J; Adak, S; Curran, CML; Stuehr, DJ				Santolini, J; Adak, S; Curran, CML; Stuehr, DJ			A kinetic simulation model that describes catalysis and regulation in nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOPPED-FLOW ANALYSIS; L-ARGININE; ELECTRON-TRANSFER; NO SYNTHASE; SUPEROXIDE GENERATION; FEEDBACK INHIBITION; LOW-TEMPERATURE; HEME; SUBSTRATE; TETRAHYDROBIOPTERIN	After initiating NO synthesis a majority of neuronal NO synthase (nNOS) quickly partitions into a ferrous heme-NO complex. This down-regulates activity and increases enzyme K-m,K-O2. To understand this process, we developed a 10-step kinetic model in which the ferric heme-NO enzyme forms as the immediate product of catalysis, and then partitions between NO dissociation versus reduction to a ferrous heme-NO complex. Rate constants used for the model were derived from recent literature or were determined here. Computer simulations of the model precisely described both pre-steady and steady-state features of nNOS catalysis, including NADPH consumption and NO production, buildup of a heme-NO complex, changes between pre-steady and steady-state rates, and the change in enzyme K-m,K-O2 in the presence or absence of NO synthesis. The model also correctly simulated the catalytic features of nNOS mutants W409F and W409Y, which are hyperactive and display less heme-NO complex formation in the steady state. Model simulations showed how the rate of heme reduction influences several features of nNOS catalysis, including populations of NO-bound versus NO-free enzyme in the steady state and the rate of NO synthesis. The simulation predicts that there is an optimum rate of heme reduction that is close to the measured rate in nNOS, Ratio between NADPH consumption and NO synthesis is also predicted to increase with faster heme reduction. Our kinetic model is an accurate and versatile tool for understanding catalytic behavior and will provide new perspectives on NOS regulation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Santolini, Jerome/0000-0001-8919-112X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 1999, BIOCHEMISTRY-US, V38, P12446, DOI 10.1021/bi990698x; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; ADAK S, 2001, J BIOL CHEM, V276, P10118; Andersen JF, 2000, BIOCHEMISTRY-US, V39, P10118, DOI 10.1021/bi000766b; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FREY C, 1994, J BIOL CHEM, V269, P26083; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gorren ACF, 2000, BIOCHEM J, V347, P475, DOI 10.1042/0264-6021:3470475; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEMMENS B, 1997, METHOD MOL BIOL, V100, P1; HEVEL JM, 1993, ADV EXP MED BIOL, V338, P285; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Iwanaga T, 1999, BIOCHEMISTRY-US, V38, P16629, DOI 10.1021/bi991277i; Kominami S, 1999, J BIOCHEM-TOKYO, V126, P756, DOI 10.1093/oxfordjournals.jbchem.a022513; LINCOLN J, 1997, NITRIC OXIDE HLTH DI, P27; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Nishimura JS, 1999, J BIOL CHEM, V274, P5399, DOI 10.1074/jbc.274.9.5399; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Rengasamy A, 1996, J PHARMACOL EXP THER, V276, P30; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1999, BIOCHIM BIOPHYS ACTA, V1411, P2146; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; WANG J, 1994, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705	63	81	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1233	1243		10.1074/jbc.M006858200	http://dx.doi.org/10.1074/jbc.M006858200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038356	hybrid			2022-12-25	WOS:000166430900052
J	Smith, JJ; Rachubinski, RA				Smith, JJ; Rachubinski, RA			A role for the peroxin Pex8p in Pex20p-dependent thiolase import into peroxisomes of the yeast Yarrowia lipolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; MATRIX PROTEIN; PTS1 RECEPTOR; MEMBRANE; GENE; BIOGENESIS; ENCODES; IDENTIFICATION; PROLIFERATION	Peroxins are proteins required for peroxisome assembly. The cytosolic peroxin Pex20p binds directly to the beta -oxidation enzyme thiolase and is necessary for its dimerization and peroxisomal targeting. The intraperoxisomal peroxin Pex8p has a role in the import of peroxisomal matrix proteins, including thiolase. We report the results of yeast two-hybrid analyses with various peroxins of the yeast Yarrowia lipolytica and characterize more fully the interaction between Pex8p and Pex20p. Coimmunoprecipitation showed that Pex8p and Pex20p form a complex, while in vitro binding studies demonstrated that the interaction between Pex8p and Pex20p is specific, direct, and autonomous. Pex8p fractionates with peroxisomes in cells of a PEX20 disruption strain, indicating that Pex20p is not necessary for the targeting of Pex8p to peroxisomes. In cells of a PEX8 disruption strain, thiolase is mostly cytosolic, while Pex20p and a small amount of thiolase associate with peroxisomes, suggesting the involvement of Pex8p in the import of thiolase after docking of the Pex20p-thiolase complex to the membrane. In the absence of Pex8p, peroxisomal thiolase and Pex20p are protected from the action of externally added protease. This finding, together with the fact that Pex8p is intraperoxisomal, suggests that Pex20p may accompany thiolase into peroxisomes during import.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, 5-14 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca						Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; DEVORE JL, 1987, PROBABILITY STAT ENG, P340; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Eitzen GA, 1996, J BIOL CHEM, V271, P20300, DOI 10.1074/jbc.271.34.20300; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; EITZEN GA, 1995, J BIOL CHEM, V270, P1429, DOI 10.1074/jbc.270.3.1429; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; Gotte K, 1998, MOL CELL BIOL, V18, P616; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LIU H, 1995, J BIOL CHEM, V270, P10940, DOI 10.1074/jbc.270.18.10940; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; NUTTLEY WM, 1994, J BIOL CHEM, V269, P556; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Smith JJ, 1997, MOL CELL BIOL, V17, P2511, DOI 10.1128/MCB.17.5.2511; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Titorenko VI, 1996, J BIOL CHEM, V271, P20307, DOI 10.1074/jbc.271.34.20307; Titorenko VI, 1998, J CELL BIOL, V142, P403, DOI 10.1083/jcb.142.2.403; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737	34	35	36	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1618	1625		10.1074/jbc.M005072200	http://dx.doi.org/10.1074/jbc.M005072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042200	hybrid			2022-12-25	WOS:000166430900101
J	Cho, H; Nam, GB; Lee, SH; Earm, YE; Ho, WK				Cho, H; Nam, GB; Lee, SH; Earm, YE; Ho, WK			Phosphatidylinositol 4,5-bisphosphate is acting as a signal molecule in alpha(1)-adrenergic pathway via the modulation of acetylcholine-activated K+ channels in mouse atrial myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED PHOSPHORYLATION; TONIC VAGAL-STIMULATION; G-BETA-GAMMA; MUSCARINIC RECEPTORS; POTASSIUM CHANNELS; ATP CHANNELS; CELLS; DESENSITIZATION; PIP2; MEMBRANE	We have investigated the effect of alpha (1)-adrenergic agonist phenylephrine (PE) on acetylcholine-activated K+ currents (I-KACh). I-KACh was recorded in mouse atrial myocytes using the patch clamp technique. I-KACh was activated by 10 muM ACh and the current decreased by 44.27 +/- 2.38% (n = 12) during 4 min due to ACh-induced desensitization. When PE was applied with ACh, the extent of desensitization was markedly increased to 69.34 +/- 2.22% (n = 9), indicating the presence of PE-induced desensitization, I-KACh was fully recovered from desensitization after a 6-min washout. PE-induced desensitization of I-KACh was not affected by protein kinase C inhibitor, calphostin C, but abolished by phospholipase C (PLC) inhibitor, neomycin, When phophatidylinositol 4,5-bisphosphate (PIP2) replenishment was blocked by wortmannin (an inhibitor of phophatidylinositol 3-kinase and phophatidylinositol 4-kinase), desensitization of I,,, in the presence of PE was further increased (97.25 +/- 7.63%, n = 6), Furthermore, the recovery from PE-induced desensitization was inhibited, and the amplitude of I,, at the second exposure after washout was reduced to 19.65 +/- 2.61% (n = 6) of the preceding level. These data suggest that the K-ACh, channel is modulated by PE through PLC stimulation and depletion of PIP2.	Seoul Natl Univ, Coll Med, Dept Physiol & Biophys, Chongno Ku, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Natl Res Lab Cellular Signalling, Seoul 110799, South Korea; Asan Med Ctr, Dept Internal Med, Seoul 138140, South Korea	Seoul National University (SNU); Seoul National University (SNU); University of Ulsan; Asan Medical Center	Ho, WK (corresponding author), Seoul Natl Univ, Coll Med, Dept Physiol & Biophys, Chongno Ku, 28 Yonkeun Dong, Seoul 110799, South Korea.		Ho, Won-Kyung/J-2798-2012; Lee, Suk-Ho/D-6344-2012	Lee, Suk-Ho/0000-0003-4117-5619				Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BOYETT MR, 1987, J PHYSIOL-LONDON, V393, P171, DOI 10.1113/jphysiol.1987.sp016818; BOYETT MR, 1988, J PHYSIOL-LONDON, V404, P613, DOI 10.1113/jphysiol.1988.sp017309; BRAUN AP, 1992, PFLUG ARCH EUR J PHY, V421, P431, DOI 10.1007/BF00370253; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CARMELIET E, 1986, J PHYSIOL-LONDON, V371, P239, DOI 10.1113/jphysiol.1986.sp015971; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; HARRISON SM, 1992, J PHYSIOL-LONDON, V449, P517, DOI 10.1113/jphysiol.1992.sp019100; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; HONJO H, 1992, AM J PHYSIOL, V263, pH1779, DOI 10.1152/ajpheart.1992.263.6.H1779; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; JENKINSON S, 1994, MOL PHARMACOL, V46, P1138; Kim D, 1999, J PHYSIOL-LONDON, V517, P59, DOI 10.1111/j.1469-7793.1999.0059z.x; Kobrinsky E, 1999, BIOPHYS J, V76, pA411; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KURACHI Y, 1986, AM J PHYSIOL, V251, pH681, DOI 10.1152/ajpheart.1986.251.3.H681; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; Logothetis DE, 1999, J PHYSIOL-LONDON, V520, P630, DOI 10.1111/j.1469-7793.1999.00630.x; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; MARTIN P, 1983, J PHYSIOL-LONDON, V245, pH584; MARTIN P, 1982, J PHYSIOL-LONDON, V243, pH219; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SHUI Z, 1995, J PHYSIOL-LONDON, V487, P359, DOI 10.1113/jphysiol.1995.sp020885; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; SIMMONS MA, 1987, PFLUG ARCH EUR J PHY, V409, P454, DOI 10.1007/BF00583801; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Vorobiov D, 1998, PFLUG ARCH EUR J PHY, V436, P56, DOI 10.1007/s004240050604; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292; Yamaguchi H, 1997, AM J PHYSIOL-HEART C, V273, pH1745, DOI 10.1152/ajpheart.1997.273.4.H1745; Zhainazarov AB, 1999, J NEUROSCI, V19, P2929; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	39	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					159	164		10.1074/jbc.M004826200	http://dx.doi.org/10.1074/jbc.M004826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029461	hybrid			2022-12-25	WOS:000166280700023
J	Datta, PK; Blake, MC; Moses, HL				Datta, PK; Blake, MC; Moses, HL			Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta-induced physical and functional interactions between Smads and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; DIHYDROFOLATE-REDUCTASE; INDUCIBLE ELEMENTS; DIRECT BINDING; PROMOTER; TRANSCRIPTION; SYNERGIZE; PROTEINS; COLLAGEN; FAST-1	Members of the transforming growth factor-beta (TGF-beta) superfamily mediate a broad range of biological activities by regulating the expression of target genes. Smad proteins play a critical role in this process by binding directly to the promoter elements and/or associating with other transcription factors. TGF-beta1 up-regulates several genes transcriptionally through Sp1 binding sites; however, the mechanism of TGF-beta induction of gene expression through Sp1 sites is largely unknown. Here we report the identification of a novel 38-base pair TGF-beta -responsive element in the human plasminogen activator inhibitor-1 (PAI-1) promoter, which contains two Sp1 binding sites, and is required for TGF-beta -induced Smad-dependent transcriptional activation. Three canonical Sp1 binding sites also support strong transcriptional activation by TGF-beta and Smads from a minimal heterologous promoter. TGF-beta induction of PAI-1 and p21 is blocked by the Sp1 inhibitor mithramycin, implicating Sp1 in the in vivo regulation of these genes by TGF-beta, We show that the association between endogenous Sp1 and Smad3 is induced by TGF-beta in several cell lines; however, Smad4 shows constitutive interaction with Sp1, These data provide novel insights into the mechanism by which TGF-beta up-regulates several gene expression by activating Sp1-dependent transcription through the induction of Smad/Sp1 complex formation.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Moses, HL (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Cell Biol, 649 Med Res Bldg 2, Nashville, TN 37232 USA.	hal.moses@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA085492, R35CA042572] Funding Source: NIH RePORTER; NCI NIH HHS [CA42572, CA85492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	26	126	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40014	40019		10.1074/jbc.C000508200	http://dx.doi.org/10.1074/jbc.C000508200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11054406	hybrid			2022-12-25	WOS:000166039500031
J	Hiltunen, MO; Turunen, MP; Turunen, AM; Rissanen, TT; Laitinen, M; Kosma, VM; Yla-Herttuala, S				Hiltunen, MO; Turunen, MP; Turunen, AM; Rissanen, TT; Laitinen, M; Kosma, VM; Yla-Herttuala, S			Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods	FASEB JOURNAL			English	Article						adenovirus; biodistribution; vascular gene therapy	CAROTID-ARTERY; RECOMBINANT ADENOVIRUS; RETROVIRUSES; COMPLEXES; INVIVO	Expression of transgene other than in the target tissue may cause side effects and safety problems in gene therapy. We analyzed biodistribution of transgene expression after intravascular and periadventitial gene delivery methods using the first generation nuclear-targeted lacZ adenovirus. RT-PCR and X-Gal stainings were used to study transgene expression 14 days after the gene transfer. After intravascular catheter-mediated gene transfer to rabbit aorta mimicking angioplasty procedure, the target vessel showed 1.1% +/- 0.5 gene transfer efficiency. Other tissues showed varying lacZ gene expression indicating a systemic leakage of the vector with the highest transfection efficiency in hepatocytes (0.7% +/- 0.5). X-Gal staining of blood cells 24 h after the intravascular gene transfer indicated that a significant portion (1.8% +/- 0.8) of circulating monocytes was transfected. X-Gal-positive cells were also found in testis. After periadventitial gene transfer using a closed silicon capsule placed around the artery, 0.1% +/- 0.1 lacZ-positive cells were detected in the artery wall. Positive cells were also found in the liver and testis (<0.01%), indicating that the virus escapes even from the periadventitial space, although less extensively than during the intravascular application. We conclude that catheter-mediated intravascular and, to a lesser extent, periadventitial gene transfer lead to leakage of adenovirus to systemic circulation, followed by expression of the transgene in several tissues. Possible consequences of the ectopic expression of the transgene should be evaluated in gene therapy trials even if local gene delivery methods are used.	Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Gene Therapy Unit, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Pathol & Forens Med, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; University of Eastern Finland	Yla-Herttuala, S (corresponding author), Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70211 Kuopio, Finland.			Rissanen, Tuomas/0000-0002-1914-2282; Yla-Herttuala, Seppo/0000-0001-7593-2708				BARR E, 1994, GENE THER, V1, P51; *CELL GEN THER PRO, US PHARM, pCH104; HERMANN KL, 1988, LAB DIAGNOSIS INFECT, V2, P82; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Laitinen M, 1997, HUM GENE THER, V8, P1645, DOI 10.1089/hum.1997.8.14-1645; Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; Palasis M, 2000, HUM GENE THER, V11, P237, DOI 10.1089/10430340050015987; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; SOMA MR, 1993, ARTERIOSCLER THROMB, V13, P571, DOI 10.1161/01.ATV.13.4.571; STEG PG, 1994, CIRCULATION, V90, P1648, DOI 10.1161/01.CIR.90.4.1648; Turunen MP, 1999, GENE THER, V6, P6, DOI 10.1038/sj.gt.3300800; van der Eb MM, 1998, GENE THER, V5, P451, DOI 10.1038/sj.gt.3300637; VanPut DJM, 1995, EUR J PHARMACOL, V294, P753, DOI 10.1016/0014-2999(95)00635-4; WILLARD JE, 1994, CIRCULATION, V89, P2190, DOI 10.1161/01.CIR.89.5.2190; Ye XH, 1998, HUM GENE THER, V9, P2135, DOI 10.1089/hum.1998.9.14-2135; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971	19	77	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2230	2236		10.1096/fj.00-0145com	http://dx.doi.org/10.1096/fj.00-0145com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053244				2022-12-25	WOS:000165190800016
J	Cinti, C; Claudio, PP; De Luca, A; Cuccurese, M; Howard, CM; D'Esposito, M; Paggi, MG; La Sala, D; Azzoni, L; Halazonetis, TD; Giordano, A; Maraldi, NM				Cinti, C; Claudio, PP; De Luca, A; Cuccurese, M; Howard, CM; D'Esposito, M; Paggi, MG; La Sala, D; Azzoni, L; Halazonetis, TD; Giordano, A; Maraldi, NM			A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line	ONCOGENE			English	Article						drug resistance; p53 mutations; apoptotic genes; T-lymphoblastoid cells	TUMOR-SUPPRESSOR GENE; TRANSCRIPTIONALLY ACTIVE P53; PROTEIN-KINASE; P53-DEPENDENT APOPTOSIS; MUTANT P53; BAX GENE; PHOSPHORYLATION; CHEMOTHERAPY; GROWTH; CANCER	The p53 protein accumulates rapidly through posttranscriptional mechanisms following cellular exposure to DNA damaging agents and is also activated as a transcription factor leading to growth arrest or apoptosis, Phosphorylation of p53 occurs after DNA damage thereby modulating its activity and impeding the interaction of p53 with its negative regulator oncogene Mdm2. The serines 15 and 37 present in the amino terminal region of p53 are phosphorylated by the DNA-dependent protein kinase (DNA-PK) in response to DNA damage, In order to verify if specific p53 mutations occur in the multi-drug resistance phenotype, we analysed the p53 gene in two T-lymphoblastoid cell lines, CCRF-CEM and its multi-drug-resistant clone CCRF-CEM VLB100, selected for resistance to vinblastine sulfate and cross-resistant to other cytotoxic drugs, Both cell lines showed two heterozygous mutations in the DNA binding domain at codons 175 and 248. The multi-drug resistant cell line, CCRF-CEM VLB100, showed an additional mutation that involves the serine 37 whose phosphorylation is important to modulate the protein activity in response to DNA damage, The effects of these mutations on p53 transactivation capacity were evaluated, The activity of p53 on pro-apoptotic genes expression in response to DNA damage induced by (-irradiation, was affected in the vinblastine (VLB) resistant cell line but not in CCRF-CEM sensitive cell Line resulting in a much reduced apoptotic cell death of the multi-drug resistant cells.	IOR, CNR, Ist Citomorfol Normale & Patol, I-40136 Bologna, Italy; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Naples Federico II, Lab Cell Odontostomatol & Maxillofacciali, I-80131 Naples, Italy; Regina Elena Inst Canc Res, Ctr Expt Res, Lab Cell Metab & Pharmacokinet, I-00158 Rome, Italy; CNR, Int Inst Genet & Biophys, Genome Res & Sequencing Lab, I-80125 Naples, Italy; Wistar Inst Anat & Biol, Dept Mol Oncol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; IOR, Lab Cell Biol & Electron Microscopy, I-40136 Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); Jefferson University; University of Naples Federico II; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); The Wistar Institute; Jefferson University	Cinti, C (corresponding author), IOR, CNR, Ist Citomorfol Normale & Patol, Via Barbiano 1-10, I-40136 Bologna, Italy.		Claudio, Pier Paolo/AAW-7282-2021; Paggi, Marco G./K-3494-2018; Giordano, Antonio/F-1927-2010; De Luca, Antonio/AAD-9562-2020; Halazonetis, Thanos/D-7923-2011	Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X; De Luca, Antonio/0000-0002-3905-6154; Howard, Candace/0000-0001-6537-3551; Cinti, Caterina/0000-0001-8049-0369				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CIANFRIGLIA M, 1991, INT J CANCER, V49, P394, DOI 10.1002/ijc.2910490314; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Delia D, 1996, NAT MED, V2, P724, DOI 10.1038/nm0796-724; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRITSCHE M, 1993, ONCOGENE, V8, P307; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hecker D, 1996, ONCOGENE, V12, P953; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOOPER ML, 1994, J CELL SCI, P13; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAYR GA, 1995, CANCER RES, V55, P2410; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MEEK DW, 1997, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MIYASHITA T, 1995, CELL, V80, P293; MOYRET C, 1994, ONCOGENE, V9, P1739; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OITVAI ZN, 1993, CELL, V74, P609; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PARK DJ, 1994, ONCOGENE, V9, P1899; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Righetti SC, 1996, CANCER RES, V56, P689; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; Shelling AN, 1997, LANCET, V349, P744, DOI 10.1016/S0140-6736(05)60195-X; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; TISHLER RB, 1995, CANCER RES, V55, P6021; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2	52	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5098	5105		10.1038/sj.onc.1203848	http://dx.doi.org/10.1038/sj.onc.1203848			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042698				2022-12-25	WOS:000089930100007
J	Kusano, H; Shimizu, S; Koya, RC; Fujita, H; Kamada, S; Kuzumaki, N; Tsujimoto, Y				Kusano, H; Shimizu, S; Koya, RC; Fujita, H; Kamada, S; Kuzumaki, N; Tsujimoto, Y			Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC	ONCOGENE			English	Article						gelsolin; VDAC; apoptosis	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; REGULATORY PROTEIN; BAX; MEMBRANE; FAMILY; PLASMA; GENE	Gelsolin is a Ca2+-dependent actin-regulatory protein that modulates actin assembly and disassembly, and is believed to regulate cell motility through modulation of the actin network. Gelsolin was also recently suggested to be involved in the regulation of apoptosis: human gelsolin (hGsn) has anti-apoptotic activity, whereas mouse gelsolin (mGsn) exerts either proapoptotic or anti-apoptotic activity depending on different cell types. Here, we studied the basis of anti-apoptotic activity of hGsn, We showed that both endogenous and overexpressed hGsn has anti-apoptotic activity, that depends on its C-terminal half. We also found that hGsn and its C-terminal half but not mGsn could prevent apoptotic mitochondrial changes such as Delta psi loss and cytochrome c release in isolated mitochondria to a similar extent as Bcl-x(L), indicating that hGsn targets the mitochondria to prevent apoptosis via its C-terminal half. In the same way as anti-apoptotic Bcl-xL, which we recently found to prevent apoptotic mitochondrial changes by binding and closing the voltage-dependent anion channel (VDAC), hGsn and its C-terminal half inhibited the activity of VDAC on liposomes through direct binding in a Ca2+-dependent manner. These results suggest that hGsn inhibits apoptosis by blocking mitochondrial VDAC activity.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Suita, Osaka 5650871, Japan; JST, CREST, Suita, Osaka, Japan; Hokkaido Univ, Inst Med Genet, Div Canc Gene Regulat, Kita Ku, Sapporo, Hokkaido, Japan	Osaka University; Japan Science & Technology Agency (JST); Hokkaido University	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fujita H, 1997, EUR J BIOCHEM, V248, P834, DOI 10.1111/j.1432-1033.1997.00834.x; FUJITA H, 1995, EUR J BIOCHEM, V229, P615, DOI 10.1111/j.1432-1033.1995.tb20505.x; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Rappaport L, 1998, MOL CELL BIOCHEM, V184, P101, DOI 10.1023/A:1006843113166; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	34	145	148	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4807	4814		10.1038/sj.onc.1203868	http://dx.doi.org/10.1038/sj.onc.1203868			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039896				2022-12-25	WOS:000089757800001
J	Jenkins, GM; Hannun, YA				Jenkins, GM; Hannun, YA			Role for de novo sphingoid base biosynthesis in the heat-induced transient cell cycle arrest of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SHOCK PROTEINS; MUTANT STRAINS; YEAST; SPHINGOLIPIDS; STRESS; GENE; REQUIREMENT; ENDOCYTOSIS; EXPRESSION	The recent findings of sphingolipids as potential mediators of yeast heat stress responses led us to investigate their possible role in the heat-induced cell cycle arrest and subsequent recovery. The sphingolipid-deficient yeast strain 7R4 was found to lack the cell cycle arrest seen in the isogenic wild type, Furthermore, strain lcb1-100, which harbors a temperature-sensitive serine palmitoyltransferase, lacked increased de novo generated sphingoid bases upon heat stress, Importantly, this strain was found to lack the transient heat-induced G(0)/G(1) arrest. These results indicate a role for sphingolipids and specifically those generated in the de novo pathway in the cell cycle arrest response to heat. To determine the bioactive sphingolipid regulating this response, an analysis of key mutants in the sphingolipid biosynthetic and degradation pathways was performed. Strains deleted in sphingoid base kinases, sphingoid phosphate phosphatase, lyase, or dihydrosphingosine hydroxylase were found to display the cell cycle arrest. Also, the knockout of a fatty acyl elongation enzyme, which severely attenuates ceramide production, displayed the arrest. These experiments suggested that the active species for cell cycle arrest were the sphingoid bases. In further support of these findings, exogenous phytosphingosine (10 muM) was found to induce transient arrest. Stearylamine did not induce an arrest, demonstrating chemical specificity, and L-erythro- was not as potent as D-erythro-dihydrosphingosine showing stereospecificity, To investigate a possible arrest mechanism, we studied the hyperstable Cln3 (Cln3-1) strain LDW6GA that has been previously shown to be resistant to heat stress-induced cell cycle arrest. The strain containing Cln3-1 was found to be resistant to cell cycle arrest induced by exogenous phytosphingosine, indicating that Cln3 acts downstream of the sphingoid bases in this response. Interestingly, cell cycle recovery from the transient arrest was found to be dependent upon the sphingoid base kinases (LCB4, LCB5), Overall, this combination of genetic and pharmacologic results demonstrates a role for de novo sphingoid base biosynthesis by serine palmitoyltransferase in the transient G(0)/G(1) arrest mediated through Cln3 via a novel mechanism.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29482 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA	Medical University of South Carolina; Duke University	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 14 Doughty St,POB 250780, Charleston, SC 29482 USA.				NIGMS NIH HHS [GM-43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Friant S, 2000, EMBO J, V19, P2834, DOI 10.1093/emboj/19.12.2834; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HOTTIGER T, 1992, EUR J BIOCHEM, V210, P125, DOI 10.1111/j.1432-1033.1992.tb17399.x; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; JOHNSTON GC, 1980, MOL GEN GENET, V178, P357, DOI 10.1007/BF00270484; LESTER RL, 1993, J BIOL CHEM, V268, P845; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; MCALISTER L, 1985, J BIOL CHEM, V260, P5019; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MILLER MJ, 1979, P NATL ACAD SCI USA, V76, P5222, DOI 10.1073/pnas.76.10.5222; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; ROWLEY A, 1993, MOL CELL BIOL, V13, P1034, DOI 10.1128/MCB.13.2.1034; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; SHIN DY, 1987, MOL CELL BIOL, V7, P244, DOI 10.1128/MCB.7.1.244; Sutterlin C, 1997, J CELL SCI, V110, P2703; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; WIEMKEN A, 1990, ANTON LEEUW INT J G, V58, P209, DOI 10.1007/BF00548935; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824	30	101	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8574	8581		10.1074/jbc.M007425200	http://dx.doi.org/10.1074/jbc.M007425200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11056159	hybrid			2022-12-25	WOS:000167474900120
J	Ono, S; McGough, A; Pope, BJ; Tolbert, VT; Bui, A; Pohl, J; Benian, GM; Gernert, KM; Weeds, AG				Ono, S; McGough, A; Pope, BJ; Tolbert, VT; Bui, A; Pohl, J; Benian, GM; Gernert, KM; Weeds, AG			The C-terminal tail of UNC-60B (actin depolymerizing factor/cofilin) is critical for maintaining its stable association with F-actin and is implicated in the second actin-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; FILAMENT TURNOVER; FACTOR ADF/COFILIN; FACTOR COFILIN; YEAST COFILIN; SUBDOMAIN 2; PROTEIN; GELSOLIN; ADF; ACTOPHORIN	Actin depolymerizing factor (ADF)/cofilin changes the twist of actin filaments by binding two longitudinally associated actin subunits, In the absence of an atomic model of the ADF/cofilin-F-actin complex, we have identified residues in ADF/cofilin that are essential for filament binding. Here, we have characterized the C-terminal tail of UNC-60B (a nematode ADF/cofilin isoform) as a novel determinant for its association with F-actin, Removal of the C-terminal isoleucine (Ile(152)) by carboxypeptidase A or truncation by mutagenesis eliminated F-actin binding activity but strongly enhanced actin depolymerizing activity, Replacement of Ile(152) by Ala had a similar but less marked effect; F-actin binding was weakened and depolymerizing activity slightly enhanced. Truncation of both Arg(151) and Ile(152) or replacement of Arg(151) with Ala also abolished F-actin binding and enhanced depolymerizing activity. Loss of F-actin binding in these mutants was accompanied by loss or greatly decreased severing activity. All of the variants of UNC-60B interacted with G-actin in an indistinguishable manner from wild type. Cryoelectron microscopy showed that UNC-60B changed the twist of F-actin to a similar extent to vertebrate ADF/cofilins. Helical reconstruction and structural modeling of UNC-60B-F-actin complex reveal how the C terminus of UNC-60B might be involved in one of the two actin-binding sites.	Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Purdue Univ, Dept Sci Biol, W Lafayette, IN 47907 USA; Emory Univ, Winship Canc Inst, Microchem Facil, Atlanta, GA 30322 USA; Frederick Douglas High Sch, Decatur, GA 30030 USA; Emory Univ, BIMCORE, Atlanta, GA 30322 USA	Emory University; MRC Laboratory Molecular Biology; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Emory University; Emory University	Ono, S (corresponding author), Emory Univ, Dept Pathol, 1639 Pierce Dr,Woodruff Mem Bldg,Rm 7109C, Atlanta, GA 30322 USA.	ono@bimcore.emory.edu	Ono, Shoichiro/A-6475-2015	Ono, Shoichiro/0000-0002-4763-0398	NCRR NIH HHS [RR13948, RR12878] Funding Source: Medline; NIGMS NIH HHS [GM59677] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012878, S10RR013948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059677] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; Du JY, 1998, BIOCHEMISTRY-US, V37, P13276, DOI 10.1021/bi981117r; Fedorov AA, 1997, NAT STRUCT BIOL, V4, P366, DOI 10.1038/nsb0597-366; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; Ichetovkin I, 2000, CELL MOTIL CYTOSKEL, V45, P293, DOI 10.1002/(SICI)1097-0169(200004)45:4<293::AID-CM5>3.0.CO;2-1; Jiang CJ, 1997, P NATL ACAD SCI USA, V94, P9973, DOI 10.1073/pnas.94.18.9973; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim E, 1995, BIOPHYS J, V69, P2024, DOI 10.1016/S0006-3495(95)80072-X; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Leonard SA, 1997, NAT STRUCT BIOL, V4, P369, DOI 10.1038/nsb0597-369; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; Maciver SK, 1998, EUR J BIOCHEM, V256, P388, DOI 10.1046/j.1432-1327.1998.2560388.x; McGough A, 1999, J MOL BIOL, V291, P513, DOI 10.1006/jmbi.1999.2968; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Moraczewska J, 1996, BIOCHEM J, V317, P605, DOI 10.1042/bj3170605; Moriyama K, 1999, EMBO J, V18, P6752, DOI 10.1093/emboj/18.23.6752; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; Ono S, 1999, J CELL BIOL, V145, P491, DOI 10.1083/jcb.145.3.491; Ono S, 1999, CELL MOTIL CYTOSKEL, V43, P128, DOI 10.1002/(SICI)1097-0169(1999)43:2&lt;128::AID-CM4&gt;3.0.CO;2-C; Ono S, 1998, J BIOL CHEM, V273, P3778, DOI 10.1074/jbc.273.6.3778; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pope BJ, 2000, J MOL BIOL, V298, P649, DOI 10.1006/jmbi.2000.3688; Ressad F, 1999, J BIOL CHEM, V274, P20970, DOI 10.1074/jbc.274.30.20970; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; SAFER D, 1989, ANAL BIOCHEM, V178, P32, DOI 10.1016/0003-2697(89)90351-5; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Smertenko AP, 1998, PLANT J, V14, P187, DOI 10.1046/j.1365-313X.1998.00107.x; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Van Troys M, 1997, J BIOL CHEM, V272, P32750, DOI 10.1074/jbc.272.52.32750; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; Wriggers W, 1998, J MOL BIOL, V282, P921, DOI 10.1006/jmbi.1998.2048; Yeoh S, 1999, MOL BIOL CELL, V10, p156A; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485; Zhou ZH, 1996, J STRUCT BIOL, V116, P216, DOI 10.1006/jsbi.1996.0033	55	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5952	5958		10.1074/jbc.M007563200	http://dx.doi.org/10.1074/jbc.M007563200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11050090	hybrid			2022-12-25	WOS:000167115100073
J	Brecht, S; Carruthers, VB; Ferguson, DJP; Giddings, OK; Wang, G; Jakle, U; Harper, JM; Sibley, LD; Soldati, D				Brecht, S; Carruthers, VB; Ferguson, DJP; Giddings, OK; Wang, G; Jakle, U; Harper, JM; Sibley, LD; Soldati, D			The toxoplasma micronemal protein MIC4 is an adhesin composed of six conserved apple domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICOMPLEXA CYST MEROZOITES; CELL INVASION MACHINERY; COAGULATION-FACTOR-XI; SARCOCYSTIS-MURIS; BINDING-SITE; GLIDING MOTILITY; DISULFIDE BONDS; IN-VITRO; GONDII; EXPRESSION	The initial stage of invasion by apicomplexan parasites involves the exocytosis of the micronemes-containing molecules that contribute to host cell attachment and penetration. MIC4 was previously described as a protein secreted by Toxoplasma gondii tachyzoites upon stimulation of micronemes exocytosis. We have microsequenced the mature protein, purified after discharge from micronemes and cloned the corresponding gene. The deduced amino acid sequence of MIC4 predicts a 61-kDa protein that contains 6 conserved apple domains. Apple domains are composed of six spacely conserved cysteine residues which form disulfide bridges and are also present in micronemal proteins from two closely related apicomplexan parasites, Sarcocystis muris and Eimeria species, and several mammalian serum proteins, including kallikrein. Here we show that MIC4 localizes in the micronemes of all the invasive forms of T. gondii, tachyzoites, bradyzoites; sporozoites, and merozoites. The protein is proteolytically processed both at the N and the C terminus only upon release from the organelle. MIC4 binds efficiently to host cells, and the adhesive motif maps in the most C-terminal apple domain.	Zentrum Mol Biol, D-69120 Heidelberg, Germany; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Oxford, John Radcliffe Hosp, Unit Nuffield Dept Pathol, Oxford OX3 9DU, England	Ruprecht Karls University Heidelberg; Washington University (WUSTL); University of Oxford	Soldati, D (corresponding author), Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.		Sibley, L. David/C-4616-2008; Soldati-Favre, Dominique/A-2999-2009	Ferguson, David/0000-0001-5045-819X; Carruthers, Vern/0000-0001-6859-8895	NIAID NIH HHS [R01 AI034036, AI34046] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034036] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHBAROU A, 1991, MOL BIOCHEM PARASIT, V47, P223, DOI 10.1016/0166-6851(91)90182-6; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; Baglia FA, 1996, J BIOL CHEM, V271, P3652; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Brown PJ, 2000, MOL BIOCHEM PARASIT, V107, P91, DOI 10.1016/S0166-6851(00)00179-1; Brydges SD, 2000, MOL BIOCHEM PARASIT, V111, P51, DOI 10.1016/S0166-6851(00)00296-6; Carruthers VB, 1999, BIOCHEM J, V342, P379, DOI 10.1042/0264-6021:3420379; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 2000, INFECT IMMUN, V68, P4005, DOI 10.1128/IAI.68.7.4005-4011.2000; Coppel RL, 1998, CURR OPIN MICROBIOL, V1, P472, DOI 10.1016/S1369-5274(98)80068-4; DECARVALHO L, 1991, J PARASITOL, V77, P156, DOI 10.2307/3282574; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dobrowolski JM, 1997, CELL MOTIL CYTOSKEL, V37, P253, DOI 10.1002/(SICI)1097-0169(1997)37:3&lt;253::AID-CM7&gt;3.0.CO;2-7; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; ENTZEROTH R, 1992, EUR J CELL BIOL, V59, P405; ESCHENBACHER KH, 1993, MOL BIOCHEM PARASIT, V62, P27, DOI 10.1016/0166-6851(93)90174-V; Ferguson DJP, 2000, INT J PARASITOL, V30, P1203, DOI 10.1016/S0020-7519(00)00096-5; Fourmaux MN, 1996, MOL BIOCHEM PARASIT, V83, P201, DOI 10.1016/S0166-6851(96)02773-9; GARCIAREGUET N, 2001, IN PRESS MOL MICROBI; Hettmann C, 2000, MOL BIOL CELL, V11, P1385, DOI 10.1091/mbc.11.4.1385; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; Klein H, 1998, GLYCOCONJUGATE J, V15, P147, DOI 10.1023/A:1006964105349; Klein H, 1996, PARASITOL RES, V82, P468, DOI 10.1007/s004360050146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; Mercier C, 1996, MOL MICROBIOL, V21, P421, DOI 10.1046/j.1365-2958.1996.6501361.x; MINEO JR, 1993, J IMMUNOL, V150, P3951; Naitza S, 1998, PARASITOL TODAY, V14, P479, DOI 10.1016/S0169-4758(98)01346-5; Nakaar V, 1998, MOL BIOCHEM PARASIT, V92, P229, DOI 10.1016/S0166-6851(97)00220-X; Ortega-Barria E, 1999, J BIOL CHEM, V274, P1267, DOI 10.1074/jbc.274.3.1267; POHL U, 1989, PARASITOL RES, V75, P199, DOI 10.1007/BF00931276; Seeber F, 1996, GENE, V169, P39, DOI 10.1016/0378-1119(95)00786-5; SOLDATI D, 1995, MOL CELL BIOL, V15, P87, DOI 10.1128/MCB.15.1.87; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; TOMLEY FM, 2001, IN PRESS PARASITOL T; Wan KL, 1996, MOL BIOCHEM PARASIT, V75, P179, DOI 10.1016/0166-6851(95)02524-3; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X	40	114	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4119	4127		10.1074/jbc.M008294200	http://dx.doi.org/10.1074/jbc.M008294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053441	hybrid			2022-12-25	WOS:000166921200053
J	Lim, EK; Li, Y; Parr, A; Jackson, R; Ashford, DA; Bowles, DJ				Lim, EK; Li, Y; Parr, A; Jackson, R; Ashford, DA; Bowles, DJ			Identification of glucosyltransferase genes involved in sinapate metabolism and lignin synthesis in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCOSE GLUCOSYLTRANSFERASE; BIOCHEMICAL-CHARACTERIZATION; O-GLUCOSYLTRANSFERASE; SALICYLIC-ACID; EXPRESSION; CLONING; PURIFICATION; 5-O-GLUCOSYLTRANSFERASE; FERULATE-5-HYDROXYLASE; ANTHOCYANIN	Sinapic acid is a major phenylpropanoid in Brassicaceae providing intermediates in two distinct metabolic pathways leading to sinapoyl esters and lignin synthesis. Glucosyltransferases play key roles in the formation of these intermediates, either through the production of the high energy compound 1-O-sinapoyl-glucose leading to sinapoylmalate and sinapoylcholine or through the production of sinapyl alcohol-4-O-glucoside, potentially leading to the syringyl units found in lignins. While the importance of these glucosyltransferases has been recognized for more than 20 years, their corresponding genes have not been identified. Combining sequence information in the Arabidopsis genomic data base with biochemical data from screening the activity of recombinant proteins in vitro, we have now identified five gene sequences encoding enzymes that can glucosylate sinapic acid, sinapyl alcohol, and their related phenylpropanoids. The data provide a foundation for future understanding and manipulation of sinapate metabolism and lignin biology in Arabidopsis.	Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England; Inst Food Res, Norwich NR4 7UA, Norfolk, England	University of York - UK; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Bowles, DJ (corresponding author), Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England.	djb32@york.ac.uk						BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; CHAPPLE CCS, 1992, PLANT CELL, V4, P1413, DOI 10.1105/tpc.4.11.1413; DHARMAWARDHANA DP, 1995, PLANT PHYSIOL, V107, P331, DOI 10.1104/pp.107.2.331; Ford CM, 1998, J BIOL CHEM, V273, P9224, DOI 10.1074/jbc.273.15.9224; Fraissinet-Tachet L, 1998, FEBS LETT, V437, P319, DOI 10.1016/S0014-5793(98)01257-5; Gorinova N, 1999, BIOTECHNOL BIOTEC EQ, V13, P13, DOI 10.1080/13102818.1999.10819011; Hostel W., 1981, BIOCH PLANTS, V7, P725; HUGHES J, 1994, DNA SEQUENCE, V5, P41, DOI 10.3109/10425179409039703; Ibrahim RK, 1998, PLANT MOL BIOL, V36, P1, DOI 10.1023/A:1005939803300; IBRAHIM RK, 1976, ARCH BIOCHEM BIOPHYS, V176, P700, DOI 10.1016/0003-9861(76)90214-9; ISHIMARU K, 1990, PHYTOCHEMISTRY, V29, P3823, DOI 10.1016/0031-9422(90)85340-L; Jones PR, 1999, J BIOL CHEM, V274, P35483, DOI 10.1074/jbc.274.50.35483; LANDRY LG, 1995, PLANT PHYSIOL, V109, P1159, DOI 10.1104/pp.109.4.1159; Lee H, 1999, J BIOL CHEM, V274, P36637, DOI 10.1074/jbc.274.51.36637; LEE HI, 1995, P NATL ACAD SCI USA, V92, P4076, DOI 10.1073/pnas.92.10.4076; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 1998, J BIOL CHEM, V273, P34920, DOI 10.1074/jbc.273.52.34920; Lorenzen M, 1996, PLANT PHYSIOL, V112, P1625, DOI 10.1104/pp.112.4.1625; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Martin RC, 1999, P NATL ACAD SCI USA, V96, P284, DOI 10.1073/pnas.96.1.284; Meyer K, 1996, P NATL ACAD SCI USA, V93, P6869, DOI 10.1073/pnas.93.14.6869; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; Moehs CP, 1997, PLANT J, V11, P227, DOI 10.1046/j.1365-313X.1997.11020227.x; O'Donnell PJ, 1998, PLANT J, V14, P137, DOI 10.1046/j.1365-313X.1998.00110.x; PIERS KL, 1993, GENE, V134, P7, DOI 10.1016/0378-1119(93)90168-3; Ruegger M, 1999, PLANT PHYSIOL, V119, P101, DOI 10.1104/pp.119.1.101; SAMBROOK J, 1989, MOL CLONING LAB MANU, V18, P47; SHARMA V, 1985, PLANTA, V163, P563, DOI 10.1007/BF00392714; Solecka D, 1997, ACTA PHYSIOL PLANT, V19, P257, DOI 10.1007/s11738-997-0001-1; STRACK D, 1983, Z NATURFORSCH C, V38, P21; STRACK D, 1977, Z PFLANZENPHYSIOL, V84, P139, DOI 10.1016/S0044-328X(77)80186-4; SUGIYAMA M, 1993, PHYTOCHEMISTRY, V33, P1215, DOI 10.1016/0031-9422(93)85052-S; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; Tanaka Y, 1996, PLANT CELL PHYSIOL, V37, P711, DOI 10.1093/oxfordjournals.pcp.a029004; Truesdale M. R., 1996, PLANT PHYSIOL, V112, P446; VANCE CP, 1980, ANNU REV PHYTOPATHOL, V18, P259, DOI 10.1146/annurev.py.18.090180.001355; Vogt T, 1999, PLANT J, V19, P509, DOI 10.1046/j.1365-313X.1999.00540.x; Warnecke DC, 1997, PLANT MOL BIOL, V35, P597, DOI 10.1023/A:1005806119807; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; Winkel-Shirley B, 1999, PHYSIOL PLANTARUM, V107, P142, DOI 10.1034/j.1399-3054.1999.100119.x; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405	41	158	182	6	39	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4344	4349		10.1074/jbc.M007263200	http://dx.doi.org/10.1074/jbc.M007263200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042211	hybrid			2022-12-25	WOS:000166921200082
J	Benedict, CA; Norris, PS; Prigozy, TI; Bodmer, JL; Mahr, JA; Garnett, CT; Martinon, F; Tschopp, J; Gooding, LR; Ware, CF				Benedict, CA; Norris, PS; Prigozy, TI; Bodmer, JL; Mahr, JA; Garnett, CT; Martinon, F; Tschopp, J; Gooding, LR; Ware, CF			Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LYMPHOTOXIN-BETA-RECEPTOR; GROWTH-FACTOR RECEPTOR; FADD-DEPENDENT APOPTOSIS; REGION E3; MEDIATED APOPTOSIS; RETROVIRAL VECTORS; MEMBRANE-PROTEIN; DEATH; TRAIL	Adenovirus encodes multiple gene products that regulate proapoptotic cellular responses to viral infection mediated by both the innate and adaptive immune systems. The E3-10.4K and 14.5K gene products are known to modulate the death receptor Fas. In this study, we demonstrate that an additional viral E3 protein, 6.7K, functions in the specific modulation of the two death receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), The 6.7K protein is expressed on the cell surface and forms a complex with the 10.4K and 14.5K proteins, and this complex is sufficient to induce down-modulation of TRAIL receptor-1 and -2 from the cell surface and reverse the sensitivity of infected cells to TRAIL-mediated apoptosis. Down-modulation of TRAIL-R2 by the E3 complex is dependent on the cytoplasmic tail of the receptor, but the death domain alone is not sufficient. These results identify a mechanism for viral modulation of TRAIL receptor-mediated apoptosis and suggest the E3 protein complex has evolved to regulate the signaling of selected cytokine receptors.	La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, Div Dev Immunol, San Diego, CA 92121 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	La Jolla Institute for Immunology; La Jolla Institute for Immunology; Emory University; University of Lausanne	Ware, CF (corresponding author), La Jolla Inst Allergy & Immunol, Div Mol Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	carl_ware@liai.org	Martinon, Fabio/A-5575-2009	Martinon, Fabio/0000-0002-6969-822X	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000252] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA69381] Funding Source: Medline; NIAID NIH HHS [AI03368] Funding Source: Medline; NIA NIH HHS [T32AG00252] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Benedict CA, 1999, J IMMUNOL, V162, P6967; Benedict CA, 1999, HUM GENE THER, V10, P545, DOI 10.1089/10430349950018625; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; BRADY HA, 1987, NUCLEIC ACIDS RES, V15, P9397, DOI 10.1093/nar/15.22.9397; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; CARLIN CR, 1989, CELL, V57, P135, DOI 10.1016/0092-8674(89)90179-7; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CLADARAS C, 1985, VIROLOGY, V140, P44, DOI 10.1016/0042-6822(85)90444-1; Cook JL, 1996, ONCOGENE, V13, P833; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Elsing A, 1998, P NATL ACAD SCI USA, V95, P10072, DOI 10.1073/pnas.95.17.10072; Force WR, 2000, J BIOL CHEM, V275, P11121, DOI 10.1074/jbc.275.15.11121; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1999, J IMMUNOL, V162, P2597; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HOFFMAN P, 1992, J BIOL CHEM, V267, P13480; Johnsen AC, 1999, CYTOKINE, V11, P664, DOI 10.1006/cyto.1999.0489; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Klefstrom J, 1999, ONCOGENE, V18, P2181, DOI 10.1038/sj.onc.1202546; KRAJCSI P, 1992, VIROLOGY, V187, P131, DOI 10.1016/0042-6822(92)90302-6; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Mahr JA, 1999, IMMUNOL REV, V168, P121, DOI 10.1111/j.1600-065X.1999.tb01287.x; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Rooney IA, 2000, J BIOL CHEM, V275, P14307, DOI 10.1074/jbc.275.19.14307; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shisler J, 1997, J VIROL, V71, P8299, DOI 10.1128/JVI.71.11.8299-8306.1997; Shisler JL, 1998, TRENDS MICROBIOL, V6, P337, DOI 10.1016/S0966-842X(98)01342-0; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Sparer TE, 1996, J VIROL, V70, P2431, DOI 10.1128/JVI.70.4.2431-2439.1996; STEWART AR, 1995, J VIROL, V69, P172, DOI 10.1128/JVI.69.1.172-181.1995; Thomas WD, 1998, J IMMUNOL, V161, P2195; TOLLEFSON AE, 1991, J VIROL, V65, P3095, DOI 10.1128/JVI.65.6.3095-3105.1991; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WILSONRAWLS J, 1993, VIROLOGY, V195, P6, DOI 10.1006/viro.1993.1341; WILSONRAWLS J, 1990, VIROLOGY, V178, P204, DOI 10.1016/0042-6822(90)90395-8; WOLD WSM, 1986, VIROLOGY, V148, P168, DOI 10.1016/0042-6822(86)90412-5; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961	47	111	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3270	3278		10.1074/jbc.M008218200	http://dx.doi.org/10.1074/jbc.M008218200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11050095	hybrid			2022-12-25	WOS:000166784900039
J	Rane, MJ; Coxon, PY; Powell, DW; Webster, R; Klein, JB; Pierce, W; Ping, PP; McLeish, KR				Rane, MJ; Coxon, PY; Powell, DW; Webster, R; Klein, JB; Pierce, W; Ping, PP; McLeish, KR			p38 kinase-dependent MAPKAPK-2 activation functions as 3-phosphoinositide-dependent kinase-2 for Akt in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYL PEPTIDE RECEPTORS; HEAT-SHOCK PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PHOSPHORYLATION; PATHWAYS; CASCADES; BINDING	Akt activation requires phosphorylation of Thr(308) and Ser(473) by 3-phosphoinositide-dependent kinase-1 and a (PDK1 and PDK2), respectively. While PDK1 has been cloned and sequenced, PDK2 has yet to be identified. The present study shows that phosphatidyl inositol 3-kinase-dependent p38 kinase activation regulates Akt phosphorylation and activity in human neutrophils, Inhibition of p38 kinase activity with SB203580 inhibited Akt Ser473 phosphorylation following neutrophil stimulation with formyl-methionyl-leucyl phenylalanine, Fc gammaR cross-linking, or phosphatidylinositol 3,4,5-trisphosphate. Concentration inhibition studies showed that Ser473 phosphorylation was inhibited by 0.3 muM SB203580, while inhibition of Thr(308) phosphorylation required 10 muM SB203580. Transient transfection of HEK293 cells with adenoviruses containing constitutively active MKK3 or MKK6 resulted in activation of both p38 kinase and Akt, Immunoprecipitation and glutathione S-transferase (GST) pull-down studies showed that Akt was associated with p38 kinase, MK2, and Hsp27 in neutrophils, and Hsp27 dissociated from the complex upon activation. Active recombinant MK2 phosphorylated recombinant Akt and Akt in anti-Akt, anti-MK2, anti-p38, and anti-Hsp27 immunoprecipitates, and this was inhibited by an MK2 inhibitory peptide. We conclude that Akt exists in a signaling complex containing p38 kinase, MK2, and Hsp27 and that p38-dependent MK2 activation functions as PDK2 in human neutrophils.	Univ Louisville, Mol Signalling Grp, Kidney Dis Program, Hlth Sci Ctr,Dept Med, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Dept Physiol & Biophys, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Rane, MJ (corresponding author), Univ Louisville, Mol Signalling Grp, Kidney Dis Program, Hlth Sci Ctr,Dept Med, 615 S Preston St, Louisville, KY 40202 USA.		Klein, Jon/B-9833-2013; McLeish, Kenneth R./B-9819-2013; Powell, David W/E-9288-2013	McLeish, Kenneth R./0000-0002-7816-3286; 	NCRR NIH HHS [1S10RR11368-01A1] Funding Source: Medline; NHLBI NIH HHS [HL63901] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011368] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063901, R37HL063901] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Coxon PY, 2000, J IMMUNOL, V164, P6530, DOI 10.4049/jimmunol.164.12.6530; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; DOOLEY DC, 1982, EXP HEMATOL, V10, P591; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Jensen ON, 1999, METH MOL B, V112, P513; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P835, DOI 10.1002/jlb.64.6.835; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; Rane MJ, 1997, J IMMUNOL, V159, P5070; Rane MJ, 1998, J BIOL CHEM, V273, P20916, DOI 10.1074/jbc.273.33.20916; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287; ZU YL, 1992, J BIOL CHEM, V267, P20181	40	224	232	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3517	3523		10.1074/jbc.M005953200	http://dx.doi.org/10.1074/jbc.M005953200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042204	hybrid			2022-12-25	WOS:000166784900069
J	Avdi, NJ; Nick, JA; Whitlock, BB; Billstrom, MA; Henson, PM; Johnson, GL; Worthen, GS				Avdi, NJ; Nick, JA; Whitlock, BB; Billstrom, MA; Henson, PM; Johnson, GL; Worthen, GS			Tumor necrosis factor-alpha activation of the c-Jun N-terminal kinase pathway in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; KAPPA-B ACTIVATION; MAP KINASE; SIGNAL-TRANSDUCTION; RESPIRATORY BURST; NH2-TERMINAL KINASE; TNF-ALPHA; MECHANICAL-PROPERTIES; MOLECULAR-CLONING	The intensity and duration of an inflammatory response depends on the balance of factors that favor perpetuation versus resolution. At sites of inflammation, neutrophils adherent to other cells or matrix components are exposed to tumor necrosis factor-alpha (TNF alpha), Although TNF alpha has been implicated in induction of pro-inflammatory responses, it may also inhibit the intensity of neutrophilic inflammation by promoting apoptosis, Since TNF alpha is not only an important activator of the stress-induced pathways leading to p38 MAPk and c-Jun N-terminal kinase (JNK) but also a potent effector of apoptosis, we investigated the effects of TNF alpha on the JNK pathway in adherent human neutrophils and the potential involvement of this pathway in neutrophil apoptosis. Stimulation with TNF alpha was found to result in beta (2) integrin-mediated activation of the cytoplasmic tyrosine kinases Pyk2 and Syk, and activation of a three-part MAPk module composed of MEKK1, MKK7, and/or MKK4 and JNK1. JNK activation was attenuated by blocking antibodies to beta (2) integrins, the tyrosine kinase inhibitors, genistein, and tyrphostin A9, a Pyk2-specific inhibitor, and piceatannol, a Syk-specific inhibitor, Exposure of adherent neutrophils to TNF alpha led to the rapid onset of apoptosis that was demonstrated by augmented annexin V binding and caspase-3 cleavage. TNF alpha -induced increases in annexin V binding to neutrophils were attenuated by blocking antibodies to beta (2) integrins, and the caspase-3 cleavage was attenuated by tyrphostin A9. Hence, exposure of adherent neutrophils to TNF alpha leads to utilization of the JNK-signaling pathways that may contribute to diverse functional responses including induction of apoptosis and subsequent resolution of the inflammatory response.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Cell Biol Program, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Med, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Worthen, GS (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061407, P50HL040784] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61407, HL40784, HL13403] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM E, 1995, J EXP MED, V181, P569, DOI 10.1084/jem.181.2.569; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; Astier A, 1997, J BIOL CHEM, V272, P228; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Berton G, 1996, INT J CLIN LAB RES, V26, P160, DOI 10.1007/BF02592978; Berton G, 1999, CELL SIGNAL, V11, P621, DOI 10.1016/S0898-6568(99)00003-0; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coffer PJ, 1997, IMMUNOL LETT, V57, P27, DOI 10.1016/S0165-2478(97)00067-9; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; DAPINO P, 1993, CLIN EXP IMMUNOL, V94, P533; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ERZURUM SC, 1991, AM J RESP CELL MOL, V5, P230, DOI 10.1165/ajrcmb/5.3.230; ERZURUM SC, 1992, J IMMUNOL, V149, P154; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Gavin AC, 1997, MOL REPROD DEV, V46, P383, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;383::AID-MRD18&gt;3.0.CO;2-#; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; HENSON PM, 1988, HUMAN INFLAMMATORY D, V1, P69; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LLOYDS D, 1995, IMMUNOLOGY, V84, P220; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Meszaros AJ, 2000, J IMMUNOL, V165, P435, DOI 10.4049/jimmunol.165.1.435; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Mori L, 1996, J IMMUNOL, V157, P3178; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; NATHAN C, 1990, J CELL BIOL, V111, P2171, DOI 10.1083/jcb.111.5.2171; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1989, BLOOD, V73, P301; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OTTONELLO L, 1994, AGENTS ACTIONS, V41, P57, DOI 10.1007/BF01986395; PARSONS PE, 1992, AM REV RESPIR DIS, V146, P694, DOI 10.1164/ajrccm/146.3.694; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Walzog B, 1997, FASEB J, V11, P1177, DOI 10.1096/fasebj.11.13.9367353; WINDSOR ACJ, 1994, ARCH SURG-CHICAGO, V129, P80; WINDSOR ACJ, 1993, J CLIN INVEST, V91, P1459, DOI 10.1172/JCI116351; Winston BW, 1997, J IMMUNOL, V159, P4491; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; Yan SR, 1999, FEBS LETT, V451, P33, DOI 10.1016/S0014-5793(99)00539-6; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	95	94	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2189	2199		10.1074/jbc.M007527200	http://dx.doi.org/10.1074/jbc.M007527200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053415	hybrid			2022-12-25	WOS:000166528000073
J	Gong, F; Yanofsky, C				Gong, F; Yanofsky, C			Reproducing tna operon regulation in vitro in an S-30 system - Tryptophan induction inhibits cleavage of TnaC peptidyl-RNA?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTION TERMINATION; ESCHERICHIA-COLI; LEADER PEPTIDE; NUCLEOTIDE-SEQUENCE; EXPRESSION; RHO; RELEASE; BICYCLOMYCIN; TRANSLATION; ATTENUATION	Expression of the tryptophanase (tna) operon of Escherichia coli is regulated by catabolite repression and tryptophan-induced transcription antitermination, Catabolite repression regulates transcription initiation, whereas excess tryptophan induces antitermination at Rho factor-dependent termination sites in the leader region of the operon, Synthesis of the leader peptide, TnaC, is essential for antitermination. BoxA and rut sites in the immediate vicinity of the tnaC stop codon are required for termination. In this paper we use an in vitro S-30 cell-free system to analyze the features of tna operon regulation. We show that transcription initiation is cyclic AMP (cAMP)-dependent and is not influenced by tryptophan, Continuation of transcription beyond the leader region requires the presence of inducing levels of tryptophan and synthesis of the TnaC leader peptide. Using a tnaA'-'trpE fusion, we demonstrate that induction results in a 15-20-fold increase in synthesis of the tryptophan-free TnaA-TrpE fusion protein. Replacing Trp codon 12 of tnaC by an Arg codon, or changing the tnaC start codon to a stop codon, eliminates induction. Addition of bicyclomycin, a specific inhibitor of Rho factor action, substantially increases basal level expression. Analyses of tna mRNA synthesis in vitro demonstrate that, in the absence of inducer transcription is terminated and the terminated transcripts are degraded, In the presence of inducer, antitermination increases the synthesis of the read-through transcript. TnaC synthesis is observed in the cell-free system. However, in the presence of tryptophan, a peptidyl-tRNA also appears, TnaC-tRNA(Pro). Our findings suggest that inducer acts by preventing cleavage of TnaC peptidyl-tRNA The ribosome associated with this newly synthesized peptidyl-tRNA presumably stalls at the tnaC stop codon, blocking Rho's access to the BoxA and rut sites, thereby preventing termination. 1-Methyltryptophan also is an effective inducer in vitro, This tryptophan analog is not incorporated into TnaC.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Yanofsky, C (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	yanofsky@cmgm.stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM009738, R37GM009738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM09738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BILEZIKIAN JP, 1967, J MOL BIOL, V27, P495, DOI 10.1016/0022-2836(67)90054-X; BOTSFORD JL, 1971, J BACTERIOL, V105, P303, DOI 10.1128/JB.105.1.303-312.1971; CAO JH, 1995, J VIROL, V69, P1030, DOI 10.1128/JVI.69.2.1030-1036.1995; Cao JH, 1996, MOL CELL BIOL, V16, P7109; Cao JH, 1998, RNA, V4, P181; DEELEY MC, 1981, J BACTERIOL, V147, P787, DOI 10.1128/JB.147.3.787-796.1981; EDWARDS RM, 1982, BIOCHEM J, V204, P617, DOI 10.1042/bj2040617; GISH K, 1995, J BACTERIOL, V177, P7245, DOI 10.1128/jb.177.24.7245-7254.1995; GOLLNICK P, 1990, J BACTERIOL, V172, P3100, DOI 10.1128/jb.172.6.3100-3107.1990; Hopkins FG, 1903, J PHYSIOL-LONDON, V29, P451; KAMATH AV, 1992, J BIOL CHEM, V267, P19978; KAZARINOFF MN, 1977, J BIOL CHEM, V252, P7598; Konan KV, 1997, J BACTERIOL, V179, P1774, DOI 10.1128/jb.179.5.1774-1779.1997; Konan KV, 1999, J BACTERIOL, V181, P1530, DOI 10.1128/JB.181.5.1530-1536.1999; Konan KV, 2000, J BACTERIOL, V182, P3981, DOI 10.1128/JB.182.14.3981-3988.2000; Lesley S A, 1995, Methods Mol Biol, V37, P265; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; NEWTON WA, 1964, P NATL ACAD SCI USA, V51, P382, DOI 10.1073/pnas.51.3.382; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SQUIRES CL, 1973, NATURE-NEW BIOL, V245, P131, DOI 10.1038/newbio245131a0; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STEWART V, 1986, J BACTERIOL, V167, P383, DOI 10.1128/jb.167.1.383-386.1986; STEWART V, 1985, J BACTERIOL, V164, P731, DOI 10.1128/JB.164.2.731-740.1985; WATANABE T, 1972, P NATL ACAD SCI USA, V69, P1086, DOI 10.1073/pnas.69.5.1086; WINKLER ME, 1981, BIOCHEMISTRY-US, V20, P3738, DOI 10.1021/bi00516a011; YANOFSKY C, 1995, J BACTERIOL, V177, P4451, DOI 10.1128/jb.177.15.4451-4456.1995; YANOFSKY C, 1994, J BACTERIOL, V176, P6245, DOI 10.1128/jb.176.20.6245-6254.1994; Yanofsky C, 1996, BIOCHIMIE, V78, P1017, DOI 10.1016/S0300-9084(97)86725-9; Yanofsky C, 1996, J BACTERIOL, V178, P3755, DOI 10.1128/jb.178.13.3755-3762.1996; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991; YANOFSKY C, 1999, ENCY MOL BIOL, V4, P2676; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411; ZWIEFKA A, 1993, BIOCHEMISTRY-US, V32, P3564, DOI 10.1021/bi00065a007	36	52	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1974	1983		10.1074/jbc.M008892200	http://dx.doi.org/10.1074/jbc.M008892200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050101	hybrid			2022-12-25	WOS:000166528000046
J	Kimura, H; Weisz, A; Ogura, T; Hitomi, Y; Kurashima, Y; Hashimoto, K; D'Acquisto, F; Makuuchi, M; Esumi, H				Kimura, H; Weisz, A; Ogura, T; Hitomi, Y; Kurashima, Y; Hashimoto, K; D'Acquisto, F; Makuuchi, M; Esumi, H			Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE-DEHYDROGENASE-A; RESPONSE ELEMENTS; FACTOR-I; TRANSCRIPTIONAL ACTIVATION; CARBON-MONOXIDE; BINDING; 5'-ENHANCER; EXPRESSION; INHIBITION; ENHANCER	Transcription of hypoxia-inducible genes is regulated by hypoxia response elements (HREs) located in either the promoter or enhancer regions. Analysis of these elements reveals the presence of one or more binding sites for hypoxia-inducible factor 1 (HIF-1). Hypoxia-inducible genes include vascular endothelial growth factor (VEGF), erythropoietin, and glycolytic enzyme genes. Site-directed mutational analysis of the VEGF gene promoter revealed that an HIF-1 binding site (HBS) and its downstream HIF-1 ancillary sequence (HAS) within the HRE are required as cis-elements for the transcriptional activation of VEGF by either hypoxia or nitric oxide (NO). The core sequences of the HBS and the HAS were determined as TACGTG and CAGGT, respectively. These elements form an imperfect inverted repeat, and the spacing between these motifs is crucial for activity of the promoter. Gel shift assays demonstrate that as yet unknown protein complexes constitutively bind to the HAS regardless of the presence of these stimuli in several cell lines, in contrast with hypoxia- or NO-induced activation of HIF-1 binding to the HBS. A common structure of the HRE, which consists of the HBS and the HAS, is seen among several hypoxia-inducible genes, suggesting the presence of a novel mechanism mediated by the HAS for the regulation of these genes.	Natl Canc Ctr, Res Inst E, Investigat Treatment Div, Kashiwa, Chiba 2778577, Japan; Univ Naples 2, Inst Gen Pathol & Oncol, I-80138 Naples, Italy; Univ Naples Federico II, Dept Expt Pharmacol, I-80131 Naples, Italy; Univ Tokyo, Dept Surg, Tokyo 1138654, Japan	National Cancer Center - Japan; Universita della Campania Vanvitelli; University of Naples Federico II; University of Tokyo	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Investigat Treatment Div, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.		幕内, 雅敏 m/A-2140-2012; Weisz, Alessandro/A-1317-2014; D'Acquisto, Fulvio/E-7204-2018	Weisz, Alessandro/0000-0003-0455-2083; D'Acquisto, Fulvio/0000-0002-4513-1608				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; Dulak J, 2000, ARTERIOSCL THROM VAS, V20, P659, DOI 10.1161/01.ATV.20.3.659; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; KATO S, 1995, MOL CELL BIOL, V15, P5858; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Kuntz MA, 1997, J BIOL CHEM, V272, P27949, DOI 10.1074/jbc.272.44.27949; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Long WP, 1999, J BIOL CHEM, V274, P12391, DOI 10.1074/jbc.274.18.12391; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, BIOL CHEM, V378, P609	30	215	226	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2292	2298		10.1074/jbc.M008398200	http://dx.doi.org/10.1074/jbc.M008398200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11056166	hybrid			2022-12-25	WOS:000166528000086
J	Martinez-Maza, R; Poyatos, I; Lopez-Corcuera, B; Nunez, E; Gimenez, C; Zafra, F; Aragon, C				Martinez-Maza, R; Poyatos, I; Lopez-Corcuera, B; Nunez, E; Gimenez, C; Zafra, F; Aragon, C			The role of N-glycosylation in transport to the plasma membrane and sorting of the neuronal glycine transporter GLYT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; CANINE KIDNEY-CELLS; EPITHELIAL-CELLS; RAT-BRAIN; NOREPINEPHRINE TRANSPORTER; SEROTONIN TRANSPORTER; LINKED GLYCOSYLATION; GOLGI-NETWORK; SPINAL-CORD; MOUSE-BRAIN	Glycine transporter GLYT2 is an axonal glycoprotein involved in the removal of glycine from the synaptic cleft. To elucidate the role of the carbohydrate moiety on GLYT2 function, we analyzed the effect of the disruption of the putative N-glycosylation sites on the transport activity, intracellular traffic in COS cells, and asymmetrical distribution of this protein in polarized Madin-Darby canine kidney (MDCK) cells. Transport activity was reduced by 35-40% after enzymatic deglycosylation of the transporter reconstituted into liposomes, Site-directed mutagenesis of the four glycosylation sites (Asn-345, Asn-355, Asn-360, and Asn-366), located in the large extracellular loop of GLYT2, produced an inactive protein that was retained in intracellular compartments when transiently transfected in COS cells or in nonpolarized MDCK cells. When expressed in polarized MDCK cells, wild type GLYT2 localizes in the apical surface as assessed by transport and biotinylation assays. However, a partially unglycosylated mutant (triple mutant) was distributed in a nonpolarized manner in MDCK cells. The apical localization of GLYT2 occurred by a glycolipid rafts independent pathway.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Aragon, C (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain.	caragon@cbm.uam.es	Aragon, Carmen/K-9783-2014; Gimenez, Cecilio/K-8027-2014; Zafra, Francisco/A-6121-2008; Corcuera, Beatriz López/D-5188-2009	Aragon, Carmen/0000-0001-8287-9386; Gimenez, Cecilio/0000-0001-6726-8405; Zafra, Francisco/0000-0003-3801-3109; Corcuera, Beatriz López/0000-0002-0383-4241				Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Asano S, 2000, J BIOL CHEM, V275, P8324, DOI 10.1074/jbc.275.12.8324; Bergeron R, 1998, P NATL ACAD SCI USA, V95, P15730, DOI 10.1073/pnas.95.26.15730; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Gahmberg CG, 1996, TRENDS BIOCHEM SCI, V21, P308, DOI 10.1016/0968-0004(96)10034-7; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HAYES G, 1994, J BIOL CHEM, V269, P24143; HIGUCHI E, 1990, PCR PROTOCOLS, P177; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; Jursky F, 1996, J NEUROCHEM, V67, P336; KIM KM, 1994, MOL PHARMACOL, V45, P608; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOPEZCORCUERA B, 1991, J BIOL CHEM, V266, P24809; LOPEZCORCUERA B, 1989, EUR J BIOCHEM, V181, P519, DOI 10.1111/j.1432-1033.1989.tb14754.x; LUQUE JM, 1995, NEUROSCIENCE, V64, P525, DOI 10.1016/0306-4522(94)00404-S; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MINELLI A, 1995, J NEUROSCI, V15, P7734, DOI 10.1523/jneurosci.15-11-07734.1995; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Nguyen TT, 1996, J NEUROCHEM, V67, P645; Nirenberg MJ, 1997, J NEUROSCI, V17, P6899; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; Ponce J, 1998, NEUROSCI LETT, V242, P25, DOI 10.1016/S0304-3940(98)00037-8; Poyatos I, 2000, MOL CELL NEUROSCI, V15, P99, DOI 10.1006/mcne.1999.0807; Puertollano R, 1999, J CELL BIOL, V145, P141, DOI 10.1083/jcb.145.1.141; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; Spike RC, 1997, NEUROSCIENCE, V77, P543, DOI 10.1016/S0306-4522(96)00501-5; Supplisson S, 1997, J NEUROSCI, V17, P4580; Sur C, 1996, NEUROSCIENCE, V73, P217, DOI 10.1016/0306-4522(96)00030-9; TATE CG, 1994, J BIOL CHEM, V269, P26303; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197; ZAFRA F, 1995, EUR J NEUROSCI, V7, P1342, DOI 10.1111/j.1460-9568.1995.tb01125.x; ZAFRA F, 1995, J NEUROSCI, V15, P3952; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596	53	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2168	2173		10.1074/jbc.M006774200	http://dx.doi.org/10.1074/jbc.M006774200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11036075	hybrid			2022-12-25	WOS:000166528000070
J	Yan, B; Heus, J; Lu, N; Nichols, RC; Raben, N; Plotz, PH				Yan, B; Heus, J; Lu, N; Nichols, RC; Raben, N; Plotz, PH			Transcriptional regulation of the human acid alpha-glucosidase gene - Identification of a repressor element and its transcription factors Hes-1 and YY1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX FACTORS; ACHAETE-SCUTE HOMOLOG-1; CELL FATE; MAMMALIAN HAIRY; NERVOUS-SYSTEM; DROSOPHILA; ENHANCER; SPLIT; DIFFERENTIATION; NOTCH	Acid alpha -glucosidase, the product of a housekeeping gene, is a lysosomal enzyme that degrades glycogen. A deficiency of this enzyme is responsible for a recessively inherited myopathy and cardiomyopathy, glycogenesis type II. We have previously demonstrated that the human acid alpha -glucosidase gene expression is regulated by a silencer within intron 1, which is located in the 5'-untranslated region. In this study, we have used deletion analysis, electrophoretic mobility shift assay, and footprint analysis to further localize the silencer to a 25-base pair element, The repressive effect on the TK promoter was about 50% in both orientations in expression plasmid, and two transcriptional factors were identified with antibodies binding specifically to the element. Mutagenesis and functional analyses of the element demonstrated that the mammalian homologue 1 of Drosophila hairy and Enhancer of split (Hes-l) binding to an E box (CACGCG) and global transcription factor-YY1 binding to its core site function as a transcriptional repressor, Furthermore, the overexpression of Hes-l significantly enhanced the repressive effect of the silencer element. The data should be helpful in understanding the expression and regulation of the human acid alpha -glucosidase gene as well as other lysosomal enzyme genes.	NIAMS, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA; Pharming Technol BV, NL-2333 CA Leiden, Netherlands; Dartmouth Med Sch, Lebanon, NH 03756 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Dartmouth College	Plotz, PH (corresponding author), NIAMS, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA.	plotzp@mail.nih.gov						Antoine M, 1998, BIOCHEM J, V336, P327, DOI 10.1042/bj3360327; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Barolo S, 1997, EMBO J, V16, P2883, DOI 10.1093/emboj/16.10.2883; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HERS HG, 1963, BIOCHEM J, V86, P11, DOI 10.1042/bj0860011; HOEFSLOOT LH, 1990, BIOCHEM J, V272, P493, DOI 10.1042/bj2720493; HUIE ML, 1994, HUM MOL GENET, V3, P2231; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JEFFREY PL, 1970, BIOCHEMISTRY-US, V9, P1403, DOI 10.1021/bi00808a015; JEFFREY PL, 1970, BIOCHEMISTRY-US, V9, P1416, DOI 10.1021/bi00808a016; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; LEBLANC B, 1994, DNA PROTEIN INTERACT, P1; MARTINIUK F, 1991, DNA CELL BIOL, V10, P283, DOI 10.1089/dna.1991.10.283; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ponce E, 1999, AM J PATHOL, V154, P1089, DOI 10.1016/S0002-9440(10)65361-8; Raben N, 1996, HUM MOL GENET, V5, P995, DOI 10.1093/hmg/5.7.995; Robey E, 1999, ANNU REV IMMUNOL, V17, P283, DOI 10.1146/annurev.immunol.17.1.283; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; TAYLOR JD, 1994, DNA PROTEIN INTERACT, P263; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729	33	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1789	1793		10.1074/jbc.M005959200	http://dx.doi.org/10.1074/jbc.M005959200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038350	hybrid			2022-12-25	WOS:000166528000020
J	Li, J; Saxena, S; Pain, D; Dancis, A				Li, J; Saxena, S; Pain, D; Dancis, A			Adrenodoxin reductase homolog (Arh1p) of yeast mitochondria required for iron homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SULFUR CLUSTER; MOLECULAR-BIOLOGY; ESSENTIAL GENE; PROTEIN; FRATAXIN; DEFICIENCY; ACONITASE; SYSTEM; CODES	Arh1p is an essential mitochondrial protein of yeast with reductase activity. Here we show that this protein is involved in iron metabolism. A yeast strain was constructed in which the open reading frame was placed under the control of a galactose-regulated promoter. Protein expression was induced by galactose and repressed to undetectable levels in the absence of galactose, although cells grew quite well in the absence of inducer. Under noninducing conditions, cellular iron uptake was dysregulated, exhibiting a failure to repress in response to medium iron. Iron trafficking within the cell was also disturbed. Exposure of Arh1p-depleted cells to increasing iron concentrations during growth led to drastic increases in mitochondrial iron, indicating a loss of homeostatic control. Activity of aconitase, a prototype Fe-S protein, was deficient at all concentrations of mitochondrial iron, although the protein level was unaltered, Heme protein deficiencies were exacerbated in the iron-loaded mitochondria, suggesting a toxic side effect of accumulated iron. Finally, a time course correlated the cellular depletion of Arh1p with the coordinated appearance of various mutant phenotypes including dysregulated cellular iron uptake, deficiency of Fe-S protein activities in mitochondria and cytoplasm, and deficiency of hemoproteins. Thus, Arh1p is required for control of cellular and mitochondrial iron levels and for the activities of Fe-S cluster proteins.	Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Dancis, A (corresponding author), Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.	adancis@mail.med.upenn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053953, R01DK053953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057067] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53953] Funding Source: Medline; NIGMS NIH HHS [GM57067] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Barros MH, 1999, GENE, V233, P197, DOI 10.1016/S0378-1119(99)00137-7; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Brittenham GM, 2000, HEMATOLOGY BASIC PRI, P397; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Freeman MR, 1999, DEVELOPMENT, V126, P4591; Halliwell B., 1991, FREE RADICALS BIOL M; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P423; Lacour T, 1998, J BIOL CHEM, V273, P23984, DOI 10.1074/jbc.273.37.23984; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Manzella L, 1998, YEAST, V14, P839, DOI 10.1002/(SICI)1097-0061(19980630)14:9<839::AID-YEA283>3.0.CO;2-A; Martin H, 1998, ANAL BIOCHEM, V265, P123, DOI 10.1006/abio.1998.2863; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; SIKORSKI RS, 1989, GENETICS, V122, P19; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	39	101	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1503	1509		10.1074/jbc.M007198200	http://dx.doi.org/10.1074/jbc.M007198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035018	hybrid			2022-12-25	WOS:000166430900086
J	Qin, CL; Cook, RG; Orkiszewski, RS; Butler, WT				Qin, CL; Cook, RG; Orkiszewski, RS; Butler, WT			Identification and characterization of the carboxyl-terminal region of rat dentin sialoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALOPHOSPHOPROTEIN DSPP GENE; IMPERFECTA TYPE-II; SEQUENCE DETERMINATION; MATRIX PROTEINS; PHOSPHOPROTEIN; PHOSPHOPHORYN; ENAMELYSIN; CLEAVAGE; DOMAIN; BONE	Two acidic proteins, dentin sialoprotein (DSP) and dentin phosphoprotein (DPP), are present in the extracellular matrix of dentin but not in bone. These two proteins are expressed in odontoblasts and preameloblasts as a single cDNA transcript coding a large precursor protein termed dentin sialophosphoprotein (DSPP). DSPP is specifically cleaved into two unique proteins, DSP and DPP, However, the cleavage site(s) of DSPP and the mechanisms for regulating the cleavages are unknown. To identify the specific site(s) of DSPP that are cleaved when the initial translation product is converted to DSP and DPP, we performed a detailed analysis (Edman degradation and mass spectrometry) on selected tryptic peptides of a size originating from the COOH-terminal region of rat DSP, After cleavage with trypsin, the DSP fragments were separated by a two-dimensional method (size-exclusion chromatography followed by reversed phase high performance liquid chromatography). We characterized 13 peptides from various regions of DSP, The analyses showed that peptide Il(409)-Tyr(421) was the major COOH-terminal fragment, ending at Tyr(421) only 9 residues from the NH, terminus of DPP, Peptide Gln(385)-His(406) represented a second, minor COOH-terminal peptide that terminated at His(406), Both of these residues are well beyond the COOH terminus predicted previously by two independent studies estimating that rat DSP contained 360-370 amino acids. Careful studies on two peptides showed that, among 9 potential casein kinase II phosphorylation sites, 2 serines were phosphorylated, We found that rat DSP was heterogeneous with respect to phosphorylation, because this same peptide sequence eluted in two discrete peaks, one with 2 phosphoserines and the other having 1. The finding that 3 lysines just preceding the COOH termini were modified by a 43-Da substituent (possibly a carbamoyl substituent) suggests that the lysines in this region were particularly susceptible to attachment of this substituent.	Univ Texas, Hlth Sci Ctr, Dept Basic Sci, Dent Branch, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Prot Chem Core Lab, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine	Qin, CL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Basic Sci, Dent Branch, 6516 John Freeman Ave,DBB,Rm 4-133, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE005092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE005092] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE05092] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		APLIN HM, 1995, GENOMICS, V30, P347, DOI 10.1006/geno.1995.9867; Bartlett JD, 1999, CRIT REV ORAL BIOL M, V10, P425, DOI 10.1177/10454411990100040101; BARTLETT JD, 1996, GENE AMST, V183, P13; Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P254, DOI 10.1111/j.1600-0722.1998.tb02184.x; Butler W T, 1995, Connect Tissue Res, V33, P59, DOI 10.3109/03008209509016983; BUTLER WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P178, DOI 10.1016/0003-9861(83)90021-8; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; BUTLER WT, 1995, INT J DEV BIOL, V39, P169; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; BUTLER WT, 1987, METHOD ENZYMOL, V145, P290; Chang SR, 1996, CALCIFIED TISSUE INT, V59, P149, DOI 10.1007/s002239900101; Crosby AH, 1996, MAMM GENOME, V7, P149, DOI 10.1007/s003359900037; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; FUJISAWA R, 1993, J DENT RES, V72, P1222, DOI 10.1177/00220345930720081001; George A, 1998, EUR J ORAL SCI, V106, P221, DOI 10.1111/j.1600-0722.1998.tb02179.x; George A, 1996, J BIOL CHEM, V271, P32869, DOI 10.1074/jbc.271.51.32869; Gu K, 2000, EUR J ORAL SCI, V108, P35, DOI 10.1034/j.1600-0722.2000.00765.x; Li W, 1999, EUR J ORAL SCI, V107, P352, DOI 10.1046/j.0909-8836.1999.eos107506.x; Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1998, EUR J ORAL SCI, V106, P227, DOI 10.1111/j.1600-0722.1998.tb02180.x; Neame PJ, 1996, CONNECT TISSUE RES, V35, P145, DOI 10.3109/03008209609029185; Ritchie HH, 1998, EUR J ORAL SCI, V106, P211, DOI 10.1111/j.1600-0722.1998.tb02178.x; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695; Ryu OH, 1999, J DENT RES, V78, P743, DOI 10.1177/00220345990780030601; VEIS A, 1993, J BONE MINER RES, V8, P5493	28	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					904	909		10.1074/jbc.M006271200	http://dx.doi.org/10.1074/jbc.M006271200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042175	hybrid			2022-12-25	WOS:000166430900007
J	Glover, KE; Spencer, DF; Gray, MW				Glover, KE; Spencer, DF; Gray, MW			Identification and structural characterization of nucleus-encoded transfer RNAs imported into wheat mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVERWORT MARCHANTIA-POLYMORPHA; NUCLEOTIDE-SEQUENCE; PLANT-MITOCHONDRIA; PHASEOLUS-VULGARIS; TRANSFER RNAHIS; TRANSFER RNATYR; GENES; DNA; GENOME; ORGANIZATION	Despite its large size (200-2400 kilobase pairs), the mitochondrial genome of angiosperms does not encode the minimal set of tRNAs required to support mitochondrial protein synthesis. Here we report the identification of cytosolic-like tRNAs in wheat mitochondria using a method involving quantitative hybridization to distinguish among three tRNA classes: (i) those encoded by mitochondrial DNA (mtDNA) and localized in mitochondria, (ii) those encoded by nuclear DNA and located in the cytosol, and (iii) those encoded by nuclear DNA and found in both the cytosol and mitochondria. The latter class comprises tRNA species that are considered to be imported into mitochondria to compensate for the deficiency of mtDNA-encoded tRNAs, In a comprehensive survey of the wheat mitochondrial tRNA population, we identified 14 such imported tRNAs, the structural characterization of which is presented here. These imported tRNAs complement 16 mtDNA-encoded tRNAs, for a total of at least 30 distinct tRNA species in wheat mitochondria. Considering differences in the set of mtDNA-encoded and imported tRNAs in the mitochondria of various land plants, the import system must be able to adapt relatively rapidly over evolutionary time with regard to the particular cytosolic-like tRNA that are brought into mitochondria.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Gray, MW (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.			Gray, Michael/0000-0001-7125-2625				Akashi K, 1996, CURR GENET, V30, P181, DOI 10.1007/s002940050118; Akashi K, 1998, NUCLEIC ACIDS RES, V26, P2168, DOI 10.1093/nar/26.9.2168; Akashi K, 1997, BBA-GENE STRUCT EXPR, V1350, P262, DOI 10.1016/S0167-4781(96)00239-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARCISZEWSKA M, 1988, NUCLEIC ACIDS RES, V16, P8175, DOI 10.1093/nar/16.16.8175; BARCISZEWSKA M, 1987, NUCLEIC ACIDS RES, V15, P1333, DOI 10.1093/nar/15.3.1333; BARCISZEWSKA MZ, 1986, BIOCHIMIE, V68, P319, DOI 10.1016/S0300-9084(86)80029-3; BARCISZEWSKA MZ, 1986, PLANT SCI, V47, P103, DOI 10.1016/0168-9452(86)90056-7; Baum M, 1998, NUCLEIC ACIDS RES, V26, P1390, DOI 10.1093/nar/26.6.1390; BEIER H, 1984, EMBO J, V3, P351, DOI 10.1002/j.1460-2075.1984.tb01810.x; BINDER S, 1990, CURR GENET, V17, P353, DOI 10.1007/BF00314884; BONEN L, 1980, NUCLEIC ACIDS RES, V8, P319, DOI 10.1093/nar/8.2.319; BURKARD G, 1982, METHODS CHLOROPLAST, P347; Ceci LR, 1996, DNA SEQUENCE, V6, P159, DOI 10.3109/10425179609010203; CECI LR, 1989, PLANT SCI, V61, P219, DOI 10.1016/0168-9452(89)90228-8; CHANG SH, 1973, BIOCHEM BIOPH RES CO, V51, P951, DOI 10.1016/0006-291X(73)90019-3; Chen HC, 1997, BIOCHEM BIOPH RES CO, V237, P432, DOI 10.1006/bbrc.1997.7138; deBarros JPP, 1996, NUCLEIC ACIDS RES, V24, P1489; DIETRICH A, 1992, ANNU REV CELL BIOL, V8, P115, DOI 10.1146/annurev.cb.08.110192.000555; DUDOCK BS, 1969, J BIOL CHEM, V244, P3069; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; GELIEBTER J, 1987, FOCUS, V9, P5; GLOVER K, 1995, THESIS DALHOUSIE U H; Gray MW, 1998, NUCLEIC ACIDS RES, V26, P865, DOI 10.1093/nar/26.4.865; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; GREEN GA, 1987, PLANT MOL BIOL, V10, P13, DOI 10.1007/BF00014182; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; IAMS K P, 1985, Plant Molecular Biology, V4, P225, DOI 10.1007/BF02418240; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; JOYCE PBM, 1988, PLANT MOL BIOL, V10, P251, DOI 10.1007/BF00027402; JOYCE PBM, 1989, NUCLEIC ACIDS RES, V17, P7865, DOI 10.1093/nar/17.19.7865; JOYCE PBM, 1989, NUCLEIC ACIDS RES, V17, P5461, DOI 10.1093/nar/17.14.5461; JOYCE PBM, 1989, THESIS DALHOUSIE U H; JUKES TH, 1990, EXPERIENTIA, V46, P1117, DOI 10.1007/BF01936921; Kanno A, 1997, PLANT MOL BIOL, V34, P353, DOI 10.1023/A:1005828728036; Kumar R, 1996, MOL GEN GENET, V252, P404, DOI 10.1007/BF02173005; KUSAMAEGUCHI K, 1991, BIOCHEM BIOPH RES CO, V177, P745, DOI 10.1016/0006-291X(91)91851-3; MARCU K, 1978, NUCLEIC ACIDS RES, V5, P1075, DOI 10.1093/nar/5.4.1075; MARCU KB, 1977, BIOCHEMISTRY-US, V16, P797, DOI 10.1021/bi00623a036; MARECHAL L, 1985, PLANT MOL BIOL, V5, P347, DOI 10.1007/BF00037555; MarechalDrouard L, 1995, METHOD ENZYMOL, V260, P310, DOI 10.1016/0076-6879(95)60148-1; MARECHALDROUARD L, 1988, NUCLEIC ACIDS RES, V16, P4777, DOI 10.1093/nar/16.11.4777; MARECHALDROUARD L, 1990, NUCLEIC ACIDS RES, V18, P3689, DOI 10.1093/nar/18.13.3689; MARECHALDROUARD L, 1993, ANNU REV PLANT PHYS, V44, P13, DOI 10.1146/annurev.pp.44.060193.000305; MARTIN RP, 1990, BIOCHEMISTRY-US, V29, P956, DOI 10.1021/bi00456a016; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; ODA K, 1992, NUCLEIC ACIDS RES, V20, P3773, DOI 10.1093/nar/20.14.3773; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PFITZINGER H, 1990, PLANT MOL BIOL, V14, P805, DOI 10.1007/BF00016513; SANGARE A, 1990, MOL GEN GENET, V223, P224, DOI 10.1007/BF00265058; SCHNARE MN, 1985, CURR GENET, V9, P389, DOI 10.1007/BF00421610; SPENCER DF, 1992, MOD METHOD PLANT, V14, P347; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57; WATANABE N, 1994, CURR GENET, V26, P512, DOI 10.1007/BF00309942; WEBERLOTFI F, 1993, PLANT MOL BIOL, V21, P403, DOI 10.1007/BF00019957; ZEFF RA, 1987, FOCUS, V9, P1	57	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					639	648		10.1074/jbc.M007708200	http://dx.doi.org/10.1074/jbc.M007708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027690	hybrid			2022-12-25	WOS:000166280700086
J	Wu, WI; Schwindinger, WF; Aparicio, LF; Levine, MA				Wu, WI; Schwindinger, WF; Aparicio, LF; Levine, MA			Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of G alpha(s) - A cause of pseudohypoparathyroidism type Ib	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALBRIGHT-HEREDITARY-OSTEODYSTROPHY; GRADIENT GEL-ELECTROPHORESIS; STIMULATORY G-PROTEIN; (PTH)/PTH-RELATED PEPTIDE RECEPTOR; NUCLEOTIDE-BINDING-PROTEIN; HUMAN GNAS1 GENE; ADENYLYL-CYCLASE; ALPHA-SUBUNIT; DEOXYRIBONUCLEIC-ACID; PARENTAL ORIGIN	G(s) is a heterotrimeric (alpha, beta, and gamma chains) G protein that couples heptahelical plasma membrane receptors to stimulation of adenylyl cyclase, Inactivation of one GNAS1 gene allele encoding the a chain of G(s) (G alpha (s)) causes pseudohypoparathyroidism type Ia. Affected subjects have resistance to parathyroid hormone (PTH) and other hormones that activate adenylyl cyclase plus somatic features termed Albright hereditary ostesdystrophy. By contrast, subjects with pseudohspoparathyroidism type Ib have hormone resistance that is limited to PTH and lack Albright hereditary osteodystrophy, The molecular basis for pseudohypoparathyroidism type Ib is unknown. We analyzed the GNAS1 gene for mutations using polymerase chain reaction to amplify genomic DNA from three brothers with pseudohypoparathyroidism type Ib. We identified a novel heterozygous 3-base pair deletion causing loss of isoleucine 382 in the three affected boys and their clinically unaffected mother and maternal grandfather, This mutation was absent in other family members and 15 additional unrelated subjects with pseudohypoparathyroidism type Ib. To characterize the signaling properties of the mutant G alpha (s), we used site-directed mutagenesis to introduce the isoleucine 382 deletion into a wild type G alpha (s) cDNA, transfected HEK293 cells with either wild type or mutant G alpha (s) cDNA, plus cDNAs encoding heptahelical receptors for PTH, thyrotropic hormone, or luteinizing hormone, and we measured cAMP production in response to hormone stimulation. The mutant G alpha (s) protein was unable to interact with the receptor for PTH but showed normal coupling to the other coexpressed heptahelical receptors, These results provide evidence of selective uncoupling of the mutant G alpha (s) from PTH receptors and explain PTH-specific hormone resistance in these three brothers with pseudohypoparathyroidism type Ib. The absence of PTH resistance in the mother and maternal grandfather who carry the same mutation is consistent with current models of paternal imprinting of time GNAS1 gene.	Johns Hopkins Univ, Sch Med, Div Pediat Endocrinol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Ilyssa Ctr Mol & Cellular Endocrinol, Dept Pediat, Baltimore, MD 21287 USA; Metab Dis Associates, Erie, PA 16507 USA	Johns Hopkins University; Johns Hopkins University	Levine, MA (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Endocrinol, Pk Bldg,Rm 211,600 N Wolfe St, Baltimore, MD 21287 USA.			Levine, Michael/0000-0003-0036-7809	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034281] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0035] Funding Source: Medline; NIDDK NIH HHS [DK34281] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS AE, 1995, BIOCHEMISTRY-US, V34, P10553, DOI 10.1021/bi00033a030; ALBRIGHT F, 1952, T ASSOC AM PHYSICIAN, V65, P337; Albright F, 1942, ENDOCRINOLOGY, V30, P922; ALLEN DB, 1988, AM J MED GENET, V31, P153, DOI 10.1002/ajmg.1320310118; Bettoun JD, 1997, J CLIN ENDOCR METAB, V82, P1031, DOI 10.1210/jc.82.4.1031; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BURNSTEIN MI, 1985, RADIOLOGY, V155, P351, DOI 10.1148/radiology.155.2.3983385; CAIN CD, 1987, J BONE MINER RES, V2, P437; CAMPBELL R, 1994, J MED GENET, V31, P607, DOI 10.1136/jmg.31.8.607; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Conklin BR, 1996, MOL PHARMACOL, V50, P885; DAVIES SJ, 1993, J MED GENET, V30, P101, DOI 10.1136/jmg.30.2.101; DEBEUR SMJ, 1998, P END SOC ANN M ABST, P62; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; Fukumoto S, 1996, J CLIN ENDOCR METAB, V81, P2554, DOI 10.1210/jc.81.7.2554; GEJMAN PV, 1991, GENOMICS, V9, P782, DOI 10.1016/0888-7543(91)90377-Q; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P15475, DOI 10.1073/pnas.95.26.15475; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; Jobert AS, 1998, J CLIN INVEST, V102, P34, DOI 10.1172/JCI2918; Juppner H, 1998, P NATL ACAD SCI USA, V95, P11798, DOI 10.1073/pnas.95.20.11798; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEVINE MA, 1986, J CLIN ENDOCR METAB, V62, P497, DOI 10.1210/jcem-62-3-497; LEVINE MA, 1983, J CLIN INVEST, V72, P316, DOI 10.1172/JCI110971; Levine MA, 1999, J BONE MINER RES, V14, P1255, DOI 10.1359/jbmr.1999.14.8.1255; LEVINE MA, 1983, AM J MED, V74, P545, DOI 10.1016/0002-9343(83)91008-2; Levine MA, 2000, ENDOCRINOLOGY, P1133; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; Liu J, 2000, MOL CELL BIOL, V20, P5808, DOI 10.1128/MCB.20.16.5808-5817.2000; MIRIC A, 1993, J CLIN ENDOCR METAB, V76, P1560, DOI 10.1210/jc.76.6.1560; MURRAY TM, 1993, J BONE MINER RES, V8, P83; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3111, DOI 10.1093/nar/13.9.3111; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; Nakamoto JM, 1998, AM J MED GENET, V77, P261; Namnoum AB, 1998, J CLIN ENDOCR METAB, V83, P824, DOI 10.1210/jc.83.3.824; NUSYNOWITZ ML, 1976, MEDICINE, V55, P105, DOI 10.1097/00005792-197603000-00001; PANTALONI C, 1993, J RECEPTOR RES, V13, P591, DOI 10.3109/10799899309073681; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PATTEN JL, 1990, J CLIN ENDOCR METAB, V71, P1208, DOI 10.1210/jcem-71-5-1208; RALL T, 1987, FEBS LETT, V224, P365, DOI 10.1016/0014-5793(87)80486-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; SCHWINDINGER WF, 1994, J BIOL CHEM, V269, P25387; SCHWINDINGER WF, 1998, P 80 ANN M END SOC N, P480; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; Spiegel A M, 1990, Biochem Soc Symp, V56, P61; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; SWAROOP A, 1991, NUCLEIC ACIDS RES, V19, P4725, DOI 10.1093/nar/19.17.4725; Warner DR, 1998, J BIOL CHEM, V273, P23976, DOI 10.1074/jbc.273.37.23976; Warner DR, 1997, MOL ENDOCRINOL, V11, P1718, DOI 10.1210/me.11.11.1718; Weinstein LS, 2000, AM J PHYSIOL-RENAL, V278, pF507, DOI 10.1152/ajprenal.2000.278.4.F507; WILSON LC, 1994, J MED GENET, V31, P835, DOI 10.1136/jmg.31.11.835; WINTER JSD, 1980, CAN MED ASSOC J, V123, P26; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715	58	49	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					165	171		10.1074/jbc.M006032200	http://dx.doi.org/10.1074/jbc.M006032200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029463	hybrid			2022-12-25	WOS:000166280700024
J	Biederer, T; Sudhof, TC				Biederer, T; Sudhof, TC			Mints as adaptors - Direct binding to neurexins and recruitment of Munc18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; SYNAPTIC VESICLE EXOCYTOSIS; CELL-SURFACE PROTEINS; EPITHELIAL-CELLS; RECEPTOR; GENE; LOCALIZATION; ADHESION; COMPLEX; DOMAINS	Mint1 (X11/human Lin-10) and Mint2 are neuronal adaptor proteins that bind to Munc18-1 (n/rb-sec1), a protein essential for synaptic vesicle exocytosis. Mint1 has previously been characterized in a complex with CASK, another adaptor protein that in turn interacts with neurexins. Neurexins are neuron-specific cell surface proteins that act as receptors for the excitatory neurotoxin cw-latrotoxin. Hence, one possible function for Mint1 is to mediate the recruitment of Munc18 to neurexins. In agreement with this hypothesis, we now show that the cytoplasmic tail of neurexins captures Munc18 via a multiprotein complex that involves Mint1. Furthermore, we demonstrate that both Mint1 and Mint2 can directly bind to neurexins in a PDZ domain-mediated interaction. Various Mint and/or CASK-containing complexes can be assembled on neurexins, and we demonstrate that Mint1 can bind to Munc18 and CASK simultaneously. Our data support a model whereby one of the functions of Mints is to localize the vesicle fusion protein Munc18 to those sites at the plasma membrane that are defined by neurexins, presumably in the vicinity of points of exocytosis.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Biederer, T (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Biederer, Thomas/AAZ-6133-2021	Biederer, Thomas/0000-0003-0912-1514				Blanco G, 1998, MAMM GENOME, V9, P473, DOI 10.1007/s003359900800; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cowburn D, 1997, CURR OPIN STRUC BIOL, V7, P835, DOI 10.1016/S0959-440X(97)80155-8; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; Hata Y, 1996, J NEUROSCI, V16, P2488; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Okamoto M, 2000, EUR J NEUROSCI, V12, P3067, DOI 10.1046/j.1460-9568.2000.00200.x; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Okamoto M, 1998, EUR J CELL BIOL, V77, P161, DOI 10.1016/S0171-9335(98)80103-9; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087	22	182	190	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39803	39806		10.1074/jbc.C000656200	http://dx.doi.org/10.1074/jbc.C000656200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11036064	hybrid			2022-12-25	WOS:000166039500001
J	Bujnicki, JM				Bujnicki, JM			Phylogenomic analysis of 16S rRNA :(guanine-N2) methyltransferases suggests new family members and reveals highly conserved motifs and a domain structure similar to other nucleic acid amino-methyltransferases	FASEB JOURNAL			English	Article						RNA modification; sequence alignment; molecular evolution; structure prediction	ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES; S-ADENOSYLMETHIONINE; DNA METHYLTRANSFERASES; SEQUENCE ALIGNMENT; ESCHERICHIA-COLI; RNA; PROTEIN; IDENTIFICATION; GENERATION; ENZYMES	The sequences of known Escherichia coli 16S rRNA:m(2)G1207 methyltransferase (MTase) RsmC and hypothetical 168 rRNA:m(2)G966 MTase encoded by the ygjo open reading frame were used to carry out a database search of other putative m(2)G-generating enzymes in finished and unfinished genomic sequences. Sequence comparison and phylogenetic analysis of 21 close homologs of RsmC and YgjO revealed the presence of the third paralogous lineage in E. coli and other gamma -Proteobacteria, which might correspond to the subfamily of MTases specific for G1516 in 16S rRNA. In addition, the comparative sequence analysis supported by sequence/structure threading suggests that rRNA:m(2)G MTases are very closely related to RNA and DNA:m(6)A MTases and that these two enzyme families share common architecture of the active site and presumably a similar mechanism of methyl group transfer onto the exocyclic amino group of their target bases.-Bujnicki, J. M. Phylogenomic analysis of 16S rRNA (guanine-N2) methyltransferases suggests new family members and reveals highly conserved motifs and a domain structure similar to other nucleic acid amino-methyltransferases.	Int Inst Mol & Cell Biol, Bioinformat Unit, PL-02109 Warsaw, Poland; Henry Ford Hlth Syst, Mol Biol Res Program, Detroit, MI 48202 USA	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Henry Ford Health System; Henry Ford Hospital	Bujnicki, JM (corresponding author), Int Inst Mol & Cell Biol, Bioinformat Unit, Ul Ks Trojdena 4, PL-02109 Warsaw, Poland.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bujnicki Janusz M., 1999, Acta Microbiologica Polonica, V48, P19; Bujnicki JM, 1999, IUBMB LIFE, V48, P247, DOI 10.1080/713803519; Bujnicki JM, 1999, NUCLEIC ACIDS RES, V27, P4501, DOI 10.1093/nar/27.22.4501; BUJNICKI JM, 1999, SILICO BIOL, V1, P1; Cheng X, 1999, S ADENOSYLMETHIONINE; FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Grosjean H, 1998, MODIFICATION EDITING, P21; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; OGARA M, 1995, GENE, V157, P135, DOI 10.1016/0378-1119(94)00669-J; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Radlinska M, 1999, PROTEINS, V37, P717, DOI 10.1002/(SICI)1097-0134(19991201)37:4<717::AID-PROT20>3.0.CO;2-P; Reid R, 1999, NUCLEIC ACIDS RES, V27, P3138, DOI 10.1093/nar/27.15.3138; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHLUCKEBIER G, 1995, GENE, V157, P131, DOI 10.1016/0378-1119(94)00690-T; Schluckebier G, 1998, BIOL CHEM, V379, P389; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tscherne JS, 1999, J BIOL CHEM, V274, P924, DOI 10.1074/jbc.274.2.924; Yu LP, 1997, NAT STRUCT BIOL, V4, P483, DOI 10.1038/nsb0697-483	28	39	39	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2365	2368		10.1096/fj.00-0076com	http://dx.doi.org/10.1096/fj.00-0076com			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053259				2022-12-25	WOS:000165190800031
J	Venuti, A; Salani, D; Manni, V; Poggiali, F; Bagnato, A				Venuti, A; Salani, D; Manni, V; Poggiali, F; Bagnato, A			Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy	FASEB JOURNAL			English	Article						ETAR antagonists; genital tumors; tumor growth; papillomavirus; autocrine loop	GROWTH-FACTOR RECEPTOR; HUMAN-PAPILLOMAVIRUS; HUMAN KERATINOCYTES; OVARIAN-CARCINOMA; PROSTATE-CANCER; E5 ONCOPROTEIN; CELL-GROWTH; TUMOR; SUBTYPE	Human papillomaviruses (HPV) are associated with cervical cancer and interact with growth factors that may enhance malignant transformation of cervical carcinoma cells. Endothelin-1 (ET-1) is released from HPV transfected keratinocytes and induces increased growth response in these cell lines in comparison with normal cells. In the present study several cervical carcinoma cell Lines have been analyzed to investigate the expression of ET-1 and its receptors as well as their involvement in tumor growth, All HPV-positive cancer cells secreted ET-1 and expressed mRNA for ET-1 and its receptors, whereas a HPV-negative carcinoma cell line expressed only the ETBR mRNA and didn't secrete ET-1, Binding studies showed that HPV-associated cells expressed an increased number of functional ETAR. ET-1 stimulated a marked dose-dependent increase in [H-3]-thymidine incorporation with respect to the normal cells whereas ET-3 and ETBR agonists had no effect, In HPV-positive cancer cells, a specific antagonist of ETAR inhibited the proliferation induced by ET-1 and substantially reduced the basal growth rate of unstimulated cervical tumor cells, whereas the ETBR antagonist had no effect, These results demonstrate that ET-1 participates in the progression of neoplastic growth in HPV-associated carcinoma, in which ETAR are increased and could be targeted for antitumor therapy.-Venuti, A., Salani, D., Manni, V., Poggiali, F., Bagnato, A. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy.	Regina Elena Canc Inst, Virol Lab, I-00158 Rome, Italy; Regina Elena Canc Inst, Lab Mol Pathol & Ultrastruct, I-00158 Rome, Italy		Venuti, A (corresponding author), Regina Elena Canc Inst, Virol Lab, Via Messi Oro 156, I-00158 Rome, Italy.		Bagnato, Anna/G-9747-2016; Venuti, Aldo/K-9637-2016	Bagnato, Anna/0000-0002-7269-9522; Venuti, Aldo/0000-0003-2322-6857				BAGNATO A, 1995, BIOCHEM BIOPH RES CO, V209, P80, DOI 10.1006/bbrc.1995.1473; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1998, TRENDS ENDOCRIN MET, V9, P378, DOI 10.1016/S1043-2760(98)00094-0; Bagnato A, 1995, CLIN CANCER RES, V1, P1059; Bagnato A, 1997, CANCER RES, V57, P1306; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; FRANCO EL, 1995, JNCI-J NATL CANCER I, V87, P779, DOI 10.1093/jnci/87.11.779; FUKAHIRO T, 1994, BIOCHEM BIOPH RES CO, V199, P1461; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; Nelson JB, 1996, CANCER RES, V56, P663; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Nelson JB, 1998, NAT MED, V4, P1011, DOI 10.1038/1998; PEKONEN F, 1995, BRIT J CANCER, V71, P59, DOI 10.1038/bjc.1995.12; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SIZEMORE N, 1993, CANCER RES, V53, P4511; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; Venuti A, 1998, VIROLOGY, V248, P1, DOI 10.1006/viro.1998.9227; Venuti A, 1997, J VIROL, V71, P6898, DOI 10.1128/JVI.71.9.6898-6904.1997; YAMASHITA J, 1992, CANCER RES, V52, P4046; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; zurHausen H, 1996, J CANCER RES CLIN, V122, P3	26	51	53	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2277	2283		10.1096/fj.00-0024com	http://dx.doi.org/10.1096/fj.00-0024com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053249				2022-12-25	WOS:000165190800021
J	Dean, G; Young, DA; Edwards, DR; Clark, IM				Dean, G; Young, DA; Edwards, DR; Clark, IM			The human tissue inhibitor of metalloproteinases (TIMP)-1 gene contains repressive elements within the promoter and intron 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTORS; BINDING-SITE; SP-FAMILY; EXPRESSION; FIBROBLASTS; ACTIVATION; DOMAINS; TIMP-1	Expression of the TIMP-1 (tissue inhibitor of metalloproteinases-l) gene is tightly controlled during embryonic development and in the adult animal, Previous studies have focused on elements within the gene promoter which activate transcription of the gene. Here, we identify two regions of the gene which repress transcription: An element upstream of the basal gene promoter at -1718/-1458, represses expression of a reporter gene by approximately 50%; addition of the first intron to any promoter-reporter construct also strongly represses gene expression. The TIMP-1 gene has a short first exon which is transcribed but not translated, with the translation start site located in exon 2, Deletion analysis through intron 1 reveals a number of potential regions which might mediate its effect. Protein binding studies and mutational analyses reveal that a repressive element at +684/+748 binds Sp1, Sp3, and an unidentified Ets-related factor to suppress transcription.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Clark, IM (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	i.clark@uea.ac.uk	Edwards, Dylan R/B-4734-2009; Clark, Ian M/D-1920-2009; Young, David/GOV-5677-2022	Edwards, Dylan R/0000-0002-3292-2064; Young, David/0000-0002-7078-6745				Bornstein P, 1996, MATRIX BIOL, V15, P3, DOI 10.1016/S0945-053X(96)90121-3; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Edwards DR, 2000, CANC DRUG DISC DEV, P67; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KRISTIE TM, 1986, P NATL ACAD SCI USA, V83, P4700, DOI 10.1073/pnas.83.13.4700; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LOTZ M, 1991, J BIOL CHEM, V266, P2017; MAIER R, 1993, J BIOL CHEM, V268, P21527; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; SATO T, 1990, BIOCHEM BIOPH RES CO, V170, P824, DOI 10.1016/0006-291X(90)92165-V; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; Woessner JF, 1999, ANN NY ACAD SCI, V878, P388, DOI 10.1111/j.1749-6632.1999.tb07697.x	23	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32664	32671		10.1074/jbc.275.42.32664	http://dx.doi.org/10.1074/jbc.275.42.32664			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	11032844	hybrid			2022-12-25	WOS:000090003800041
J	Mercuri, FA; Maciewicz, RA; Tart, J; Last, K; Fosang, AJ				Mercuri, FA; Maciewicz, RA; Tart, J; Last, K; Fosang, AJ			Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns - Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL COLLAGENASE MMP-8; HUMAN ARTICULAR-CARTILAGE; ANTIGEN-INDUCED ARTHRITIS; HUMAN SYNOVIAL-FLUID; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; TERMINAL DOMAIN; ADAMTS FAMILY; CATHEPSIN-B; DEGRADATION	We have expressed G1-G2 mutants with amino acid changes at the DIPEN(341)down arrow (342)FFGVG and ITEGE(373)down arrow (374)-ARGSV cleavage sites, in order to investigate the relationship between matrix metalloproteinase (MMP) and aggrecanase activities in the interglobular domain (IGD) of aggrecan. The mutation DIPEN341 to DIGSA(341) partially blocked cleavage by MMP-13 and MMP-8 at the MMP site, while the mutation (342)FFGVG to (342)GTRVG; completely blocked cleavage at this site by MMP-1, -2, -3, -7, -8, -9, -13, -14. Each of the MMP cleavage site mutants, including a four-amino acid deletion mutant lacking residues ENFF343, were efficiently cleaved by aggrecanase, suggesting that the primary sequence at the MMP site had no effect on aggrecanase activity in the IGD. The mutation (374)ARGSV to (NVYSV)-N-374 completely blocked cleavage at the aggrecanase site by aggrecanase, MMP-8 and atrolysin C but had no effect on the ability of MMP-8 and MMP-13 to cleave at the Asn(341)down arrow Phe bond. Susceptibility to atrolysin C cleavage at the MMP site was conferred in the DIGSA(341) mutant but absent in the wildtype, (342)GTRVG, (NVYSV)-N-374, and deletion mutants. To further explore the relationship between MMP and aggrecanase activities, sequential digest experiments were done in which MMP degradation products were subsequently digested with aggrecanase and vice versa. Aggrecanase-derived G1 domains with ITEGE(373) C termini were viable substrates for MMPs; however, MMP-derived G2 fragments were resistant to cleavage by aggrecanase. A 10-mer peptide FVDIPENFFG, which is a substrate analogue for the MMP cleavage site, inhibited aggrecanase cleavage at the Glu(373)down arrow Ala bond. This study demonstrates that MMPs and aggrecanase have unique substrate recognition in the IGD of aggrecan and suggests that sequences at the C terminus of the DIPEN341 G1 domain may be important for regulating aggrecanase cleavage.	Univ Melbourne, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; AstraZeneca, Resp & Inflammat Res Dept, Macclesfield SK10 4TG, Cheshire, England	University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; AstraZeneca	Fosang, AJ (corresponding author), Univ Melbourne, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia.	fosang@cryptic.rch.unimelb.edu.au		Last, Karena/0000-0002-4396-8404; Fosang, Amanda/0000-0002-5523-5427; Mercuri, Francesca/0000-0003-1026-2672				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1999, ANN NY ACAD SCI, V878, P92, DOI 10.1111/j.1749-6632.1999.tb07676.x; Arner EC, 1997, J BIOL CHEM, V272, P9294; Dodge GR, 1998, ARTHRITIS RHEUM-US, V41, P274; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; Fosang AJ, 2000, J BIOL CHEM, V275, P33027, DOI 10.1074/jbc.M910207199; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; FOSANG AJ, 1998, T ORTHOP RES SOC, V23, P3; FOSANG AJ, 1999, METALLOPROTEINS TARG; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; Ilic MZ, 1998, J BIOL CHEM, V273, P17451, DOI 10.1074/jbc.273.28.17451; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Lark MW, 1995, ACTA ORTHOP SCAND, V66, P92, DOI 10.3109/17453679509157660; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; Lohmander LS, 1995, ACTA ORTHOP SCAND, V66, P84; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Mercuri FA, 1999, J BIOL CHEM, V274, P32387, DOI 10.1074/jbc.274.45.32387; Mort JS, 1998, BIOCHEM J, V335, P491, DOI 10.1042/bj3350491; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olszewski J, 1996, ARTHRITIS RHEUM, V39, P1234, DOI 10.1002/art.1780390724; Parks WC, 1998, BIOL EXTRAC, P263; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Singer II, 1997, OSTEOARTHR CARTILAGE, V5, P407, DOI 10.1016/S1063-4584(97)80045-3; SINGER II, 1995, J CLIN INVEST, V95, P2178, DOI 10.1172/JCI117907; Sztrolovics R, 1997, BIOCHEM J, V326, P235, DOI 10.1042/bj3260235; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella MD, 1998, J BIOL CHEM, V273, P5846, DOI 10.1074/jbc.273.10.5846; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; van Meurs J, 1999, ARTHRITIS RHEUM-US, V42, P2074, DOI 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5; van Meurs JBJ, 1998, ARTHRITIS RHEUM, V41, P647, DOI 10.1002/1529-0131(199804)41:4<647::AID-ART11>3.0.CO;2-T; van Meurs JBJ, 1999, ANN RHEUM DIS, V58, P350, DOI 10.1136/ard.58.6.350; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179	55	43	46	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33038	33045		10.1074/jbc.275.42.33038	http://dx.doi.org/10.1074/jbc.275.42.33038			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	11032846	hybrid			2022-12-25	WOS:000090003800090
J	Lee, JH; Han, SU; Cho, H; Jennings, B; Gerrard, B; Dean, M; Schmidt, L; Zbar, B; Vande Woude, GF				Lee, JH; Han, SU; Cho, H; Jennings, B; Gerrard, B; Dean, M; Schmidt, L; Zbar, B; Vande Woude, GF			A novel germ line juxtamembrane Met mutation in human gastric cancer	ONCOGENE			English	Article						gastric cancer; germ line; juxtamembrane Met mutation	HEPATOCYTE GROWTH-FACTOR; PAPILLARY RENAL CARCINOMAS; SCATTER FACTOR; TYROSINE KINASE; FACTOR RECEPTOR; C-MET; EPITHELIAL-CELLS; PROTOONCOGENE PRODUCT; SOMATIC MUTATIONS; TUMORIGENICITY	Activating mutations in the Met receptor tyrosine kinase, both germline and somatic, have been identified in human papillary renal cancer. Here we report a novel germline missense Met mutation, P1009S, in a patient with primary gastric cancer. The dosage of the mutant Met DNA was elevated in the tumor when compared to its matched normal DNA. Therefore, as with hereditary renal papillary cancer, the mutant Met allele may also be selectively duplicated in the tumor. Different from previously reported Met mutations, which occur in the tyrosine kinase domain, this missense mutation is located at the juxtamembrane domain, and is not constitutively activated. However, following treatment with HGF/SF, the P1009S mutant Met protein, expressed in NIH3T3 cells, displays increased and persistent tyrosine phosphorylation compared to the wild-type Met. Importantly, these cells also form colonies in soft agar, and are highly tumorigenic in athymic nude mice. A second nucleotide change in this region of Met, T1010I, was found in a breast cancer biopsy and a large cell lung cancer cell line. Although this previously reported 'polymorphism' did not stimulate NIH3T3 cell growth in soft agar, it was more active than the wild-type Met in the athymic nude mice tumorigenesis assay, suggesting that it may have effects on tumorigenesis. Met has been shown to be highly expressed in human gastric carcinoma cell lines, and our results raise the possibility that activating missense Met mutations could contribute to tumorigenesis of gastric cancer.	Van Andel Res Inst, Grand Rapids, MI 49503 USA; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Ajou Univ, Sch Med, Dept Surg, Paldal Gu, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Biochem, Paldal Gu, Suwon 442749, South Korea; Norfolk & Norwich Healthcare NHS Trust, Norwich, Norfolk, England; NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Div Intramural Res Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Genom Divers, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA	Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Ajou University; Ajou University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vande Woude, GF (corresponding author), Van Andel Res Inst, 333 Bostwick,NE, Grand Rapids, MI 49503 USA.		Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; Cho, Hyeseong/0000-0002-4672-8887	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLUSCI S, 1994, ONCOGENE, V9, P1091; Blair D G, 1983, Prog Clin Biol Res, V119, P79; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Caldas C, 1999, J MED GENET, V36, P873; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; FALETTO DL, 1992, ONCOGENE, V7, P1149; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Higashio K, 1993, EXS, V65, P351; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, CELL GROWTH DIFFER, V7, P1805; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kanda H, 1993, Nihon Rinsho, V51, P380; Matturri L, 1998, ANTICANCER RES, V18, P2819; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 1999, CANCER RES, V59, P307; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; PONZETTO C, 1991, ONCOGENE, V6, P553; RAO PH, 1993, DIAGN MOL PATHOL, V2, P264, DOI 10.1097/00019606-199312000-00006; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tanyi J, 1999, Pathol Oncol Res, V5, P187, DOI 10.1053/paor.1999.0219; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	47	276	292	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4947	4953		10.1038/sj.onc.1203874	http://dx.doi.org/10.1038/sj.onc.1203874			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042681				2022-12-25	WOS:000089834300001
J	Grothey, A; Hashizume, R; Ji, H; Tubb, BE; Patrick, CW; Yu, DH; Mooney, EE; McCrea, PD				Grothey, A; Hashizume, R; Ji, H; Tubb, BE; Patrick, CW; Yu, DH; Mooney, EE; McCrea, PD			C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines	ONCOGENE			English	Article						C-erbB-2; fascin; breast cancer; cell motility; actin	BETA-CATENIN; TYROSINE PHOSPHORYLATION; SELECTIVE-INHIBITION; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; NEU ONCOGENE; IN-VIVO; EXPRESSION; METASTASIS; KINASE	The over-expression of c-erbS-2/ HER-2, a receptor tyrosine kinase, correlates with poor prognosis in patients with breast and ovarian cancer. In the human breast cancer cell line, MDA-MB-435, c-erbB-2 overexpression results in increased chemoinvasion and higher metastatic properties in nude mice. I-ion ever, the mechanisms by which c-erbB-2 increases the malignant potential of cells remains unclear. We have determined that over-expression of c-erbB-2 in MDA-MB-435 cells, and in some additional breast cancer cell lines, is associated with graphic increases in mRNA and protein levels of the actin bundling protein fascin, Heightened fascin expression has been observed in other systems to result in greatly increased cell motility, and indeed, our work employing semi-automated time-lapse microscopy demonstrates that MDA-MB-435 cells over-expressing c-erbB-2 exhibit significantly heightened cellular dynamics and locomotion, while visualization of bundled microfilaments within fixed cells revealed enhanced formation of dendritic-like processes, microspikes and other dynamic actin based structures. To address the means by which c-erbB-2 over-expression might result in elevated fascin levels, we identified multiple perfect match TCF and NF-kappa B consensus sites in fascin's promoter and first intron,which appeared consistent with the greater endogenous transcriptional activities of TCF and NF-kappa B in c-erbB-2 over-expressing MDA-MB-435 cells. While such transcriptional modulation may occur in the context of the intact gene/chromatin, subsequent tests using reporter constructs did not support involvement of these signaling pathways. In conclusion, highly increased fascin levels were observed in MDA-MB-435 over-expressing c-erbB-2, likely contributing to these cells' altered actin dynamics, and increased cell motility and malignancy. Studies in progress aim to discern the means by which c-erbB-2 over-expression leads to transcriptional activation of the fascin gene.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Plast Surg, Program Genes & Dev, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McCrea, PD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Yu, Dihua/0000-0001-6231-9381	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052112] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM052112, R01 GM 52112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Adams JC, 1999, MOL BIOL CELL, V10, P4177, DOI 10.1091/mbc.10.12.4177; Aljada A, 1999, J CLIN ENDOCR METAB, V84, P3386, DOI 10.1210/jc.84.9.3386; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CANO RJ, 1992, BIOTECHNIQUES, V12, P264; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; DECORTE V, 1994, J CELL SCI, V107, P405; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; del Peso L, 1997, ONCOGENE, V15, P3047; DHALIWAL MK, 1990, ANTICANCER RES, V10, P113; DICKASON RR, 1995, J IMMUNOL METHODS, V185, P237, DOI 10.1016/0022-1759(95)00119-U; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; EDWARDS RA, 1995, CELL MOTIL CYTOSKEL, V32, P1, DOI 10.1002/cm.970320102; EDWARDS RA, 1995, J BIOL CHEM, V270, P10764, DOI 10.1074/jbc.270.18.10764; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GAFFNEY EV, 1982, CELL TISSUE RES, V227, P563, DOI 10.1007/BF00204786; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GROTHEY A, 2000, BR J CANC, V88; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hung MC, 1999, SEMIN ONCOL, V26, P51; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klapper LN, 2000, ADV CANCER RES, V77, P25; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kzhyshkowska JG, 1996, IMMUNOL LETT, V53, P101, DOI 10.1016/S0165-2478(96)02625-9; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Montross WT, 2000, J CELL SCI, V113, P1759; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; PELES E, 1992, J BIOL CHEM, V267, P12266; Pinkus GS, 1997, AM J PATHOL, V150, P543; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; SEGATTO O, 1993, ONCOGENE, V8, P2105; Shibata T, 1996, ONCOGENE, V13, P883; Tan M, 1999, CANCER RES, V59, P1620; Tan M, 1997, CANCER RES, V57, P1199; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Tilney LG, 1998, J CELL BIOL, V143, P121, DOI 10.1083/jcb.143.1.121; VAN AD, 1996, SCIENCE, V274, P787; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	51	97	114	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4864	4875		10.1038/sj.onc.1203838	http://dx.doi.org/10.1038/sj.onc.1203838			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039904				2022-12-25	WOS:000089757800009
J	Price, AC; Choi, KH; Heath, RJ; Li, ZM; White, SW; Rock, CO				Price, AC; Choi, KH; Heath, RJ; Li, ZM; White, SW; Rock, CO			Inhibition of beta-ketoacyl-acyl carrier protein syntheses by thiolactomycin and cerulenin - Structure and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; SYNTHASE III FABH; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ANTIBIOTIC CERULENIN; THERMAL REGULATION; CONDENSING ENZYMES; TARGET; OVERPRODUCTION; BINDING	The beta -ketoacyl-acyl carrier protein (ACP) synthases are key regulators of type II fatty acid synthesis and are the targets for two natural products, thiolactomycin (TLM) and cerulenin. The high resolution structures of the FabB-TLM and FabB-cerulenin binary complexes were determined. TLM mimics malonyl-ACP in the FabB active site. It forms strong hydrogen bond interactions with the two catalytic histidines, and the unsaturated alkyl side chain interaction with a small hydrophobic pocket is stabilized by pi stacking interactions. Cerulenin binding mimics the condensation transition state. The subtle differences between the FabB-cerulenin and FabF-cerulenin (Moche, M., Schneider, G., Edwards, P., Dehesh, K., and Lindqvist, Y. (1999) J. Biol. Chem. 244, 6031-6034) structures explain the differences in the sensitivity of the two enzymes to the antibiotic and may reflect the distinct substrate specificities that differentiate the two enzymes. The FabB[H333N] protein was prepared to convert the FabB His-His Cys active site triad into the FabH His-Asn-Cys configuration to test the importance of the two His residues in TLM and cerulenin binding. FabB[H333N] was significantly more resistant to both antibiotics than FabB and had an affinity for TLM an order of magnitude less than the wild-type enzyme, illustrating that the two-histidine active site architecture is critical to protein-antibiotic interaction. These data provide a structural framework for understanding antibiotic sensitivity within this group of enzymes.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	charles.rock@stjude.org	White, Stephen W/N-8164-2018	Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM44973, GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P1604, DOI 10.1021/bi00405a032; ARIMURA N, 1993, ARCH MICROBIOL, V160, P158, DOI 10.1007/BF00288719; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; BUTTKE TM, 1978, BIOCHEMISTRY-US, V17, P5282, DOI 10.1021/bi00617a031; Choi KH, 2000, J BIOL CHEM, V275, P28201; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Cronan J.E., 1996, BIOSYNTHESIS MEMBRAN, V2nd, P612; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; DEMENDOZA D, 1983, TRENDS BIOCHEM SCI, V8, P49, DOI 10.1016/0968-0004(83)90388-2; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; HAMADA S, 1990, ORAL MICROBIOL IMMUN, V5, P340, DOI 10.1111/j.1399-302X.1990.tb00438.x; HAYASHI T, 1984, J ANTIBIOT, V37, P1456, DOI 10.7164/antibiotics.37.1456; HAYASHI T, 1983, BIOCHEM BIOPH RES CO, V115, P1108, DOI 10.1016/S0006-291X(83)80050-3; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; Jones AL, 2000, BIOCHEM J, V347, P205, DOI 10.1042/0264-6021:3470205; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KAWAGUCHI A, 1982, J BIOCHEM-TOKYO, V92, P7, DOI 10.1093/oxfordjournals.jbchem.a133933; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MIYAKAWA S, 1982, J ANTIBIOT, V35, P411, DOI 10.7164/antibiotics.35.411; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Morita YS, 2000, SCIENCE, V288, P140, DOI 10.1126/science.288.5463.140; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NOTO T, 1982, J ANTIBIOT, V35, P401, DOI 10.7164/antibiotics.35.401; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; Omura S, 1981, Methods Enzymol, V72, P520; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; Rock C O, 1981, Methods Enzymol, V72, P397; ROCK CO, 1979, J BIOL CHEM, V254, P7123; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; ROSENFELD IS, 1973, J BIOL CHEM, V248, P2452; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Subrahmanyam S, 1998, J BACTERIOL, V180, P4596, DOI 10.1128/JB.180.17.4596-4602.1998; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; TSAY JT, 1992, J BIOL CHEM, V267, P6807; Val D, 2000, STRUCT FOLD DES, V8, P565, DOI 10.1016/S0969-2126(00)00146-5; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352	59	281	292	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6551	6559		10.1074/jbc.M007101200	http://dx.doi.org/10.1074/jbc.M007101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11050088	hybrid			2022-12-25	WOS:000167261000065
J	Qiu, JZ; Li, XW; Frank, G; Shen, BH				Qiu, JZ; Li, XW; Frank, G; Shen, BH			Cell cycle-dependent and DNA damage-inducible nuclear localization of FEN-1 nuclease is consistent with its dual functions in DNA replication and repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FLAP ENDONUCLEASE-1; NUCLEOTIDE EXCISION-REPAIR; B TRANSCRIPTION FACTOR; STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; TARGETING SEQUENCES; PROTEIN-TRANSPORT; IN-VITRO	Flap endonuclease-1 (FEN-1), a 43-kDa protein, is a structure-specific and multifunctional nuclease. It plays important roles in RNA primer removal of Okazaki fragments during DNA replication, DNA base excision repair, and maintenance of genome stability. Three functional motifs of the enzyme were proposed to be responsible for its nuclease activities, interaction with proliferating cell nuclear antigen, and nuclear localization. In this study, we demonstrate in HeLa cells that a signal located at the C terminus (the nuclear localization signal (NLS) motif) facilitates nuclear localization of the enzyme during S phase of the cell cycle and in response to DNA damage. Truncation of the NLS motif prevents migration of the protein from the cytoplasm to the nucleus, while having no effect on the nuclease activities and its proliferating cell nuclear antigen interaction capability. Site-directed mutagenesis further revealed that a mutation of the KRK cluster to three alanine residues completely blocked the localization of FEN-1 into the nucleus, whereas mutagenesis of the KKK cluster led to a partial defect of nuclear localization in HeLa cells without observable phenotype in yeast. Therefore, the KRKXYXXYXYXKKK motif may be a bipartite NLS driving the protein into nuclei. Yeast RAD27 Delta cells transformed with human mutant M-krk survived poorly upon methyl methanesulfonate treatment or when they were incubated at an elevated temperature.	City Hope Natl Med Ctr, Dept Cell & Tumor Biol, Duarte, CA 91010 USA	City of Hope	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Cell & Tumor Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.			Shen, Binghui/0000-0002-4408-407X	NCI NIH HHS [CA 73764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073764, R01CA073764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN J, 1996, GENE TRANSCRIPTION D, P140; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Boulikas T, 1997, ANTICANCER RES, V17, P843; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Frank G, 1998, J BIOL CHEM, V273, P33064, DOI 10.1074/jbc.273.49.33064; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRIEDBERG EC, 1992, TRENDS BIOCHEM SCI, V17, P347, DOI 10.1016/0968-0004(92)90312-W; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Knauf JA, 1996, MUTAT RES-DNA REPAIR, V363, P67, DOI 10.1016/0921-8777(95)00062-3; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; PETERSEN LN, 1995, MOL CELL BIOL, V15, P3731; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Sherman F., 1986, METHODS YEAST GENETI; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TISHKOFF DX, 1997, CELL, V88, P263; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WHITESIDE ST, 1993, J CELL SCI, V104, P949; Yoneda Y, 1997, J BIOCHEM, V121, P811	53	55	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4901	4908		10.1074/jbc.M007825200	http://dx.doi.org/10.1074/jbc.M007825200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11053418	hybrid			2022-12-25	WOS:000168484300052
J	Dignam, JD; Qu, XG; Chaires, JB				Dignam, JD; Qu, XG; Chaires, JB			Equilibrium unfolding of Bombyx mori glycyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; EVOLUTIONARY RELATIONSHIPS; THERMUS-THERMOPHILUS; COILED-COIL; PROTEIN; DISSOCIATION; SEQUENCE; INTERMEDIATE; ASSOCIATION; BINDING	Unfolding of Bombyx mori glycyl-tRNA synthetase was examined by multiple spectroscopic techniques. Tryptophan fluorescence of wild type enzyme and an N-terminally truncated form (N55) increased at low concentrations of urea or guanidine-HCl followed by a reduction in intensity at intermediate denaturant concentrations; a transition at higher denaturant was detected as decreased fluorescence intensity and a red-shifted emission. Solute quenching of fluorescence indicated that tryptophans become progressively solvent-exposed during unfolding. mild type enzyme had stronger negative CD bands between 220 and 230 Bm than the mutant, indicative of greater alpha -helical content. Urea or guanidine-HCl caused a reduction in ellipticity at 222 nm at low denaturant concentration with the wild type enzyme, a transition that is absent in the mutant; both enzymes exhibited a cooperative transition at higher denaturant concentrations. Both enzymes dissociate to monomers in 1.5 M urea. Unfolding of wild type enzyme is described by a multistate unfolding and a parallel two state unfolding, the two-state component is absent in the mutant. Changes in spectral properties associated with unfolding were largely reversible after dilution to low denaturant. Unfolding of glycyl-tRNA synthetase is complex with a native state, a native-like monomer, partially unfolded states, and the unfolded state.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Dignam, JD (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, 3035 Arlington Ave,Block Hlth Sci Bldg, Toledo, OH 43614 USA.	jdignam@mco.edu		Chaires, Jonathan/0000-0001-5477-945X	NATIONAL CANCER INSTITUTE [R01CA035635] Funding Source: NIH RePORTER; NCI NIH HHS [CA35635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; ARTYMIUK PJ, 1994, NAT STRUCT BIOL, V1, P758, DOI 10.1038/nsb1194-758; Barry JK, 1999, BIOCHEMISTRY-US, V38, P6520, DOI 10.1021/bi9900727; Bevington PR., 2002, DATA REDUCTION ERROR; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; Cahuzac B, 2000, EMBO J, V19, P445, DOI 10.1093/emboj/19.3.445; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CLARK AC, 1993, J BIOL CHEM, V268, P10773; Cohn E. J., 1943, PROTEINS AMINO ACIDS; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1993, BIOCHIMIE, V75, P1077, DOI 10.1016/0300-9084(93)90006-E; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DEYOUNG LR, 1993, ACCOUNTS CHEM RES, V26, P614, DOI 10.1021/ar00036a002; DIGNAM SS, 1984, J BIOL CHEM, V259, P4043; Eftink MR, 1997, BIOPHYS CHEM, V64, P175, DOI 10.1016/S0301-4622(96)02237-5; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Eftink MR, 1995, METHOD ENZYMOL, V259, P487; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIJMAN L, 1991, BIOCHEMISTRY-US, V30, P1595, DOI 10.1021/bi00220a022; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Grimsley JK, 1997, BIOCHEMISTRY-US, V36, P14366, DOI 10.1021/bi971596e; HENDLER RW, 1994, J BIOCHEM BIOPH METH, V28, P1, DOI 10.1016/0165-022X(94)90061-2; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; Jaenicke R, 1996, CURR TOP CELL REGUL, V34, P209, DOI 10.1016/S0070-2137(96)80008-2; KAWAKAMI M, 1985, J BIOCHEM, V98, P177, DOI 10.1093/oxfordjournals.jbchem.a135256; KERN D, 1981, BIOCHEMISTRY-US, V20, P122, DOI 10.1021/bi00504a021; Lakowicz J.R., 1999, PRINCIPLES FLUORESCE, P239; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAWS WR, 1992, METHOD ENZYMOL, V210, P448; LEBERMAN R, 1991, BIOCHIM BIOPHYS ACTA, V1089, P287, DOI 10.1016/0167-4781(91)90168-L; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Makhatadze GI, 1999, J PHYS CHEM B, V103, P4781, DOI 10.1021/jp990413q; MAYR LM, 1993, BIOCHEMISTRY-US, V32, P7994, DOI 10.1021/bi00082a021; MORJANA NA, 1993, P NATL ACAD SCI USA, V90, P2107, DOI 10.1073/pnas.90.6.2107; Motono C, 1999, BIOCHEMISTRY-US, V38, P1332, DOI 10.1021/bi982380v; NAGEL GM, 1995, J MOL EVOL, V40, P487; NAGEL GM, 1991, P NATL ACAD SCI USA, V88, P8121, DOI 10.1073/pnas.88.18.8121; Nakatsu T, 1998, NAT STRUCT BIOL, V5, P15, DOI 10.1038/nsb0198-15; Nameki N, 1997, J MOL BIOL, V268, P640, DOI 10.1006/jmbi.1997.0993; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Oakley MG, 1997, BIOCHEMISTRY-US, V36, P2544, DOI 10.1021/bi962391t; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; Park YC, 1998, J BIOL CHEM, V273, P18052, DOI 10.1074/jbc.273.29.18052; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; RABEN N, 1994, J BIOL CHEM, V269, P24277; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHRAY B, 1991, NUCLEIC ACIDS RES, V19, P5307, DOI 10.1093/nar/19.19.5307; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; SILVA JL, 1989, J BIOL CHEM, V264, P15863; SILVA JL, 1988, J MOL BIOL, V199, P149, DOI 10.1016/0022-2836(88)90385-3; Smith JS, 1996, BIOCHEMISTRY-US, V35, P7292, DOI 10.1021/bi960341i; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Uversky VN, 1998, P NATL ACAD SCI USA, V95, P5480, DOI 10.1073/pnas.95.10.5480; Uversky VN, 1999, PROTEIN SCI, V8, P161; Waldburger CD, 1996, P NATL ACAD SCI USA, V93, P2629, DOI 10.1073/pnas.93.7.2629; Wu H, 1995, BIOCHEMISTRY-US, V34, P16327, DOI 10.1021/bi00050a013	66	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4028	4037		10.1074/jbc.M006840200	http://dx.doi.org/10.1074/jbc.M006840200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11056158	hybrid			2022-12-25	WOS:000166921200042
J	Petaja-Repo, UE; Hogue, M; Laperriere, A; Bhalla, S; Walker, P; Bouvier, M				Petaja-Repo, UE; Hogue, M; Laperriere, A; Bhalla, S; Walker, P; Bouvier, M			Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER QUALITY-CONTROL; I HEAVY-CHAINS; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; PROTEIN TRANSLOCATION; SECRETORY PROTEIN; MEMBRANE-PROTEIN; DEGRADATION; PATHWAY; PROTEOLYSIS; INTERNALIZATION	We have previously shown that only a fraction of the newly synthesized human delta opioid receptors is able to leave the endoplasmic reticulum (ER) and reach the cell surface (Petaja-Repo, U. E, Hogue, M., Laperriere, A., Walker, P., and Bouvier, M. (2000) J. Biol Chem 275, 13727-13736). In the present study, we investigated the fate of those receptors that are retained intracellularly. Pulse-chase experiments revealed that the disappearance of the receptor precursor form (M-r 45,000) and of two Smaller species (M-r 42,000 and 39,000) is inhibited by the proteasome blocker, lactacystin. The treatment also promoted accumulation of the mature receptor form (ICI, 55,000), indicating that the ER quality control actively routes a significant proportion of rescuable receptors for proteasome degradation. In addition, degradation intermediates that included full-length deglycosylated (M-r 39,000) and ubiquitinated forms of the receptor were found to accumulate in the cytosol upon inhibition of proteasome function. Finally, coimmunoprecipitation experiments with the beta -subunit of the Sec61 translocon complex revealed that the receptor precursor and its deglycosylated degradation intermediates interact with the translocon. Taken together, these results support a model in which misfolded or incompletely folded receptors are transported to the cytoplasmic side of the ER membrane via the Sec61 translocon, deglycosylated and conjugated with ubiquitin prior to degradation by the cytoplasmic 26 S proteasomes.	Univ Oulu, Dept Anat & Cell Biol, FIN-90014 Oulu, Finland; AstraZeneca Res & Dev Montreal, St Laurent, PQ H4S 1Z9, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	University of Oulu; AstraZeneca; Universite de Montreal	Petaja-Repo, UE (corresponding author), Univ Oulu, Dept Anat & Cell Biol, POB 5000, FIN-90014 Oulu, Finland.		Petäjä-Repo, Ulla/AAV-6115-2021; Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fitzgerald J, 1999, J BIOL CHEM, V274, P27392, DOI 10.1074/jbc.274.39.27392; Galan JM, 1998, FASEB J, V12, P315, DOI 10.1096/fasebj.12.3.315; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latronico AC, 1999, AM J HUM GENET, V65, P949, DOI 10.1086/302602; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lester D, 2000, BIOCHEM BIOPH RES CO, V269, P474, DOI 10.1006/bbrc.2000.2302; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Roberts BJ, 1997, J BIOL CHEM, V272, P9771; Romisch K, 1999, J CELL SCI, V112, P4185; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; Suzuki T, 1997, P NATL ACAD SCI USA, V94, P6244, DOI 10.1073/pnas.94.12.6244; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V278, pG39, DOI 10.1152/ajpgi.2000.278.1.G39; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weng S, 1997, BIOCHEM J, V322, P655, DOI 10.1042/bj3220655; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; White AL, 1999, J LIPID RES, V40, P275; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wigley WC, 1999, J CELL BIOL, V145, P481; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	72	176	179	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4416	4423		10.1074/jbc.M007151200	http://dx.doi.org/10.1074/jbc.M007151200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11054417	Green Published, hybrid			2022-12-25	WOS:000166921200091
J	Palacios, S; Lalioti, V; Martinez-Arca, S; Chattopadhyay, S; Sandoval, IV				Palacios, S; Lalioti, V; Martinez-Arca, S; Chattopadhyay, S; Sandoval, IV			Recycling of the insulin-sensitive glucose transporter GLUT4 - Access of surface internalized GLUT4 molecules to the perinuclear storage compartment is mediated by the Phe(5)-Gln(6)-Gln(7)-Ile(8) MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR TRAFFICKING KINETICS; INTEGRAL MEMBRANE-PROTEINS; GTP-BINDING-PROTEINS; RAT SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; TRANSFERRIN RECEPTOR; GOLGI-APPARATUS; CELLS; LOCALIZATION; TRANSLOCATION	The insulin-sensitive glucose transporter GLUT4 is translocated to the plasma membrane in response to insulin and recycled back to the intracellular store(s) after removal of the hormone. We have used clonal 3T3-L1 fibroblasts and adipocyte-like cells stably expressing wild-type GLUT4 to characterize (a) the intracellular compartment where the bulk of GLUT4 is intracellularly stored and (b) the mechanisms involved in the recycling of endocytosed GLUT4 to the store compartment. Surface internalized GLUT4 is targeted to a large, flat, fenestrated saccular structure resistant to brefeldin A that localized to the vicinity of the Golgi complex is sealed to endocytosed transferrin (GLUT4 storage compartment). Recycling of endocytosed GLUT4 was studied by comparing the cellular distributions of anti-body/biotin tagged GLUT4 and GLUT4(Ser(5)), a mutant with the Phe(5)-Gln(6)-Gln(7)-Ile(8) inactivated by the substitution of Ser for Phe(5). Ablation of the Phe(5)-Gln(6)-Gln(7)-Ile(8) inhibits the recycling of endocytosed GLUT4 to the GLUT4 store compartment and results in its transport to late endosomes/lysosomes where it is rapidly degraded.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Sandoval, IV (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Mol Biol, E-28049 Madrid, Spain.			LALIOTI, VASILIKI/0000-0002-4273-6126				ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; ALEDO JC, 1995, BIOCHEM BIOPH RES CO, V215, P321, DOI 10.1006/bbrc.1995.2469; Apelt J, 1999, J NEUROSCI RES, V57, P693, DOI 10.1002/(SICI)1097-4547(19990901)57:5<693::AID-JNR11>3.0.CO;2-X; Araki S, 1996, BIOCHEM J, V315, P153, DOI 10.1042/bj3150153; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Cormont M, 1996, MOL CELL BIOL, V16, P6879; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; Courtoy P J, 1988, Prog Clin Biol Res, V270, P169; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; El Messari S, 1998, J COMP NEUROL, V399, P492, DOI 10.1002/(SICI)1096-9861(19981005)399:4<492::AID-CNE4>3.0.CO;2-X; El-Jack AK, 1999, MOL BIOL CELL, V10, P1581, DOI 10.1091/mbc.10.5.1581; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HUDSON AW, 1993, J CELL BIOL, V122, P579, DOI 10.1083/jcb.122.3.579; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; Kobayashi M, 1996, NEUROSCI LETT, V213, P103, DOI 10.1016/0304-3940(96)12845-7; Koumanov F, 1998, BIOCHEM J, V330, P1209, DOI 10.1042/bj3301209; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; Leloup C, 1996, MOL BRAIN RES, V38, P45, DOI 10.1016/0169-328X(95)00306-D; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; McCall AL, 1997, BRAIN RES, V744, P318, DOI 10.1016/S0006-8993(96)01122-5; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; Ralston E, 1996, J CELL SCI, V109, P2967; RAMBOURG A, 1986, AM J ANAT, V176, P393, DOI 10.1002/aja.1001760403; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Thurmond DC, 2000, EMBO J, V19, P3565, DOI 10.1093/emboj/19.14.3565; UPHUES I, 1994, BIOCHEM J, V301, P177, DOI 10.1042/bj3010177; Vannucci SJ, 1998, BRAIN RES, V797, P1, DOI 10.1016/S0006-8993(98)00103-6; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Vollenweider P, 1997, ENDOCRINOLOGY, V138, P4941, DOI 10.1210/en.138.11.4941; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; YANG J, 1993, J BIOL CHEM, V268, P4600; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	59	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3371	3383		10.1074/jbc.M006739200	http://dx.doi.org/10.1074/jbc.M006739200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11031262	hybrid			2022-12-25	WOS:000166784900052
J	Zhang, M; Dwyer, NK; Neufeld, EB; Love, DC; Cooney, A; Comly, M; Patel, S; Watari, H; Strauss, JF; Pentchev, PG; Hanover, JA; Blanchette-Mackie, EJ				Zhang, M; Dwyer, NK; Neufeld, EB; Love, DC; Cooney, A; Comly, M; Patel, S; Watari, H; Strauss, JF; Pentchev, PG; Hanover, JA; Blanchette-Mackie, EJ			Sterol-modulated glycolipid sorting occurs in Niemann-Pick C1 late endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MANNOSE 6-PHOSPHATE RECEPTOR; CHOLESTEROL STORAGE; PRELYSOSOMAL COMPARTMENT; ENDOCYTIC PATHWAY; ONE SET; DISEASE; TRANSPORT; ACCUMULATION; FIBROBLASTS	The Niemann-Pick C1 (NPC1) protein and endocytosed low density lipoprotein (LDL)-derived cholesterol were shown to enrich separate subsets of vesicles containing lysosomal associated membrane protein 2, Localization of Rab7 in the NPC1-containing vesicles and enrichment of lysosomal hydrolases in the cholesterol-containing vesicles confirmed that these organelles were late endosomes and lysosomes, respectively. Lyso-bisphosphatidic acid, a lipid marker of the late endosomal pathway, was found in the cholesterol-enriched lysosomes, Recruitment of NPC1 to Rab7 compartments was stimulated by cellular uptake of cholesterol, The NPC1 compartment was shown to be enriched ill glyco lipids, and internalization of GalNAc beta1-4[NeuAc alpha2-3]Gal beta1-4Glc beta1-1'-ceramide (G(M2)) into endocytic vesicles depends on the presence of NPC1 protein. The glycolipid profiles of the NPC1 compartment could be modulated by LDL uptake and accumulation of lysosomal cholesterol, Expression in cells of biologically active NPC1 protein fused to green fluorescent protein revealed rapidly moving and flexible tubular extensions emanating from the NPC1-containing vesicles. We conclude that the NPC1 compartment is a dynamic, sterol-modulated sorting organelle involved in the trafficking of plasma membrane-derived glycolipids as well as plasma membrane and endocytosed LDL cholesterol,	NINDK, Lipid Cell Biol Sect, NIH, Bethesda, MD 20892 USA; NINDK, Cell Biochem Sect, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA; NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA; Vet Affairs Med Ctr, Neurol Res Lab, Newington, CT 06111 USA; Univ Penn, Ctr Res & Reprod & Womens Hlth, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Pennsylvania; Pennsylvania Medicine	Blanchette-Mackie, EJ (corresponding author), NINDK, Lipid Cell Biol Sect, NIH, Bldg 8,Rm 427,MSC 0850, Bethesda, MD 20892 USA.		Neufeld, Edward/R-3819-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003, Z01DK060000, Z01DK060001, ZIADK060003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANSAL R, 1992, J NEUROSCI RES, V32, P309, DOI 10.1002/jnr.490320303; Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; Blanchette-Mackie EJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P53; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; CARSTEA ED, 1997, SCIENCE, V277, P288; COXEY RA, 1993, J LIPID RES, V34, P1165; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FISHMAN PH, 1977, BIOCHEMISTRY-US, V16, P1871, DOI 10.1021/bi00628a017; GHOSH RN, 1994, J CELL SCI, V107, P2177; GRIFFITHS G, 1990, J CELL SCI, V95, P441; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Hirst J, 1998, MOL BIOL CELL, V9, P809, DOI 10.1091/mbc.9.4.809; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KOTANI M, 1992, BIOCHIM BIOPHYS ACTA, V1117, P97, DOI 10.1016/0304-4165(92)90168-T; KOTANI M, 1994, ARCH BIOCHEM BIOPHYS, V310, P89, DOI 10.1006/abbi.1994.1144; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Patel RC, 1997, PROTEIN ENG, V10, P621, DOI 10.1093/protein/10.6.621; PATERSON MC, 2001, METABOLIC MOL BASIS, P3611; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; PROIA RL, 1988, P NATL ACAD SCI USA, V85, P1883, DOI 10.1073/pnas.85.6.1883; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SOKOL J, 1988, J BIOL CHEM, V263, P3411; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Suresh S, 1998, J NEUROCHEM, V70, P242; Vanier MT, 1996, AM J HUM GENET, V58, P118; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861	34	92	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3417	3425		10.1074/jbc.M005393200	http://dx.doi.org/10.1074/jbc.M005393200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11032830	hybrid			2022-12-25	WOS:000166784900057
J	Friesen, WJ; Darby, MK				Friesen, WJ; Darby, MK			Specific RNA binding by a single C2H2 zinc finger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; 5-S RIBOSOMAL-RNA; HIV-1 REV PROTEIN; IN-VITRO; 5S RNA; MAJOR GROOVE; ALPHA-HELIX; DNA; RECOGNITION; SELECTION	Zinc finger proteins with high affinity for human immunodeficiency virus Rev responsive element stem loop IIB (RRE-IIB) were previously isolated from a phage display zinc finger library, Zinc fingers from one of these proteins, RR1, were expressed individually and assayed for RRE-IIB affinity. The C-terminal zinc finger retained much of the binding affinity of the two-finger parent and was disrupted by mutations predicted to narrow the RRE-IIB major groove and which disrupt Rev binding. In contrast, the N-terminal zinc finger has a calculated affinity at least 1000-fold lower. Despite the high affinity and specificity of RR1 for RRE-IIB, binding affinity for a 234-nucleotide human immunodeficiency virus Rev responsive element (RRE234) was significantly lower. Therefore, zinc finger proteins that bind specifically to RRE234 were constructed using an in vitro selection and recombination approach. These zinc fingers bound RRE234 with subnanomolar dissociation constants and bound the isolated RRE-IIB stem loop with an affinity 2 orders of magnitude lower but similar to the affinity of an arginine-rich peptide derived from Rev. These data show that single C2H2, zinc fingers can bind RNA specifically and suggest that their binding to stem loop IIB is similar to that of Rev peptide. However, binding to RRE234 is either different from stem loop IIB binding or the tertiary structure of stem loop IIB is changed within the Rev responsive element.	Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University	Darby, MK (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, 233 S 10th St, Philadelphia, PA 19107 USA.							Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BAUDIN F, 1991, J MOL BIOL, V218, P69, DOI 10.1016/0022-2836(91)90874-6; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; Blancafort P, 1999, CHEM BIOL, V6, P585, DOI 10.1016/S1074-5521(99)80091-X; CHRISTIANSEN J, 1987, EMBO J, V6, P453, DOI 10.1002/j.1460-2075.1987.tb04775.x; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; Friesen WJ, 1997, J BIOL CHEM, V272, P10994; Friesen WJ, 1998, NAT STRUCT BIOL, V5, P543, DOI 10.1038/794; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; McColl DJ, 1999, P NATL ACAD SCI USA, V96, P9521, DOI 10.1073/pnas.96.17.9521; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Setzer DR, 1996, RNA, V2, P1254; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; Theunissen O, 1998, EUR J BIOCHEM, V258, P758, DOI 10.1046/j.1432-1327.1998.2580758.x; Van Ryk DI, 1999, J BIOL CHEM, V274, P17452, DOI 10.1074/jbc.274.25.17452; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; YANG WP, 1995, J IMMUNOL METHODS, V183, P175, DOI 10.1016/0022-1759(95)00048-F; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	33	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1968	1973		10.1074/jbc.M008927200	http://dx.doi.org/10.1074/jbc.M008927200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11056173	hybrid			2022-12-25	WOS:000166528000045
J	Chuang, LC; Yew, PR				Chuang, LC; Yew, PR			Regulation of nuclear transport and degradation of the Xenopus cyclin-dependent kinase inhibitor, p27(Xic1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED DEGRADATION; CELL-CYCLE; DNA-REPLICATION; CDK INHIBITOR; P27(KIP1); PHOSPHORYLATION; PROTEOLYSIS; INITIATION; COMPLEX; PHASE	The regulation of the vertebrate cell cycle is controlled by the function of cyclin-dependent kinases (CDKs), cyclins, and CDK inhibitors. The Xenopus Laevis kinase inhibitor, p27(Xic1) (Xic1) is a member of the p21(Cip1)/p27(Kip1)/p57(Kip2) CDK inhibitor family and inhibits CDK2-cyclin E in vitro as well as DNA replication in Xenopus egg extracts. Xic1 is targeted for degradation in interphase extracts in a manner dependent on both the ubiquitin conjugating enzyme, Cdc34, and nuclei. Here we show that ubiquitination of Xic1 occurs exclusively in the nucleus and that nuclear localization of Xic1 is necessary for its degradation. We find that Xic1 nuclear localization is independently mediated by binding to CDK2-cyclin E and by nuclear localization sequences within the C terminus of Xic1, Our results also indicate that binding of Xic1 to CDK2-cyclin E is dispensable for Xic1 ubiquitination and degradation. Moreover, Re show that amino acids 180-183 of Xic1 are critical determinants of Xic1 degradation. This region of Xic1 may define a motif of Xic1 essential for recognition by the ubiquitin conjugation machinery or for binding an alternate protein required for degradation.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Yew, PR (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	yew@uthscsa.edu						Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; GOEHL MG, 1988, SCIENCE, V241, P1331; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; KAEPP DM, 1999, CELL, V97, P491; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koff A, 1995, Prog Cell Cycle Res, V1, P141; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Laskey RA, 1996, EXP CELL RES, V229, P204, DOI 10.1006/excr.1996.0361; LASKEY RA, 1990, TRENDS GENET, V6, P406, DOI 10.1016/0168-9525(90)90301-L; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Scheffner M, 1999, NATURE, V398, P103, DOI 10.1038/18105; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Willems AR, 1999, PHILOS T ROY SOC B, V354, P1533, DOI 10.1098/rstb.1999.0497; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	50	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1610	1617		10.1074/jbc.M008896200	http://dx.doi.org/10.1074/jbc.M008896200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11044455	hybrid			2022-12-25	WOS:000166430900100
J	Andric, SA; Kostic, TS; Tomic, M; Koshimizu, T; Stojilkovic, SS				Andric, SA; Kostic, TS; Tomic, M; Koshimizu, T; Stojilkovic, SS			Dependence of soluble guanylyl cyclase activity on calcium signaling in pituitary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE SECRETION; NITRIC-OXIDE SYNTHASES; PROTEIN-KINASE-A; CA2+ OSCILLATIONS; INTRACELLULAR CALCIUM; GH(3) CELLS; SELECTIVE-INHIBITION; PROLACTIN-RELEASE; RAT SOMATOTROPHS; MECHANISM	The role of nitric oxide (NO) in the stimulation of soluble guanylyl cyclase (sGC) is well established, but the mechanism by which the enzyme is inactivated during the prolonged NO stimulation has not been characterized. In this paper we studied the interactions between NO and intracellular Ca2+ in the control of sGC in rat anterior pituitary cells. Experiments were done in cultured cells, which expressed neuronal and endothelial NO synthases, and in cells with elevated NO levels induced by the expression of inducible NO synthase and by the addition of several NO donors. Basal sGC-dependent cGMP production was stimulated by the increase in NO levels in a time-dependent manner. In contrast, depolarization of cells by high K+ and Bay K 8644, an L-type Ca2+ channel agonist, inhibited sGC activity. Depolarization-induced down-regulation of sGC activity was also observed in cells with inhibited cGMP-dependent phosphodiesterases but not in cells bathed in Ca2+ deficient medium. This inhibition was independent from the pattern of Ca2+ signaling (oscillatory versus nonoscillatory) and NO levels, and was determined by averaged concentration of intracellular Ca2+. These results indicate that inactivation of sGC by intracellular Ca2+ serves as a negative feedback to break the stimulatory action of NO on enzyme activity in intact pituitary cells.	NICHD, Sect Cellular Signalling, ERRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHD, Sect Cellular Signalling, ERRB, NIH, Bldg 49,Room 6A-36,49 Convent Dr, Bethesda, MD 20892 USA.		Koshimizu, Taka-aki/G-2740-2015; Tomic, Melanija/C-3371-2016; Kostic, Tatjana S/H-4038-2012	Andric, Silvana/0000-0002-2908-8136; Kostic, Tatjana/0000-0003-3440-8998; Koshimizu, Taka-aki/0000-0001-5292-7535	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Cataldi M, 1999, BBA-MOL CELL RES, V1449, P186, DOI 10.1016/S0167-4889(99)00013-0; Charles A, 1999, NAT CELL BIOL, V1, pE193, DOI 10.1038/70221; Charles AC, 1999, J BIOL CHEM, V274, P7508, DOI 10.1074/jbc.274.11.7508; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; DUVILANSKI BH, 1995, P NATL ACAD SCI USA, V92, P170, DOI 10.1073/pnas.92.1.170; Feelisch M, 1998, N-S ARCH PHARMACOL, V358, P113, DOI 10.1007/PL00005231; Fiekers JF, 1996, CELL CALCIUM, V19, P327, DOI 10.1016/S0143-4160(96)90073-1; GARBERS DL, 1992, CELL, V71, P1; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HARTT DJ, 1995, BIOCHEM BIOPH RES CO, V214, P918, DOI 10.1006/bbrc.1995.2374; HERRINGTON J, 1994, ENDOCRINOLOGY, V135, P1100, DOI 10.1210/en.135.3.1100; HOLL RW, 1988, J BIOL CHEM, V263, P9682; KATO M, 1992, ENDOCRINOLOGY, V131, P2133, DOI 10.1210/en.131.5.2133; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KURYSHEV YA, 1995, ENDOCRINOLOGY, V136, P3925, DOI 10.1210/en.136.9.3925; Kwiecien R, 1997, J PHYSIOL-LONDON, V499, P613, DOI 10.1113/jphysiol.1997.sp021954; Kwiecien R, 1998, NEUROENDOCRINOLOGY, V68, P135, DOI 10.1159/000054360; Lozach A, 1998, MOL CELL ENDOCRINOL, V143, P43, DOI 10.1016/S0303-7207(98)00135-X; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P592, DOI 10.1210/endo-128-1-592; Mayer B, 1998, N-S ARCH PHARMACOL, V358, P127, DOI 10.1007/PL00005233; Olesen SP, 1998, BRIT J PHARMACOL, V123, P299, DOI 10.1038/sj.bjp.0701603; Parkinson SJ, 1999, BIOCHEMISTRY-US, V38, P6441, DOI 10.1021/bi990154v; Patel S, 1999, NAT CELL BIOL, V1, P467, DOI 10.1038/70249; Pinilla L, 1998, NEUROENDOCRINOLOGY, V68, P180, DOI 10.1159/000054364; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; Tomic M, 1999, J NEUROSCI, V19, P7721; Tomic M, 1999, J BIOL CHEM, V274, P35693, DOI 10.1074/jbc.274.50.35693; Tsumori W, 1999, J NEUROENDOCRINOL, V11, P451; VANCELECOM H, 1997, J HISTOCHEM CYTOCHEM, V45, P847; Vitalis EA, 2000, P NATL ACAD SCI USA, V97, P1861, DOI 10.1073/pnas.040545197; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175; Wei JY, 1998, PROG NEUROBIOL, V56, P37, DOI 10.1016/S0301-0082(98)00029-X; Willmott NJ, 2000, J NEUROSCI, V20, P1767; Wolbring G, 1996, BIOCHEMISTRY-US, V35, P11013, DOI 10.1021/bi960699e; WOLFF D, 1992, BIOCHEM J, V128, P201; YAMAMOTO T, 1983, J BIOL CHEM, V258, P4173; Yermolaieva O, 2000, P NATL ACAD SCI USA, V97, P448, DOI 10.1073/pnas.97.1.448; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	47	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					844	849		10.1074/jbc.M004406200	http://dx.doi.org/10.1074/jbc.M004406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031255	hybrid			2022-12-25	WOS:000166280700113
J	Yang, BX; Ma, TH; Verkman, KS				Yang, BX; Ma, TH; Verkman, KS			Erythrocyte water permeability and renal function in double knockout mice lacking aquaporin-1 and aquaporin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UREA TRANSPORTERS; NULL MICE; CHANNEL; LOCALIZATION; PROTEIN; CHIP28; KIDNEY; CELLS	Aquaporin (AQP) water channel AQP3 has been proposed to be the major glycerol and non-AQP1 water transporter in erythrocytes, AQP1 and AQP3 are also expressed in the kidney where their deletion in mice produces distinct forms of nephrogenic diabetes insipidus. Here AQP1/AQP3 double knockout mice were generated and analyzed to investigate the functional role of AQP3 in erythrocytes and kidneys. 53 double knockout mice were born out of 756 pups from breeding double heterozygous mice. The double knockout mice had reduced survival and impaired growth compared with the single knockout mice. Erythrocyte water permeability was 7-fold reduced by AQP1 deletion but not further reduced in AQP1/AQP3 null mice. AQP3 deletion did not affect erythrocyte glycerol permeability or its inhibition by phloretin, Daily urine output in AQP1/AQP3 double knockout mice (15 ml) was 9-fold greater than in wildtype mice, and urine osmolality (194 mosM) was 8.4-fold reduced. The mice remained polyuric after DDAVP administration or water deprivation. The renal medulla in most AQP1/AQP3 null mice by age 4 weeks was atrophic and fluid-filled due to the severe polyuria and hydronephrosis. Our data provide direct evidence that AQP3 is not functionally important in erythrocyte water or glycerol permeability, The renal function studies indicate independent roles of AQP1 and AQP3 in countercurrent exchange and collecting duct osmotic equilibration, respectively.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, KS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Ma, Tonghui/0000-0001-9338-1030	NHLBI NIH HHS [HL60288, HL59198] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; FISCHBARG J, 1989, P NATL ACAD SCI USA, V86, P8397, DOI 10.1073/pnas.86.21.8397; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 2001, AM J PHYSIOL-CELL PH, V280, pC126; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; MACEY RI, 1996, J BIOL CHEM, V271, P1309; Meinild AK, 2000, AM J PHYSIOL-RENAL, V278, pF777, DOI 10.1152/ajprenal.2000.278.5.F777; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; Pallone TL, 2000, J CLIN INVEST, V105, P215, DOI 10.1172/JCI8214; Ramirez-Lorca R, 1999, PFLUG ARCH EUR J PHY, V438, P94, DOI 10.1007/s004240050884; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; Sands JM, 1999, J AM SOC NEPHROL, V10, P635; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Sidoux-Walter F, 1999, J BIOL CHEM, V274, P30228, DOI 10.1074/jbc.274.42.30228; Silberstein C, 1999, BRAZ J MED BIOL RES, V32, P1303, DOI 10.1590/S0100-879X1999001000018; Song LL, 2000, J GEN PHYSIOL, V115, P17, DOI 10.1085/jgp.115.1.17; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Trinh-Trang-Tan MM, 1998, EXP NEPHROL, V6, P471; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; Verkman AS, 2000, AM J PHYSIOL-LUNG C, V278, pL867, DOI 10.1152/ajplung.2000.278.5.L867; Yang BX, 1998, J BIOL CHEM, V273, P9369, DOI 10.1074/jbc.273.16.9369	27	89	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					624	628		10.1074/jbc.M008664200	http://dx.doi.org/10.1074/jbc.M008664200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035042	hybrid			2022-12-25	WOS:000166280700084
J	Scalia, R; Coyle, KM; Levine, BJ; Booth, G; Lefer, AM				Scalia, R; Coyle, KM; Levine, BJ; Booth, G; Lefer, AM			C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction	FASEB JOURNAL			English	Article						intravital microscopy; inflammation; rat; diabetes; nitric oxide synthase	DEPENDENT DIABETIC-PATIENTS; NITRIC-OXIDE; P-SELECTIN; ISCHEMIA-REPERFUSION; MYOCARDIAL-ISCHEMIA; CELL-ADHESION; BIOLOGICAL-ACTIVITY; GLUCOSE-UTILIZATION; IDDM PATIENTS; INSULIN	C-peptide is a cleavage product that comes from processing proinsulin to insulin that induces nitric oxide (NO) -mediated vasodilation, NO modulates leukocyte-endothelium interaction. We hypothesized that C-peptide might inhibit leukocyte-endothelium interaction via increased release of endothelial NO, Using intravital microscopy of the rat mesentery, we measured leukocyte-endothelium interactions after administration of C-peptide to the rat. Superfusion of the rat mesentery with either thrombin or L-NAME consistently and significantly increased the number of rolling, adhering, and transmigrated leukocytes, C-peptide significantly attenuated either thrombin- or L-NAME-induced leukocyte-endothelium interactions in rat mesenteric venules. A control scrambled sequence of C-peptide characterized by the same amino acid composition in a randomized sequence failed to inhibit leukocyte-endothelium interactions. These effects of C-peptide were associated with decreased surface expression of the cell adhesion molecules P-selectin and ICAM-1 on the microvascular endothelium. Endothelial nitric oxide synthase (eNOS) mRNA levels were increased in rats injected with C-peptide. This enhanced eNOS expression was associated with a marked increase in basal NO release from the aorta of C-peptide-treated rats. We conclude that C-peptide is a potent inhibitor of leukocyte-endothelium interaction and that this effect is specifically related to inhibition of endothelial cell adhesion molecules via maintenance of NO release from the vascular endothelium.-Scalia, R., Coyle, K. M., Levine, B, J., Booth, G., Lefer, A. M. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA	Jefferson University	Scalia, R (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, 1020 Locust St, Philadelphia, PA 19107 USA.			Scalia, Rosario/0000-0002-1829-943X	NHLBI NIH HHS [HL-07599, HL-07845] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007845] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOKI N, 1990, AM J PHYSIOL, V258, pG275, DOI 10.1152/ajpgi.1990.258.2.G275; BARROSOARANDA J, 1988, CIRC RES, V63, P437, DOI 10.1161/01.RES.63.2.437; BORDERS JL, 1984, MICROVASC RES, V27, P117, DOI 10.1016/0026-2862(84)90047-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1; DE CR, 1995, J CLIN INVEST, V96, P60; ENTMAN ML, 1990, J CLIN INVEST, V85, P1497, DOI 10.1172/JCI114596; Forst T, 1998, EXP CLIN ENDOCR DIAB, V106, P270, DOI 10.1055/s-0029-1212190; Forst T, 1998, J CLIN INVEST, V101, P2036, DOI 10.1172/JCI2147; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; GAUTHIER TW, 1995, ARTERIOSCL THROM VAS, V15, P1652, DOI 10.1161/01.ATV.15.10.1652; GRANGER DN, 1989, AM J PHYSIOL, V257, pG683, DOI 10.1152/ajpgi.1989.257.5.G683; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; Guo JP, 1996, J APPL PHYSIOL, V81, P774, DOI 10.1152/jappl.1996.81.2.774; Hickey MJ, 1997, EXP PHYSIOL, V82, P339, DOI 10.1113/expphysiol.1997.sp004029; Ido Y, 1997, SCIENCE, V277, P563, DOI 10.1126/science.277.5325.563; Jensen ME, 1999, AM J PHYSIOL-HEART C, V276, pH1223, DOI 10.1152/ajpheart.1999.276.4.H1223; JOHANSSON BL, 1992, DIABETOLOGIA, V35, P1151, DOI 10.1007/BF00401369; JOHANSSON BL, 1992, DIABETOLOGIA, V35, P121, DOI 10.1007/BF00402543; Johansson BL, 1996, DIABETOLOGIA, V39, P687; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUROSE I, 1993, HEPATOLOGY, V18, P380, DOI 10.1002/hep.1840180223; Lefer AM, 1996, CARDIOVASC RES, V32, P743, DOI 10.1016/0008-6363(96)00073-9; LEFER AM, 1993, J CARDIOVASC PHAR S7, V22, P27; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MCEVER RP, 1994, ANN NY ACAD SCI, V714, P185, DOI 10.1111/j.1749-6632.1994.tb12043.x; Minchenko AG, 1999, ENDOTHELIUM-NEW YORK, V6, P303, DOI 10.3109/10623329909078497; OSBORNE JA, 1989, AM J PHYSIOL, V256, P591; Pieper GM, 1998, HYPERTENSION, V31, P1047, DOI 10.1161/01.HYP.31.5.1047; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; Rojas A, 2000, CIRC RES, V86, pE50, DOI 10.1161/01.RES.86.3.e50; Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967; Scalia R, 1999, FASEB J, V13, P1039, DOI 10.1096/fasebj.13.9.1039; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; Tung DKL, 1997, J LEUKOCYTE BIOL, V62, P163, DOI 10.1002/jlb.62.2.163; Wakelin MW, 1996, J EXP MED, V184, P229, DOI 10.1084/jem.184.1.229; WEYRICH AS, 1995, J LEUKOCYTE BIOL, V57, P45, DOI 10.1002/jlb.57.1.45; WEYRICH AS, 1994, CIRC RES, V75, P692, DOI 10.1161/01.RES.75.4.692; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501	43	78	82	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2357	2364		10.1096/fj.00-0183com	http://dx.doi.org/10.1096/fj.00-0183com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053258				2022-12-25	WOS:000165190800030
J	Lopez-Ocejo, O; Viloria-Petit, A; Bequet-Romero, M; Mukhopadhyay, D; Rak, J; Kerbel, RS				Lopez-Ocejo, O; Viloria-Petit, A; Bequet-Romero, M; Mukhopadhyay, D; Rak, J; Kerbel, RS			Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner	ONCOGENE			English	Article						tumor; angiogenesis; oncogenes; cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; K14-HPV16 TRANSGENIC MICE; CERVICAL-CARCINOMA CELLS; FACTOR MESSENGER-RNA; FACTOR RECEPTOR; PERMEABILITY FACTOR; FACTOR EXPRESSION; HUMAN KERATINOCYTES; SUPPRESSOR GENE; DNA-BINDING	Like other types of pre-malignant lesions and carcinoma, angiogenesis is associated with high-grade cervical dysplasia and with invasive squamous carcinoma of the cervix, Vascular endothelial cell growth factor (VEGF) is known to be one of the most important inducers of angiogenesis and is upregulated in carcinoma of the cervix, Human Papilloma Virus 16 (HPV-16) has been etiologically linked to human cervical cancer, and the major oncogenic proteins encoded by the viral genome, E6 and E7, are involved in the immortalization of target cells, Because several oncogenes including mutant ras, EGF receptor, ErbB2/Her2, c-myc and v-src upregulate VEGF expression, we asked whether HVP-16 E6 oncoprotein could act in a similar fashion. We found that HPV-16 E6-positive cells generally express high levels of VEGF message. Furthermore, co-expression of the VEGF promoter-Luc (luciferase) reporter gene with E6 in both human keratinocytes and mouse fibroblast showed that E6 oncoprotein upregulates VEGF promoter activity, and does so in a p53 independent manner. An E6 responsive region which comprises four Sp-1 sites, between -194 and -50 bp of the VEGF promoter, is also necessary for constitutive VEGF transcription, Taken together, our results suggest the possibility that the HPV oncoprotein E6 may contribute to tumor angiogenesis by direct stimulation of the VEGF gene.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Int Ctr Genet Engn & Biotechnol, Vaccine Div, Havana 10600, Cuba; Int Ctr Genet Engn & Biotechnol, Div Pharmaceut, Havana 10600, Cuba; Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; McMaster Univ, Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8W 1C3, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; McMaster University	Kerbel, RS (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol Res, S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Bequet-Romero, Monica/M-3356-2017	Bequet-Romero, Monica/0000-0003-0351-857X	NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BARBOSA MS, 1989, ONCOGENE, V4, P1529; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; BenBassat H, 1997, CANCER RES, V57, P3741; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; Coussens LM, 1996, AM J PATHOL, V149, P1899; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Davis S, 1999, CURR TOP MICROBIOL, V237, P173; DERYNCK R, 1987, CANCER RES, V47, P707; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; Dey A, 1997, VIROLOGY, V228, P190, DOI 10.1006/viro.1996.8363; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; FAN Z, 1993, CANCER RES, V53, P4637; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Herrington CS, 1999, J PATHOL, V189, P1; Hove MGM, 1999, J REPROD MED, V44, P493; Hu GY, 1997, JNCI-J NATL CANCER I, V89, P1271, DOI 10.1093/jnci/89.17.1271; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; KIESER A, 1994, ONCOGENE, V9, P963; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; MALLON RG, 1987, J VIROL, V61, P1655, DOI 10.1128/JVI.61.5.1655-1660.1987; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; Mateo C, 1997, IMMUNOTECHNOLOGY, V3, P71, DOI 10.1016/S1380-2933(97)00065-1; Mazure NM, 1996, CANCER RES, V56, P3436; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUNGER K, 1989, J VIROL, V63, P4417; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; PARK NH, 1995, ONCOGENE, V10, P2145; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Petit AMV, 1997, AM J PATHOL, V151, P1523; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Ravi R, 2000, GENE DEV, V14, P34; ROHLFS M, 1991, VIROLOGY, V183, P331, DOI 10.1016/0042-6822(91)90146-3; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SIF S, 1993, ONCOGENE, V8, P2501; SILLMAN F, 1981, AM J OBSTET GYNECOL, V139, P154, DOI 10.1016/0002-9378(81)90438-5; SmithMcCune K, 1997, CANCER RES, V57, P1294; SMITHMCCUNE KK, 1994, CANCER RES, V54, P800; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Stoler MH, 2000, INT J GYNECOL PATHOL, V19, P16, DOI 10.1097/00004347-200001000-00004; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tokumo K, 1998, GYNECOL ONCOL, V68, P38, DOI 10.1006/gyno.1997.4876; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Webster NJG, 1996, CANCER RES, V56, P2781; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; WOODWORTH CD, 1988, CANCER RES, V48, P4620; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	82	159	176	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4611	4620		10.1038/sj.onc.1203817	http://dx.doi.org/10.1038/sj.onc.1203817			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030150	Bronze			2022-12-25	WOS:000089438200007
J	Ensor, E; Smith, MD; Latchman, DS				Ensor, E; Smith, MD; Latchman, DS			The BRN-3A transcription factor protects sensory but not sympathetic neurons from programmed cell death/apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MOTOR-NEURONS; CANCER CELLS; FAMILY; DOMAIN; DIFFERENTIATION; SURVIVAL; ACTIVATION; MOTONEURONS; OUTGROWTH	Inactivation of the gene encoding the POU domain transcription factor BRN-3A results in the absence of specific neurons in knockout mice. Here we demonstrate for the first time a direct effect of BRN-3A on the survival of neuronal cells. Specifically, overexpression of BRN-3A in cultured trigeminal ganglion or dorsal root ganglion sensory neurons enhanced their survival following the withdrawal of nerve growth factor. Moreover, reduction of BRN-3A levels impaired the survival of these neurons, The survival of sympathetic neurons was not affected by either approach. Similarly, overexpression of BRN-3A activated the endogenous Bcl-2 gene in trigeminal neurons, but not in sympathetic neurons. The protective effect of BRN-3A on trigeminal neuron survival following nerve growth factor withdrawal significantly increased during embryonic development. In contrast, overexpression of the related factor BRN-3B enhanced survival of trigeminal neurons only at an early stage of embryonic development. Thus, BRN-3A (and in some circumstances, BRN-3B) can promote the survival of nerve growth factor-dependent sensory but not sympathetic neurons, allowing it to play a direct role in the survival of some (but not all) neuronal populations in the developing and adult nervous systems.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England	University of London; University College London	Latchman, DS (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	d.latchman@ich.ucl.ac.uk			MRC [G9901318] Funding Source: UKRI; Medical Research Council [G9901318] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Athlan ES, 1997, J NEUROSCI RES, V47, P300; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; CAMU W, 1992, J NEUROSCI METH, V44, P59, DOI 10.1016/0165-0270(92)90114-S; Coffin RS, 1996, GENE THER, V3, P886; Davies A. M., 1995, NEURAL CELL CULTURE, P153; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DUPREY P, 1995, INT J DEV BIOL, V39, P443; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; Huang EJ, 1999, DEVELOPMENT, V126, P2869; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; Latchman DS, 1996, PHILOS T R SOC B, V351, P511, DOI 10.1098/rstb.1996.0049; Latchman DS, 1997, INT J ONCOL, V10, P1133; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; McQuillin A, 1997, NEUROREPORT, V8, P1481, DOI 10.1097/00001756-199704140-00031; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Smith MD, 1997, J BIOL CHEM, V272, P21325, DOI 10.1074/jbc.272.34.21325; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VAHAUA O, 1954, SCIENCE, V279, P1950; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; Wyatt S, 1998, MOL BRAIN RES, V55, P254, DOI 10.1016/S0169-328X(98)00006-0; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG M, 1955, P NATL ACAD SCI USA, V93, P11950	40	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5204	5212		10.1074/jbc.M007068200	http://dx.doi.org/10.1074/jbc.M007068200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11053412	hybrid			2022-12-25	WOS:000168484300090
J	Wang, JY; Arbuzova, A; Hangyas-Mihalyne, G; McLaughlin, S				Wang, JY; Arbuzova, A; Hangyas-Mihalyne, G; McLaughlin, S			The effector domain of myristoylated alanine-rich C kinase substrate binds strongly to phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MONOLAYER SURFACE PRESSURE; BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; INOSITOL TRISPHOSPHATE; MEMBRANE-BINDING; HIGH-AFFINITY; ELECTROSTATIC PROPERTIES; BASIC PEPTIDES; ACIDIC LIPIDS	Both the myristoylated alanine-rich protein kinase C substrate protein (MARCKS) and a peptide corresponding to its basic effector domain, MARCKS-(151-175), inhibit phosphoinositide-specific phospholipase C (PLC)catalyzed hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP,) in vesicles (Glaser, M., Wanaski, S., Buser, C. A., Boguslavsky, V., Rashidzada, W., Morris, k, Rebecchi, M., Scarlata, S. F., Runnels, L. W., Prestwich, G. D., Chen, J., Aderem, A., Ahn, J., and McLaughlin, S. (1996) J. Biol. Chem. 271, 26187-26193). We report here that adding 10-100 nM MARCRS-(151-175) to a subphase containing either PLC-delta or -beta inhibits hydrolysis of PIP, in a monolayer and that this inhibition is due to the strong binding of the peptide to PIP2. Two direct binding measurements, based on centrifugation and fluorescence, show that approximate to 10 nM PIP2, in the form of vesicles containing 0.01%, 0.1%, or 1% PIP2, binds 50% of MARCKS-(151-175). Both electrophoretic mobility measurements and competition experiments suggest that MARCKS-(151-175) forms an electroneutral complex with approximate to4 PIP2. MARCKS-(151-175) binds equally well to PI(4,5)P-2 and PI(3,4)P-2. Local electrostatic interactions of PIP2 with MARCKS-(151-175) contribute to the binding energy because increasing the salt concentration from 100 to 500 mM decreases the binding 100-fold. We hypothesize that the effector domain of MARCKS can bind a significant fraction of the PIP2 in the plasma membrane, and release the bound PIP2 upon interaction with Ca2+/calmodulin or phosphorylation by protein kinase C.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	McLaughlin, S (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	smcl@epo.som.sunysb.edu		Arbuzova, Anna/0000-0003-2462-147X	NIGMS NIH HHS [GM24971, GM43422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043422, R37GM024971, R01GM043422, R01GM024971] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; Arbuzova A, 2000, BBA-BIOMEMBRANES, V1464, P35, DOI 10.1016/S0005-2736(99)00243-6; Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Arbuzova A, 1998, BBA-REV BIOMEMBRANES, V1376, P369, DOI 10.1016/S0304-4157(98)00011-2; BenTal N, 1997, BIOPHYS J, V73, P1717, DOI 10.1016/S0006-3495(97)78203-1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; Buser CA, 1998, METH MOL B, V84, P267; CAFISO D, 1989, METHOD ENZYMOL, V171, P342; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Denisov G, 1998, BIOPHYS J, V74, P731, DOI 10.1016/S0006-3495(98)73998-0; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Flanagan LA, 2000, FR MOLEC B, V27, P166; FROMHERZ P, 1975, REV SCI INSTRUM, V46, P1380, DOI 10.1063/1.1134025; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUNTER RJ, 1981, ZETA POTNTIAL COLLOI; James SR, 1997, BIOCHEMISTRY-US, V36, P848, DOI 10.1021/bi962108q; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; May S, 2000, BIOPHYS J, V79, P1747, DOI 10.1016/S0006-3495(00)76427-7; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MORRIS AJ, 1995, MOL PHARMACOL, V48, P532; Murray D, 1999, BIOPHYS J, V77, P3176, DOI 10.1016/S0006-3495(99)77148-1; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Newton AC, 2000, PRINCIPLES OF MOLECULAR REGULATION, P205; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; Rhee SG, 2000, FR MOLEC B, V27, P1; Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Sciorra VA, 2000, FR MOLEC B, V27, P268; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Tall EG, 2000, CURR BIOL, V10, P743, DOI 10.1016/S0960-9822(00)00541-8; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; Tolias KF, 2000, FR MOLEC B, V27, P109; TONER M, 1988, BIOCHEMISTRY-US, V27, P7435, DOI 10.1021/bi00419a039; VANPARIDON PA, 1986, BIOCHIM BIOPHYS ACTA, V877, P216, DOI 10.1016/0005-2760(86)90137-2; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; Wang LP, 1996, J BIOL CHEM, V271, P24505, DOI 10.1074/jbc.271.40.24505; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537; YANG L, 1995, BIOCHEMISTRY-US, V34, P1500, DOI 10.1021/bi00005a005	69	146	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5012	5019		10.1074/jbc.M008355200	http://dx.doi.org/10.1074/jbc.M008355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11053422	hybrid			2022-12-25	WOS:000168484300066
J	Bittova, L; Stahelin, RV; Cho, W				Bittova, L; Stahelin, RV; Cho, W			Roles of ionic residues of the C1 domain in protein kinase C-alpha activation and the origin of phosphatidylserine specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; CYSTEINE-RICH DOMAINS; MEMBRANE-BINDING; MONOLAYERS; DIACYLGLYCEROL; CA2+; COMPLEX	On the basis of extensive structure-function studies of protein kinase C-Cy (PRC-OL), We have proposed an activation mechanism for conventional PKCs in which the C2 domain and the C1 domain interact sequentially with membranes (Medkova, M., and Cho, W. (1999) J. Biol Chem. 274, 19852-19881), To further elucidate the interactions between the C1 and C2 domains during PKC activation and the origin of phosphatidylserine specificity, we mutated several charged residues in two CI domains (Cla and Gib) of PHC-alpha. We then measured the membrane binding affinities, activities, and monolayer penetration of these mutants. Results indicate that cationic residues of the C1a domain, most notably Arg(77), interact nonspecifically with anionic phospholipids prior to the membrane penetration of hydrophobic residues. The mutation of a single aspartate (Asp(55)) in the C1a domain to Ala or Lys resulted in dramatically reduced phosphatidylserine specificity in vesicle binding, activity, and monolayer penetration. In particular, D55A showed much higher vesicle affinity, activity, and monolayer penetration power than wild type under nonactivating conditions, i.e. with phosphatidylglycerol and in the absence of Ca2+, indicating that Asp(55) in involved in the tethering of the Cia domain to another part of PKC-alpha, which keeps it in an inactive conformation at the resting state, Based on these results, we propose a refined model for the activation of conventional PKC, in which phosphatidylserine specifically disrupts the C1a domain tethering by competing with Asp(55), which then leads to membrane penetration and diacylglycerol binding of the Cia domain and PKC activation.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C 111, Chicago, IL 60607 USA.		Bittova, Lenka/K-4375-2015; Stahelin, Robert/L-3567-2019	Bittova, Lenka/0000-0002-3556-5234; Stahelin, Robert/0000-0001-5443-7863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; HANNUN YA, 1985, J BIOL CHEM, V260, P39; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; Pepio AM, 1998, BIOCHEMISTRY-US, V37, P1256, DOI 10.1021/bi971841u; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	35	107	108	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4218	4226		10.1074/jbc.M008491200	http://dx.doi.org/10.1074/jbc.M008491200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11029472	hybrid			2022-12-25	WOS:000166921200066
J	Shen, HH; Kang, CW				Shen, HH; Kang, CW			Two site contact of elongating transcripts to phage T7 RNA polymerase at C-terminal regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-TEMPLATE; COMPLEX; INITIATION; BACTERIOPHAGE-T7; BINDING; PROCESSIVITY; EXPRESSION; PROMOTER	A series of active elongation complexes of the phage T7 RNA polymerase were obtained through stepwise walking of the polymerase along an immobilized DNA template. Transcripts were radiolabeled at the 16th to 18th residues, and a photocross-linkable 4-thio-UMP was separately incorporated at the 22nd, 24th, 32nd, and 38th residues. Such complexes (up to 51 nucleotides) produced by the incorporation of one nucleotide at a time were isolated and individually subjected to long wave UV cross-linking. Only when the cross-linker was positioned at the 3'-end (-1) of the elongating RNA and 8 nucleotides upstream (-9), was the RNA substantially cross-linked to the polymerase, regardless of how far it was from the 5'-end of the transcripts. Linkage of the 3'-end residue was mapped to the Thr(636)-Met(666) region, which contains nucleotide-binding sites. The -9 residue was cross-linked to the Ala(724)-Met(750) region rather than to the N-terminal region. These two contacts were maintained throughout the elongation complexes and reveal a route of nascent RNA through the T7 RNA polymerase in elongation complexes.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Yusong Gu, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Kang, CW (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Yusong Gu, 373-1 Kusong Dong, Taejon 305701, South Korea.		Kang, Changwon/C-1938-2011	Kang, Changwon/0000-0002-0867-6385				CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; Han KG, 1999, PROTEIN EXPRES PURIF, V16, P103, DOI 10.1006/prep.1999.1061; He B, 1997, J MOL BIOL, V265, P275, DOI 10.1006/jmbi.1996.0741; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; LEE S S, 1991, Korean Biochemical Journal, V24, P673; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; Meisenheimer KM, 1997, CRIT REV BIOCHEM MOL, V32, P101, DOI 10.3109/10409239709108550; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Sambrook J, 1989, MOL CLONING LAB MANU, P1860; Sastry S, 1998, P NATL ACAD SCI USA, V95, P9111, DOI 10.1073/pnas.95.16.9111; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)90921-R; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Ujvari A, 2000, J MOL BIOL, V295, P1173, DOI 10.1006/jmbi.1999.3418; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU W, 1994, BIOCHEMISTRY-US, V33, P14926, DOI 10.1021/bi00253a032; [No title captured]	28	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4080	4084		10.1074/jbc.M008616200	http://dx.doi.org/10.1074/jbc.M008616200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11056170	hybrid			2022-12-25	WOS:000166921200048
J	Free, A; Wakefield, RID; Smith, BO; Dryden, DTF; Barlow, PN; Bird, AP				Free, A; Wakefield, RID; Smith, BO; Dryden, DTF; Barlow, PN; Bird, AP			DNA recognition by the methyl-CpG binding domain of MeCP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETT-SYNDROME; TRANSCRIPTIONAL REPRESSION; MUTATION TYPE; SELECTIVITY; DYNAMICS	The methyl-CpG binding domain (MBD) of the transcriptional repressor MeCP2 has been proposed to recognize a single symmetrically methylated CpG base pair via hydrophobic patches on an otherwise positively charged DNA binding surface. We have tested this binding model by analysis of mutant derivatives of the MeCP2 MBD in electrophoretic mobility shift assays complemented by NMR structural analysis. Exposed arginine side chains on the binding face, in particular Arg-lll, were found to be critical for binding. Arg-111 was found to interact with the conserved aspartate side chain Asp-121, which is proposed to orientate the arginine side chain to allow specific contacts with the DNA. The conformational flexibility of the disordered B-C loop region, which forms part of the binding face, was also shown to be important. In contrast, mutation off the exposed hydrophobic side chains had a less severe effect on DNA binding. This suggests that the Arg-lll side chain may contribute to sequence-specific recognition of the CpG site rather than simply making nonspecific contacts with the phosphate backbone. The majority of missense mutations within the MBD found in the human genetic disorder Rett syndrome were shown or predicted to affect folding of the domain rather than the DNA recognition event directly.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Edinburgh, Edinburgh Ctr Prot Technol, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Free, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Swann Bldg,Kings Bldgs,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	andrew.free@ed.ac.uk	Smith, Brian O/J-1899-2015; Free, Andrew/AAX-2632-2020; Barlow, Paul N/G-2853-2011; Smith, Brian/AAJ-9393-2020	Smith, Brian O/0000-0003-3363-4168; Smith, Brian/0000-0003-3363-4168; Free, Andrew/0000-0002-1787-4965; Bird, Adrian/0000-0002-8600-0372				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Amir RE, 2000, ANN NEUROL, V47, P670, DOI 10.1002/1531-8249(200005)47:5<670::AID-ANA20>3.3.CO;2-6; Ballestar E, 2000, BIOCHEMISTRY-US, V39, P7100, DOI 10.1021/bi0001271; Bienvenu T, 2000, HUM MOL GENET, V9, P1377, DOI 10.1093/hmg/9.9.1377; Cheadle JP, 2000, HUM MOL GENET, V9, P1119, DOI 10.1093/hmg/9.7.1119; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Elrod-Erickson M, 1999, J BIOL CHEM, V274, P19281, DOI 10.1074/jbc.274.27.19281; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2000, CURR BIOL, V10, pR60, DOI 10.1016/S0960-9822(00)00286-4; Huppke P, 2000, HUM MOL GENET, V9, P1369, DOI 10.1093/hmg/9.9.1369; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Ohki I, 1999, EMBO J, V18, P6653, DOI 10.1093/emboj/18.23.6653; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Wan MM, 1999, AM J HUM GENET, V65, P1520, DOI 10.1086/302690; Xiang FQ, 2000, J MED GENET, V37, P250, DOI 10.1136/jmg.37.4.250; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	26	78	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3353	3360		10.1074/jbc.M007224200	http://dx.doi.org/10.1074/jbc.M007224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035019	hybrid			2022-12-25	WOS:000166784900050
J	Maes, K; Missiaen, L; Parys, JB; De Smet, P; Sienaert, I; Waelkens, E; Callewaert, G; De Smedt, H				Maes, K; Missiaen, L; Parys, JB; De Smet, P; Sienaert, I; Waelkens, E; Callewaert, G; De Smedt, H			Mapping of the ATP-binding sites on inositol 1,4,5-trisphosphate receptor type 1 and type 3 homotetramers by controlled proteolysis and photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; CALCIUM-RELEASE; TRISPHOSPHATE RECEPTOR; ADENINE-NUCLEOTIDES; LIGAND-BINDING; EPITHELIAL-CELLS; SMOOTH-MUSCLE; CA2+ SIGNALS; PROTEIN; PURIFICATION	Submillimolar ATP concentrations strongly enhance the inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release, by binding specifically to ATP-binding sites on the IP3, receptor (IP3R). To locate those ATP-binding sites on IP(3)R1 and IP(3)R3, both proteins were expressed in Sf9 insect cells and covalently labeled with 8-azido-[alpha -32P]ATP. IP(3)R1 and IP(3)R3 were then purified and subjected to a controlled proteolysis, and the labeled proteolytic fragments were identified by site-specific antibodies. Two fragments of IP(3)R1 were labeled, each containing one of the previously proposed ATP-binding sites with amino acid sequence GXGXXG (amino acids 1773-1780 and 2016-2021, respectively). In IP(3)R3, only one fragment was labeled. This fragment contained the GXGXXG sequence (amino acids 1920-1925), which is conserved in the three IP3R isoforms, The presence of multiple interaction sites for ATP was also evident from the IP3-induced Ca2+ release in permeabilized A7r5 cells, which depended on ATP over a very broad concentration range from micromolar to millimolar.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Biochem Lab, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Maes, K (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Karlien.Maes@med.kuleuven.ac.be		Parys, Jan/0000-0002-3591-4967				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; DeSmedt H, 1997, BIOCHEM J, V322, P575; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; GUILLEMETTE G, 1989, MOL PHARMACOL, V35, P339; Hagar RE, 2000, BIOPHYS J, V79, P271, DOI 10.1016/S0006-3495(00)76289-8; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Kaplin AI, 1996, J NEUROSCI, V16, P2002; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; Maes K, 1999, CELL CALCIUM, V25, P143, DOI 10.1054/ceca.1998.0011; Maes K, 2000, CELL CALCIUM, V27, P257, DOI 10.1054/ceca.2000.0121; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Missiaen L, 1997, BIOCHEM J, V325, P661, DOI 10.1042/bj3250661; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Nucifora FC, 1996, MOL BIOL CELL, V7, P949, DOI 10.1091/mbc.7.6.949; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; Sienaert I, 1998, PFLUG ARCH EUR J PHY, V436, P40, DOI 10.1007/s004240050602; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; Sipma H, 1999, J BIOL CHEM, V274, P12157, DOI 10.1074/jbc.274.17.12157; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Vanlingen S, 1997, CELL CALCIUM, V22, P475, DOI 10.1016/S0143-4160(97)90075-0; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WILLCOCKS AL, 1987, BIOCHEM BIOPH RES CO, V146, P1071, DOI 10.1016/0006-291X(87)90756-X; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316	50	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3492	3497		10.1074/jbc.M006082200	http://dx.doi.org/10.1074/jbc.M006082200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035010	hybrid			2022-12-25	WOS:000166784900066
J	Hoshino, R; Tanimura, S; Watanabe, K; Kataoka, T; Kohno, M				Hoshino, R; Tanimura, S; Watanabe, K; Kataoka, T; Kohno, M			Blockade of the extracellular signal-regulated kinase pathway induces marked G(1) cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated - Up-regulation of p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; INDEPENDENT MECHANISMS; MAMMALIAN-CELLS; GROWTH; DEATH; EXPRESSION; INHIBITOR; DNA; TRANSFORMATION; FRAGMENTATION	Constitutive activation of the ERK pathway is associated with the neoplastic phenotype of a relatively large number of human tumor cells. Blockade of the ERK pathway by treatment with PD98059, a specific inhibitor of mitogen-activated protein (MAP) kinase/ERK kinase (MEK), completely suppressed the growth of tumor cells in which the pathway is constitutively activated (RPMI-SE and HT1080 cells). Consistent with its prominent antiproliferative effect, PD98059 induced a remarkable G(1) cell cycle arrest, followed by a modest apoptotic response, in these tumor cells. Selective up-regulation of p27(Kip1) was observed after PD98059 treatment of RPMI-SE and HT1080 cells. Overexpression in RPMI-SE cells of either a kinase-negative form of MEK1 or wild-type MAP kinase phosphatase-3 also induced up-regulation of p27(Kip1), The up-regulation of p27(Kip1) correlated with increased association of p27(Kip1) With cyclin E-cyclin-dependent kinase (CDK) 2 complexes, a concomitant inhibition of cyclin E-CDK2 kinase activity, and a consequent decrease in the phosphorylation state of retinoblastoma protein, which would culminate in the marked G(1), cell cycle arrest observed in these tumor cells. These results suggest that the complete growth suppression that follows specific blockade of the ERK pathway in tumor cells in which the pathway is constitutively activated is mediated by up-regulation of p27(Kip1).	Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, Nagasaki 8528131, Japan; Gifu Pharmaceut Univ, Gifu 5028585, Japan	Nagasaki University; Gifu Pharmaceutical University	Kohno, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, 1-14 Bunkyo Machi, Nagasaki 8528131, Japan.		Kohno, Michiaki/R-6532-2019	Kohno, Michiaki/0000-0002-7644-0059				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P421; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gioeli D, 1999, CANCER RES, V59, P279; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Katayose Y, 1997, CANCER RES, V57, P5441; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Muda M, 1996, J BIOL CHEM, V271, P4319; NAKATSU Y, 1985, COLD SPRING HARB SYM, V51, P1001; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OKA H, 1995, CANCER RES, V55, P4182; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335	33	120	133	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2686	2692		10.1074/jbc.M006132200	http://dx.doi.org/10.1074/jbc.M006132200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11031257	hybrid			2022-12-25	WOS:000166784800054
J	Ritzel, MWL; Ng, AML; Yao, SYM; Graham, K; Loewen, SK; Smith, KN; Ritzel, RG; Mowles, DA; Carpenter, P; Chen, XZ; Karpinski, E; Hyde, RJ; Baldwin, SA; Cass, CE; Young, JD				Ritzel, MWL; Ng, AML; Yao, SYM; Graham, K; Loewen, SK; Smith, KN; Ritzel, RG; Mowles, DA; Carpenter, P; Chen, XZ; Karpinski, E; Hyde, RJ; Baldwin, SA; Cass, CE; Young, JD			Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; XENOPUS-LAEVIS OOCYTES; FUNCTIONAL EXPRESSION; TRANSPORT-SYSTEM; SODIUM/NUCLEOSIDE COTRANSPORTERS; HL-60 CELLS; CLONING; ADENOSINE; EI; DIFFERENTIATION	The human concentrative (Na+-linked) plasma membrane transport proteins hCNT1 and hCNT2 are selective for pyrimidine nucleosides (system cit) and purine nucleosides (system cif), respectively. Both have homologs in other mammalian species and belong to a gene family (CNT) that also includes hfCNT, a newly identified broad specificity pyrimidine and purine Na+-nucleoside symporter (system cib) from the ancient marine vertebrate, the Pacific hagfish (Eptatretus stouti). We now report the cDNA cloning and characterization of cib homologs of hfCNT from human mammary gland, differentiated human myeloid HL-60 cells, and mouse liver. The 691- and 703-residue human and mouse proteins, designated hCNT3 and mCNT3, respectively, were 79% identical in amino acid sequence and contained 13 putative transmembrane helices. hCNT3 was 48, 47, and 57% identical to hCNT1, hCNT2, and hfCNT, respectively. When produced in Xenopus oocytes, both proteins exhibited Na+-dependent cib-type functional activities. hCNT3 was electrogenic, and a sigmoidal dependence of uridine influx on Na+ concentration indicated a Na+: uridine coupling ratio of at least 2:1 for both hCNT3 and mCNT3 (cf 1:1 for hCNT1/2). Phorbol myristate acetate-induced differentiation of HL-60 cells led to the parallel appearance of cib-type activity and hCNT3 mRNA. Tissues containing hCNT3 transcripts included pancreas, bone marrow, trachea, mammary gland, liver, prostrate, and regions of intestine, brain, and heart. The hCNT3 gene mapped to chromosome 9q22.2 and included an upstream phorbol myristate acetate response element.	Univ Alberta, Dept Physiol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Transport Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.		Cass, Carol E/F-5861-2010					Anderson CM, 1996, MOL BRAIN RES, V42, P358, DOI 10.1016/S0169-328X(96)00244-6; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BELT J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P20; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; Boleti H, 1997, NEUROPHARMACOLOGY, V36, P1167, DOI 10.1016/S0028-3908(97)00136-6; CASS CE, 1995, DRUG TRANSPORT ANTIM, P404; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1999, J BIOL CHEM, V274, P2773, DOI 10.1074/jbc.274.5.2773; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; Fang X, 1996, BIOCHEM J, V317, P457, DOI 10.1042/bj3170457; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; FREDHOLM BB, 1997, CURR MED CHEM, V4, P35; Graham KA, 2000, NUCLEOS NUCLEOT NUCL, V19, P415, DOI 10.1080/15257770008033018; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HANDSCHUMACHER RE, 1993, CANC METABOLISM, P712; Hong M, 2000, J PHARMACOL EXP THER, V292, P366; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; Lee Chee-Wee, 1994, In Vivo (Attiki), V8, P795; LEE CW, 1991, BIOCHEM J, V274, P85, DOI 10.1042/bj2740085; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Mackey JR, 1998, CANCER RES, V58, P4349; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; Mackey JR, 1999, JNCI-J NATL CANCER I, V91, P1876, DOI 10.1093/jnci/91.21.1876; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; Paterson AR, 1993, P AM ASSOC CANC RES, V34, pA84; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Roy L, 1996, INT J RADIAT BIOL, V70, P665, DOI 10.1080/095530096144545; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wang J, 1997, J BIOL CHEM, V272, P28845, DOI 10.1074/jbc.272.46.28845; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; WU XC, 1992, J BIOL CHEM, V267, P8813; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	53	292	304	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2914	2927		10.1074/jbc.M007746200	http://dx.doi.org/10.1074/jbc.M007746200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11032837	hybrid			2022-12-25	WOS:000166784800084
J	Bone, JR; Roth, SY				Bone, JR; Roth, SY			Recruitment of the yeast Tup1p-Ssn6p repressor is associated with localized decreases in histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IN-VIVO; TRANSCRIPTIONAL REPRESSION; CHROMATIN STRUCTURE; GLUCOSE REPRESSION; INVERTASE SYNTHESIS; GENE-REGULATION; HOMEO DOMAIN; ALPHA-2; TUP1	Posttranslational acetylation of histones is an important element of transcriptional regulation. The yeast Tup1p repressor is one of only a few non-enzyme proteins known to interact directly with the amino-terminal tail domains of histones H3 and H4 that are subject to acetylation. We demonstrated previously that Tup1p interacts poorly with more highly acetylated isoforms of these histones in vitro. Here we show that two separate classes of promoters repressed by Tup1p are associated with underacetylated histones in vivo. This decreased histone acetylation is dependent upon Tup1p and its partner Ssn6p and is localized to sequences near the point of Tup1p-Ssn6p recruitment. Increased acetylation of histones H3 and H4 is observed upon activation of these genes, but this increase is not dependent on transcription per se. Direct recruitment of Tup1p-Ssn6p complexes via fusion of Tup1p to the lexA DNA binding domain is sufficient to confer repression and induce decreased acetylation of H3 and H4 at a target promoter. Taken together, our results suggest that stable decreases in histone acetylation levels are directed and/or maintained by the Tup1p-Ssn6p repressor complex.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Roth, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd,Box 117, Houston, TX 77030 USA.		Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269	NIGMS NIH HHS [GM51189] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CARLSON M, 1984, GENETICS, V107, P19; CARLSON M, 1981, GENETICS, V98, P25; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; CHEN SM, 1993, MOL CELL BIOL, V13, P831, DOI 10.1128/MCB.13.2.831; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; Edmondson DG, 1998, COLD SPRING HARB SYM, V63, P459, DOI 10.1101/sqb.1998.63.459; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Huang L, 1997, MOL CELL BIOL, V17, P6555, DOI 10.1128/MCB.17.11.6555; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; NEIGEBORN L, 1984, GENETICS, V108, P845; NEIGEBORN L, 1987, GENETICS, V115, P247; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Redd MJ, 1997, J BIOL CHEM, V272, P11193; Rose MD., 1990, METHODS YEAST GENETI; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SAROKIN L, 1985, MOL CELL BIOL, V5, P2521, DOI 10.1128/MCB.5.10.2521; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Wahi M, 1998, COLD SPRING HARB SYM, V63, P447, DOI 10.1101/sqb.1998.63.447; WAHI M, 1995, GENETICS, V140, P79; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500	54	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1808	1813		10.1074/jbc.M008668200	http://dx.doi.org/10.1074/jbc.M008668200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11056171	hybrid			2022-12-25	WOS:000166528000023
J	Chang, WT; Kang, JJ; Lee, KY; Wei, K; Anderson, E; Gotmare, S; Ross, JA; Rosen, GD				Chang, WT; Kang, JJ; Lee, KY; Wei, K; Anderson, E; Gotmare, S; Ross, JA; Rosen, GD			Triptolide and chemotherapy cooperate in tumor cell apoptosis - A role for the p53 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTISITE PHOSPHORYLATION; TRIPTERYGIUM-WILFORDII; THYMIDYLATE SYNTHASE; DNA-DAMAGE; IN-VIVO; EXPRESSION; PROTEIN; ACTIVATION; REPRESSION; RADIATION	Triptolide (PG490), a diterpene triepoxide, is a potent immunosuppressive agent extracted from the Chinese herb Tripterygium wilfordii. We have previously shown that triptolide blocks NF-kappaB activation and sensitizes tumor necrosis factor (TNF-alpha)-resistant tumor cell lines to TNF-alpha -induced apoptosis. We show here that triptolide enhances chemotherapy-induced apoptosis. In triptolide-treated cells, the expression of p53 increased but the transcriptional function of p53 was inhibited, and we observed a down-regulation of p21(waf1/cip1), a p53-responsive gene. The increase in levels of the p53 protein was mediated by enhanced translation of the p53 protein. Additionally, triptolide induced accumulation of cells in S phase and blocked doxorubicin-mediated accumulation of cells in G(2)/M and doxorubicin-mediated induction of p21. Our data suggest that triptolide, by blocking p21-mediated growth arrest, enhances apoptosis in tumor cells.	Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; NIH, Transgen Oncogenesis Grp, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Dankook Univ Hosp, Dept Internal Med, Div Pulmonol, Cheonan 330180, Chungnam, South Korea	Stanford University; National Institutes of Health (NIH) - USA; Dankook University; Dankook University Hospital	Rosen, GD (corresponding author), Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, 300 Pasteur Dr, Stanford, CA 94305 USA.							Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chu E, 1999, MOL CELL BIOL, V19, P1582; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Haupt Y, 1996, Behring Inst Mitt, P32; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Ju JF, 1999, P NATL ACAD SCI USA, V96, P3769, DOI 10.1073/pnas.96.7.3769; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369; Liu M, 1998, CANCER RES, V58, P1723; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Shamon LA, 1997, CANCER LETT, V112, P113, DOI 10.1016/S0304-3835(96)04554-5; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	27	148	175	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2221	2227		10.1074/jbc.M009713200	http://dx.doi.org/10.1074/jbc.M009713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053449	hybrid			2022-12-25	WOS:000166528000076
J	Miranda, KM; Espey, MG; Yamada, K; Krishna, M; Ludwick, N; Kim, S; Jourd'heuil, D; Grisham, MB; Feelisch, M; Fukuto, JM; Wink, DA				Miranda, KM; Espey, MG; Yamada, K; Krishna, M; Ludwick, N; Kim, S; Jourd'heuil, D; Grisham, MB; Feelisch, M; Fukuto, JM; Wink, DA			Unique oxidative mechanisms for the reactive nitrogen oxide species, nitroxyl anion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXYNITRITE-MEDIATED OXIDATION; FREE NITRIC-OXIDE; CARBON-DIOXIDE; SUPEROXIDE-DISMUTASE; BIOLOGICAL-ACTIVITY; HYDROGEN-PEROXIDE; NITROSYL HYDRIDE; NO; NITRATION; DIHYDRORHODAMINE-123	The nitroxyl anion (NO-) is a highly reactive molecule that may be involved in pathophysiological actions associated with increased formation of reactive nitrogen oxide species. Angeli's salt (Na2N2O3; AS) is a NO- donor that has been shown to exert marked cytotoxicity. However, its decomposition intermediates have not been well characterized. In this study, the chemical reactivity of AS was examined and compared with that of peroxynitrite (ONOO-) and NO/N2O3. Under aerobic conditions, AS and ONOO- exhibited similar and considerably higher affinities for dihydrorhodamine (DHR) than NO/N2O3. Quenching of DHR oxidation by azide and nitrosation of diaminonaphthalene were exclusively observed with NO/N2O3. Additional comparison of ONOO- and AS chemistry demonstrated that ONOO- was a far more potent one-electron oxidant and nitrating agent of hydroxyphenylacetic acid than was AS. However, AS was more effective at hydroxylating benzoic acid than was ONOO-. Taken together, these data indicate that neither NO/N2O3 nor ONOO- is an intermediate of AS decomposition. Evaluation of the stoichiometry of AS decomposition and O-2 consumption revealed a 1:1 molar ratio. Indeed, oxidation of DHR mediated by AS proved to be oxygen dependent. Analysis of the end products of AS decomposition demonstrated formation of NO2- and NO3- in approximately stoichiometric ratios. Several mechanisms are proposed for O-2 adduct formation followed by decomposition to NO3- or by oxidation of an HN2O3- molecule to form NO2-. Given that the cytotoxicity of AS is far greater than that of either NO/N2O3 or NO + O-2(-) this study provides important new insights into the implications of the potential endogenous formation of NO- under inflammatory conditions in vivo.	NCI, Tumor Biol Sect, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Dept Mol Pharmacol, Los Angeles, CA 90269 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Los Angeles; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Miranda, KM (corresponding author), NCI, Tumor Biol Sect, Radiat Biol Branch, NIH, Bldg 10,Rm B3-B69, Bethesda, MD 20892 USA.		Yamada, Ken-ichi/E-6318-2012; Miranda, Katrina M/B-7823-2009; Feelisch, Martin/C-3042-2008; Cook, Natalie Mikki/J-5401-2019	Yamada, Ken-ichi/0000-0003-2100-8477; Feelisch, Martin/0000-0003-2320-1158; Jourd'heuil, David/0000-0002-6555-5061; Wink, David/0000-0002-5652-7480; Azad, Mahan/0000-0002-8633-3513				ADAK S, 2000, IN PRESS J BIOL CHEM; AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; Bonner F.T., 2010, CHEMINFORM, V28, DOI [10.1002/chin.199715245, DOI 10.1002/CHIN.199715245]; BONNER FT, 1978, INORG CHEM, V17, P2487, DOI 10.1021/ic50187a030; Briviba K, 1998, BIOCHEM PHARMACOL, V55, P817, DOI 10.1016/S0006-2952(97)00542-X; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; DONALD CE, 1986, INORG CHEM, V25, P2676, DOI 10.1021/ic00236a004; DOYLE MP, 1988, J AM CHEM SOC, V110, P593, DOI 10.1021/ja00210a047; Feelisch M., 1996, METHODS NITRIC OXIDE, P71; Forstner H., 1983, POLAROGRAPHIC OXYGEN, P321, DOI [10.1007/978-3-642-81863-9_28, DOI 10.1007/978-3-642-81863-9_28]; FUKUTO JM, 1993, BIOCHEM BIOPH RES CO, V196, P707, DOI 10.1006/bbrc.1993.2307; GALLUP GA, 1975, INORG CHEM, V14, P563, DOI 10.1021/ic50145a023; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P1003; HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992; HUGHES MN, 1968, J CHEM SOC A, P451; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; Ischiropoulos H, 1996, FREE RADICAL BIO MED, V20, P373, DOI 10.1016/0891-5849(95)02098-5; ISHAWATA T, 1974, CHEM PHYS LETT, V27, P260; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Khan AU, 2000, P NATL ACAD SCI USA, V97, P2984, DOI 10.1073/pnas.050587297; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Lemercier JN, 1997, ARCH BIOCHEM BIOPHYS, V345, P160, DOI 10.1006/abbi.1997.0240; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; ROBINSON J, 1970, ANAL BIOCHEM, V33, P390, DOI 10.1016/0003-2697(70)90310-6; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; WILLIAMS DLH, 1988, NITROSATION, P179; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; Wink DA, 1997, J BIOL CHEM, V272, P11147; Wink DA, 1996, ARCH BIOCHEM BIOPHYS, V331, P241, DOI 10.1006/abbi.1996.0304; WINK DA, 1996, METHODS NITRIC OXIDE, P403; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g	43	121	123	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1720	1727		10.1074/jbc.M006174200	http://dx.doi.org/10.1074/jbc.M006174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042174	hybrid			2022-12-25	WOS:000166528000011
J	Safa, O; Hensley, K; Smirnov, MD; Esmon, CT; Esmon, NL				Safa, O; Hensley, K; Smirnov, MD; Esmon, CT; Esmon, NL			Lipid oxidation enhances the function of activated protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTIPHOSPHOLIPID ANTIBODIES; ENDOTHELIAL-CELLS; ANTICOAGULANT ACTIVITY; THROMBIN GENERATION; ENZYME COMPLEXES; BINDING-SITES; FACTOR-VIII; P-SELECTIN	Although lipid oxidation products are usually associated with tissue injury, it is now recognized that they can also contribute to cell activation and elicit antiinflammatory lipid mediators. In this study, we report that membrane phospholipid oxidation can modulate the hemostatic balance. Oxidation of natural phospholipids results in an increased ability of the membrane surface to support the function of the natural anticoagulant, activated protein C (APC), without significantly altering the ability to support thrombin generation. Lipid oxidation also potentiated the ability of protein S to enhance APC-mediated factor Va inactivation. Phosphatidylethanolamine, phosphatidylserine, and polyunsaturation of the fatty acids were all required for the oxidation-dependent enhancement of APC function. A subgroup of thrombotic patients with anti-phospholipid antibodies specifically blocked the oxidation-dependent enhancement of APC function. Since leukocytes are recruited and activated at the thrombus or sites of vessel injury, our findings suggest that after the initial thrombus formation, lipid oxidation can remodel the membrane surface resulting in increased anticoagulant function, thereby reducing the thrombogenicity of the thrombus or injured vessel surface. Anti-phospholipid antibodies that block this process would therefore be expected to contribute to thrombus growth and disease.	Oklahoma Med Res Fdn, Dept Cardiovasc Biol, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Dept Free Rad Biol & Aging, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Esmon, NL (corresponding author), Oklahoma Med Res Fdn, Dept Cardiovasc Biol, 825 NE 13th St, Oklahoma City, OK 73104 USA.	Naomi-esmon@omrf.ouhsc.edu			NHLBI NIH HHS [P50 HL54502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arora A, 2000, ARCH BIOCHEM BIOPHYS, V373, P102, DOI 10.1006/abbi.1999.1525; BARROWCLIFFE TW, 1982, HAEMOSTASIS, V11, P96; BILLY D, 1995, J BIOL CHEM, V270, P26883, DOI 10.1074/jbc.270.45.26883; Brady H R, 1996, Curr Opin Nephrol Hypertens, V5, P20, DOI 10.1097/00041552-199601000-00006; Camire RM, 1998, BLOOD, V91, P2818, DOI 10.1182/blood.V91.8.2818.2818_2818_2829; Cattaneo M, 1998, ARTERIOSCL THROM VAS, V18, P1371, DOI 10.1161/01.ATV.18.9.1371; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Cines DB, 1998, BLOOD, V91, P3527; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; Esmon CT, 1998, IMMUNOLOGIST, V6, P84; ESMON CT, 1992, TRENDS CARDIOVAS MED, V2, P214, DOI 10.1016/1050-1738(92)90027-P; ESMON CT, 1993, ANNU REV CELL BIOL, V9, P1; ESMON CT, 1973, THESIS WASHINGTON U; Esmon NL, 1997, HAEMATOLOGICA, V82, P474; Gallo R, 1998, CIRCULATION, V97, P581; GILBERT GE, 1995, J BIOL CHEM, V270, P18500, DOI 10.1074/jbc.270.31.18500; Gilbert GE, 1998, BIOCHEMISTRY-US, V37, P13526, DOI 10.1021/bi972944f; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; Griffin JH, 1999, J CLIN INVEST, V103, P219, DOI 10.1172/JCI5006; GRUBER A, 1989, BLOOD, V73, P639; Hahnel D, 1999, ARTERIOSCL THROM VAS, V19, P2431, DOI 10.1161/01.ATV.19.10.2431; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; Horkko S, 1997, P NATL ACAD SCI USA, V94, P10356, DOI 10.1073/pnas.94.19.10356; Horkko S, 1996, J CLIN INVEST, V98, P815, DOI 10.1172/JCI118854; Iuliano L, 1997, BLOOD, V90, P3931, DOI 10.1182/blood.V90.10.3931; JAIN SK, 1985, J CLIN INVEST, V76, P281, DOI 10.1172/JCI111958; Khaselev N, 1999, FREE RADICAL BIO MED, V26, P275, DOI 10.1016/S0891-5849(98)00211-1; KLEIN RA, 1970, BIOCHIM BIOPHYS ACTA, V210, P486, DOI 10.1016/0005-2736(70)90231-2; KRAMER JH, 1995, J MOL CELL CARDIOL, V27, P371, DOI 10.1016/S0022-2828(08)80034-X; KUNG C, 1994, J BIOL CHEM, V269, P25838; Levine JS, 1999, EXP MOL PATHOL, V66, P82, DOI 10.1006/exmp.1999.2243; Ma SF, 1997, J LAB CLIN MED, V129, P611, DOI 10.1016/S0022-2143(97)90195-5; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V269, P390, DOI 10.1016/0003-9861(89)90122-7; Moyer MP, 1998, ARTERIOSCL THROM VAS, V18, P458, DOI 10.1161/01.ATV.18.3.458; MULLANE K, 1991, TRENDS CARDIOVAS MED, V1, P282, DOI 10.1016/1050-1738(91)90044-F; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; OWEN WG, 1974, J BIOL CHEM, V249, P594; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; Patel RP, 1997, BIOCHEM J, V322, P425, DOI 10.1042/bj3220425; PEI G, 1993, J BIOL CHEM, V268, P3226; Perez-Gilabert M, 1998, ARCH BIOCHEM BIOPHYS, V354, P18, DOI 10.1006/abbi.1998.0673; Pratico D, 1999, BLOOD, V93, P3401, DOI 10.1182/blood.V93.10.3401.410k36_3401_3407; Rauch J, 1998, THROMB HAEMOSTASIS, V80, P936; Rijkers DTS, 1998, THROMB RES, V89, P161, DOI 10.1016/S0049-3848(97)00312-5; Rosing J, 1997, BRIT J HAEMATOL, V97, P233, DOI 10.1046/j.1365-2141.1997.192707.x; Rota S, 1998, BLOOD, V91, P508, DOI 10.1182/blood.V91.2.508.508_508_515; Safa O, 1999, BIOCHEMISTRY-US, V38, P1829, DOI 10.1021/bi981730a; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Smeets EF, 1996, THROMB RES, V81, P419, DOI 10.1016/0049-3848(96)00014-X; SMIRNOV MD, 1995, J CLIN INVEST, V95, P309, DOI 10.1172/JCI117657; Smirnov MD, 1999, BIOCHEMISTRY-US, V38, P3591, DOI 10.1021/bi982538b; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Subang R, 2000, J AUTOIMMUN, V15, P21, DOI 10.1006/jaut.2000.0382; Subbaiah PV, 1999, J BIOL CHEM, V274, P36409, DOI 10.1074/jbc.274.51.36409; Taylor FB, 2000, BLOOD, V95, P1680, DOI 10.1182/blood.V95.5.1680.005k33_1680_1686; URANO S, 1988, BIOCHEM BIOPH RES CO, V150, P469, DOI 10.1016/0006-291X(88)90544-X; VAARALA O, 1993, LANCET, V341, P923, DOI 10.1016/0140-6736(93)91213-6; Vance D. E., 1991, BIOCH LIPIDS LIPOPRO; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367; WANG JY, 1994, CHEM PHYS LIPIDS, V71, P197, DOI 10.1016/0009-3084(94)90071-X; Weinstein EA, 2000, J BIOL CHEM, V275, P22925, DOI 10.1074/jbc.M002438200; Wu R, 1999, CLIN EXP IMMUNOL, V115, P561; Xu J, 2000, J BIOL CHEM, V275, P6038, DOI 10.1074/jbc.275.8.6038; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; Zoller B, 1999, HAEMATOLOGICA, V84, P59	74	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1829	1836		10.1074/jbc.M005931200	http://dx.doi.org/10.1074/jbc.M005931200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11054414	hybrid			2022-12-25	WOS:000166528000026
J	van Bennekum, AM; Wei, SH; Gamble, MV; Vogel, S; Piantedosi, R; Gottesman, M; Episkopou, V; Blaner, WS				van Bennekum, AM; Wei, SH; Gamble, MV; Vogel, S; Piantedosi, R; Gottesman, M; Episkopou, V; Blaner, WS			Biochemical basis for depressed serum retinol levels in transthyretin-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; ACUTE-RENAL-FAILURE; PLASMA RETINOL; ENDOPLASMIC-RETICULUM; HELA-CELLS; METABOLISM; RAT; COMPLEX; INTERNALIZATION; EXPRESSION	Transthyretin (TTR) acts physiologically in the transport of retinol in the circulation. We previously reported the generation and partial characterization of TTR-deficient (TTR-) mice. TTR- mice have very low circulating levels of retinol and its specific transport protein, retinol-binding protein (RBP). We have examined the biochemical basis for the low plasma retinol-RBP levels. Cultured primary hepatocytes isolated from wild type (WT) and TTR- mice accumulated REP in their media to an identical degree, suggesting that REP was being secreted from the hepatocytes at the same rate, In vivo experiments support; this conclusion. For the first 11 h after complete nephrectomy, the levels retinol and REP rose in the circulations of WT and TTR- mice at nearly identical rates. However, human retinol-RBP injected intravenously was more rapidly cleared from the circulation (t(1/2) = 0.5 h for TTR- versus t(1/2) > 6 h for WT) and accumulated faster in the kidneys of TTR- compared with WT mice. The rate of infiltration of the retinol-RBP complex from the circulation to tissue interstitial fluids was identical in both strains. Taken together, these data indicate that low circulating retinol-RBP levels in TTRmice arise from increased renal filtration of the retinol-RBP complex.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Inst Canc Res, New York, NY 10032 USA; Hammersmith Hosp, MRC, London W12 0NN, England	Columbia University; Columbia University; Columbia University; Columbia University; Imperial College London	Blaner, WS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Hammer Hlth Sci Bldg,Rm 502,701 W 168th St, New York, NY 10032 USA.		Episkopou, Vasso/E-2952-2010		Medical Research Council [MC_U120074332] Funding Source: Medline; NEI NIH HHS [EY12858] Funding Source: Medline; NIDDK NIH HHS [DK52444] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052444] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bellovino D, 1996, EXP CELL RES, V222, P77, DOI 10.1006/excr.1996.0010; Blaner William S., 1994, P229; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BLANER WS, 1990, METHOD ENZYMOL, V189, P193; BRONZERT TJ, 1977, CLIN CHEM, V23, P2089; BROUWER A, 1988, CHEM-BIOL INTERACT, V68, P203, DOI 10.1016/0009-2797(88)90017-8; Cooper AD, 1997, J LIPID RES, V38, P2173; DIVINO CM, 1990, J BIOL CHEM, V265, P1425; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; GERLACH TH, 1990, FASEB J, V4, P2511, DOI 10.1096/fasebj.4.8.2335274; GERLACH TH, 1991, J LIPID RES, V32, P515; GOODMAN DS, 1965, J LIPID RES, V6, P390; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; KATO M, 1985, J BIOL CHEM, V260, P4832; KRASINSKI SD, 1990, METABOLISM, V39, P357, DOI 10.1016/0026-0495(90)90249-C; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MELHUS H, 1992, J BIOL CHEM, V267, P12036; MELHUS H, 1991, EXP CELL RES, V197, P119, DOI 10.1016/0014-4827(91)90488-G; RITTER SJ, 1995, J NUTR BIOCHEM, V6, P689, DOI 10.1016/0955-2863(95)00149-2; SCHINDLER R, 1986, INT J VITAM NUTR RES, V56, P21; SENOO H, 1990, J LIPID RES, V31, P1229; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; van Bennekum AM, 1999, J LIPID RES, V40, P565; VOGEL S, 1999, HANDB EXP PHARM, V139, P31; Waynforth H, 1992, EXPT SURG TECHNIQUE, P274; WEI SH, 1995, J BIOL CHEM, V270, P866, DOI 10.1074/jbc.270.2.866	28	95	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1107	1113		10.1074/jbc.M008091200	http://dx.doi.org/10.1074/jbc.M008091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11036082	hybrid			2022-12-25	WOS:000166430900035
J	Gustafson, MP; Thomas, CF; Rusnak, F; Limper, AH; Leof, EB				Gustafson, MP; Thomas, CF; Rusnak, F; Limper, AH; Leof, EB			Differential regulation of growth and checkpoint control mediated by a Cdc25 mitotic phosphatase from Pneumocystis carinii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; REPLICATION CHECKPOINT; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; ACTIVATION; PNEUMONIA; PARASITE; CDS1; IDENTIFICATION; CONTAINS	Pneumocystis carinii is an opportunistic fungal pathogen phylogenetically related to the fission yeast Schizosaccharomyces pombe. P. carinii causes severe pneumonia in immunocompromised patients with AIDS and malignancies. Although the life cycle of P, carinii remains poorly characterized, morphologic studies of infected lung tissue indicate that P. carinii alternates between numerous small trophic forms and fewer large cystic forms. To understand further the molecular mechanisms that regulate progression of the cell cycle of P, carinii, we have sought to identify and characterize genes in P. carinii that are important regulators of eukaryotic cell cycle progression. In this study, we have isolated a cDNA from P. carinii that exhibits significant homology, but unique functional characteristics, to the mitotic phosphatase Cdc25 found in S. pombe. P. carinii Cdc25 was shown to rescue growth of the temperature-sensitive S. pombe cdc25-22 strain and thus provides an additional tool to investigate the unique P.. carinii life cycle. Although P. carinii Cdc25 could also restore the DNA damage checkpoint in cdc25-22 cells, it was unable to restore fully the DNA replication checkpoint. The dissociation of checkpoint control at the level of Cdc25 indicates that Cdc25 may be under distinct regulatory control in mediating checkpoint signaling.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Pulm Crit Care & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Hematol Res Sect, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Leof, EB (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Guggenheim 642C, Rochester, MN 55905 USA.	leof.edward@mayo.edu	Gustafson, Michael P./H-4056-2011	Gustafson, Michael P./0000-0002-5514-7072	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057125, R01HL062150, R01HL055934] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL55934, R01 HL 57125, R01 HL 62150] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baber-Furnari BA, 2000, MOL BIOL CELL, V11, P1; BARTLETT MS, 1988, J CLIN MICROBIOL, V26, P1100, DOI 10.1128/JCM.26.6.1100-1102.1988; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Bruns TD, 1992, MOL PHYLOGENET EVOL, V1, P231, DOI 10.1016/1055-7903(92)90020-H; CUSHION MT, 1993, J CLIN MICROBIOL, V31, P1217, DOI 10.1128/JCM.31.5.1217-1223.1993; CUSHION MT, 1993, INFECT IMMUN, V61, P4801, DOI 10.1128/IAI.61.11.4801-4813.1993; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Eckstein JW, 1996, PROTEIN SCI, V5, P5; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; Fleig U N, 1991, Semin Cell Biol, V2, P195; FLETCHER LD, 1993, GENE, V129, P307, DOI 10.1016/0378-1119(93)90285-B; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; Haase G, 1997, INFECT IMMUN, V65, P4365, DOI 10.1128/IAI.65.10.4365-4366.1997; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HONG ST, 1990, J CLIN MICROBIOL, V28, P1785, DOI 10.1128/JCM.28.8.1785-1795.1990; Honigberg SM, 1993, CURR OPIN CELL BIOL, V5, P219, DOI 10.1016/0955-0674(93)90106-Z; IINO Y, 1995, GENETICS, V140, P1235; Kottom TJ, 1999, J EUKARYOT MICROBIOL, V46, p131S; Kottom TJ, 2000, AM J RESP CELL MOL, V22, P722, DOI 10.1165/ajrcmb.22.6.3838; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; Limper A. H., 1995, Journal of Investigative Medicine, V43, p466A; LIMPER AH, 1990, J CLIN INVEST, V85, P391, DOI 10.1172/JCI114451; LIMPER AH, 1989, AM REV RESPIR DIS, V140, P1204, DOI 10.1164/ajrccm/140.5.1204; Limper AH, 1997, J LAB CLIN MED, V130, P132, DOI 10.1016/S0022-2143(97)90089-5; LONG EG, 1986, LAB INVEST, V54, P609; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MACNEILL SA, 1993, CELL CYCLE PRACTICAL, P106; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Merali S, 1999, P NATL ACAD SCI USA, V96, P2402, DOI 10.1073/pnas.96.5.2402; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1993, CELL CYCLE INTRO, P42; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Raleigh JM, 2000, J CELL SCI, V113, P1727; Rhind N, 1998, MOL CELL BIOL, V18, P3782, DOI 10.1128/MCB.18.7.3782; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; RUFFOLO JJ, 1994, PNEUMOCYSTIS CARINII, P25; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Safrin S, 1993, Semin Respir Infect, V8, P96; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHMATZ DM, 1990, P NATL ACAD SCI USA, V87, P5950, DOI 10.1073/pnas.87.15.5950; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Thomas CF, 1998, AM J PHYSIOL-LUNG C, V275, pL193, DOI 10.1152/ajplung.1998.275.1.L193; Thomas CF, 1998, AM J RESP CELL MOL, V18, P297, DOI 10.1165/ajrcmb.18.3.3122; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	59	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					835	843		10.1074/jbc.M007814200	http://dx.doi.org/10.1074/jbc.M007814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029470	hybrid			2022-12-25	WOS:000166280700112
J	Jeong, SJ; Kim, HS; Chang, KA; Geum, DH; Park, CH; Seo, JH; Rah, JC; Lee, JH; Choi, SH; Lee, SG; Kim, K; Suh, YH				Jeong, SJ; Kim, HS; Chang, KA; Geum, DH; Park, CH; Seo, JH; Rah, JC; Lee, JH; Choi, SH; Lee, SG; Kim, K; Suh, YH			Subcellular localization of presenilins during mouse preimplantation development	FASEB JOURNAL			English	Article						preimplantation embryos; nucleus; centrosome-kinetochore microtubule; cell division	FAMILIAL ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; MISSENSE MUTATIONS; BETA-CATENIN; CELL-CYCLE; EXPRESSION; PROTEASOME; GENE; CLONING; MUTANT	The genes defective hi familial Alzheimer's disease encode the proteins presenilin 1 and 2 (PS1 and 2). Expression of presenilins (PSs) and their proteolytic processing are regulated during neuronal development. Even though these proteins are detected and regulated mainly in Golgi and endoplasmic reticulum, their subcellular distribution during the development is not known. The present study aimed to investigate the localization of PSs and their role during early developmental stage using mouse embryo model. At preimplantation stage, PSs were detected not only in cytoplasm, but also in the nucleus from oocyte to 2.5 dpc (day postcoitum), then disappeared in the nucleus at blastocyst stage (3.5 dpc). Antisense against PS1 and PS2 decreased the transition to blastocyst stage, whereas each antisense alone had no effect. Treatment with lactacystin (26S proteosome inhibitor), which arrest cell cycle at M phase, redistributed PSs into centrosome-kinetochore microtubule. PS2 overexpression in HEK 293 cell arrested cell cycle at S phase. These data suggest that PSs play key roles in cell division and differentiation during early development.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Chongno Gu, Seoul 110799, South Korea; Seoul Natl Univ, Med Res Ctr, Neurosci Res Inst, Seoul 110799, South Korea; Korea Natl Inst Hlth, Biomed Brain Res Ctr, Seoul 110799, South Korea; Seoul Natl Univ, Coll Nat Sci, Dept Mol Biol, Seoul 151742, South Korea; Seoul Natl Univ, Coll Nat Sci, Cell Differentiat Res Ctr, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Seoul National University (SNU); Seoul National University (SNU)	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Chongno Gu, 28 Yongon Dong, Seoul 110799, South Korea.		Kim, Hye Sun/J-2752-2012; Suh, Yoo-Hun/J-2761-2012	Rah, Jong-Cheol/0000-0003-3780-0522				BRYAN J, 1971, P NATL ACAD SCI USA, V68, P1762, DOI 10.1073/pnas.68.8.1762; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dix DJ, 1998, MOL REPROD DEV, V51, P373, DOI 10.1002/(SICI)1098-2795(199812)51:4&lt;373::AID-MRD3&gt;3.0.CO;2-E; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; FISHER S, 1991, P NATL ACAD SCI USA, V88, P1779, DOI 10.1073/pnas.88.5.1779; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Honda T, 1999, J NEUROCHEM, V72, P255, DOI 10.1046/j.1471-4159.1999.0720255.x; Janicki SM, 1999, AM J PATHOL, V155, P135, DOI 10.1016/S0002-9440(10)65108-5; Kim TW, 1997, J BIOL CHEM, V272, P11006; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; LUDUENA RF, 1977, J BIOL CHEM, V252, P7006; Mattson MP, 1998, J NEUROCHEM, V70, P1; Mengual E, 1996, J NEUROSCI, V16, P6331; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Ohsugi M, 1996, DEV DYNAM, V206, P391, DOI 10.1002/(SICI)1097-0177(199608)206:4<391::AID-AJA5>3.0.CO;2-D; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Oyama F, 1998, J NEUROCHEM, V71, P313; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Smith MA, 1998, INT REV NEUROBIOL, V42, P1, DOI 10.1016/S0074-7742(08)60607-8; Takahashi H, 1996, NEUROSCI LETT, V206, P113, DOI 10.1016/S0304-3940(96)12449-6; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tsark EC, 1997, MOL REPROD DEV, V47, P271, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;271::AID-MRD6&gt;3.0.CO;2-I; Tsujimura A, 1997, BIOCHEM BIOPH RES CO, V231, P392, DOI 10.1006/bbrc.1996.6043; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5; Zhang WJ, 1998, J NEUROSCI, V18, P914	36	16	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2171	2176		10.1096/fj.99-1068com	http://dx.doi.org/10.1096/fj.99-1068com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053237				2022-12-25	WOS:000165190800009
J	Zsembery, A; Strazzabosco, M; Graf, J				Zsembery, A; Strazzabosco, M; Graf, J			Ca2+-activated Cl- channels can substitute for CFTR in stimulation of pancreatic duct bicarbonate secretion	FASEB JOURNAL			English	Article						cystic fibrosis; anion exchange; purinergic stimulation; K+ channel function	TRANSMEMBRANE CONDUCTANCE REGULATOR; VASOACTIVE-INTESTINAL-PEPTIDE; ADENOCARCINOMA CELL-LINE; CYSTIC-FIBROSIS PATIENTS; EPITHELIAL-CELLS; CHLORIDE CONDUCTANCE; MEMBRANE VOLTAGE; SODIUM-CHANNELS; CFPAC-1 CELLS; ATP	This study addresses the mechanisms by which a defect in CFTR impairs pancreatic duct bicarbonate secretion in cystic fibrosis, We used control (PANC-1) and CFTR-deficient (CEPAC-1; Delta F508 mutation) cell lines and measured HCO3- extrusion by the rate of recovery of intracellular pH after an alkaline load and recorded whole cell membrane currents using patch clamp techniques. 1) In PANC-1 cells, cAMP causes parallel activation of Cl- channels and of HCO3- extrusion by DIDS-sensitive and Na+-independent Cl-/HCO3- exchange, both effects being inhibited by Cl- channel blockers NPPB and glibenclamide, 2) In CFPAC-1 cells, cAMP fails to stimulate Cl-/HCO3- exchange and Cl- channels, except after promoting surface expression of Delta F508-CFTR by glycerol treatment. Instead, raising intracellular Ca concentration to 1 mu mol/l or stimulating purinergic receptors with ATP (10 and 100 mu mol/l) leads to parallel activation of Cl- channels and HCO3- extrusion, 3) K+ channel function is required for coupling cAMP- and Ca2+-dependent Cl- channel activation to effective stimulation of Cl-/HCO3- exchange in control and CF cells, respectively. It is concluded that stimulation of pancreatic duct bicarbonate secretion via Cl-/HCO3- exchange is directly correlated to activation of apical membrane Cl- channels. Reduced bicarbonate secretion in cystic fibrosis results from defective cAMP-activated Cl- channels, This defect is partially compensated for by an increased sensitivity of CF cells to purinergic stimulation and by alternative activation of Ca2+-dependent Cl- channels, mechanisms of interest with respect to possible treatment of cystic fibrosis and of related chronic pancreatic diseases.Zsembery, A., Strazzabosco, M., Graf, J, Ca2+-activated Cl- channels can substitute for CFTR in stimulation of pancreatic duct bicarbonate secretion.	Univ Vienna, Dept Gen & Expt Pathol, A-1090 Vienna, Austria; Univ Azienda Osped Padova, Ist Med Interna, Padua, Italy; Semmelweis Univ, Fac Med, Dept Pathophysiol, H-1085 Budapest, Hungary	University of Vienna; University of Padua; Azienda Ospedaliera - Universita di Padova; Semmelweis University	Graf, J (corresponding author), Univ Vienna, Dept Gen & Expt Pathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	juerg.graf@univie.ac.at			Telethon [E.0873] Funding Source: Medline	Telethon(Fondazione Telethon)		ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; AlNakkash L, 1996, INT J PANCREATOL, V19, P39; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Argent B. E., 1994, P1473; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARO I, 1994, J PHYSIOL-LONDON, V478, P469, DOI 10.1113/jphysiol.1994.sp020266; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; Boron WF, 1992, KIDNEY PHYSL PATHOPH, P219; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CASAVOLA V, 1995, AM J PHYSIOL-CELL PH, V269, pC226, DOI 10.1152/ajpcell.1995.269.1.C226; Chan HC, 1996, AM J PHYSIOL-CELL PH, V271, pC469, DOI 10.1152/ajpcell.1996.271.2.C469; Chan HC, 1997, J MEMBRANE BIOL, V156, P241, DOI 10.1007/s002329900204; CHAO AC, 1995, J CLIN INVEST, V96, P1794, DOI 10.1172/JCI118225; Dray-Charier N, 1999, HEPATOLOGY, V29, P1624, DOI 10.1002/hep.510290634; DURIE PR, 1989, J ROY SOC MED, V82, P2; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; ELGAVISH A, 1991, BIOCHEM BIOPH RES CO, V180, P342, DOI 10.1016/S0006-291X(05)81298-7; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GALIETTA LJV, 1994, PFLUG ARCH EUR J PHY, V426, P534, DOI 10.1007/BF00378531; GASKIN KJ, 1982, PEDIATR RES, V16, P554, DOI 10.1203/00006450-198207000-00012; GRAY MA, 1994, AM J PHYSIOL, V266, pC213, DOI 10.1152/ajpcell.1994.266.1.C213; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hogan DL, 1997, AM J PHYSIOL-GASTR L, V272, pG872, DOI 10.1152/ajpgi.1997.272.4.G872; Hyde K, 1999, BIOCHEM BIOPH RES CO, V263, P315, DOI 10.1006/bbrc.1999.1367; Ismailov II, 1996, J BIOL CHEM, V271, P4725; Jiang SP, 1997, CANCER RES, V57, P1475; KOPELMAN H, 1993, J CLIN INVEST, V91, P1253, DOI 10.1172/JCI116289; KOPELMAN HR, 1988, GASTROENTEROLOGY, V98, P349; Lee MG, 1999, J BIOL CHEM, V274, P3414, DOI 10.1074/jbc.274.6.3414; Lindblad A, 1998, HEPATOLOGY, V27, P166, DOI 10.1002/hep.510270126; Loussouarn G, 1996, AM J PHYSIOL-CELL PH, V271, pC1565, DOI 10.1152/ajpcell.1996.271.5.C1565; MADDEN ME, 1988, PANCREAS, V5, P512; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MARINO CR, 1992, GASTROENTEROLOGY, V103, P681, DOI 10.1016/0016-5085(92)90866-W; MCGILL J, 1996, GASTROENTEROLOGY, V107, P236; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Nguyen TD, 1998, AM J PHYSIOL-GASTR L, V275, pG76, DOI 10.1152/ajpgi.1998.275.1.G76; Nguyen TD, 1998, AM J PHYSIOL-GASTR L, V275, pG104, DOI 10.1152/ajpgi.1998.275.1.G104; NOVAK I, 1993, PFLUG ARCH EUR J PHY, V425, P272, DOI 10.1007/BF00374178; NOVAK I, 1988, PFLUG ARCH EUR J PHY, V411, P58, DOI 10.1007/BF00581647; O'Reilly CM, 1998, BRIT J PHARMACOL, V124, P1597, DOI 10.1038/sj.bjp.0701990; PAHL C, 1993, PFLUG ARCH EUR J PHY, V424, P315, DOI 10.1007/BF00384358; Poulsen JH, 1996, PFLUG ARCH EUR J PHY, V432, P546, DOI 10.1007/s004240050168; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rubenstein Ronald C., 1998, Current Opinion in Pediatrics, V10, P250, DOI 10.1097/00008480-199806000-00005; RUGOLO M, 1993, J BIOL CHEM, V268, P24779; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Schreiber R, 1997, PFLUG ARCH EUR J PHY, V434, P841, DOI 10.1007/s004240050473; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; SHEPPARD DN, 1993, ANN NY ACAD SCI, V707, P275, DOI 10.1111/j.1749-6632.1993.tb38058.x; Shumaker H, 1999, AM J PHYSIOL-CELL PH, V276, pC16, DOI 10.1152/ajpcell.1999.276.1.C16; SLIMAK GG, 1993, PANCREAS, V8, P212, DOI 10.1097/00006676-199303000-00012; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Tauc M, 1996, J MEMBRANE BIOL, V150, P255, DOI 10.1007/s002329900049; VEEZE HJ, 1994, J CLIN INVEST, V93, P461, DOI 10.1172/JCI116993; VILLANGER O, 1995, GASTROENTEROLOGY, V108, P850, DOI 10.1016/0016-5085(95)90460-3; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WARTH R, 1993, CELL PHYSIOL BIOCHEM, V3, P2, DOI 10.1159/000154663; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Winpenny JP, 1998, PFLUG ARCH EUR J PHY, V435, P796, DOI 10.1007/s004240050586; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57	68	49	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2345	2356		10.1096/fj.99-0509com	http://dx.doi.org/10.1096/fj.99-0509com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053257				2022-12-25	WOS:000165190800029
J	Baek, JH; Jang, JE; Kang, CM; Chung, HY; Kim, ND; Kim, KW				Baek, JH; Jang, JE; Kang, CM; Chung, HY; Kim, ND; Kim, KW			Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis	ONCOGENE			English	Article						hypoxia; apoptosis; VEGF; bax; bcl-2; MAPK/ERK	ENDOTHELIAL GROWTH-FACTOR; HUMAN HEPATOCELLULAR-CARCINOMA; ACID-INDUCED APOPTOSIS; CYTOCHROME-C; CELL-DEATH; TRANSCRIPTIONAL REGULATION; GENE-TRANSCRIPTION; EXPRESSION; ACTIVATION; RELEASE	Low oxygen and nutrient depletion play critical roles in tumorigenesis, but little is known about how they interact to produce tumor survival and tumor malignancy. In the present study, we investigated the mechanism underlying hypoxia-modulated apoptosis of serum-deprived HepG2 cells, Our results showed that hypoxia blocked the apoptosis, which was accompanied with decreased Bax/ Bcl-2 ratio, inhibited cytochrome c release, and reduced caspase-3 activity. More importantly, increased expressions of VEGF and its receptor-2 (KDR) under hypoxic/ serum-deprived condition suggest that VEGF may act as a survival factor in a self-promoting manner. Data were further supported by results that recombinant human VEGF (rhVEGF) suppressed the serum deprivation-induced apoptosis, and anti-VEGF neutralizing antibody block anti-apoptotic activity of hypoxia, In addition, inhibitors of receptor tyrosine kinase blocked anti-apoptosis of hypoxia, Our study further showed that rhVEGF or hypoxia induced ERK phosphorylation in serum-deprived cells, and that a specific inhibitor of MAPK/ERK, PD98059 eliminated the anti-apoptotic activity of rhVEGF or hypoxia by increasing Bax/Bcl-2 ratio and caspase-3 activity. Our data led us to conclude that induction of ERK phosphorylation and decrease of Bax/Bcl-2 ratio by rhVEGF implies that hypoxia-induced VEGF prevents apoptosis of serum-deprived cells by activating the MAPK/ERK pathway. Taken together, we propose that hypoxia enhances survival of nutrient-depleted tumor cells by reducing susceptibility to apoptosis, which consequently leads to tumor malignancy.	Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Seoul Natl Univ, WHO, Collaborat Ctr Phys Culture & Aging Res Hlth Prom, Seoul 110799, South Korea; Pusan Natl Univ, Dept Pharm, Pusan 609735, South Korea	Pusan National University; Seoul National University (SNU); World Health Organization; Pusan National University	Kim, KW (corresponding author), Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea.							ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Bae SK, 1998, CANCER LETT, V126, P97, DOI 10.1016/S0304-3835(97)00538-7; Baek JH, 1996, J BIOCHEM MOL BIOL, V29, P68; Baek JH, 1997, INT J CANCER, V73, P725, DOI 10.1002/(SICI)1097-0215(19971127)73:5<725::AID-IJC19>3.3.CO;2-T; Bhalla RC, 1997, AM J PHYSIOL-HEART C, V272, pH1996, DOI 10.1152/ajpheart.1997.272.4.H1996; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; DOLBEARE F, 1994, METHOD CELL BIOL, V41, P297; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gotz ME, 1999, J NEUROSCI RES, V56, P420; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hockel M, 1996, CANCER RES, V56, P4509; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Jinno H, 1999, CARCINOGENESIS, V20, P229, DOI 10.1093/carcin/20.2.229; Kim KW, 1998, CANCER RES, V58, P348; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; KWO P, 1995, AM J PHYSIOL-GASTR L, V268, pG613, DOI 10.1152/ajpgi.1995.268.4.G613; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Piossek C, 1999, J BIOL CHEM, V274, P5612, DOI 10.1074/jbc.274.9.5612; Rempel A, 1996, CANCER RES, V56, P2468; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Satoh T, 1996, BRAIN RES, V733, P9, DOI 10.1016/0006-8993(96)00527-6; SCHUSTER SJ, 1989, BLOOD, V73, P13; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; WANG TTY, 1995, CANCER RES, V55, P2487; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Younes M, 1996, CANCER RES, V56, P1164	48	151	168	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4621	4631		10.1038/sj.onc.1203814	http://dx.doi.org/10.1038/sj.onc.1203814			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030151				2022-12-25	WOS:000089438200008
J	Gon, S; Giudici-Orticoni, MT; Mejean, V; Iobbi-Nivol, C				Gon, S; Giudici-Orticoni, MT; Mejean, V; Iobbi-Nivol, C			Electron transfer and binding of the c-type cytochrome TorC to the trimethylamine N-oxide reductase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; CRYSTAL-STRUCTURE; RHODOBACTER-CAPSULATUS; ANGSTROM RESOLUTION; MOLECULAR-CLONING; DMSO REDUCTASE; RESPIRATION; EXPRESSION; OPERON; SYSTEM	Reduction of trimethylamine N oxide (E'(0(TMAO/TMA)) = +130 mV) in Escherichia coli is carried out by the Tor system, an electron transfer chain encoded by the torCAD operon and made up of the periplasmic terminal reductase TorA and the membrane-anchored pentahemic c-type cytochrome TorC. Although the role of TorA in the reduction of trimethylamine N-oxide (TMAO) has been clearly established, no direct evidence for TorC involvement has been presented. TorC belongs to the NirT/NapC c-type cytochrome family based on homologies of its N-terminal tetrahemic domain (TorC(N)) to the cytochromes of this family, but TorC contains a C-terminal extension (TorC(C)) with an additional heme-binding site. In this study, we show that both domains are required for the anaerobic bacterial growth with TMAO, The intact TorC protein and its two domains, TorC(N) and TorC(C), were produced independently and purified for a biochemical characterization. The reduced form of TorC exhibited visible absorption maxima at 552, 523, and 417 nm. Mediated redox potentiometry of the heme centers of the purified components identified two negative midpoint potentials (-177 and -98 mV) localized in the tetrahemic TorC(N) and one positive midpoint potential (+120 mV) in the monohemic TorC(C). In agreement with these values, the in vitro reconstitution of electron transfer between TorC, TorC(N), or TorC(C) and TorA showed that only TorC and TorC(C) were capable of electron transfer to TorA, Surprisingly, interaction studies revealed that only TorC and TorC(N) strongly bind TorA. Therefore, TorC(C) directly transfers electrons to TorA, whereas TorC,, which probably receives electrons from the menaquinone pool, is involved in both the electron transfer to TorC(C) and the binding to TorA.	CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille 20, France; CNRS, Inst Biol Struct & Microbiol, Lab Bioenerget & Ingn Prot, F-13402 Marseille, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Iobbi-Nivol, C (corresponding author), CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier,BP 71, F-13402 Marseille 20, France.		GON, Stephanie/O-8324-2016	GON, Stephanie/0000-0002-1513-5018; Mejean, Vincent/0000-0001-6533-5846				Ansaldi M, 1999, MOL MICROBIOL, V33, P284, DOI 10.1046/j.1365-2958.1999.01468.x; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; BERKS BC, 1995, BIOCHEM J, V309, P983, DOI 10.1042/bj3090983; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BILOUS PT, 1988, J BACTERIOL, V170, P1511, DOI 10.1128/jb.170.4.1511-1518.1988; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; Dos Santos JP, 1998, J MOL BIOL, V284, P421, DOI 10.1006/jmbi.1998.2155; Dutton P L, 1978, Methods Enzymol, V54, P411; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Gon S, 2000, J BACTERIOL, V182, P5779, DOI 10.1128/JB.182.20.5779-5786.2000; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hartig E, 1999, J BACTERIOL, V181, P161; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Jourlin C, 1996, J BACTERIOL, V178, P1219, DOI 10.1128/jb.178.4.1219-1223.1996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McAlpine AS, 1997, J BIOL INORG CHEM, V2, P690, DOI 10.1007/s007750050185; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; Miller J.H., 1972, EXPT MOL GENETICS; MOORE GR, 1990, CYTOCHROMES EVOLUTIO, P309; Mouncey NJ, 1997, J BACTERIOL, V179, P7617, DOI 10.1128/jb.179.24.7617-7624.1997; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Pommier J, 1998, J BIOL CHEM, V273, P16615, DOI 10.1074/jbc.273.26.16615; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; Roldan MD, 1998, J BIOL CHEM, V273, P28785, DOI 10.1074/jbc.273.44.28785; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; Shaw AL, 1999, J BIOL CHEM, V274, P9911, DOI 10.1074/jbc.274.15.9911; SILVESTRO A, 1989, BIOCHIM BIOPHYS ACTA, V999, P208, DOI 10.1016/0167-4838(89)90220-3; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; WISSENBACH U, 1992, ARCH MICROBIOL, V158, P68, DOI 10.1007/BF00249068	37	71	72	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11545	11551		10.1074/jbc.M008875200	http://dx.doi.org/10.1074/jbc.M008875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11056172	hybrid			2022-12-25	WOS:000168081800019
J	Caccuri, AM; Antonini, G; Board, PG; Flanagan, J; Parker, MW; Paolesse, R; Turella, P; Chelvanayagam, G; Ricci, G				Caccuri, AM; Antonini, G; Board, PG; Flanagan, J; Parker, MW; Paolesse, R; Turella, P; Chelvanayagam, G; Ricci, G			Human glutathione transferase T2-2 discloses some evolutionary strategies for optimization of the catalytic activity of glutathione transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; S-TRANSFERASES; BIOCHEMICAL PATHWAYS; KINETIC-ANALYSIS; PROTON RELEASE; HELIX 2; P1-1; MECHANISM; BINDING; FLEXIBILITY	Steady state, pre-steady state kinetic experiments, and site-directed mutagenesis have been used to dissect the catalytic mechanism of human glutathione transferase T2-2 with 1-menaphthyl sulfate as co-substrate, This enzyme is close to the ancestral precursor of the more recently evolved glutathione transferases belonging to Alpha, Pi, and Mu classes. The enzyme displays a random kinetic mechanism with very low k(cat) and k(cat)/ K-m(GSH) values and with a rate-limiting step identified as the product release. The chemical step, which is fast and causes product accumulation before the steady state catalysis, strictly depends on the deprotonation of the bound GSH. Replacement of Arg-107 with Ala dramatically affects the fast phase, indicating that this residue is crucial both in the activation and orientation of GSH in the ternary complex. All pre-steady state and steady state kinetic data were convincingly fit to a kinetic mechanism that reflects a quite primordial catalytic efficiency of this enzyme. It involves two slowly interconverting or not interconverting enzyme populations (or active sites of the dimeric enzyme) both able to bind and activate GSH and strongly inhibited by the product. Only one population or subunit is catalytically competent. The proposed mechanism accounts for the apparent half-site behavior of this enzyme and for the apparent negative cooperativity observed under steady state conditions. These findings also suggest some evolutionary strategies in the glutathione transferase family that have been adopted for the optimization of the catalytic activity, which are mainly based on an increased flexibility of critical protein segments and on an optimal orientation of the substrate.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Aquila, Dept Basic & Appl Biol, I-67010 Coppito, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia; St Vincents Inst Med Res, Ian Potter Fdn Prot Crystallog Lab, Fitzroy, Vic 3065, Australia; Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Childrens Hosp IRCCS Bambin Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of L'Aquila; Sapienza University Rome; Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research; University of Rome Tor Vergata; IRCCS Bambino Gesu	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, Viale Ric Sci, I-00133 Rome, Italy.	riccig@uniroma2.it	Parker, Michael W/F-9069-2013; CACCURI, ANNA MARIA/AFU-2643-2022; Paolesse, Roberto/AAI-3182-2020; Paolesse, Roberto/B-8966-2013	Parker, Michael W/0000-0002-3101-1138; Paolesse, Roberto/0000-0002-2380-1404; CACCURI, ANNA MARIA/0000-0002-3756-4163; Antonini, Giovanni/0000-0002-2115-8961; Ricci, Giorgio/0000-0002-7108-2846				Antonini G, 1996, BIOCHEM J, V314, P533, DOI 10.1042/bj3140533; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Board PG, 1997, BIOCHEM J, V328, P929; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 1998, BIOCHEMISTRY-US, V37, P3028, DOI 10.1021/bi971903g; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; CHENG DJ, 1988, MRL B RES DEV, V2, P27; CLAPP JJ, 1970, BIOCHEM J, V118, P765, DOI 10.1042/bj1180765; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Flanagan JU, 1999, PROTEIN SCI, V8, P2205, DOI 10.1110/ps.8.10.2205; HENDLER RW, 1994, J BIOCHEM BIOPH METH, V28, P1, DOI 10.1016/0165-022X(94)90061-2; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; IVANETICH KM, 1990, BIOCHEM PHARMACOL, V39, P1999, DOI 10.1016/0006-2952(90)90621-Q; Jemth P, 1999, BIOCHEMISTRY-US, V38, P9982, DOI 10.1021/bi983065b; Jemth P, 2000, J BIOL CHEM, V275, P8618, DOI 10.1074/jbc.275.12.8618; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Mendes P, 1998, BIOINFORMATICS, V14, P869, DOI 10.1093/bioinformatics/14.10.869; Nieslanik BS, 1999, BIOCHEMISTRY-US, V38, P6971, DOI 10.1021/bi9829130; Parsons JF, 1998, BIOCHEMISTRY-US, V37, P6286, DOI 10.1021/bi980219e; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Salinas AE, 1999, CURR MED CHEM, V6, P279; Stella L, 1998, J BIOL CHEM, V273, P23267, DOI 10.1074/jbc.273.36.23267; Stella L, 1999, PROTEINS, V37, P10, DOI 10.1002/(SICI)1097-0134(19991001)37:1<10::AID-PROT2>3.0.CO;2-0; Stella L, 1999, PROTEINS, V37, P1; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; Widersten M, 1996, BIOCHEMISTRY-US, V35, P7731, DOI 10.1021/bi9601619; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	32	10	10	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5432	5437		10.1074/jbc.M002818200	http://dx.doi.org/10.1074/jbc.M002818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11044441	hybrid			2022-12-25	WOS:000167115100005
J	Ma, B; Hernandez, N				Ma, B; Hernandez, N			A map of protein-protein contacts within the small nuclear RNA-activating protein complex SNAP(c)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL SEQUENCE ELEMENT; HUMAN SNRNA GENES; OCT-1 POU DOMAIN; POLYMERASE-III; TRANSCRIPTION FACTOR; SUBUNIT; TBP; EXPRESSION; PROMOTERS; CLONING	The nucleation of RNA polymerases I-III transcription complexes is usually directed by distinct multisubunit factors. In the case of the human RNA polymerase II and III small nuclear RNA (snRNA) genes, whose core promoters consist of a proximal sequence element (PSE) and a PSE combined with a TATA box, respectively, the same multisubunit complex is involved in the establishment of RNA polymerase II and III initiation complexes. This factor, the snRNA-activating protein complex or SNAP(c), binds to the PSE of both types of promoters and contains five types of subunits, SNAP190, SNAP50, SNAP45, SNAP43, and SNAP19, SNAP(c) binds cooperatively with both Oct-1, an activator of snRNA promoters, and in the RNA polymerase III snRNA promoters, with TATA-binding protein, which binds to the TATA box located downstream of the PSE. Here we have defined subunit domains required for SNAP, subunit-subunit association, and we show that complexes containing little more than the domains mapped here as required for subunit-subunit contacts bind specifically to the PSE, These data provide a detailed map of the subunit-subunit interactions within a multifunctional basal transcription complex.	Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Hernandez, N (corresponding author), Cold Spring Harbor Lab, Howard Hughes Med Inst, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	Hernande@cshl.org		Hernandez, Nouria/0000-0003-1465-4585	NIGMS NIH HHS [GM38810] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038810] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ford E, 1998, GENE DEV, V12, P3528, DOI 10.1101/gad.12.22.3528; Ford E, 1997, J BIOL CHEM, V272, P16048, DOI 10.1074/jbc.272.25.16048; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Henry RW, 1996, EMBO J, V15, P7129, DOI 10.1002/j.1460-2075.1996.tb01104.x; Henry RW, 1998, GENE DEV, V12, P2664, DOI 10.1101/gad.12.17.2664; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Yoon JB, 1996, MOL CELL BIOL, V16, P1; YOON JB, 1995, MOL CELL BIOL, V15, P2019	20	37	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5027	5035		10.1074/jbc.M009301200	http://dx.doi.org/10.1074/jbc.M009301200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11056176	hybrid			2022-12-25	WOS:000168484300068
J	Augustine, JG; de la Calle, A; Knarr, G; Buchner, J; Frederick, CA				Augustine, JG; de la Calle, A; Knarr, G; Buchner, J; Frederick, CA			The crystal structure of the Fab fragment of the monoclonal antibody MAK33 - Implications for folding and interaction with the chaperone BiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; HEAVY-CHAIN; PEPTIDE-BINDING; ASSOCIATION; SPECIFICITY; COMPLEX; DOMAIN; SEQUENCES; MOLTEN; STATE	The Feb fragment of the murine monoclonal antibody, MAK33, directed against human creatine kinase of the muscle-type, was crystallized and the three-dimensional structure was determined to 2.9 Angstrom. The antigen-binding surface of MAK33 shows a convex overall shape typical for immunoglobulins binding large antigens, The structure allows us to analyze the environment of cis-prolylpeptide bonds whose isomerization is of key importance in the folding process. These residues seem to be involved with not only domain stability but also seem to play a role in the association of heavy and light chains, reinforcing the importance of beta -strand recognition in antibody assembly. The structure also allows the localization of segments of primary sequence postulated to represent binding sites for the ER-specific chaperone BiP within the context of the entire Feb fragment. These sequences are found primarily in beta -strands that are necessary for interactions between the individual domains.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Technical University of Munich	Frederick, CA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, SM1036,44 Binney St, Boston, MA 02115 USA.	caf@red.dfci.harvard.edu	Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				ATHERTON E, 1978, J CHEM SOC CHEM COMM, P537, DOI 10.1039/c39780000537; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESCAR J, 1995, J BIOL CHEM, V270, P18067, DOI 10.1074/jbc.270.30.18067; LILIE H, 1995, FEBS LETT, V362, P43, DOI 10.1016/0014-5793(95)00203-L; LILIE H, 1994, J BIOL CHEM, V269, P14290; LILIE H, 1993, PROTEIN SCI, V2, P1490, DOI 10.1002/pro.5560020913; LILIE H, 1995, J MOL BIOL, V248, P190, DOI 10.1006/jmbi.1995.0211; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1993, DAT COLL PROC P CCP4; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Ptitsyn O, 1996, NAT STRUCT BIOL, V3, P488, DOI 10.1038/nsb0696-488; PTITSYN OB, 1994, FEBS LETT, V341, P15, DOI 10.1016/0014-5793(94)80231-9; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; Skowronek MH, 1998, P NATL ACAD SCI USA, V95, P1574, DOI 10.1073/pnas.95.4.1574; Thies MJW, 1999, J MOL BIOL, V293, P67, DOI 10.1006/jmbi.1999.3128; WIECH H, 1993, J BIOL CHEM, V268, P7414; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	43	25	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3287	3294		10.1074/jbc.M005221200	http://dx.doi.org/10.1074/jbc.M005221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11036070	hybrid			2022-12-25	WOS:000166784900041
J	Kotenko, SV; Izotova, LS; Mirochnitchenko, OV; Esterova, E; Dickensheets, H; Donnelly, RP; Pestka, S				Kotenko, SV; Izotova, LS; Mirochnitchenko, OV; Esterova, E; Dickensheets, H; Donnelly, RP; Pestka, S			Identification of the functional interleukin-22 (IL-22) receptor complex - The IL-10R2 chain (IL-10R beta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-ASSOCIATED GENE; HUMAN-MELANOMA DIFFERENTIATION; INTERFERON-GAMMA RECEPTOR; TRANSGENIC MICE; CANDIDATE GENE; PROTEIN-KINASE; ASTHMA; EXPRESSION; LINKAGE; HYPERRESPONSIVENESS	Interleukin-10 (IL-10)-related T cell-derived inducible factor (IL-TIF; provisionally designated IL-22) is a cytokine with limited homology to IL-10, We report here the identification of a functional IL-TIF receptor complex that consists of two receptor chains, the orphan CRF2-9 and IL-10R2, the second chain of the IL-10 receptor complex. Expression of the CRF2-9 chain in monkey COS cells renders them sensitive to IL-TIF, However, in hamster cells both chains, CRF2-9 and IL-10R2, must be expressed to assemble the functional IL-TIF receptor complex. The CRF2-9 chain (or the IL-TIF-R1 chain) is responsible for Stat recruitment. Substitution of the CRF2-9 intracellular domain with the IFN-gamma R1 intracellular domain changes the pattern of IL-TIF-induced Stat activation. The CRF2-9 gene is expressed in normal liver and kidney, suggesting a possible role for IL-TIF in regulating gene expression in these tissues. Each chain, CRF2-9 and IL-10R2, is capable of binding IL-TIF independently and can be cross-linked to the radiolabeled IL-TIF, However, binding of IL-TIF to the receptor complex is greater than binding to either receptor chain alone. Sharing of the common IL-10R2 chain between the IL-10 and IL-TIF receptor complexes is the first such case for receptor complexes with chains belonging to the class II cytokine receptor family, establishing a novel paradigm for IL-10-related ligands similar to the shared use of the gamma common chain (gamma (c)) by several cytokines, including IL-2, IL-4, IL-7, IL-9, and IL-15,	Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; US FDA, Ctr Biol Evaluat & Res, Div Therapeut Prot, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; US Food & Drug Administration (FDA)	Kotenko, SV (corresponding author), Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA.		Donnelly, Raymond P./AFT-8600-2022	Donnelly, Raymond P./0000-0002-0695-5276	NATIONAL CANCER INSTITUTE [R01CA046465, P30CA072720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043369, R01AI036450] Funding Source: NIH RePORTER; NCI NIH HHS [1P30-CA72720, R01-CA46465] Funding Source: Medline; NIAID NIH HHS [R01-AI43369, R01-AI36450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P485, DOI 10.1016/S0091-6749(99)70398-2; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bernabei P., 1999, Journal of Interferon and Cytokine Research, V19, pS87; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Hayden C, 1997, CLIN EXP ALLERGY, V27, P1412, DOI 10.1111/j.1365-2222.1997.tb02985.x; Jiang HP, 1995, ONCOGENE, V11, P2477; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Kotenko SV, 1999, P NATL ACAD SCI USA, V96, P5007, DOI 10.1073/pnas.96.9.5007; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kotenko SV, 2000, P NATL ACAD SCI USA, V97, P1695, DOI 10.1073/pnas.97.4.1695; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Krause CD, 1998, EUR CYTOKINE NETW, V9, P456; Levitt RC, 1999, J ALLERGY CLIN IMMUN, V103, pS485, DOI 10.1016/S0091-6749(99)70165-X; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LIU Y, 1994, J IMMUNOL, V152, P1821; Lockridge KM, 2000, VIROLOGY, V268, P272, DOI 10.1006/viro.2000.0195; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Pestka S, 1999, PROTEIN EXPRES PURIF, V17, P203, DOI 10.1006/prep.1999.1118; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; Soo C, 1999, J CELL BIOCHEM, V74, P1; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; Wilkinson J, 1999, INT ARCH ALLERGY IMM, V118, P265, DOI 10.1159/000024095; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Zdanov A, 1997, J MOL BIOL, V268, P460, DOI 10.1006/jmbi.1997.0990; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	41	324	370	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2725	2732		10.1074/jbc.M007837200	http://dx.doi.org/10.1074/jbc.M007837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035029	hybrid			2022-12-25	WOS:000166784800059
J	Latunde-Dada, AO; Cabello-Hurtado, F; Czittrich, N; Didierjean, L; Schopfer, C; Hertkorn, N; Werck-Reichhart, D; Ebel, J				Latunde-Dada, AO; Cabello-Hurtado, F; Czittrich, N; Didierjean, L; Schopfer, C; Hertkorn, N; Werck-Reichhart, D; Ebel, J			Flavonoid 6-hydroxylase from soybean (Glycine max L.), a novel plant P-450 monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCYRRHIZA-ECHINATA L.; FUNCTIONAL EXPRESSION; CYTOCHROME-P450 CDNA; POLYHYDROXYLATED ISOFLAVONES; MOLECULAR CHARACTERIZATION; LIVER-MICROSOMES; YEAST EXPRESSION; SYNTHASE-II; BIOSYNTHESIS; CLONING	Cytochrome P-450-dependent hydroxylases are typical enzymes for the modification of basic flavonoid skeletons. We show in this study that CYP71D9 cDNA, previously isolated from elicitor-induced soybean (Glycine max L.) cells, codes for a protein with a novel hydroxylase activity. When heterologously expressed in yeast, this protein bound various flavonoids with high affinity (1.6 to 52 muM) and showed typical type I absorption spectra. These flavonoids were hydroxylated at position 6 of both resorcinol- and phloroglucinol-based A-rings. Flavonoid 6-hydroxylase (CYP71D9) catalyzed the conversion of flavanones more efficiently than flavones. Isoflavones were hardly hydroxylated. As soybean produces isoflavonoid constituents possessing 6,7-dihydroxy substitution patterns on ring A, the biosynthetic relationship of flavonoid B-hydroxylase to isoflavonoid biosynthesis was investigated. Recombinant 8-hydroxyisoflavanone synthase (CYP93C1v2) efficiently used 6,7,4'-trihydroxyflavanone as substrate. For its structural identification, the chemically labile reaction product was converted to 6,7,4'-trihydroxyisoflavone by acid treatment. The structures of the final reaction products for both enzymes were confirmed by MMR and mass spectrometry. Our results strongly support the conclusion that, in soybean, the B-hydroxylation of the A-ring occurs before the 1,2-aryl migration of the flavonoid B-ring during isoflavanone formation. This is the first identification of a flavonoid B-hydroxylase cDNA from any plant species.	Univ Munich, Inst Bot, D-80638 Munich, Germany; CNRS, Inst Plant Mol Biol, Dept Stress Responses, FRE 2161, F-67083 Strasbourg, France; GSF Forschungszentrum Umwelt & Gesundheit, Inst Okol Chem, D-85764 Neuherberg, Germany	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Ebel, J (corresponding author), Univ Munich, Inst Bot, Menzinger Str 67, D-80638 Munich, Germany.		Hertkorn, Norbert/AAA-5990-2022; WERCK-REICHHART, Danièle/U-3713-2019	WERCK-REICHHART, Danièle/0000-0003-2869-4262				Agrawal PK., 1989, CARBON 13 NMR FLAVON, P96; Akashi T, 1999, PLANT PHYSIOL, V121, P821, DOI 10.1104/pp.121.3.821; Akashi T, 1998, BIOCHEM BIOPH RES CO, V251, P67, DOI 10.1006/bbrc.1998.9414; Akashi T, 1998, FEBS LETT, V431, P287, DOI 10.1016/S0014-5793(98)00781-9; Akashi T, 1999, PLANT CELL PHYSIOL, V40, P1182, DOI 10.1093/oxfordjournals.pcp.a029505; BRITSCH L, 1990, ARCH BIOCHEM BIOPHYS, V282, P152, DOI 10.1016/0003-9861(90)90099-K; Brugliera F, 1999, PLANT J, V19, P441, DOI 10.1046/j.1365-313X.1999.00539.x; CABALLERO P, 1986, J NAT PROD, V49, P1126, DOI 10.1021/np50048a030; Cabello-Hurtado F, 1998, J BIOL CHEM, V273, P7260, DOI 10.1074/jbc.273.13.7260; DIESPERGER H, 1974, FEBS LETT, V43, P155, DOI 10.1016/0014-5793(74)80990-7; Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; EBEL J, 1988, TRENDS BIOCHEM SCI, V13, P23, DOI 10.1016/0968-0004(88)90014-X; EBEL J, 1976, PLANT PHYSIOL, V57, P775, DOI 10.1104/pp.57.5.775; FORKMANN G, 1994, FLAVONOIDS ADV RES 1, P537; GYORGY PAUL, 1964, NATURE, V203, P870, DOI 10.1038/203870a0; Hakamatsuka T, 1998, PHYTOCHEMISTRY, V49, P497, DOI 10.1016/S0031-9422(98)00266-0; Harborne J.B., 1994, FLAVONOIDS ADV RES 1, P589; HARBORNE JB, 1994, FLAVONOIDS ADV RES 1, P1; HASHIM MF, 1990, FEBS LETT, V271, P219, DOI 10.1016/0014-5793(90)80410-K; Heller W., 1993, ADV RES 1986, P499; HOLTON TA, 1993, NATURE, V366, P276, DOI 10.1038/366276a0; JHA HC, 1990, 2ND AS S NONS SOYB F, P4; Jung W, 2000, NAT BIOTECHNOL, V18, P208, DOI 10.1038/72671; Klus K, 1995, ARCH MICROBIOL, V164, P428, DOI 10.1007/s002030050285; Klus K, 1998, PHYTOCHEMISTRY, V47, P1045, DOI 10.1016/S0031-9422(97)00648-1; KOCHS G, 1986, EUR J BIOCHEM, V155, P311, DOI 10.1111/j.1432-1033.1986.tb09492.x; KUDOU S, 1991, AGR BIOL CHEM TOKYO, V55, P2227, DOI 10.1080/00021369.1991.10870966; Le Bail JC, 1998, CANCER LETT, V133, P101, DOI 10.1016/S0304-3835(98)00211-0; LEE H, 1994, MUTAGENESIS, V9, P101, DOI 10.1093/mutage/9.2.101; LI Y, 1994, DRUG METAB DISPOS, V22, P566; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; Lupien S, 1999, ARCH BIOCHEM BIOPHYS, V368, P181, DOI 10.1006/abbi.1999.1298; MARFENS S, 1999, PLANT J, V20, P611; Middleton E., 1994, FLAVONOIDS ADV RES 1, P619; MITCHELL MJ, 1993, INSECT BIOCHEM MOLEC, V23, P65, DOI 10.1016/0965-1748(93)90083-5; NAIM M, 1974, J AGR FOOD CHEM, V22, P806, DOI 10.1021/jf60195a031; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; Robineau T, 1998, PLANT PHYSIOL, V118, P1049, DOI 10.1104/pp.118.3.1049; Schalk M, 1997, BIOCHEMISTRY-US, V36, P15253, DOI 10.1021/bi971575k; SCHMIDT WE, 1987, P NATL ACAD SCI USA, V84, P4117, DOI 10.1073/pnas.84.12.4117; SCHOPFER C, 1998, THESIS U MUNICH GERM; Schopfer CR, 1998, FEBS LETT, V432, P182, DOI 10.1016/S0014-5793(98)00866-7; Schopfer CR, 1998, MOL GEN GENET, V258, P315, DOI 10.1007/s004380050736; Schroder G, 1999, FEBS LETT, V458, P97, DOI 10.1016/S0014-5793(99)01138-2; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; Steele CL, 1999, ARCH BIOCHEM BIOPHYS, V367, P146, DOI 10.1006/abbi.1999.1238; TRUAN G, 1993, GENE, V125, P49, DOI 10.1016/0378-1119(93)90744-N; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; URBAN P, 1990, BIOCHIMIE, V72, P463, DOI 10.1016/0300-9084(90)90070-W; Urban P, 1997, J BIOL CHEM, V272, P19176, DOI 10.1074/jbc.272.31.19176	53	88	104	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1688	1695		10.1074/jbc.M006277200	http://dx.doi.org/10.1074/jbc.M006277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11027686	hybrid			2022-12-25	WOS:000166528000006
J	Fulop, V; Szeltner, Z; Renner, V; Polgar, L				Fulop, V; Szeltner, Z; Renner, V; Polgar, L			Structures of prolyl oligopeptidase substrate/inhibitor complexes - Use of inhibitor binding for titration of the catalytic histidine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEPTIDASE; PEPTIDASES; IDENTIFICATION; ENZYME; MAPS; SITE	Structure determination of the inactive S554A variant of prolyl oligopeptidase complexed with an octapeptide has shown that substrate binding is restricted to the P4-P2' region. In addition, it has revealed a hydrogen bond network of potential catalytic importance not detected in other serine peptidases, This involves a unique intramolecular hydrogen bond between the P1' amide and P2 carbonyl groups and another between the P2' amide and N epsilon2 of the catalytic histidine 680 residue. It is argued that both hydrogen bonds promote proton transfer from the imidazolium ion to the leaving group. Another complex formed with the product-like inhibitor benzyloxycarbonyl-glycyl-proline, indicating that the carboxyl group of the inhibitor forms a hydrogen bond with the N epsilon2 of HiS(680). Because a protonated histidine makes a stronger interaction with the carboxyl group, it offers a possibility of the determination of the real pK(alpha) of the catalytic histidine residue. This was found to be 6,25, lower than that of the well studied serine proteases. The new titration method gave a single pK(alpha) for prolyl oligopeptidase, whose reaction exhibited a complex pH dependence for k(cat)/K-m, and indicated that the observed pK(alpha) values are apparent. The procedure presented may be applicable for other serine peptidases.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest 112, Hungary; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; University of Warwick	Polgar, L (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest 112, Hungary.	polgar@enzim.hu	Fulop, Vilmos/AAZ-7720-2021					ATACK JR, 1991, EUR J PHARMACOL, V205, P157, DOI 10.1016/0014-2999(91)90814-7; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fulop V, 2000, EMBO REP, V1, P277, DOI 10.1093/embo-reports/kvd048; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leatherbarrow R. J, 1998, GRAFIT VERSION 4; MAES M, 1994, BIOL PSYCHIAT, V35, P545, DOI 10.1016/0006-3223(94)90101-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polg?r L., 1987, NEW COMPREHENSIVE BI, V16, P159; POLGAR L, 1993, FEBS LETT, V322, P227, DOI 10.1016/0014-5793(93)81575-K; POLGAR L, 1995, BIOCHEM J, V312, P267, DOI 10.1042/bj3120267; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1991, EUR J BIOCHEM, V197, P441, DOI 10.1111/j.1432-1033.1991.tb15930.x; POLGAR L, 1994, METHOD ENZYMOL, V244, P188; POLGAR L, 1989, MECHANISMS PROTEASE, P87; Portevin B, 1996, J MED CHEM, V39, P2379, DOI 10.1021/jm950858c; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; Szeltner Z, 2000, J BIOL CHEM, V275, P15000, DOI 10.1074/jbc.M000942200; Szeltner Z, 2000, PROTEIN SCI, V9, P353; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; YOSHIMOTO T, 1987, J PHARMACOBIO-DYNAM, V10, P730, DOI 10.1248/bpb1978.10.730	31	76	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1262	1266		10.1074/jbc.M007003200	http://dx.doi.org/10.1074/jbc.M007003200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11031266	hybrid			2022-12-25	WOS:000166430900055
J	Mitchell, LW; Volin, M; Martins, J; Jaffe, EK				Mitchell, LW; Volin, M; Martins, J; Jaffe, EK			Mechanistic implications of mutations to the active site lysine of porphobilinogen syntheses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-AMINOLEVULINIC ACID DEHYDRATASE; X-RAY-STRUCTURE; ESCHERICHIA-COLI; BINDING SITES; SYNTHASE; ENZYME; PURIFICATION; GENE	Porphobilinogen synthase (PBGS) is a homo-octameric protein that catalyzes the complex asymmetric condensation of two molecules of B-aminolevulinic acid (ALA). The only characterized intermediate in the PBGS-catalyzed reaction is a Schiff base that forms between the first ALA that binds and a conserved lysine, which in Escherichia coli PBGS is Lys-246 and in human PBGS is Lys-252, In this study, E. coli PBGS mutants K246H, K246M, K246W, K246N, and K246G and human PBGS mutant K252G were characterized. Alterations to this lysine result in a disabled but not totally inactive protein suggesting an alternate mechanism in which proximity and orientation are major catalytic devices. C-13 NMR studies of [3,5-C-13]porphobilinogen bound at the active sites of the E. coli PBGS and the mutants show only minor chemical shift differences, i.e. environmental alterations. Mammalian PBGS is established to have four functional active sites, whereas the crystal structure of E. coli PBGS shows eight spatially distinct and structurally equivalent subunits, Biochemical data for E. coli PBGS have been interpreted to support both four and eight active sites. A unifying hypothesis is that formation of the Schiff base between this lysine and ALA triggers a conformational change that results in asymmetry. Product binding studies with wild-type E, coli PBGS and K246G demonstrate that both bind porphobilinogen at four per octamer although the latter cannot form the Schiff base from substrate. Thus, formation of the lysine to ALA Schiff base is not required to initiate the asymmetry that results in half-site reactivity.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Jaffe, EK (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	EK_Jaffe@fccc.edu	Volin, Michael/U-4115-2019		NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003654] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NIEHS NIH HHS [ES03654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEVAN DR, 1980, J BIOL CHEM, V255, P2030; DENT AJ, 1990, BIOCHEMISTRY-US, V29, P7822, DOI 10.1021/bi00486a007; ECHELARD Y, 1988, MOL GEN GENET, V214, P503, DOI 10.1007/BF00330487; Erskine PT, 2000, ACTA CRYSTALLOGR D, V56, P421, DOI 10.1107/S0907444900000597; Erskine PT, 1999, BIOCHEMISTRY-US, V38, P4266, DOI 10.1021/bi982137w; Erskine PT, 1999, PROTEIN SCI, V8, P1250, DOI 10.1110/ps.8.6.1250; Erskine PT, 1997, NAT STRUCT BIOL, V4, P1025, DOI 10.1038/nsb1297-1025; EVANS JNS, 1985, MAGN RESON CHEM, V23, P939, DOI 10.1002/mrc.1260231112; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13968, DOI 10.1021/bi9906468; JAFFE EK, 1995, BIOCHEMISTRY-US, V34, P244, DOI 10.1021/bi00001a029; JAFFE EK, 1990, BIOCHEMISTRY-US, V29, P8345, DOI 10.1021/bi00488a021; JAFFE EK, 1986, J BIOL CHEM, V261, P9348; JAFFE EK, 1987, BIOCHEMISTRY-US, V26, P4258, DOI 10.1021/bi00388a012; Jaffe EK, 2000, ACTA CRYSTALLOGR D, V56, P115, DOI 10.1107/S0907444999014894; JAFFE EK, 1984, J BIOL CHEM, V259, P5032; JAFFE EK, 1992, BIOCHEMISTRY-US, V31, P2113, DOI 10.1021/bi00122a032; Jaffe EK, 2000, J BIOL CHEM, V275, P2619, DOI 10.1074/jbc.275.4.2619; JORDAN PM, 1985, BIOCHEM J, V227, P1015, DOI 10.1042/bj2271015; LI JM, 1989, GENE, V75, P177, DOI 10.1016/0378-1119(89)90394-6; MITCHELL LW, 1995, J BIOL CHEM, V270, P24054, DOI 10.1074/jbc.270.41.24054; MITCHELL LW, 1993, ARCH BIOCHEM BIOPHYS, V300, P169, DOI 10.1006/abbi.1993.1024; NANDI DL, 1968, J BIOL CHEM, V243, P1236; Petrovich RM, 1996, J BIOL CHEM, V271, P8692, DOI 10.1074/jbc.271.15.8692; ROESSNER CA, 1995, PROTEIN EXPRES PURIF, V6, P155, DOI 10.1006/prep.1995.1019; SEEHRA JS, 1981, EUR J BIOCHEM, V113, P435, DOI 10.1111/j.1432-1033.1981.tb05083.x; Senior NM, 1996, BIOCHEM J, V320, P401; SHEMIN D, 1976, PHILOS T ROY SOC B, V273, P109, DOI 10.1098/rstb.1976.0004; SPENCER P, 1993, BIOCHEM J, V290, P279, DOI 10.1042/bj2900279; SPENCER P, 1995, BIOCHEM J, V305, P151, DOI 10.1042/bj3050151; SPENCER P, 1994, BIOCHEM J, V300, P373, DOI 10.1042/bj3000373; UMANOFF H, 1988, J BACTERIOL, V170, P4969, DOI 10.1128/jb.170.10.4969-4971.1988	32	4	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1538	1544		10.1074/jbc.M008505200	http://dx.doi.org/10.1074/jbc.M008505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032841	hybrid			2022-12-25	WOS:000166430900091
J	Yahalom, A; Kim, TH; Winter, E; Karniol, B; von Arnim, AG; Chamovitz, DA				Yahalom, A; Kim, TH; Winter, E; Karniol, B; von Arnim, AG; Chamovitz, DA			Arabidopsis eIF3e (INT-6) associates with both eIF3c and the COP9 signalosome subunit CSN7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION-FACTOR-3 EIF3; PROTEASOME REGULATORY COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEIN COMPLEX; MAMMALIAN-CELLS; LIGHT CONTROL; PRT1 PROTEIN; RNA-BINDING; YEAST; INTERACTS	The Arabidopsis COP9 signalosome is a multisubunit repressor of photomorphogenesis that is conserved among eukaryotes, This complex may have a general role in development. As a step in dissecting the biochemical mode of action of the COP9 signalosome, we determined the sequence of proteins that copurify with this complex. Here we describe the association between components of the COP9 signalosome (CSN1, CSN7, and CSN8) and two subunits of eukaryotic translation initiation factor 3 (eIF3), eIF3e (p48, known also as INT-6) and eIF3e (p105), To obtain a biochemical marker for Arabidopsis eIF3, we cloned the Arabidopsis ortholog of the eIF3 subunit eIF3b (PRT1), eIF3e coimmunoprecipitated with CSN7, and eIF3c coimmunoprecipitated with eIF3e, eIF3b, CSN8, and CSN1, eIF3e directly interacted with CSN7 and eIF3c, However, eIF3e and eIF3b cofractionated by gel filtration chromatography in a complex that was larger than the COP9 signalosome, Whereas eIF3, as detected through eIF3b, localized solely to the cytoplasm, eIF3e, like CSN7, was also found in the nucleus. This suggests that eIF3e and eIF3c are probably components of multiple complexes and that eIF3e and eIF3c associate with subunits of the COP9 signalosome, even though they are not components of the COP9 signalosome core complex. This interaction may allow for translational control by the COP9 signalosome.	Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Univ Tennessee, Dept Bot, Knoxville, TN 37996 USA	Tel Aviv University; University of Tennessee System; University of Tennessee Knoxville	Chamovitz, DA (corresponding author), Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel.		Chamovitz, Daniel/S-5021-2019	Chamovitz, Daniel/0000-0002-2815-2909; von Arnim, Albrecht/0000-0003-3472-3357				Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; Brent R, 1997, ANNU REV GENET, V31, P663, DOI 10.1146/annurev.genet.31.1.663; BURKS EA, 2001, IN PRESS J BIOL CHEM, V276; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Desbois C, 1999, J CELL SCI, V112, P3331; Dickey LF, 1998, PLANT CELL, V10, P475, DOI 10.1105/tpc.10.3.475; FINLEY RL, 1989, MOL CELL BIOL, V9, P4282, DOI 10.1128/MCB.9.10.4282; Gallie DR, 1998, PLANT J, V14, P715, DOI 10.1046/j.1365-313x.1998.00175.x; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Karniol B, 1998, FEBS LETT, V439, P173, DOI 10.1016/S0014-5793(98)01367-2; Karniol B, 1999, PLANT CELL, V11, P839, DOI 10.1105/tpc.11.5.839; Karniol B, 2000, CURR OPIN PLANT BIOL, V3, P387, DOI 10.1016/S1369-5266(00)00101-1; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kwok SF, 1999, J MOL BIOL, V285, P85, DOI 10.1006/jmbi.1998.2315; Kwok SF, 1998, PLANT CELL, V10, P1779, DOI 10.1105/tpc.10.11.1779; LAUER SJ, 1985, BIOCHEMISTRY-US, V24, P2924, DOI 10.1021/bi00333a016; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MATSUI M, 1995, P NATL ACAD SCI USA, V92, P4239, DOI 10.1073/pnas.92.10.4239; MCNELLIS TW, 1994, PLANT CELL, V6, P1391, DOI 10.1105/tpc.6.10.1391; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Vierstra RD, 1996, PLANT MOL BIOL, V32, P275, DOI 10.1007/BF00039386; von Arnim AG, 1998, GENE, V221, P35, DOI 10.1016/S0378-1119(98)00433-8; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7	44	67	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					334	340		10.1074/jbc.M006721200	http://dx.doi.org/10.1074/jbc.M006721200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029466	hybrid			2022-12-25	WOS:000166280700046
J	Al-Mehdi, AB; Song, C; Tozawa, K; Fisher, AB				Al-Mehdi, AB; Song, C; Tozawa, K; Fisher, AB			Ca2+- and phosphatidylinositol 3-kinase-dependent nitric oxide generation in lung endothelial cells in situ with ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHEAR-STRESS; IN-SITU; FLOW; SYNTHASE; CALCIUM; MECHANOTRANSDUCTION; PHOSPHORYLATION; ACTIVATION; EXPRESSION; CALMODULIN	Endothelial cells generate nitric oxide (NO) in response to agonist stimulation or increased shear stress. In this study, we evaluated the effects of abrupt cessation of shear stress on pulmonary endothelial NO generation and its relationship to changes in intracellular Ca2+. In situ endothelial generation of NO and changes in intracellular Ca2+ in isolated, intact rat lungs were evaluated using fluorescence microscopy with diamino-fluorescein diacetate, an NO probe, and Fluo-3, a Ca2+ probe. The onset of increased NO generation in endothelial cells of subpleural microvessels in situ occurred between 30 and 90 s after onset of ischemia and was preceded by an increase in intracellular Ca2+ due to both influx of extracellular Ca2+ and release from intracellular stores, Flow cessation-induced NO generation in endothelial cells in situ was Ca2+-, calmodulin-, and PI3-kinase-dependent. The similarity of endothelial cell response (increased NO generation) to either increased flow or cessation of flow suggests that cells respond to an imposed alteration from a state of adaptation. This response to flow cessation may constitute a compensatory vasodilatatory mechanism and may play a role in signaling for cell proliferation and vascular remodeling.	Univ Penn, Med Ctr, Inst Environm Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Fisher, AB (corresponding author), Univ Penn, Med Ctr, Inst Environm Med, 1 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.		Al-Mehdi, Abu-Bakr/A-8636-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060290] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50HL60290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; ALMEHDI AB, 1997, AM J RESP CELL MOL B, V18, P653; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; BOSSU JL, 1989, FEBS LETT, V255, P377, DOI 10.1016/0014-5793(89)81126-3; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Dahm P, 1997, CRIT CARE MED, V25, P280, DOI 10.1097/00003246-199702000-00015; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1984, J CLIN INVEST, V73, P1121, DOI 10.1172/JCI111298; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fisslthaler B, 2000, ACTA PHYSIOL SCAND, V168, P81; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fouty B, 1998, AM J PHYSIOL-HEART C, V274, pH672, DOI 10.1152/ajpheart.1998.274.2.H672; Fukaya Y, 1996, AM J PHYSIOL-HEART C, V270, pH99, DOI 10.1152/ajpheart.1996.270.1.H99; Hsieh HJ, 1998, J CELL PHYSIOL, V175, P156, DOI 10.1002/(SICI)1097-4652(199805)175:2<156::AID-JCP5>3.0.CO;2-N; JAMES NL, 1995, FASEB J, V9, P968, DOI 10.1096/fasebj.9.10.7615166; KORENAGA R, 1994, BIOCHEM BIOPH RES CO, V198, P213, DOI 10.1006/bbrc.1994.1030; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Martin E, 2000, SEMIN PERINATOL, V24, P2, DOI 10.1016/S0146-0005(00)80045-2; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Tozawa K, 1999, ANTIOXID REDOX SIGN, V1, P145, DOI 10.1089/ars.1999.1.2-145; Wei ZH, 1999, CIRC RES, V85, P682, DOI 10.1161/01.RES.85.8.682	25	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39807	39810		10.1074/jbc.C000702200	http://dx.doi.org/10.1074/jbc.C000702200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11042195	hybrid			2022-12-25	WOS:000166039500002
J	Xiong, JP; Li, R; Essafi, M; Stehle, T; Arnaout, MA				Xiong, JP; Li, R; Essafi, M; Stehle, T; Arnaout, MA			An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; FUNCTION-ASSOCIATED ANTIGEN-1; NEUTROPHIL INHIBITORY FACTOR; LIGAND-BINDING SITE; I-DOMAIN; CRYSTAL-STRUCTURE; DIVALENT-CATION; ALPHA-SUBUNIT; ACTIVATION; ALPHA(M)BETA(2)	In response to cell activation signals, integrins switch from a low to a high affinity state. Physiologic ligands bind to integrins through a von Willebrand Factor A-type domain. Crystallographic studies revealed two conformations of this domain, "closed" and "open." The latter crystallizes in complex with a pseudoligand or ligand, suggesting that it represents the high affinity state; data linking structure and activity are lacking however. In this communication, we expressed stable low and high affinity forms of integrin CD11b A-domain and determined their binding isotherms and crystal structures. The low affinity form, generated by deleting an N-terminal extension extrinsic to the domain, did not bind to physiologic ligands, and crystallized in the closed conformation. The high affinity form was generated by either deleting or substituting an invariable C-terminal Ile(316), wedged into a hydrophobic socket in the closed form, but displaced from it in the open structure. Both mutants crystallized in the open conformation, and the Ile316 --> Gly-modified integrin displayed high affinity. Structural differences between the low and high affinity forms were detected in solution. These data establish the structure-function correlates for the CD11b A-domain, and define a ligand-independent isoleucine-based allosteric switch intrinsic to this domain that controls its conformation and affinity.	Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Arnaout, MA (corresponding author), Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, 149 13th St, Charlestown, MA 02129 USA.		Essafi, Makram/V-8411-2019		NHLBI NIH HHS [HL54227] Funding Source: Medline; NIDDK NIH HHS [DK48549] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; Bock CW, 1999, J AM CHEM SOC, V121, P7360, DOI 10.1021/ja9906960; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Edwards CP, 1998, J BIOL CHEM, V273, P28937, DOI 10.1074/jbc.273.44.28937; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Feng Y, 1998, J BIOL CHEM, V273, P5625, DOI 10.1074/jbc.273.10.5625; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KARLSSON R, 1993, J IMMUNOL METHODS, V166, P75, DOI 10.1016/0022-1759(93)90330-A; Katz AK, 1996, J AM CHEM SOC, V118, P5752, DOI 10.1021/ja953943i; KERN A, 1994, J BIOL CHEM, V269, P22811; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; SMITH JW, 1988, J BIOL CHEM, V263, P18726; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558	37	122	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38762	38767		10.1074/jbc.C000563200	http://dx.doi.org/10.1074/jbc.C000563200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11034990	hybrid			2022-12-25	WOS:000165739800085
J	Dorowski, A; Hofmann, A; Steegborn, C; Boicu, M; Huber, R				Dorowski, A; Hofmann, A; Steegborn, C; Boicu, M; Huber, R			Crystal structure of paprika ferredoxin-NADP(+) reductase - Implications for the electron transfer pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHTHALATE DIOXYGENASE REDUCTASE; ANABAENA SP PCC-7119; AMINO-ACID-RESIDUES; X-RAY-STRUCTURE; NADP+ REDUCTASE; ANGSTROM RESOLUTION; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; BINDING; COMPLEX	cDNA of Capsicum annuum Yolo Wonder (paprika) has been prepared from total cellular RNA, and the complete gene encoding paprika ferredoxin-NADP(+) reductase (pFNR) precursor was sequenced and cloned from this cDNA. Fusion to a T7 promoter allowed expression in Escherichia coli. Both native and recombinant pFNR were purified to homogeneity and crystallized. The crystal structure of pFNR has been solved by Patterson search techniques using the structure of spinach ferredoxin-NADP+ reductase as search model. The structure was refined at 2.5-Angstrom resolution to a crystallographic R-factor of 19.8% (R-free = 26.5%). The overall structure of pFNR is similar to other members of the ferredoxin-NADP(+) reductase family, the major differences concern a long loop (residues 167-177) that forms part of the FAD binding site and some of the variable loops in surface regions. The different orientation of the FAD binding loop leads to a tighter interaction between pFNR and the adenine moiety of FAD. The physiological redox partners [2Fe-2S]-ferredoxin I and NADP(+) were modeled into the native structure of pFNR. The complexes reveal a protein-protein interaction site that is consistent with existing biochemical data and imply possible orientations for the side chain of tyrosine 362, which has to be displaced by the nicotinamide moiety of NADP(+) upon binding. A reasonable electron transfer pathway could be deduced from the modeled structures of the complexes.	Max Planck Inst Biochem, Abt Struktforsch, D-82152 Planegg Martinsried, Germany; Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Planegg Martinsried, Germany; NCI, Macromol Struct Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Max Planck Society; Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Dorowski, A (corresponding author), Max Planck Inst Biochem, Abt Struktforsch, Klopferspitz 18A, D-82152 Planegg Martinsried, Germany.	anja.dorowski@gmx.de	Hofmann, Andreas/B-9515-2008; Hofmann, Andreas/M-9870-2019	Hofmann, Andreas/0000-0003-4408-5467; Hofmann, Andreas/0000-0003-4408-5467				ALIVERTI A, 1994, FEBS LETT, V343, P247, DOI 10.1016/0014-5793(94)80565-2; ALIVERTI A, 1990, EUR J BIOCHEM, V191, P551, DOI 10.1111/j.1432-1033.1990.tb19156.x; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Binda C, 1998, ACTA CRYSTALLOGR D, V54, P1353, DOI 10.1107/S0907444998005137; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; Carrillo N, 1987, TOPICS PHOTOSYNTHESI, V8, P527; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; DEPASCALIS AR, 1993, PROTEIN SCI, V2, P1126, DOI 10.1002/pro.5560020707; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FOUST GP, 1969, J BIOL CHEM, V244, P964; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Hurley JK, 1999, PROTEIN SCI, V8, P1614, DOI 10.1110/ps.8.8.1614; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; JELESAROV I, 1993, EUR J BIOCHEM, V216, P57, DOI 10.1111/j.1432-1033.1993.tb18116.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, O MANUAL; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, RECENT CHANGES MOSFL; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEDINA M, 1992, FEBS LETT, V298, P25, DOI 10.1016/0014-5793(92)80014-8; MEDINA M, 1992, ARCH BIOCHEM BIOPHYS, V299, P281, DOI 10.1016/0003-9861(92)90276-3; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; PLATO M, 1989, FEBS LETT, V249, P70, DOI 10.1016/0014-5793(89)80018-3; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitz S, 1998, BBA-BIOENERGETICS, V1363, P85, DOI 10.1016/S0005-2728(97)00085-6; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TURK D, 1992, THESIS TU MUNICH; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; ZANETTI G, 1988, BIOCHEMISTRY-US, V27, P3753, DOI 10.1021/bi00410a035; ZANETTI G, 1984, J BIOL CHEM, V259, P6153	57	35	36	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9253	9263		10.1074/jbc.M004576200	http://dx.doi.org/10.1074/jbc.M004576200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11053431	hybrid			2022-12-25	WOS:000167607700085
J	Conrath, KE; Lauwereys, M; Wyns, L; Muyldermans, S				Conrath, KE; Lauwereys, M; Wyns, L; Muyldermans, S			Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE DISPLAY; FRAGMENTS; ENZYME	Single-domain antibodies against various antigens are isolated from the unique heavy-chain antibodies of immunized camels and llamas. These minimal sized binders:are very robust and bind the antigen with high affinity in a monomeric state. We evaluated the feasibility to produce soluble, functional bispecific and bivalent antibodies in Escherichia coli with camel single-domain antibody fragments as building blocks. Two single-domain antibody: fragments were tethered by the structural upper hinge of a natural antibody to generate bispecific molecules. This linker was chosen for its protease resistance in serum and its natural flexibility to reorient the upstream and downstream located domains. The expression levels, ease of purification, and the solubility of the recombinant proteins were comparable with those of the constituent monomers. The individual moieties fully retain the binding capacity and the binding characteristics within the recombinant bispecific constructs. The easy generation steps and the biophysical properties of these bispecific and bivalent constructs based on camel single-domain antibody fragments makes them particularly attractive for use in therapeutic dr diagnostic programs.	Free Univ Brussels VIB, Dept Ultrastruct, B-1640 Rhode St Genese, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Conrath, KE (corresponding author), Free Univ Brussels VIB, Dept Ultrastruct, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	kconrath@vub.ac.be	Muyldermans, Serge/AAC-7374-2019; Muyldermans, Serge V/C-6418-2016	Muyldermans, Serge/0000-0002-3678-3575; Muyldermans, Serge V/0000-0002-3678-3575				BOHLEN H, 1993, CANCER RES, V53, P4310; BRINKMANN U, 1995, J IMMUNOL METHODS, V182, P41, DOI 10.1016/0022-1759(95)00016-4; Colcher D, 1998, Q J NUCL MED, V42, P225; De Jonge J, 1998, J IMMUNOL, V161, P1454; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; Frenken LGJ, 2000, J BIOTECHNOL, V78, P11, DOI 10.1016/S0168-1656(99)00228-X; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Lawrence LJ, 1998, FEBS LETT, V425, P479, DOI 10.1016/S0014-5793(98)00292-0; MILSTEIN C, 1983, NATURE, V305, P537, DOI 10.1038/305537a0; Muller KM, 1998, FEBS LETT, V432, P45, DOI 10.1016/S0014-5793(98)00829-1; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Riechmann L, 1999, J IMMUNOL METHODS, V231, P25, DOI 10.1016/S0022-1759(99)00138-6; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; Roux KH, 1998, J IMMUNOL, V161, P4083; SCHUHMACHER J, 1995, CANCER RES, V55, P115; Segal DM, 1999, CURR OPIN IMMUNOL, V11, P558, DOI 10.1016/S0952-7915(99)00015-1; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Transue TR, 1998, PROTEINS, V32, P515, DOI 10.1002/(SICI)1097-0134(19980901)32:4<515::AID-PROT9>3.0.CO;2-E; van der Linden R, 2000, J IMMUNOL METHODS, V240, P185, DOI 10.1016/S0022-1759(00)00188-5; Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6; Zhu ZP, 1997, PROTEIN SCI, V6, P781	27	222	371	0	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7346	7350		10.1074/jbc.M007734200	http://dx.doi.org/10.1074/jbc.M007734200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11053416				2022-12-25	WOS:000167442900067
J	Tomas-Zuber, M; Mary, JL; Lamour, F; Bur, D; Lesslauer, W				Tomas-Zuber, M; Mary, JL; Lamour, F; Bur, D; Lesslauer, W			C-terminal elements control location, activation threshold, and p38 docking of ribosomal S6 kinase B (RSKB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PROTEIN-KINASE; MAP KINASE; PHOSPHORYLATION SITES; FORCE-FIELD; IDENTIFICATION; P90(RSK); RSK; AUTOPHOSPHORYLATION; TRANSDUCTION	RSKB, a p90 ribosomal S6 protein kinase with two catalytic domains, is activated by p38- and extracellular signal-regulated kinase mitogen-activated protein kinase pathways. The sequences between the two catalytic domains and of the C-terminal extension contain elements that control RSKB activity. The C-terminal extension of RSRB presents a putative bipartite (713)KRX(14)KRRKQKLRS(737) nuclear location signal. The distinct cytoplasmic and nuclear locations of various C-terminal truncation mutants supported the hypothesis that the nuclear location signal was essential to direct RSKB to the nuclear compartment;. The (725)APLA-KRRKQKLRS(737) sequence also was essential for the intermolecular association of RSKB with p38. The activation of RSKB through p38 could be dissociated from p38 docking, because RSRB truncated at Ser(681) strongly responded to p38 pathway activity. Interestingly, Delta (725-772)-RSKB was nearly nonresponsive to p38. Sequence alignment with the autoinhibitory C-terminal extension of Ca+2/calmodulin-dependent protein kinase I predicted a conserved regulatory (708)AFN(710) motif. Alanine mutation of the key Phe(709) residue resulted in strongly elevated basal level RSKB activity. A regulatory role also was assigned to Thr(687), which is located in a mitogen-activated protein kinase phosphorylation consensus site. These findings support that the RSKB C-terminal extension contains elements that control activation threshold, subcellular location, and p38 docking.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; F Hoffmann La Roche & Co Ltd, Dept Cent Nervous Syst Dis, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Dept Vasc & Metab Dis, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Dept Discovery Chem, CH-4070 Basel, Switzerland	Yale University; Yale University; Roche Holding; Roche Holding; Roche Holding	Lesslauer, W (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, POB 208034, New Haven, CT 06520 USA.	werner.lesslauer@yale.edu						Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gavin AC, 1999, MOL BIOL CELL, V10, P2971, DOI 10.1091/mbc.10.9.2971; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Gerber PR, 1998, J COMPUT AID MOL DES, V12, P37, DOI 10.1023/A:1007902804814; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Merienne K, 1999, NAT GENET, V22, P13, DOI 10.1038/8719; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Pende M, 1997, J NEUROSCI, V17, P1291; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tomas-Zuber M, 2000, J BIOL CHEM, V275, P23549, DOI 10.1074/jbc.M002586200; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199; Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zhu SG, 1998, HUM GENET, V103, P674, DOI 10.1007/s004390050890	48	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5892	5899		10.1074/jbc.M005822200	http://dx.doi.org/10.1074/jbc.M005822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11035004	hybrid			2022-12-25	WOS:000167115100066
J	Jones, RB; Wang, F; Luo, YD; Yu, CD; Jin, CL; Suzuki, T; Kan, M; McKeehan, WL				Jones, RB; Wang, F; Luo, YD; Yu, CD; Jin, CL; Suzuki, T; Kan, M; McKeehan, WL			The nonsense-mediated decay pathway and mutually exclusive expression of alternatively spliced FGFR2IIIb and -IIIc mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-2; PROSTATE EPITHELIAL-CELLS; MESSENGER-RNA; FIBROBLAST; EXON; TRANSLATION; SEQUENCE; SURVEILLANCE; COMPLEX; INTRON	Exons IIIb and me of the FGFR2 gene are alternatively spliced in a mutually exclusive manner in different cell types. A switch from expression of FGFR2IIIb to FGFR2IIIc accompanies the transition of nonmalignant rat prostate tumor epithelial cells (DTE) to cells comprising malignant AT3 tumors. Here we used transfection of minigenes with and without alterations in reading frame and with and without introns to examine how translation affects observed FGFR2 splice products. We observed that nonsense mutations in other than the last exon led to a dramatic reduction in mRNA that is abrogated by removal of downstream introns in both DTE and AT3 cells. The mRNA, devoid of both IIIb and me exons (C1-C2), is a major splice product from minigenes lacking an intron downstream of the second common exon C2. From these observations, we suggest that repression of exon me and activation of exon mb inclusion in DTE cells lead to the generation of both IIIb-C2 and C1-C2 products. However, the C1-C2 product hom the native gene is degraded due to a frameshift and a premature termination codon caused by splicing C1 and C2 together. Derepression of exon me and repression of exon IIIb lead to the generation of both C1-IIIc-C2 and C1-C2 products in AT3 cells, but the C1-C2 product is degraded. The C1-IIIb-IIIc-C2 mRNA containing a premature termination codon in exon me was present, but at apparently trace levels in both cell types. The nonsense-mediated mRNA decay pathway and cell type-dependent rates of inclusion of exons IIIb and me result in the mutually exclusive expression of FGFR2IIIb and IIIc.	Texas A&M Univ Syst, Inst Biosci & Technol, Hlth Sci Ctr, Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station	McKeehan, WL (corresponding author), Texas A&M Univ Syst, Inst Biosci & Technol, Hlth Sci Ctr, Ctr Canc Biol & Nutr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040732, R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK40732, DK35310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Feng SJ, 1997, CANCER RES, V57, P5369; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; Li SL, 1997, J EXP MED, V185, P985, DOI 10.1084/jem.185.6.985; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; Maquat LE, 1996, AM J HUM GENET, V59, P279; MAQUAT LE, 1995, RNA, V1, P453; Matsubara A, 1998, CANCER RES, V58, P1509; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; SHI E, 1991, J BIOL CHEM, V266, P5774; Valentine CR, 1997, RNA, V3, P660; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Wang F, 1997, J BIOL CHEM, V272, P23887, DOI 10.1074/jbc.272.38.23887; Wang F, 1999, BIOCHEMISTRY-US, V38, P160, DOI 10.1021/bi981758m; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272; Zhang J, 1997, EMBO J, V16, P826, DOI 10.1093/emboj/16.4.826	34	46	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4158	4167		10.1074/jbc.M006151200	http://dx.doi.org/10.1074/jbc.M006151200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042206	hybrid			2022-12-25	WOS:000166921200058
J	Rudders, S; Gaspar, J; Madore, R; Voland, C; Grall, F; Patel, A; Pellacani, A; Perrella, MK; Libermann, TA; Oettgen, P				Rudders, S; Gaspar, J; Madore, R; Voland, C; Grall, F; Patel, A; Pellacani, A; Perrella, MK; Libermann, TA; Oettgen, P			ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kappa B to regulate the inducible nitric-oxide synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MOBILITY GROUP-I(Y) PROTEIN; INTERFERON-GAMMA; ETS FAMILY; T-CELLS; EXPRESSION; INDUCTION; PROMOTER; BINDING; INTERLEUKIN-1-BETA	Inflammation is a hallmark of several vascular diseases. The nuclear factor kappaB (NF-kappaB) transcription factors are dimeric proteins involved in the activation of a large number of genes in response to inflammatory stimuli. We report the involvement of a novel member of the ETS transcription factor, ESE-1, in mediating vascular inflammation. ESE-1 is induced in response to inflammatory cytokines and lipopolysaccharide in vascular smooth muscle cells, endothelial cells, and cells of the monocyte-macrophage lineage. This induction occurs within hours of stimulation and is mediated by NF-kappaB transactivation of the ESE-1 promoter. We have identified the inducible form of nitric-oxide synthase (NOS2) as a putative target for ESE-1, ESE-1 can bind to the p50 subunit of NF-kappaB, and cotransfection of ESE-1 with the p50 and p65 subunits of NF-kappaB synergistically enhances transactivation of the NOS2 promoter by ESE-1, An ESE-1-binding site within the NOS2 promoter has been identified, the site-directed mutagenesis of which completely abolishes the ability of ESE-1 to transactivate the NOS2 promoter. Finally, in a mouse model of endotoxemia, associated with acute vascular inflammation, ESE-1 is strongly expressed in vascular endothelium and smooth muscle cells. In summary, ESE-1 represents a novel mediator of vascular inflammation.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Oettgen, P (corresponding author), Harvard Univ, Sch Med, Inst Med, 4 Blackfan Circle, Boston, MA 02115 USA.	joettgen@caregroup.harvard.edu	Libermann, Towia/F-9866-2010; Oettgen, Peter/AAF-5026-2021	Libermann, Towia/0000-0002-4006-8179	NATIONAL CANCER INSTITUTE [R01CA076323, K08CA071429] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788, R01HL063008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NCI NIH HHS [R01/CA76323, KO8/CA71429] Funding Source: Medline; NHLBI NIH HHS [R01/HL63008, HL60788] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambs S, 1998, CANCER RES, V58, P334; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Buttery LDK, 1996, LAB INVEST, V75, P77; CONCA W, 1991, J BIOL CHEM, V266, P16265; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Esaki T, 1997, ATHEROSCLEROSIS, V128, P39, DOI 10.1016/S0021-9150(96)05976-X; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Fu SD, 1999, GASTROENTEROLOGY, V116, P1319, DOI 10.1016/S0016-5085(99)70496-8; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ikeda U, 1998, CLIN CARDIOL, V21, P473, DOI 10.1002/clc.4960210705; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P490, DOI 10.1161/01.ATV.17.3.490; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KRAMER B, 1995, J BIOL CHEM, V270, P6577; LafondWalker A, 1997, AM J PATHOL, V151, P919; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Naito S, 1998, AM J PHYSIOL-CELL PH, V274, pC472, DOI 10.1152/ajpcell.1998.274.2.C472; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; Oettgen P, 1997, GENOMICS, V45, P456, DOI 10.1006/geno.1997.4974; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; Pellacani A, 1999, J BIOL CHEM, V274, P1525, DOI 10.1074/jbc.274.3.1525; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; Rife TK, 2000, MOL BRAIN RES, V75, P225, DOI 10.1016/S0169-328X(99)00293-4; Rikitake Y, 1998, ATHEROSCLEROSIS, V136, P51, DOI 10.1016/S0021-9150(97)00186-X; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sherman TS, 1999, AM J PHYSIOL-LUNG C, V276, pL383, DOI 10.1152/ajplung.1999.276.2.L383; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xu R, 1999, LIFE SCI, V64, P2451, DOI 10.1016/S0024-3205(99)00202-7; Zhang XM, 1999, J BIOL CHEM, V274, P20235, DOI 10.1074/jbc.274.29.20235	53	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3302	3309		10.1074/jbc.M006507200	http://dx.doi.org/10.1074/jbc.M006507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11036073	hybrid			2022-12-25	WOS:000166784900043
J	Guo, B; Godzik, A; Reed, JC				Guo, B; Godzik, A; Reed, JC			Bcl-G, a novel pro-apoptotic member of the Bcl-2 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; BH3 DOMAIN; DEFICIENT MICE; IN-VIVO; X-L; BAX; PROTEINS; MITOCHONDRIA; GENE; BIM	A new member of the Bcl-2 family was identified, Bcl-G, The human BCL-G gene consists of 6 exons, resides on chromosome 12p12, and encodes two proteins through alternative mRNA splicing, Bcl-G(L) (long) and Bcl-G(S) (short) consisting of 327 and 252 amino acids in length, respectively. Bcl-G(L) and Bcl-G(S) have identical sequences for the first 226 amino acids but diverge thereafter. Among the Bcl-2 homology (BH) domains previously recognized in Bcl-2 family proteins, the BH3 domain is found in both Bcl-G(L) and Bcl-G(S), but only the longer Bcl-G(L) protein possesses a BH2 domain. Bcl-G(L) mRNA is expressed widely in adult human tissues, whereas Bcl-G(S) mRNA was found only in testis. Overexpression of Bcl-G(L) or Bcl-G(S) in cells induced apoptosis although Bcl-G(S) was far more potent than Bcl-G(L), Apoptosis induction by Bcl-G(S) depended on the BH3 domain and was suppressed by coexpression of anti-apoptotic Bcl-X-L protein. Bcl-X-L also coimmunoprecipitated with Bcl-G(S) but not with mutants of Bcl-G(S) in which the BH3 domain was deleted or mutated or with Bcl-G(L). Bcl-G(S) was predominantly localized to cytosolic organelles, whereas Bcl-G(L) was diffusely distributed throughout the cytosol. A mutant of Bcl-G(L) in which the BH2 domain was deleted displayed increased apoptotic activity and coimmunoprecipitated with Bcl-X-L, suggesting that the BH2 domain autorepresses Bcl-G(L).	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Godzik, Adam/AAW-1467-2020; Godzik, Adam/A-7279-2009	Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X	NIGMS NIH HHS [GM60554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aissani B, 1999, LEUKEMIA LYMPHOMA, V34, P231, DOI 10.3109/10428199909050948; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Hengartner MO, 1998, NATURE, V391, P441, DOI 10.1038/35036; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kibel AS, 2000, J UROLOGY, V164, P192, DOI 10.1016/S0022-5347(05)67493-9; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Silke J, 1998, CURR BIOL, V8, pR528, DOI 10.1016/S0960-9822(07)00339-9; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; YANG E, 1994, BLOOD, V84, pA373; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	42	131	148	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2780	2785		10.1074/jbc.M005889200	http://dx.doi.org/10.1074/jbc.M005889200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11054413	hybrid			2022-12-25	WOS:000166784800066
J	Sato, N; Imaizumi, K; Manabe, T; Taniguchi, M; Hitomi, J; Katayama, T; Yoneda, T; Morihara, T; Yasuda, Y; Takagi, T; Kudo, T; Tsuda, T; Itoyama, Y; Makifuchi, T; Fraser, PE; St George-Hyslop, P; Tohyama, M				Sato, N; Imaizumi, K; Manabe, T; Taniguchi, M; Hitomi, J; Katayama, T; Yoneda, T; Morihara, T; Yasuda, Y; Takagi, T; Kudo, T; Tsuda, T; Itoyama, Y; Makifuchi, T; Fraser, PE; St George-Hyslop, P; Tohyama, M			Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; UNFOLDED-PROTEIN RESPONSE; PRECURSOR PROTEIN; MISSENSE MUTATIONS; SIGNALING PATHWAY; GENE	An alternative spliced form of the presinilin 2 (PS2) gene (PS2V) lacking exon 5 has previously been reported to be expressed in human brains in sporadic Alzheimer's disease (AD). PS2V encodes the amino-terminal portion of PS2, which contains residues Met(1)-Leu(119) and 5 additional amino acid residues (SSMAG) at its carboxyl terminus. Here we report that PS2V protein impaired the signaling pathway of the unfolded protein response, similarly to familial AD-linked PS1 mutants and caused significant increases in the production of both amyloid beta (40) and beta (42). Interestingly, PS2V-encoding protein was expressed in neuropathologically affected neurons of the hippocampal CA1 region and temporal cortex in AD patients. These findings suggest that the aberrant splicing of the PS2 gene may be implicated in the neuropathology of sporadic AD.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Clin Neurosci, Suita, Osaka 5650871, Japan; Tohoku Univ, Sch Med, Dept Neurol, Sendai, Miyagi 9808574, Japan; Saigata Natl Hosp, Dept Clin Res, Niigata 9493193, Japan; Univ Toronto, Dept Med Neurol, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 1A8, Canada; Japan Sci & Techol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Tohoku University; University of Toronto; Japan Science & Technology Agency (JST)	Imaizumi, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Morihara, Takashi/AAK-2709-2021					Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; JONGHE CD, 1999, HUM MOL GENET, V8, P1529; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; OKADA AA, 1995, BIOCHEMISTRY-US, V34, P10272; PerezTur J, 1995, NEUROREPORT, V7, P297; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sato N, 1999, J NEUROCHEM, V72, P2498, DOI 10.1046/j.1471-4159.1999.0722498.x; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tysoe C, 1998, AM J HUM GENET, V62, P70, DOI 10.1086/301672; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552	23	105	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2108	2114		10.1074/jbc.M006886200	http://dx.doi.org/10.1074/jbc.M006886200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11031265	hybrid			2022-12-25	WOS:000166528000063
J	Shou, M; Dai, R; Cui, D; Korzekwa, KR; Baillie, TA; Rushmore, TH				Shou, M; Dai, R; Cui, D; Korzekwa, KR; Baillie, TA; Rushmore, TH			A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER-MICROSOMES; BINDING SITES; ACTIVATION; LOSARTAN; OXIDATION; PHARMACOKINETICS; HYDROXYLATION; INHIBITION; PHARMACODYNAMICS; COOPERATIVITY	In many cases, CYP3A4 exhibits unusual kinetic characteristics that result from the metabolism of multiple substrates that coexist at the active site. In the present study, we observed that alpha -naphthoflavone (alpha -NF) exhibited a differential effect on CYP3A4 mediated product formation as shown by an increase and decrease, respectively, of the carboxylic acid (P-2) and omega -3-hydroxylated (P-1) metabolites of losartan, while losartan was found to be an inhibitor of the formation of the 5,6-epoxide of alpha -NF. Thus, to address this problem, a kinetic model was developed on the assumption that CYP3A4 can accommodate two distinct and independent binding domains for the substrates within the active site, and the resulting velocity equations were employed to predict the kinetic parameters for all possible enzyme-substrate species. Our results indicate that the predicted values had a good fit with the experimental observations. Therefore, the kinetic constants can be used to adequately describe the nature of the metabolic interaction between the two substrate. Applications of the model provide some new insights into the mechanism of drug-drug interactions at the level of CYP3A4.	Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA; NCI, Mol Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Camitro Corp, Menlo Pk, CA 94025 USA	Merck & Company; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shou, M (corresponding author), Merck Res Labs, Dept Drug Metab, WP75A-203, West Point, PA 19486 USA.	magang_shou@merck.com						ANDRIES MJ, 1990, MOL PHARMACOL, V37, P990; BANCI L, 1994, J AM CHEM SOC, V116, P4866, DOI 10.1021/ja00090a035; BOLT HM, 1977, ACTA ENDOCRINOL-COP, V85, P189; CARANASOS GJ, 1985, ANNU REV PHARMACOL, V25, P67, DOI 10.1146/annurev.pa.25.040185.000435; Dai RK, 1997, LIFE SCI, V61, pPL75, DOI 10.1016/S0024-3205(97)00541-9; Domanski TL, 2000, J PHARMACOL EXP THER, V293, P585; Domanski TL, 1998, ARCH BIOCHEM BIOPHYS, V350, P223, DOI 10.1006/abbi.1997.0525; Goldberg MR, 1996, CLIN PHARMACOL THER, V59, P268, DOI 10.1016/S0009-9236(96)80004-X; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENGERICH FP, 1988, MOL PHARMACOL, V33, P500; Guengerich FP, 1994, ASSESSMENT USE SINGL, P161; GUENGERICH FP, 1995, CYTOCHROME P450, P1259; HARDMAN JG, 1996, PHARM BASIS THERAPEI; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; HUANG MT, 1981, J BIOL CHEM, V256, P6829; HUANG MT, 1981, J BIOL CHEM, V256, P897; HUNTER J, 1976, PROGR DRUG METABOLIS, V1, P129; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; KELLIS JT, 1984, SCIENCE, V225, P1032, DOI 10.1126/science.6474163; Kerr B.M., 1994, BIOCHEM PHARMACOL, V47, P169; Koley AP, 1997, J BIOL CHEM, V272, P3149, DOI 10.1074/jbc.272.6.3149; KONG ANT, 1995, J CLIN PHARMACOL, V35, P1008, DOI 10.1002/j.1552-4604.1995.tb04018.x; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; LEE CA, 1991, DRUG METAB DISPOS, V19, P966; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Middleton E, 1986, FLAVONOIDS ADV RES 1, V1993, P619; MILLER DM, 1994, J AM ACAD DERMATOL, V30, P1008, DOI 10.1016/S0190-9622(94)70127-X; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NELSON E, 1992, AM J HYPERTENS, V5, P19; Ngui JS, 2000, DRUG METAB DISPOS, V28, P1043; OKUDA H, 1995, XENOBIOTIC METAB D S, V10, pS166; RANEY KD, 1992, CHEM RES TOXICOL, V5, P202, DOI 10.1021/tx00026a009; Rowland M, 1995, CLIN PHARMACOKINET, P267; Schrag ML, 2000, DRUG METAB DISPOS, V28, P1198; SCHWAB GE, 1988, MOL PHARMACOL, V33, P493; Segel IH., 1993, ENZYME KINETICS BEHA; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Shou MG, 1999, BIOCHEM J, V340, P845, DOI 10.1042/0264-6021:3400845; STEARNS RA, 1995, DRUG METAB DISPOS, V23, P207; SWEET CS, 1993, J HYPERTENS, V11, pS63; UENG YF, 1995, CHEM RES TOXICOL, V8, P218, DOI 10.1021/tx00044a006; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; WANG PP, 1983, BIOCHEMISTRY-US, V22, P5375, DOI 10.1021/bi00292a019; WONG PC, 1990, J PHARMACOL EXP THER, V255, P211; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YUN CH, 1995, DRUG METAB DISPOS, V23, P285	49	107	116	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2256	2262		10.1074/jbc.M008799200	http://dx.doi.org/10.1074/jbc.M008799200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11054425	hybrid			2022-12-25	WOS:000166528000081
J	Daily, D; Vlamis-Gardikas, A; Offen, D; Mittelman, L; Melamed, E; Holmgren, A; Barzilai, A				Daily, D; Vlamis-Gardikas, A; Offen, D; Mittelman, L; Melamed, E; Holmgren, A; Barzilai, A			Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI GLUTAREDOXIN; CELL-DEATH; TRANSCRIPTION FACTOR; REDOX REGULATION; ENDONUCLEASE EXPRESSION; THIOREDOXIN REDUCTASE; NUCLEAR TRANSLOCATION; DISULFIDE-ISOMERASE	The neurotransmitter dopamine (DA) induces apoptosis via its oxidative metabolites. This study shows that glutaredoxin 2 (Grx2) from Escherichia coli and human glutaredoxin could protect cerebellar granule neurons from DA-induced apoptosis, E. coli Grx2, which catalyzes glutathione-disulfide oxidoreduction via its -Cys-Pro-Tyr-Cys- active site, penetrates into cerebellar granule neurons and exerts its activity via NF-kappaB activation. Analysis of single and double cysteine to serine substitutions in the active site of Grx2 showed that both cysteine residues were essential for activity. Although DA significantly reduced NF-kappaB binding activity, Grx2 could stimulate the binding of NF-kappaB to DNA by: (i) translocating NF-kappaB from the cytoplasm to the nucleus after promoting the phosphorylation and degradation of I-kappaB alpha, and (ii) activating the binding of pre existing nuclear NF-kappaB. The DNA binding activity of NF-kappaB itself was essential for neuronal survival. Overexpression of I-kappaB dominant negative gene (I-kappaB-DeltaN) in granule neurons significantly reduced their viability, irrespective of the presence of Grx2. Ref-1 expression was down-regulated by DA but up-regulated by Grx2, while treatment of neurons with Ref-1 antisense oligonucleotide reduced the ability of Grx2 to activate NF-kappaB binding activity. These results show that Grx2 exerts its anti apoptotic activity through the activation of Ref-1, which then activates NF-kappaB.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Karolinska Inst, Med Nobel Inst Biochem, Dept Biochem & Biophys, S-17177 Stockholm, Sweden; Tel Aviv Univ, Rabin Med Ctr, Dept Neurol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Rabin Med Ctr, Felsenstein Med Res Inst, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Interdept Core Facil, IL-69978 Tel Aviv, Israel	Tel Aviv University; Karolinska Institutet; Rabin Medical Center; Tel Aviv University; Rabin Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Barzilai, A (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	barzilai@post.tau.ac.il	Vlamis, Alexios/AAF-5152-2020	Vlamis, Alexios/0000-0001-5068-6459				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AHN BY, 1992, P NATL ACAD SCI USA, V89, P7060, DOI 10.1073/pnas.89.15.7060; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENSHACHAR D, 1995, J NEUROCHEM, V64, P718, DOI 10.1046/j.1471-4159.1995.64020718.x; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Chen F, 1999, J BIOL CHEM, V274, P20307, DOI 10.1074/jbc.274.29.20307; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DRAGUNOW M, 1995, NEUROSCI LETT, V191, P189, DOI 10.1016/0304-3940(95)11589-O; DUGUID JR, 1995, CANCER RES, V55, P6097; FILLOUX F, 1993, EXP NEUROL, V119, P79, DOI 10.1006/exnr.1993.1008; Fire E, 1997, J BIOL CHEM, V272, P29538, DOI 10.1074/jbc.272.47.29538; GAN ZR, 1990, BIOCHEM BIOPH RES CO, V168, P944, DOI 10.1016/0006-291X(90)91120-H; GAN ZR, 1987, J BIOL CHEM, V262, P6699; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRILLI M, 1993, INT REV CYTOL, V143, P1; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Harlow E., 1988, ANTIBODIES LAB MANUA; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; HOPPER S, 1989, J BIOL CHEM, V264, P20438; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kawase M, 1999, STROKE, V30, P441, DOI 10.1161/01.STR.30.2.441; KLINTROT IM, 1984, EUR J BIOCHEM, V144, P417, DOI 10.1111/j.1432-1033.1984.tb08481.x; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; LASHER RS, 1972, BRAIN RES, V41, P482, DOI 10.1016/0006-8993(72)90521-5; Legrand-Poels S, 1998, J PHOTOCH PHOTOBIO B, V45, P1, DOI 10.1016/S1011-1344(98)00118-3; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lundstrom-Ljung J, 1999, FEBS LETT, V443, P85, DOI 10.1016/S0014-5793(98)01698-6; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; McLaughlin BA, 1998, J NEUROCHEM, V70, P2406; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; MINAKUCHI K, 1994, FEBS LETT, V337, P157, DOI 10.1016/0014-5793(94)80264-5; Moulder KL, 1999, J NEUROSCI, V19, P705; MYTILINEOU C, 1993, J NEUROCHEM, V61, P1470, DOI 10.1111/j.1471-4159.1993.tb13642.x; Nakamura H, 1998, FREE RADICAL BIO MED, V24, P1176, DOI 10.1016/S0891-5849(97)00429-2; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; OKUNO H, 1993, ONCOGENE, V8, P695; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; POWIS G, 1994, ONCOL RES, V6, P539; PRASAD AV, 1994, NEUROSCI LETT, V170, P145, DOI 10.1016/0304-3940(94)90260-7; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; Rong YQ, 1996, J NEUROCHEM, V67, P662; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Sandvig Kirsten, 1994, Trends in Cell Biology, V4, P275, DOI 10.1016/0962-8924(94)90211-9; SCHRAMM M, 1990, P NATL ACAD SCI USA, V87, P1193, DOI 10.1073/pnas.87.3.1193; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; TANAKA M, 1991, J NEUROL SCI, V101, P198, DOI 10.1016/0022-510X(91)90046-A; Terai K, 1996, BRAIN RES, V735, P159; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Walton M, 1997, MOL BRAIN RES, V44, P167, DOI 10.1016/S0169-328X(96)00291-4; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; ZilkhaFalb R, 1997, CELL MOL NEUROBIOL, V17, P101, DOI 10.1023/A:1026333222008; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	83	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1335	1344		10.1074/jbc.M008121200	http://dx.doi.org/10.1074/jbc.M008121200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035035	hybrid			2022-12-25	WOS:000166430900065
J	Nika, J; Rippel, S; Hannig, EM				Nika, J; Rippel, S; Hannig, EM			Biochemical analysis of the eIF2 beta gamma complex reveals a structural function for eIF2 alpha in catalyzed nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; EUKARYOTIC PROTEIN-SYNTHESIS; TRANSLATION INITIATION; SACCHAROMYCES-CEREVISIAE; GAMMA-SUBUNIT; FACTOR EIF-2; TERNARY COMPLEXES; CHAIN INITIATION; ALPHA-SUBUNIT; BETA-SUBUNIT	Eukaryotic translation initiation factor eIF2 is a heterotrimer that binds and delivers Met-tRNA(i)(Met) to the 40 S ribosomal subunit in a GTP-dependent manner. Initiation requires hydrolysis of eIF2-bound GTP, which releases an eIF2 GDP complex that is recycled to the GTP form by the nucleotide exchange factor eIF2B. The ru-subunit of eIF2 plays a critical role in regulating nucleotide exchange via phosphorylation at serine 51, which converts eIF2 into a competitive inhibitor of the eIF2B-catalyzed exchange reaction. We purified a form of eIF2 (eIF2 beta gamma) completely devoid of the alpha -subunit to further study the role of eIF2 alpha in eIF2 function. These studies utilized a yeast strain genetically altered to bypass a deletion of the normally essential eIF2 alpha structural gene (SU12), Removal of the alpha -subunit did not appear to significantly alter binding of guanine nucleotide or Met-tRN(i)(Met) ligands by eIF2 in vifro. Qualitative assays to detect 43 S initiation complex formation and eIF5-dependent GTP hydrolysis revealed no differences between eIF2 beta gamma and the wild-type eIF2 heterotrimer. However, steady-state kinetic analysis of eIF2B-catalyzed nucleotide exchange revealed that the absence of the a-subunit increased K-m for eIF2 beta gamma (.)GDP by an order of magnitude, with a smaller increase in V-max. These data indicate that eIF2 alpha is required for structural interactions between eIF2 and eIF2B that promote wild-type rates of nucleotide exchange, We suggest that this function contributes to the ability of the alpha -subunit to control the rate of nucleotide exchange through reversible phosphorylation.	Univ Texas, Dept Mol & Cell Biol, Mail Stn FO31, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	Hannig, EM (corresponding author), Univ Texas, Dept Mol & Cell Biol, Mail Stn FO31, POB 830688, Richardson, TX 75083 USA.			Hannig, Ernest/0000-0002-2260-3342				AHMAD MF, 1985, J BIOL CHEM, V260, P6960; ANTHONY DD, 1990, ARCH BIOCHEM BIOPHYS, V281, P157, DOI 10.1016/0003-9861(90)90426-Y; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; BARRIEUX A, 1977, J BIOL CHEM, V252, P3843; BOMMER UA, 1991, BIOCHIM BIOPHYS ACTA, V1079, P308, DOI 10.1016/0167-4838(91)90074-A; BOMMER UA, 1989, FEBS LETT, V244, P323, DOI 10.1016/0014-5793(89)80555-1; CASTILHOVALAVICIUS B, 1990, GENETICS, V124, P483; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; COOPER HL, 1981, J BIOL CHEM, V256, P7461; Das S, 2000, MOL CELL BIOL, V20, P3942, DOI 10.1128/MCB.20.11.3942-3950.2000; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DORRIS DR, 1995, EMBO J, V14, P2239, DOI 10.1002/j.1460-2075.1995.tb07218.x; Erickson FL, 1997, MOL GEN GENET, V253, P711; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; FLYNN A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P117, DOI 10.1016/0167-4781(93)90105-M; GASPAR NJ, 1994, J BIOL CHEM, V269, P3415; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; GRIBSKOV M, 1992, GENE, V119, P107, DOI 10.1016/0378-1119(92)90073-X; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, P627; Keeling PJ, 1998, J MOL EVOL, V47, P649, DOI 10.1007/PL00006422; Kimball SR, 1998, J BIOL CHEM, V273, P3039, DOI 10.1074/jbc.273.5.3039; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; MANCHESTER KL, 1989, BIOCHEM INT, V18, P1279; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Mouat MF, 1998, MOL CELL BIOCHEM, V183, P69, DOI 10.1023/A:1006829615464; NARANDA T, 1995, FEBS LETT, V372, P249, DOI 10.1016/0014-5793(95)00993-J; Nika J, 2000, J BIOL CHEM, V275, P26011, DOI 10.1074/jbc.M003718200; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PANNIERS R, 1994, BIOCHIMIE, V76, P737, DOI 10.1016/0300-9084(94)90078-7; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; SAFER B, 1981, BIOCHIMIE, V63, P709, DOI 10.1016/S0300-9084(81)80219-2; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WESTERMANN P, 1980, NUCLEIC ACIDS RES, V8, P3065, DOI 10.1093/nar/8.14.3065; Yang WM, 1996, MOL CELL BIOL, V16, P6603	57	50	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1051	1056		10.1074/jbc.M007398200	http://dx.doi.org/10.1074/jbc.M007398200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042214	hybrid			2022-12-25	WOS:000166430900027
J	Cannon, W; Gallegos, MT; Buck, M				Cannon, W; Gallegos, MT; Buck, M			DNA melting within a binary sigma(54)-promoter DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; SIGMA(70) SUBUNIT; ENHANCER RESPONSIVENESS; TERMINAL SEQUENCES; MECHANISM INVIVO; REGION-I; PROMOTER; BINDING; TRANSCRIPTION	The sigma 54 subunit of the bacterial RNA polymerase requires the action of specialized enhancer-binding activators to initiate transcription. Here we show that sigma (54) is able to melt promoter DNA when it is bound to a DNA structure representing the initial nucleation of DNA opening found in closed complexes. Melting occurs in response to activator in a nucleotide-hydrolyzing reaction and appears to spread downstream from the nucleation point toward the transcription start site. We show that sigma (54) contains some weak determinants for DNA melting that are masked by the Region I sequences and some strong ones that require Region I. It seems that sigma (54) binds to DNA in a self-inhibited state, and one function of the activator is therefore to promote a conformational change in sigma (54) to reveal its DNA-melting activity. Results with the holoenzyme bound to early melted DNA suggest an ordered series of events in which changes in core to sigma (54) interactions and sigma (54)-DNA interactions occur in response to activator to allow sigma (54) isomerization and the holoenzyme to progress from the closed complex to the open complex.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England; CSIC, Dept Bioquim Biol Mol & Celular Plantas, Estac Expt Zaidin, E-18008 Granada, Spain	Imperial College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)	Buck, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Sir Alexander Fleming Bldg, London SW7 2AZ, England.		Gallegos, María-Trinidad M.T./K-6501-2014	Gallegos, María-Trinidad M.T./0000-0001-7633-8807				Brodolin K, 2000, J BIOL CHEM, V275, P3661, DOI 10.1074/jbc.275.5.3661; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Cannon WV, 1997, P NATL ACAD SCI USA, V94, P5006, DOI 10.1073/pnas.94.10.5006; Casaz P, 1999, J MOL BIOL, V292, P229, DOI 10.1006/jmbi.1999.3076; Casaz P, 1999, J MOL BIOL, V285, P507, DOI 10.1006/jmbi.1998.2328; Chaney M, 1999, MOL MICROBIOL, V33, P1200, DOI 10.1046/j.1365-2958.1999.01566.x; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gallegos MT, 2000, J MOL BIOL, V297, P849, DOI 10.1006/jmbi.2000.3608; Gallegos MT, 1999, J BIOL CHEM, V274, P25285, DOI 10.1074/jbc.274.36.25285; Gallegos MT, 1999, J MOL BIOL, V288, P539, DOI 10.1006/jmbi.1999.2704; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Jovanovic G, 1999, J MOL BIOL, V285, P469, DOI 10.1006/jmbi.1998.2263; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MORRIS L, 1994, J BIOL CHEM, V269, P11563; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; Syed A, 1997, MOL MICROBIOL, V23, P987, DOI 10.1046/j.1365-2958.1997.2851651.x; Syed A, 1998, J BACTERIOL, V180, P5619, DOI 10.1128/JB.180.21.5619-5625.1998; TINTUT Y, 1995, GENE DEV, V9, P2305, DOI 10.1101/gad.9.18.2305; Wang JT, 1996, J BIOL CHEM, V271, P32707, DOI 10.1074/jbc.271.51.32707; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; Wang JT, 1997, P NATL ACAD SCI USA, V94, P9538, DOI 10.1073/pnas.94.18.9538; Wang L, 1999, J BACTERIOL, V181, P7558, DOI 10.1128/JB.181.24.7558-7565.1999; Wang L, 1998, J BACTERIOL, V180, P5626, DOI 10.1128/JB.180.21.5626-5631.1998; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; Wigneshweraraj SR, 2000, EMBO J, V19, P3038, DOI 10.1093/emboj/19.12.3038	41	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					386	394		10.1074/jbc.M007779200	http://dx.doi.org/10.1074/jbc.M007779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11036081	Green Published, hybrid			2022-12-25	WOS:000166280700053
J	Coleman, ST; Fang, TK; Rovinsky, SA; Turano, FJ; Moye-Rowley, WS				Coleman, ST; Fang, TK; Rovinsky, SA; Turano, FJ; Moye-Rowley, WS			Expression of a glutamate decarboxylase homologue is required for normal oxidative stress tolerance in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINIC SEMIALDEHYDE DEHYDROGENASE; CALMODULIN-BINDING; ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; PROTEIN; GENE; TRANSFORMATION; GLUTATHIONE; SEQUENCE	The action of gamma -aminobutyrate (GABA) as an intercellular signaling molecule has been intensively studied, but the role of this amino acid metabolite in intracellular metabolism is poorly understood. In this work, we identify a Saccharomyces cerevisiae homologue of the GABA-producing enzyme glutamate decarboxylase (GAD) that is required for normal oxidative stress tolerance. A high copy number plasmid bearing the glutamate decarboxylase gene (GAD1) increases resistance to two different oxidants, H2O2 and diamide, in cells that contain an intact glutamate catabolic pathway. Structural similarity of the S. cerevisiae GAD to previously studied plant enzymes was demonstrated by the crossreaction of the yeast enzyme to a antiserum directed against the plant GAD. The yeast GAD also bound to calmodulin as did the plant enzyme, suggesting a conservation of calcium regulation of this protein. Loss of either gene encoding the downstream steps in the conversion of glutamate to succinate reduced oxidative stress tolerance in normal cells and was epistatic to high copy number GAD1. The gene encoding succinate semialdehyde dehydrogenase (UGA5) was identified and found to be induced by H2O2 exposure. Together, these data strongly suggest that increases in activity of the glutamate catabolic pathway can act to buffer redox changes in the cell.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; USDA ARS, Climate Stress Lab, Beltsville, MD 20705 USA	University of Iowa; United States Department of Agriculture (USDA)	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-612 Bowen Sci Bldg, Iowa City, IA 52242 USA.	moyerowl@blue.weeg.uiowa.edu	Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM49825] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderlund M, 1999, APPL ENVIRON MICROB, V65, P2333; ANDRE B, 1993, MOL GEN GENET, V237, P17; ANDRE B, 1990, NUCLEIC ACIDS RES, V18, P3049, DOI 10.1093/nar/18.10.3049; BAUM G, 1993, J BIOL CHEM, V268, P19610; Baum G, 1996, EMBO J, V15, P2988, DOI 10.1002/j.1460-2075.1996.tb00662.x; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Busch KB, 1999, PLANT PHYSIOL, V121, P589, DOI 10.1104/pp.121.2.589; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Castanie-Cornet MP, 1999, J BACTERIOL, V181, P3525, DOI 10.1128/JB.181.11.3525-3535.1999; CUNNINGHAM TS, 1994, J BACTERIOL, V176, P4718, DOI 10.1128/JB.176.15.4718-4725.1994; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; GALLEGO PP, 1995, PLANT MOL BIOL, V27, P1143, DOI 10.1007/BF00020887; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HEARL WG, 1984, J BIOL CHEM, V259, P1459; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Juhnke H, 1996, MOL GEN GENET, V252, P456, DOI 10.1007/BF02173011; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LING V, 1994, PLANT CELL, V6, P1135, DOI 10.1105/tpc.6.8.1135; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; Nisbet AP, 1996, NEUROSCIENCE, V75, P389, DOI 10.1016/0306-4522(96)00299-0; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; Pearl PL, 2006, FUTUR NEUROL, V1, P631, DOI 10.2217/14796708.1.5.631; RAMOS F, 1985, EUR J BIOCHEM, V149, P401, DOI 10.1111/j.1432-1033.1985.tb08939.x; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Satin LS, 1998, ENDOCRINE, V8, P213, DOI 10.1385/ENDO:8:3:213; Shelp BJ, 1999, TRENDS PLANT SCI, V4, P446, DOI 10.1016/S1360-1385(99)01486-7; Sherman F, 1979, METHODS YEAST GENETI; Sherwin AL, 1999, NEUROCHEM RES, V24, P1385, DOI 10.1023/A:1022580506443; SIKORSKI RS, 1989, GENETICS, V122, P19; Snedden WA, 1996, J BIOL CHEM, V271, P4148; TALIBI D, 1995, NUCLEIC ACIDS RES, V23, P550, DOI 10.1093/nar/23.4.550; Tramonti A, 1998, J BIOL CHEM, V273, P1939, DOI 10.1074/jbc.273.4.1939; Turano FJ, 1998, PLANT PHYSIOL, V117, P1411, DOI 10.1104/pp.117.4.1411; VISSERS S, 1990, EUR J BIOCHEM, V187, P611, DOI 10.1111/j.1432-1033.1990.tb15344.x; WU AL, 1993, J BIOL CHEM, V268, P18850; Yuan T, 1998, J BIOL CHEM, V273, P30328, DOI 10.1074/jbc.273.46.30328; Zik M, 1998, PLANT MOL BIOL, V37, P967, DOI 10.1023/A:1006047623263	46	164	199	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					244	250		10.1074/jbc.M007103200	http://dx.doi.org/10.1074/jbc.M007103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031268	hybrid			2022-12-25	WOS:000166280700034
J	Mamelak, D; Lingwood, C				Mamelak, D; Lingwood, C			The ATPase domain of hsp70 possesses a unique binding specificity for 3 '-sulfogalactolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; GLYCOLIPID RECEPTOR FUNCTION; MOLECULAR CHAPERONE DNAK; IMMOBILIZING PROTEIN; NUCLEOTIDE EXCHANGE; HELICOBACTER-PYLORI; HYDROLYTIC ACTIVITY; ESCHERICHIA-COLI; STRUCTURAL BASIS; SULFATIDE	The region(s) of hsp70 critical for sulfogalactolipid (SGL) recognition has been defined through deletion analysis and site-directed mutagenesis. Truncated polymerase chain reaction products of hsp70 generated N-terminal fragments of 43, 35, 29, and 22 kDa. The C terminus substrate-binding domain (28 kDa) was also expressed. The N-terminal ATPase domain (rP43) shared the binding specificity of hsp70, because only sulfogalactosyl ceramide and sulfogalactosyl glycerolipid were recognized by both TLC overlay and RELISA. The C-terminal domain showed no binding. SGL binding of rP29 and rP22 was severely reduced. The loss of SGL binding for rP35 by RELISA but not TLC overlay was considered as a function of receptor presentation. The truncation of rP43 to rP35 demonstrates that residues 318-387 (the base of the ATP binding cleft) are critical for high affinity SGL binding. Mutagenesis showed that Arg(342) and Phe(198) are crucial for this process. SGL binding, mediated by these conserved residues within the ATPase domain of hsp70, implies that this binding specificity is evolutionarily conserved.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Hosp Sick Children, Res Inst, Div Infect Immun Injury & Repair, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Lingwood, C (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 100 Coll St, Toronto, ON M5G 1L5, Canada.							Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BHAT S, 1993, AIDS RES HUM RETROV, V9, P175, DOI 10.1089/aid.1993.9.175; Botzler C, 1998, CELL STRESS CHAPERON, V3, P6, DOI 10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2; BOULANGER J, 1995, J CELL PHYSIOL, V165, P7, DOI 10.1002/jcp.1041650103; BOYD B, 1994, EUR J BIOCHEM, V223, P873, DOI 10.1111/j.1432-1033.1994.tb19064.x; BUKAU B, 1993, J GEN MICROBIOL, V139, P95, DOI 10.1099/00221287-139-1-95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURKART T, 1981, DEV BIOL, V83, P42, DOI 10.1016/S0012-1606(81)80006-1; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; Choi BK, 1999, INFECT IMMUN, V67, P5755, DOI 10.1128/IAI.67.11.5755-5761.1999; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; HANSEN LK, 1995, BBA-PROTEIN STRUCT M, V1252, P135, DOI 10.1016/0167-4838(95)00113-9; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hartmann E, 1997, INFECT IMMUN, V65, P1729, DOI 10.1128/IAI.65.5.1729-1733.1997; HOLT GD, 1990, J BIOL CHEM, V265, P2852; Huesca M, 1998, INFECT IMMUN, V66, P4061; Huesca M, 1996, INFECT IMMUN, V64, P2643, DOI 10.1128/IAI.64.7.2643-2648.1996; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; ISHIZUKA I, 1978, J BIOL CHEM, V253, P898; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P220; KUBUSHIRO K, 1989, ARCH BIOCHEM BIOPHYS, V268, P129, DOI 10.1016/0003-9861(89)90573-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW H, 1988, J CELL PHYSIOL, V137, P462, DOI 10.1002/jcp.1041370310; LEVINE M, 1976, BIOCHIM BIOPHYS ACTA, V441, P134, DOI 10.1016/0005-2760(76)90288-5; LINGWOOD C, 1981, CAN J BIOCHEM CELL B, V59, P556, DOI 10.1139/o81-077; LINGWOOD C, 1991, J CELL PHYSIOL, V146, P258, DOI 10.1002/jcp.1041460210; Lingwood CA, 1996, GLYCOCONJUGATE J, V13, P495, DOI 10.1007/BF00731435; LINGWOOD CA, 1980, J IMMUNOL, V124, P769; LINGWOOD CA, 1985, CAN J BIOCHEM CELL B, V63, P1077, DOI 10.1139/o85-134; Macellaro A, 1998, INFECT IMMUN, V66, P5882, DOI 10.1128/IAI.66.12.5882-5888.1998; Mamelak D, 1997, GLYCOCONJUGATE J, V14, P715, DOI 10.1023/A:1018569417218; MILLER D, 1992, HUM REPROD, V7, P637, DOI 10.1093/oxfordjournals.humrep.a137711; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Multhoff G, 1997, J IMMUNOL, V158, P4341; Murry R. K., 1980, ACS SYM SER, V128, P105; NATOMI H, 1993, LIPIDS, V28, P737, DOI 10.1007/BF02535996; NATOMI H, 1988, BIOCHIM BIOPHYS ACTA, V961, P213; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PELLIZZARI A, 1992, BIOCHEMISTRY-US, V31, P1363, DOI 10.1021/bi00120a011; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; RAULSTON JE, 1993, J BIOL CHEM, V268, P23139; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; ROBERTS DD, 1986, CHEM PHYS LIPIDS, V42, P173, DOI 10.1016/0009-3084(86)90051-4; SCORPIO A, 1994, J BACTERIOL, V176, P6449, DOI 10.1128/JB.176.21.6449-6456.1994; TANPHAICHITR N, 1993, DEV BIOL, V156, P164, DOI 10.1006/dbio.1993.1067; TANPHAICHITR N, 1992, MOL REPROD DEV, V32, P17, DOI 10.1002/mrd.1080320104; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893	57	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					449	456		10.1074/jbc.M006732200	http://dx.doi.org/10.1074/jbc.M006732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024054	hybrid			2022-12-25	WOS:000166280700061
J	Qiu, ZY; Nicoll, DA; Philipson, KD				Qiu, ZY; Nicoll, DA; Philipson, KD			Helix packing of functionally important regions of the cardiac Na+-Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE CROSS-LINKING; NA-CA EXCHANGER; TRANSMEMBRANE SEGMENTS; EXPRESSION; TOPOLOGY; DOMAIN	In a revised topological model of the cardiac Na+-Ca2+ exchanger, there are nine transmembrane segments (TMSs) and two possible re-entrant loops (Nicoll, D, A., Ottolia, M., Lu, Y., Lu, L., and Philipson, K. D. (1999) J. Biol Chem. 274, 910-917; Iwamoto, T., Nakamura, T. Y., Pan, Y., Uehara, A, Imanaga, I., and Shigekawa, M. (1999) FEES Lett. 446, 264-268). The TMSs form two clusters separated by a large intracellular loop between TMS5 and TMS6. We have combined cysteine mutagenesis and oxidative cross-linking to study proximity relationships of TMSs in the exchanger. Pairs of cysteines were reintroduced into a cysteine-less exchanger, one in a TMS in the NH2-terminal cluster (TMSs 1-5) and the other in a TMS in the COOP-terminal cluster (TMSs 6-9). The mutant exchanger proteins were expressed in HEK293 cells, and disulfide bond formation between introduced cysteines was analyzed by gel mobility shifts. Western blots showed that S117C/V804C, A122C/Y892C, A151C/T815C, and A151C/A821C mutant proteins migrated at 120 kDa under reducing conditions and displayed a partial mobility shift to 160 kDa under nonreducing conditions. This shift indicates the formation of a disulfide bond between these paired cysteine residues. Copper phenanthroline and the cross-linker N',N'-o-phenylenedimaleimide enhanced the mobility shift to 160 kDa. Our data suggest that TMS7 is close to TMS3 near the intracellular side of the membrane and is in the vicinity of TMS2 near the extracellular surface. Also, TMS2 must adjoin TMS8. This initial packing model of the exchanger brings two functionally important domains in the exchanger, the alpha1 and alpha2 repeats, close to each other.	Univ Calif Los Angeles, Cardiovasc Res Labs, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Philipson, KD (corresponding author), Univ Calif Los Angeles, Cardiovasc Res Labs, Sch Med, MRL 3-645, Los Angeles, CA 90095 USA.	Kphilipson@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49101] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cook O, 1998, BBA-BIOMEMBRANES, V1371, P40, DOI 10.1016/S0005-2736(97)00272-1; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; LEE SL, 1994, J BIOL CHEM, V269, P14849; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; REEVES JP, 1984, J BIOL CHEM, V259, P7733; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; SAHINTOTH M, 1995, BIOCHEM BIOPH RES CO, V212, P968, DOI 10.1006/bbrc.1995.2064; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099	23	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					194	199		10.1074/jbc.M005571200	http://dx.doi.org/10.1074/jbc.M005571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035002	hybrid			2022-12-25	WOS:000166280700028
J	Gelb, MH; Valentin, E; Ghomashchi, F; Lazdunski, M; Lambeau, G				Gelb, MH; Valentin, E; Ghomashchi, F; Lazdunski, M; Lambeau, G			Cloning and recombinant expression of a structurally novel human secreted phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFACIAL CATALYSIS; MOUSE; MECHANISM; FAMILY; CELLS; VENOM; IIA	Mammals contain a diverse set of secreted phospholipases A(2) (sPLA(2)s) that liberate arachidonic acid from phospholipids for the production of eicosanoids and exert a variety of physiological and pathological effects. We report the cloning, recombinant expression, and kinetic properties of a novel human sPLA(2) that defines a new structural class of sPLA(2)s called group XII. The human group XII (hGXII) cDNA contains a putative signal peptide of 22 residues followed by a mature protein of 167 amino acids that displays homology to all known sPLA(2)s only over a short stretch of amino acids in the active site region. Northern blot and reverse transcription-polymerase chain reaction analyses show that the tissue distribution of hGXII is distinct from the other human sPLA(2)s with strong expression in heart, skeletal muscle, kidney, and pancreas and weaker expression in brain, liver, small intestine, lung, placenta, ovaries, testis, and prostate. Catalytically active hGXII was produced in Escherichia coli and shown to be Ca2+-dependent despite the fact that it is predicted to have an unusual Ca2+-binding loop. Similar to the previously characterized mouse group IIE sPLA(2)s, the specific activity of hGXII is low in comparison to that of other mammalian sPLA(2), suggesting that hGXII could have novel functions that are independent of its phospholipase A(2) activity.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.		Lambeau, Gerard/GRJ-5624-2022	gelb, michael/0000-0001-7000-5219; Lambeau, Gerard/0000-0002-9239-518X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036235] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL036235, HL36236] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARITA H, 1993, J LIPID MEDIATOR, V6, P217; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BEKKERS ACAPA, 1991, BIOCHIM BIOPHYS ACTA, V1076, P374, DOI 10.1016/0167-4838(91)90479-J; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Hanasaki K, 1999, ARCH BIOCHEM BIOPHYS, V372, P215, DOI 10.1006/abbi.1999.1511; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; Kim JY, 1999, BBA-GENE STRUCT EXPR, V1489, P389, DOI 10.1016/S0167-4781(99)00193-1; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LIU CS, 1990, TOXICON, V28, P1457, DOI 10.1016/0041-0101(90)90159-5; MCINTOSH JM, 1995, J BIOL CHEM, V270, P3518, DOI 10.1074/jbc.270.8.3518; Mounier CM, 2000, EUR J BIOCHEM, V267, P4960, DOI 10.1046/j.1432-1327.2000.01523.x; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PRUZANSKI W, 1993, J LIPID MEDIATOR, V8, P161; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Rae D., 1996, SCAND J GASTROENTE S, V219, P24; Sartipy P, 1998, ARTERIOSCL THROM VAS, V18, P1934, DOI 10.1161/01.ATV.18.12.1934; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Stahl U, 1998, PLANT PHYSIOL, V117, P197, DOI 10.1104/pp.117.1.197; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; VALENTIN E, 2000, IN PRESS BIOCH BIOPH; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; Yuan CH, 1999, BBA-MOL CELL BIOL L, V1441, P215, DOI 10.1016/S1388-1981(99)00156-0	37	135	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39823	39826		10.1074/jbc.C000671200	http://dx.doi.org/10.1074/jbc.C000671200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11031251	Green Accepted, hybrid			2022-12-25	WOS:000166039500006
J	Browne, KA; Johnstone, RW; Jans, DA; Trapani, JA				Browne, KA; Johnstone, RW; Jans, DA; Trapani, JA			Filamin (280-kDa actin-binding protein) is a caspase substrate and is also cleaved directly by the cytotoxic T lymphocyte protease granzyme B during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; CYTOSOLIC DELIVERY; DNA FRAGMENTATION; TARGET-CELLS; PERFORIN; GELSOLIN; FAMILY; GENE; DEPENDENCE; ABP-280	We used yeast two-hybrid screening to identify the cytoskeletal protein filamin as a ligand for the proapoptotic protease granzyme B, produced by cytotoxic T lymphocytes. Filamin was directly cleaved by granzyme B when target cells were exposed to granzyme B and the lytic protein perforin, but it was also cleaved in a caspase-dependent manner following the ligation of Fas receptors. A similar pattern of filamin cleavage to polypeptides of similar to 110 and 95 kDa was observed in Jurkat cells killed by either mechanism. However, filamin cleavage in response to granzyme B was not inhibited by the caspase inhibitor z-Val-Ala-Asp-fluoromethylketone at concentrations that abolished DNA fragmentation. Filamin staining was redistributed from the cell membrane into the cytoplasm of Jurkat cells exposed to granzyme B and perforin and following Ligation of Fas receptors, coincident with the morphological changes of apoptosis. Filamin-deficient human melanoma cells were significantly (although not completely) protected from granzyme B-mediated death compared with isogenic filamin-expressing cells, both in clonogenic survival and Cr-51 release assays, whereas death from multiple other stimuli was not affected by filamin deficiency. Thus, filamin is a functionally important substrate for granzyme B, as its cleavage may account at least partly for caspase-independent cell death mediated by the granzyme.	Peter MacCallum Canc Inst, Canc Immunol Lab, Melbourne, Vic 8006, Australia; Australian Natl Univ, John Curtin Sch Med Res, Dept Biochem & Mol Biol, Nucl Signaling Lab, Canberra, ACT 2601, Australia	Peter Maccallum Cancer Center; Australian National University; John Curtin School of Medical Research	Trapani, JA (corresponding author), Peter MacCallum Canc Inst, Canc Immunol Lab, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.		Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532				Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8; Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; BOLDIN MP, 1996, CELL, V85, P813; Browne KA, 1999, MOL CELL BIOL, V19, P8604; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V229, P44, DOI 10.1006/bbrc.1996.1755; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Jans DA, 1998, J CELL SCI, V111, P2645; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; KAGI D, 1994, EUR J IMMUNOL, V24, P3068, DOI 10.1002/eji.1830241223; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; Posey SC, 2000, BLOOD, V95, P3483, DOI 10.1182/blood.V95.11.3483.011k05_3483_3488; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Sarin A, 1998, J IMMUNOL, V161, P2810; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Trapani JA, 1998, SPRINGER SEMIN IMMUN, V19, P323, DOI 10.1007/BF00787229; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 1999, IMMUNOL TODAY, V20, P351, DOI 10.1016/S0167-5699(99)01488-7; Trapani JA, 1998, CELL DEATH DIFFER, V5, P488, DOI 10.1038/sj.cdd.4400373; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278	43	68	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39262	39266		10.1074/jbc.C000622200	http://dx.doi.org/10.1074/jbc.C000622200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11050075	hybrid			2022-12-25	WOS:000165953100044
J	Krynetskaia, NF; Cai, XJ; Nitiss, JL; Krynetski, EY; Relling, MV				Krynetskaia, NF; Cai, XJ; Nitiss, JL; Krynetski, EY; Relling, MV			Thioguanine substitution alters DNA cleavage mediated by topoisomerase II	FASEB JOURNAL			English	Article						thioguanylated oligodeoxyribonucleotides etoposide; thiopurine; leukemogenesis	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BLOOD LEUKOCYTE DNA; SECONDARY LEUKEMIA; MISMATCH REPAIR; ETOPOSIDE; TUMORS; 6-THIOGUANINE; CHILDREN; THERAPY	Thiopurines and topoisomerase II-targeted drugs (e.g., etoposide) are widely used anticancer drugs. However, topoisomerase Ii-targeted drugs can cause acute myeloid leukemia, with the risk of this secondary leukemia linked to a genetic defect in thiopurine catabolism. Chronic thiopurines result in thioguanine substitution in DNA. The effect of these substitutions on DNA topoisomerase II activity is not known. Our goal was to determine whether deoxthio-guanosine substitution alters DNA cleavage stabilized by human topoisomerase If. We studied four variations of a 40 mer oligonucleotide with a topoisomerase II cleavage site, each with a single deoxythioguanosine in a different position relative to the cleavage site (-1 or +2 in the top and +2 or +4 in the bottom strand). Deoxythioguanosine substitution caused position-dependent quantitative effects on cleavage. With the -1 or +2 top and +2 or +4 bottom substitutions, mean topoisomerase II-induced cleavage was 0.6-, 2.0-, 1.1-, and 3.3-fold that with the wild-type substrate (P=0.011, < 0.008, 0.51, and < 0.001, respectively). In the presence of 100 muM etoposide, cleavage was enhanced for wild-type and all thioguanosin-modified substrates relative to no etoposide, with the +4 bottom substitution showing greater etoposide-induced cleavage than the wild-type substrate (P=0.015). We conclude that thioguanine incorporation alters the DNA cleavage induced by topoisomerase II in the presence and absence of etoposide, providing new insights to the mechanism of thiopurine effect and on the leukemogenesis of thiopurines, with or without topoisomerase inhibitors.-Krynetskaia, N. F., Cai, X., Nitiss, J. L., Krynetski, E. Y., Relling, M. V. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Relling, MV (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	mary.relling@stjude.org	Nitiss, John/E-9974-2010	Nitiss, John/0000-0002-1013-4972	NATIONAL CANCER INSTITUTE [R01CA082313, R37CA036401, R01CA036401, R01CA052814] Funding Source: NIH RePORTER; NCI NIH HHS [CA52814, CA36401, CA82313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; BOSHOFF C, 1995, ANN ONCOL, V6, P35, DOI 10.1093/oxfordjournals.annonc.a059037; Budavari S., 1989, MERCK INDEX; CHEN GL, 1984, J BIOL CHEM, V259, P3560; Cuffari C, 1996, CAN J PHYSIOL PHARM, V74, P580, DOI 10.1139/cjpp-74-5-580; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; FELIX CA, 1995, CANCER RES, V55, P4287; FRIEDBERG EC, 1995, TRENDS BIOCHEM SCI, V20, P381, DOI 10.1016/S0968-0004(00)89082-9; Gantchev TG, 1997, ANTI-CANCER DRUG, V8, P164, DOI 10.1097/00001813-199702000-00007; Glaab WE, 1998, CARCINOGENESIS, V19, P1931, DOI 10.1093/carcin/19.11.1931; Hsieh T, 1990, CURR OPIN CELL BIOL, V2, P461, DOI 10.1016/0955-0674(90)90128-2; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; Kollmannsberger C, 1998, J CLIN ONCOL, V16, P3386, DOI 10.1200/JCO.1998.16.10.3386; Krynetskaia NF, 1999, MOL PHARMACOL, V56, P841; Kushner BH, 1998, J CLIN ONCOL, V16, P3016, DOI 10.1200/JCO.1998.16.9.3016; LING YH, 1992, MOL PHARMACOL, V42, P802; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; Pedersen-Bjergaard J, 1998, J CLIN ONCOL, V16, P1897, DOI 10.1200/JCO.1998.16.5.1897; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RATAIN MJ, 1992, ANN ONCOL, V3, P107, DOI 10.1093/oxfordjournals.annonc.a058121; Relling MV, 1998, LEUKEMIA, V12, P346, DOI 10.1038/sj.leu.2400928; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; SANDER M, 1983, J BIOL CHEM, V258, P8421; Smith MA, 1999, J CLIN ONCOL, V17, P569, DOI 10.1200/JCO.1999.17.2.569; Smith MA, 1996, JNCI-J NATL CANCER I, V88, P407, DOI 10.1093/jnci/88.7.407; SPITZLEY T, 1989, RATIO, V2, P63, DOI 10.1111/j.1467-9329.1989.tb00127.x; Stine KC, 1997, J CLIN ONCOL, V15, P1583, DOI 10.1200/JCO.1997.15.4.1583; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Thomsen JB, 1999, CANCER-AM CANCER SOC, V86, P1080, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1080::AID-CNCR26>3.0.CO;2-5; WARREN DJ, 1995, CANCER RES, V55, P1670; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	37	40	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2339	2344		10.1096/fj.00-0089com	http://dx.doi.org/10.1096/fj.00-0089com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053256				2022-12-25	WOS:000165190800028
J	Hooks, SB; Santos, WL; Im, DS; Heise, CE; Macdonald, TL; Lynch, KR				Hooks, SB; Santos, WL; Im, DS; Heise, CE; Macdonald, TL; Lynch, KR			Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE RECEPTOR; PLATELET-AGGREGATION; MOLECULAR-CLONING; ACTIVATING-FACTOR; PHOSPHORIC-ACIDS; XENOPUS OOCYTES; CELLS; IDENTIFICATION; INHIBITION	Lysophosphatidic acid (LPA) is an extracellular signaling mediator with a broad range of cellular responses. Three G-protein-coupled receptors (Edg-2, -4, and -7) have been identified as receptors for LPA. In this study, the ectophosphatase lipid phosphate phosphatase 1 (LPP1) has been shown to down-regulate LPA-mediated mitogenesis. Furthermore, using degradation-resistant phosphonate analogs of LPA and stereoselective agonists of the Edg receptors we have demonstrated that the mitogenic and platelet aggregation responses to LPA are independent of Edg-2, -4, and -7. Specifically, we found that LPA degradation is insufficient to account for the decrease in LPA potency in mitogenic assays, and the stereoselectivity observed at the Edg receptors is not reflected in mitogenesis. Additionally, RH7777 cells, which are devoid of Edg-2, -4, and -7 receptor mRNA, have a mitogenic response to LPA and LPA analogs. Finally, we have determined that the ligand selectivity of the platelet aggregation response is consistent with that of mitogenesis, but not with Edg-2, -4, and -7.	Univ Virginia, Hlth Sci Ctr, Dept Biochem, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Chem, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Hooks, SB (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem, Jordan Hall,Box 440,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.			Hooks, Shelley/0000-0003-4702-0490; IM, DONG-SOON/0000-0001-8054-8946; Santos, Webster/0000-0002-4731-8548	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA005927] Funding Source: NIH RePORTER; NIDA NIH HHS [F31-DA05927] Funding Source: Medline; NIGMS NIH HHS [R01-GM52722] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard J, 1998, EUR J NEUROSCI, V10, P1045, DOI 10.1046/j.1460-9568.1998.00117.x; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Dillon DA, 1997, J BIOL CHEM, V272, P10361; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Gueguen G, 1999, BIOCHEMISTRY-US, V38, P8440, DOI 10.1021/bi9816756; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hooks SB, 1998, FEBS LETT, V427, P188, DOI 10.1016/S0014-5793(98)00421-9; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; Hopper DW, 1999, J MED CHEM, V42, P963, DOI 10.1021/jm970809v; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; JALINK K, 1990, J BIOL CHEM, V265, P12232; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kanoh H, 1999, CHEM PHYS LIPIDS, V98, P119, DOI 10.1016/S0009-3084(99)00024-9; KANOH H, 1992, J BIOL CHEM, V267, P25309; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liliom K, 1996, MOL PHARMACOL, V50, P616; Lynch KR, 1997, MOL PHARMACOL, V52, P75, DOI 10.1124/mol.52.1.75; Moller T, 1999, NEUROREPORT, V10, P2929; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; PROLL MA, 1985, MOL PHARMACOL, V28, P331; PROLL MA, 1991, MOL PHARMACOL, V39, P740; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; SIMON MF, 1982, BIOCHEM BIOPH RES CO, V108, P1743, DOI 10.1016/S0006-291X(82)80113-7; SMYTH SS, 1992, J BIOL CHEM, V267, P15568; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; Svetlov SI, 1996, ARCH BIOCHEM BIOPHYS, V336, P59, DOI 10.1006/abbi.1996.0532; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TOKUMURA A, 1981, BIOCHEM BIOPH RES CO, V99, P391, DOI 10.1016/0006-291X(81)91758-7; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Van Brocklyn JR, 2000, BLOOD, V95, P2624; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WALSH JP, 1990, J BIOL CHEM, V265, P4374; Weiner JA, 1998, J COMP NEUROL, V398, P587; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Xu J, 2000, J BIOL CHEM, V275, P27520; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	58	123	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4611	4621		10.1074/jbc.M007782200	http://dx.doi.org/10.1074/jbc.M007782200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11042183	hybrid			2022-12-25	WOS:000168484300014
J	Blahos, J; Fischer, T; Brabet, I; Stauffer, D; Rovelli, G; Bockaert, J; Pin, JP				Blahos, J; Fischer, T; Brabet, I; Stauffer, D; Rovelli, G; Bockaert, J; Pin, JP			A novel site on the G alpha-protein that recognizes heptahelical receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CHEMOKINE RECEPTORS; INOSITOL PHOSPHATES; CRYSTAL-STRUCTURE; AMINO-ACIDS; BETA-GAMMA; SUBUNIT; ACTIVATION	Specific domains of the G-protein a subunit have been shown to control coupling to heptahelical receptors, The extreme N and C termini and a region between alpha4 and alpha5 helices of the G-protein alpha subunit are known to determine selective interaction with the receptors, The metabotropic glutamate receptor 2 activated both mouse G alpha (15) and its human homologue G alpha (16), whereas metabotropic glutamate receptor 8 activated G alpha (15) only. The extreme C-terminal 20 amino acid residues are identical between the G alpha (15) and G alpha (16) and are therefore unlikely to be involved in coupling selectivity, Our data reveal two regions on G alpha (16) that inhibit its coupling to metabotropic glutamate receptor 8, On a three-dimensional model, both regions are found in a close proximity to the extreme C terminus of G alpha (16). One module comprises alpha4 helix, alpha4-beta6 loop (L9 Loop), beta6 sheet, and alpha5 helix. The other, not described previously, is located within the loop that links the N-terminal alpha helix to the beta1 strand of the Res-like domain of the alpha subunit, Coupling of G alpha (16) protein to the metabotropic glutamate receptor 8 is partially modulated by each module alone, whereas both modules are needed to eliminate the coupling fully.	CNRS, UPR9023, CCIPE, F-34094 Montpellier, France; Acad Sci Czech Republ, Inst Physiol, Prague 2, Czech Republic; Charles Univ, Fac Med 3, Dept Physiol, Lab Mol Physiol, Prague, Czech Republic; Univ Montpellier 2, INSERM, U431, F-34095 Montpellier, France; Novartis Pharma Res, CH-4002 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Charles University Prague; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Novartis	Blahos, J (corresponding author), CNRS, UPR9023, CCIPE, 141 Rue Cardonille, F-34094 Montpellier 5, France.		Blahos, Jaroslav/G-4397-2014; Pin, Jean-Philippe/Y-6668-2019; Blahos, Jaroslav/G-8325-2017	Pin, Jean-Philippe/0000-0002-1423-345X; Fischer, Thierry/0000-0002-9542-322X; Blahos, Jaroslav/0000-0003-3355-1469; Blahos, Jaroslav/0000-0001-9803-0061				AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Bae H, 1999, J BIOL CHEM, V274, P14963, DOI 10.1074/jbc.274.21.14963; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Blahos J, 1998, J BIOL CHEM, V273, P25765, DOI 10.1074/jbc.273.40.25765; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BONE EA, 1984, BIOCHEM J, V221, P803, DOI 10.1042/bj2210803; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Coleman DE, 1998, BIOCHEMISTRY-US, V37, P14376, DOI 10.1021/bi9810306; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; De Colle C, 2000, EUR J PHARMACOL, V394, P17, DOI 10.1016/S0014-2999(00)00113-8; Gomeza J, 1996, MOL PHARMACOL, V50, P923; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1998, J BIOL CHEM, V273, P17886, DOI 10.1074/jbc.273.28.17886; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008	42	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3262	3269		10.1074/jbc.M004880200	http://dx.doi.org/10.1074/jbc.M004880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11027680	hybrid			2022-12-25	WOS:000166784900038
J	Das, A; Chendil, D; Dey, S; Mohiuddin, M; Mohiuddin, M; Milbrandt, J; Rangnekar, VM; Ahmed, MM				Das, A; Chendil, D; Dey, S; Mohiuddin, M; Mohiuddin, M; Milbrandt, J; Rangnekar, VM; Ahmed, MM			Ionizing radiation down-regulates p53 protein in primary Egr-1(-/-) mouse embryonic fibroblast cells causing enhanced resistance to apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; WILMS-TUMOR GENE; TRANSCRIPTION FACTOR EGR-1; IRRADIATED MURINE TUMORS; A-CHAIN GENE; NF-KAPPA-B; GROWTH-FACTOR; DNA-BINDING; NGFI-A; PROMOTER	In this study, we sought to investigate the mechanism of the proapoptotic function of Egr-1 in relation to p53 status in normal isogenic cell backgrounds by using primary MEF cells established from homozygous (Egr-1(-/-)) and heterozygous (Egr-1(+/-)) Egr-1 knock-out mice. Ionizing radiation caused significantly enhanced apoptosis in Egr-1(+/-) cells (22.8%; p < 0.0001) when compared with Egr-1(-/-) cells (3.5%). Radiation elevated p53 protein in Egr-1(+/-) cells in 3-6 h, However, in Egr-1(-/-) cells, the p53 protein was down-regulated 1 h after radiation and was completely degraded at the later time points. Radiation elevated the p53-CAT activity in Egr-1(+/-) cells but not in Egr-1(-/-) cells. Interestingly, transient overexpression of EGR-1 in p53(-/-) MEF cells caused marginal induction of radiation-induced apoptosis when compared with p53(+/+) MEF cells. Together, these results indicate that Egr-1 may transregulate p53, and both EGR-1 and p53 functions are essential to mediate radiation-induced apoptosis, Rb, an Egr-1 target gene, forms a trimeric complex with p53 and MDM2 to prevent MDM2-mediated p53 degradation. Low levels of Rb including hypophosphorylated forms were observed in Egr-1(-/-) MEF cells before and after radiation when compared with the levels observed in Egr-1(+/-) cells. Elevated amounts of the p53-MDM2 complex and low amounts of Rb-MDM-2 complex were observed in Egr-1(-/-) cells after radiation. Because of a reduction in Rb binding to MDM2 and an increase in MDM2 binding with p53, p53 is directly degraded by MDM2, and this leads to inactivation of the p53-mediated apoptotic pathway in Egr-1(-/-) MEF cells. Thus, the proapoptotic function of Egr-1 may involve the mediation of Rb protein that is essential tot overcome the antiapoptotic function of MDM2 on p53.	Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; Washington Univ, Dept Pathol, St Louis, MO 63130 USA	University of Kentucky; University of Kentucky; Washington University (WUSTL)	Ahmed, MM (corresponding author), Univ Kentucky, Dept Radiat Med, 800 Rose St, Lexington, KY 40536 USA.		Ahmed, Mansoor/AAK-5988-2020; Das, Anindita/K-8003-2013	Das, Anindita/0000-0003-4422-7277; Milbrandt, Jeffrey/0000-0002-5477-7689				ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DAY ML, 1993, CANCER RES, V53, P5597; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; HUANG RP, 1995, CANCER RES, V55, P5054; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; MIYASHITA T, 1995, CELL, V80, P293; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STEPHENS LC, 1993, RADIAT RES, V135, P75, DOI 10.2307/3578399; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WANG ZY, 1992, BIOCHEM BIOPH RES CO, V188, P433, DOI 10.1016/0006-291X(92)92403-K; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WU HY, 1994, J BIOL CHEM, V269, P20067	49	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3279	3286		10.1074/jbc.M008454200	http://dx.doi.org/10.1074/jbc.M008454200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035041	hybrid			2022-12-25	WOS:000166784900040
J	Lykidis, A; Wang, J; Karim, MA; Jackowski, S				Lykidis, A; Wang, J; Karim, MA; Jackowski, S			Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE KINASE; RAT-LIVER; PHOSPHATIDYLETHANOLAMINE BIOSYNTHESIS; MOLECULAR-CLONING; HAMSTER HEART; PURIFICATION; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; PRECURSOR; MUTATION	Ethanolamine kinase (EKI) is the first committed step in phosphatidylethanolamine (PtdEtn) biosynthesis via the CDP-ethanolamine pathway. We identify a human cDNA encoding an ethanolamine-specific kinase EKI1 and the structure of the EKI1 gene located on chromosome 12. EKI1 overexpression in COS-7 cells results in a 170-fold increase in ethanolamine kinase-specific activity and accelerates the rate of [H-3]ethanolamine incorporation into PtdEtn as a function of the ethanolamine concentration in the culture medium. Acceleration of the CDP-ethanolamine pathway does not result in elevated cellular PtdEtn levels, but rather the excess PtdEtn is degraded to glycerophosphoethanolamine. EKI1 has negligible choline kinase activity in vitro and does not influence phosphatidylcholine biosynthesis. Acceleration of the CDP-ethanolamine pathway also does not change the rate of PtdEtn formation via the decarboxylation of phosphatidylserine. The data demonstrate the existence of separate ethanolamine and choline kinases in mammals and show that ethanolamine kinase can be a rate-controlling step in PtdEtn biosynthesis.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.		Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoyama C, 1998, BBA-LIPID LIPID MET, V1393, P179, DOI 10.1016/S0005-2760(98)00062-9; ARTHUR G, 1991, BIOCHEM J, V273, P121, DOI 10.1042/bj2730121; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; Bladergroen BA, 1997, BBA-LIPID LIPID MET, V1348, P91, DOI 10.1016/S0005-2760(97)00113-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROPHY PJ, 1977, EUR J BIOCHEM, V78, P491, DOI 10.1111/j.1432-1033.1977.tb11761.x; DRAUS E, 1990, BIOCHIM BIOPHYS ACTA, V1045, P195, DOI 10.1016/0005-2760(90)90120-M; HOSAKA K, 1992, FEBS LETT, V304, P229, DOI 10.1016/0014-5793(92)80625-Q; HOUWELING M, 1992, BIOCHEM J, V283, P55, DOI 10.1042/bj2830055; INFANTE JP, 1977, BIOCHEM J, V167, P847, DOI 10.1042/bj1670847; ISHIDATE K, 1985, BIOCHIM BIOPHYS ACTA, V836, P119; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCMASTER CR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P13, DOI 10.1016/0005-2760(92)90119-G; MILLER MA, 1986, J BIOL CHEM, V261, P9753; PAVLIDIS P, 1994, CELL, V79, P23, DOI 10.1016/0092-8674(94)90397-2; PORTER TJ, 1990, J BIOL CHEM, V265, P414; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; UCHIDA T, 1994, J BIOCHEM-TOKYO, V116, P508, DOI 10.1093/oxfordjournals.jbchem.a124554; UCHIDA T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P281, DOI 10.1016/0005-2760(90)90028-V; Uchida T, 1997, BBA-LIPID LIPID MET, V1349, P13, DOI 10.1016/S0005-2760(97)00059-3; UPRETI RK, 1976, ARCH BIOCHEM BIOPHYS, V174, P658, DOI 10.1016/0003-9861(76)90396-9; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5135, DOI 10.1021/bi00722a013; XU ZL, 1991, J BIOL CHEM, V266, P2143; ZELINSKI TA, 1982, CAN J BIOCHEM CELL B, V60, P817, DOI 10.1139/o82-102	30	78	81	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2174	2179		10.1074/jbc.M008794200	http://dx.doi.org/10.1074/jbc.M008794200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11044454	hybrid			2022-12-25	WOS:000166528000071
J	Somani, AK; Yuen, K; Xu, FH; Zhang, JY; Branch, DR; Siminovitch, KA				Somani, AK; Yuen, K; Xu, FH; Zhang, JY; Branch, DR; Siminovitch, KA			The SH2 domain containing tyrosine phosphatase-1 down-regulates activation of Lyn and Lyn-induced tyrosine phosphorylation of the CD19 receptor in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC ACTIVITY; KINASE-ACTIVITY; LINEAGE CELLS; CO-LIGATION; MOTH-EATEN; PROTEIN; SHP-1	SHP-1 is a cytosolic tyrosine phosphatase implicated in down-regulation of B cell antigen receptor signaling. SHP-1 effects on the antigen receptor reflect its capacity to dephosphorylate this receptor as well as several inhibitory comodulators. In view of our observation that antigen receptor-induced CD19 tyrosine phosphorylation is constitutively increased in B cells from SHP-1-deficient motheaten mice, we investigated the possibility that CD19, a positive modulator of antigen receptor signaling, represents another substrate for SHP-1. However, analysis of CD19 coimmunoprecipitable tyrosine phosphatase activity in CD19 immunoprecipitates from SHP-1-deficient and wild-type B cells revealed that SHP-1 accounts for only a minor portion of CD19-associated tyrosine phosphatase activity. As CD19 tyrosine phosphorylation is modulated by the Lyn protein-tyrosine kinase, Lyn activity was evaluated in wild-type and motheaten B cells. The results revealed both Lyn as well as CD19-associated Lyn kinase activity to be constitutively and inducibly increased in SHP-1-deficient compared with wild-type B cells. The data also demonstrated SHP-1 to be associated with Lyn in stimulated but not in resting B cells and indicated this interaction to be mediated via Lyn binding to the SHP-1 N terminal SH2 domain. These findings, together with cyanogen bromide cleavage data revealing that SHP-1 dephosphorylates the Lyn autophosphorylation site, identify Lyn deactivation/dephosphorylation as a likely mechanism whereby SHP-1 exerts its influence on CD19 tyrosine phosphorylation and, by extension, its inhibitory effect on B cell antigen receptor signaling.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Immunol & Med Genet, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Hlth Network Res Inst, Dept Oncol Res, Toronto, ON M5G 2M1, Canada; Canadian Blood Serv, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; Canadian Blood Services	Siminovitch, KA (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Rm 656A,600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Somani, ally-khan/AAA-9656-2020; Siminovitch, Katherine/K-1475-2013	Somani, Ally-Khan/0000-0003-2166-4896				ARNOLD LW, 1983, J IMMUNOL, V131, P2064; Blasioli J, 1999, J BIOL CHEM, V274, P2303, DOI 10.1074/jbc.274.4.2303; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BURG DL, 1994, J BIOL CHEM, V269, P28136; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Dustin LB, 1999, J IMMUNOL, V162, P2717; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Fujimoto M, 1999, J IMMUNOL, V162, P7088; GOLD MR, 1994, J IMMUNOL, V152, P42; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; Justement LB, 2000, CURR TOP MICROBIOL, V245, P1; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; Krop I, 1996, EUR J IMMUNOL, V26, P238, DOI 10.1002/eji.1830260137; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P9575, DOI 10.1073/pnas.92.21.9575; Nadler MJS, 1997, J BIOL CHEM, V272, P20038, DOI 10.1074/jbc.272.32.20038; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Nomura T, 1996, INT IMMUNOL, V8, P867, DOI 10.1093/intimm/8.6.867; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1997, J EXP MED, V186, P581, DOI 10.1084/jem.186.4.581; Pao LI, 1997, J IMMUNOL, V158, P2663; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Sato S, 1996, J IMMUNOL, V157, P4371; SAXTON TM, 1994, J IMMUNOL, V153, P623; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Smith KGC, 2000, CURR TOP MICROBIOL, V245, P195; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Tedder TF, 1998, SEMIN IMMUNOL, V10, P259, DOI 10.1006/smim.1998.0118; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; WENG WK, 1994, J BIOL CHEM, V269, P32514; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; Yang WT, 1998, EXP HEMATOL, V26, P1126; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663	63	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1938	1944		10.1074/jbc.M006820200	http://dx.doi.org/10.1074/jbc.M006820200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042209	hybrid			2022-12-25	WOS:000166528000041
J	Bagowski, CP; Xiong, W; Ferrell, JE				Bagowski, CP; Xiong, W; Ferrell, JE			c-jun N-terminal kinase activation in Xenopus laevis eggs and embryos - A possible non-genomic role for the JNK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR DEVELOPMENTAL TRANSITION; CYTOPLASMIC RETENTION SIGNAL; SPINDLE ASSEMBLY CHECKPOINT; PROTEIN-KINASE; OOCYTE MATURATION; MAP KINASE; CELL-CYCLE; APOPTOSIS; DROSOPHILA; MOS	The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase family that play critical roles in stress responses and apoptosis, We have discovered that JNK is present in Xenopus oocytes, an experimental system that offers a variety of powerful experimental approaches to questions of protein function and regulation. Like ERK2/p42 MAPK, JNK is activated just prior to germinal vesicle breakdown during Xenopus oocyte maturation and remains active throughout meiosis I and II. However, unlike p42 MAPK which is inactivated about 30 min after eggs are fertilized or parthenogenetically activated, JNK stays constitutively active until the early gastrula stage of embryogenesis, These findings suggest that the JNK pathway may play a role in oocyte maturation and embryogenesis, JNK was activated by microinjection of Mos, by activation of an estrogen-inducible form of Raf, and by a constitutively active MEK-1 (MEK R4F), indicating that the p42 MAPK cascade can trigger JNK activation. However, the MEK inhibitor U0126 blocked progesterone-induced p42 MAPK activation but not progesterone-induced JNK activation, Thus, progesterone can stimulate JNK activation both through the MEK/p42 MAPK pathway and through MEK/p42 MAPK-independent pathways. Many of the key substrates of JNKs identified to date are transcriptional regulators. However, since transcription is not required for germinal vesicle breakdown in progesterone-treated oocytes or for the early embryonic cell cycles, our findings suggest that in these contexts the JNK pathway exerts nongenomic effects.	Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Dept Mol Pharmacol, 269 W Campus Dr, Stanford, CA 94305 USA.				NIGMS NIH HHS [GM46383] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JA, 1997, MOL BIOL CELL, V8, P1195, DOI 10.1091/mbc.8.7.1195; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; BAULIEU EE, 1978, NATURE, V275, P593, DOI 10.1038/275593a0; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; Fisher DL, 1999, DEVELOPMENT, V126, P4537; Goberdhan DCI, 1998, BIOESSAYS, V20, P1009, DOI 10.1002/(SICI)1521-1878(199812)20:12<1009::AID-BIES7>3.0.CO;2-D; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hensey C, 1997, MECH DEVELOP, V69, P183, DOI 10.1016/S0925-4773(97)00191-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roy LM, 1996, ONCOGENE, V12, P2203; Sible JC, 1997, DEV BIOL, V189, P335, DOI 10.1006/dbio.1997.8683; Stack JH, 1997, DEVELOPMENT, V124, P3185; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Yoshitome S, 1998, BIOL CELL, V90, P509, DOI 10.1016/S0248-4900(99)80009-4; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	51	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1459	1465		10.1074/jbc.M008050200	http://dx.doi.org/10.1074/jbc.M008050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11029471	hybrid			2022-12-25	WOS:000166430900080
J	Folcher, M; Morris, RP; Dale, G; Salah-Bey-Hocini, K; Viollier, PH; Thompson, CJ				Folcher, M; Morris, RP; Dale, G; Salah-Bey-Hocini, K; Viollier, PH; Thompson, CJ			A transcriptional regulator of a pristinamycin resistance gene in Streptomyces coelicolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; EXPRESSION; PRISTINAESPIRALIS; BIOSYNTHESIS; BINDING; CLUSTER; IDENTIFICATION; SEQUENCE; COMPLEX	Pip is a pristinamycin-induced transcriptional regulator protein detected in many Streptomyces species by its ability to specifically bind sequence motifs within the promoter of a Streptomyces pristinaespiralis multidrug resistance gene (ptr). To investigate the possible role of Pip in regulating multidrug resistance, it was purified from a genetically characterized species, Streptomyces coelicolor, utilizing an affinity matrix of the ptr promoter conjugated to magnetic beads. Reverse genetics identified the corresponding locus and confirmed that it encoded Pip, a protein belonging to the TetR family of procaryotic transcriptional repressors. Pip binding motifs were located upstream of the adjacent gene pep, encoding a major facilitator antiporter homologous to ptr. bz vivo analysis of antibiotic susceptibility profiles demonstrated that pep conferred elevated levels of resistance only to pristinamycin I (PI), a streptogramin B antibiotic having clinical importance. Purified recombinant Pip was a dimer tin the presence or absence of PI) and displayed a high affinity for its palindromic binding motifs within the ptr promoter and the upstream region of pep, The Pip/ptr promoter complex was dissociated by PI but not by any of the other nonstreptogramin antibiotics that were described previously as transcriptional inducers. These procaryotic regulatory elements served as the basis for the development of systems allowing repression or induction of cloned genes in mammalian and plant cells in response to streptogramin antibiotics (including pristinamycin, virginiamycin, and Synercid(R).	Univ Basel, Biozentrum, Dept Microbiol, CH-4056 Basel, Switzerland	University of Basel	Thompson, CJ (corresponding author), Univ Basel, Biozentrum, Dept Microbiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Viollier, Patrick/AAD-9405-2021; Morris, Rowan/HGU-9105-2022	Viollier, Patrick/0000-0002-5249-9910				ARIZA RR, 1995, J BACTERIOL, V177, P1655, DOI 10.1128/jb.177.7.1655-1661.1995; August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Bamas-Jacques N, 1999, J APPL MICROBIOL, V87, P939, DOI 10.1046/j.1365-2672.1999.00955.x; BARRIERE JC, 1994, EXPERT OPIN INV DRUG, V3, P115; Blanc V, 1997, MOL MICROBIOL, V23, P191, DOI 10.1046/j.1365-2958.1997.2031574.x; BLANC V, 1995, MOL MICROBIOL, V17, P989, DOI 10.1111/j.1365-2958.1995.mmi_17050989.x; Blau HM, 1999, P NATL ACAD SCI USA, V96, P797, DOI 10.1073/pnas.96.3.797; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; Fussenegger M, 2000, NAT BIOTECHNOL, V18, P1203, DOI 10.1038/81208; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; GUILFOILE PG, 1992, J BACTERIOL, V174, P3651, DOI 10.1128/JB.174.11.3651-3658.1992; GUILFOILE PG, 1992, J BACTERIOL, V174, P3659, DOI 10.1128/JB.174.11.3659-3666.1992; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P343; Hopwood D. A., 1985, GENETIC MANIPULATION; Lee CK, 1999, J BACTERIOL, V181, P3293, DOI 10.1128/JB.181.10.3293-3297.1999; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; PREUDHOM.J, 1968, B SOC CHIM FR, P585; Rouquette C, 1999, MOL MICROBIOL, V33, P651, DOI 10.1046/j.1365-2958.1999.01517.x; SALAHBEY K, 1995, MOL MICROBIOL, V17, P1109, DOI 10.1111/j.1365-2958.1995.mmi_17061109.x; SALAHBEY K, 1995, MOL MICROBIOL, V17, P1001, DOI 10.1111/j.1365-2958.1995.mmi_17051001.x; Sambrook J., 1989, MOL CLONING, pA1; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; TAKAHASHI M, 1986, J MOL BIOL, V187, P341, DOI 10.1016/0022-2836(86)90437-7; THOMPSON CJ, 1983, P NATL ACAD SCI-BIOL, V80, P5190, DOI 10.1073/pnas.80.17.5190; Westrich L, 1999, FEMS MICROBIOL LETT, V170, P381, DOI 10.1111/j.1574-6968.1999.tb13398.x; White DG, 1997, J BACTERIOL, V179, P6122, DOI 10.1128/jb.179.19.6122-6126.1997; Wu SW, 1996, J BACTERIOL, V178, P6036, DOI 10.1128/jb.178.20.6036-6042.1996; ZHOU YN, 1988, J BACTERIOL, V170, P3640, DOI 10.1128/jb.170.8.3640-3649.1988	33	49	51	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1479	1485		10.1074/jbc.M007690200	http://dx.doi.org/10.1074/jbc.M007690200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050092	hybrid			2022-12-25	WOS:000166430900083
J	Moore, ML; Wang, GL; Belaguli, NS; Schwartz, RJ; McMillin, JB				Moore, ML; Wang, GL; Belaguli, NS; Schwartz, RJ; McMillin, JB			GATA-4 and serum response factor regulate transcription of the muscle-specific carnitine palmitoyltransferase I beta in rat heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; ACTIN GENE-TRANSCRIPTION; CARDIAC TRANSCRIPTION; DNA-BINDING; PPAR-ALPHA; CPT-I; EXPRESSION; PROTEIN; ORGANIZATION; NKX-2.5	Transcriptional regulation of nuclear encoded mitochondrial proteins is dependent on nuclear transcription factors that act on genes encoding key components of mitochondrial transcription, replication, and heme biosynthetic machinery. Cellular factors that target expression of proteins to the heart have been well characterized with respect to excitation-contraction coupling. No information currently exists that examines whether parallel transcriptional mechanisms regulate nuclear encoded expression of heart-specific mitochondrial isoforms. The muscle CPT-I beta isoform in heart is a TATAless gene that uses Sp-1 proteins to support basal expression. The rat cardiac fatty acid response element (-301/-289), previously characterized in the human gene, is responsive to oleic acid following serum deprivation, Deletion and mutational analysis of the 5'-flanking sequence of the carnitine palmitoyltransferase I beta (CPT-I beta) gene defines regulatory regions in the -391/+80 promoter luciferase construct. When deleted or mutated constructs were individually transfected into cardiac myocytes, CPT-I/luciferase reporter gene expression was significantly depressed at sites involving a putative MEF2 sequence downstream from the fatty acid response element and a cluster of heart-specific regulatory regions flanked by two Sp1 elements. Each site demonstrated binding to cardiac nuclear proteins and competition specificity (or supershifts) with oligonucleotides and antibodies. Individual expression vectors for Nkx2,5, serum response factor (SRF), and GATA4 enhanced CPT-I reporter gene expression 4-36-fold in CV-1 cells. Although cotransfection of Nkx and SRF produced additive luciferase expression, the combination of SRF and GATA-4 cotransfection resulted in synergistic activation of CPT-I beta, The results demonstrate that SRF and the tissue-restricted isoform, GATA-4, drive robust gene transcription of a mitochondrial protein highly expressed in heart.	Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Sch Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine	McMillin, JB (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Sch Med, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038863, P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL49953, R01 HL38863] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Bhavsar PK, 2000, J MOL CELL CARDIOL, V32, P95, DOI 10.1006/jmcc.1999.1058; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; Charron F, 1999, MOL CELL BIOL, V19, P4355; Chen CY, 1996, MOL CELL BIOL, V16, P6372; COOK GA, 1984, J BIOL CHEM, V259, P2030; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Djouadi F, 1999, PROSTAG LEUKOTR ESS, V60, P339, DOI 10.1016/S0952-3278(99)80009-X; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; MCMILLIN JB, 1993, METHODS TOXICOL, V2, P301; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; MYNATT RL, 1992, BIOCHIM BIOPHYS ACTA, V1128, P105, DOI 10.1016/0005-2760(92)90263-U; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; Nicholas SB, 1999, AM J PHYSIOL-HEART C, V277, pH324, DOI 10.1152/ajpheart.1999.277.1.H324; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wang DC, 1998, GENOMICS, V48, P314, DOI 10.1006/geno.1997.5184; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Xiao QX, 1998, J MOL CELL CARDIOL, V30, P87, DOI 10.1006/jmcc.1997.0574; Zhao JL, 2000, J BIOL CHEM, V275, P8903, DOI 10.1074/jbc.275.12.8903	36	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1026	1033		10.1074/jbc.M009352200	http://dx.doi.org/10.1074/jbc.M009352200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038368	hybrid			2022-12-25	WOS:000166430900024
J	Franek, WR; Horowitz, S; Stansberry, L; Kazzaz, JA; Koo, HC; Li, YC; Arita, Y; Davis, JM; Mantell, AS; Scott, W; Mantell, LL				Franek, WR; Horowitz, S; Stansberry, L; Kazzaz, JA; Koo, HC; Li, YC; Arita, Y; Davis, JM; Mantell, AS; Scott, W; Mantell, LL			Hyperoxia inhibits oxidant-induced apoptosis in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; SUPEROXIDE-DISMUTASE; HEME OXYGENASE-1; OXIDATIVE STRESS; GENE-EXPRESSION; TNF-ALPHA; IN-VIVO; DEATH; BCL-2	It has previously been shown that hyperoxia induces non-apoptotic cell death in cultured lung epithelial cells, whereas hydrogen peroxide (H2O2) and paraquat cause apoptosis, To test whether pathways leading to oxidative apoptosis in epithelial cells are sensitive to molecular O-2, A549 cells were exposed to 95% O-2, prior to exposure to lethal concentrations of H2O2. The extent of H2O2-induced apoptosis was significantly reduced in cells preexposed to hyperoxia compared with room-air controls. Preexposure of the hyperoxia-resistant HeLa-80 cell line to 80% O-2 also inhibited oxidant-induced apoptosis, suggesting that this inhibition is not due to O-2, toxicity. Because hyperoxia generates reactive oxygen species and activates the redox-sensitive transcription factor nuclear factor kappaB (NF-kappaB), the role of antioxidant enzymes and NF-kappaB were examined in this inhibitory process. The onset of inhibition appeared to be directly related to the degradation of I kappaB and subsequent activation of NF-kappaB (either by hyperoxia or TNF-alpha), whereas no significant up-regulation of endogenous antioxidant enzyme activities was found. In addition, suppression of NF-kappaB activities by transfecting A549 cells with a dominant-negative mutant construct of I kappaB significantly augmented the extent of H2O2-induced apoptosis. These data suggest that hyperoxia inhibits oxidant-induced apoptosis and that this inhibition is mediated by NF-kappaB.	SUNY Stony Brook, Winthrop Univ Hosp, CardioPulm Res Inst, Mineola, NY 11501 USA; SUNY Stony Brook, Winthrop Univ Hosp, Dept Med, Mineola, NY 11501 USA; SUNY Stony Brook, Winthrop Univ Hosp, Dept Pediat, Mineola, NY 11501 USA; SUNY Stony Brook, Winthrop Univ Hosp, Dept Cardiovasc Thorac Surg, Mineola, NY 11501 USA; Hofstra Univ, Hempstead, NY 11549 USA; Univ Louisville, Dept Med, Jewish Hosp Heart & Lung Inst, Louisville, KY 40202 USA; Univ Louisville, Dept Pharmacol & Toxicol, Jewish Hosp Heart & Lung Inst, Louisville, KY 40202 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; Hofstra University; University of Louisville; University of Louisville	Mantell, LL (corresponding author), SUNY Stony Brook, Winthrop Univ Hosp, CardioPulm Res Inst, Mineola, NY 11501 USA.	lmantell@winthrop.org						Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEERS RF, 1952, J BIOL CHEM, V195, P133; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Capellier G, 1999, Minerva Anestesiol, V65, P388; Cappelletti G, 1998, CELL BIOL INT, V22, P671, DOI 10.1006/cbir.1998.0305; CHOI AMK, 1995, AM J RESP CELL MOL, V13, P74, DOI 10.1165/ajrcmb.13.1.7598940; CLERCH LB, 1993, J CLIN INVEST, V91, P499, DOI 10.1172/JCI116228; Crapo J D, 1978, Methods Enzymol, V53, P382; CRAPO JD, 1974, AM J PHYSIOL, V226, P1401, DOI 10.1152/ajplegacy.1974.226.6.1401; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Fabisiak JP, 1997, AM J PHYSIOL-CELL PH, V272, pC675, DOI 10.1152/ajpcell.1997.272.2.C675; FREEMAN BA, 1986, EXP LUNG RES, V10, P203, DOI 10.3109/01902148609061493; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; Hampton MB, 1998, TOXICOL LETT, V103, P355, DOI 10.1016/S0378-4274(98)00333-6; JOENJE H, 1985, LAB INVEST, V52, P420; JOENJE H, 1997, OXYGEN EXPRESSION CE, P67; Jyonouchi H, 1998, AM J RESP CELL MOL, V19, P426, DOI 10.1165/ajrcmb.19.3.2862m; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Lavrovsky Y, 2000, MECH AGEING DEV, V114, P49, DOI 10.1016/S0047-6374(00)00087-7; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lee PJ, 1996, AM J RESP CELL MOL, V14, P556, DOI 10.1165/ajrcmb.14.6.8652184; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mantell LL, 1997, CELL DEATH DIFFER, V4, P600, DOI 10.1038/sj.cdd.4400278; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; NAKATA T, 1993, INT J CANCER, V55, P646, DOI 10.1002/ijc.2910550422; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pietarinen-Runtti P, 1998, AM J RESP CELL MOL, V19, P286, DOI 10.1165/ajrcmb.19.2.2836; POGREBNIAK HW, 1991, J THORAC CARDIOV SUR, V102, P904, DOI 10.1016/S0022-5223(19)33941-8; Pyatt DW, 1999, BLOOD, V93, P3302, DOI 10.1182/blood.V93.10.3302.410a38_3302_3308; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Shea LM, 1996, J IMMUNOL, V157, P3902; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; YOO JH, 1994, J CLIN INVEST, V93, P297, DOI 10.1172/JCI116959; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009	41	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					569	575		10.1074/jbc.M004716200	http://dx.doi.org/10.1074/jbc.M004716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11034997	hybrid			2022-12-25	WOS:000166280700077
J	Primm, TP; Gilbert, HF				Primm, TP; Gilbert, HF			Hormone binding by protein disulfide isomerase, a high capacity hormone reservoir of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CHAPERONE ACTIVITY; PEPTIDE BINDING; PROLYL 4-HYDROXYLASE; RIBONUCLEASE-A; BETA-SUBUNIT; SITE; PURIFICATION; BACITRACIN; CATALYSIS; DOMAIN	Protein disulfide isomerase (PDI) is a folding assistant of the eukaryotic endoplasmic reticulum, but it also binds the hormones, estradiol, and 3,3',5-triiodo-L-thyronine (T-3), Hormone binding could be at discrete hormone binding sites, or it could be a nonphysiological consequence of binding site(s) that are involved in the interaction PDI with its peptide and protein substrates, Equilibrium dialysis, fluorescent hydrophobic probe binding (4,4'-dianilino-1,1 '-binaphthyl-5,5'-disulfonic acid (bis-ANS)), competition binding, and enzyme activity assays reveal that the hormone binding sites are distinct from the peptide/protein binding sites. PDI has one estradiol binding site with modest affinity (2.1 +/- 0.5 muM). There are two binding sites with comparable affinity for T-3 (4.3 +/- 1.4 muM), One of these overlaps the estradiol site, whereas the other binds the hydrophobic probe, bis-ANS, Neither estradiol nor T-3 inhibit the catalytic or chaperone activity of PDI, Although the affinity of PDI for the hormones estradiol and T-3 is modest, the high local concentration of PDI in the endoplasmic reticulum (>200 muM) would drive hormone binding and result in the association of a substantial fraction (>90%) of the hormones in the cell with PDI, High capacity, low affinity hormone sites may function to buffer hormone concentration in the cell and allow tight, specific binding to the true receptor while preserving a reasonable number of hormone molecules in the very small volume of the cellular environment.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine	Gilbert, HF (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA.	hgilbert@bcm.tmc.edu			NIGMS NIH HHS [GM40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BUTLER J, 1988, ANN CLIN BIOCHEM, P25536; CANNON DJ, 1969, BIOCHEM BIOPH RES CO, V35, P403, DOI 10.1016/0006-291X(69)90513-0; Dai Y, 1997, J BIOL CHEM, V272, P27572, DOI 10.1074/jbc.272.44.27572; DANEL L, 1982, CANCER RES, V42, P4701; ERICKSON GF, 1986, SEMIN REPROD ENDOCR, V4, P233, DOI 10.1055/s-2007-1022504; FARRIS FJ, 1978, J AM CHEM SOC, V100, P4469, DOI 10.1021/ja00482a026; FERREIRO B, 1990, ACTA ENDOCRINOL-COP, V123, P95, DOI 10.1530/acta.0.1230095; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gabrielsson J, 1996, Acta Obstet Gynecol Scand Suppl, V163, P26; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GILBERT HF, 1994, PROLYL HYDROXYLASE, P341; Guthapfel R, 1996, EUR J BIOCHEM, V242, P315, DOI 10.1111/j.1432-1033.1996.0315r.x; HORIUCHI R, 1989, EUR J BIOCHEM, V183, P529, DOI 10.1111/j.1432-1033.1989.tb21081.x; IKAI Y, 1995, J ANTIBIOT, V48, P233, DOI 10.7164/antibiotics.48.233; KEMMINK J, 1995, PROTEIN SCI, V4, P2587, DOI 10.1002/pro.5560041216; KITAGAWA S, 1987, J BIOL CHEM, V262, P3903; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; KOIVU J, 1987, J BIOL CHEM, V262, P6447; Korchev YE, 2000, BIOPHYS J, V78, P451, DOI 10.1016/S0006-3495(00)76607-0; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LEBECHE D, 1994, BIOCHEM BIOPH RES CO, V202, P556, DOI 10.1006/bbrc.1994.1964; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MEDINA V, 1993, BIOCHEM MED METAB B, V49, P255, DOI 10.1006/bmmb.1993.1027; MIZUNAGA T, 1990, J BIOCHEM, V108, P846, DOI 10.1093/oxfordjournals.jbchem.a123291; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NACHTIGALL L, 1968, AM J OBSTET GYNECOL, V101, P638, DOI 10.1016/0002-9378(68)90301-3; NEFF S, 1994, MOL ENDOCRINOL, V8, P1215, DOI 10.1210/me.8.9.1215; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1991, J BIOL CHEM, V266, P19645; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; OBATA T, 1988, J BIOL CHEM, V263, P782; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; ROTH RA, 1981, BIOCHEM BIOPH RES CO, V98, P431, DOI 10.1016/0006-291X(81)90858-5; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; SIEGEL MM, 1994, BIOL MASS SPECTROM, V23, P186, DOI 10.1002/bms.1200230403; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; TSIBRIS JCM, 1989, J BIOL CHEM, V264, P13967; WALENT JH, 1990, ENDOCRINOLOGY, V126, P2383, DOI 10.1210/endo-126-5-2383; Walker KW, 1997, J BIOL CHEM, V272, P8845; WALKER KW, 1997, STRUCTURE FUNCTION M, P331; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; Westphal V, 1998, J BIOL CHEM, V273, P24992, DOI 10.1074/jbc.273.39.24992; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	55	90	92	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					281	286		10.1074/jbc.M007670200	http://dx.doi.org/10.1074/jbc.M007670200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035025	hybrid			2022-12-25	WOS:000166280700039
J	Yarov-Yarovoy, V; Brown, J; Sharp, EM; Clare, JJ; Scheuer, T; Catterall, WA				Yarov-Yarovoy, V; Brown, J; Sharp, EM; Clare, JJ; Scheuer, T; Catterall, WA			Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs in transmembrane segment IIIS6 of the Na+ channel alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HIPPOCAMPAL-NEURONS; LOCAL-ANESTHETIC RECEPTOR; SODIUM-CHANNELS; K+-CHANNEL; ANTIARRHYTHMIC DRUGS; MEMBRANE-PROTEINS; FAST INACTIVATION; BRAIN; LAMOTRIGINE; STATE	Mutations of amino acid residues in the inner two-thirds of the S6 segment in domain III of the rat brain type IIA Na+ channel (G1460A to I1473A) caused periodic positive and negative shifts in the voltage dependence of activation, consistent with an cu-helix having one face on which mutations to alanine oppose activation. Mutations in the outer one-third of the IIIS6 segment all favored activation. Mutations in the inner half of IIIS6 had strong effects on the voltage dependence of inactivation from closed states without effect on open-state inactivation. Only three mutations had strong effects on block by local anesthetics and anticonvulsants. Mutations L1465A and I1469A decreased affinity of inactivated Na+ channels up to 8-fold for the anticonvulsant lamotrigine and its congeners 227c89, 4030w92, and 619c89 as well as for the local anesthetic etidocaine. N1466A decreased affinity of inactivated Na+ channels for the anticonvulsant 4030w92 and etidocaine by 3- and 8-fold, respectively, but had no effect on affinity of the other tested compounds. Leu-1465, Asn-1466, and Ile-1469 are located on one side of the IIISG helix, and mutation of each caused a positive shift in the voltage dependence of activation. Evidently, these amino acid residues face the lumen of the pore, contribute to formation of the high-affinity receptor site for pore-blocking drugs, and are involved in voltage-dependent activation and coupling to closed-state inactivation.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Glaxo Wellcome Ltd, Dept Mol Pharmacol, Stevenage, Herts, England	University of Washington; University of Washington Seattle; GlaxoSmithKline	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, Mail Stop 357280, Seattle, WA 98195 USA.		Yarov-Yarovoy, Vladimir/ABE-5454-2020	Yarov-Yarovoy, Vladimir/0000-0002-2325-4834	NINDS NIH HHS [NS15751] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BRODIE MJ, 1994, EPILEPSIA, V35, pS41, DOI 10.1111/j.1528-1157.1994.tb05966.x; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; Carter AJ, 2000, P NATL ACAD SCI USA, V97, P4944, DOI 10.1073/pnas.040577097; CATTERALL WA, 1987, TRENDS PHARMACOL SCI, V8, P57, DOI 10.1016/0165-6147(87)90011-3; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; Cohen S A, 1993, Int Rev Cytol, V137C, P55; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; GOA KL, 1993, DRUGS, V46, P152, DOI 10.2165/00003495-199346010-00009; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; HONDEGHEM LM, 1984, ANNU REV PHARMACOL, V24, P387, DOI 10.1146/annurev.pa.24.040184.002131; HONDEGHEM LM, 1977, BIOCHIM BIOPHYS ACTA, V472, P373, DOI 10.1016/0304-4157(77)90003-X; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KOMIYA H, 1988, P NATL ACAD SCI USA, V85, P9012, DOI 10.1073/pnas.85.23.9012; KUO CC, 1994, MOL PHARMACOL, V46, P716; Li HL, 1999, MOL PHARMACOL, V55, P134, DOI 10.1124/mol.55.1.134; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; Liu GY, 1998, BIOPHYS J, V74, pA399; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; QU YS, 1995, P NATL ACAD SCI USA, V92, P11839, DOI 10.1073/pnas.92.25.11839; Ragsdale DS, 1996, P NATL ACAD SCI USA, V93, P9270, DOI 10.1073/pnas.93.17.9270; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; Tatulian SA, 1998, FEBS LETT, V423, P205, DOI 10.1016/S0014-5793(98)00091-X; Wang GK, 1998, MOL PHARMACOL, V54, P389, DOI 10.1124/mol.54.2.389; Wang GK, 1998, PFLUG ARCH EUR J PHY, V435, P293; Weiser T, 1999, MOL PHARMACOL, V56, P1238, DOI 10.1124/mol.56.6.1238; Wright SN, 1998, MOL PHARMACOL, V54, P733; Xie XM, 1996, NEUROSCIENCE, V73, P951, DOI 10.1016/0306-4522(96)00092-9; XIE XM, 1995, PFLUG ARCH EUR J PHY, V430, P437, DOI 10.1007/BF00373920	46	188	196	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					20	27		10.1074/jbc.M006992200	http://dx.doi.org/10.1074/jbc.M006992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024055	hybrid			2022-12-25	WOS:000166280700004
J	Jiang, W; Nordeen, SK; Kadonaga, JT				Jiang, W; Nordeen, SK; Kadonaga, JT			Transcriptional analysis of chromatin assembled with purified ACF and dNAP1 reveals that acetyl-CoA is required for preinitiation complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; HISTONE ACETYLTRANSFERASE COMPLEXES; SOLUBLE NUCLEAR FRACTION; DROSOPHILA EMBRYOS; FUNCTIONAL STEPS; ACTIVATION; INITIATION; EXTRACT; REINITIATION; TEMPLATES	To investigate the role of chromatin structure in the regulation of transcription by RNA polymerase II, we developed a chromatin transcription system in which periodic nucleosome arrays are assembled with purified recombinant ATP-utilizing chromatin assembly and remodeling factor (ACF), purified recombinant nucleosome assembly protein 1 (dNAP1), purified native core histones, plasmid DNA, and ATP. With this chromatin, we observed robust activation of transcription with three different transcription factor sets (nuclear factor kappaB p65 + Sp1 estrogen receptor, and Ga14-VP16) added either before or after chromatin assembly. In fact, the efficiency of activated transcription from the ACF + dNAP1-assembled chromatin was observed to be comparable with that from naked DNA templates or chromatin assembled with a crude Drosophila extract (S190). With ACF + dNAP1-assembled chromatin, we found that transcriptional activation is dependent upon acetyl-CoA. This effect was not seen with naked DNA templates or with crude S190-assembled chromatin. We further determined that acetyl-CoA is required at the time of preinitiation complex assembly but not during assembly of the chromatin template. These findings suggest that there is at least one key acetylation event that is needed to assemble a functional transcription preinitiation complex with a chromatin template.	Univ Calif San Diego, Sect Mol Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kadonaga, JT (corresponding author), Univ Calif San Diego, Sect Mol Biol, 0347 Pacific Hall,Rm 2212B, La Jolla, CA 92093 USA.				NIDDK NIH HHS [DK37061] Funding Source: Medline; NIGMS NIH HHS [GM58272, GM46995] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058272] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bulger M., 1994, METH MOL G, V5, P241; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; Glass CK, 2000, GENE DEV, V14, P121; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KAMAKAKA RT, 1994, METHOD CELL BIOL, V44, P225, DOI 10.1016/S0091-679X(08)60916-4; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; KRAUS WL, 1999, NUCL RECEPTORS PRACT, P167; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Robinson KM, 1998, BBA-REV CANCER, V1378, pM1, DOI 10.1016/S0304-419X(98)00008-0; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Steger DJ, 1999, METHODS, V19, P410, DOI 10.1006/meth.1999.0877; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wolffe A., 1995, CHROMATIN STRUCTURE; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	35	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39819	39822		10.1074/jbc.C000713200	http://dx.doi.org/10.1074/jbc.C000713200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11054407	hybrid			2022-12-25	WOS:000166039500005
J	Goepfert, TM; McCarthy, M; Kittrell, FS; Stephens, C; Ullrich, RL; Brinkley, BR; Medina, D				Goepfert, TM; McCarthy, M; Kittrell, FS; Stephens, C; Ullrich, RL; Brinkley, BR; Medina, D			Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells	FASEB JOURNAL			English	Article						estrogen; aneuploidy; centrosomes; steroid hormone	BREAST-CANCER-CELLS; IN-SITU; GENETIC INSTABILITY; BALB/C MICE; RECEPTOR; TUMORS; GLAND; ESTROGEN; DIFFERENTIATION; CARCINOGENESIS	Mammary epithelial cells from p53 null mice have been shown recently to exhibit an increased risk for tumor development, Hormonal stimulation markedly increased tumor development in p53 null mammary cells. Here we demonstrate that mammary tumors arising in p53 null mammary cells are highly aneuploid, with greater than 70% of the tumor cells containing altered chromosome number and a mean chromosome number of 56, Normal mammary cells of p53 null genotype and aged less than 14 wk do not exhibit aneuploidy in primary cell culture, Significantly, the hormone progesterone, but not estrogen, increases the incidence of aneuploidy in morphologically normal p53 null mammary epithelial cells. Such cells exhibited 40% aneuploidy and a mean chromosome number of 54, The increase in aneuploidy measured in p53 null tumor cells or hormonally stimulated normal p53 null cells was not accompanied by centrosome amplification. These results suggest that normal levels of progesterone can facilitate chromosomal instability in the absence of the tumor suppressor gene, p53, The results support the emerging hypothesis based both on human epidemiological and animal model studies that progesterone markedly enhances mammary tumorigenesis.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Radiat Therapy, Galveston, TX 77550 USA; Univ Texas, MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; UTMD Anderson Cancer Center	Medina, D (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,MS 112A, Houston, TX 77030 USA.	dmedina@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R37CA041424, R01CA043322, R01CA041424, P01CA064255] Funding Source: NIH RePORTER; NCI NIH HHS [CA43322, CA41424, CA64255] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aardema MJ, 1997, CANCER GENET CYTOGEN, V96, P140, DOI 10.1016/S0165-4608(96)00301-9; ALDAZ CM, 1995, CANCER RES, V55, P3976; ALLRED DC, 2000, DIS BREAST, P355; ALLRED DC, 1997, DUCTAL CARCINOMA IN, P37; BARDON S, 1987, CANCER RES, V47, P1441; BARRETT JC, 1987, MECHANISMS ENV CARCI, V2, P73; BERARDO MD, 1996, HORMONE DEPENDENT CA, P1; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; BUTEL JS, 1977, CANCER RES, V37, P1892; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; CHRISTOV K, 1993, CARCINOGENESIS, V14, P2019, DOI 10.1093/carcin/14.10.2019; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, PROG CLIN BIOL RES, V395, P1; ETHIER SP, 1993, CANCER RES, V53, P627; ETHIER SP, 1982, CANCER RES, V42, P1753; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; GANTT R, 1978, P NATL ACAD SCI USA, V75, P3809, DOI 10.1073/pnas.75.8.3809; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Greendale GA, 1999, ANN INTERN MED, V130, P262, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00003; Guzman RC, 1999, P NATL ACAD SCI USA, V96, P2520, DOI 10.1073/pnas.96.5.2520; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; Imagawa Walter, 1994, P1033; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; JULL JW, 1954, J PATHOL BACTERIOL, V68, P547, DOI 10.1002/path.1700680227; KITTRELL FS, 1992, CANCER RES, V52, P1924; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LENGAUER C, 1977, NATURE, V386, P623; LI ML, 1995, J CELL PHYSIOL, V164, P1, DOI 10.1002/jcp.1041640102; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lydon JP, 1999, CANCER RES, V59, P4276; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MEDINA D, 1996, MAMMARY TUMOR CELL C, P37; MEDINA D, 2000, IN PRESS J MANNARY G, V5; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Mendelin J, 1999, LAB INVEST, V79, P387; Meyn RE, 1996, INT J CANCER, V65, P466, DOI 10.1002/(SICI)1097-0215(19960208)65:4<466::AID-IJC13>3.0.CO;2-8; MITELMAN F, 1981, HEREDITAS, V95, P79; O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697; OSHIMURA M, 1986, ENVIRON MUTAGEN, V8, P129, DOI 10.1002/em.2860080112; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 1998, CANCER RES, V58, P3974; Plaut K, 1999, J CELL PHYSIOL, V180, P298, DOI 10.1002/(SICI)1097-4652(199908)180:2<298::AID-JCP17>3.0.CO;2-V; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Prives C, 1999, J PATHOL, V187, P112; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Shyamala G, 1997, TRENDS ENDOCRIN MET, V8, P34, DOI 10.1016/S1043-2760(96)00207-X; Silberstein GB, 1996, CELL GROWTH DIFFER, V7, P945; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; TSUKADA T, 1993, ONCOGENE, V8, P3313; VISSCHER DW, 1993, J CELL BIOCHEM, P114; Wang CN, 1998, APPL ACOUST, V53, P35, DOI 10.1016/S0003-682X(97)00042-X; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	59	66	69	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2221	2229		10.1096/fj.00-0165com	http://dx.doi.org/10.1096/fj.00-0165com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053243				2022-12-25	WOS:000165190800015
J	Bouton, C; Demple, B				Bouton, C; Demple, B			Nitric oxide-inducible expression of heme oxygenase-1 in human cells - Translation-independent stabilization of the mRNA and evidence for direct action of nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; SMOOTH-MUSCLE CELLS; HAMSTER OVARY CELLS; MESSENGER-RNAS; TRANSFERRIN RECEPTOR; PROVIDES PROTECTION; OXIDATIVE STRESS; LUNG INJURY; RAT-BRAIN; INDUCTION	Expression of heme oxygenase-l (HO-1) in mammalian cells contributes to resistance to various types of free radical damage. Nitric oxide (NO) induces HO-1 in many cell types, but the specific contribution of transcriptional or post-transcriptional effects to this induction have remained unresolved. Here we show that the extent of HO-1 mRNA expression in IMR-90 and HeLa cells depends on the rate of NO delivery, and that the induction occurs more slowly in HeLa than in human fibroblast (IMR-90) cells. We used a specific NO scavenger (2-(4-carboxylphenyl)-4,4,5,5-tetramethylimidazolin-1 1-oxyl 3-oxide) that completely prevented the inducible expression of HO-1 by NO, pointing to direct signaling action of NO in this induction. By inhibiting transcription during the NO exposure, we have confirmed that NO treatment activates a mechanism that stabilizes HO-1 mRNA The increase in the HO-1 mRNA half-life in IMR-90 cells was directly correlated with increasing rates of NO release. We also show here that the stabilization of the HO-1 message does not require de novo protein synthesis. Collectively, these results show that stabilization of HO-1 mRNA can be finely tuned to the NO exposure, and that the effect in human fibroblasts is mediated by a pre-existing protein.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.		Bouton, Cecile/J-8663-2013		NCI NIH HHS [CA82737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; AGARWAL A, 1995, KIDNEY INT, V48, P1298, DOI 10.1038/ki.1995.414; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Bishop A, 1999, FREE RADICAL BIO MED, V26, P978, DOI 10.1016/S0891-5849(98)00284-6; Bouton C, 1999, CELL MOL LIFE SCI, V55, P1043, DOI 10.1007/s000180050355; CASEY JL, 1988, P NATL ACAD SCI USA, V85, P1787, DOI 10.1073/pnas.85.6.1787; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CRUSE I, 1988, J BIOL CHEM, V263, P3348; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Hara E, 1999, BIOCHEM PHARMACOL, V58, P227, DOI 10.1016/S0006-2952(99)00097-0; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Keefer LK, 1998, CHEMTECH, V28, P30; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; Kitamura Y, 1998, LIFE SCI, V62, P1717, DOI 10.1016/S0024-3205(98)00134-9; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Marquis JC, 1998, CANCER RES, V58, P3435; Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107, DOI 10.1152/ajpheart.1996.270.1.H107; MURPHY BJ, 1991, BRIT J CANCER, V64, P69, DOI 10.1038/bjc.1991.241; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Panahian N, 1999, J NEUROCHEM, V72, P1187; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; SAUNDERS EL, 1991, ARCH BIOCHEM BIOPHYS, V288, P368, DOI 10.1016/0003-9861(91)90208-Z; SHIBAHARA S, 1978, ARCH BIOCHEM BIOPHYS, V188, P243, DOI 10.1016/S0003-9861(78)80006-X; SRIVASTAVA KK, 1993, EUR J BIOCHEM, V213, P909, DOI 10.1111/j.1432-1033.1993.tb17835.x; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUN Y, 1990, J BIOL CHEM, V265, P8212; Takahashi K, 1997, J BIOCHEM-TOKYO, V121, P1162; Takahashi K, 1996, J NEUROCHEM, V67, P482; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; Visner GA, 1996, AM J PHYSIOL-LUNG C, V270, pL517, DOI 10.1152/ajplung.1996.270.4.L517; WILLIS D, 1995, BIOCHEM BIOPH RES CO, V214, P1152, DOI 10.1006/bbrc.1995.2406; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; YOSHIDA K, 1993, INFECT IMMUN, V61, P3552, DOI 10.1128/IAI.61.8.3552-3555.1993	49	121	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32688	32693		10.1074/jbc.275.42.32688	http://dx.doi.org/10.1074/jbc.275.42.32688			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	11032845	hybrid			2022-12-25	WOS:000090003800044
J	Ducret, C; Maira, SM; Lutz, Y; Wasylyk, B				Ducret, C; Maira, SM; Lutz, Y; Wasylyk, B			The ternary complex factor Net contains two distinct elements that mediate different responses to MAP kinase signalling cascades	ONCOGENE			English	Article						docking; phosphorylation; Ras; transcription; repression; export	ACTIVATED PROTEIN-KINASES; TRANSCRIPTION FACTOR PHO4; CYCLIN-CDK COMPLEX; C-JUN; TRANSDUCTION PATHWAY; SIGNALING SPECIFICITY; UV-LIGHT; HA-RAS; DOMAIN; JNK	The ternary complex factors (TCFs), Elk-1, Sap-1a and Net, are key integrators of the transcriptional response to different signalling pathways. Classically, three MAP kinase pathways, involving ERK, JNK, and p38, transduce various extracellular stimuli to the nucleus. Net is a repressor that is converted into an activator by Ras/ERK signalling. Net is also exported from the nucleus in response to stress stimuli transduced through the JNK pathway, leading to relief from repression. Here we show that ERK and p38 bind to the D box and that binding is required for phosphorylation of the adjacent C-terminally located C-domain, The D box as web as the phosphorylation sites in the C-domain (the DC element) are required for transcription activation by Pas. On the other hand, JNK binds to the J box in the middle of the protein, and binding is required for phosphorylation of the adjacent EXport motif. Both the binding and phosphorylation sites (the JEX element) are important for Net export. In conclusion, specific targeting of Net by MAP kinase pathways involves two different docking sites and phosphorylation of two different domains. These two elements, DC and JEX, mediate two distinct functional responses.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Ducret C, 1999, MOL CELL BIOL, V19, P7076; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Sprague GF, 1998, GENE DEV, V12, P2817, DOI 10.1101/gad.12.18.2817; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	46	49	51	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5063	5072		10.1038/sj.onc.1203892	http://dx.doi.org/10.1038/sj.onc.1203892			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042694				2022-12-25	WOS:000089930100003
J	Llovera, M; Pichard, C; Bernichtein, S; Jeay, S; Touraine, P; Kelly, PA; Goffin, V				Llovera, M; Pichard, C; Bernichtein, S; Jeay, S; Touraine, P; Kelly, PA; Goffin, V			Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation	ONCOGENE			English	Article						prolactin; prolactin receptor; breast cancer; antagonist; signaling; proliferation	GROWTH-HORMONE RECEPTOR; PROTEIN-KINASE-C; CARCINOMA CELLS; EXPRESSION; BINDING; GENE; INDUCTION; APOPTOSIS; FAMILY; STAT3	The involvement of human prolactin (hPRL) in breast cancer has been recently reconsidered based on its autocrine/paracrine proliferative effect described in human mammary tumor epithelial cells. Therefore, there is growing interest in the development of potent hPRL antagonists that may inhibit this effect. We previously designed hPRL analogs displaying antagonistic properties in a human transcriptional bioassay. We now report that the most potent of those analogs, G129R-hPRL, antagonizes all hPRL-induced effects analysed in various breast cancer cell lines, including cell proliferation. The analog per sc lacks intrinsic agonistic activity on PRL receptor-activated signaling cascades, cell proliferation and apoptosis, indicating that its mode of action only occurs through competitive inhibition of hPRL. We provide some molecular basis of this antagonistic effect by demonstrating that G129R-hPRL competitively inhibits hPRL-activation of the JAK-STAT and MAPK pathways, two signaling cascades involved in the mitogenic effect of hPRL in mammary epithelial cells. This competitive inhibition persists for at least 48 h, as evidenced by long term analysis of STAT5b activation or of progression through cell cycle. These results are the first demonstration at the molecular level that hPRL antagonists interfering with receptor dimerization disrupt signaling events in breast cancer cells, which prevents hPRL-induced cell proliferation.	Fac Med Necker Enfants Malad, INSERM, U344, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Goffin, V (corresponding author), Fac Med Necker Enfants Malad, INSERM, U344, 156 Rue Vaugirard, F-75730 Paris 15, France.		Llovera, Marta/AAE-4230-2021; Llovera, Marta/B-5585-2009; GOFFIN, Vincent/G-3322-2013; Kelly, Paul/A-7951-2008	Llovera, Marta/0000-0001-8399-6867; GOFFIN, Vincent/0000-0002-8021-3086; JEAY, SEBASTIEN/0000-0001-7476-3340				BANERJEE R, 1992, MOL CELL ENDOCRINOL, V90, P61, DOI 10.1016/0303-7207(92)90102-C; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; Chen WY, 1999, CLIN CANCER RES, V5, P3583; Clevenger CV, 1997, J MAMMARY GLAND BIOL, V2, P59, DOI 10.1023/A:1026325630359; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Das R, 1996, BREAST CANCER RES TR, V40, P141, DOI 10.1007/BF01806209; Das R, 1996, ONCOGENE, V13, P1139; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; Dickson C, 2000, ONCOGENE, V19, P1097, DOI 10.1038/sj.onc.1203267; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GINSBURG E, 1995, CANCER RES, V55, P2591; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; Goffin V, 1999, ENDOCRINOLOGY, V140, P3853, DOI 10.1210/en.140.8.3853; Goffin V, 1996, ENDOCR REV, V17, P385, DOI 10.1210/er.17.4.385; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; GORDON KE, 2000, BREAST CANCER RES, V2, P1; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kinet S, 1999, J BIOL CHEM, V274, P26033, DOI 10.1074/jbc.274.37.26033; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Llovera M, 2000, EXP GERONTOL, V35, P41, DOI 10.1016/S0531-5565(99)00078-9; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Saraste A, 1999, HERZ, V24, P189, DOI 10.1007/BF03044961; Schaber JD, 1998, CANCER RES, V58, P1914; ShawBruha CM, 1997, BREAST CANCER RES TR, V44, P243, DOI 10.1023/A:1005879103367; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Vonderhaar BK, 1998, PHARMACOL THERAPEUT, V79, P169, DOI 10.1016/S0163-7258(98)00017-5; WATERS SB, 1989, MOL CELL ENDOCRINOL, V63, P159, DOI 10.1016/0303-7207(89)90092-0; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0; Zhou JN, 1998, MOL CARCINOGEN, V21, P234, DOI 10.1002/(SICI)1098-2744(199804)21:4<234::AID-MC2>3.0.CO;2-K	54	85	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4695	4705		10.1038/sj.onc.1203846	http://dx.doi.org/10.1038/sj.onc.1203846			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032019				2022-12-25	WOS:000089528800003
J	Rusyn, EV; Reynolds, ER; Shao, HP; Grana, TM; Chan, TO; Andres, DA; Cox, AD				Rusyn, EV; Reynolds, ER; Shao, HP; Grana, TM; Chan, TO; Andres, DA; Cox, AD			Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways	ONCOGENE			English	Article						Rit; Ras; signaling; transformation; lipid modification; farnesyltransferase	GDP DISSOCIATION STIMULATOR; C-FOS PROMOTER; R-RAS; CELLULAR-TRANSFORMATION; FARNESYLTRANSFERASE INHIBITORS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; INDEPENDENT PATHWAYS; SIGNALING PATHWAYS; BIOLOGICAL ASSAYS	The biological functions of Rit (Ras-like protein in tissues) and Rin (Ras-like protein in neurons), members of a novel branch of Ras-related GTP-binding proteins that are similar to 50% identical to Ras, have not been characterized. Therefore, we assessed their activity in growth control, transformation and signaling. NM cells stably expressing a constitutively activated mutant of Rit [Rit(79L)] (analogous to the oncogenic mutant H-Ras(61L)) demonstrated strong growth transformation, proliferating rapidly in low serum and forming colonies in soft agar and tumors in nude mice. Although Rit(79L) alone did not promote morphologically transformed foci, it cooperated with both Raf and RhoA to form Rac/Rho-like foci, Rin [Rin(78L)] cooperated only with Raf, Rit(79L) but not Rin(78L) stimulated transcription from luciferase reporter constructs regulated by SRF, NF-kappa B, Elk-l and Jun. However, neither activated ERK, JNK or p38, or PI3-K/Akt kinases in immune complex kinase assays. Interestingly, although Rit lacks any known recognition signal for C-terminal lipidation, Rit-transformed cell growth and survival in low serum is dependent on a farnesylated protein, as treatment with farnesyltransferase inhibitors caused apoptosis, Rin cooperated with Raf in focus assays but did not otherwise function in these assays, perhaps due to a lack of appropriate effector pathways in NIH3T3 fibroblasts for this neural-specific Ras family member. In summary, although Rit shares most core effector domain residues with Ras, our results suggest that Rit uses novel effector pathways to regulate proliferation and transformation.	Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Kentucky; Jefferson University	Cox, AD (corresponding author), Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, CB 7512, Chapel Hill, NC 27599 USA.			Chan, Tung/0000-0001-6574-9555; Cox, Adrienne D./0000-0002-4901-2454	NCI NIH HHS [CA67771, CA70692] Funding Source: Medline; NEI NIH HHS [EY11231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY011231] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COX AD, 1994, METHOD ENZYMOL, V238, P277; COX AD, 1995, METHOD ENZYMOL, V255, P195; COX AD, 1994, ONCOGENE, V9, P3281; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; Du W, 1999, CANCER RES, V59, P4208; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIRODALISI JJ, 2000, IN PRESS METHODS ENZ, V332; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1997, CANCER RES, V57, P708; Lee CHJ, 1996, J NEUROSCI, V16, P6784; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Murai H, 1997, J BIOL CHEM, V272, P10483; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Osada M, 1999, MOL CELL BIOL, V19, P6333; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SAEZ R, 1994, ONCOGENE, V9, P2977; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YEN A, 1994, EUR J CELL BIOL, V65, P103; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	60	41	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4685	4694		10.1038/sj.onc.1203836	http://dx.doi.org/10.1038/sj.onc.1203836			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032018				2022-12-25	WOS:000089528800002
J	Affar, EB; Germain, M; Winstall, E; Vodenicharov, M; Shah, RG; Salvesen, GS; Poirier, GG				Affar, EB; Germain, M; Winstall, E; Vodenicharov, M; Shah, RG; Salvesen, GS; Poirier, GG			Caspase-3-mediated processing of poly(ADP-ribose) glycohydrolase during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LIVER; KINASE-C-DELTA; (ADP-RIBOSE)N GLYCOHYDROLASE; PROTEOLYTIC ACTIVATION; MAMMALIAN-CELLS; DNA-DAMAGE; IN-VIVO; POLYMERASE; CLEAVAGE; CASPASES	Poly(ADP-ribose) glycohydrolase (PARG) is responsible for the catabolism of poly(ADP-ribose) synthesized by poly(ADP-ribose) polymerase (PARP-1) and other PARP-1-like enzymes. In this work, we report that PARG is cleaved during etoposide-, staurosporine-, and Fas-induced apoptosis in human cells. This cleavage is concomitant with PARP-1 processing and generates two C-terminal fragments of 85 and 74 kDa. In vitro cleavage assays using apoptotic cell extracts showed that a protease of the caspase family is responsible for PARG processing. A complete inhibition of this cleavage was achieved at nanomolar concentrations of the caspase inhibitor acetyl-Asp-Glu-Val-Asp-aldehyde, suggesting the involvement of caspase-3-like proteases. Consistently, recombinant caspase-3 efficiently cleaved PARG in vitro, suggesting the involvement of this protease in PARG processing in vivo, Furthermore, caspase-3-deficient MCF-7 cells did not show any PARG cleavage in response to staurosporine treatment. The cleavage sites identified by site-directed mutagenesis are DEID256 down arrow V and the unconventional site MDVD307 down arrow N. Kinetic studies have shown similar maximal velocity (V-max) and affinity (K-m) for both full-length PARG and its apoptotic fragments, suggesting that caspase-3 may affect PARG function without altering its enzymatic activity. The early cleavage of both PARP-1 and PARG by caspases during apoptosis suggests an important function for poly(ADP-ribose) metabolism regulation during this cell death process.	Univ Laval, CHU Laval, Med Res Ctr, Hlth & Environm Unit, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada; Burnham Inst, La Jolla, CA 92037 USA	Laval University; Laval University; Sanford Burnham Prebys Medical Discovery Institute	Poirier, GG (corresponding author), CHU Laval, Ctr Rech, Unite Sante & Environm, 2705 Blvd Laurier,Local 9700, Quebec City, PQ G1V 4G2, Canada.	guy.poirier@crchul.ulaval.ca		Poirier, Guy/0000-0002-4869-1424; Vodenicharov, Momchil/0000-0002-5509-9891				Affar EB, 1998, ANAL BIOCHEM, V259, P280, DOI 10.1006/abio.1998.2664; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCHU G, 1994, ANAL BIOCHEM, V218, P265, DOI 10.1006/abio.1994.1177; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Duriez PJ, 1997, BBA-GEN SUBJECTS, V1334, P65, DOI 10.1016/S0304-4165(96)00077-3; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; HATAKEYAMA K, 1986, J BIOL CHEM, V261, P4902; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; JONSSON GG, 1988, CANCER RES, V48, P4240; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lin WS, 1997, J BIOL CHEM, V272, P11895, DOI 10.1074/jbc.272.18.11895; MALANGA M, 1994, J BIOL CHEM, V269, P17691; MARUTA H, 1991, BIOCHEMISTRY-US, V30, P5907, DOI 10.1021/bi00238a014; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Negri C, 1997, EXP CELL RES, V234, P174, DOI 10.1006/excr.1997.3591; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TANUMA S, 1990, EUR J BIOCHEM, V191, P57, DOI 10.1111/j.1432-1033.1990.tb19093.x; TANUMA SI, 1986, J BIOL CHEM, V261, P965; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMASSIN H, 1990, NUCLEIC ACIDS RES, V18, P4691, DOI 10.1093/nar/18.16.4691; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UCHIDA K, 1993, J BIOL CHEM, V268, P3194; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Winstall E, 1999, EXP CELL RES, V246, P395, DOI 10.1006/excr.1998.4321; Winstall E, 1999, EXP CELL RES, V251, P372, DOI 10.1006/excr.1999.4594; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	53	100	102	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2935	2942		10.1074/jbc.M007269200	http://dx.doi.org/10.1074/jbc.M007269200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053413	hybrid			2022-12-25	WOS:000166784800086
J	Miyakawa, Y; Rojnuckarin, P; Habib, T; Kaushansky, K				Miyakawa, Y; Rojnuckarin, P; Habib, T; Kaushansky, K			Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; C-MPL; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ERYTHROID-CELLS; KINASE-C; GROWTH; PHOSPHATASE; LIGAND; DIFFERENTIATION	Thrombopoietin (TPO) is a recently characterized member of the hematopoietic growth factor family that serves as the primary regulator of megakaryocyte (MK) and platelet production. The hormone acts by binding to the Mpl receptor, the product of the cellular proto-oncogene c-mpl, Although many downstream signaling targets of TPO have been identified in cell lines, primary MKs, and platelets, the molecular mechanism(s) by which many of these molecules are activated remains uncertain. In this report we demonstrate that the TPO-induced activation of phosphoinositol 3-kinase (PI3K), a signaling intermediate vital for cellular survival and proliferation, occurs through its association with inducible signaling complexes in both BaF3 cells engineered to express Mpl (BaF3/Mpl) and in primary murine MKs. Although a direct association between PI3K and Mpl could not be demonstrated, we found that several proteins, including SHP2, Gab2, and IRS2, undergo phosphorylation and association in BaF3/Mpl cells in response to TPO stimulation, complexes that recruit and enhance the enzymatic activity of PI3K. To verify the physiological relevance of the complex, SHP2-Gab2 association was disrupted by overexpressing a dominant negative SHP2 construct. TPO-induced Akt phosphorylation was significantly decreased in transfected cells suggesting an important role of SHP2 in the complex to enhance PI3K activity. In primary murine MKs, TPO also induced phosphorylation of SHP2, its association with p85 and enhanced PI3K activity, but in contrast to the results in cell lines, neither Gab2 nor IRS2 are phosphorylated in MKs. Instead, a 100-kDa tyrosine-phosphorylated protein (pp100) co-immunoprecipitated with the regulatory subunit of PI3K. These findings support a model where PI3K activity is dependent on its recruitment into TPO-induced multiphosphoprotein complexes, implicate the existence of a scaffolding protein in primary MKs distinct from the known Gab and IRS proteins, and suggest that, in contrast to erythroid progenitor cells that employ Gab1 in PI3K signaling complexes, utilization of an alternate member of the Gab/IRS family could be responsible for specificity in TPO signaling.	Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kaushansky, K (corresponding author), Univ Washington, Sch Med, Div Hematol, Box 357710,1959 NE Pacific St, Seattle, WA 98195 USA.	kkaushan@u.washington.edu						Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHOI ES, 1995, BLOOD, V85, P402; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DEBILI N, 1995, BLOOD, V86, P2516; DEL PL, 1997, SCIENCE, V278, P687; Dorsch M, 1999, BLOOD, V94, P2676, DOI 10.1182/blood.V94.8.2676.420k28_2676_2685; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Geddis AE, 1999, BLOOD, V94, p654A; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; Haseyama Y, 1999, BLOOD, V94, P1568, DOI 10.1182/blood.V94.5.1568.417a07_1568_1577; Hong Y, 1998, BLOOD, V91, P813, DOI 10.1182/blood.V91.3.813.813_813_822; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Ku H, 1996, BLOOD, V87, P4544, DOI 10.1182/blood.V87.11.4544.bloodjournal87114544; Kunitama M, 1997, BIOCHEM BIOPH RES CO, V231, P290, DOI 10.1006/bbrc.1996.5969; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Long Michael W., 1995, P274; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Ritchie A, 1999, ONCOGENE, V18, P1465, DOI 10.1038/sj.onc.1202439; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; ROINUCKARIN P, 2001, IN PRESS BLOOD; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Sattler M, 1997, J CELL PHYSIOL, V171, P28; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	56	98	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2494	2502		10.1074/jbc.M002633200	http://dx.doi.org/10.1074/jbc.M002633200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11054408	hybrid			2022-12-25	WOS:000166784800028
J	Fotiadis, D; Jeno, P; Mini, T; Wirtz, S; Muller, SA; Fraysse, L; Kjellbom, P; Engel, A				Fotiadis, D; Jeno, P; Mini, T; Wirtz, S; Muller, SA; Fraysse, L; Kjellbom, P; Engel, A			Structural characterization of two aquaporins isolated from native spinach leaf plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC PROTEIN MIP; WATER CHANNELS; MASS-SPECTROMETRY; XENOPUS-OOCYTES; RECONSTITUTION; IMAGES; FAMILY; CHIP; PHOSPHORYLATION; MICROSCOPY	Two members of the aquaporin family, PM28A and a new one, PM28C, were isolated and shown to be the major constituents of spinach leaf plasma membranes. These two isoforms were identified and characterized by matrix-assisted laser desorption ionization-mass spectrometry, Edman degradation yielded the amino acid sequence of two domains belonging to the new isoform. PM28B, a previously described isoform, was not found in our preparations. Scanning transmission electron microscopy mass analysis revealed both PM28 isoforms to be tetrameric, Two types of particles, a larger and a smaller one, were found by transmission electron microscopy of negatively stained solubilized proteins and by atomic force microscopy of PM28 two-dimensional crystals. The ratio of larger to smaller particles observed by transmission electron microscopy and single particle analysis correlated with the ratio of PM28A to PM28C determined by matrix-assisted laser desorption ionization-mass spectrometry, The absence of PM28B and the ratio of PM28A to PM28C indicate that these plasma membrane intrinsic proteins are differentially-expressed in spinach leaves. These findings suggest that differential expression of the various aquaporin isoforms may regulate the water flux across the plasma membrane, in addition to the known mechanism of regulation by phosphorylation.	Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland; Univ Basel, Biozentrum, Div Biochem, CH-4056 Basel, Switzerland; Lund Univ, Dept Plant Biochem, S-22100 Lund, Sweden	University of Basel; University of Basel; Lund University	Engel, A (corresponding author), Univ Basel, Biozentrum, ME Muller Inst Microscopy, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Andreas.Engel@unibas.ch						Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Braun T, 2000, EMBO REP, V1, P183, DOI 10.1093/embo-reports/kvd022; BRETAUDIERE JP, 1986, J MICROSC-OXFORD, V144, P1, DOI 10.1111/j.1365-2818.1986.tb04669.x; Chaumont F, 2000, PLANT PHYSIOL, V122, P1025, DOI 10.1104/pp.122.4.1025; DENKER BM, 1988, J BIOL CHEM, V263, P15634; Engel A, 2000, EMBO J, V19, P800, DOI 10.1093/emboj/19.5.800; Fotiadis D, 2000, J MOL BIOL, V300, P779, DOI 10.1006/jmbi.2000.3920; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; Ghaim JB, 1997, BBA-BIOMEMBRANES, V1330, P113, DOI 10.1016/S0005-2736(97)00127-2; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; Hasler L, 1998, J MOL BIOL, V279, P855, DOI 10.1006/jmbi.1998.1796; Heymann JB, 1999, NEWS PHYSIOL SCI, V14, P187; Heymann JB, 2000, J MOL BIOL, V295, P1039, DOI 10.1006/jmbi.1999.3413; Johansson I, 2000, BBA-BIOMEMBRANES, V1465, P324, DOI 10.1016/S0005-2736(00)00147-4; Johansson I, 1998, PLANT CELL, V10, P451, DOI 10.1105/tpc.10.3.451; Johansson I, 1996, PLANT CELL, V8, P1181, DOI 10.1105/tpc.8.7.1181; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KAMMERLOHER W, 1994, PLANT J, V6, P187, DOI 10.1046/j.1365-313X.1994.6020187.x; KISTLER J, 1994, J CELL BIOL, V126, P1047, DOI 10.1083/jcb.126.4.1047; KJELLBOM P, 1984, PHYSIOL PLANTARUM, V62, P501, DOI 10.1111/j.1399-3054.1984.tb02791.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; le Coutre J, 2000, BIOCHEMISTRY-US, V39, P4237, DOI 10.1021/bi000150m; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; Muller DJ, 1999, BIOPHYS J, V76, P1101, DOI 10.1016/S0006-3495(99)77275-9; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; Ringler P, 1999, J MOL BIOL, V291, P1181, DOI 10.1006/jmbi.1999.3031; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Santoni V, 2000, CURR OPIN PLANT BIOL, V3, P476, DOI 10.1016/S1369-5266(00)00116-3; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SCHABERT FA, 1994, BIOPHYS J, V67, P2394, DOI 10.1016/S0006-3495(94)80726-X; Scheuring S, 1999, EMBO J, V18, P4981, DOI 10.1093/emboj/18.18.4981; SCHEY KL, 1992, BIOPHYS J, V63, P1240, DOI 10.1016/S0006-3495(92)81699-5; SIDEL VW, 1957, J GEN PHYSIOL, V41, P243, DOI 10.1085/jgp.41.2.243; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; ThumanCommike PA, 1996, J STRUCT BIOL, V116, P41, DOI 10.1006/jsbi.1996.0008; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; VANHEEL M, 1984, ULTRAMICROSCOPY, V13, P165, DOI 10.1016/0304-3991(84)90066-4; WALZ T, 1994, EMBO J, V13, P2985, DOI 10.1002/j.1460-2075.1994.tb06597.x; Zhuang JP, 1999, J STRUCT BIOL, V125, P63, DOI 10.1006/jsbi.1998.4059	48	67	82	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1707	1714		10.1074/jbc.M009383200	http://dx.doi.org/10.1074/jbc.M009383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050104	hybrid			2022-12-25	WOS:000166528000009
J	Shi, XY; Potvin, B; Huang, TM; Hilgard, P; Spray, DC; Suadicani, SO; Wolkoff, AW; Stanley, P; Stockert, RJ				Shi, XY; Potvin, B; Huang, TM; Hilgard, P; Spray, DC; Suadicani, SO; Wolkoff, AW; Stanley, P; Stockert, RJ			A novel casein kinase 2 alpha-subunit regulates membrane protein traffic in the human hepatoma cell line HuH-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY-LIPOPROTEIN; TRANS-GOLGI NETWORK; ASIALOGLYCOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; GENE CSNK2A1; II ACTIVITY; PHOSPHORYLATION; EXPRESSION; MUTANT	A previously isolated endocytic trafficking mutant (TRF1) isolated from HuH-7 cells is defective in the distribution of subpopulations of cell-surface receptors for asialoorosomucoid (asialoglycoprotein receptor (ASGR)), transferrin, and mannose-terminating glycoproteins. The pleiotropic phenotype of TRF1 also includes an increased sensitivity to Pseudomonas toxin and deficient assembly and function of gap junctions. HuH-7xTRF1 hybrids exhibited a normal subcellular distribution of ASGR, consistent with the TRF1 mutation being recessive, A cDNA expression library derived from HuH-7 mRNA was transfected into TRF1 cells, which were subsequently selected for resistance to Pseudomonas toxin. Sequence analysis of a recovered cDNA revealed a unique isoform of casein kinase 2 (CK2), CK2 alpha ", Western blot analysis of TRF1 proteins revealed a 60% reduction in total CK2 alpha expression. Consistent with this finding, the hybrids HuH-7xHuH-7 and HuH-7xTRF1 expressed equivalent amounts of total CK2 alpha. Immunoblots using antibodies against peptides unique to the previously described CK2 isoforms CK2 alpha and CK2 alpha' and the novel CK2 alpha " isoform showed that, although TRF1 and parental HuH-7 cells expressed comparable amounts of CK2 alpha and CK2 alpha', the mutant did not express CK2 alpha " Eased on the genomic DNA sequence, RNA transcripts encoding CK2 alpha " apparently originate from alternative splicing of a primary transcript. Protein overexpression following transfection of TRF1 cells with cDNAs encoding either CK2 alpha or the newly cloned CK2 alpha " restored the parental HuH-7 phenotype, including Pseudomonas toxin resistance, cell-surface ASGR binding activity, phosphorylation, and the assembly of gap junctions. This study suggests that HuH-7 cells express at least three CK2 alpha isoforms and that the pleiotropic TRF1 phenotype is a consequence of a reduction in total CK2 expression.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Univ Sao Judas Tadeu, BR-03166000 Sao Paulo, Brazil	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Universidade Sao Judas Tadeu	Stockert, RJ (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Ullmann 517,1300 Morris Pk Ave, Bronx, NY 10461 USA.			Stanley, Pamela/0000-0001-5704-3747; Spray, David/0000-0001-8368-5073	NIDDK NIH HHS [DK-32972, DK-41918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041918, R01DK032972] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; Brosius J, 1999, GENE, V238, P115, DOI 10.1016/S0378-1119(99)00227-9; BUCCI M, 1994, SOMAT CELL MOLEC GEN, V20, P47, DOI 10.1007/BF02257485; Cotlin LF, 1999, J BIOL CHEM, V274, P30550, DOI 10.1074/jbc.274.43.30550; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; HAYNES PA, 1994, J BIOL CHEM, V269, P33152; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KRIEGER M, 1983, P NATL ACAD SCI-BIOL, V80, P5607, DOI 10.1073/pnas.80.18.5607; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; MALMSTROM K, 1991, J BIOL CHEM, V266, P24025; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; MELLMAN I, 1996, ANNU REV CELL DEV BI, V12, P675; Mighell AJ, 2000, FEBS LETT, V468, P109, DOI 10.1016/S0014-5793(00)01199-6; MOSTOV KE, 1995, HISTOL HISTOPATHOL, V10, P423; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; Penner CG, 1997, J CELL BIOCHEM, V64, P525; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; STOCKERT RJ, 1995, J BIOL CHEM, V270, P16107, DOI 10.1074/jbc.270.27.16107; Stockert RJ, 1999, HEPATOLOGY, V30, P740, DOI 10.1002/hep.510300304; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Weigel P H, 1993, Subcell Biochem, V19, P125; Weigel PH, 1998, BIOCHEM BIOPH RES CO, V246, P563, DOI 10.1006/bbrc.1998.8491; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; Wirkner U, 1999, MOL CELL BIOCHEM, V191, P59, DOI 10.1023/A:1006848814894; Wirkner U, 1998, GENOMICS, V48, P71, DOI 10.1006/geno.1997.5136; WIRKNER U, 1994, GENOMICS, V19, P257, DOI 10.1006/geno.1994.1056; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; YANGFENG TL, 1994, GENOMICS, V19, P173, DOI 10.1006/geno.1994.1032; Yin XY, 2000, J BIOL CHEM, V275, P6850, DOI 10.1074/jbc.275.10.6850	36	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2075	2082		10.1074/jbc.M008583200	http://dx.doi.org/10.1074/jbc.M008583200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038365	hybrid			2022-12-25	WOS:000166528000059
J	Xia, ZP; Zhou, Q; Lin, JL; Liu, YC				Xia, ZP; Zhou, Q; Lin, JL; Liu, YC			Stable SNARE complex prior to evoked synaptic vesicle fusion revealed by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; T-SNARE; SNAP-25; SYNTAXIN; PROTEIN; CORE; SYNAPTOTAGMIN; EXOCYTOSIS; DOMAIN; CA2+	Although it is clear that soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor (SNARE) complex plays an essential role in synaptic vesicle fusion, the dynamics of SNARE assembly during vesicle fusion remain to be determined. In this report, we employ fluorescence resonance energy transfer technique to study the formation of SNARE complexes. Donor/acceptor pair variants of green fluorescent protein (GFP), cyan fluorescent protein (CFP), and yellow fluorescent protein (YFP) are fused with the N termini of SNAP-25 and synaptobrevin, respectively. lit vitro assembly of SNARE core complex in the presence of syntaxin shows strong fluorescence resonance energy transfer (FRET) between the CFP-SNAP-25 and YFP-synaptobrevin. Under the same conditions, CFP fused to the C terminus of SNAP-25, and YFP- synaptobrevin have no FRET, Adenovirus-mediated gene transfer is used to express the fusion proteins in PC12 cells and cultured rat cerebellar granule cells. Strong FRET is associated with neurite membranes and vesicular structures in PC12 cells co expressing CFP-SNAP-25 and YFP-synaptobrevin, In cultured rat cerebellar granule cells, FRET between CFP-SNAP-25 and YFP-synaptobrevin is mostly associated with sites presumed to be synaptic junctions, Neurosecretion in PC12 cells initiated by KCl depolarization leads to an increase in the extent of FRET. These results demonstrate that significant amounts of stable SNARE complex exist prior to evoked synaptic vesicle fusion and that the assembly of SNARE complex occurs during vesicle docking/priming stage. Moreover, it demonstrates that FRET can be used as an effective tool for investigating dynamic SNARE interactions during synaptic vesicle fusion.	Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Liu, YC (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, POB 26901, Oklahoma City, OK 73190 USA.				NINDS NIH HHS [NS35167] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035167] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hua SY, 1999, NAT NEUROSCI, V2, P1078, DOI 10.1038/16005; Jacob JM, 2000, J NEUROSCI RES, V61, P61, DOI 10.1002/1097-4547(20000701)61:1<61::AID-JNR7>3.0.CO;2-S; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Lane SR, 1997, J NEUROCHEM, V69, P1864; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; MARINI AM, 1992, P NATL ACAD SCI USA, V89, P6555, DOI 10.1073/pnas.89.14.6555; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Sanders JD, 1998, J NEUROSCI RES, V53, P670, DOI 10.1002/(SICI)1097-4547(19980915)53:6<670::AID-JNR5>3.3.CO;2-H; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Yang YZ, 2000, J BIOL CHEM, V275, P29482, DOI 10.1074/jbc.M003237200; Zhou Q, 2000, J NEUROSCI RES, V61, P321, DOI 10.1002/1097-4547(20000801)61:3<321::AID-JNR10>3.0.CO;2-L	38	46	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1766	1771		10.1074/jbc.M008741200	http://dx.doi.org/10.1074/jbc.M008741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035043	hybrid			2022-12-25	WOS:000166528000017
J	Dans, M; Gagnoux-Palacios, L; Blaikie, P; Klein, S; Mariotti, A; Giancotti, FG				Dans, M; Gagnoux-Palacios, L; Blaikie, P; Klein, S; Mariotti, A; Giancotti, FG			Tyrosine phosphorylation of the beta(4) integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE INTERACTION DOMAIN; BULLOUS PEMPHIGOID ANTIGEN-180; GROWTH-FACTOR RECEPTOR; ALPHA(6)BETA(4) INTEGRIN; ADAPTER PROTEIN; CARCINOMA-CELLS; SUBUNIT; TRANSDUCTION; ADHESION; BINDING	Ligation of the alpha (6)beta (4) integrin induces tyrosine phosphorylation of the beta (4) cytoplasmic domain, followed by recruitment of the adaptor protein She and activation of mitogen-activated protein kinase cascades. We have used Far Western analysis and phosphopeptide competition assays to map the sites in the cytoplasmic domain of a, that are required for interaction with She. Our results indicate that, upon phosphorylation, Tyr(1440), or secondarily Tyr(1422), interacts with the SH2 domain of She, whereas Tyr(1526), Or secondarily Tyr(1642), interacts with its phosphotyrosine binding (PTB) domain. An inactivating mutation in the PTB domain of She, but not one in its SM2 domain, suppresses the activation of She by alpha (6)beta (4) In addition, mutation of beta (4) Tyr(1526) which binds to the PTB domain of She, but not of Tyr(1422) and Tyr(1440) which interact with its SH2 domain, abolishes the activation of ERK by alpha (6)beta (4). Phenylalanine substitution of the beta (4) tyrosines able to interact with the SH2 or PTB domain of She does not affect incorporation of alpha (6)beta (4) in the hemidesmosomes of 804G cells. Exposure to the tyrosine phosphatase inhibitor orthovanadate increases tyrosine phosphorylation of beta (4) and disrupts the hemidesmosomes of 804G cells expressing recombinant wild type beta (4). This treatment, however, exerts a decreasing degree of inhibition on the hemidesmosomes of cells expressing versions of beta (4) containing phenylalanine substitutions at Tyr(1422) and Tyr(1440), at Tyr(1526) and Tyr(1642), or at all four tyrosine phosphorylation sites. These results suggest that beta (4) Tyr(1526) interacts in a phosphorylation-dependent manner with the PTB domain of She. This event is required for subsequent tyrosine phosphorylation of She and signaling to ERK but not formation of hemidesmosomes.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Giancotti, FG (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, Box 216,1275 York Ave, New York, NY 10021 USA.		Gagnoux, Laurent/O-9990-2016; Gagnoux, Laurent/O-9954-2016	Mariotti, Agnese/0000-0002-3704-7908	NATIONAL CANCER INSTITUTE [R01CA058976, F32CA079516, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58976, F32-CA79516, P30-CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; Borradori L, 1997, J CELL BIOL, V136, P1333, DOI 10.1083/jcb.136.6.1333; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Giancotti FG, 1996, J CELL SCI, V109, P1165; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUYRE RG, 1997, J BIOL CHEM, V272, P843; IZUMI K, 1981, CANCER RES, V41, P405; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LI NX, 1994, ONCOGENE, V9, P3457; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Niessen CM, 1997, J CELL SCI, V110, P1705; Nievers MG, 1998, J CELL SCI, V111, P1659; PELICCI G, 1995, ONCOGENE, V10, P1631; Pulkkinen L, 1999, MATRIX BIOL, V18, P29, DOI 10.1016/S0945-053X(98)00005-5; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; RIDDELLE KS, 1992, J CELL SCI, V103, P475; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	42	110	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1494	1502		10.1074/jbc.M008663200	http://dx.doi.org/10.1074/jbc.M008663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11044453	hybrid			2022-12-25	WOS:000166430900085
J	Okun, VM; Moser, R; Ronacher, B; Kenndler, E; Blaas, D				Okun, VM; Moser, R; Ronacher, B; Kenndler, E; Blaas, D			VLDL receptor fragments of different lengths bind to human rhinovirus HRV2 with different stoichiometry - An analysis of virus-receptor complexes by capillary electrophoresis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; COMMON COLD VIRUS; NEUTRALIZING ANTIBODY; ZONE-ELECTROPHORESIS; HELA-CELLS; DOMAINS; PROTEIN; ICAM-1; IDENTIFICATION; SEROTYPE-2	The formation of complexes between the minor receptor group human rhinovirus HRV2 and two recombinant soluble receptor fragments derived from the human very low density lipoprotein receptor (VLDLR) and containing ligand-binding repeats 1-3 (MBP.VLDLR1-3) or 1-8 (MBP.VLDLR1-8) fused to the carboxyl terminus of the maltose binding protein was analyzed by affinity capillary electrophoresis. At low molar ratios of receptor/virus, the peaks corresponding to substoichiometric complexes were broad indicating heterogeneity. When the receptors were present in molar excess with respect to the virus, the peaks were sharp, suggesting saturation of all binding sites. For the determination of the stoichiometry, constant amounts of receptor were incubated with increasing amounts of virus, and the peak areas corresponding to free receptor were measured and plotted versus total virus concentration. Extrapolation of the linear part of the resulting curve to zero concentration of free receptor enabled quantitation of the molar ratios of the components present in the complex. Using this method, we determined that about 60 molecules of MBP.VLDLR1-3 but only about 30 molecules of MBP.VLDLR1-8 were bound per virion.	Univ Vienna, Vienna Bioctr, Inst Med Biochem, A-1030 Vienna, Austria; Univ Vienna, Inst Analyt Chem, A-1090 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); University of Vienna	Blaas, D (corresponding author), Univ Vienna, Vienna Bioctr, Inst Med Biochem, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.							Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; Casasnovas Jose M., 1994, Methods (Orlando), V6, P157, DOI 10.1006/meth.1994.1018; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; COUCH RB, 1996, FIELDS VIROLOGY, V1, P713; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GRUENBERGER M, 1995, J VIROL, V69, P7244, DOI 10.1128/JVI.69.11.7244-7247.1995; Hewat EA, 1996, EMBO J, V15, P1515, DOI 10.1002/j.1460-2075.1996.tb00495.x; HEWET EA, 2000, EMBO J, V19, P1; HOFER F, 1992, J GEN VIROL, V73, P627, DOI 10.1099/0022-1317-73-3-627; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Jeon H, 2000, J BIOL CHEM, V275, P30465, DOI 10.1074/jbc.M002582200; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; Kurniawan ND, 2000, PROTEIN SCI, V9, P1282, DOI 10.1110/ps.9.7.1282; Marlovits TC, 1998, J BIOL CHEM, V273, P33835, DOI 10.1074/jbc.273.50.33835; Marlovits TC, 1998, FASEB J, V12, P695, DOI 10.1096/fasebj.12.9.695; Marlovits TC, 1998, J VIROL, V72, P10246, DOI 10.1128/JVI.72.12.10246-10250.1998; Mikhailenko I, 1999, J CELL SCI, V112, P3269; Okun VM, 2000, ANAL CHEM, V72, P4634, DOI 10.1021/ac000250y; Okun VM, 1999, ANAL CHEM, V71, P4480, DOI 10.1021/ac990503r; Okun VM, 1999, ANAL CHEM, V71, P2028, DOI 10.1021/ac981324x; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; RONACHER B, 2000, IN PRESS VIROLOGY; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; Rueckert RR., 1976, COMPREHENSIVE VIROLO, V6, P131; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SKERN T, 1984, VIROLOGY, V136, P125, DOI 10.1016/0042-6822(84)90253-8; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Thouvenin E, 1997, J MOL BIOL, V270, P238, DOI 10.1006/jmbi.1997.1095; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; Tormo J, 1995, PROTEINS, V23, P491, DOI 10.1002/prot.340230404; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V	36	34	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1057	1062		10.1074/jbc.M008039200	http://dx.doi.org/10.1074/jbc.M008039200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11054420	hybrid			2022-12-25	WOS:000166430900028
J	Bertin, J; Guo, Y; Wang, L; Srinivasula, SM; Jacobson, MD; Poyet, JL; Merriam, S; Du, MQ; Dyer, MJS; Robison, KE; DiStefano, PS; Alnemri, ES				Bertin, J; Guo, Y; Wang, L; Srinivasula, SM; Jacobson, MD; Poyet, JL; Merriam, S; Du, MQ; Dyer, MJS; Robison, KE; DiStefano, PS; Alnemri, ES			CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED COILS; RECEPTOR; PATHWAY; GENE; RIP	BCL10/CLAP is an activator of apoptosis and NF-kappaB signaling pathways and has been implicated in B cell lymphomas of mucosa-associated lymphoid tissue. Although its role in apoptosis remains to be determined, BCL10 likely activates NF-kappaB through the IKK complex in response to upstream stimuli. The N-terminal caspase recruitment domain (CARD) of BCL10 has been proposed to function as an activation domain that mediates hemophilic interactions with an upstream CARD-containing NF-kappaB activator. To identify upstream signaling partners of BCL10, we performed a mammalian two-hybrid analysis and identified CARDS as a novel CARD-containing protein that interacts selectively with the CARD activation domain of BCL10. When expressed in cells, CARDS binds to BCL10 and activates NF-kappaB. Furthermore, endogenous CARDS is found associated with BCL10 suggesting that both proteins form a pre-existing signaling complex within cells. CARDS also self-associates and contains extensive coiled-coil motifs that may function as oligomerization domains. We propose here that CARDS is an upstream activator of BCL10 and NF-kappaB signaling.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; Thomas Jefferson Univ, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; UCL Royal Free & Univ Coll Med Sch, Dept Histopathol, London, England; Inst Canc Res, Acad Dept Haematol & Cytogenet, Sutton, Surrey, England	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Jefferson University; Jefferson University; University of London; University College London; UCL Medical School; University of London; Institute of Cancer Research - UK	Bertin, J (corresponding author), Millennium Pharmaceut Inc, 640 Memorial Dr, Cambridge, MA 02139 USA.	bertin@mpi.com; E_Alnemri@lac.jci.tju.edu	Alnemri, Emad S/B-4526-2010; Poyet, Jean-Luc/G-7114-2017; Dyer, Martin/F-2691-2014	Poyet, Jean-Luc/0000-0002-3747-255X; Dyer, Martin/0000-0002-5033-2236; Du, Ming-Qing/0000-0002-1017-5045	NATIONAL CANCER INSTITUTE [R01CA085421] Funding Source: NIH RePORTER; NCI NIH HHS [CA85421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad M, 1997, CANCER RES, V57, P615; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Pawson T, 2000, GENE DEV, V14, P1027; POYET JL, 2000, IN PRESS J BIOL CHEM; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Ye HT, 2000, AM J PATHOL, V157, P1147, DOI 10.1016/S0002-9440(10)64630-5; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	21	181	199	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41082	41086		10.1074/jbc.C000726200	http://dx.doi.org/10.1074/jbc.C000726200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11053425	hybrid			2022-12-25	WOS:000166114600057
J	Campbell, MJ; Gombart, AF; Kwok, SH; Park, S; Koeffler, HP				Campbell, MJ; Gombart, AF; Kwok, SH; Park, S; Koeffler, HP			The anti-proliferative effects of 1 alpha,25(OH)(2)D-3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression	ONCOGENE			English	Article						BRCA1; 1 alpha,25(OH)(2)D-3; vitamin D-3 receptor; antisense; gene expression	VITAMIN-D-RECEPTOR; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; CLONAL PROLIFERATION; GROWTH-RETARDATION; POTENT INHIBITORS; ANDROGEN RECEPTOR; OVARIAN-CANCER; DIFFERENTIATION; LINES	The anti-proliferative action of the seco-steroid hormone 1 alpha,25-dihydroxyvitamin D-3 [1 alpha,25(OH)(2)D-3] extends to some, but not all breast and prostate cancer cell lines. By elucidating the molecular mechanisms mediating the sensitivity of these cells, we can identify critical target genes regulated directly or indirectly by 1 alpha,25(OH)(2)D-3 and pathways potentially disrupted during transformation. In this study, we demonstrated the induction of expression of BRCA1 mRNA and protein as well as transcriptional activation from the BRCA1-promoter by 1 alpha,25(OH)(2)D-3 in the sensitive breast cancer cell line MCF-7, This was not observed in the 1 alpha,25(OH)(2)D-3-resistant breast cancer cell Line MDA-MB-436. The induction of BRCA1 mRNA was blocked by cyclohexamide, This indicated that transcriptional activation was mediated indirectly by the vitamin D receptor (VDR). Inhibition of VDR protein levels by stable transformation of the anti-sense VDR in MCF-7 reduced the sensitivity of MCF-7 to 1 alpha,25(OH)(2)D-3 by 50-fold. In addition, the induction of BRCA1 protein and transcriptional activation of a BRCA1 promoter-luciferase reporter construct was abrogated in the stable transformant with the greatest reduction of VDR levels. Examination of other breast and prostate cancer cell lines revealed that sensitivity to the anti-proliferative effects of 1 alpha,25(OH)(2)D-3 was strongly associated with an ability to modulate BRCA1 protein. Furthermore, the expression of the estrogen receptor in these cell lines strongly correlated with their sensitivity to 1 alpha,25(OH)(2)D-3 and their ability to modulate BRCA1 expression. Taken together, our data support a model whereby the anti-proliferative effects of 1 alpha,25(OH)(2)D-3 are mediated, in part, by the induction of BRCA1 gene expression via transcriptional activation by factors induced by the VDR and that this pathway is disrupted during the development of prostate and breast cancers.	Univ Birmingham, Queen Elizabeth Hosp, Clin Res Inst, Div Med Sci,Dept Med, Birmingham B15 2TH, W Midlands, England; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA	University of Birmingham; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Campbell, MJ (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Clin Res Inst, Div Med Sci,Dept Med, Birmingham B15 2TH, W Midlands, England.		Campbell, Moray J/A-1311-2013; Campbell, Moray/ABF-1264-2021	Campbell, Moray/0000-0002-3355-0928				ARASON A, 1993, AM J HUM GENET, V52, P711; Asou H, 1998, BLOOD, V92, P2441, DOI 10.1182/blood.V92.7.2441.2441_2441_2449; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Campbell MJ, 1997, J CELL BIOCHEM, V66, P413, DOI 10.1002/(SICI)1097-4644(19970901)66:3<413::AID-JCB13>3.3.CO;2-0; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CARRUBA G, 1994, CANCER RES, V54, P1190; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; Deng HW, 1998, HUM GENET, V103, P576, DOI 10.1007/s004390050872; ELSTNER E, 1995, CANCER RES, V55, P2822; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fasco MJ, 1998, MOL CELL ENDOCRINOL, V138, P51, DOI 10.1016/S0303-7207(98)00048-3; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GAO X, 1995, CANCER RES, V55, P1002; Gennari L, 1998, J CLIN ENDOCR METAB, V83, P939, DOI 10.1210/jc.83.3.939; Gombart AF, 1997, LEUKEMIA, V11, P1673, DOI 10.1038/sj.leu.2400840; GUDAS JM, 1995, CANCER RES, V55, P4561; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Ingles SA, 1997, J NATL CANCER I, V89, P166, DOI 10.1093/jnci/89.2.166; ISSACS WB, 1994, COLD SPRING HARB SYM, V59, P653; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Langston AA, 1996, AM J HUM GENET, V58, P881; Leygue E, 1999, CANCER RES, V59, P1175; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lundin AC, 1999, CANCER RES, V59, P2332; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER GJ, 1992, CANCER RES, V52, P515; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; MURAKAMI YS, 1995, CANCER RES, V55, P3389; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Suarez F, 1998, J CLIN ENDOCR METAB, V83, P3563, DOI 10.1210/jcem.83.10.5199; Tamimi Y, 1996, BRIT J CANCER, V74, P120, DOI 10.1038/bjc.1996.325; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; VILJOEN TC, 1995, PROSTATE, V27, P160, DOI 10.1002/pros.2990270307; Vladusic EA, 1998, CANCER RES, V58, P210; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; ZHANG SH, 1997, MOL CELL ENDOCRINOL, V126, P83	48	89	90	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5091	5097		10.1038/sj.onc.1203888	http://dx.doi.org/10.1038/sj.onc.1203888			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042697				2022-12-25	WOS:000089930100006
J	Canhoto, AJ; Chestukhin, A; Litovchick, L; DeCaprio, JA				Canhoto, AJ; Chestukhin, A; Litovchick, L; DeCaprio, JA			Phosphorylation of the retinoblastoma-related protein p130 in growth-arrested cells	ONCOGENE			English	Article						p130; G0; growth arrest; pRb	LARGE-T-ANTIGEN; PHOSPHOAMINO ACID ANALYSIS; LAYER CELLULOSE PLATES; PRB-RELATED PROTEINS; GENE-PRODUCT; SUSCEPTIBILITY GENE; TRANSCRIPTIONAL REPRESSOR; FUNCTIONAL INACTIVATION; TUMOR-SUPPRESSOR; FAMILY PROTEINS	The retinoblastoma family of proteins including pRB, p107 and p130 undergoes cell cycle dependent phosphorylation during the mid-G1 to S phase transition. This phosphorylation is dependent upon the activity of cyclin D/cdk4. In contrast to pRB and p107, p130 is phosphorylated during G0 and the early GT phase of the cell cycle, We observed that p130 is specifically phosphorylated on serine and threonine residues in T98G cells arrested in G0 by serum deprivation or density arrest. Identification of the phospho-serine and phosphothreonine residues revealed that most were clustered within a short co-linear region unique to p130, defined as the Loop, Deletion of the Loop region resulted in a change in the phosphorylation status of p130 under growth arrest conditions. Notably, deletion of the Loop did not affect the ability of p130 to bind to E2F-4 or SV40 Large T antigen, to induce growth arrest in Saos-2 cells, and to become hyperphosphorylated during the proliferative phase of the cell cycle. p130 undergoes specific G0 phosphorylation in a manner that distinguishes it from pRB and p107.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	DeCaprio, JA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Mayer 457,44 Binney St, Boston, MA 02115 USA.			Litovchick, Larisa/0000-0002-9540-597X	NATIONAL CANCER INSTITUTE [R01CA063113, T32CA009031, T32CA009361] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09031, R01-CA63113, 2T32CA09361] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; Cinti C, 2000, CANCER RES, V60, P383; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hansen K, 1999, ELECTROPHORESIS, V20, P372, DOI 10.1002/(SICI)1522-2683(19990201)20:2<372::AID-ELPS372>3.0.CO;2-R; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HERZINGER T, 1995, ONCOGENE, V10, P2079; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Moberg K, 1996, MOL CELL BIOL, V16, P1436; POLLACK IF, 1990, J NEUROSURG, V73, P106, DOI 10.3171/jns.1990.73.1.0106; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Starborg M, 1996, J CELL SCI, V109, P143; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WOLF DA, 1995, ONCOGENE, V10, P2067; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	61	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5116	5122		10.1038/sj.onc.1203893	http://dx.doi.org/10.1038/sj.onc.1203893			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042701				2022-12-25	WOS:000089930100010
J	Pereira, R; Raingeaud, J; Pironin, M; Ghysdael, J; Quang, CT				Pereira, R; Raingeaud, J; Pironin, M; Ghysdael, J; Quang, CT			SPI-1 transforming properties depend upon specifically activated forms of the EPOR	ONCOGENE			English	Article						friend erythroleukemia; SPI-1/PU.1; SFFV GP55; erythropoietin receptor; oncogene cooperation	ERYTHROID PROGENITOR CELLS; PU.1 TRANSCRIPTION FACTOR; ERYTHROPOIETIN RECEPTOR; PRIMARY ERYTHROBLASTS; DIFFERENTIATION; PROLIFERATION; ERYTHROLEUKEMIA; PHOSPHORYLATION; EXPRESSION; KINASE	Friend erythroleukemia induced in mice by the spleen focus forming virus (SFFV) is a multi-step process, The pre-leukemic phase of the disease results from the abnormal activation of the Erythropoietin (Epo) receptor by the gp55 env gene product of SFFV, Later in disease progression, the emergence of leukemic clones is associated with recurrent genetic events, in particular the activation of the expression of SPI-1, an ETS family transcriptional regulator. We show here that the expression of either SPI-1 or GP55 with the mouse EPOR in arian primary erythroblasts only marginally affects their normal Epo-induced terminal differentiation. In contrast, the co-expression of GP55 and SPI-1 resulted in inhibition of Epo-induced differentiation of EPOR-expressing erythroblasts, promoting instead their proliferation. Co-expression of SPI-1 and GP55 also inhibited the apoptotic cell. death program normally induced in response to Epo withdrawal. This cooperation between SPI-1 and GP55 to induce primary erythroblast transformation suggests that progression of Friend erythroleukemia critically depends upon inter-dependent interactions between the molecular events specific of the early and late phase of the disease.	Ctr Univ Orsay, Inst Curie, CNRS, UMR146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Ghysdael, J (corresponding author), Ctr Univ Orsay, Inst Curie, CNRS, UMR146, Bat 110, F-91405 Orsay, France.		GHYSDAEL, Jacques/F-3377-2013; QUANG, christine TRAN/G-7508-2016					Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Constantinescu SN, 1998, BLOOD, V91, P1163, DOI 10.1182/blood.V91.4.1163; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; HANKINS WD, 1980, CELL, V22, P693; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Muszynski KW, 1998, J VIROL, V72, P919, DOI 10.1128/JVI.72.2.919-925.1998; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; Tamir A, 1999, MOL CELL BIOL, V19, P4452; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	23	6	6	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5106	5110		10.1038/sj.onc.1203886	http://dx.doi.org/10.1038/sj.onc.1203886			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042699				2022-12-25	WOS:000089930100008
J	Rangan, A; Fedoroff, OY; Hurley, LH				Rangan, A; Fedoroff, OY; Hurley, LH			Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEASE-HYPERSENSITIVE ELEMENT; UNUSUAL DNA STRUCTURES; TELOMERIC DNA; GENE; TRANSCRIPTION; BINDING; INHIBITION; CHROMATIN; RIBONUCLEOPROTEIN; REGULATORS	A major control element of the human c-myc oncogene is the nuclease-hypersensitive purine/pyrimidine-rich sequence. This double-stranded DNA fragment, corresponding to the 27-base pair segment in the nuclease-hypersensitive element of the c-myc promoter region, forms a stable Watson-Crick double helix under physiological conditions. However, this duplex DNA can be effectively converted to G-quadruplex DNA by a small molecular weight ligand. Both intermolecular and intramolecular G-quadruplex forms can be induced by this ligand. Similar transitional changes are also observed with the duplex telomeric sequence from the Oxytricha species. These results provide additional support to the idea that G-quadruplex structures may play structural roles in vivo and also provide insight into novel methodologies for rational drug design. These structurally altered DNA elements might serve as regulatory signals in gene expression or in telomere dynamics and hence are promising targets for drug action.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA; Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Texas System; University of Texas Austin	Hurley, LH (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.		Fedorov, Oleg Y./B-6412-2014	Fedorov, Oleg Y./0000-0001-9004-1815; Rangan, Anupama/0000-0001-7462-8309	NATIONAL CANCER INSTITUTE [R01CA049751, R35CA049751] Funding Source: NIH RePORTER; NCI NIH HHS [CA49751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERBERICH SJ, 1995, ONCOGENE, V10, P2343; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BOUFFLER S, 1993, BIOESSAYS, V15, P409, DOI 10.1002/bies.950150607; BRAHMACHARI SK, 1995, ELECTROPHORESIS, V16, P1705, DOI 10.1002/elps.11501601283; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chan PP, 1997, J MOL MED, V75, P267, DOI 10.1007/s001090050112; Chen Q, 1996, P NATL ACAD SCI USA, V93, P2635, DOI 10.1073/pnas.93.7.2635; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; Fedoroff OY, 2000, BIOCHEMISTRY-US, V39, P15083, DOI 10.1021/bi001528j; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; Giovannangeli C, 1997, ANTISENSE NUCLEIC A, V7, P413, DOI 10.1089/oli.1.1997.7.413; Han FXG, 1999, J AM CHEM SOC, V121, P3561, DOI 10.1021/ja984153m; Han HY, 1999, BIOCHEMISTRY-US, V38, P6981, DOI 10.1021/bi9905922; Han HY, 2000, BIOCHEMISTRY-US, V39, P9311, DOI 10.1021/bi000482r; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HORWITZ MSZ, 1989, NUCLEIC ACIDS RES, V17, P5537, DOI 10.1093/nar/17.14.5537; KINNIBURGH AJ, 1994, GENE, V149, P93, DOI 10.1016/0378-1119(94)90416-2; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; Simonsson T, 2000, BIOCHEM BIOPH RES CO, V278, P158, DOI 10.1006/bbrc.2000.3783; Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167; Spiro C, 1997, J BIOL CHEM, V272, P33145, DOI 10.1074/jbc.272.52.33145; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WELLS RD, 1988, J BIOL CHEM, V263, P1095; Wemmer DE, 1997, CURR OPIN STRUC BIOL, V7, P355, DOI 10.1016/S0959-440X(97)80051-6; YANIV M, 1986, CRIT REV BIOCHEM MOL, V21, P1, DOI 10.3109/10409238609113607	34	180	185	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4640	4646		10.1074/jbc.M005962200	http://dx.doi.org/10.1074/jbc.M005962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11035006	hybrid			2022-12-25	WOS:000168484300017
J	Berger, M; Sionov, RV; Levine, AJ; Haupt, Y				Berger, M; Sionov, RV; Levine, AJ; Haupt, Y			A role for the polyproline domain of p53 in its regulation by Mdm2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; FUNCTIONAL DOMAIN; CELLULAR-RESPONSE; APOPTOSIS; GROWTH; ARREST; TARGET; TRANSACTIVATION; IDENTIFICATION; MUTATIONS	The p53 protein plays a key role in the cellular response to stress by inducing cell growth arrest or apoptosis. The polyproline region of p53 has been shown to be important for its growth suppression activity, p53 protein lacking the polyproline region has impaired apoptotic activity and altered specificity for certain apoptotic target genes. Here we describe the role of this region in the regulation of p53 by its inhibitor Mdm2. p53 lacking the polyproline region was identified to be more susceptible to inhibition by Mdm2. Furthermore, the absence of this region renders p53 more accessible to ubiquitination, nuclear export, and Mdm2-mediated degradation. This increased sensitivity to Mdm2 results from an enhanced affinity of Mdm2 toward p53 lacking the polyproline region. Our results provide a new explanation for the impaired growth suppression activity of p53 lacking this region. The polyproline region is proposed to be important in the modulation of the inhibitory effects of Mdm2 on p53 activities and stability.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Rockefeller Univ, New York, NY 10021 USA	Hebrew University of Jerusalem; Rockefeller University	Haupt, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel.	haupt@md.huji.ac.il		Haupt, Ygal/0000-0001-5925-0096				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Attardi LD, 2000, GENE DEV, V14, P704; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; McMasters KM, 1996, ONCOGENE, V13, P1731; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Sun XF, 1996, ONCOGENE, V13, P407; Taylor JA, 1996, CANCER RES, V56, P294; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	35	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3785	3790		10.1074/jbc.M008879200	http://dx.doi.org/10.1074/jbc.M008879200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053443	hybrid			2022-12-25	WOS:000166921200010
J	Webb, JH; Villoutreix, BO; Dahlback, B; Blom, AM				Webb, JH; Villoutreix, BO; Dahlback, B; Blom, AM			Localization of a hydrophobic binding site for anticoagulant protein S on the beta-chain of complement regulator C4b-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4-BINDING PROTEIN; C4B BINDING; AFFINITY; MODULE; PROTEOLYSIS; COMPONENT; HOMOLOGY; CHIMERAS; DOMAINS; CD46	C4b-binding protein (C4BP) is a plasma glycoprotein involved in regulation of the complement system. C4BP consists of seven alpha -chains and one unique beta -chain, all constructed of repeating complement control protein (CCP) modules. The beta -chain, made up of three CCPs, binds tightly to vitamin K-dependent protein S, a cofactor to anticoagulant activated protein C. When bound to C4BP, protein S loses its activated protein C cofactor function. In this study, we have mutated potentially important amino acids located at the surface of CCP1 of the beta -chain to probe the protein S-C4BP interaction. The substitutions were designed after analysis of a homology-based three-dimensional structure of the beta -chain and were L2T/F45Q, I16SN18S, V31T/I33N, I16S/V18S/V31T/I33N, L38S/V39S, and K41E/K42E. The mutants were expressed in a prokaryotic system, purified using an N-terminal His-tag, refolded using an oxido-shuffling system, and tested in several assays for their ability to bind protein S. Our data define Ile(16), Val(18), Val(31), and Ile(33) as crucial for protein S binding, with secondary effects from Leu(38) and Val(39). In addition, Lys(41) and Lys(42) contribute slightly to the interaction. Our results further confirm that surface hydrophobicity analysis may be used to identify ligand recognition sites.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Clin Chem, S-20502 Malmo, Sweden; Univ Paris 05, INSERM U428, F-75006 Paris, France	Lund University; Skane University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dahlback, B (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Clin Chem, S-20502 Malmo, Sweden.	Bjorn.Dahlback@klkemi.mas.lu.se	Blom, Anna/AFS-7369-2022; Villoutreix, Bruno/I-4565-2015; Blom, Anna/B-9607-2009	Villoutreix, Bruno/0000-0002-6456-7730; Blom, Anna/0000-0002-1348-1734; Dahlback, Bjorn/0000-0003-1546-0328				Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; Blom AM, 1998, BBA-PROTEIN STRUCT M, V1388, P181, DOI 10.1016/S0167-4838(98)00178-2; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cordes MHJ, 1999, PROTEIN SCI, V8, P318; DAHLBACK B, 1995, THROMB RES, V77, P1, DOI 10.1016/0049-3848(94)00138-4; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Evenas P, 1999, EUR J BIOCHEM, V266, P935, DOI 10.1046/j.1432-1327.1999.00928.x; FERNANDEZ JA, 1994, J BIOL CHEM, V269, P2535; FERNANDEZ JA, 1994, BIOCHEMISTRY-US, V33, P11073, DOI 10.1021/bi00203a003; Freund C, 1999, NAT STRUCT BIOL, V6, P656, DOI 10.1038/10712; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; FURMANIAKKAZMIERCZAK E, 1993, BLOOD, V81, P405; GRIFFIN JH, 1992, BLOOD, V79, P3203; Hardig Y, 1996, J BIOL CHEM, V271, P20861, DOI 10.1074/jbc.271.34.20861; HARDIG Y, 1993, J BIOL CHEM, V268, P3033; He XH, 1997, BIOCHEMISTRY-US, V36, P3745, DOI 10.1021/bi962315q; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; HILLARP A, 1988, J BIOL CHEM, V263, P12759; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; Jonsson AP, 1999, RAPID COMMUN MASS SP, V13, P1782, DOI 10.1002/(SICI)1097-0231(19990930)13:18<1782::AID-RCM714>3.0.CO;2-W; Lijnzaad P, 1996, PROTEINS, V25, P389, DOI 10.1002/(SICI)1097-0134(199607)25:3<389::AID-PROT10>3.3.CO;2-S; Lum K, 1999, J PHYS CHEM B, V103, P4570, DOI 10.1021/jp984327m; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Qasba PK, 2000, CARBOHYD POLYM, V41, P293, DOI 10.1016/S0144-8617(99)00148-4; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; Stenberg Y, 1999, J MOL BIOL, V293, P653, DOI 10.1006/jmbi.1999.3139; van de Poel RHL, 1999, J BIOL CHEM, V274, P15144, DOI 10.1074/jbc.274.21.15144; van de Poel RHL, 1999, BLOOD CELL MOL DIS, V25, P279, DOI 10.1006/bcmd.1999.0255; Villoutreix BO, 1995, PROTEIN ENG, V8, P1253, DOI 10.1093/protein/8.12.1253; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; YOUNG L, 1994, PROTEIN SCI, V3, P717; ZOLLER B, 1995, BLOOD, V85, P3524, DOI 10.1182/blood.V85.12.3524.bloodjournal85123524	41	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4330	4337		10.1074/jbc.M006541200	http://dx.doi.org/10.1074/jbc.M006541200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050085	hybrid			2022-12-25	WOS:000166921200080
J	Witting, PK; Douglas, DJ; Mauk, AG				Witting, PK; Douglas, DJ; Mauk, AG			Reaction of human myoglobin and nitric oxide - Heme iron or protein sulfhydryl (S) nitrosation dependence on the absence or presence of oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; HUMAN SKELETAL-MUSCLE; RELAXING FACTOR; VASCULAR TONE; SMOOTH-MUSCLE; HEMOGLOBIN; NITROSOTHIOLS; METMYOGLOBIN; GLUTATHIONE; OXIDATION	The amino acid sequence of human myoglobin (Mb) is similar to other mammalian Mb except for a unique cysteine residue at position 110 (Cys(110)). Anaerobic treatment of ferrous forms of wild-type human Rib, the C110A variant of human Mb or horse heart Mb, with either authentic NO or chemically derived NO in vitro yields heme-NO complexes as detected by electron paramagnetic resonance spectroscopy (EPR). By contrast, no EPR-detectable heme-NO complex was observed from the aerobic reactions of NO and either the ferric or oxy-Mb forms of wild-type human or horse heart myoglobins, Mass analyses of wild-type human Mb treated aerobically with NO indicated a mass increase of similar to 30 atomic mass units (i.e,, NO/Mb = 1 mol/mol), Mass analyses of the corresponding apoprotein after heme removal showed that NO was associated with the apoprotein fraction. New electronic maxima were detected at A(333) nm (epsilon = 3665 +/- 90 mol(-1) cm(-1); mean +/- S.D.) and A(545) nm (epsilon = 44 +/- 3 mol(-1) cm(-1)) in solutions of S-nitrosated wild-type human Mb (similar to S-nitrosoglutathione), Importantly, the sulfhydryl S-H stretch vibration for Cys(110) measured by Fourier transform infrared (nu similar to 2552 cm(-1)) was absent for both holo- and apo- forms of the wild-type human protein after aerobic treatment of the protein with NO. Together, these data indicate that the reaction of wild-type human Mb and NO yields either heme-NO or a novel S-nitrosated protein dependent on the oxidation state of the heme iron and the presence or absence of dioxygen.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	University of British Columbia; University of British Columbia	Mauk, AG (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.		Witting, Paul/L-9786-2019; Witting, Paul/ABD-2053-2020	Witting, Paul/0000-0003-2237-7004				ALBEN JO, 1974, NATURE, V252, P736, DOI 10.1038/252736a0; AMEZCUA JL, 1989, BRIT J PHARMACOL, V97, P1119, DOI 10.1111/j.1476-5381.1989.tb12569.x; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P40; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Gross SS, 1999, P NATL ACAD SCI USA, V96, P9967, DOI 10.1073/pnas.96.18.9967; HAGLER L, 1979, J BIOL CHEM, V254, P6505; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Holzhutter HG, 1997, EUR J BIOCHEM, V245, P608, DOI 10.1111/j.1432-1033.1997.00608.x; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; Hunter CL, 1997, BIOCHEMISTRY-US, V36, P1018, DOI 10.1021/bi961993+; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Kalyanaraman B, 1996, METHODS ENZYMOL, V268, P168; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KOBAYASHI K, 1982, BIOCHEMISTRY-US, V21, P729, DOI 10.1021/bi00533a022; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LUI Z, 1998, J PHARMACOL EXP THER, V284, P526; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Masuda K, 1999, EUR J APPL PHYSIOL O, V79, P347, DOI 10.1007/s004210050519; McMahon TJ, 1999, METHOD ENZYMOL, V301, P99; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEITES L, 1948, ANAL CHEM, V20, P984, DOI 10.1021/ac60022a044; MOLLER P, 1981, SCAND J CLIN LAB INV, V41, P479, DOI 10.3109/00365518109090486; MONEADA S, 1991, PHARMACOL REV, V43, P109; MORSE RH, 1980, J BIOL CHEM, V255, P7876; Mutus B, 1999, FEBS LETT, V449, P79, DOI 10.1016/S0014-5793(99)00311-7; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; Osipov AN, 1996, METHOD ENZYMOL, V268, P193; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; PERKOFF GT, 1958, METABOLISM, V7, P751; Qiu Y, 1998, J BIOL CHEM, V273, P23426, DOI 10.1074/jbc.273.36.23426; RAGAVAN V, 1985, P NATL ACAD SCI USA, V82, P5681; REDDY D, 1983, SCIENCE, V221, P769, DOI 10.1126/science.6308761; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; Silvester JA, 1998, FREE RADICAL BIO MED, V24, P754, DOI 10.1016/S0891-5849(97)00327-4; SINGH RJ, 1995, FEBS LETT, V360, P47, DOI 10.1016/0014-5793(95)00065-H; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TSAI AL, 1994, FEBS LETT, V341, P141, DOI 10.1016/0014-5793(94)80445-1; WHERLAND S, 1975, J AM CHEM SOC, V97, P5260, DOI 10.1021/ja00851a040; Williams DLH, 1999, ACCOUNTS CHEM RES, V32, P869, DOI 10.1021/ar9800439; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200	58	53	53	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3991	3998		10.1074/jbc.M005758200	http://dx.doi.org/10.1074/jbc.M005758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053410	hybrid			2022-12-25	WOS:000166921200038
J	Ichida, M; Finkel, T				Ichida, M; Finkel, T			Ras regulates NFAT3 activity in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COUPLED RECEPTOR AGONISTS; MUSCLE CELL HYPERTROPHY; NUCLEAR FACTOR; T-CELLS; VENTRICULAR MYOCYTES; GENE-EXPRESSION; ALPHA(1)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; EFFECTOR PATHWAYS	Multiple distinct signal transduction pathways have been implicated in the development of cardiac myocyte hypertrophy. These hypertrophic pathways include those regulated by the Ras superfamily of small GTPases and a separate calcineurin-regulated pathway that culminates in the activation of the transcription factor NFAT3, In this report, we demonstrate a functional interaction between Ras-regulated and calcineurin-regulated pathways. In particular, expression in neonatal myocytes of a constitutively active form of Res (V12ras), but not activating mutants of Rad, RhoA, or Cdc42, results in an increase in NFAT activity. Similarly, expression of an activated Ras, but not other small GTPases, results in the nuclear translocation of an NFAT3 fusion protein. Expression of a dominant negative ras gene product blocks phenylephrine-stimulated NEAT transcriptional activity and the ligand-stimulated NFAT3 nuclear localization. Res proteins appear to function upstream of calcineurin, because cyclosporin A blocks the ability of V12ras to stimulate NFAT-dependent transcription and nuclear localization. Similarly, expression of a dominant negative ras gene inhibits phenylephrine-stimulated calcineurin activity. Pharmacological inhibition of MEK1 or expression of a dominant negative form of c-Raf or ERK2 inhibits phenylephrine-stimulated NFAT3 activation Conversely, NEAT activity was stimulated by expression of constitutively active forms of c-Raf or MEK1, Taken together, these results imply that, in cardiac myocytes, a Res-regulated pathway involving stimulation of mitogen-activated protein kinase regulates NFAT3 activity.	NHLBI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Mol Biol Lab, NIH, Bldg 10,10-6N-240,10 Ctr Dr, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005012, ZIAHL005012] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Cacace AM, 1996, ONCOGENE, V13, P2517; Cachero TG, 1998, CELL, V93, P1077, DOI 10.1016/S0092-8674(00)81212-X; CANTRELL D, 1994, ADV EXP MED BIOL, V365, P73; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Ding B, 1999, CIRC RES, V84, P729, DOI 10.1161/01.RES.84.6.729; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; Ho PD, 1998, J BIOL CHEM, V273, P21730, DOI 10.1074/jbc.273.34.21730; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Sussman MA, 2000, J CLIN INVEST, V105, P875, DOI 10.1172/JCI8497; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; THORBURN A, 1993, J BIOL CHEM, V268, P2244; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Turner H, 1998, J EXP MED, V188, P527, DOI 10.1084/jem.188.3.527; Turner H, 1997, J EXP MED, V185, P43, DOI 10.1084/jem.185.1.43; VAN AL, 1997, GENE DEV, V11, P2295; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722	46	81	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3524	3530		10.1074/jbc.M004275200	http://dx.doi.org/10.1074/jbc.M004275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11044444	hybrid			2022-12-25	WOS:000166784900070
J	Ito, T; Yamauchi, M; Nishina, M; Yamamichi, N; Mizutani, T; Ui, M; Murakami, M; Iba, H				Ito, T; Yamauchi, M; Nishina, M; Yamamichi, N; Mizutani, T; Ui, M; Murakami, M; Iba, H			Identification of SWI center dot SNF complex subunit BAF60a as a determinant of the transactivation potential of Fos/Jun dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWI/SNF COMPLEX; TRANSCRIPTIONAL ACTIVATION; JUN ACTIVITY; FOS; AP-1; BINDING; RECEPTOR; ONCOGENE; FRA-2; STIMULATION	Fos family proteins form stable heterodimers with Jun family proteins, and each heterodimer shows distinctive transactivating potential for regulating cellular growth, differentiation, and development via AP-1 binding sites. However, the molecular mechanism underlying dimer specificity and the molecules that facilitate transactivation remain undefined. Here, we show that BAF60a, a subunit of the SWI.SNF chromatin remodeling complex, is a determinant of the transactivation potential of Fos/Jun dimers. BAF60a binds to a specific subset of Fos/Jun heterodimers using two different interfaces for c-Fos and c-Jun, respectively. Only when the functional SWI.SNF complex is present, can c-Fos/c-Jun (high affinity to BAF60a) but not Fra-2/JunD (no affinity to BAF60a) induce the endogenous AP-1-regulated genes such as collagenase and c-met, These results indicate that a specific subset of Fos/Jun dimers recruits SWI.SNF complex via BAF60a to initiate transcription.	Univ Tokyo, Inst Med Sci, Dept Gene Regulat, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Gene Regulat, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Bannister AJ, 1995, ONCOGENE, V11, P2509; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gebuhr TC, 2000, GENESIS, V26, P189, DOI 10.1002/(SICI)1526-968X(200003)26:3<189::AID-GENE4>3.0.CO;2-5; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Ito T, 1998, NUCLEIC ACIDS RES, V26, P4868, DOI 10.1093/nar/26.21.4868; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kameda T, 1998, CANCER RES, V58, P867; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Seol DW, 2000, ONCOGENE, V19, P1132, DOI 10.1038/sj.onc.1203404; SHULE R, 1990, CELL, V62, P1217; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369	32	116	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2852	2857		10.1074/jbc.M009633200	http://dx.doi.org/10.1074/jbc.M009633200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053448	hybrid			2022-12-25	WOS:000166784800076
J	Sattler, M; Verma, S; Pride, YB; Salgia, R; Rohrschneider, LR; Griffin, JD				Sattler, M; Verma, S; Pride, YB; Salgia, R; Rohrschneider, LR; Griffin, JD			SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; INOSITOL PHOSPHATASE SHIP; POLYPHOSPHATE 5-PHOSPHATASE SHIP; PHOSPHOTYROSINE BINDING DOMAIN; MULTIPLE CYTOKINES; INSULIN-RECEPTOR; ADAPTER PROTEINS; KINASE-ACTIVITY; CELL-MIGRATION; GROWTH-FACTORS	SHIP1 is an SH2 domain containing inositol-5-phosphatase that appears to be a negative regulator of hematopoiesis, The tyrosine kinase oncogene BCR/ABL drastically reduces expression of SHIP1. The major effect of re-expressing SHIP1 in BCR/ABL-transformed cells is reduction of hypermotility, To investigate the potential signaling pathways involving SHIP1 in hematopoietic cells, we overexpressed SHIP1 in a murine BCR/ABL-transformed Ba/F3 cell line and identified SHIP1-associated proteins. SHIP1 was found to form a novel signaling complex with BCR/ABL that includes DOK1 (p62(DOK)), phosphatidylinositol 3-kinase (PI3K), and CRKL, each of which has been previously shown to regulate migration in diverse cell types. We found that DOK1 binds directly through its PTB domain to SHIP1. Direct interaction of SHIP1 with CRKL was mediated through the CRKL-SH2 domain. Go-precipitation experiments suggest that Tyr(917) and Tyr(1020) in SHIP1 are likely to mediate interactions with DOK1, In contrast to wild type SHIP1, expression of tyrosine mutant SHIP1 by transient transfection did not alter migration. PI3K was likely linked to this complex by CRKL, Thus, this complex may serve to generate a very specific set of phosphoinositol products, possibly involved in regulating migration. Overall, these data suggest that proteins that interact with SHIP1 through Tyr(917) and Tr-1020, such as DOK1 and SHC, are likely to be involved in the regulation of SHIP1 dependent migration.	Harvard Univ, Sch Med, Dept Adult Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Fred Hutchinson Cancer Center	Sattler, M (corresponding author), Harvard Univ, Sch Med, Dept Adult Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.			Pride, Yuri/0000-0002-5884-0964	NCI NIH HHS [CA78348, CA82499] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Chacko GW, 1996, J IMMUNOL, V157, P2234; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dunant NM, 2000, CELL SIGNAL, V12, P317, DOI 10.1016/S0898-6568(00)00073-5; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; HEJNA JA, 1995, GENOMICS, V29, P285, DOI 10.1006/geno.1995.1247; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Hunter MG, 1998, J IMMUNOL, V160, P4979; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kim CH, 1999, J CLIN INVEST, V104, P1751, DOI 10.1172/JCI7310; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lee T, 1996, DEVELOPMENT, V122, P409; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P10998; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Lucas DM, 1999, BLOOD, V93, P1922, DOI 10.1182/blood.V93.6.1922.406k21_1922_1933; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; NICHOLS GL, 1994, BLOOD, V84, P2912; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; ODA T, 1994, J BIOL CHEM, V269, P22925; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Park RK, 1999, BLOOD, V94, P2112; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; REYNOLDS FH, 1980, J VIROL, V36, P374, DOI 10.1128/JVI.36.2.374-386.1980; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Siegel J, 1999, ONCOGENE, V18, P7135, DOI 10.1038/sj.onc.1203212; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; TENHOEVE J, 1994, BLOOD, V84, P1731; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Ueoka Y, 2000, BRIT J CANCER, V82, P891, DOI 10.1054/bjoc.1999.1016; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; Wisniewski D, 1996, LEUKEMIA, V10, P229; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	60	48	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2451	2458		10.1074/jbc.M006250200	http://dx.doi.org/10.1074/jbc.M006250200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11031258	hybrid			2022-12-25	WOS:000166784800022
J	Chung, KC; Sung, JY; Ahn, W; Rhim, H; Oh, TH; Lee, MG; Ahn, YS				Chung, KC; Sung, JY; Ahn, W; Rhim, H; Oh, TH; Lee, MG; Ahn, YS			Intracellular calcium mobilization induces immediate early gene pip92 via Src and mitogen-activated protein kinase in immortalized hippocampal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ANGIOTENSIN-II; C-SRC; SIGNAL-TRANSDUCTION; TYROSINE KINASE; NEURONAL CELLS; SH3 DOMAIN; PC12 CELLS; V-SRC; EXPRESSION	Regulation of intracellular calcium levels plays a central role in cell survival, proliferation, and differentiation. A cell-permeable, tumor-promoting thapsigarin elevates the intracellular calcium levels by inhibiting endoplasmic reticulum Ca2+-ATPase. The Src-tyrosine kinase family is involved in a broad range of cellular responses ranging from cell growth and cytoskeletal rearrangement to differentiation. The immediate early gene pip92 is induced in neuronal cell death as well as cell growth and differentiation. To resolve the molecular mechanism of cell growth by intracellular calcium mobilization, we have examined the effect of thapsigargin and subsequent intracellular calcium influx on pip92 expression in immortalized rat hippocampal H19-7 cells. An increase of intracellular calcium ion levels induced by thapsigargin stimulated the expression of pip92 in H19-7 cells. Transient transfection of the cells with kinase-inactive mitogen-activated protein kinase kinase (MER) and Src kinase or pretreatment with the chemical MEK inhibitor PD98059 significantly inhibited pip92 expression induced by thapsigargin. When constitutively active v-Src or MEK was overexpressed, the transcriptional activity of the pip92 gene was markedly increased. Dominant inhibitory Raf-l blocked the transcriptional activity of pip92 induced by thapsigarin. The transcription factor Elk1 is activated during thapsigargin-induced pip92 expression, Taken together, these results suggest that an increase of intracellular calcium ion levels by thapsigargin stimulates the pip92 expression via Raf-MEK-extracellular signal-regulated protein kinase- as well as Src kinase-dependent signaling pathways.	Yonsei Univ, Coll Med, Dept Pharmacol, Seodaemun Gu, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Res Inst, Seoul 120752, South Korea; Korea Inst Sci & Technol, Ctr Biomed Res, Seoul 130650, South Korea; Univ Maryland, Sch Med, Dept Neurobiol & Anat, Baltimore, MD 21201 USA	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Korea Institute of Science & Technology (KIST); University System of Maryland; University of Maryland Baltimore	Chung, KC (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, Seodaemun Gu, Shinchon Dong 134, Seoul 120752, South Korea.		Lee, Min Goo/AAS-4636-2020; Lee, Min Goo/D-5635-2012	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ALEXANDROPOULOS K, 1992, CELL GROWTH DIFFER, V3, P731; Bading H, 1997, BIOCHEM BIOPH RES CO, V236, P541, DOI 10.1006/bbrc.1997.7037; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; CHAN TS, 1997, CANCER RES, V57, P3168; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHARLES CH, 1990, MOL CELL BIOL, V10, P6769, DOI 10.1128/MCB.10.12.6769; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; Chung KC, 2000, J NEUROCHEM, V75, P9, DOI 10.1046/j.1471-4159.2000.0750009.x; COLECLOUGH C, 1990, P NATL ACAD SCI USA, V87, P1753, DOI 10.1073/pnas.87.5.1753; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Gazit G, 1999, BREAST CANCER RES TR, V54, P135, DOI 10.1023/A:1006102411439; Hardingham GE, 1999, MICROSC RES TECHNIQ, V46, P348, DOI 10.1002/(SICI)1097-0029(19990915)46:6<348::AID-JEMT3>3.3.CO;2-1; Hille B., 1992, IONIC CHANNELS EXCIT; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tsunoda Y, 1996, BIOCHEM BIOPH RES CO, V227, P876, DOI 10.1006/bbrc.1996.1599; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; van Haasteren G, 1999, J RECEPT SIGNAL TR R, V19, P481, DOI 10.3109/10799899909036666; Xu J, 1997, BIOCHEM BIOPH RES CO, V235, P394, DOI 10.1006/bbrc.1997.6800	45	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2132	2138		10.1074/jbc.M007492200	http://dx.doi.org/10.1074/jbc.M007492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053438	hybrid			2022-12-25	WOS:000166528000066
J	Wiedemann, I; Breukink, E; van Kraaij, C; Kuipers, OP; Bierbaum, G; de Kruijff, B; Sahl, HG				Wiedemann, I; Breukink, E; van Kraaij, C; Kuipers, OP; Bierbaum, G; de Kruijff, B; Sahl, HG			Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; C-TERMINAL PART; LANTIBIOTIC MERSACIDIN; LACTOCOCCUS-LACTIS; ANTIMICROBIAL PEPTIDE; MEMBRANE; VESICLES; DODECYLPHOSPHOCHOLINE; ORIENTATION; MECHANISM	Unlike numerous pore-forming amphiphilic peptide antibiotics, the lantibiotic nisin is active in nanomolar concentrations, which results from its ability to use the Lipid-bound cell wall precursor lipid II as a docking molecule for subsequent pore formation. Here we use genetically engineered nisin variants to identify the structural requirements for the interaction of the peptide with lipid II. Mutations affecting the conformation of the N-terminal part of nisin comprising rings A through C, e.g. [S3T]nisin, led to reduced binding and increased the peptide concentration necessary for pore formation, The binding constant for the S3T mutant was 0.043 x 10(7) M-1 compared with 2 x 10(7) M-1 for the wildtype peptide, and the minimum concentration for pore formation increased from the 1 nM to the 50 nM range. In contrast, peptides mutated in the flexible hinge region, e,g, [Delta N20/Delta M21]nisin, were completely inactive in the pore formation assay, but were reduced to some extent in their in vivo activity. We found the remaining in vivo activity to result from the unaltered capacity of the mutated peptide to bind to lipid II and thus to inhibit its incorporation into the peptidoglycan network, Therefore, through interaction with the membrane-bound cell wall precursor lipid II, nisin inhibits peptidoglycan synthesis and forms highly specific pores. The combination of two killing mechanisms in one molecule potentiates antibiotic activity and results in nanomolar MIC values, a strategy that may well be worth considering for the construction of novel antibiotics.	Univ Bonn, Inst Med Mikrobiol & Immunol, D-53105 Bonn, Germany; Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Biochem & Membranes, NL-3584 CH Utrecht, Netherlands; NIZO Food Res, Microbial Ingredients Sect, NL-6710 BA Ede, Netherlands	University of Bonn; Utrecht University; NIZO Food Research	Sahl, HG (corresponding author), Univ Groningen, Inst Biomol Sci & Biotechnol, POB 14, NL-9750 AA Haren, Netherlands.	sahl@mibi03.meb.uni-bonn.de	Breukink, Eefjan/I-3039-2016; Kuipers, Oscar/B-6752-2009	Breukink, Eefjan/0000-0002-7311-0660; Kuipers, Oscar/0000-0001-5596-7735				Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Breukink E, 1998, BIOCHEMISTRY-US, V37, P8153, DOI 10.1021/bi972797l; Breukink E, 1997, BIOCHEMISTRY-US, V36, P6968, DOI 10.1021/bi970008u; Brotz H, 2000, J ANTIMICROB CHEMOTH, V46, P1, DOI 10.1093/jac/46.1.1; BROTZ H, 1995, ANTIMICROB AGENTS CH, V39, P714, DOI 10.1128/AAC.39.3.714; Brotz H, 1998, MOL MICROBIOL, V30, P317, DOI 10.1046/j.1365-2958.1998.01065.x; Brotz H, 1997, EUR J BIOCHEM, V246, P193, DOI 10.1111/j.1432-1033.1997.t01-1-00193.x; Brotz H, 1998, ANTIMICROB AGENTS CH, V42, P154, DOI 10.1128/AAC.42.1.154; Chan WC, 1996, FEBS LETT, V390, P129, DOI 10.1016/0014-5793(96)00638-2; CHAN WC, 1989, FEBS LETT, V252, P29, DOI 10.1016/0014-5793(89)80884-1; DEVOS WM, 1993, APPL ENVIRON MICROB, V59, P213, DOI 10.1128/AEM.59.1.213-218.1993; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; DRIESSEN AJM, 1995, BIOCHEMISTRY-US, V34, P1606, DOI 10.1021/bi00005a017; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1993, FEBS LETT, V330, P23, DOI 10.1016/0014-5793(93)80911-D; Kuipers OP, 1996, ANTON LEEUW INT J G, V69, P161, DOI 10.1007/BF00399421; KUIPERS OP, 1991, NISIN NOVEL LANTIBIO, P250; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P12553, DOI 10.1021/bi00039a009; Mattick ATR, 1944, NATURE, V154, P551, DOI 10.1038/154551a0; Moll GN, 1996, ANTON LEEUW INT J G, V69, P185, DOI 10.1007/BF00399423; OTTENWALDER B, 1995, APPL ENVIRON MICROB, V61, P3894; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; RALSTON E, 1981, BIOCHIM BIOPHYS ACTA, V649, P133, DOI 10.1016/0005-2736(81)90019-5; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; RUHR E, 1985, ANTIMICROB AGENTS CH, V27, P841, DOI 10.1128/AAC.27.5.841; SAHL HG, 1987, ARCH MICROBIOL, V149, P120, DOI 10.1007/BF00425076; SAHL HG, 1985, ANTIMICROB AGENTS CH, V27, P836, DOI 10.1128/AAC.27.5.836; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; van Kraaij C, 1998, BIOCHEMISTRY-US, V37, P16033, DOI 10.1021/bi980931b; van Kraaij C, 2000, EUR J BIOCHEM, V267, P901, DOI 10.1046/j.1432-1327.2000.01075.x; vandenHooven HW, 1996, EUR J BIOCHEM, V235, P382, DOI 10.1111/j.1432-1033.1996.00382.x; vandenHooven HW, 1996, EUR J BIOCHEM, V235, P394, DOI 10.1111/j.1432-1033.1996.00394.x; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; VanKraaij C, 1997, EUR J BIOCHEM, V247, P114; Verheul A, 1997, APPL ENVIRON MICROB, V63, P3451, DOI 10.1128/AEM.63.9.3451-3457.1997; WADE D, 1992, INT J PEPT PROT RES, V40, P429	39	551	570	1	90	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1772	1779		10.1074/jbc.M006770200	http://dx.doi.org/10.1074/jbc.M006770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038353	Green Published, hybrid			2022-12-25	WOS:000166528000018
J	Casarosa, P; Bakker, RA; Verzijl, D; Navis, M; Timmerman, H; Leurs, R; Smit, MJ				Casarosa, P; Bakker, RA; Verzijl, D; Navis, M; Timmerman, H; Leurs, R; Smit, MJ			Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; FACTOR-KAPPA-B; G-BETA-GAMMA; KAPOSIS-SARCOMA; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; ACTIVATION; SUBUNITS; ALPHA	Previously it was shown that the HHV-8-encoded chemokine receptor ORF74 shows considerable agonist-independent, constitutive activity giving rise to oncogenic transformation (Arvanitakis, L., Geras-Raaka, E., Varma, A., Grershengorn, M. C., and Cesarman, E. (1997) Nature 385, 347-350), In this study we report that a second viral-encoded chemokine receptor, the human cytomegalovirus-encoded US28, also efficiently signals in an agonist-independent manner. Transient expression of US28 in COS-7 cells leads to the constitutive activation of phospholipase C and NF-kappaB signaling via G(q/11) protein-dependent pathways. Whereas phospholipase C activation is mediated via G alpha (q/11) subunits, the activation of NF-KB strongly depends on py subunits with a preference for the beta (2)gamma (1) dimer. The CC chemokines RANTES (regulated on activation, normal T cell expressed and secreted) and MCP-1 (monocyte chemotactic protein-1) act as neutral antagonists at US28, whereas the CX,C chemokine fractalkine acts as a partial inverse agonist with IC50 values of 1-5 nM. Our data suggest that a high level of constitutive activity might be a more general characteristic of viral G protein-coupled receptors and that human cytomegalovirus might exploit this G protein-coupled receptor property to modulate the homeostasis of infected cells via the early gene product US28.	Vrije Univ Amsterdam, Leiden Amsterdam Ctr Drug Res, Div Med Chem, Fac Chem, NL-1081 HV Amsterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Leurs, R (corresponding author), Vrije Univ Amsterdam, Leiden Amsterdam Ctr Drug Res, Div Med Chem, Fac Chem, De Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.	leurs@chem.vu.nl	Leurs, Rob/AAC-8508-2022; Leurs, Rob/ABB-4299-2021	Leurs, Rob/0000-0003-1354-2848; Verzijl, Dennis/0000-0002-7716-9838; Smit, Martine/0000-0003-2713-0238				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Chen F, 1999, CLIN CHEM, V45, P7; DavisPoynter NJ, 1996, IMMUNOL CELL BIOL, V74, P513, DOI 10.1038/icb.1996.84; Diviani D, 1996, J BIOL CHEM, V271, P5049; Epstein SE, 1999, AM HEART J, V138, pS476, DOI 10.1016/S0002-8703(99)70279-6; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; GAO JL, 1994, J BIOL CHEM, V269, P28539; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Lalani AS, 2000, IMMUNOL TODAY, V21, P100, DOI 10.1016/S0167-5699(99)01556-X; LEE SB, 1993, J BIOL CHEM, V268, P25952; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 1997, NATURE, V385, P296, DOI 10.1038/385296a0; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; Pleskoff O, 1998, J VIROL, V72, P6389, DOI 10.1128/JVI.72.8.6389-6397.1998; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; Wilson SH, 2000, ATHEROSCLEROSIS, V148, P23, DOI 10.1016/S0021-9150(99)00211-7; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827; Zou P, 1999, J VIROL, V73, P5926, DOI 10.1128/JVI.73.7.5926-5933.1999	49	201	209	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1133	1137		10.1074/jbc.M008965200	http://dx.doi.org/10.1074/jbc.M008965200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050102	Green Published, hybrid			2022-12-25	WOS:000166430900039
J	Cieslik, K; Abrams, CS; Wu, KK				Cieslik, K; Abrams, CS; Wu, KK			Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma/Janus kinase 2/MEK-1-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PROTEIN-COUPLED RECEPTORS; LYMPHOCYTE-T ACTIVATION; SMOOTH-MUSCLE CELLS; II AT(1) RECEPTOR; MAP KINASE; PHOSPHOINOSITIDE 3-KINASE-GAMMA; SIGNALING PATHWAY; HUMAN-MONOCYTES; CYTOSKELETAL REORGANIZATION	Our recent study indicates that lysophosphatidylcholine (LPC) enhances Spl binding and Spl-dependent endothelial nitric oxide synthase (eNOS) promoter activity via the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1 (MEK-1) signaling pathway (Cieslik, K,, Lee, C.-M, Tang, J,-L., and Wu, K, K, (1999) J, Biol, Chem. 274, 84669-94675). To identify upstream signaling molecules, we transfected human endothelial cells with dominant negative and active mutants of Bas and evaluated their effects on eNOS promoter activity. Neither mutant altered the basal or LPC-induced eNOS promoter function. By contrast, a dominant negative mutant of phosphatidylinositol 3-kinase gamma (PI-3K gamma) blocked the promoter activity induced by LPC, Wortmannin and LY 294002 had a similar effect. AG-490, a selective inhibitor of Janus kinase 2 (Jak2), also reduced the LPC-induced Spl binding and eNOS promoter activity to the basal level. LPC induced Jak2 phosphorylation, which was abolished by LY 294002 and the dominant negative mutant of PI-3K gamma. LY 294002 and AG-490 abrogated MEK-1 phosphorylation induced by LPC but had no effect on Raf-l. These results indicate that PI-SKy and Jak2 are essential for LPC-induced eNOS promoter activity. This signaling pathway was sensitive to pertussis toxin, suggesting the involvement of a Gi protein in PI-SK gamma activation. These results indicate that LPC enhances Sp1-dependent eNOS promoter activity by a pertussis toxin-sensitive, Res-independent novel pathway, PI-3K gamma /Jak2/MEK-1/ERK1/2.	Univ Texas, Sch Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Hematol, Houston, TX 77030 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Texas System; University of Texas System; University of Pennsylvania	Wu, KK (corresponding author), Univ Texas, Sch Med, Vasc Biol Res Ctr, 6431 Fannin,MSB 5-016, Houston, TX 77030 USA.		Wu, Kenneth Kun-Yu/B-1070-2010; Cieslik, Katarzyna/AAO-1982-2021	Cieslik, Katarzyna/0000-0002-2167-7921	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL50675] Funding Source: Medline; NINDS NIH HHS [P50 NS23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; Cieslik K, 1999, J BIOL CHEM, V274, P34669, DOI 10.1074/jbc.274.49.34669; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; Engelmann B, 1999, ARTERIOSCL THROM VAS, V19, P47, DOI 10.1161/01.ATV.19.1.47; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; INOUE N, 1995, ARTERIOSCL THROM VAS, V15, P1255, DOI 10.1161/01.ATV.15.8.1255; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Ma AD, 1999, J BIOL CHEM, V274, P28730, DOI 10.1074/jbc.274.40.28730; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MOHANDAS N, 1982, J BIOL CHEM, V257, P6537; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nadaud S, 1996, CIRC RES, V79, P857, DOI 10.1161/01.RES.79.4.857; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; Nishioka H, 1998, FEBS LETT, V441, P63, DOI 10.1016/S0014-5793(98)01526-9; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Rikitake Y, 2000, ARTERIOSCL THROM VAS, V20, P1006, DOI 10.1161/01.ATV.20.4.1006; RODRIGUEZLINARES B, 1994, FEBS LETT, V352, P335, DOI 10.1016/0014-5793(94)00983-X; SAKAI M, 1994, J BIOL CHEM, V269, P31430; Santibanez JF, 2000, BIOCHEM BIOPH RES CO, V273, P521, DOI 10.1006/bbrc.2000.2946; Sato N, 1998, THROMB HAEMOSTASIS, V79, P217; Sato N, 1998, J BIOCHEM-TOKYO, V123, P1119; SESSA WC, 1994, CIRC RES, V74, P3349; SHINGU T, 1994, J BIOL CHEM, V269, P32551; Storz P, 1999, FEBS LETT, V464, P159, DOI 10.1016/S0014-5793(99)01689-0; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; TANG JL, 1995, BIOCHEM BIOPH RES CO, V213, P673, DOI 10.1006/bbrc.1995.2184; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Ueno Y, 1999, FEBS LETT, V457, P241, DOI 10.1016/S0014-5793(99)01049-2; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wong JT, 1998, J BIOL CHEM, V273, P6830, DOI 10.1074/jbc.273.12.6830; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; Wu KK, 1998, P ASSOC AM PHYSICIAN, V110, P163; Yamakawa T, 1998, HYPERTENSION, V31, P248, DOI 10.1161/01.HYP.31.1.248; Yamamoto H, 1999, EUR J BIOCHEM, V264, P110, DOI 10.1046/j.1432-1327.1999.00584.x; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Zhu Y, 1997, BBA-LIPID LIPID MET, V1345, P93, DOI 10.1016/S0005-2760(96)00169-5	59	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1211	1219		10.1074/jbc.M005305200	http://dx.doi.org/10.1074/jbc.M005305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042169	hybrid			2022-12-25	WOS:000166430900049
J	Toulokhonov, II; Shulgina, I; Hernandez, VJ				Toulokhonov, II; Shulgina, I; Hernandez, VJ			Binding of the transcription effector ppGpp to Escherichia coli RNA polymerase is allosteric, modular, and occurs near the N terminus of the beta '-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANOSINE TETRAPHOSPHATE; ELONGATION COMPLEX; RIBOSOMAL-RNA; STRINGENT CONTROL; MESSENGER-RNA; BETA-SUBUNIT; PURIFICATION; SITES; ORGANIZATION; PROMOTERS	Among the prokaryotae, the nucleotide ppGpp is a second messenger of physiological stress and starvation. The target of ppGpp is RNA polymerase, where it putatively binds and alters the enzyme's activity. Previous data had implicated the beta -subunit of Escherichia coli RNA polymerase as containing a single ppGpp binding site. In this study, a photocross-linkable derivative of ppGpp, 6-thioguanosine-3',5'-(bis)pyrophosphate (6-thio-ppGpp), was used to localize the ppGpp binding site. In in vitro transcription assays, 6-thio-ppGpp inhibited transcription from the argT promoter identically to bona fide ppGpp, The thio group of 6-thio-ppGpp is directly photoactivatable and is thus a zero-length crosslinker, Cross-linking of RNA polymerase was directed primarily to the beta'-subunit and could be competed efficiently by native ppGpp but not by GTP or GDP, Cyanogen bromide digestion analysis of the cross-linked beta'-subunit was consistent with an extreme N-terminal cross-link. To assess allosteric consequences of ppGpp binding to RNA polymerase, high level trypsin resistance in the presence and absence of ppGpp was monitored. Trypsin digestion of RNA polymerase bound to ppGpp leads to protection of an N-terminal fragment of the beta'-subunit and a C-terminal fragment of the beta -subunit. We propose that the N terminus of beta' together with the C terminus of beta constitute a modular ppGpp binding site.	SUNY Buffalo, Sch Med, Ctr Microbial Pathogenesis, Dept Microbiol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Hernandez, VJ (corresponding author), SUNY Buffalo, Sch Med, Ctr Microbial Pathogenesis, Dept Microbiol, Buffalo, NY 14214 USA.	vjh@buffalo.edu			NIGMS NIH HHS [GM57189] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057189] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CASHEL M, 1974, ANAL BIOCHEM, V57, P100, DOI 10.1016/0003-2697(74)90056-6; CASHEL M, 1970, J BIOL CHEM, V245, P2309; Cashel M., 1994, METH MOL G, V3, P341; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHASHEL M, 1969, NATURE, V221, P838, DOI 10.1038/221838a0; Chatterji D, 1998, GENES CELLS, V3, P279, DOI 10.1046/j.1365-2443.1998.00190.x; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; Gourse RL, 1998, COLD SPRING HARB SYM, V63, P131, DOI 10.1101/sqb.1998.63.131; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; Hsu LM, 1996, METHOD ENZYMOL, V273, P59; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; LITTLE R, 1983, J BACTERIOL, V154, P787, DOI 10.1128/JB.154.2.787-792.1983; LITTLE R, 1983, J BACTERIOL, V155, P1162, DOI 10.1128/JB.155.3.1162-1170.1983; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; McMahan SA, 1999, BIOCHEMISTRY-US, V38, P12424, DOI 10.1021/bi990824x; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; ROWLEY KB, 1993, J BACTERIOL, V175, P1309, DOI 10.1128/JB.175.5.1309-1315.1993; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; Sergiev PV, 1997, RNA, V3, P464; TEDIN K, 1992, J BIOL CHEM, V267, P2337; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; Vogel U, 1997, J BIOL CHEM, V272, P12265, DOI 10.1074/jbc.272.19.12265; VOGEL U, 1994, J BIOL CHEM, V269, P16236; Wang DG, 1997, P NATL ACAD SCI USA, V94, P8433, DOI 10.1073/pnas.94.16.8433; WELLINGTON SR, 1991, BIOCHEM BIOPH RES CO, V179, P1107, DOI 10.1016/0006-291X(91)91934-5; WOODY AYM, 1987, BIOCHIM BIOPHYS ACTA, V909, P115, DOI 10.1016/0167-4781(87)90033-9; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	40	88	94	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1220	1225		10.1074/jbc.M007184200	http://dx.doi.org/10.1074/jbc.M007184200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035017	hybrid			2022-12-25	WOS:000166430900050
